<SEC-DOCUMENT>0001493152-24-017983.txt : 20240507
<SEC-HEADER>0001493152-24-017983.hdr.sgml : 20240507
<ACCEPTANCE-DATETIME>20240506215014
ACCESSION NUMBER:		0001493152-24-017983
CONFORMED SUBMISSION TYPE:	S-1/A
PUBLIC DOCUMENT COUNT:		100
FILED AS OF DATE:		20240507
DATE AS OF CHANGE:		20240506

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			OneMedNet Corp
		CENTRAL INDEX KEY:			0001849380
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				862076743
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-276130
		FILM NUMBER:		24919373

	BUSINESS ADDRESS:	
		STREET 1:		TRIDENT COURT, 1 OAKCROFT ROAD
		STREET 2:		CHESSINGTON
		CITY:			SURREY
		STATE:			X0
		ZIP:			KT9 1BD
		BUSINESS PHONE:		011-44-208-090-2009

	MAIL ADDRESS:	
		STREET 1:		TRIDENT COURT, 1 OAKCROFT ROAD
		STREET 2:		CHESSINGTON
		CITY:			SURREY
		STATE:			X0
		ZIP:			KT9 1BD

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Data Knights Acquisition Corp.
		DATE OF NAME CHANGE:	20210304
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1/A
<SEQUENCE>1
<FILENAME>forms-1a.htm
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:ONMD="http://onemednet.com/20231231">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02C_US%2DGAAP%2D2023 -->
<!-- Field: Set; Name: xdx; ID: xdx_03B_ONMD_onemednet.com_20231231 -->
<!-- Field: Set; Name: xdx; ID: xdx_04A_20230101_20231231 -->
<!-- Field: Set; Name: xdx; ID: xdx_055_edei%2D%2DAmendmentFlag_true -->
<!-- Field: Set; Name: xdx; ID: xdx_058_edei%2D%2DEntityCentralIndexKey_0001849380 -->
<!-- Field: Set; Name: xdx; ID: xdx_07A_XDX_Z%2D%2D\2024 OPERATIONS\EDGAR\04 APRIL\ONEMEDNET CORPORATION\04%2D12%2D2024\Form S%2D1A\Draft\Production\form10%2Dk.xdx -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<!-- Field: Set; Name: xdx; ID: xdx_064_Integer_5_Integer -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000003" name="dei:AmendmentFlag">true</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000004" name="dei:EntityCentralIndexKey">0001849380</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl0012" name="dei:DocumentType">S-1/A</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:AssetsHeldInTrustCurrent" contextRef="AsOf2023-12-31" id="xdx2ixbrl0042" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:SalesAndExciseTaxPayableCurrent" contextRef="AsOf2022-12-31" id="xdx2ixbrl0073" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ONMD:LoanExtensionsCurrent" contextRef="AsOf2022-12-31" id="xdx2ixbrl0076" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:LoansPayable" contextRef="AsOf2022-12-31" id="xdx2ixbrl0082" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ConvertibleDebtCurrent" contextRef="AsOf2023-12-31" id="xdx2ixbrl0084" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:UnsecuredDebtCurrent" contextRef="AsOf2022-12-31" id="xdx2ixbrl0088" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent" contextRef="AsOf2023-12-31" id="xdx2ixbrl0093" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:OtherNotesPayableCurrent" contextRef="AsOf2022-12-31" id="xdx2ixbrl0097" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ONMD:DeferredUnderwriterFeePayableCurrent" contextRef="AsOf2022-12-31" id="xdx2ixbrl0100" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="AsOf2022-12-31_us-gaap_RelatedPartyMember" id="xdx2ixbrl0118" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ONMD:DeferredUnderwriterFeePayableNonCurrent" contextRef="AsOf2023-12-31" id="xdx2ixbrl0123" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ONMD:WorkingCapitalLoan" contextRef="AsOf2023-12-31" id="xdx2ixbrl0126" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:LongTermLoansPayable" contextRef="AsOf2023-12-31" id="xdx2ixbrl0129" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2023-12-31_custom_SeriesATwoPreferredStockMember" id="xdx2ixbrl0138" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2023-12-31_custom_SeriesAOnePreferredStockMember" id="xdx2ixbrl0145" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2023-12-31_custom_SeriesAOnePreferredStockMember" id="xdx2ixbrl0152" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2023-12-31_us-gaap_CommonClassAMember" id="xdx2ixbrl0162" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2023-12-31_custom_CommonClassAOneMember" id="xdx2ixbrl0169" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2023-12-31_custom_CommonClassAOneMember" id="xdx2ixbrl0176" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2023-12-31" id="xdx2ixbrl0179" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl0230" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ONMD:UnrealizedGainLoss" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl0245" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2022-01-012022-12-31_custom_CommitmentMember" id="xdx2ixbrl0288" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-01-012022-12-31_custom_CommitmentMember" id="xdx2ixbrl0300" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="From2022-01-012022-12-31_custom_CommitmentMember" id="xdx2ixbrl0313" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ONMD:CommonStockSubjectToPossibleRedemptionValue" contextRef="From2022-01-012022-12-31_custom_CommitmentMember" id="xdx2ixbrl0325" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-12-31_custom_CommitmentMember" id="xdx2ixbrl0335" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_custom_SeriesATwoPreferredStockMember" id="xdx2ixbrl0340" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_custom_SeriesAOnePreferredStockMember" id="xdx2ixbrl0341" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember_custom_DataKnightsAcquisitionCorpMember" id="xdx2ixbrl0342" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassBMember_custom_DataKnightsAcquisitionCorpMember" id="xdx2ixbrl0343" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_custom_CommitmentMember" id="xdx2ixbrl0345" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2023-01-012023-12-31_custom_CommitmentMember" id="xdx2ixbrl0405" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ONMD:StockIssuedDuringPeriodValueConvertibleNotesToCommonStock" contextRef="From2023-01-012023-12-31_custom_CommitmentMember" id="xdx2ixbrl0421" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ONMD:StockIssuedDuringPeriodValueStockOptionsToCommonStock" contextRef="From2023-01-012023-12-31_custom_CommitmentMember" id="xdx2ixbrl0433" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ONMD:StockIssuedDuringPeriodValueConvertingOfWarrantsToCommonStock" contextRef="From2023-01-012023-12-31_custom_CommitmentMember" id="xdx2ixbrl0445" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-01-012023-12-31_custom_CommitmentMember" id="xdx2ixbrl0457" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2023-01-012023-12-31_custom_CommitmentMember" id="xdx2ixbrl0469" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ONMD:StockIssuedDuringPeriodValueConvertingDataKnightsCommonShares" contextRef="From2023-01-012023-12-31_custom_CommitmentMember" id="xdx2ixbrl0479" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31_custom_CommitmentMember" id="xdx2ixbrl0505" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ONMD:RetainedEarningsAdjustment" contextRef="From2023-01-012023-12-31_custom_CommitmentMember" id="xdx2ixbrl0517" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_SeriesATwoPreferredStockMember" id="xdx2ixbrl0522" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_SeriesAOnePreferredStockMember" id="xdx2ixbrl0523" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember_custom_DataKnightsAcquisitionCorpMember" id="xdx2ixbrl0524" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_SeriesATwoPreferredStockMember" id="xdx2ixbrl0532" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_SeriesAOnePreferredStockMember" id="xdx2ixbrl0533" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember_custom_DataKnightsAcquisitionCorpMember" id="xdx2ixbrl0534" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ONMD:BusinessCombinationCost" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0595" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl0597" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl0606" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ONMD:ProceedsFromIssuanceOfCommonStockOne" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl0648" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0658" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ONMD:ProceedsFromDeferredUnderwritingFee" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0667" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ONMD:ProceedsFromIssuanceOfCommonStockTwo" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0676" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ONMD:ClassBCommonStock" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0679" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-01-012023-12-31_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerTwoMember" id="xdx2ixbrl0725" unitRef="Pure" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-01-012023-12-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerOneMember" id="xdx2ixbrl0733" unitRef="Pure" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-01-012022-12-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerTwoMember" id="xdx2ixbrl0737" unitRef="Pure" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-01-012022-12-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerThreeMember" id="xdx2ixbrl0740" unitRef="Pure" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-01-012023-12-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerFourMember" id="xdx2ixbrl0742" unitRef="Pure" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-01-012022-12-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerFiveMember" id="xdx2ixbrl0746" unitRef="Pure" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="AsOf2023-12-31" id="xdx2ixbrl0821" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2023-12-31" id="xdx2ixbrl0830" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2022-12-31" id="xdx2ixbrl0831" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0917" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AssetsHeldInTrustCurrent" contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member_custom_InvestmentsHeldInTrustMember" id="xdx2ixbrl0996" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AssetsHeldInTrustCurrent" contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member_custom_InvestmentsHeldInTrustMember" id="xdx2ixbrl0998" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AssetsHeldInTrustCurrent" contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member_custom_InvestmentsHeldInTrustMember" id="xdx2ixbrl1000" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AssetsHeldInTrustCurrent" contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_custom_InvestmentsHeldInTrustMember" id="xdx2ixbrl1002" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AssetsHeldInTrustCurrent" contextRef="AsOf2022-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member_custom_InvestmentsHeldInTrustMember" id="xdx2ixbrl1006" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AssetsHeldInTrustCurrent" contextRef="AsOf2022-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member_custom_InvestmentsHeldInTrustMember" id="xdx2ixbrl1008" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AssetsHeldInTrustCurrent" contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl1012" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AssetsHeldInTrustCurrent" contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1014" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AssetsHeldInTrustCurrent" contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl1016" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AssetsHeldInTrustCurrent" contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember" id="xdx2ixbrl1018" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AssetsHeldInTrustCurrent" contextRef="AsOf2022-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1022" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AssetsHeldInTrustCurrent" contextRef="AsOf2022-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1024" unitRef="USD" xs:nil="true"/>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="onmd-20231231.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2023-01-01to2023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_dei_BusinessContactMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_SeriesATwoPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ONMD:SeriesATwoPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_SeriesATwoPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ONMD:SeriesATwoPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_SeriesAOnePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ONMD:SeriesAOnePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_SeriesAOnePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ONMD:SeriesAOnePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_CommonClassAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_CommonClassAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_CommonClassAOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ONMD:CommonClassAOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_CommonClassAOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ONMD:CommonClassAOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesATwoPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ONMD:SeriesATwoPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesAOnePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ONMD:SeriesAOnePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember_custom_DataKnightsAcquisitionCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ONMD:DataKnightsAcquisitionCorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassBMember_custom_DataKnightsAcquisitionCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ONMD:DataKnightsAcquisitionCorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_CommitmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ONMD:CommitmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesATwoPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ONMD:SeriesATwoPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesAOnePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ONMD:SeriesAOnePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember_custom_DataKnightsAcquisitionCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ONMD:DataKnightsAcquisitionCorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassBMember_custom_DataKnightsAcquisitionCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ONMD:DataKnightsAcquisitionCorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_CommitmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ONMD:CommitmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_PreferredStockMember_custom_SeriesATwoPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ONMD:SeriesATwoPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_PreferredStockMember_custom_SeriesAOnePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ONMD:SeriesAOnePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember_custom_DataKnightsAcquisitionCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ONMD:DataKnightsAcquisitionCorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassBMember_custom_DataKnightsAcquisitionCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ONMD:DataKnightsAcquisitionCorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_CommitmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ONMD:CommitmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_SeriesATwoPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ONMD:SeriesATwoPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_SeriesAOnePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ONMD:SeriesAOnePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember_custom_DataKnightsAcquisitionCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ONMD:DataKnightsAcquisitionCorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassBMember_custom_DataKnightsAcquisitionCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ONMD:DataKnightsAcquisitionCorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_CommitmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ONMD:CommitmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesATwoPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ONMD:SeriesATwoPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesAOnePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ONMD:SeriesAOnePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember_custom_DataKnightsAcquisitionCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ONMD:DataKnightsAcquisitionCorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassBMember_custom_DataKnightsAcquisitionCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ONMD:DataKnightsAcquisitionCorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_CommitmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ONMD:CommitmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-06-282023-06-28_custom_SecuritiesPurchaseAgreementMember_custom_DataKnightsAcquisitionCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ONMD:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ONMD:DataKnightsAcquisitionCorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-06-28</xbrli:startDate>
        <xbrli:endDate>2023-06-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-28_custom_SecuritiesPurchaseAgreementMember_custom_DataKnightsAcquisitionCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ONMD:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ONMD:DataKnightsAcquisitionCorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_CustomerConcentrationRiskMember_custom_OneCustomerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ONMD:OneCustomerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_CustomerConcentrationRiskMember_custom_TwoCustomersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ONMD:TwoCustomersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_ThreeCustomersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ONMD:ThreeCustomersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_TwoCustomersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ONMD:TwoCustomersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ONMD:CustomerOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ONMD:CustomerOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ONMD:CustomerTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ONMD:CustomerTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ONMD:CustomersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ONMD:CustomersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ONMD:CustomerOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ONMD:CustomerOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ONMD:CustomerTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ONMD:CustomerTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ONMD:CustomerThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ONMD:CustomerThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ONMD:CustomerFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ONMD:CustomerFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerFiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ONMD:CustomerFiveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerFiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ONMD:CustomerFiveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ONMD:CustomersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ONMD:CustomersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_ComputerEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_ComputerEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_DomesticCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_StateAndLocalJurisdictionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_DataKnightsAcquisitionCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ONMD:DataKnightsAcquisitionCorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_DataKnightsAcquisitionCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ONMD:DataKnightsAcquisitionCorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_NonrelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_NonrelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-11-11_us-gaap_RelatedPartyMember_custom_ConvertiblePromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ONMD:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-11-11</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-11-102022-11-11_us-gaap_RelatedPartyMember_custom_ConvertiblePromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ONMD:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-11-10</xbrli:startDate>
        <xbrli:endDate>2022-11-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-11-11_us-gaap_RelatedPartyMember_custom_SeriesATwoPreferredStockMember_custom_ConvertiblePromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ONMD:SeriesATwoPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ONMD:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-11-11</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-11-30_us-gaap_RelatedPartyMember_custom_ConvertiblePromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ONMD:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-11-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_ConvertiblePromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ONMD:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-11-30_us-gaap_RelatedPartyMember_custom_DataKnightsAcquisitionCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ONMD:DataKnightsAcquisitionCorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-11-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-12-012020-12-31_custom_CEBALoanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ONMD:CEBALoanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-12-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_CEBALoanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ONMD:CEBALoanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_CEBALoanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ONMD:CEBALoanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_SeriesATwoPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ONMD:SeriesATwoPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_SeriesAOnePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ONMD:SeriesAOnePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_BoardOfDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ONMD:BoardOfDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_BoardOfDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ONMD:BoardOfDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_BoardOfDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ONMD:BoardOfDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_CommonStockMember_srt_BoardOfDirectorsChairmanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_CommonStockMember_srt_BoardOfDirectorsChairmanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_CommonStockMember_srt_BoardOfDirectorsChairmanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_EmployeesDirectorsAndConsultantsMember_custom_NewEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ONMD:EmployeesDirectorsAndConsultantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ONMD:NewEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_EmployeesDirectorsAndConsultantsMember_custom_NewEquityIncentivePlanMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ONMD:EmployeesDirectorsAndConsultantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ONMD:NewEquityIncentivePlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_EmployeesDirectorsAndConsultantsMember_custom_NewEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ONMD:EmployeesDirectorsAndConsultantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ONMD:NewEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-11-07">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-11-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-172023-10-17">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-17</xbrli:startDate>
        <xbrli:endDate>2023-10-17</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_MeasurementInputExpectedTermMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_MeasurementInputExpectedTermMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_MeasurementInputExpectedDividendRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_MeasurementInputExpectedDividendRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_MeasurementInputPriceVolatilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_MeasurementInputPriceVolatilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_TwentyTwentyOneServiceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ONMD:TwentyTwentyOneServiceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_TwentyTwentyTwoServiceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ONMD:TwentyTwentyTwoServiceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_ConvertiableNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ONMD:ConvertiableNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_ConvertiableNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ONMD:ConvertiableNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_WarrantOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ONMD:WarrantOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_PubliclyTradedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ONMD:PubliclyTradedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_PubliclyTradedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ONMD:PubliclyTradedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_PrivateWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ONMD:PrivateWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_PrivateWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ONMD:PrivateWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member_custom_InvestmentsHeldInTrustMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ONMD:InvestmentsHeldInTrustMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member_custom_InvestmentsHeldInTrustMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ONMD:InvestmentsHeldInTrustMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member_custom_InvestmentsHeldInTrustMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ONMD:InvestmentsHeldInTrustMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_custom_InvestmentsHeldInTrustMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ONMD:InvestmentsHeldInTrustMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member_custom_InvestmentsHeldInTrustMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ONMD:InvestmentsHeldInTrustMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member_custom_InvestmentsHeldInTrustMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ONMD:InvestmentsHeldInTrustMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member_custom_InvestmentsHeldInTrustMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ONMD:InvestmentsHeldInTrustMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueMeasurementsRecurringMember_custom_InvestmentsHeldInTrustMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ONMD:InvestmentsHeldInTrustMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_DataKnightsAcquisitionCorpMember_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ONMD:DataKnightsAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_RelatedPartyMember_custom_ManagementAndDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ONMD:ManagementAndDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-11-012023-11-30_custom_SecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ONMD:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-11-01</xbrli:startDate>
        <xbrli:endDate>2023-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-11-012023-11-30_custom_SeniorConvertibleNotesMember_custom_SecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ONMD:SeniorConvertibleNotesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ONMD:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-11-01</xbrli:startDate>
        <xbrli:endDate>2023-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-11-30_us-gaap_RelatedPartyMember_custom_SecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ONMD:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-11-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-11-012023-11-30_custom_SecuritiesPurchaseAgreementMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ONMD:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-11-01</xbrli:startDate>
        <xbrli:endDate>2023-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-11-30_custom_SecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ONMD:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-11-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_srt_ScenarioForecastMember_custom_EFHuttonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ONMD:EFHuttonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_srt_ScenarioForecastMember_custom_KingwoodCapitalPartnersLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ONMD:KingwoodCapitalPartnersLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_srt_ScenarioForecastMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_SubsequentEventMember_us-gaap_MajorityShareholderMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-03-262024-03-27_srt_ScenarioForecastMember_srt_BoardOfDirectorsChairmanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-03-26</xbrli:startDate>
        <xbrli:endDate>2024-03-27</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-27_srt_ScenarioForecastMember_srt_BoardOfDirectorsChairmanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-27</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Integer">
      <xbrli:measure>ONMD:Integer</xbrli:measure>
    </xbrli:unit>
  <ix:relationship fromRefs="Fact000256" toRefs="Footnote000261"/>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>As
filed with the Securities and Exchange Commission on May 6, 2024</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Registration
No. 333-276130</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Rule-Page --><div style="font-family: Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 4pt solid; border-bottom: Black 1.5pt solid; font: 1pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span id="xdx_90D_edei--AmendmentDescription_c20230101__20231231_zGSGX1UafJW6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000011" name="dei:AmendmentDescription">Amendment No. 2</ix:nonNumeric></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_90D_edei--DocumentType_dxL_c20230101__20231231_zedv9KsdYDC2" title="::XDX::S-1%2FA"><span style="-sec-ix-hidden: xdx2ixbrl0012">S-1</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>REGISTRATION
STATEMENT<br/>
UNDER THE SECURITIES ACT OF 1933</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span id="xdx_90F_edei--EntityRegistrantName_c20230101__20231231_zrHq1sxC5jTe"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000013" name="dei:EntityRegistrantName">ONEMEDNET
CORPORATION</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of registrant as specified in its charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_904_edei--EntityIncorporationStateCountryCode_c20230101__20231231_zFXgXPKrFrji"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt-sec:stateprovnameen" id="Fact000014" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3721</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_908_edei--EntityTaxIdentificationNumber_c20230101__20231231_zjcYBCcJT5hl"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000015" name="dei:EntityTaxIdentificationNumber">86-2049355</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
                                            or other jurisdiction</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of
    incorporation or organization)</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Primary
                                            Standard Industrial</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Classification
    Code Number)</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S.
                                            Employer</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification
    Number)</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OneMedNet
Corporation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_909_edei--EntityAddressAddressLine1_c20230101__20231231_zREhlIbanb6g"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000016" name="dei:EntityAddressAddressLine1">6385
Old Shady Oak Road</ix:nonNumeric></span>, <span id="xdx_904_edei--EntityAddressAddressLine2_c20230101__20231231_zYFe1tQ6uyK3"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000017" name="dei:EntityAddressAddressLine2">Suite 250</ix:nonNumeric></span><br/>
<span id="xdx_906_edei--EntityAddressCityOrTown_c20230101__20231231_ze0G2u6e2Wu4"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000018" name="dei:EntityAddressCityOrTown">Eden Prairie</ix:nonNumeric></span>, <span id="xdx_90F_edei--EntityAddressStateOrProvince_c20230101__20231231_zLtJkkly3Wu5"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000019" name="dei:EntityAddressStateOrProvince">MN</ix:nonNumeric></span> <span id="xdx_904_edei--EntityAddressPostalZipCode_c20230101__20231231_zKIbcBAiM9p6"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000020" name="dei:EntityAddressPostalZipCode">55344</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Telephone:
<span id="xdx_906_edei--CityAreaCode_c20230101__20231231_zrjPvUIko6Z8"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000021" name="dei:CityAreaCode">800</ix:nonNumeric></span>-<span id="xdx_909_edei--LocalPhoneNumber_c20230101__20231231_zCrNlOqpEaod"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000022" name="dei:LocalPhoneNumber">918-7189</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address,
including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>The
Corporation Trust Company</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>Corporation
Trust Center </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>1209
Orange Street</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>Wilmington,
DE 19801</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Telephone:
<span style="background-color: white">302-658-7581</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Name,
address, including zip code, and telephone number, including area code, of agent for service)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Copies
to:</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_901_edei--ContactPersonnelName_c20230101__20231231__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zHJjl379SXO8"><ix:nonNumeric contextRef="From2023-01-012023-12-31_dei_BusinessContactMember" id="Fact000023" name="dei:ContactPersonnelName">Debbie
A. Klis, Esq.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Rimon
P.C.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90D_edei--EntityAddressAddressLine1_c20230101__20231231__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zcujXy0Nu909"><ix:nonNumeric contextRef="From2023-01-012023-12-31_dei_BusinessContactMember" id="Fact000024" name="dei:EntityAddressAddressLine1">1990
K. Street</ix:nonNumeric></span>, <span id="xdx_90E_edei--EntityAddressAddressLine2_c20230101__20231231__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zwHaj5iHh3I4"><ix:nonNumeric contextRef="From2023-01-012023-12-31_dei_BusinessContactMember" id="Fact000025" name="dei:EntityAddressAddressLine2">NW, Suite 420</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_905_edei--EntityAddressAddressLine3_c20230101__20231231__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zdSyP0spQzHc"><ix:nonNumeric contextRef="From2023-01-012023-12-31_dei_BusinessContactMember" id="Fact000026" name="dei:EntityAddressAddressLine3">Washington</ix:nonNumeric></span>,
<span id="xdx_90D_edei--EntityAddressStateOrProvince_c20230101__20231231__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zynbiaRaVuk6"><ix:nonNumeric contextRef="From2023-01-012023-12-31_dei_BusinessContactMember" id="Fact000027" name="dei:EntityAddressStateOrProvince">DC</ix:nonNumeric></span> <span id="xdx_900_edei--EntityAddressPostalZipCode_c20230101__20231231__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_za55v7I5RUlc"><ix:nonNumeric contextRef="From2023-01-012023-12-31_dei_BusinessContactMember" id="Fact000028" name="dei:EntityAddressPostalZipCode">20006</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Telephone:
<span id="xdx_90C_edei--CityAreaCode_c20230101__20231231__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zUCX8oSPAMp7"><ix:nonNumeric contextRef="From2023-01-012023-12-31_dei_BusinessContactMember" id="Fact000029" name="dei:CityAreaCode">(202)</ix:nonNumeric></span> <span id="xdx_909_edei--LocalPhoneNumber_c20230101__20231231__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_z7pkB7YewqE7"><ix:nonNumeric contextRef="From2023-01-012023-12-31_dei_BusinessContactMember" id="Fact000030" name="dei:LocalPhoneNumber">935-3390</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approximate
date of commencement of proposed sale to the public: <b>As soon as practicable after the effective date of this registration statement.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the
Securities Act of 1933 check the following box. &#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the
following box and list the Securities Act registration statement number of the earlier effective registration statement for the same
offering. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large-accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of &#8220;large-accelerated filer,&#8221; &#8220;accelerated filer,&#8221;
&#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large-accelerated
    filer &#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
    filer &#9744;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_edei--EntityFilerCategory_c20230101__20231231_z1dihY0YcuT9"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt-sec:entityfilercategoryen" id="Fact000031" name="dei:EntityFilerCategory">Non-accelerated
    filer</ix:nonNumeric></span> &#9746;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
    reporting company <span id="xdx_90B_edei--EntitySmallBusiness_c20230101__20231231_zpcFk8RwBDY4"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt:booleantrue" id="Fact000032" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
    growth company <span id="xdx_90E_edei--EntityEmergingGrowthCompany_c20230101__20231231_zuw3nNXmCInb"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt:booleantrue" id="Fact000033" name="dei:EntityEmergingGrowthCompany">&#9746;</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check market if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. <span id="xdx_90B_edei--EntityExTransitionPeriod_c20230101__20231231_zB2dV3zL9fbl"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt:booleanfalse" id="Fact000034" name="dei:EntityExTransitionPeriod">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the
registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective
in accordance with section 8(a) of the Securities Act of 1933 or until the registration statement shall become effective on such date
as the Commission acting pursuant to said section 8(a), may determine.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"></p>

<!-- Field: Rule-Page --><div style="font-family: Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; border-bottom: Black 4pt solid; font: 1pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white; color: red"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
information in this preliminary prospectus is not complete and may be changed. We may not sell these securities until the registration
statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities
and is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: red"><b>PRELIMINARY
    PROSPECTUS</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: red">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: red"><b>SUBJECT
    TO COMPLETION</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: red">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: red"><b>DATED
    MAY __, 2024</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="forms-1_001.jpg" alt="A logo with blue and black letters&#10;&#10;Description automatically generated" style="height: 95px; width: 234px"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Primary
Offering of</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Up
to 12,085,275 Shares of Common Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Upon the Exercise of Warrants</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Secondary
Offering of</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Up
to 19,683,367 Shares of Common Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Up
to 681,019 Warrants</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus relates to the primary issuance by us of up to an aggregate of 12,085,275 shares of common stock, par value $0.0001 per share
(the &#8220;Common Stock&#8221;), of OneMedNet Corporation, a Delaware corporation (&#8220;we,&#8221; &#8220;us,&#8221; the &#8220;Company&#8221;
and &#8220;OneMedNet&#8221;), which consists of (i) up to 11,500,000 shares of Common Stock issuable upon the exercise of 11,500,000
warrants (the &#8220;Public Warrants&#8221;) originally issued and registered in the initial public offering of Data Knights Acquisition
Corp&#8221; as a special purpose acquisition company (&#8220;DKAC&#8221;) <span style="background-color: white">at a price of $10.00
per unit with each unit consisting of one share of Class&#160;A common stock and one warrant (each Public Warrant entitles the holder
thereof to purchase one share of Class&#160;A common stock at a price of $11.50 per share)</span>, and (ii)&#160;up to an aggregate
of 585,275 shares of Common Stock issuable upon the exercise of 585,275 warrants (the &#8220;Placement Warrants,&#8221; together with
the Public Warrants, the &#8220;Warrants&#8221;) that made up a part of the private units originally issued in a private placement in
connection with DKAC&#8217;s initial public offering at a price of $10.00 per unit, for an aggregate purchase price of $5,852,750.
We will receive the proceeds from any exercise of the Warrants for cash.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus also relates to the offer and resale from time to time, upon the expiration of lock-up agreements, if applicable, by: (a)&#160;the
selling shareholders named in this prospectus (including their permitted transferees, donees, pledgees and other successors-in-interest)
(collectively, the &#8220;Selling Securityholders&#8221;) of up to an aggregate of 19,683,367 shares of Common Stock consisting of (i)&#160;797,872
shares of Common Stock upon conversion of up to $1,595,744.70 of OneMedNet Senior Secured Convertible Notes (the &#8220;Pre-Closing PIPE
Notes&#8221;) issued at the closing of the Business Combination (as defined below) <span style="letter-spacing: 0.2pt">that are convertible
into shares of Common Stock at the PIPE investors election at a conversion price equal to the lower of (i) $10.00 per share, and (ii)
92.5% of the lowest volume weighted average trading price for the ten (10) trading days immediately preceding the Conversion Date,</span>
subject to a floor price of $2.00 per share of common stock pursuant to the terms of the Securities Purchase Agreement dated June
28, 2023, by and among Data Knights Acquisition Corp, a Delaware corporation (&#8220;Data Knights&#8221;) and the named investors (the
&#8220;Pre-Closing PIPE&#8221;), (ii) 95,744 shares underlying 95,744 warrants issued to the PIPE investors as additional consideration
for the PIPE investors investment in the Pre-Closing PIPE Notes, which Warrant Agreements were executed at the closing
of the Business Combination, (iii) 7,312,817 shares of Common Stock upon conversion (the &#8220;Conversion Shares) of up to $4,547,500
of funding to the Company pursuant to the Securities Purchase Agreement and convertible promissory notes <span style="background-color: white">dated
</span>March 28, 2024 <span style="background-color: white">(the &#8220;PIPE Notes Financing&#8221;), at the price of $0.62 per share
of Common Stock, with Helena Global Investment Opportunities 1 Ltd. (the &#8220;Notes Investor&#8221;),</span> (iv) 3,656,408 shares
underlying 3,656,408 warrants issued to the Notes Investor as additional consideration for the <span style="background-color: white">PIPE
Notes Financing</span> with the Notes Investor, (v) 277,778 shares of Common Stock issued pursuant to the terms of the Satisfaction
and Discharge Agreement at $10.88 per share of Common Stock dated as of June 28, 2023, by and among the Company, Data Knights, and EF
Hutton LLC (&#8220;EF Hutton&#8221;), (vi) 1,315,840 shares of Common Stock issuable pursuant to the outstanding loans converted to equity
at $1.00 per share of Common Stock to Data Knights to fund its extension payments prior to the Business Combination by
certain of the Selling Securityholders named in this prospectus, (vii) 1,439,563 shares of Common Stock issued upon the closing of the
Business Combination to ARC Group Limited, as consideration for its financial advisory services <span style="background-color: white">at
a cash price of $0.00 per share</span> of Common Stock, (viii) 1,327,070 shares of Common Stock at $0.7535 <span style="background-color: white">per
share</span> of Common Stock (95% of VWAP 10-day average $0.7932) for $1,000,000 investment by Dr. Thomas Kosasa, and (ix)&#160;3,609,859
shares of Common Stock issued to Data Knights LLC (the &#8220;Sponsor&#8221;) and its affiliates, including 2,875,000 shares of Common
Stock originally issued as share of Class B Stock in connection with the initial public offering of DKAC for aggregate consideration
of $25,000, or approximately $0.009 per share, and 585,275 shares of Common Stock originally issued to Sponsor as part of the Placement
Units issued to the Sponsor in connection with DKAC&#8217;s initial public offering at $10.00 per unit, and which are subject to six
month lock-up restrictions set forth herein; and (b)&#160;the selling warrant holders named in this prospectus (including their permitted
transferees, donees, pledgees and other successors-in-interest) (collectively, the &#8220;Selling Warrantholders&#8221; and, together
with the Selling Shareholders and including their permitted transferees, the &#8220;Selling Securityholders&#8221;) of up to an aggregate
of 585,275 Placement Warrants. Even though the current trading price is at or significantly below DKAC&#8217;s initial public offering
price, the private investors have an incentive to sell because they will still profit on sales because of the lower price that they purchased
their shares than the public investors.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 25, 2022, the Company, Data Knights Merger Sub, Inc., a Delaware corporation (&#8220;Merger Sub&#8221;), and Data Knights, LLC,
the Company&#8217;s sponsor (the &#8220;Sponsor&#8221;), entered into a definitive Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;)
with OneMedNet Corporation, Inc., a Delaware corporation (the &#8220;Target,&#8221; which has since been renamed &#8220;OneMedNet Solutions
Corporation&#8221;), and together with the Company and Merger Sub, the &#8220;Parties&#8221;) and Paul Casey, as seller representative
(&#8220;Casey&#8221;). Pursuant to the Merger Agreement, upon the closing (the &#8220;Closing&#8221;) of the transactions contemplated
in the Merger Agreement (collectively, the &#8220;Business Combination&#8221;), the Parties would consummate the merger of Merger Sub
with and into the Target, with the Target continuing as the surviving entity (the &#8220;Merger&#8221;), which would result in all of
the issued and outstanding capital stock of the Target being exchanged for shares of the Company&#8217;s Common Stock upon the terms
set forth in the Merger Agreement. The Merger and Merger Agreement and the related transactions were approved unanimously by the boards
of directors of each of the Company and the Target.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
described herein, the Selling Securityholders named in this prospectus or their permitted transferees, may resell from time to time up
to 19,683,367 shares of our Common Stock and 681,019 Warrants. We are registering the offer and sale of these securities to satisfy certain
registration rights we have granted. The Selling Securityholders may offer, sell or distribute all or a portion of the securities hereby
registered publicly or through private transactions at prevailing market prices or at negotiated prices. We will not receive any of the
proceeds from such sales of our shares of our Common Stock or Warrants, except with respect to amounts received by us upon the exercise
of the Warrants. We will bear all costs, expenses and fees in connection with the registration of these securities, including with regard
to compliance with state securities or &#8220;blue sky&#8221; laws. The Selling Securityholders will bear all commissions and discounts,
if any, attributable to their sale of shares of our Common Stock or Warrants. See section entitled &#8220;<i>Plan of Distribution</i>&#8221;
beginning on page 61 of this prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Common Stock and warrants are listed on The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) under the symbols, &#8220;ONMD&#8221; and
&#8220;ONMDW.&#8221; As of April 15, 2024, we had approximately 23,850,010 shares of <span style="background-color: white">Common Stock
</span>and 12,181,019 warrants outstanding. On April 15, 2024, the last reported closing price of our <span style="background-color: white">of
Common Stock </span>and warrants as reported on Nasdaq was $0.68 per share and $0.180 per warrant. While the Sponsor, private placement
investors, PIPE investors and other Selling Securityholders may experience a positive rate of return based on the current trading price
of the Company&#8217;s Common Stock, the public securityholders may not experience a similar rate of return on the securities they purchased
due to differences in the purchase prices and the current trading price. Even though the current trading price is at or significantly below DKAC&#8217;s
initial public offering price, the private investors have an incentive to sell because they will still profit on sales because of the
lower price that they purchased their shares than the public investors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>We
are an &#8220;emerging growth company&#8221; as that term is used in the Jumpstart Our Business Startups Act of 2012 and, as such, have
elected to comply with certain reduced public company reporting requirements. We may amend or supplement this prospectus from time
to time by filing amendments or supplements as required. You should read this entire prospectus and any amendments or supplements carefully
before you make your investment decision.</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Investing
in our securities involves a high degree of risk. See &#8220;Risk Factors&#8221; beginning on page 32 of this prospectus for a discussion
of information that should be considered in connection with an investment in our securities.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neither
the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined
if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prospectus
dated ______, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TABLE
OF CONTENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"/>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 0.5in; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_001">ABOUT THIS PROSPECTUS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">1</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_002">MARKET AND INDUSTRY DATA</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">1</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_003">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">2</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_004">TRADEMARKS AND COPYRIGHTS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">3</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_005">IMPLICATIONS OF BEING AN EMERGING GROWTH COMPANY AND A SMALLER REPORTING COMPANY</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">3</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_006">PROSPECTUS SUMMARY</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">4</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_007">THE OFFERING</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">31</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_008">RISK FACTORS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">32</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_009">USE OF PROCEEDS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">46</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_010">DILUTION</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">46</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_011">DESCRIPTION OF SECURITIES WE ARE OFFERING</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">47</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_012">SHARES ELIGIBLE FOR FUTURE SALE</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">49</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_014">LEGAL MATTERS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">62</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_015">EXPERTS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">62</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#mkj_001">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">62</td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_016">LEGAL PROCEEDINGS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 0.5in">69</td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_019">WHERE YOU CAN FIND MORE INFORMATION</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">70</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_020">INCORPORATION OF DOCUMENTS BY REFERENCE</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">70</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 25%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should rely only on the information contained in this prospectus or any supplement. Neither we nor the Selling Securityholders have authorized
anyone else to provide you with different information. The securities offered by this prospectus are being offered only in jurisdictions
where the offer is permitted. You should not assume that the information in this prospectus or any supplement is accurate as of any date
other than the date on the front of each document. Our business, financial condition, results of operations and prospects may have changed
since that date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 27pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as otherwise set forth in this prospectus, neither we nor the Selling Securityholders have taken any action to permit a public offering
of these securities outside the United States or to permit the possession or distribution of this prospectus outside the United States.
Persons outside the United States who come into possession of this prospectus must inform themselves about and observe any restrictions
relating to the offering of these securities and the distribution of this prospectus outside the United States.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"></p>


<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_001"></span>ABOUT
THIS PROSPECTUS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus is part of a registration statement that we filed with the SEC using a &#8220;shelf&#8221; registration process. By using
a shelf registration statement, the Selling Securityholders may sell up to 19,683,367 shares of Common Stock and up to 681,019 Warrants
from time to time in one or more offerings as described in this prospectus. We will not receive any proceeds from the sale of Common
Stock or Warrants by the Selling Securityholders. This prospectus also relates to the issuance by up to 12,085,275 Common Stock upon
the exercise of Warrants. We will receive the proceeds from any exercise of the Warrants for cash.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may also file a prospectus supplement or post-effective amendment to the registration statement of which this prospectus forms a part
that may contain material information relating to these offerings. The prospectus supplement or post-effective amendment, as the case
may be, may add, update or change information contained in this prospectus with respect to such offering. If there is any inconsistency
between the information in this prospectus and the applicable prospectus supplement or post-effective amendment, you should rely on the
prospectus supplement or post-effective amendment, as applicable. Before purchasing any of the Common Stock or Warrants, you should carefully
read this prospectus and any prospectus supplement and/or post-effective amendment, as applicable, together with the additional information
described under &#8220;<i>Where You Can Find More Information</i>.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
we nor the Selling Securityholders have authorized anyone to provide you with any information or to make any representations other than
those contained in this prospectus and any prospectus supplement and/or post-effective amendment, as applicable, prepared by or on behalf
of us or to which we have referred you. We and the Selling Securityholders take no responsibility for, and can provide no assurance as
to the reliability of, any other information that others may give you. We and the Selling Securityholders will not make an offer to sell
the Common Stock or Warrants in any jurisdiction where the offer or sale is not permitted. You should assume that the information appearing
in this prospectus and any prospectus supplement and/or post-effective amendment, as applicable, is accurate only as of the date on the
respective cover. Our business, prospects, financial condition or results of operations may have changed since those dates. This prospectus
contains, and any prospectus supplement or post-effective amendment may contain, market data and industry statistics and forecasts that
are based on independent industry publications and other publicly available information. Although we believe these sources are reliable,
we do not guarantee the accuracy or completeness of this information and we have not independently verified this information. In addition,
the market and industry data and forecasts that may be included in this prospectus and any prospectus supplement and/or post-effective
amendment, as applicable, may involve estimates, assumptions and other risks and uncertainties and are subject to change based on various
factors, including those discussed under &#8220;<i>Risk Factors</i>&#8221; in this prospectus and any prospectus supplement and/or post-effective
amendment, as applicable. Accordingly, investors should not place undue reliance on this information.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_002"></span>MARKET
AND INDUSTRY DATA</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise indicated, information contained in this prospectus concerning our industry and the regions in which we operate, including
our general expectations and market position, market opportunity, market share and other management estimates, is based on information
obtained from various independent publicly available sources and other industry publications, surveys and forecasts. While we believe
that the market data, industry forecasts and similar information included in this prospectus are generally reliable, such information
is inherently imprecise. In addition, assumptions and estimates of our future performance and growth objectives and the future performance
of our industry and the markets in which we operate are necessarily subject to a high degree of uncertainty and risk due to a variety
of factors, including those discussed under the headings &#8220;Risk Factors,&#8221; &#8220;Cautionary Note Regarding Forward-Looking
Statements&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in this
prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
contained in this prospectus concerning our industry, market and competitive position data in this prospectus from our own internal estimates
and research as well as from publicly available information, industry and general publications and research, surveys and studies conducted
by third parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Industry
publications and forecasts generally state that the information they contain has been obtained from sources believed to be reliable,
but such information is inherently imprecise. Forecasts and other forward-looking information obtained from these sources are subject
to the same qualifications and uncertainties as the other forward-looking statements in this prospectus. These forecasts and forward-looking
information are subject to uncertainty and risk due to a variety of factors, including those described under &#8220;Risk Factors.&#8221;
These and other factors could cause results to differ materially from those expressed in any forecasts or estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_003"></span>CAUTIONARY
NOTE REGARDING FORWARD-LOOKING STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus contains forward-looking statements that involve risks and uncertainties. You should not place undue reliance on these forward-looking
statements. All statements other than statements of historical facts contained in this prospectus are forward-looking statements. The
forward-looking statements in this prospectus are only predictions. We have based these forward-looking statements largely on our current
expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and
results of operations. In some cases, you can identify these forward-looking statements by terms such as &#8220;anticipate,&#8221; &#8220;believe,&#8221;
&#8220;continue,&#8221; &#8220;could,&#8221; &#8220;depends,&#8221; &#8220;estimate,&#8221; &#8220;expects,&#8221; &#8220;intend,&#8221;
&#8220;may,&#8221; &#8220;ongoing,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221;
&#8220;should,&#8221; &#8220;will,&#8221; &#8220;would&#8221; or the negative of those terms or other similar expressions, although not
all forward-looking statements contain those words. We have based these forward-looking statements on our current expectations and projections
about future events and trends that we believe may affect our financial condition, results of operations, strategy, short- and long-term
business operations and objectives, and financial needs. These forward-looking statements include, but are not limited to, statements
concerning the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    projected financial position and estimated cash burn rate; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    estimates regarding expenses, future revenues and capital requirements; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to continue as a going concern; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    need to raise substantial additional capital to fund our operations; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to compete in the global space industry; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to obtain and maintain intellectual property protection for our current products and services; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to protect our intellectual property rights and the potential for us to incur substantial costs from lawsuits to enforce
    or protect our intellectual property rights; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    possibility that a third party may claim we have infringed, misappropriated or otherwise violated their intellectual property rights
    and that we may incur substantial costs and be required to devote substantial time defending against these claims; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    reliance on third-party suppliers and manufacturers; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    success of competing products or services that are or become available; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to expand our organization to accommodate potential growth and our ability to retain and attract key personnel; and </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    potential for us to incur substantial costs resulting from lawsuits against us and the potential for these lawsuits to cause us to
    limit our commercialization of our products and services. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described in &#8220;Risk
Factors.&#8221; Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is
not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which
any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements
we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this prospectus
may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected
in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events
and circumstances reflected in the forward-looking statements will be achieved or occur. Moreover, except as required by law, neither
we nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements. We undertake no obligation
to update publicly any forward-looking statements for any reason after the date of this prospectus to conform these statements to actual
results or to changes in our expectations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should read this prospectus and the documents that we reference in this prospectus and have filed with the SEC as exhibits to the registration
statement of which this prospectus is a part with the understanding that our actual future results, levels of activity, performance and
events and circumstances may be materially different from what we expect. As a result of a number of known and unknown risks and uncertainties,
our actual results or performance may be materially different from those expressed or implied by these forward-looking statements including
those described in the &#8220;Risk Factors&#8221; section beginning on page 32 and elsewhere in this prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_004"></span>TRADEMARKS
AND COPYRIGHTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
own or have rights to trademarks or trade names that we use in connection with the operation of our business, including our corporate
names, logos and website names. In addition, we own or have the rights to copyrights, trade secrets and other proprietary rights that
protect the content of our products and the formulations for such products. This prospectus may also contain trademarks, service marks
and trade names of other companies, which are the property of their respective owners. Our use or display of third parties&#8217; trademarks,
service marks, trade names or products in this prospectus is not intended to, and should not be read to, imply a relationship with or
endorsement or sponsorship of us. Solely for convenience, some of the copyrights, trade names and trademarks referred to in this prospectus
are listed without their &#169;, &#174; and &#8482; symbols, but we will assert, to the fullest extent under applicable law, our rights
to our copyrights, trade names and trademarks. All other trademarks are the property of their respective owners.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_005"></span>IMPLICATIONS
OF BEING AN EMERGING GROWTH COMPANY AND</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A
SMALLER REPORTING COMPANY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
qualify as an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;).
For so long as we remain an emerging growth company, we are permitted, and currently intend, to rely on the following provisions of the
JOBS Act that contain exceptions from disclosure and other requirements that otherwise are applicable to public companies and file periodic
reports with the SEC. These provisions include, but are not limited to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48pt; text-align: justify; text-indent: -24pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">being
    permitted to present only two years of audited financial statements and selected financial data and only two years of related &#8220;<i>Management&#8217;s
    Discussion and Analysis of Financial Condition and Results of Operations</i>&#8221; in our periodic reports and registration statements,
    including this prospectus, subject to certain exceptions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">not
    being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, as amended (&#8220;SOX&#8221;);</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduced
    disclosure obligations regarding executive compensation in our periodic reports, proxy statements, and registration statements, including
    in this prospectus;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">not
    being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board (the &#8220;PCAOB&#8221;)
    regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the
    audit and the financial statements; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">exemptions
    from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute
    payments not previously approved.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will remain an emerging growth company until the earliest to occur of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31, 2028 (the last day of the fiscal year that follows the fifth anniversary of the completion of our initial public offering);</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>



<p style="margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    last day of the fiscal year in which we have total annual gross revenue of at least $1.235 billion;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    date on which we are deemed to be a &#8220;large-accelerated filer,&#8221; as defined in the U.S. Securities Exchange Act of 1934,
    as amended (the &#8220;Exchange Act&#8221;); and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    date on which we have issued more than $1 billion in non-convertible debt over a three-year period.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have elected to take advantage of certain of the reduced disclosure obligations in this prospectus and may elect to take advantage of
other reduced reporting requirements in our future filings with the SEC. As a result, the information that we provide to holders of our
Common Stock may be different than what you might receive from other public reporting companies in which you hold equity interests. We
have elected to avail ourselves of the provision of the JOBS Act that permits emerging growth companies to take advantage of an extended
transition period to comply with new or revised accounting standards applicable to public companies. As a result, we will not be subject
to new or revised accounting standards at the same time as other public companies that are not emerging growth companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are also a &#8220;smaller reporting company&#8221; as defined in the Exchange Act. We may continue to be a smaller reporting company
even after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller
reporting companies until the fiscal year following the determination that our voting and non-voting common stock held by non-affiliates
is $250 million or more measured on the last business day of our second fiscal quarter, or our annual revenues are less than $100 million
during the most recently completed fiscal year and our voting and non-voting common stock held by non-affiliates is $700 million or more
measured on the last business day of our second fiscal quarter.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_006"></span>PROSPECTUS
SUMMARY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>This
summary of the prospectus highlights material information concerning our business and this offering. This summary does not contain all
of the information that you should consider before making your investment decision. You should carefully read the entire prospectus,
including the information presented under the section entitled &#8220;Risk Factors&#8221; and the financial data and related notes, before
making an investment decision. It does not contain all the information that may be important to you and your investment decision. You
should carefully read this entire prospectus, including the matters set forth under &#8220;Risk Factors,&#8221; &#8220;Management&#8217;s
Discussion and Analysis of Financial Condition and Results of Operations,&#8221; and our financial statements and related notes included
elsewhere in this prospectus. This summary contains forward-looking statements that involve risks and uncertainties. Our actual results
may differ significantly from future results contemplated in the forward-looking statements as a result of factors such as those set
forth in &#8220;Risk Factors&#8221; and &#8220;Cautionary Statement Regarding Forward-Looking Statements.&#8221;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>In
this prospectus, unless the context indicates otherwise, &#8220;OneMedNet,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221;
&#8220;ours&#8221; or &#8220;us&#8221; refer to OneMedNet Corporation a Delaware corporation, and its direct and indirect subsidiaries,
including, but not limited to, OneMedNet Solutions Corporation, a Delaware corporation and its wholly-owned subsidiary, OneMedNet Technologies
(Canada) Inc., incorporated on October 16, 2015 under the provisions of the Business Corporations Act of British Columbia whose functional
currency is the Canadian dollar.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not authorized anyone to provide you with different information and you must not rely on any unauthorized information or representation.
We are not making an offer to sell these securities in any jurisdiction where an offer or sale is not permitted. This document may only
be used where it is legal to sell these securities. You should assume that the information appearing in this prospectus is accurate only
as of the date on the front of this prospectus, regardless of the time of delivery of this prospectus, or any sale of our Common Stock.
Our business, financial condition and results of operations may have changed since the date on the front of this prospectus. We urge
you to carefully read this prospectus before deciding whether to invest in any of the Common Stock being offered.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
Company</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">OneMedNet
Corporation a Delaware corporation (the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;OneMedNet&#8221;) together
with its wholly-owned subsidiary OneMedNet Solutions Corporation, a Delaware corporation, founded in 2009 and incorporated in November
20, 2015, and its wholly-owned subsidiary, OneMedNet Technologies (Canada) Inc., incorporated on October 16, 2015 under the provisions
of the Business Corporations Act of British Columbia whose functional currency is the Canadian dollar. All refences in this prospectus
to the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;OneMedNet&#8221; include OneMedNet Solutions Corporation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Corporate
History</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
were originally incorporated in Delaware on February 8, 2021 under the name &#8220;Data Knights Acquisition Corp&#8221; as a special
purpose acquisition company, formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase,
reorganization or similar business combination with one or more businesses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 11, 2021, we consummated an initial public offering (the &#8220;Initial Public Offering&#8221;). The registration statement for the
Company&#8217;s Initial Public Offering was declared effective on May 6, 2021. The Company&#8217;s Initial Public Offering of 10,000,000
units (the &#8220;Units&#8221; and, with respect to the Common Stock included in the Units being offered, the &#8220;Public Shares&#8221;),
at $10.00 per Unit, generated gross proceeds of $100,000,000. The Company granted the underwriter a 45-day option to purchase up to an
additional 1,500,000 Units at the Initial Public Offering price to cover over-allotments, which the underwriters exercised the over-allotment
option in full, and the closing of the issuance and sale of the additional Units occurred (the &#8220;Over-allotment Option Units&#8221;).
The total aggregate issuance by the Company of 1,500,000 units at a price of $10.00 per unit resulted in total gross proceeds of $15,000,000.
Simultaneously with the consummation of the closing of the Offering, the Company consummated the private placement of an aggregate of
585,275 units (the &#8220;Placement Units&#8221;) to the Sponsor at a price of $10.00 per Placement Unit, generating total gross proceeds
of $5,852,750 (the &#8220;Private Placement&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Placement Units were issued pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended, as the transactions did not involve
a public offering. A total of $117,300,000, comprised of the proceeds from the Offering and the proceeds of private placements that closed
on May 11, 2021, net of the underwriting commissions, discounts, and offering expenses, was deposited in a trust account established
for the benefit of the Company&#8217;s public stockholders. On June 22, 2021, the Common Stock and Public Warrant included in the Units
began separate trading.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
payments for our expenses were made in the offering described above directly or indirectly to (i) any of our directors, officers or their
associates, (ii) any person(s) owning 10% or more of any class of our equity securities or (iii) any of our affiliates, except in connection
with the repayment of outstanding loans and pursuant to the administrative support agreement disclosed herein which we entered into with
our sponsor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 25, 2022, the Company, Data Knights Merger Sub, Inc., a Delaware corporation (&#8220;Merger Sub&#8221;), and Data Knights, LLC,
the Company&#8217;s sponsor (the &#8220;Sponsor&#8221;), entered into a definitive Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;)
with OneMedNet Corporation, Inc., a Delaware corporation (the &#8220;Target,&#8221; which has since been renamed &#8220;OneMedNet Solutions
Corporation&#8221;), and together with the Company and Merger Sub, the &#8220;Parties&#8221;) and Paul Casey, as seller representative
(&#8220;Casey&#8221;). Pursuant to the Merger Agreement, upon the closing (the &#8220;Closing&#8221;) of the transactions contemplated
in the Merger Agreement (collectively, the &#8220;Business Combination&#8221;), the Parties would consummate the merger of Merger Sub
with and into the Target, with the Target continuing as the surviving entity (the &#8220;Merger&#8221;), which would result in all of
the issued and outstanding capital stock of the Target being exchanged for shares of the Company&#8217;s Common Stock upon the terms
set forth in the Merger Agreement. The Merger and Merger Agreement and the related transactions were approved unanimously by the boards
of directors of each of the Company and the Target.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 31, 2022, substantially all of the assets held in the Trust Account were held in mutual funds.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 28, 2023, the Company executed a Securities Purchase Agreement for PIPE financing in the aggregate original principal amount of
$1,595,744.70 and a purchase price of $1.5 million (the &#8220;Pre-Closing PIPE&#8221;). Pursuant to the Securities Purchase Agreement,
the Company agreed to issue and sell to each of Thomas Kosasa, Dr. Jeffrey Yu, Aaron Green and Steve Kester (the &#8220;PIPE Investors&#8221;),
a new series of senior secured convertible notes (the &#8220;Pre-Closing PIPE Notes&#8221;), which Notes shall be convertible
into shares of Common Stock at the PIPE Investors election at the conversion price (rounded to the nearest 1/100th of one cent) which
shall be computed as the lesser of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
with respect to a conversion pursuant to Section 4.1 of the Securities Purchase Agreement (discussed below), the lesser of: (i) a price
per share equal to the product of (x) 100% less the Discount and (y) the lowest per share purchase price of the Equity Securities issued
in the Next Equity Financing; and (ii) $2.50 per share; and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
with respect to a conversion pursuant to Section 4.2 (discussed below), (relating to payment at maturity) or Section 4.3, $2.50 per share.
The Securities Purchase agreement provided that the PIPE Investors&#8217; $1.5 million investment in the Pre-Closing PIPE Notes
would close and fund contemporaneous to the Closing of the Business Combination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
4.1 of the Securities Purchase Agreement provides that the principal balance and unpaid accrued interest on each Note will automatically
convert into the PIPE Conversion Shares upon the closing of the Next Equity Financing (&#8220;Next Equity Financing&#8221; means the
next sale or series of related sales by the Company of its Common Stock in one or more offerings relying on Section 4(a)(2) of the Securities
Act or Regulation D thereunder for exemption from the registration requirements of Section 5 of the Securities Act, from which the Company
receives gross proceeds of not less than US$5,000,000 (excluding, for the avoidance of doubt, the aggregate principal amount of the Notes).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
4.2 of the Securities Purchase Agreement provides that in the event of a Corporate Transaction or the repayment of such Note, at the
closing of a corporate transaction, the holder of each Note may elect that either: (a) the Company will pay the holder of such Note an
amount equal to the sum of (x) the outstanding principal balance of such Note, and (y) a premium equal to 20% of the outstanding principal
balance of such Note (which premium, is in lieu of all accrued and unpaid interest due on such Note); or (b) such Note will convert into
that number of Conversion Shares equal to the quotient (rounded down to the nearest whole share) obtained by dividing (x) the outstanding
principal balance and unpaid accrued interest of such Note on a date that is no more than five days prior to the closing of such corporate
transaction by (y) the applicable Conversion Price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
the foregoing, any sale (or series of related sales) of the Company&#8217;s Equity Securities to a special purpose acquisition company
will not be deemed a &#8220;Next Equity Financing. Notwithstanding the foregoing, the Company may, at its option, pay any unpaid accrued
interest on each Note in cash at the time of conversion. The number of PIPE Conversion Shares the Company issues upon such conversion
will equal the quotient (rounded down to the nearest whole share) obtained by dividing (x) the outstanding principal balance and unpaid
accrued interest under each converting Note on a date that is no more than five days prior to the closing of the Next Equity Financing
by (y) the applicable Conversion Price. At least five days prior to the closing of the Next Equity Financing, the Company will notify
the holder of each Note in writing of the terms of the Equity Securities that are expected to be issued in such financing. The issuance
of PIPE Conversion Shares pursuant to the conversion of each Note will be on, and subject to, the same terms and conditions applicable
to the Equity Securities issued in the Next Equity Financing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Also
on June 28, 2023, EF Hutton LLC (&#8220;<span style="text-decoration: underline">EF Hutton</span>&#8221;) waived $3,025,000 of the $4,025,000
cash deferred underwriting commission do to it at the Closing of the Business Combination, pursuant to a Satisfaction and Discharge Agreement.
In accordance with the Satisfaction and Discharge Agreement, EF Hutton accepted, in lieu of the cash deferred underwriting commission
due at closing (i) a one-time cash payment of $500,000 at the time of the Closing; (ii) a $500,000 promissory note executed by the Company
on June 30, 2023 in which it is obligated to make six monthly payments to EF Hutton in the cash amount of $83,333.33 commencing after
the Closing; and (iii) 277,778 shares of common stock of the Company (the &#8220;Common Stock&#8221;) at $10.89 per share, for an aggregate
value of $3,025,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 21, 2023, the Securities and Exchange Commission (the &#8220;SEC&#8221;) declared effective the Company&#8217;s registration
statement and proxy statement/prospectus on Form S-4 (the &#8220;Definitive Proxy&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the close of business on September 20, 2023 (the &#8220;Record Date&#8221;), 5,172,973 shares of common stock of the Company (the
&#8220;Common Stock&#8221;) were issued and outstanding and entitled to vote at the Special Meeting. On October 17, 2023, the Company
held a special meeting of its stockholders (the &#8220;Stockholders&#8221;) in lieu of its 2023 annual meeting of Stockholders (the &#8220;Special
Meeting&#8221;) in connection with the transactions contemplated by the Merger Agreement. At the Special Meeting, the Stockholders were
asked to consider and vote on the proposals identified in the Definitive Proxy; 4,690,565 shares of Common Stock were represented in
person or by proxy at the Special Meeting, and, therefore, a quorum was present and all proposal were approved.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 7, 2023, we held the Closing of the previously announced Merger whereby Merger Sub merged with and into OneMedNet Solutions
Corporation (formerly named OneMedNet Corporation), with OneMedNet Solutions Corporation continuing as the surviving entity, which resulted
in all of the issued and outstanding capital stock of OneMedNet Solutions Corporation being exchanged for shares of the Company&#8217;s
Common Stock upon the terms set forth in the Merger Agreement. The Merger and other transactions that closed on November 7, 2023, pursuant
to the Merger Agreement, led to Data Knights changing its name to &#8220;OneMedNet Corporation&#8221; and the business of the Company
became the business of OneMedNet Solutions Corporation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the terms of the Merger Agreement, the total consideration for the Business Combination and related transactions (the &#8220;Merger
Consideration&#8221;) was approximately $200 million. In connection with the Special Meeting, certain public holders (the &#8220;Redeeming
Stockholders&#8221;) holding 1,600,741 shares of Common Stock exercised their right to redeem such shares for a pro rata portion of the
funds held by Continental Stock Transfer &amp; Trust Company, as trustee (&#8220;Continental&#8221;) in the trust account established
in connection with Data Knights&#8217; initial public offering (the &#8220;Trust Account&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
November 7, 2023, Data Knights&#8217; units ceased trading, and effective November 8, 2023, OneMedNet&#8217;s common stock began trading
on the Nasdaq Capital Market under the symbol &#8220;ONMD&#8221; and the warrants began trading on the Nasdaq Capital Market under the
symbol &#8220;ONMDW.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the Merger and the Business Combination, holders of Data Knights common stock automatically received common stock of OneMedNet,
and holders of Data Knights warrants automatically received warrants of OneMedNet with substantively identical terms. At the Closing
of the Business Combination, all shares of Data Knights owned by the Sponsor (consisting of shares of Common Stock and shares of Class
B common stock, which we refer to as the founder shares), automatically converted into an equal number of shares of OneMedNet&#8217;s
Common Stock, and the Private Placement Warrants held by the Sponsor, automatically converted into warrants to purchase one share of
OneMedNet Common Stock with substantively identical terms.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
as of the Closing on November 7, 2023, among other holders, public stockholders own 98,178 shares of OneMedNet Common Stock approximately
representing 0.35% of the outstanding shares of OneMedNet Common Stock; the Sponsor and its affiliates own approximately 15.1% of the
outstanding shares of OneMedNet common stock (inclusive of shares received upon conversion of the Sponsor&#8217;s loan); OneMedNet&#8217;s
former security holders own approximately 61.992% of the outstanding shares of OneMedNet common stock from the conversion of their shares;
PIPE investors own 0.46% of the outstanding shares of OneMedNet Common Stock and former convertible note holders own approximately 16.24%
of the outstanding shares of OneMedNet Common Stock resulting from the issuance of 5,238,800 shares of Common Stock upon conversion of
their notes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 28, 2024, the Company&#160;<span style="background-color: white">entered into a definitive securities purchase agreement (the &#8220;Notes
Securities Purchase Agreement&#8221;) with Helena Global Investment Opportunities 1 Ltd. (the &#8220;Notes Investor&#8221;), an affiliate
of Helena Partners Inc., a Cayman-Islands based advisor and investor providing for up to USD$</span>4.54 million&#160;<span style="background-color: white">in
funding through a private placement (the &#8220;PIPE Notes Financing&#8221;) for the issuance of senior secured convertible notes (the
&#8220;PIPE Notes&#8221;).</span> In connection with the issuance of the Notes, the Company will issue to the Investor common stock purchase
warrants (the &#8220;Warrants&#8221;) across multiple tranches (the &#8220;Tranches&#8221;) consisting of an initial tranche (the &#8220;Initial
Tranche&#8221;) of (i) an aggregate principal amount $2,000,000.00 and including an original issue discount (&#8220;OID&#8221;) of up
to an aggregate of $300,000.00 plus Warrants to purchase a number of shares of Common Stock equal to the applicable Warrant Share Amounts
(defined below). The second tranche (the &#8220;Second Tranche&#8221;) consists of an aggregate principal amount of Notes of up to $350,000.00
and including an OID of up to $52,500.00 and Warrants to purchase a number of shares of Common Stock equal to the applicable Warrant
Share Amounts with respect to such Tranche. The Notes Securities Purchase Agreement contemplates three subsequent Tranches each of which
shall be in an aggregate principal amount of Notes of up to $1,000,000 each and each including an OID of 15.0% of the applicable principal
amount, and Warrants to purchase a number of shares of Common Stock equal to the applicable Warrant Share Amounts with respect to such
Tranches.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
purchase price of a PIPE Note and its accompanying Warrant shall be computed by subtracting the portion of the OID represented by that
such PIPE Note from the portion of the principal amount represented by such Note (a &#8220;Purchase Price&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Notes Securities Purchase Agreement defines Warrant Share Amounts means in respect of any Warrant issued in a Closing the initial amount
of shares of Common Stock (the &#8220;Warrant Shares&#8221;) for which such Warrant may be exercised and which shall be equal to the
applicable principal amount of the Note issued to the Investor in such closing multiplied by 50% and divided by the 95% of lowest VWAP
over the ten Trading Day period immediately preceding the applicable Closing Date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the closings of each Tranche, a portion of the proceeds will be held in escrow (the &#8220;Escrow&#8221;) pursuant to
an executed Escrow Agreement dated as of March 28, 2024 in accordance with the following: (i) $1,350,000.00 of the net proceeds of the
Initial Tranche will be paid into the Escrow Account for distribution in accordance with the release of proceeds conditions (the &#8220;Release
Conditions&#8221; discussed below), with the balance of the net proceeds paid to the Company less initial closing expenses relating to
such Initial Tranche; (ii) 100% of the net proceeds of the Third Tranche shall be paid into the Escrow Account for distribution in accordance
with the Release Conditions; and (iii) 75% of the net proceeds of the Third Tranche shall be paid into the Escrow Account for distribution
in accordance with the Release Conditions with the balance of the net proceeds of the Third Tranche being paid to the Company less initial
closing expenses relating to such Third Tranche.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Securities Purchase Agreement provides that the amounts in Escrow (the &#8220;Escrowed Proceeds&#8221;) related to the Initial Tranche,
Second Tranche and Third Tranche are governed by the following terms:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Escrowed Proceeds will be released to the Investor for payment amounts owing in respect of the Notes, if the closing price of the
    Common Stock shall have been less than the then Floor Price (as defined in the Notes) for a period of 10-consecutive trading days,
    or an event of default shall have occurred;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Escrowed Proceeds will be released to the Company if the aggregate outstanding amount is equal to zero;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    on the date that is 20 trading days following the closing of the Initial Tranche, the aggregate outstanding amount is more than zero
    but less than $1,700,000.00, then the Escrowed Proceeds will be released to the Company in an amount equal to the difference between
    $1,700,000.00 and the aggregate outstanding amount; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    on the date that is 40 trading days following the Closing Date of the Initial Tranche and every 20 trading days thereafter, the aggregate
    outstanding amount is more than zero but less than $1,700,000.00 minus the amount of any prior disbursement from the Escrow Account
    pursuant to this provision (d) or provision (c) above (the &#8220;Adjusted Escrow Reference Amount&#8221;), then the Escrowed Proceeds
    will be released to the Company an amount equal to the difference between the Adjusted Escrow Reference Amount and such aggregate
    outstanding amount.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Notes Securities Purchase Agreement, the Company and the Investor also entered into a Registration Rights Agreement,
dated as of March 28, 2024 (the &#8220;RRA&#8221;), providing for the registration of the Note shares (the &#8220;Note Conversion Shares&#8221;)
and the Warrant Shares (the &#8220;Registerable Securities&#8221;). The Company has agreed to prepare and file a registration statement
(the &#8220;Registration Statement&#8221;) with the Securities and Exchange Commission (the &#8220;SEC&#8221;) promptly, and in any event
within 30 days of the closing of the private placement. The Company has granted the Investor customary indemnification rights in connection
with the Registration Rights Agreement. The Investors have also granted the Company customary indemnification rights in connection with
the Registration Statement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
securities to be issued pursuant to the Notes&#160;<span style="background-color: white">Securities Purchase Agreement</span>&#160;was
made in reliance on the exemption from registration provided by Section 3(a)(9) of the Securities Act of 1933, as amended (the &#8220;Securities
Act&#8221;), as promulgated by the Securities and Exchange Commission under the Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Who
We Are</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are OneMedNet, and our goal is to be a leader in the <b>future of regulatory-grade Imaging Real Word Data (&#8220;RWD</b>&#8221;) through
our intelligent, thoughtful and inclusive iRWD<sup>TM</sup> solution. We strive to revolutionize access fast and secure access to curated
medical images with our strategic thinking, successful market entry and execution to continue to open new possibilities for providing
clinical imaging evidence.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are <b>bold, decisive</b> and <b>eager to advance</b> a global platform for our OneMedNet <b>iRWD&#8482;</b> solution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
aim to <b>constantly push boundaries</b> in our approach to technology, service innovation, customer engagement and curation excellence,
all for the sake of delivering an exceptional customer experience.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
mission is <b>affect a material positive impact on the lives of tens of millions of people while improving our customers&#8217; business
productivity</b>. First and foremost, OneMedNet&#8217;s iRWD<sup>TM </sup>offering plays a significant role in enabling Life Science
companies to bring safer and more effective patient care to market sooner. Using our highly curated de-identified clinical data in our
iRWD<sup>TM </sup>offering in Life Science product development, validation, and regulatory approval processes, they contribute to patient
care advancements in more meaningful ways, which Life Sciences industry can improve their product development and validation processes,
which benefits all parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
OneMedNet, our <b>motto is to &#8220;Unlock the Value in Imaging Archives<sup>TM</sup>&#8221;.</b> By utilizing OneMedNet&#8217;s iRWD<sup>TM
</sup>offering, providers can greatly improve their research efforts with streamlined data access. Health care providers such as hospitals,
clinics, and imaging centers can also accelerate life science patient care innovations by sharing de-identified data in a well-defined
and de-identified and secure manner. In return for doing so, income is generated and applied to critical and possibly unfunded provider
projects. In that spirit, we are breaking boundaries by focusing on the future, constantly innovating from a technology and user experience
perspective and are ready to push forward. With that said, we recognize that we cannot do this alone, and we urge those who share this
desire to unite with us on our journey to a brighter and greener future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Come
join the charge with us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Business</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">OneMedNet
is a global provider of clinical imaging innovation and curator of regulatory-grade Imaging Real-World Data3 or iRWD<sup>TM</sup>. OneMedNet&#8217;s
innovative solutions connect healthcare providers and patients satisfying a crucial need within the Life Sciences field offering direct
access to clinical images and the associated contextual patient record. OneMedNet&#8217;s innovative technology proved the commercial
and regulatory viability of imaging Real-World Data, an emerging market, and provides regulatory-grade image-centric iRWD<sup>TM</sup>
that exactly matches OMN&#8217;s Life Science partners Case Selection Protocols and paves the way for Real World Evidence.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">OneMedNet
was founded to solve a deficiency in how clinical images were shared between healthcare providers. This resulted in OMN&#8217;s initial
product BEAM<sup>TM</sup> image exchange that enabled the successful sharing of images for more than a decade with OMN&#8217;s largest
customer being the Country of Ireland.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">OneMedNet
continued to innovate by responding to the demand for and utilization of Real-World Data and Real-World Evidence, specifically data that
focused on clinical images with its associated contextual clinical record. We were able to leverage internal technological competencies
along with OneMedNet&#8217;s formidable healthcare provider installed base from its first product with BEAM<sup>TM</sup> to become the
first RWD solution for Life Science companies with its launch of iRWD<sup>TM</sup> in 2019.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">OneMedNet
provides innovative solutions that unlock the significant value contained within clinical image archives. With a growing federated network
of 95+ healthcare facilities, OneMedNet has the immediate ability to quickly search and extensively curate multi-layer data from a Federated
group of healthcare facilities. The term &#8220;healthcare facilities&#8221; refers specifically to the hospitals, integrated delivery
networks (&#8220;IDNs&#8221;) and imaging centers that provide imaging to OneMedNet, which represent the core source of our data. At
present, OneMedNet works with more than 95 facilities who provide regulatory grade imaging to us. OneMedNet has access to these more
than 95 facilities because these 95+ contracted facilities have more than 200 locations among them including offices and clinics, which
in total generates regulatory grade imaging from more than 200 customers. Among these customers, all are data providers and some are
data purchasers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">OneMedNet
is ahead of the curve when it comes to providing fast and secure access to curated medical images. Initially, it was all about solving
the diverse access needs of patient care providers. This focus systematically evolved to addressing the rapidly growing needs of image
analysis and researchers, clinicians, regulators, scientists and more.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="forms-1_002.jpg" alt="" style="height: 60px; width: 624px"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Real-world
data is any data that is collected in the context of the routine delivery of care, in contrast to data collected within a clinical trial
where study design controls variability in ways that are not representative of real-world care and outcomes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
key component driving its mission is that OneMedNet believes we have a unique opportunity to affect a material positive impact on the
lives of tens of millions of people while improving our customers&#8217; business productivity. First and foremost, OneMedNet&#8217;s
iRWD<sup>TM</sup> offering plays a significant role in enabling Life Science companies to bring safer and more effective patient care
to market sooner. Using our highly curated de-identified clinical data in our iRWD<sup>TM</sup> offering in Life Science product development,
validation, and regulatory approval processes, they contribute to patient care advancements in more meaningful ways. Moreover, Life Sciences
improve their product development and validation processes, which benefits all parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
documentation exists that shows that Real-World Data can provide expanded insights across broader and more representative patient populations.<sup>1
</sup>For this reason, the Food and Drug Administration (&#8220;FDA&#8221;) has instituted Real-World Data guidelines for regulatory
approvals. Utilization of highly reliable and quality Real-World Data that strictly adheres to all of the very specific data stratification
requirements can supplement or supplant clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">OneMedNet
covers the complete value chain in imaging Real-World Data; it begins with our 10+ year federated network of providers and is supported
by a multi-faceted data curation process managed by an expert in-house clinical team. Additionally, we work hand-in-hand with our Life
Science partners regarding the Case Selection Protocol and when required producing Case Report Forms for regulatory clearance. We are
focused on delivering value by supporting Life Science Advancements with OneMedNet&#8217;s iRWD<sup>TM</sup> which holds the key to unlocking
boundless patient care advances. We unleash the power of research-grade image-centric iRWD<sup>TM</sup> that is highly curated to painstakingly
meet every cohort requirement and stand up to all of the rigors of prospective clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Today,
life science companies, including pharmaceutical companies, artificial intelligence (AI) developers, medical device businesses, and clinical
research organizations share the same widespread challenge in obtaining insight-rich, high-quality patient data that explicitly matches
their precise cohort specifications. A substantial portion of patient diagnosis involves clinical imaging and approximately 90% of healthcare
data, by size, is associated with imaging. Historically, much of imaging value has been derived from its initial review and further gains
from the image archives have been very limited.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Rule-Page --><div style="margin: 0pt; font-family: Times New Roman, Times, Serif; width: 30%"><div style="border-top: Black 1.5pt solid; font: 1pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><sup>1
</sup><i>See</i> https://www.fda.gov/media/120060/download</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
help providers to &#8220;Unlock the Value in Imaging Archives&#8221;.<sup>TM</sup> By utilizing OneMedNet&#8217;s iRWD<sup>TM</sup> offering,
providers can greatly improve their research efforts with streamlined data access. Health care providers such as hospitals, clinics,
and imaging centers can also accelerate life science patient care innovations by sharing de-identified data in a well-defined and de-identified
and secure manner. In return for doing so, income is generated and applied to critical and possibly unfunded provider projects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
OneMedNet Difference</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">OneMedNet
has been a leader in the business of extracting, securing, and transferring medical data for 12+ years. Doing so requires specialized
expertise in:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compliancy
    (HIPAA, GDPR, 21 Part11)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advanced
    privacy &amp; security measures</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
    patient condition(s) and hospital processes</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Radiology
    interpretation</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AI/ML
    technology</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attaining
in-house expertise in all essential elements is quite a challenge and deters many organizations from even attempting such a venture.
We take pride in this ambitious achievement &#8211; while continually working to maintain state-of-the-art expertise. OneMedNet strictly
adheres to the highest level of professional and ethical standards and applicable regulations throughout all interactions and activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
believe there is a reason OneMedNet is the leader in an uncrowded field of regulatory-grade imaging RWD curators. Doing so requires specialized
expertise in AI/ML technology, data privacy/security, as well as expertise in clinical patient condition(s) and healthcare record keeping.
Having, or achieving, expertise in all essential disciplines is a challenging achievement. OneMedNet had a significant head start with
our clinical image exchange solution which served to launch the company nearly a decade ago. All data remains &#8220;native&#8221; within
the federated OneMedNet iRWD<sup>TM</sup> provider network &#8211; meaning all the data remains locally onsite until specific de-identified
data is licensed for a particular Life Science research opportunity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="forms-1_003.jpg" alt="A close-up of a text&#10;&#10;Description automatically generated" style="height: 141px; width: 623px"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OneMedNet&#8217;s
Competitive Advantages</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that OneMedNet iRWD<sup>TM</sup> offers the best of advanced technology, clinical expert curation, and service. Medical imaging
and associated clinical data is indexed at each network site using state-of-the-art AI/ML technology. This typically includes electronic
health records (&#8220;EHR&#8221;), radiology, cardiology, lab, path and more. Our in-house clinical team performs intensive curation
of the data ensuring that results meet the exact specification and requirements of Life Science Data Collection Protocol (&#8220;DCP&#8221;)
&#8211; regardless of the complexity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that OneMedNet unlocks the value in imaging and electronic health records data in the following three principal ways:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulatory
    Grade &#8212; Our imaging results serve as proof of effectiveness for regulatory agencies, meeting requirements for quality &amp;
    diversity; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    Demand &#8212; Our powerful indexing platform access and harmonizes complete patient profiles across fragmented data silos, delivering
    images and records on-demand;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expertly
    Curated &#8212; We curate to the most stringent multi-level stratified requirements, providing unmatched data accuracy and completeness.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="forms-1_004.jpg" alt="A diagram of a data security system&#10;&#10;Description automatically generated" style="height: 258px; width: 671px"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">OneMedNet&#8217;s
data is fully de-identified using a multi-step quality control process and goes beyond PHI to include PII (personally identifiable information),
SII (Site Identifiable Information), and more. Importantly, Life Science users receive the data in the exact format that they require.
No data sifting or manipulation is needed. The data is simply ready for use. Moreover, OneMedNet has the unique combination of knowledge,
tools, and experience to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Access
    and harmonize complete patient profiles across fragmented data silos;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provide
    unmatched data accuracy and completeness;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ensure
    the security and privacy of patients&#8217; Protected Health Information (PHI)Imaging RWD is our singular passion and focus and no
    one does it better.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Finally,
OneMedNet has the most experienced and clinically trained data curators in the industry. This team appreciates the complexity and criticality
of clinical data and can effectively communicate with both Provider and Life Science specialists.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">&#160;</span></p>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="forms-1_005.jpg" alt="A diagram of a company's company&#10;&#10;Description automatically generated" style="height: 215px; width: 671px"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">OneMedNet
has been a leader in the business of extracting, securing, and transferring medical data for 12+ years. Doing so requires specialized
expertise in:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compliancy
    (HIPAA, GDPR, 21 Part11)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advanced
    privacy &amp; security measures</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
    patient condition(s) and hospital processes</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Radiology
    interpretation</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AI/ML
    technology</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attaining
in-house expertise in all essential elements is quite a challenge and deters many organizations from even attempting such a venture.
We take pride in this ambitious achievement &#8211; while continually working to maintain state-of-the-art expertise. OneMedNet strictly
adheres to the highest level of professional and ethical standards and applicable regulations throughout all interactions and activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Industry
Background</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
2016 analysis published in the Journal of Health Economics and authored by the Tufts Center for the Study of Drug Development placed
the cost of bringing a drug to market, including post-approval research and development, at a staggering $2.87 billion.<sup>2</sup> Meanwhile,
a 2018 study from the Tufts Center noted that the timeline for new drug development ranged from 12.8 years for the average drug to 17.2
years for ultra-orphan drugs that only affect several hundred patients.<sup>3</sup> This places the onus on life science organizations
to find ways to deliver treatments to patients faster&#8201;&#8212;&#8201;especially those who cannot wait 17 years for a potentially
life-saving treatment. Knowing how a medicinal product is actually used by patients can help stakeholders across the healthcare ecosystem
make important and potentially life-saving real-time decisions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Real-World
Data is observational data typically gathered when an approved medical product is on the market and used by &#8220;real&#8221; patients
in real life, as opposed to clinical trials or real world images for real patients. The FDA cites several potential sources of Real-World
Data, including electronic health records (&#8220;EHRs&#8221;), claims, disease and product registries, there are multiple types of data
including structured and unstructured data, clinical and billing data, transactional and claims data, patient-generated data, and data
gathered from additional sources that can shed light on a patient&#8217;s health status and more. As reliance on healthcare data grows
exponentially, OneMedNet has observed that the reliance on information has increased coming from multiple additional sources including
EHRs, claims, registries, clinical trials, patient and provider surveys, wearable devices and more. These additional sources include
the internet of things (&#8220;IoT&#8221;), social media forums and blogs. Real-World Data has the potential to break down inefficiencies
and fill gaps in information silos among stakeholders throughout the healthcare ecosystem of providers, payers, manufacturers, government
entities and patients. This information sharing, in turn, enables all parties to derive new insights, support value-based care and deliver
better health outcomes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commercializing
a drug requires its developer to harness various sources of Real-World Data to identify patient populations and refine sales and marketing
strategies for those populations among many other undertakings. Historically, this practice involved purchasing large amounts of data
from data aggregators or data platforms, if not directly from the source itself, sometimes without much knowledge about the quality of
the data. Preparing this data for analysis is both expensive and time-consuming thus many organizations would outsource the process to
consultants or third-party vendors; moreover, the process of preparing this data for analysis by untrained consultants can yield a static
analysis that is difficult to modify or rerun in response to follow-up questions or potential discrepancies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<!-- Field: Rule-Page --><div style="margin: 0pt; font-family: Times New Roman, Times, Serif; width: 35%"><div style="border-top: Black 1.5pt solid; font: 1pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>





























<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>2
</sup>https://www.outsourcing-pharma.com/Article/2016/03/14/Tufts-examines-2.87bn-drug-development-cost</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>3
</sup>https://www.hcplive.com/view/new-data-reinforces-difficulty-orphan-drug-development</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Definitions
of Real-World Data and Real-World Evidence</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Real-World
Data has become a powerful tool in the life sciences industry. After decades of relying on clinical data as the gold standard for decision
making, industry leaders now recognize how data collected in the real world adds valuable context and insight to their efforts. From
identifying unmet medical needs and defining the patient journey, to supporting regulatory submissions, proving value to payers, and
shaping market strategies, Real-World Data adds value at every stage of the drug development lifecycle. Real-World Data also sets the
foundation for Real World Evidence, and while the terms are often used interchangeably, they are distinct and they are changing health
care. Here&#8217;s how it happens:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">First,
    Real-World Data are data relating to patient health status and/or the delivery of health care routinely collected from a variety
    of sources. Real-World Data is aggregated and transformed such as through OneMedNet&#8217;s robust analytics. Real-World Data are
    the data relating to patient health status and/or the delivery of health care routinely collected from a variety of sources. There
    are many different types, sources and uses of Real-World Data, for example:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Clinical
    Data</i> <b>&#8212;</b> For example, clinical data from EHRs and case report forms (&#8220;eCRF&#8221;) including biopsies and other
    pathology tests, diagnostic imaging, social determinants of health, cancer organoids, that provide patient demographics, family history,
    comorbidities, procedure and treatment history, and outcomes.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Patient
    Generated Data &#8212;</i> For example, patient-generated data from patient-reported outcome surveys, which data provide insights
    directly from the patient, and they help researchers understand what happens outside of clinic visits, procedures, and hospital stays.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Cost
    and Utilization Data (Qualitative Studies)</i>&#8201;&#8212;&#8201;For example, cost and utilization data from claims and public
    datasets, which data provides information regarding healthcare services utilization, population coverage, and prescribing patterns.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Public
    Health Data</i> <b>&#8212;</b> For example, public health data from various government data sources. These add critical information
    to enable stakeholders to best serve the needs of the populations they serve.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
availability of medical imaging in Real-World Data such as that provided by OneMedNet is facilitated by the development of digital image
analysis to increase the accuracy of diagnostics and conduct passive screening on large databases of medical images using artificial-intelligence
(&#8220;AI&#8221;) algorithms such as those applied by OneMedNet. Algorithms can also help identify additional diagnostic tests of value
from medical images with pathology.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Real-World
Evidence is the clinical evidence regarding the usage and potential benefits or risks of a medical product derived from analysis of Real-World
Data, as defined by the Food and Drug Administration. Real-World Evidence can be generated by different study designs or analyses, including
but not limited to, randomized trials, including large simple trials, pragmatic trials, and observational studies (prospective and/or
retrospective). The difference in Real World Evidence and Real World Data focuses on the end use case. Real World Data can take the form
of claims, electronic health records, labs, data etc. Often this insight is used to better understand a patient&#8217;s journey or a
natural history of a disorder (how does a disease progress if left untreated.)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="forms-1_006.jpg" alt="A diagram of data and information&#10;&#10;Description automatically generated with medium confidence" style="height: 255px; width: 595px"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Real
World Evidence in contrast builds upon many of these data sets and prepares them for submission, as part of regulatory review such as
to the Food and Drug Administration or the European Medicines Agency, for example, in support of a customer&#8217;s clinical trial application.
When data and in particular imaging data is submitted to the FDA the agency requires the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Guard
    against biased&#8201;&#8212;&#8201;evidence must align with the patient population being study&#8201;&#8212;&#8201;expectations
    focus on the similar patient demographics, comorbidities, disease severity, etc.;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Traceability&#8201;&#8212;&#8201;confirm
    the chain of custody, the source of the data is known and can be validated if required; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Go
    forward basis&#8201;&#8212;&#8201;regulatory agencies seek evidence that aligns with the trials timeframe and when possible collect
    evidence that mirrors the clinical trials timeline.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">One
area where Real World Evidence has been relief on heavily relates to oncology approvals. Food and Drug Administration&#8217;s Oncology
Center of Excellence actually presented an analysis of this at American Society of Clinical Oncology in 2021, looking at oncology applications
containing Real-World Data and Real-World Evidence. That analysis looked at 94 applications that were submitted from 2011-2020, and showed
that inclusion of Real-World Data to support regulatory decision-making has increased dramatically over that period. In 2020 alone, there
were 28 submissions for oncology products that contained Real-World Data. Outside of the oncology context, probably the most notable
recent example of an approval relying on Real World Evidence is the July 2021 approval of a new indication for Astellas&#8217; drug Prograf
(or tacrolimus) for the prevention of organ rejection in lung transplant patients. The approval there was based on a non-interventional
study providing Real-World Evidence of effectiveness.<sup>4</sup> FDA&#8217;s press release announcing the approval noted that the approval
was &#8220;significant because it reflects how a well-designed, non-interventional study relying on fit-for-purpose real-world data,
when compared to a suitable control, can be considered adequate and well-controlled under FDA regulations.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<!-- Field: Rule-Page --><div style="margin: 0pt; font-family: Times New Roman, Times, Serif; width: 35%"><div style="border-top: Black 1.5pt solid; font: 1pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><sup>4</sup><span style="font-size: 10pt"><i>See </i>https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-new-use-transplant-drug-based-real-world-evidence</span></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
additional recent approval of note was the December 2021 approval of the supplemental BLA for Orencia to prevent graft versus host disease.<sup>5 </sup>The application included data from a randomized clinical trial, with additional evidence of effectiveness provided by a
registry-based clinical study that was conducted using real-world data from the Center for International Blood and Marrow Transplant
Research.<sup>6 </sup>And that registry study analyzed outcomes of 54 patients treated with Orencia for the prevention of graft versus
host disease, in combination with standard immunosuppressive drugs, versus 162 patients treated with the standard immunosuppressive drugs
alone, and showed efficacy in that indication.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AI
is employed in Real-World Data to enhance data anomaly detection, standardization, and quality checking at the pre-processing stage.
AI is expected to offer pharma and biotech companies the ability to increase meaningful Real World Evidence output, decrease time to
insights, and make the most of the available vast data sources. A Real World Evidence technology platform that delivers smart data processing,
analysis, and outcomes offers an unparalleled opportunity to capitalize on these computing advancements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
used as part of an overall comprehensive Real World Evidence strategy, AI innovations can enhance drug development, improve patient treatment
and access, and drive valuable new business opportunities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
post-marketing studies, adverse events reporting is an area where AI is used, creating greater automation and efficiency in historical
data sets. Techniques like natural language processing (&#8220;NLP&#8221;) enable AI to scan tens of thousands of records and quickly
find adverse event details. AI integrated analytics and automation provide access to crucial insights from historical clinical trial
Real-World Data and Real World Evidence, expanding end-to-end clinical trial capabilities:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
  <td style="font-family: Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
  <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Data
  ingestion&#8201;&#8212;&#8201;publicly/historical available Real-World Data</span></td></tr>
<tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
  <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
  <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
  <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
  <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Text
  extraction&#8201;&#8212;&#8201;NLP used to extract key entities from clinical trial documents</span></td></tr>
<tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
  <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
  <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
  <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
  <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Data
  transformation &amp; standardization&#8201;&#8212;&#8201;data standardization using pre-built models</span></td></tr>
<tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
  <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
  <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
  <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
  <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">AI
  model deployment&#8201;&#8212;&#8201;predicting trial design impacts on costs, feasibility, cycle times, and quality risk</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AI
is driving ground-breaking leaps in protein structure identification, and advances in regulations are providing healthcare research organizations
with access to real-world data to accelerate clinical trial processes. We believe that AI-enabled technologies have unparalleled potential
to offer innovative trial design and collection, organizing, and analyzing the increasing amount of data generated by clinical trials.
AI has many applications in clinical trials, both short and long-term. AI technologies make possible innovations crucial for transforming
clinical trials, such as seamlessly combining Phases I and II, developing novel patient-centered endpoints, and collecting and analyzing
Real-World Data.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">OneMedNet
believes that AI tools also have wider benefits for hospitals and health systems. Professor Alexander Wong, University of Waterloo Canada
Research Chair in AI and Medical Imaging, points out that AI benefits include the potential to ease the burden on radiology departments
in terms of assessing scans and predicting upcoming demand for general hospital and intensive care beds, and demand for equipment such
as respirators and ventilators, medicines, masks, and ventilator mouthpieces, as well as aiding workforce planning.<sup>7</sup></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>&#160;</sup></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Across
a diverse set of imaging modalities, digital images typically include metadata and/or annotations that may include protected health information
(<i>e.g.,</i> patient name, date of birth). Although diagnostic images generally do not warrant the same level of privacy concerns as
genomic data, researchers must also remove facial characteristics or other features that could identify a patient.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Digital
image analysis can be used to support research and development by analyzing large volumes of tissue specimens or other medical images
to run molecular screens that model biomarkers and treatment responses by transplanting a portion of a patient&#8217;s tumor into humanized
mice or 3D tissue cultures derived from stem cells that resemble miniature organs. These models allow researchers to conduct controlled
laboratory experiments that can inform treatment approaches and link predicted treatment response to actual clinical outcomes by linking
this data to EHR, claims, and other sources of Real-World Data. Similarly, preclinical studies can be informed by safety assessments
conducted in animal models or studies of animal molecular biomarkers or anatomic abnormalities to minimize the burden on human study
participants. Findings can also inform clinical trial optimization by stratifying participants according to predicted response and determining
appropriate eligibility criteria.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Rule-Page --><div style="margin: 0pt; font-family: Times New Roman, Times, Serif; width: 35%"><div style="border-top: Black 1.5pt solid; font: 1pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>5
                                            </sup><i>See </i> https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-prevent-graft-versus-host-disease</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>6
</sup><span style="font-weight: normal"><i>See</i> <span style="font-style: normal">https://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-orencia-abatacept-prophylaxis-acute-graft-versus-host-disease</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif"><sup>7
</sup></span><span style="font: normal 10pt Times New Roman, Times, Serif"><i>See</i> <span style="font-style: normal">https://www.eurekalert.org/news-releases/936861</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Second,
Real-World Evidence is the clinical evidence about the usage and potential benefits or risks of a medical product derived from analysis
of Real-World Data. Real World Evidence provides clinically-rich insights into what actually happens in everyday practice and why. The
FD&amp;C Act defines Real-World Evidence as &#8220;<i>data regarding the usage, or the potential benefits or risks, of a drug derived
from sources other than traditional clinical trials.</i>&#8221;<sup>8</sup> In developing its Real-World Evidence program, FDA believes
it is helpful to distinguish between the sources of Real-World Data and the evidence derived from that data.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluating
Real-World Evidence in the context of regulatory decision-making depends not only on the evaluation of the methodologies used to generate
the evidence but also on the reliability and relevance of the underlying Real-World Data; these constructs may raise different types
of considerations. Real-World Evidence refers to evidence about the risks and benefits of a product derived from analysis of the Real-World
Data. For example, the FDA has used Real-World Data and Real-World Evidence, derived from its Sentinel system for monitoring the safety
of regulated products, in place of post-marketing studies. It has carried this out for nine potential safety issues involving five products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Real-World
Evidence is the clinical evidence regarding the usage and potential benefits or risks of a medical product derived from analysis of Real-World
Data. Real World Evidence can be generated by different study designs or analysis, including but not limited to, randomized trials, including
large simple trials, pragmatic trials, and observational studies (prospective and/or retrospective).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unlike
traditional clinical trials, where necessary data elements can be curated and collection mandated, the creation of Real World Evidence
requires assessing, validating and aggregating various, often disparate, sources of data available through routine clinical practice.
Real-world evidence is used by different stakeholders in many different ways.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
    gives life sciences companies insight into how their drugs are being used.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"/>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
    helps providers improve the delivery of care.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"/>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
    enables regulatory authorities to monitor post-market safety and adverse events.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"/>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
    helps payers assess outcomes from treatments.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>From
Real-World Data to Real World Evidence</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
creation of Real World Evidence requires a combination of high-powered analytics, a validated approach and a robust knowledge of available
Real-World Data sources (<i>e.g.,</i> what data is captured within existing quality registries, what data can be captured through electronic
health records and case report forms or claims, which patient organizations capture data on relevant patient cohorts). This process includes
several steps, which are summarized here:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Defining
    a study protocol answering relevant clinical questions.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Defining
    which data elements can be collected from which Real-World Data sources.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Establishing
    data capture arrangements and protocols with existing Real-World Data sources.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Blending
    disparate data sources through probabilistic record matching algorithms.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Validating
    and supplementing blended data through editable eCRFs.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Defining
    and calculating clinically relevant outcomes and measures.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Appropriately
    assessing and controlling for variability in data quality, availability and confounding patient factors affecting measured outcomes.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Real
    World Evidence can provide a holistic view of patients that in many cases cannot be studied through traditional clinical trials.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Rule-Page --><div style="margin: 0pt; font-family: Times New Roman, Times, Serif; width: 35%"><div style="border-top: Black 1.5pt solid; font: 1pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>8
</sup><i>See</i> 21 U.S.C. 355(g)(b).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Real
World Evidence has been proven to fill a gap between research (what we learn) and everyday practice (what we do) in healthcare, and it
creates a difference between what is expected to happen and what really happens. Driving measurable improvements in healthcare requires
us all to be rooted in the reality of what actually happens before, during, and after clinical procedures, interventions, and office
visits. Real World Evidence fill those gaps and documents the truth by establishing definitively what really happens when doctors treat
a wide range of patients that do not look like the homogeneous patient groups in a clinical trial. Because of this, Real World Evidence
serves many uses and provides many benefits across the healthcare ecosystem.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
more countries battle to contain healthcare costs, and as the population ages and the number of patients with chronic diseases increases,
the need to remove inefficiencies and upgrade the delivery of coordinated care that improves outcomes is more pressing. At the same time,
life sciences companies are facing tumultuous times. Industry globalization, the end of the blockbuster era, and an increasingly complex
regulatory environment all add to the difficulty of bringing products to market. And across the board, companies are moving toward a
patient-centric and outcome-focused model. In this environment, Real World Evidence can be transformative for the industry when Real-World
Data is combined with the right technology framework and the regulatory intelligence to make sense of it. As data is consumed across
life sciences in different ways and by different stakeholders, it can provide valuable insights and &#8220;evidence&#8221; across the
product life cycle. In addition, stakeholders across the healthcare ecosystem use this new knowledge to support decision-making and improve
safety and effectiveness, and ultimately, patient outcomes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Uses
of Real World Evidence in Life Sciences, Among Regulators, Clinicians, Researchers and Healthcare Systems</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">According
to repeated studies by Deloitte,<sup>9</sup> the importance of Real World Evidence continues to rise as it promises to accelerate regulatory
decision-making and support the approval of new indications for drugs already on the market. Life Sciences, pharmaceutical and medical
device companies are significant consumers of Real World Evidence because it can provide value across the entire product lifecycle from
pre-trial design to clinical studies and trials to post-market surveillance. Medical product developers are using Real World Evidence
to support clinical trial designs (<i>e.g.,</i> large simple trials, pragmatic clinical trials) and observational studies to generate
innovative, new treatment approaches.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Real
World Evidence can be used to make clinical trials more effective and efficient, for example in patient recruitment or label extension,
Real World Evidence gathered from other studies or from currently marketed products in a similar category, for example, can have a positive
effect on the product portfolio by exposing positive side effects as new potential indications. The most famous example is Viagra, which
was initially studied as a drug to lower blood pressure, but an unexpected side effect led to the drug ultimately being approved for
erectile dysfunction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
benefits of Real World Evidence derived from Real-World Data are increasingly being recognized by regulatory authorities. The FDA released
a framework for using Real World Evidence to support the process of drug regulation and submission. This is a major step toward recognizing
that clinical trials, while still relevant, are not the only way to assess the efficacy and safety of a product. Indeed, the FDA is soon
expected to conduct its first full post-market safety approval using only Real World Evidence.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Real
World Evidence is now accepted as a reliable source of information for regulatory decision making in certain circumstances. A primary
rationale for the FDA to use Real World Evidence E is to help support the approval of a new or extended use for a drug approved under
the FD&amp;C Act and to help support or satisfy post-approval study requirements always with the condition that the data quality is up
to the standard required. In a recent statement, the FDA even noted how new tools for capturing data in the post-market period, including
more sophisticated use of Real-World Data and Real-World Evidence are providing new approaches to address important questions about the
safety and benefits of new drugs in real world settings and that these approaches have the potential to do to so more rapidly and with
greater efficiency than traditional methods.<sup>10</sup></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Rule-Page --><div style="margin: 0pt; font-family: Times New Roman, Times, Serif; width: 35%"><div style="border-top: Black 1.5pt solid; font: 1pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><sup>9
</sup><i>See</i> https://www2.deloitte.com/content/dam/insights/us/articles/4354_Real-World-Evidence/DI_Real-World-Evidence.pdf</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>10
</sup><i>See</i> https://www.fda.gov/science-research/science-and-research-special-topics/real-world- evidence </span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Why
Do We Need Real-World Evidence?</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There&#8217;s
a gap between research (what we learn) and everyday practice (what we do) in healthcare, and it creates a difference between what is
expected to happen and what really happens. But it&#8217;s what really happens that matters. Driving measurable improvements in healthcare
requires us all to be rooted in the reality of what actually happens before, during, and after clinical procedures, interventions, and
office visits. Real-World Evidence is here to fill those gaps and root us in truth. It tells us what really happens when doctors treat
a wide range of patients that don&#8217;t look like the homogeneous patient groups in a clinical trial. Because of this, Real-World Evidence
serves many uses and provides many benefits across the healthcare ecosystem.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Uses
of Real-World Evidence in Pharmaceutical and Device Companies</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pharmaceutical
and medical device companies are major consumers of Real-World Evidence, as it can provide value across the entire product lifecycle.
Real-World Evidence plays an important role for research across the product lifecycle for both pharmaceutical and device companies. It
can inform pre-trial study design by helping researchers identify potential patients and create proper inclusion criteria for clinical
trials. Much of medical innovation is driven by traditional clinical trials, where new pharmaceuticals and devices are rigorously studied
and tracked before they can be sold and widely distributed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
clinical trials are incredibly important to determine the safety and efficacy of new technologies, when compared to real-world evidence
they do have some limitations. For example, traditional clinical trials can have strict inclusion criteria that makes it challenging
for providers to accurately extrapolate the results of a clinical trial to a broader population. Clinical trial participation is often
limited by who the study administrators are able to recruit, and various demographics are often not able to participate. This again challenges
the generalizability of clinical trial results across patient populations. Real-world evidence can help overcome the limitations of clinical
trials by providing information about a broader cross-section of society. This can help clinicians, researchers, and industry partners
better understand their products and how they work.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Once
a product is approved and marketed, Real-World Evidence assists pharmaceutical or medical device company understand their products&#8217;
relative safety, effectiveness, value, off-label use and more. This post-market surveillance, or post-marketing surveillance, is valuable
to stakeholders across the healthcare industry.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 21; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="forms-1_007.jpg" alt="A diagram of a patient's health&#10;&#10;Description automatically generated" style="height: 334px; width: 624px"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
AI-enabled patient enrichment and recruitment process can improve suitable cohorts and increase clinical trial effectiveness, data management,
analysis, and interpretation of multiple Real-World Data sources, including EHRs and medical imaging data. This presents a unique opportunity
for NLP to perform the sophisticated analysis necessary to combine genomic data with electronic medical records (&#8220;EMRs&#8221;)
and other patient data, present in various locations, owners, and formats&#8201;&#8212;&#8201;from handwritten paper copies to digital
medical images&#8201;&#8212;&#8201;to surface biomarkers that lead to endpoints that can be more efficiently measured, and thereby
identify and characterize appropriate patient subpopulations. AI-enabled systems can help to improve patient cohort composition and aid
with patient recruitment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AI
technologies can help biopharma companies identify target locations, qualified investigators, and priority candidates and collect and
collate evidence to satisfy regulators that the trial process complies with good clinical practice (&#8220;GMP&#8221;) requirements.
One of the most important elements of a clinical trial is a selection of high-functioning investigator sites. Site qualities such as
resource availability, administrative procedures, and experienced clinicians with in-depth knowledge and understanding of the disease
can shape study timelines and data quality, accuracy, completeness, and consistency.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AI
integrated clinical trial programs can help monitor and manage patients by automating real-world data capture, sharing data across systems,
and digitalizing standard clinical assessments. AI technologies and wearable technologies can help enable continuous patient monitoring
and generate real-time insights into the safety and effectiveness of treatment while predicting the possible risk of dropouts, thereby
enhancing patient engagement and retention. To comply with trial adherence criteria, patients must keep detailed records of their medication
intake and other data points related to their bodily functions, response to medication, and daily protocols. This can be an overwhelming
and tedious task, leading to 40% of patients becoming non-adherent after 150 days into a clinical trial. Wearable devices/sensors and
video monitoring are used to collect patient data automatically and continuously, thereby relieving the patient of this task. In combination
with wearable technology, AI techniques offer new approaches to developing real-time, power-efficient, mobile, and personalized patient
monitoring systems.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Among
regulators, clinicians, academic researchers and healthcare systems, the reliance on curated Real World Evidence has grown significantly
because of the value it can provide, which is unique relative to each parties&#8217; objectives and mandates. It also helps that the
FDA has also sharpened its focus on Real-World Data and Real World Evidence. For example, late last year, the FDA published proposed
guidance related to data standards for product submissions with Real-World Data and also weighed in on the use of Real-World Data and
Real World Evidence to support regulatory decision-making for drugs and biological products with specific advice for data from electronic
health records and medical claims.<sup>11</sup> In addition, the FDA uses Real-World Data and Real World Evidence to monitor post-market
safety and adverse events and to make regulatory decisions. The health care community is using these data to support coverage decisions
and to develop guidelines and decision support tools for use in clinical practice.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Rule-Page --><div style="margin: 0pt; font-family: Times New Roman, Times, Serif; width: 35%"><div style="border-top: Black 1.5pt solid; font: 1pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>11</sup><i>See
</i>https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-use-real-world-data-and-real-world-evidence-support-regulatory-decision-making-drug</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 22; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">AI
with deep-learning capability is also helpful in organizing and translating a vast amount of structured and unstructured data to RWE.<sup>12
</sup>The human mind can possibly manage 4-5 variables, therefore, AI-enabled data mapping and integration and their normalization into
a common data model according to disease pathway and workflow will likely be useful for both quality management in clinical trials and
generating meaningful insight for human disease by providing a broader perspective based on real-world data.<sup>13</sup></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><sup>&#160;</sup></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Market
Size</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
global real world evidence solutions market is projected to grow from $16.13 billion in 2023 to $36.24 billion by 2030, at a CAGR of
12.3%.<sup>14</sup> The drug development and approvals segment accounted for the highest revenue share of around 28.9% in 2020. Real-world
evidence solutions services allow pharmaceutical companies and healthcare providers as well as payers for efficient management of operations
and accelerate the process of drug development and its approval, which fuels market growth. Support from regulatory bodies for using
Real World Evidence solutions and an increase in research and development spending are anticipated to boost the market growth.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="forms-1_008.jpg" alt="A graph of a bar chart&#10;&#10;Description automatically generated" style="height: 205px; width: 662px"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on end user, the global Real World Evidence solutions market is segmented into pharmaceutical, biotechnology, and medical device companies;
healthcare payers; healthcare providers; and other end-users (academic research institutions, patient advocacy groups, regulators, and
health technology assessment agencies). In 2021, the pharmaceutical, biotechnology, and medical device companies segment is estimated
to account for the largest share of 36.5% of the global real-world evidence solutions market. The large share of this segment is primarily
attributed to the increasing importance of Real World Evidence studies in drug development and approvals and the growing need to avoid
costly drug recalls and assess drug performance in real-world settings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
the growing need for evidence generated from Real-World Data, the increasing importance of epidemiological data in decision making, and
a shift from volume to value-based care, there has been an increased focus on patient registries, a rise in the adoption of EMR in hospitals,
and exponential growth in mobile health data and social media which have resulted in the generation of huge amounts of medical data.
In 2021, the real-world datasets segment is estimated to account for the larger share of 51.2% of the global real-world evidence solutions
market.<sup>15</sup> <span style="background-color: white">According to Coherent Market Insights, the global real-World Data market is
estimated to be valued at $1.59 billion in 2023 and is expected to exhibit a CAGR of 14.4% during the forecast period (2023-2030).<sup>16</sup></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Rule-Page --><div style="margin-right: 0pt; font-family: Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 35%"><div style="border-top: Black 1.5pt solid; font: 1pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><sup>12
</sup>Franklin JM, Schneeweiss S. When and how can real world data analyses substitute for randomized controlled trials? Clin Pharmacol
Ther. 2017;102(6):924-33.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><sup>13
</sup>From real-world data to real-world evidence: An interregional perspective | RAPS, July 30, 2021</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><sup>14
</sup>https://www.fortunebusinessinsights.com/real-world-evidence-solutions-market-107676</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><sup>15
</sup>Meticulous Research&#174; Analysis, which derived its analysis after a detailed assessment of various quantitative and qualitative
factors, such as the historical revenue growth trends of leading players, major market growth drivers, restraints, and challenges, along
with their impacts over the forecast period and relevant macroeconomic and microeconomic indicators.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><sup>16
</sup>Real-world Data (RWD) Market to reach $4.07 billion by (globenewswire.com)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Long-Term Growth Strategies</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
long-term growth strategy is anchored on the following key pillars:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Increase
    Global Reach to Meet Demand: </i></b>Our strategy is to continue growing our global footprint into areas where we expect high demand
    growth in t</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">he global real world evidence solutions
    market, which is projected to grow from $16.13 billion in 2023 to $36.24 billion by 2030, at a CAGR of 12.3%. <span style="background-color: white">There
    is a rise in emphasis on evidence-based medicine that relies on Real-World Evidence, which comes from Real-World Data. Market players
    in healthcare industries, including regulators, healthcare providers, and payers are becoming more aware of the importance of using
    Real-World Data for making informed decisions regarding comparative effectiveness, treatment effectiveness, cost-effectiveness, and
    safety. As a result, the demand for real world data solutions is increasing rapidly, which is further driving growth of the market.</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Regulatory
    agencies such as the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) are making use of real-world
    evidence in regulatory decision making processes. These regulatory authorities have frameworks and guidelines for using Real-World
    Evidence and Real-World Data in regulatory submissions, post-market surveillance, and drug approvals. As a result, the demand for
    real-world data is rising, which in turn is expected to support growth of the market in the coming future.<sup>17</sup></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
    use of Real-World Evidence derived from Real-World Data demonstrates value and cost-effectiveness of medical devices and drugs for
    healthcare technology assessment agencies and payers. With this Real-World Evidence, market access becomes easier and it also enables
    reimbursement negotiations. This further facilities the inclusion of new therapies in the coverage of healthcare, which in turn creates
    major opportunities in the global market.<sup>18</sup></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"/>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Innovate
    Our Commercial Approach to Drive Incremental Market Share: </i></b>We intend to rapidly expand our sales network across the globe,
    while simultaneously building out our sales infrastructure. We intend to focus on our target markets, which include (i) Imaging
    AI; (ii) medical device companies; and (iii) pharmaceutical companies, as summarized here: </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="forms-1_009.jpg" alt="A screenshot of a device&#10;&#10;Description automatically generated" style="height: 250px; width: 628px"/></span></p>

<p style="margin-right: 0pt; font-family: Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin-right: 0pt; font-family: Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Rule-Page --><div style="margin-right: 0pt; font-family: Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 35%"><div style="border-top: Black 1.5pt solid; font: 1pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page -->

<p style="margin-right: 0pt; font-family: Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<p style="margin-right: 0pt; font-family: Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">17
<i>Id.</i></span></p>

<p style="margin-right: 0pt; font-family: Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">18
<i>Id.</i></span></p>

<p style="margin-right: 0pt; font-family: Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Enhance
    and Refine Our Service Offering: </i></b>Building on our customer-centric mindset throughout our development, curation and commercial
    processes, we plan to continue expanding and improving our service offering. As we continue to expand into additional geographies
    globally, we plan to build upon these three pillars:</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="forms-1_010.jpg" alt="A screenshot of a phone&#10;&#10;Description automatically generated" style="height: 289px; width: 624px"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><p style="margin-right: 0pt; font-family: Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
                                                                                <p style="margin-right: 0pt; font-family: Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>
                                                                                <p style="margin-right: 0pt; font-family: Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Expand
    Our Product Offering:</i></b> We plan to continually evaluate the benefits of expanding our portfolio into other high-growth, high-demand
    Real-World Data and Real-World Evidence solutions in the future. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Corporate
Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
were originally incorporated in Delaware on February 8, 2021 under the name &#8220;Data Knights Acquisition Corp&#8221; as a special
purpose acquisition company, formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase,
reorganization or similar business combination with one or more businesses. On November 7, 2023, we held the Closing of the previously
announced Merger whereby Merger Sub merged with and into OneMedNet Solutions Corporation (formerly named OneMedNet Corporation), with
OneMedNet Solutions Corporation continuing as the surviving entity, which resulted in all of the issued and outstanding capital stock
of OneMedNet Solutions Corporation being exchanged for shares of the Company&#8217;s Common Stock upon the terms set forth in the Merger
Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 25; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Merger and other transactions that closed on November 7, 2023, pursuant to the Merger Agreement, led to Data Knights changing its name
to &#8220;OneMedNet Corporation&#8221; and the business of the Company became the business of OneMedNet Solutions Corporation. We are
located at 6385 Old Shady Oak Road, Suite 250, Eden Prairie, MN 55344 and reachable by telephone on 800-918-7189.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information contained on our website is not incorporated by reference into this prospectus, and you should not consider any information
contained on, or that can be accessed through, our website as part of this prospectus or in deciding whether to purchase our Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">OneMedNet
Corporation a Delaware corporation (the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;OneMedNet&#8221;) together
with its wholly-owned subsidiary OneMedNet Solutions Corporation, a Delaware corporation, founded on October 13, 2009 in the State of
Hawaii and later incorporated in the State of Delaware on November 20, 2015 and its wholly-owned subsidiary, OneMedNet Technologies (Canada)
Inc., incorporated on October 16, 2015 under the provisions of the Business Corporations Act of British Columbia whose functional currency
is the Canadian dollar. All refences in this prospectus to the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;OneMedNet&#8221;
include OneMedNet Solutions Corporation and its wholly-owned subsidiary, OneMedNet Technologies (Canada) Inc., incorporated on October
16, 2015 under the provisions of the Business Corporations Act of British Columbia whose functional currency is the Canadian dollar.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recent
Developments</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Closing
of Business Combination</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">OneMedNet
Corporation, a Delaware corporation (the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; or &#8220;OneMedNet&#8221;) together
with its wholly-owned subsidiary, OneMedNet Solutions Corporation, a Delaware corporation, and its wholly-owned subsidiary, OneMedNet
Technologies (Canada) Inc., incorporated under the provisions of the Business Corporations Act of British Columbia whose functional currency
is the Canadian dollar. All references in this prospectus to the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;OneMedNet&#8221;
include OneMedNet Corporation and both OneMedNet Solutions Corporation and OneMedNet Technologies (Canada) Inc., except that references
to the &#8220;Company&#8221; &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;Data Knights&#8221; in this Item 7 refer to OneMedNet Corporation
<i>f/k/a</i> Data Knights Acquisition Corp.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
were originally incorporated in Delaware on February 8, 2021 under the name &#8220;Data Knights Acquisition Corp&#8221; as a special
purpose acquisition company, formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase,
reorganization or similar business combination with one or more businesses. On May 11, 2021, we consummated an initial public offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 7, 2023, following the approval at the special meeting of the shareholders of Data Knights Acquisition Corp., a Delaware corporation
held on October 17, 2023 (the &#8220;Special Meeting&#8221;), Data Knights Merger Sub, Inc., a Delaware corporation (&#8220;Merger Sub&#8221;)
and a wholly-owned subsidiary of Data Knights Acquisition Corp., a Delaware corporation (&#8220;Data Knights&#8221;), consummated a merger
(the &#8220;Merger&#8221;) with and into OneMedNet Solutions Corporation (formerly named OneMedNet Corporation), a Delaware corporation
(&#8220;OneMedNet&#8221;) pursuant to an agreement and plan of merger, dated as of April 25, 2022 (the &#8220;Merger Agreement&#8221;),
by and among Data Knights, Merger Sub, OneMedNet, Data Knights, LLC, a Delaware limited liability company (&#8220;Sponsor&#8221; or &#8220;Purchaser
Representative&#8221;) in its capacity as the representative of the stockholders of Data Knights, and Paul Casey in his capacity as the
representative of the stockholders of OneMedNet (&#8220;Seller Representative&#8221;). Accordingly, the Merger Agreement was adopted,
and the Merger and other transactions contemplated thereby (collectively, the &#8220;Business Combination&#8221;) were approved and completed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the closing, on November 7, 2023, of the Business Combination pursuant to the Merger Agreement, Merger Sub merged with and into OneMedNet
with OneMedNet surviving the Merger, as a wholly-owned subsidiary of Data Knights, and Data Knights changed its name to &#8220;OneMedNet
Corporation.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Business Combination was accounted for as a reverse recapitalization in accordance with U.S. GAAP. Under this method of accounting, Data
Knights was treated as the acquired company and OneMedNet Corporation was treated as the acquirer for financial statement reporting purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 26; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the closing of the Merger, holders of Data Knights common stock automatically received common stock of OneMedNet, and holders of Data
Knights warrants automatically received warrants of OneMedNet with substantively identical terms. At the Closing of the Business Combination,
all shares of Data Knights owned by the Sponsor (consisting of shares of Class A common stock and shares of Class B common stock), which
we refer to as the founder shares, automatically converted into an equal number of shares of OneMedNet&#8217;s common stock, and Private
Placement Warrants held by the Sponsor, automatically converted into warrants to purchase one share of OneMedNet common stock with substantively
identical terms.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Closing
of the Pre-Closing PIPE</i></b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 28, 2023, the Company and Data Knights entered into a Securities Purchase Agreement (the &#8220;PIPE SPA&#8221;) with certain investors
(collectively referred to herein as the &#8220;Purchasers&#8221;) for PIPE financing (the &#8220;Pre-Closing PIPE&#8221;) in the
aggregate original principal amount of $1,595,744.70 and the purchase price of $1.5 million. Pursuant to the Securities Purchase Agreement,
Data Knights will issue and sell to each of the Purchasers, a new series of senior secured convertible notes (the &#8220;Pre-Closing
PIPE Notes&#8221;), which are convertible into shares of Common Stock at the Purchasers election at a conversion price equal to the
lower of (i) $10.00 per share, and (ii) 92.5% of the lowest volume weighted average trading price for the ten (10) Trading Days immediately
preceding the Conversion Date. The Purchasers&#8217; $1.5 million investment in the Pre-Closing PIPE Notes closed and funded contemporaneous
to the Closing of the Business Combination. Effective immediately prior to the Closing, Data Knights issued the Pre-Closing PIPE
Notes to the Purchasers pursuant to the private offering rules under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the Closing, among other holders, public stockholders own 98,178 shares of OneMedNet common stock approximately representing 0.35%
of the outstanding shares of OneMedNet common stock; the Sponsor and its affiliates own approximately 15.1% of the outstanding shares
of OneMedNet common stock (inclusive of shares received upon conversion of the Sponsor&#8217;s loan); OneMedNet&#8217;s former security
holders own approximately 61.992% of the outstanding shares of OneMedNet common stock from the conversion of their shares; PIPE investors
own 0.46% of the outstanding shares of OneMedNet common stock and former convertible note holders own approximately 16.24% of the outstanding
shares of OneMedNet common stock resulting from the issuance of 5,238,800 shares of Common Stock upon conversion of their notes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, at the closing of the Merger, the Company issued an aggregate of 277,778 shares of the Company&#8217;s Company Stock at $10.89
per share, for an aggregate value of $3,025,000 (the &#8220;Compensation Shares&#8221;) to EF Hutton LLC,  (&#8220;EF Hutton&#8221;) win partial satisfaction of fees due to them in connection with the Merger.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Lock-up
Agreements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
April 25, 2022, in connection with the execution of the Merger Agreement, certain stockholders of OneMedNet and certain of OneMedNet&#8217;s
officers and directors (such stockholders, the &#8220;Company Holders&#8221;) entered into a lock-up agreement (the &#8220;Lock-up Agreement&#8221;)
pursuant to which the Company Holders will be contractually restricted, during the Lock-up Period (as defined below), from selling or
transferring any of (i) their shares of OneMedNet common stock held immediately following the Closing and (ii) any of their shares of
OneMedNet common stock that result from converting securities held immediately following the Closing (the &#8220;Lock-up Shares&#8221;).
Effective November 7, 2023, the newly appointed officers and directors of OneMedNet Corporation have entered into a Lock-Up Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
&#8220;Lock-up Period&#8221; means the period commencing at Closing and end the earliest of: (a) six months from the Closing, and (b)
the date after the Closing on which the Purchaser consummates a liquidation, merger, capital stock exchange, reorganization, or other
similar transaction with an unaffiliated third party that results in all of the Purchaser&#8217;s stockholders having the right to exchange
their shares of the Purchaser Common Stock for cash, securities, or other property: (i) lend, offer, pledge, hypothecate, encumber, donate,
assign, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right
or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any Restricted Securities, (ii) enter into any swap
or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the Restricted
Securities, or (iii) publicly disclose the intention to do any of the foregoing, whether any such transaction described in clauses (i),
(ii), or (iii) above is to be settled by delivery of Restricted Securities or other securities, in cash or otherwise (any of the foregoing
described in clauses (i), (ii), or (iii), a &#8220;Prohibited Transfer&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 27; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the Sponsor is subject to a lock-up pursuant to a letter agreement (the &#8220;Sponsor Lock-up Agreement&#8221;), entered into
on May 6, 2021, at the time of the IPO (as defined below), among Data Knights, the Sponsor and each of the individuals who were a member
of Data Knights&#8217; board of directors and/or management team (each, an &#8220;Insider&#8221; and collectively, the &#8220;Insiders&#8221;),
who agreed that it, he or she shall not transfer any founder shares which means the 2,875,000 shares of Data Knights Class B common stock,
par value $0.0001 per share, initially held by the Sponsor, or shares of OneMedNet&#8217;s Common Stock issuable upon conversion thereof)
until the earlier of (A) six months after the date of Data Knights&#8217; initial Business Combination or (B) subsequent to the initial
Business Combination, (x) if the reported last sale price of the Common Stock equals or exceeds $12.00 per share (as adjusted for stock
splits, stock dividends, right issuances, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading
day period commencing at least 150 days after the Company&#8217;s initial Business Combination, or (y) the date on which the Company
completes a liquidation, merger, capital stock exchange, reorganization or other similar transaction that results in all of our stockholders
having the right to exchange their shares of common stock for cash, securities or other property. Further, the Sponsor and each of the
Insiders agreed further in the Sponsor Lock-Up Agreement that he, she or it shall not transfer any private placement units, the private
placement shares, the private placement warrants or shares of Common Stock issued or issuable upon the exercise of the private placement
warrants, until 30 days after the completion of the initial Business Combination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Registration
Rights Agreements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the Closing of the Business Combination and funding of the PIPE, the PIPE Investors each executed a PIPE Note and a PIPE Warrant in the
amount corresponding to each PIPE Investor&#8217;s investment amount and in accordance with the terms set forth in the PIPE SPA as well
as a registration rights agreement (the &#8220;PIPE Registration Rights Agreement&#8221;). We are registering the offer and sale of these
securities to satisfy the registration rights we have granted in the <span style="letter-spacing: 0.2pt">PIPE Registration Rights Agreement</span>.
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> At the Closing of the Business Combination, OneMedNet,
Data Knights and the Sponsor entered into a registration rights agreement (the &#8220;Registration Rights Agreement&#8221;), pursuant
to which, among other things, the Company is obligated to file a registration statement to register the resale of certain securities
of the Company held by the holders, as defined in the Registration Rights Agreement and the Sponsor. The Registration Rights Agreement
also provides the holders and the Sponsor with &#8220;piggy-back&#8221; registration rights, subject to certain requirements and customary
conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Voting
Agreement and Sponsor Support Agreement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with entry into the Merger Agreement, the Company entered into voting agreements (the &#8220;Voting Agreements&#8221;) with
certain stockholders of OneMedNet representing approximately 55% of the outstanding voting power of OneMedNet&#8217;s equity securities
(the &#8220;OneMedNet Stockholders&#8221;) pursuant to which OneMedNet Stockholders agreed to vote their securities in favor of the approval
of the Merger Agreement and the Business Combination, be bound by certain covenants and agreements related to the Business Combination
and to take other customary actions to cause the Business Combination to occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with entry into the Merger Agreement, the Company, the Sponsor and OneMedNet entered into a sponsor support agreement (the
&#8220;Sponsor Support Agreement&#8221;) pursuant to which the Sponsor agreed to vote its Data Knights securities in favor of the approval
of the Merger Agreement and the Business Combination and to take other customary actions to cause the Business Combination to occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Executive
Employment Agreements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Closing of the Business Combination, the Company has entered into employment agreements (the &#8220;Employment Agreements&#8221;)
with executive officers: Aaron Green (President), Lisa Embree (Chief Financial Officer), and Paul Casey (Chief Executive Officer). The
Employment Agreements provide for at-will employment that may be terminated by the Company with or without cause, by the executive with
or without good reason, or mutually terminated by the parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Employment Agreement for Mr. Green provides for $350,000 annual salary, eligibility to receive an annual cash performance bonus of $175,000
upon his achievement of the performance goals set by the Company&#8217;s CEO and Board of Directors, and eligibility to receive 600,000
of the Company&#8217;s outstanding shares at closing, as part of the Company&#8217;s Restricted Stock Unit Plan, subject to the approval
of the Company&#8217;s Board of Directors. In the event that his employment is terminated by the Company without Cause (as defined in
the Employment Agreement), or is terminated by Mr. Green for Good Reason (as defined in the Employment Agreement), after six months of
employment, and he signs and does not revoke a standard release of claims with the Company in a form reasonably satisfactory to the Company&#8217;s
Board of Directors (a &#8220;Release&#8221;), which Release becomes irrevocable no later than sixty (60) days (the &#8220;Release Deadline&#8221;),
after the date of his termination of employment (the &#8220;Termination Date&#8221;) he will be entitled to the following severance payment,
as follows: (a) if the Termination Date is after six (6) months&#8217; of employment, but before he has completed 12 months&#8217; of
employment, he will receive three (3) months&#8217; salary; and (b) if the Termination Date is after 12 months&#8217; employment he will
receive six (6) months&#8217; salary. If the Release does not become effective and irrevocable by the Release Deadline, he will forfeit
any right to severance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 28; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Employment Agreement for Ms. Embree provides for $225,000 annual salary, eligibility to receive an annual cash performance bonus of twenty-five
percent (25%) of her annual salary upon her achievement of the performance goals set by the Company&#8217;s CEO and Board of Directors,
and eligibility to receive 260,000 of the Company&#8217;s outstanding shares, as part of the Company&#8217;s Restricted Stock Unit Plan,
subject to the approval of the Company&#8217;s Board of Directors. In the event that her employment with the Company is terminated by
the Company without Cause (as defined in the Employment Agreement) or is terminated by Ms. Embree for Good Reason (as defined in the
Employment Agreement) she will receive six (6) months&#8217; salary as a Severance Payment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Employment Agreement for Mr. Casey provides for $144,000 annual salary, eligible to receive 147,000 shares of stock upon the successful
fundraising of an amount equal to or greater than $5,000,000 and, as part of the Company&#8217;s Restricted Stock Unit Plan, further
equity will be rewarded to Mr. Casey subject to the approval of the Company&#8217;s Board of Directors. In the event that his employment
with the Company is terminated by the Company without Cause (as defined in the Employment Agreement) or is terminated by Mr. Casey for
Good Reason (as defined in the Employment Agreement) he will receive six (6) months&#8217; salary as a Severance Payment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Note
Securities</i></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> Purchase Agreement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 28, 2024, the Company&#160;<span style="background-color: white">entered into a definitive securities purchase agreement (the &#8220;Notes
Securities Purchase Agreement&#8221;) with Helena Global Investment Opportunities 1 Ltd. (the &#8220;Investor&#8221;), an affiliate of
Helena Partners Inc., a Cayman-Islands based advisor and investor providing for up to USD$</span>4.54 million&#160;<span style="background-color: white">in
funding through a private placement for the issuance of senior secured convertible notes (the &#8220;Notes&#8221;).</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the issuance of the Notes, the Company will issue to the Investor common stock purchase warrants (the &#8220;Warrants&#8221;)
across multiple tranches (the &#8220;Tranches&#8221;) consisting of an initial tranche (the &#8220;Initial Tranche&#8221;) of (i) an
aggregate principal amount $2,000,000.00 and including an original issue discount (&#8220;OID&#8221;) of up to an aggregate of $300,000.00
plus Warrants to purchase a number of shares of Common Stock equal to the applicable Warrant Share Amounts (defined below). The second
tranche (the &#8220;Second Tranche&#8221;) consists of an aggregate principal amount of Notes of up to $350,000.00 and including an OID
of up to $52,500.00 and Warrants to purchase a number of shares of Common Stock equal to the applicable Warrant Share Amounts with respect
to such Tranche. The Notes Securities Purchase Agreement contemplates three subsequent Tranches each of which shall be in an aggregate
principal amount of Notes of up to $1,000,000 each and each including an OID of 15.0% of the applicable principal amount, and Warrants
to purchase a number of shares of Common Stock equal to the applicable Warrant Share Amounts with respect to such Tranches.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
purchase price of a Note and its accompanying Warrant shall be computed by subtracting the portion of the OID represented by that such
Note from the portion of the principal amount represented by such Note (a &#8220;Purchase Price&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Notes Securities Purchase Agreement defines Warrant Share Amounts means in respect of any Warrant issued in a Closing the initial amount
of shares of Common Stock (the &#8220;Warrant Shares&#8221;) for which such Warrant may be exercised and which shall be equal to the
applicable principal amount of the Note issued to the Investor in such closing multiplied by 50% and divided by the 95% of lowest VWAP
over the ten Trading Day period immediately preceding the applicable Closing Date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the closings of each Tranche, a portion of the proceeds will be held in escrow (the &#8220;Escrow&#8221;) pursuant to
an executed Escrow Agreement dated as of March 28, 2024 in accordance with the following: (i) $1,350,000.00 of the net proceeds of the
Initial Tranche will be paid into the Escrow Account for distribution in accordance with the release of proceeds conditions (the &#8220;Release
Conditions&#8221; discussed below), with the balance of the net proceeds paid to the Company less initial closing expenses relating to
such Initial Tranche; (ii) 100% of the net proceeds of the Third Tranche shall be paid into the Escrow Account for distribution in accordance
with the Release Conditions; and (iii) 75% of the net proceeds of the Third Tranche shall be paid into the Escrow Account for distribution
in accordance with the Release Conditions with the balance of the net proceeds of the Third Tranche being paid to the Company less initial
closing expenses relating to such Third Tranche.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Securities Purchase Agreement provides that the amounts in Escrow (the &#8220;Escrowed Proceeds&#8221;) related to the Initial Tranche,
Second Tranche and Third Tranche are governed by the following terms:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Escrowed Proceeds will be released to the Investor for payment amounts owing in respect of the Notes, if the closing price of the
    Common Stock shall have been less than the then Floor Price (as defined in the Notes) for a period of 10-consecutive trading days,
    or an event of default shall have occurred;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Escrowed Proceeds will be released to the Company if the aggregate outstanding amount is equal to zero;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    on the date that is 20 trading days following the closing of the Initial Tranche, the aggregate outstanding amount is more than zero
    but less than $1,700,000.00, then the Escrowed Proceeds will be released to the Company in an amount equal to the difference between
    $1,700,000.00 and the aggregate outstanding amount; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    on the date that is 40 trading days following the Closing Date of the Initial Tranche and every 20 trading days thereafter, the aggregate
    outstanding amount is more than zero but less than $1,700,000.00 minus the amount of any prior disbursement from the Escrow Account
    pursuant to this provision (d) or provision (c) above (the &#8220;Adjusted Escrow Reference Amount&#8221;), then the Escrowed Proceeds
    will be released to the Company an amount equal to the difference between the Adjusted Escrow Reference Amount and such aggregate
    outstanding amount.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Notes Securities Purchase Agreement, the Company and the Investor also entered into a Registration Rights Agreement,
dated as of March 28, 2024 (the &#8220;RRA&#8221;), providing for the registration of the Note shares (the &#8220;Note Conversion Shares&#8221;)
and the Warrant Shares (the &#8220;Registerable Securities&#8221;). The Company has agreed to prepare and file a registration statement
(the &#8220;Registration Statement&#8221;) with the Securities and Exchange Commission (the &#8220;SEC&#8221;) promptly, and in any event
within 30 days of the closing of the private placement. The Company has granted the Investor customary indemnification rights in connection
with the Registration Rights Agreement. The Investors have also granted the Company customary indemnification rights in connection with
the Registration Statement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
securities to be issued pursuant to the Notes&#160;<span style="background-color: white">Securities Purchase Agreement</span>&#160;was
made in reliance on the exemption from registration provided by Section 3(a)(9) of the Securities Act of 1933, as amended (the &#8220;Securities
Act&#8221;), as promulgated by the Securities and Exchange Commission under the Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Government
Regulation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
aspects of our businesses are regulated by federal and state laws, rules and regulations. Accordingly, we maintain a robust compliance
program aimed at ensuring we operate our business in compliance with all existing legal requirements material to the operation of our
businesses. There are, however, occasionally uncertainties involving the application of various legal requirements, the violation of
which could result in, among other things, fines or other sanctions. <i>See</i> &#8220;Risk Factors&#8221; for additional detail.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Regulation
of Patient Information.</i></b> Our information management services relate to the processing of information regarding patient diagnosis
and treatment of disease and are, therefore, subject to substantial governmental regulation. In addition, the confidentiality of patient-specific
information and the circumstances under which such patient-specific records may be released for inclusion in our databases or used in
other aspects of our business is heavily regulated. Federal, state and foreign governments are contemplating or have proposed or adopted
additional legislation governing the possession, use and dissemination of personal data, such as personal health information and personal
financial data, as well as security breach notification rules for loss or theft of such data. Additional legislation or regulation of
this type might, among other things, require us to implement additional security measures and processes or bring within the legislation
or regulation deidentified health or other data, each of which may require substantial expenditures or limit our ability to offer some
of our services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 30; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
particular, personal health information is recognized as a special, sensitive category of personal information, subject to additional
mandatory protections. Violations of data protection regulations are subject to administrative penalties, civil money penalties and criminal
prosecution, including corporate fines and personal liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Data
Privacy</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patient
health information is among the most sensitive of personal information, and it is critically important that information about an individual&#8217;s
healthcare is properly protected from inappropriate access, use and disclosure. Real world evidence&#8201;&#8212;&#8201;information
that allows us to examine actual practices and outcomes&#8201;&#8212;&#8201;is essential to increase access to care, improve outcomes,
and lower costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">OneMedNet
uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information
on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed
for better outcomes. We employ a wide variety of methods to manage privacy requirements, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">governance,
    frameworks, models and training to promote good decision making and accountability;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    layered approach to privacy and security management to avoid a single point of failure;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ongoing
    evaluation of privacy and security practices to promote continuous improvement;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">use
    of technical, administrative, physical and organizational safeguards and controls;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaboration
    with data suppliers and trusted third parties for our syndicated market research and analytics offerings to remove identifiable information
    or employ effective encryption or other techniques to render information non-identified before data is delivered to us; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">work
    with leading researchers, policy makers, thought leaders and others in a variety of fields relevant to the application of effective
    privacy and security practices, including statistical, epidemiological and cryptographic sciences, legal, information security and
    compliance, and privacy.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have relied on expertise in the industry with de-identifying data. Our capabilities allow us to render data non-identified while still
maintaining data utility, thus protecting privacy while still advancing innovation. Not only do we make use of de-identification techniques
with respect to the data we hold, but we also share our expertise in this area with policymakers, regulators and others to help them
understand de-identification methodologies and practical considerations to avoid re-identification risk. We operate in more than 100
countries around the world, many of which have data protection and privacy laws and regulations based on similar core principles (<i>e.g.,
</i>openness, accountability, security safeguards, etc.). We apply those principles globally and augment our practices to address local
laws, contractual obligations and other data privacy requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Compliance team, led by our Chief Compliance Officer, is comprised of privacy professionals and privacy law experts who drive our strategy
and develop and manage our policies and standards. The Compliance team provides subject matter expertise related to the proper management
of all data types. In addition, our Compliance team liaises with our Legal, IT, Information Security and other teams so that privacy
requirements are addressed in technology, contracting, offerings and other business activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
OneMedNet Privacy Policy (the &#8220;Privacy Policy&#8221;) is our foundational privacy policy. It explains how, when applicable, we
collect, hold, use and disclose personal information, including that of our personnel, consumers, healthcare professionals, patients,
medical research subjects, clinical investigators, customers, suppliers, vendors, business partners and investors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cybersecurity</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
employ an array of data security technologies, processes, and methods across our infrastructure to protect systems and sensitive information
from unauthorized access. OneMedNet maintains comprehensive identity and access management practices (<i>e.g.,</i> roles and access privileges
for each user; multi-factor authentication, privileged user accounts, single sign-on, user lifecycle management) and employs a variety
of security information and event management tools. We developed, maintain and utilize a global integrated information security framework
to guide our practices, based on relevant industry frameworks and laws, including, but not limited to NIST, GxP, HITRUST, the ISO 27000
family, COBIT, GDPR, and HIPAA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 31; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
framework consists of policies, standards, procedures, work Instructions and documentation. Information is classified into four categories
to help individuals apply the right level of controls and safeguards to information, applications and systems. Our cybersecurity program
focuses on all areas of our business, including cloud-based environments, data centers, devices used by employees and contractors, facilities,
networks, applications, vendors, disaster recovery / business continuity and controls and safeguards enabled through business processes
and tools. We continuously monitor for threats and unauthorized access.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
draw on the knowledge and insight of external cybersecurity experts and vendors, and internally employ dedicated, certified, cybersecurity
staff, such as but not limited to, CISSP, CISM, CISA, CSSP or other equivalent certifications, that leverage an array of third-party
tools to secure OneMedNet information infrastructure and protect systems and information from unauthorized access. Non-technical safeguards
also play an important role in our cybersecurity program. We provide various training programs and tools to employees so they can avoid
risky practices and help us promptly identify potential or actual issues. We also have global incident response procedures, global service
tools to log incidents and issues for investigation, and an ethics line to report concerns and follow-up on matters already reported.
The Compliance team, led by our Chief Compliance Officer, develops and implements our strategy, as well as monitors systems and devices
for risks and threats.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Regulatory
Quality Compliance (FDA 21 CFR Part 11)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">OneMedNet
provides high-quality, de-identified, regulatory-grade imaging and clinical data; as such OneMedNet adheres to all applicable local and
Federal regulatory quality requirements, including but not limited to FDA 21 CFR Part 11. OneMedNet maintains a rigorous and ongoing
internal quality management system to enable the organization to produce the highest quality regulatory compliant clinical data for our
clients and consumers. This program includes:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ongoing
    internal audits, policy reviews, and procedure testing to ensure validation, audit trails, legacy systems, and record handling and
    retention adhere to the latest regulatory guidelines and best practices.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regular
    third-party or client initiated external audits to assess the compliance of OneMedNet to ensure operations are in accordance with,
    but not limited to the applicable regulations, standards, policies, and standard operation procedures.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Organizational
Structure</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a current organizational chart of our Company:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="forms-1_011.jpg" alt="A diagram of a company&#10;&#10;Description automatically generated" style="height: 280px; width: 267px"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employees</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
workforce is comprised of approximately 20 employees (as of December 31, 2023), including approximately 0 part-time employees (references
herein to &#8220;employees&#8221; include to the employees of our subsidiaries). Our Board of Directors and its committees oversee human
capital matters through regular reporting from management and advisors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Facilities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to the closing of the Business Combination, the Company&#8217;s executive offices were located at Unit G6, Frome Business Park, Manor
Road, Frome, United Kingdom, BA11 4FN and its telephone number was +44 203 833 4000. The Company agreed to pay ARC Group Ltd., an affiliate
of the Sponsor, up to an amount of $10,000 per month for office space, secretarial and administrative support. For the nine months ended
September 30, 2023 and 2022, we had incurred $60,000 in fees under this agreement, respectively. Upon completion of our Business Combination,
the Company ceased paying these monthly fees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
the closing of the Business Combination, our headquarters is located at 6385 Old Shady Oak Road, Suite 250, Eden Prairie, MN 55344 and
our telephone number is (800) 918-7189, where we lease and occupy our office space with an aggregate floor area of approximately 67 square
feet from unrelated third parties under operating lease agreements. We consider our current office space adequate for our current operations
and needs and that, should it be needed, suitable additional or alternative space will be available to accommodate our operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Implications
of Being an Emerging Growth Company </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a company with less than $1.235 billion in revenues during our last fiscal year, we qualify as an emerging growth company as defined
in the Jumpstart Our Business Startups Act (&#8220;JOBS Act&#8221;) enacted in 2012. As an emerging growth company, we expect to take
advantage of reduced reporting requirements that are otherwise applicable to public companies. These provisions include, but are not
limited to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">being
    permitted to present only two years of audited financial statements, in addition to any required unaudited interim financial statements,
    with correspondingly reduced &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221;
    disclosure in this prospectus; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">not
    being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, as amended (&#8220;Sarbanes-Oxley
    Act&#8221;); </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduced
    disclosure obligations regarding executive compensation in our periodic reports, proxy statements and registration statements; and
    </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">exemptions
    from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute
    payments not previously approved. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 33; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_007"></span>THE
OFFERING</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 34%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Issuer:</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 2%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 64%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">OneMedNet
    Corporation</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common
    Stock Offered by us:</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,085,275
    shares of Common Stock issuable upon the exercise of Warrants.</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common
    Stock Offered by the Selling Securityholders</b></span><b>:</b></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Up
    to 19,683,367 shares of Common Stock.</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="background-color: white"><b>Offering
    prices for resales:</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">The Selling Securityholders may
    resell or otherwise dispose of all, some or none of the shares of Class A common stock included in this prospectus, at any time
    or from time to time in a number of different ways in its discretion and at varying prices. See the section titled &#8220;Plan of
    Distribution&#8221; for more information about how the Selling Securityholders may sell or otherwise dispose of the shares of Class&#160;A
    common stock being offered in this prospectus.</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><b>&#160;</b></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants
    Offered by the Selling Securityholders</b></span><b>:</b></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Up
    to 681,019 Warrants.</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise
    Price of Warrants</b></span><b>:</b></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$11.50
    per share, subject to adjustment as defined herein.</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shares
    Outstanding Prior to Exercise of All Warrants</b></span><b>:</b></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23,850,010
    shares.</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shares
    Outstanding Assuming Exercise of All Warrants</b></span><b>:</b></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">35,935,285
    shares.</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Use
    of Proceeds</b></span><b>:</b></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    will not receive any proceeds from the sale of Common Stock or Warrants by the Selling Securityholders. We would receive up to an
    aggregate of approximately $138.9 million from the exercise of the warrants, assuming the exercise in full of all of such warrants
    for cash, however, it is not certain how many warrants would be exercised for cash or if at all. We expect to use the net proceeds
    from the exercise of any warrants for general corporate purposes. See &#8220;<i>Use of Proceeds</i>.&#8221;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: justify; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Market
    for Common Stock and Public Warrants:</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    Common Stock and our Public Warrants are listed on the Nasdaq Capital Market under the symbols &#8220;ONMD&#8221; and &#8220;ONMDW,&#8221;
    respectively.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risk
    Factors:</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    investment in the securities offered hereby is speculative and involves a high degree of risk. You should carefully consider the
    information set forth under &#8220;<i>Risk Factors</i>&#8221; and elsewhere in this prospectus.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
this prospectus, unless otherwise indicated, the number of shares of Common Stock outstanding as of April 15, 2024 and the other information
based thereon:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Does
    not reflect 1,685,881 shares of Common Stock reserved for issuance under our 2022 Equity Incentive Plan; or</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Does
    not reflect the exercise of Warrants to purchase up to 12,085,275 shares of Common Stock.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 34; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->



<p style="margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_008"></span>RISK
FACTORS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>An
investment in our securities involves a high degree of risk. This prospectus contains a discussion of the risks applicable to an investment
in our securities. The risks and uncertainties we have described are not the only ones we face. Additional risks and uncertainties not
presently known to us or that we currently deem immaterial may also affect our operations. The occurrence of any of these known or unknown
risks might cause you to lose all or part of your investment in the offered securities</i>. <i>We may not be successful in preventing
the material adverse effects that any of the following risks and uncertainties may cause. You could lose all or a significant portion
of your investment due to any of these risks and uncertainties. </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>You
should carefully consider the following risks, as well as the other information contained in this prospectus, including our historical
financial statements and related notes included elsewhere in this prospectus before you decide to purchase our securities. Any one of
these risks and uncertainties has the potential to cause material adverse effects on our business, prospects, financial condition and
operating results which could cause actual results to differ materially from any forward-looking statements expressed by us and a significant
decrease in the value of our Common Stock shares and warrants. Refer to &#8220;Cautionary Statement Regarding Forward-Looking Statements.&#8221;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to this Offering and Our Common Stock </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
stock price may be volatile, and purchasers of our Common Stock could incur substantial losses. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
stock market in general has experienced significant price and volume fluctuations that have often been unrelated or disproportionate
to operating performance of individual companies, particularly following a public offering of a company with a small public float. There
is the potential for rapid and substantial price volatility of our Common Stock following this offering. These broad market factors may
seriously harm the market price of our Common Stock, regardless of our actual or expected operating performance and financial condition
or prospects, which may make it difficult for investors to assess the rapidly changing value of our Common Stock. While the Sponsor,
private placement investors, PIPE investors and other Selling Securityholders may experience a positive rate of return based on the current
trading price of the Company&#8217;s Common Stock, the public securityholders may not experience a similar rate of return on the securities
they purchased due to differences in the purchase prices and the current trading price.&#160;Even though the current trading price is
at or significantly below DKAC&#8217;s initial public offering price, the private investors have an incentive to sell because they will
still profit on sales because of the lower price that they purchased their shares than the public investors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are currently listed on The Nasdaq Capital Market. If we are unable to maintain listing of our securities on Nasdaq or any stock exchange,
our stock price could be adversely affected and the liquidity of our stock and our ability to obtain financing could be impaired and
it may be more difficult for our stockholders to sell their securities. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
our Common Stock is currently listed on The Nasdaq Capital Market, we may not be able to continue to meet the exchange&#8217;s minimum
listing requirements or those of any other national exchange. If we are unable to maintain listing on Nasdaq or if a liquid market for
our Common Stock does not develop or is sustained, our Common Stock may remain thinly traded.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
listing rules of Nasdaq require listing issuers to comply with certain standards in order to remain listed on its exchange. If, for any
reason, we should fail to maintain compliance with these listing standards and Nasdaq should delist our securities from trading on its
exchange and we are unable to obtain listing on another national securities exchange, a reduction in some or all of the following may
occur, each of which could have a material adverse effect on our stockholders:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    liquidity of our Common Stock; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    market price of our Common Stock; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to obtain financing for the continuation of our operations; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    number of institutional and general investors that will consider investing in our Common Stock; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    number of investors in general that will consider investing in our Common Stock; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    number of market makers in our Common Stock; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    availability of information concerning the trading prices and volume of our Common Stock; and </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    number of broker-dealers willing to execute trades in shares of our Common Stock. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>


<!-- Field: Page; Sequence: 35; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
principal stockholders will continue to have significant influence over the election of our board of directors and approval of any significant
corporate actions, including any sale of the company.</i></b></span></p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
founders, executive officers, directors, and other principal stockholders, in the aggregate, beneficially own a majority of our outstanding
stock. These stockholders currently have, and likely will continue to have, significant influence with respect to the election of our
board of directors and approval or disapproval of all significant corporate actions. The concentrated voting power of these stockholders
could have the effect of delaying or preventing an acquisition of the company or another significant corporate transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have broad discretion in the use of the net proceeds from this offering and may not use them effectively. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management will have broad discretion in the application of the net proceeds from this offering, including for any of the currently intended
purposes described in the section entitled &#8220;Use of Proceeds.&#8221; Because of the number and variability of factors that will
determine our use of the net proceeds from this offering, their ultimate use may vary substantially from their currently intended use.
Our management may not apply our cash from this offering in ways that ultimately increase the value of any investment in our securities
or enhance stockholder value. The failure by our management to apply these funds effectively could harm our business. Pending their use,
we may invest the net proceeds from this offering in short-term, investment-grade, interest-bearing securities. These investments may
not yield a favorable return to our stockholders. If we do not invest or apply our cash in ways that enhance stockholder value, we may
fail to achieve expected financial results, which may result in a decline in the price of our shares of Common Stock, and, therefore,
may negatively impact our ability to raise capital, invest in or expand our business, acquire additional products or licenses, commercialize
our product, or continue our operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
could be subject to securities class action litigation. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the past, securities class action litigation has often been brought against companies following a decline in the market price of their
securities. <span style="background-color: white">In 2020, 22% of </span>securities class action litigation <span style="background-color: white">filings
were against defendants in the health technology and services sector, which accounted for 22% of new filings</span>. If we face such
litigation, it could result in substantial costs and a diversion of management&#8217;s attention and resources, which could harm our
business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, the market
price for the shares and trading volume could decline. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
trading market for our Common Stock will depend in part on the research and reports that securities or industry analysts publish about
us or our business. If research analysts do not establish and maintain adequate research coverage or if one or more of the analysts who
covers us downgrades our Common Stock or publishes inaccurate or unfavorable research about our business, the market price for our Common
Stock would likely decline. If one or more of these analysts cease coverage of our company or fail to publish reports on us regularly,
we could lose visibility in the financial markets, which, in turn, could cause the market price or trading volume for our common stock
to decline.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
do not expect to pay dividends in the foreseeable future, and you must rely on price appreciation of your shares of Common Stock for
return on your investment. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have paid no cash dividends on any class of our stock to date, and we do not anticipate paying cash dividends in the near term. For the
foreseeable future, we intend to retain any earnings to finance the development and expansion of our business, and we do not anticipate
paying any cash dividends on our stock. Accordingly, investors must be prepared to rely on sales of their shares after price appreciation
to earn an investment return, which may never occur. Investors seeking cash dividends should not purchase our shares. Any determination
to pay dividends in the future will be made at the discretion of our board of directors and will depend on our results of operations,
financial condition, contractual restrictions, restrictions imposed by applicable law and other factors our board deems relevant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>As
the public offering price is substantially higher than our net tangible book value per share, you will experience immediate and substantial
dilution. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you purchase Common Stock in this offering, you will pay more for your shares of Common Stock than the amount paid by our existing stockholders
for their shares on a per share basis. As a result, you will experience immediate and substantial dilution in net tangible book value
per share in relation to the price that you paid for your shares.  In addition, you will experience further dilution to the
extent that our shares are issued upon the exercise of any warrants or exercise of stock options under any stock incentive plans. See
&#8220;Dilution&#8221; for a more complete description of how the value of your investment in our shares will be diluted upon completion
of this offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 36; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Future
sales of substantial amounts of our Common Stock or securities convertible into or exchangeable or exercisable for shares of Common Stock,
either by us or by our existing stockholders, or the possibility that such sales could occur, could adversely affect the market price
of our Common Stock. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
sales in the public market of shares of our Common Stock or securities convertible into or exchangeable or exercisable for shares of
Common Stock, shares held by our existing stockholders or shares issued upon exercise of our outstanding stock options or warrants, or
the perception by the market that these sales could occur, could lower the market price of our Common Stock or make it difficult for
us to raise additional capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>There
is no public market for the warrants being offered in this offering. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is no established public trading market for the warrants being offered in this offering, and we do not expect
a market to develop. In addition, we do not intend to apply to list the warrants on any securities exchange or
nationally recognized trading system, including The Nasdaq Capital Market. Without an active market, the liquidity of the warrants will be limited.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Holders
of the warrants purchased in this offering will have no rights as common stockholders until such holders exercise such warrants
and acquire our Common Stock. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Until
holders of the warrants acquire shares of our Common Stock upon exercise of such warrants, holders of the warrants will
have no rights with respect to the shares of our Common Stock underlying such warrants. Upon exercise of the warrants, the holders will
be entitled to exercise the rights of a Common Stockholder only as to matters for which the record date occurs after the exercise date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
will incur increased costs as a public company, and our management will be required to devote substantial time to new compliance initiatives
and corporate governance practices. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a public company, and particularly after we no longer qualify as an emerging growth company, we will incur significant legal, accounting,
and other expenses that we did not incur previously. The Sarbanes-Oxley Act of 2002 (&#8220;SOX&#8221;), the Dodd-Frank Wall Street Reform
and Consumer Protection Act, the listing requirements of Nasdaq, and other applicable securities rules and regulations impose various
requirements on U.S. reporting public companies, including the establishment and maintenance of effective disclosure and financial controls
and corporate governance practices. Our management and other personnel will need to devote a substantial amount of time to these compliance
initiatives. Moreover, these rules and regulations will increase our legal and financial compliance costs and will make some activities
more time-consuming and costly. For example, we expect that these rules and regulations may make it more expensive for us to obtain director
and officer liability insurance, which in turn could make it more difficult for us to attract and retain qualified senior management
personnel or members for our board of directors. In addition, these rules and regulations are often subject to varying interpretations,
and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies.
This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure
and governance practices. Pursuant to Section 404 of SOX (&#8220;Section 404&#8221;), we will be required to furnish a report by our
senior management on our internal control over financial reporting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
we remain an emerging growth company, we will not be required to include an attestation report on internal control over financial reporting
issued by our independent registered public accounting firm. To prepare for eventual compliance with Section 404, once we no longer qualify
as an emerging growth company, we will be engaged in a process to document and evaluate our internal control over financial reporting,
which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside
consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue
steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and implement
a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that
we will not be able to conclude, within the prescribed timeframe or at all, that our internal control over financial reporting is effective
as required by Section 404.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>


<!-- Field: Page; Sequence: 37; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are an &#8220;emerging growth company,&#8221; and the reduced reporting requirements applicable to emerging growth companies may make
our common stock less attractive to investors.</i></b></span></p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act (&#8220;the JOBS Act&#8221;).
For as long as we continue to be an emerging growth company, we may take advantage of exemptions from various reporting requirements
that are applicable to other public companies that are not emerging growth companies, including exemption from compliance with the
auditor attestation requirements of Section 404, reduced disclosure obligations regarding executive compensation and exemptions from
the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute
payments not previously approved. We will remain an emerging growth company until the earlier of (1) the last day of the fiscal year
(a) following the fifth anniversary of the closing of our initial public offering, (b) in which we have total annual gross revenue
of at least $1.235 billion or (c) in which we are deemed to be a large accelerated filer, which means the market value of our common
stock held by non-affiliates exceeds $700 million as of the end of our prior second fiscal quarter, and (2) the date on which we
have issued more than $1 billion in non-convertible debt during the prior three-year period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, under the JOBS Act, emerging growth companies may delay adopting new or revised accounting standards until such time as those
standards apply to private companies. We may elect not to avail ourselves of this exemption from new or revised accounting standards
and, therefore, may be subject to the same new or revised accounting standards as other public companies that are not emerging growth
companies. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some
investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our share
price may be more volatile.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Anti-takeover
provisions contained in our certificate of incorporation and bylaws as well as provisions of Delaware law, could impair a takeover attempt.
</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
certificate of incorporation, bylaws and Delaware law contain provisions which could have the effect of rendering more difficult, delaying
or preventing an acquisition deemed undesirable by our board of directors. Our corporate governance documents include provisions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">authorizing
    &#8220;blank check&#8221; preferred stock, which could be issued by our board of directors without stockholder approval and may contain
    voting, liquidation, dividend, and other rights superior to our common stock; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">limiting
    the liability of, and providing indemnification to, our directors and officers; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">limiting
    the ability of our stockholders to call and bring business before special meetings; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">requiring
    advance notice of stockholder proposals for business to be conducted at meetings of our stockholders and for nominations of candidates
    for election to our board of directors; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">controlling
    the procedures for the conduct and scheduling of board of directors and stockholder meetings; and </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">providing
    our board of directors with the express power to postpone previously scheduled annual meetings and to cancel previously scheduled
    special meetings. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
provisions, alone or together, could delay or prevent hostile takeovers and changes in control or changes in our management. As a Delaware
corporation, we are also subject to provisions of Delaware law, including Section 203 of the Delaware General Corporation law, which
prevents some stockholders holding more than 15% of our outstanding common stock from engaging in certain business combinations without
approval of the holders of substantially all of our outstanding common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
provision of our certificate of incorporation, bylaws or Delaware law that has the effect of delaying or deterring a change in control
could limit the opportunity for our stockholders to receive a premium for their shares of our Common Stock and could also affect the
price that some investors are willing to pay for our Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>


<!-- Field: Page; Sequence: 38; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
amended and restated certificate of incorporation, as amended, designates the Court of Chancery of the State of Delaware as the sole
and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders&#8217;
ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or other employees.</i></b></span></p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
certificate of incorporation requires that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery
of the State of Delaware will, to the fullest extent permitted by law, be the sole and exclusive forum for each of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    derivative action or proceeding brought on our behalf; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    action asserting a claim for breach of any fiduciary duty owed by any director, officer, or other employee of ours to the Company
    or our stockholders, creditors or other constituents; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    action asserting a claim against us or any director or officer of ours arising pursuant to, or a claim against us or any of our directors
    or officers, with respect to the interpretation or application of any provision of, the DGCL, our certificate of incorporation or
    bylaws; or </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    action asserting a claim governed by the internal affairs doctrine; </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">provided,
that, if and only if the Court of Chancery of the State of Delaware dismisses any of the foregoing actions for lack of subject matter
jurisdiction, any such action or actions may be brought in another state court sitting in the State of Delaware.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
exclusive forum provision is limited to the extent permitted by law, and it will not apply to claims arising under the Securities Exchange
Act of 1934, as amended (the &#8220;Exchange Act&#8221;), the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;),
or for any other federal securities laws which provide for exclusive federal jurisdiction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Amended and Restated Certificate of Incorporation, as amended, provides that unless we consent in writing to the selection of an alternative
forum, the federal district courts of the United States of America will be the exclusive forum for the resolution of any complaint asserting
a cause of action arising under the Securities Act or the Securities Exchange Act of 1934, as amended. Any person or entity purchasing
or otherwise acquiring any interest in shares of our capital stock are deemed to have notice of and consented to this provision.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly,
both state and federal courts have jurisdiction to entertain such claims. To prevent having to litigate claims in multiple jurisdictions
and the threat of inconsistent or contrary rulings by different courts, among other considerations, our second amended and restated certificate
of incorporation provides that the federal district courts of the United States of America will be the exclusive forum for resolving
any complaint asserting a cause of action arising under the Securities Act. While the Delaware courts have determined that such choice
of forum provisions are facially valid, a stockholder may nevertheless seek to bring such a claim arising under the Securities Act against
us, our directors, officers, or other employees in a venue other than in the federal district courts of the United States of America.
In such instance, we would expect to vigorously assert the validity and enforceability of the exclusive forum provisions of our second
amended and restated certificate of incorporation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we believe this provision benefits us by providing increased consistency in the application of Delaware law in the types of lawsuits
to which it applies, this provision may limit or discourage a stockholder&#8217;s ability to bring a claim in a judicial forum that it
finds favorable for disputes with us or our directors, officers, or other employees, which may discourage such lawsuits against us and
our directors, officers and other employees. Alternatively, if a court were to find the choice of forum provision contained in our certificate
of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action
in other jurisdictions, which could adversely affect our business and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
note that there is uncertainty as to whether a court would enforce the provision and that investors cannot waive compliance with the
federal securities laws and the rules and regulations thereunder. Although we believe this provision benefits us by providing increased
consistency in the application of Delaware law in the types of lawsuits to which it applies, the provision may have the effect of discouraging
lawsuits against our directors and officers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 39; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/107% Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Business Risks</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have a history of operating losses and may never achieve profitability in the future</i>.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have experienced significant recurring operating losses and negative cash flows from operating activities since inception. For example,
for the years ended December 31, 2023 and 2022, we had net losses of approximately $8.2 million and $11.06 million,
respectively. As of December 31, 2023, we had accumulated deficit of $55,082,677.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect to continue to incur significant losses in the development, marketing, sale and delivery of our services. If we do not grow our
revenues or if we lose existing customers, we expect to continue to incur losses from operations for the foreseeable future. Because
of the numerous risks and uncertainties associated with the development, marketing, sale and delivery of our imaging real world data
(&#8220;iRWD<sup>TM</sup>&#8221;) services, we may experience larger than expected future losses and may never become profitable. Moreover,
there is a substantial risk that we may not be able to successfully commercialize our iRWD<sup>TM</sup> services, which would make it
unlikely that we would ever achieve profitability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">OneMedNet
believes it has demonstrated its quality and responsiveness in clinical imaging and curation of RWD based upon success in compiling one
of the largest networks of imaging centers (comprised of hospitals, imaging centers and clinics) throughout the United States covering
more than 15 million patients to date. On the global front, OneMedNet works with hospitals and life science companies around the world
including Ireland, United Kingdom, Ghana, Denmark and South Korea and growing. We base these claims on our understanding of our competition
in the United States and globally. However, if we were to lose these relationships with our network of imaging centers or lose our customers
or our competitors&#8217; technology surpasses ours, our competitors could claim a greater market share domestically or abroad, which
could reduce our growth and our profits, which could harm our business, financial position, results of operations and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Two
significant customers represented 53% and 52% of our revenues for 2022 and 2023 respectively, and is expected
to continue to represent a significant portion of our forecasted revenue for 2024.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change
Healthcare and Siemens Medical Solutions USA, collectively represented 53% and 52% of our revenues in 2023 and 2022, respectively.
Change Healthcare is expected to continue to represent a significant portion of our forecasted revenue for 2024. If we fail
to maintain and grow our relationships with Change Healthcare, we could lose a significant portion of our revenue for 2023, which
would materially adversely affect our results of operations and our business. If OneMedNet were to lose one or more of its
significant customers, its revenue may significantly decline. In addition, revenue from significant customers may vary from period
to period depending on the timing of renewing existing agreements or entering into new agreements for additional OneMedNet products
as well as other unforeseen risks and variables discussed in this proxy statement/prospectus. The loss of one or more of
OneMedNet&#8217;s significant customers could adversely affect its business, results of operations and financial condition. You
should not rely on our historical relationship with these companies as an indication of our future performance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 40; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may encounter difficulties in managing our attempted growth of our business, which could negatively impact our operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
we expand, market, sell and deliver our service offerings, we anticipate that we will need to increase our service development, sales
and marketing and administrative headcount. Such an evolution may impact our strategic focus and our deployment and allocation of resources.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to manage our operations and growth effectively depends upon the continual improvement of our procedures, reporting systems and
operational, financial and management controls. We may not be able to implement administrative and operational improvements in an efficient
or timely manner and may discover deficiencies in existing systems and controls. If we do not meet these challenges, we may be unable
to execute our business strategies and may be forced to expend more resources than anticipated addressing these issues.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may acquire additional technology and complementary businesses in the future. Acquisitions involve many risks, any of which could materially
harm our business, including the diversion of management&#8217;s attention from core business concerns, failure to effectively exploit
acquired technologies, failure to successfully integrate the acquired business or realize expected synergies or the loss of key employees
from either our business or the acquired businesses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, in order to continue to meet our obligations as a public listed company in both Australia and the United States and to support
our anticipated long-term growth, we will need to increase our general and administrative capabilities. Our management, personnel and
systems may not be adequate to support this future growth. If we are unable to successfully manage our growth and the increased complexity
of our operations, our business, financial position, results of operations and prospects may be harmed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
recent growth rates may not be sustainable, or indicative of future growth.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
historical revenue is extremely low in absolute dollars. While our revenues grew significantly on a percentage basis from 2020 to 2022,
our revenue declined in 2023 over 2022 due to our attention to the Business Combination. The Company has historically been unable
to meet forecasted revenue targets. During the fourth quarter of 2023, the Company shifted its focus to include the full patient data
market. This shift in market space may take time and costs to build our brand and increase market awareness. Our future rate of growth
may not be sustainable or indicative of our future rate of growth. We believe that our continued revenue growth, as well as our ability
to reach profitability, will depend upon, among other factors, our ability to address the challenges, risks and difficulties described
elsewhere in this proxy statement/prospectus. We cannot provide assurance that we will be able to successfully manage any such challenges
or risks to our future growth. Any of these factors could cause our revenue growth to decline and may adversely affect our margins and
reaching profitability. Failure to continue our revenue growth or improve margins would have a material adverse effect on our business,
financial condition and results of operations. You should not rely on our historical rate of revenue growth as an indication of our future
performance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 41; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be unable to execute our business objectives and growth strategies successfully or sustain our growth and, as a result, this could
have a material adverse effect on our operating results.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
highly complex nature of our industry requires that we effectively execute and manage our business objectives and growth strategies,
such as expanding our marketing and commercialization of our services in the U.S. and internationally, adding new customers, and increasing
our service delivery capacity. However, we may not be able to execute on these strategies as effectively as anticipated. Our ability
to execute on these strategies depends on a number of factors, including, without limitation:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to obtain adequate capital resources to execute our growth plans;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to <span style="letter-spacing: 0.2pt">hire, train and retain skilled managers and
                                            personnel, including quality and production personnel, and marketing and commercial specialists;</span></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to protect our existing and new services by registering and defending our intellectual
                                            property rights; and </span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">our
                                            ability to expand to new markets</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to successfully add new customers.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent we are unable to execute on our growth strategies in accordance with our expectations, this could have a material adverse
effect on our business, financial condition, and future results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
real-world data and real-world evidence business market continues to evolve, is highly competitive, and we may not be successful in competing
in this industry or establishing and maintaining confidence in our long-term business prospects among current and future partners and
customers.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
real-world data and real-world evidence business market in which we compete continues to evolve and is highly competitive. To date, we
have focused our efforts on its expertise in clinical imaging innovation solutions that connects healthcare providers and patients and
satisfies a crucial need with the life sciences. We offer direct access to clinical images and associated contextual patient record.
OneMedNet proved the commercial and regulatory viability of imaging Regulatory Grade Real-World Data (&#8220;iRWD<sup>TM</sup>&#8221;),
a promising emerging market, that exactly matches OneMedNet&#8217;s life science partners&#8217; case selection protocol. OneMedNet has
the immediate ability to quickly search and extensively curate multi-layer data from a federated group of healthcare facilities and to
provide fast access to curated medical images that has proved the commercial and regulatory viability of imaging RWD and covers the complete
value chain in imaging RWD, validated by an increasing federated network of providers. However, real-world data and real-world evidence
has been increasingly adopted and our current competitors have, and future competitors may have, greater resources than we do and may
also be able to devote greater resources to the development of their current and future technologies. These competitors also may have
greater access to customers and may be able to establish cooperative or strategic relationships amongst themselves or with third parties
that may further enhance their resources and competitive positioning.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Developments
in improvements in real-world data and real-world evidence curation by competitors may materially adversely affect the sales, pricing
and gross margins of our business. If a competing technology or process is developed that has superior operational or price performance,
our business will be harmed. Similarly, if we fail to accurately predict and ensure that our real-world data and real-world evidence
offering can address customers&#8217; changing needs or emerging technological trends, or if our customers fail to achieve the benefits
expected from our real-world data and real-world evidence offering, our business will be harmed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
must continue to commit resources to develop our real-world data and real-world evidence technology in order to establish a competitive
position, and these commitments will be made without knowing whether such investments will result in products potential customers will
accept. There is no assurance we will successfully identify new customer requirements, develop and bring our real-world data and real-world
evidence to market on a timely basis, or that products and technologies developed by others will not render our real-world data and real-world
evidence obsolete or noncompetitive, any of which would adversely affect our business and operating results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we are unable to attract and retain key employees and qualified personnel, our ability to compete could be harmed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
depend on the talents and continued efforts of our senior management and key employees. The loss of members of our management or key
employees may disrupt our business and harm our results of operations. Further, our ability to manage further expansion will require
us to continue to attract, motivate and retain additional qualified personnel. Competition for this type of personnel is intense, and
we may not be successful in attracting, integrating and retaining the personnel required to grow and operate our business effectively.
There can be no assurance that our current management team or any new members of our management team will be able to successfully execute
our business and operating strategies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
operating and financial results forecast relies in large part upon assumptions and analyses developed by us. If these assumptions or
analyses prove to be incorrect, our actual operating results may be materially different from our forecasted results.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
projected financial and operating information appearing elsewhere in this prospectus reflect current estimates of future performance.
Whether actual operating and financial results and business developments will be consistent with our expectations and assumptions as
reflected in our forecasts depends on a number of factors, many of which are outside our control, including, but not limited to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Aptos; width: 100%">
  <tr>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">success
    and timing of development activity;</span></td></tr>
  <tr>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">customer
    acceptance of our products;</span></td></tr>
  <tr>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">competition,
    including from established and future competitors;</span></td></tr>
  <tr>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    we can obtain sufficient capital to sustain and grow our business;</span></td></tr>
  <tr>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to manage our growth;</span></td></tr>
  <tr>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    we can manage and add relationships with key suppliers;</span></td></tr>
  <tr>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to expand into additional markets</span></td></tr>
  <tr>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to retain existing key management, integrate recent hires and attract, retain and motivate qualified personnel; and</span></td></tr>
  <tr>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    overall strength and stability of domestic and international economies. </span></td></tr>
  <tr>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Having
    the capital requirements to expand resources</span></td></tr>
  </table>
<p style="font: 11pt/107% Aptos; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unfavorable
changes in any of these or other factors, most of which are beyond our control, could materially and adversely affect our business, results
of operations and financial results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
operations could be damaged or adversely affected as a result of natural disasters and other catastrophic events.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
operations could be adversely affected by events outside of our control, such as natural disasters, wars, health epidemics, and other calamities<i>.</i> We cannot assure you that any backup systems will be adequate to protect us from
the effects of fire, floods, typhoons, earthquakes, power loss, telecommunications failures, break-ins, war, riots, terrorist attacks
or similar events. Any of the foregoing events may give rise to interruptions, breakdowns, system failures, technology platform failures
or internet failures, which could cause the loss or corruption of data or malfunctions of software or hardware as well as adversely affect
our ability to provide services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Any
financial or economic crisis, or perceived threat of such a crisis, including a significant decrease in consumer confidence, may materially
and adversely affect our business, financial condition, and results of operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
recent years, the United States and global economies suffered dramatic downturns as the result of the COVID-19 pandemic, a deterioration
in the credit markets and related financial crisis as well as a variety of other factors including, among other things, extreme volatility
in security prices, severely diminished liquidity and credit availability, ratings downgrades of certain investments and declining valuations
of others. The United States and certain foreign governments have taken unprecedented actions in an attempt to address and rectify these
extreme market and economic conditions by providing liquidity and stability to the financial markets. If the actions taken by these governments
are not successful, the return of adverse economic conditions may negatively impact the demand for iRWD<sup>TM</sup> offering and may
negatively impact our ability to raise capital, if needed, on a timely basis and on acceptable terms or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 43; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
ability to utilize our net operating loss and tax credit carryforwards to offset future taxable income may be subject to certain limitations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, under Section 382 of the Code, a corporation that undergoes an &#8220;ownership change&#8221; is subject to limitations on its
ability to use its pre-change net operating loss carryforwards (&#8220;NOLs&#8221;), to offset future taxable income. The limitations
apply if a corporation undergoes an &#8220;ownership change,&#8221; which is generally defined as a greater than 50 percentage point
change (by value) in its equity ownership by certain stockholders over a three-year period. If we have experienced an ownership change
at any time since our incorporation, we may already be subject to limitations on our ability to utilize our existing NOLs and other tax
attributes to offset taxable income or tax liability. In addition, the Business Combination and future changes in our stock ownership,
which may be outside of our control, may trigger an ownership change. Similar provisions of state tax law may also apply to limit our
use of accumulated state tax attributes. As a result, even if we earn net taxable income in the future, our ability to use these or our
pre-change NOL carryforwards and other tax attributes to offset such taxable income or tax liability may be subject to limitations, which
could potentially result in increased future income tax liability to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is also a risk that changes in law or regulatory changes made in response to the need for some jurisdictions to raise additional revenue
to help counter the fiscal impact from unforeseen reasons, including suspensions on the use of net operating losses or tax credits, possibly
with retroactive effect, may result in our existing net operating losses or tax credits expiring or otherwise being unavailable to offset
future income tax liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are subject to many hazards and operational risks that can disrupt our business, some of which may not be insured or fully covered by
insurance.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
operations are subject to many hazards and operational risks inherent to our business, including: (a) general business risks; (b) warranty
liability; and (c) damage to third parties (e.g., our vendors), our infrastructure or properties caused by fires, floods and other natural
disasters, power losses, telecommunications failures, terrorist attacks, riots, cyberattacks, public health crises such as the current
COVID-19 pandemic (and other future pandemics or epidemics), human errors and similar events. As a result of the COVID-19 outbreak, or
similar pandemics, we have and may in the future experience disruptions that could severely impact our business and the business of our
customers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
insurance coverage may be inadequate to cover our liabilities related to such hazards or operational risks. For example, we do not currently
maintain cybersecurity insurance and our insurance providers may take the position that our coverage, under present circumstances, does
not extend to business interruptions as they relate to the COVID-19 pandemic. In addition, we may not be able to maintain adequate insurance
in the future at rates we consider reasonable and commercially justifiable, and insurance may not continue to be available on terms as
favorable as our current arrangements. The occurrence of a significant uninsured claim or a claim in excess of the insurance coverage
limits maintained by us could have a material adverse effect on our business, financial condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
management has limited experience in operating a public company.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
executive officers have limited experience in the management of a publicly traded company. Our management team may not successfully or
effectively manage our transition to a public company that will be subject to significant regulatory oversight and reporting obligations
under federal securities laws. For example, in connection with the closing of the Business Combination, the Company was required to
restate and refile its Form 10-Q for quarter end September 30, 2023. The Company failed to file timely a disclosure under Item 4.02 Form
8-K to announce the restatement and refiling of the Form 10-Q, which it filed December 15, 2023 and its related failure to file a Form
NT 10-Q for the quarter ended September 30, 2023 to <span>disclose in SEC Form 12b-25 filings a request
for seeking a delayed quarterly or annual reporting filing was caused by an anticipated restatement or correction of prior financial
reporting, which filing failures reflect certain of the Company&#8217;s </span>executive officers limited experience in the management
of a publicly traded company. Their limited experience in dealing with the increasingly complex laws pertaining to public companies
could be a significant disadvantage in that it is likely that an increasing amount of their time may be devoted to these activities which
will result in less time being devoted to the management and growth of our Company. We may not have adequate personnel with the appropriate
level of knowledge, experience, and training in the accounting policies, practices or internal controls over financial reporting required
of public companies in the United States. The development and implementation of the standards and controls necessary for us to achieve
the level of accounting standards required of a public company in the United States may require costs greater than expected. It is possible
that we will be required to expand our employee base and hire additional employees to support our operations as a public company which
will increase our operating costs in future periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 44; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
requirements of being a public company may strain our resources and divert management&#8217;s attention, and the increases in legal,
accounting, insurance and compliance expenses may be greater than we anticipate.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a public company, and as such (and particularly after we are no longer an &#8220;emerging growth company&#8221;), will incur significant
legal, accounting and other expenses that OneMedNet did not incur prior to the business combination. We are subject to the reporting
requirements of the Exchange Act, and are required to comply with the applicable requirements of the Sarbanes-Oxley Act and the Dodd-Frank
Wall Street Reform and Consumer Protection Act, as well as the rules and regulations subsequently implemented by the SEC and the listing
standards of The Nasdaq Stock Market, including changes in corporate governance practices and the establishment and maintenance of effective
disclosure and financial controls. Compliance with these rules and regulations can be burdensome. Our management and other personnel
need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations will increase our
historical legal and financial compliance costs and will make some activities more time-consuming and costly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
example, we expect that these rules and regulations may make it more difficult and more expensive for us to attract and retain qualified
members of our Board as compared to OneMedNet prior to the business combination as well as significantly more expensive to provide the
required insurance. In particular, we expect to incur significant expenses and devote substantial management effort toward ensuring compliance
with the requirements of Section&#160;404 of the Sarbanes-Oxley Act, which will increase when we are no longer an &#8220;emerging growth
company.&#8221; We will need to hire additional accounting and financial staff, and engage outside consultants, all with appropriate
public company experience and technical accounting knowledge and maintain an internal audit function, which will increase our operating
expenses. Moreover, we could incur additional compensation costs in the event that we decide to pay cash compensation closer to that
of other public companies, which would increase our general and administrative expenses and could materially and adversely affect our
profitability. We are evaluating these rules and regulations, and cannot predict or estimate the amount of additional costs we may incur
or the timing of such costs.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
securities or industry analysts do not publish or cease publishing research or reports about us, our business, or the market in which
we operate, or if they change their recommendations regarding our securities adversely, the price and trading volume of our securities
could decline.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
trading market for our securities will be influenced by the research and reports that industry or securities analysts may publish about
us, our business, market or competitors. Securities and industry analysts do not currently, and may never, publish research on us. If
no securities or industry analysts commence coverage of us, our share price and trading volume would likely be negatively impacted. If
any of the analysts who may cover us change their recommendation regarding our shares of Common Stock adversely, or provide more favorable
relative recommendations about our competitors, the price of our shares of Common Stock would likely decline. If any analyst who may
cover us were to cease our coverage of us or fail to regularly publish reports on it, we could lose visibility in the financial markets,
which in turn could cause our share price or trading volume to decline.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Ownership of Our Common Stock, this Offering, and Our Certificate of Incorporation and Bylaws Provisions</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
Common Stock has been and may in the future continue to be subject to extreme volatility.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
trading price of our Common Stock may be subject to extreme volatility. We cannot predict the magnitude of future fluctuations in the
trading price of our Common Stock. The trading price of our Common Stock may be affected by a number of factors, including events described
in the risk factors set forth in this prospectus and in our periodic reports filed with the SEC from time to time, as well as our operating
results, financial condition and other events or factors. Any of the factors listed below could have a material adverse effect on your
investment in our securities. Factors affecting the trading price of our securities may include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
    by us or our competitors regarding technical developments and levels of performance achieved by our or their real-world data and
    real-world evidence offering;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
    by us regarding developments in our relationship with existing and future key customers;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to bring our products and technologies to market on a timely basis, or at all;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    operating results or development efforts failing to meet the expectation of securities analysts or investors in a particular period;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual
    or anticipated fluctuations in our quarterly financial results or the quarterly financial results of companies perceived to be similar
    to it;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in the market&#8217;s expectations about our operating results or the real-world data and real-world evidence industry;</span></td></tr>
</table>

<p style="padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Page; Sequence: 45; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">success
    of competitors actual or perceived development efforts;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in financial estimates and recommendations by securities analysts concerning the Company or the real-world data and real-world evidence
    industry in general;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">operating
    and share price performance of other companies that investors deem comparable to the Company;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disputes
    or other developments related to proprietary rights, including patents, litigation matters and our ability to obtain intellectual
    property protection for our technologies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in laws and regulations affecting our business;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to meet compliance requirements;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">commencement
    of, or involvement in, litigation involving the Company;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in our capital structure, such as future issuances of securities or the incurrence of additional debt;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    volume of shares of Common Stock available for public sale;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    level of demand for our Common Stock, including the amount of short interest in our stock;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    major change in our Board or management;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">sales
    of substantial amounts of the shares of Common Stock by our directors, executive officers or significant stockholders or the perception
    that such sales could occur;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    expiration of contractual lock-up agreements with our executive officers, directors and stockholders, which we have entered into
    and may enter into in the future from time to time; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">general
    economic and political conditions such as recessions, interest rates, fuel prices, international currency fluctuations and acts of
    war or terrorism.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Broad
market and industry factors may materially harm the market price of our securities irrespective of our operating performance. The stock
market in general, and the Nasdaq in particular, have experienced price and volume fluctuations that have often been unrelated or disproportionate
to the operating performance of the particular companies affected. The trading prices and valuations of these stocks, and of our securities,
may not be predictable. A loss of investor confidence in the market for retail stocks or the stocks of other companies which investors
perceive to be similar to the Company could depress our share price regardless of our business, prospects, financial conditions or results
of operations. A decline in the market price of our securities also could adversely affect our ability to issue additional securities
and our ability to obtain additional financing in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
certain periods of volatility in the market price of our securities, we may become subject of securities litigation. We have experienced,
and may in the future experience additional litigation following periods of volatility. This type of litigation may result in substantial
costs and a diversion of management&#8217;s attention and resources.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Sales
of substantial amounts of our Common Stock in the public markets, or the perception that such sales could occur, could reduce the price
that our Common Stock might otherwise attain.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
of a substantial number of shares of our Common Stock in the public market after this offering, or the perception that such sales could
occur, could adversely affect the market price of our Common Stock and may make it more difficult for you to sell your Common Stock at
a time and price that you deem appropriate. Based on the total number of outstanding shares, approximately <span style="background-color: white">23,850,010
</span>shares of our Common Stock as of that date hereof, the issuance of up to 19,683,367 shares of Common Stock
pursuant to this offering would represent a substantial amount of dilution to existing stockholders. A majority of the shares
of Common Stock sold in this offering will be freely tradable without restrictions or further registration under the Securities Act,
except for any shares held by existing officers and directors of the Company and former officers and directors of DKAC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Future
sales, or the perception of future sales, by us or our stockholders in the public market could cause the market price for our Common
Stock to decline.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
sale of our Common Stock in the public market, or the perception that such sales could occur, could harm the prevailing market price
of our Common Stock. These sales, or the possibility that these sales may occur, also might make it more difficult for us to sell equity
securities in the future at a time and at a price that it deems appropriate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
additional capital will be needed in the future to continue our planned operations, including further development of our iRWD<sup>TM
</sup>offering, growth of our sales and marketing team, development activities and costs associated with operating a public company.
To raise capital, we may sell common stock, convertible securities or other equity securities in one or more transactions at prices and
in a manner as determined from time to time. If we sell common stock, convertible securities or other equity securities, investors may
be materially diluted by subsequent sales. Such sales may also result in material dilution to existing stockholders, and new investors
could gain rights, preferences and privileges senior to the holders of our Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 46; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Company&#8217;s 2022 Equity Incentive Plan, our board of directors or compensation committee is authorized to grant stock
options to our employees, directors and consultants. Initially, the maximum aggregate number of shares of Common Stock that may be issued
pursuant to stock awards under the 2022 Equity Incentive Plan is 1,685,881 shares of Common Stock. Additionally, the number of
shares of Common Stock reserved for issuance under the 2022 Equity Incentive Plan will automatically increase on January 1 of
each year, beginning on January 1, 2025 and continuing through and including January 1, 2032, by 5% of the total number of shares of
Common Stock outstanding on December 31 of the preceding calendar year, subject to a maximum annual increase of 1,000,000 shares of Common
Stock or a lesser number of shares determined by our board of directors. Unless our board of directors elects not to increase the number
of shares available for future grant each year, our stockholders may experience additional dilution, which could cause our stock price
to fall. Our issuance of additional shares of common stock or other equity securities of equal or senior rank would, all else being equal,
have the following effects:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    amount of cash available per share, including for payment of dividends in the future, may decrease;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    relative voting strength of each previously outstanding share of common stock would be diminished; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    market price of shares of shares of Common Stock may decline.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the future, we may also issue its securities in connection with investments or acquisitions. The amount of Common Stock issued in connection
with an investment or acquisition could constitute a material portion of the then-outstanding Common Stock. Any issuance of additional
securities in connection with investments or acquisitions may result in additional dilution to our stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
unaudited pro forma financial information included herein is not indicative of what our actual financial position or results of operations
would have been.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unaudited pro forma financial information included herein is presented for illustrative purposes only and is not necessarily indicative
of what our actual financial position or results of operations would have been had the Business Combination been completed on the dates
indicated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>There
is no guarantee that the warrants will ever be in the money; they may expire worthless or the terms of warrants may be amended.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
exercise price for the warrants is $11.50 per share of Common Stock. There is no guarantee that the Public Warrants will ever be in the
money prior to their expiration, and as such, the warrants may expire worthless.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, our warrants were issued in registered form under a warrant agreement between Continental Stock Transfer&#160;&amp; Trust Company,
as warrant agent, and DKAC. The warrant agreement provides that the terms of the warrants may be amended without the consent of any holder
to cure any ambiguity or correct any defective provision, but requires the approval by the holders of at least a majority of the then
outstanding Public Warrants to make any other change. Accordingly, we may amend the terms of the warrants in a manner adverse to a holder
if holders of at least a majority of the then outstanding Public Warrants approve of such amendment. Although our ability to amend the
terms of the warrants with the consent of at least a majority of the then outstanding Public Warrants is unlimited, examples of such
amendments could be amendments to, among other things, increase the exercise price of the warrants, shorten the exercise period or decrease
the number of shares and their respective affiliates and associates have of shares of Common Stock purchasable upon exercise of a warrant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
certain holders of our Common Stock sell a significant portion of their securities, it may negatively impact the market price of the
shares of our Common Stock and such holders still may receive significant proceeds.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this prospectus, the market price of our common stock is below $10.00 per share, which was the price per share of Class
A Common Stock sold in the initial public offering of our predecessor, Data Knights, the per share price of the PIPE shares sold to certain
investors in connection with our Pre-Closing PIPE financing and also the per share value of the consideration issued to former Selling
Securityholders of OneMedNet upon consummation of our Business Combination. However, certain of our stockholders who hold shares of our
Common Stock that were originally purchased by our predecessor&#8217;s sponsor, Data Knights LLC, in a private placement prior to our
predecessor&#8217;s initial public offering (the &#8220;Founder Shares&#8221;). In particular, 2,875,000 of the currently outstanding
Founder Shares were purchased at an effective price of $0.009 per share, and the 1,439,563 of the currently outstanding shares of Common
Stock held by ARC Group Limited and registered for resale in this prospectus were issued solely in consideration for services to Data
Knights. Accordingly, holders of these shares of Common Stock could sell their securities at a per share price that is less than $10.00
and still realize a significant return from the sale of those securities that could not be realized by our other stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
securities being offered in this prospectus represent a substantial percentage of our outstanding Common Stock, and the sales of such
securities, or the perception that these sales could occur, could cause the market price of our Common Stock to decline significantly.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus relates to the offer and sale from time to time by the Selling Securityholders of of up to an aggregate of 19,683,367 shares
of Common Stock consisting of (i)&#160;797,872 shares of Common Stock upon conversion of up to $1,595,744.70 of OneMedNet Senior Secured
Convertible Notes (the &#8220;Pre-Closing PIPE Notes&#8221;) issued at the closing of the Business Combination (as defined below) that
are convertible into shares of Common Stock at the PIPE investors election at a conversion price equal to the lower of (i) $10.00 per
share, and (ii) 92.5% of the lowest volume weighted average trading price for the ten (10) trading days immediately preceding the Conversion
Date, subject to a floor price of $2.00 per share of common stock pursuant to the terms of the Securities Purchase Agreement dated June
28, 2023, by and among Data Knights Acquisition Corp, a Delaware corporation (&#8220;Data Knights&#8221;) and the named investors (the
&#8220;Pre-Closing PIPE&#8221;), (ii) 95,744 shares underlying 95,744 warrants issued to the PIPE investors as additional consideration
for the PIPE investors investment in the Pre-Closing PIPE Notes, which Warrant Agreements were executed at the closing of the Business
Combination, (iii) 7,312,817 shares of Common Stock upon conversion (the &#8220;Conversion Shares) of up to $4,547,500 of funding to
the Company pursuant to the Securities Purchase Agreement and convertible promissory notes <span style="background-color: white">dated
</span>March 28, 2024 <span style="background-color: white">(the &#8220;PIPE Notes Financing&#8221;), at the price of $0.62 per share
of Common Stock, with Helena Global Investment Opportunities 1 Ltd. (the &#8220;Notes Investor&#8221;),</span> (iv) 3,656,408 shares
underlying 3,656,408 warrants issued to the Notes Investor as additional consideration for the <span style="background-color: white">PIPE
Notes Financing</span> with the Notes Investor, (v) 277,778 shares of Common Stock issued pursuant to the terms of the Satisfaction and
Discharge Agreement at $10.88 per share of Common Stock dated as of June 28, 2023, by and among the Company, Data Knights, and EF Hutton
LLC (&#8220;EF Hutton&#8221;), (vi) 1,315,840 shares of Common Stock issuable pursuant to the outstanding loans converted to equity at
$1.00 per share of Common Stock to Data Knights to fund its extension payments prior to the Business Combination by certain of the Selling
Securityholders named in this prospectus, (vii) 1,439,563 shares of Common Stock issued upon the closing of the Business Combination
to ARC Group Limited, as consideration for its financial advisory services <span style="background-color: white">&#160;at a cash price
of $0.00 per share</span> of Common Stock, (viii) 1,327,070 shares of Common Stock at $0.7535 <span style="background-color: white">per
share</span> of Common Stock (95% of VWAP 10-day average $0.7932) for $1,000,000 investment by Dr. Thomas Kosasa, and (ix)&#160;3,609,859
shares of Common Stock issued to Data Knights LLC (the &#8220;Sponsor&#8221;) and its affiliates, including 2,875,000 shares of Common
Stock originally issued as share of Class B Stock in connection with the initial public offering of DKAC for aggregate consideration
of $25,000, or approximately $0.009 per share for the founder shares, and 585,275 shares of Common Stock originally issued to Sponsor
as part of the Placement Units issued to the Sponsor in connection with DKAC&#8217;s initial public offering at $10.00 per unit, and
which are subject to six month lock-up restrictions set forth herein; and (b)&#160;the selling warrant holders named in this prospectus
(including their permitted transferees, donees, pledgees and other successors-in-interest) (collectively, the &#8220;Selling Warrantholders&#8221;
and, together with the Selling Shareholders and including their permitted transferees, the &#8220;Selling Securityholders&#8221;) of
up to an aggregate of 585,275 Placement Warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus also relates to the issuance by us of up to of (i) up to 11,500,000 shares of Common Stock issuable upon the exercise of 11,500,000
warrants (the &#8220;Public Warrants&#8221;) originally issued and registered in the initial public offering of Data Knights Acquisition
Corp&#8221; as a special purpose acquisition company (&#8220;DKAC&#8221;) <span style="background-color: white">at a price of $10.00
per unit with each unit consisting of one share of Class&#160;A common stock and one warrant (each Public Warrant entitles the holder
thereof to purchase one share of Class A common stock at a price of $11.50 per share)</span>, and (ii)&#160;up to an aggregate of 585,275
shares of Common Stock issuable upon the exercise of 585,275 warrants (the &#8220;Placement Warrants,&#8221; together with the Public
Warrants, the &#8220;Warrants&#8221;) that made up a part of the private units originally issued in a private placement in connection
with DKAC&#8217;s initial public offering at a price of $10.00 per unit, for an aggregate purchase price of $5,852,750. We will receive
the proceeds from any exercise of the Warrants for cash.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 47; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this prospectus, the price at which our <span style="background-color: white">common stock </span>trade is lower than
the initial trading price of the shares sold pursuant to the initial public offering of DKAC. Despite the differences in the trading
price of our securities and the initial trading price of the securities of DKAC, certain of the Selling Securityholders may be incentivized
to sell their shares because they may experience a positive rate of return on the securities they purchased due to the differences in
the purchase prices described in the preceding paragraph and the public trading price of our securities. Based on the closing price of
our Common Stock of $0.57 as of May 2, 2024, upon the sale of our Common Stock, (a) the PIPE investors in the Pre-Closing PIPE Notes
may experience a potential loss of up to $1.43 per share, (b) the investors in the <span style="background-color: white">PIPE Notes Financing
</span>may experience a potential loss of up to $0.05 per share, (c) EF Hutton LLC may experience a potential loss of up to $10.31 per
share, (d) the Sponsor may experience a potential profit of $0.57 per share on the founder shares and may experience a potential loss
of up to $9.43 per share on the private placement shares, (e) the DKAC outstanding loans conversion shares may experience a potential
loss of up to $0.43 per share, (f) ARC Group may experience a potential profit of $0.57 per share, and (g) Dr. Thomas Kosasa may experience
a potential loss of up to $0.18.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
though the current trading price is at or significantly below DKAC&#8217;s initial public offering price, the private investors have
an incentive to sell because they will still profit on sales because of the lower price that they purchased their shares than the public
investors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
the Sponsor, private placement investors, PIPE investors and other Selling Securityholders may experience a positive rate of return based
on the current trading price of the Company&#8217;s Common Stock, the public securityholders may not experience a similar rate of return
on the securities they purchased due to differences in the purchase prices and the current trading price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Common Stock and Warrants being offered for resale in this prospectus represent a substantial percentage of the total outstanding shares
of our Common Stock as of the date of this prospectus. The outstanding Common Stock being offered in this prospectus represent approximately
82.5% of our outstanding. Additionally, if all the Warrants are exercised, the Selling Securityholders would own an additional<b>&#160;</b>12,085,275
shares of Common Stock, representing an additional 50.7% of the total outstanding Common Stock. The sale of all the securities being
offered in this prospectus, or the perception that these sales could occur, could result in a significant decline in the public trading
price of our Common Stock.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the transactions contemplated by the Merger Agreement (the &#8220;Transactions&#8221;), certain holders of the Company&#8217;s
securities entered into a Lock-Up Agreement pursuant to which they agreed to certain restrictions on the transfer of their Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
PIPE Investors under the Pre-Closing PIPE are entitled to require us to register shares underlying the Pre-Closing PIPE Notes and the
PIPE Warrants owned by them for public sale in the United States, and the Investors under the Notes Securities Purchase Agreement are
entitled to require us to register shares underlying the Notes and Warrants related thereto, thus we are filing this proxy statement/prospectus,
to register those shares of Common Stock. Subject to the satisfaction of applicable exercise periods and expiration of the lock-up agreements
referred to above, the shares issued upon exercise of the Pre-Closing PIPE Notes and the PIPE Warrants will be available for immediate
resale in the United States in the open market. See the section titled &#8220;<i>Shares Eligible for Future Sale</i>&#8221; for additional
information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may redeem the unexpired warrants prior to their exercise at a time that is disadvantageous to warrant holders, thereby making their
warrants worthless.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have the ability to redeem outstanding warrants at any time after they become exercisable and prior to their expiration, at a price
of $0.01 per warrant, provided that the last reported sales price of the Common Stock equals or exceeds $18.00 per share for any 20
trading days within a 30 trading-day period ending on the third&#160;trading day prior to the date we send the notice of redemption
to the warrant holders. If and when the warrants become redeemable by us, we may exercise its redemption right even if we are unable
to register or qualify the underlying securities for sale under all applicable state securities laws. Additionally, ninety
(90)&#160;days after the warrants become exercisable, we may redeem all (but not less than all) of the outstanding warrants at $0.01
per warrant upon a minimum of 30&#160;days&#8217; prior written notice of redemption if the following conditions are satisfied:
(i) the last reported sale prices of the Common Stock equals or exceeds $18.00 per share (as may be adjusted for stock splits,
stock dividends, reorganizations, recapitalizations or the like) on the trading day prior to the date of the notice;
(ii)&#160;the private placement warrants are also concurrently exchanged at the same price as the outstanding Public Warrants; and
(iii)&#160;there is an effective registration statement covering the issuance of Common Stock issuable upon exercise of the warrants
and a current prospectus relating thereto available throughout the 30-day period after written notice of redemption is given. In
either case, redemption of the outstanding warrants could force you (i)&#160;to exercise your warrants and pay the exercise price
therefor at a time when it may be disadvantageous for you to do so, (ii)&#160;to sell your warrants at the then-current market price
when you might otherwise wish to hold your warrants or (iii)&#160;to accept the nominal redemption price which, at the time the
outstanding warrants are called for redemption, is likely to be substantially less than the market value of your
warrants.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have broad discretion in the use of the net proceeds from this offering and may not use them effectively.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management has broad discretion in the application of the net proceeds from this offering, including to provide sufficient funding to
grow our customer base and for working capital and general corporate purposes, and we may spend or invest these proceeds in a way with
which our stockholders disagree. Because of the number and variability of factors that will determine our use of the net proceeds from
this offering, their ultimate use may vary substantially from their currently intended use. The failure by our management to apply these
funds effectively could harm our business. Pending their use, we may invest such proceeds in a manner that does not produce income or
that loses value, which may negatively impact the market price of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
business model is capital-intensive, and we may not be able to raise additional capital on attractive terms, if at all, which could be
dilutive to stockholders. If we cannot raise additional capital when needed, our operations and prospects could be materially and adversely
affected.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
can be expected to continue to sustain substantial operating expenses without generating sufficient revenues to cover expenditures. Over
time, we expect that we will need to raise additional funds, including through the issuance of equity, equity-related or debt securities
or through obtaining credit from financial institutions to fund, together with our principal sources of liquidity, ongoing costs, any
significant unplanned or accelerated expenses, and new strategic investments. We cannot be certain that additional capital will be available
on attractive terms, if at all, when needed, which could be dilutive to stockholders, and our financial condition, results of operations,
business and prospects could be materially and adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
do not expect to declare any dividends in the foreseeable future.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not anticipate declaring any cash dividends to holders of our Common Stock in the foreseeable future. Consequently, investors may
need to rely on sales of their shares after price appreciation, which may never occur, as the only way to realize any future gains on
their investment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>There
can be no assurance that we will be able to comply with the continued listing standards of the Nasdaq.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Common Stock and public Warrants are listed on the Nasdaq under the symbols &#8220;ONMD&#8221; and &#8220;ONMDW&#8221;, respectively.
If the Nasdaq delists our securities from trading on its exchange for failure to meet the listing standards and we are not able to list
such securities on another national securities exchange, we expect such securities could be quoted on an over-the-counter market. If
this were to occur, we and our stockholders could face significant material adverse consequences including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    limited availability of market quotations for our securities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduced
    liquidity for our securities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    limited amount of news and analyst coverage; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    decreased ability to issue additional securities or obtain additional financing in the future.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Warrants</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may redeem unexpired Warrants prior to their exercise at a time that is disadvantageous to Warrantholders.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
public Warrants are currently exercisable for one share of Common Stock at a price of $11.50 per share. We have the ability to redeem
outstanding Warrants at any time prior to their expiration, at a price of $0.01 per Warrant, provided that the last reported sales price
of Common Stock equals or exceeds $18.00 per share for any 20 trading days within a 30-trading day period ending on the third trading
day prior to the date we send the notice of redemption to Warrantholders and provided certain other conditions are met. If and when the
Warrants become redeemable by us, we may exercise our redemption rights even if we are unable to register or qualify the underlying securities
for sale under all applicable state securities laws. As a result, we may redeem the Warrants, as set forth above even if the holders
are otherwise unable to exercise the Warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Redemption
of the outstanding Warrants could force Warrantholders (i) to exercise their Warrants and pay the exercise price therefor at a time when
it may be disadvantageous for them to do so, (ii) to sell their Warrants at the then-current market price when they might otherwise wish
to hold their Warrants or (iii) to accept the nominal redemption price which, at the time the outstanding Warrants are called for redemption,
we expect would be substantially less than the market value of their Warrants. None of the private placement Warrants will be redeemable
by us so long as they are held by the Sponsor or its permitted transferees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="background-color: white">We
believe the likelihood that warrant holders will exercise their Warrants, and therefore the amount of cash proceeds that we would receive,
is dependent upon the market price of our shares of Common Stock. When the market price for our shares of Common Stock is less than $11.50&#160;per
share (<i>i.e.,</i> the Warrants are &#8220;out of the money&#8221;), which it is at the time of this prospectus, we believe warrant
holders will be unlikely to exercise their Warrants.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 48; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_009"></span>USE
OF PROCEEDS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of the shares of Common Stock offered by the Selling Securityholders pursuant to this prospectus will be sold by the Selling Securityholders
for their respective accounts. The Company will not receive any of the proceeds from these sales.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company will receive up to an aggregate of approximately $138.9&#160;million from the exercise of the Warrants, assuming the exercise
in full of all of the Warrants for cash. The Company expects to use the net proceeds from the exercise such warrants for other general
corporate purposes. There is no assurance that the holders of the Warrants will elect to exercise any or all of such warrants. To the
extent that warrants are exercised on a &#8220;cashless basis,&#8221; the amount of cash we would receive from the exercise of such warrants
will decrease. See &#8220;<i>Description of Securities we are Offering</i>&#8221; for additional information regarding the warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Selling Securityholders will pay any underwriting fees, discounts and selling commissions incurred by such Selling Securityholders in
disposing of their Common Stock. Pursuant to the Registration Rights Agreement, the Company will bear all other costs, fees and expenses
incurred in effecting the registration of the Common Stock covered by this prospectus, including, without limitation, all registration
and filing fees, Nasdaq listing fees and fees and expenses of counsel and independent registered public accountants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_010"></span>DILUTION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you invest in our securities, your ownership interest will be diluted to the extent of the difference between public offering price per
share of our Common Stock and the as adjusted net tangible book value per share of our Common Stock immediately after this offering. </span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">As
of December 31, 2023 we had a historical net tangible book value of $(12,859,605), or $(0.55) per share of Common
Stock, based on 23,572,232 shares of Common Stock outstanding at December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent that stock options or warrants are exercised, new stock options are issued under our equity incentive plan, or we issue additional
common stock in the future, there will be further dilution to investors participating in this offering. In addition, we may choose to
raise additional capital because of market conditions or strategic considerations, even if we believe that we have sufficient funds for
our current or future operating plans. If we raise additional capital through the sale of equity or convertible debt securities, the
issuance of these securities could result in further dilution to our stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 49; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_011"></span>DESCRIPTION
OF SECURITIES WE ARE OFFERING</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common
Stock </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
description of our Common Stock under the section &#8220;Description of Capital Stock&#8221; in this prospectus is incorporated herein
by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants
</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>General
- </i></b>The following is a brief summary of certain terms and conditions of the warrants being offered by us. The following description
is subject in all respects to the provisions contained in the form of warrant, the form of which will be filed as an exhibit to the registration
statement of which this prospectus forms a part.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Duration
and Exercise Price - </i></b>The warrants offered hereby will have an exercise price of $[*] per share. The warrants will be immediately
exercisable and may be exercised at any time on or after the initial exercise date and on or before the five-year anniversary of the
date of issuance. The exercise prices and numbers of shares of Common Stock issuable upon exercise are subject to appropriate adjustment
in the event of stock dividends, stock splits, reorganizations or similar events affecting our Common Stock. Warrants will be issued
in certificated form only.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Exercisability
- </i></b>The warrants will be exercisable, at the option of each holder, in whole or in part, by delivering to us a duly executed exercise
notice accompanied by payment in full for the number of shares of our Common Stock purchased upon such exercise (except in the case of
a cashless exercise as discussed below). A holder (together with its affiliates) may not exercise any portion of such holder&#8217;s
warrants to the extent that the holder would own more than 4.99% (or 9.99%, at the holder&#8217;s election) of our outstanding Common
Stock immediately after exercise, except that upon notice from the holder to us, the holder may decrease or increase the limitation of
ownership of outstanding stock after exercising the holder&#8217;s warrants up to 9.99% of the number of shares of our Common Stock outstanding
immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the warrants,
provided that any increase in such limitation shall not be effective until 61 days following notice to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cashless
Exercise - </i></b>If, at the time a holder exercises its warrants, a registration statement registering the issuance of the shares of
Common Stock underlying the warrants under the Securities Act, is not then effective or available for the issuance of such shares, then
in lieu of making the cash payment otherwise contemplated to be made to us upon such exercise in payment of the aggregate exercise price,
the holder may elect instead to receive upon such exercise (either in whole or in part) the net number of shares of Common Stock determined
according to a formula set forth in the warrant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Alternative
Cashless Exercise - </i></b>On or after the thirty (30) day anniversary of the date of the underwriting agreement, a holder of common
warrants may also provide notice and elect an &#8220;alternative cashless exercise&#8221; pursuant to which they would receive an aggregate
number of shares equal to the product of (x) the aggregate number of shares of common stock that would be issuable upon a cash exercise
and (y) [*].</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 50; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Transferability
- </i></b>A warrant may be transferred at the option of the holder upon surrender of the warrant to us together with the appropriate
instruments of transfer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Fractional
Shares - </i></b>No fractional shares of Common Stock will be issued upon the exercise of the warrants. Rather, the number of shares
of Common Stock to be issued will, at our election, either be rounded up to the nearest whole number or we will pay a cash adjustment
in respect of such final fraction in an amount equal to such fraction multiplied by the exercise price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Trading
Market - </i></b>There is no established trading market for any of the warrants, and we do not expect a market to develop. We do not
intend to apply for a listing for any of the warrants on any securities exchange or other nationally recognized trading system. Without
an active trading market, the liquidity of the warrants will be limited.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Rights
as a Shareholder - </i></b>Except as otherwise provided in the warrants or by virtue of the holders&#8217; ownership of shares of our
Common Stock, the holders of warrants do not have the rights or privileges of holders of our Common Stock, including any voting rights,
until such warrant holders exercise their warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Fundamental
Transaction - </i></b>In the event of a fundamental transaction, as described in the warrants and generally including any reorganization,
recapitalization or reclassification of our common stock, the sale, transfer or other disposition of all or substantially all of our
properties or assets, our consolidation or merger with or into another person, the acquisition of more than 50% of our outstanding Common
Stock, or any person or group becoming the beneficial owner of 50% of the voting power represented by our outstanding common stock, the
holders of the warrants will be entitled to receive upon exercise of the warrants the kind and amount of securities, cash or other property
that the holders would have received had they exercised the warrants immediately prior to such fundamental transaction. In the event
of a Change of Control (as defined in each common warrant) approved by our Board of Directors, the holders of the common warrants have
the right to require us or a successor entity to redeem the common warrants for cash in the amount of the Black-Scholes Value (as defined
in each common warrant) of the unexercised portion of the common warrants on the date of the consummation of the Change of Control. In
the event of a Change of Control which is not approved by our Board of Directors, the holders of the common warrants have the right to
require us or a successor entity to redeem the common warrants for the consideration paid in the Change of Control in the amount of the
Black-Scholes Value of the unexercised portion of the common warrants on the date of the consummation of the Change of Control.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Waivers
and Amendments - </i></b>No term of the warrants may be amended or waived without the written consent of the holder of such warrant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 51; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_012"></span>SHARES
ELIGIBLE FOR FUTURE SALE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Common Stock is listed on NASDAQ under the symbol &#8220;ONMD&#8221;. Future sales of substantial amounts of our Common Stock in the
public market could adversely affect market prices prevailing from time to time and future distributions of the shares owned by the
PIPE Investors  could also adversely affect the market price of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Sale
of Restricted Shares</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023, we had approximately 23,572,232 shares of Common Stock issued and outstanding. Of these shares, all
of the shares of our Common Stock received in the distribution are, and all of the shares sold pursuant to this registration statement
of which this prospectus forms a part will be freely transferable without restriction under the Securities Act, unless purchased by our
&#8220;affiliates&#8221; as that term is defined in Rule 144 under the Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Rule
144</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, under Rule 144 as currently in effect, a person (or persons whose shares are aggregated) who is not deemed to be or have been
one of our affiliates for purposes of the Securities Act at any time during 90 days preceding a sale and who has beneficially owned the
shares proposed to be sold for at least six months, including the holding period of any prior owner other than an affiliate, is entitled
to sell such shares without registration, subject to compliance with the public information requirements of Rule 144. If such a person
has beneficially owned the shares proposed to be sold for at least one year, including the holding period of a prior owner other than
an affiliate, then such person is entitled to sell such shares without complying with any of the requirements of Rule 144.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, under Rule 144, as currently in effect, our affiliates or persons selling shares on behalf of our affiliates, who have met the
six-month holding period for beneficial ownership of &#8220;restricted shares&#8221; of our Common Stock, are entitled to sell within
any three-month period, a number of shares that does not exceed the greater of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.0%
    of our then-outstanding shares of Common Stock, which will equal approximately 2,357,223 shares immediately after this offering;
    and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    average weekly trading volume of our Common Stock on NASDAQ during the four calendar weeks preceding the filing of a notice of the
    sale on Form 144.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
under Rule 144 by our affiliates or persons selling shares on behalf of our affiliates are also subject to certain manner of sale provisions
and notice requirements and to the availability of current public information about us. The sale of these shares, or the perception that
sales will be made, could adversely affect the price of our common stock after this offering because a greater supply of shares would
be, or would be perceived to be, available for sale in the public market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Registration
Statement on Form S-8</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the near future, we intend to file with the SEC a Registration Statement on Form S-8 registering an aggregate of 360,000 shares
of Common Stock underlying equity awards we have made and will make to our employees and certain other qualifying individuals,
and the resale of those shares of common stock. The Form S-8 became effective upon filing and shares of common stock so registered will
become freely tradable when issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Registration
Rights</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have entered into the stockholder and registration rights agreement with the PIPE Investors. This prospectus is part of the registration
statement filed pursuant to the stockholder and registration rights agreement. We do not have any other contractual obligations to register
our Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Notes Securities Purchase Agreement, the Company and the Investor also entered into a Registration Rights Agreement,
dated as of March 28, 2024 (the &#8220;RRA&#8221;), providing for the registration of the Note shares (the &#8220;Note Conversion Shares&#8221;)
and the Warrant Shares (the &#8220;Registerable Securities&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><br/></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"></p>

<!-- Field: Page; Sequence: 52; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ds_001"></span>DESCRIPTION
OF CAPITAL STOCK</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
following summary is not intended to be a complete summary of the rights and preferences of such securities, and is qualified by reference
to the Articles, a copy of which is filed as an exhibit to the registration statement of which this prospectus forms a part. We urge
you to read the Articles in their entirety for a complete description of the rights and preferences of our securities following the consummation
of the Business Combination.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
exist under the laws of the State of Delaware and our affairs are governed by our Certificate of Incorporation and its Bylaws, each as
amended and restated from time to time. Pursuant to the governing documents, our authorized share structure consists of 101,000,000 shares,
consisting of (a) 100,000,000 shares of common stock (the &#8220;<b><i>Common Stock</i></b>&#8221;), (b) 1,000,000 shares of preferred
stock.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common
Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of Common Stock are entitled to receive notice of and to attend any meetings of shareholders of the Company and at any meetings of shareholders
to cast one vote for each such share of Common Stock held. Holders of Common Stock do not have cumulative voting rights. Save and except
for certain conversion rights, as described below, the rights attaching to all Common Stock rank pari passu in all respects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of the DKAC Class&#160;B shares of Common Stock were converted into Common Stock shares of OneMedNet automatically on the closing of
the Business Combination, on a one-to-one basis. In connection with and as consideration for the signing of the Business Combination
Agreement DKAC and the Sponsor agreed to waive all anti-dilution adjustments with respect to the DKAC Class B Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board will be divided into three staggered classes, each of which will generally serve for a term of three years with only one class
of directors being elected in each year. There is no cumulative voting with respect to the appointment of directors, with the result
that the holders of more than 50% of the shares voted for the appointment of directors can appoint all of the directors. Holders of Common
Stock are entitled to receive dividends as and when declared by the Board at its discretion from funds legally available therefor and
to receive a pro rata share of the assets of OneMedNet available for distribution to the shareholders in the event of the liquidation,
dissolution or winding-up of OneMedNet after payment of debts and other liabilities, in each case subject to the rights, privileges,
restrictions and conditions attached to any other series or class of shares ranking senior in priority to or on a pro-rata basis with
the holders of Common Stock with respect to dividends or liquidation. There are no pre-emptive, subscription, conversion or redemption
rights attached to the Common Stock nor do they contain any sinking or purchase fund provisions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 53; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
whole warrant entitles the registered holder to purchase one share of Common Stock at a price of $11.50 per share, subject to adjustment
as discussed below, at any time commencing 30&#160;days after the completion of the initial Business Combination. Pursuant to the warrant
agreement, a warrant holder may exercise its warrants only for a whole number of shares of Common Stock. This means only a whole warrant
may be exercised at a given time by a warrant holder. No fractional warrants will be issued upon separation of the units and only whole
warrants will trade.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
warrants will at 5:00&#160;p.m., New&#160;York City time, on November 7, 2028, or earlier upon redemption or liquidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">OneMedNet
will not be obligated to deliver any shares of Common Stock pursuant to the exercise of a warrant and will have no obligation to settle
such warrant exercise unless a registration statement under the Securities Act with respect to the shares of Common Stock underlying
the warrants is then effective and a current prospectus relating thereto is current, subject to OneMedNet satisfying its obligations
described below with respect to registration. No warrant will be exercisable, and OneMedNet will not be obligated to issue shares of
Common Stock upon exercise of a warrant unless shares of Common Stock issuable upon such warrant exercise has been registered, qualified
or deemed to be exempt under the securities laws of the state of residence of the registered holder of the warrants. In the event that
the conditions in the two immediately preceding sentences are not satisfied with respect to a warrant, the holder of such warrant will
not be entitled to exercise such warrant and such warrant may have no value and expire worthless. In no event will DKAC be required to
net cash settle any warrant. In the event that a registration statement is not effective for the exercised warrants, the purchaser of
a unit containing such warrant, if not cash settled, will have paid the full purchase price for the unit solely for the shares of Common
Stock and warrants underlying such unit.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have agreed that as soon as practicable, but in no event later than 20&#160;business days after the closing of the Business Combination,
to use its best efforts to file with the SEC a registration statement registering the issuance of the shares of Common Stock issuable
upon exercise of the warrants, to cause such registration statement to become effective and to maintain a current prospectus relating
to those shares of Common Stock until the warrants expire or are redeemed, as specified in the Warrant Agreement. If a registration statement
covering the shares of Common Stock issuable upon exercise of the warrants is not effective by the 60<sup>th</sup>&#160;business&#160;day
after the closing of the Business Combination or within a specified period following the consummation of the Business Combination, warrant
holders may, until such time as there is an effective registration statement and during any period when we shall have failed to maintain
an effective registration statement, exercise warrants on a &#8220;cashless basis&#8221; pursuant to the exemption provided by Section&#160;3(a)(9)&#160;of
the Securities Act; provided that such exemption is available. If that exemption, or another exemption, is not available, holders will
not be able to exercise their warrants on a cashless basis. Once the warrants become exercisable, we may call the warrants for redemption:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    whole and not in part;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">at
    a price of $0.01 per warrant;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">upon
    not less than 30&#160;days&#8217; prior written notice of redemption given after the warrants become exercisable (the &#8220;30-day
    redemption period&#8221;) to each warrant holder; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if,
    and only if, the reported last sale price of the shares of Common Stock equals or exceeds $18.00 per share (as adjusted for stock
    splits, stock dividends, reorganizations, recapitalizations and the like) for any 20&#160;trading days within a 30-trading&#160;day
    period commencing once the warrants become exercisable and ending three&#160;business days before we send the notice of redemption
    to the warrant holders.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt"></p>

<!-- Field: Page; Sequence: 54; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
and when the warrants become redeemable by us, we may not exercise our redemption right if the issuance of shares of Common Stock upon
exercise of the warrants is not exempt from registration or qualification under applicable state blue sky laws or we are unable to effect
such registration or qualification. We have established the last of the redemption criterion discussed above to prevent a redemption
call unless there is at the time of the call a significant premium to the warrant exercise price. If the foregoing conditions are satisfied
and we issue a notice of redemption of the warrants, each warrant holder will be entitled to exercise its warrant prior to the scheduled
redemption date. However, the price of the shares of Common Stock may fall below the $18.00 redemption trigger price (as adjusted for
stock splits, stock dividends, reorganizations, recapitalizations and the like) as well as the $11.50 warrant exercise price after the
redemption notice is issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we call the warrants for redemption as described above, our management will have the option to require any holder that wishes to exercise
its warrant to do so on a &#8220;cashless basis.&#8221; In determining whether to require all holders to exercise their warrants on a
&#8220;cashless basis,&#8221; our management will consider, among other factors, its cash position, the number of warrants that are outstanding
and the dilutive effect on shareholders of issuing the maximum number of shares of Common Stock issuable upon the exercise of the warrants.
If our management takes advantage of this option, all holders of warrants would pay the exercise price by surrendering their warrants
for that number of shares of Common Stock equal to the quotient obtained by dividing (x)&#160;the product of the number of shares of
Common Stock underlying the warrants, multiplied by the difference between the exercise price of the warrants and the &#8220;fair market
value&#8221; (defined below) by (y)&#160;the fair market value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
&#8220;fair market value&#8221; for this purpose shall mean the average reported last sale price of the shares of Common Stock for the
10&#160;trading days ending on the third&#160;trading day prior to the date on which the notice of redemption is sent to the holders
of warrants. If our management takes advantage of this option, the notice of redemption will contain the information necessary to calculate
the number of shares of Common Stock to be received upon exercise of the warrants, including the &#8220;fair market value&#8221; in such
case. Requiring a cashless exercise in this manner will reduce the number of shares to be issued and thereby lessen the dilutive effect
of a warrant redemption. We believe this feature is an attractive option to us if we do not need the cash from the exercise of the warrants
after the Business Combination. If we call the warrants for redemption and our management does not take advantage of this option, the
Sponsor and its permitted transferees would still be entitled to exercise their placement warrants for cash or on a cashless basis using
the same formula described above that other warrant holders would have been required to use had all warrant holders been required to
exercise their warrants on a cashless basis, as described in more detail below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
holder of a warrant may notify us in writing in the event it elects to be subject to a requirement that such holder will not have the
right to exercise such warrant, to the extent that after giving effect to such exercise, such person (together with such person&#8217;s
affiliates), to the warrant agent&#8217;s actual knowledge, would beneficially own in excess of 4.9% or 9.8% (or such other amount as
a holder may specify) of the shares of Common Stock outstanding immediately after giving effect to such exercise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the number of outstanding shares of Common Stock is increased by a stock dividend payable in shares of Common Stock, or by a split-up
of shares of Common Stock or other similar event, then, on the effective date of such stock dividend, split-up or similar event, the
number of shares of Common Stock issuable on exercise of each whole warrant will be increased in proportion to such increase in the outstanding
shares of Common Stock. A rights offering to holders of shares of Common Stock entitling holders to purchase shares of Common Stock at
a price less than the fair market value will be deemed a stock dividend of a number of shares of Common Stock equal to the product of
(i)&#160;the number of shares of Common Stock actually sold in such rights offering (or issuable under any other equity securities sold
in such rights offering that are convertible into or exercisable for shares of Common Stock) and (ii)&#160;one (1)&#160;minus the quotient
of (x)&#160;the price per shares of Common Stock paid in such rights offering divided by (y)&#160;the fair market value. For these purposes
(i)&#160;if the rights offering is for securities convertible into or exercisable for shares of Common Stock, in determining the price
payable for shares of Common Stock, there will be taken into account any consideration received for such rights, as well as any additional
amount payable upon exercise or conversion and (ii)&#160;fair market value means the volume weighted average price of shares of Common
Stock as reported during the ten (10)&#160;trading day period ending on the&#160;trading day prior to the first date on which the shares
of Common Stock trade on the applicable exchange or in the applicable market, regular way, without the right to receive such rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 55; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, if we, at any time while the warrants are outstanding and unexpired, pay a dividend or make a distribution in cash, securities
or other assets to the holders of shares of Common Stock on account of such shares of Common Stock (or other shares of our capital shares
into which the warrants are convertible), other than as described above, or certain ordinary cash dividends, then the warrant exercise
price will be decreased, effective immediately after the effective date of such event, by the amount of cash and/or the fair market value
of any securities or other assets paid on each shares of Common Stock in respect of such event.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the number of outstanding shares of Common Stock is decreased by a consolidation, combination, reverse stock split or reclassification
of shares of Common Stock or other similar event, then, on the effective date of such consolidation, combination, reverse stock split,
reclassification or similar event, the number of shares of Common Stock issuable on exercise of each warrant will be decreased in proportion
to such decrease in outstanding shares of Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Whenever
the number of shares of Common Stock purchasable upon the exercise of the warrants is adjusted, as described above, the warrant exercise
price will be adjusted by multiplying the warrant exercise price immediately prior to such adjustment by a fraction (x)&#160;the numerator
of which will be the number of shares of Common Stock purchasable upon the exercise of the warrants immediately prior to such adjustment,
and (y)&#160;the denominator of which will be the number of shares of Common Stock so purchasable immediately thereafter.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
case of any reclassification or reorganization of the outstanding shares of Common Stock (other than those described above or that solely
affects the par value of such shares of Common Stock), or in the case of any merger or consolidation us with or into another corporation
(other than a consolidation or merger in which we are the continuing corporation and that does not result in any reclassification or
reorganization of our outstanding shares of Common Stock), or in the case of any sale or conveyance to another corporation or entity
of the assets or other property of us as an entirety or substantially as an entirety in connection with which we are dissolved, the holders
of the warrants will thereafter have the right to purchase and receive, upon the basis and upon the terms and conditions specified in
the warrants and in lieu of the shares of Common Stock immediately theretofore purchasable and receivable upon the exercise of the rights
represented thereby, the kind and amount of shares of stock or other securities or property (including cash) receivable upon such reclassification,
reorganization, merger or consolidation, or upon a dissolution following any such sale or transfer, that the holder of the warrants would
have received if such holder had exercised their warrants immediately prior to such event.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">However,
if less than 70% of the consideration receivable by the holders of shares of Common Stock in such a transaction is payable in the form
of shares of Common Stock in the successor entity that is listed for trading on a national securities exchange or is quoted in an established
over-the-counter market, or is to be so listed for trading or quoted immediately following such event, and if the registered holder of
the warrant properly exercises the warrant within thirty&#160;days following public disclosure of such transaction, the warrant exercise
price will be reduced as specified in the warrant agreement based on the Black-Scholes value (as defined in the warrant agreement) of
the warrant. The purpose of such exercise price reduction is to provide additional value to holders of the warrants when an extraordinary
transaction occurs during the exercise period of the warrants pursuant to which the holders of the warrants otherwise do not receive
the full potential value of the warrants in order to determine and realize the option value component of the warrant. This formula is
to compensate the warrant holder for the loss of the option value portion of the warrant due to the requirement that the warrant holder
exercise the warrant within 30&#160;days of the event. The Black-Scholes model is an accepted pricing model for estimating fair market
value where no quoted market price for an instrument is available.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
warrants were issued in registered form under the Warrant Agreement between Continental Stock Transfer&#160;&amp; Trust Company, as warrant
agent, and DKAC. You should review a copy of the Warrant Agreement, which has been filed by DKAC with the SEC, for a complete description
of the terms and conditions applicable to the warrants. The warrant agreement provides that the terms of the warrants may be amended
without the consent of any holder to cure any ambiguity or correct any mistake, including to conform the provisions of the warrant agreement
to the description of the terms of the warrants and the warrant agreement set forth in this prospectus, or defective provision, but requires
the approval by the holders of at least a majority of the then outstanding public warrants to make any change that adversely affects
the interests of the registered holders of public warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 56; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
warrants may be exercised upon surrender of the warrant certificate on or prior to the expiration date at the offices of the warrant
agent, with the exercise form on the reverse side of the warrant certificate completed and executed as indicated, accompanied by full
payment of the exercise price (or on a cashless basis, if applicable), by certified or official bank check payable to OneMedNet, for
the number of warrants being exercised. The warrant holders do not have the rights or privileges of holders of shares of Common Stock
and any voting rights until they exercise their warrants and receive shares of Common Stock. After the issuance of shares of Common Stock
upon exercise of the warrants, each holder will be entitled to one (1)&#160;vote for each share held of record on all matters to be voted
on by shareholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
fractional shares will be issued upon exercise of the warrants. If, upon exercise of the warrants, a holder would be entitled to receive
a fractional interest in a share, we will, upon exercise, round down to the nearest whole number of shares of Common Stock to be issued
to the warrant holder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
believe the likelihood that warrant holders will exercise their Warrants, and therefore the amount of cash proceeds that we would receive,
is dependent upon the market price of our shares of Common Stock. When the market price for our shares of Common Stock is less than $11.50&#160;per
share (<i>i.e.,</i> the Warrants are &#8220;out of the money&#8221;), which it is at the time of this prospectus, we believe warrant
holders will be unlikely to exercise their Warrants.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have agreed that, subject to applicable law, any action, proceeding or claim against us arising out of or relating in any way to the
Warrant Agreement will be brought and enforced in the courts of the State of New&#160;York or the United&#160;States District Court
for the Southern District of New&#160;York, and we irrevocably submits to such jurisdiction, which jurisdiction will be the
exclusive forum for any such action, proceeding or claim. See &#8220;<i>Risk Factors&#160;&#8212;&#160;Our warrant agreement will
designate the courts of the State of New York or the United&#160;States District Court for the Southern District of New&#160;York as
the sole and exclusive forum for certain types of actions and proceedings that may be initiated by holders of our warrants, which
could limit the ability of warrant holders to obtain a favorable judicial forum for disputes with our company</i>.&#8221; This
provision applies to claims under the Securities Act but does not apply to claims under the Exchange Act or any claim for which
the federal district courts of the United States of America are the sole and exclusive forum.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Transfer
Agent</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
transfer agent for our shares of Common Stock is Continental Stock Transfer&#160;&amp; Trust Company. We have agreed to indemnify Continental
Stock Transfer&#160;&amp; Trust Company in its role as transfer agent, its agents and each of its shareholders, directors, officers and
employees against all claims and losses that may arise out of acts performed or omitted for its activities in that capacity, except for
any claims and losses due to any gross negligence or intentional misconduct of the indemnified person or entity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Listing
of Securities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
shares of Common Stock and warrants are listed on Nasdaq under the symbols &#8220;ONMD&#8221; and &#8220;ONMDW.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 57; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CERTAIN
U.S. FEDERAL INCOME AND ESTATE TAX CONSEQUENCES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TO
NON-U.S. HOLDERS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of certain U.S. federal income and estate tax consequences of the purchase, ownership and disposition of our common
stock as of the date hereof. Except where noted, this summary deals only with common stock that is held as a capital asset by a non-U.S.
holder (as defined below).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
&#8220;non-U.S. holder&#8221; means a beneficial owner of our common stock (other than an entity treated as a partnership for U.S. federal
income tax purposes) that is not, for U.S. federal income tax purposes, any of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    individual citizen or resident of the United States;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    corporation (or any other entity treated as a corporation for U.S. federal income tax purposes) created or organized in or under
    the laws of the United States, any state thereof or the District of Columbia;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    estate the income of which is subject to U.S. federal income taxation regardless of its source; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    trust if it (1) is subject to the primary supervision of a court within the United States and one or more United States persons have
    the authority to control all substantial decisions of the trust or (2) has a valid election in effect under applicable United States
    Treasury regulations to be treated as a United States person.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
summary is based upon provisions of the Code, and regulations, rulings and judicial decisions as of the date hereof. Those authorities
may be changed, perhaps retroactively, so as to result in U.S. federal income and estate tax consequences different from those summarized
below. This summary does not address all aspects of U.S. federal income and estate taxes and does not deal with foreign, state, local
or other tax considerations that may be relevant to non-U.S. holders in light of their particular circumstances. In addition, it does
not represent a detailed description of the U.S. federal income and estate tax consequences applicable to you if you are subject to special
treatment under the U.S. federal income tax laws (including if you are a United States expatriate, foreign pension fund, &#8220;controlled
foreign corporation,&#8221; &#8220;passive foreign investment company&#8221; or a partnership or other pass-through entity for U.S. federal
income tax purposes). We cannot assure you that a change in law will not alter significantly the tax considerations that we describe
in this summary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a partnership (or other entity treated as a partnership for U.S. federal income tax purposes) holds our common stock, the tax treatment
of a partner will generally depend upon the status of the partner and the activities of the partnership. If you are a partner of a partnership
holding our common stock, you should consult your tax advisors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>If
you are considering the purchase of our Common Stock, you should consult your own tax advisors concerning the particular U.S. federal
income and estate tax consequences to you of the purchase, ownership and disposition of our Common Stock, as well as the consequences
to you arising under other U.S. federal tax laws and the laws of any other taxing jurisdiction.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dividends</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event that we make a distribution of cash or other property (other than certain pro rata distributions of our stock) in respect of
our common stock, the distribution generally will be treated as a dividend for U.S. federal income tax purposes to the extent it is paid
from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. Any portion of a distribution
that exceeds our current and accumulated earnings and profits generally will be treated first as a tax-free return of capital, causing
a reduction in the adjusted tax basis of a non-U.S. holder&#8217;s common stock, and to the extent the amount of the distribution exceeds
a non-U.S. holder&#8217;s adjusted tax basis in our common stock, the excess will be treated as gain from the disposition of our common
stock (the tax treatment of which is discussed below under &#8220;&#8212;Gain on Disposition of Common Stock&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividends
paid to a non-U.S. holder generally will be subject to withholding of U.S. federal income tax at a 30% rate or such lower rate as may
be specified by an applicable income tax treaty. However, dividends that are effectively connected with the conduct of a trade or business
by the non-U.S. holder within the United States (and, if required by an applicable income tax treaty, are attributable to a United States
permanent establishment) are not subject to the withholding tax, provided certain certification and disclosure requirements are satisfied.
Instead, such dividends are subject to U.S. federal income tax on a net income basis in the same manner as if the non-U.S. holder were
a United States person as defined under the Code. Any such effectively connected dividends received by a foreign corporation may be subject
to an additional &#8220;branch profits tax&#8221; at a 30% rate or such lower rate as may be specified by an applicable income tax treaty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 58; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
non-U.S. holder who wishes to claim the benefit of an applicable treaty rate and avoid backup withholding, as discussed below, for dividends
will be required (a) to provide the applicable withholding agent with a properly executed IRS Form W-BEN or Form W-8BEN-E (or other applicable
form) certifying under penalty of perjury that such holder is not a United States person as defined under the Code and is eligible for
treaty benefits or (b) if our common stock is held through certain foreign intermediaries, to satisfy the relevant certification requirements
of applicable United States Treasury regulations. Special certification and other requirements apply to certain non-U.S. holders that
are pass-through entities rather than corporations or individuals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
non-U.S. holder eligible for a reduced rate of U.S. federal withholding tax pursuant to an income tax treaty may obtain a refund of any
excess amounts withheld by timely filing an appropriate claim for refund with the IRS.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Gain
on Disposition of Common Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the discussion of backup withholding below, any gain realized by a non-U.S. holder on the sale or other disposition of our common
stock generally will not be subject to U.S. federal income tax unless:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    gain is effectively connected with a trade or business of the non-U.S. holder in the United States (and, if required by an applicable
    income tax treaty, is attributable to a United States permanent establishment of the non-U.S. holder);</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    non-U.S. holder is an individual who is present in the United States for 183 days or more in the taxable year of that disposition,
    and certain other conditions are met; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    are or have been a &#8220;United States real property holding corporation&#8221; for U.S. federal income tax purposes and certain
    other conditions are met.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
non-U.S. holder described in the first bullet point immediately above will be subject to tax on the gain derived from the sale or other
disposition in the same manner as if the non-U.S. holder were a United States person as defined under the Code. In addition, if any non-U.S.
holder described in the first bullet point immediately above is a foreign corporation, the gain realized by such non-U.S. holder may
be subject to an additional &#8220;branch profits tax&#8221; at a 30% rate or such lower rate as may be specified by an applicable income
tax treaty. An individual non-U.S. holder described in the second bullet point immediately above will be subject to a 30% (or such lower
rate as may be specified by an applicable income tax treaty) tax on the gain derived from the sale or other disposition, which gain may
be offset by United States source capital losses even though the individual is not considered a resident of the United States.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Generally,
a corporation is a &#8220;United States real property holding corporation&#8221; if the fair market value of its United States real property
interests equals or exceeds 50% of the sum of the fair market value of its worldwide real property interests and its other assets used
or held for use in a trade or business (all as determined for U.S. federal income tax purposes). We believe we are not and do not anticipate
becoming a &#8220;United States real property holding corporation&#8221; for U.S. federal income tax purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Federal
Estate Tax</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
Stock held by an individual non-U.S. holder at the time of death will be included in such holder&#8217;s gross estate for U.S. federal
estate tax purposes, unless an applicable estate tax treaty provides otherwise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Information
Reporting and Backup Withholding</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Distributions
paid to a non-U.S. holder and the amount of any tax withheld with respect to such distributions generally will be reported to the IRS.
Copies of the information returns reporting such distributions and any withholding may also be made available to the tax authorities
in the country in which the non-U.S. holder resides under the provisions of an applicable income tax treaty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 59; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
non-U.S. holder will not be subject to backup withholding on dividends received if such holder certifies under penalty of perjury that
it is a non-U.S. holder (and the payor does not have actual knowledge or reason to know that such holder is a United States person as
defined under the Code), or such holder otherwise establishes an exemption.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
reporting and, depending on the circumstances, backup withholding will apply to the proceeds of a sale or other disposition of our common
stock made within the United States or conducted through certain United States-related financial intermediaries, unless the beneficial
owner certifies under penalty of perjury that it is a non-U.S. holder (and the payor does not have actual knowledge or reason to know
that the beneficial owner is a United States person as defined under the Code), or such owner otherwise establishes an exemption.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Backup
withholding is not an additional tax and any amounts withheld under the backup withholding rules will be allowed as a refund or a credit
against a non-U.S. holder&#8217;s U.S. federal income tax liability provided the required information is timely furnished to the IRS.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Additional
Withholding Requirements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
Sections 1471 through 1474 of the Code (such Sections commonly referred to as &#8220;FATCA&#8221;), a 30% U.S. federal withholding tax
may apply to any dividends paid on our common stock to (i) a &#8220;foreign financial institution&#8221; (as specifically defined in
the Code) which does not provide sufficient documentation, typically on IRS Form W-8BEN-E, evidencing either (x) an exemption from FATCA,
or (y) its compliance (or deemed compliance) with FATCA (which may alternatively be in the form of compliance with an intergovernmental
agreement with the United States) in a manner which avoids withholding, or (ii) a &#8220;non-financial foreign entity&#8221; (as specifically
defined in the Code) which does not provide sufficient documentation, typically on IRS Form W-8BEN-E, evidencing either (x) an exemption
from FATCA, or (y) adequate information regarding certain substantial United States beneficial owners of such entity (if any). If a dividend
payment is both subject to withholding under FATCA and subject to the withholding tax discussed above under &#8220;&#8212;Dividends,&#8221;
the withholding under FATCA may be credited against, and therefore reduce, such other withholding tax. You should consult your own tax
advisors regarding these requirements and whether they may be relevant to your ownership and disposition of our Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 60; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ds_002"></span>SELLING
SECURITYHOLDERS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Selling Securityholders may offer and sell, from time to time, any or all of the Common Stock or Warrants being offered for resale by
this prospectus, which consist of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 12pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">797,872
                                            shares of Common Stock upon conversion of up to $1,595,744.70 of OneMedNet Senior Secured
                                            Convertible Notes (the &#8220;Pre-Copsing PIPE Notes&#8221;) issued at the closing of the
                                            Business Combination (as defined below) subject to a floor price of $2.00 per share pursuant
                                            to the terms of the Securities Purchase Agreement dated June 28, 2023, by and among Data
                                            Knights Acquisition Corp, a Delaware corporation (&#8220;Data Knights&#8221;) and the named
                                            investors (the &#8220;Pre-Closing PIPE&#8221;), </span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 12pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">95,744
                                            shares underlying 95,744 warrants related to the Pre-Closing PIPE and the Warrant Agreements
                                            executed at the closing of the Business Combination, </span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 12pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,312,817
                                            shares of Common Stock upon conversion (the &#8220;Conversion Shares) of up to $4,547,500
                                            of funding to the Company pursuant to the Securities Purchase Agreement and convertible promissory
                                            notes <span style="background-color: white">dated</span> March 28, 2024 <span style="background-color: white">(the
                                            &#8220;PIPE Notes Financing&#8221;) with Helena Global Investment Opportunities 1 Ltd. (the
                                            &#8220;Notes Investor&#8221;),</span></span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 12pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,656,408
                                            shares underlying 3,656,408 warrants related to the <span style="background-color: white">PIPE
                                            Notes Financing</span> with the Notes Investor, </span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 12pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">277,778
                                            shares of Common Stock issued pursuant to the terms of the Satisfaction and Discharge Agreement
                                            at $10.88 per share dated as of June 28, 2023, by and among the Company, Data Knights, and
                                            EF Hutton LLC (&#8220;EF Hutton&#8221;), </span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 12pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,315,840
                                            shares of Common Stock issuable pursuant to the outstanding loans converted to equity at
                                            $1 per share to Data Knights to fund its extension payments prior to the Business Combination
                                            by certain of the Selling Securityholders named in this prospectus, </span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 12pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,439,563
                                            shares of Common Stock issued upon the closing of the Business Combination to ARC Group Limited,
                                            as consideration for its financial advisory services, </span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 12pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,327,070
                                            shares of Common Stock at $0.7535 (95% of VWAP 10-day average $0.7932) for $1,000,000 investment
                                            by Dr. Thomas Kosasa on January 2, 2024, and </span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 12pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,609,859
                                            shares of Common Stock issued to Data Knights LLC (the &#8220;Sponsor&#8221;) and its affiliates,
                                            including 2,875,000 shares of Common Stock originally issued as share of Class B Stock in
                                            connection with the initial public offering of DKAC for aggregate consideration of $25,000,
                                            or approximately $0.009 per share, and 585,275 shares of Common Stock originally issued to
                                            the Sponsor as part of the Placement Units issued to Sponsor in connection with DKAC&#8217;s
                                            initial public offering at $10.00 per unit, and which are subject to six month lock-up restrictions
                                            set forth herein</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Selling Securityholders may from time to time offer and sell any or all of the Common Stock and Warrants set forth in the table below
pursuant to this prospectus. When we refer to the &#8220;Selling Securityholders&#8221; in this prospectus, we refer to the persons listed
in the table below, and the pledgees, donees, transferees, assignees, successors and other permitted transferees that hold any of the
Selling Securityholders&#8217; interest in the shares of Common Stock or warrants after the date of this prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following tables provide, as of the date of this prospectus, information regarding the beneficial ownership of our Common Stock and Warrants
of each Selling Securityholder, the number of shares of Common Stock or Warrants that may be sold by each Selling Securityholder under
this prospectus and that each Selling Securityholder will beneficially own after this offering. The immediately following table also
sets forth the percentage of shares of Common Stock or Warrants beneficially owned by a Selling Securityholder after giving effect to
the sale by the Selling Securityholder of all securities being offered hereby, based on 23,850,010 shares of Common Stock outstanding
including approximately 20,000,000 shares issued as Transaction consideration, 200,000 shares of Common Stock issued in connection with
the PIPE financing, and reflects the valid redemption of 11,388,043 shares of Class A Common Stock by public shareholders of DKAC. The
Common Stock issuable upon exercise of the Warrants are not included in the table below as the table assumes the Warrants are sold in
the offering prior to their exercise by the applicable Selling Securityholder. The following table does not include Public Warrants or
the primary issuance of Common Stock underlying the Public Warrants, but includes the 681,019&#160;warrants outstanding as of the date hereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 61; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot advise you as to whether the Selling Securityholders will in fact sell any or all of such Common Stock or Warrants. In particular,
the Selling Securityholders identified below may have sold, transferred or otherwise disposed of all or a portion of their securities
after the date on which they provided us with information regarding their securities in transactions exempt from registration under the
Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth certain information provided by or on behalf of the Selling Securityholders concerning the Common Stock and
Warrants that may be offered from time to time by each Selling Securityholder with this prospectus. For the purposes of this following
table, we have assumed that the Selling Securityholders will have sold all of the securities covered by this prospectus upon the completion
of the offering. Please see the section entitled &#8220;Plan of Distribution&#8221; for further information regarding the Selling Securityholders&#8217;
method of distributing the Common Stock and Warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise indicated below, the address of each beneficial owner listed in the tables below is c/o OneMedNet Corporation, 6385 Old Shady
Oak Road,&#160;Suite 250, Eden Prairie, MN 55344.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    of Selling<br/> Securityholder</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
    of<br/> Shares of Common Stock<br/> Owned Prior<br/> to&#160;the Offering</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
    of<br/> Warrants<br/> Owned<br/> Prior to<br/> the<br/> Offering<sup>(11)</sup></b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Maximum<br/>
    Number<br/> of Shares of Common Stock<br/> To Be<br/> Sold Pursuant<br/> to this<br/> Prospectus</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Maximum
    Number<br/> of Warrants<br/> To Be<br/> Sold<br/> Pursuant<br/> to this<br/> Prospectus<sup>(11)</sup></b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
    of<br/> Shares of Common Stock<br/> Owned After<br/> the Offering</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%(1)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
    of<br/> Warrants<br/> Owned<br/> After&#160;the<br/> Offering</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 38%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Data
    Knights, LLC <sup>(2)(10)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,609,859</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">585,275</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,609,859</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">585,275</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">--</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">--</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">--</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EF
    Hutton LLC<sup>(3)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">--</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">--</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">277,778</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">--</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">277,778</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">--</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARC
    Group Limited<sup>(4)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">--</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">--</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,439,563</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">--</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,439,563</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">--</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thomas
    Kosasa<sup>(5)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,333,824</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31,914</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,477,070</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31,914</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,842,808</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">45</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31,914</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jeffrey
    Yu <sup>(6)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,435,617</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31,914</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">516,256</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31,914</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,983,787</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31,914</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Helena
    Global Investment Opportunities 1 Ltd.<sup>(7)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">--</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">--</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,312,817</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,656,408</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,969,225</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">46</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,656,408</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aaron
    Green<sup>(8)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">--</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15,958</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">148,936</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15,958</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">164,894</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15,958</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steven
    Kester<sup>(9)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">444,942</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15,958</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">148,936</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15,958</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">164,894</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15,958</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 62; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    percentage of beneficial ownership after this offering is calculated based on <span style="background-color: white">23,850,010 </span>shares
    of Common Stock outstanding as of the date of this prospectus. Unless otherwise indicated, we believe that all persons named in the
    table have sole voting and investment power with respect to all shares beneficially owned by them.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Data
    Knights LLC is Sponsor of DKAC, our predecessor company, and certain former officers and directors of DKAC
    may have a pecuniary interest in Data Knights LLC that consisted of the Founders Shares and 585,275 shares of Common Stock from the
    conversion of the Placement Units. Data Knights LLC disclaims any such beneficial ownership except to the extent of its pecuniary
    interest.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EF
    Hutton LLC was the underwriter in DKAC&#8217;s initial public offering. Consists of 277,778 shares of Common Stock issued pursuant
    to the terms of the Satisfaction and Discharge Agreement at $10.88 per share dated as of June 28, 2023, by and among the Company,
    Data Knights, and EF Hutton LLC. EF Hutton&#8217;s address is 590 Madison Ave, 39th Floor, New York, NY, 10022.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
    of 1,439,563 shares of Common Stock issued upon the closing of the Business Combination to ARC Group Limited, as consideration for
    its financial advisory services.&#160;ARC Group Limited&#8217;s address is 1118 Yan&#8217;an Xi Road, Suite 2605, Shanghai 200050,
    China.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
    of 8,333,824 existing shares of Common Stock plus 2,227,070 shares of Common Stock a<span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">nd 250,000</span> upon conversion of the Pre-Closing
    PIPE Notes and 31,914 shares underlying 31,914 warrants related to the Pre-Closing PIPE and the Warrant Agreements executed at the
    closing of the Business Combination to Thomas Kosasa, a member of our Board of Directors.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
    of 2,435,617 existing shares of Common Stock plus 266,256 share of Common Stock and 250,000 upon conversion of the Pre-Closing PIPE
    Notes and 31,914 shares underlying 31,914 warrants related to the Pre-Closing PIPE and the Warrant Agreements executed at the
    closing of the Business Combination to Jeffrey Yu, our founder and Chairman of the Board, and to the Revocable Trust of Jeffrey N.C.
    Yu. Mr. Yi disclaims any such beneficial ownership except to the extent of his pecuniary interest.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
    of 10,969,225 shares of Common Stock potentially to be issued to <span style="background-color: white">Helena Global Investment
    Opportunities 1 Ltd. representing up to (a) </span>7,312,817 shares of Common Stock upon conversion of up to $4,547,500 of funding
    to the Company pursuant to the Securities Purchase Agreement and convertible promissory notes <span style="background-color: white">dated</span>
    March 28, 2024 and (b) 3,656,408 shares underlying 3,656,408 warrants related to the <span style="background-color: white">financing and the percentage ownership assumes conversion of the notes and exercise of the warrants</span>.<span style="background-color: white">&#160;&#160;</span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
    of up to 148,936 shares of Common Stock issuable to Aaron Green, our chief executive officer, president and a member of the Board
    of Directors, upon conversion of the Pre-Closing PIPE Notes and 15,958 shares underlying 15,958 warrants related to the Pre-Closing
    PIPE and the Warrant Agreements executed at the closing of the Business Combination.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
                                            of existing 444,942 shares of Common Stock and up to 148,936 shares of Common Stock issuable
                                            to Iron Family Holdings LLC owned by Steve Kester upon conversion of the Pre-Closing PIPE
                                            Notes and 15,958 shares underlying 15,958 warrants related to the Pre-Closing PIPE and the
                                            Warrant Agreements executed at the closing of the Business Combination.</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    1,777,926 shares of Common Stock issuable pursuant to the outstanding loans converted to equity for Data Knights to
    fund its extension payments prior to the Business Combination that are not otherwise allocated to Selling Securityholders referenced
    herein.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">(11)</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Excludes 11,500,000 public warrants sold in DKAC&#8217;s
    initial public offering which converted to OneMedNet warrants at the closing of the Business Combination.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<!-- Field: Page; Sequence: 63; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PLAN
OF DISTRIBUTION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
Selling Securityholder of the securities and any of their pledgees, assignees and successors-in- interest may, from time to time, sell
any or all of their securities covered hereby on the principal trading market for such securities or any other stock exchange, market
or trading facility on which the securities are traded or in private transactions. These sales may be at fixed or negotiated prices.
A Selling Securityholder may use any one or more of the following methods when selling securities:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ordinary
    brokerage transactions and transactions in which the broker-dealer solicits Subscribers;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">block
    trades in which the broker-dealer will attempt to sell the securities as agent but may position and resell a portion of the block
    as principal to facilitate the transaction;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">purchases
    by a broker-dealer as principal and resale by the broker-dealer for its account;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    exchange distribution in accordance with the rules&#160;of the applicable exchange;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">privately
    negotiated transactions;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">settlement
    of short sales;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    transactions through broker-dealers that agree with the Selling Securityholders to sell a specified number of such securities at
    a stipulated price per security;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">through
    the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    combination of any such methods of sale; or</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    other method permitted pursuant to applicable law.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Selling Securityholders may also sell securities under Rule&#160;144 or any other exemption from registration under the Securities Act,
if available, rather than under this prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Broker-dealers
engaged by the Selling Securityholders may arrange for other brokers-dealers to participate in sales. Broker-dealers may receive commissions
or discounts from the Selling Securityholders (or, if any broker-dealer acts as agent for the Subscriber of securities, from the Subscriber)
in amounts to be negotiated, but except as set forth in a supplement to this Prospectus, in the case of an agency transaction not in
excess of a customary brokerage commission in compliance with FINRA Rule&#160;2440; and in the case of a principal transaction a markup
or markdown in compliance with FINRA IM-2440.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the sale of the securities or interests therein, the Selling Securityholders may enter into hedging transactions with
broker-dealers or other financial institutions, which may in turn engage in short sales of the securities in the course of hedging the
positions they assume. The Selling Securityholders may also sell securities short and deliver these securities to close out their short
positions, or loan or pledge the securities to broker-dealers that in turn may sell these securities. The Selling Securityholders may
also enter into option or other transactions with broker-dealers or other financial institutions or create one or more derivative securities
which require the delivery to such broker-dealer or other financial institution of securities offered by this prospectus, which securities
such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such
transaction).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Selling Securityholders and any broker-dealers or agents that are involved in selling the securities may be deemed to be &#8220;underwriters&#8221;
within the meaning of the Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers
or agents and any profit on the resale of the securities purchased by them may be deemed to be underwriting commissions or discounts
under the Securities Act. Each Selling Securityholder has informed the Company that it does not have any written or oral agreement or
understanding, directly or indirectly, with any person to distribute the securities.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is required to pay certain fees and expenses incurred incident to the registration of the securities. The Company has agreed
to indemnify the Selling Securityholders against certain losses, claims, damages and liabilities, including liabilities under the Securities
Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
agreed to keep this prospectus effective until the earlier of (i)&#160;all of the securities have been sold pursuant to this prospectus
or Rule&#160;144 under the Securities Act or any other rule&#160;of similar effect, (ii)&#160;they may be sold pursuant to Rule&#160;144
without volume or manner-of-sale restrictions; or (iii)&#160;it has been two years from the Closing Date. The resale securities will
be sold only through registered or licensed brokers or dealers if required under applicable state securities laws. In addition, in certain
states, the resale securities covered hereby may not be sold unless they have been registered or qualified for sale in the applicable
state or an exemption from the registration or qualification requirement is available and is complied with.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
applicable rules&#160;and regulations under the Exchange Act, any person engaged in the distribution of the resale securities may not
simultaneously engage in market making activities with respect to the shares of Common Stock for the applicable restricted period, as
defined in Regulation M, prior to the commencement of the distribution. In addition, the Selling Securityholders will be subject to applicable
provisions of the Exchange Act and the rules&#160;and regulations thereunder, including Regulation M, which may limit the timing of purchases
and sales of the shares of Common Stock by the Selling Securityholders or any other person. We will make copies of this prospectus available
to the Selling Securityholders and have informed them of the need to deliver a copy of this prospectus to each Subscriber at or prior
to the time of the sale (including by compliance with Rule&#160;172 under the Securities Act).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 64; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LEGAL
<span style="letter-spacing: -0.1pt"><span id="a_014"></span>MATTERS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 33.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
validity of the issuance of the shares of Common Stock and accompanying warrants offered by us in this offering
will be passed upon for us by Rimon P.C., Washington DC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 33.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 33.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nelson Mullins Riley &amp; Scarborough LLP (Washington, DC) has acted
as counsel for the underwriters in connection with certain legal matters related to this offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 33.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_015"></span>EXPERTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements of OneMedNet Corporation (<i>fka </i>Date Knights Acquisition Corp), as of December 31, 2023 and 2022
and for each of the years then ended incorporated by reference in this Registration Statement, of which this prospectus forms a part,
have been so included in reliance on the report of BF Borgers CPA PC, an independent registered public accounting firm, appearing elsewhere
herein, given on the authority of said firm as experts in auditing and accounting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="mkj_001"></span>MANAGEMENT&#8217;S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Company
Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Founded
in 2009, we provide innovative solutions that unlock the significant value contained within the clinical image archives of healthcare
providers. Employing our proven OneMedNet iRWD&#8482; solution, we securely de-identifies, searches, and curates a data archive locally,
bringing a wealth of internal and third-party research opportunities to providers. By leveraging this extensive federated provider network,
together with industry leading technology and in-house clinical expertise, OneMedNet successfully meets the most rigorous RWD Life Science
requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Business
Combination</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 7, 2023, we held the closing of the previously announced merger (the &#8220;Merger&#8221;) whereby Data Knights Merger Sub,
Inc., merged with and into OneMedNet Solutions Corporation (formerly named OneMedNet Corporation), with OneMedNet Solutions Corporation
continuing as the surviving entity, which resulted in all of the issued and outstanding capital stock of OneMedNet Solutions Corporation
being exchanged for shares of the Company&#8217;s Common Stock upon the terms set forth in the Merger Agreement (collectively, the &#8220;the
Business Combination&#8221;). The Merger and other transactions that closed on November 7, 2023, pursuant to the Merger Agreement, led
to Data Knights changing its name to &#8220;OneMedNet Corporation&#8221; and the business of the Company became the business of OneMedNet
Solutions Corporation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the terms of the Merger Agreement, the total consideration for the Business Combination and related transactions (the &#8220;Merger
Consideration&#8221;) was approximately $200 million. In connection with the Special Meeting, certain public holders (the &#8220;Redeeming
Stockholders&#8221;) holding 1,600,741 shares of Common Stock exercised their right to redeem such shares for a pro rata portion of the
funds held by Continental Stock Transfer &amp; Trust Company, as trustee (&#8220;Continental&#8221;) in the trust account established
in connection with Data Knights&#8217; initial public offering (the &#8220;Trust Account&#8221;). Effective November 7, 2023, Data Knights&#8217;
units ceased trading, and effective November 8, 2023, OneMedNet&#8217;s common stock began trading on the Nasdaq Global Market under
the symbol &#8220;ONMD&#8221; and the warrants began trading on the Nasdaq Global Market under the symbol &#8220;ONMDW.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the Merger and the Business Combination, holders of Data Knights common stock automatically received common stock of OneMedNet,
and holders of Data Knights warrants automatically received warrants of OneMedNet with substantively identical terms. At the Closing
of the Business Combination, all shares of Data Knights owned by the Sponsor (consisting of shares of Common Stock and shares of Class
B common stock, which we refer to as the founder shares), automatically converted into an equal number of shares of OneMedNet&#8217;s
Common Stock, and the Private Placement Warrants held by the Sponsor, automatically converted into warrants to purchase one share of
OneMedNet Common Stock with substantively identical terms.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Key
Components of Consolidated Statements of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Revenue</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company generates revenue from two streams: (1) iRWD (imaging Real World Data) which provides regulatory grade imaging and clinical data
in the Pharmaceutical, Device Manufacturing, CRO&#8217;s and AI markets and (2) BEAM which is a Medical Imaging Exchange platform between
Hospital/Healthcare Systems, Imaging Centers, Physicians and Patients. iRWD is sold on a fixed fee basis based on the number of data
units and the cost per data unit committed to in the customer contract. Revenue is recognized when the data is delivered to the customer.
Beam revenue is subscription-based revenue which is recognized ratably over the subscription period committed to by the customer. The
Company invoices its Beam customers quarterly or annually in advance with the customer contracts automatically renewing unless the customer
issues a cancellation notice.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company excludes from revenue taxes collected from a customer that are assessed by a governmental authority and imposed on and concurrent
with a specific revenue-producing transaction. The transaction price for the products is the invoiced amount. Advanced billings from
contracts are deferred and recognized as revenue when earned. Deferred revenue consists of payments received in advance of performance
under the contract. Such amounts are generally recognized as revenue over the contractual period. The Company receives payments from
customers based upon contractual billing schedules. Accounts receivable is recorded when the right to consideration becomes unconditional.
Payment terms on invoiced amounts typically range from zero to 90 days, with typical terms of 30 days.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cost
of Revenue</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
cost of revenue is composed of our distinct performance obligations of hosting, labor, and data cost.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"></p>

<!-- Field: Page; Sequence: 65; Options: NewSection; Value: 62 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>General,
and Administrative</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative functions, includes finance, legal, human resources, and information technology support. These functions include costs
for items such as salaries and benefits and other personnel-related costs, maintenance and supplies, professional fees for external legal,
accounting, and other consulting services, and depreciation expense.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 12.95pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Operation
services</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operations
consists primarily of labor cost for our operations team who provides services to our customers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Research
and Development</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs
incurred in the research and development of our products are expensed as incurred. Research and development costs include personnel,
contracted services, materials, and indirect costs involved in the design and development of new products and services, as well as hosting
expense.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Sales
&amp; Marketing</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
sales and marketing costs consist of labor and tradeshow costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Interest
Expense</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
incurred on convertible notes and shareholder loans.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Other
Expense</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign
exchange and tax expenses related to the Company&#8217;s operations and revenue outside of the United States.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Results
of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following tables set forth our Consolidated Statements of Operations data for the periods presented:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year Ended December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 60%">Revenue</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">1,021,651</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">1,152,738</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Cost of Revenue</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,149,551</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,513,428</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Gross Margin</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(127,900</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(360,690</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Operating Expenses</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">General and administrative</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5,273,503</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">8,755,620</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Operations</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">226,257</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">398,760</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">Sales &amp; Marketing</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,114,977</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">957,690</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Research and Development</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,631,613</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">952,701</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Total Operating Expenses</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">8,246,350</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">11,064,771</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Operating loss</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(8,374,250</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(11,425,461</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Other Expense (income)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt">Impairment</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">10,504,327</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 20pt">Income tax provision</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">214,850</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 20pt">Interest expense</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">749,213</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">403,307</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 20pt">Other expense</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">52,256</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">46,820</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 20pt">Change in FV of Warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(46,822</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(4,489,110</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 20pt">Stock Expense</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,572,232</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">Unrealized gain or loss</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,371,689</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">14,831,206</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(5,195,822</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Net loss</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(23,205,456</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(6,229,639</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"></p>

<!-- Field: Page; Sequence: 66; Value: 62 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year
Ended December 31, 2023 Compared to the Year Ended December 31, 2022</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Revenue</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year Ended<br/> December 31,<br/>
    2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year Ended<br/> December 31,<br/>
    2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>%</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Percentage</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Change</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 46%; text-align: left">Data Exchange (Beam)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">878,416</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">678,138</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">30</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Data Broker (RWD)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">143,235</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">474,600</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-70</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Master Reseller Agreement</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,021,651</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,152,738</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-11</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
revenue comprises of sales made from our data exchange (BEAM) and from data broker (RWD). For the year ended 2023, overall revenue was
down by 11%. The primary driver for the 30% exchange revenue increase was delivery of revenue to a significant customer. The primary
driver for the 70% decrease in broker revenue was due to revenue deliveries pushed to Q1 of Fiscal 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cost
of Revenue</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year Ended<br/> December 31, 2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year Ended<br/> December 31, 2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%">Cost of Revenue</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">1,149,551</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">1,513,428</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">As a percentage of Revenue</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">113</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">131</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2023 we were able to reduce our cost of revenue as a percentage of revenue by 24%. In the year ended 2023 our Software cost, iRWD consultants
and iRWD Data cost each decreased by $0.2 million. The decrease was partially offset by a $0.2 million increase in payroll expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>General
and Administrative</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
general and administrative expense increased year over year by $1.8 million from the year ended 2022 compared to the year ended 2023.
The increase is primarily due to the additional cost incurred in connection with our Business Combination. We incurred an additional
$1.0 million legal cost, $0.7 million on warrants issued to convertible note holders that were converted into share of commons stock,
$0.4 million additional employees&#8217; salaries, $0.3 million for investor relations cost, and $0.3 million in additional audit fees.
The increase in general and administrative expenses were partially offset by $0.2 million decrease in both recruitment fees and bad debt
expense.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Operation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
operations expense includes payroll and consultant costs. Operations expense decreased year over year by $0.2 million from the year ended
2022 compared with the year ended 2023. This decrease was primarily due to a decrease in headcount.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Sales
&amp; Marketing</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
sales &amp; marketing expense increased by $0.15 million year over year from the year ended 2022 compared to the year ended 2023. The
increase is due to the addition of an employee and consultant in 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Research
and development</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
research and development expense increased by $0.7 million year over year from the year ended 2022 compared to the year ended 2023. The
increase is primarily due to the additional cost in salaries for curators, consultants and increased hosting costs, which increased by
$0.4 million, $0.2 million and $0.1 million, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"></p>

<!-- Field: Page; Sequence: 67; Value: 62 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Impairment</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recorded goodwill of $10.5 million in connection with the Business Combination. In December 2023, the Company concluded that
the entire goodwill was impaired, as such the $10.5 million of goodwill was written-off.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Income
tax provision</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended 2023, the Company is in a significant loss, as such we did not record any income tax provision.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Interest
Expense</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company incurred interest expense on Loan extensions associated with the Business Combination, convertible promissory notes, the Pipe
Senior Secured Convertible Notes and Loans made from related parties (Management and Directors). Interest expense in the year ended 2023
increased by $0.3 million. The increase was mainly from the Pipe Senior Secured Convertible Notes issued in 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Change
in Fair Value of Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
change in Warrant Fair Value was due to the closing of the Business Combination Agreement and the resulting fluctuations of the share
market price<i>.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stock
Expense</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company incurred approximately $3.5 million in common stock issuance expense for the Data Knight shares converted to OneMedNet Corporation
shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Non-GAAP
Financial Measure</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to providing financial measurements based on generally accepted accounting principles in the United States of America, or GAAP,
we provide an additional financial metric that is not prepared in accordance with GAAP, or non-GAAP financial measure. We use this non-GAAP
financial measure, in addition to GAAP financial measures, to understand and compare operating results across accounting periods, for
financial and operational decision making, for planning and forecasting purposes, to measure executive compensation, and to evaluate
our financial performance. This non-GAAP financial measure is Adjusted EBITDA, as discussed below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that this non-GAAP financial measure reflects our ongoing business in a manner that allows for meaningful comparisons and analysis
of trends in the business, as it facilitates comparing financial results across accounting periods and to those of peer companies. We
also believe that this non-GAAP financial measure enables investors to evaluate our operating results and future prospects in the same
manner as we do. This non-GAAP financial measure may exclude expenses and gains that may be unusual in nature, infrequent, or not reflective
of our ongoing operating results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
non-GAAP financial measure does not replace the presentation of our GAAP financial measures and should only be used as a supplement to,
not as a substitute for, our financial results presented in accordance with GAAP.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
consider Adjusted EBITDA to be an important indicator of the operational strength and performance of our business and a good measure
of our historical operating trends. Adjusted EBITDA eliminates items that we do not consider to be part of our core operations. We define
Adjusted EBITDA as GAAP net loss excluding the following items: interest income; income taxes; depreciation and amortization of tangible
and intangible assets; unit and stock-based compensation; Business Combination transaction expenses; and other non-recurring items that
may arise from time to time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"></p>

<!-- Field: Page; Sequence: 68; Value: 62 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
non-GAAP adjustments, and our basis for excluding them from our non-GAAP financial measure, are outlined below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Unit
    and Stock-based compensation&#160;</b>&#8211; Although unit and stock-based compensation is an important aspect of the compensation
    paid to our employees, the grant date fair value varies based on the derived stock price at the time of grant, varying valuation
    methodologies, subjective assumptions, and the variety of award types. This makes the comparison of our current financial results
    to previous and future periods difficult to interpret; therefore, we believe it is useful to exclude unit and stock-based compensation
    from our non-GAAP financial measures in order to highlight the performance of our business and to be consistent with the way many
    investors evaluate our performance and compare our operating results to peer companies.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Business
    Combination transaction expenses&#160;</b>&#8211; Business Combination transaction expenses represent the expenses incurred solely
    related to the Business Combination, which we completed on June 7, 2022. It primarily includes investment banker fees, legal fees,
    professional fees for accountants, transaction fees, advisory fees, due diligence costs, certain other professional fees, and other
    direct costs associated with strategic activities. These amounts are impacted by the timing of the Business Combination. We exclude
    Business Combination transaction expenses from our non-GAAP financial measures to provide a useful comparison of our operating results
    to prior periods and to our peer companies because such amounts vary significantly based on the magnitude of the Business Combination
    transaction and do not reflect our core operations.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table reconciles GAAP net loss to Adjusted EBITDA during the periods presented (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year Ended<br/> December 31, 2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year Ended<br/> December 31, 2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Net loss</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">(23,205,456</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">(6,229,639</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Interest Expense</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">749,213</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">403,307</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Impairment</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">10,504,327</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Depreciation and amortization</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">27,983</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">24,807</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Unit and Stock-based compensation</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,572,232</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">45,584</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Business combination transaction expenses</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,427,73</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">900,152</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Adjusted EBITDA</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(6,932,966</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(4,855,789</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity
and Capital Resources</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023, our principal sources of liquidity were net proceeds received related to the Business Combination, f<span style="background-color: white">rom
the issuance of </span>&#160;$1,595,744.70 of OneMedNet senior secured convertible notes (the &#8220;Pre-Closing PIPE Notes&#8221;) issued
at the closing of the Business Combination and cash <span style="background-color: white">generated from operating activities</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table shows net cash and cash equivalents provided by (used in) operating activities, net cash and cash equivalents used in
investing activities, and net cash and cash equivalents provided by financing activities during the periods presented:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 12.95pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year Ended</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">December 31, 2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">December 31, 2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Net cash provided by (used in)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left; padding-left: 10pt">Operating activities</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">8,220,910</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">87,239,622</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">Investing activities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(43,757</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(58,137</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">Financing Activities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(8,431,875</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(88,032,226</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Operating
Activities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
net cash and cash equivalents provided by (used in) operating activities consists of net loss adjusted for certain non-cash items, including
depreciation and amortization, business combination cost, stock-based compensation expense, cash held in trust account, and as well as
changes in operating assets and liabilities. The primary changes in working capital items, such as the changes in accounts receivable
and deferred revenue, result from the difference in timing of payments from our customers related to contract performance obligation.
This may result in an operating cash flow source or use for the period, depending on the timing of payments received as compared to the
fulfillment of the performance obligation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"></p>

<!-- Field: Page; Sequence: 69; Value: 62 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in operating activities was $8.2 million during the year ended December 31, 2023. Net cash used in operating activities was
due to our net loss of $23.2 million adjusted for non-cash items of $31.4 million, primarily consisting of the redemption of public shares
in connection with the Business Combination causing the withdrawal of $29.0 million of cash held in the trust account, $0.9 million business
combination cost, $0.4 million extension loan, and use of cash for operating assets and liabilities of $1.1million due to the timing
of cash payments to vendors and cash receipts from customers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By
comparison, the Company&#8217;s net cash provided by operating activities was $87.2 million during the year ended December 31, 2022.
Net cash provided by operating activities was due to our net loss of $6.2 million adjusted for non-cash items of $93.5 million, primarily
consisting of the redemption of public shares in connection with the Business Combination causing the withdrawal of $88.3 million of
cash held in trust account $1.6 million of stock-based compensation expense, $2.5 million extension loan, less $0.5 million and use of
cash for operating assets and liabilities of $.5 million due to the timing of cash payments to vendors and cash receipts from customers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Investing
Activities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
investing activities have consisted primarily of property and equipment purchases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash and cash equivalents used in investing activities during the year ended December 31, 2023 consisted of $44 thousand of purchased
property and equipment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By
comparison, the Company&#8217;s net cash and cash equivalents used in investing activities during the year ended December 31, 2022 consisted
primarily of $58 thousand of purchased property and equipment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Financing
Activities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash flows from financing activities was ($8.4 million) for the year ended December 31, 2023, which primarily consisted of $10.7 million
repayment on convertible promissory note payable, $1.5 million proceeds from issuance of PIPE Convertible Notes and Warrants, $0.5 proceeds
from related loan, $28.8 million from Common Stock subject to redemption in connection with the Business Combination, $0.5 million underwriting
fee related to the Business Combination, $0.3 million decrease in warrant liability, $18.2 million additional paid in capital and $11.6
million retained earning adjustment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white">We
believe the likelihood that warrant holders will exercise their Warrants, and therefore the amount of cash proceeds that we would receive,
is dependent upon the market price of our shares of Common Stock. When the market price for our shares of Common Stock is less than $11.50&#160;per
share (<i>i.e.,</i> the Warrants are &#8220;out of the money&#8221;), which it is at the time of this prospectus, we believe warrant
holders will be unlikely to exercise their Warrants.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By
comparison, the Company&#8217;s net cash flows from financing activities was ($88.0 million) for the year ended December 31, 2023, which
primarily consisted of $5.5 million proceeds from convertible promissory notes payable, $88.5 million from common stock subject to redemption
in connection with the Business Combination, $4.5 million decrease in warrant liability, $2.8 million additional paid in capital and
$3.4 million retained earning adjustment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 12.95pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Our
future capital requirements depend on many factors including our growth rate, the continuing market acceptance of our offerings, the
timing and extent of spending to support our expansion of sales and marketing activities, and the expansion of our business into new
geographies and markets. Further, as part of our growth strategy, we expect to enter into arrangements to acquire or invest in businesses,
products, services, and/or technologies. To enhance our liquidity position or increase our cash reserve for future investments or operations
through additional financing activities, we currently expect to utilize our financing arrangement under definitive securities purchase
agreement (the &#8220;Securities Purchase Agreement&#8221;) with Helena Global Investment Opportunities 1 Ltd. and we may in the future
seek additional equity or debt financing. The issuance and sale of additional equity would result in further dilution to our shareholders.
The incurrence of indebtedness would result in increased fixed obligations and could result in operating covenants that would restrict
our operations. The sale of a substantial percentage of the securities being offered pursuant to this prospectus or the perception that
these sales could occur, may make it more difficult for the Company to issue additional equity financing on favorable terms, or at all.
If we are unable to obtain adequate financing on terms satisfactory to it or within the timeframe it requires, its ability to continue
to support its business growth and to respond to business challenges could be significantly limited, and the Company&#8217;s business,
financial condition and operating results could be adversely affected.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 12.95pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 12.95pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Contractual
Obligations and Commitments and Liquidity Outlook</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently,
management does not believe the cash and cash equivalents is sufficient to meet our foreseeable cash needs for at least the next 12 months.
Our foreseeable cash needs, in addition to our recurring operating expenses, include our expected capital expenditures to support the
expansion of our infrastructure and workforce, interest expense and minimum contractual obligations. Management hopes to raise cash either
through a public offering, shareholder loans or private debt and equity offering. Our inability to raise cash would cause to operate
as a going concern and may affect the ability to meet growth, revenue, and expense targets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future capital requirements will depend on many factors, including our growth rate, ability to meet revenue targets, expansion of
data network, extent of spending to support research and development efforts, the expansion of sales and marketing activities including
expansion to additional markets, the introduction of new and enhanced product and service offerings, and the cost of any future acquisitions
of technology or businesses. In the event that additional financing is required from outside sources, we may be unable to raise the funds
on acceptable terms, if at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes our current and long-term material cash requirements as of December 31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 12.95pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Payments due in:</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Less than 1 year</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">1-3 years</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 46%; text-align: left">Accounts payable and accrued expenses</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">4,184,398</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">4,184,398</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Excise tax</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">113,353</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">113,353</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Income tax payable</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">120,017</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">120,017</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">PIPE Notes, net of discount including interest</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,549,820</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,549,820</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Loan, related party of OMN including interest</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">465,023</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">465,023</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">6,432,610</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">5,967.587</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">465,023</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"></p>

<!-- Field: Page; Sequence: 70; Value: 62 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical
Accounting Policies and Estimates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management&#8217;s discussion and analysis of financial condition and results of operations is based on our consolidated financial statements
which have been prepared in accordance with accounting principles generally accepted in the United States of America. In preparing our
financial statements, we make estimates, assumptions, and judgments that can have a significant impact on our reported revenue, results
of operations, and net income or loss, as well as on the value of certain assets and liabilities on our balance sheet during and as of
the reporting periods. These estimates, assumptions, and judgments are necessary because future events and their effects on our results
and the value of our assets cannot be determined with certainty and are made based on our historical experience and on other assumptions
that we believe to be reasonable under the circumstances. These estimates may change as new events occur or additional information is
obtained, and we may periodically be faced with uncertainties, the outcomes of which are not within our control and may not be known
for a prolonged period of time. Because the use of estimates is inherent in the financial reporting process, actual results could differ
from those estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that the assumptions and estimates associated with the following critical accounting policies involve significant judgment and
thus have the most significant potential impact on our Consolidated Financial Statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Revenue
Recognition</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
generate revenue from the sale of products and services. A description of our revenue recognition policies is included in Note 2,&#160;<i>Summary
of Significant Accounting Policies</i>&#160;in the Notes to the Consolidated Financial Statements included elsewhere in this Annual Report
on Form 10-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
most of our sales agreements contain standard terms and conditions, certain agreements contain multiple performance obligations or non-standard
terms and conditions. For customer contracts that contain more than one performance obligation, we allocate the total transaction consideration
to each performance obligation based on the relative stand-alone selling price of each performance obligation within the contract. We
rely on either observable standalone sales or an expected cost plus a margin approach to determine the standalone selling price of offerings,
depending on the nature of the performance obligation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
we further discuss in Note 2,&#160;<i>Summary of Significant Accounting Policies</i>&#160;in the Notes to the Consolidated Financial
Statements included elsewhere in this Annual Report on Form 10-K, for contracts with customers entered into during fiscal years 2023
and 2022, revenue from the sales of our iRWD and BEAM are recognized over time as the asset created by our performance does not have
alternative use to us and an enforceable right to payment for performance completed to date is present. We recognize revenue as work
progresses, using costs incurred to date relative to total estimated costs at completion. Incurred costs represent work performed, which
correspond with and best depict transfer of control to the customer. Contract costs are incurred over a period of time, which can span
periods, and the estimation of these costs requires management&#8217;s judgment. Due to the nature of the work required to be performed
on the iRWD and BEAM and our reliance on the availability the estimation of total revenue and cost at completion is complex, subject
to many variables, and requires significant judgment on a contract-by-contract basis. As part of this process, we review information
including, but not limited to, any outstanding key contract matters, progress towards completion and the related program schedule, identified
risks and opportunities and the related changes in estimates of revenue and costs. The risks and opportunities relate to our judgment
about the delays that may or may not be within our control. Risks and opportunities may also relate to supply chain trends and commodity
pricing, as well as changes in foreign currencies. Changes in estimates of net sales, cost of sales, and the related impact to operating
profit are recognized on a cumulative catch-up basis, which recognizes the cumulative effect of the profit changes on current and prior
periods based on a performance obligation&#8217;s percentage of completion in the current period. A significant change in one or more
of these estimates could affect the profitability of one of more of our performance obligations and could have a material impact on our
financial condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"></p>

<!-- Field: Page; Sequence: 71; Value: 62 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stock-based
Compensation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 12.95pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to the Business Combination, OneMedNet Corporation (now OneMedNet Solutions Corporation) had five authorized classes of membership interests,
consisting of a class of common units known as the Class A Common Units (the &#8220;Class A Units&#8221;), a class of preferred units
known as the Series A-2 Preferred Units (the &#8220;A-2 Preferred Units&#8221;), a class of preferred units known as the Series A-1 Preferred
Units (the &#8220;A-1 Preferred Units&#8221;), Convertible Notes, Stock Options units, known as the Options and Warrants units granted
to employees, officers, and directors pursuant to an incentive plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 12.95pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
the Business Combination, the Company has authorized 101,000,000 shares of common stock, including 100,000,000 shares of Common Stock
and 1,000,000 shares of Preferred Stock. In addition, the Company has three classes of warrants (<i>i.e.</i>, Public Warrants, Private
Warrants and PIPE Warrants) issued and outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 12.95pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
the Business Combination is accounted for as a reverse recapitalization, all periods prior to the Business Combination have been retroactively
adjusted using the Exchange Ratio as stipulated by the Merger Agreement for the equivalent number of shares outstanding immediately after
the Merger to effect the reverse recapitalization. The Class A Units, A-2 Preferred Units, A-1 Preferred Units, Options and Warrants
were converted into Common Stock using an exchange ratio of 1:1, the Convertible Notes were converted into Common Stock using an exchange
ratio of 2.5 per share. This is presented within the consolidated statements of changes in redeemable preferred and common units and
equity (deficit).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 12.95pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
typically issue restricted stock units (&#8220;RSUs&#8221;) as stock-based compensation. For RSUs, the fair value is the closing market
price of the stock on the date immediately preceding the grant. We recognize compensation expense over the requisite service period for
awards expected to vest. We account for forfeitures as they occur, rather than applying an estimated forfeiture rate. The graded-vesting
method of expense recognition is applied to all awards with service-only conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 12.95pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
RSUs involve stock to be issued upon the achievement of certain performance conditions. Such RSUs become available, subject to time-based
vesting conditions if, and to the extent that, financial performance criteria for the applicable period are achieved. Accordingly, the
number of RSUs earned will vary based on the level of achievement of financial performance objectives for the applicable period. Until
such time that our financial performance can ultimately be determined, each quarter we estimate the number of RSUs to be earned based
on an evaluation of the probability of achieving the financial performance objectives. Such estimates are revised, if necessary, in subsequent
periods when the underlying factors change our evaluation of the probability of achieving the financial performance objectives. Accordingly,
stock-based compensation expense associated with performance-based RSUs may differ significantly from the amount recorded in the current
period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 12.95pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
assumptions used in calculating the fair value of stock-based compensation awards represent management&#8217;s best estimates, but these
estimates involve inherent uncertainties and the application of management&#8217;s judgment. As a result, if factors change and we use
different assumptions, our stock-based compensation expense could be materially different in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Warrant
transactions</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PIPE
Warrants to purchase our shares of Common Stock may be accounted for as either liability or equity instruments depending on the terms
of the warrant agreements. The warrants issued by us are accounted for as equity instruments due to our ability to settle the warrants
through the issuance of units and the absence of terms which would require liability classification, including the rights of the grantee
to require cash settlement. We classify these equity instruments within additional paid-in capital on the consolidated balance sheets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Private
Warrants to purchase units accounted for as liability instruments represent the warrants issued to significant shareholders and related
parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to calculate warrant charges, we used the Black-Scholes pricing model, which required key inputs including volatility and risk-free
interest rate and certain unobservable inputs for which there is little or no market data, requiring us to develop our own assumptions.
We estimated the fair value of unvested warrants, considered to be probable of vesting, at the time. Based on that estimated fair value,
we determined warrant charges, which were recorded as a reduction of the transaction price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_016"></span>LEGAL
PROCEEDINGS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time and in the course of business, we may become involved in various legal proceedings seeking monetary damages and other relief.
The amount of the ultimate liability, if any, from such claims cannot be determined. As of the date hereof, there are no legal claims
currently pending or, to our knowledge, threatened against us or any of our officers or directors in their capacity as such or against
any of our properties that, in the opinion of our management, would be likely to have a material adverse effect on our financial position,
results of operations or cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p>


<!-- Field: Page; Sequence: 72; Value: 62 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_019"></span>WHERE
YOU CAN FIND MORE <span style="letter-spacing: -0.1pt">INFORMATION</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus is part of a registration statement we filed with the SEC. This prospectus does not contain all of the information set forth
in the registration statement and the exhibits to the registration statement. For further information with respect to us and the securities
we are offering under this prospectus, we refer you to the registration statement and the exhibits and schedules filed as a part of the
registration statement. You should rely only on the information contained in this prospectus or incorporated by reference into this prospectus.
We have not authorized anyone else to provide you with different information. We are not making an offer of these securities in any jurisdiction
where the offer is not permitted. You should assume that the information contained in this prospectus, or any document incorporated by
reference in this prospectus, is accurate only as of the date of those respective documents, regardless of the time of delivery of this
prospectus or any sale of our securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the
public from commercial document retrieval services and over the Internet at the SEC&#8217;s website at http://www.sec.gov. We maintain
a website at www.sonnetbio.com. You may access our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form
8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act with the SEC free of charge
at our website as soon as reasonably practicable after such material is electronically filed with, or furnished to, the SEC. The information
contained in, or that can be accessed through, our website is not incorporated by reference into, and is not part of, this prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_020"></span>INCORPORATION
OF DOCUMENTS BY <span style="letter-spacing: -0.1pt">REFERENCE</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus is part of the registration statement but the registration statement includes and incorporates by reference additional information
and exhibits. The SEC permits us to &#8220;incorporate by reference&#8221; the information contained in documents we file with the SEC,
which means that we can disclose important information to you by referring you to those documents rather than by including them in this
prospectus. Information that is incorporated by reference is considered to be part of this prospectus and you should read it with the
same care that you read this prospectus. Information that we file later with the SEC will automatically update and supersede the information
that is either contained, or incorporated by reference, in this prospectus, and will be considered to be a part of this prospectus from
the date those documents are filed. We have filed with the SEC, and incorporate by reference in this prospectus:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annual
Report on Form 10-K for the year ended December 31, 2022 filed with the SEC on April 9, 2024 and for December 31, 2022 filed with
the SEC on March <span style="letter-spacing: -0.05pt">31</span>, <span style="letter-spacing: -0.1pt">2023; </span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
    Reports on Form 8-K, filed with the SEC on November 13, 2023, January 3, 2025, February 9, 2024, and April 2, 2024;
    <span style="letter-spacing: -0.25pt">and</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    description of our Common Stock contained in our Registration Statement on Form 8-A12b filed <span style="letter-spacing: -0.2pt">with
    </span>the SEC on May 5, 2021, and any amendments or reports filed updating such <span style="letter-spacing: -0.1pt">description.</span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
the statements in the preceding paragraphs, no document, report or exhibit (or portion of any of the foregoing) or any other information
that we have &#8220;furnished&#8221; to the SEC pursuant to the Securities Exchange Act of 1934, as amended shall be incorporated by
reference into this prospectus. We will furnish without charge to you, on written or oral request, a copy of any or all of the documents
incorporated by reference in this prospectus, including exhibits to these documents. You should direct any requests for documents to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">OneMedNet
Corporation</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6385
Old Shady Oak Road, Suite 250<br/>
Eden Prairie, MN 55344</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telephone:
800-918-7189</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
also may access these filings on our website at http://www.sidusspace.com. We do not incorporate the information on our website into
this prospectus or any supplement to this prospectus and you should not consider any information on, or that can be accessed through,
our website as part of this prospectus or any supplement to this prospectus (other than those filings with the SEC that we specifically
incorporate by reference into this prospectus or any supplement to this prospectus).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
statement contained in a document incorporated or deemed to be incorporated by reference in this prospectus will be deemed modified,
superseded or replaced for purposes of this prospectus to the extent that a statement contained in this prospectus modifies, supersedes
or replaces such statement. Any statement contained herein or in any document incorporated or deemed to be incorporated by reference
shall be deemed to be modified or superseded for purposes of the registration statement of which this prospectus forms a part to the
extent that a statement contained in any other subsequently filed document which also is or is deemed to be incorporated by reference
modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed to constitute a part of the registration
statement of which this prospectus forms a part, except as so modified or superseded.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 73; Value: 62 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART
I - FINANCIAL INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
1. Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#F_001">Report
    of Independent Registered Public Accounting Firm</a> (PCAOB ID No. <span>5041</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-1&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#F_002">Consolidated
    Balance Sheets</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#F_003">Consolidated
    Statements of Operations</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-</span>3</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#F_004">Consolidated
    Statements of Changes in Redeemable Preferred and Common Units and Equity (Deficit)</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-</span>4</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#F_005">Consolidated
    Statements of Cash Flows</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-</span>5</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#F_006">Notes
    to the Consolidated Financial Statements</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-</span>6</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 74 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="F_001"></span>Report
of Independent Registered Public Accounting Firm</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the shareholders and the board of directors of OneMedNet Corporation</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Opinion
on the Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited the accompanying consolidated balance sheets of OneMedNet Corporation as of December 31, 2023 and 2022, the related statements
of operations, stockholders&#8217; equity (deficit), and cash flows for the years then ended, and the related notes (collectively referred
to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the
financial position of the Company as of December 31, 2023 and 2022, and the results of its operations and its cash flows for the years
then ended, in conformity with accounting principles generally accepted in the United States.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Substantial
Doubt about the Company&#8217;s Ability to Continue as a Going Concern</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note
2 to the financial statements, the Company has suffered recurring losses from operations and has a significant accumulated deficit. In
addition, the Company continues to experience negative cash flows from operations. These factors raise substantial doubt about the Company&#8217;s
ability to continue as a going concern. Management&#8217;s plans in regard to these matters are also described in Note 2. The financial
statements do not include any adjustments that might result from the outcome of this uncertainty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis
for Opinion</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s
financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board
(United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal
securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company
is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits
we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion
on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or
fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding
the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant
estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides
a reasonable basis for our opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
<span>BF Borgers CPA PC</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BF
Borgers CPA PC (PCAOB ID 5041)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have served as the Company&#8217;s auditor since 2022</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lakewood,
CO</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
9, 2024</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 75; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="F_002"></span>ONEMEDNET
CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
BALANCE SHEETS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30B_111_zR1o5K17uzpk" summary="xdx: Statement - Consolidated Balance Sheets" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20231231_znqbia1saWX1" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December
    31, 2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20221231_zwjNF8CsyxCk" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December
    31, 2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AssetsCurrentAbstract_iB_zlixzv8vn9mf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Current Assets</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01I_maACziwX_zE6XiA5gPVG8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; width: 60%; text-align: left">Cash and cash equivalents</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2023-12-31" id="Fact000039" format="ixt:numdotdecimal" decimals="0" unitRef="USD">47,008</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2022-12-31" id="Fact000040" format="ixt:numdotdecimal" decimals="0" unitRef="USD">301,730</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AssetsHeldInTrustCurrent_i01I_maACziwX_zCXkxqfdAae3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; text-align: left">Investments held in Trust</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0042">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AssetsHeldInTrustCurrent" contextRef="AsOf2022-12-31" id="Fact000043" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,029,415</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AccountsReceivableNetCurrent_i01I_maACziwX_zbJqfYBKGnw5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; text-align: left">Accounts receivable, net of allowance</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2023-12-31" id="Fact000045" format="ixt:numdotdecimal" decimals="0" unitRef="USD">151,640</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2022-12-31" id="Fact000046" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,975</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i01I_maACziwX_zfo9WveiLJle" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; text-align: left">Prepaid expenses and other assets</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2023-12-31" id="Fact000048" format="ixt:numdotdecimal" decimals="0" unitRef="USD">165,538</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2022-12-31" id="Fact000049" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,945</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OtherReceivables_i01I_maACziwX_zIPcwYWJbStc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; text-align: left">Receivable from SPAC</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><ix:nonFraction name="us-gaap:OtherReceivables" contextRef="AsOf2022-12-31" id="Fact000052" format="ixt:numdotdecimal" decimals="0" unitRef="USD">900,152</ix:nonFraction></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AssetsCurrent_i01TI_mtACziwX_maAzezs_zMzQ4UbFwn21" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Total current assets</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2023-12-31" id="Fact000054" format="ixt:numdotdecimal" decimals="0" unitRef="USD">364,186</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2022-12-31" id="Fact000055" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,351,217</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentNet_iI_maAzezs_zagdDnexTUwj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Property and Equipment, Net</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2023-12-31" id="Fact000057" format="ixt:numdotdecimal" decimals="0" unitRef="USD">98,871</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2022-12-31" id="Fact000058" format="ixt:numdotdecimal" decimals="0" unitRef="USD">83,097</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--Assets_iTI_mtAzezs_zZkjtrFTUp0j" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total assets</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2023-12-31" id="Fact000060" format="ixt:numdotdecimal" decimals="0" unitRef="USD">463,057</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2022-12-31" id="Fact000061" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,434,314</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LiabilitiesCurrentAbstract_i01B_zGhYC9TsZKH8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Current Liabilities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_i02I_maLCz0I4_zA553IAQS68d" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; text-align: left">Accounts payable &amp; accrued expenses</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact000066" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,184,398</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="AsOf2022-12-31" id="Fact000067" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,814,570</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OtherShortTermBorrowings_i02I_maLCz0I4_zoJd3CqTmqie" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; text-align: left">Loan Amount due to related parties</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OtherShortTermBorrowings" contextRef="AsOf2023-12-31" id="Fact000069" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,200</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OtherShortTermBorrowings" contextRef="AsOf2022-12-31" id="Fact000070" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,500</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--SalesAndExciseTaxPayableCurrent_i02I_maLCz0I4_z6riaLiiOLPh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; text-align: left">Excise tax</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:SalesAndExciseTaxPayableCurrent" contextRef="AsOf2023-12-31" id="Fact000072" format="ixt:numdotdecimal" decimals="0" unitRef="USD">113,353</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0073">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--LoanExtensionsCurrent_i02I_maLCz0I4_zEukamD6cBQk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; text-align: left">Loan Extensions</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ONMD:LoanExtensionsCurrent" contextRef="AsOf2023-12-31" id="Fact000075" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,991,679</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0076">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredRevenueCurrent_i02I_maLCz0I4_z7NUyA9WHj8h" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; text-align: left">Deferred revenues</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DeferredRevenueCurrent" contextRef="AsOf2023-12-31" id="Fact000078" format="ixt:numdotdecimal" decimals="0" unitRef="USD">253,997</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DeferredRevenueCurrent" contextRef="AsOf2022-12-31" id="Fact000079" format="ixt:numdotdecimal" decimals="0" unitRef="USD">183,683</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LoansPayable_i02I_maLCz0I4_zlQ8R3mPPLR7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; text-align: left">Loan Payable</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LoansPayable" contextRef="AsOf2023-12-31" id="Fact000081" format="ixt:numdotdecimal" decimals="0" unitRef="USD">38,921</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0082">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--ConvertibleDebtCurrent_i02I_maLCz0I4_zoqivVILT77g" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; text-align: left">Convertible promissory notes</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0084">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ConvertibleDebtCurrent" contextRef="AsOf2022-12-31" id="Fact000085" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,490,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--UnsecuredDebtCurrent_i02I_maLCz0I4_zxrTQVM3xuEk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; text-align: left">Canada Emergency Business Loan Act</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:UnsecuredDebtCurrent" contextRef="AsOf2023-12-31" id="Fact000087" format="ixt:numdotdecimal" decimals="0" unitRef="USD">44,673</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0088">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AccruedIncomeTaxesCurrent_i02I_maLCz0I4_zLE43xeIxs7f" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; text-align: left">Income tax payable</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AccruedIncomeTaxesCurrent" contextRef="AsOf2023-12-31" id="Fact000090" format="ixt:numdotdecimal" decimals="0" unitRef="USD">120,017</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AccruedIncomeTaxesCurrent" contextRef="AsOf2022-12-31" id="Fact000091" format="ixt:numdotdecimal" decimals="0" unitRef="USD">214,850</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AccrualForTaxesOtherThanIncomeTaxesCurrent_i02I_maLCz0I4_zQt36rL91IAb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; text-align: left">Franchise tax payable</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0093">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent" contextRef="AsOf2022-12-31" id="Fact000094" format="ixt:numdotdecimal" decimals="0" unitRef="USD">69,966</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--OtherNotesPayableCurrent_i02I_maLCz0I4_ztC1Mdb1jkdd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; text-align: left">Pipe Notes, net of discount including interest</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OtherNotesPayableCurrent" contextRef="AsOf2023-12-31" id="Fact000096" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,549,820</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0097">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--DeferredUnderwriterFeePayableCurrent_i02I_maLCz0I4_zLam7rbaqFZ9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; text-align: left; padding-bottom: 1.5pt">Deferred underwriter fee payable</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ONMD:DeferredUnderwriterFeePayableCurrent" contextRef="AsOf2023-12-31" id="Fact000099" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,525,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0100">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LiabilitiesCurrent_i02TI_mtLCz0I4_maLzbd1_z9jM8uDDgwB4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; text-align: left">Total current liabilities</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact000102" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,833,058</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2022-12-31" id="Fact000103" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,784,569</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LiabilitiesNoncurrentAbstract_i01B_zyuGgAvJZlWh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Long Term Liabilities</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--ConvertibleDebtNoncurrent_i02I_maLzbd1_zhPoWs61jy0f" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Convertible promissory note</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ConvertibleDebtNoncurrent" contextRef="AsOf2022-12-31" id="Fact000109" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,500,000</ix:nonFraction></span></p></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--UnsecuredDebt_i02I_maLzbd1_zmOcqYN9YVw4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Canada Emergency Business Loan Act</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><ix:nonFraction name="us-gaap:UnsecuredDebt" contextRef="AsOf2022-12-31" id="Fact000112" format="ixt:numdotdecimal" decimals="0" unitRef="USD">44,144</ix:nonFraction></p></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--AccruedInterestRelatedParty_i02I_maLzbd1_zIUdlg31A1b9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Accrued interest</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><ix:nonFraction name="ONMD:AccruedInterestRelatedParty" contextRef="AsOf2022-12-31" id="Fact000115" format="ixt:numdotdecimal" decimals="0" unitRef="USD">690,772</ix:nonFraction></p></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OtherLiabilitiesNoncurrent_i02I_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_maLzbd1_zPOataMRYYo6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; text-align: left">Loan, related party of OMN</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember" id="Fact000117" format="ixt:numdotdecimal" decimals="0" unitRef="USD">465,023</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><span style="-sec-ix-hidden: xdx2ixbrl0118">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--WarrantLiabilityNonCurrent_i02I_maLzbd1_zPAlk7T7YBx" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; text-align: left">Warrant liabilities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ONMD:WarrantLiabilityNonCurrent" contextRef="AsOf2023-12-31" id="Fact000120" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,582</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ONMD:WarrantLiabilityNonCurrent" contextRef="AsOf2022-12-31" id="Fact000121" format="ixt:numdotdecimal" decimals="0" unitRef="USD">362,558</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--DeferredUnderwriterFeePayableNonCurrent_i02I_maLzbd1_zk0LFC0Evg6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; text-align: left">Deferred underwriter fee payable</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0123">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ONMD:DeferredUnderwriterFeePayableNonCurrent" contextRef="AsOf2022-12-31" id="Fact000124" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,025,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--WorkingCapitalLoan_i02I_maLzbd1_z2AuP7K7QM63" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; text-align: left">Working capital Loan</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0126">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ONMD:WorkingCapitalLoan" contextRef="AsOf2022-12-31" id="Fact000127" format="ixt:numdotdecimal" decimals="0" unitRef="USD">207,081</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LongTermLoansPayable_i02I_maLzbd1_zUstmBDyI6m" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; text-align: left; padding-bottom: 1.5pt">Extension loans</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0129">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LongTermLoansPayable" contextRef="AsOf2022-12-31" id="Fact000130" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,545,839</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--Liabilities_i01TI_maLASEzyWZ_mtLzbd1_zeBhXqVB6tP2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; text-align: left">Total liabilities</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2023-12-31" id="Fact000132" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,322,663</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2022-12-31" id="Fact000133" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,159,963</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: -10pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--StockholdersEquityAbstract_i01B_zQdQOCJAl5H8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Stockholders&#8217; Equity (Deficit)</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PreferredStockValue_i02I_hus-gaap--StatementClassOfStockAxis__custom--SeriesATwoPreferredStockMember_maSEz11V_zuNF5jdFSsW8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt">Preferred Series A-2, par value $<span id="xdx_908_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesATwoPreferredStockMember_zymggFOt8pp4"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2022-12-31_custom_SeriesATwoPreferredStockMember" id="Fact000140" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span>,
    <span id="xdx_90B_eus-gaap--PreferredStockSharesAuthorized_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesATwoPreferredStockMember_zJt4n55VBz51"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2022-12-31_custom_SeriesATwoPreferredStockMember" id="Fact000141" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,200,000</ix:nonFraction>
    </span>shares authorized and, <span id="xdx_90B_eus-gaap--PreferredStockSharesOutstanding_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesATwoPreferredStockMember_z60NvI1oBRXe"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2023-12-31_custom_SeriesATwoPreferredStockMember" id="Fact000142" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction>
    </span>and <span id="xdx_90B_eus-gaap--PreferredStockSharesOutstanding_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesATwoPreferredStockMember_zvqTelhZS8v9"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2022-12-31_custom_SeriesATwoPreferredStockMember" id="Fact000143" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,853,797</ix:nonFraction>
    </span>shares issued and outstanding as of December 31, 2023 and December 31, 2022</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0138">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2022-12-31_custom_SeriesATwoPreferredStockMember" id="Fact000139" format="ixt:numdotdecimal" decimals="0" unitRef="USD">385</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--PreferredStockValue_i02I_hus-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember_maSEz11V_zLaMybXOZdbd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt">Preferred Shares A-1, par value $<span id="xdx_90A_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember_zbCrbDuLJM47"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2022-12-31_custom_SeriesAOnePreferredStockMember" id="Fact000147" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span>,
    <span id="xdx_900_eus-gaap--PreferredStockSharesAuthorized_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember_zGSg4vCxRNX7"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2022-12-31_custom_SeriesAOnePreferredStockMember" id="Fact000148" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,400,000</ix:nonFraction>
    </span>shares authorized and, <span id="xdx_90B_eus-gaap--PreferredStockSharesOutstanding_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember_zSYc2RILCxbi"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2023-12-31_custom_SeriesAOnePreferredStockMember" id="Fact000149" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction>
    </span>and <span id="xdx_907_eus-gaap--PreferredStockSharesOutstanding_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember_zVuRq4LY8wXf"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2022-12-31_custom_SeriesAOnePreferredStockMember" id="Fact000150" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,204,000</ix:nonFraction>
    </span>shares issued and outstanding as of December 31, 2023 and December 31, 2022</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0145">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2022-12-31_custom_SeriesAOnePreferredStockMember" id="Fact000146" format="ixt:numdotdecimal" decimals="0" unitRef="USD">320</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PreferredStockValue_i02I_hus-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember_maSEz11V_zhJ9bvK8ottf" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; display: none; padding-left: 0pt">Preferred value</td><td style="font: 10pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0152">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: right"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2022-12-31_custom_SeriesAOnePreferredStockMember" id="Fact000153" format="ixt:numdotdecimal" decimals="0" unitRef="USD">320</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--CommonStockValue_i02I_maSEz11V_zeZRwjIV77b6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt">Common Stock, par value $<span id="xdx_907_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20221231_zHxPl6xSXWM6"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2022-12-31" id="Fact000157" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span>,
    <span id="xdx_90E_eus-gaap--CommonStockSharesAuthorized_iI_c20221231_zfcnS6woGn52"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-12-31" id="Fact000158" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">30,000,000</ix:nonFraction></span> shares authorized and
    <span id="xdx_901_eus-gaap--CommonStockSharesOutstanding_iI_c20231231_zTT9XuPby2qh"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-12-31" id="Fact000159" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">23,572,232</ix:nonFraction></span> and <span id="xdx_90D_eus-gaap--CommonStockSharesOutstanding_iI_c20221231_z3FS1RRUxYA7"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-12-31" id="Fact000160" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,550,166</ix:nonFraction>
    </span>shares issued and outstanding as of December 31, 2023 and December 31, 2022</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2023-12-31" id="Fact000155" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,357</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2022-12-31" id="Fact000156" format="ixt:numdotdecimal" decimals="0" unitRef="USD">455</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--CommonStockValue_i02I_hus-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_maSEz11V_zHE77ODzmH3c" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; text-align: left">Data Knights Acquisition Corp. Class A Common Stock, par value $<span id="xdx_90C_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zt3vQrUFgZH"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2022-12-31_us-gaap_CommonClassAMember" id="Fact000164" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span>,
    <span id="xdx_902_eus-gaap--CommonStockSharesAuthorized_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_znbKJqW2gyik"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-12-31_us-gaap_CommonClassAMember" id="Fact000165" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,200,000</ix:nonFraction>
    </span>shares authorized and, <span id="xdx_903_eus-gaap--CommonStockSharesOutstanding_iI_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zgM7jPN772g1"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonClassAMember" id="Fact000166" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction>
    </span>and <span id="xdx_90B_eus-gaap--CommonStockSharesOutstanding_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zhjUF6NPLNh4"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonClassAMember" id="Fact000167" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,853,797</ix:nonFraction>
    </span>shares issued and outstanding as of December 31, 2023 and December 31, 2022</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0162">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2022-12-31_us-gaap_CommonClassAMember" id="Fact000163" format="ixt:numdotdecimal" decimals="0" unitRef="USD">59</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CommonStockValue_i02I_hus-gaap--StatementClassOfStockAxis__custom--CommonClassAOneMember_maSEz11V_z7E5KBZvKk0h" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; text-align: left">Data Knights Acquisition Corp. Class A Common Stock, par value $<span id="xdx_906_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--CommonClassAOneMember_zvLKTr8fEfCd"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2022-12-31_custom_CommonClassAOneMember" id="Fact000171" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span>,
    <span id="xdx_90D_eus-gaap--CommonStockSharesAuthorized_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--CommonClassAOneMember_zrTWuCwrWzpi"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-12-31_custom_CommonClassAOneMember" id="Fact000172" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,200,000</ix:nonFraction>
    </span>shares authorized and, <span id="xdx_905_eus-gaap--CommonStockSharesOutstanding_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--CommonClassAOneMember_z2hyUc7SBQw9"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-12-31_custom_CommonClassAOneMember" id="Fact000173" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction>
    </span>and <span id="xdx_906_eus-gaap--CommonStockSharesOutstanding_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--CommonClassAOneMember_zpCgHEAO8B5f"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-12-31_custom_CommonClassAOneMember" id="Fact000174" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,853,797</ix:nonFraction>
    </span>shares issued and outstanding as of December 31, 2023 and December 31, 2022</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0169">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2022-12-31_custom_CommonClassAOneMember" id="Fact000170" format="ixt:numdotdecimal" decimals="0" unitRef="USD">425</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--CommonStockValue_i02I_hus-gaap--StatementClassOfStockAxis__custom--CommonClassAOneMember_maSEz11V_zXBt6DFn3bZ6" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; display: none; padding-left: 0pt; text-align: left">Common stock value</td><td style="font: 10pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0176">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2022-12-31_custom_CommonClassAOneMember" id="Fact000177" format="ixt:numdotdecimal" decimals="0" unitRef="USD">425</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--CommitmentsAndContingencies_i02I_maSEz11V_zZcmxQvlJUs3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; text-align: left">Commitments and contingencies</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0179">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2022-12-31" id="Fact000180" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,750,110</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AdditionalPaidInCapital_i02I_maSEz11V_zjjk9l46Y8t4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; text-align: left">Additional paid in capital</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2023-12-31" id="Fact000182" format="ixt:numdotdecimal" decimals="0" unitRef="USD">42,220,714</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2022-12-31" id="Fact000183" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,032,561</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_maSEz11V_zHRqMxBRqdI9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; text-align: left; padding-bottom: 1.5pt">Accumulated deficit</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2023-12-31" id="Fact000185" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">55,082,677</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2022-12-31" id="Fact000186" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">43,509,964</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--StockholdersEquity_i02TI_maLASEzyWZ_mtSEz11V_z8RVieEKGQRi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-left: 0pt; text-align: left; padding-bottom: 1.5pt">Total stockholders&#8217; equity (deficit)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000188" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">12,859,606</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" id="Fact000189" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,274,351</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_mtLASEzyWZ_zu5FfgWqkfwi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; text-align: left; padding-bottom: 2.5pt">Total liabilities and stockholders&#8217; equity (deficit)</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000191" format="ixt:numdotdecimal" decimals="0" unitRef="USD">463,057</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2022-12-31" id="Fact000192" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,434,314</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 76; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="F_003"></span>ONEMEDNET
CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
STATEMENTS OF OPERATIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_300_113_z8VrNlyelII3" summary="xdx: Statement - Consolidated Statements of Operations" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; display: none">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20230101__20231231_zWGyTOSVAv2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; display: none; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_490_20220101__20221231_zFH5E0dFJ2ig" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; display: none; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year Ended</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_maGPzI7h_znL6uYkeP1df" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 60%">Revenue</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-01-01to2023-12-31" id="Fact000194" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,021,651</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-01-012022-12-31" id="Fact000195" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,152,738</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--CostOfRevenue_i01_msGPzI7h_zsc34gfgqjM7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; padding-bottom: 1.5pt">Cost of Revenue</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2023-01-01to2023-12-31" id="Fact000197" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,149,551</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2022-01-012022-12-31" id="Fact000198" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,513,428</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--GrossProfit_i01_mtGPzI7h_maOILzsEt_zka7D4fZGAY2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Gross Margin</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2023-01-01to2023-12-31" id="Fact000200" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">127,900</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2022-01-012022-12-31" id="Fact000201" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">360,690</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OperatingExpensesAbstract_iB_zGk4QVujTTJ" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Operating Expenses</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--GeneralAndAdministrativeExpense_i01_maOEzLOr_zXBq6Q4QCZJh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">General and administrative</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-01-01to2023-12-31" id="Fact000206" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,273,503</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2022-01-012022-12-31" id="Fact000207" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,755,620</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OtherGeneralExpense_i01_maOEzLOr_znsEOPxmLdBb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Operations</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OtherGeneralExpense" contextRef="From2023-01-01to2023-12-31" id="Fact000209" format="ixt:numdotdecimal" decimals="0" unitRef="USD">226,257</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OtherGeneralExpense" contextRef="From2022-01-012022-12-31" id="Fact000210" format="ixt:numdotdecimal" decimals="0" unitRef="USD">398,760</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--SellingAndMarketingExpense_i01_maOEzLOr_zjC34v1NMe7i" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Sales &amp; Marketing</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:SellingAndMarketingExpense" contextRef="From2023-01-01to2023-12-31" id="Fact000212" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,114,977</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:SellingAndMarketingExpense" contextRef="From2022-01-012022-12-31" id="Fact000213" format="ixt:numdotdecimal" decimals="0" unitRef="USD">957,690</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--ResearchAndDevelopmentExpense_i01_maOEzLOr_zDrNSO1N7uh7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Research and development</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-01to2023-12-31" id="Fact000215" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,631,613</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-12-31" id="Fact000216" format="ixt:numdotdecimal" decimals="0" unitRef="USD">952,701</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--OperatingExpenses_i01T_mtOEzLOr_msOILzsEt_zDK1qPSqNPQj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; text-align: left">Total Operating Expenses</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2023-01-01to2023-12-31" id="Fact000218" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,246,350</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2022-01-012022-12-31" id="Fact000219" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,064,771</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--OperatingIncomeLoss_iT_mtOILzsEt_maNILzord_zaz690UgzPM3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; text-align: left">Operating loss</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-01-01to2023-12-31" id="Fact000221" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,374,250</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2022-01-012022-12-31" id="Fact000222" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">11,425,461</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_zvC83dTE62xg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-left: 0pt; text-align: left">Other Expense (income)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AssetImpairmentCharges_i01_msNIEzJuG_z0YTEWtWRTXh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Impairment</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AssetImpairmentCharges" contextRef="From2023-01-01to2023-12-31" id="Fact000227" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,504,327</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--IncomeTaxExpenseBenefit_i01_msNIEzJuG_z3sym4o0Az8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Income tax provision</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0230">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2022-01-012022-12-31" id="Fact000231" format="ixt:numdotdecimal" decimals="0" unitRef="USD">214,850</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--InterestExpense_i01_msNIEzJuG_zQ5p3vVtXzl6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Interest expense</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2023-01-01to2023-12-31" id="Fact000233" format="ixt:numdotdecimal" decimals="0" unitRef="USD">749,213</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2022-01-012022-12-31" id="Fact000234" format="ixt:numdotdecimal" decimals="0" unitRef="USD">403,307</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OtherNonoperatingExpense_i01_msNIEzJuG_z15VGyfsV3L7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Other expense</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingExpense" contextRef="From2023-01-01to2023-12-31" id="Fact000236" format="ixt:numdotdecimal" decimals="0" unitRef="USD">52,256</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingExpense" contextRef="From2022-01-012022-12-31" id="Fact000237" format="ixt:numdotdecimal" decimals="0" unitRef="USD">46,820</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--FairValueAdjustmentOfWarrants_i01_msNIEzJuG_ztHwTSfBTAuk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Change in FV of Warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2023-01-01to2023-12-31" id="Fact000239" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">46,822</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2022-01-012022-12-31" id="Fact000240" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,489,110</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--StockOptionPlanExpense_i01_msNIEzJuG_zwXS7Tnef28g" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Stock Expense</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="From2023-01-01to2023-12-31" id="Fact000242" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,572,232</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--UnrealizedGainLoss_iN_di_maNIEzJuG_zAuL7oar0g1a" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Unrealized gain or loss</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0245">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="ONMD:UnrealizedGainLoss" contextRef="From2022-01-012022-12-31" id="Fact000246" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,371,689</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--NonoperatingIncomeExpense_iNT_di_mtNIEzJuG_maNILzord_zdyy44WnTbni" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other Expense (income)</span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2023-01-01to2023-12-31" id="Fact000248" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">14,831,206</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2022-01-012022-12-31" id="Fact000249" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,195,822</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--NetIncomeLoss_iT_mtNILzord_zcMuDgJ8X0G9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-01to2023-12-31" id="Fact000251" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">23,205,456</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31" id="Fact000252" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,229,639</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--EarningsPerShareAbstract_iB_zoTluw15CT0f" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss per share of
    Common Stock<sup>:(1)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Basic and Diluted</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_" id="xdx_905_eus-gaap--EarningsPerShareDiluted_c20230101__20231231_fKDEp_zG2Wa0gTAnc2">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-01-01to2023-12-31" id="Fact000256" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.98</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/M
                                            </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasicAbstract_iB_z0i70up5JA94" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Weighted-average shares of Common Stock outstanding:</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Basic and Diluted</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_" id="xdx_900_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20231231_zn8oNiVfPrH3"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-01-01to2023-12-31" id="Fact000260" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">23,572,232</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/M
                                            </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F08_zVwyFvHtN0Ug" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F17_zd4kNx4Ix6T7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote000261" xml:lang="en-US">Loss
    per share information has not been presented for periods prior to the Business Combination (as defined in Note 3, <i>Business Combination</i>),
    as it resulted in values that would not be meaningful to the users of these consolidated financial statements. Refer to Note 3, <i>Business
    Combination</i> for further information. This has been indicated on these statements of operations as &#8220;N/M&#8221;.</ix:footnote></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 77; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="F_004"></span>ONEMEDNET
CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
STATEMENTS OF STOCKHOLDERS&#8217; EQUITY (DEFICIT)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<table cellpadding="0" cellspacing="0" id="xdx_305_114_zGUZMU1mk3Ed" summary="xdx: Statement - Consolidated Statements of Stockholders Equity (Deficit)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_4BE_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_us-gaap--StatementClassOfStockAxis_custom--SeriesATwoPreferredStockMember_zIyHQvd2UIM5" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_4B8_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_us-gaap--StatementClassOfStockAxis_custom--SeriesAOnePreferredStockMember_z0g8wiv21sve" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_4B5_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_us-gaap--StatementClassOfStockAxis_us-gaap--CommonClassAMember_us-gaap--BusinessAcquisitionAxis_custom--DataKnightsAcquisitionCorpMember_z6oZWvZxVVc1" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_4BD_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_us-gaap--StatementClassOfStockAxis_us-gaap--CommonClassBMember_us-gaap--BusinessAcquisitionAxis_custom--DataKnightsAcquisitionCorpMember_zRG8wXPXzLmi" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_4B3_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_us-gaap--StatementClassOfStockAxis_us-gaap--CommonClassAMember_zcXo4M9P1ZTe" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_4B9_us-gaap--StatementEquityComponentsAxis_custom--CommitmentMember_z47Rc7wagRB" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_4BA_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zfKJ6kCoMcZc" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_4B0_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zT5QBR9bt2B7" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_4B4_zO5EQGXpv7v7" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"/><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Data
    Knights Acquisition Corp.</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="8" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Data
    Knights Acquisition Corp.</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Series
    A-2 Preferred Stock</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Series
    A-1 Preferred Stock</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Class
    A-Common Stock</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;<b>Class
    B-Common Stock</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;<b>Class
    A-Common Stock</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Additional
    Paid-in</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Accumulated</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><b>Stockholders&#8217;</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Shares</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Amount</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Shares</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Amount</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Shares</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Amount</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Shares</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Amount</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Shares</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Amount</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Commitments</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Capital</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Deficit</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Equity</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr id="xdx_43B_c20220101__20221231_eus-gaap--StockholdersEquity_iS_zRqNYgjFdBEb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 44%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Balances,
    December 31, 2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td id="xdx_98C_eus-gaap--SharesOutstanding_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesATwoPreferredStockMember_zsBwkAhciKXj" title="Beginning balance, shares" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesATwoPreferredStockMember" id="Fact000273" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,853,797</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesATwoPreferredStockMember" id="Fact000263" format="ixt:numdotdecimal" decimals="0" unitRef="USD">385</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td id="xdx_98E_eus-gaap--SharesOutstanding_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember_z70EMc1LFKd" title="Beginning balance, shares" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesAOnePreferredStockMember" id="Fact000275" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,204,000</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesAOnePreferredStockMember" id="Fact000264" format="ixt:numdotdecimal" decimals="0" unitRef="USD">320</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td id="xdx_98C_eus-gaap--SharesOutstanding_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--BusinessAcquisitionAxis__custom--DataKnightsAcquisitionCorpMember_zXgMoM1HAYWg" title="Beginning balance, shares" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember_custom_DataKnightsAcquisitionCorpMember" id="Fact000277" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">585,275</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember_custom_DataKnightsAcquisitionCorpMember" id="Fact000265" format="ixt:numdotdecimal" decimals="0" unitRef="USD">59</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td id="xdx_988_eus-gaap--SharesOutstanding_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember__us-gaap--BusinessAcquisitionAxis__custom--DataKnightsAcquisitionCorpMember_zxQO7xNZiIa8" title="Beginning balance, shares" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassBMember_custom_DataKnightsAcquisitionCorpMember" id="Fact000279" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,875,000</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassBMember_custom_DataKnightsAcquisitionCorpMember" id="Fact000266" format="ixt:numdotdecimal" decimals="0" unitRef="USD">288</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td id="xdx_982_eus-gaap--SharesOutstanding_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_z0LHDqLGq0jb" title="Beginning balance, shares" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember" id="Fact000281" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,342,666</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember" id="Fact000267" format="ixt:numdotdecimal" decimals="0" unitRef="USD">434</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_custom_CommitmentMember" id="Fact000268" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,750,110</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000269" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,607,173</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember" id="Fact000270" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">33,920,734</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" id="Fact000271" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,438,035</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_zxKKj6jjvkrh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Issuance
    of common shares in exchange for services</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zGyBHblsAXhi" title="Issuance of common shares in exchange for services, share" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember" id="Fact000293" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">200,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember" id="Fact000287" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0288">-</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000289" format="ixt:numdotdecimal" decimals="0" unitRef="USD">199,980</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2022-01-012022-12-31" id="Fact000291" format="ixt:numdotdecimal" decimals="0" unitRef="USD">200,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zudmTmS4gYGg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Issuance
    of common shares in exchange for cash at $<span id="xdx_906_eus-gaap--SharePrice_iI_c20221231_zp7XxzbGJ3i1"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2022-12-31" id="Fact000304" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></span></span>
    <span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">per share</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_znDXCm7Fi1ik" title="Issuance of common shares in exchange for cash at $1.00 per share, share" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember" id="Fact000306" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,500</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember" id="Fact000299" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0300">-</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000301" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,499</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-01-012022-12-31" id="Fact000303" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,500</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--StockIssuedDuringPeriodValueAcquisitions_zA24kYsyofW7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Issuance
    of Data Knights Acquisition Corp. Class B Common Stock</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember__us-gaap--BusinessAcquisitionAxis__custom--DataKnightsAcquisitionCorpMember_zPcPRCb2Dwxc" title="Issuance of common class B stock, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassBMember_custom_DataKnightsAcquisitionCorpMember" id="Fact000318" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,378,517</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassBMember_custom_DataKnightsAcquisitionCorpMember" id="Fact000311" format="ixt:numdotdecimal" decimals="0" unitRef="USD">137</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0313">-</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000314" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,825,823</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="From2022-01-012022-12-31" id="Fact000316" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,825,960</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr id="xdx_40A_ecustom--CommonStockSubjectToPossibleRedemptionValue_zRK0NkvpI83c" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Re-Measurement
    of Data Knights Acquisition Corp. Class A Common Stock Subject to Possible Redemption</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0325">-</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction name="ONMD:CommonStockSubjectToPossibleRedemptionValue" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="Fact000327" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,359,591</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction name="ONMD:CommonStockSubjectToPossibleRedemptionValue" contextRef="From2022-01-012022-12-31" id="Fact000328" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,359,591</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td></tr>
  <tr id="xdx_40D_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zZ3LzpbcEiSa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Stock-based
    compensation expense</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0335">-</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000336" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,392,086</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-12-31" id="Fact000338" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,392,086</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--NetIncomeLoss_zZJEk2iuFHKd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">2022
    net loss</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0340">-</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0341">-</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0342">-</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0343">-</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0345">-</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="Fact000347" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,229,639</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31" id="Fact000348" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,229,639</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td></tr>
  <tr id="xdx_43B_c20230101__20231231_eus-gaap--StockholdersEquity_iS_zijC4SrJEfdd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Balances,
    December 31, 2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td id="xdx_98E_eus-gaap--SharesOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesATwoPreferredStockMember_z0Cgfh7hv8U7" title="Beginning balance, shares" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesATwoPreferredStockMember" id="Fact000360" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,853,797</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesATwoPreferredStockMember" id="Fact000350" format="ixt:numdotdecimal" decimals="0" unitRef="USD">385</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td id="xdx_989_eus-gaap--SharesOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember_zuFH3cOOM6s" title="Beginning balance, shares" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesAOnePreferredStockMember" id="Fact000362" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,204,000</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesAOnePreferredStockMember" id="Fact000351" format="ixt:numdotdecimal" decimals="0" unitRef="USD">320</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td id="xdx_985_eus-gaap--SharesOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--BusinessAcquisitionAxis__custom--DataKnightsAcquisitionCorpMember_zdx4WWRSQsPl" title="Beginning balance, shares" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember_custom_DataKnightsAcquisitionCorpMember" id="Fact000364" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">585,275</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember_custom_DataKnightsAcquisitionCorpMember" id="Fact000352" format="ixt:numdotdecimal" decimals="0" unitRef="USD">59</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td id="xdx_988_eus-gaap--SharesOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember__us-gaap--BusinessAcquisitionAxis__custom--DataKnightsAcquisitionCorpMember_zGocy6riD7W4" title="Beginning balance, shares" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassBMember_custom_DataKnightsAcquisitionCorpMember" id="Fact000366" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,253,517</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassBMember_custom_DataKnightsAcquisitionCorpMember" id="Fact000353" format="ixt:numdotdecimal" decimals="0" unitRef="USD">425</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td id="xdx_98D_eus-gaap--SharesOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zNiMtgr2U5Q7" title="Beginning balance, shares" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember" id="Fact000368" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,550,166</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember" id="Fact000354" format="ixt:numdotdecimal" decimals="0" unitRef="USD">455</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_custom_CommitmentMember" id="Fact000355" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,750,110</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000356" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,032,561</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" id="Fact000357" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">43,509,964</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" id="Fact000358" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,274,351</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr id="xdx_43F_c20230101__20231231_eus-gaap--StockholdersEquity_iS_zoRB2i29rOkl" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Beginning
    balance</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td id="xdx_98F_eus-gaap--SharesOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesATwoPreferredStockMember_zVnQTWthaMyf" title="Beginning balance, shares" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesATwoPreferredStockMember" id="Fact000380" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,853,797</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesATwoPreferredStockMember" id="Fact000370" format="ixt:numdotdecimal" decimals="0" unitRef="USD">385</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td id="xdx_98C_eus-gaap--SharesOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember_zrZyucErBtLh" title="Beginning balance, shares" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesAOnePreferredStockMember" id="Fact000382" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,204,000</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesAOnePreferredStockMember" id="Fact000371" format="ixt:numdotdecimal" decimals="0" unitRef="USD">320</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td id="xdx_98E_eus-gaap--SharesOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--BusinessAcquisitionAxis__custom--DataKnightsAcquisitionCorpMember_zQ5kN0rY8Zuc" title="Beginning balance, shares" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember_custom_DataKnightsAcquisitionCorpMember" id="Fact000384" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">585,275</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember_custom_DataKnightsAcquisitionCorpMember" id="Fact000372" format="ixt:numdotdecimal" decimals="0" unitRef="USD">59</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td id="xdx_98F_eus-gaap--SharesOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember__us-gaap--BusinessAcquisitionAxis__custom--DataKnightsAcquisitionCorpMember_zlYOhyeh7Sg5" title="Beginning balance, shares" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassBMember_custom_DataKnightsAcquisitionCorpMember" id="Fact000386" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,253,517</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassBMember_custom_DataKnightsAcquisitionCorpMember" id="Fact000373" format="ixt:numdotdecimal" decimals="0" unitRef="USD">425</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td id="xdx_985_eus-gaap--SharesOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zdMjPwoVwqyd" title="Beginning balance, shares" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember" id="Fact000388" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,550,166</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember" id="Fact000374" format="ixt:numdotdecimal" decimals="0" unitRef="USD">455</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_custom_CommitmentMember" id="Fact000375" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,750,110</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000376" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,032,561</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" id="Fact000377" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">43,509,964</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" id="Fact000378" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,274,351</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
<tr id="xdx_40B_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_ziXfjOdSj5p3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Stock-based
    compensation expense</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000396" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,892,741</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-01to2023-12-31" id="Fact000398" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,892,741</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_zPJFPrPxd8X2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Preferred
    Stock to Common Stock</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td id="xdx_986_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesATwoPreferredStockMember_zgsUE91NmZJf" title="Preferred stock to common stock, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_SeriesATwoPreferredStockMember" id="Fact000410" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">3,853,797</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_SeriesATwoPreferredStockMember" id="Fact000400" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">385</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember_zh78uLAkiRXl" title="Preferred stock to common stock, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_SeriesAOnePreferredStockMember" id="Fact000412" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">3,204,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_SeriesAOnePreferredStockMember" id="Fact000401" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">320</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zkLKVI4glZr" title="Preferred stock to common stock, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember" id="Fact000414" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,057,797</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember" id="Fact000404" format="ixt:numdotdecimal" decimals="0" unitRef="USD">706</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0405">-</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000406" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,057,091</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2023-01-01to2023-12-31" id="Fact000408" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,057,092</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr id="xdx_40B_ecustom--StockIssuedDuringPeriodValueConvertibleNotesToCommonStock_zJYeaonjWyK8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Convertible
    Notes to Common Stock</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td id="xdx_98B_ecustom--StockIssuedDuringPeriodSharesConvertibleNotesToCommonStock_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zvpZCywBgN8d" title="Convertible notes to common stock, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="ONMD:StockIssuedDuringPeriodSharesConvertibleNotesToCommonStock" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember" id="Fact000426" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,177,229</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="ONMD:StockIssuedDuringPeriodValueConvertibleNotesToCommonStock" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember" id="Fact000420" format="ixt:numdotdecimal" decimals="0" unitRef="USD">618</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0421">-</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="ONMD:StockIssuedDuringPeriodValueConvertibleNotesToCommonStock" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000422" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,176,611</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="ONMD:StockIssuedDuringPeriodValueConvertibleNotesToCommonStock" contextRef="From2023-01-01to2023-12-31" id="Fact000424" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,177,229</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr id="xdx_40A_ecustom--StockIssuedDuringPeriodValueStockOptionsToCommonStock_zJVgRPglkaag" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Stock
    Options to Common Stock</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-<span style="font-size: 8pt">&#160;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td id="xdx_989_ecustom--StockIssuedDuringPeriodSharesStockOptionsToCommonStock_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_z4otiuuCAZBi" title="Stock issued during period shares options to common stock" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="ONMD:StockIssuedDuringPeriodSharesStockOptionsToCommonStock" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember" id="Fact000438" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">612,670</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="ONMD:StockIssuedDuringPeriodValueStockOptionsToCommonStock" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember" id="Fact000432" format="ixt:numdotdecimal" decimals="0" unitRef="USD">61</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0433">-</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="ONMD:StockIssuedDuringPeriodValueStockOptionsToCommonStock" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000434" format="ixt:numdotdecimal" decimals="0" unitRef="USD">612,609</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="ONMD:StockIssuedDuringPeriodValueStockOptionsToCommonStock" contextRef="From2023-01-01to2023-12-31" id="Fact000436" format="ixt:numdotdecimal" decimals="0" unitRef="USD">612,670</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr id="xdx_40E_ecustom--StockIssuedDuringPeriodValueConvertingOfWarrantsToCommonStock_zecHU6JoUF45" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Converting
    of Warrants to Common Stock</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td id="xdx_980_ecustom--StockIssuedDuringPeriodSharesConvertingOfWarrantsToCommonStock_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zSyCmIBnQkAf" title="Converting of warrants to common stock, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="ONMD:StockIssuedDuringPeriodSharesConvertingOfWarrantsToCommonStock" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember" id="Fact000450" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,859,464</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="ONMD:StockIssuedDuringPeriodValueConvertingOfWarrantsToCommonStock" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember" id="Fact000444" format="ixt:numdotdecimal" decimals="0" unitRef="USD">386</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0445">-</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="ONMD:StockIssuedDuringPeriodValueConvertingOfWarrantsToCommonStock" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000446" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,859,078</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="ONMD:StockIssuedDuringPeriodValueConvertingOfWarrantsToCommonStock" contextRef="From2023-01-01to2023-12-31" id="Fact000448" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,859,464</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--StockIssuedDuringPeriodValueOther_z7hDTjWnwN5i" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Private
    OneMedNet to ONMD Public Shares</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesOther_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zOnTX5LWUMof" title="Stock issued during period shares other" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember" id="Fact000462" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">2,257,326</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember" id="Fact000456" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">226</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0457">-</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000458" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,257,100</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-01-01to2023-12-31" id="Fact000460" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,257,326</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td></tr>
  <tr id="xdx_40E_eus-gaap--AdjustmentsToAdditionalPaidInCapitalWarrantIssued_zVyqsgMcDwW9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Issuance
    of PIPE Warrants</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0469">-</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000470" format="ixt:numdotdecimal" decimals="0" unitRef="USD">101,071</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2023-01-01to2023-12-31" id="Fact000472" format="ixt:numdotdecimal" decimals="0" unitRef="USD">101,071</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr id="xdx_402_ecustom--StockIssuedDuringPeriodValueConvertingDataKnightsCommonShares_zULMQH6yQiLj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Converting
    Data Knights Common Shares (A and B) to ONMD Public Shares</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td id="xdx_987_ecustom--StockIssuedDuringPeriodSharesConvertingDataKnightsCommonShares_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--BusinessAcquisitionAxis__custom--DataKnightsAcquisitionCorpMember_zN3vOjDBntRe" title="Converting Data Knights Common Shares (A and B) to ONMD Public Shares, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction name="ONMD:StockIssuedDuringPeriodSharesConvertingDataKnightsCommonShares" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember_custom_DataKnightsAcquisitionCorpMember" id="Fact000484" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">585,275</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction name="ONMD:StockIssuedDuringPeriodValueConvertingDataKnightsCommonShares" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember_custom_DataKnightsAcquisitionCorpMember" id="Fact000476" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">59</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td id="xdx_984_ecustom--StockIssuedDuringPeriodSharesConvertingDataKnightsCommonShares_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember__us-gaap--BusinessAcquisitionAxis__custom--DataKnightsAcquisitionCorpMember_zd0E8sN6f2Db" title="Converting Data Knights Common Shares (A and B) to ONMD Public Shares, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction name="ONMD:StockIssuedDuringPeriodSharesConvertingDataKnightsCommonShares" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassBMember_custom_DataKnightsAcquisitionCorpMember" id="Fact000486" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">4,253,517</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction name="ONMD:StockIssuedDuringPeriodValueConvertingDataKnightsCommonShares" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassBMember_custom_DataKnightsAcquisitionCorpMember" id="Fact000477" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">425</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td id="xdx_985_ecustom--StockIssuedDuringPeriodSharesConvertingDataKnightsCommonShares_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zCCOaBqmR1w8" title="Converting Data Knights Common Shares (A and B) to ONMD Public Shares, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="ONMD:StockIssuedDuringPeriodSharesConvertingDataKnightsCommonShares" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember" id="Fact000488" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,460,275</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="ONMD:StockIssuedDuringPeriodValueConvertingDataKnightsCommonShares" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember" id="Fact000478" format="ixt:numdotdecimal" decimals="0" unitRef="USD">346</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0479">-</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="ONMD:StockIssuedDuringPeriodValueConvertingDataKnightsCommonShares" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000480" format="ixt:numdotdecimal" decimals="0" unitRef="USD">634,106</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="ONMD:StockIssuedDuringPeriodValueConvertingDataKnightsCommonShares" contextRef="From2023-01-01to2023-12-31" id="Fact000482" format="ixt:numdotdecimal" decimals="0" unitRef="USD">633,968</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr id="xdx_40C_ecustom--CommonStockSubjectToPossibleRedemptionValue_zwV1wmmJRI8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Common
    stock redemption</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction name="ONMD:CommonStockSubjectToPossibleRedemptionValue" contextRef="From2023-01-012023-12-31_custom_CommitmentMember" id="Fact000495" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">28,750,110</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction name="ONMD:CommonStockSubjectToPossibleRedemptionValue" contextRef="From2023-01-01to2023-12-31" id="Fact000498" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">28,750,110</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td></tr>
  <tr id="xdx_40C_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zj6mNZ16aSLg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Issuance
    Public Shares</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zickvcU8ulO6" title="Issuance public shares, share" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember" id="Fact000510" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">111,957</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember" id="Fact000504" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0505">-</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000506" format="ixt:numdotdecimal" decimals="0" unitRef="USD">111,946</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-01to2023-12-31" id="Fact000508" format="ixt:numdotdecimal" decimals="0" unitRef="USD">111,957</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr id="xdx_403_ecustom--RetainedEarningsAdjustment_ziK4fMHhM0Bc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Retained
    earnings adjustment</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0517">-</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="ONMD:RetainedEarningsAdjustment" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="Fact000519" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,632,743</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="ONMD:RetainedEarningsAdjustment" contextRef="From2023-01-01to2023-12-31" id="Fact000520" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,632,743</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--NetIncomeLoss_zMQtLLT4g0D8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">2023
    net loss</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0522">-</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0523">-</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0524">-</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="Fact000529" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">23,205,456</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-01to2023-12-31" id="Fact000530" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">23,205,456</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td></tr>
  <tr id="xdx_40A_eus-gaap--NetIncomeLoss_zub9CiK8vw6j" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Net
    loss</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0532">-</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0533">-</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0534">-</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="Fact000539" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">23,205,456</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-01to2023-12-31" id="Fact000540" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">23,205,456</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td></tr>
<tr id="xdx_433_c20230101__20231231_eus-gaap--StockholdersEquity_iE_zk2C7A9dCD68" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Balances,
    December 31, 2023</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td id="xdx_98B_eus-gaap--SharesOutstanding_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesATwoPreferredStockMember_zW8vVCZm85E7" title="Ending balance, shares" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesATwoPreferredStockMember" id="Fact000552" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesATwoPreferredStockMember" id="Fact000542" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td id="xdx_987_eus-gaap--SharesOutstanding_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember_zfVv7Ubxt8W5" title="Ending balance, shares" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesAOnePreferredStockMember" id="Fact000554" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesAOnePreferredStockMember" id="Fact000543" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td id="xdx_98B_eus-gaap--SharesOutstanding_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--BusinessAcquisitionAxis__custom--DataKnightsAcquisitionCorpMember_zRcw9BgpOidj" title="Ending balance, shares" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember_custom_DataKnightsAcquisitionCorpMember" id="Fact000556" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember_custom_DataKnightsAcquisitionCorpMember" id="Fact000544" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td id="xdx_98F_eus-gaap--SharesOutstanding_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember__us-gaap--BusinessAcquisitionAxis__custom--DataKnightsAcquisitionCorpMember_zsoMDzlqu8me" title="Ending balance, shares" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassBMember_custom_DataKnightsAcquisitionCorpMember" id="Fact000558" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassBMember_custom_DataKnightsAcquisitionCorpMember" id="Fact000545" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td id="xdx_98B_eus-gaap--SharesOutstanding_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zBJRNQdueoZa" title="Ending balance, shares" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember" id="Fact000560" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">23,572,232</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember" id="Fact000546" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,357</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_custom_CommitmentMember" id="Fact000547" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000548" format="ixt:numdotdecimal" decimals="0" unitRef="USD">42,220,714</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" id="Fact000549" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">55,082,677</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000550" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">12,859,606</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td></tr>
  <tr id="xdx_439_c20230101__20231231_eus-gaap--StockholdersEquity_iE_zyJ6ajGFwz6d" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Ending
    Balance</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td id="xdx_989_eus-gaap--SharesOutstanding_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesATwoPreferredStockMember_zVZNyqx5FVRa" title="Ending balance, shares" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesATwoPreferredStockMember" id="Fact000572" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesATwoPreferredStockMember" id="Fact000562" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td id="xdx_984_eus-gaap--SharesOutstanding_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember_zVoyXAQ6TLD8" title="Ending balance, shares" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesAOnePreferredStockMember" id="Fact000574" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesAOnePreferredStockMember" id="Fact000563" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td id="xdx_989_eus-gaap--SharesOutstanding_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--BusinessAcquisitionAxis__custom--DataKnightsAcquisitionCorpMember_zU9M0NvGOirh" title="Ending balance, shares" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember_custom_DataKnightsAcquisitionCorpMember" id="Fact000576" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember_custom_DataKnightsAcquisitionCorpMember" id="Fact000564" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td id="xdx_98F_eus-gaap--SharesOutstanding_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember__us-gaap--BusinessAcquisitionAxis__custom--DataKnightsAcquisitionCorpMember_zEQfI13U1bs7" title="Ending balance, shares" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassBMember_custom_DataKnightsAcquisitionCorpMember" id="Fact000578" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassBMember_custom_DataKnightsAcquisitionCorpMember" id="Fact000565" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td id="xdx_980_eus-gaap--SharesOutstanding_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zpyHj1sixGxe" title="Ending balance, shares" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember" id="Fact000580" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">23,572,232</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember" id="Fact000566" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,357</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_custom_CommitmentMember" id="Fact000567" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000568" format="ixt:numdotdecimal" decimals="0" unitRef="USD">42,220,714</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" id="Fact000569" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">55,082,677</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000570" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">12,859,606</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 78; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="F_005"></span>ONEMEDNET
CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
STATEMENTS OF CASH FLOWS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" id="xdx_307_112_zo5kPf3RrZB6" summary="xdx: Statement - Consolidated Statements of Cash Flows" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20230101__20231231_z41ooGBklSdj" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">December
    31, 2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20220101__20221231_zR4V4tkKIG9b" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">December
    31, 2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year Ended</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">December 31, 2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">December 31, 2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zVlhVOMXBkCa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Cash flow from Operating Activities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--NetIncomeLoss_i01_maNCPBUzSqX_z6cAz0YzFvLg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 60%; text-align: left">Net Loss</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-01to2023-12-31" id="Fact000585" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">23,205,456</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31" id="Fact000586" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,229,639</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zcdKRxRb6wD2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Adjustments to reconcile net loss to net cash flows from operating activities:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DepreciationDepletionAndAmortization_i02_maNCPBUzSqX_zEJpzj1chCY2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Depreciation and amortization</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2023-01-01to2023-12-31" id="Fact000591" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,983</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2022-01-012022-12-31" id="Fact000592" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,807</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--BusinessCombinationCost_i02_maNCPBUzSqX_zflj2ojzalQe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Business combination cost</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ONMD:BusinessCombinationCost" contextRef="From2023-01-01to2023-12-31" id="Fact000594" format="ixt:numdotdecimal" decimals="0" unitRef="USD">900,152</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0595">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--ShareBasedCompensation_i02_maNCPBUzSqX_z2nFr0WzWPe5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Stock-based compensation expense</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0597">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-12-31" id="Fact000598" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,599,586</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--CashHeldInTrustAccount_i02_maNCPBUzSqX_zt3DWvy5Zkxj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Cash Held in Trust Account</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ONMD:CashHeldInTrustAccount" contextRef="From2023-01-01to2023-12-31" id="Fact000600" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,029,416</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ONMD:CashHeldInTrustAccount" contextRef="From2022-01-012022-12-31" id="Fact000601" format="ixt:numdotdecimal" decimals="0" unitRef="USD">88,291,558</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--IncreaseDecreaseInPrepaidExpense_i02N_di_msNCPBUzSqX_zW5OzzZgP1y4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Prepaid Expenses</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2023-01-01to2023-12-31" id="Fact000603" format="ixt:numdotdecimal" decimals="0" unitRef="USD">64,594</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--IncreaseDecreaseInOtherCurrentAssets_i02N_di_msNCPBUzSqX_z2xc27zhBls6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Other current assets</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0606">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" contextRef="From2022-01-012022-12-31" id="Fact000607" format="ixt:numdotdecimal" decimals="0" unitRef="USD">875,803</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_i02_maNCPBUzSqX_zSZFCvQD7Kv6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Accounts payable and accrued Expenses</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="From2023-01-01to2023-12-31" id="Fact000609" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,369,825</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="From2022-01-012022-12-31" id="Fact000610" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,929,787</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--IncreaseDecreaseInAccountsReceivable_i02N_di_msNCPBUzSqX_zJQOEqbGKsdd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Accounts receivable, net of allowance</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2023-01-01to2023-12-31" id="Fact000612" format="ixt:numdotdecimal" decimals="0" unitRef="USD">132,665</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2022-01-012022-12-31" id="Fact000613" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">72,767</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--IncreaseDecreaseInContractWithCustomerLiability_i02_maNCPBUzSqX_zFHF3mKrj9P2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Deferred Revenue &amp; Customer Deposits</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="From2023-01-01to2023-12-31" id="Fact000615" format="ixt:numdotdecimal" decimals="0" unitRef="USD">70,314</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="From2022-01-012022-12-31" id="Fact000616" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">458,667</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--IncreaseDecreaseInDueToRelatedParties_i02_maNCPBUzSqX_zVUL0xuIlwA6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Amount due to related party</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInDueToRelatedParties" contextRef="From2023-01-01to2023-12-31" id="Fact000618" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">300</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInDueToRelatedParties" contextRef="From2022-01-012022-12-31" id="Fact000619" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,500</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--IncreaseDecreaseInExerciseTaxLiability_i02_maNCPBUzSqX_zkibAioQTCLi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt">Exercise tax liability</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ONMD:IncreaseDecreaseInExerciseTaxLiability" contextRef="From2023-01-01to2023-12-31" id="Fact000621" format="ixt:numdotdecimal" decimals="0" unitRef="USD">113,353</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--IncreaseDecreaseInExtensionLoan_i02_maNCPBUzSqX_zcKR0CJzw3Oi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Extension loan</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ONMD:IncreaseDecreaseInExtensionLoan" contextRef="From2023-01-01to2023-12-31" id="Fact000624" format="ixt:numdotdecimal" decimals="0" unitRef="USD">445,840</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ONMD:IncreaseDecreaseInExtensionLoan" contextRef="From2022-01-012022-12-31" id="Fact000625" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,545,838</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--IncreaseDecreaseFranchiseTaxPayable_i02_maNCPBUzSqX_zrAYQpi2d7K2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Franchise tax payable</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="ONMD:IncreaseDecreaseFranchiseTaxPayable" contextRef="From2023-01-01to2023-12-31" id="Fact000627" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">69,966</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="ONMD:IncreaseDecreaseFranchiseTaxPayable" contextRef="From2022-01-012022-12-31" id="Fact000628" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">94,043</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--IncreaseDecreaseInAccruedIncomeTaxesPayable_i02_maNCPBUzSqX_zEwQjhD4SSZj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Income Tax Payable</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" contextRef="From2023-01-01to2023-12-31" id="Fact000630" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">94,833</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" contextRef="From2022-01-012022-12-31" id="Fact000631" format="ixt:numdotdecimal" decimals="0" unitRef="USD">214,850</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--IncreaseDecreaseInWorkingCapitalLoan_i02_maNCPBUzSqX_z7juf3V80Dg5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Working capital loan</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="ONMD:IncreaseDecreaseInWorkingCapitalLoan" contextRef="From2023-01-01to2023-12-31" id="Fact000633" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">168,159</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ONMD:IncreaseDecreaseInWorkingCapitalLoan" contextRef="From2022-01-012022-12-31" id="Fact000634" format="ixt:numdotdecimal" decimals="0" unitRef="USD">207,081</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_mtNCPBUzSqX_maCCERCz6V6_zv8EpghlQGRi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Net cash flows used in operating activities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2023-01-01to2023-12-31" id="Fact000636" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,220,910</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2022-01-012022-12-31" id="Fact000637" format="ixt:numdotdecimal" decimals="0" unitRef="USD">87,239,622</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_z34yLskL7ZL6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Cash used for Investing Activities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_i01N_di_msCCERCz6V6_zXbP96dL4Ikh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Purchase of property and equipment</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2023-01-01to2023-12-31" id="Fact000642" format="ixt:numdotdecimal" decimals="0" unitRef="USD">43,757</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2022-01-012022-12-31" id="Fact000643" format="ixt:numdotdecimal" decimals="0" unitRef="USD">58,137</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zIdmBe79H1v2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Cash flow from Financing Activities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--ProceedsFromIssuanceOfCommonStockOne_i01_maNCPBUzy34_zL9ARQBm6PD1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Class B Common Stock</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0648">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ONMD:ProceedsFromIssuanceOfCommonStockOne" contextRef="From2022-01-012022-12-31" id="Fact000649" format="ixt:numdotdecimal" decimals="0" unitRef="USD">137</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--ProceedsFromRepaymentsOfNotesPayable_i01_maNCPBUzy34_z9YweHOajmU6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Proceeds (repayment) from issuance of convertible promissory note payable</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:ProceedsFromRepaymentsOfNotesPayable" contextRef="From2023-01-01to2023-12-31" id="Fact000651" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,680,772</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromRepaymentsOfNotesPayable" contextRef="From2022-01-012022-12-31" id="Fact000652" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,543,162</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--ProceedsFromConvertibleDebt_i01_maNCPBUzy34_zalI9wve8Tk5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Proceeds from issuance of PIPE Convertible Notes and Warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="From2023-01-01to2023-12-31" id="Fact000654" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,549,820</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--ProceedsFromRelatedPartyDebt_i01_maNCPBUzy34_zZ7gqYueUav2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Proceed from related party loan</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="From2023-01-01to2023-12-31" id="Fact000657" format="ixt:numdotdecimal" decimals="0" unitRef="USD">465,024</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0658">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--ProceedsFromBusinessLoan_i01_maNCPBUzy34_zXzZ4AZk7Ufb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Proceeds from Canada Emergency Business Loan Act</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ONMD:ProceedsFromBusinessLoan" contextRef="From2023-01-01to2023-12-31" id="Fact000660" format="ixt:numdotdecimal" decimals="0" unitRef="USD">529</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="ONMD:ProceedsFromBusinessLoan" contextRef="From2022-01-012022-12-31" id="Fact000661" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,754</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_40A_ecustom--ProceedsFromCommonStockSubjectToRedemption_i01_maNCPBUzy34_zJtv9rc0NjU8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Common Stock Subject to Redemption</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="ONMD:ProceedsFromCommonStockSubjectToRedemption" contextRef="From2023-01-01to2023-12-31" id="Fact000663" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">28,750,109</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="ONMD:ProceedsFromCommonStockSubjectToRedemption" contextRef="From2022-01-012022-12-31" id="Fact000664" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">88,549,890</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_405_ecustom--ProceedsFromDeferredUnderwritingFee_i01_maNCPBUzy34_zTJOqBPjeY2a" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Deferred underwriting fee</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="ONMD:ProceedsFromDeferredUnderwritingFee" contextRef="From2023-01-01to2023-12-31" id="Fact000666" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">500,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0667">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--ProceedsFromWarrantLiability_i01N_di_msNCPBUzy34_zi36FpyBidcc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Warrant liability</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="ONMD:ProceedsFromWarrantLiability" contextRef="From2023-01-01to2023-12-31" id="Fact000669" format="ixt:numdotdecimal" decimals="0" unitRef="USD">337,976</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="ONMD:ProceedsFromWarrantLiability" contextRef="From2022-01-012022-12-31" id="Fact000670" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,489,110</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--ProceedsFromContributedCapital_i01_maNCPBUzy34_zPEox9j77pA" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Additional Paid-in Capital</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromContributedCapital" contextRef="From2023-01-01to2023-12-31" id="Fact000672" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,189,350</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromContributedCapital" contextRef="From2022-01-012022-12-31" id="Fact000673" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,825,823</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--ProceedsFromIssuanceOfCommonStockTwo_i01_maNCPBUzy34_zJtAeE11oCt9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Class A Common Stock</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="ONMD:ProceedsFromIssuanceOfCommonStockTwo" contextRef="From2023-01-01to2023-12-31" id="Fact000675" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">59</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0676">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--ClassBCommonStock_i01_maNCPBUzy34_zQZDSLRwsp3c" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Class B Common Stock</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="ONMD:ClassBCommonStock" contextRef="From2023-01-01to2023-12-31" id="Fact000678" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">425</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0679">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--ProccedsFromRetainedEarningsAdjustment_i01_maNCPBUzy34_z5nnzjVlDIG6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Retained Earnings adjustment</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ONMD:ProccedsFromRetainedEarningsAdjustment" contextRef="From2023-01-01to2023-12-31" id="Fact000681" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,632,743</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="ONMD:ProccedsFromRetainedEarningsAdjustment" contextRef="From2022-01-012022-12-31" id="Fact000682" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,359,594</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_mtNCPBUzy34_maCCERCz6V6_zrgWMJEEfI52" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; text-align: left">Net cash flows from financing activities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2023-01-01to2023-12-31" id="Fact000684" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,431,875</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2022-01-012022-12-31" id="Fact000685" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">88,032,226</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_mtCCERCz6V6_zhcnFUHCL5L3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Net change in cash and cash equivalents</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2023-01-01to2023-12-31" id="Fact000687" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">254,722</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2022-01-012022-12-31" id="Fact000688" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">850,741</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iS_zO55ceezozi5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Cash and Cash Equivalents, Beginning</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2022-12-31" id="Fact000690" format="ixt:numdotdecimal" decimals="0" unitRef="USD">301,730</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2021-12-31" id="Fact000691" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,152,471</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iE_z7BIaoI5oXn5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Cash and Cash Equivalents, Ending</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2023-12-31" id="Fact000693" format="ixt:numdotdecimal" decimals="0" unitRef="USD">47,008</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2022-12-31" id="Fact000694" format="ixt:numdotdecimal" decimals="0" unitRef="USD">301,730</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 79; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="F_006"></span>ONEMEDNET
CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000696" name="us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"><p id="xdx_809_eus-gaap--OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_zV9YseO4iab1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.
<span id="xdx_82A_zfz7jzRiBva7">Organization and Operations</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">OneMedNet
Corporation (the &#8220;Company&#8221;) is a healthcare software company with solutions focused on digital medical image management,
exchange, and sharing. The Company was incorporated in Delaware on September 20, 2006. The Company has been solely focused on creating
solutions that simplify digital medical image management, exchange, and sharing. The Company has one wholly-owned subsidiary, OneMedNet
Technologies (Canada) Inc., incorporated on October 16, 2015 under the provisions of the Business Corporations Act of British Columbia
whose functional currency is the Canadian dollar. The Company&#8217;s headquarters location is Eden Prairie, Minnesota.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 12.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 7, 2023, as contemplated by the Company, Data Knights Merger Sub, Inc., a Delaware corporation (&#8220;Merger Sub&#8221;), and
Data Knights, LLC, the Merger Sub&#8217;s sponsor merged with and into OneMedNet Corporation, with OneMedNet Corporation surviving the
merger. The Business Combination is further described in Note 3, <span style="background-color: white"><i>Business Combination.</i></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 12.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i>Data
Knights Acquisition Corp Merger</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
November 7, 2023, we consummated a merger (the &#8220;Merger&#8221;) </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">following
the approval at the special meeting of the shareholders of Data Knights Acquisition Corp., a Delaware corporation held on October 17,
2023 (the &#8220;Special Meeting&#8221;), Data Knights Merger Sub, Inc., a Delaware corporation (&#8220;Merger Sub&#8221;) and a wholly-owned
subsidiary of Data Knights Acquisition Corp., a Delaware corporation (&#8220;Data Knights&#8221;), consummated a merger (the &#8220;Merger&#8221;)
with and into OneMedNet Solutions Corporation (formerly named OneMedNet Corporation), a Delaware corporation (&#8220;OneMedNet&#8221;)
pursuant to an agreement and plan of merger, dated as of April 25, 2022 (the &#8220;Merger Agreement&#8221;), by and among Data Knights,
Merger Sub, OneMedNet, Data Knights, LLC, a Delaware limited liability company (&#8220;Sponsor&#8221; or &#8220;Purchaser Representative&#8221;)
in its capacity as the representative of the stockholders of Data Knights, and Paul Casey in his capacity as the representative of the
stockholders of OneMedNet (&#8220;Seller Representative&#8221;). Accordingly, the Merger Agreement was adopted, and the Merger and other
transactions contemplated thereby (collectively, the &#8220;Business Combination&#8221;) were approved and completed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Business Combination was accounted for as a </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">as
a reverse recapitalization with OneMedNet as the accounting acquirer <span style="background-color: white">under the accounting principles
generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;). Accordingly, the financial statements of the combined company
represent a continuation of the financial statements of OneMedNet.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
June 28, 2023, the Company and Data Knights entered into a Securities Purchase Agreement (the &#8220;SPA&#8221;) with certain investors
(collectively referred to herein as the &#8220;Purchasers&#8221;) for PIPE financing in the aggregate original principal amount of $<span id="xdx_902_eus-gaap--DebtInstrumentIssuedPrincipal_pp2d_c20230628__20230628__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--BusinessAcquisitionAxis__custom--DataKnightsAcquisitionCorpMember_zd35VsLoAFv9"><ix:nonFraction name="us-gaap:DebtInstrumentIssuedPrincipal" contextRef="From2023-06-282023-06-28_custom_SecuritiesPurchaseAgreementMember_custom_DataKnightsAcquisitionCorpMember" id="Fact000697" format="ixt:numdotdecimal" decimals="2" unitRef="USD">1,595,744.70</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">and the purchase
price of $<span id="xdx_904_eus-gaap--PaymentsToAcquireBusinessesGross_pn5n6_c20230628__20230628__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--BusinessAcquisitionAxis__custom--DataKnightsAcquisitionCorpMember_zLfq0MnZLOhi"><ix:nonFraction name="us-gaap:PaymentsToAcquireBusinessesGross" contextRef="From2023-06-282023-06-28_custom_SecuritiesPurchaseAgreementMember_custom_DataKnightsAcquisitionCorpMember" id="Fact000698" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.5</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">million. <span id="xdx_90A_eus-gaap--DebtInstrumentDescription_c20230628__20230628__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--BusinessAcquisitionAxis__custom--DataKnightsAcquisitionCorpMember_zcrEXy9YpNK3"><ix:nonNumeric contextRef="From2023-06-282023-06-28_custom_SecuritiesPurchaseAgreementMember_custom_DataKnightsAcquisitionCorpMember" id="Fact000699" name="us-gaap:DebtInstrumentDescription">Pursuant
to the Securities Purchase Agreement, Data Knights will issue and sell to each of the Purchasers, a new series of senior secured convertible
notes (the &#8220;PIPE Notes&#8221;), which are convertible into shares of Common Stock at the Purchasers election at a conversion price
equal to the lower of (i) $10.00 per share, and (ii) 92.5% of the lowest volume weighted average trading price for the ten (10) Trading
Days immediately preceding the Conversion Date.</ix:nonNumeric></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Purchasers&#8217; $<span id="xdx_904_eus-gaap--Investments_iI_pn5n6_c20230628__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--BusinessAcquisitionAxis__custom--DataKnightsAcquisitionCorpMember_z2iQWtEALUT4"><ix:nonFraction name="us-gaap:Investments" contextRef="AsOf2023-06-28_custom_SecuritiesPurchaseAgreementMember_custom_DataKnightsAcquisitionCorpMember" id="Fact000700" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.5</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">million investment
in the PIPE Notes closed and funded contemporaneous to the Closing of the Business Combination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Effective
immediately prior to the Closing, OneMedNet, Inc. issued the PIPE Notes to the Purchasers under the private offering exemptions under
Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Risks
and Uncertainties</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is subject to risks common to companies in the markets it serves, including, but not limited to, global economic and financial
market conditions, fluctuations in customer demand, acceptance of new products, development by its competitors of new technological innovations,
dependence on key personnel, and protection of proprietary technology.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
previously reported on Form 8-K on February 9, 2024, the Company received written notice (the &#8220;Nasdaq Notice&#8221;), dated February
7, 2024, from the Nasdaq Stock Market (&#8220;Nasdaq&#8221;) indicating that for the preceding 30 consecutive business days, the market
value of the Company&#8217;s listed securities (&#8220;MVLS&#8221;) did not maintain a minimum market value of $50,000,000 (the &#8220;Minimum
MVLS Requirement&#8221;) as required by Nasdaq Listing Rule 5450(b)(2)(A). In accordance with Nasdaq Listing Rule 5810(c)(3)(C), the
Company has a compliance period of 180 calendar days, or until August 5, 2024, to regain compliance with the Minimum MVLS Requirement.
Compliance may be achieved if the Company&#8217;s MVLS closes at $50,000,000 or more for a minimum of ten consecutive business days at
any time during the 180-day compliance period, in which case Nasdaq will notify the Company of its compliance and the matter will be
closed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 12.95pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the Company does not regain compliance with the Minimum MVLS Requirement by August 5, 2024, Nasdaq will provide written notification
to the Company that its common stock is subject to delisting. At that time, the Company may appeal the relevant delisting determination
to a hearings panel pursuant to the procedures set forth in the applicable Nasdaq Listing Rules. However, there can be no assurance,
if the Company does appeal the delisting determination by Nasdaq to the hearings panel, that such appeal would be successful. In such
event, the Company may also seek to apply for a transfer to The Nasdaq Global Market if it meets the requirements for continued listing
thereon. The Nasdaq Notice received have no immediate effect on the Company&#8217;s continued listing on the Nasdaq Global Market or
the trading of Company&#8217;s common stock, subject to the Company&#8217;s compliance with the other continued listing requirements.
The Company is presently evaluating potential actions to regain compliance with all applicable requirements for continued listing on
the Nasdaq Global Market. There can be no assurance that the Company will be successful in maintaining the listing of its common stock
on the Nasdaq Global Market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<ix:exclude><!-- Field: Page; Sequence: 80; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000702" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p id="xdx_802_eus-gaap--SignificantAccountingPoliciesTextBlock_zGbBSfC6KOC7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.
<span id="xdx_820_zKg7KUIVwbK9">Summary of Significant Accounting Policies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000704" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock"><p id="xdx_842_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zvzejhltBzmk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span id="xdx_86A_zHiorFzUGPkd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Basis
of Presentation and Foreign Currency Translation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 12.95pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements have been prepared in U.S. dollars, in accordance with accounting principles generally accepted in
the United States of America (&#8220;GAAP&#8221;). The accompanying consolidated financial statements include the accounts of the Company
and its wholly owned subsidiaries. The consolidated financial statements include 100% of the accounts of wholly-owned subsidiaries. All
intercompany balances and transactions have been eliminated in consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000706" name="us-gaap:BusinessCombinationsPolicy"><p id="xdx_840_eus-gaap--BusinessCombinationsPolicy_zndaSaMzFgIb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span id="xdx_868_z9lk6RJzb8ma" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Business
Combination</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
account for business acquisitions under ASC Topic 805, Business Combinations (&#8220;ASC Topic 805&#8221;). The total purchase consideration
for an acquisition is measured as the fair value of the assets given, equity instruments issued, and liabilities assumed at the acquisition
date. Costs that are directly attributable to the acquisition are expensed as incurred. Identifiable assets (including intangible assets)
and liabilities assumed (including contingent liabilities) are measured initially at their fair values at the acquisition date. We recognize
goodwill if the fair value of the total purchase consideration is in excess of the net fair value of the identifiable assets acquired
and the liabilities assumed. We recognize a bargain purchase gain within Other income (expense), net, in the consolidated statement of
operations if the net fair value of the identifiable assets acquired and the liabilities assumed is in excess of the fair value of the
total purchase consideration. We include the results of operations of the acquired business in the consolidated financial statements
beginning on the acquisition date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 12.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000708" name="us-gaap:UseOfEstimates"><p id="xdx_843_eus-gaap--UseOfEstimates_zjt1UdiaaVH7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span id="xdx_869_zIt7XWTLer6d" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Use
of Estimates</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of consolidated financial statements in conformity with GAAP requires management to make estimates, judgments, and assumptions
that affect the reported amounts of assets, liabilities, revenue, and expenses, and the amounts disclosed in the related notes to the
consolidated financial statements. Actual results and outcomes may differ materially from management&#8217;s estimates, judgments, and
assumptions. Significant estimates, judgments, and assumptions used in these financial statements include, but are not limited to, those
related to revenue, useful lives and realizability of long-lived assets, accounting for income taxes and related valuation allowances,
and unit and stock-based compensation. Estimates are periodically reviewed in light of changes in circumstances, facts, and experience.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000710" name="ONMD:OperatingSegmentsPolicyTextBlock"><p id="xdx_843_ecustom--OperatingSegmentsPolicyTextBlock_zACDXJyzWbLk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span id="xdx_862_zQstZ0yF89o" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Operating
Segments</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company operates as one operating segment. Operating segments are defined as components of an enterprise for which separate financial
information is regularly evaluated by the chief operating decision maker (&#8220;CODM&#8221;), which is the Company&#8217;s Chief Executive
Officer, in deciding how to allocate resources and assess performance. The Company&#8217;s CODM evaluates the Company&#8217;s financial
information and resources and assesses the performance of these resources on a consolidated basis. The Company is not organized by market
and is managed and operated as one business. A single management team that reports to the chief executive officer comprehensively manages
the entire business. Accordingly, the Company does not accumulate discrete financial information with respect to separate divisions and
does not have separate operating or reportable segments. Since the Company operates in one operating segment, all required financial
segment information can be found in the consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000712" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_84C_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zMlRvLLBGcYl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span id="xdx_867_zKdmKLGHFwQ8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cash
and Cash Equivalents</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
and cash equivalents consist of highly liquid, short-term investments with a maturity of three months or less when purchased. Cash equivalents
consist of money market funds and are carried at cost, which approximates fair value. The balances, at times, may exceed FDIC Insured
limits. The Company believes that, as of December 31, 2023, its risk relating to deposits exceeding federally insured limits was not
significant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000714" name="us-gaap:TradeAndOtherAccountsReceivablePolicy"><p id="xdx_84D_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zHSkOZjoaDAg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span id="xdx_863_zDnAqV8hKKmb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Accounts
Receivable</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
receivable are unsecured, recorded at net realizable value, and do not bear interest. Accounts receivable are considered past due if
not paid within the terms established between the Company and the customer. Amounts are only written off after all attempts at collections
have been exhausted. The Company determines the need for an allowance for doubtful accounts based upon factors surrounding the credit
risk of specific customers, historical trends and other information. As of December 31, 2023 and 2022, the Company established allowances
of $<span id="xdx_90D_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20231231_zsgeggHAEi86"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" contextRef="AsOf2023-12-31" id="Fact000715" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and
$<span id="xdx_904_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20221231_zELlL3nc7kY7"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" contextRef="AsOf2022-12-31" id="Fact000716" format="ixt:numdotdecimal" decimals="0" unitRef="USD">102,700</ix:nonFraction></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">respectively.
The net receivable balances outstanding are fully collectible.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company believes its credit policies are prudent and reflect normal industry terms and business risk. The Company generally does not
require collateral from its customers and generally requires payment from 0 to 90 days from the invoice date. For the year ended December
31, 2023, there was 1 customer that accounted for <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneCustomerMember_zYlEzIbkEdmk"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-01-012023-12-31_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_CustomerConcentrationRiskMember_custom_OneCustomerMember" id="Fact000717" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
or more of total revenue, and there were 2 customers that accounted for <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--TwoCustomersMember_zWk6srTqOOyb"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-01-012022-12-31_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_CustomerConcentrationRiskMember_custom_TwoCustomersMember" id="Fact000718" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
or more of total revenue for the years ended December 31, 2022 . The following table represents these customers&#8217; aggregate percent
of total revenue:</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000720" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"><p id="xdx_899_eus-gaap--SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_zQi7JmXQvsj9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B2_zGLv6h4dCOii">Schedule
Of Aggregate Percentage Revenue and Accounts Receivable</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20230101__20231231_zUGdB37NKUn6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December
    31, 2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20220101__20221231_zcYb7a6l5vo2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December
    31, 2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year Ended</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31, 2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31, 2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zEHO2Q3PAb9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 56%">Customer 1</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-01-012023-12-31_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerOneMember" id="Fact000722" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">52</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-01-012022-12-31_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerOneMember" id="Fact000723" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">31</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_405_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_zZGLElbzyVq4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Customer 2</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0725">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-01-012022-12-31_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerTwoMember" id="Fact000726" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">22</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr id="xdx_40F_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomersMember_z5Y4MjatHXV" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Aggregate Percent of Total Revenue</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-01-012023-12-31_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomersMember" id="Fact000728" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">52</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-01-012022-12-31_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomersMember" id="Fact000729" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">53</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 12.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 81; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023, three customers accounted for more than <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--ThreeCustomersMember_zaeCBpShTQP9"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-01-012023-12-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_ThreeCustomersMember" id="Fact000730" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
of the Company&#8217;s accounts receivable balance, and two customers accounted for over <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--TwoCustomersMember_z1pBVCbDsh6b"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-01-012022-12-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_TwoCustomersMember" id="Fact000731" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
of the Company&#8217;s accounts receivable balance at December 31, 2022. The following table represents these customers&#8217; aggregate
percent of total accounts receivable:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 12.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20230101__20231231_zFefwqYRVOU8" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December
    31, 2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20220101__20221231_z2cFFNbI99Sb" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December
    31, 2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year Ended</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31, 2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31, 2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zUQw8G4cVKZe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%">Customer 1</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0733">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-01-012022-12-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerOneMember" id="Fact000734" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">40</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_400_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_zbivTlCYEB3g" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">Customer 2</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-01-012023-12-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerTwoMember" id="Fact000736" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">36</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0737">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerThreeMember_zUf1RqDmH0z5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Customer 3</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-01-012023-12-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerThreeMember" id="Fact000739" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">33</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0740">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerFourMember_zMcJm0AG6jMd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">Customer 4</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0742">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-01-012022-12-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerFourMember" id="Fact000743" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">32</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr id="xdx_404_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerFiveMember_zXVSrVaFghWj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Customer 5</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-01-012023-12-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerFiveMember" id="Fact000745" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">27</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0746">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomersMember_zdgdbAAO0zIb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Aggregate Percent of Total Accounts Receivable</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-01-012023-12-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomersMember" id="Fact000748" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">96</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">%</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-01-012022-12-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomersMember" id="Fact000749" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">72</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr id="xdx_40F_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomersMember_zg1FiXjCH2xe" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Aggregate Percent of Revenue and Accounts Receivable</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-01-012023-12-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomersMember" id="Fact000751" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">96</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">%</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-01-012022-12-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomersMember" id="Fact000752" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">72</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">%</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8A5_zHDNCw2Iq6Qc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 12.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000754" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock"><p id="xdx_846_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zoEI6ToaNBQc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span id="xdx_868_z4IcW1vRIm1b" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Property
and Equipment</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are recorded at cost. The straight-line method is used for computing depreciation and amortization. Assets are depreciated
over their estimated useful lives ranging from three to five years. Cost of maintenance and repairs are charged to expense when incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000756" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"><p id="xdx_841_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zqQEFN1kkqcg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span id="xdx_862_zNNfTwY6IbVa" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Impairment
of Long-Lived Assets</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company reviews long-lived assets, including property and equipment, for impairment whenever events or changes in business circumstances
indicate that the carrying amount of an asset may not be fully recoverable. An impairment loss would be recognized when the estimated
future undiscounted net cash flows from the use of the asset are less than the carrying amount of that asset. There have been <span id="xdx_90A_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_do_c20220101__20221231_zU0HgIgIqy09"><ix:nonFraction name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" contextRef="From2022-01-012022-12-31" id="Fact000757" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">no
</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">losses during the years ended December
31, 2023 or December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000759" name="us-gaap:FairValueOfFinancialInstrumentsPolicy"><p id="xdx_845_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zDiDCTuKvzr" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span id="xdx_865_zS2oqDkolOjj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Fair
Value of Financial Instruments</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between
market participants at the measurement date. To increase the comparability of fair value measures, the following hierarchy prioritizes
the inputs to valuation methodologies used to measure fair value:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 12.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level
1</b> &#8212; Valuations based on quoted prices for identical assets and liabilities in active markets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level
2</b> &#8212; Valuations based on observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets
and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, or other
inputs that are observable or can be corroborated by observable market data.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level
3</b> &#8212; Valuations based on unobservable inputs reflecting our own assumptions, consistent with reasonably available assumptions
made by other market participants. These valuations require significant judgment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 12.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
measure the fair value of money market funds and certain marketable equity securities based on quoted prices in active markets for identical
assets or liabilities. Other marketable securities were valued either based on recent trades of securities in inactive markets or based
on quoted market prices of similar instruments and other significant inputs derived from or corroborated by observable market data. We
did not hold significant amounts of marketable securities categorized as Level 3 assets as of the years ended December 31, 2022 and December
31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s financial instruments consist of cash and cash equivalents, accounts receivable, accounts payable, convertible notes
payable and certain privately issued warrants. The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable
financial instruments approximate their fair value due to their short-term nature. The Company&#8217;s Private Warrants estimated fair
values are provided by a third party pricing vendor and are reviewed by the Company&#8217;s management. The Private Warrants valuations
are based on unobservable inputs reflecting the vendor&#8217;s assumptions, consistent with reasonably available assumptions made by
other market participants and thus are classified as Level 3.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000761" name="us-gaap:RevenueRecognitionPolicyTextBlock"><p id="xdx_848_eus-gaap--RevenueRecognitionPolicyTextBlock_z8kXah7HUIp5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span id="xdx_860_zetssCGQ3aL3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Revenue
Recognition</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue
is recognized in accordance with the five-step model set forth by Accounting Standards Update (&#8220;ASU&#8221;) 2014-09, Revenue from
Contracts with Customers (&#8220;Topic 606&#8221;), which involves identification of the contract, identification of performance obligations
in the contract, determination of the transaction price, allocation of the transaction price to the previously identified performance
obligations, and revenue recognition as the performance obligations are satisfied.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 12.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue
from all customers is recognized when a performance obligation is satisfied by transferring control of a distinct good or service to
a customer. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit
of account under Topic 606. A contract&#8217;s transaction price is allocated to each distinct performance obligation in proportion to
the standalone selling price for each and recognized as revenue when, or as, the performance obligation is satisfied.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 12.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 82; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Individual
promised goods and services in a contract are considered a performance obligation and accounted for separately if the good or service
is distinct. A good or service is considered distinct if the customer can benefit from the good or service on its own or with other resources
that are readily available to the customer and the good or service is separately identifiable from other promises in the arrangement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 12.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
transaction price for the products is the invoiced amount. Advanced billings from contracts are deferred and recognized as revenue when
earned. Revenue is recognized only to the extent that it is probable that a significant reversal of revenue will not occur and when collection
is considered probable The Company excludes from revenue taxes collected from a customer that are assessed by a governmental authority
and imposed on and concurrent with a specific revenue-producing transaction. Deferred revenue consists of payments received in advance
of performance under the contract. Such amounts are generally recognized as revenue over the contractual period. The Company receives
payments from customers based upon contractual billing schedules. Accounts receivable is recorded when the right to consideration becomes
unconditional. Payment terms on invoiced amounts typically range from zero to 90 days, with typical terms of 30 days.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 12.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company generates revenue from two streams: (1) iRWD (imaging Real World Data) which provides regulatory grade imaging and clinical data
in the Pharmaceutical, Device Manufacturing, CRO&#8217;s and AI markets and (2) BEAM which is a Medical Imaging Exchange platform between
Hospital/Healthcare Systems, Imaging Centers, Physicians and Patients. iRWD is sold on a fixed fee basis based on the number of data
units and the cost per data unit committed to in the customer contract. Revenue is recognized when the data is delivered to the customer.
Beam revenue is subscription-based revenue which is recognized ratably over the subscription period committed to by the customer. The
Company invoices its Beam customers quarterly or annually in advance with the customer contracts automatically renewing unless the customer
issues a cancellation notice.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000763" name="us-gaap:IncomeTaxPolicyTextBlock"><p id="xdx_846_eus-gaap--IncomeTaxPolicyTextBlock_zJ6mvQ9t6Vg8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span id="xdx_86A_zWc184B7YKG7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Income
Taxes</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is subject to U.S. federal, state and local income taxes. The Company accounts for income taxes in accordance with ASC Topic
740, Accounting for Income Taxes (&#8220;ASC Topic 740&#8221;), which requires the recognition of tax benefits or expenses on temporary
differences between the financial reporting and tax bases of its assets and liabilities by applying the enacted tax rates in effect for
the year in which the differences are expected to reverse. Such net tax effects on temporary differences are reflected on the Company&#8217;s
consolidated balance sheets as deferred tax assets and liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC
Topic 740 prescribes a two-step approach for the recognition and measurement of tax benefits associated with the positions taken or expected
to be taken in a tax return that affects amounts reported in the financial statements. The Company has reviewed and will continue to
review the conclusions reached regarding uncertain tax positions, which may be subject to review and adjustment at a later date based
on ongoing analyses of tax laws, regulations and interpretations thereof. To the extent that the Company&#8217;s assessment of the conclusions
reached regarding uncertain tax positions changes as a result of the evaluation of new information, such change in estimate will be recorded
in the period in which such determination is made. The Company reports income tax-related interest and penalties relating to uncertain
tax positions, if applicable, as a component of income tax expense</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
tax assets are reduced by a valuation allowance when the Company believes that it is more-likely-than-not that some portion or all of
the deferred tax assets will not be realized. The Company provides deferred taxes at the enacted tax rate that is expected to apply when
the temporary differences reverse. The Company has recorded a full valuation allowance against the net deferred tax asset due to the
uncertainty of realizing the related benefits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000765" name="ONMD:PatentsAndTrademarksPolicyTextBlock"><p id="xdx_843_ecustom--PatentsAndTrademarksPolicyTextBlock_zllmj1Dmzjha" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span id="xdx_866_zbuYUjfdq4qd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Patents
and Trademarks</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs
associated with the submission of a patent application are expensed as incurred given the uncertainty of the patents resulting in probable
future economic benefits to the Company and are included in research and development expenses on the consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 30pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000767" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p id="xdx_84F_eus-gaap--ResearchAndDevelopmentExpensePolicy_zqccu0sxztVd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span id="xdx_86F_zoLfadaIiS4e" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Research
and Development</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 30pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company account for its research and development cost in accordance with ASC Topic 730, Research and Development (&#8220;ASC Topic 730&#8221;).
ASC Topic 730 requires that all R&amp;D costs be recognized as an expense as incurred. However, some costs associated with R&amp;D activities
that have an alternative future use (e.g., materials, equipment, facilities) may be capitalizable. For the years ended December 31, 2023
and December 31, 2022 research and development expenditures were charged to operating expense as incurred..</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 30pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000769" name="us-gaap:CompensationRelatedCostsPolicyTextBlock"><p id="xdx_845_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zY1upFaeMacf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span id="xdx_869_z2L8cRNHHXpg" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stock-based
Compensation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has a stock-based compensation plan, which is described in more detail in Note 8. The fair value of stock option and warrant
grants are determined on the date of grant using the Black Scholes valuation model. Forfeitures of stock based awards are recorded as
the actual forfeitures occur. Stock based compensation expense is recognized over the service period, net of estimated forfeitures, using
the straight-line method. The Company converted all unvested stock based compensation awards to common shares in the year ended December
31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>


<ix:exclude><!-- Field: Page; Sequence: 83; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000771" name="us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock"><p id="xdx_846_eus-gaap--SellingGeneralAndAdministrativeExpensesPolicyTextBlock_zob83QmMzd2g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span id="xdx_862_zp3OEq1qEjda" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>General,
and Administrative Expenses</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses include all costs that are not directly related to satisfaction of customer contracts. General, and administrative
expenses include items for the Company&#8217;s selling and administrative functions, such as sales, finance, legal, human resources,
and information technology support. These functions include costs for items such as salaries and benefits and other personnel-related
costs, maintenance and supplies, professional fees for external legal, accounting, and other consulting services, intangible asset amortization,
and depreciation expense.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000773" name="ONMD:EmergingGrowthCompanyPolicyTextBlock"><p id="xdx_84B_ecustom--EmergingGrowthCompanyPolicyTextBlock_zSv3ZJ534jDd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span id="xdx_861_zPmGBlQam70g" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Emerging
Growth Company</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is an emerging growth company, as defined in Section 2(a) of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;),
as modified by the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;). Section 102(b)(1) of the JOBS Act exempts
emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that
is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered
under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;)) are required to comply with the new or revised
financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply
with the requirements that apply to non-emerging growth companies but any such an election to opt out is irrevocable. The Company has
not elected to opt out of such extended transition period which means that when a standard is issued or revised and it has different
application dates for public or private companies, the Company, as an emerging growth company , can adopt the new or revised standard
at the time private companies adopt the new or revised standard.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000775" name="ONMD:AccountingPronouncementsNotYetAdoptedPolicyTextBlock"><p id="xdx_845_ecustom--AccountingPronouncementsNotYetAdoptedPolicyTextBlock_zkriRDHeinT3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span id="xdx_86B_zXnyAgn1N81h" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Accounting
Pronouncements Not Yet Adopted</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU No. 2023-07, Improvements to Reportable Segment
Disclosures (Topic 280). This ASU updates reportable segment disclosure requirements by requiring disclosures of significant reportable
segment expenses that are regularly provided to the Chief Operating Decision Maker (&#8220;CODM&#8221;) and included within each reported
measure of a segment&#8217;s profit or loss. This ASU also requires disclosure of the title and position of the individual identified
as the CODM and an explanation of how the CODM uses the reported measures of a segment&#8217;s profit or loss in assessing segment performance
and deciding how to allocate resources. The ASU is effective for annual periods beginning after December 15, 2023, and interim periods
within fiscal years beginning after December 15, 2024. Adoption of the ASU should be applied retrospectively to all prior periods presented
in the financial statements. Early adoption is also permitted. This ASU will likely result in us including the additional required disclosures
when adopted. We are currently evaluating the provisions of this ASU and expect to adopt them for the year ending December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2023, the Financial Accounting Standards Board issued an Accounting Standards Update (&#8220;ASU&#8221;) amending existing income
tax disclosure guidance, primarily requiring more detailed disclosure for income taxes paid and the effective tax rate reconciliation.
The ASU is effective for annual reporting periods beginning after December 15, 2024, with early adoption permitted and can be applied
on either a prospective or retroactive basis. We are currently evaluating the ASU to determine its impact on our income tax disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000777" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_840_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zMFQj8yXoSH2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span id="xdx_86F_zcTBCyVWS00i" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Recently
adopted accounting pronouncements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2021, the FASB issued ASU No. 2021-08, Accounting for Contract Assets and Contract Liabilities from Contracts with Customers
(ASC Topic 805). This ASU requires an acquirer in a business combination to recognize and measure contract assets and contract liabilities
(deferred revenue) from acquired contracts using the revenue recognition guidance in Topic 606. At the acquisition date, the acquirer
applies the revenue model as if it had originated the acquired contracts. The ASU is effective for annual periods beginning after December
15, 2022, including interim periods within those fiscal years. We adopted this ASU prospectively on January 1, 2023. This ASU has not
and is currently not expected to have a material impact on our consolidated financial statements.</span></p>

</ix:nonNumeric><p id="xdx_85B_zXwne0u5Kej2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000779" name="us-gaap:BusinessCombinationDisclosureTextBlock"><p id="xdx_80D_eus-gaap--BusinessCombinationDisclosureTextBlock_z4vKWwQH9wHb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.
<span id="xdx_82B_zeoEFUOzArqf">Business Combination</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Business Combination was accounted for as a reverse recapitalization as OneMedNet Corporation was determined to be the accounting acquirer
under Financial Accounting Standards Board&#8217;s (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) Topic 805,
Business Combinations. This determination was primarily based on OneMedNet Corporation comprising the ongoing operations of the combined
entity, OneMedNet Corporation&#8217;s senior management comprising of all the senior management of the combined company, and the prior
shareholders of OneMedNet owning a majority of the voting power of the combined entity. Accordingly, for accounting purposes, the financial
statements of the combined entity upon consummation of the Business Combination represented a continuation of the financial statements
of OneMedNet Corporation with the merger being treated as the equivalent of OneMedNet issuing stock for the net assets of Data Knights
Inc., accompanied by a recapitalization. Operations prior to the Business Combination are presented as those of OneMedNet Corporation
in future reports of the combined entity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000781" name="us-gaap:SubstantialDoubtAboutGoingConcernTextBlock"><p id="xdx_80C_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_z9GQMeGj2eO9" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
<span id="xdx_820_zNMLide1oM86">Going Concern</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets
and satisfaction of liabilities and commitments in the normal course of business. The Company does not have adequate liquidity to fund
its operations through at least twelve months from the date these financial statements were available for issuance. The Company has an
accumulated deficit <span id="xdx_900_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_di_c20231231_zLT6O9l1Mpdd"><ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2023-12-31" id="Fact000782" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">55,082,677</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">as of year-end December 31, 2023 and $<span id="xdx_90A_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_di_c20221231_zFrRkvZ0DDf6"><ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2022-12-31" id="Fact000783" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">43,509,964</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
as of year-end December 31, 2022 and has had negative cash flows from operating activities for the year ended December 31, 2023. These
conditions raise substantial doubt about the Company&#8217;s ability to continue as a going concern. To continue in existence and expand
its operations, the Company will be required to, and management plans to, raise additional working capital through an equity or debt
offering and ultimately attain profitable operations. If the Company is not able to raise additional working capital, it would have a
material adverse effect on the operations of the Company and continuing research and development of its product. The consolidated financial
statements do not include any adjustments relating to the recoverability and classification of assets and liabilities that might be necessary
should the Company be unable to continue as a going concern. The Company&#8217;s continuation as a going concern is dependent upon its
ability to continue receiving working capital cash payments and generating cash flow from operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 84; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000785" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock"><p id="xdx_80B_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_z2S0u7LSVuZ2" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
<span id="xdx_822_zswcSU5RuXy">Property and Equipment</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are summarized as of December 31:</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000787" name="us-gaap:PropertyPlantAndEquipmentTextBlock"><p id="xdx_89A_eus-gaap--PropertyPlantAndEquipmentTextBlock_zAazqlokgi91" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B2_z8Gw2Lkw6J59">Schedule
of Property And Equipment </span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%; margin-left: 0.75in">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20231231_zxbghYXtYgG" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20221231_zt0fc4NDUIdi" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_ziE4TvzcdXC8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%">Computers</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-12-31_us-gaap_ComputerEquipmentMember" id="Fact000789" format="ixt:numdotdecimal" decimals="0" unitRef="USD">246,578</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2022-12-31_us-gaap_ComputerEquipmentMember" id="Fact000790" format="ixt:numdotdecimal" decimals="0" unitRef="USD">259,207</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zo9jdq1Pm0n1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Furniture and equipment</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-12-31_us-gaap_FurnitureAndFixturesMember" id="Fact000792" format="ixt:numdotdecimal" decimals="0" unitRef="USD">35,708</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2022-12-31_us-gaap_FurnitureAndFixturesMember" id="Fact000793" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,785</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzSdJ_zRVEXvJRbLte" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Total Property and Equipment</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-12-31" id="Fact000795" format="ixt:numdotdecimal" decimals="0" unitRef="USD">282,286</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2022-12-31" id="Fact000796" format="ixt:numdotdecimal" decimals="0" unitRef="USD">262,992</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzSdJ_zESw8MyMt588" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Less: accumulated depreciation</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2023-12-31" id="Fact000798" format="ixt:numdotdecimal" decimals="0" unitRef="USD">183,415</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2022-12-31" id="Fact000799" format="ixt:numdotdecimal" decimals="0" unitRef="USD">179,895</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzSdJ_zkzCLNMdEYJ2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Net Property and Equipment</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2023-12-31" id="Fact000801" format="ixt:numdotdecimal" decimals="0" unitRef="USD">98,871</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2022-12-31" id="Fact000802" format="ixt:numdotdecimal" decimals="0" unitRef="USD">83,097</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A2_z2Z5jWJEfOhc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
and amortization expense was $<span id="xdx_905_eus-gaap--DepreciationAndAmortization_c20230101__20231231_z4c8S5We6ZWd"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2023-01-01to2023-12-31" id="Fact000803" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,983</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_901_eus-gaap--DepreciationAndAmortization_c20220101__20221231_zRDHKmXJDHP7"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2022-01-012022-12-31" id="Fact000804" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,807</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for the years ended December 31, 2023
and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000806" name="us-gaap:IncomeTaxDisclosureTextBlock"><p id="xdx_80C_eus-gaap--IncomeTaxDisclosureTextBlock_zQGKlG3kSa4g" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.
<span id="xdx_828_zYHZpHPvRJn6">Income Taxes</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has generated both federal and state net operating losses (NOL) of approximately $<span id="xdx_90E_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_iI_pn6n6_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zrJBbv8G4Dve"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" contextRef="AsOf2023-12-31_us-gaap_DomesticCountryMember" id="Fact000807" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">21</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million and $<span id="xdx_905_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_iI_pn6n6_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_z5CpxqCHQ7id"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" contextRef="AsOf2023-12-31_us-gaap_StateAndLocalJurisdictionMember" id="Fact000808" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">23</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million, respectively, which if not used,
will begin to expire in 2030. The Company believes that its ability to fully utilize the existing NOL carryforwards could be restricted
on a portion of the NOL by changes in control that may have occurred or may occur in the future and by its ability to generate net income.
The Company has not yet conducted a formal study of whether, or to what extent, past changes in control of the Company impairs its NOL
carryforwards because such NOL carryforwards cannot be utilized until the Company achieves profitability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000810" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"><p id="xdx_897_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zOTyCca4QW1c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Components
of deferred income taxes are as follows as of December 31:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span id="xdx_8B6_zo03RUu2UEKe" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
of Deferred Income Taxes</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_490_20231231_zuzdypJa1VJe" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20221231_zvNXwFlUwyx6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsNetAbstract_iB_z1AfkgxFsRQc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Deferred Tax Assets</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzqvH_z5F5Wc4Dlonj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Net operating loss carry forward</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2023-12-31" id="Fact000815" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,823,785</ix:nonFraction>&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2022-12-31" id="Fact000816" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,973,587</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTAGzqvH_znQ6MjBxc6q2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Stock Compensation</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2023-12-31" id="Fact000818" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,035,947</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2022-12-31" id="Fact000819" format="ixt:numdotdecimal" decimals="0" unitRef="USD">481,144</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsOther_iI_maDTAGzqvH_zYoSYWKgPhFb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; padding-bottom: 1.5pt">Other</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0821">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="AsOf2022-12-31" id="Fact000822" format="ixt:numdotdecimal" decimals="0" unitRef="USD">53,268</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzqvH_maDTANzhf6_zP6nBXkfV5Hc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Gross deferred tax assets</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2023-12-31" id="Fact000824" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,859,732</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2022-12-31" id="Fact000825" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,507,999</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzhf6_zvM5foPdYXh1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Less valuation allowance</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2023-12-31" id="Fact000827" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,859,732</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2022-12-31" id="Fact000828" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,507,999</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzhf6_zpjeP5OEWge3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Net deferred tax assets</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0830">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0831">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A1_z2sdkuOVvkC" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
change in the valuation allowance was $<span id="xdx_901_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_c20230101__20231231_z0SoQZV1P5eh"><ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="From2023-01-01to2023-12-31" id="Fact000832" format="ixt:numdotdecimal" decimals="0" unitRef="USD">351,734</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_907_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_c20220101__20221231_zDJsXDusfHxb"><ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="From2022-01-012022-12-31" id="Fact000833" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,384,220</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for the years ended December 31, 2023
and 2022, respectively. The effective tax rate for the years ended December 31, 2023 and 2022 differs from the federal and state statutory
rates due to the full valuation allowance. The Company recognizes the financial statement benefit of a tax position only after determining
that the relevant tax authority would more likely than not sustain the position following an audit. The tax years from inception through
December 31, 2023 remain subject to examination by all major taxing authorities due to the net operating loss carryovers. The Company
is not currently under examination by any taxing jurisdiction. The Company did not incur any interest or penalties during the years ended
December 31, 2023 or 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the Business Combination, the Company was appointed as the sole managing member of Data Knights. The Company is subject to
U.S. federal income taxes, in addition to state and local income taxes. The Company accounts for income taxes using the asset and liability
method, which requires the recognition of deferred tax assets and liabilities for the estimated future tax consequences attributable
to temporary differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective
tax base. Deferred tax assets and liabilities are determined on the basis of the differences between the consolidated financial statements
and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the temporary differences are expected
to be settled or recovered. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. In assessing
the realizability of deferred tax assets, the Company considers whether it is more likely than not that some portion or all of the deferred
tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income
during the periods in which those temporary differences become deductible. The Company considers the scheduled reversal of deferred tax
liabilities, projected future income, and tax planning strategies in making this assessment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has established a valuation allowance related deferred tax assets on deductible temporary differences, tax losses, and tax credit
carryforwards. The valuation allowance as of December 31, 2023 was $<span id="xdx_90C_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_pn5n6_c20231231__us-gaap--BusinessAcquisitionAxis__custom--DataKnightsAcquisitionCorpMember_zc9I8GCxiNOl"><ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2023-12-31_custom_DataKnightsAcquisitionCorpMember" id="Fact000834" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">168.3</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
The increase in the valuation allowance in fiscal year 2023 of $<span id="xdx_90C_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn5n6_c20230101__20231231__us-gaap--BusinessAcquisitionAxis__custom--DataKnightsAcquisitionCorpMember_zAXOyzAGvkna"><ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="From2023-01-012023-12-31_custom_DataKnightsAcquisitionCorpMember" id="Fact000835" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">155.7</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million primarily relates to the Company&#8217;s
investment in Data Knights, and tax carryforward attributes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 85; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023, the Company had a U.S. federal net operating loss carryforwards of $<span id="xdx_903_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_z3uZn3tL8Luk"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2023-12-31_us-gaap_DomesticCountryMember" id="Fact000836" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">10.3</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million and gross state net operating
loss carryforwards of $<span id="xdx_903_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zW99MiPyTjFe"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2023-12-31_us-gaap_StateAndLocalJurisdictionMember" id="Fact000837" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">8.9</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million.</span></p>
<!-- Field: Split-Segment; Name: 001 -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000839" name="us-gaap:LongTermDebtTextBlock"><p id="xdx_804_eus-gaap--LongTermDebtTextBlock_zs77GuAQ061c" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.
<span id="xdx_822_zC14DSedB2je">Convertible Promissory Notes held by Related Party</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2023, the Company entered various Convertible Promissory Notes (&#8220;Note&#8221;) with related party investors totaling $<span id="xdx_90E_eus-gaap--ConvertibleNotesPayable_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zJ0A9yJtOCIj"><ix:nonFraction name="us-gaap:ConvertibleNotesPayable" contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember" id="Fact000840" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,300,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2022 - $<span id="xdx_909_eus-gaap--ConvertibleNotesPayable_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zvGkZMJNdQSf"><ix:nonFraction name="us-gaap:ConvertibleNotesPayable" contextRef="AsOf2022-12-31_us-gaap_RelatedPartyMember" id="Fact000841" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,700,000</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)
and unrelated party investors of $<span id="xdx_90B_eus-gaap--ConvertibleNotesPayable_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_ze08HTFx5wN"><ix:nonFraction name="us-gaap:ConvertibleNotesPayable" contextRef="AsOf2023-12-31_us-gaap_NonrelatedPartyMember" id="Fact000842" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,875,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2022 - $<span id="xdx_909_eus-gaap--ConvertibleNotesPayable_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zO5hNPsSKwdd"><ix:nonFraction name="us-gaap:ConvertibleNotesPayable" contextRef="AsOf2022-12-31_us-gaap_NonrelatedPartyMember" id="Fact000843" format="ixt:numdotdecimal" decimals="0" unitRef="USD">440,000</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">).
The Notes issued are unsecured and bear an interest rate of six percent annually from the date of issuance until the outstanding principal
is paid or converted. On November 11, 2022 the Convertible note agreement was amended and restated in order to (i) provide for the sale
and issuance to Purchasers from the effective date of January 1, 2022 and after the date of this Agreement of up to an additional $<span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_c20221111__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNotesMember_ze3YghPcbhM5"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2022-11-11_us-gaap_RelatedPartyMember_custom_ConvertiblePromissoryNotesMember" id="Fact000844" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,000,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">aggregate principal amount of Notes and
warrants to purchase shares of the Company&#8217;s capital stock, (ii) provide for the sale and issuance to Purchasers who purchased
Notes under the Prior Agreement between the Effective Date and the date of this Agreement of warrants to purchase shares of the Company&#8217;s
common stock at an exercise price of $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221111__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z0g21z8lG49c"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-11-11_us-gaap_RelatedPartyMember_custom_ConvertiblePromissoryNotesMember" id="Fact000845" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share; (iii) extend the maturity date
of all outstanding Notes from December 31, 2022 to November 7, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
principal and unpaid accrued interest on each Note will convert: (i) automatically, upon the Company&#8217;s issuance of equity securities
(the &#8220;Next Equity Financing&#8221;) in a single transaction, or series of related transactions, with aggregate gross proceeds to
the Company of at least $<span id="xdx_907_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_c20221110__20221111__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNotesMember_zAHMpalxTCIi"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2022-11-102022-11-11_us-gaap_RelatedPartyMember_custom_ConvertiblePromissoryNotesMember" id="Fact000846" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,000,000</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
into shares of the Company&#8217;s capital stock issued to investors in the Next Equity Financing, at a conversion price equal to the
lesser of (A) <span id="xdx_906_ecustom--EquityFinancingDescription_c20221110__20221111__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNotesMember_zP3bi3FMTxA8"><ix:nonNumeric contextRef="From2022-11-102022-11-11_us-gaap_RelatedPartyMember_custom_ConvertiblePromissoryNotesMember" id="Fact000847" name="ONMD:EquityFinancingDescription">a
20% discount to the lowest price per share of shares sold in the Next Equity Financing, or (B) $2.50 per share; (ii) at the noteholder&#8217;s
option, in the event of a defined Corporate Transaction while such Note remains outstanding, into shares of the Company&#8217;s Series
A-2 Preferred Stock at a conversion price equal to $</ix:nonNumeric></span></span><span id="xdx_907_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_c20221111__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__us-gaap--StatementClassOfStockAxis__custom--SeriesATwoPreferredStockMember__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNotesMember_zzxoqgGTU0af" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:PreferredStockConvertibleConversionPrice" contextRef="AsOf2022-11-11_us-gaap_RelatedPartyMember_custom_SeriesATwoPreferredStockMember_custom_ConvertiblePromissoryNotesMember" id="Fact000848" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.50</ix:nonFraction>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per
share; and (iii) at the noteholder&#8217;s option, on or after the Maturity Date while such Note remains outstanding, into shares of
the Company&#8217;s Series A-2 Preferred Stock at a conversion price equal to $</span><span id="xdx_901_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_c20221111__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__us-gaap--StatementClassOfStockAxis__custom--SeriesATwoPreferredStockMember__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNotesMember_zwlO38ap7fT2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:PreferredStockConvertibleConversionPrice" contextRef="AsOf2022-11-11_us-gaap_RelatedPartyMember_custom_SeriesATwoPreferredStockMember_custom_ConvertiblePromissoryNotesMember" id="Fact000849" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.50</ix:nonFraction>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per
share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a Corporate Transaction occurs before the repayment or conversion of the Notes, the Company will pay at the closing of the Corporate
Transaction to each noteholder that elects not to convert its Notes in connection with such Corporate Transaction an amount equal to
the outstanding principal amount of such noteholder&#8217;s Note plus a 20% premium. &#8220;Corporate Transaction&#8221; means (a) a
sale by the Company of all or substantially all of its assets, (b) a merger of the Company with or into another entity (if after such
merger the holders of a majority of the Company&#8217;s voting securities immediately prior to the transaction do not hold a majority
of the voting securities of the successor entity) or (c) the transfer of more than 50% of the Company&#8217;s voting securities to a
person or group.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
November 2019, the Company entered into a Convertible Promissory Note (&#8220;Note&#8221;) agreement with a related party investor. The
total amount of the Note is $<span id="xdx_90B_eus-gaap--ConvertibleNotesPayable_iI_c20191130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNotesMember_zv56oApNNbeh"><ix:nonFraction name="us-gaap:ConvertibleNotesPayable" contextRef="AsOf2019-11-30_us-gaap_RelatedPartyMember_custom_ConvertiblePromissoryNotesMember" id="Fact000850" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,500,000</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
The Note is unsecured and bears interest at a rate of four percent annually from the date of issuance until the outstanding principal
is paid or converted. The Note matures on January 1, 2025. The Note shall automatically convert into the next offering of preferred stock
upon closing of such next equity financing. The number of shares of preferred stock to be issued upon conversion shall be equal to the
number obtained by dividing the outstanding principal and unpaid accrued interest owed on the date of conversion, by the conversion price.
The conversion price is 100 percent of the lowest price per share paid for the next equity preferred stock by other investors in the
next equity financing. In the event that prior to the conversion or repayment of amounts owed, the Company completes a financing transaction
in which the Company sells equity securities but such transaction does not qualify as next equity financing (i.e., an &#8220;alternative
financing&#8221;), then the principal and unpaid accrued interest may (upon written election of the purchaser holding the Note) convert
into the securities issued by the Company in the alternative financing. The number of alternative financing equity securities to be issued
upon such conversion shall be equal to the number obtained by dividing the outstanding principal and unpaid accrued interest owed by
an amount equal to 100 percent multiplied by the lowest price per share at which the alternative financing equity securities are sold
and issued for cash in the alternative financing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022 there was $<span id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20221231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNotesMember_zzQfngxlNZv"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2022-12-31_custom_ConvertiblePromissoryNotesMember" id="Fact000851" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">9.9</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million outstanding principal balance
on the Notes and $<span id="xdx_90D_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_c20221231_zdNy3XL0rF12"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" contextRef="AsOf2022-12-31" id="Fact000852" format="ixt:numdotdecimal" decimals="0" unitRef="USD">690,771</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in accrued interest, all included in long-term liabilities
on the balance sheet. There were no payments of principal or interest during 2022. In connection with the $<span id="xdx_909_eus-gaap--ConvertibleNotesPayable_iI_c20221231_zHeJIptueIbd"><ix:nonFraction name="us-gaap:ConvertibleNotesPayable" contextRef="AsOf2022-12-31" id="Fact000853" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,140,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in convertible notes issued in 2022, <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231_ztjzjo3Remni"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2022-12-31" id="Fact000854" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,056,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in warrants were issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2023, the Business Combination between Data Knights and the Company triggered the Notes&#8217; conversion to common stock. Approximately
$<span id="xdx_90F_eus-gaap--ConvertibleNotesPayable_iI_pn5n6_c20231130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__us-gaap--BusinessAcquisitionAxis__custom--DataKnightsAcquisitionCorpMember_zWFSXJD2XsXd"><ix:nonFraction name="us-gaap:ConvertibleNotesPayable" contextRef="AsOf2023-11-30_us-gaap_RelatedPartyMember_custom_DataKnightsAcquisitionCorpMember" id="Fact000855" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">15.4</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million of the total outstanding Notes
plus accrued interest were converted at $<span id="xdx_900_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20231130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__us-gaap--BusinessAcquisitionAxis__custom--DataKnightsAcquisitionCorpMember_z22nSokD3835"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2023-11-30_us-gaap_RelatedPartyMember_custom_DataKnightsAcquisitionCorpMember" id="Fact000856" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.50</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 29.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000858" name="us-gaap:DebtDisclosureTextBlock"><p id="xdx_80B_eus-gaap--DebtDisclosureTextBlock_zoh1A7v8pgNb" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.
<span id="xdx_823_z8QgZaljwfyc">Canadian Emergency Business Loan Act (CEBA)</span></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
December 2020, the Company applied for and received a $<span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOfUnsecuredDebt_c20201201__20201231__us-gaap--DebtInstrumentAxis__custom--CEBALoanMember_z9FBa1FDxqQ1"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfUnsecuredDebt" contextRef="From2020-12-012020-12-31_custom_CEBALoanMember" id="Fact000859" format="ixt:numdotdecimal" decimals="0" unitRef="USD">44,673</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">USD CEBA loan. The loan was provided by
the Government of Canada to provide capital to organizations to see them through the current challenges and better position them to return
to providing services and creating employment. The loan is unsecured. The loan was interest free through December 31, 2023. If the loan
is paid back by January 18, 2024, $<span id="xdx_90B_eus-gaap--DebtInstrumentDecreaseForgiveness_c20200101__20201231__us-gaap--DebtInstrumentAxis__custom--CEBALoanMember_zHgzJPz57Uf1"><ix:nonFraction name="us-gaap:DebtInstrumentDecreaseForgiveness" contextRef="From2020-01-012020-12-31_custom_CEBALoanMember" id="Fact000860" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,742</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of the loan will be forgiven. If the loan
is not paid back by January 18, 2023, the full $<span id="xdx_90F_eus-gaap--DebtConversionOriginalDebtAmount1_c20200101__20201231__us-gaap--DebtInstrumentAxis__custom--CEBALoanMember_zezZ4lDkBQNf"><ix:nonFraction name="us-gaap:DebtConversionOriginalDebtAmount1" contextRef="From2020-01-012020-12-31_custom_CEBALoanMember" id="Fact000861" format="ixt:numdotdecimal" decimals="0" unitRef="USD">44,673</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">loan will be converted to loan repayable
over <span id="xdx_90A_eus-gaap--DebtInstrumentTerm_dc_c20200101__20201231__us-gaap--DebtInstrumentAxis__custom--CEBALoanMember_z527KNug8vY8"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_CEBALoanMember" format="ixt-sec:durwordsen" id="Fact000862" name="us-gaap:DebtInstrumentTerm">three
years</ix:nonNumeric></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">with a <span id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20201231__us-gaap--DebtInstrumentAxis__custom--CEBALoanMember_z3pHMKrhHD42"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2020-12-31_custom_CEBALoanMember" id="Fact000863" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5</ix:nonFraction>%
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">interest rate. The loan was paid back
prior January 18, 2024. At December 31, 2023 the loans is classified as Canada Emergency Business Loan Act under Current Liabilities
on the Consolidated Balance Sheet.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounted for the loan as debt in accordance with FASB Accounting Standards Codification 470 Debt and accrued interest in accordance
with the interest method under FASB ASC 835-30.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 86; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000865" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_802_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zwIUK3ZPhU96" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.
<span id="xdx_82C_zMJnazzhoipg">Shareholders&#8217; Equity</span></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Series
A-2 Preferred Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s previously issued and outstanding Series A-2 preferred stock included a $<span id="xdx_909_eus-gaap--SharesIssuedPricePerShare_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesATwoPreferredStockMember_zq4f8awROcvj"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2023-12-31_custom_SeriesATwoPreferredStockMember" id="Fact000866" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.15</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share annual noncumulative dividend
when and if declared by the board of directors. <span id="xdx_90A_eus-gaap--DividendsPreferredStock_do_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesATwoPreferredStockMember_zfb2qGerALUh">No
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">dividends were declared in the years ended
December 31, 2023 or December 31 2022. The Series A-2 preferred stock also includes a liquidation preference of 1.25 times the original
issue price plus any declared but unpaid dividends upon the liquidation, dissolution, merger or sale of substantially all the assets
of the Company and have a preference upon liquidation over Series A-1 preferred stock and common stock. Each share of Series A-2 preferred
stock may be converted into equal shares of common stock at the option of the holder at any time. In addition, the Series A-2 preferred
stock shares are automatically convertible into common shares upon the sale of shares of common stock to the public at the then applicable
conversion price in a firm commitment underwritten public offering pursuant to an effective registration statement under the Securities
Act of 1933, as amended, resulting in at least $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_pn5n6_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesATwoPreferredStockMember_z2VdHHmRJnT"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" contextRef="From2023-01-012023-12-31_custom_SeriesATwoPreferredStockMember" id="Fact000868" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">20</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million in proceeds, net of underwriting
discounts and commissions. Each share of Series A-2 preferred stock has voting rights equal to the number of shares of common stock then
issuable upon conversion of such share of preferred stock. The Company is obligated to redeem shares of Series A-2 Preferred Stock in
the occurrence of a Deemed Liquidation Event unless a majority of the holders of Series A-2 Preferred Stock and a majority of the Series
A-1 Preferred Stock consent otherwise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2023, the Business Combination between Data Knights and the Company triggered the <span id="xdx_90A_eus-gaap--ConvertiblePreferredStockTermsOfConversion_c20230101__20231231_zq6xgWTwPSXg"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000869" name="us-gaap:ConvertiblePreferredStockTermsOfConversion">Series
A-2 Preferred Stock and Series A-1 Preferred Stock convert 1-1 to commons stock</ix:nonNumeric></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Series
A-1 Preferred Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s previously issued and outstanding Series A-1 preferred stock included a $<span id="xdx_909_eus-gaap--SharesIssuedPricePerShare_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember_zPFWdKqH8CR2"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2023-12-31_custom_SeriesAOnePreferredStockMember" id="Fact000870" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.15</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share annual noncumulative dividend
when and if declared by the board of directors. <span id="xdx_905_eus-gaap--DividendsPreferredStock_do_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember_zcOAGK1oCteb">No
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">dividends were declared in the years ended
December 31, 2023 or December 31 2022. The Series A-1 preferred stock also includes a liquidation preference of 1.25 times the original
issue price plus any declared but unpaid dividends upon the liquidation, dissolution, merger or sale of substantially all the assets
of the Company and have a preference upon liquidation over common stock. Each share of Series A-1 preferred stock may be converted into
equal shares of common stock at the option of the holder at any time. In addition, the Series A-1 preferred stock shares are automatically
convertible into common shares upon the sale of shares of common stock to the public at the then applicable conversion price in a firm
commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended,
resulting in at least $<span id="xdx_909_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_pn5n6_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember_ziTTDyaYppZj"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" contextRef="From2023-01-012023-12-31_custom_SeriesAOnePreferredStockMember" id="Fact000872" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">20</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million in proceeds, net of underwriting
discounts and commissions. Each share of Series A-1 preferred stock has voting rights equal to the number of shares of common stock then
issuable upon conversion of such share of preferred stock. The Company is obligated to redeem shares of Series A-1 Preferred Stock in
the occurrence of a Deemed Liquidation Event unless a majority of the holders of Series A-1 Preferred Stock consent otherwise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2023, the Business Combination between Data Knights and the Company triggered the <span id="xdx_90A_eus-gaap--ConvertiblePreferredStockTermsOfConversion_c20230101__20231231_zPmigUwb7mv3"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000873" name="us-gaap:ConvertiblePreferredStockTermsOfConversion">Series
A-2 Preferred Stock and Series A-1 Preferred Stock convert 1-1 to commons stock</ix:nonNumeric></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common
Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2023, in connection with services performed by the Board of Directors common shares of <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230101__20231231__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_zUbEE9Udi2H9"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2023-01-012023-12-31_custom_BoardOfDirectorsMember" id="Fact000874" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20220101__20221231__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_zvCTDm0x78h6"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2022-01-012022-12-31_custom_BoardOfDirectorsMember" id="Fact000875" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-
2022) were issued at $<span id="xdx_902_eus-gaap--SharePrice_iI_c20231231__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_zoQnKnHOJV64"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2023-12-31_custom_BoardOfDirectorsMember" id="Fact000876" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share. These were expensed as general
and administrative expenses in the Statement of Operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000878" name="us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock"><p id="xdx_893_eus-gaap--ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_z57uq3swwTu3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font: normal 10pt Times New Roman, Times, Serif">The
table below summarizes the Common Stock activities during the year ended December 31, 2023.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span id="xdx_8B9_z64bu48q1ymf" style="font: normal 10pt Times New Roman, Times, Serif">Schedule
of Common Stock Activities</span><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 1in">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_z2msICVrt1Qb" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">Common
    Stock</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--SharesOutstanding_iS_zLHH8ANuCOvi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 80%">Balances, December 31, 2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember_srt_BoardOfDirectorsChairmanMember" id="Fact000880" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,550,166</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--SharesOutstanding_iS_zW2yvdRyeAgd" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif">Balance</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember_srt_BoardOfDirectorsChairmanMember" id="Fact000882" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,550,166</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_z2wlaGxg9Xb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Preferred Stock to Common Stock</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember_srt_BoardOfDirectorsChairmanMember" id="Fact000884" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,057,797</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--StockIssuedDuringPeriodSharesConvertibleNotesToCommonStock_zJwjfDx64uRl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Convertible Notes to Common Stock</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ONMD:StockIssuedDuringPeriodSharesConvertibleNotesToCommonStock" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember_srt_BoardOfDirectorsChairmanMember" id="Fact000886" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,177,229</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--StockIssuedDuringPeriodSharesStockOptionsToCommonStock_z3uhYW1PO4Ql" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Stock Options to Common Stock</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ONMD:StockIssuedDuringPeriodSharesStockOptionsToCommonStock" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember_srt_BoardOfDirectorsChairmanMember" id="Fact000888" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">612,670</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--StockIssuedDuringPeriodSharesConvertingOfWarrantsToCommonStock_z3UmWOkuvHcd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Converting of Warrants to Common Stock</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ONMD:StockIssuedDuringPeriodSharesConvertingOfWarrantsToCommonStock" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember_srt_BoardOfDirectorsChairmanMember" id="Fact000890" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,859,464</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--StockIssuedDuringPeriodSharesOther_zuvjfYqYrP3e" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Private OneMedNet to ONMD Public Shares</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember_srt_BoardOfDirectorsChairmanMember" id="Fact000892" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">2,257,326</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_407_ecustom--StockIssuedDuringPeriodSharesConvertingDataKnightsCommonShares_zO0iuFy9if3i" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Converting Data Knights Common Stock (A and B) to ONMD Public Shares</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ONMD:StockIssuedDuringPeriodSharesConvertingDataKnightsCommonShares" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember_srt_BoardOfDirectorsChairmanMember" id="Fact000894" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,460,275</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_z2eiIknVjv5e" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Issuance Public Shares</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember_srt_BoardOfDirectorsChairmanMember" id="Fact000896" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">111,957</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--SharesOutstanding_iE_zyOXDTAsVnxi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif">Balances, December 31, 2023</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember_srt_BoardOfDirectorsChairmanMember" id="Fact000898" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">23,572,232</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--SharesOutstanding_iE_zOLEX9Io8sth" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif">Balance</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember_srt_BoardOfDirectorsChairmanMember" id="Fact000900" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">23,572,232</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8A0_z6jRMRei6Rl1" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000902" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"><p id="xdx_806_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zAjaUuhHpcC9" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.
<span id="xdx_828_zssYNJtF6ti3">Stock Options</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2020, the Company adopted a new equity incentive plan (the Plan), which provides for the granting of incentive and nonqualified stock
options to employees, directors, and consultants. As of December 31, 2020, the Company has reserved <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20200101__20201231__srt--TitleOfIndividualAxis__custom--EmployeesDirectorsAndConsultantsMember__us-gaap--PlanNameAxis__custom--NewEquityIncentivePlanMember_zOPY3Epoom39"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2020-01-012020-12-31_custom_EmployeesDirectorsAndConsultantsMember_custom_NewEquityIncentivePlanMember" id="Fact000903" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,000,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock under the Plan.
The Company believes that such awards better align the interests of its employees with those of its stockholders. Option awards are generally
granted with an exercise price equal to the fair market value of the Company&#8217;s stock at the date of grant; those option awards
generally vest with a range of one
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc_c20200101__20201231__srt--TitleOfIndividualAxis__custom--EmployeesDirectorsAndConsultantsMember__us-gaap--PlanNameAxis__custom--NewEquityIncentivePlanMember__srt--RangeAxis__srt--MaximumMember_zana3dh21Z82"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_EmployeesDirectorsAndConsultantsMember_custom_NewEquityIncentivePlanMember_srt_MaximumMember" format="ixt-sec:durwordsen" id="Fact000904" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">four
years</ix:nonNumeric></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of continuous service and have ten-year
contractual terms. As there is no public data available for the share price valuation, the Company considers the Fair Market Value of
$<span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_c20201231__srt--TitleOfIndividualAxis__custom--EmployeesDirectorsAndConsultantsMember__us-gaap--PlanNameAxis__custom--NewEquityIncentivePlanMember_zuowjumEyy9k"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2020-12-31_custom_EmployeesDirectorsAndConsultantsMember_custom_NewEquityIncentivePlanMember" id="Fact000905" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to be on the conservative side and similar
to the exercise price. Certain option awards provide for accelerated vesting if there is a change in control, as defined in the Plan.
The Plan also permits the granting of restricted stock and other stock-based awards. Unexercised options are cancelled upon termination
of employment and become available under the Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 87; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000907" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><p id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zOOwKvbrQpb1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
with respect to options outstanding is summarized as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span id="xdx_8B8_zQRZFYMZHvh1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
of Options Outstanding</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Options Outstanding</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Weighted- Average Exercise Price</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Aggregate Intrinsic Value</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 52%">Outstanding as of December 31, 2020</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210101__20211231_zadM3myKcRSg" title="Options outstanding, begining balance" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2020-12-31" id="Fact000909" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,995,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231_zP106pErband" title="Weighted average exercise price, begining balance" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-12-31" id="Fact000911" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20210101__20211231_z121yn1pvKH9" title="Aggregate Intrinsic value, begining balance" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2020-12-31" id="Fact000913" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,995,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Granted - under the Plan</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210101__20211231_zXHo6mISQpKb" title="Options, Granted - under the Plan" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2021-01-012021-12-31" id="Fact000915" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Exercised</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20210101__20211231_zyywVTg5nGIa" title="Options, Granted - under the Plan" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0917">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Cancelled</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20210101__20211231_zSn9l0NAWEk4" title="Options, cancelled" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" contextRef="From2021-01-012021-12-31" id="Fact000919" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,072,816</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Outstanding as of December 31, 2021</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220101__20221231_zaCQmCo4rgci" title="Options outstanding, ending balance" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-12-31" id="Fact000921" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">947,184</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210101__20211231_zXDcIpQgUsAi" title="Weighted average exercise price, ending balance" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-12-31" id="Fact000923" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20210101__20211231_zhXfMFmK7TH1" title="Aggregate Intrinsic value, ending balance" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2021-12-31" id="Fact000925" format="ixt:numdotdecimal" decimals="0" unitRef="USD">947,184</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Granted - under the Plan</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231_z3d4RVyP48Li" title="Options, Granted - under the Plan" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2022-01-012022-12-31" id="Fact000927" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">577,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Exercised</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20220101__20221231_z3Cg4GHDeiCb" title="Options, Granted - under the Plan" style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2022-01-012022-12-31" id="Fact000929" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,500</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Cancelled</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20220101__20221231_z6qJl1wVmuyk" title="Options, cancelled" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" contextRef="From2022-01-012022-12-31" id="Fact000931" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">485,684</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Outstanding as of December 31, 2022</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20220101__20221231_zS1IVj8CRw3j" title="Options outstanding, ending balance" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-12-31" id="Fact000933" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,031,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231_zX1i6YPg8JM9" title="Weighted average exercise price, ending balance" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-12-31" id="Fact000935" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20220101__20221231_zM05DsMkmdHa" title="Aggregate Intrinsic value, ending balance" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2022-12-31" id="Fact000937" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,031,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Options exercisable as of December 31, 2022</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20220101__20221231_ztwl4L855yl8" title="Options exercisable" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2022-12-31" id="Fact000939" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">567,581</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20220101__20221231_zYrTENj4cnQg" title="Weighted average exercise price, exercisable" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2022-12-31" id="Fact000941" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_c20220101__20221231_zj3Qf8Lulmh7" title="Aggregate Intrinsic value, exercisable" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2022-12-31" id="Fact000943" format="ixt:numdotdecimal" decimals="0" unitRef="USD">567,581</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A8_z8EfnFrKpN6b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022 and 2021, there were <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20221231_zCusyY0Eadkf"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-12-31" id="Fact000944" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,031,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20211231_z60y0LjYvs75"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-12-31" id="Fact000945" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">947,184</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">common stock options outstanding with
a weighted average remaining contractual life of <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231_zTZjpFpO9Ie2"><ix:nonNumeric contextRef="From2022-01-012022-12-31" format="ixt-sec:duryear" id="Fact000946" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">7.11</ix:nonNumeric>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">years and <span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231_zCiL8vS0y486"><ix:nonNumeric contextRef="From2021-01-012021-12-31" format="ixt-sec:duryear" id="Fact000947" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">6.01</ix:nonNumeric>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">years, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022 and 2021, there were <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20221231_zQD82gnRuEM2"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2022-12-31" id="Fact000948" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">567,581</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20211231_zX6RDBNpqYZi"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2021-12-31" id="Fact000949" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">723,431</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">common stock options exercisable at a
weighted average remaining contractual life of <span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231_zCQqssRftxz1"><ix:nonNumeric contextRef="From2022-01-012022-12-31" format="ixt-sec:duryear" id="Fact000950" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">5.56</ix:nonNumeric>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">years and <span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20210101__20211231_zoakaW2uUSNa"><ix:nonNumeric contextRef="From2021-01-012021-12-31" format="ixt-sec:duryear" id="Fact000951" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">5.27</ix:nonNumeric>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">years, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 7, 2023, the Company issued shares of common stock for <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_pid_c20231107_zC2U5iJKuiKl"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="AsOf2023-11-07" id="Fact000952" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">692,153</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">vested options less an exercise price
of $<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_pid_c20231107_zIYsl5WuH4K1"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-11-07" id="Fact000953" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">At
the Special Meeting </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">held on October 17, 2023<span style="background-color: white">,
Data Knights shareholders considered and approved the OneMedNet Corporation 2022 Equity Incentive Plan (the &#8220;Plan&#8221;) and reserved
an amount of shares of <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_pid_c20231017__20231017_zIGkitfX4Hnb"><ix:nonNumeric contextRef="From2023-10-172023-10-17" id="Fact000954" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">common
stock equal to 10% of the number of shares of common stock of OneMedNet following the Business Combination for issuance thereunder</ix:nonNumeric></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">.
The Plan was approved by the OneMedNet pre-Closing board of directors on October 17, 2023. The Plan became effective immediately upon
the Closing of the Business Combination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font: normal 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Black
Scholes Assumptions</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
determination of the fair value of stock options using an option valuation model is affected by the Company&#8217;s stock price valuation,
as well as assumptions regarding a number of complex and subjective variables. The volatility assumption is based on volatilities of
similar companies over a period of time equal to the expected term of the stock options. The volatilities of similar companies are used
in conjunction with the Company&#8217;s historical volatility because of the lack of sufficient relevant history for the Company&#8217;s
common stock equal to the expected term. The expected term of the employee stock options represents the weighted average period for which
the stock options are expected to remain outstanding. The expected term assumption is estimated based primarily on the options&#8217;
vesting terms and remaining contractual life and employees&#8217; expected exercise and post- vesting employment termination behavior.
The risk-free rate for periods within the contractual life of the option is based on the U.S. Treasury yield curve in effect at the time
of grant. The dividend yield assumption is based on the expectation of no future dividend payouts by the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000956" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"><p id="xdx_898_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zay0AEYnB9Ej" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of the Company&#8217;s previous stock options was estimated assuming no expected dividends and the following weighted average
assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span id="xdx_8B6_zJo0ngyYGTwc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
of Fair Value of Stock Options</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2021</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Expected life in years</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span id="xdx_901_ecustom--EquitySecuritiesFvNiMeasurementTerm_dtY_c20220101__20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zoolrrCQTN9h"><ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_MeasurementInputExpectedTermMember" format="ixt-sec:duryear" id="Fact000957" name="ONMD:EquitySecuritiesFvNiMeasurementTerm">5.89</ix:nonNumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span id="xdx_905_ecustom--EquitySecuritiesFvNiMeasurementTerm_dtY_c20210101__20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zyneyj3ZuwJ"><ix:nonNumeric contextRef="From2021-01-012021-12-31_us-gaap_MeasurementInputExpectedTermMember" format="ixt-sec:duryear" id="Fact000958" name="ONMD:EquitySecuritiesFvNiMeasurementTerm">6.08</ix:nonNumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Risk-free interest rate</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z9y58LCpnxXh"><ix:nonFraction name="us-gaap:EquitySecuritiesFvNiMeasurementInput" contextRef="AsOf2022-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember" id="Fact000959" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">0.55</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90C_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zWq5I7FYdBS2"><ix:nonFraction name="us-gaap:EquitySecuritiesFvNiMeasurementInput" contextRef="AsOf2021-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember" id="Fact000960" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">0.49</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Expected dividend yield</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_900_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z69uRpV0a13b"><ix:nonFraction name="us-gaap:EquitySecuritiesFvNiMeasurementInput" contextRef="AsOf2022-12-31_us-gaap_MeasurementInputExpectedDividendRateMember" id="Fact000961" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">0.00</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90A_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z4ohD9teCjj4"><ix:nonFraction name="us-gaap:EquitySecuritiesFvNiMeasurementInput" contextRef="AsOf2021-12-31_us-gaap_MeasurementInputExpectedDividendRateMember" id="Fact000962" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">0.00</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Expected volatility</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90D_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zY9O0q7FP8Pk"><ix:nonFraction name="us-gaap:EquitySecuritiesFvNiMeasurementInput" contextRef="AsOf2022-12-31_us-gaap_MeasurementInputPriceVolatilityMember" id="Fact000963" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">32</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zSQ9xugXtAYb"><ix:nonFraction name="us-gaap:EquitySecuritiesFvNiMeasurementInput" contextRef="AsOf2021-12-31_us-gaap_MeasurementInputPriceVolatilityMember" id="Fact000964" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">60</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AF_zPAh7czH2RHd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
total expense recognized for share-based payments was $<span id="xdx_903_eus-gaap--AllocatedShareBasedCompensationExpense_c20220101__20221231_zs5NCE7xjYwb"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-01-012022-12-31" id="Fact000965" format="ixt:numdotdecimal" decimals="0" unitRef="USD">45,584</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_906_eus-gaap--AllocatedShareBasedCompensationExpense_c20210101__20211231_zh4A4jq44eFh"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-01-012021-12-31" id="Fact000966" format="ixt:numdotdecimal" decimals="0" unitRef="USD">47,071</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for the years ended December 31, 2022
and 2021, respectively. These costs are included in the statements of operations. As of December 31, 2022, there was $<span id="xdx_909_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_c20221231_z0GkDmV9WgF7"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="AsOf2022-12-31" id="Fact000967" format="ixt:numdotdecimal" decimals="0" unitRef="USD">75,987</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of unrecognized compensation costs related
to stock option grants which will be recognized over the next four years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2023, the Company issued common stock to employees and extinguished all outstanding stock options. The <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zyhahePb5iy"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember" id="Fact000968" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">612,720</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares outstanding were recorded as stock
expense in the Consolidated Statement of Operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 88; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000970" name="ONMD:StockWarrantsDisclosureTextBlock"><p id="xdx_806_ecustom--StockWarrantsDisclosureTextBlock_z8PGkPv4zKwa" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.
<span id="xdx_82B_zW0uKdrIgtgh">Stock Warrants</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2021, there were <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20211231_zVMpckQCE4Bf"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2021-12-31" id="Fact000971" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">174,102</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">OneMedNet Corporation outstanding common
stock warrants issued for service at a weighted average exercise price of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20211231_zc6DmaF0LKM7"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2021-12-31" id="Fact000972" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.10</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
In 2022 for the exercise price of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231_zgf5jJhyAZkb"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-12-31" id="Fact000973" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
the OneMedNet Corporation issued <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__us-gaap--AwardTypeAxis__custom--TwentyTwentyOneServiceMember_zx0H5C9JD5ok"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2022-12-31_custom_TwentyTwentyOneServiceMember" id="Fact000974" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">145,746</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warrants for 2021 service and <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__us-gaap--AwardTypeAxis__custom--TwentyTwentyTwoServiceMember_zF9lMoCrpHyc"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2022-12-31_custom_TwentyTwentyTwoServiceMember" id="Fact000975" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">294,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warrants for 2022 service, <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--ConvertiableNotesMember_zo7PsnZa1bXl"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2022-12-31_custom_ConvertiableNotesMember" id="Fact000976" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,056,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in warrants were issued attached to convertible
notes. The Company expensed $<span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfWarrants_c20220101__20221231_ziimEIM50841"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="From2022-01-012022-12-31" id="Fact000977" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,346,288</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in 2022 in relation to the issuance of the Warrants. In 2023
for the exercise price of $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231_zwObMnOHBCT1"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-12-31" id="Fact000978" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
the OneMedNet issued <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--ConvertiableNotesMember_zbfmaPMF2PY9"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-12-31_custom_ConvertiableNotesMember" id="Fact000979" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,670,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in warrants attached to convertible notes.
OneMedNet Corporation converted <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantOneMember_zYX8MxovCp9d"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2023-12-31_custom_WarrantOneMember" id="Fact000980" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,165,746</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warrants outstanding to common stock at
an exercise price of $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantOneMember_zDVAXmd1vmK9"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-12-31_custom_WarrantOneMember" id="Fact000981" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and converted <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zy008UtCDFD9"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000982" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">174,102</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warrants outstanding to common stock at
an exercise price of $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zGTMTgjKR4f3"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000983" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.10</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023 and December 31, 2022, the Company had <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--PubliclyTradedWarrantsMember_zlBN1dUU6NMh"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2022-12-31_custom_PubliclyTradedWarrantsMember" id="Fact000984" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,500,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of publicly traded warrants. The warrants
trade on the Nasdaq had closing price of $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PubliclyTradedWarrantsMember_zYDKyHofnc49"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-12-31_custom_PubliclyTradedWarrantsMember" id="Fact000985" decimals="INF" unitRef="USDPShares">.0149</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--PubliclyTradedWarrantsMember_z3715RMmux9c"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-12-31_custom_PubliclyTradedWarrantsMember" id="Fact000986" decimals="INF" unitRef="USDPShares">.0400</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">at December 31, 2023 and December 31,
2022 respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023 and December 31, 2022, the Company had <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivateWarrantsMember_zGRZgpppUqL1"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2023-12-31_custom_PrivateWarrantsMember" id="Fact000987" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">681,019</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivateWarrantsMember_zoyczQ9iZHv2"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2022-12-31_custom_PrivateWarrantsMember" id="Fact000988" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">585,275</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of private warrants outstanding. These
warrants are classified as liability on the Consolidated Balance Sheet. Changes in the warrant liabilities are recorded in the Statement
of Operations. As of December 31, 2023 and December 31, 2022, the warrant liabilities were $<span id="xdx_907_eus-gaap--OtherLiabilities_iI_pn5n6_c20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_ztu26qdbHEN6"><ix:nonFraction name="us-gaap:OtherLiabilities" contextRef="AsOf2023-12-31_us-gaap_WarrantMember" id="Fact000989" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.6</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million and $<span id="xdx_906_eus-gaap--OtherLiabilities_iI_pn5n6_c20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z5jxlvTWlcW8"><ix:nonFraction name="us-gaap:OtherLiabilities" contextRef="AsOf2022-12-31_us-gaap_WarrantMember" id="Fact000990" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.4</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000992" name="us-gaap:FairValueDisclosuresTextBlock"><p id="xdx_803_eus-gaap--FairValueDisclosuresTextBlock_zR5YrFIBCSuh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>12.
<span id="xdx_829_zGhU1cTHD9La">Fair Value Measures</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value measurement accounting standards establish a framework for measuring fair value and expand disclosures about fair value measurements.
The standard does not require any new fair value measurements; rather, it applies to other accounting pronouncements that require or
permit fair value measurements. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability
in the principal or most advantageous market in an orderly transaction between market participants on the measurement date. This pronouncement
also establishes a three-level hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable
inputs when measuring fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
valuation hierarchy is based upon the transparency of inputs to the valuation of an asset or liability on the measurement date. The three
levels are defined as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1&#8212;inputs to the valuation methodology are quoted prices (unadjusted) for an identical asset or liability in an active market</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2&#8212;inputs to the valuation methodology include quoted prices for a similar asset or liability in an active market or model-derived
valuations in which all significant inputs are observable for substantially the full term of the asset or liability</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3&#8212;inputs to the valuation methodology are unobservable and significant to the fair value measurement of the asset or liability</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000994" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock"><p id="xdx_89F_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisTextBlock_zF46BGIp4EFd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the Company&#8217;s financial assets measured and recorded at fair value on a recurring basis using the above
input categories as of December 31, 2023 and December 31, 2022 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span id="xdx_8BF_zdP5BhYaW47c" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
of Financial Assets</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="30" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year Ended</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><b>December 31, 2023</b></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><b>December 31, 2022</b></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level 1</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level 2</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level 3</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level 1</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level 2</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level 3</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Assets:</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 28%; text-align: left">Investments held in Trust</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--AssetsHeldInTrustCurrent_iI_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByAssetClassAxis__custom--InvestmentsHeldInTrustMember_zEQFhQkyIfN" title="Investments held in Trust" style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0996">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--AssetsHeldInTrustCurrent_iI_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByAssetClassAxis__custom--InvestmentsHeldInTrustMember_zLZI52abmujj" title="Investments held in Trust" style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0998">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--AssetsHeldInTrustCurrent_iI_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByAssetClassAxis__custom--InvestmentsHeldInTrustMember_zoUYLwzbPZ09" title="Investments held in Trust" style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1000">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--AssetsHeldInTrustCurrent_iI_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--InvestmentsHeldInTrustMember_zXBMFEw6Jxej" title="Investments held in Trust" style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1002">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--AssetsHeldInTrustCurrent_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByAssetClassAxis__custom--InvestmentsHeldInTrustMember_zvIGgDiejqOl" title="Investments held in Trust" style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><ix:nonFraction name="us-gaap:AssetsHeldInTrustCurrent" contextRef="AsOf2022-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member_custom_InvestmentsHeldInTrustMember" id="Fact001004" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,029,416</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--AssetsHeldInTrustCurrent_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByAssetClassAxis__custom--InvestmentsHeldInTrustMember_zcCKPwhX93uc" title="Investments held in Trust" style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1006">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--AssetsHeldInTrustCurrent_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByAssetClassAxis__custom--InvestmentsHeldInTrustMember_zvXhmGsmuOr7" title="Investments held in Trust" style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1008">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--AssetsHeldInTrustCurrent_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--InvestmentsHeldInTrustMember_zrAoAx5qHUz5" title="Investments held in Trust" style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><ix:nonFraction name="us-gaap:AssetsHeldInTrustCurrent" contextRef="AsOf2022-12-31_us-gaap_FairValueMeasurementsRecurringMember_custom_InvestmentsHeldInTrustMember" id="Fact001010" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,029,416</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Total Assets</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_eus-gaap--AssetsHeldInTrustCurrent_iI_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zmIvjjLwQdvj" title="Assets measured and recorded fair value" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1012">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98A_eus-gaap--AssetsHeldInTrustCurrent_iI_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zVtsygBqkh22" title="Assets measured and recorded fair value" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1014">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98F_eus-gaap--AssetsHeldInTrustCurrent_iI_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zUnskt8YvWJ7" title="Assets measured and recorded fair value" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1016">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98B_eus-gaap--AssetsHeldInTrustCurrent_iI_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zYdjoewzQqGk" title="Assets measured and recorded fair value" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1018">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98A_eus-gaap--AssetsHeldInTrustCurrent_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zJDtEWqItAIb" title="Assets measured and recorded fair value" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AssetsHeldInTrustCurrent" contextRef="AsOf2022-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member" id="Fact001020" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,029,416</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98A_eus-gaap--AssetsHeldInTrustCurrent_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zWmgRXu5v5Aj" title="Assets measured and recorded fair value" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1022">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98C_eus-gaap--AssetsHeldInTrustCurrent_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zMRKEoTtJrC9" title="Assets measured and recorded fair value" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1024">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_986_eus-gaap--AssetsHeldInTrustCurrent_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_ziDpKsUYsNjf" title="Assets measured and recorded fair value" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AssetsHeldInTrustCurrent" contextRef="AsOf2022-12-31_us-gaap_FairValueMeasurementsRecurringMember" id="Fact001026" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,029,416</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001028" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p id="xdx_805_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zVfbIOnskmzk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>13.
<span id="xdx_829_z8h35XY0FX7d">Related Party Transactions</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Loan
Extensions</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>


<ix:exclude><!-- Field: Page; Sequence: 89; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Data
Knights closed its initial public offering in May 2021 and had 12 months to complete a business combination. Alternatively, the Data
Knight could extend the period up to two times for an additional three months each time with an extension costing $<span id="xdx_908_eus-gaap--ConvertibleNotesPayable_iI_pn5n6_c20231231__us-gaap--BusinessAcquisitionAxis__custom--DataKnightsAcquisitionCorpMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z0CG6fi9Tq7i"><ix:nonFraction name="us-gaap:ConvertibleNotesPayable" contextRef="AsOf2023-12-31_custom_DataKnightsAcquisitionCorpMember_us-gaap_RelatedPartyMember" id="Fact001029" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.2</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million. Data Knights received a total
of $<span id="xdx_90D_ecustom--ExtensionLoan_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__srt--TitleOfIndividualAxis__custom--ManagementAndDirectorsMember_zA1fifUXV765"><ix:nonFraction name="ONMD:ExtensionLoan" contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember_custom_ManagementAndDirectorsMember" id="Fact001030" format="ixt:numdotdecimal" decimals="0" unitRef="USD">300,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">from members of the Company&#8217;s Management
and Directors. As of December 31, 2023 and December 31, 2022 the total extension loan including interest outstanding was $<span id="xdx_905_ecustom--ExtensionLoan_iI_pn5n6_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zO7QOwXdAHNg"><ix:nonFraction name="ONMD:ExtensionLoan" contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember" id="Fact001031" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.0</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million and $<span id="xdx_90C_ecustom--ExtensionLoan_iI_pn5n6_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zn10KaDPlSY"><ix:nonFraction name="ONMD:ExtensionLoan" contextRef="AsOf2022-12-31_us-gaap_RelatedPartyMember" id="Fact001032" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.5</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>PIPE
Convertible Notes and Warrants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2023, the Company entered into a Securities Purchase Agreement (SPA) in which the Company was required to sell senior secured
convertible notes and warrants to Directors of the Company. The SPA stipulates a collateral security agreement between the Company and
the Directors for punctual payment and performance by the Company on its Obligations to the Directors. The Intellectual Property of the
Company serves as the collateral for the Directors. The senior secured convertible notes and warrants were issued through a private issuance
of a public entity (PIPE) transaction, which is a form of debt and equity offering under an exception in the securities law for qualifying
private placements by issuers of publicly traded securities. The Company received a total of $<span id="xdx_909_eus-gaap--ProceedsFromConvertibleDebt_pn5n6_c20231101__20231130__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zHfl035q52V8"><ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="From2023-11-012023-11-30_custom_SecuritiesPurchaseAgreementMember" id="Fact001033" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.5</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million from the director in exchange
for senior convertible notes of $<span id="xdx_901_eus-gaap--ProceedsFromConvertibleDebt_pn5n6_c20231101__20231130__us-gaap--DebtInstrumentAxis__custom--SeniorConvertibleNotesMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zBMVzI03gT53"><ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="From2023-11-012023-11-30_custom_SeniorConvertibleNotesMember_custom_SecuritiesPurchaseAgreementMember" id="Fact001034" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.6</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million (plus accrued interest of $<span id="xdx_902_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_pn5n6_c20231130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zWkuosgJLyol"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" contextRef="AsOf2023-11-30_us-gaap_RelatedPartyMember_custom_SecuritiesPurchaseAgreementMember" id="Fact001035" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.1</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million) and <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20231101__20231130__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z3r0Tli7e5mb"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" contextRef="From2023-11-012023-11-30_custom_SecuritiesPurchaseAgreementMember_us-gaap_WarrantMember" id="Fact001036" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">95,745</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warrants to acquire common stock. <span id="xdx_909_eus-gaap--DebtInstrumentDescription_c20231101__20231130__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z4uH06NxL485"><ix:nonNumeric contextRef="From2023-11-012023-11-30_custom_SecuritiesPurchaseAgreementMember" id="Fact001037" name="us-gaap:DebtInstrumentDescription">The
senior secured notes are convertible to the conversion rate of $</ix:nonNumeric></span></span><span id="xdx_904_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20231130__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zo5virPJQB77" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2023-11-30_custom_SecuritiesPurchaseAgreementMember" id="Fact001038" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.00</ix:nonFraction>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per
share, and 92.5% of the lowest VWAP for the ten (10) trading days immediately preceding the conversion Date, subject to the floor price
of $1.14 (representing 20% of the closing price on the last trading day before the closing of the Business Combination), or the alternative
conversion ratio the greater of the floor price and the lesser of 80% of the VWAP of the common stock as of the trading day and 80% of
the price computed as the quotient of the sum of the VWAP of the Common Stock for each of the three Trading Days with the lowest VWAP
of the Common Stock during the fifteen consecutive trading day period ending and including the trading day immediately preceding the
delivery or deemed delivery of the applicable Conversion Notice, divided by three</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
All such determinations to be appropriately adjusted for any stock dividend, stock split, stock combination, reclassification or similar
transaction that proportionately decreases or increases the common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
warrants are classified as equity and the total proceeds received from the Directors are allocated based on the relative fair values
of the convertible notes and the warrants at the issued date. The portion allocable to warrants is accounted for as paid-in capital.
The senior secured convertible notes are classified as long term debt in the Consolidated Balance Sheet. The estimate fair value of the
senior secured convertible notes at December 31, 2023 was $<span id="xdx_90A_eus-gaap--SeniorNotesCurrent_iI_pn5n6_c20231231_z2qCGfNbO6v4"><ix:nonFraction name="us-gaap:SeniorNotesCurrent" contextRef="AsOf2023-12-31" id="Fact001039" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.2</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001041" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_808_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zwxSvY1JlXvj" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.
<span id="xdx_826_zgUaC2z4h9U3">Commitments, Contingencies, and Concentrations Operating lease</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has a month-to-month lease for a suite at a cost of $<span id="xdx_905_eus-gaap--OperatingLeaseCost_c20230101__20231231_zPWRhci46SQk"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2023-01-01to2023-12-31" id="Fact001042" format="ixt:numdotdecimal" decimals="0" unitRef="USD">575</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per month. The Company incurred $<span id="xdx_908_eus-gaap--OperatingLeasesRentExpenseNet_c20230101__20231231_zin38NTu1i35"><ix:nonFraction name="us-gaap:OperatingLeasesRentExpenseNet" contextRef="From2023-01-01to2023-12-31" id="Fact001043" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,695</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_909_eus-gaap--OperatingLeasesRentExpenseNet_c20220101__20221231_zCwDNKWtXxr1"><ix:nonFraction name="us-gaap:OperatingLeasesRentExpenseNet" contextRef="From2022-01-012022-12-31" id="Fact001044" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,694</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of rent expense, including common tenant
costs and cancellation costs, during the years ended December 31, 2023 and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001046" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_80F_eus-gaap--SubsequentEventsTextBlock_zJvyAX1Zop84" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.
<span id="xdx_82C_zUZBTByM5AI1">Subsequent Events</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has evaluated subsequent events occurring through April 9, 2024, the date the financial statements were available for issuance,
for events requiring recording or disclosure in the Company&#8217;s financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2024, through to the date of this report, the Company issued <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20241231__srt--StatementScenarioAxis__srt--ScenarioForecastMember__dei--LegalEntityAxis__custom--EFHuttonMember_zaAfsIKOPiMl"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-01-012024-12-31_srt_ScenarioForecastMember_custom_EFHuttonMember" id="Fact001047" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">256,944</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20241231__srt--StatementScenarioAxis__srt--ScenarioForecastMember__dei--LegalEntityAxis__custom--KingwoodCapitalPartnersLLCMember_zuM3Moi0ltog"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-01-012024-12-31_srt_ScenarioForecastMember_custom_KingwoodCapitalPartnersLLCMember" id="Fact001048" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,834</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of Common Stock to EF Hutton LLC
and Kingwood Capital Partners, LLC, respectively, as consideration for $<span id="xdx_903_eus-gaap--BusinessCombinationConsiderationTransferred1_pn5n6_c20240101__20241231__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zuOa4HNu8XSg"><ix:nonFraction name="us-gaap:BusinessCombinationConsiderationTransferred1" contextRef="From2024-01-012024-12-31_srt_ScenarioForecastMember" id="Fact001049" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.0</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million owed by the Company for underwriting
commission due at the closing of the Business Combination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2024, through to the date of this report, the Company bought back <span id="xdx_907_eus-gaap--StockRepurchasedDuringPeriodShares_c20240101__20241231__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zotKVRYt0Kbh"><ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodShares" contextRef="From2024-01-012024-12-31_srt_ScenarioForecastMember" id="Fact001050" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">187,745</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of Common Stock from a convertible
note holder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2024, through to the date of this report, the Company received $<span id="xdx_902_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20240101__20241231__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--MajorityShareholderMember_z3LcYbfqQwm3"><ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="From2024-01-012024-12-31_us-gaap_SubsequentEventMember_us-gaap_MajorityShareholderMember" id="Fact001051" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">from a majority shareholder for the purchase
of shares, and an additional $<span id="xdx_90A_eus-gaap--ProceedsFromRelatedPartyDebt_c20240101__20241231__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zz1aR5stuiD7"><ix:nonFraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="From2024-01-012024-12-31_srt_ScenarioForecastMember" id="Fact001052" format="ixt:numdotdecimal" decimals="0" unitRef="USD">300,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">treated as a shareholder loan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2024, through to the date of this report, the Company entered into a definitive securities purchase agreement with an institutional investor
providing up to&#160;$<span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn4n6_c20240101__20241231__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z10C4pdnNwd9"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="From2024-01-012024-12-31_us-gaap_SubsequentEventMember" id="Fact001053" format="ixt:numdotdecimal" decimals="-4" scale="6" unitRef="USD">4.54</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million&#160;in funding through a private
placement for the issuance of senior convertible notes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">As previously announced
on Form 8-K, on March 28, 2024, OneMedNet Corporation (the &#8220;Company&#8221;) <span style="background-color: white">entered into
a definitive securities purchase agreement (the &#8220;Securities Purchase Agreement&#8221;) with Helena Global Investment Opportunities
1 Ltd., an affiliate of Helena Partners Inc., a Cayman-Islands based advisor and investor providing for up to USD$</span>4.54 million
<span style="background-color: white">in funding through a private placement for the issuance of senior secured convertible notes (the
&#8220;Notes&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">As previously announced
on Form 8-K, on March 27, 2024, Paul J. Casey, Chief, Chief Executive Officer of the Company, notified the Company of his intention to
retire as Chief Executive Officer of the Company effective March 29, 2024. Mr. Casey will continue to serve as a member of the Board
of Directors (the &#8220;Board&#8221;) of the Company. In connection with Mr. Casey&#8217;s service on the Advisory Board of the Company,
the Board approved a Stock Option Grant (the &#8220;Option Grant&#8221;) providing for the grant of <span id="xdx_901_eus-gaap--StockRepurchasedDuringPeriodShares_c20240326__20240327__srt--StatementScenarioAxis__srt--ScenarioForecastMember__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zuUqsqqUT0Ph"><ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodShares" contextRef="From2024-03-262024-03-27_srt_ScenarioForecastMember_srt_BoardOfDirectorsChairmanMember" id="Fact001054" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">147,000</ix:nonFraction>
</span>five-year options exercisable at $<span id="xdx_90A_eus-gaap--SharePrice_iI_c20240327__srt--StatementScenarioAxis__srt--ScenarioForecastMember__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zm1HBlB7Oone"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-03-27_srt_ScenarioForecastMember_srt_BoardOfDirectorsChairmanMember" id="Fact001055" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction>
</span>per share adviser to Mr. Casey. Also on March 27, 2024, Scott Holbrook, a member of the Board of the Company and a member
of the Company&#8217;s Audit Committee, notified the Company of his intention to retire from the Company&#8217;s Board effective March
29, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Effective March 29, 2024,
the Board (i) appointed Mr. Aaron Green, to serve as Chief Executive Officer of the Company to fill the vacancy created by the retirement
of Paul Casey; (ii) appointed Mr. Aaron Green, to serve as a member of the Board to fill the vacancy created by the retirement of Scott
Holbrook; and (iii) appointed Board member, Dr. Thomas Kosasa, to serve on the Company&#8217;s Audit Committee, also to fill the vacancy
created by the retirement of Scott Holbrook.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

</ix:nonNumeric><p id="xdx_81F_zaZzrmNFRqz9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 90; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_021"></span>PART
II&#8212;INFORMATION NOT REQUIRED IN PROSPECTUS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
13. Other Expenses of Issuance and Distribution</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth all expenses, other than the underwriting discounts and commissions, payable by the registrant in connection
with the sale of the securities being registered. All the amounts shown are estimates except the SEC registration fee and the FINRA filing
fee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount
    to be paid</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 78%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SEC
    registration fee</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#160;&#160;&#160;]</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounting
    fees and expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal
    fees and expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Printing
    and engraving expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
    fees are calculated based on the securities offered and the number of issuances and accordingly cannot be determined at this time.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
14. Indemnification of Directors and Officers</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
102 of the General Corporation Law of the State of Delaware (the &#8220;DGCL&#8221;) permits a corporation to eliminate the personal
liability of directors of a corporation to the corporation or its stockholders for monetary damages for a breach of fiduciary duty as
a director, except where the director breached his duty of loyalty, failed to act in good faith, engaged in intentional misconduct or
knowingly violated a law, authorized the payment of a dividend or approved a stock repurchase in violation of Delaware corporate law
or obtained an improper personal benefit. Our Amended and Restated Certificate of Incorporation, as amended, provides that no director
of the Company shall be personally liable to it or its stockholders for monetary damages for any breach of fiduciary duty as a director,
notwithstanding any provision of law imposing such liability, except to the extent that the DGCL prohibits the elimination or limitation
of liability of directors for breaches of fiduciary duty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
145 of the DGCL provides that a corporation has the power to indemnify a director, officer, employee, or agent of the corporation, or
a person serving at the request of the corporation for another corporation, partnership, joint venture, trust or other enterprise in
related capacities against expenses (including attorneys&#8217; fees), judgments, fines and amounts paid in settlement actually and reasonably
incurred by the person in connection with an action, suit or proceeding to which he was or is a party or is threatened to be made a party
to any threatened, ending or completed action, suit or proceeding by reason of such position, if such person acted in good faith and
in a manner he reasonably believed to be in or not opposed to the best interests of the corporation, and, in any criminal action or proceeding,
had no reasonable cause to believe his conduct was unlawful, except that, in the case of actions brought by or in the right of the corporation,
no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable
to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines that, despite the
adjudication of liability but in view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnity
for such expenses which the Court of Chancery or such other court shall deem proper.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 91; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Amended and Restated Certificate of Incorporation, as amended, and Amended and Restated Bylaws provide indemnification for our directors
and officers to the fullest extent permitted by the DGCL. We will indemnify each person who was or is a party or threatened to be made
a party to any threatened, pending or completed action, suit or proceeding (other than an action by or in the right of us) by reason
of the fact that he or she is or was, or has agreed to become, a director or officer, or is or was serving, or has agreed to serve, at
our request as a director, officer, partner, employee or trustee of, or in a similar capacity with, another corporation, partnership,
joint venture, trust or other enterprise (all such persons being referred to as an &#8220;Indemnitee&#8221;), or by reason of any action
alleged to have been taken or omitted in such capacity, against all expenses (including attorneys&#8217; fees), judgments, fines and
amounts paid in settlement actually and reasonably incurred in connection with such action, suit or proceeding and any appeal therefrom,
if such Indemnitee acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, our best interests,
and, with respect to any criminal action or proceeding, he or she had no reasonable cause to believe his or her conduct was unlawful.
Our Amended and Restated Certificate of Incorporation, as amended, and Amended and Restated Bylaws will provide that we will indemnify
any Indemnitee who was or is a party to an action or suit by or in the right of us to procure a judgment in our favor by reason of the
fact that the Indemnitee is or was, or has agreed to become, a director or officer, or is or was serving, or has agreed to serve, at
our request as a director, officer, partner, employee or trustee of, or in a similar capacity with, another corporation, partnership,
joint venture, trust or other enterprise, or by reason of any action alleged to have been taken or omitted in such capacity, against
all expenses (including attorneys&#8217; fees) and, to the extent permitted by law, amounts paid in settlement actually and reasonably
incurred in connection with such action, suit or proceeding, and any appeal therefrom, if the Indemnitee acted in good faith and in a
manner he or she reasonably believed to be in, or not opposed to, our best interests, except that no indemnification shall be made with
respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to us, unless a court determines
that, despite such adjudication but in view of all of the circumstances, he or she is entitled to indemnification of such expenses. Notwithstanding
the foregoing, to the extent that any Indemnitee has been successful, on the merits or otherwise, he or she will be indemnified by us
against all expenses (including attorneys&#8217; fees) actually and reasonably incurred in connection therewith. Expenses must be advanced
to an Indemnitee under certain circumstances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have entered into separate indemnification agreements with each of our directors and executive officers. Each indemnification agreement
provide, among other things, for indemnification to the fullest extent permitted by law and our Amended and Restated Certificate of Incorporation,
as amended, and Amended and Restated Bylaws against any and all expenses, judgments, fines, penalties and amounts paid in settlement
of any claim. The indemnification agreements provide for the advancement or payment of all expenses to the indemnitee and for the reimbursement
to us if it is found that such indemnitee is not entitled to such indemnification under applicable law and our Amended and Restated Certificate
of Incorporation, as amended, and Amended and Restated Bylaws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also have a general liability insurance policy that covers certain liabilities of directors and officers of our corporation arising out
of claims based on acts or omissions in their capacities as directors or officers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
15. Recent Sales of Unregistered Securities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 28, 2023, the Company (formerly as Data Knights Acquisition Corp) and OneMedNet Solutions Corporation (formerly as OneMedNet Corporate)
entered into a Securities Purchase Agreement (the &#8220;SPA&#8221;) with certain investors (collectively referred to herein as the &#8220;Purchasers&#8221;)
for PIPE financing in the aggregate original principal amount of $1,595,744.70 and the purchase price of $1.5 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
immediately prior to the Closing on September 7, 2023, as provided under the SPA, the Company issued and sold to each of the Purchasers,
a new series of senior secured convertible notes (the &#8220;Pre-Closing PIPE Notes&#8221;), which are convertible into shares
of Common Stock at the Purchasers election at a conversion price equal to the lower of (i) $10.00 per share, and (ii) 92.5% of the lowest
volume weighted average trading price for the ten (10) Trading Days immediately preceding the Conversion Date. We deemed the offer, sale
and issuance of such securities to be exempt from registration under the Securities Act in reliance on Section 4(2) of the Securities
Act, including Regulation D and Rule 506 promulgated thereunder, relative to transactions by an issuer not involving a public offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 28, 2024, OneMedNet Corporation (the &#8220;Company&#8221;)&#160;<span>entered into a definitive
securities purchase agreement (the &#8220;Securities Purchase Agreement&#8221;) with Helena Global Investment Opportunities 1 Ltd. (the
&#8220;Investor&#8221;), an affiliate of Helena Partners Inc., a Cayman-Islands based advisor and investor providing for up to USD$</span>4.54
million&#160;<span style="background-color: white">in funding through a private placement for the issuance of senior secured convertible
notes (the &#8220;Notes&#8221;). </span>In connection with the issuance of the Notes, the Company will issue to the Investor common stock
purchase warrants (the &#8220;Warrants&#8221;) across multiple tranches (the &#8220;Tranches&#8221;) consisting of an initial tranche
(the &#8220;Initial Tranche&#8221;) of (i) an aggregate principal amount $2,000,000.00 and including an original issue discount (&#8220;OID&#8221;)
of up to an aggregate of $300,000.00 plus Warrants to purchase a number of shares of Common Stock equal to the applicable Warrant Share
Amounts (defined below). The second tranche (the &#8220;Second Tranche&#8221;) consists of an aggregate principal amount of Notes of
up to $350,000.00 and including an OID of up to $52,500.00 and Warrants to purchase a number of shares of Common Stock equal to the applicable
Warrant Share Amounts with respect to such Tranche. The Securities Purchase Agreement contemplates three subsequent Tranches each of
which shall be in an aggregate principal amount of Notes of up to $1,000,000 each and each including an OID of 15.0% of the applicable
principal amount, and Warrants to purchase a number of shares of Common Stock equal to the applicable Warrant Share Amounts with respect
to such Tranches.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
purchase price of a Note and its accompanying Warrant shall be computed by subtracting the portion of the OID represented by that such
Note from the portion of the principal amount represented by such Note (a &#8220;Purchase Price&#8221;). The Securities Purchase Agreement
defines Warrant Share Amounts means in respect of any Warrant issued in a Closing the initial amount of shares of Common Stock (the &#8220;Warrant
Shares&#8221;) for which such Warrant may be exercised and which shall be equal to the applicable principal amount of the Note issued
to the Investor in such closing multiplied by 50% and divided by the 95% of lowest VWAP over the ten Trading Day period immediately preceding
the applicable Closing Date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the closings of each Tranche, a portion of the proceeds will be held in escrow (the &#8220;Escrow&#8221;) pursuant to
an executed Escrow Agreement dated as of March 28, 2024 in accordance with the following: (i) $1,350,000.00 of the net proceeds of the
Initial Tranche will be paid into the Escrow Account for distribution in accordance with the release of proceeds conditions (the &#8220;Release
Conditions&#8221; discussed below), with the balance of the net proceeds paid to the Company less initial closing expenses relating to
such Initial Tranche; (ii) 100% of the net proceeds of the Third Tranche shall be paid into the Escrow Account for distribution in accordance
with the Release Conditions; and (iii) 75% of the net proceeds of the Third Tranche shall be paid into the Escrow Account for distribution
in accordance with the Release Conditions with the balance of the net proceeds of the Third Tranche being paid to the Company less initial
closing expenses relating to such Third Tranche.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
16. Exhibits and Financial Statement Schedules</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXHIBIT
INDEX</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit
    No.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title
    of Document</b></span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1&#8224;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agreement
    and Plan of Merger, dated April 25, 2022, by and among Data Knights, Merger Sub, Sponsor, OneMedNet, and Paul Casey.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="ex3-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third Amended and Restated Certificate of Incorporation of OneMedNet Corporation.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="ex3-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Bylaws of OneMedNet Corporation.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex4-1.htm">Warrant
    Agreement, dated May 6, 2021, by and between Continental Stock Transfer &amp; Trust Company and Data Knights Acquisition Corp.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="ex4-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Specimen Unit Certificate of Data Knights Acquisition Corp.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="ex4-3.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Specimen Class A Common Stock Certificate of Data Knights Acquisition Corp.</span></a></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 92; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="ex4-4.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Specimen Warrant Certificate of Data Knights Acquisition Corp.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1*+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="ex10-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of OneMedNet Corporation 2022 Equity Incentive Plan.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex10-2.htm">Form of Registration Rights Agreement by certain OneMedNet equity holders.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex10-3.htm">Lockup Agreement by certain OneMedNet equity holders.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="ex10-4.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sponsor Lock-up Agreement.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="ex10-5.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Letter Agreement, dated May 6, 2021, by and between Data Knights, the initial security holders and the officers and directors of the Data Knights.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1849380/000110465922049684/tm2213454d1_ex2-1.htm" style="-sec-extract: exhibit">Voting Agreement incorporated by reference to Form 8-K filed April 25, 2022 which is included as Appendix A to Exhibit 2.2.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="ex10-7.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sponsor Support Agreement dated as of April 25, 2022.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8*+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="ex10-8.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment Agreement between OneMedNet Corporation and Aaron Green, President.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9*+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="ex10-9.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment Agreement between OneMedNet Corporation and Lisa Embree, Chief Financial Officer.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10</span>*</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="ex10-10.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities Purchase Agreement dated June 28, 2023 with OneMedNet Corporation.</span></a></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex10-11.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities Purchase Agreement entered into as of March 28, 2024, by and between OneMedNet Corporation and each investor identified on the signature pages thereto.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex10-12.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registration Rights Agreement dated as of March 28, 2024, by and among OneMedNet Corporation and each of the investors to the Securities Purchase Agreement.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex10-13.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subscription Escrow Agreement effective March 28, 2024, by and among OneMedNet Corporation, each investor identified on the signature pages thereto, and Rimon, P.C., as the Escrow Agent.</span></a></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="ex14-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Code of Ethics</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="ex21-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsidiaries of the Registrant incorporated by reference to Exhibit 21.1 to the Company&#8217;s Form S-4, filed with the SEC on September 21, 2023).</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><a href="ex23-1.htm">Consent of BF Borgers CPA PC.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top">24</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="#poa_1">Power of Attorney (included on signature page hereto).</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top">107*</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="ex107.htm">Filing Fee Table</a></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">*</td>
    <td style="font: 10pt Times New Roman, Times, Serif">Filed herewith</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 97%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicates
    a management or compensatory plan.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8224;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedules
    to this exhibit have been omitted pursuant to Item 601(b)(2) of Registration S-K. The Registrant hereby agrees to furnish a copy
    of any omitted schedules to the SEC upon request.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 93; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
17. Undertakings</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned registrant hereby undertakes:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    include any prospectus required by section 10(a)(3) of the Securities Act of 1933;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent
    post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set
    forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if
    the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end
    of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b)
    if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set
    forth in the &#8220;Calculation of Registration Fee&#8221; table in the effective registration statement.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
                                            include any material information with respect to the plan of distribution not previously
                                            disclosed in the registration statement or any material change to such information in the
                                            registration statement; provided, however, that paragraphs (i), (ii) and (iii) do not apply
                                            if the registration statement is on Form S-1 <span style="background-color: white">and the
                                            information required to be included in a post-effective amendment by those paragraphs is
                                            contained in reports filed with or furnished to the Commission by the registrant pursuant
                                            to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 that are incorporated
                                            by reference in the registration statement, or is contained in a form of prospectus filed
                                            pursuant to Rule 424(b) that is part of the registration statement;</span></span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">That,
    for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed
    to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall
    be deemed to be the initial bona fide offering thereof.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the
    termination of the offering.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">That,
    for the purpose of determining liability under the Securities Act of 1933 to any purchaser: each prospectus filed pursuant to Rule
    424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other
    than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of
    the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus
    that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration
    statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior
    to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the
    registration statement or made in any such document immediately prior to such date of first use; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">That,
    for the purpose of determining liability of the registrant under the Securities Act of 1933 to any purchaser in the initial distribution
    of the securities: the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant
    to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities
    are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller
    to the purchaser and will be considered to offer or sell such securities to such purchaser:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule
    424;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by
    the undersigned registrant;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant
    or its securities provided by or on behalf of the undersigned registrant; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    other communication that is an offer in the offering made by the undersigned registrant to the purchaser.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insofar
    as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling
    persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion
    of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act of 1933
    and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment
    by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense
    of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities
    being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent,
    submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed
    in the Act and will be governed by the final adjudication of such issue.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>


<!-- Field: Page; Sequence: 94; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Act of 1933, as amended, the registrant has duly caused this Registration Statement on Form S-1
to be signed on its behalf by the undersigned, thereunto duly authorized on the 6<sup>th</sup> day of May 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ONEMEDNET
    CORPORATION</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Aaron Green</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aaron
    Green</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Chief
    Executive Officer and Director</i></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="poa_1"></span>KNOW
ALL MEN BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Carol Craig, his or her true and lawful
attorney-in-fact and agent with full power of substitution and re-substitution, for him or her and in his or her name, place and stead,
in any and all capacities to sign any or all amendments (including, without limitation, post-effective amendments) to this Registration
Statement, any related Registration Statement filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended, and any or
all pre- or post-effective amendments thereto, and to file the same, with all exhibits thereto, and all other documents in connection
therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent, full power and authority to do
and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully for all intents and purposes
as he or she might or could do in person, hereby ratifying and confirming that said attorney-in-fact and agent, or any substitute or
substitutes for him, may lawfully do or cause to be done by virtue hereof. Pursuant to the requirements of the Securities Act of 1933,
as amended, the following persons in the capacities and on the dates indicated have signed this Registration Statement below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Act of 1933, as amended, this Registration Statement on Form S-1 has been signed by the following
persons in the capacities and on the dates indicated below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 35%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Signature</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 42%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 19%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Aaron Green</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer (Principal Executive Officer) and Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
    6,</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> 2024</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aaron
    Green</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Lisa Embree</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
    6,</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> 2024</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lisa
    Embree</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Financial and Accounting Officer)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    <span style="letter-spacing: 0.2pt">Dr. Jeffrey Yu</span></i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: 0.2pt">Chairman
    of the Board of Directors, Founder, Chief Medical Officer, Vice President</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
    6,</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> 2024</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: 0.2pt"><i>Dr.
    Jeffrey Yu</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    <span style="letter-spacing: 0.2pt">Erkan Akyuz</span></i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May_6,</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> 2024</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: 0.2pt">Erkan
    Akyuz</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    <span style="letter-spacing: 0.2pt">Eric Casaburi</span></i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
    6,</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> 2024</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: 0.2pt">Eric
    Casaburi</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: 0.2pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    <span style="letter-spacing: 0.2pt">Robert Golden</span></i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
    6,</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> 2024</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: 0.2pt">Robert
    Golden</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    <span style="letter-spacing: 0.2pt">Dr. Julianne Huh</span></i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
    6,</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> 2024</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: 0.2pt">Dr.
    Julianne Huh</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    <span style="letter-spacing: 0.2pt">Dr. Thomas Kosasa</span></i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
    6,</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> 2024</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: 0.2pt">Dr.
    Thomas Kosasa</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: 0.2pt"><i>/s/
    Paul J. Casey</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
    6,</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> 2024</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: 0.2pt">Paul
    J. Casey</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<!-- Field: Page; Sequence: 95; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>ex3-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
3.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>THIRD
AMENDED AND RESTATED</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATE
OF INCORPORATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OF</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ONEMEDNET CORPORATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>November
8, 2023</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OneMedNet
Corporation, a corporation organized and existing under the laws of the State of Delaware (the &ldquo;<B><I>Corporation</I></B>&rdquo;),
DOES HEREBY CERTIFY AS FOLLOWS:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
The name of the Corporation is &ldquo;Data Knights Acquisition Corp&rdquo; and hereby changes its name to &ldquo;OneMedNet Corporation&rdquo;
The original certificate of incorporation of the Corporation was filed with the Secretary of State of the State of Delaware on February
8, 2021, was amended and restated on March 8, 2021 by the First Amended and Restated Certificate, and was amended and restated on April
6, 2021 by the Second Amended and Restated Certificate, which Second Amended and Restated Certificate was further amended by the First
Amendment to the Second Amended and Restated Certificate on November 11, 2022 and the Second Amendment to the Second Amended and Restated
Certificate on August 11, 2023 (the &ldquo;<B><I>Certificate</I></B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
This Third Amended and Restated Certificate of Incorporation (this &ldquo;<B><I>Third Amended and Restated Certificate</I></B>&rdquo;),
which both restates and amends the provisions of the Certificate, was duly adopted in accordance with Sections 228, 242 and 245 of the
General Corporation Law of the State of Delaware, as amended from time to time (the &ldquo;<B><I>DGCL</I></B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
This Third Amended and Restated Certificate shall become effective on the date of filing with Secretary of State of Delaware.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
The texts of the Certificate, as amended to the date hereof, is hereby restated and amended in their entirety to read as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
I</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NAME</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
name of the corporation is OneMedNet Corporation (the &ldquo;<B><I>Corporation</I></B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
II</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PURPOSE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
purpose of the Corporation is to engage in any lawful act or activity for which a corporation may be organized under the General Corporation
Law of the State of Delaware (the &ldquo;<B><I>DGCL</I></B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
III</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REGISTERED
OFFICE AND AGENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
address of the Corporation&rsquo;s registered office in the State of Delaware is 1209 Orange Street, Corporation Trust Center, City of
Wilmington, County of New Castle, 19801. The name of its registered agent at that address is The Corporation Trust Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
IV</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CAPITAL
STOCK</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
4.1</B> The total number of shares of all classes of capital stock, each with a par value of $0.0001 per share, which the Corporation
is authorized to issue is 101,000,000 shares, consisting of (a) 100,000,000 shares of common stock (the &ldquo;<B><I>Common Stock</I></B>&rdquo;),
(b) 1,000,000 shares of preferred stock (the &ldquo;<B><I>Preferred Stock</I></B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">&nbsp;</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
4.2</B> Shares of Preferred Stock may be issued from time to time in one or more classes or series. The Board of Directors of the Corporation
(the &ldquo;<B><I>Board of Directors</I></B>&rdquo;) is hereby authorized to provide from time to time by resolution or resolutions for
the creation and issuance, out of the authorized and unissued shares of Preferred Stock, of one or more classes or series of Preferred
Stock by filing a certificate (a &ldquo;<B><I>Certificate of Designation</I></B>&rdquo;) pursuant to the DGCL, setting forth such resolution
and, with respect to each such series, establishing the designation of such class or series and the number of shares to be included in
such class or series and fixing the voting powers (full or limited, or no voting power), preferences and relative, participating, optional
or other special rights, and the qualifications, limitations and restrictions thereof, of the shares of each such class or series. Without
limiting the generality of the foregoing, the resolution or resolutions providing for the establishment of any class or series of Preferred
Stock may, to the extent permitted by law, provide that such class or series shall be superior to, rank equally with or be junior to
the Preferred Stock of any other class or series. The powers, preferences and relative, participating, optional and other special rights
of each class or series of Preferred Stock, and the qualifications, limitations, or restrictions thereof, if any, may be different from
those of any and all other classes or series at any time outstanding. Except as otherwise expressly provided in the resolution or resolutions
providing for the establishment of any class or series of Preferred Stock, no vote of the holders of shares of Preferred Stock or Common
Stock shall be a prerequisite to the issuance of any shares of any class or series of the Preferred Stock so authorized in accordance
with this Third Amended and Restated Certificate. Unless otherwise provided in the Certificate of Designation establishing a class or
series of Preferred Stock, the Board of Directors may, by resolution or resolutions, increase or decrease (but not below the number of
shares of such class or series then outstanding) the number of shares of such class or series and, if the number of shares of such class
or series shall be so decreased, the shares constituting such decrease shall resume the status that they had prior to the adoption of
the resolution originally fixing the number of shares of such class or series.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
4.3</B> The Corporation has the authority to create and issue rights, warrants, and options entitling the holders thereof to purchase
shares of any class or series of the Corporation&rsquo;s capital stock or other securities of the Corporation, and such rights, warrants
and options shall be evidenced by or in instrument(s) approved by the Board of Directors. The Board of Directors is empowered to set
the exercise price, duration, times for exercise and other terms and conditions of such rights, warrants or options; provided, however,
that the consideration to be received for any shares of capital stock subject thereto may not be less than the par value thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
4.4</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Except as otherwise required by law or this Third Amended and Restated Certificate (or any Certificate of Designation made hereunder),
the holders of Common Stock shall exclusively possess all voting power with respect to the Corporation. The holders of shares of Common
Stock shall be entitled to one vote for each such share on each matter properly submitted to the stockholders on which the holders of
the Common Stock are entitled to vote. The holders of shares of the Common Stock shall at all times vote together as one class on all
matters submitted to a vote of the stockholders of the Corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Except as otherwise required by law or this Third Amended and Restated Certificate (or any Certificate of Designation made hereunder),
at any annual or special meetings of the stockholders of the Corporation, the holders of the Common Stock shall have the exclusive right
to vote for the election of directors and on all other matters properly submitted to a vote of the stockholders. Notwithstanding the
foregoing, except as otherwise required by law or this Third Amended and Restated Certificate (or any Certificate of Designation made
hereunder), the holders of the Common Stock shall not be entitled to vote on any amendment to this Third Amended and Restated Certificate
(or any Certificate of Designation made hereunder) that relates solely to the terms of one or more outstanding class or series of the
Preferred Stock if the holders of such affected class or series of Preferred Stock are entitled, either separately or together with the
holders of one or more other such class or series, to vote thereon pursuant to this Third Amended and Restated Certificate (or any Certificate
of Designation made hereunder) or the DGCL.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Subject to applicable law and the rights, if any, of the holders of any outstanding class or series of the Preferred Stock, the holders
of the shares of the Common Stock shall be entitled to receive such dividends and other distributions (payable in cash, property or capital
stock of the Corporation) when, as and if declared thereon by the Board from time to time out of any assets or funds of the Corporation
legally available therefor, and shall share equally on a per share basis in such dividends and distributions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Subject to applicable law and the rights, if any, of the holders of any outstanding class or series of the Preferred Stock, in the event
of any voluntary or involuntary liquidation, dissolution or winding-up of the Corporation, after payment or provision for payment of
the debts and other liabilities of the Corporation, the holders of the shares of the Common Stock shall be entitled to receive all the
remaining assets of the Corporation available for distribution to its stockholders, ratably in proportion to the number of shares of
the Common Stock held by them.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">&nbsp;</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
V</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BOARD
OF DIRECTORS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the management of the business and for the conduct of the affairs of the Corporation it is further provided that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
5.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
The management of the business and the conduct of the affairs of the Corporation shall be vested in the Board of Directors. The number
of directors of the Corporation shall be nine (9), which number may be increased or decreased by one or more resolutions adopted from
time to time by the Board of Directors, subject to Sections 5.1(c) and 5.1(d). The Board of Directors shall be classified, with respect
to the term for which the directors hold office, into three classes, one class serving for a term expiring at the annual meeting of stockholders
to be held in 2023, the second class serving for a term expiring at the annual meeting of stockholders to be held in 2024, and the third
class serving for a term expiring at the annual meeting of stockholders to be held in 2025. At each annual meeting of stockholders, directors
elected to succeed those directors whose terms expire shall be elected for a term of office to expire at the third succeeding annual
meeting of stockholders after their election. Notwithstanding the foregoing, the directors elected to each class shall hold office until
their successors are duly elected and qualified or until their earlier resignation, death, or removal. If the number of directors is
hereafter changed, any newly created directorships or decrease in directorships shall be so apportioned among the classes as to make
all classes as nearly equal in number as is practicable, provided that no decrease in the number of directors constituting the entire
Board shall shorten the term of any incumbent director. No reduction in the number of directors shall cause the removal of any director
from office prior to the expiration of his or her term.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Except as may otherwise be provided in the terms of any Preferred Stock issued by the Corporation, the Board of Directors or any individual
director may be removed from office at any time but only by the affirmative vote of the holders of at least a majority of the voting
power of all of the then outstanding shares of voting stock of the Corporation with the power to vote at an election of directors (the
&ldquo;<B><I>Voting Stock</I></B>&rdquo;) and, in addition to and without limitation of the foregoing only for cause.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Except as may otherwise be provided in the terms of any Preferred Stock issued by the Corporation and subject to Section 5.1(d) below,
any vacancies on the Board of Directors resulting from death, resignation, disqualification, retirement, removal or other causes and
any newly created directorships resulting from any increase in the number of directors shall, unless the Board of Directors determines
by resolution that any such vacancies or newly created directorships shall be filled by the stockholders, and except as otherwise provided
by law, be filled only by the affirmative vote of a majority of the directors then in office, even though less than a quorum, or by a
sole remaining director, and shall not be filled by the stockholders. Any director appointed in accordance with the preceding sentence
shall hold office for a term that shall coincide with the remaining term of the vacancy to which the director shall have been appointed
and until such director&rsquo;s successor shall have been elected and qualified or until his or her earlier death, resignation, disqualification,
retirement, or removal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Effective as of the date of filing of this Third Amended and Restated Certificate, the Board of Directors of the Corporation shall consist
of nine (9) members, constituted as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
in the director class whose term expires at the annual meeting held in 2023, three (3) directors nominated by OneMedNet Technologies
Corporation, f/k/a OneMedNet Corporation, a Delaware corporation (&ldquo;OneMedNet Technologies&rdquo;), one of whom shall qualify as
an independent director under the rules of The Nasdaq Stock Market (an &ldquo;<B><I>Independent Director</I></B>&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
in the director class whose term expires at the annual meeting held in 2024, (A) two (2) directors designated by OneMedNet Technologies,
one (1) of whom shall be an Independent Director, and (B) one (1) director designated by Data Knights, LLC, a Delaware limited liability
company and the Corporation&rsquo;s sponsor (the &ldquo;<B><I>Sponsor</I></B>&rdquo;), who shall be an Independent Director; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
in the director class whose term expires at the annual meeting held in 2025, (A) two (2) directors designated by OneMedNet Technologies,
one (1) of whom shall be an Independent Director, and (B) one (1) director designated by the Sponsor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">&nbsp;</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
5.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
In furtherance and not in limitation of the powers conferred by statute, the Board of Directors is expressly authorized to adopt, amend,
alter, or repeal the Bylaws of the Corporation. In addition to any vote of the holders of any class or series of stock of the Corporation
required by applicable law or by this Third Amended and Restated Certificate (including any Certificate of Designation in respect of
one or more classes or series of Preferred Stock), the adoption, amendment or repeal of the Bylaws of the Corporation by the stockholders
of the Corporation shall require the affirmative vote of the holders of at least sixty-six and two-thirds percent (66-2/3%) of the voting
power of all the then-outstanding shares of the Voting Stock, voting together as a single class; provided that no Bylaws hereafter adopted
by the stockholders of the Corporation shall invalidate any prior act of the Board of Directors that would have been valid if such Bylaws
had not been adopted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
The directors of the Corporation need not be elected by written ballot unless the Bylaws so provide.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
VI</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>STOCKHOLDERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
6.1 </B>Subject to the special rights of the holders of one or more classes or series of Preferred Stock, any action required or permitted
to be taken by the stockholders of the Corporation must be effected at a duly called annual or special meetings of the stockholders of
the Corporation, and the taking of any action by written consent of the stockholders in lieu of a meeting of the stockholders is specifically
denied.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
6.2 </B>Subject to the special rights of the holders of one or more classes or series of Preferred Stock, special meetings of the stockholders
of the Corporation may be called, for any purpose or purposes as is a proper matter for stockholder action under the DGCL, by (i) the
Chairperson of the Board of Directors, (ii) the Chief Executive Officer, or (iii) the Board of Directors pursuant to a resolution adopted
by a majority of the total number of authorized directors (whether or not there exist any vacancies in previously authorized directorships
at the time any such resolution is presented to the Board of Directors for adoption). Such special meetings may not be called by stockholders
or any other person or persons.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
6.3 </B>Advance notice of stockholder nominations for the election of directors and of other business proposed to be brought by stockholders
before any meeting of the stockholders of the Corporation shall be given in the manner provided in the Bylaws of the Corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
VII</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>LIABILITY
AND INDEMNIFICATION; CORPORATE OPPORTUNITY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
7.1 </B>To the fullest extent permitted by the DGCL, as the same exists or as may hereafter be amended, a director of the Corporation
shall not be personally liable to the Corporation or its stockholders for monetary damages for breach of fiduciary duty as a director.
If the DGCL is amended after approval by the stockholders of this Article VII to authorize corporate action further eliminating or limiting
the personal liability of directors, then the liability of a director of the Corporation shall be eliminated or limited to the fullest
extent permitted by the DGCL as so amended, automatically and without further action, upon the date of such amendment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
7.2 </B>The Corporation, to the fullest extent permitted by law, shall indemnify and advance expenses to any person made or threatened
to be made a party to an action, suit or proceeding, whether criminal, civil, administrative or investigative, by reason of the fact
that he or she, or his or her testator or intestate, is or was a director or officer of the Corporation or any predecessor of the Corporation,
or serves or served at any other enterprise as a director or officer at the request of the Corporation or any predecessor to the Corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
7.3 </B>The Corporation, to the fullest extent permitted by law, may indemnify and advance expenses to any person made or threatened
to be made a party to an action, suit or proceeding, whether criminal, civil, administrative or investigative, by reason of the fact
that he or she, or his or her testator or intestate, is or was an employee or agent of the Corporation or any predecessor of the Corporation,
or serves or served at any other enterprise as an employee or agent at the request of the Corporation or any predecessor to the Corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">&nbsp;</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
7.4 </B>Neither any amendment nor repeal of this Article VII, nor the adoption by amendment of this Third Amended and Restated Certificate
of any provision inconsistent with this Article VII, shall eliminate or reduce the effect of this Article VII in respect of any matter
occurring, or any action or proceeding accruing or arising (or that, but for this Article VII, would accrue or arise) prior to such amendment
or repeal or adoption of an inconsistent provision.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
VIII</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BUSINESS
COMBINATIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
8.1 </B>The Corporation will be subject to Section 203 of the DGCL.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
8.2 </B>Notwithstanding Section 8.1, the Corporation shall not engage in any business combination (as defined below), at any point in
time at which the Corporation&rsquo;s common stock is registered under Section 12(b) or 12(g) of the Exchange Act, with any interested
stockholder (as defined below) for a period of three years following the time that such stockholder of the Corporation became an interested
stockholder, unless:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
prior to such time, the Board approved either the business combination or the transaction which resulted in the stockholder becoming
an interested stockholder, or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder
owned at least 85% of the voting stock (as defined below) of the Corporation outstanding at the time the transaction commenced, excluding
for purposes of determining the voting stock outstanding (but not the outstanding voting stock owned by the interested stockholder) those
shares owned by (i) persons who are directors and also officers of the Corporation or (ii) employee stock plans in which employee participants
do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer,
or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
at or subsequent to such time, the business combination is approved by the Board and authorized at an annual or special meeting of stockholders,
and not by written consent, by the affirmative vote of at least 662&#8725;3% of the outstanding voting stock of the Corporation which
is not owned by the interested stockholder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
8.3</B> For the purposes of this Article VIII:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
&ldquo;affiliate&rdquo; means a person that directly, or indirectly through one or more intermediaries, controls, or is controlled by,
or is under common control with, another person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
&ldquo;associate,&rdquo; when used to indicate a relationship with any person, means: (i) any corporation, partnership, unincorporated
association or other entity of which such person is a director, officer or partner or is, directly or indirectly, the owner of 20% or
more of any class of voting stock; (ii) any trust or other estate in which such person has at least a 20% beneficial interest or as to
which such person serves as trustee or in a similar fiduciary capacity; and (iii) any relative or spouse of such person, or any relative
of such spouse, who has the same residence as such person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
&ldquo;business combination,&rdquo; when used in reference to the Corporation and any interested stockholder, means:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
any merger or consolidation of the Corporation or any direct or indirect majority-owned subsidiary of the Corporation (A) with the interested
stockholder, or (B) with any other corporation, partnership, unincorporated association or other entity if the merger or consolidation
is caused by the interested stockholder and as a result of such merger or consolidation Article XI is not applicable to the surviving
entity;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
any sale, lease, exchange, mortgage, pledge, transfer or other disposition (in one transaction or a series of transactions), except proportionately
as a stockholder of the Corporation, to or with the interested stockholder, whether as part of a dissolution or otherwise, of assets
of the Corporation or of any direct or indirect majority-owned subsidiary of the Corporation which assets have an aggregate market value
equal to 10% or more of either the aggregate market value of all the assets of the Corporation determined on a consolidated basis or
the aggregate market value of all the outstanding stock of the Corporation;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
any transaction which results in the issuance or transfer by the Corporation or by any direct or indirect majority-owned subsidiary of
the Corporation of any stock of the Corporation or of such subsidiary to the interested stockholder, except: (A) pursuant to the exercise,
exchange or conversion of securities exercisable for, exchangeable for or convertible into stock of the Corporation or any such subsidiary
which securities were outstanding prior to the time that the interested stockholder became such; (B) pursuant to a merger under Section
251(g) of the DGCL; (C) pursuant to a dividend or distribution paid or made, or the exercise, exchange or conversion of securities exercisable
for, exchangeable for or convertible into stock of the Corporation or any such subsidiary which security is distributed, pro rata to
all holders of a class or series of stock of the Corporation subsequent to the time the interested stockholder became such; (D) pursuant
to an exchange offer by the Corporation to purchase stock made on the same terms to all holders of said stock; or (E) any issuance or
transfer of stock by the Corporation; provided, however, that in no case under items (C)-(E) of this subsection (iii) shall there be
an increase in the interested stockholder&rsquo;s proportionate share of the stock of any class or series of the Corporation or of the
voting stock of the Corporation (except as a result of immaterial changes due to fractional share adjustments);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">&nbsp;</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
any transaction involving the Corporation or any direct or indirect majority-owned subsidiary of the Corporation which has the effect,
directly or indirectly, of increasing the proportionate share of the stock of any class or series, or securities convertible into the
stock of any class or series, of the Corporation or of any such subsidiary which is owned by the interested stockholder, except as a
result of immaterial changes due to fractional share adjustments or as a result of any purchase or redemption of any shares of stock
not caused, directly or indirectly, by the interested stockholder; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
any receipt by the interested stockholder of the benefit, directly or indirectly (except proportionately as a stockholder of the Corporation),
of any loans, advances, guarantees or pledges (other than those expressly permitted in subsections (i)-(iv) above) provided by or through
the Corporation or any direct or indirect majority-owned subsidiary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
&ldquo;control,&rdquo; including the terms &ldquo;controlling,&rdquo; &ldquo;controlled by&rdquo; and &ldquo;under common control with,&rdquo;
means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a person,
whether through the ownership of voting stock, by contract, or otherwise. A person who is the owner of 20% or more of the outstanding
voting stock of the Corporation, partnership, unincorporated association or other entity shall be presumed to have control of such entity,
in the absence of proof by a preponderance of the evidence to the contrary. Notwithstanding the foregoing, a presumption of control shall
not apply where such person holds voting stock, in good faith and not for the purpose of circumventing this Article VIII, as an agent,
bank, broker, nominee, custodian or trustee for one or more owners who do not individually or as a group have control of such entity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
&ldquo;interested stockholder&rdquo; means any person (other than the Corporation or any direct or indirect majority-owned subsidiary
of the Corporation) that (i) is the owner of 15% or more of the outstanding voting stock of the Corporation, or (ii) is an affiliate
or associate of the Corporation and was the owner of 15% or more of the outstanding voting stock of the Corporation at any time within
the three year period immediately prior to the date on which it is sought to be determined whether such person is an interested stockholder,
and the affiliates and associates of such person; provided, however, that the term &ldquo;interested stockholder&rdquo; shall not include
(A) the Principal Stockholder or Principal Stockholder Transferees or any &ldquo;group&rdquo; (within
the meaning of Rule 13d-5 of the Exchange Act) that includes any Principal Stockholder or Principal Stockholder Transferee or (B) any
person whose ownership of shares in excess of the 15% limitation set forth herein is the result of any action taken solely by the Corporation;
provided that such person specified in this clause (B) shall be an interested stockholder if thereafter such person acquires additional
shares of voting stock of the Corporation, except as a result of further corporate action not caused, directly or indirectly, by such
person. For the purpose of determining whether a person is an interested stockholder, the voting stock of the Corporation deemed to be
outstanding shall include stock deemed to be owned by the person through application of the definition of &ldquo;owner&rdquo; below but
shall not include any other unissued stock of the Corporation which may be issuable pursuant to any agreement, arrangement or understanding,
or upon exercise of conversion rights, warrants or options, or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
&ldquo;owner,&rdquo; including the terms &ldquo;own&rdquo; and &ldquo;owned,&rdquo; when used with respect to any stock, means a person
that individually or with or through any of its affiliates or associates:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">&nbsp;</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
beneficially owns such stock, directly or indirectly; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
has (A) the right to acquire such stock (whether such right is exercisable immediately or only after the passage of time) pursuant to
any agreement, arrangement or understanding, or upon the exercise of conversion rights, exchange rights, warrants or options, or otherwise;
provided, however, that a person shall not be deemed the owner of stock tendered pursuant to a tender or exchange offer made by such
person or any of such person&rsquo;s affiliates or associates until such tendered stock is accepted for purchase or exchange; or (B)
the right to vote such stock pursuant to any agreement, arrangement or understanding; provided, however, that a person shall not be deemed
the owner of any stock because of such person&rsquo;s right to vote such stock if the agreement, arrangement or understanding to vote
such stock arises solely from a revocable proxy or consent given in response to a proxy or consent solicitation made to ten or more persons;
or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
has any agreement, arrangement or understanding for the purpose of acquiring, holding, voting (except voting pursuant to a revocable
proxy or consent as described in item (B) of subsection (ii) above), or disposing of such stock with any other person that beneficially
owns, or whose affiliates or associates beneficially own, directly or indirectly, such stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
&ldquo;person&rdquo; means any individual, corporation, partnership, unincorporated association or other entity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
&ldquo;stock&rdquo; means, with respect to any corporation, capital stock and, with respect to any other entity, any equity interest.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
&ldquo;Principal Stockholder&rdquo; means, collectively, (i) the Sponsor and (ii) any affiliate or successor of a person referenced in
clauses (i) and (ii) of this definition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)
&ldquo;Principal Stockholder Transferee&rdquo; means any Person who acquires voting stock of the Corporation from the Principal Stockholder
(other than in connection with a public offering) and who is designated in writing by the Principal Stockholder as a &ldquo;Principal
Stockholder Transferee.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)
&ldquo;voting stock&rdquo; means stock of any class or series entitled to vote generally in matters submitted for stockholders&rsquo;
approval other than the election of directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
IX</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXCLUSIVE
FORUM</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
9.1 </B>Unless the Corporation consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware
shall, to the fullest extent permitted by law, be the sole and exclusive forum for (a) any derivative action or proceeding brought on
behalf of the Corporation, (b) any action asserting a claim of breach of fiduciary duty owed by any director, officer, employee, agent
or stockholder of the Corporation to the Corporation or the Corporation&rsquo;s stockholders, creditors or other constituents, (c) any
action asserting a claim arising pursuant to any provision of the DGCL or this Third Amended and Restated Certificate or the Bylaws of
the Corporation, or (d) any action asserting a claim governed by the internal affairs doctrine, in each case subject to said Court of
Chancery having personal jurisdiction over the indispensable parties named as defendants therein; provided that suits brought to enforce
any liability or duty created by the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, or any other
claim for which the federal courts have exclusive jurisdiction, shall be brought in the federal district court for the district of Delaware;
and provided further that, if and only if the Court of Chancery of the State of Delaware dismisses any such action for lack of subject
matter jurisdiction, such action may be brought in another state or federal court sitting in the State of Delaware. To the fullest extent
permitted by applicable law, any person or entity purchasing or otherwise acquiring or holding any interest in shares of capital stock
of the Corporation shall be deemed to have notice of and consented to the provisions of this Article VIII. Notwithstanding any other
provisions of law, this Third Amended and Restated Certificate or the Bylaws of the Corporation, and notwithstanding the fact that a
lesser percentage may be specified by law, the affirmative vote of the holders of at least two-thirds in voting power of the outstanding
shares of capital stock of the Corporation entitled to vote thereon shall be required to amend or repeal, or to adopt any provision inconsistent
with, this Article VIII. If any provision or provisions of this Article VIII shall be held to be invalid, illegal or unenforceable as
applied to any person or entity or circumstance for any reason whatsoever, then, to the fullest extent permitted by law, the validity,
legality and enforceability of such provisions in any other circumstance and of the remaining provisions of this Article VIII (including,
without limitation, each portion of any sentence of this Article VIII containing any such provision held to be invalid, illegal or unenforceable
that is not itself held to be invalid, illegal or unenforceable) and the application of such provision to other persons or entities and
circumstances shall not in any way be affected or impaired thereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">&nbsp;</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
9.2 </B>If any action the subject matter of which is within the scope of Section 9.1 is filed in a court other than within the State
of Delaware (a &ldquo;<B><I>Foreign Action</I></B>&rdquo;) in the name of any stockholder, such stockholder shall be deemed to have consented
to (i) the personal jurisdiction of the state and federal courts of the State of Delaware in connection with any action brought in any
such court to enforce Section 9.1 (an &ldquo;<B><I>FSC Enforcement Action</I></B>&rdquo;) and (ii) having service of process made upon
such stockholder in any such FSC Enforcement Action by service upon such stockholder&rsquo;s counsel in the Foreign Action as agent for
such stockholder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
9.3 </B>If any provision or provisions of this Article VIII shall be held to be invalid, illegal or unenforceable as applied to any person
or entity or circumstance for any reason whatsoever, then, to the fullest extent permitted by law, the validity, legality and enforceability
of such provisions in any other circumstance and of the remaining provisions of this Article VIII (including, without limitation, each
portion of any sentence of this Article VIII containing any such provision held to be invalid, illegal or unenforceable that is not itself
held to be invalid, illegal or unenforceable) and the application of such provision to other persons or entities and circumstances shall
not in any way be affected or impaired thereby. Any person or entity purchasing or otherwise acquiring any interest in shares of capital
stock of the Corporation shall be deemed to have notice of and consented to the provisions of this Article VIII.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
X</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AMENDMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
any other provisions of this Third Amended and Restated Certificate or any provision of law which might otherwise permit a lesser vote
or no vote, but in addition to any affirmative vote of the holders of any particular class or series of the Voting Stock required by
law or by this Third Amended and Restated Certificate (including any Certificate of Designation in respect of one or more series of Preferred
Stock), the affirmative vote of the holders of at least sixty-six and two-thirds percent (66-2/3%) of the voting power of all of the
then-outstanding shares of the Voting Stock, voting together as a single class, shall be required to alter, amend or repeal Articles
V, VI, VII, VIII, IX and this Article X.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*****</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, OneMedNet Corporation has caused this Amended and Restated Certificate to be duly executed and acknowledged in its name
and on its behalf by an authorized officer as of the date first set forth above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ONEMEDNET
    CORPORATION</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Paul Casey</I></FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul
    Casey</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 256.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.2
<SEQUENCE>3
<FILENAME>ex3-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
3.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><IMG SRC="ex3-2_001.jpg" ALT=""></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AMENDED
AND RESTATED BYLAWS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OF</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ONEMEDNET
CORPORATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>(THE
&ldquo;CORPORATION&rdquo;)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Adopted
November 8, 2023)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
I</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OFFICES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
1.1. Registered Office</B>. The registered office of the Corporation within the State of Delaware shall be located at either (a) the
principal place of business of the Corporation in the State of Delaware or (b) the office of the corporation or individual acting as
the Corporation&rsquo;s registered agent in Delaware.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
1.2. Additional Offices</B>. The Corporation may, in addition to its registered office in the State of Delaware, have such other offices
and places of business, both within and outside the State of Delaware, as the Board of Directors of the Corporation (the &ldquo;<B><I>Board</I></B>&rdquo;)
may from time to time determine or as the business and affairs of the Corporation may require.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
II</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>STOCKHOLDERS
MEETINGS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
2.1. Annual Meetings</B>. The annual meeting of stockholders shall be held at such place, either within or without the State of Delaware,
and time and on such date as shall be determined by the Board and stated in the notice of the meeting, provided that the Board may in
its sole discretion determine that the meeting shall not be held at any place, but may instead be held solely by means of remote communication
pursuant to <U>Section 9.5(a)</U>. At each annual meeting, the stockholders entitled to vote on such matters shall elect those directors
of the Corporation to fill any term of a directorship that expires on the date of such annual meeting and may transact any other business
as may properly be brought before the meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
2.2. Special Meetings</B>. Subject to the rights of the holders of any outstanding series of the preferred stock of the Corporation (&ldquo;<B><I>Preferred
Stock</I></B>&rdquo;), and to the requirements of applicable law, special meetings of stockholders, for any purpose or purposes, may
be called only by the Chairman of the Board, Chief Executive Officer, or the Board pursuant to a resolution adopted by a majority of
the Board, and may not be called by any other person. Special meetings of stockholders shall be held at such place, either within or
without the State of Delaware, and at such time and on such date as shall be determined by the Board and stated in the Corporation&rsquo;s
notice of the meeting, provided that the Board may in its sole discretion determine that the meeting shall not be held at any place,
but may instead be held solely by means of remote communication pursuant to <U>Section 9.5(a)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
2.3. Notices.</B> Written notice of each stockholders meeting stating the place, if any, date, and time of the meeting, and the means
of remote communication, if any, by which stockholders and proxy holders may be deemed to be present in person and vote at such meeting
and the record date for determining the stockholders entitled to vote at the meeting, if such date is different from the record date
for determining stockholders entitled to notice of the meeting, shall be given in the manner permitted by <U>Section 9.3</U> to each
stockholder entitled to vote thereat as of the record date for determining the stockholders entitled to notice of the meeting, by the
Corporation not less than 10 nor more than 60 days before the date of the meeting unless otherwise required by the General Corporation
Law of the State of Delaware (the &ldquo;<B><I>DGCL</I></B>&rdquo;). If said notice is for a stockholders meeting other than an annual
meeting, it shall in addition state the purpose or purposes for which the meeting is called, and the business transacted at such meeting
shall be limited to the matters so stated in the Corporation&rsquo;s notice of meeting (or any supplement thereto). Any meeting of stockholders
as to which notice has been given may be postponed, and any meeting of stockholders as to which notice has been given may be cancelled,
by the Board upon public announcement (as defined in Section 2.7(c)) given before the date previously scheduled for such meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
2.4. Quorum</B>. Except as otherwise provided by applicable law, the Corporation&rsquo;s Certificate of Incorporation, as the same may
be amended or restated from time to time (the &ldquo;<B><I>Certificate of Incorporation</I></B>&rdquo;) or these By Laws, the presence,
in person or by proxy, at a stockholders meeting of the holders of shares of outstanding capital stock of the Corporation representing
a majority of the voting power of all outstanding shares of capital stock of the Corporation entitled to vote at such meeting shall constitute
a quorum for the transaction of business at such meeting, except that when specified business is to be voted on by a class or series
of stock voting as a class, the holders of shares representing a majority of the voting power of the outstanding shares of such class
or series shall constitute a quorum of such class or series for the transaction of such business. If a quorum shall not be present or
represented by proxy at any meeting of the stockholders of the Corporation, the chairman of the meeting may adjourn the meeting from
time to time in the manner provided in <U>Section 2.6</U> until a quorum shall attend. The stockholders present at a duly convened meeting
may continue to transact business until adjournment, notwithstanding the withdrawal of enough stockholders to leave less than a quorum.
Shares of its own stock belonging to the Corporation or to another corporation, if a majority of the voting power of the shares entitled
to vote in the election of directors of such other corporation is held, directly or indirectly, by the Corporation, shall neither be
entitled to vote nor be counted for quorum purposes; provided, however, that the foregoing shall not limit the right of the Corporation
or any such other corporation to vote shares held by it in a fiduciary capacity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
2.5. Voting of Shares</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Voting Lists</U>. The Secretary of the Corporation (the &ldquo;<B><I>Secretary</I></B>&rdquo;) shall prepare, or shall cause the officer
or agent who has charge of the stock ledger of the Corporation to prepare and make, at least 10 days before every meeting of stockholders,
a complete list of the stockholders of record entitled to vote at such meeting; provided, however, that if the record date for determining
the stockholders entitled to vote is less than 10 days before the meeting date, the list shall reflect the stockholders entitled to vote
as of the tenth day before the meeting date, arranged in alphabetical order and showing the address and the number and class of shares
registered in the name of each stockholder. Nothing contained in this Section 2.5(a) shall require the Corporation to include electronic
mail addresses or other electronic contact information on such list. Such list shall be open to the examination of any stockholder, for
any purpose germane to the meeting, during ordinary business hours for a period of at least 10 days prior to the meeting: (i) on a reasonably
accessible electronic network, provided that the information required to gain access to such list is provided with the notice of the
meeting, or (ii) during ordinary business hours, at the principal place of business of the Corporation. In the event that the Corporation
determines to make the list available on an electronic network, the Corporation may take reasonable steps to ensure that such information
is available only to stockholders of the Corporation. If the meeting is to be held at a place, then the list shall be produced and kept
at the time and place of the meeting during the whole time thereof, and may be inspected by any stockholder who is present. If a meeting
of stockholders is to be held solely by means of remote communication as permitted by Section 9.5(a), the list shall be open to the examination
of any stockholder during the whole time of the meeting on a reasonably accessible electronic network, and the information required to
access such list shall be provided with the notice of meeting. The stock ledger shall be the only evidence as to who are the stockholders
entitled to examine the list required by this Section 2.5(a) or to vote in person or by proxy at any meeting of stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Manner of Voting</U>. At any stockholders meeting, every stockholder entitled to vote may vote in person or by proxy. If authorized
by the Board, the voting by stockholders or proxy holders at any meeting conducted by remote communication may be effected by a ballot
submitted by electronic transmission (as defined in <U>Section 9.3</U>), provided that any such electronic transmission must either set
forth or be submitted with information from which the Corporation can determine that the electronic transmission was authorized by the
stockholder or proxy holder. The Board, in its discretion, or the chairman of the meeting of stockholders, in such person&rsquo;s discretion,
may require that any votes cast at such meeting shall be cast by written ballot.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Proxies</U>. Each stockholder entitled to vote at a meeting of stockholders or to express consent or dissent to corporate action in
writing without a meeting may authorize another person or persons to act for such stockholder by proxy, but no such proxy shall be voted
or acted upon after three years from its date, unless the proxy provides for a longer period. Proxies need not be filed with the Secretary
until the meeting is called to order, but shall be filed with the Secretary before being voted. Without limiting the manner in which
a stockholder may authorize another person or persons to act for such stockholder as proxy, either of the following shall constitute
a valid means by which a stockholder may grant such authority. No stockholder shall have cumulative voting rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 48.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 40pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
A stockholder may execute a writing authorizing another person or persons to act for such stockholder as proxy. Execution may be accomplished
by the stockholder or such stockholder&rsquo;s authorized officer, director, employee or agent signing such writing or causing such person&rsquo;s
signature to be affixed to such writing by any reasonable means, including, but not limited to, by facsimile signature.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 40pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
A stockholder may authorize another person or persons to act for such stockholder as proxy by transmitting or authorizing the transmission
of an electronic transmission to the person who will be the holder of the proxy or to a proxy solicitation firm, proxy support service
organization or like agent duly authorized by the person who will be the holder of the proxy to receive such transmission, provided that
any such electronic transmission must either set forth or be submitted with information from which it can be determined that the electronic
transmission was authorized by the stockholder. Any copy, facsimile telecommunication or other reliable reproduction of the writing or
transmission authorizing another person or persons to act as proxy for a stockholder may be substituted or used in lieu of the original
writing or transmission for any and all purposes for which the original writing or transmission could be used; provided that such copy,
facsimile telecommunication or other reproduction shall be a complete reproduction of the entire original writing or transmission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 48.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<U>Required Vote</U>. Subject to the rights of the holders of one or more series of Preferred Stock, voting separately by class or series,
to elect directors pursuant to the terms of one or more series of Preferred Stock, at all meetings of stockholders at which a quorum
is present, the election of directors shall be determined by a plurality of the votes cast by the stockholders present in person or represented
by proxy at the meeting and entitled to vote thereon. All other matters presented to the stockholders at a meeting at which a quorum
is present shall be determined by the vote of a majority of the votes cast by the stockholders present in person or represented by proxy
at the meeting and entitled to vote thereon, unless the matter is one upon which, by applicable law, the Certificate of Incorporation,
these By Laws or applicable stock exchange rules, a different vote is required, in which case such provision shall govern and control
the decision of such matter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
<U>Inspectors of Election</U>. The Board may, and shall if required by law, in advance of any meeting of stockholders, appoint one or
more persons as inspectors of election, who may be employees of the Corporation or otherwise serve the Corporation in other capacities,
to act at such meeting of stockholders or any adjournment thereof and to make a written report thereof. The Board may appoint one or
more persons as alternate inspectors to replace any inspector who fails to act. If no inspectors of election or alternates are appointed
by the Board, the chairman of the meeting shall appoint one or more inspectors to act at the meeting. Each inspector, before discharging
his or her duties, shall take and sign an oath faithfully to execute the duties of inspector with strict impartiality and according to
the best of his or her ability. The inspectors shall ascertain and report the number of outstanding shares and the voting power of each;
determine the number of shares present in person or represented by proxy at the meeting and the validity of proxies and ballots; count
all votes and ballots and report the results; determine and retain for a reasonable period a record of the disposition of any challenges
made to any determination by the inspectors; and certify their determination of the number of shares represented at the meeting and their
count of all votes and ballots. No person who is a candidate for an office at an election may serve as an inspector at such election.
Each report of an inspector shall be in writing and signed by the inspector or by a majority of them if there is more than one inspector
acting at such meeting. If there is more than one inspector, the report of a majority shall be the report of the inspectors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
2.6. Adjournments</B>. Any meeting of stockholders, annual or special, may be adjourned by the chairman of the meeting, from time to
time, whether or not there is a quorum, to reconvene at the same or some other place. Notice need not be given of any such adjourned
meeting if the date, time, and place, if any, thereof, and the means of remote communication, if any, by which stockholders and proxy
holders may be deemed to be present in person and vote at such adjourned meeting are announced at the meeting at which the adjournment
is taken. At the adjourned meeting the stockholders, or the holders of any class or series of stock entitled to vote separately as a
class, as the case may be, may transact any business that might have been transacted at the original meeting. If the adjournment is for
more than 30 days, notice of the adjourned meeting shall be given to each stockholder of record entitled to vote at the meeting. If after
the adjournment a new record date for stockholders entitled to vote is fixed for the adjourned meeting, the Board shall fix a new record
date for notice of such adjourned meeting in accordance with <U>Section 9.2</U>, and shall give notice of the adjourned meeting to each
stockholder of record entitled to vote at such adjourned meeting as of the record date fixed for notice of such adjourned meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
2.7. Advance Notice for Business</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Annual Meetings of Stockholders</U>. No business may be transacted at an annual meeting of stockholders, other than business that
is either (i) specified in the Corporation&rsquo;s notice of meeting (or any supplement thereto) given by or at the direction of the
Board, (ii) otherwise properly brought before the annual meeting by or at the direction of the Board or (iii) otherwise properly brought
before the annual meeting by any stockholder of the Corporation (x) who is a stockholder of record entitled to vote at such annual meeting
on the date of the giving of the notice provided for in this <U>Section 2.7(a)</U> and on the record date for the determination of stockholders
entitled to vote at such annual meeting and (y) who complies with the notice procedures set forth in this <U>Section 2.7(a)</U>. Notwithstanding
anything in this <U>Section 2.7(a)</U> to the contrary, only persons nominated for election as a director to fill any term of a directorship
that expires on the date of the annual meeting pursuant to <U>Section 3.5</U> will be considered for election at such meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 48.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 40pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
In addition to any other applicable requirements, for business (other than nominations) to be properly brought before an annual meeting
by a stockholder, such stockholder must have given timely notice thereof in proper written form to the Secretary and such business must
otherwise be a proper matter for stockholder action. Subject to <U>Section 2.7(a)(iii)</U>, a stockholder&rsquo;s notice to the Secretary
with respect to such business, to be timely, must be received by the Secretary at the principal executive offices of the Corporation
not later than the close of business on the 90th day nor earlier than the opening of business on the 120th day before the anniversary
date of the immediately preceding annual meeting of stockholders; provided, however, that in the event that the annual meeting is more
than 30 days before or more than 60 days after such anniversary date, notice by the stockholder to be timely must be so delivered not
earlier than the close of business on the 120th day before the meeting and not later than the later of (x) the close of business on the
90th day before the meeting or (y) the close of business on the 10th day following the day on which public announcement of the date of
the annual meeting is first made by the Corporation. The public announcement of an adjournment or postponement of an annual meeting shall
not commence a new time period (or extend any time period) for the giving of a stockholder&rsquo;s notice as described in this Section
2.7(a).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 40pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
To be in proper written form, a stockholder&rsquo;s notice to the Secretary with respect to any business (other than nominations) must
set forth as to each such matter such stockholder proposes to bring before the annual meeting (A) a brief description of the business
desired to be brought before the annual meeting, the text of the proposal or business (including the text of any resolutions proposed
for consideration and in the event such business includes a proposal to amend these By Laws, the language of the proposed amendment)
and the reasons for conducting such business at the annual meeting, (B) the name and record address of such stockholder and the name
and address of the beneficial owner, if any, on whose behalf the proposal is made, (C) the class or series and number of shares of capital
stock of the Corporation that are owned beneficially and of record by such stockholder and by the beneficial owner, if any, on whose
behalf the proposal is made, (D) a description of all arrangements or understandings between such stockholder and the beneficial owner,
if any, on whose behalf the proposal is made and any other person or persons (including their names) in connection with the proposal
of such business by such stockholder, (E) any material interest of such stockholder and the beneficial owner, if any, on whose behalf
the proposal is made in such business and (F) a representation that such stockholder (or a qualified representative of such stockholder)
intends to appear in person or by proxy at the annual meeting to bring such business before the meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 40pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 40pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
The foregoing notice requirements of this <U>Section 2.7(a)</U> shall be deemed satisfied by a stockholder as to any proposal (other
than nominations) if the stockholder has notified the Corporation of such stockholder&rsquo;s intention to present such proposal at an
annual meeting in compliance with Rule 14a-8 (or any successor thereof) of the Securities Exchange Act of 1934, as amended (the &ldquo;<B><I>Exchange
Act</I></B>&rdquo;), and such stockholder has complied with the requirements of such Rule for inclusion of such proposal in a proxy statement
prepared by the Corporation to solicit proxies for such annual meeting. No business shall be conducted at the annual meeting of stockholders
except business brought before the annual meeting in accordance with the procedures set forth in this <U>Section 2.7(a)</U>, provided,
however, that once business has been properly brought before the annual meeting in accordance with such procedures, nothing in this <U>Section
2.7(a)</U> shall be deemed to preclude discussion by any stockholder of any such business. If the Board or the chairman of the annual
meeting determines that any stockholder proposal was not made in accordance with the provisions of this <U>Section 2.7(a)</U> or that
the information provided in a stockholder&rsquo;s notice does not satisfy the information requirements of this <U>Section 2.7(a)</U>,
such proposal shall not be presented for action at the annual meeting. Notwithstanding the foregoing provisions of this <U>Section 2.7(a)</U>,
if the stockholder (or a qualified representative of the stockholder) does not appear at the annual meeting of stockholders of the Corporation
to present the proposed business, such proposed business shall not be transacted, notwithstanding that proxies in respect of such matter
may have been received by the Corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 40pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 40pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
In addition to the provisions of this <U>Section 2.7(a)</U>, a stockholder shall also comply with all applicable requirements of the
Exchange Act and the rules and regulations thereunder with respect to the matters set forth herein. Nothing in this <U>Section 2.7(a)
</U>shall be deemed to affect any rights of stockholders to request inclusion of proposals in the Corporation&rsquo;s proxy statement
pursuant to Rule 14a-8 under the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Special Meetings of Stockholders</U>. Only such business shall be conducted at a special meeting of stockholders as shall have been
brought before the meeting pursuant to the Corporation&rsquo;s notice of meeting. Nominations of persons for election to the Board may
be made at a special meeting of stockholders at which directors are to be elected pursuant to the Corporation&rsquo;s notice of meeting
only pursuant to <U>Section 3.5</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Public Announcement</U>. For purposes of these By Laws, &ldquo;<B><I>public announcement</I></B>&rdquo; shall mean disclosure in a
press release reported by the Dow Jones News Service, Associated Press or comparable national news service or in a document publicly
filed by the Corporation with the Securities and Exchange Commission pursuant to Sections 13, 14 or 15(d) of the Exchange Act (or any
successor thereto).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
2.8. Conduct of Meetings</B>. The chairman of each annual and special meeting of stockholders shall be the Chairman of the Board or,
in the absence (or inability or refusal to act) of the Chairman of the Board, any Chief Executive Officer (if he or she shall be a director)
or, in the absence (or inability or refusal to act of a Chief Executive Officer or if a Chief Executive Officer is not a director, the
President (if he or she shall be a director) or, in the absence (or inability or refusal to act) of the President or if the President
is not a director, such other person as shall be appointed by the Board. The date and time of the opening and the closing of the polls
for each matter upon which the stockholders will vote at a meeting shall be announced at the meeting by the chairman of the meeting.
The Board may adopt such rules and regulations for the conduct of the meeting of stockholders as it shall deem appropriate. Except to
the extent inconsistent with these By Laws or such rules and regulations as adopted by the Board, the chairman of any meeting of stockholders
shall have the right and authority to convene and to adjourn the meeting, to prescribe such rules, regulations and procedures and to
do all such acts as, in the judgment of such chairman, are appropriate for the proper conduct of the meeting. Such rules, regulations
or procedures, whether adopted by the Board or prescribed by the chairman of the meeting, may include, without limitation, the following:
(a) the establishment of an agenda or order of business for the meeting; (b) rules and procedures for maintaining order at the meeting
and the safety of those present; (c) limitations on attendance at or participation in the meeting to stockholders of record of the Corporation,
their duly authorized and constituted proxies or such other persons as the chairman of the meeting shall determine; (d) restrictions
on entry to the meeting after the time fixed for the commencement thereof; and (e) limitations on the time allotted to questions or comments
by participants. Unless and to the extent determined by the Board or the chairman of the meeting, meetings of stockholders shall not
be required to be held in accordance with the rules of parliamentary procedure. The secretary of each annual and special meeting of stockholders
shall be the Secretary or, in the absence (or inability or refusal to act) of the Secretary, an Assistant Secretary so appointed to act
by the chairman of the meeting. In the absence (or inability or refusal to act) of the Secretary and all Assistant Secretaries, the chairman
of the meeting may appoint any person to act as secretary of the meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
2.9. Consents in Lieu of Meeting</B>. Unless otherwise provided by the Certificate of Incorporation, until the Corporation consummates
an initial public offering (&ldquo;<B><I>Offering</I></B>&rdquo;), any action required to be taken at any annual or special meeting of
stockholders, or any action which may be taken at any annual or special meeting of such stockholders, may be taken without a meeting,
without prior notice and without a vote, if a consent in writing, setting forth the action so taken, shall be signed by the holders of
outstanding stock entitled to vote thereon having not less than the minimum number of votes that would be necessary to authorize or take
such action at a meeting at which all shares entitled to vote thereon were present and voted, and shall be delivered to the Corporation
by delivery to its registered office in the State of Delaware, its principal place of business, or an officer or agent of the Corporation
having custody of the book in which proceedings of meetings of stockholders are recorded. Delivery made to the Corporation&rsquo;s registered
office shall be by hand or by certified or registered mail, return receipt requested.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Every
written consent shall bear the date of signature of each stockholder who signs the consent, and no written consent shall be effective
to take the corporate action referred to therein unless, within 60 days of the earliest dated consent delivered in the manner required
by this section and the DGCL to the Corporation, written consents signed by a sufficient number of holders entitled to vote to take action
are delivered to the Corporation by delivery to its registered office in Delaware, its principal place of business or an officer or agent
of the Corporation having custody of the book in which proceedings of meetings of stockholders are recorded. Delivery made to the Corporation&rsquo;s
registered office shall be by hand or by certified or registered mail, return receipt requested.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
III</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DIRECTORS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
3.1. Powers; Number</B>. The business and affairs of the Corporation shall be managed by or under the direction of the Board, which may
exercise all such powers of the Corporation and do all such lawful acts and things as are not by statute or by the Certificate of Incorporation
or by these By Laws required to be exercised or done by the stockholders. Directors need not be stockholders or residents of the State
of Delaware. Subject to the Certificate of Incorporation, the number of directors shall be fixed exclusively by resolution of the Board.
Each director shall hold office until a successor is duly elected and qualified or until the director&rsquo;s earlier death, resignation,
disqualification, or removal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
3.2. Newly Created Directorships and Vacancies. </B>Any newly created directorships resulting from an increase in the authorized number
of directors and any vacancies occurring in the Board of Directors, may be filled by the affirmative votes of a majority of the remaining
members of the Board of Directors, although less than a quorum, or by a sole remaining director. A director so elected shall be elected
to hold office until the earlier of the expiration of the term of office of the director whom he or she has replaced, a successor is
duly elected and qualified, or the earlier of such director&rsquo;s death, resignation, or removal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
3.3. Resignations. </B>Any director may resign at any time by notice given in writing or by electronic transmission to the Corporation.
Such resignation shall take effect at the date of receipt of such notice by the Corporation or at such later effective date or upon the
happening of an event or events as is therein specified.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
3.4. Removals. </B>Except as prohibited by applicable law or the Certificate of Incorporation, the stockholders holding a majority of
the shares then entitled to vote at an election of directors may remove any director from office with or without cause.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
3.5. Advance Notice for Nomination of Directors</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Only persons who are nominated in accordance with the following procedures shall be eligible for election as directors of the Corporation,
except as may be otherwise provided by the terms of one or more series of Preferred Stock with respect to the rights of holders of one
or more series of Preferred Stock to elect directors. Nominations of persons for election to the Board at any annual meeting of stockholders,
or at any special meeting of stockholders called for the purpose of electing directors as set forth in the Corporation&rsquo;s notice
of such special meeting, may be made (i) by or at the direction of the Board or (ii) by any stockholder of the Corporation (x) who is
a stockholder of record entitled to vote in the election of directors on the date of the giving of the notice provided for in this <U>Section
3.5</U> and on the record date for the determination of stockholders entitled to vote at such meeting and (y) who complies with the notice
procedures set forth in this <U>Section 3.5</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
In addition to any other applicable requirements, for a nomination to be made by a stockholder, such stockholder must have given timely
notice thereof in proper written form to the Secretary. To be timely, a stockholder&rsquo;s notice to the Secretary must be received
by the Secretary at the principal executive offices of the Corporation (i) in the case of an annual meeting, not later than the close
of business on the 90th day nor earlier than the opening of business on the 120th day before the anniversary date of the immediately
preceding annual meeting of stockholders; provided, however, that in the event that the annual meeting is more than 30 days before or
more than 60 days after such anniversary date, notice by the stockholder to be timely must be so received not earlier than the opening
of business on the 120th day before the meeting and not later than the later of (x) the close of business on the 90th day before the
meeting or (y) the close of business on the 10th day following the day on which public announcement of the date of the annual meeting
was first made by the Corporation; and (ii) in the case of a special meeting of stockholders called for the purpose of electing directors,
not later than the close of business on the 10th day following the day on which public announcement of the date of the special meeting
is first made by the Corporation. In no event shall the public announcement of an adjournment or postponement of an annual meeting or
special meeting commence a new time period (or extend any time period) for the giving of a stockholder&rsquo;s notice as described in
this <U>Section 3.5</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Notwithstanding anything in paragraph (b) to the contrary, in the event that the number of directors to be elected to the Board at an
annual meeting is greater than the number of directors whose terms expire on the date of the annual meeting and there is no public announcement
by the Corporation naming all of the nominees for the additional directors to be elected or specifying the size of the increased Board
before the close of business on the 90th day prior to the anniversary date of the immediately preceding annual meeting of stockholders,
a stockholder&rsquo;s notice required by this <U>Section 3.5</U> shall also be considered timely, but only with respect to nominees for
the additional directorships created by such increase that are to be filled by election at such annual meeting, if it shall be received
by the Secretary at the principal executive offices of the Corporation not later than the close of business on the 10th day following
the date on which such public announcement was first made by the Corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
To be in proper written form, a stockholder&rsquo;s notice to the Secretary must set forth (i) as to each person whom the stockholder
proposes to nominate for election as a director (A) the name, age, business address and residence address of the person, (B) the principal
occupation or employment of the person, (C) the class or series and number of shares of capital stock of the Corporation that are owned
beneficially or of record by the person and (D) any other information relating to the person that would be required to be disclosed in
a proxy statement or other filings required to be made in connection with solicitations of proxies for election of directors pursuant
to Section 14 of the Exchange Act and the rules and regulations promulgated thereunder; and (ii) as to the stockholder giving the notice
(A) the name and record address of such stockholder as they appear on the Corporation&rsquo;s books and the name and address of the beneficial
owner, if any, on whose behalf the nomination is made, (B) the class or series and number of shares of capital stock of the Corporation
that are owned beneficially and of record by such stockholder and the beneficial owner, if any, on whose behalf the nomination is made,
(C) a description of all arrangements or understandings relating to the nomination to be made by such stockholder among such stockholder,
the beneficial owner, if any, on whose behalf the nomination is made, each proposed nominee and any other person or persons (including
their names), (D) a representation that such stockholder (or a qualified representative of such stockholder) intends to appear in person
or by proxy at the meeting to nominate the persons named in its notice and (E) any other information relating to such stockholder and
the beneficial owner, if any, on whose behalf the nomination is made that would be required to be disclosed in a proxy statement or other
filings required to be made in connection with solicitations of proxies for election of directors pursuant to Section 14 of the Exchange
Act and the rules and regulations promulgated thereunder. Such notice must be accompanied by a written consent of each proposed nominee
to being named as a nominee and to serve as a director if elected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
If the Board or the chairman of the meeting of stockholders determines that any nomination was not made in accordance with the provisions
of this <U>Section 3.5</U>, or that the information provided in a stockholder&rsquo;s notice does not satisfy the information requirements
of this <U>Section 3.5</U>, then such nomination shall not be considered at the meeting in question. Notwithstanding the foregoing provisions
of this <U>Section 3.5</U>, if the stockholder (or a qualified representative of the stockholder) does not appear at the meeting of stockholders
of the Corporation to present the nomination, such nomination shall be disregarded, notwithstanding that proxies in respect of such nomination
may have been received by the Corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
In addition to the provisions of this <U>Section 3.5</U>, a stockholder shall also comply with all of the applicable requirements of
the Exchange Act and the rules and regulations thereunder with respect to the matters set forth herein. Nothing in this <U>Section 3.5
</U>shall be deemed to affect any rights of the holders of Preferred Stock to elect directors pursuant to the Certificate of Incorporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
3.6. Compensation</B>. Unless otherwise restricted by the Certificate of Incorporation or these By Laws, the Board shall have the authority
to fix the compensation of directors, including for service on a committee of the Board, and may be paid either a fixed sum for attendance
at each meeting of the Board or other compensation as director. The directors may be reimbursed their expenses, if any, of attendance
at each meeting of the Board. No such payment shall preclude any director from serving the Corporation in any other capacity and receiving
compensation therefor. Members of committees of the Board may be allowed like compensation and reimbursement of expenses for service
on the committee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
IV</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BOARD
MEETINGS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
4.1. Annual Meetings</B>. The Board shall meet as soon as practicable after the adjournment of each annual stockholders meeting at the
place of the annual stockholders meeting unless the Board shall fix another time and place and give notice thereof in the manner required
herein for special meetings of the Board. No notice to the directors shall be necessary to legally convene this meeting, except as provided
in this <U>Section 4.1</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
4.2. Regular Meetings</B>. Regularly scheduled, periodic meetings of the Board may be held without notice at such times, dates and places
(within or without the State of Delaware) as shall from time to time be determined by the Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
4.3. Special Meetings</B>. Special meetings of the Board (a) may be called by the Chairman of the Board or President and (b) shall be
called by the Chairman of the Board, President or Secretary on the written request of at least a majority of directors then in office,
or the sole director, as the case may be, and shall be held at such time, date and place (within or without the State of Delaware) as
may be determined by the person calling the meeting or, if called upon the request of directors or the sole director, as specified in
such written request. Notice of each special meeting of the Board shall be given, as provided in <U>Section 9.3</U>, to each director
(i) at least 24 hours before the meeting if such notice is oral notice given personally or by telephone or written notice given by hand
delivery or by means of a form of electronic transmission and delivery; (ii) at least two days before the meeting if such notice is sent
by a nationally recognized overnight delivery service; and (iii) at least five days before the meeting if such notice is sent through
the United States mail. If the Secretary shall fail or refuse to give such notice, then the notice may be given by the officer who called
the meeting or the directors who requested the meeting. Any and all business that may be transacted at a regular meeting of the Board
may be transacted at a special meeting. Except as may be otherwise expressly provided by applicable law, the Certificate of Incorporation,
or these By Laws, neither the business to be transacted at, nor the purpose of, any special meeting need be specified in the notice or
waiver of notice of such meeting. A special meeting may be held at any time without notice if all the directors are present or if those
not present waive notice of the meeting in accordance with <U>Section 9.4</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
4.4. Quorum; Required Vote</B>. A majority of the Board shall constitute a quorum for the transaction of business at any meeting of the
Board, and the act of a majority of the directors present at any meeting at which there is a quorum shall be the act of the Board, except
as may be otherwise specifically provided by applicable law, the Certificate of Incorporation or these By Laws. If a quorum shall not
be present at any meeting, a majority of the directors present may adjourn the meeting from time to time, without notice other than announcement
at the meeting, until a quorum is present.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
4.5. Consent In Lieu of Meeting</B>. Unless otherwise restricted by the Certificate of Incorporation or these By Laws, any action required
or permitted to be taken at any meeting of the Board or any committee thereof may be taken without a meeting if all members of the Board
or committee, as the case may be, consent thereto in writing or by electronic transmission, and the writing or writings or electronic
transmission or transmissions (or paper reproductions thereof) are filed with the minutes of proceedings of the Board or committee. Such
filing shall be in paper form if the minutes are maintained in paper form and shall be in electronic form if the minutes are maintained
in electronic form.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
4.6. Organization</B>. The chairman of each meeting of the Board shall be the Chairman of the Board or, in the absence (or inability
or refusal to act) of the Chairman of the Board, any Chief Executive Officer (if he or she shall be a director) or, in the absence (or
inability or refusal to act) of a Chief Executive Officer or if a Chief Executive Officer is not a director, the President (if he or
she shall be a director) or in the absence (or inability or refusal to act) of the President or if the President is not a director, a
chairman elected from the directors present. The Secretary shall act as secretary of all meetings of the Board. In the absence (or inability
or refusal to act) of the Secretary, an Assistant Secretary shall perform the duties of the Secretary at such meeting. In the absence
(or inability or refusal to act) of the Secretary and all Assistant Secretaries, the chairman of the meeting may appoint any person to
act as secretary of the meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
V</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>COMMITTEES
OF DIRECTORS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
5.1. Establishment</B>. The Board may by resolution of the Board designate one or more committees, each committee to consist of one or
more of the directors of the Corporation. Each committee shall keep regular minutes of its meetings and report the same to the Board
when required by the resolution designating such committee. The Board shall have the power at any time to fill vacancies in, to change
the membership of, or to dissolve any such committee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
5.2. Available Powers</B>. Any committee established pursuant to <U>Section 5.1</U> hereof, to the extent permitted by applicable law
and by resolution of the Board, shall have and may exercise all of the powers and authority of the Board in the management of the business
and affairs of the Corporation, and may authorize the seal of the Corporation to be affixed to all papers that may require it.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
5.3. Alternate Members</B>. The Board may designate one or more directors as alternate members of any committee, who may replace any
absent or disqualified member at any meeting of such committee. In the absence or disqualification of a member of the committee, the
member or members thereof present at any meeting and not disqualified from voting, whether or not he, she or they constitute a quorum,
may unanimously appoint another member of the Board to act at the meeting in place of any such absent or disqualified member.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
5.4. Procedures</B>. Unless the Board otherwise provides, the time, date, place, if any, and notice of meetings of a committee shall
be determined by such committee. At meetings of a committee, a majority of the number of members of the committee (but not including
any alternate member, unless such alternate member has replaced any absent or disqualified member at the time of, or in connection with,
such meeting) shall constitute a quorum for the transaction of business. The act of a majority of the members present at any meeting
at which a quorum is present shall be the act of the committee, except as otherwise specifically provided by applicable law, the Certificate
of Incorporation, these By Laws or the Board. If a quorum is not present at a meeting of a committee, the members present may adjourn
the meeting from time to time, without notice other than an announcement at the meeting, until a quorum is present. Unless the Board
otherwise provides and except as provided in these By Laws, each committee designated by the Board may make, alter, amend and repeal
rules for the conduct of its business. In the absence of such rules each committee shall conduct its business in the same manner as the
Board is authorized to conduct its business pursuant to <U>Article III</U> and <U>Article IV </U>of these By Laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
VI</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OFFICERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
6.1. Officers</B>. The officers of the Corporation elected by the Board shall be one or more Chief Executive Officers, a Chief Financial
Officer, a Secretary and such other officers (including without limitation, a Chairman of the Board, Presidents, Vice Presidents, Assistant
Secretaries and a Treasurer) as the Board from time to time may determine. Officers elected by the Board shall each have such powers
and duties as generally pertain to their respective offices, subject to the specific provisions of this <U>Article VI</U>. Such officers
shall also have such powers and duties as from time to time may be conferred by the Board. Any Chief Executive Officer or President may
also appoint such other officers (including without limitation one or more Vice Presidents and Controllers) as may be necessary or desirable
for the conduct of the business of the Corporation. Such other officers shall have such powers and duties and shall hold their offices
for such terms as may be provided in these By Laws or as may be prescribed by the Board or, if such officer has been appointed by any
Chief Executive Officer or President, as may be prescribed by the appointing officer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Chairman of the Board</U>. The Chairman of the Board shall preside when present at all meetings of the stockholders and the Board.
The Chairman of the Board shall have general supervision and control of the acquisition activities of the Corporation subject to the
ultimate authority of the Board, and shall be responsible for the execution of the policies of the Board with respect to such matters.
In the absence (or inability or refusal to act) of the Chairman of the Board, any Chief Executive Officer (if he or she shall be a director)
shall preside when present at all meetings of the stockholders and the Board. The powers and duties of the Chairman of the Board shall
not include supervision or control of the preparation of the financial statements of the Corporation (other than through participation
as a member of the Board). The position of Chairman of the Board and Chief Executive Officer may be held by the same person and may be
held by more than one person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Chief Executive Officer</U>. One or more Chief Executive Officers shall be the chief executive officer(s) of the Corporation, shall
have general supervision of the affairs of the Corporation and general control of all of its business subject to the ultimate authority
of the Board, and shall be responsible for the execution of the policies of the Board with respect to such matters, except to the extent
any such powers and duties have been prescribed to the Chairman of the Board pursuant to <U>Section 6.1(a)</U> above. In the absence
(or inability or refusal to act) of the Chairman of the Board, any Chief Executive Officer (if he or she shall be a director) shall preside
when present at all meetings of the stockholders and the Board. The position of Chief Executive Officer and President may be held by
the same person and may be held by more than one person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>President</U>. The President shall make recommendations to any Chief Executive Officer on all operational matters that would normally
be reserved for the final executive responsibility of any Chief Executive Officer. In the absence (or inability or refusal to act) of
the Chairman of the Board and a Chief Executive Officer, the President (if he or she shall be a director) shall preside when present
at all meetings of the stockholders and the Board. The President shall also perform such duties and have such powers as shall be designated
by the Board. The position of President and Chief Executive Officer may be held by the same person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<U>Vice Presidents</U>. In the absence (or inability or refusal to act) of the President, the Vice President (or in the event there be
more than one Vice President, the Vice Presidents in the order designated by the Board) shall perform the duties and have the powers
of the President. Any one or more of the Vice Presidents may be given an additional designation of rank or function.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
<U>Secretary</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 48.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 40pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
The Secretary shall attend all meetings of the stockholders, the Board and (as required) committees of the Board and shall record the
proceedings of such meetings in books to be kept for that purpose. The Secretary shall give, or cause to be given, notice of all meetings
of the stockholders and special meetings of the Board and shall perform such other duties as may be prescribed by the Board, the Chairman
of the Board, any Chief Executive Officer or President. The Secretary shall have custody of the corporate seal of the Corporation and
the Secretary, or any Assistant Secretary, shall have authority to affix the same to any instrument requiring it, and when so affixed,
it may be attested by his or her signature or by the signature of such Assistant Secretary. The Board may give general authority to any
other officer to affix the seal of the Corporation and to attest the affixing thereof by his or her signature.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 40pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 40pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
The Secretary shall keep, or cause to be kept, at the principal executive office of the Corporation or at the office of the Corporation&rsquo;s
transfer agent or registrar, if one has been appointed, a stock ledger, or duplicate stock ledger, showing the names of the stockholders
and their addresses, the number and classes of shares held by each and, with respect to certificated shares, the number and date of certificates
issued for the same and the number and date of certificates cancelled.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
<U>Assistant Secretaries</U>. The Assistant Secretary or, if there be more than one, the Assistant Secretaries in the order determined
by the Board shall, in the absence (or inability or refusal to act) of the Secretary, perform the duties and have the powers of the Secretary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
<U>Chief Financial Officer</U>. The Chief Financial Officer shall perform all duties commonly incident to that office (including, without
limitation, the care and custody of the funds and securities of the Corporation, which from time to time may come into the Chief Financial
Officer&rsquo;s hands and the deposit of the funds of the Corporation in such banks or trust companies as the Board, any Chief Executive
Officer or the President may authorize).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
<U>Treasurer</U>. The Treasurer shall, in the absence (or inability or refusal to act) of the Chief Financial Officer, perform the duties
and exercise the powers of the Chief Financial Officer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
6.2. Term of Office; Removal; Vacancies</B>. The elected officers of the Corporation shall be appointed by the Board and shall hold office
until their successors are duly elected and qualified by the Board or until their earlier death, resignation, retirement, disqualification,
or removal from office. Any officer may be removed, with or without cause, at any time by the Board. Any officer appointed by any Chief
Executive Officer or President may also be removed, with or without cause, by any Chief Executive Officer or President, as the case may
be, unless the Board otherwise provides. Any vacancy occurring in any elected office of the Corporation may be filled by the Board. Any
vacancy occurring in any office appointed by any Chief Executive Officer or President may be filled by any Chief Executive Officer, or
President, as the case may be, unless the Board then determines that such office shall thereupon be elected by the Board, in which case
the Board shall elect such officer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
6.3. Other Officers</B>. The Board may delegate the power to appoint such other officers and agents, and may also remove such officers
and agents or delegate the power to remove same, as it shall from time to time deem necessary or desirable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
6.4. Multiple Officeholders; Stockholder and Director Officers</B>. Any number of offices may be held by the same person unless the Certificate
of Incorporation or these By Laws otherwise provide. Officers need not be stockholders or residents of the State of Delaware.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
VII</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SHARES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
7.1. Certificated and Uncertificated Shares</B>. The shares of the Corporation may be certificated or uncertificated, subject to the
sole discretion of the Board and the requirements of the DGCL.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
7.2. Multiple Classes of Stock</B>. If the Corporation shall be authorized to issue more than one class of stock or more than one series
of any class, the Corporation shall (a) cause the powers, designations, preferences and relative, participating, optional or other special
rights of each class of stock or series thereof and the qualifications, limitations or restrictions of such preferences and/or rights
to be set forth in full or summarized on the face or back of any certificate that the Corporation issues to represent shares of such
class or series of stock or (b) in the case of uncertificated shares, within a reasonable time after the issuance or transfer of such
shares, send to the registered owner thereof a written notice containing the information required to be set forth on certificates as
specified in clause (a) above; provided, however, that, except as otherwise provided by applicable law, in lieu of the foregoing requirements,
there may be set forth on the face or back of such certificate or, in the case of uncertificated shares, on such written notice a statement
that the Corporation will furnish without charge to each stockholder who so requests the powers, designations, preferences and relative,
participating, optional or other special rights of each class of stock or series thereof and the qualifications, limitations or restrictions
of such preferences or rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
7.3. Signatures</B>. Each certificate representing capital stock of the Corporation shall be signed by or in the name of the Corporation
by (a) the Chairman of the Board, any Chief Executive Officer, the President or a Vice President and (b) the Treasurer, an Assistant
Treasurer, the Secretary or an Assistant Secretary of the Corporation. Any or all the signatures on the certificate may be a facsimile.
In case any officer, transfer agent or registrar who has signed or whose facsimile signature has been placed upon a certificate shall
have ceased to be such officer, transfer agent or registrar before such certificate is issued, such certificate may be issued by the
Corporation with the same effect as if such person were such officer, transfer agent or registrar on the date of issue.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
7.4. Consideration and Payment for Shares</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Subject to applicable law and the Certificate of Incorporation, shares of stock may be issued for such consideration, having in the case
of shares with par value a value not less than the par value thereof, and to such persons, as determined from time to time by the Board.
The consideration may consist of any tangible or intangible property or any benefit to the Corporation including cash, promissory notes,
services performed, contracts for services to be performed or other securities, or any combination thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Subject to applicable law and the Certificate of Incorporation, shares may not be issued until the full amount of the consideration has
been paid, unless upon the face or back of each certificate issued to represent any partly paid shares of capital stock or upon the books
and records of the Corporation in the case of partly paid uncertificated shares, there shall have been set forth the total amount of
the consideration to be paid therefor and the amount paid thereon up to and including the time said certificate representing certificated
shares or said uncertificated shares are issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
7.5. Lost, Destroyed or Wrongfully Taken Certificates</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
If an owner of a certificate representing shares claims that such certificate has been lost, destroyed or wrongfully taken, the Corporation
shall issue a new certificate representing such shares or such shares in uncertificated form if the owner: (i) requests such a new certificate
before the Corporation has notice that the certificate representing such shares has been acquired by a protected purchaser; (ii) if requested
by the Corporation, delivers to the Corporation a bond sufficient to indemnify the Corporation against any claim that may be made against
the Corporation on account of the alleged loss, wrongful taking or destruction of such certificate or the issuance of such new certificate
or uncertificated shares; and (iii) satisfies other reasonable requirements imposed by the Corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
If a certificate representing shares has been lost, apparently destroyed or wrongfully taken, and the owner fails to notify the Corporation
of that fact within a reasonable time after the owner has notice of such loss, apparent destruction or wrongful taking and the Corporation
registers a transfer of such shares before receiving notification, the owner shall be precluded from asserting against the Corporation
any claim for registering such transfer or a claim to a new certificate representing such shares or such shares in uncertificated form.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
7.6. Transfer of Stock</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
If a certificate representing shares of the Corporation is presented to the Corporation with an endorsement requesting the registration
of transfer of such shares or an instruction is presented to the Corporation requesting the registration of transfer of uncertificated
shares, the Corporation shall register the transfer as requested if:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 48.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 40pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
in the case of certificated shares, the certificate representing such shares has been surrendered;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 40pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 40pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
(A) with respect to certificated shares, the endorsement is made by the person specified by the certificate as entitled to such shares;
(B) with respect to uncertificated shares, an instruction is made by the registered owner of such uncertificated shares; or (C) with
respect to certificated shares or uncertificated shares, the endorsement or instruction is made by any other appropriate person or by
an agent who has actual authority to act on behalf of the appropriate person;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 40pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 40pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
the Corporation has received a guarantee of signature of the person signing such endorsement or instruction or such other reasonable
assurance that the endorsement or instruction is genuine and authorized as the Corporation may request;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 40pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 40pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
the transfer does not violate any restriction on transfer imposed by the Corporation that is enforceable in accordance with <U>Section
7.8(a)</U>; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 40pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 40pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
such other conditions for such transfer as shall be provided for under applicable law have been satisfied.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Whenever any transfer of shares shall be made for collateral security and not absolutely, the Corporation shall so record such fact in
the entry of transfer if, when the certificate for such shares is presented to the Corporation for transfer or, if such shares are uncertificated,
when the instruction for registration of transfer thereof is presented to the Corporation, both the transferor and transferee request
the Corporation to do so.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
7.7. Registered Stockholders</B>. Before due presentment for registration of transfer of a certificate representing shares of the Corporation
or of an instruction requesting registration of transfer of uncertificated shares, the Corporation may treat the registered owner as
the person exclusively entitled to inspect for any proper purpose the stock ledger and the other books and records of the Corporation,
vote such shares, receive dividends or notifications with respect to such shares and otherwise exercise all the rights and powers of
the owner of such shares, except that a person who is the beneficial owner of such shares (if held in a voting trust or by a nominee
on behalf of such person) may, upon providing documentary evidence of beneficial ownership of such shares and satisfying such other conditions
as are provided under applicable law, may also so inspect the books and records of the Corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
7.8. Effect of the Corporation&rsquo;s Restriction on Transfer</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
A written restriction on the transfer or registration of transfer of shares of the Corporation or on the amount of shares of the Corporation
that may be owned by any person or group of persons, if permitted by the DGCL and noted conspicuously on the certificate representing
such shares or, in the case of uncertificated shares, contained in a notice, offering circular or prospectus sent by the Corporation
to the registered owner of such shares within a reasonable time prior to or after the issuance or transfer of such shares, may be enforced
against the holder of such shares or any successor or transferee of the holder including an executor, administrator, trustee, guardian
or other fiduciary entrusted with like responsibility for the person or estate of the holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
A restriction imposed by the Corporation on the transfer or the registration of shares of the Corporation or on the amount of shares
of the Corporation that may be owned by any person or group of persons, even if otherwise lawful, is ineffective against a person without
actual knowledge of such restriction unless: (i) the shares are certificated and such restriction is noted conspicuously on the certificate;
or (ii) the shares are uncertificated and such restriction was contained in a notice, offering circular or prospectus sent by the Corporation
to the registered owner of such shares within a reasonable time prior to or after the issuance or transfer of such shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
7.9. Regulations</B>. The Board shall have power and authority to make such additional rules and regulations, subject to any applicable
requirement of law, as the Board may deem necessary and appropriate with respect to the issue, transfer or registration of transfer of
shares of stock or certificates representing shares. The Board may appoint one or more transfer agents or registrars and may require
for the validity thereof that certificates representing shares bear the signature of any transfer agent or registrar so appointed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
VIII</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INDEMNIFICATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
8.1. Right to Indemnification</B>. To the fullest extent permitted by applicable law, as the same exists or may hereafter be amended,
the Corporation shall indemnify and hold harmless each person who was or is made a party or is threatened to be made a party to or is
otherwise involved in any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative
(hereinafter a &ldquo;<B><I>proceeding</I></B>&rdquo;), by reason of the fact that he or she is or was a director or officer of the Corporation
or, while a director or officer of the Corporation, is or was serving at the request of the Corporation as a director, officer, employee
or agent of another corporation or of a partnership, joint venture, trust, other enterprise or nonprofit entity, including service with
respect to an employee benefit plan (hereinafter an &ldquo;<B><I>Indemnitee</I></B>&rdquo;), whether the basis of such proceeding is
alleged action in an official capacity as a director, officer, employee or agent, or in any other capacity while serving as a director,
officer, employee or agent, against all liability and loss suffered and expenses (including, without limitation, attorneys&rsquo; fees,
judgments, fines, ERISA excise taxes and penalties and amounts paid in settlement) reasonably incurred by such Indemnitee in connection
with such proceeding; provided, however, that, except as provided in <U>Section 8.3</U> with respect to proceedings to enforce rights
to indemnification, the Corporation shall indemnify an Indemnitee in connection with a proceeding (or part thereof) initiated by such
Indemnitee only if such proceeding (or part thereof) was authorized by the Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
8.2. Right to Advancement of Expenses</B>. In addition to the right to indemnification conferred in <U>Section 8.1</U>, an Indemnitee
shall also have the right to be paid by the Corporation to the fullest extent not prohibited by applicable law the expenses (including,
without limitation, attorneys&rsquo; fees) incurred in defending or otherwise participating in any such proceeding in advance of its
final disposition (hereinafter an &ldquo;<B><I>advancement of expenses</I></B>&rdquo;); provided, however, that, if the DGCL requires,
an advancement of expenses incurred by an Indemnitee in his or her capacity as a director or officer of the Corporation (and not in any
other capacity in which service was or is rendered by such Indemnitee, including, without limitation, service to an employee benefit
plan) shall be made only upon the Corporation&rsquo;s receipt of an undertaking (hereinafter an &ldquo;<B><I>undertaking</I></B>&rdquo;),
by or on behalf of such Indemnitee, to repay all amounts so advanced if it shall ultimately be determined that such Indemnitee is not
entitled to be indemnified under this <U>Article VIII</U> or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
8.3. Right of Indemnitee to Bring Suit</B>. If a claim under <U>Section 8.1</U> or <U>Section 8.2</U> is not paid in full by the Corporation
within 60 days after a written claim therefor has been received by the Corporation, except in the case of a claim for an advancement
of expenses, in which case the applicable period shall be 20 days, the Indemnitee may at any time thereafter bring suit against the Corporation
to recover the unpaid amount of the claim. If successful in whole or in part in any such suit, or in a suit brought by the Corporation
to recover an advancement of expenses pursuant to the terms of an undertaking, the Indemnitee shall also be entitled to be paid the expense
of prosecuting or defending such suit. In (a) any suit brought by the Indemnitee to enforce a right to indemnification hereunder (but
not in a suit brought by an Indemnitee to enforce a right to an advancement of expenses) it shall be a defense that, and (b) in any suit
brought by the Corporation to recover an advancement of expenses pursuant to the terms of an undertaking, the Corporation shall be entitled
to recover such expenses upon a final judicial decision from which there is no further right to appeal (hereinafter a &ldquo;<B><I>final
adjudication</I></B>&rdquo;) that, the Indemnitee has not met any applicable standard for indemnification set forth in the DGCL. Neither
the failure of the Corporation (including its directors who are not parties to such action, a committee of such directors, independent
legal counsel, or its stockholders) to have made a determination prior to the commencement of such suit that indemnification of the Indemnitee
is proper in the circumstances because the Indemnitee has met the applicable standard of conduct set forth in the DGCL, nor an actual
determination by the Corporation (including a determination by its directors who are not parties to such action, a committee of such
directors, independent legal counsel, or its stockholders) that the Indemnitee has not met such applicable standard of conduct, shall
create a presumption that the Indemnitee has not met the applicable standard of conduct or, in the case of such a suit brought by the
Indemnitee, shall be a defense to such suit. In any suit brought by the Indemnitee to enforce a right to indemnification or to an advancement
of expenses hereunder, or by the Corporation to recover an advancement of expenses pursuant to the terms of an undertaking, the burden
of proving that the Indemnitee is not entitled to be indemnified, or to such advancement of expenses, under this <U>Article VIII</U>
or otherwise shall be on the Corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
8.4. Non-Exclusivity of Rights</B>. The rights provided to any Indemnitee pursuant to this <U>Article VIII</U> shall not be exclusive
of any other right, which such Indemnitee may have or hereafter acquire under applicable law, the Certificate of Incorporation, these
By Laws, an agreement, a vote of stockholders or disinterested directors, or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
8.5. Insurance</B>. The Corporation may maintain insurance, at its expense, to protect itself and/or any director, officer, employee
or agent of the Corporation or another corporation, partnership, joint venture, trust or other enterprise against any expense, liability
or loss, whether or not the Corporation would have the power to indemnify such person against such expense, liability or loss under the
DGCL.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
8.6. Indemnification of Other Persons</B>. This <U>Article VIII</U> shall not limit the right of the Corporation to the extent and in
the manner authorized or permitted by law to indemnify and to advance expenses to persons other than Indemnitees. Without limiting the
foregoing, the Corporation may, to the extent authorized from time to time by the Board, grant rights to indemnification and to the advancement
of expenses to any employee or agent of the Corporation and to any other person who is or was serving at the request of the Corporation
as a director, officer, employee or agent of another corporation or of a partnership, joint venture, trust or other enterprise, including
service with respect to an employee benefit plan, to the fullest extent of the provisions of this <U>Article VIII</U> with respect to
the indemnification and advancement of expenses of Indemnitees under this <U>Article VIII</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
8.7. Amendments</B>. Any repeal or amendment of this <U>Article VIII</U> by the Board or the stockholders of the Corporation or by changes
in applicable law, or the adoption of any other provision of these By Laws inconsistent with this <U>Article VIII</U>, will, to the extent
permitted by applicable law, be prospective only (except to the extent such amendment or change in applicable law permits the Corporation
to provide broader indemnification rights to Indemnitees on a retroactive basis than permitted prior thereto), and will not in any way
diminish or adversely affect any right or protection existing hereunder in respect of any act or omission occurring prior to such repeal
or amendment or adoption of such inconsistent provision; provided however, that amendments or repeals of this <U>Article VIII</U> shall
require the affirmative vote of the stockholders holding at least 66.7% of the voting power of all outstanding shares of capital stock
of the Corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
8.8. Certain Definitions</B>. For purposes of this <U>Article VIII</U>, (a) references to &ldquo;<B><I>other enterprise</I></B>&rdquo;
shall include any employee benefit plan; (b) references to &ldquo;<B><I>fines</I></B>&rdquo; shall include any excise taxes assessed
on a person with respect to an employee benefit plan; (c) references to &ldquo;<B><I>serving at the request of the Corporation</I></B>&rdquo;
shall include any service that imposes duties on, or involves services by, a person with respect to any employee benefit plan, its participants,
or beneficiaries; and (d) a person who acted in good faith and in a manner such person reasonably believed to be in the interest of the
participants and beneficiaries of an employee benefit plan shall be deemed to have acted in a manner &ldquo;not opposed to the best interest
of the Corporation&rdquo; for purposes of Section 145 of the DGCL.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
8.9. Contract Rights</B>. The rights provided to Indemnitees pursuant to this <U>Article VIII</U> shall be contract rights and such rights
shall continue as to an Indemnitee who has ceased to be a director, officer, agent or employee and shall inure to the benefit of the
Indemnitee&rsquo;s heirs, executors and administrators.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
8.10. Severability</B>. If any provision or provisions of this <U>Article VIII</U> shall be held to be invalid, illegal or unenforceable
for any reason whatsoever: (a) the validity, legality and enforceability of the remaining provisions of this <U>Article VIII</U> shall
not in any way be affected or impaired thereby; and (b) to the fullest extent possible, the provisions of this <U>Article VIII</U> (including,
without limitation, each such portion of this <U>Article VIII</U> containing any such provision held to be invalid, illegal or unenforceable)
shall be construed so as to give effect to the intent manifested by the provision held invalid, illegal or unenforceable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
IX</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MISCELLANEOUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
9.1. Place of Meetings</B>. If the place of any meeting of stockholders, the Board or committee of the Board for which notice is required
under these By Laws is not designated in the notice of such meeting, such meeting shall be held at the principal business office of the
Corporation; provided, however, if the Board has, in its sole discretion, determined that a meeting shall not be held at any place, but
instead shall be held by means of remote communication pursuant to <U>Section 9.5</U> hereof, then such meeting shall not be held at
any place.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
9.2. Fixing Record Dates</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
In order that the Corporation may determine the stockholders entitled to notice of any meeting of stockholders or any adjournment thereof,
the Board may fix a record date, which shall not precede the date upon which the resolution fixing the record date is adopted by the
Board, and which record date shall not be more than 60 nor less than 10 days before the date of such meeting. If the Board so fixes a
date, such date shall also be the record date for determining the stockholders entitled to vote at such meeting unless the Board determines,
at the time it fixes such record date, that a later date on or before the date of the meeting shall be the date for making such determination.
If no record date is fixed by the Board, the record date for determining stockholders entitled to notice of and to vote at a meeting
of stockholders shall be at the close of business on the business day next preceding the day on which notice is given, or, if notice
is waived, at the close of business on the business day next preceding the day on which the meeting is held. A determination of stockholders
of record entitled to notice of or to vote at a meeting of stockholders shall apply to any adjournment of the meeting; provided, however,
that the Board may fix a new record date for the adjourned meeting, and in such case shall also fix as the record date for stockholders
entitled to notice of such adjourned meeting the same or an earlier date as that fixed for determination of stockholders entitled to
vote in accordance with the foregoing provisions of this <U>Section 9.2(a)</U> at the adjourned meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
In order that the Corporation may determine the stockholders entitled to receive payment of any dividend or other distribution or allotment
of any rights or the stockholders entitled to exercise any rights in respect of any change, conversion or exchange of stock, or for the
purpose of any other lawful action, the Board may fix a record date, which record date shall not precede the date upon which the resolution
fixing the record date is adopted, and which record date shall be not more than 60 days prior to such action. If no record date is fixed,
the record date for determining stockholders for any such purpose shall be at the close of business on the day on which the Board adopts
the resolution relating thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
9.3. Means of Giving Notice</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Notice to Directors</U>. Whenever under applicable law, the Certificate of Incorporation or these By Laws notice is required to be
given to any director, such notice shall be given either (i) in writing and sent by mail, or by a nationally recognized delivery service,
(ii) by means of facsimile telecommunication or other form of electronic transmission, or (iii) by oral notice given personally or by
telephone. A notice to a director will be deemed given as follows: (i) if given by hand delivery, orally, or by telephone, when actually
received by the director, (ii) if sent through the United States mail, when deposited in the United States mail, with postage and fees
thereon prepaid, addressed to the director at the director&rsquo;s address appearing on the records of the Corporation, (iii) if sent
for next day delivery by a nationally recognized overnight delivery service, when deposited with such service, with fees thereon prepaid,
addressed to the director at the director&rsquo;s address appearing on the records of the Corporation, (iv) if sent by facsimile telecommunication,
when sent to the facsimile transmission number for such director appearing on the records of the Corporation, (v) if sent by electronic
mail, when sent to the electronic mail address for such director appearing on the records of the Corporation, or (vi) if sent by any
other form of electronic transmission, when sent to the address, location or number (as applicable) for such director appearing on the
records of the Corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Notice to Stockholders</U>. Whenever under applicable law, the Certificate of Incorporation or these By Laws notice is required to
be given to any stockholder, such notice may be given (i) in writing and sent either by hand delivery, through the United States mail,
or by a nationally recognized overnight delivery service for next day delivery, or (ii) by means of a form of electronic transmission
consented to by the stockholder, to the extent permitted by, and subject to the conditions set forth in Section 232 of the DGCL. A notice
to a stockholder shall be deemed given as follows: (i) if given by hand delivery, when actually received by the stockholder, (ii) if
sent through the United States mail, when deposited in the United States mail, with postage and fees thereon prepaid, addressed to the
stockholder at the stockholder&rsquo;s address appearing on the stock ledger of the Corporation, (iii) if sent for next day delivery
by a nationally recognized overnight delivery service, when deposited with such service, with fees thereon prepaid, addressed to the
stockholder at the stockholder&rsquo;s address appearing on the stock ledger of the Corporation, and (iv) if given by a form of electronic
transmission consented to by the stockholder to whom the notice is given and otherwise meeting the requirements set forth above, (A)
if by facsimile transmission, when directed to a number at which the stockholder has consented to receive notice, (B) if by electronic
mail, when directed to an electronic mail address at which the stockholder has consented to receive notice, (C) if by a posting on an
electronic network together with separate notice to the stockholder of such specified posting, upon the later of (1) such posting and
(2) the giving of such separate notice, and (D) if by any other form of electronic transmission, when directed to the stockholder. A
stockholder may revoke such stockholder&rsquo;s consent to receiving notice by means of electronic communication by giving written notice
of such revocation to the Corporation. Any such consent shall be deemed revoked if (1) the Corporation is unable to deliver by electronic
transmission two consecutive notices given by the Corporation in accordance with such consent and (2) such inability becomes known to
the Secretary or an Assistant Secretary or to the Corporation&rsquo;s transfer agent, or other person responsible for the giving of notice;
provided, however, the inadvertent failure to treat such inability as a revocation shall not invalidate any meeting or other action.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Electronic Transmission</U>. &ldquo;<B><I>Electronic transmission</I></B>&rdquo; means any form of communication, not directly involving
the physical transmission of paper, that creates a record that may be retained, retrieved and reviewed by a recipient thereof, and that
may be directly reproduced in paper form by such a recipient through an automated process, including but not limited to transmission
by telex, facsimile telecommunication, electronic mail, telegram and cablegram.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<U>Notice to Stockholders Sharing Same Address</U>. Without limiting the manner by which notice otherwise may be given effectively by
the Corporation to stockholders, any notice to stockholders given by the Corporation under any provision of the DGCL, the Certificate
of Incorporation or these By Laws shall be effective if given by a single written notice to stockholders who share an address if consented
to by the stockholders at that address to whom such notice is given. A stockholder may revoke such stockholder&rsquo;s consent by delivering
written notice of such revocation to the Corporation. Any stockholder who fails to object in writing to the Corporation within 60 days
of having been given written notice by the Corporation of its intention to send such a single written notice shall be deemed to have
consented to receiving such single written notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
<U>Exceptions to Notice Requirements</U>. Whenever notice is required to be given, under the DGCL, the Certificate of Incorporation or
these By Laws, to any person with whom communication is unlawful, the giving of such notice to such person shall not be required and
there shall be no duty to apply to any governmental authority or agency for a license or permit to give such notice to such person. Any
action or meeting that shall be taken or held without notice to any such person with whom communication is unlawful shall have the same
force and effect as if such notice had been duly given. In the event that the action taken by the Corporation is such as to require the
filing of a certificate with the Secretary of State of Delaware, the certificate shall state, if such is the fact and if notice is required,
that notice was given to all persons entitled to receive notice except such persons with whom communication is unlawful. Whenever notice
is required to be given by the Corporation, under any provision of the DGCL, the Certificate of Incorporation or these By Laws, to any
stockholder to whom (1) notice of two consecutive annual meetings of stockholders and all notices of stockholder meetings or of the taking
of action by written consent of stockholders without a meeting to such stockholder during the period between such two consecutive annual
meetings, or (2) all, and at least two payments (if sent by first-class mail) of dividends or interest on securities during a 12-month
period, have been mailed addressed to such stockholder at such stockholder&rsquo;s address as shown on the records of the Corporation
and have been returned undeliverable, the giving of such notice to such stockholder shall not be required. Any action or meeting that
shall be taken or held without notice to such stockholder shall have the same force and effect as if such notice had been duly given.
If any such stockholder shall deliver to the Corporation a written notice setting forth such stockholder&rsquo;s then current address,
the requirement that notice be given to such stockholder shall be reinstated. In the event that the action taken by the Corporation is
such as to require the filing of a certificate with the Secretary of State of Delaware, the certificate need not state that notice was
not given to persons to whom notice was not required to be given pursuant to Section 230(b) of the DGCL. The exception in subsection
(1) of the first sentence of this paragraph to the requirement that notice be given shall not be applicable to any notice returned as
undeliverable if the notice was given by electronic transmission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
9.4. Waiver of Notice</B>. Whenever any notice is required to be given under applicable law, the Certificate of Incorporation, or these
By Laws, a written waiver of such notice, signed by the person or persons entitled to said notice, or a waiver by electronic transmission
by the person entitled to said notice, whether before or after the time stated therein, shall be deemed equivalent to such required notice.
All such waivers shall be kept with the books of the Corporation. Attendance at a meeting shall constitute a waiver of notice of such
meeting, except where a person attends for the express purpose of objecting to the transaction of any business on the ground that the
meeting was not lawfully called or convened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
9.5. Meeting Attendance via Remote Communication Equipment.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Stockholder Meetings</U>. If authorized by the Board in its sole discretion, and subject to such guidelines and procedures as the
Board may adopt, stockholders entitled to vote at such meeting and proxy holders not physically present at a meeting of stockholders
may, by means of remote communication:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 48.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 40pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
participate in a meeting of stockholders; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 40pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 40pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
be deemed present in person and vote at a meeting of stockholders, whether such meeting is to be held at a designated place or solely
by means of remote communication, provided that (A) the Corporation shall implement reasonable measures to verify that each person deemed
present and permitted to vote at the meeting by means of remote communication is a stockholder or proxy holder, (B) the Corporation shall
implement reasonable measures to provide such stockholders and proxy holders a reasonable opportunity to participate in the meeting and,
if entitled to vote, to vote on matters submitted to the applicable stockholders, including an opportunity to read or hear the proceedings
of the meeting substantially concurrently with such proceedings, and (C) if any stockholder or proxy holder votes or takes other action
at the meeting by means of remote communication, a record of such votes or other action shall be maintained by the Corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Board Meetings</U>. Unless otherwise restricted by applicable law, the Certificate of Incorporation or these By Laws, members of the
Board or any committee thereof may participate in a meeting of the Board or any committee thereof by means of conference telephone or
other communications equipment by means of which all persons participating in the meeting can hear each other. Such participation in
a meeting shall constitute presence in person at the meeting, except where a person participates in the meeting for the express purpose
of objecting to the transaction of any business on the ground that the meeting was not lawfully called or convened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
9.6. Dividends</B>. The Board may from time to time declare, and the Corporation may pay, dividends (payable in cash, property or shares
of the Corporation&rsquo;s capital stock) on the Corporation&rsquo;s outstanding shares of capital stock, subject to applicable law and
the Certificate of Incorporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
9.7. Reserves</B>. The Board may set apart out of the funds of the Corporation available for dividends a reserve or reserves for any
proper purpose and may abolish any such reserve.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
9.8. Contracts and Negotiable Instruments</B>. Except as otherwise provided by applicable law, the Certificate of Incorporation or these
By Laws, any contract, bond, deed, lease, mortgage or other instrument may be executed and delivered in the name and on behalf of the
Corporation by such officer or officers or other employee or employees of the Corporation as the Board may from time to time authorize.
Such authority may be general or confined to specific instances as the Board may determine. The Chairman of the Board, any Chief Executive
Officer, the President, the Chief Financial Officer, the Treasurer or any Vice President may execute and deliver any contract, bond,
deed, lease, mortgage or other instrument in the name and on behalf of the Corporation. Subject to any restrictions imposed by the Board,
the Chairman of the Board , any Chief Executive Officer, President, the Chief Financial Officer, the Treasurer or any Vice President
may delegate powers to execute and deliver any contract, bond, deed, lease, mortgage or other instrument in the name and on behalf of
the Corporation to other officers or employees of the Corporation under such person&rsquo;s supervision and authority, it being understood,
however, that any such delegation of power shall not relieve such officer of responsibility with respect to the exercise of such delegated
power.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
9.9. Fiscal Year</B>. The fiscal year of the Corporation shall be fixed by the Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
9.10. Seal</B>. The Board may adopt a corporate seal, which shall be in such form as the Board determines. The seal may be used by causing
it or a facsimile thereof to be impressed, affixed or otherwise reproduced.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
9.11. Books and Records</B>. The books and records of the Corporation may be kept within or outside the State of Delaware at such place
or places as may from time to time be designated by the Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
9.12. Resignation</B>. Any director, committee member or officer may resign by giving notice thereof in writing or by electronic transmission
to the Chairman of the Board, any Chief Executive Officer, the President or the Secretary. The resignation shall take effect at the time
it is delivered unless the resignation specifies a later effective date or an effective date determined upon the happening of an event
or events. Unless otherwise specified therein, the acceptance of such resignation shall not be necessary to make it effective.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
9.13. Surety Bonds</B>. Such officers, employees and agents of the Corporation (if any) as the Chairman of the Board, any Chief Executive
Officer, President or the Board may direct, from time to time, shall be bonded for the faithful performance of their duties and for the
restoration to the Corporation, in case of their death, resignation, retirement, disqualification or removal from office, of all books,
papers, vouchers, money and other property of whatever kind in their possession or under their control belonging to the Corporation,
in such amounts and by such surety companies as the Chairman of the Board, any Chief Executive Officer, President or the Board may determine.
The premiums on such bonds shall be paid by the Corporation and the bonds so furnished shall be in the custody of the Secretary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
9.14. Securities of Other Corporations</B>. Powers of attorney, proxies, waivers of notice of meeting, consents in writing and other
instruments relating to securities owned by the Corporation may be executed in the name of and on behalf of the Corporation by the Chairman
of the Board, any Chief Executive Officer, President, any Vice President or any officers authorized by the Board. Any such officer, may,
in the name of and on behalf of the Corporation, take all such action as any such officer may deem advisable to vote in person or by
proxy at any meeting of security holders of any corporation in which the Corporation may own securities, or to consent in writing, in
the name of the Corporation as such holder, to any action by such corporation, and at any such meeting or with respect to any such consent
shall possess and may exercise any and all rights and power incident to the ownership of such securities and which, as the owner thereof,
the Corporation might have exercised and possessed. The Board may from time to time confer like powers upon any other person or persons.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
9.15. Amendments</B>. The Board shall have the power to adopt, amend, alter or repeal the By Laws. The affirmative vote of a majority
of the Board shall be required to adopt, amend, alter or repeal the By Laws. The By Laws also may be adopted, amended, altered or repealed
by the stockholders; provided, however, that in addition to any vote of the holders of any class or series of capital stock of the Corporation
required by applicable law or the Certificate of Incorporation, the affirmative vote of the holders of at least a majority of the voting
power (except as otherwise provided in Section 8.7) of all outstanding shares of capital stock of the Corporation entitled to vote generally
in the election of directors, voting together as a single class, shall be required for the stockholders to adopt, amend, alter or repeal
the By Laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>4
<FILENAME>ex4-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
4.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WARRANT
AGREEMENT<BR>
between<BR>
DATA KNIGHTS ACQUISITION CORP.<BR>
and<BR>
CONTINENTAL STOCK TRANSFER &amp; TRUST COMPANY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THIS
WARRANT AGREEMENT (this &ldquo;<B><I>Agreement</I></B>&rdquo;), dated as of [&nbsp;&nbsp;], 2021, is by and between Data Knights Acquisition Corp.,
a Delaware corporation (the &ldquo;<B><I>Company</I></B>&rdquo;), and Continental Stock Transfer &amp; Trust Company, a New York corporation,
as warrant agent (the &ldquo;<B><I>Warrant Agent</I></B>&rdquo;, also referred to herein as the &ldquo;<B><I>Transfer Agent</I></B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
the Company is engaged in an initial public offering (the &ldquo;<B><I>Offering</I></B>&rdquo;) of units of the Company&rsquo;s equity
securities, each such unit comprised of one share of Class A common stock of the Company, par value $0.0001 per share (&ldquo;<B><I>Common
Stock</I></B>&rdquo;), and one redeemable Public Warrant (as defined below) (the &ldquo;<B><I>Public Units</I></B>&rdquo;) and, in connection
therewith, has determined to issue and deliver up to 10,000,000 warrants (or up to 11,500,000 warrants if the Over-allotment Option (as
defined below) is exercised in full) to public investors in the Offering (the &ldquo;<B><I>Public Warrants</I></B>&rdquo;). Each Warrant
entitles the holder thereof to purchase one share of Common Stock for $11.50 per share, subject to adjustment as described herein; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
on [&nbsp;&nbsp;], 2021, the Company entered into that certain Placement Unit Purchase Agreement with Data Knights, LLC, a Delaware limited liability
company (the &ldquo;<B><I>Sponsor</I></B>&rdquo;), pursuant to which the Sponsor agreed to purchase an aggregate of 525,275 private placement
units (or up to 585,275 private placement units if the underwriters in the Offering exercise their Over-allotment Option in full) simultaneously
with the closing of the Offering (and the closing the Over-allotment Option, if applicable) (the &ldquo;<B><I>Private Placement Units</I></B>&rdquo;
and, together with the Public Units, the &ldquo;<B><I>Units</I></B>&rdquo;) at a purchase price of $10.00 per Unit, and, in connection
therewith, will issue and deliver up to an aggregate of 525,275 warrants (or up to 585,275 warrants if the Over-allotment Option is exercised
in full) underlying such Private Placement Units bearing the legend set forth in Exhibit B hereto (&ldquo;<B><I>Private Placement Warrants</I></B>&rdquo;);
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
in order to finance the Company&rsquo;s transaction costs in connection with an intended initial Business Combination (as defined below),
the Sponsor or an affiliate of the Sponsor or certain of the Company&rsquo;s executive officers and directors may, but are not obligated
to, loan to the Company funds as the Company may require, of which up to $1,500,000 of such loans may be convertible into up to an additional
150,000 Units at a price of $10.00 per Unit, and, in connection therewith, will issue and deliver up to an aggregate of 150,000 warrants
(the &ldquo;<B><I>Working Capital Warrants</I></B>&rdquo;); and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
in order to extend the period of time the Company has to consummate a Business Combination (defined below) as described in the Prospectus
(as defined below), the Sponsor or its affiliates or designees may, but are not obligated to, loan the Company funds as the Company may
require, of which up to $2,000,000 (or up to $2,300,000 if the Over-allotment Option is exercised in full) of such loans may be convertible
into up to an additional 200,000 Units (or up to 230,000 Units if the Over-allotment Option is exercised in full) at a price of $10.00
per Unit at the option of the lender, and, in connection therewith, will issue and deliver up to an additional of 200,000 Warrants (or
up to 230,000 Warrants if the Over-allotment Option is exercised in full) (the &ldquo;<B><I>Extension Warrants</I></B>&rdquo;); and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
following consummation of the Offering, the Company may issue additional warrants (&ldquo;<B><I>Post IPO Warrants</I></B>,&rdquo; and,
together with the Private Placement Warrants, the Working Capital Warrants, the Extension Warrants and the Public Warrants, the &ldquo;<B><I>Warrants</I></B>&rdquo;)
in connection with, or following the consummation by the Company of, a Business Combination (defined below); and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
the Company has filed with the Securities and Exchange Commission (the &ldquo;<B><I>Commission</I></B>&rdquo;) a registration statement
on Form S-1, File No. 333-254029 (the &ldquo;<B><I>Registration Statement</I></B>&rdquo;) and prospectus (the &ldquo;<B><I>Prospectus</I></B>&rdquo;),
for the registration, under the Securities Act of 1933, as amended (the &ldquo;<B><I>Securities Act</I></B>&rdquo;), of the Public Units,
and the Public Warrants and the Common Stock included in the Public Units; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
the Company desires the Warrant Agent to act on behalf of the Company, and the Warrant Agent is willing to so act, in connection with
the issuance, registration, transfer, exchange, redemption and exercise of the Warrants; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
the Company desires to provide for the form and provisions of the Warrants, the terms upon which they shall be issued and exercised,
and the respective rights, limitation of rights, and immunities of the Company, the Warrant Agent, and the holders of the Warrants; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
all acts and things have been done and performed which are necessary to make the Warrants, when executed on behalf of the Company and
countersigned by or on behalf of the Warrant Agent (if a physical certificate is issued), as provided herein, the valid, binding and
legal obligations of the Company, and to authorize the execution and delivery of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOW,
THEREFORE, in consideration of the mutual agreements herein contained, the parties hereto agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
<U>Appointment of Warrant Agent</U>. The Company hereby appoints the Warrant Agent to act as agent for the Company for the Warrants,
and the Warrant Agent hereby accepts such appointment and agrees to perform the same in accordance with the terms and conditions set
forth in this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
<U>Warrants</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1
<U>Form of Warrant</U>. Each Warrant shall be issued in registered form only.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2
<U>Effect of Countersignature</U>. If a physical certificate is issued, unless and until countersigned by the Warrant Agent pursuant
to this Agreement, a Warrant represented by such physical certificate shall be invalid and of no effect and may not be exercised by the
holder thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3
<U>Registration</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3.1
<U>Warrant Register</U>. The Warrant Agent shall maintain books (the &ldquo;<B><I>Warrant Register</I></B>&rdquo;), for the registration
of original issuance and the registration of transfer of the Warrants. Upon the initial issuance of the Warrants in book entry form,
the Warrant Agent shall issue and register the Warrants in the names of the respective holders thereof in such denominations and otherwise
in accordance with instructions delivered to the Warrant Agent by the Company. Ownership of beneficial interests in the Public Warrants
shall be shown on, and the transfer of such ownership shall be effected through, records maintained by institutions that have accounts
with the Depository Trust Company (the &ldquo;<B><I>Depositary</I></B>&rdquo;) (such institution, with respect to a Warrant in its account,
a &ldquo;<B><I>Participant</I></B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the Depositary subsequently ceases to make its book-entry settlement system available for the Public Warrants, the Company may instruct
the Warrant Agent regarding making other arrangements for book-entry settlement. In the event that the Public Warrants are not eligible
for, or it is no longer necessary to have the Public Warrants available in, book-entry form, the Warrant Agent shall provide written
instructions to the Depositary to deliver to the Warrant Agent for cancellation each book-entry Public Warrant, and the Company shall
instruct the Warrant Agent to deliver to the Depositary definitive certificates in physical form evidencing such Warrants which shall
be in the form annexed hereto as Exhibit A.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Physical
certificates, if issued, shall be signed by, or bear the facsimile signature of, the Chairman of the Board, Chief Executive Officer,
Chief Financial Officer, Secretary or other principal officer of the Company. In the event the person whose facsimile signature has been
placed upon any Warrant shall have ceased to serve in the capacity in which such person signed the Warrant before such Warrant is issued,
it may be issued with the same effect as if he or she had not ceased to be such at the date of issuance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3.2
<U>Registered Holder</U>. Prior to due presentment for registration of transfer of any Warrant, the Company and the Warrant Agent may
deem and treat the person in whose name such Warrant is registered in the Warrant Register (the &ldquo;<B><I>Registered Holder</I></B>&rdquo;)
as the absolute owner of such Warrant and of each Warrant represented thereby (notwithstanding any notation of ownership or other writing
on any physical certificate made by anyone other than the Company or the Warrant Agent), for the purpose of any exercise thereof, and
for all other purposes, and neither the Company nor the Warrant Agent shall be affected by any notice to the contrary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4
<U>Detachability of Warrants</U>. The Common Stock and the Public Warrants comprising the Public Units shall begin separate trading on
the 52nd day following the date of the Prospectus or, if such 52nd day is not on a day, other than a Saturday, Sunday or federal holiday,
on which banks in New York City are generally open for normal business (a &ldquo;<B><I>Business Day</I></B>&rdquo;), then on the immediately
succeeding Business Day following such date, or earlier (the &ldquo;<B><I>Detachment Date</I></B>&rdquo;) with the consent of Kingswood
Capital Markets, division of Benchmark Investments, Inc. (&ldquo;<B><I>Kingswood</I></B>&rdquo;), as the representative of the several
underwriters for the Offering, but in no event shall the Common Stock and the Public Warrants comprising the Public Units be separately
traded until (A) the Company has filed a current report on Form 8-K with the Commission containing an audited balance sheet reflecting
the receipt by the Company of the gross proceeds of the Offering, including the proceeds received by the Company from the exercise by
the underwriters of their right to purchase additional Public Units in the Offering (the &ldquo;<B><I>Over-allotment Option</I></B>&rdquo;),
if the Over-allotment Option is exercised prior to the filing of the Form 8-K, and (B) the Company issues a press release and files with
the Commission a current report on Form 8-K announcing when such separate trading shall begin. If the Over-allotment Option is exercised
following the filing of a current report on Form 8-K pursuant to (A) above, a second or amended current report on Form 8-K will be filed
to provide updated financial information to reflect the exercise of the Over-allotment Option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.5
<U>No Fractional Warrants</U>. The Company shall not issue fractional Warrants. If, upon the detachment of Public Warrants from Public
Units or otherwise, a holder of Warrants would be entitled to receive a fractional Warrant, the Company shall round down to the nearest
whole number the number of Warrants to be issued to such holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.6
<U>Private Placement Warrants</U>, <U>Working Capital Warrants</U>, and Extension Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Private Placement Warrants, the Working Capital Warrants, and the Extension Warrants shall be identical to the Public Warrants, except
that so long as they are held by the Sponsor or any of its Permitted Transferees (as defined below), as applicable, the Private Placement
Warrants, the Working Capital Warrants, and the Extension Warrants: (i) may be exercised for cash or on a cashless basis, pursuant to
subsection 3.3.1(c) hereof, (ii) may not be transferred, assigned or sold until 30 days after the completion by the Company of an initial
Business Combination (as defined below), and (iii) shall not be redeemable by the Company; provided, however, that in the case of (ii),
the Private Placement Warrants, the Working Capital Warrants, the Extension Warrants , and any shares of Common Stock held by the Sponsor
or any of its Permitted Transferees, and issued upon exercise of the Private Placement Warrants, the Working Capital Warrants, or the
Extension Warrants may be transferred by the holders thereof:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
to the Company&rsquo;s officers or directors, any affiliates or family members of any of the Company&rsquo;s officers or directors, any
affiliate of the Sponsor, or to any members of the Sponsor or any of its affiliates, officers, directors and direct and indirect equity
holders;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
in the case of an individual, by gift to a member of the individual&rsquo;s immediate family, to a trust, the beneficiary of which is
a member of the individual&rsquo;s immediate family, or an affiliate of such person, or to a charitable organization;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
in the case of an individual, by virtue of the laws of descent and distribution upon death of such individual;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
in the case of an individual, pursuant to a qualified domestic relations order;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
by private sales or transfers made in connection with the consummation of the Company&rsquo;s initial Business Combination at prices
no greater than the price at which the Warrants were originally purchased;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
in the event of the Company&rsquo;s liquidation prior to the completion of the Company&rsquo;s initial Business Combination; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
by virtue of the laws of the State of Delaware or the Sponsor&rsquo;s limited liability company agreement upon dissolution of the Sponsor;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">provided,
however, that, in the case of clauses (a) through (e), or (g), these transferees (the &ldquo;<B><I>Permitted Transferees</I></B>&rdquo;)
must enter into a written agreement agreeing to be bound by the transfer restrictions in this Agreement and the other restrictions contained
in the letter agreement, dated as of the date hereof, by and among the Company, the Sponsor and the Company&rsquo;s directors and officers
and by the same agreements entered into by the Sponsor with respect to such securities (including provisions relating to voting, the
trust account and liquidation distributions described elsewhere in the Prospectus).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.7
<U>Post-IPO Warrants</U>. The Post-IPO Warrants, when and if issued, shall have the same terms and be in the same form as the Public
Warrants except as may be agreed upon by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
<U>Terms and Exercise of Warrants</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1
<U>Warrant Price</U>. Each Warrant shall, when countersigned by the Warrant Agent (if a physical certificate is issued), entitle the
Registered Holder thereof, subject to the provisions of such Warrant and of this Agreement, to purchase from the Company the number of
shares of Common Stock stated therein, at the price of $11.50 per share, subject to the adjustments provided in Section 4 hereof and
in the last sentence of this Section 3.1. The term &ldquo;<B><I>Warrant Price</I></B>&rdquo; as used in this Agreement shall mean the
price per share at which shares of Common Stock may be purchased at the time a Warrant is exercised. The Company in its sole discretion
may lower the Warrant Price at any time prior to the Expiration Date (as defined below) for a period of not less than twenty (20) Business
Days, provided, that the Company shall provide at least twenty (20) days prior written notice of such reduction to Registered Holders
of the Warrants and, provided further that any such reduction shall be identical among all of the Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2
<U>Duration of Warrants</U>. A Warrant may be exercised only during the period (the &ldquo;<B><I>Exercise Period</I></B>&rdquo;) commencing
on the later of: (i) the date that is thirty (30) days from the date on which the Company completes a merger, capital stock exchange,
asset acquisition, stock purchase, reorganization or similar business combination, involving the Company and one or more businesses (a
&ldquo;<B><I>Business Combination</I></B>&rdquo;), and (ii) the date that is twelve (12) months from the date of the closing of the Offering,
and terminating at 5:00 p.m., New York City time on the earlier to occur of: (w) the date that is five (5) years after the date on which
the Company completes its Business Combination, (x) the liquidation of the Company in accordance with the Company&rsquo;s amended and
restated certificate of incorporation, as amended from time to time, if the Company fails to complete a Business Combination, or (y)
other than with respect to the Private Placement Warrants, Working Capital Warrants, or the Extension Warrants then held by the Sponsor
or any officers or directors of the Company, or any of their Permitted Transferees as provided in <U>Section 6.1</U>, the Redemption
Date (as defined below) as provided in <U>Section 6.2</U> hereof (the &ldquo;<B><I>Expiration Date</I></B>&rdquo;); provided, however,
that the exercise of any Warrant shall be subject to the satisfaction of any applicable conditions, as set forth in <U>subsection 3.3.2
</U>below with respect to an effective registration statement. Except with respect to the right to receive the Redemption Price (as defined
below), in the event of a redemption (as set forth in Section 6 hereof), each outstanding Warrant (other than a Private Placement Warrant,
Working Capital Warrant, or Extension Warrant held by the Sponsor or any officers or directors of the Company, or their Permitted Transferees,
in the event of a redemption for cash) not exercised on or before the Expiration Date shall become void, and all rights thereunder and
all rights in respect thereof under this Agreement shall cease at 5:00 p.m. New York City time on the Expiration Date. The Company in
its sole discretion may extend the duration of the Warrants by delaying the Expiration Date; provided, that the Company shall provide
at least twenty (20) days prior written notice of any such extension to Registered Holders of the Warrants and, provided further that
any such extension shall be identical in duration among all the Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3
<U>Exercise of Warrants</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3.1
<U>Payment</U>. Subject to the provisions of the Warrant and this Agreement, a Warrant, when countersigned by the Warrant Agent (if a
physical certificate is issued), may be exercised by the Registered Holder thereof by surrendering it, at the office of the Warrant Agent,
or at the office of its successor as Warrant Agent, in the Borough of Manhattan, City and State of New York, with the subscription form,
as set forth in the Warrant, duly executed, and by paying in full the Warrant Price for each full share of Common Stock as to which the
Warrant is exercised and any and all applicable taxes due in connection with the exercise of the Warrant, the exchange of the Warrant
for the shares of Common Stock and the issuance of such shares of Common Stock, as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
in lawful money of the United States, in good certified check, good bank draft or wire payable to the Warrant Agent;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
in the event of a redemption pursuant to Section 6 hereof in which the Company&rsquo;s board of directors (the &ldquo;<B><I>Board</I></B>&rdquo;)
has elected to require all holders of the Warrants to exercise such Warrants on a &ldquo;cashless basis,&rdquo; by surrendering the Warrants
for that number of shares of Common Stock equal to the quotient obtained by dividing (x) the product of the number of shares of Common
Stock underlying the Warrants, multiplied by the excess of the &ldquo;<B><I>Fair Market Value</I></B>&rdquo;, as defined in this <U>subsection
3.3.1(b)</U>, over the Warrant Price by (y) the Fair Market Value. Solely for purposes of this <U>subsection 3.3.1(b)</U> and <U>Section
6.3</U>, the &ldquo;<B><I>Fair Market Value</I></B>&rdquo; shall mean the average last reported sale price of the Common Stock for the
ten (10) trading days ending on the third trading day prior to the date on which the notice of redemption is sent to the holders of the
Warrants, pursuant to Section 6 hereof;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
with respect to any Private Placement Warrant, Working Capital Warrant, or Extension Warrant, so long as such Private Placement Warrant,
Working Capital Warrant, or Extension Warrant is held by the Sponsor or any officer or director of the Company, or their Permitted Transferees,
by surrendering the Warrants for that number of shares of Common Stock equal to the quotient obtained by dividing (x) the product of
the number of shares of Common Stock underlying the Warrants, multiplied by the excess of the &ldquo;<B><I>Fair Market Value</I></B>&rdquo;,
as defined in this <U>subsection 3.3.1(c)</U>, over the Warrant Price by (y) the Fair Market Value. Solely for purposes of this <U>subsection
3.3.1(c)</U>, the &ldquo;<B><I>Fair Market Value</I></B>&rdquo; shall mean the average last reported sale price of the Common Stock for
the ten (10) trading days ending on the third trading day prior to the date on which notice of exercise of the Private Placement Warrant,
Working Capital Warrant, or Extension Warrants is sent to the Warrant Agent; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
as provided in <U>Section 7.4</U> hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3.2
<U>Issuance of Shares of Common Stock on Exercise</U>. As soon as practicable after the exercise of any Warrant and the clearance of
the funds in payment of the Warrant Price (if payment is pursuant to <U>subsection 3.3.1(a)</U>), the Company shall issue to the Registered
Holder of such Warrant a book-entry position or certificate, as applicable, for the number of full shares of Common Stock to which he,
she or it is entitled, registered in such name or names as may be directed by him, her or it, and if such Warrant shall not have been
exercised in full, a new book-entry position or countersigned Warrant, as applicable, for the number of shares of Common Stock as to
which such Warrant shall not have been exercised. Notwithstanding the foregoing, the Company shall not be obligated to deliver any shares
of Common Stock pursuant to the exercise of a Warrant and shall have no obligation to settle such Warrant exercise unless a registration
statement under the Securities Act with respect to the shares of Common Stock underlying the Public Warrants is then effective and a
prospectus relating thereto is current, subject to the Company&rsquo;s satisfying its obligations under <U>Section 7.4</U>. No Warrant
shall be exercisable and the Company shall not be obligated to issue shares of Common Stock upon exercise of a Warrant unless the Common
Stock issuable upon such Warrant exercise has been registered, qualified or deemed to be exempt from registration or qualification under
the securities laws of the state of residence of the Registered Holder of the Warrants. In the event that the conditions in the two immediately
preceding sentences are not satisfied with respect to a Warrant, the holder of such Warrant shall not be entitled to exercise such Warrant
and such Warrant may have no value and expire worthless, in which case the purchaser of a Unit containing such Public Warrants shall
have paid the full purchase price for the Unit solely for the shares of Common Stock underlying such Unit. In no event will the Company
be required to net cash settle the Warrant exercise. The Company may require holders of Public Warrants to settle the Warrant on a &ldquo;cashless
basis&rdquo; pursuant to <U>Section 7.4</U>. If, by reason of any exercise of warrants on a &ldquo;cashless basis&rdquo;, the holder
of any Warrant would be entitled, upon the exercise of such Warrant, to receive a fractional interest in a share of Common Stock, the
Company shall round down to the nearest whole number, the number of shares of Common Stock to be issued to such holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3.3
<U>Valid Issuance</U>. All shares of Common Stock issued upon the proper exercise of a Warrant in conformity with this Agreement shall
be validly issued, fully paid and non-assessable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3.4
<U>Date of Issuance</U>. Each person in whose name any book-entry position or certificate, as applicable, for shares of Common Stock
is issued shall for all purposes be deemed to have become the holder of record of such shares of Common Stock on the date on which the
Warrant, or book-entry position representing such Warrant, was surrendered and payment of the Warrant Price was made, irrespective of
the date of delivery of such certificate in the case of a certificated Warrant, except that, if the date of such surrender and payment
is a date when the share transfer books of the Company or book-entry system of the Warrant Agent are closed, such person shall be deemed
to have become the holder of such shares of Common Stock at the close of business on the next succeeding date on which the share transfer
books or book-entry system are open.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3.5
<U>Maximum Percentage</U>. A holder of a Warrant may notify the Company in writing in the event it elects to be subject to the provisions
contained in this <U>subsection 3.3.5</U>; however, no holder of a Warrant shall be subject to this <U>subsection 3.3.5 </U>unless he,
she or it makes such election. If the election is made by a holder, the Warrant Agent shall not effect the exercise of the holder&rsquo;s
Warrant, and such holder shall not have the right to exercise such Warrant, to the extent that after giving effect to such exercise,
such person and any of its affiliates or any other person subject to aggregation with such person for purposes of the &ldquo;beneficial
ownership&rdquo; test under Section 13 of the Securities Exchange Act of 1934, as amended (the &ldquo;<B><I>Exchange Act</I></B>&rdquo;),
or any &ldquo;group&rdquo; (within the meaning of Section 13 of the Exchange Act) of which such person is or may be deemed to be a part,
would beneficially own (within the meaning of Section 13 of the Exchange Act) (or to the extent that for any reason the equivalent calculation
under Section 16 of the Exchange Act and the rules and regulations thereunder would result in a higher ownership percentage, such higher
percentage would be) in excess of 4.9% or 9.8% (as specified by the holder) (the &ldquo;<B><I>Maximum Percentage</I></B>&rdquo;) of the
shares of Common Stock outstanding immediately after giving effect to such exercise. For purposes of the foregoing sentence, the aggregate
number of shares of Common Stock beneficially owned by such person and its affiliates or any such other person or group shall include
the number of shares of Common Stock issuable upon exercise of the Warrant with respect to which the determination of such sentence is
being made, but shall exclude shares of Common Stock that would be issuable upon (x) exercise of the remaining, unexercised portion of
the Warrant beneficially owned by such person and its affiliates and (y) exercise or conversion of the unexercised or unconverted portion
of any other securities of the Company beneficially owned by such person and its affiliates (including, without limitation, any convertible
notes or convertible preferred stock or warrants) subject to a limitation on conversion or exercise analogous to the limitation contained
herein. Except as set forth in the preceding sentence, for purposes of this paragraph, beneficial ownership shall be calculated in accordance
with Section 13(d) of the Exchange Act. For purposes of the Warrant, in determining the number of outstanding shares of Common Stock,
the holder may rely on the number of outstanding shares of Common Stock as reflected in (1) the Company&rsquo;s most recent annual report
on Form 10-K, quarterly report on Form 10-Q, current report on Form 8-K or other public filing with the Commission as the case may be,
(2) a more recent public announcement by the Company or (3) any other notice by the Company or the Transfer Agent setting forth the number
of shares of Common Stock outstanding. For any reason at any time, upon the written request of the holder of the Warrant, the Company
shall, within two (2) Business Days, confirm orally and in writing to such holder the number of shares of Common Stock then outstanding.
In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of
equity securities of the Company by the holder and its affiliates since the date as of which such number of outstanding shares of Common
Stock was reported. By written notice to the Company, the holder of a Warrant may from time to time increase or decrease the Maximum
Percentage applicable to such holder to any other percentage specified in such notice; provided, however, that any such increase shall
not be effective until the sixty-first (61st) day after such notice is delivered to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
<U>Adjustments</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1
<U>Stock Dividends</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1.1
<U>Split-Ups</U>. If after the date hereof, and subject to the provisions of <U>Section 4.6</U> below, the number of outstanding shares
of Common Stock is increased by a stock dividend payable in shares of Common Stock, or by a split-up of shares of Common Stock or other
similar event, then, on the effective date of such stock dividend, split-up or similar event, the number of shares of Common Stock issuable
on exercise of each Warrant shall be increased in proportion to such increase in the outstanding shares of Common Stock. A rights offering
to holders of the Common Stock entitling holders to purchase shares of Common Stock at a price less than the &ldquo;<B><I>Fair Market
Value</I></B>&rdquo; (as defined below) shall be deemed a stock dividend of a number of shares of Common Stock equal to the product of
(i) the number of shares of Common Stock actually sold in such rights offering (or issuable under any other equity securities sold in
such rights offering that are convertible into or exercisable for the Common Stock) multiplied by (ii) one (1) minus the quotient of
(x) the price per share of Common Stock paid in such rights offering divided by (y) the Fair Market Value. For purposes of this subsection
4.1.1, (i) if the rights offering is for securities convertible into or exercisable for Common Stock, in determining the price payable
for Common Stock, there shall be taken into account any consideration received for such rights, as well as any additional amount payable
upon exercise or conversion and (ii) &ldquo;<B><I>Fair Market Value</I></B>&rdquo; means the volume weighted average price of the Common
Stock as reported during the ten (10) trading day period ending on the trading day prior to the first date on which the shares of Common
Stock trade on the applicable exchange or in the applicable market, regular way, without the right to receive such rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1.2
<U>Extraordinary Dividends</U>. If the Company, at any time while the Warrants are outstanding and unexpired, shall pay a dividend or
make a distribution in cash, securities or other assets to the holders of the Common Stock on account of such shares of Common Stock
(or other shares of the Company&rsquo;s capital stock into which the Warrants are convertible), other than (a) as described in <U>subsection
4.1.1 </U>above, (b) Ordinary Cash Dividends (as defined below), (c) to satisfy the redemption rights of the holders of the Common Stock
in connection with a proposed initial Business Combination, (d) to satisfy the redemption rights of the holders of Common Stock in connection
with a stockholder vote to amend the Company&rsquo;s amended and restated certificate of incorporation (i) to modify the substance or
timing of the Company&rsquo;s obligation to redeem 100% of the shares of Common Stock included in the Public Units sold in the Offering
if the Company does not complete the Business Combination within the time period set forth in the Company&rsquo;s amended and restated
certificate of incorporation or (ii) with respect to any other provisions relating to stockholders&rsquo; rights or pre-initial business
combination activity or (e) in connection with the redemption of the shares of Common Stock included in the Public Units sold in the
Offering upon the failure of the Company to complete its initial Business Combination and any subsequent distribution of its assets upon
its liquidation (any such non-excluded event being referred to herein as an &ldquo;<B><I>Extraordinary Dividend</I></B>&rdquo;), then
the Warrant Price shall be decreased, effective immediately after the effective date of such Extraordinary Dividend, by the amount of
cash and/or the fair market value (as determined by the Board, in good faith) of any securities or other assets paid on each share of
Common Stock in respect of such Extraordinary Dividend. For purposes of this <U>subsection 4.1.2</U>, &ldquo;<B><I>Ordinary Cash Dividends</I></B>&rdquo;
means any cash dividend or cash distribution which, when combined on a per share basis, with the per share amounts of all other cash
dividends and cash distributions paid on the Common Stock during the 365-day period ending on the date of declaration of such dividend
or distribution (as adjusted to appropriately reflect any of the events referred to in other subsections of this Section 4 and excluding
cash dividends or cash distributions that resulted in an adjustment to the Warrant Price or to the number of shares of Common Stock issuable
on exercise of each Warrant) does not exceed $0.50 (being 5% of the offering price of the Public Units in the Offering).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2
<U>Aggregation of Shares</U>. If after the date hereof, and subject to the provisions of <U>Section 4.6</U> hereof, the number of outstanding
shares of Common Stock is decreased by a consolidation, combination, reverse stock split or reclassification of shares of Common Stock
or other similar event, then, on the effective date of such consolidation, combination, reverse stock split, reclassification or similar
event, the number of shares of Common Stock issuable on exercise of each Warrant shall be decreased in proportion to such decrease in
outstanding shares of Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3
<U>Adjustments in Warrant Price</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3.1
Whenever the number of shares of Common Stock purchasable upon the exercise of the Warrants is adjusted, as provided in <U>subsection
4.1.1</U> or <U>Section 4.2</U> above, the Warrant Price shall be adjusted (to the nearest cent) by multiplying such Warrant Price immediately
prior to such adjustment by a fraction (x) the numerator of which shall be the number of shares of Common Stock purchasable upon the
exercise of the Warrants immediately prior to such adjustment, and (y) the denominator of which shall be the number of shares of Common
Stock so purchasable immediately thereafter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3.2
If (x) the Company issues additional shares of Common Stock or securities convertible into or exercisable or exchangeable for shares
of Common Stock for capital raising purposes in connection with the closing of its initial Business Combination at an issue price or
effective issue price of less than $9.20 per share of Common Stock (as adjusted for stock splits, stock dividends, rights issuances,
subdivisions, reorganizations, recapitalizations and the like), with such issue price or effective issue price to be determined in good
faith by the Board (and in the case of any such issuance to the initial stockholders (as defined in the Prospectus) or their affiliates,
without taking into account any founder shares held by such stockholders or their affiliates, as applicable, prior to such issuance)(the
&ldquo;<B><I>New Issuance Price</I></B>&rdquo;), (y) the aggregate gross proceeds from such issuances represent more than 60% of the
total equity proceeds, and interest thereon, available for the funding of its initial business combination on the date of the consummation
of its initial business combination (net of redemptions), and (z) the volume weighted average trading price of common stock during the
20 trading day period starting on the trading day prior to the day on which the Company consummates its initial business combination
(such price, the &ldquo;<B><I>Market Value</I></B>&rdquo;) is below $9.20 per share (as adjusted for stock splits, stock dividends, rights
issuances, subdivisions, reorganizations, recapitalizations and the like), then the Warrant Price shall be adjusted (to the nearest cent)
to be equal to 115% of the greater of the Market Value and the New Issuance Price and the Redemption Trigger Price (as defined below)
will be adjusted (to the nearest cent) to 180% of the greater of the Market Value and the New Issuance Price.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4
Replacement of Securities upon Reorganization, etc. In case of any reclassification or reorganization of the outstanding shares of Common
Stock (other than a change under subsections 4.1.1 or 4.1.2 or Section 4.2 hereof or that solely affects the par value of such shares
of Common Stock), or in the case of any merger or consolidation of the Company with or into another entity or conversion of the Company
as another entity (other than a consolidation or merger in which the Company is the continuing corporation and that does not result in
any reclassification or reorganization of the outstanding shares of Common Stock), or in the case of any sale or conveyance to another
corporation or entity of the assets or other property of the Company as an entirety or substantially as an entirety in connection with
which the Company is dissolved, the holders of the Warrants shall thereafter have the right to purchase and receive, upon the basis and
upon the terms and conditions specified in the Warrants and in lieu of the shares of Common Stock of the Company immediately theretofore
purchasable and receivable upon the exercise of the rights represented thereby, the kind and amount of shares of stock or other securities
or property (including cash) receivable upon such reclassification, reorganization, merger or consolidation, or upon a dissolution following
any such sale or transfer, that the holder of the Warrants would have received if such holder had exercised his, her or its Warrant(s)
immediately prior to such event (the &ldquo;<B><I>Alternative Issuance</I></B>&rdquo; ); provided, however, that (i) if the holders of
the Common Stock were entitled to exercise a right of election as to the kind or amount of securities, cash or other assets receivable
upon such consolidation or merger, then the kind and amount of securities, cash or other assets constituting the Alternative Issuance
for which each Warrant shall become exercisable shall be deemed to be the weighted average of the kind and amount received per share
by the holders of the Common Stock in such consolidation or merger that affirmatively make such election, and (ii) if a tender, exchange
or redemption offer shall have been made to and accepted by the holders of the Common Stock (other than a tender, exchange or redemption
offer made by the Company in connection with redemption rights held by stockholders of the Company as provided for in the Company&rsquo;s
amended and restated certificate of incorporation or as a result of the repurchase of shares of Common Stock by the Company if a proposed
initial Business Combination is presented to the stockholders of the Company for approval) under circumstances in which, upon completion
of such tender or exchange offer, the maker thereof, together with members of any group (within the meaning of Rule 13d-5(b)(1) under
the Exchange Act (or any successor rule)) of which such maker is a part, and together with any affiliate or associate of such maker (within
the meaning of Rule 12b-2 under the Exchange Act (or any successor rule)) and any members of any such group of which any such affiliate
or associate is a part, own beneficially (within the meaning of Rule 13d-3 under the Exchange Act (or any successor rule)) more than
50% of the outstanding shares of Common Stock, the holder of a Warrant shall be entitled to receive as the Alternative Issuance, the
highest amount of cash, securities or other property to which such holder would actually have been entitled as a stockholder if such
Warrant holder had exercised the Warrant prior to the expiration of such tender or exchange offer, accepted such offer and all of the
Common Stock held by such holder had been purchased pursuant to such tender or exchange offer, subject to adjustments (from and after
the consummation of such tender or exchange offer) as nearly equivalent as possible to the adjustments provided for in this Section 4;
provided, further, that if less than 70% of the consideration receivable by the holders of the Common Stock in the applicable event is
payable in the form of common stock in the successor entity that is listed for trading on a national securities exchange or is quoted
in an established over-the-counter market, or is to be so listed for trading or quoted immediately following such event, and if the Registered
Holder properly exercises the Warrant within thirty (30) days following the public disclosure of the consummation of such applicable
event by the Company pursuant to a Current Report on Form 8-K filed with the Commission, the Warrant Price shall be reduced by an amount
(in dollars) equal to the difference of (i) the Warrant Price in effect prior to such reduction minus (ii) (A) the Per Share Consideration
(as defined below) (but in no event less than zero) minus (B) the Black-Scholes Warrant Value (as defined below). The &ldquo;<B><I>Black-Scholes
Warrant Value</I></B>&rdquo; means the value of a Warrant immediately prior to the consummation of the applicable event based on the
Black-Scholes Warrant Model for a Capped American Call on Bloomberg Financial Markets (&ldquo;<B><I>Bloomberg</I></B>&rdquo;). For purposes
of calculating such amount, (1) <U>Section 6</U> of this Agreement shall be taken into account, (2) the price of each share of Common
Stock shall be the volume weighted average price of the Common Stock as reported during the ten (10) trading day period ending on the
trading day prior to the effective date of the applicable event, (3) the assumed volatility shall be the 90 day volatility obtained from
the HVT function on Bloomberg determined as of the trading day immediately prior to the day of the announcement of the applicable event,
and (4) the assumed risk-free interest rate shall correspond to the U.S. Treasury rate for a period equal to the remaining term of the
Warrant. &ldquo;<B><I>Per Share Consideration</I></B>&rdquo; means (i) if the consideration paid to holders of the Common Stock consists
exclusively of cash, the amount of such cash per share of Common Stock, and (ii) in all other cases, the volume weighted average price
of the Common Stock as reported during the ten (10) trading day period ending on the trading day prior to the effective date of the applicable
event. If any reclassification or reorganization also results in a change in shares of Common Stock covered by subsection 4.1.1, then
such adjustment shall be made pursuant to <U>subsection 4.1.1</U> or <U>Sections 4.2</U>, <U>4.3</U> and this <U>Section 4.4</U>. The
provisions of this <U>Section 4.4</U> shall similarly apply to successive reclassifications, reorganizations, mergers or consolidations,
sales or other transfers. In no event will the Warrant Price be reduced to less than the par value per share issuable upon exercise of
the Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5
<U>Notices of Changes in Warrant</U>. Upon every adjustment of the Warrant Price or the number of shares of Common Stock issuable upon
exercise of a Warrant, the Company shall give written notice thereof to the Warrant Agent, which notice shall state the Warrant Price
resulting from such adjustment and the increase or decrease, if any, in the number of shares of Common Stock purchasable at such price
upon the exercise of a Warrant, setting forth in reasonable detail the method of calculation and the facts upon which such calculation
is based. Upon the occurrence of any event specified in <U>Sections 4.1</U>, <U>4.2</U>, <U>4.3</U> or <U>4.4</U>, the Company shall
give written notice of the occurrence of such event to each holder of a Warrant, at the last address set forth for such holder in the
Warrant Register, of the record date or the effective date of the event. Failure to give such notice, or any defect therein, shall not
affect the legality or validity of such event.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6
<U>No Fractional Shares</U>. Notwithstanding any provision contained in this Agreement to the contrary, the Company shall not issue fractional
shares of Common Stock upon the exercise of Warrants. If, by reason of any adjustment made pursuant to this <U>Section 4</U>, the holder
of any Warrant would be entitled, upon the exercise of such Warrant, to receive a fractional interest in a share, the Company shall,
upon such exercise, round down to the nearest whole number the number of shares of Common Stock to be issued to such holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7
<U>Form of Warrant</U>. The form of Warrant need not be changed because of any adjustment pursuant to this Section 4, and Warrants issued
after such adjustment may state the same Warrant Price and the same number of shares of Common Stock as is stated in the Warrants initially
issued pursuant to this Agreement; provided, however, that the Company may at any time in its sole discretion make any change in the
form of Warrant that the Company may deem appropriate and that does not affect the substance thereof, and any Warrant thereafter issued
or countersigned, whether in exchange or substitution for an outstanding Warrant or otherwise, may be in the form as so changed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8
<U>Other Events</U>. In case any event shall occur affecting the Company as to which none of the provisions of the preceding subsections
of this Section 4 are strictly applicable, but which would require an adjustment to the terms of the Warrants in order to (i) avoid an
adverse impact on the Warrants and (ii) effectuate the intent and purpose of this Section 4, then, in each such case, the Company shall
appoint a firm of independent public accountants, investment banking or other appraisal firm of recognized national standing, which shall
give its opinion as to whether or not any adjustment to the rights represented by the Warrants is necessary to effectuate the intent
and purpose of this Section 4 and, if they determine that an adjustment is necessary, the terms of such adjustment; provided, however,
that under no circumstances shall the Warrants be adjusted pursuant to this <U>Section 4.8</U> (i) as a result of any issuance of securities
in connection with a Business Combination or (ii) solely as a result of an adjustment to the conversion ratio of the Company&rsquo;s
Class B common stock, $0.0001 par value per share, into Common Stock. The Company shall adjust the terms of the Warrants in a manner
that is consistent with any adjustment recommended in such opinion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
<U>Transfer and Exchange of Warrants</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1
<U>Registration of Transfer</U>. The Warrant Agent shall register the transfer, from time to time, of any outstanding Warrant upon the
Warrant Register, upon surrender of such Warrant for transfer, in the case of certificated warrants, properly endorsed with signatures
properly guaranteed and accompanied by appropriate instructions for transfer. Upon any such transfer, a new Warrant representing an equal
aggregate number of Warrants shall be issued and the old Warrant shall be cancelled by the Warrant Agent. In the case of certificated
warrants, the Warrants so cancelled shall be delivered by the Warrant Agent to the Company from time to time upon request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2
<U>Procedure for Surrender of Warrants</U>. Warrants may be surrendered to the Warrant Agent, together with a written request for exchange
or transfer, and thereupon the Warrant Agent shall issue in exchange therefor one or more new Warrants as requested by the Registered
Holder of the Warrants so surrendered, representing an equal aggregate number of Warrants; provided, however, that in the event that
a Warrant surrendered for transfer bears a restrictive legend (as in the case of the Private Placement Warrants, the Working Capital
Warrants, and the Extension Warrants), the Warrant Agent shall not cancel such Warrant and issue new Warrants in exchange thereof until
the Warrant Agent has received an opinion of counsel for the Company stating that such transfer may be made and indicating whether the
new Warrants must also bear a restrictive legend.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.3
<U>Fractional Warrants</U>. The Warrant Agent shall not be required to effect any registration of transfer or exchange which shall result
in the issuance of a warrant certificate or book-entry position for a fraction of a warrant, except as part of the Units.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.4
<U>Service Charges</U>. No service charge shall be made for any exchange or registration of transfer of Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.5
<U>Warrant Execution and Countersignature</U>. If a physical certificate is issued, the Warrant Agent is hereby authorized to countersign
and to deliver, in accordance with the terms of this Agreement, the Warrants required to be issued, pursuant to the provisions of this
Section 5, and the Company, whenever required by the Warrant Agent, shall supply the Warrant Agent with Warrants duly executed on behalf
of the Company for such purpose.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.6
<U>Transfer of Warrants</U>. Prior to the Detachment Date, the Public Warrants may be transferred or exchanged only together with the
Unit in which such Warrant is included, and only for the purpose of effecting, or in conjunction with, a transfer or exchange of such
Unit. Furthermore, each transfer of a Unit on the register relating to such Units shall operate also to transfer the Warrants included
in such Unit. Notwithstanding the foregoing, the provisions of this Section 5.6 shall have no effect on any transfer of Warrants on and
after the Detachment Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.
<U>Redemption</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.1
<U>Redemption of Warrants for Cash</U>. Subject to Section 6.4 hereof, not less than all of the outstanding Warrants may be redeemed,
at the option of the Company, at any time while they are exercisable and prior to their expiration, at the office of the Warrant Agent,
upon notice to the Registered Holders of the Warrants, as described in Section 6.2 below, at the price (the &ldquo;<B><I>Redemption Price</I></B>&rdquo;)
of $0.01 per Warrant, provided that the last reported sales price of the Common Stock reported has been at least $18.00 per share (subject
to adjustment in compliance with Section 4 hereof) (the &ldquo;<B><I>Redemption Trigger Price</I></B>&rdquo;), on each of twenty (20)
trading days within the thirty (30) trading-day period ending on the third day prior to the date on which notice of the redemption is
given and provided that there is an effective registration statement covering the shares of Common Stock issuable upon exercise of the
Warrants, and a current prospectus relating thereto, available throughout the 30-day Redemption Period (as defined in Section 6.2 below)
or the Company has elected to require the exercise of the Warrants on a &ldquo;cashless basis&rdquo; pursuant to subsection 3.3.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.2
<U>Date Fixed for, and Notice of, Redemption</U>. In the event that the Company elects to redeem all of the Warrants pursuant to Section
6.1, the Company shall fix a date for the redemption (the &ldquo;<B><I>Redemption Date</I></B>&rdquo;). Notice of redemption shall be
mailed by first class mail, postage prepaid, by the Company not less than thirty (30) days prior to the Redemption Date (the &ldquo;<B><I>30-day
Redemption Period</I></B>&rdquo;) to the Registered Holders of the Warrants to be redeemed at their last addresses as they shall appear
on the registration books. Any notice mailed in the manner herein provided shall be conclusively presumed to have been duly given whether
or not the Registered Holder received such notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.3
<U>Exercise after Notice of Redemption</U>. The Warrants may be exercised, for cash (or on a &ldquo;cashless basis&rdquo; in accordance
with subsection 3.3.1(b) of this Agreement) at any time after notice of redemption shall have been given by the Company pursuant to Section
6.2 hereof and prior to the Redemption Date. In the event that the Company determines to require all holders of Warrants to exercise
their Warrants on a &ldquo;cashless basis&rdquo; pursuant to subsection 3.3.1, the notice of redemption shall contain the information
necessary to calculate the number of shares of Common Stock to be received upon exercise of the Warrants, including the &ldquo;Fair Market
Value&rdquo; (as such term is defined in subsection 3.3.1(b) hereof) in such case. On and after the Redemption Date, the record holder
of the Warrants shall have no further rights except to receive, upon surrender of the Warrants, the Redemption Price.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.4
<U>Exclusion of Certain Warrants</U>. The Company agrees that the redemption rights provided in Section 6.1 shall not apply to the Private
Placement Warrants, the Working Capital Warrants, the Extension Warrants, or the Post-IPO Warrants (if such Post-IPO Warrants provide
that they are non-redeemable by the Company) if at the time of the redemption such Private Placement Warrants, Working Capital Warrants,
Extension Warrants, or Post-IPO Warrants continue to be held by the Sponsor, or any officers or directors of the Company, or any of their
Permitted Transferees, as applicable. However, once such Private Placement Warrants, Working Capital Warrants, Extension Warrants, or
Post-IPO Warrants are transferred (other than to Permitted Transferees under Section 2.6), the Company may redeem the Private Placement
Warrants, the Working Capital Warrants, the Extension Warrants, or the Post-IPO Warrants (if the Post-IPO Warrants permit such redemption
by their terms) pursuant to <U>Section 6.1</U> hereof, provided that the criteria for redemption are met, including the opportunity of
the holder of such Private Placement Warrants, Working Capital Warrants, Extension Warrants, or Post-IPO Warrants to exercise such Private
Placement Warrants, Working Capital Warrants, Extension Warrants, or Post-IPO Warrants prior to redemption pursuant to Section 6.1. The
Private Placement Warrants, the Working Capital Warrants, the Extension Warrants, or the Post-IPO Warrants (if such Post-IPO Warrants
provide that they are non-redeemable by the Company) that are transferred to persons other than Permitted Transferees shall upon such
transfer cease to be Private Placement Warrants, Working Capital Warrants, Extension Warrants, or Post-IPO Warrants and shall become
Public Warrants under this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.
<U>Other Provisions Relating to Rights of Holders of Warrants</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.1
<U>No Rights as Stockholder</U>. A Warrant does not entitle the Registered Holder thereof to any of the rights of a stockholder of the
Company, including, without limitation, the right to receive dividends, or other distributions, exercise any preemptive rights to vote
or to consent or to receive notice as a stockholder in respect of the meetings of stockholders or the election of directors of the Company
or any other matter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.2
<U>Lost, Stolen, Mutilated, or Destroyed Warrants</U>. If any Warrant is lost, stolen, mutilated, or destroyed, the Company and the Warrant
Agent may on such terms as to indemnity or otherwise as they may in their discretion impose (which shall, in the case of a mutilated
Warrant, include the surrender thereof), issue a new Warrant of like denomination, tenor, and date as the Warrant so lost, stolen, mutilated,
or destroyed. Any such new Warrant shall constitute a substitute contractual obligation of the Company, whether or not the allegedly
lost, stolen, mutilated, or destroyed Warrant shall be at any time enforceable by anyone.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.3
<U>Reservation of Common Stock</U>. The Company shall at all times reserve and keep available a number of its authorized but unissued
shares of Common Stock that shall be sufficient to permit the exercise in full of all outstanding Warrants issued pursuant to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.4
<U>Registration of Common Stock; Cashless Exercise at Company&rsquo;s Option</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.4.1
<U>Registration of the Common Stock</U>. The Company agrees that as soon as practicable, but in no event later than fifteen (15) Business
Days after the closing of its initial Business Combination, it shall use its reasonable best efforts to file with the Commission a registration
statement for the registration, under the Securities Act, of the shares of Common Stock issuable upon exercise of the Warrants. The Company
shall use its reasonable best efforts to cause the same to become effective and to maintain the effectiveness of such registration statement,
and a current prospectus relating thereto, until the expiration of the Warrants in accordance with the provisions of this Agreement.
If any such registration statement has not been declared effective by the 60th Business Day following the closing of the Business Combination,
holders of the Warrants shall have the right, during the period beginning on the 61st Business Day after the closing of the initial Business
Combination and ending upon such registration statement being declared effective by the Commission, and during any other period when
the Company shall fail to have maintained an effective registration statement covering the shares of Common Stock issuable upon exercise
of the Warrants, to exercise such Warrants on a &ldquo;cashless basis,&rdquo; by exchanging the Warrants (in accordance with Section
3(a)(9) of the Securities Act (or any successor rule) or another exemption) for that number of shares of Common Stock equal to the quotient
obtained by dividing (x) the product of the number of shares of Common Stock underlying the Warrants, multiplied by the excess of the
&ldquo;<B><I>Fair Market Value</I></B>&rdquo; (as defined below) over the Warrant Price by (y) the Fair Market Value. Solely for purposes
of this subsection 7.4.1, &ldquo;<B><I>Fair Market Value</I></B>&rdquo; shall mean the volume weighted average price of the Common Stock
as reported during the ten (10) trading day period ending on the trading day prior to the date that notice of exercise is received by
the Warrant Agent from the holder of such Warrants or its securities broker or intermediary. The date that notice of cashless exercise
is received by the Warrant Agent shall be conclusively determined by the Warrant Agent. In connection with the &ldquo;cashless exercise&rdquo;
of a Public Warrant, the Company shall, upon request, provide the Warrant Agent with an opinion of counsel for the Company (which shall
be an outside law firm with securities law experience) stating that (i) the exercise of the Warrants on a cashless basis in accordance
with this <U>subsection 7.4.1</U> is not required to be registered under the Securities Act and (ii) the shares of Common Stock issued
upon such exercise shall be freely tradable under United States federal securities laws by anyone who is not an affiliate (as such term
is defined in Rule 144 under the Securities Act (or any successor rule)) of the Company and, accordingly, shall not be required to bear
a restrictive legend. Except as provided in <U>subsection 7.4.2</U>, for the avoidance of any doubt, unless and until all of the Warrants
have been exercised, the Company shall continue to be obligated to comply with its registration obligations under the first three sentences
of this <U>subsection 7.4.1</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.4.2
<U>Cashless Exercise at Company&rsquo;s Option</U>. If the Common Stock is at the time of any exercise of a Warrant not listed on a national
securities exchange such that it satisfies the definition of a &ldquo;covered security&rdquo; under <U>Section 18(b)(1) </U>of the Securities
Act (or any successor rule), the Company may, at its option, (i) require holders of Public Warrants who exercise Public Warrants to exercise
such Public Warrants on a &ldquo;cashless basis&rdquo; in accordance with <U>Section 3(a)(9) </U>of the Securities Act (or any successor
rule) as described in subsection 7.4.1 and (ii) in the event the Company so elects, the Company shall not be required to file or maintain
in effect a registration statement for the registration, under the Securities Act, of the Common Stock issuable upon exercise of the
Warrants, notwithstanding anything in this Agreement to the contrary. If the Company does not elect at the time of exercise to require
a holder of Public Warrants who exercises Public Warrants to exercise such Public Warrants on a &ldquo;cashless basis,&rdquo; it agrees
to use its best efforts to register or qualify for sale the Common Stock issuable upon exercise of the Public Warrant under the blue
sky laws of the state of residence in those states in which the Public Warrants were initially offered by the Company of the exercising
Public Warrant holder to the extent an exemption is not available.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.
<U>Concerning the Warrant Agent and Other Matters</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1
<U>Payment of Taxes</U>. The Company shall from time to time promptly pay all taxes and charges that may be imposed upon the Company
or the Warrant Agent in respect of the issuance or delivery of shares of Common Stock upon the exercise of the Warrants, but the Company
shall not be obligated to pay any transfer taxes in respect of the Warrants or such shares of Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.2
<U>Resignation, Consolidation, or Merger of Warrant Agent</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.2.1
<U>Appointment of Successor Warrant Agent</U>. The Warrant Agent, or any successor to it hereafter appointed, may resign its duties and
be discharged from all further duties and liabilities hereunder after giving sixty (60) days&rsquo; notice in writing to the Company.
If the office of the Warrant Agent becomes vacant by resignation or incapacity to act or otherwise, the Company shall appoint in writing
a successor Warrant Agent in place of the Warrant Agent. If the Company shall fail to make such appointment within a period of thirty
(30) days after it has been notified in writing of such resignation or incapacity by the Warrant Agent or by the holder of a Warrant
(who shall, with such notice, submit his, her or its Warrant for inspection by the Company), then the holder of any Warrant may apply
to the Supreme Court of the State of New York for the County of New York for the appointment of a successor Warrant Agent at the Company&rsquo;s
cost. Any successor Warrant Agent, whether appointed by the Company or by such court, shall be a corporation organized and existing under
the laws of the State of New York, in good standing and having its principal office in the Borough of Manhattan, City and State of New
York, and authorized under such laws to exercise corporate trust powers and subject to supervision or examination by federal or state
authority. After appointment, any successor Warrant Agent shall be vested with all the authority, powers, rights, immunities, duties,
and obligations of its predecessor Warrant Agent with like effect as if originally named as Warrant Agent hereunder, without any further
act or deed; but if for any reason it becomes necessary or appropriate, the predecessor Warrant Agent shall execute and deliver, at the
expense of the Company, an instrument transferring to such successor Warrant Agent all the authority, powers, and rights of such predecessor
Warrant Agent hereunder; and upon request of any successor Warrant Agent the Company shall make, execute, acknowledge, and deliver any
and all instruments in writing for more fully and effectually vesting in and confirming to such successor Warrant Agent all such authority,
powers, rights, immunities, duties, and obligations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.2.2
<U>Notice of Successor Warrant Agent</U>. In the event a successor Warrant Agent shall be appointed, the Company shall give notice thereof
to the predecessor Warrant Agent and the Transfer Agent for the Common Stock not later than the effective date of any such appointment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.2.3
<U>Merger or Consolidation of Warrant Agent</U>. Any corporation into which the Warrant Agent may be merged or with which it may be consolidated
or any corporation resulting from any merger or consolidation to which the Warrant Agent shall be a party shall be the successor Warrant
Agent under this Agreement without any further act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.3
<U>Fees and Expenses of Warrant Agent</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.3.1
<U>Remuneration</U>. The Company agrees to pay the Warrant Agent reasonable remuneration for its services as such Warrant Agent hereunder
and shall, pursuant to its obligations under this Agreement, reimburse the Warrant Agent upon demand for all expenditures that the Warrant
Agent may reasonably incur in the execution of its duties hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.3.2
<U>Further Assurances</U>. The Company agrees to perform, execute, acknowledge, and deliver or cause to be performed, executed, acknowledged,
and delivered all such further and other acts, instruments, and assurances as may reasonably be required by the Warrant Agent for the
carrying out or performing of the provisions of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.4
<U>Liability of Warrant Agent</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.4.1
<U>Reliance on Company Statement</U>. Whenever in the performance of its duties under this Agreement, the Warrant Agent shall deem it
necessary or desirable that any fact or matter be proved or established by the Company prior to taking or suffering any action hereunder,
such fact or matter (unless other evidence in respect thereof be herein specifically prescribed) may be deemed to be conclusively proved
and established by a statement signed by the Chief Executive Officer, Chief Financial Officer, Secretary or Chairman of the Board of
the Company and delivered to the Warrant Agent. The Warrant Agent may rely upon such statement for any action taken or suffered in good
faith by it pursuant to the provisions of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.4.2
<U>Indemnity</U>. The Warrant Agent shall be liable hereunder only for its own gross negligence, willful misconduct or bad faith. The
Company agrees to indemnify the Warrant Agent and save it harmless against any and all liabilities, including judgments, costs and reasonable
counsel fees, for anything done or omitted by the Warrant Agent in the execution of this Agreement, except as a result of the Warrant
Agent&rsquo;s gross negligence, willful misconduct or bad faith.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.4.3
<U>Exclusions</U>. The Warrant Agent shall have no responsibility with respect to the validity of this Agreement or with respect to the
validity or execution of any Warrant (except its countersignature thereof). The Warrant Agent shall not be responsible for any breach
by the Company of any covenant or condition contained in this Agreement or in any Warrant. The Warrant Agent shall not be responsible
to make any adjustments required under the provisions of Section 4 hereof or responsible for the manner, method, or amount of any such
adjustment or the ascertaining of the existence of facts that would require any such adjustment; nor shall it by any act hereunder be
deemed to make any representation or warranty as to the authorization or reservation of any shares of Common Stock to be issued pursuant
to this Agreement or any Warrant or as to whether any shares of Common Stock shall, when issued, be valid and fully paid and non-assessable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.5
<U>Acceptance of Agency</U>. The Warrant Agent hereby accepts the agency established by this Agreement and agrees to perform the same
upon the terms and conditions herein set forth and among other things, shall account promptly to the Company with respect to Warrants
exercised and concurrently account for, and pay to the Company, all monies received by the Warrant Agent for the purchase of shares of
Common Stock through the exercise of the Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.6
<U>Waiver</U>. The Warrant Agent has no right of set-off or any other right, title, interest or claim of any kind (&ldquo;<B><I>Claim</I></B>&rdquo;)
in, or to any distribution of, the Trust Account (as defined in that certain Investment Management Trust Agreement, dated as of the date
hereof, by and between the Company and the Warrant Agent as trustee thereunder) and hereby agrees not to seek recourse, reimbursement,
payment or satisfaction for any Claim against the Trust Account for any reason whatsoever. The Warrant Agent hereby waives any and all
Claims against the Trust Account and any and all rights to seek access to the Trust Account.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.
<U>Miscellaneous Provisions</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.1
<U>Successors</U>. All the covenants and provisions of this Agreement by or for the benefit of the Company or the Warrant Agent shall
bind and inure to the benefit of their respective successors and assigns.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.2
<U>Notices</U>. Any notice, statement or demand authorized by this Agreement to be given or made by the Warrant Agent or by the holder
of any Warrant to or on the Company shall be sufficiently given when so delivered if by hand or overnight delivery or if sent by certified
mail or private courier service within five (5) days after deposit of such notice, postage prepaid, addressed (until another address
is filed in writing by the Company with the Warrant Agent), as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Data
Knights Acquisition Corp.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trident
Court, 1 Oakcroft Road</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chessington
Surrey KT9 1BD</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">United
Kingdom</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn.:
Barry Anderson, Chief Executive Officer</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
notice, statement or demand authorized by this Agreement to be given or made by the holder of any Warrant or by the Company to or on
the Warrant Agent shall be sufficiently given when so delivered if by hand or overnight delivery or if sent by certified mail or private
courier service within five (5) days after deposit of such notice, postage prepaid, addressed (until another address is filed in writing
by the Warrant Agent with the Company), as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Continental
Stock Transfer &amp; Trust Company</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1
State Street, 30th Floor</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
York, NY 10004</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:
Compliance Department</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.3
<U>Applicable Law and Exclusive Forum</U>. The validity, interpretation, and performance of this Agreement and of the Warrants shall
be governed in all respects by the laws of the State of New York, without giving effect to conflicts of law principles that would result
in the application of the substantive laws of another jurisdiction. The Company hereby agrees that any action, proceeding or claim against
it arising out of or relating in any way to this Agreement shall be brought and enforced in the courts of the City of New York, County
of New York, State of New York or the United States District Court for the Southern District of New York, and irrevocably submits to
such jurisdiction, which jurisdiction shall be exclusive, forum for any such action, proceeding or claim. The Company hereby waives any
objection to such exclusive jurisdiction and that such courts represent an inconvenient forum. Notwithstanding the foregoing, the provisions
of this paragraph will not apply to suits brought to enforce any liability or duty created by the Exchange Act or any other claim for
which the federal district courts of the United States of America are the sole and exclusive forum.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
person or entity purchasing or otherwise acquiring any interest in the Warrants shall be deemed to have notice of and to have consented
to the forum provisions in this Section 9.3. If any action, the subject matter of which is within the scope the forum provisions above,
is filed in a court other than a court located within the State of New York or the United States District Court for the Southern District
of New York (a &ldquo;<B><I>foreign action</I></B>&rdquo;) in the name of any warrant holder, such warrant holder shall be deemed to
have consented to: (x) the personal jurisdiction of the state and federal courts located within the State of New York or the United States
District Court for the Southern District of New York in connection with any action brought in any such court to enforce the forum provisions
(an &ldquo;<B><I>enforcement action</I></B>&rdquo;), and (y) having service of process made upon such warrant holder in any such enforcement
action by service upon such warrant holder&rsquo;s counsel in the foreign action as agent for such warrant holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.4
<U>Persons Having Rights under this Agreement</U>. Nothing in this Agreement shall be construed to confer upon, or give to, any person
or corporation other than the parties hereto and the Registered Holders of the Warrants any right, remedy, or claim under or by reason
of this Agreement or of any covenant, condition, stipulation, promise, or agreement hereof. All covenants, conditions, stipulations,
promises, and agreements contained in this Agreement shall be for the sole and exclusive benefit of the parties hereto and their successors
and assigns and of the Registered Holders of the Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.5
<U>Examination of the Warrant Agreement</U>. A copy of this Agreement shall be available at all reasonable times at the office of the
Warrant Agent in the Borough of Manhattan, City and State of New York, for inspection by the Registered Holder of any Warrant. The Warrant
Agent may require any such holder to submit such holder&rsquo;s Warrant for inspection by the Warrant Agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.6
<U>Counterparts</U>. This Agreement may be executed in any number of original or facsimile counterparts and each of such counterparts
shall for all purposes be deemed to be an original, and all such counterparts shall together constitute but one and the same instrument.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.7
<U>Effect of Headings</U>. The section headings herein are for convenience only and are not part of this Agreement and shall not affect
the interpretation thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.8
<U>Amendments</U>. This Agreement may be amended by the parties hereto without the consent of any Registered Holder for the purpose of
curing any ambiguity, or curing, correcting or supplementing any defective provision contained herein or adding or changing any other
provisions with respect to matters or questions arising under this Agreement as the parties may deem necessary or desirable and that
the parties deem shall not adversely affect the interest of the Registered Holders. All other modifications or amendments, including
any amendment to increase the Warrant Price or shorten the Exercise Period, shall require the vote or written consent of the Registered
Holders of 50% of the then-outstanding Public Warrants and, solely with respect to any amendment to the terms of the Private Placement
Warrants, the Working Capital Warrants, the Extension Warrants, or the Post-IPO Warrants or any provision of this Agreement with respect
to the Private Placement Warrants, the Working Capital Warrants, or the Extension Warrants, 50% of the number of the then outstanding
Private Placement Warrants, Working Capital Warrants, or Extension Warrants, as applicable. Notwithstanding the foregoing, the Company
may lower the Warrant Price or extend the duration of the Exercise Period pursuant to <U>Sections 3.1</U> and <U>3.2</U>, respectively,
without the consent of the Registered Holders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.9
<U>Severability</U>. This Agreement shall be deemed severable, and the invalidity or unenforceability of any term or provision hereof
shall not affect the validity or enforceability of this Agreement or of any other term or provision hereof. Furthermore, in lieu of any
such invalid or unenforceable term or provision, the parties hereto intend that there shall be added as a part of this Agreement a provision
as similar in terms to such invalid or unenforceable provision as may be possible and be valid and enforceable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
A &mdash; Form of Warrant Certificate</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
B &mdash; Legend &mdash; Private Placement Warrants, Working Capital Warrants, and Extension Warrants</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed as of the date first above written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DATA KNIGHTS ACQUISITION CORP.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%">&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONTINENTAL STOCK TRANSFER &amp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TRUST COMPANY, as Warrant Agent</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<!-- Field: Page; Sequence: 15; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>5
<FILENAME>ex4-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="letter-spacing: -0.2pt"><B>Exhibit 4.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="letter-spacing: -0.2pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="letter-spacing: -0.2pt"></FONT></P>



<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font: 11pt Aptos; text-align: center; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNITS</B></FONT></TD>
    <TD STYLE="font: 11pt Aptos; width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font: 11pt Aptos; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SEE REVERSE FOR<B><BR>
</B>CERTAIN DEFINITIONS</FONT></TD>
    <TD STYLE="font: 11pt Aptos"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DATA KNIGHTS ACQUISITION CORP.</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="letter-spacing: -0.2pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="letter-spacing: -0.2pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>CUSIP [*]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>UNITS CONSISTING OF ONE SHARE OF CLASS A COMMON
STOCK AND ONE WARRANT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">THIS CERTIFIES THAT ______________________________________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">is the owner of _____________________________________________________________________________________________________
Units.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Each Unit (&ldquo;Unit&rdquo;) consists of one share
of Class A common stock, with a par value $0.0001 per share (&ldquo;Class A Common Stock&rdquo;), of Data Knights Acquisition Corp., a
Delaware corporation (the &ldquo;Company&rdquo;), and one redeemable warrant (&ldquo;Warrant&rdquo;). Each redeemable Warrant entitles
the holder thereof to purchase one share of Class A Common Stock at a price of $11.50 per full share (subject to adjustment), upon the
later to occur of (i) 30 days after the Company&rsquo;s completion of a merger, share exchange, asset acquisition, share purchase, recapitalization,
reorganization or other similar business combination with one or more businesses or entities (a &ldquo;Business Combination&rdquo;) or
(ii) one year from the closing of the Company&rsquo;s initial public offering. The shares of Class A Common Stock and Warrants comprising
the Units represented by this certificate are not transferable separately prior to the fifty-second (52nd) day after the date of the prospectus
relating to the Company&rsquo;s initial public offering, unless Kingswood Capital Markets, division of Benchmark Investments, Inc. (&ldquo;Kingswood&rdquo;)
determines that an earlier date is acceptable, but in no event will the shares of Class A Common Stock and Warrants be traded separately
until the Company files with the Securities and Exchange Commission (the &ldquo;SEC&rdquo;) a current report on Form 8-K which includes
an audited balance sheet reflecting the receipt by the Company of the gross proceeds from its initial public offering including the proceeds
received by the Company from the exercise of the over-allotment option thereto, if the over-allotment option is exercised. If the over-allotment
option is exercised after the date of the prospectus, we will file an amendment to the Form 8-K or a new Form 8-K to provide updated financial
information to reflect the exercise of the over-allotment option. We will also include in the Form 8-K, or amendment thereto, or in a
subsequent Form 8-K, information indicating if the underwriters has allowed separate trading of the shares of Class A Common Stock and
Warrants prior to the 52nd day after the date of the prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The terms of the Warrants are governed by a Warrant
Agreement, dated as of , 2021, between the Company and Continental Stock Transfer &amp; Trust Company, as Warrant Agent, and are subject
to the terms and provisions contained therein, all of which terms and provisions the holder of this certificate consents to by acceptance
hereof. Copies of the Warrant Agreement are on file at the office of Continental Stock Transfer &amp; Trust Company at 1 State Street,
30th Floor, New York, New York 10004, and are available to any Warrant holder on written request and without cost.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This certificate is not valid unless countersigned
by the Transfer Agent and Registrar of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Witness the facsimile seal of the Company and the
facsimile signatures of its duly authorized officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This Unit Certificate shall be governed and construed
in accordance with the internal laws of the State of New York, without regard to conflicts of laws principles thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="4" STYLE="text-align: center"><FONT STYLE="font-size: 10pt">[Seal]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 16%">&nbsp;</TD>
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 68%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">By</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Chairman</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Data Knights Acquisition Corp.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company will furnish without
charge to each stockholder who so requests, a statement of the powers, designations, preferences and relative, participating, optional
or other special rights of each class of shares or series thereof of the Company and the qualifications, limitations, or restrictions
of such preferences and/or rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following abbreviations, when
used in the inscription on the face of this certificate, shall be construed as though they were written out in full according to applicable
laws or regulations:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">TEN COM &ndash;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">as tenants in common</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">UNIF GIFT MIN ACT -</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Custodian</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">TEN ENT &ndash;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">as tenants by the entireties</FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Cust)</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Minor)</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">JT TEN &ndash;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">as joint tenants with right of survivorship</FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="4"><FONT STYLE="font-size: 10pt">under Uniform Gifts to Minors</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 20%">&nbsp;</TD>
    <TD STYLE="width: 29%"><FONT STYLE="font-size: 10pt">and not as tenants in common</FONT></TD>
    <TD STYLE="width: 15%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-size: 10pt">Act</FONT></TD>
    <TD STYLE="width: 10%; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="width: 8%; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="width: 12%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(State)</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Additional Abbreviations may also be used though not
in the above list.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><I>For value received, ___________________________
hereby sell(s), assign(s) and transfer(s) unto</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">PLEASE INSERT SOCIAL SECURITY OR OTHER&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">IDENTIFYING NUMBER OF ASSIGNEE(S)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border-top: black 1pt solid; border-right: black 1pt solid; border-left: black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0; margin-right: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(PLEASE PRINT OR TYPEWRITE NAME AND ADDRESS, INCLUDING
ZIP CODE, OF ASSIGNEE(S))</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 96%; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="width: 4%"><FONT STYLE="font-size: 10pt"><I>&nbsp;Units</I></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>represented by the within Certificate, and do hereby
irrevocably constitute and appoint</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 95%; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt"><I>&nbsp;Attorney</I></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>to transfer the said Units on the books of the
within named Company will full power of substitution in the premises.</I>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%"><FONT STYLE="font-size: 10pt"><I>Dated </I></FONT></TD>
    <TD STYLE="width: 7%">&nbsp;</TD>
    <TD STYLE="width: 53%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt"><B>Notice:</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The signature to this assignment must correspond with the name as written upon the face of the certificate in every particular, without alteration or enlargement or any change whatever.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Signature(s) Guaranteed:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">THE SIGNATURE(S) SHOULD BE GUARANTEED BY AN ELIGIBLE GUARANTOR INSTITUTION (BANKS, STOCKBROKERS, SAVINGS AND LOAN ASSOCIATIONS AND CREDIT UNIONS WITH MEMBERSHIP IN AN APPROVED SIGNATURE GUARANTEE MEDALLION PROGRAM, PURSUANT TO S.E.C. RULE 17Ad-15).</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The holder of this certificate shall be entitled to
receive funds with respect to the underlying common stock from the trust fund only in the event of the Company&rsquo;s liquidation upon
failure to consummate a business combination or if the holder seeks to convert his or her respective common stock underlying the unit
upon consummation of such business combination or in connection with certain amendments to the Company&rsquo;s Amended and Restated Certificate
of Incorporation. In no other circumstances shall the holder have any right or interest of any kind in or to the trust fund.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="letter-spacing: -0.2pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="letter-spacing: -0.2pt"></FONT></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.3
<SEQUENCE>6
<FILENAME>ex4-3.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="letter-spacing: -0.2pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="letter-spacing: -0.2pt"><B>Exhibit 4.3</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="letter-spacing: -0.2pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; padding-bottom: 2.9pt; padding-left: 6pt; text-align: right"><FONT STYLE="font-size: 10pt"><B>UNITS</B></FONT></TD>
    <TD COLSPAN="5">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 6pt; padding-left: 6pt; text-align: center"><FONT STYLE="font-size: 10pt">SEE REVERSE FOR<B><BR>
</B>CERTAIN DEFINITIONS</FONT></TD>
    <TD COLSPAN="3" STYLE="padding-right: 6pt; padding-left: 6pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>DATA KNIGHTS ACQUISITION CORP.</B></FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 6pt; padding-left: 6pt; text-align: center">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="width: 24%">&nbsp;</TD>
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 42%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 19%">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>CUSIP [*]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>UNITS CONSISTING OF ONE SHARE OF CLASS A COMMON
STOCK AND ONE WARRANT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">THIS CERTIFIES THAT ______________________________________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">is the owner of _____________________________________________________________________________________________________
Units.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Each Unit (&ldquo;Unit&rdquo;) consists of one share
of Class A common stock, with a par value $0.0001 per share (&ldquo;Class A Common Stock&rdquo;), of Data Knights Acquisition Corp., a
Delaware corporation (the &ldquo;Company&rdquo;), and one redeemable warrant (&ldquo;Warrant&rdquo;). Each redeemable Warrant entitles
the holder thereof to purchase one share of Class A Common Stock at a price of $11.50 per full share (subject to adjustment), upon the
later to occur of (i) 30 days after the Company&rsquo;s completion of a merger, share exchange, asset acquisition, share purchase, recapitalization,
reorganization or other similar business combination with one or more businesses or entities (a &ldquo;Business Combination&rdquo;) or
(ii) one year from the closing of the Company&rsquo;s initial public offering. The shares of Class A Common Stock and Warrants comprising
the Units represented by this certificate are not transferable separately prior to the fifty-second (52nd) day after the date of the prospectus
relating to the Company&rsquo;s initial public offering, unless Kingswood Capital Markets, division of Benchmark Investments, Inc. (&ldquo;Kingswood&rdquo;)
determines that an earlier date is acceptable, but in no event will the shares of Class A Common Stock and Warrants be traded separately
until the Company files with the Securities and Exchange Commission (the &ldquo;SEC&rdquo;) a current report on Form 8-K which includes
an audited balance sheet reflecting the receipt by the Company of the gross proceeds from its initial public offering including the proceeds
received by the Company from the exercise of the over-allotment option thereto, if the over-allotment option is exercised. If the over-allotment
option is exercised after the date of the prospectus, we will file an amendment to the Form 8-K or a new Form 8-K to provide updated financial
information to reflect the exercise of the over-allotment option. We will also include in the Form 8-K, or amendment thereto, or in a
subsequent Form 8-K, information indicating if the underwriters has allowed separate trading of the shares of Class A Common Stock and
Warrants prior to the 52nd day after the date of the prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The terms of the Warrants are governed by a Warrant
Agreement, dated as of , 2021, between the Company and Continental Stock Transfer &amp; Trust Company, as Warrant Agent, and are subject
to the terms and provisions contained therein, all of which terms and provisions the holder of this certificate consents to by acceptance
hereof. Copies of the Warrant Agreement are on file at the office of Continental Stock Transfer &amp; Trust Company at 1 State Street,
30th Floor, New York, New York 10004, and are available to any Warrant holder on written request and without cost.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This certificate is not valid unless countersigned
by the Transfer Agent and Registrar of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Witness the facsimile seal of the Company and the
facsimile signatures of its duly authorized officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This Unit Certificate shall be governed and construed
in accordance with the internal laws of the State of New York, without regard to conflicts of laws principles thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="4" STYLE="text-align: center"><FONT STYLE="font-size: 10pt">[Seal]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 21%">&nbsp;</TD>
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 63%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">By</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Chairman</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Data Knights Acquisition Corp.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company will furnish without
charge to each stockholder who so requests, a statement of the powers, designations, preferences and relative, participating, optional
or other special rights of each class of shares or series thereof of the Company and the qualifications, limitations, or restrictions
of such preferences and/or rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following abbreviations, when
used in the inscription on the face of this certificate, shall be construed as though they were written out in full according to applicable
laws or regulations:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">TEN COM &ndash;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">as tenants in common</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">UNIF GIFT MIN ACT -</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Custodian</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">TEN ENT &ndash;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">as tenants by the entireties</FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Cust)</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Minor)</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">JT TEN &ndash;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">as joint tenants with right of survivorship</FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="4"><FONT STYLE="font-size: 10pt">under Uniform Gifts to Minors</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 12%">&nbsp;</TD>
    <TD STYLE="width: 37%"><FONT STYLE="font-size: 10pt">and not as tenants in common</FONT></TD>
    <TD STYLE="width: 16%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-size: 10pt">Act</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; width: 10%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; width: 2%">&nbsp;</TD>
    <TD STYLE="width: 17%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(State)</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Additional Abbreviations may also be used though not
in the above list.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><I>For value received, ___________________________
hereby sell(s), assign(s) and transfer(s) unto</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">PLEASE INSERT SOCIAL SECURITY OR OTHER&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">IDENTIFYING NUMBER OF ASSIGNEE(S)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: black 1pt solid; width: 100%; border-right: black 1pt solid; border-left: black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(PLEASE PRINT OR TYPEWRITE NAME AND ADDRESS, INCLUDING
ZIP CODE, OF ASSIGNEE(S))</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid; width: 93%">&nbsp;</TD>
    <TD STYLE="width: 7%"><FONT STYLE="font-size: 10pt"><I>&nbsp;Units</I></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>represented by the within Certificate, and do hereby
irrevocably constitute and appoint</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid; width: 91%">&nbsp;</TD>
    <TD STYLE="width: 9%"><FONT STYLE="font-size: 10pt"><I>&nbsp;Attorney</I></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>to transfer the said Units on the books of the
within named Company will full power of substitution in the premises.</I>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 37%"><FONT STYLE="font-size: 10pt"><I>Dated </I></FONT></TD>
    <TD STYLE="width: 7%">&nbsp;</TD>
    <TD STYLE="width: 56%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt"><B>Notice:</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The signature to this assignment must correspond with the name as written upon the face of the certificate in every particular, without alteration or enlargement or any change whatever.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Signature(s) Guaranteed:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">THE SIGNATURE(S) SHOULD BE GUARANTEED BY AN ELIGIBLE GUARANTOR INSTITUTION (BANKS, STOCKBROKERS, SAVINGS AND LOAN ASSOCIATIONS AND CREDIT UNIONS WITH MEMBERSHIP IN AN APPROVED SIGNATURE GUARANTEE MEDALLION PROGRAM, PURSUANT TO S.E.C. RULE 17Ad-15).</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The holder of this certificate shall be entitled to
receive funds with respect to the underlying common stock from the trust fund only in the event of the Company&rsquo;s liquidation upon
failure to consummate a business combination or if the holder seeks to convert his or her respective common stock underlying the unit
upon consummation of such business combination or in connection with certain amendments to the Company&rsquo;s Amended and Restated Certificate
of Incorporation. In no other circumstances shall the holder have any right or interest of any kind in or to the trust fund.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="letter-spacing: -0.2pt"><B></B></FONT></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="letter-spacing: -0.2pt"><B>&nbsp;</B></FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.4
<SEQUENCE>7
<FILENAME>ex4-4.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
4.4</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Form
of Warrant Certificate</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[FACE]</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>THIS
WARRANT SHALL BE VOID IF NOT EXERCISED PRIOR TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>THE
EXPIRATION OF THE EXERCISE PERIOD PROVIDED FOR</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IN
THE WARRANT AGREEMENT DESCRIBED BELOW</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DATA
KNIGHTS ACQUISITION CORP.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Incorporated
Under the Laws of the State of Delaware</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CUSIP
[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Warrant
Certificate</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Warrant Certificate certifies that , or registered assigns, is the registered holder of warrant(s) evidenced hereby (the &ldquo;<B><I>Warrants</I></B>&rdquo;
and each, a &ldquo;<B><I>Warrant</I></B>&rdquo;) to purchase shares of Class A common stock, $0.0001 par value per share (&ldquo;<B><I>Common
Stock</I></B>&rdquo;), of Data Knights Acquisition Corp., a Delaware corporation (the &ldquo;<B><I>Company</I></B>&rdquo;). Each Warrant
entitles the holder, upon exercise during the period set forth in the Warrant Agreement referred to below, to receive from the Company
that number of fully paid and non-assessable shares of Common Stock as set forth below, at the exercise price (the &ldquo;<B><I>Exercise
Price</I></B>&rdquo;) as determined pursuant to the Warrant Agreement, payable in lawful money (or through &ldquo;cashless exercise&rdquo;
as provided for in the Warrant Agreement) of the United States of America upon surrender of this Warrant Certificate and payment of the
Exercise Price at the office or agency of the Warrant Agent referred to below, subject to the conditions set forth herein and in the
Warrant Agreement. Defined terms used in this Warrant Certificate but not defined herein shall have the meanings given to them in the
Warrant Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
whole Warrant is initially exercisable for one fully paid and non-assessable share of Common Stock. No fractional shares will be issued
upon exercise of any Warrant. If, upon the exercise of Warrant, a holder would be entitled to receive a fractional interest in a share,
the Company will, upon exercise, round down to the nearest whole number of the number of shares of Common Stock to be issued to the holder.
The number of shares of Common Stock issuable upon exercise of the Warrants is subject to adjustment upon the occurrence of certain events
set forth in the Warrant Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
initial Exercise Price per share of Common Stock for any Warrant is equal to $11.50 per share. The Exercise Price is subject to adjustment
upon the occurrence of certain events set forth in the Warrant Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the conditions set forth in the Warrant Agreement, the Warrants may be exercised only during the Exercise Period and to the extent
not exercised by the end of such Exercise Period, such Warrants shall become void.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Warrants may be redeemed, subject to certain conditions, as set forth in the Warrant Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reference
is hereby made to the further provisions of this Warrant Certificate set forth on the reverse hereof and such further provisions shall
for all purposes have the same effect as though fully set forth at this place.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Warrant Certificate shall not be valid unless countersigned by the Warrant Agent, as such term is used in the Warrant Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Warrant Certificate shall be governed by and construed in accordance with the internal laws of the State of New York, without regard
to conflicts of laws principles thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DATA KNIGHTS ACQUISITION CORP.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 45%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONTINENTAL STOCK TRANSFER</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&amp; TRUST COMPANY, as Warrant Agent</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Form
of Warrant Certificate</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[REVERSE]</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Warrants evidenced by this Warrant Certificate are part of a duly authorized issue of Warrants entitling the holder on exercise to receive
shares of Common Stock and are issued or to be issued pursuant to a Warrant Agreement dated as of , 2021 (the &ldquo;<B><I>Warrant Agreement</I></B>&rdquo;),
duly executed and delivered by the Company to Continental Stock Transfer &amp; Trust Company, a New York corporation, as warrant agent
(the &ldquo;<B><I>Warrant Agent</I></B>&rdquo;), which Warrant Agreement is hereby incorporated by reference in and made a part of this
instrument and is hereby referred to for a description of the rights, limitation of rights, obligations, duties and immunities thereunder
of the Warrant Agent, the Company and the holders (the words &ldquo;<B><I>holders</I></B>&rdquo; or &ldquo;holder&rdquo; meaning the
Registered Holders or Registered Holder) of the Warrants. A copy of the Warrant Agreement may be obtained by the holder hereof upon written
request to the Company. Defined terms used in this Warrant Certificate but not defined herein shall have the meanings given to them in
the Warrant Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
may be exercised at any time during the Exercise Period set forth in the Warrant Agreement. The holder of Warrants evidenced by this
Warrant Certificate may exercise them by surrendering this Warrant Certificate, with the form of election to purchase set forth hereon
properly completed and executed, together with payment of the Exercise Price as specified in the Warrant Agreement (or through &ldquo;cashless
exercise&rdquo; as provided for in the Warrant Agreement) at the principal corporate trust office of the Warrant Agent. In the event
that upon any exercise of Warrants evidenced hereby the number of Warrants exercised shall be less than the total number of Warrants
evidenced hereby, there shall be issued to the holder hereof or his, her or its assignee, a new Warrant Certificate evidencing the number
of Warrants not exercised.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
anything else in this Warrant Certificate or the Warrant Agreement, no Warrant may be exercised unless at the time of exercise (i) a
registration statement covering the shares of Common Stock to be issued upon exercise is effective under the Securities Act and (ii)
a prospectus thereunder relating to the shares of Common Stock is current, except through &ldquo;cashless exercise&rdquo; as provided
for in the Warrant Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Warrant Agreement provides that upon the occurrence of certain events the number of shares of Common Stock issuable upon exercise of
the Warrants set forth on the face hereof may, subject to certain conditions, be adjusted. If, upon exercise of a Warrant, the holder
thereof would be entitled to receive a fractional interest in a share of Common Stock, the Company shall, upon exercise, round down to
the nearest whole number of shares of Common Stock to be issued to the holder of the Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant
Certificates, when surrendered at the principal corporate trust office of the Warrant Agent by the Registered Holder thereof in person
or by legal representative or attorney duly authorized in writing, may be exchanged, in the manner and subject to the limitations provided
in the Warrant Agreement, but without payment of any service charge, for another Warrant Certificate or Warrant Certificates of like
tenor evidencing in the aggregate a like number of Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
due presentation for registration of transfer of this Warrant Certificate at the office of the Warrant Agent a new Warrant Certificate
or Warrant Certificates of like tenor and evidencing in the aggregate a like number of Warrants shall be issued to the transferee(s)
in exchange for this Warrant Certificate, subject to the limitations provided in the Warrant Agreement, without charge except for any
tax or other governmental charge imposed in connection therewith.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company and the Warrant Agent may deem and treat the Registered Holder(s) hereof as the absolute owner(s) of this Warrant Certificate
(notwithstanding any notation of ownership or other writing hereon made by anyone), for the purpose of any exercise hereof, of any distribution
to the holder(s) hereof, and for all other purposes, and neither the Company nor the Warrant Agent shall be affected by any notice to
the contrary. Neither the Warrants nor this Warrant Certificate entitles any holder hereof to any rights of a stockholder of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Election
to Purchase</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(To
Be Executed Upon Exercise of Warrant)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned hereby irrevocably elects to exercise the right, represented by this Warrant Certificate, to receive shares of Common Stock
and herewith tenders payment for such shares of Common Stock to the order of Data Knights Acquisition Corp. (the &ldquo;<B><I>Company</I></B>&rdquo;)
in the amount of $ in accordance with the terms hereof. The undersigned requests that a certificate for such shares of Common Stock be
registered in the name of , whose address is and that such shares of Common Stock be delivered to whose address is . If said number of
shares of Common Stock is less than all of the shares of Common Stock purchasable hereunder, the undersigned requests that a new Warrant
Certificate representing the remaining balance of such shares of Common Stock be registered in the name of , whose address is and that
such Warrant Certificate be delivered to , whose address is .</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event that the Warrant has been called for redemption by the Company pursuant to Section 6.1 of the Warrant Agreement and the Company
has required cashless exercise pursuant to Section 6.3 of the Warrant Agreement, the number of shares of Common Stock that this Warrant
is exercisable for shall be determined in accordance with subsection 3.3.1(b) and Section 6.3 of the Warrant Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event that the Warrant is a Private Placement Warrant, a Working Capital Warrant, or an Extension Warrant that is to be exercised
on a &ldquo;cashless&rdquo; basis pursuant to subsection 3.3.1(c) of the Warrant Agreement, the number of shares of Common Stock that
this Warrant is exercisable for shall be determined in accordance with subsection 3.3.1(c) of the Warrant Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event that the Warrant is to be exercised on a &ldquo;cashless&rdquo; basis pursuant to Section 7.4 of the Warrant Agreement, the
number of shares of Common Stock that this Warrant is exercisable for shall be determined in accordance with Section 7.4 of the Warrant
Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event that the Warrant may be exercised, to the extent allowed by the Warrant Agreement, through cashless exercise (i) the number
of shares of Common Stock that this Warrant is exercisable for would be determined in accordance with the relevant section of the Warrant
Agreement which allows for such cashless exercise and (ii) the holder hereof shall complete the following: The undersigned hereby irrevocably
elects to exercise the right, represented by this Warrant Certificate, through the cashless exercise provisions of the Warrant Agreement,
to receive shares of Common Stock. If said number of shares is less than all of the shares of Common Stock purchasable hereunder (after
giving effect to the cashless exercise), the undersigned requests that a new Warrant Certificate representing the remaining balance of
such shares of Common Stock be registered in the name of , whose address is and that such Warrant Certificate be delivered to , whose
address is .</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Signature
Page Follows]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
    2021</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Signature)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Tax
    Identification Numbers)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature
    Guaranteed</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THE
SIGNATURE(S) SHOULD BE GUARANTEED BY AN ELIGIBLE GUARANTOR INSTITUTION (BANKS, STOCKBROKERS, SAVINGS AND LOAN ASSOCIATIONS AND CREDIT
UNIONS WITH MEMBERSHIP IN AN APPROVED SIGNATURE GUARANTEE MEDALLION PROGRAM, PURSUANT TO S.E.C. RULE 17Ad-15 UNDER THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED (OR ANY SUCCESSOR RULE)).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>8
<FILENAME>ex10-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="letter-spacing: -0.2pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="letter-spacing: -0.2pt"><B>Exhibit 10.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="letter-spacing: -0.2pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="letter-spacing: -0.2pt"><B>DATA KNIGHTS
ACQUISITION CORP.</B></FONT><B><FONT STYLE="letter-spacing: -0.15pt">1</FONT><FONT STYLE="letter-spacing: -0.2pt">&nbsp;2022 EQUITY INCENTIVE
PLAN</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="letter-spacing: -0.2pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">1.
<I>Purpose</I>. The purpose of the Data Knights Acquisition Corp. 2022 Equity Incentive Plan (the &ldquo;Plan&rdquo;) is to provide a
means through which the Company and its Affiliates may attract and retain key personnel and to provide a means whereby Directors, officers,
Employees, and Consultants (and prospective Directors, officers, Employees, and Consultants) of the Company and its Affiliates can acquire
and maintain an equity interest in the Company, or be paid incentive compensation, which may (but need not) be measured by reference to
the value of Common Shares, thereby strengthening their commitment to the welfare of the Company and its Affiliates and aligning their
interests with those of the Company&rsquo;s stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="letter-spacing: 0.2pt">2. <I>Definitions</I>.
The following definitions shall be applicable throughout the Plan:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(a)
&ldquo;<I>Affiliate</I>&rdquo; means (i)&nbsp;any person or entity that directly or indirectly controls, is controlled by or is under
common control with the Company and/or (ii)&nbsp;to the extent provided by the Committee, any person or entity in which the Company has
a significant interest. The term &ldquo;control&rdquo; &nbsp;(including, with correlative meaning, the terms
&ldquo;controlled by&rdquo; and &ldquo;under common control with&rdquo;), as applied to any person or entity, means the possession, directly
or indirectly, of the power to direct or cause the direction of the management and policies of such person or entity, whether through
the ownership of voting or other securities, by contract or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(b)
&ldquo;Award&rdquo; means, individually or collectively, any Incentive Stock Option, Nonqualified Stock Option, Stock Appreciation
Right, Restricted Stock, Restricted Stock Unit, Stock Bonus Award, and Performance Compensation Award granted under the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(c)
<I>&ldquo;Award Agreement&rdquo;</I>&nbsp;means a written or electronic agreement between the Company and a Participant setting forth
the terms, conditions and restrictions of the Award granted to the Participant</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"><FONT STYLE="letter-spacing: 0.2pt">(d)
&ldquo;<I>Board</I>&rdquo; means the Board of Directors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(e)
&ldquo;<I>Business Combination</I>&rdquo; has the meaning given such term in the definition of &ldquo;Change in Control.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(f)
&ldquo;<I>Cause</I>&rdquo; means, in the case of a particular Award, unless the applicable Award Agreement or the Participant&rsquo;s
employment agreement with the Company states otherwise, the Company&rsquo;s termination of the Participant&rsquo;s employment with the
Company as a result of: (i)&nbsp;fraud, embezzlement or other willful act of material dishonesty by the Participant in connection with
or relating to the Participant&rsquo;s employment with the Company; (ii)&nbsp;theft or misappropriation of property, information or other
assets by the Participant in connection with the Participant&rsquo;s employment with the Company which results in or could reasonably
be expected to result in material loss, damage or injury to the Company, its goodwill, business or reputation; (iii)&nbsp;the Participant&rsquo;s
commission, guilty plea, no contest plea or similar plea for any felony or crime involving moral turpitude; (iv)&nbsp;the Participant&rsquo;s
use of alcohol or drugs while working that materially interferes with the Participant&rsquo;s duties under this Agreement; (v)&nbsp;material
breach of a material Company policy, or material breach of a Company policy that results in or could reasonably be expected to result
in material loss, damage or injury to the Company, its goodwill, business or reputation; (vi)&nbsp;the Participant&rsquo;s material breach
of any of Participant&rsquo;s obligations under this Agreement; or (vii)&nbsp;the Participant&rsquo;s repeated insubordination, or refusal
(other than as a result of a Disability or physical or mental illness) to carry out or follow specific reasonable and lawful instructions,
duties or assignments given by the Board which are consistent with the Participant&rsquo;s position with the Company. Additionally, in
the event that the basis for Cause is, in the reasonable good faith determination of the Company not reasonably subject to cure, then
such thirty (30) days&rsquo; prior notice of termination for Cause shall not be required, and such termination shall be effective on the
date the Company delivers notice of such termination for Cause.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="letter-spacing: 0.2pt">Company name to
be changed to OneMedNet Corporation upon stockholder approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"><FONT STYLE="letter-spacing: 0.2pt">(g)
&ldquo;<I>Change in Control</I>&rdquo; shall, in the case of a particular Award, unless the applicable Award Agreement states otherwise or contains
a different definition of &ldquo;Change in Control,&rdquo; be deemed to occur upon:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(i)
Any sale, lease, exchange or other transfer (in one or a series of related transactions) of all or substantially all of the assets of
the Company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(ii)
Any &ldquo;Person&rdquo; as such term is used in Section&nbsp;13(d) and Section&nbsp;14(d) of the Securities Exchange Act of 1934, as
amended (the &ldquo;Exchange Act&rdquo;) becomes, directly or indirectly, the &ldquo;beneficial owner&rdquo; as defined in Rule&nbsp;13d-3
under the Exchange Act of securities of the Company that represent more than 50% of the combined voting power of the Company&rsquo;s then
outstanding voting securities (the &ldquo;Outstanding Company Voting Securities&rdquo;);&nbsp;provided,&nbsp;however, that for purposes
of this&nbsp;Section&nbsp;2(f)(ii), the following acquisitions shall not constitute a Change in Control: (I)&nbsp;any acquisition directly
from the Company principally for bona fide equity financing purposes, (II)&nbsp;any acquisition by the Company, (III)&nbsp;any acquisition
by any employee benefit plan (or related trust) sponsored or maintained by the Company or any Affiliate, (IV)&nbsp;any acquisition by
any corporation pursuant to a transaction that complies with&nbsp;Sections&nbsp;2(f)(iv)(A)&nbsp;and&nbsp;2(f)(iv)(B), and (V)&nbsp;any
acquisition involving beneficial ownership of less than 50% of the then-outstanding Common Shares (the &ldquo;Outstanding Company Common
Shares&rdquo;) or the Outstanding Company Voting Securities that is determined by the Board, based on review of public disclosure by the
acquiring Person with respect to its passive investment intent, not to have a purpose or effect of changing or influencing the control
of the Company;&nbsp;provided,&nbsp;however, that for purposes of this clause (V), any such acquisition in connection with (x)&nbsp;an
actual or threatened election contest with respect to the election or removal of directors or other actual or threatened solicitation
of proxies or consents or (y)&nbsp;any &ldquo;Business Combination&rdquo; &nbsp;(as defined below) shall be presumed
to be for the purpose or with the effect of changing or influencing the control of the Company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(iii)
During any period of not more than two (2)&nbsp;consecutive&nbsp;years, individuals who constitute the Board as of the beginning of the
period (the &ldquo;Incumbent Directors&rdquo;) cease for any reason to constitute at least a majority of the Board,&nbsp;provided that&nbsp;any
person becoming a director subsequent to the beginning of such period, whose election or nomination for election was approved by a vote
of at least two-thirds of the Incumbent Directors then on the Board (either by a specific vote or by approval of the proxy statement of
the Company in which such person is named as a nominee for director, without written objection to such nomination) will be an Incumbent
Director;&nbsp;provided,&nbsp;however, that no individual initially elected or nominated as a director of the Company as a result of an
actual or threatened election contest with respect to directors or as a result of any other actual or threatened solicitation of proxies
by or on behalf of any person other than the Board will be deemed to be an Incumbent Director;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(iv)
Consummation of a merger, amalgamation or consolidation (a &ldquo;Business Combination&rdquo;) of the Company with any other corporation,
unless, following such Business Combination, (A)&nbsp;all or substantially all of the individuals and entities that were the beneficial
owners of the Outstanding Company Common Shares and the Outstanding Company Voting Securities immediately prior to such Business Combination
beneficially own, directly or indirectly, more than 50% of the then-outstanding shares of common stock (or, for a non-corporate entity,
equivalent securities) and the combined voting power of the then-outstanding voting securities entitled to vote generally in the election
of directors (or, for a non-corporate entity, equivalent governing body), as the case may be, of the entity resulting from such Business
Combination (including, without limitation, an entity that, as a result of such transaction, owns the Company or all or substantially
all of the Company&rsquo;s assets either directly or through one or more subsidiaries) in substantially the same proportions as their
ownership immediately prior to such Business Combination of the Outstanding Company Common Shares and the Outstanding Company Voting Securities,
as the case may be, and (B)&nbsp;at least a majority of the members of the board of directors (or, for a non-corporate entity, equivalent
governing body) of the entity resulting from such Business Combination were Incumbent Directors at the time of the execution of the initial
agreement or of the action of the Board providing for such Business Combination;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 22.5pt"><FONT STYLE="letter-spacing: 0.2pt">(v) Stockholder
approval of a plan of complete liquidation of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(vi)
A transaction shall not constitute a Change in Control if its sole purpose is to change the state of the Company&rsquo;s incorporation
or to create a holding company that will be owned in substantially the same proportions by the persons who held the Company&rsquo;s securities
immediately before such transactions. In addition, if any Person (as defined above) is considered to be in effective control of the Company,
the acquisition of additional control of the Company by the same Person will not be considered to cause a Change in Control. If required
for compliance with Code Section&nbsp;409A, in no event will a Change in Control be deemed to have occurred if such transaction is not
also a &ldquo;change in the ownership or effective control of&rdquo; the Company or &ldquo;a change in the ownership of a substantial
portion of the assets of&rdquo; the Company as determined under Treasury Regulation&nbsp;Section&nbsp;1.409A-3(i)(5) (without regard to
any alternative definition thereunder).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(h)
&ldquo;<I>Code</I>&rdquo; means the Internal Revenue Code of 1986, as amended, and any successor thereto. Reference in the Plan to any section
of the Code shall be deemed to include any regulations or other interpretative guidance under such section, and any amendments or successor
provisions to such section, regulations or guidance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(i)
&ldquo;<I>Committee</I>&rdquo; means a committee of at least two people as the Board may appoint to administer the Plan or, if no such
committee has been appointed by the Board, the Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(j)
&ldquo;<I>Common Shares</I>&rdquo; means shares of the Company&rsquo;s Class&nbsp;A common stock (and any stock or other securities into
which such ordinary shares may be converted or into which they may be exchanged).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="letter-spacing: 0.2pt">(k) &ldquo;<I>Company</I>&rdquo;
means Data Knights Acquisition Corp.</FONT><FONT STYLE="letter-spacing: 0.15pt">2</FONT><FONT STYLE="letter-spacing: 0.2pt">, a Delaware
corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(l)
&ldquo;<I>Consultant</I>&rdquo; means any person, including an advisor, consultant or agent, engaged by the Company or a Parent or Subsidiary
to render services to such entity or who renders, or has rendered, services to the Company, or any Parent, Subsidiary or affiliate and
is compensated for such services.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(m)
&ldquo;<I>Date of Grant</I>&rdquo; means the date on which the granting of an Award is authorized, or such other date as may be specified
in such authorization.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="letter-spacing: 0.2pt">(n) &ldquo;<I>Director</I>&rdquo;
means a member of the Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(o)
&ldquo;<I>Disability</I>&rdquo; means, for the purpose of Incentive Stock Options, total and permanent disability as defined in Code Section&nbsp;22(e)(3);
and for the purpose of Awards other than Incentive Stock Options, means the inability of the Participant to perform the Participant&rsquo;s
material duties hereunder with a reasonable accommodation due to a physical or mental injury, infirmity or incapacity for one hundred
and twenty (120) days (including weekends and holidays) in any three hundred sixty-five (365) day period. The Participant shall reasonably
cooperate with the Company if a question arises as to whether the Participant has become disabled (including, without limitation, submitting
to reasonable examinations by one or more medical doctors and other health care specialists reasonably selected by the Company and authorizing
such medical doctors and other health care specialists to discuss the Participant&rsquo;s condition with the Company).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(p)
&ldquo;<I>Effective Date</I>&rdquo; means the date means the date on which the Plan is approved by the stockholders of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(q)
&ldquo;<I>Eligible Director</I>&rdquo; means a person who is a &ldquo;non-employee director&rdquo; within the meaning of Rule&nbsp;16b-3
under the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(r)
&ldquo;<I>Eligible Person</I>&rdquo; with respect to an Award denominated in Common Shares, means any (i)&nbsp;Employee;&nbsp;provided,&nbsp;however,
that no such employee covered by a collective bargaining agreement shall be an Eligible Person unless and to the extent that such eligibility
is set forth in such collective bargaining agreement which includes rules regarding equity entitlement or in an agreement or instrument
relating thereto; (ii)&nbsp;Director of the Company or an Affiliate; (iii)&nbsp;Consultant to the Company or an Affiliate;&nbsp;provided&nbsp;that
if the Securities Act applies such persons must be eligible to be offered securities registrable on Form S-8 under the Securities Act;
or (iv)&nbsp;prospective employees, directors, officers, consultants or advisors who have accepted offers of employment or consultancy
from the Company named to be changed to OneMedNet Corporation upon stockholder approval. Company or its Affiliates (and would satisfy
the provisions of clauses (i)&nbsp;through (iii)&nbsp;above once he or she begins employment with or begins providing services to the
Company or its Affiliates).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(s)
&ldquo;<I>Employee</I>&rdquo; means any person, including officers and Directors, employed by the Company or any Affiliate or Subsidiary
of the Company. Neither service as a Director nor payment of a director&rsquo;s fee by the Company will be sufficient to constitute &ldquo;employment&rdquo;
by the Company</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(t)
&ldquo;<I>Exchange Act</I>&rdquo; has the meaning given such term in the definition of &ldquo;Change in Control,&rdquo; and any reference
in the Plan to any section of (or rule promulgated under) the Exchange Act shall be deemed to include any rules, regulations or other
interpretative guidance under such section or rule, and any amendments or successor provisions to such section, rules, regulations or
guidance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(u)
&ldquo;<I>Exchange Program</I>&rdquo; means a program under which outstanding Awards are amended to provide for a lower Exercise Price
or surrendered or cancelled in exchange for (i)&nbsp;Awards with a lower Exercise Price, (ii)&nbsp;a different type of Award or awards
under a different equity incentive plan, (iii)&nbsp;cash, or (iv)&nbsp;a combination of (i), (ii)&nbsp;and/or (iii). Notwithstanding the
preceding, the term Exchange Program does not include (A)&nbsp;any action taken in connection with&nbsp;Section&nbsp;13&nbsp;or with a
Change in Control transaction nor (B)&nbsp;any transfer or other disposition permitted under&nbsp;Section&nbsp;15(c). For the purpose
of clarity, each of the actions described in the prior sentence, none of which constitute an Exchange Program, may be undertaken (or authorized)
by the Committee in its sole discretion without approval by the Company&rsquo;s stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"><FONT STYLE="letter-spacing: 0.2pt">(v)
&ldquo;<I>Exercise Price</I>&rdquo; has the meaning given such term in&nbsp;Section&nbsp;7(b)&nbsp;of the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(w)
&ldquo;<I>Fair Market Value</I>&rdquo; means, as of any date, the value of Common Shares determined as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(i)
If the Common Shares are listed on any established stock exchange or a national market system will be the closing sales price for such
shares (or the closing bid, if no sales were reported) as quoted on such exchange or system on the day of determination, as reported in&nbsp;<I>The
Wall Street Journal</I>&nbsp;or such other source as the Committee deems reliable;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(ii)
If the Common Shares are regularly quoted by a recognized securities dealer but selling prices are not reported, the Fair Market Value
of a Common Share will be the mean between the high bid and low asked prices for the Common Shares on the day of determination, as reported
in&nbsp;<I>The Wall Street Journal</I>&nbsp;or such other source as the Committee deems reliable; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(iii)
In the absence of an established market for the Common Shares, the Fair Market Value will be determined in good faith by the Committee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(x)
&ldquo;<I>Good Reason</I>&rdquo; means, in the case of a particular Award, unless the applicable Award Agreement or the Participant&rsquo;s
employment agreement with the Company states otherwise, the occurrence of any of the following events, without the express written consent
of the Participant: (i)&nbsp;the Company&rsquo;s material breach of any of its obligations under the Participant&rsquo;s employment agreement
with the Company or this Agreement, (ii)&nbsp;reduction in the Participant&rsquo;s total annual cash compensation opportunity (i.e.,
base salary and target annual bonus) as described in the Participant&rsquo;s employment agreement with the Company, (iii)&nbsp;a material
relocation of the Participant&rsquo;s principal place of employment to a location more than fifty (50) miles from the current principal
place of employment approved by the Company, or (iv)&nbsp;the failure of a successor to the Company to assume the Company&rsquo;s obligations
under the Participant&rsquo;s employment agreement with the Company or this Agreement,&nbsp;provided, that, for (i)&nbsp;&thinsp;&ndash;&thinsp;(iv)&nbsp;above,
the Participant has given written notice to the Company of the condition giving rise to Good Reason within ninety (90) days after its
initial occurrence and the Company fails to cure such condition within thirty (30) days following the receipt of such written notification
by the Participant to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 40pt"><FONT STYLE="letter-spacing: 0.2pt">(y)
&ldquo;<I>Immediate Family Members</I>&rdquo; shall have the meaning set forth in&nbsp;Section&nbsp;16(b)&nbsp;of the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 40pt"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(z)
&ldquo;<I>Incentive Stock Option</I>&rdquo; means an Option that is designated by the Committee as an incentive stock option as described
in Code Section&nbsp;422 and otherwise meets the requirements set forth in the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="letter-spacing: 0.2pt">(aa) &ldquo;<I>Indemnifiable
Person</I>&rdquo; shall have the meaning set forth in&nbsp;Section&nbsp;4(e)&nbsp;of the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(bb)
<I>&ldquo;Mature Shares</I>&rdquo; means Common Shares owned by a Participant that are not subject to any pledge or security interest
and that have been either previously acquired by the Participant on the open market or meet such other requirements, if any, as the Committee
may determine are necessary in order to avoid an accounting earnings charge on account of the use of such shares to pay the Exercise Price
or satisfy a tax or deduction obligation of the Participant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(cc)
&ldquo;<I>Nonqualified Stock Option</I>&rdquo; means an Option that is not designated by the Committee as an Incentive Stock Option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="letter-spacing: 0.2pt">(dd) &ldquo;<I>Option</I>&rdquo;
means an Award granted under&nbsp;Section&nbsp;7&nbsp;of the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="letter-spacing: 0.2pt">(ee) &ldquo;<I>Option
Period</I>&rdquo; has the meaning given such term in&nbsp;Section&nbsp;7(c)&nbsp;of the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(ff)
&ldquo;<I>Other Cash-Based Award</I>&rdquo; shall mean a right or other interest granted to a Participant pursuant to&nbsp;Section&nbsp;11&nbsp;of
the Plan other than an Other Stock-Based Award.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(gg)
&ldquo;<I>Other Stock-Based Award</I>&rdquo; shall mean a right or other interest granted to a Participant, valued in whole or in part
by reference to, or otherwise based on, or related to, Common Stock pursuant to&nbsp;Section&nbsp;11&nbsp;of the Plan including but not
limited to (i)&nbsp;unrestricted Common Stock awarded as a bonus or upon the attainment of performance goals or otherwise as permitted
under the Plan, and (ii)&nbsp;a right granted to a Participant to acquire Common Stock from the Company containing terms and conditions
prescribed by the Committee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(hh)
&ldquo;<I>Outstanding Company Common Shares</I>&rdquo; has the meaning given such term in the definition of &ldquo;Change in Control.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(ii)
&ldquo;<I>Outstanding Company Voting Securities</I>&rdquo; has the meaning given such term in the definition of &ldquo;Change in Control.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(jj)
&ldquo;<I>Participant</I>&rdquo; means an Eligible Person who has been selected by the Committee to participate in the Plan and to receive
an Award pursuant to&nbsp;Section&nbsp;6&nbsp;of the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(kk)
&ldquo;<I>Performance Compensation Award</I>&rdquo; shall mean any Award designated by the Committee as a Performance Compensation Award
pursuant to&nbsp;Section&nbsp;11&nbsp;of the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(ll)
&ldquo;<I>Performance Criteria</I>&rdquo; shall mean the criterion or criteria that the Committee shall select for purposes of establishing
the Performance Goal(s) for a Performance Period with respect to any Performance Compensation Award under the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(mm)
&ldquo;<I>Performance Formula</I>&rdquo; shall mean, for a Performance Period, the one or more formulae applied against the relevant Performance
Goal to determine, with regard to the Performance Compensation Award of a particular Participant, whether all, some portion but less than
all, or none of the Performance Compensation Award has been earned for the Performance Period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(nn)
&ldquo;<I>Performance Goals</I>&rdquo; shall mean, for a Performance Period, the one or more goals established by the Committee for the
Performance Period based upon the Performance Criteria.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(oo)
&ldquo;<I>Performance Period</I>&rdquo; shall mean the one or more periods of time, as the Committee may select, over which the attainment
of one or more Performance Goals will be measured for the purpose of determining a Participant&rsquo;s right to, and the payment of, a
Performance Compensation Award.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 13.5pt"><FONT STYLE="letter-spacing: 0.2pt">(pp)
&ldquo;<I>Permitted Transferee</I>&rdquo; shall have the meaning set forth in&nbsp;Section&nbsp;16(b)&nbsp;of the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 13.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 13.5pt"><FONT STYLE="letter-spacing: 0.2pt">(qq)
&ldquo;<I>Person</I>&rdquo; has the meaning given such term in the definition of &ldquo;Change in Control.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 13.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(rr)
&ldquo;<I>Plan</I>&rdquo; means this Data Knights Acquisition Corp.</FONT><FONT STYLE="letter-spacing: 0.15pt">3</FONT><FONT STYLE="letter-spacing: 0.2pt">&nbsp;2022
Equity Incentive Plan, as amended from time to time. Company name to be changed to OneMedNet Corporation upon stockholder approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 13.5pt"><FONT STYLE="letter-spacing: 0.2pt">(ss) &ldquo;<I>Qualifying Termination</I>&rdquo; means, except as otherwise provided by the Committee
as set forth in the Award, the occurrence of either a termination of a Participant&rsquo;s employment by the Company without Cause or
for Good Reason, in either case, occurring on or within the 12-month period (or such other period specified in the applicable Award Agreement)
following the consummation of a Change in Control.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 13.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(tt)
&ldquo;<I>Restricted Period</I>&rdquo; means the period of time determined by the Committee during which an Award is subject to restrictions
or, as applicable, the period of time within which performance is measured for purposes of determining whether an Award has been earned.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(uu)
&ldquo;<I>Restricted Stock Unit</I>&rdquo; means an unfunded and unsecured promise to deliver Common Shares, cash, other securities or
other property, subject to certain performance or time-based restrictions (including, without limitation, a requirement that the Participant
remain continuously employed or provide continuous services for a specified period of time), granted under&nbsp;Section&nbsp;9&nbsp;of
the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(vv)
&ldquo;<I>Restricted Stock</I>&rdquo; means Common Shares, subject to certain specified performance or time-based restrictions (including,
without limitation, a requirement that the Participant remain continuously employed or provide continuous services for a specified period
of time), granted under&nbsp;Section&nbsp;9&nbsp;of the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(ww)
&ldquo;<I>Retirement</I>&rdquo; means, in the case of a particular Award, the definition set forth in the applicable Award Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="letter-spacing: 0.2pt">(xx) &ldquo;<I>SAR
Period</I>&rdquo; has the meaning given such term in&nbsp;Section&nbsp;8(b)&nbsp;of the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(yy)
&ldquo;<I>Securities Act</I>&rdquo; means the Securities Act of 1933, as amended, and any successor thereto. Reference in the Plan to
any section of the Securities Act shall be deemed to include any rules, regulations or other interpretative guidance under such section,
and any amendments or successor provisions to such section, rules, regulations or guidance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 40pt"><FONT STYLE="letter-spacing: 0.2pt">(zz)
&ldquo;<I>Stock Appreciation Right</I>&rdquo; or&nbsp;<I>&ldquo;SAR&rdquo;</I>&nbsp;means an Award granted under&nbsp;Section&nbsp;8&nbsp;of
the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="letter-spacing: 0.2pt">(aaa) &ldquo;<I>Stock
Bonus Award</I>&rdquo; means an Award granted under&nbsp;Section&nbsp;10&nbsp;of the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(bbb)
&ldquo;<I>Strike Price</I>&rdquo; means, except as otherwise provided by the Committee in the case of Substitute Awards, (i)&nbsp;in the
case of a SAR granted in tandem with an Option, the Exercise Price of the related Option, or (ii)&nbsp;in the case of a SAR granted independent
of an Option, the Fair Market Value on the Date of Grant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="letter-spacing: 0.2pt">(ccc) &ldquo;<I>Subsidiary</I>&rdquo;
means, with respect to any specified Person:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(i)
any corporation, association or other business entity of which more than 50% of the total voting power of shares (without regard to the
occurrence of any contingency and after giving effect to any voting agreement or stockholders&rsquo; agreement that effectively transfers
voting power) is at the time owned or controlled, directly or indirectly, by that Person or one or more of the other Subsidiaries of that
Person (or a combination thereof); and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(ii)
any partnership (or any comparable foreign entity (a)&nbsp;the sole general partner (or functional equivalent thereof) or the managing
general partner of which is such Person or Subsidiary of such Person or (b)&nbsp;the only general partners (or functional equivalents
thereof) of which are that Person or one or more Subsidiaries of that Person (or any combination thereof).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="letter-spacing: 0.2pt">(iii) &ldquo;<I>Substitute
Award</I>&rdquo; has the meaning given such term in&nbsp;Section&nbsp;5(e)&nbsp;of the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">3.
<I>Effective Date; Duration</I>. The Plan shall be effective as of the Effective Date. The expiration date of the Plan, on and after which
date no Awards may be granted hereunder, shall be the tenth anniversary of the Effective Date;&nbsp;provided,&nbsp;however, that such
expiration shall not affect Awards then outstanding, and the terms and conditions of the Plan shall continue to apply to such Awards.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="letter-spacing: 0.2pt">4. <I>Administration</I>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(a)
The Committee shall administer the Plan. To the extent required to comply with the applicable provisions of Rule&nbsp;16b-3 promulgated
under the Exchange Act (if the Board is not acting as the Committee under the Plan), it is intended that each member of the Committee
shall, at the time he or she takes any action with respect to an Award under the Plan, be an Eligible Director. However, the fact that
a Committee member shall fail to qualify as an Eligible Director shall not invalidate any Award granted by the Committee that is otherwise
validly granted under the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(b)
Subject to the provisions of the Plan and applicable law, the Committee shall have the sole and plenary authority, in addition to other
express powers and authorizations conferred on the Committee by the Plan or by the Board, to: (i)&nbsp;designate Participants; (ii)&nbsp;determine
the type or types of Awards to be granted to a Participant; (iii)&nbsp;determine the number of Common Shares to be covered by, or with
respect to which payments, rights, or other matters are to be calculated in connection with, Awards; (iv)&nbsp;determine the form of Award
Agreement and the terms and conditions of any Award; (v)&nbsp;determine whether, to what extent, and under what circumstances Awards may
be settled or exercised in cash, Common Shares, other securities, other Awards or other property, or canceled, forfeited, or suspended
and the method or methods by which Awards may be settled, exercised, canceled, forfeited, or suspended; (vi)&nbsp;determine whether, to
what extent, and under what circumstances the delivery of cash, Common Shares, other securities, other Awards or other property and other
amounts payable with respect to an Award shall be deferred either automatically or at the election of the Participant or of the Committee;
(vii)&nbsp;interpret, administer, reconcile any inconsistency in, correct any defect in and/or supply any omission in the Plan and any
instrument or agreement relating to, or Award granted under, the Plan; (viii)&nbsp;establish, amend, suspend, or waive any rules and regulations
and appoint such agents as the Committee shall deem appropriate for the proper administration of the Plan; (ix)&nbsp;accelerate the vesting
or exercisability of, payment for or lapse of restrictions on, Awards, including, but not limited to, upon a Qualifying Termination; (x)&nbsp;to
institute and determine the terms and conditions of an Exchange Program; provided, however, that the Committee shall not implement an
Exchange Program without the approval of the holders of a majority of the Shares that are present in person or by proxy and entitled to
vote at any annual or special meeting of Company&rsquo;s stockholders; and (xi)&nbsp;make any other determination and take any other action
that the Committee deems necessary or desirable for the administration of the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(c)
The Committee may delegate to one or more officers of the Company or any Affiliate the authority to act on behalf of the Committee with
respect to any matter, right, obligation, or election that is the responsibility of or that is allocated to the Committee herein, and
that may be so delegated as a matter of law, except for grants of Awards to persons subject to Section&nbsp;16 of the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(d)
Unless otherwise expressly provided in the Plan, all designations, determinations, interpretations, and other decisions under or with
respect to the Plan or any Award or any documents evidencing Awards granted pursuant to the Plan shall be within the sole discretion of
the Committee, may be made at any time and shall be final, conclusive and binding upon all persons or entities, including, without limitation,
the Company, any Affiliate, any Participant, any holder or beneficiary of any Award, and any stockholder of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(e)
No member of the Board, the Committee, delegate of the Committee or any employee or agent of the Company (each such person, an &ldquo;Indemnifiable
Person&rdquo;) shall be liable for any action taken or omitted to be taken or any determination made in good faith with respect to the
Plan or any Award hereunder. Each Indemnifiable Person shall be indemnified and held harmless by the Company against and from any loss,
cost, liability, or expense (including attorneys&rsquo; fees) that may be imposed upon or incurred by such Indemnifiable Person in connection
with or resulting from any action, suit or proceeding to which such Indemnifiable Person may be a party or in which such Indemnifiable&nbsp;Person
may be involved by reason of any action taken or omitted to be taken under the Plan or any Award Agreement and against and from any and
all amounts paid by such Indemnifiable Person with the Company&rsquo;s approval, in settlement thereof, or paid by such Indemnifiable
Person in satisfaction of any judgment in any such action, suit or proceeding against such Indemnifiable Person,&nbsp;provided&nbsp;that
the Company shall have the right, at its own expense, to assume and defend any such action, suit or proceeding and once the Company gives
notice of its intent to assume the defense, the Company shall have sole control over such defense with counsel of the Company&rsquo;s
choice. The foregoing right of indemnification shall not be available to an Indemnifiable Person to the extent that a final judgment or
other final adjudication (in either case not subject to further appeal) binding upon such Indemnifiable Person determines that the acts
or omissions of such Indemnifiable Person giving rise to the indemnification claim resulted from such Indemnifiable Person&rsquo;s bad
faith, fraud or willful criminal act or omission or that such right of indemnification is otherwise prohibited by law or by the Company&rsquo;s
Articles of Incorporation or Bylaws. The foregoing right of indemnification shall not be exclusive of any other rights of indemnification
to which such Indemnifiable Persons may be entitled under the Company&rsquo;s Articles of Incorporation or Bylaws, as a matter of law,
or otherwise, or any other power that the Company may have to indemnify such Indemnifiable Persons or hold them harmless.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(f)
Notwithstanding anything to the contrary contained in the Plan, the Board may, in its sole discretion, at any time and from time to time,
grant Awards and administer the Plan with respect to such Awards. In any such case, the Board shall have all the authority granted to
the Committee under the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="letter-spacing: 0.2pt">5. <I>Grant of
Awards; Shares Subject to the Plan; Limitations</I>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(a)
The Committee may, from time to time, grant Options, Stock Appreciation Rights, Restricted Stock, Restricted Stock Units, Stock Bonus
Awards and/or Performance Compensation Awards to one or more Eligible Persons.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(b)
Subject to&nbsp;Section&nbsp;13&nbsp;of the Plan, Awards granted under the Plan shall be subject to the following limitations: (i)&nbsp;the
Committee is authorized to deliver under the Plan an aggregate of [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;]</FONT><FONT STYLE="letter-spacing: 0.15pt">4</FONT><FONT STYLE="letter-spacing: 0.2pt">&nbsp;Common
Shares; provided, that total number of Common Shares that will be reserved, and that may be issued, under the Plan will automatically
increase on the first trading day of each calendar year, beginning with calendar year 2023, by a number of Common Shares equal to five&nbsp;percent
(5%) of the total outstanding Common Shares on the last day of the prior calendar year (subject to a maximum annual increase of 1,000,000
Common Shares), (ii)&nbsp;in no event shall the maximum aggregate number of Common Shares that may be issued under the Plan pursuant to
Incentive Stock Options exceed the aggregate number of Common Shares set forth in&nbsp;Section&nbsp;5(b)(i)&nbsp;of the Plan plus, to
the extent allowable under Code Section&nbsp;422 and the regulations promulgated thereunder, any Common Shares that again become available
for issuance pursuant to&nbsp;Section&nbsp;5(c)&nbsp;of the Plan and (iii)&nbsp;the maximum number of Common Shares that may be granted
under the Plan during any single fiscal year to any Participant who is a non-employee director, when taken together with any cash fees
paid to such non-employee director during such year in respect of his or her service as a non-employee director (including service as
a member or chair of any committee of the Board), shall not exceed $750,000 in total value (calculating the value of any such Awards based
on the grant date fair value of such Awards for financial reporting purposes);&nbsp;provided&nbsp;that the non-employee directors who
are considered independent (under the rules of The NASDAQ Stock Market or other securities exchange on which the Common Shares are traded)
may make exceptions to this limit for a non-executive chair of the Board, if any, in which case the non-employee Director receiving such
additional compensation may not participate in the decision to award such compensation. Notwithstanding the automatic annual increase
set forth in (i)&nbsp;above, the Board may act prior to January&nbsp;1st of a given year to provide that there will be no such increase
in the share reserve for such year or that the increase in the share reserve for such year will be a lesser number of Common Shares than
would otherwise occur pursuant to the stipulated&nbsp;percentage.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(c)
In the event that (i)&nbsp;any Option or other Award granted hereunder is exercised through the tendering of Common Shares (either actually
or by attestation) or by the withholding of Common Shares by the Company, or (ii)&nbsp;tax or deduction liabilities arising from such
Option or other Award are satisfied by the tendering of Common Shares (either actually or by attestation) or by the withholding of Common
Shares by the Company, then in each such case the Common Shares so tendered or withheld shall be added to the Common Shares available
for grant under the Plan on a one-for-one basis. Shares underlying Awards under this Plan that are forfeited, cancelled, expire unexercised,
or are settled in cash are available again for Awards under the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(d)
Common Shares delivered by the Company in settlement of Awards may be authorized and unissued shares, shares held in the treasury of the
Company, shares purchased on the open market or by private purchase, or a combination of the foregoing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(e)
Awards may, in the sole discretion of the Committee, be granted under the Plan in assumption of, or in substitution for, outstanding awards
previously granted by an entity acquired by the Company or with which the Company combines (&ldquo;Substitute Awards&rdquo;). The number
of Common Shares underlying any Substitute Awards shall not be counted against the aggregate number of Common Shares available for Awards
under the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">6.
<I>Eligibility</I>. Participation shall be limited to Eligible Persons who have entered into an Award Agreement or who have received written
notification from the Committee, or from a person designated by the Committee, that they have been selected to participate in the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="letter-spacing: 0.2pt">7. <I>Options</I>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(a)
<I>Generally</I>. Each Option granted under the Plan shall be evidenced by an Award Agreement (whether in paper or electronic medium (including
email or the posting on a web site maintained by the Company or a third party under contract with the Company)). Each Option so granted
shall be subject to the conditions set forth in this&nbsp;Section&nbsp;7, and to such other conditions not inconsistent with the Plan
as may be reflected in the applicable Award Agreement. All Options granted under the Plan shall be Nonqualified Stock Options unless the
applicable Award Agreement expressly states that the Option is intended to be an Incentive Stock Option. Incentive Stock Options shall
be granted only to Eligible Persons who are employees of the Company and its Affiliates, and no Incentive Stock Option shall be granted
to any Eligible Person who is ineligible to receive an Incentive Stock Option under the Code. No Option shall be treated as an Incentive
Stock Option unless the Plan has been approved by the stockholders of the Company in a manner intended to comply with the stockholder
approval requirements of Code Section&nbsp;422(b)(1);&nbsp;provided&nbsp;that any Option intended to be an Incentive Stock Option shall
not fail to be effective solely on account of a failure to obtain such approval, but rather such Option shall be treated as a Nonqualified
Stock Option unless and until such approval is obtained. In the case of an Incentive Stock Option, the terms and conditions of such grant
shall be subject to and comply with such rules as may be prescribed by Code Section&nbsp;422. If for any reason an Option intended to
be an Incentive Stock Option (or any portion thereof) shall not qualify as an Incentive Stock Option, then, to the extent of such non-qualification,
such Option or portion thereof shall be regarded as a Nonqualified Stock Option appropriately granted under the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(b)
<I>Exercise Price</I>. Except with respect to Substitute Awards, the exercise price (&ldquo;Exercise Price&rdquo;) per Common Share for
each Option shall not be less than 100% of the Fair Market Value of such share determined as of the Date of Grant;&nbsp;provided,&nbsp;however,
that in the case of an Incentive Stock Option granted to an employee who, at the time of the grant of such Option, owns shares representing
more than 10% of the total combined voting power of all classes of shares of the Company or any related corporation (as determined in
accordance with Treasury Regulation&nbsp;Section&nbsp;1.422-2(f)), the Exercise Price per share shall not be less than 110% of the Fair
Market Value per share on the Date of Grant and&nbsp;provided further, that, notwithstanding any provision herein to the contrary, the
Exercise Price shall not be less than the par value per Common Share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(c)
<I>Vesting and Expiration</I>. Options shall vest and become exercisable in such manner and on such date or dates determined by the Committee
and shall expire after such period, not to exceed ten&nbsp;years, as may be determined by the Committee (the &ldquo;Option Period&rdquo;);&nbsp;provided,&nbsp;however,
that the Option Period shall not exceed five&nbsp;years from the Date of Grant in the case of an Incentive Stock Option granted to a Participant
who on the Date of Grant owns shares representing more than 10% of the total combined voting power of all classes of shares of the Company
or any related corporation (as determined in accordance with Treasury Regulation&nbsp;Section&nbsp;1.422-2(f));&nbsp;provided,&nbsp;further,
that notwithstanding any vesting dates set by the Committee, the Committee may, in its sole discretion, accelerate the exercisability
of any Option, which acceleration shall not affect the terms and conditions of such Option other than with respect to exercisability.
Unless otherwise provided by the Committee in an Award Agreement: (i)&nbsp;the unvested portion of an Option shall expire upon termination
of employment or service of the Participant granted the Option, and the vested portion of such Option shall remain exercisable for (A)&nbsp;one
year following termination of employment or service by reason of such Participant&rsquo;s death or disability (as determined by the Committee),
but not later than the expiration of the Option Period or (B)&nbsp;ninety (90) days following termination of employment or service for
any reason other than such Participant&rsquo;s death or disability, and other than such Participant&rsquo;s termination of employment
or service for Cause, but not later than the expiration of the Option Period; and (ii)&nbsp;both the unvested and the vested portion of
an Option shall expire upon the termination of the Participant&rsquo;s employment or service by the Company for Cause. If the Option would
expire at a time when the exercise of the Option would violate applicable securities laws, the expiration date applicable to the Option
will be automatically extended to a date that is thirty (30) calendar days following the date such exercise would no longer violate applicable
securities laws (so long as such extension shall not violate Code Section&nbsp;409A);&nbsp;provided, that in no event shall such expiration
date be extended beyond the expiration of the Option Period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(d)
<I>Method of Exercise and Form of Payment</I>. No Common Shares shall be delivered pursuant to any exercise of an Option until payment
in full of the Exercise Price therefor is received by the Company and the Participant has paid to the Company an amount equal to any taxes
required to be withheld or paid. Options that have become exercisable may be exercised by delivery of written or electronic notice of
exercise to the Company in accordance with the terms of the Option accompanied by payment of the Exercise Price. The Exercise Price shall
be payable (i)&nbsp;in cash, check, cash equivalent and/or Common Shares valued at the fair market value at the time the Option is exercised
(including, pursuant to procedures approved by the Committee, by means of attestation of ownership of a sufficient number of Common Shares
in lieu of actual delivery of such shares to the Company); provided that such Common Shares are not subject to any pledge or other security
interest and are Mature Shares and; (ii)&nbsp;by such other method as the Committee may permit in accordance with applicable law, in its
sole discretion, on a case by case basis, including without limitation: (A)&nbsp;in other property having a fair market value on the date
of exercise equal to the Exercise Price or (B)&nbsp;if there is a public market for the Common Shares at such time, by means of a broker-assisted
&ldquo;cashless exercise&rdquo; pursuant to which the Company is delivered a copy of irrevocable instructions to a stockbroker to sell
the Common Shares otherwise deliverable upon the exercise of the Option and to deliver promptly to the Company an amount equal to the
Exercise Price or (C)&nbsp;by a &ldquo;net exercise&rdquo; method whereby the Company withholds from the delivery of the Common Shares
for which the Option was exercised that number of Common Shares having a fair market value equal to the aggregate Exercise Price for the
Common Shares for which the Option was exercised. No fractional Common Shares shall be issued or delivered pursuant to the Plan or any
Award, and the Committee shall determine whether cash, other securities or other property shall be paid or transferred in lieu of any
fractional Common Shares, or whether such fractional Common Shares or any rights thereto shall be canceled, terminated or otherwise eliminated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(e)
<I>Notification upon Disqualifying Disposition of an Incentive Stock Option</I>. Each Participant awarded an Incentive Stock Option under
the Plan shall notify the Company in writing immediately after the date he makes a disqualifying disposition of any Common Shares acquired
pursuant to the exercise of such Incentive Stock Option. A disqualifying disposition is any disposition (including, without limitation,
any sale) of such Common Shares before the later of (A)&nbsp;two (2)&nbsp;years after the Date of Grant of the Incentive Stock Option
or (B)&nbsp;one (1)&nbsp;year after the date of exercise of the Incentive Stock Option. The Company may, if determined by the Committee
and in accordance with procedures established by the Committee, retain possession of any Common Shares acquired pursuant to the exercise
of an Incentive Stock Option as agent for the applicable Participant until the end of the period described in the preceding sentence.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(f)
<I>Compliance with Laws, etc</I>. Notwithstanding the foregoing, in no event shall a Participant be permitted to exercise an Option in
a manner that the Committee determines would violate the Sarbanes-Oxley Act of 2002, if applicable, or any other applicable law or the
applicable rules and regulations of the Securities and Exchange Commission or the applicable rules and regulations of any securities exchange
or inter-dealer quotation system on which the securities of the Company are listed or traded.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="letter-spacing: 0.2pt">8. <I>Stock Appreciation
Rights</I>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(a)
<I>Generally</I>. Each SAR granted under the Plan shall be evidenced by an Award Agreement (whether in paper or electronic medium (including
email or the posting on a web site maintained by the Company or a third party under contract with the Company)). Each SAR so granted shall
be subject to the conditions set forth in this&nbsp;Section&nbsp;8, and to such other conditions not inconsistent with the Plan as may
be reflected in the applicable Award Agreement. Any Option granted under the Plan may include tandem SARs. The Committee also may award
SARs to Eligible Persons independent of any Option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(b)
<I>Exercise Price</I>. The Exercise Price per Common Share for each SAR shall not be less than 100% of the Fair Market Value of such share
determined as of the Date of Grant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(c)
<I>Vesting and Expiration</I>. A SAR granted in connection with an Option shall become exercisable and shall expire according to the same
vesting schedule and expiration provisions as the corresponding Option. A SAR granted independent of an Option shall vest and become exercisable
and shall expire in such manner and on such date or dates determined by the Committee and shall expire after such period, not to exceed
ten&nbsp;years, as may be determined by the Committee (the &ldquo;SAR Period&rdquo;);&nbsp;provided,&nbsp;however, that notwithstanding
any vesting dates set by the Committee, the Committee may, in its sole discretion, accelerate the exercisability of any SAR, which acceleration
shall not affect the terms and conditions of such SAR other than with respect to exercisability. Unless otherwise provided by the Committee
in an Award Agreement: (i)&nbsp;the unvested portion of a SAR shall expire upon termination of employment or service of the Participant
granted the SAR, and the vested portion of such SAR shall remain exercisable for (A)&nbsp;one year following termination of employment
or service by reason of such Participant&rsquo;s death or disability (as determined by the Committee), but not later than the expiration
of the SAR Period or (B)&nbsp;90&nbsp;days following termination of employment or service for any reason other than such Participant&rsquo;s
death or disability, and other than such Participant&rsquo;s termination of employment or service for Cause, but not later than the expiration
of the SAR Period; and (ii)&nbsp;both the unvested and the vested portion of a SAR shall expire upon the termination of the Participant&rsquo;s
employment or service by the Company for Cause. If the SAR would expire at a time when the exercise of the SAR would violate applicable
securities laws, the expiration date applicable to the SAR will be automatically extended to a date that is thirty (30) calendar days
following the date such exercise would no longer violate applicable securities laws (so long as such extension shall not violate Code
Section&nbsp;409A);&nbsp;provided, that in no event shall such expiration date be extended beyond the expiration of the SAR Period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(d)
<I>Method of Exercise</I>. SARs that have become exercisable may be exercised by delivery of written or electronic notice of exercise
to the Company in accordance with the terms of the Award, specifying the number of SARs to be exercised and the date on which such SARs
were awarded. Notwithstanding the foregoing, if on the last day of the Option Period (or in the case of a SAR independent of an option,
the SAR Period), the fair market value exceeds the Strike Price, the Participant has not exercised the SAR or the corresponding Option
(if applicable), and neither the SAR nor the corresponding Option (if applicable) has expired, such SAR shall be deemed to have been exercised
by the Participant on such last day and the Company shall make the appropriate payment therefor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(e)
<I>Payment</I>. Upon the exercise of a SAR, the Company shall pay to the Participant an amount equal to the number of shares subject to
the SAR that are being exercised multiplied by the excess, if any, of the fair market value of one Common Share on the exercise date over
the Strike Price, less an amount equal to any taxes required to be withheld or paid. The Company shall pay such amount in cash, in Common
Shares valued at fair market value, or any combination thereof, as determined by the Committee. No fractional Common Shares shall be issued
or delivered pursuant to the Plan or any Award, and the Committee shall determine whether cash, other securities or other property shall
be paid or transferred in lieu of any fractional Common Shares, or whether such fractional Common Shares or any rights thereto shall be
canceled, terminated or otherwise eliminated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="letter-spacing: 0.2pt">9. <I>Restricted
Stock and Restricted Stock Units</I>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(a)
<I>Generally</I>. Each grant of Restricted Stock and Restricted Stock Units shall be evidenced by an Award Agreement (whether in paper
or electronic medium (including email or the posting on a web site maintained by the Company or a third party under contract with the
Company)). Each such grant shall be subject to the conditions set forth in this&nbsp;Section&nbsp;9, and to such other conditions not
inconsistent with the Plan as may be reflected in the applicable Award Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(b)
<I>Restricted Accounts; Escrow or Similar Arrangement</I>. Upon the grant of Restricted Stock, a book entry in a restricted account shall
be established in the Participant&rsquo;s name at the Company&rsquo;s transfer agent and, if the Committee determines that the Restricted
Stock shall be held by the Company or in escrow rather than held in such restricted account pending the release of the applicable restrictions,
the Committee may require the Participant to additionally execute and deliver to the Company (i)&nbsp;an escrow agreement satisfactory
to the Committee, if applicable, and (ii)&nbsp;the appropriate share power (endorsed in blank) with respect to the Restricted Stock covered
by such agreement. If a Participant shall fail to execute an agreement evidencing an Award of Restricted Stock and, if applicable, an
escrow agreement and blank share power within the amount of time specified by the Committee, the Award shall be null and void. Subject
to the restrictions set forth in this&nbsp;Section&nbsp;9&nbsp;and the applicable Award Agreement, the Participant generally shall have
the rights and privileges of a stockholder as to such Restricted Stock, including without limitation the right to vote such Restricted
Stock and the right to receive dividends, if applicable. To the extent shares of Restricted Stock are forfeited, any share certificates
issued to the Participant evidencing such shares shall be returned to the Company, and all rights of the Participant to such shares and
as a stockholder with respect thereto shall terminate without further obligation on the part of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(c)
<I>Vesting; Acceleration of Lapse of Restrictions</I>. Unless otherwise provided by the Committee in an Award Agreement the unvested portion
of Restricted Stock and Restricted Stock Units shall terminate and be forfeited upon termination of employment or service of the Participant
granted the applicable Award.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="letter-spacing: 0.2pt">(d) <I>Delivery
of Restricted Stock and Settlement of Restricted Stock Units</I>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(i)
Upon the expiration of the Restricted Period with respect to any shares of Restricted Stock, the restrictions set forth in the applicable
Award Agreement shall be of no further force or effect with respect to such shares, except as set forth in the applicable Award Agreement.
If an escrow arrangement is used, upon such expiration, the Company shall deliver to the Participant, or his beneficiary, without charge,
the share certificate evidencing the shares of Restricted Stock that have not then been forfeited and with respect to which the Restricted
Period has expired (rounded down to the nearest full share). Dividends, if any, that may have been withheld by the Committee and attributable
to any particular share of Restricted Stock shall be distributed to the Committee and attributable to any particular share of Restricted
Stock shall be distributed to the Participant in cash or, at the sole discretion of the Committee, in Common Shares having a fair market
value equal to the amount of such dividends, upon the release of restrictions on such share and, if such share is forfeited, the Participant
shall have no right to such dividends (except as otherwise set forth by the Committee in the applicable Award Agreement).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(ii)
Unless otherwise provided by the Committee in an Award Agreement, upon the expiration of the Restricted Period with respect to any outstanding
Restricted Stock Units, the Company shall deliver to the Participant, or his beneficiary, without charge, one Common Share for each such
outstanding Restricted Stock Unit;&nbsp;provided,&nbsp;however, that the Committee may, in its sole discretion, elect to (i)&nbsp;pay
cash or part cash and part Common Share in lieu of delivering only Common Shares in respect of such Restricted Stock Units or (ii)&nbsp;defer
the delivery of Common Shares (or cash or part Common Shares and part cash, as the case may be) beyond the expiration of the Restricted
Period if such delivery would result in a violation of applicable law until such time as is no longer the case. If a cash payment is made
in lieu of delivering Common Shares, the amount of such payment shall be equal to the fair market value of the Common Shares as of the
date on which the Restricted Period lapsed with respect to such Restricted Stock Units, less an amount equal to any taxes required to
be withheld or paid.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">10.
<I>Stock Bonus Awards</I>. The Committee may issue unrestricted Common Shares, or other Awards denominated in Common Shares, under the
Plan to Eligible Persons, either alone or in tandem with other awards, in such amounts as the Committee shall from time to time in its
sole discretion determine. Each Stock Bonus Award granted under the Plan shall be evidenced by an Award Agreement (whether in paper or
electronic medium (including email or the posting on a web site maintained by the Company or a third party under contract with the Company)).
Each Stock Bonus Award so granted shall be subject to such conditions not inconsistent with the Plan as may be reflected in the applicable
Award Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="letter-spacing: 0.2pt">11. <I>Performance
Compensation Awards</I>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(a)
<I>Generally</I>. The Committee shall have the authority, at the time of grant of any Award described in&nbsp;Sections&nbsp;7&nbsp;through&nbsp;10&nbsp;of
the Plan, to designate such Award as a Performance Compensation Award. The Committee shall have the authority to make an award of a cash
bonus to any Participant and designate such Award as a Performance Compensation Award. Unless otherwise determined by the Committee, all
Performance Compensation Awards shall be evidenced by an Award Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(b)
<I>Discretion of Committee with Respect to Performance Compensation Awards</I>. The Committee shall have the discretion to establish the
terms, conditions and restrictions of any Performance Compensation Award. With regard to a particular Performance Period, the Committee
shall have sole discretion to select the length of such Performance Period, the type(s) of Performance Compensation Awards to be issued,
the Performance Criteria that will be used to establish the Performance Goal (s), the kind(s) and/or level(s) of the Performance Goals(s)
that is (are) to apply and the Performance Formula.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(c)
<I>Performance Criteria</I>. The Committee may establish Performance Criteria that will be used to establish the Performance Goal(s) for
Performance Compensation Awards which may be based on the attainment of specific levels of performance of the Company (and/or one or more
Affiliates, divisions, business segments or operational&nbsp;units, or any combination of the foregoing) and may include, without limitation,
any of the following: (i)&nbsp;net earnings or net income (before or after taxes); (ii)&nbsp;basic or diluted earnings per share (before
or after taxes); (iii)&nbsp;revenue or revenue growth (measured on a net or gross basis); (iv)&nbsp;gross profit or gross profit growth;
(v)&nbsp;operating profit (before or after taxes); (vi)&nbsp;return measures (including, but not limited to, return on assets, capital,
invested capital, equity, or sales); (vii)&nbsp;cash flow (including, but not limited to, operating cash flow, free cash flow, net cash
provided by operations and cash flow return on capital); (viii)&nbsp;financing and other capital raising transactions (including, but
not limited to, sales of the Company&rsquo;s equity or debt securities); (ix)&nbsp;earnings before or after taxes, interest, depreciation
and/or amortization; (x)&nbsp;gross or operating margins; (xi)&nbsp;productivity ratios; (xii)&nbsp;share price (including, but not limited
to, growth measures and total stockholder return); (xiii)&nbsp;expense targets; (xiv)&nbsp;margins; (xv)&nbsp;productivity and operating
efficiencies; (xvi)&nbsp;customer satisfaction; (xvii)&nbsp;customer growth; (xviii) working capital targets; (xix)&nbsp;measures of economic
value added; (xx)&nbsp;inventory control; (xxi)&nbsp;enterprise value; (xxii)&nbsp;sales; (xxiii) debt levels and net debt; (xxiv)&nbsp;combined
ratio; (xxv)&nbsp;timely launch of new facilities; (xxvi)&nbsp;client retention; (xxvii) employee retention; (xxviii) timely completion
of rollouts of new products and services; (xxix)&nbsp;cost targets; (xxx)&nbsp;reductions and savings; (xxxi)&nbsp;productivity and efficiencies;
(xxxii) strategic partnerships or transactions; and (xxxiii) personal targets, goals or completion of projects. Any one or more of the
Performance Criteria may be used on an absolute or relative basis to measure the performance of the Company and/or one or more Affiliates
as a whole or any business unit(s) of the Company and/or one or more Affiliates or any combination thereof, as the Committee may deem
appropriate, or any of the above Performance Criteria may be compared to the performance of a selected group of comparison or peer companies,
or a published or special index that the Committee, in its sole discretion, deems appropriate, or as compared to various stock market
indices. The Committee also has the authority to provide for accelerated vesting of any Award based on the achievement of Performance
Goals pursuant to the Performance Criteria specified in this paragraph. Any Performance Criteria that are financial metrics, may be determined
in accordance with United States Generally Accepted Accounting Principles (&ldquo;GAAP&rdquo;) or may be adjusted when established to
include or exclude any items otherwise includable or excludable under GAAP.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(d)
<I>Modification of Performance Goal(s)</I>. The Committee is authorized at any time to adjust or modify the calculation of a Performance
Goal for such Performance Period, based on and in order to appropriately reflect any specified circumstance or event that occurs during
a Performance Period, including but not limited to the following: (i)&nbsp;asset write-downs; (ii)&nbsp;litigation or claim judgments
or settlements; (iii)&nbsp;the effect of changes in tax laws, accounting principles, or other laws or regulatory rules affecting reported
results; (iv)&nbsp;any reorganization and restructuring programs; (v)&nbsp;unusual and/or infrequently occurring items as described in
Accounting Principles Board Opinion No. 30 (or any successor pronouncement thereto) and/or in management&rsquo;s discussion and analysis
of financial condition and results of operations appearing in the Company&rsquo;s annual report to stockholders for the applicable year;
(vi)&nbsp;acquisitions or divestitures; (vii)&nbsp;discontinued operations; (viii)&nbsp;any other specific unusual or infrequently occurring
or non-recurring events, or objectively determinable category thereof; (ix)&nbsp;foreign exchange gains and losses; and (x)&nbsp;a change
in the Company&rsquo;s fiscal year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(e)
<I>Terms and Conditions to Receipt of Payment</I>. Unless otherwise provided in the applicable Award Agreement, a Participant must be
employed by the Company on the last day of a Performance Period to be eligible for payment in respect of a Performance Compensation Award
for such Performance Period. A Participant shall be eligible to receive payment in respect of a Performance Compensation Award only to
the extent that: (A)&nbsp;the Performance Goals for such period are achieved; and (B)&nbsp;all or some of the portion of such Participant&rsquo;s
Performance Compensation Award has been earned for the Performance Period based on the application of the Performance Formula to such
achieved Performance Goals. Following the completion of a Performance Period, the Committee shall determine whether, and to what extent,
the Performance Goals for the Performance Period have been achieved and, if so, calculate the amount of the Performance Compensation Awards
earned for the period based upon the Performance Formula. The Committee shall then determine the amount of each Participant&rsquo;s Performance
Compensation Award actually payable for the Performance Period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(f)
<I>Timing of Award Payments</I>. Except as provided in an Award Agreement, Performance Compensation Awards granted for a Performance Period
shall be paid to Participants as soon as administratively practicable following the Committee&rsquo;s determination in accordance with&nbsp;Section&nbsp;11(e).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">12.
<I>Other Stock-or Cash-Based Awards</I>. The Committee is authorized to grant Awards to Participants in the form of Other Stock-Based
Awards or Other Cash-Based Awards, as deemed by the Committee to be consistent with the purposes of the Plan. To the extent necessary
to satisfy the short-term deferral exception to Code Section&nbsp;409A, unless the Committee shall determine otherwise, the Awards shall
provide that payment shall be made within 2&nbsp;</FONT><FONT STYLE="letter-spacing: 0.15pt">1</FONT><FONT STYLE="letter-spacing: 0.2pt">&#8725;</FONT><FONT STYLE="letter-spacing: 0.15pt">2</FONT><FONT STYLE="letter-spacing: 0.2pt">&nbsp;months
after the end of the year in which the Participant has a legally binding vested right to such Award. The Committee may establish such
other rules applicable to the Other Stock- or Cash-Based Awards as it deems appropriate, to the extent not inconsistent with the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">13.
<I>Changes in Capital Structure and Similar Events</I>. In the event of (i)&nbsp;any dividend (other than ordinary cash dividends) or
other distribution (whether in the form of cash, Common Shares, other securities or other property), recapitalization, stock split, reverse
stock split, reorganization, merger, amalgamation, consolidation, spin-off, split-up, split-off, combination, repurchase or exchange of
Common Shares or other securities of the Company, issuance of warrants or other rights to acquire Common Shares or other securities of
the Company, or other similar corporate transaction or event (including, without limitation, a Change in Control) that affects the Common
Shares, or (ii)&nbsp;unusual or infrequently occurring events (including, without limitation, a Change in Control) affecting the Company,
any Affiliate, or the financial statements of the Company or any Affiliate, or changes in applicable rules, rulings, regulations or other
requirements of any governmental body or securities exchange or inter-dealer quotation system, accounting principles or law, such that
in either case an adjustment is determined by the Committee in its sole discretion to be necessary or appropriate, then the Committee
shall make any such adjustments in such manner as it may deem equitable, including without limitation any or all of the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(a)
adjusting any or all of (A)&nbsp;the number of Common Shares or other securities of the Company (or number and kind of other securities
or other property) that may be delivered in respect of Awards or with respect to which Awards may be granted under the Plan (including,
without limitation, adjusting any or all of the limitations under&nbsp;Section&nbsp;5&nbsp;of the Plan) and (B)&nbsp;the terms of any
outstanding Award, including, without limitation, (1)&nbsp;the number of Common Shares or other securities of the Company (or number and
kind of other securities or other property) subject to outstanding Awards or to which outstanding Awards relate, (2)&nbsp;the Exercise
Price or Strike Price with respect to any Award or (3)&nbsp;any applicable performance measures (including, without limitation, Performance
Criteria and Performance Goals);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(b)
providing for a substitution or assumption of Awards in a manner that substantially preserves the applicable terms of such Awards;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(c)
accelerating the exercisability or vesting of, lapse of restrictions on, or termination of, Awards or providing for a period of time for
exercise prior to the occurrence of such event;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(d)
modifying the terms of Awards to add events, conditions or circumstances (including termination of employment within a specified period
after a Change in Control) upon which the exercisability or vesting of or lapse of restrictions thereon will accelerate;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="letter-spacing: 0.2pt">(e) deeming any
performance measures (including, without limitation, Performance Criteria and Performance Goals) satisfied at target, maximum or actual
performance through closing or such other level determined by the Committee in its sole discretion, or providing for the performance measures
to continue (as is or as adjusted by the Committee) after closing;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(f)
providing that for a period prior to the Change in Control determined by the Committee in its sole discretion, any Options or SARs that
would not otherwise become exercisable prior to the Change in Control will be exercisable as to all Common Shares subject thereto (but
any such exercise will be contingent upon and subject to the occurrence of the Change in Control and if the Change in Control does not
take place after giving such notice for any reason whatsoever, the exercise will be null and void) and that any Options or SARs not exercised
prior to the consummation of the Change in Control will terminate and be of no further force and effect as of the consummation of the
Change in Control; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(g)
canceling any one or more outstanding Awards and causing to be paid to the holders thereof, in cash, Common Shares, other securities or
other property, or any combination thereof, the value of such Awards, if any, as determined by the Committee (which if applicable may
be based upon the price per Common Share received or to be received by other stockholders of the Company in such event), including without
limitation, in the case of an outstanding Option or SAR, a cash payment in an amount equal to the excess, if any, of the fair market value
(as of a date specified by the Committee) of the Common Shares subject to such Option or SAR over the aggregate Exercise Price or Strike
Price of such Option or SAR, respectively (it being understood that, in such event, any Option or SAR having a per share Exercise Price
or Strike Price equal to, or in excess of, the fair market value of a Common Share subject thereto may be canceled and terminated without
any payment or consideration therefor); provided, however, that in the case of any &ldquo;equity restructuring&rdquo; &nbsp;(within
the meaning of the Financial Accounting Standards Board Accounting Standards Codification Topic 718), the Committee shall make an equitable
or proportionate adjustment to outstanding Awards to reflect such equity restructuring. The Company shall give each Participant notice
of an adjustment hereunder and, upon notice, such adjustment shall be conclusive and binding for all purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="letter-spacing: 0.2pt">14. <I>Amendments
and Termination</I>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(a)
<I>Amendment and Termination of the Plan</I>. The Board may amend, alter, suspend, discontinue, or terminate the Plan or any portion thereof
at any time;&nbsp;provided&nbsp;that (i)&nbsp;no amendment to&nbsp;Section&nbsp;14(b)&nbsp;(to the extent required by the proviso in such&nbsp;Section&nbsp;14(b))
shall be made without stockholder approval and (ii)&nbsp;no such amendment, alteration, suspension, discontinuation or termination shall
be made without stockholder approval if such approval is necessary to comply with any tax or regulatory requirement applicable to the
Plan (including, without limitation, as necessary to comply with any rules or requirements of any securities exchange or inter-dealer
quotation system on which the Common Shares may be listed or quoted);&nbsp;provided,&nbsp;further, that any such amendment, alteration,
suspension, discontinuance or termination that would materially and adversely affect the rights of any Participant or any holder or beneficiary
of any Award theretofore granted shall not to that extent be effective without the consent of the affected Participant, holder or beneficiary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(b)
<I>Amendment of Award Agreements</I>. The Committee may, to the extent consistent with the terms of any applicable Award Agreement, waive
any conditions or rights under, amend any terms of, or alter, suspend, discontinue, cancel or terminate, any Award theretofore granted
or the associated Award Agreement, prospectively or retroactively;&nbsp;provided&nbsp;that any such waiver, amendment, alteration, suspension,
discontinuance, cancellation or termination that would materially and adversely affect the rights of any Participant with respect to any
Award theretofore granted shall not to that extent be effective without the consent of the affected Participant;&nbsp;provided,&nbsp;further,
that without stockholder approval, except as otherwise permitted under&nbsp;Section&nbsp;13&nbsp;of the Plan, (i)&nbsp;no amendment or
modification may reduce the Exercise Price of any Option or the Strike Price of any SAR, (ii)&nbsp;the Committee may not cancel any outstanding
Option or SAR where the Fair Market Value of the Common Shares underlying such Option or SAR is less than its Exercise Price and replace
it with a new Option or SAR, another Award or cash and (iii)&nbsp;the Committee may not take any other action that is considered a &ldquo;repricing&rdquo;
for purposes of the stockholder approval rules of the applicable securities exchange or inter-dealer quotation system on which the Common
Shares are listed or quoted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="letter-spacing: 0.2pt">15. <I>General</I>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(a)
<I>Award Agreements</I>. Each Award under the Plan shall be evidenced by an Award Agreement, which shall be delivered to the Participant
(whether in paper or electronic medium (including email or the posting on a web site maintained by the Company or a third party under
contract with the Company)) and shall specify the terms and conditions of the Award and any rules applicable thereto, including without
limitation, the effect on such Award of the death, disability or termination of employment or service of a Participant, or of such other
events as may be determined by the Committee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="letter-spacing: 0.2pt">(b) <I>Nontransferability</I>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(i)
Each Award shall be exercisable only by a Participant during the Participant&rsquo;s lifetime, or, if permissible under applicable law,
by the Participant&rsquo;s legal guardian or representative. No Award may be assigned, alienated, pledged, attached, sold or otherwise
transferred or encumbered by a Participant other than by will or by the laws of descent and distribution and any such purported assignment,
alienation, pledge, attachment, sale, transfer or encumbrance shall be void and unenforceable against the Company or an Affiliate;&nbsp;provided&nbsp;that
the designation of a beneficiary shall not constitute an assignment, alienation, pledge, attachment, sale, transfer or encumbrance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(ii)
Notwithstanding the foregoing, the Committee may, in its sole discretion, permit&nbsp;Awards (other than Incentive Stock Options) to be
transferred by a Participant, without consideration, subject to such rules as the Committee may adopt consistent with any applicable Award
Agreement to preserve the purposes of the Plan, to: (A)&nbsp;any person who is a &ldquo;family member&rdquo; of the Participant, as such
term is used in the instructions to Form S-8 under the Securities Act (collectively, the &ldquo;Immediate Family Members&rdquo;); (B)&nbsp;a
trust solely for the benefit of the Participant and his or her Immediate Family Members; (C)&nbsp;a partnership or limited liability company
whose only partners or stockholders are the Participant and his or her Immediate Family Members; or (D)&nbsp;any other transferee as may
be approved either (I)&nbsp;by the Board or the Committee in its sole discretion, or (II)&nbsp;as provided in the applicable Award Agreement
(each transferee described in clauses (A), (B), (C)&nbsp;and (D)&nbsp;above is hereinafter referred to as a &ldquo;Permitted Transferee&rdquo;);&nbsp;provided&nbsp;that
the Participant gives the Committee advance written notice describing the terms and conditions of the proposed transfer and the Committee
notifies the Participant in writing that such a transfer would comply with the requirements of the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(iii)
The terms of any Award transferred in accordance with the immediately preceding sentence shall apply to the Permitted Transferee and any
reference in the Plan, or in any applicable Award Agreement, to a Participant shall be deemed to refer to the Permitted Transferee, except
that (A)&nbsp;Permitted Transferees shall not be entitled to transfer any Award, other than by will or the laws of descent and distribution;
(B)&nbsp;Permitted Transferees shall not be entitled to exercise any transferred Option unless there shall be in effect a registration
statement on an appropriate form covering the Common Shares to be acquired pursuant to the exercise of such Option if the Committee determines,
consistent with any applicable Award Agreement, that such a registration statement is necessary or appropriate; (C)&nbsp;the Committee
or the Company shall not be required to provide any notice to a Permitted Transferee, whether or not such notice is or would otherwise
have been required to be given to the Participant under the Plan or otherwise; and (D)&nbsp;the consequences of the termination of the
Participant&rsquo;s employment by, or services to, the Company or an Affiliate under the terms of the Plan and the applicable Award Agreement
shall continue to be applied with respect to the Participant, including, without limitation, that an Option shall be exercisable by the
Permitted Transferee only to the extent, and for the periods, specified in the Plan and the applicable Award Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="letter-spacing: 0.2pt">(c) <I>Tax Withholding
and Deductions</I>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(i)
A Participant shall be required to pay to the Company or any Affiliate, and the Company or any Affiliate shall have the right and is hereby
authorized to deduct and withhold, from any cash, Common Shares, other securities or other property deliverable under any Award or from
any compensation or other amounts owing to a Participant, the amount (in cash, Common Shares,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="letter-spacing: 0.2pt">other securities
or other property) of any required taxes (up to the maximum statutory rate under applicable law as in effect from time to time as determined
by the Committee) and deduction in respect of an Award, its grant, vesting or exercise, or any payment or transfer under an Award or under
the Plan and to take such other action as may be necessary in the opinion of the Committee or the Company to satisfy all obligations for
the payment of such taxes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(ii)
Without limiting the generality of clause (i)&nbsp;above, the Committee may, in its sole discretion, determined on a case by case basis,
permit a Participant to satisfy, in whole or in part, the foregoing tax and deduction liability by (A)&nbsp;the delivery of Common Shares
(which are not subject to any pledge or other security interest and are Mature Shares, except as otherwise determined by the Committee)
owned by the Participant having a fair market value equal to such liability or (B)&nbsp;having the Company withhold from the number of
Common Shares otherwise issuable or deliverable pursuant to the exercise or settlement of the Award a number of shares with a fair market
value equal to such liability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(d)
<I>No Claim to Awards; No Rights to Continued Employment; Waiver</I>. No employee of the Company or an Affiliate, or other person, shall
have any claim or right to be granted an Award under the Plan or, having been selected for the grant of an Award, to be selected for a
grant of any other Award. There is no obligation for uniformity of treatment of Participants or holders or beneficiaries of Awards. The
terms and conditions of Awards and the Committee&rsquo;s determinations and interpretations with respect thereto need not be the same
with respect to each Participant and may be made selectively among Participants, whether or not such Participants are similarly situated.
Neither the Plan nor any action taken hereunder shall be construed as giving any Participant any right to be retained in the employ or
service of the Company or an Affiliate, nor shall it be construed as giving any Participant any rights to continued service on the Board.
The Company or any of its Affiliates may at any time dismiss a Participant from employment or discontinue any consulting relationship,
free from any liability or any claim under the Plan, unless otherwise expressly provided in the Plan or any Award Agreement. By accepting
an Award under the Plan, a Participant shall thereby be deemed to have waived any claim to continued exercise or vesting of an Award or
to damages or severance entitlement related to non-continuation of the Award beyond the period provided under the Plan or any Award Agreement,
notwithstanding any provision to the contrary in any written employment contract or other agreement between the Company and its Affiliates
and the Participant, whether any such agreement is executed before, on or after the Date of Grant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(e)
<I>Addenda/International Participants</I>. The Committee may adopt such addenda to the Plan as it may consider necessary or appropriate
for the purpose of granting Awards, which Awards may contain such terms and conditions as the Committee deems necessary or appropriate
to accommodate differences in local law, tax policy or custom, which may deviate from the terms and conditions set forth in this Plan&nbsp;The
terms of any such addenda shall supersede the terms of the Plan to the extent necessary to accommodate such differences but shall not
otherwise affect the terms of the Plan as in effect for any other purpose. With respect to Participants who reside or work outside of
the United States of America, the Committee may in its sole discretion amend the terms of the Plan or outstanding Awards with respect
to such Participants in order to conform such terms with the requirements of local law or to obtain more favorable tax or other treatment
for a Participant, the Company or its Affiliates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(f)
<I>Designation and Change of Beneficiary</I>. Each Participant may file with the Committee a written designation of one or more persons
as the beneficiary(ies) who shall be entitled to receive the amounts payable with respect to an Award, if any, due under the Plan upon
his death. A Participant may, from time to time, revoke or change his beneficiary designation without the consent of any prior beneficiary
by filing a new designation with the Committee. The last such designation received by the Committee shall be controlling;&nbsp;provided,&nbsp;however,
that no designation, or change or revocation thereof, shall be effective unless received by the Committee prior to the Participant&rsquo;s
death, and in no event shall it be effective as of a date prior to such receipt. If no beneficiary designation is filed by a Participant,
the beneficiary shall be deemed to be his or her spouse or, if the Participant is unmarried at the time of death, his or her estate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(g)
<I>Termination of Employment/Service</I>. Unless determined otherwise by the Committee at any point following such event: (i)&nbsp;neither
a temporary absence from employment or service due to illness, vacation or leave of absence nor a transfer from employment or service
with the Company to employment or service with an Affiliate (or vice-versa) shall be considered a termination of employment or service
with the Company or an Affiliate; and (ii)&nbsp;if a Participant&rsquo;s employment with the Company and its Affiliates terminates, but
such Participant continues to provide services to the Company and its Affiliates in a non-employee capacity (or vice-versa), such change
in status shall not be considered a termination of employment with the Company or an Affiliate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(h)
<I>Leaves of Absence/Transfer Between Locations</I>. The Committee shall have the discretion to determine at any time whether and to what
extent the vesting of Awards shall be suspended during any leave of absence; provided, however, that in the absence of such determination,
vesting of Awards shall continue during any paid leave and during any unpaid leave (unless otherwise required by applicable Laws). A Participant
will not cease to be an Employee in the case of (a)&nbsp;any leave of absence approved by the Participant&rsquo;s employer or (b)&nbsp;transfers
between locations of the Company or between the Company or any Subsidiary. If an Employee is holding an Incentive Stock Option and such
leave exceeds three (3)&nbsp;months then, for purposes of Incentive Stock Option status only, such Employee&rsquo;s service as an Employee
shall be deemed terminated on the first (1</FONT><FONT STYLE="letter-spacing: 0.15pt">st</FONT><FONT STYLE="letter-spacing: 0.2pt">) day
following such three (3)&nbsp;month period and the Incentive Stock Option shall thereafter automatically treated for tax purposes as a
Nonstatutory Stock Option in accordance with applicable laws, unless reemployment upon the expiration of such leave is guaranteed by contract
or statute, or unless provided otherwise pursuant to a written Company policy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(i)
<I>No Rights as a Stockholder</I>. Except as otherwise specifically provided in the Plan or any Award Agreement, no person shall be entitled
to the privileges of ownership in respect of Common Shares or other securities that are subject to Awards hereunder until such shares
have been issued or delivered to that person<I>.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="letter-spacing: 0.2pt">(j) <I>Government
and Other Regulations</I>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(i)
The obligation of the Company to settle Awards in Common Shares or other consideration shall be subject to all applicable laws, rules,
and regulations, and to such approvals by governmental agencies as may be required. Notwithstanding any terms or conditions of any Award
to the contrary, the Company shall be under no obligation to offer to sell or to sell, and shall be prohibited from offering to sell or
selling, any Common Shares or other securities pursuant to an Award unless such shares have been properly registered for sale pursuant
to the Securities Act with the Securities and Exchange Commission or unless the Company has received an opinion of counsel, satisfactory
to the Company, that such shares may be offered or sold without such registration pursuant to an available exemption therefrom and the
terms and conditions of such exemption have been fully complied with. The Company shall be under no obligation to register for sale under
the Securities Act any of the Common Shares or other securities to be offered or sold under the Plan. The Committee shall have the authority
to provide that all certificates for Common Shares or other securities of the Company or any Affiliate delivered under the Plan shall
be subject to such stop transfer orders and other restrictions as the Committee may deem advisable under the Plan, the applicable Award
Agreement, the federal securities laws, or the rules, regulations and other requirements of the Securities and Exchange Commission, any
securities exchange or inter-dealer quotation system upon which such shares or other securities are then listed or quoted and any other
applicable federal, state, local or non-U.S. laws, and, without limiting the generality of&nbsp;Section&nbsp;9&nbsp;of the Plan, the Committee
may cause a legend or legends to be put on any such certificates to make appropriate reference to such restrictions. Notwithstanding any
provision in the Plan to the contrary, the Committee reserves the right to add any additional terms or provisions to any Award granted
under the Plan that it in its sole discretion deems necessary or advisable in order that such Award complies with the legal requirements
of any governmental entity to whose jurisdiction the Award is subject.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(ii)
The Committee may cancel an Award or any portion thereof if it determines, in its sole discretion, that legal or contractual restrictions
and/or blockage and/or other market considerations would make the Company&rsquo;s acquisition of Common Shares from the public markets,
the Company&rsquo;s issuance of Common Shares or other securities to the Participant, the Participant&rsquo;s acquisition of Common Shares
or other securities from the Company and/or the Participant&rsquo;s sale of Common Shares to the public markets, illegal, impracticable
or inadvisable. If the Committee determines to cancel all or any portion of an Award denominated in Common Shares in accordance with the
foregoing, the Company shall pay to the Participant an amount equal to the excess of (A)&nbsp;the aggregate fair market value of the Common
Shares subject to such Award or portion thereof canceled (determined as of the applicable exercise date, or the date that the shares would
have been vested or delivered, as applicable), over (B)&nbsp;the aggregate Exercise Price or Strike Price (in the case of an Option or
SAR, respectively) or any amount payable as a condition of delivery of Common Shares (in the case of any other Award). Such amount shall
be delivered to the Participant as soon as practicable following the cancellation of such Award or portion thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(k)
<I>Payments to Persons Other Than Participants</I>. If the Committee shall find that any person to whom any amount is payable under the
Plan is unable to care for his affairs because of illness or accident, or is a minor, or has died, then any payment due to such person
or his estate (unless a prior claim therefor has been made by a duly appointed legal representative) may, if the Committee so directs
the Company, be paid to his spouse, child, relative, an institution maintaining or having custody of such person, or any other person
deemed by the Committee to be a proper recipient on behalf of such person otherwise entitled to payment. Any such payment shall be a complete
discharge of the liability of the Committee and the Company therefor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(l)
<I>Nonexclusivity of the Plan</I>. Neither the adoption of this Plan by the Board nor the submission of this Plan to the stockholders
of the Company for approval shall be construed as creating any limitations on the power of the Board to adopt such other incentive arrangements
as it may deem desirable, including, without limitation, the granting of stock options or other equity-based awards otherwise than under
this Plan, and such arrangements may be either applicable generally or only in specific cases.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(m)
<I>No Trust or Fund&nbsp;Created</I>. Neither the Plan nor any Award shall create or be construed to create a trust or separate fund of
any kind or a fiduciary relationship between the Company or any Affiliate, on the one hand, and a Participant or other person or entity,
on the other hand. No provision of the Plan or any Award shall require the Company, for the purpose of satisfying any obligations under
the Plan, to purchase assets or place any assets in a trust or other entity to which contributions are made or otherwise to segregate
any assets, nor shall the Company maintain separate bank accounts, books, records or other evidence of the existence of a segregated or
separately maintained or administered fund for such purposes. Participants shall have no rights under the Plan other than as unsecured
general creditors of the Company, except that insofar as they may have become entitled to payment of additional compensation by performance
of services, they shall have the same rights as other employees under general law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(n)
<I>Reliance on Reports</I>. Each member of the Committee and each member of the Board shall be fully justified in acting or failing to
act, as the case may be, and shall not be liable for having so acted or failed to act in good faith, in reliance upon any report made
by the independent public accountant of the Company and its Affiliates and/or any other information furnished in connection with the Plan
by any agent of the Company or the Committee or the Board, other than himself.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(o)
<I>Relationship to Other Benefits</I>. No payment under the Plan shall be taken into account in determining any benefits under any pension,
retirement, profit sharing, group insurance or other benefit plan of the Company except as otherwise specifically provided in such other
plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(p)
<I>Governing Law</I>. The Plan shall be governed by and construed in accordance with the internal laws of the State of Delaware applicable
to contracts made and performed wholly within the State of Delaware, without giving effect to the conflict of laws provisions thereof.
Each party hereby irrevocably and unconditionally submits, for itself and its property, to the exclusive jurisdiction of the state and
federal courts seated in Wilmington, Delaware (and any appellate courts thereof) in any action or proceeding arising out of or relating
to this Plan, and each of the parties hereby irrevocably and unconditionally (a)&nbsp;agrees not to commence any such action or proceeding
except in such courts, (b)&nbsp;agrees that any claim in respect of any such action or proceeding may be heard and determined in such
court, (c)&nbsp;waives, to the fullest extent it may legally and effectively do so, any objection which it may now or hereafter have to
the laying of venue of any such action or proceeding in any such court, and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="letter-spacing: 0.2pt">(d)&nbsp;waives,
to the fullest extent permitted by law, the defense of an inconvenient forum to the maintenance of such action or proceeding in any such
court. Each party agrees that a final judgment in any such action or proceeding shall be conclusive and may be enforced in other jurisdictions
by suit on the judgment or in any other manner provided by law. Each party hereby knowingly, voluntarily and intentionally irrevocably
waives the right to a trial by jury in respect to any litigation, dispute, claim, legal action or other legal proceeding based hereon,
or arising out of, under, or in connection with, this Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(q)
<I>Severability</I>. If any provision of the Plan or any Award or Award Agreement is or becomes or is deemed to be invalid, illegal, or
unenforceable in any jurisdiction or as to any person or entity or Award, or would disqualify the Plan or any Award under any law deemed
applicable by the Committee, such provision shall be construed or deemed amended to conform to the applicable laws, or if it cannot be
construed or deemed amended without, in the determination of the Committee, materially altering the intent of the Plan or the Award, such
provision shall be construed or deemed stricken as to such jurisdiction, person or entity or Award and the remainder of the Plan and any
such Award shall remain in full force and effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(r)
<I>Obligations Binding on Successors</I>. The obligations of the Company under the Plan shall be binding upon any successor corporation
or organization resulting from the merger, amalgamation, consolidation or other reorganization of the Company, or upon any successor corporation
or organization succeeding to substantially all of the assets and business of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(s)
<I>Status under ERISA</I>. It is the intent of the Company that the Plan shall not constitute an &ldquo;employee benefit plan&rdquo; for
purposes of Section&nbsp;3(3) of the Employee Retirement Income Security Act of 1974, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="letter-spacing: 0.2pt">(t) <I>Code Section&nbsp;409A</I>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(i)
Notwithstanding any provision of this Plan to the contrary, all Awards made under this Plan are intended to be exempt from or, in the
alternative, comply with Code Section&nbsp;409A and the interpretive guidance thereunder, including the exceptions for stock rights and
short-term deferrals. The Plan shall be construed and interpreted in accordance with such intent. Each payment under an Award shall be
treated as a separate payment for purposes of Code Section&nbsp;409A.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(ii)
If a Participant is a &ldquo;specified employee&rdquo; &nbsp;(as such term is defined for purposes of Code Section&nbsp;409A)
at the time of his or her termination of service, no amount that is nonqualified deferred compensation subject to Code Section&nbsp;409A
and that becomes payable by reason of such termination of service shall be paid to the Participant (or in the event of the Participant&rsquo;s
death, the Participant&rsquo;s representative or estate) before the earlier of (x)&nbsp;the first business day after the date that is
six&nbsp;months following the date of the Participant&rsquo;s termination of service, and (y)&nbsp;within 30&nbsp;days following the date
of the Participant&rsquo;s death. For purposes of Code Section&nbsp;409A, a termination of service shall be deemed to occur only if it
is a &ldquo;separation from service&rdquo; within the meaning of Code Section&nbsp;409A, and references in the Plan and any Award Agreement
to &ldquo;termination of service&rdquo; or similar terms shall mean a &ldquo;separation from service.&rdquo; If any Award is or becomes
subject to Code Section&nbsp;409A, unless the applicable Award Agreement provides otherwise, such Award shall be payable upon the Participant&rsquo;s
&ldquo;separation from service&rdquo; within the meaning of Code Section&nbsp;409A. If any Award is or becomes subject to Code Section&nbsp;409A
and if payment of such Award would be accelerated or otherwise triggered under a Change in Control, then the definition of Change in Control
shall be deemed modified, only to the extent necessary to avoid the imposition of an excise tax under Code Section&nbsp;409A, to mean
a &ldquo;change in control event&rdquo; as such term is defined for purposes of Code Section&nbsp;409A.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(iii)
Any adjustments made pursuant to&nbsp;Section&nbsp;13&nbsp;to Awards that are subject to Code Section&nbsp;409A shall be made in compliance
with the requirements of Code Section&nbsp;409A, and any adjustments made pursuant to&nbsp;Section&nbsp;13&nbsp;to Awards that are not
subject to Code Section&nbsp;409A shall be made in such a manner as to ensure that after such adjustment, the Awards either (x)&nbsp;continue
not to be subject to Code Section&nbsp;409A or (y)&nbsp;comply with the requirements of Code Section&nbsp;409A.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(u)
<I>Expenses; Gender; Titles and Headings</I>. The expenses of administering the Plan shall be borne by the Company and its Affiliates.
Masculine pronouns and other words of masculine gender shall refer to both men and women. The titles and headings of the sections in the
Plan are for convenience of reference only, and in the event of any conflict, the text of the Plan, rather than such titles or headings
shall control.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(v)
<I>Other Agreements</I>. Notwithstanding the above, the Committee may require, as a condition to the grant of and/or the receipt of Common
Shares or other securities under an Award, that the Participant execute lock-up, stockholder or other agreements, as it may determine
in its sole and absolute discretion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(w)
<I>Payments</I>. Participants shall be required to pay, to the extent required by applicable law, any amounts required to receive Common
Shares or other securities under any Award made under the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(x)
<I>Erroneously Awarded Compensation</I>. All Awards shall be subject (including on a retroactive basis) to (i)&nbsp;any clawback, forfeiture
or similar incentive compensation recoupment policy established from time to time by the Company, including, without limitation, any such
policy established to comply with the Dodd-Frank Wall Street Reform and Consumer Protection Act, (ii)&nbsp;applicable law (including,
without limitation, Section&nbsp;304 of the Sarbanes-Oxley Act and Section&nbsp;954 of the Dodd-Frank Wall Street Reform and Consumer
Protection Act), and/or (iii)&nbsp;the rules and regulations of the applicable securities exchange or inter-dealer quotation system on
which the Common Shares or other securities are listed or quoted, and such requirements shall be deemed incorporated by reference into
all outstanding Award Agreements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(y)
<I>Investment Representations</I>. As a condition to the exercise of an Award, the Company may require the person exercising such Award
to represent and warrant at the time of any such exercise that the Shares are being purchased only for investment and without any present
intention to sell or distribute such Shares if, in the opinion of counsel for the Company, such a representation is required.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="letter-spacing: 0.2pt">(z)
<I>Corporate Records Control</I>. In the event that the corporate records (e.g., Board consents, resolutions or minutes) documenting the
corporate action constituting the grant contain terms (e.g., exercise price, vesting schedule or number of shares) that are inconsistent
with those in the Award Agreement or related grant documents as a result of a clerical error in the papering of the Award Agreement or
related grant documents, the corporate records will control and the Participant will have no legally binding right to the incorrect term
in the Award Agreement or related grant documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 20; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>9
<FILENAME>ex10-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FORM
OF REGISTRATION RIGHTS AGREEMENT</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>THIS
REGISTRATION RIGHTS AGREEMENT</B> (this &ldquo;<B><I>Agreement</I></B>&rdquo;) is made and entered into as of November 7, 2023 (the &ldquo;<B><I>Effective
Date</I></B>&rdquo;) by and among (i) Data Knights Acquisition Corp., a Delaware corporation (including its successors, the &ldquo;<B><I>Purchaser</I></B>&rdquo;),
and (ii) and the undersigned parties listed on <U>Exhibit A</U> hereto (each such party, together with any person or entity who hereafter
becomes a party to this Agreement pursuant to <U>Section 6.2 </U>of this Agreement, a &ldquo;<B><I>Holder</I></B>&rdquo; and collectively
the &ldquo;<B><I>Holders</I></B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>,
on April 25, 2022, Purchaser, Data Knights Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of the Purchaser (&ldquo;<B><I>Merger
Sub</I></B>&rdquo;), Data Knights, LLC, a Delaware limited liability company (the &ldquo;<B><I>Purchaser Representative</I></B>&rdquo;),
Paul Casey (the &ldquo;<B><I>Seller Representative</I></B>&rdquo;), and (v) OneMedNet Corporation, a Delaware corporation (the &ldquo;<B><I>Company</I></B>&rdquo;),
entered into that certain Agreement and Plan of Merger (as amended from time to time in accordance with the terms thereof, the &ldquo;<B><I>Merger
Agreement</I></B>&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>,
pursuant to the Merger Agreement, subject to the terms and conditions thereof, upon the consummation of the transactions contemplated
thereby (the &ldquo;<B><I>Closing</I></B>&rdquo;), among other matters, Merger Sub will merge with and into the Company, with the Company
continuing as the surviving entity and a wholly-owned subsidiary of the Purchaser, and with the Holders, as stockholders of the Purchaser,
receiving shares of the Purchaser&rsquo;s Class A common stock (the &ldquo;<B><I>Merger Shares</I></B>&rdquo;), all upon the terms and
subject to the conditions set forth in the Merger Agreement and in accordance with the provisions of applicable law;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>,
the Company is a party to that certain Investors&rsquo; Rights Agreement dated as of December 31, 2009, entered into with certain investors
listed therein (the &ldquo;<B><I>Company Investors</I></B>&rdquo;) holding shares of Company capital stock to be exchanged into shares
of Purchaser&rsquo;s Class A common stock in the Merger (the &ldquo;<B><I>Prior Agreement</I></B>&rdquo;), and that certain Founders
Registration Rights Agreement with the Founders with regard to the Founder Securities (each as such term is defined below) (together
with the Prior Agreement, the &ldquo;<B><I>Existing Agreements</I></B>&rdquo;); and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>,
the parties desire to enter into this Agreement, and terminate the Existing Agreements, to provide the Holders and Founders with certain
rights relating to the registration of the Merger Shares and Founder Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOW,
THEREFORE</B>, in consideration of the mutual covenants and agreements set forth herein, and for other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">1. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>DEFINITIONS</U>.
The following capitalized terms used herein have the following meanings:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><U>Affiliate</U></B>&rdquo;
means, with respect to any specified Person, any Person that, directly or indirectly through one or more entities, controls or is controlled
by, or is under common control with, such specified Person. The term &ldquo;control&rdquo; (including the terms &ldquo;controlled by&rdquo;
and &ldquo;under common control with&rdquo;) means the possession, directly or indirectly, of the power to direct or cause the direction
of the management and policies of a Person, whether through the ownership of voting securities, by Contract or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><U>Agreement</U></B>&rdquo;
means this Agreement, as amended, restated, supplemented, or otherwise modified from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><U>Business
Combination</U></B>&rdquo; means the acquisition of direct or indirect ownership through a merger, share exchange, asset acquisition,
share purchase, recapitalization, reorganization or other similar type of transaction, of one or more businesses or entities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><U>Commission</U></B>&rdquo;
means the Securities and Exchange Commission, or any other Federal agency then administering the Securities Act or the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><U>Common
Stock</U></B>&rdquo; means the Class A common stock, par value $0.000001 per share, of the Purchaser and the Class B common stock, par
value $0.000001 per share of the Purchaser, along with any equity securities paid as dividends or distributions after the Closing with
respect to such shares or into which such shares are exchanged or converted after the Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><U>Company</U></B>&rdquo;
is defined in the preamble to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><U>Demand
Registration</U></B>&rdquo; is defined in Section 2.2.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><U>Demanding
Holder</U></B>&rdquo; is defined in Section 2.2.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><U>Effectiveness
Date</U>&rdquo;</B> means, with respect to the Initial Registration Statement, the 90th calendar day following the Filing Date (or in
the event the Registration Statement receives a &ldquo;full review&rdquo; by the Commission, the 120th day following the Filing Date)
and with respect to any additional Registration Statements which may be required pursuant to Sections 2.2 and 2.3, the 90th calendar
day following the date on which an additional Registration Statement is required to be filed hereunder; provided, however, that in the
event the Purchaser is notified by the Commission that one or more of the above Registration Statements will not be reviewed or is no
longer subject to further review and comments, the Effectiveness Date as to such Registration Statement shall be the fifth Business Day
following the date on which the Purchaser is so notified if such date precedes the dates otherwise required above; provided, further,
that, if the Effectiveness Date falls on a Saturday, Sunday or any other day which shall be a legal holiday or a day on which the Commission
is authorized or required by law or other government actions to close, the Effectiveness Date shall be the following Business Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><U>Effectiveness
Period</U></B>&rdquo; shall have the meaning set forth in Section 2.1.1</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><U>Exchange
Act</U></B>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules and regulations of the Commission promulgated
thereunder, all as the same shall be in effect at the time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><U>Filing
Date</U></B>&rdquo; means, with respect to the Initial Registration Statement required hereunder, the 30th calendar day following the
date hereof and, with respect to any additional Registration Statements which may be required pursuant to Sections 2.2 and 2.3, the earliest
practical date on which the Purchaser is permitted by Commission Guidance to file such additional Registration Statement related to the
Registrable Securities; provided, however, that, if the Filing Date falls on a Saturday, Sunday or any other day which shall be a legal
holiday or a day on which the Commission is authorized or required by law or other government actions to close, the Filing Date shall
be the following Business Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><U>Form
S-3</U></B>&rdquo; is defined in Section 2.4.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><U>Founder
Registration Rights Agreement</U></B>&rdquo; means that certain Registration Rights Agreement, dated as of May 6, 2021, by and among
Purchaser, Data Knights, LLC and certain directors of Purchaser.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><U>Founder
Securities</U></B>&rdquo; means all shares of Common Stock, and all securities convertible into or exercisable for shares of Common Stock,
held by the Founders as of the Effective Date of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><U>Founders</U></B>&rdquo;
means Data Knights, LLC, Barry Anderson, Firdauz Edmin Bin Mokhtar, Syed Musheer Ahmed, Julianne Huh and Annie Damit Undikai, and any
successors in interest thereto with respect to any Founder Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><U>Holder</U></B>&rdquo;
is defined in the preamble to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><U>Indemnified
Party</U></B>&rdquo; is defined in Section 4.3.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><U>Indemnifying
Party</U></B>&rdquo; is defined in Section 4.3.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><U>Initial
Registration Statement</U></B>&rdquo; means the Registration Statement required to be filed pursuant to Section 2.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><U>Holder
Indemnified Party</U></B>&rdquo; is defined in Section 4.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><U>Maximum
Number of Shares</U></B>&rdquo; is defined in Section 2.2.4.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><U>Merger
Shares</U></B>&rdquo; means the shares of Common Stock of the Purchaser issued or issuable to the Holders pursuant to the terms of the
Merger Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><U>Notices</U></B>&rdquo;
is defined in Section 6.3.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><U>Piggy-Back
Registration</U></B>&rdquo; is defined in Section 2.3.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><U>Pro
Rata</U></B>&rdquo; is defined in Section 2.2.4.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><U>Purchaser</U></B>&rdquo;
is defined in the preamble to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><U>Register</U></B>,&rdquo;
&ldquo;<B><U>Registered</U></B>&rdquo; and &ldquo;<B><U>Registration</U></B>&rdquo; mean a registration effected by preparing and filing
a registration statement or similar document in compliance with the requirements of the Securities Act, and the applicable rules and
regulations promulgated thereunder, and such registration statement becoming effective.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><U>Registrable
Securities</U></B>&rdquo; means (i) the Shares and any shares of Common Stock held by the Holders and Founders immediately following
the closing of the Business Combination, and (ii) any warrants, shares of capital stock or other securities of the Purchaser acquired
by a Holder or Founder after the Closing, or issued as a dividend or other distribution with respect to or in exchange for or in replacement
of such Shares. As to any particular Registrable Securities, such securities shall cease to be Registrable Securities when: (a) a Registration
Statement with respect to the sale of such securities shall have become effective under the Securities Act and such securities shall
have been sold, transferred, disposed of or exchanged in accordance with such Registration Statement; (b) such securities shall have
been otherwise transferred, new certificates for them not bearing a legend restricting further transfer shall have been delivered by
the Purchaser and subsequent public distribution of them shall not require registration under the Securities Act; (c) such securities
shall have ceased to be outstanding; or (d) the Registrable Securities are freely saleable under Rule 144 without volume limitations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><U>Registration
Statement</U></B>&rdquo; means a registration statement filed by the Purchaser with the Commission in compliance with the Securities
Act and the rules and regulations promulgated thereunder for a public offering and sale of equity securities, or securities or other
obligations exercisable or exchangeable for, or convertible into, equity securities (other than a registration statement on Form S-4
or Form S-8, or their successors, or any registration statement covering only securities proposed to be issued in exchange for securities
or assets of another entity).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><U>Securities
Act</U></B>&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations of the Commission promulgated thereunder,
all as the same shall be in effect at the time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><U>Shares</U></B>&rdquo;
means the Merger Shares and the Founder Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><U>Underwriter</U></B>&rdquo;
means, solely for the purposes of this Agreement, a securities dealer who purchases any Registrable Securities as principal in an underwritten
offering and not as part of such dealer&rsquo;s market-making activities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">2. &#8239;&#8239;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>REGISTRATION
RIGHTS</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Shelf
Registration.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1.1
On or prior to each Filing Date, the Purchaser shall prepare and file with the Commission a Registration Statement covering the resale
of all or such maximum portion of the Registrable Securities as permitted by SEC Guidance (provided that, the Purchaser shall use diligent
efforts to advocate with the Commission for the registration of all of the Registrable Securities in accordance with the SEC Guidance,
including without limitation, the Manual of Publicly Available Telephone Interpretations D.29) that are not then registered on an effective
Registration Statement for an offering to be made on a continuous basis pursuant to Rule 415. Each Registration Statement filed hereunder
shall be on Form S-1 (except if the Purchaser is then eligible to register for resale the Registrable Securities on Form S-3, such registration
shall be on Form S-3 in accordance herewith). Subject to the terms of this Agreement, the Purchaser shall use its commercially reasonable
efforts to cause a Registration Statement to be declared effective under the Securities Act as promptly as practicable after the filing
thereof, but in any event prior to the applicable Effectiveness Date, and shall use its commercially reasonable efforts to keep such
Registration Statement continuously effective under the Securities Act until all Registrable Securities covered by such Registration
Statement have been sold, or may be sold without volume or manner-of-sale restrictions pursuant to Rule 144, without the requirement
for the Purchaser to be in compliance with the current public information requirement under Rule 144, as determined by the counsel to
the Purchaser pursuant to a written opinion letter to such effect, addressed and acceptable to the Transfer Agent and the affected Holders
(the &ldquo;<B><I>Effectiveness Period</I></B>&rdquo;). The Purchaser shall telephonically request effectiveness of a Registration Statement
as of 5:00 p.m. New York City time on a Business Day. The Purchaser shall promptly notify the Holders by e-mail of the effectiveness
of a Registration Statement on the same Business Day that the Purchaser telephonically confirms effectiveness with the Commission. The
Purchaser shall, no later than the second Business Day after the effective date of such Registration Statement, file a final Prospectus
with the Commission as required by Rule 424.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1.2 Notwithstanding
any other provision of this Agreement, if any SEC Guidance sets forth a limitation on the number of Registrable Securities permitted
to be registered on a particular Registration Statement (and notwithstanding that the Purchaser used diligent efforts to advocate with
the Commission for the registration of all or a greater portion of Registrable Securities), the number of Registrable Securities to be
registered shall be reduced on a on a pro rata basis based on the total number of Registrable Securities held by such Holders (such proportion
is referred to herein as &ldquo;<B><I>Pro Rata</I></B>&rdquo;). In the event of a reduction hereunder, the Purchaser shall give the Holder
and Founders, as applicable, at least five (5) Business Days prior written notice along with the calculations as to such Holder&rsquo;s
or Founder&rsquo;s allotment. Promptly after such SEC Guidance is no longer applicable with respect to some or all of the remaining unregistered
Registrable Securities, the Purchaser shall file an additional Registration Statement in accordance with this Section 2 to with respect
to such shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1.3
Each Holder agrees to furnish to the Purchaser a completed Selling Securityholder Questionnaire within five (5) Business Days
following the date of this Agreement. Each Holder further acknowledges and agrees that it shall not be entitled to be named as a selling
security holder in the Registration Statement or use the Prospectus for offers and resales of Registrable Securities at any time unless
such Holder has returned to the Purchaser a completed and signed Selling Securityholder Questionnaire. If a Holder of Registrable
Securities returns a Selling Securityholder Questionnaire after the deadline specified in the previous sentence, the Purchaser
shall use its commercially reasonable efforts to take such actions as are required to name such Holder as a selling security holder in
the Registration Statement or any pre-effective or post-effective amendment thereto and to include (to the extent not theretofore included)
in the Registration Statement the Registrable Securities identified in such late Selling Securityholder Questionnaire; provided
that the Purchaser shall not be required to file an additional Registration Statement solely for such shares. Each Holder acknowledges
and agrees that the information in the Selling Securityholder Questionnaire will be used by the Purchaser in the preparation of
the Registration Statement and hereby consents to the inclusion of such information in the Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2 <U>Demand
Registration</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2.1 <U>Request
for Registration</U>. At any time and from time to time on or after the date of this Agreement, the Holders of twenty-five percent (25%)
of the Registrable Securities may make a written demand for registration under the Securities Act of all or part of their Registrable
Securities, as the case may be (a &ldquo;<B><I>Demand Registration</I></B>&rdquo;). Any demand for a Demand Registration shall specify
the number of shares of Registrable Securities proposed to be sold and the intended method(s) of distribution thereof. The Purchaser
will within twenty (20) days of the Purchaser&rsquo;s receipt of the Demand Registration notify all holders of Registrable Securities
of the demand, and each holder of Registrable Securities who wishes to include all or a portion of such holder&rsquo;s Registrable Securities
in the Demand Registration (each such holder including shares of Registrable Securities in such registration, a &ldquo;<B><I>Demanding
Holder</I></B>&rdquo;) shall so notify the Purchaser within ten (10) days after the receipt by the holder of the notice from the Purchaser.
Upon any such request, the Demanding Holders shall be entitled to have their Registrable Securities included in the Demand Registration,
subject to Section 2.1.4 and the provisos set forth in Section 3.1.1. The Purchaser shall not be obligated to effect no more than an
aggregate of three (3) Demand Registrations under this Section 2.1.1 in respect of all Registrable Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2.2 <U>Effective
Registration</U>. A registration will not count as a Demand Registration until the Registration Statement filed with the Commission with
respect to such Demand Registration has been declared effective and the Purchaser has complied with all of its obligations under this
Agreement with respect thereto; provided, however, that if, after such Registration Statement has been declared effective, the offering
of Registrable Securities pursuant to a Demand Registration is interfered with by any stop order or injunction of the Commission or any
other governmental agency or court, the Registration Statement with respect to such Demand Registration will be deemed not to have been
declared effective, unless and until, (i) such stop order or injunction is removed, rescinded or otherwise terminated, and (ii) a majority-in-interest
of the Demanding Holders thereafter elect to continue the offering; provided, further, that the Purchaser shall not be obligated to file
a second Registration Statement until a Registration Statement that has been filed is counted as a Demand Registration or is terminated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2.3 <U>Underwritten
Offering</U>. If a majority-in-interest of the Demanding Holders so elect and such holders so advise the Purchaser as part of their written
demand for a Demand Registration, the offering of such Registrable Securities pursuant to such Demand Registration shall be in the form
of an underwritten offering; provided that the total offering price is reasonably expected to exceed, in the aggregate, $50 million.
In such event, the right of any holder to include its Registrable Securities in such registration shall be conditioned upon such holder&rsquo;s
participation in such underwriting and the inclusion of such holder&rsquo;s Registrable Securities in the underwriting to the extent
provided herein. All Demanding Holders proposing to distribute their Registrable Securities through such underwriting shall enter into
an underwriting agreement in customary form with the Underwriter or Underwriters selected for such underwriting by a majority-in-interest
of the holders initiating the Demand Registration.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2.4 <U>Reduction
of Offering</U>. If the managing Underwriter or Underwriters for a Demand Registration that is to be an underwritten offering, in good
faith, advises the Purchaser and the Demanding Holders in writing that the dollar amount or number of shares of Registrable Securities
which the Demanding Holders desire to sell, taken together with all other shares of Common Stock or other securities which the Purchaser
desires to sell and the shares of Common Stock, if any, as to which registration has been requested pursuant to written contractual piggy-back
registration rights held by other shareholders of the Purchaser who desire to sell, exceeds the maximum dollar amount or maximum number
of shares that can be sold in such offering without adversely affecting the proposed offering price, the timing, the distribution method,
or the probability of success of such offering (such maximum dollar amount or maximum number of shares, as applicable, the &ldquo;<B><I>Maximum
Number of Shares</I></B>&rdquo; ), then the Purchaser shall include in such registration: (i) first, the Registrable Securities as to
which Demand Registration has been requested by the Demanding Holders (Pro Rata in accordance with the number of shares that each such
Person has requested be included in such registration, regardless of the number of shares held by each such Person) that can be sold
without exceeding the Maximum Number of Shares; (ii) second, to the extent that the Maximum Number of Shares has not been reached under
the foregoing clause (i), the Registrable Securities of Holders exercising their rights to register their Registrable Securities that
can be sold without exceeding the Maximum Number of Shares; and (iii) third, to the extent that the Maximum Number of Shares has not
been reached under the foregoing clauses (i) and (ii), shares of Common Stock or other securities that the Purchaser desires to sell
that can be sold without exceeding the Maximum Number of Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2.5 <U>Withdrawal</U>.
If, prior to filing of the applicable &ldquo;red herring prospectus&rdquo; or prospectus supplement used for marketing such registration,
a majority-in-interest of the Demanding Holders disapprove of the terms of any underwriting or are not entitled to include all of their
Registrable Securities in any offering, such majority-in-interest of the Demanding Holders may elect to withdraw from such offering by
giving written notice to the Purchaser and the Underwriter or Underwriters of their request to withdraw prior to the effectiveness of
the Registration Statement filed with the Commission with respect to such Demand Registration. If the majority-in-interest of the Demanding
Holders withdraws from a proposed offering relating to a Demand Registration, then such registration shall not count as a Demand Registration
provided for in Section 2.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3 <U>Piggy-Back
Registration</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3.1 <U>Piggy-Back
Rights</U>. If at any time on or after the date of this Agreement the Purchaser proposes to file a Registration Statement under the Securities
Act with respect to an offering of equity securities, or securities or other obligations exercisable or exchangeable for, or convertible
into, equity securities, by the Purchaser for its own account or for shareholders of the Purchaser for their account (or by the Purchaser
and by shareholders of the Purchaser including, without limitation, pursuant to Section 2.1), other than a Registration Statement (i)
filed in connection with any employee stock option or other benefit plan, (ii) for an exchange offer or offering of securities solely
to the Purchaser&rsquo;s existing shareholders, (iii) for an offering of debt that is convertible into equity securities of the Purchaser
or (iv) for a dividend reinvestment plan, then the Purchaser shall (x) give written notice of such proposed filing to the holders of
Registrable Securities as soon as practicable but in no event less than twenty (20) days before the anticipated filing date, which notice
shall describe the amount and type of securities to be included in such offering, the intended method(s) of distribution, and the name
of the proposed managing Underwriter or Underwriters, if any, of the offering, and (y) offer to the holders of Registrable Securities
in such notice the opportunity to register the sale of such number of shares of Registrable Securities as such holders may request in
writing within ten (10) days following receipt of such notice (a &ldquo;<B><I>Piggy-Back Registration</I></B>&rdquo; ). The Purchaser
shall, in good faith, cause such Registrable Securities to be included in such registration and shall use its best efforts to cause the
managing Underwriter or Underwriters of a proposed underwritten offering to permit the Registrable Securities requested to be included
in a Piggy-Back Registration on the same terms and conditions as any similar securities of the Purchaser and to permit the sale or other
disposition of such Registrable Securities in accordance with the intended method(s) of distribution thereof. All holders of Registrable
Securities proposing to distribute their securities through a Piggy-Back Registration that involves an Underwriter or Underwriters shall
enter into an underwriting agreement in customary form with the Underwriter or Underwriters selected for such Piggy-Back Registration.
Notwithstanding the provisions set forth in the immediately preceding sentences, the right to a Piggy-Back Registration set forth under
this Section 2.2.1 with respect to the Registrable Securities shall terminate on the seventh anniversary of the Effective Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3.2 <U>Reduction
of Offering</U>. If the managing Underwriter or Underwriters for a Piggy-Back Registration that is to be an underwritten offering advises
the Purchaser and the holders of Registrable Securities in writing that the dollar amount or number of shares of Common Stock which the
Purchaser desires to sell, taken together with the shares of Common Stock, if any, as to which registration has been demanded pursuant
to written contractual arrangements with persons other than the holders of Registrable Securities hereunder, the Registrable Securities
as to which registration has been requested under this Section 2.2, and the shares of Common Stock, if any, as to which registration
has been requested pursuant to the terms hereof exceeds the Maximum Number of Shares, then the Purchaser shall include in any such registration:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a) If
the registration is undertaken for the Purchaser&rsquo;s account: (A) first, the shares of Common Stock or other securities that the
Purchaser desires to sell that can be sold without exceeding the Maximum Number of Shares; and (B) second, to the extent that the Maximum
Number of Shares has not been reached under the foregoing clause (A), the shares of Common Stock or other securities, if any, comprised
of Registrable Securities as to which registration has been requested pursuant to the terms hereof, Pro Rata, that can be sold without
exceeding the Maximum Number of Shares; and (C) third, to the extent that the Maximum Number of Shares has not been reached under the
foregoing clauses (A) and (B), the shares of Common Stock or other securities for the account of other persons that the Purchaser is
obligated to register pursuant to written contractual piggy-back registration rights with such persons and that can be sold without exceeding
the Maximum Number of Shares;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b) If
the registration is a &ldquo;demand&rdquo; registration undertaken at the demand of persons other than the holders of Registrable Securities,
(A) first, the shares of Common Stock or other securities for the account of the demanding persons that can be sold without exceeding
the Maximum Number of Shares; (B) second, to the extent that the Maximum Number of Shares has not been reached under the foregoing clause
(A), the shares of Common Stock or other securities comprised of Registrable Securities, Pro Rata, as to which registration has been
requested pursuant to the terms hereof, that can be sold without exceeding the Maximum Number of Shares; and (C) third, to the extent
that the Maximum Number of Shares has not been reached under the foregoing clauses (A) and (B), the shares of Common Stock or other securities
that the Purchaser desires to sell that can be sold without exceeding the Maximum Number of Shares; and (D) fourth, to the extent that
the Maximum Number of Shares has not been reached under the foregoing clauses (A), (B) and (C), the shares of Common Stock or other securities
for the account of other persons that the Purchaser is obligated to register pursuant to written contractual arrangements with such persons,
that can be sold without exceeding the Maximum Number of Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3.3 <U>Withdrawal</U>.
Any holder of Registrable Securities may elect to withdraw such holder&rsquo;s request for inclusion of Registrable Securities in any
Piggy-Back Registration by giving written notice to the Purchaser of such request to withdraw prior to the effectiveness of the Registration
Statement. The Purchaser (whether on its own determination or as the result of a withdrawal by persons making a demand pursuant to written
contractual obligations) may withdraw a Registration Statement at any time prior to the effectiveness of such Registration Statement.
Notwithstanding any such withdrawal, the Purchaser shall pay all expenses incurred by the holders of Registrable Securities in connection
with such Piggy-Back Registration as provided in Section 3.3.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3.4 <U>Unlimited
Piggy-Back Registration Rights</U>. For purposes of clarity, any Registration effected pursuant to Section 2.2 hereof shall not be counted
as a Registration pursuant to a Demand Registration effected under Section 2.1 hereof. The Holders shall have unlimited Piggy-Back Registration
Rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3.5 <U>Registrations
on Form S-3</U>. The holders of Registrable Securities may at any time and from time to time, request in writing that the Purchaser register
the resale of any or all of such Registrable Securities on Form S-3 or any similar short-form registration which may be available at
such time (&ldquo;<B><I>Form S-3</I></B>&rdquo;); provided, however, that the Purchaser shall not be obligated to effect such request
through an underwritten offering. Upon receipt of such written request, the Purchaser will promptly give written notice of the proposed
registration to all other holders of Registrable Securities, and, as soon as practicable thereafter, effect the registration of all or
such portion of such holder&rsquo;s or holders&rsquo; Registrable Securities as are specified in such request, together with all or such
portion of the Registrable Securities or other securities of the Purchaser, if any, of any other holder or holders joining in such request
as are specified in a written request given within fifteen (15) days after receipt of such written notice from the Purchaser; provided,
however, that the Purchaser shall not be obligated to effect any such registration pursuant to this Section 2.3: (i) if Form S-3 is not
available for such offering; or (ii) if the holders of the Registrable Securities, together with the holders of any other securities
of the Purchaser entitled to inclusion in such registration, propose to sell Registrable Securities and such other securities (if any)
at any aggregate price to the public of less than $500,000. Registrations effected pursuant to this Section 2.3 shall not be counted
as Demand Registrations effected pursuant to Section 2.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4 <U>Block
Trades; Other Coordinated Offerings</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4.1 Notwithstanding
any other provision of this Section 2,4, at any time and from time to time when an effective Shelf Registration is on file with the Commission,
if a Demanding Holder wishes to engage in (a) an underwritten registered offering (whether firm commitment or otherwise) not involving
a &ldquo;road show&rdquo; or other substantial marketing efforts prior to pricing (commonly referred to as a &ldquo;Block Trade&rdquo;)
or (b) an otherwise coordinated &ldquo;at the market&rdquo; or similar registered offering through a broker, sales agent or distribution
agent, whether as agent or principal (an &ldquo;<B><I>Other Coordinated Offering</I></B>&rdquo;), in each case, with a total offering
price reasonably expected to exceed, in the aggregate, either (x) $10 million or (y) all remaining Registrable Securities held by the
Demanding Holder, then such Demanding Holder shall notify the Purchaser of the Block Trade or Other Coordinated Offering at least five
(5) business days prior to the day such offering is expected to commence, and the Purchaser shall as expeditiously as possible use its
commercially reasonable efforts to facilitate such Block Trade or Other Coordinated Offering; provided that the Demanding Holders representing
a majority of the Registrable Securities wishing to engage in the Block Trade or Other Coordinated Offering shall use commercially reasonable
efforts to work with the Purchaser and any Underwriters, brokers, sales agents or placement agents prior to making such request in order
to facilitate preparation of the registration statement, prospectus and other offering documentation related to the Block Trade or Other
Coordinated Offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4.2 The
Purchaser may facilitate a Block Trade or Other Coordinated Offering if it determines that sufficient shares shall be traded by any Holder
or Holders that would be more efficiently traded as a block trade.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4.3 Prior
to the filing of the applicable &ldquo;red herring&rdquo; prospectus or prospectus supplement used in connection with a Block Trade or
Other Coordinated Offering, a majority-in-interest of the Demanding Holders initiating such Block Trade or Other Coordinated Offering
shall have the right to submit a notice to the Purchaser and the Underwriter(s) if any, of their intention to withdraw from such Block
Trade or Other Coordinated Offering. Notwithstanding anything to the contrary in this Agreement, the Purchaser shall be responsible for
the Registration Expenses incurred in connection with a block trade prior to its withdrawal under this Section 2.4.3.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4.4 Notwithstanding
anything to the contrary in this Agreement, Section 2.3 shall not apply to a Block Trade or Other Coordinated Offering initiated by a
Demanding Holder pursuant to this Section 2.4.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4.5 The
Purchaser shall have the right to select the Underwriters, and brokers, sale agents or placement agents (if any) for such Block Trade
or Other Coordinated Offering, in each case, which shall consist of one or more reputable nationally recognized investment bank.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4.6 A
Holder in the aggregate may demand no more than two (2) Block Trades or Other Coordinated Offerings pursuant to this Section 2.4 in any
twelve (12) month period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">3. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>REGISTRATION
PROCEDURES</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Filings;
Information</U>. Whenever the Purchaser is required to effect the registration of any Registrable Securities pursuant to Section 2, the
Purchaser shall use its best efforts to effect the registration and sale of such Registrable Securities in accordance with the intended
method(s) of distribution thereof as expeditiously as practicable, and in connection with any such request:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.1 <U>Filing
Registration Statement</U>. The Purchaser shall use its best efforts to, as expeditiously as possible after receipt of a request for
a Demand Registration pursuant to Section 2.1, prepare and file with the Commission a Registration Statement on any form for which the
Purchaser then qualifies or which counsel for the Purchaser shall deem appropriate and which form shall be available for the sale of
all Registrable Securities to be registered thereunder in accordance with the intended method(s) of distribution thereof, and shall use
its best efforts to cause such Registration Statement to become effective and use its best efforts to keep it effective for the period
required by Section 3.1.3; provided, however, that the Purchaser shall have the right to defer any Demand Registration for up to ninety
(90) days, and any Piggy-Back Registration for such period as may be applicable to deferment of any demand registration to which such
Piggy-Back Registration relates, in each case if the Purchaser shall furnish to the holders a certificate signed by Chief Executive Officer
or Chairman of the Purchaser stating that, in the good faith judgment of the Board of Directors of the Purchaser, it would be materially
detrimental to the Purchaser and its shareholders for such Registration Statement to be effected at such time; provided further, however,
that the Purchaser shall not have the right to exercise the right set forth in this provision more than once in any 365-day period in
respect of a Demand Registration hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.2 <U>Copies</U>.
The Purchaser shall, prior to filing a Registration Statement or prospectus, or any amendment or supplement thereto, furnish without
charge to the holders of Registrable Securities included in such registration, and such holders&rsquo; legal counsel, copies of such
Registration Statement as proposed to be filed, each amendment and supplement to such Registration Statement (in each case including
all exhibits thereto and documents incorporated by reference therein), the prospectus included in such Registration Statement (including
each preliminary prospectus), and such other documents as the holders of Registrable Securities included in such registration or legal
counsel for any such holders may request in order to facilitate the disposition of the Registrable Securities owned by such holders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.3 <U>Amendments
and Supplements</U>. The Purchaser shall prepare and file with the Commission such amendments, including post-effective amendments, and
supplements to such Registration Statement and the prospectus used in connection therewith as may be necessary to keep such Registration
Statement effective and in compliance with the provisions of the Securities Act until all Registrable Securities and other securities
covered by such Registration Statement have been disposed of in accordance with the intended method(s) of distribution set forth in such
Registration Statement or such securities have been withdrawn.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.4 <U>Notification</U>.
After the filing of a Registration Statement, the Purchaser shall promptly, and in no event more than two (2) business days after such
filing, notify the holders of Registrable Securities included in such Registration Statement of such filing, and shall further notify
such holders promptly and confirm such advice in writing in all events within two (2) business days of the occurrence of any of the following:
(i) when such Registration Statement becomes effective; (ii) when any post-effective amendment to such Registration Statement becomes
effective; (iii) the issuance or threatened issuance by the Commission of any stop order (and the Purchaser shall take all actions required
to prevent the entry of such stop order or to remove it if entered); and (iv) any request by the Commission for any amendment or supplement
to such Registration Statement or any prospectus relating thereto or for additional information or of the occurrence of an event requiring
the preparation of a supplement or amendment to such prospectus so that, as thereafter delivered to the purchasers of the securities
covered by such Registration Statement, such prospectus will not contain an untrue statement of a material fact or omit to state any
material fact required to be stated therein or necessary to make the statements therein not misleading, and promptly make available to
the holders of Registrable Securities included in such Registration Statement any such supplement or amendment; except that before filing
with the Commission a Registration Statement or prospectus or any amendment or supplement thereto, including documents incorporated by
reference, the Purchaser shall furnish to the holders of Registrable Securities included in such Registration Statement and to the legal
counsel for any such holders, copies of all such documents proposed to be filed sufficiently in advance of filing to provide such holders
and legal counsel with a reasonable opportunity to review such documents and comment thereon, and the Purchaser shall not file any Registration
Statement or prospectus or amendment or supplement thereto, including documents incorporated by reference, to which such holders or their
legal counsel shall object.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.5 <U>State
Securities Laws Compliance</U>. The Purchaser shall use its best efforts to (i) register or qualify the Registrable Securities covered
by the Registration Statement under such securities or &ldquo;blue sky&rdquo; laws of such jurisdictions in the United States as the
holders of Registrable Securities included in such Registration Statement (in light of their intended plan of distribution) may request
and (ii) take such action necessary to cause such Registrable Securities covered by the Registration Statement to be registered with
or approved by such other governmental authorities as may be necessary by virtue of the business and operations of the Purchaser and
do any and all other acts and things that may be necessary or advisable to enable the holders of Registrable Securities included in such
Registration Statement to consummate the disposition of such Registrable Securities in such jurisdictions; provided, however, that the
Purchaser shall not be required to qualify generally to do business in any jurisdiction where it would not otherwise be required to qualify
but for this paragraph or subject itself to taxation in any such jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.6 <U>Agreements
for Disposition</U>. The Purchaser shall enter into customary agreements (including, if applicable, an underwriting agreement in customary
form) and take such other actions as are reasonably required in order to expedite or facilitate the disposition of such Registrable Securities.
The representations, warranties and covenants of the Purchaser in any underwriting agreement which are made to or for the benefit of
any Underwriters, to the extent applicable, shall also be made to and for the benefit of the holders of Registrable Securities included
in such registration statement. No holder of Registrable Securities included in such registration statement shall be required to make
any representations or warranties in the underwriting agreement except, if applicable, with respect to such holder&rsquo;s organization,
good standing, authority, title to Registrable Securities, lack of conflict of such sale with such holder&rsquo;s material agreements
and organizational documents, and with respect to written information relating to such holder that such holder has furnished in writing
expressly for inclusion in such Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.7 <U>Cooperation</U>.
The principal executive officer of the Purchaser, the principal financial officer of the Purchaser, the principal accounting officer
of the Purchaser and all other officers and members of the management of the Purchaser shall cooperate fully in any offering of Registrable
Securities hereunder, which cooperation shall include, without limitation, the preparation of the Registration Statement with respect
to such offering and all other offering materials and related documents, and participation in meetings with Underwriters, attorneys,
accountants and potential Holders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.8 <U>Records</U>.
The Purchaser shall make available for inspection by the holders of Registrable Securities included in such Registration Statement, any
Underwriter participating in any disposition pursuant to such registration statement and any attorney, accountant or other professional
retained by any holder of Registrable Securities included in such Registration Statement or any Underwriter, all financial and other
records, pertinent corporate documents and properties of the Purchaser, as shall be necessary to enable them to exercise their due diligence
responsibility, and cause the Purchaser&rsquo;s officers, directors and employees to supply all information requested by any of them
in connection with such Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.9 <U>Opinions
and Comfort Letters</U>. Upon request, the Purchaser shall furnish to each holder of Registrable Securities included in any Registration
Statement a signed counterpart, addressed to such holder, of (i) any opinion of counsel to the Purchaser delivered to any Underwriter
and (ii) any comfort letter from the Purchaser&rsquo;s independent public accountants delivered to any Underwriter. In the event no legal
opinion is delivered to any Underwriter, the Purchaser shall furnish to each holder of Registrable Securities included in such Registration
Statement, at any time that such holder elects to use a prospectus, an opinion of counsel to the Purchaser to the effect that the Registration
Statement containing such prospectus has been declared effective and that no stop order is in effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.10&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Earnings
Statement</U>. The Purchaser shall comply with all applicable rules and regulations of the Commission and the Securities Act, and make
available to its shareholders, as soon as practicable, an earnings statement covering a period of twelve (12) months, which earnings
statement shall satisfy the provisions of Section 11(a) of the Securities Act and Rule 158 thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.11&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Listing</U>.
The Purchaser shall use its best efforts to cause all Registrable Securities included in any registration to be listed on such exchanges
or otherwise designated for trading in the same manner as similar securities issued by the Purchaser are then listed or designated or,
if no such similar securities are then listed or designated, in a manner satisfactory to the holders of a majority of the Registrable
Securities included in such registration.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.12&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Road
Show</U>. If the registration involves the registration of Registrable Securities involving gross proceeds in excess of $50,000,000,
the Purchaser shall use its reasonable efforts to make available senior executives of the Purchaser to participate in customary &ldquo;road
show&rdquo; presentations that may be reasonably requested by the Underwriter in any underwritten offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Obligation
to Suspend Distribution</U>. Upon receipt of any notice from the Purchaser of the happening of any event of the kind described in Section
3.1.4(iv), or, in the case of a resale registration on Form S-3 pursuant to Section 2.3 hereof, upon any suspension by the Purchaser,
pursuant to a written insider trading compliance program adopted by the Purchaser&rsquo;s Board of Directors, of the ability of all &ldquo;insiders&rdquo;
covered by such program to transact in the Purchaser&rsquo;s securities because of the existence of material non-public information,
each holder of Registrable Securities included in any registration shall immediately discontinue disposition of such Registrable Securities
pursuant to the Registration Statement covering such Registrable Securities until such holder receives the supplemented or amended prospectus
contemplated by Section 3.1.4(iv) or the restriction on the ability of &ldquo;insiders&rdquo; to transact in the Purchaser&rsquo;s securities
is removed, as applicable, and, if so directed by the Purchaser, each such holder will deliver to the Purchaser all copies, other than
permanent file copies then in such holder&rsquo;s possession, of the most recent prospectus covering such Registrable Securities at the
time of receipt of such notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3 <U>Registration
Expenses</U>. The Purchaser shall bear all costs and expenses incurred in connection with any Demand Registration pursuant to Section
2.2, any Piggy-Back Registration pursuant to Section 2.3, and any registration on Form S-3 effected pursuant to Section 2.4, and all
expenses incurred in performing or complying with its other obligations under this Agreement, whether or not the Registration Statement
becomes effective, including, without limitation: (i) all registration and filing fees; (ii) fees and expenses of compliance with securities
or &ldquo;blue sky&rdquo; laws (including fees and disbursements of counsel in connection with blue sky qualifications of the Registrable
Securities); (iii) printing expenses; (iv) the fees and expenses incurred in connection with the listing of the Registrable Securities
as required by Section 3.1.11; (v) Financial Industry Regulatory Authority fees; (vi) fees and disbursements of counsel for the Purchaser
and fees and expenses for independent certified public accountants retained by the Purchaser (including the expenses or costs associated
with the delivery of any opinions or comfort letters requested pursuant to Section 3.1.9); and (viii) the reasonable fees and expenses
of any special experts retained by the Purchaser in connection with such registration. The Purchaser shall have no obligation to pay
(i) any underwriting discounts or selling commissions attributable to the Registrable Securities being sold by the holders thereof, which
underwriting discounts or selling commissions shall be borne by such holders, or (ii) the fees and expenses of any legal counsel representing
any Holders. Additionally, in an underwritten offering, all selling shareholders and the Purchaser shall bear the expenses of the Underwriter
pro rata in proportion to the respective amount of shares each is selling in such offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4 <U>Information</U>.
The holders of Registrable Securities shall provide such information as may reasonably be requested by the Purchaser, or the managing
Underwriter, if any, in connection with the preparation of any Registration Statement, including amendments and supplements thereto,
in order to effect the registration of any Registrable Securities under the Securities Act pursuant to Section 2 and in connection with
the Purchaser&rsquo;s obligation to comply with Federal and applicable state securities laws. In addition, the holders of Registrable
Securities shall comply with all prospectus delivery requirements under the Securities Act and applicable SEC regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5 <U>Legend
Removal Obligations</U>. In connection with the written request of any Holder, the Purchaser shall remove any restrictive legend included
on the certificates (or, in the case of book-entry shares, any other instrument or record) representing such Holder&rsquo;s and/or its
affiliates&rsquo; or permitted transferee&rsquo;s ownership of Registrable Securities, and promptly issue a certificate (or evidence
of the issuance of securities in book-entry form) without such restrictive legend or any other restrictive legend to the holder of the
applicable shares of Registrable Securities upon which it is stamped, if (i) such Registrable Securities are registered for resale under
the Securities Act and such Registration Statement for such Registrable Securities has not been suspended under the Securities Act, the
Exchange Act or the rules and regulations of the Commission promulgated thereunder, (ii) such Registrable Securities are sold or transferred
pursuant to Rule 144, or (iii) such Registrable Securities are eligible for sale pursuant to Section 4(a)(1) of the Securities Act or
Rule 144 without volume or manner-of-sale restrictions. Following the earlier of (A) the effective date of a Registration Statement registering
such Registrable Securities or (B) Rule 144 becoming available for the resale of such Registrable Securities without volume or manner-of-sale
restrictions, the Purchaser upon the written request of the Holder or its permitted transferee, shall instruct the Purchaser&rsquo;s
transfer agent to remove the legend from such Registrable Securities (in whatever form) and shall cause the Purchaser&rsquo;s counsel
to issue any legend removal opinion required by the transfer agent. Any reasonable and documented fees (with respect to the transfer
agent, the Purchaser&rsquo;s counsel, or otherwise) associated with the removal of such legend shall be borne by the Purchaser. If a
legend is no longer required pursuant to the foregoing, the Purchaser will, as soon as practicable following the delivery by any Holder
or its permitted transferee to the Purchaser or the transfer agent (with notice to the Purchaser) of a legended certificate (if applicable)
representing such Registrable Securities and, to the extent such sale is not pursuant to an effective registration statement, such other
documentation as reasonably requested by the Purchaser, deliver or cause to be delivered to the holder of such Registrable Securities
a certificate representing such Registrable Securities (or evidence of the issuance of such Registrable Securities in book-entry form)
that is free from all restrictive legends; provided that, notwithstanding the foregoing, the Purchaser will not be required to deliver
any opinion, authorization, certificate or direction to remove the restrictive legend pursuant to this Section 3.5 if (x) removal of
the legend would result in or facilitate transfer of securities in violation of applicable law or (y) following receipt of instruction
from the Purchaser, the transfer agent refuses to remove the legend.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">4. &#8239;&#8239;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>INDEMNIFICATION
AND CONTRIBUTION</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1 <U>Indemnification
by the Purchaser</U>. The Purchaser agrees to indemnify and hold harmless each Holder and each other holder of Registrable Securities,
and each of their respective officers, employees, affiliates, directors, partners, members, attorneys and agents, and each person, if
any, who controls an Holder and each other holder of Registrable Securities (within the meaning of Section 15 of the Securities Act or
Section 20 of the Exchange Act) (each, an &ldquo;<B><I>Holder Indemnified Party</I></B>&rdquo; ), from and against any expenses, losses,
judgments, claims, damages or liabilities, whether joint or several, arising out of or based upon any untrue statement (or allegedly
untrue statement) of a material fact contained in any Registration Statement under which the sale of such Registrable Securities was
registered under the Securities Act, any preliminary prospectus, final prospectus or summary prospectus contained in the Registration
Statement, or any amendment or supplement to such Registration Statement, or arising out of or based upon any omission (or alleged omission)
to state a material fact required to be stated therein or necessary to make the statements therein not misleading, or any violation by
the Purchaser of the Securities Act or any rule or regulation promulgated thereunder applicable to the Purchaser and relating to action
or inaction required of the Purchaser in connection with any such registration; and the Purchaser shall promptly reimburse the Holder
Indemnified Party for any legal and any other expenses reasonably incurred by such Holder Indemnified Party in connection with investigating
and defending any such expense, loss, judgment, claim, damage, liability or action; provided, however, that the Purchaser will not be
liable in any such case to the extent that any such expense, loss, claim, damage or liability arises out of or is based upon any untrue
statement or allegedly untrue statement or omission or alleged omission made in such Registration Statement, preliminary prospectus,
final prospectus, or summary prospectus, or any such amendment or supplement, in reliance upon and in conformity with information furnished
to the Purchaser, in writing, by such selling Holder expressly for use therein. The Purchaser also shall indemnify any Underwriter of
the Registrable Securities, their officers, affiliates, directors, partners, members and agents and each person who controls such Underwriter
on substantially the same basis as that of the indemnification provided above in this Section 4.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2 <U>Indemnification
by Holders of Registrable Securities</U>. Each selling Holder will, in the event that any registration is being effected under the Securities
Act pursuant to this Agreement of any Registrable Securities held by such selling Holder, indemnify and hold harmless the Purchaser,
each of its directors and officers and each Underwriter (if any), and each other selling Holder and each other person, if any, who controls
another selling Holder or such Underwriter within the meaning of the Securities Act, against any losses, claims, judgments, damages or
liabilities, whether joint or several, insofar as such losses, claims, judgments, damages or liabilities (or actions in respect thereof)
arise out of or are based upon any untrue statement or allegedly untrue statement of a material fact contained in any Registration Statement
under which the sale of such Registrable Securities was registered under the Securities Act, any preliminary prospectus, final prospectus
or summary prospectus contained in the Registration Statement, or any amendment or supplement to the Registration Statement, or arise
out of or are based upon any omission or the alleged omission to state a material fact required to be stated therein or necessary to
make the statement therein not misleading, if the statement or omission was made in reliance upon and in conformity with information
furnished in writing to the Purchaser by such selling Holder expressly for use therein, and shall reimburse the Purchaser, its directors
and officers, and each other selling holder or controlling person for any legal or other expenses reasonably incurred by any of them
in connection with investigation or defending any such loss, claim, damage, liability or action. Each selling Holder&rsquo;s indemnification
obligations hereunder shall be several and not joint and shall be limited to the amount of any net proceeds actually received by such
selling Holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3 <U>Conduct
of Indemnification Proceedings</U>. Promptly after receipt by any person of any notice of any loss, claim, damage or liability or any
action in respect of which indemnity may be sought pursuant to Section 4.1 or 4.2, such person (the &ldquo;<B><I>Indemnified Party</I></B>&rdquo;)
shall, if a claim in respect thereof is to be made against any other person for indemnification hereunder, notify such other person (the
&ldquo;<B><I>Indemnifying Party</I></B>&rdquo; ) in writing of the loss, claim, judgment, damage, liability or action; provided, however,
that the failure by the Indemnified Party to notify the Indemnifying Party shall not relieve the Indemnifying Party from any liability
which the Indemnifying Party may have to such Indemnified Party hereunder, except and solely to the extent the Indemnifying Party is
actually prejudiced by such failure. If the Indemnified Party is seeking indemnification with respect to any claim or action brought
against the Indemnified Party, then the Indemnifying Party shall be entitled to participate in such claim or action, and, to the extent
that it wishes, jointly with all other Indemnifying Parties, to assume control of the defense thereof with counsel satisfactory to the
Indemnified Party. After notice from the Indemnifying Party to the Indemnified Party of its election to assume control of the defense
of such claim or action, the Indemnifying Party shall not be liable to the Indemnified Party for any legal or other expenses subsequently
incurred by the Indemnified Party in connection with the defense thereof other than reasonable costs of investigation; provided, however,
that in any action in which both the Indemnified Party and the Indemnifying Party are named as defendants, the Indemnified Party shall
have the right to employ separate counsel (but no more than one such separate counsel) to represent the Indemnified Party and its controlling
persons who may be subject to liability arising out of any claim in respect of which indemnity may be sought by the Indemnified Party
against the Indemnifying Party, with the fees and expenses of such counsel to be paid by such Indemnifying Party if, based upon the written
opinion of counsel of such Indemnified Party, representation of both parties by the same counsel would be inappropriate due to actual
or potential differing interests between them. No Indemnifying Party shall, without the prior written consent of the Indemnified Party,
consent to entry of judgment or effect any settlement of any claim or pending or threatened proceeding in respect of which the Indemnified
Party is or could have been a party and indemnity could have been sought hereunder by such Indemnified Party, unless such judgment or
settlement includes an unconditional release of such Indemnified Party from all liability arising out of such claim or proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4 <U>Contribution</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4.1 If
the indemnification provided for in the foregoing Sections 4.1, 4.2 and 4.3 is unavailable to any Indemnified Party in respect of any
loss, claim, damage, liability or action referred to herein, then each such Indemnifying Party, in lieu of indemnifying such Indemnified
Party, shall contribute to the amount paid or payable by such Indemnified Party as a result of such loss, claim, damage, liability or
action in such proportion as is appropriate to reflect the relative fault of the Indemnified Parties and the Indemnifying Parties in
connection with the actions or omissions which resulted in such loss, claim, damage, liability or action, as well as any other relevant
equitable considerations. The relative fault of any Indemnified Party and any Indemnifying Party shall be determined by reference to,
among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a
material fact relates to information supplied by such Indemnified Party or such Indemnifying Party and the parties&rsquo; relative intent,
knowledge, access to information and opportunity to correct or prevent such statement or omission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4.2 The
parties hereto agree that it would not be just and equitable if contribution pursuant to this Section 4.4 were determined by pro rata
allocation or by any other method of allocation which does not take account of the equitable considerations referred to in the immediately
preceding Section 4.4.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4.3 The
amount paid or payable by an Indemnified Party as a result of any loss, claim, damage, liability or action referred to in the immediately
preceding paragraph shall be deemed to include, subject to the limitations set forth above, any legal or other expenses incurred by such
Indemnified Party in connection with investigating or defending any such action or claim. Notwithstanding the provisions of this Section
4.4, no holder of Registrable Securities shall be required to contribute any amount in excess of the dollar amount of the net proceeds
(after payment of any underwriting fees, discounts, commissions or taxes) actually received by such holder from the sale of Registrable
Securities which gave rise to such contribution obligation. No person guilty of fraudulent misrepresentation (within the meaning of Section
11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5 <U>Survival</U>.
The indemnification provided for under this Agreement shall remain in full force and effect regardless of any investigation made by or
on behalf of the Indemnified Party or any officer, director or controlling person of such Indemnified Party and shall survive the transfer
of securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">5. &#8239;&#8239;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>RULE
144</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1 <U>Rule
144</U>. The Purchaser covenants that it shall file any reports required to be filed by it under the Securities Act and the Exchange
Act and shall take such further action as the holders of Registrable Securities may reasonably request, all to the extent required from
time to time to enable such holders to sell Registrable Securities without registration under the Securities Act within the limitation
of the exemptions provided by Rule 144 under the Securities Act, as such Rules may be amended from time to time, or any similar rule
or regulation hereafter adopted by the Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">6. &#8239;&#8239;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>MISCELLANEOUS</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.1 <U>Other
Registration Rights</U>. The Purchaser represents and warrants that no person, other than the holders of the Registrable Securities,
has any right to require the Purchaser to register any shares of the Purchaser&rsquo;s capital stock for sale or to include shares of
the Purchaser&rsquo;s capital stock in any registration filed by the Purchaser for the sale of shares of capital stock for its own account
or for the account of any other person. Further, the Purchaser represents and warrants that this Agreement supersedes any other registration
rights agreement or agreement with similar terms and conditions and in the event of a conflict between any such agreement or agreements
and this Agreement, the terms of this Agreement shall prevail.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.2 <U>Assignment;
No Third Party Beneficiaries</U>. This Agreement and the rights, duties and obligations of the Purchaser hereunder may not be assigned
or delegated by the Purchaser in whole or in part. This Agreement and the rights, duties and obligations of the holders of Registrable
Securities hereunder may be freely assigned or delegated by such holder of Registrable Securities in conjunction with and to the extent
of any transfer of Registrable Securities by any such holder. This Agreement and the provisions hereof shall be binding upon and shall
inure to the benefit of each of the parties, to the permitted assigns of the Holders or holder of Registrable Securities or of any assignee
of the Holders or holder of Registrable Securities. This Agreement is not intended to confer any rights or benefits on any persons that
are not party hereto other than as expressly set forth in Article 4 and this Section 6.2.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.3 <U>Notices</U>.
All notices, demands, requests, consents, approvals or other communications (collectively, &ldquo;<B><I>Notices</I></B>&rdquo; ) required
or permitted to be given hereunder or which are given with respect to this Agreement shall be in writing and shall be personally served,
delivered by reputable air courier service with charges prepaid, or transmitted by hand delivery, telegram, telex or facsimile, addressed
as set forth below, or to such other address as such party shall have specified most recently by written notice. Notice shall be deemed
given on the date of service or transmission if personally served or transmitted by telegram, telex or facsimile; provided, that if such
service or transmission is not on a business day or is after normal business hours, then such notice shall be deemed given on the next
business day. Notice otherwise sent as provided herein shall be deemed given on the next business day following timely delivery of such
notice to a reputable air courier service with an order for next-day delivery.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the Purchaser after the Closing:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OneMedNet
Corporation</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6385
Old Shady Oak Road</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Suite
250</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eden
Prairie, Minnesota 55344</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:
Paul Casey</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telephone
No.: (808) 228-5998</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">E-mail:
<U>paul.casey@onemednet.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">with
a copy to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rim&ocirc;n,
P.C.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1990
K Street NW, Suite 420</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Washington,
D.C. 20006</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:
Debbie Klis</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telephone:
(202) 971-9494</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">E-mail:
<U>debbie.klis@rimonlaw.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
a Holder, to the address set forth below such Holder&rsquo;s name on <U>Exhibit A</U> hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.4 <U>Severability</U>.
This Agreement shall be deemed severable, and the invalidity or unenforceability of any term or provision hereof shall not affect the
validity or enforceability of this Agreement or of any other term or provision hereof. Furthermore, in lieu of any such invalid or unenforceable
term or provision, the parties hereto intend that there shall be added as a part of this Agreement a provision as similar in terms to
such invalid or unenforceable provision as may be possible that is valid and enforceable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.5 <U>Counterparts</U>.
This Agreement may be executed in multiple counterparts, each of which shall be deemed an original, and all of which taken together shall
constitute one and the same instrument.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.6 <U>Entire
Agreement</U>. This Agreement (including all agreements entered into pursuant hereto and all certificates and instruments delivered pursuant
hereto and thereto) constitute the entire agreement of the parties with respect to the subject matter hereof and supersede all prior
and contemporaneous agreements, representations, understandings, negotiations and discussions between the parties, whether oral or written,
including but not limited to the Existing Agreements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.7 <U>Modifications
and Amendments; Termination</U>. No amendment, modification or termination of this Agreement shall be binding upon the Purchaser unless
executed in writing by the Purchaser. No amendment, modification or termination of this Agreement shall be binding upon the holders of
the Registrable Securities unless executed in writing by the holders of the majority Registrable Securities. This Agreement shall terminate
with respect to any Holder on the date that such Holder no longer holds any Registrable Securities. The provisions of Article IV shall
survive any termination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.8 <U>Titles
and Headings</U>. Titles and headings of sections of this Agreement are for convenience only and shall not affect the construction of
any provision of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.9 <U>Waivers
and Extensions</U>. Any party to this Agreement may waive any right, breach or default which such party has the right to waive, provided
that such waiver will not be effective against the waiving party unless it is in writing, is signed by such party, and specifically refers
to this Agreement. Waivers may be made in advance or after the right waived has arisen or the breach or default waived has occurred.
Any waiver may be conditional. No waiver of any breach of any agreement or provision herein contained shall be deemed a waiver of any
preceding or succeeding breach thereof nor of any other agreement or provision herein contained. No waiver or extension of time for performance
of any obligations or acts shall be deemed a waiver or extension of the time for performance of any other obligations or acts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.10 <U>Governing
Law</U>. This Agreement shall be governed by, interpreted under, and construed in accordance with the internal laws of the State of Delaware
applicable to agreements made and to be performed within the State of Delaware, without giving effect to any choice-of-law provisions
thereof that would compel the application of the substantive laws of any other jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.11 <U>Waiver
of Trial by Jury</U>. Each party hereby irrevocably and unconditionally waives the right to a trial by jury in any action, suit, counterclaim
or other proceeding (whether based on contract, tort or otherwise) arising out of, connected with or relating to this Agreement, the
transactions contemplated hereby, or the actions of the Holder in the negotiation, administration, performance or enforcement hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.12 <U>Termination
of Existing Agreements</U>. The Existing Agreements are hereby terminated in their entirety.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[REMAINDER
OF PAGE INTENTIONALLY LEFT BLANK]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the parties have caused this Registration Rights Agreement to be executed and delivered by their duly authorized representatives
as of the date first written above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PURCHASER:</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DATA
    KNIGHTS ACQUISITION CORP.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">   &#8239;&#8239;&#8239;&#8239;&#8239;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HOLDERS:</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[_______________________]</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Exhibit
A</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Schedule
of Holders</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>10
<FILENAME>ex10-3.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.3</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>FORM
OF LOCK-UP AGREEMENT</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THIS
LOCK-UP AGREEMENT (this &ldquo;<B><I>Agreement</I></B>&rdquo;) is made and entered into as of the Closing Date (as defined in the Merger
Agreement, as defined below) by and between (i) <B>Data Knights Acquisition Corp.</B>, a Delaware corporation (including any successor
entity thereto, the &ldquo;<B><I>Purchaser</I></B>&rdquo;), and (ii) _______________ (the &ldquo;<B><I>Subject Party</I></B>&rdquo;).
Any capitalized term used but not defined in this Agreement will have the meaning ascribed to such term in the Merger Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>,
on April 25, 2022, (i) the Purchaser, (ii) Data Knights Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of the
Purchaser (&ldquo;<B><I>Merger Sub</I></B>&rdquo;<I>)</I>, (iii) Data Knights, LLC, a Delaware limited liability company (the &ldquo;<B><I>Purchaser
Representative</I></B>&rdquo;), (iv) Paul Casey (the &ldquo;<B><I>Seller Representative</I></B>&rdquo;), and (v) <B>OneMedNet Corporation</B>,
a Delaware corporation (the &ldquo;<B><I>Company</I></B>&rdquo;) entered into that certain Agreement and Plan of Merger (as amended from
time to time in accordance with the terms thereof, the &ldquo;<B><I>Merger Agreement</I></B>&rdquo;), pursuant to which the parties thereto
intend to effect the merger of Merger Sub with and into the Company, with the Company continuing as the surviving entity (the &ldquo;<B><I>Merger</I></B>&rdquo;),
as a result of which all of the issued and outstanding capital stock of the Company immediately prior to the Effective Time shall be
exchanged for the Stockholder Merger Consideration, all upon the terms and subject to the conditions set forth in this Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>,
pursuant to the Merger Agreement, and in view of the valuable consideration to be received by the Subject Party thereunder, the parties
desire to enter into this Agreement, pursuant to which the Purchaser Common Stock received by the Subject Party in the Merger (all such
securities, together with any securities paid as dividends or distributions with respect to such securities or into which such securities
are exchanged or converted, the <I>&ldquo;<B>Restricted Securities</B>&rdquo;</I>) shall become subject to limitations on disposition
as set forth herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOW,
THEREFORE</B>, in consideration of the premises set forth above, which are incorporated into this Agreement as if fully set forth below,
and intending to be legally bound hereby, the parties hereby agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
<U>Lock-Up Provisions</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
The Subject Party hereby agrees not to, during the period commencing from the Closing and ending on the earliest of (x) six (6) months
after the date of the Closing and (y) the date after the Closing on which the Purchaser consummates a liquidation, merger, capital stock
exchange, reorganization, or other similar transaction with an unaffiliated third party that results in all of the Purchaser&rsquo;s
stockholders having the right to exchange their shares of the Purchaser Common Stock for cash, securities, or other property (the &ldquo;<B><I>Lock-Up
Period</I></B>&rdquo;): (i) lend, offer, pledge, hypothecate, encumber, donate, assign, sell, contract to sell, sell any option or contract
to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose
of, directly or indirectly, any Restricted Securities, (ii) enter into any swap or other arrangement that transfers to another, in whole
or in part, any of the economic consequences of ownership of the Restricted Securities, or (iii) publicly disclose the intention to do
any of the foregoing, whether any such transaction described in clauses (i), (ii), or (iii) above is to be settled by delivery of Restricted
Securities or other securities, in cash or otherwise (any of the foregoing described in clauses (i), (ii), or (iii), a &ldquo;<B><I>Prohibited
Transfer</I></B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
The foregoing shall not apply to the transfer of any or all of the Restricted Securities (I) to any Permitted Transferee or (II) pursuant
to a court order or settlement agreement related to the distribution of assets in connection with the dissolution of marriage or civil
union; provided, however, that in either of cases (I) or (II), it shall be a condition to such transfer that such transfer complies with
the Securities Act of 1933, as amended, and other applicable law, and that the transferee executes and delivers to the Purchaser an agreement
stating that the transferee is receiving and holding the Restricted Securities subject to the provisions of this Agreement applicable
to the Subject Party, and there shall be no further transfer of such Restricted Securities except in accordance with this Agreement.
As used in this Agreement, the term &ldquo;<B><I>Permitted Transferee</I></B>&rdquo; shall mean: (1) the members of the Subject Party&rsquo;s
immediate family (for purposes of this Agreement, &ldquo;immediate family&rdquo; shall mean with respect to any natural person, any of
the following: such person&rsquo;s spouse or domestic partner, the siblings of such person and his or her spouse or domestic partner,
and the direct descendants and ascendants (including adopted and step children and parents) of such person and his or her spouses or
domestic partners and siblings), (2) any trust for the direct or indirect benefit of the Subject Party or the immediate family of the
Subject Party, (3) if the Subject Party is a trust, to the trustor or beneficiary of such trust or to the estate of a beneficiary of
such trust, (4) in the case of an entity, officers, directors, general partners, limited partners, members, or stockholders of such entity
that receive such transfer as a distribution, or related investment funds or vehicles controlled or managed by such persons or their
respective affiliates, (5) to any affiliate of the Subject Party, and (6) any transferee whereby there is no change in beneficial ownership.
The Subject Party further agrees to execute such agreements as may be reasonably requested by the Purchaser that are consistent with
the foregoing or that are necessary to give further effect thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
If any Prohibited Transfer is made or attempted contrary to the provisions of this Agreement, such purported Prohibited Transfer shall
be null and void ab initio, and the Purchaser shall refuse to recognize any such purported transferee of the Restricted Securities as
one of its equity holders for any purpose, and shall refuse to record any such purported transfer of the Restricted Securities in the
books of the Company. In order to enforce this <U>Section 1</U>, the Purchaser may impose stop-transfer instructions with respect to
the Restricted Securities of the Subject Party (and Permitted Transferees and assigns thereof) until the end of the Lock-Up Period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
During the Lock-Up Period, each certificate evidencing any Restricted Securities shall be stamped or otherwise imprinted with a legend
in substantially the following form, in addition to any other applicable legends:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;THE
SECURITIES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO RESTRICTIONS ON TRANSFER SET FORTH IN A LOCK-UP AGREEMENT, DATED AS OF [&#9679;],
2022, BY AND AMONG THE ISSUER OF SUCH SECURITIES (THE &ldquo;ISSUER&rdquo;) AND THE ISSUER&rsquo;S SECURITY HOLDER NAMED THEREIN, AS
AMENDED. A COPY OF SUCH LOCK-UP AGREEMENT WILL BE FURNISHED WITHOUT CHARGE BY THE ISSUER TO THE HOLDER HEREOF UPON WRITTEN REQUEST.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
For the avoidance of any doubt, the Subject Party shall retain all of its rights as a stockholder of the Purchaser during the Lock-Up
Period, including the right to vote any Restricted Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
The foregoing notwithstanding, to the extent any Subject Party is granted a release or waiver from the restrictions contained in this
Section 1 prior to the expiration of the Lock-Up Period, then all Subject Parties shall be automatically granted a release or waiver
from the restrictions contained in this Section to the same extent, on substantially the same terms as and on a pro rata basis with,
the Subject Party to which such release or waiver is granted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
<U>Miscellaneous; No Third-Party Beneficiaries</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Binding Effect; Assignment</U>. This Agreement and all of the provisions herein shall be binding upon and inure to the benefit of
the parties hereto and their respective permitted successors and assigns. This Agreement and all rights and obligations of a party are
personal and may not be transferred or delegated at any time. Notwithstanding the foregoing, the Purchaser may freely assign any or all
of its rights under this Agreement, in whole or in part, to any successor entity (whether by merger, consolidation, equity sale, asset
sale, or otherwise) without obtaining the consent or approval of the Subject Party. This Agreement is intended for the benefit of the
parties hereto and their respective successors and permitted assigns and is not for the benefit of, nor may any provision herein be enforced
by, any other person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Third Parties</U>. Nothing contained in this Agreement or in any instrument or document executed by any party in connection with the
transactions contemplated hereby shall create any rights in, or be deemed to have been executed for the benefit of, any person or entity
that is not a party hereto or thereto or a successor or permitted assign of such a party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Governing Law; Jurisdiction</U>. This Agreement and any dispute or controversy arising out of or relating to this Agreement shall
be governed by and construed in accordance with the laws of the State of Delaware, without regard to the conflict of law principles thereof.
All Actions arising out of or relating to this Agreement shall be heard and determined exclusively in any state or federal court located
in Wilmington, Delaware (or in any appellate courts thereof) (the &ldquo;<B><I>Specified Courts</I></B>&rdquo;). Each party hereto hereby
(i) submits to the exclusive jurisdiction of any Specified Court for the purpose of any Action arising out of or relating to this Agreement
brought by any party hereto and (ii) irrevocably waives, and agrees not to assert by way of motion, defense, or otherwise, in any such
Action, any claim that it is not subject personally to the jurisdiction of the above-named courts, that its property is exempt or immune
from attachment or execution, that the Action is brought in an inconvenient forum, that the venue of the Action is improper, or that
this Agreement or the transactions contemplated hereby may not be enforced in or by any Specified Court. Each party agrees that a final
judgment in any Action shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner
provided by Law. Each party irrevocably consents to the service of the summons and complaint and any other process in any other action
or proceeding relating to the transactions contemplated by this Agreement, on behalf of itself, or its property, by personal delivery
of copies of such process to such party at the applicable address set forth in <U>Section 2(f)</U>. Nothing in this Section shall affect
the right of any party to serve legal process in any other manner permitted by applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<U>WAIVER OF JURY TRIAL</U>. EACH OF THE PARTIES HERETO HEREBY WAIVES TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW ANY RIGHT IT
MAY HAVE TO A TRIAL BY JURY WITH RESPECT TO ANY ACTION DIRECTLY OR INDIRECTLY ARISING OUT OF, UNDER OR IN CONNECTION WITH THIS AGREEMENT
OR THE TRANSACTIONS CONTEMPLATED HEREBY. EACH PARTY HERETO (i) CERTIFIES THAT NO REPRESENTATIVE OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY
OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF ANY ACTION, SEEK TO ENFORCE THAT FOREGOING WAIVER AND (ii) ACKNOWLEDGES
THAT IT AND THE OTHER PARTIES HERETO HAVE BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS
IN THIS SECTION.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
<U>Interpretation</U>. The titles and subtitles used in this Agreement are for convenience only and are not to be considered in construing
or interpreting this Agreement. In this Agreement, unless the context otherwise requires: (i) any pronoun used in this Agreement shall
include the corresponding masculine, feminine, or neuter forms, and the singular form of nouns, pronouns, and verbs shall include the
plural and vice versa; (ii) &ldquo;including&rdquo; (and with correlative meaning &ldquo;include&rdquo;) means including without limiting
the generality of any description preceding or succeeding such term and shall be deemed in each case to be followed by the words &ldquo;without
limitation&rdquo;; (iii) the words &ldquo;herein,&rdquo; &ldquo;hereto,&rdquo; and &ldquo;hereby&rdquo; and other words of similar import
in this Agreement shall be deemed in each case to refer to this Agreement as a whole and not to any particular section or other subdivision
of this Agreement; and (iv) the term &ldquo;or&rdquo; means &ldquo;and/or&rdquo;. The parties have participated jointly in the negotiation
and drafting of this Agreement. Consequently, in the event an ambiguity or question of intent or interpretation arises, this Agreement
shall be construed as if drafted jointly by the parties hereto, and no presumption or burden of proof shall arise favoring or disfavoring
any party by virtue of the authorship of any provision of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
<U>Notices</U>. All notices, consents, waivers, and other communications hereunder shall be in writing and shall be deemed to have been
duly given when delivered (i) in person, (ii) by facsimile or other electronic means, with affirmative confirmation of receipt, (iii)
one Business Day after being sent, if sent by reputable, nationally recognized overnight courier service, or (iv) three (3) Business
Days after being mailed, if sent by registered or certified mail, pre-paid and return receipt requested, in each case to the applicable
party at the following addresses (or at such other address for a party as shall be specified by like notice):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>If
    to the Purchaser before the Closing, to:</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>with
    copies to (which shall not constitute notice):</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Data
    Knights Acquisition Corp.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nelson
    Mullins Riley &amp; Scarborough LLP</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unit
    G6, Frome Business Park,</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101
    Constitution Avenue, NW, Suite 900</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manor
    Road, Frome, BA11 4FN,</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Washington,
    D.C. 20001</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">United
    Kingdom</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:
Andrew M. Tucker, Esq.</FONT></P>
                                                                           <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tel:
    +44 203 833 4000</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Facsimile No.: (202) 689-2860</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:
    barry@dataknightsacuk.com</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telephone
    No.: (202) 689-2987</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:
    andy.tucker@nelsonmullins.com</FONT></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>If
    to the Company (or to the Purchaser after the Closing), to:</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>with
    copies to (which shall not constitute notice):</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OneMedNet
    Corporation</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6385
    Old Shady Oak Road</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rim&ocirc;n,
    P.C.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Suite
    250</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1990
    K Street NW, Suite 420</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eden
    Prairie, Minnesota 55344</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Washington,
    D.C. 20006</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:
    Paul Casey</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:
    Debbie Klis; Debra Vernon</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telephone
    No.: (808) 228-5998</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telephone:
    (202) 971-9494; (650) 292-5910</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">E-mail:
    paul.casey@onemednet.com</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">E-mail:
    debbie.klis@rimonlaw.com; debra.vernon@rimonlaw.com</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>If
to the Subject Party, to</I>: the address set forth below the Subject Party&rsquo;s name on the signature page to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
<U>Amendments and Waivers</U>. Any term of this Agreement may be amended and the observance of any term of this Agreement may be waived
(either generally or in a particular instance, and either retroactively or prospectively) only with the written consent of the Purchaser
and the Subject Party. No failure or delay by a party in exercising any right hereunder shall operate as a waiver thereof. No waivers
of or exceptions to any term, condition, or provision of this Agreement, in any one or more instances, shall be deemed to be or construed
as a further or continuing waiver of any such term, condition, or provision.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
<U>Authorization on Behalf of the Purchaser</U>. The parties acknowledge and agree that notwithstanding anything to the contrary contained
in this Agreement, any and all determinations, actions, or other authorizations under this Agreement on behalf of the Purchaser, including
enforcing the Purchaser&rsquo;s rights and remedies under this Agreement, or providing any waivers with respect to the provisions hereof,
shall solely be made, taken, and authorized by majority of the disinterested independent directors of the Purchaser&rsquo;s board of
directors. In the event that the Purchaser at any time does not have any disinterested directors, so long as the Subject Party has any
remaining obligations under this Agreement, the Purchaser will promptly appoint one in connection with this Agreement. Without limiting
the foregoing, in the event that an affiliate of a Subject Party serves as a director, officer, employee, or other authorized agent of
the Purchaser or any of its current or future affiliates, neither the Subject Party nor its affiliate shall have authority, express or
implied, to act or make any determination on behalf of the Purchaser or any of its current or future affiliates in connection with this
Agreement or any dispute or Action with respect hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
<U>Severability</U>. In case any provision in this Agreement shall be held invalid, illegal, or unenforceable in a jurisdiction, such
provision shall be modified or deleted, as to the jurisdiction involved, only to the extent necessary to render the same valid, legal,
and enforceable, and the validity, legality, and enforceability of the remaining provisions hereof shall not in any way be affected or
impaired thereby nor shall the validity, legality, or enforceability of such provision be affected thereby in any other jurisdiction.
Upon such determination that any term or other provision is invalid, illegal, or incapable of being enforced, the parties will substitute
for any invalid, illegal, or unenforceable provision a suitable and equitable provision that carries out, so far as may be valid, legal,
and enforceable, the intent and purpose of such invalid, illegal, or unenforceable provision.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)
<U>Specific Performance</U>. Each party acknowledges that its obligations under this Agreement are unique, recognizes and affirms that,
in the event of a breach of this Agreement, money damages will be inadequate and there will be no adequate remedy at law, and agrees
that irreparable damage would occur in the event that any of the provisions of this Agreement were not performed in accordance with their
specific terms or were otherwise breached. Accordingly, the adversely affected party or parties shall be entitled to an injunction or
restraining order to prevent breaches of this Agreement and to enforce specifically the terms and provisions hereof, without the requirement
to post any bond or other security, this being in addition to any other right or remedy available under this Agreement, at law or in
equity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)
<U>Entire Agreement</U>. This Agreement constitutes the full and entire understanding and agreement among the parties with respect to
the subject matter hereof, and any other written or oral agreement relating to the subject matter hereof existing between the parties
is expressly canceled; <U>provided</U>, that, for the avoidance of doubt, the foregoing shall not affect the rights and obligations of
the parties under the Merger Agreement or any Ancillary Document. Notwithstanding the foregoing, nothing in this Agreement shall limit
any of the rights or remedies or any of the obligations of the parties hereto under any other agreement between a Subject Party and the
Purchaser or any certificate or instrument delivered in connection with the Purchase, and nothing in any other agreement, certificate,
or instrument shall limit any of the rights or remedies or any of the obligations under this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)
<U>Further Assurances</U>. From time to time, at another party&rsquo;s request and without further consideration (but at the requesting
party&rsquo;s reasonable cost and expense), each party shall execute and deliver such additional documents and take all such further
action as may be reasonably necessary to consummate the transactions contemplated by this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)
<U>Counterparts; Facsimile.</U> This Agreement may also be executed and delivered by facsimile signature or by email in portable document
format in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the
same instrument.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>[Remainder
of Page Intentionally Left Blank; Signature Pages Follow]</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IN
WITNESS WHEREOF</B>, the parties have executed this Lock-Up Agreement as of the date first written above.</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I><U>The
    Purchaser:</U></I></B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DATA
    KNIGHTS ACQUISITION CORP.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>{Additional
Signatures on the Following Pages}</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I><U>The
    Subject Party:</U></I></B> </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
Baba One Irrevocable Trust dated March 26, 2021</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bradley
    Overby</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trustee</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Number of Shares and Type of Purchaser Common Stock:</I></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 28%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 22%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Purchaser
Common Stock:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Address for Notice:</I></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 8%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 42%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>with a copy (which will not constitute notice) to:</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 36%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telephone
    No.:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I><U>The Subject Party:</U></I></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The Soph One Irrevocable Trust dated March 26, 2021</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Bradley Overby<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Trustee<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Number of Shares and Type of Purchaser Common Stock:</I></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 28%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 22%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Purchaser
Common Stock:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Address for Notice:</I></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 8%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 42%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>with a copy (which will not constitute notice) to:</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telephone
    No.:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I><U>The
Subject Party:</U></I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jeffrey
Yu</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Number
    of Shares and Type of Purchaser Common Stock:</I></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 28%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 22%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Purchaser
    Common Stock:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Address
    for Notice:</I></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 44%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>with
    a copy (which will not constitute notice) to:</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 36%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telephone
    No.:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I><U>The
    Subject Party:</U></I></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
    Revocable Trust of Jerry M. Hiatt dated March 17, 1997, as amended</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Name:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Jerry M. Hiatt</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Title:</TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">Trustee</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Number of Shares and Type of Purchaser Common Stock:</I></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 28%">&nbsp;</TD>
    <TD STYLE="width: 22%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 50%">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Purchaser
Common Stock:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Address
    for Notice:</I></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 44%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>with
    a copy (which will not constitute notice) to:</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 36%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telephone
    No.:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I><U>The
Subject Party:</U></I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Paul
Casey</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Number
    of Shares and Type of Purchaser Common Stock:</I></B></FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 28%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 22%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Purchaser
Common Stock:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Address
    for Notice:</I></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 44%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>with
    a copy (which will not constitute notice) to:</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 36%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telephone
    No.:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I><U>The
Subject Party:</U></I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Thomas
Kosasa</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Number
    of Shares and Type of Purchaser Common Stock:</I></B></FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 28%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 22%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Purchaser
    Common Stock:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Address
    for Notice:</I></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 44%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>with
    a copy (which will not constitute notice) to:</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 36%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telephone
    No.:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I><U>The
    Subject Party:</U></I></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
    Revocable Trust of Jerry M. Hiatt dated March 17, 1997,</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>as
    amended, as Tenants in Common</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thomas Kosasa</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trustee</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jerry M. Hiatt</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trustee</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Number
    of Shares and Type of Purchaser Common Stock:</I></B></FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 28%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 22%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Purchaser
    Common Stock:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Address
    for Notice:</I></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 44%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>with
    a copy (which will not constitute notice) to:</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 36%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telephone
    No.:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I><U>The
Subject Party:</U></I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Erkan
Akyuz</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Number
    of Shares and Type of Purchaser Common Stock:</I></B></FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 28%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 22%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Purchaser
    Common Stock:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Address
    for Notice:</I></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 44%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>with
    a copy (which will not constitute notice) to:</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 36%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telephone
    No.:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I><U>The
Subject Party:</U></I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Lisa
Embree</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Number
    of Shares and Type of Purchaser Common Stock:</I></B></FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 28%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 22%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Purchaser
    Common Stock:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Address
    for Notice:</I></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 44%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>with
    a copy (which will not constitute notice) to:</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 36%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telephone
    No.:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>11
<FILENAME>ex10-4.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Exhibit
10.4</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>FORM
OF LOCK-UP AGREEMENT</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THIS
LOCK-UP AGREEMENT (this &ldquo;<B><I>Agreement</I></B>&rdquo;) is made and entered into as of the Closing Date (as defined in the Merger
Agreement, as defined below) by and between (i)&nbsp;<B>Data Knights Acquisition Corp.</B>, a Delaware corporation (including any successor
entity thereto, the &ldquo;<B><I>Purchaser</I></B>&rdquo;), and (ii)&nbsp;_________________________________________________ (the &ldquo;<B><I>Subject
Party</I></B>&rdquo;). Any capitalized term used but not defined in this Agreement will have the meaning ascribed to such term in the
Merger Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>,
on April 25, 2022, (i) the Purchaser, (ii) Data Knights Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of the
Purchaser (&ldquo;<B><I>Merger Sub</I></B>&rdquo;<I>)</I>, (iii) Data Knights, LLC, a Delaware limited liability company (the &ldquo;<B><I>Purchaser
Representative</I></B>&rdquo;), (iv) Paul Casey (the &ldquo;<B><I>Seller Representative</I></B>&rdquo;), and (v)&nbsp;<B>OneMedNet Corporation</B>,
a Delaware corporation (the &ldquo;<B><I>Company</I></B>&rdquo;) entered into that certain Agreement and Plan of Merger (as amended from
time to time in accordance with the terms thereof, the &ldquo;<B><I>Merger Agreement</I></B>&rdquo;), pursuant to which the parties thereto
intend to effect the merger of Merger Sub with and into the Company, with the Company continuing as the surviving entity (the &ldquo;<B><I>Merger</I></B>&rdquo;),
as a result of which all of the issued and outstanding capital stock of the Company immediately prior to the Effective Time shall be
exchanged for the Stockholder Merger Consideration, all upon the terms and subject to the conditions set forth in this Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>,
pursuant to the Merger Agreement, and in view of the valuable consideration to be received by the Subject Party thereunder, the parties
desire to enter into this Agreement, pursuant to which the Purchaser Common Stock received by the Subject Party in the Merger (all such
securities, together with any securities paid as dividends or distributions with respect to such securities or into which such securities
are exchanged or converted, the&nbsp;<I>&ldquo;<B>Restricted Securities</B>&rdquo;</I>) shall become subject to limitations on disposition
as set forth herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOW,
THEREFORE</B>, in consideration of the premises set forth above, which are incorporated into this Agreement as if fully set forth below,
and intending to be legally bound hereby, the parties hereby agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
<U>Lock-Up Provisions</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
The Subject Party hereby agrees not to, during the period commencing from the Closing and ending on the earliest of (x) six (6) months
after the date of the Closing and (y) the date after the Closing on which the Purchaser consummates a liquidation, merger, capital stock
exchange, reorganization, or other similar transaction with an unaffiliated third party that results in all of the Purchaser&rsquo;s
stockholders having the right to exchange their shares of the Purchaser Common Stock for cash, securities, or other property (the &ldquo;<B><I>Lock-Up
Period</I></B>&rdquo;): (i) lend, offer, pledge, hypothecate, encumber, donate, assign, sell, contract to sell, sell any option or contract
to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose
of, directly or indirectly, any Restricted Securities, (ii)&nbsp;enter into any swap or other arrangement that transfers to another,
in whole or in part, any of the economic consequences of ownership of the Restricted Securities, or (iii)&nbsp;publicly disclose the
intention to do any of the foregoing, whether any such transaction described in clauses (i), (ii), or (iii) above is to be settled by
delivery of Restricted Securities or other securities, in cash or otherwise (any of the foregoing described in clauses (i), (ii), or
(iii), a &ldquo;<B><I>Prohibited Transfer</I></B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
The foregoing shall not apply to the transfer of any or all of the Restricted Securities (I) to any Permitted Transferee or (II) pursuant
to a court order or settlement agreement related to the distribution of assets in connection with the dissolution of marriage or civil
union; provided, however, that in either of cases (I) or (II), it shall be a condition to such transfer that such transfer complies with
the Securities Act of 1933, as amended, and other applicable law, and that the transferee executes and delivers to the Purchaser an agreement
stating that the transferee is receiving and holding the Restricted Securities subject to the provisions of this Agreement applicable
to the Subject Party, and there shall be no further transfer of such Restricted Securities except in accordance with this Agreement.
As used in this Agreement, the term &ldquo;<B><I>Permitted Transferee</I></B>&rdquo; shall mean: (1) the members of the Subject Party&rsquo;s
immediate family (for purposes of this Agreement, &ldquo;immediate family&rdquo; shall mean with respect to any natural person, any of
the following: such person&rsquo;s spouse or domestic partner, the siblings of such person and his or her spouse or domestic partner,
and the direct descendants and ascendants (including adopted and step children and parents) of such person and his or her spouses or
domestic partners and siblings), (2) any trust for the direct or indirect benefit of the Subject Party or the immediate family of the
Subject Party, (3) if the Subject Party is a trust, to the trustor or beneficiary of such trust or to the estate of a beneficiary of
such trust, (4) in the case of an entity, officers, directors, general partners, limited partners, members, or stockholders of such entity
that receive such transfer as a distribution, or related investment funds or vehicles controlled or managed by such persons or their
respective affiliates, (5) to any affiliate of the Subject Party, and (6) any transferee whereby there is no change in beneficial ownership.
The Subject Party further agrees to execute such agreements as may be reasonably requested by the Purchaser that are consistent with
the foregoing or that are necessary to give further effect thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
If any Prohibited Transfer is made or attempted contrary to the provisions of this Agreement, such purported Prohibited Transfer shall
be null and void ab initio, and the Purchaser shall refuse to recognize any such purported transferee of the Restricted Securities as
one of its equity holders for any purpose, and shall refuse to record any such purported transfer of the Restricted Securities in the
books of the Company. In order to enforce this&nbsp;<U>Section 1</U>, the Purchaser may impose stop-transfer instructions with respect
to the Restricted Securities of the Subject Party (and Permitted Transferees and assigns thereof) until the end of the Lock-Up Period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
During the Lock-Up Period, each certificate evidencing any Restricted Securities shall be stamped or otherwise imprinted with a legend
in substantially the following form, in addition to any other applicable legends:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;THE
SECURITIES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO RESTRICTIONS ON TRANSFER SET FORTH IN A LOCK-UP AGREEMENT, DATED AS OF [&#9679;],
2022, BY AND AMONG THE ISSUER OF SUCH SECURITIES (THE &ldquo;ISSUER&rdquo;) AND THE ISSUER&rsquo;S SECURITY HOLDER NAMED THEREIN, AS
AMENDED. A COPY OF SUCH LOCK-UP AGREEMENT WILL BE FURNISHED WITHOUT CHARGE BY THE ISSUER TO THE HOLDER HEREOF UPON WRITTEN REQUEST.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
For the avoidance of any doubt, the Subject Party shall retain all of its rights as a stockholder of the Purchaser during the Lock-Up
Period, including the right to vote any Restricted Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
The foregoing notwithstanding, to the extent any Subject Party is granted a release or waiver from the restrictions contained in this
Section 1 prior to the expiration of the Lock-Up Period, then all Subject Parties shall be automatically granted a release or waiver
from the restrictions contained in this Section to the same extent, on substantially the same terms as and on a pro rata basis with,
the Subject Party to which such release or waiver is granted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
<U>Miscellaneous; No Third-Party Beneficiaries</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Binding Effect; Assignment</U>. This Agreement and all of the provisions herein shall be binding upon and inure to the benefit of
the parties hereto and their respective permitted successors and assigns. This Agreement and all rights and obligations of a party are
personal and may not be transferred or delegated at any time. Notwithstanding the foregoing, the Purchaser may freely assign any or all
of its rights under this Agreement, in whole or in part, to any successor entity (whether by merger, consolidation, equity sale, asset
sale, or otherwise) without obtaining the consent or approval of the Subject Party. This Agreement is intended for the benefit of the
parties hereto and their respective successors and permitted assigns and is not for the benefit of, nor may any provision herein be enforced
by, any other person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Third Parties</U>. Nothing contained in this Agreement or in any instrument or document executed by any party in connection with the
transactions contemplated hereby shall create any rights in, or be deemed to have been executed for the benefit of, any person or entity
that is not a party hereto or thereto or a successor or permitted assign of such a party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Governing Law; Jurisdiction</U>. This Agreement and any dispute or controversy arising out of or relating to this Agreement shall
be governed by and construed in accordance with the laws of the State of Delaware, without regard to the conflict of law principles thereof.
All Actions arising out of or relating to this Agreement shall be heard and determined exclusively in any state or federal court located
in Wilmington, Delaware (or in any appellate courts thereof) (the &ldquo;<B><I>Specified Courts</I></B>&rdquo;). Each party hereto hereby&nbsp;(i)
submits to the exclusive jurisdiction of any Specified Court for the purpose of any Action arising out of or relating to this Agreement
brought by any party hereto and (ii)&nbsp;irrevocably waives, and agrees not to assert by way of motion, defense, or otherwise, in any
such Action, any claim that it is not subject personally to the jurisdiction of the above-named courts, that its property is exempt or
immune from attachment or execution, that the Action is brought in an inconvenient forum, that the venue of the Action is improper, or
that this Agreement or the transactions contemplated hereby may not be enforced in or by any Specified Court. Each party agrees that
a final judgment in any Action shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other
manner provided by Law. Each party irrevocably consents to the service of the summons and complaint and any other process in any other
action or proceeding relating to the transactions contemplated by this Agreement, on behalf of itself, or its property, by personal delivery
of copies of such process to such party at the applicable address set forth in&nbsp;<U>Section 2(f)</U>. Nothing in this&nbsp;Section&nbsp;shall
affect the right of any party to serve legal process in any other manner permitted by applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<U>WAIVER OF JURY TRIAL</U>. EACH OF THE PARTIES HERETO HEREBY WAIVES TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW ANY RIGHT IT
MAY HAVE TO A TRIAL BY JURY WITH RESPECT TO ANY ACTION DIRECTLY OR INDIRECTLY ARISING OUT OF, UNDER OR IN CONNECTION WITH THIS AGREEMENT
OR THE TRANSACTIONS CONTEMPLATED HEREBY. EACH PARTY HERETO (i) CERTIFIES THAT NO REPRESENTATIVE OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY
OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF ANY ACTION, SEEK TO ENFORCE THAT FOREGOING WAIVER AND (ii) ACKNOWLEDGES
THAT IT AND THE OTHER PARTIES HERETO HAVE BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS
IN THIS&nbsp;SECTION.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
<U>Interpretation</U>. The titles and subtitles used in this Agreement are for convenience only and are not to be considered in construing
or interpreting this Agreement. In this Agreement, unless the context otherwise requires: (i) any pronoun used in this Agreement shall
include the corresponding masculine, feminine, or neuter forms, and the singular form of nouns, pronouns, and verbs shall include the
plural and vice versa; (ii) &ldquo;including&rdquo; (and with correlative meaning &ldquo;include&rdquo;) means including without limiting
the generality of any description preceding or succeeding such term and shall be deemed in each case to be followed by the words &ldquo;without
limitation&rdquo;; (iii) the words &ldquo;herein,&rdquo; &ldquo;hereto,&rdquo; and &ldquo;hereby&rdquo; and other words of similar import
in this Agreement shall be deemed in each case to refer to this Agreement as a whole and not to any particular section or other subdivision
of this Agreement; and (iv) the term &ldquo;or&rdquo; means &ldquo;and/or&rdquo;. The parties have participated jointly in the negotiation
and drafting of this Agreement. Consequently, in the event an ambiguity or question of intent or interpretation arises, this Agreement
shall be construed as if drafted jointly by the parties hereto, and no presumption or burden of proof shall arise favoring or disfavoring
any party by virtue of the authorship of any provision of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
<U>Notices</U>. All notices, consents, waivers, and other communications hereunder shall be in writing and shall be deemed to have been
duly given when delivered (i) in person, (ii) by facsimile or other electronic means, with affirmative confirmation of receipt, (iii)
one Business Day after being sent, if sent by reputable, nationally recognized overnight courier service, or (iv) three (3) Business
Days after being mailed, if sent by registered or certified mail, pre-paid and return receipt requested, in each case to the applicable
party at the following addresses (or at such other address for a party as shall be specified by like notice):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>If
    to the Purchaser before the Closing, to:</I></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Data
    Knights Acquisition Corp.<BR>
    Unit G6, Frome Business Park,</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manor
    Road, Frome, BA11 4FN,</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">United
    Kingdom</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tel:
    +44 203 833 4000</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:
    barry@dataknightsacuk.com</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>If
    to the Company (or to the Purchaser after the Closing), to:</I></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OneMedNet
    Corporation</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6385
    Old Shady Oak Road</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Suite
    250</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eden
    Prairie, Minnesota 55344</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:
    Paul Casey</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telephone
    No.: (808) 228-5998</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">E-mail:
    paul.casey@onemednet.com</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>with
    copies to (which shall not constitute notice):</I></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nelson
    Mullins Riley &amp; Scarborough LLP<BR>
    101 Constitution Avenue, NW, Suite 900<BR>
    Washington, D.C. 20001<BR>
    Attn: Andrew M. Tucker, Esq.<BR>
    Facsimile No.: (202) 689-2860<BR>
    Telephone No.: (202) 689-2987<BR>
    Email: andy.tucker@nelsonmullins.com</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>with
    copies to (which shall not constitute notice):</I></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rim&ocirc;n,
    P.C.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1990
    K Street NW, Suite 420</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Washington,
    D.C. 20006</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:
    Debbie Klis; Debra Vernon</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telephone:
    (202) 971-9494; (650) 292-5910</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">E-mail:
    debbie.klis@rimonlaw.com; debra.vernon@rimonlaw.com</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>If
    to the Subject Party, to</I>: the address set forth below the Subject Party&rsquo;s name on the signature page to this Agreement.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
<U>Amendments and Waivers</U>. Any term of this Agreement may be amended and the observance of any term of this Agreement may be waived
(either generally or in a particular instance, and either retroactively or prospectively) only with the written consent of the Purchaser
and the Subject Party. No failure or delay by a party in exercising any right hereunder shall operate as a waiver thereof. No waivers
of or exceptions to any term, condition, or provision of this Agreement, in any one or more instances, shall be deemed to be or construed
as a further or continuing waiver of any such term, condition, or provision.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
<U>Authorization on Behalf of the Purchaser</U>. The parties acknowledge and agree that notwithstanding anything to the contrary contained
in this Agreement, any and all determinations, actions, or other authorizations under this Agreement on behalf of the Purchaser, including
enforcing the Purchaser&rsquo;s rights and remedies under this Agreement, or providing any waivers with respect to the provisions hereof,
shall solely be made, taken, and authorized by majority of the disinterested independent directors of the Purchaser&rsquo;s board of
directors. In the event that the Purchaser at any time does not have any disinterested directors, so long as the Subject Party has any
remaining obligations under this Agreement, the Purchaser will promptly appoint one in connection with this Agreement. Without limiting
the foregoing, in the event that an affiliate of a Subject Party serves as a director, officer, employee, or other authorized agent of
the Purchaser or any of its current or future affiliates, neither the Subject Party nor its affiliate shall have authority, express or
implied, to act or make any determination on behalf of the Purchaser or any of its current or future affiliates in connection with this
Agreement or any dispute or Action with respect hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
<U>Severability</U>. In case any provision in this Agreement shall be held invalid, illegal, or unenforceable in a jurisdiction, such
provision shall be modified or deleted, as to the jurisdiction involved, only to the extent necessary to render the same valid, legal,
and enforceable, and the validity, legality, and enforceability of the remaining provisions hereof shall not in any way be affected or
impaired thereby nor shall the validity, legality, or enforceability of such provision be affected thereby in any other jurisdiction.
Upon such determination that any term or other provision is invalid, illegal, or incapable of being enforced, the parties will substitute
for any invalid, illegal, or unenforceable provision a suitable and equitable provision that carries out, so far as may be valid, legal,
and enforceable, the intent and purpose of such invalid, illegal, or unenforceable provision.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)
<U>Specific Performance</U>. Each party acknowledges that its obligations under this Agreement are unique, recognizes and affirms that,
in the event of a breach of this Agreement, money damages will be inadequate and there will be no adequate remedy at law, and agrees
that irreparable damage would occur in the event that any of the provisions of this Agreement were not performed in accordance with their
specific terms or were otherwise breached. Accordingly, the adversely affected party or parties shall be entitled to an injunction or
restraining order to prevent breaches of this Agreement and to enforce specifically the terms and provisions hereof, without the requirement
to post any bond or other security, this being in addition to any other right or remedy available under this Agreement, at law or in
equity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)
<U>Entire Agreement</U>. This Agreement constitutes the full and entire understanding and agreement among the parties with respect to
the subject matter hereof, and any other written or oral agreement relating to the subject matter hereof existing between the parties
is expressly canceled;&nbsp;<U>provided</U>, that, for the avoidance of doubt, the foregoing shall not affect the rights and obligations
of the parties under the Merger Agreement or any Ancillary Document. Notwithstanding the foregoing, nothing in this Agreement shall limit
any of the rights or remedies or any of the obligations of the parties hereto under any other agreement between a Subject Party and the
Purchaser or any certificate or instrument delivered in connection with the Purchase, and nothing in any other agreement, certificate,
or instrument shall limit any of the rights or remedies or any of the obligations under this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)
<U>Further Assurances</U>. From time to time, at another party&rsquo;s request and without further consideration (but at the requesting
party&rsquo;s reasonable cost and expense), each party shall execute and deliver such additional documents and take all such further
action as may be reasonably necessary to consummate the transactions contemplated by this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)
<U>Counterparts; Facsimile.</U>&nbsp;This Agreement may also be executed and delivered by facsimile signature or by email in portable
document format in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one
and the same instrument.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>[Remainder
of Page Intentionally Left Blank; Signature Pages Follow]</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IN
WITNESS WHEREOF</B>, the parties have executed this Lock-Up Agreement as of the date first written above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I><U>The Purchaser:</U></I></B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 46%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DATA KNIGHTS ACQUISITION CORP.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>{Additional
Signatures on the Following Pages}</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I><U>The
    Subject Party:</U></I></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The Baba
    One Irrevocable Trust dated March 26, 2021</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Bradley
    Overby</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: Trustree</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Number
    of Shares and Type of Purchaser Common Stock:</I></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Purchaser Common Stock:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Address
    for Notice:</I></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 43%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>with a copy
    (which will not constitute notice) to:</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 30%; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 59%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telephone No.:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I><U>The
    Subject Party:</U></I></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The Soph
    One Irrevocable Trust dated March 26, 2021</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Bradley
    Overby</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: Trustree</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Number
    of Shares and Type of Purchaser Common Stock:</I></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Purchaser Common Stock:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Address
    for Notice:</I></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 43%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>with a copy
    (which will not constitute notice) to:</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 30%; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 59%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telephone No.:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I><U>The
Subject Party:</U></I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jeffrey
Yu</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Number
    of Shares and Type of Purchaser Common Stock:</I></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Purchaser Common Stock:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Address
    for Notice:</I></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 43%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>with a copy
    (which will not constitute notice) to:</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 30%; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 59%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telephone No.:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I><U>The
    Subject Party:</U></I></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The Revocable
    Trust of Jerry M. Hiatt dated March 17, 1997, as amended</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Jerry
    M. Hiatt</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: Trustee</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Number
    of Shares and Type of Purchaser Common Stock:</I></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Purchaser Common Stock:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Address
    for Notice:</I></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 43%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>with a copy
    (which will not constitute notice) to:</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 30%; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 59%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telephone No.:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I><U>The
Subject Party:</U></I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Paul
Casey</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 41%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Number
    of Shares and Type of Purchaser Common Stock:</I></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Purchaser Common Stock:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Address
    for Notice:</I></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 43%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>with a copy
    (which will not constitute notice) to:</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 30%; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 59%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telephone No.:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I><U>The
Subject Party:</U></I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Thomas
Kosasa</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 41%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Number
    of Shares and Type of Purchaser Common Stock:</I></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Purchaser Common Stock:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Address
    for Notice:</I></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 43%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>with a copy
    (which will not constitute notice) to:</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 30%; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 59%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telephone No.:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I><U>The
    Subject Party:</U></I></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The Revocable
    Trust of Jerry M. Hiatt dated March 17, 1997,</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>as amended,
    as Tenants in Common</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Thomas
    Kosasa</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: Trustee</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 47%; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Jerry
    M. Hiatt</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: Trustee</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Number
    of Shares and Type of Purchaser Common Stock:</I></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Purchaser Common Stock:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Address
    for Notice:</I></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 43%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>with a copy
    (which will not constitute notice) to:</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 30%; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 59%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telephone No.:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I><U>The
Subject Party:</U></I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Erkan
Akyuz</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 41%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Number
    of Shares and Type of Purchaser Common Stock:</I></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Purchaser Common Stock:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Address
    for Notice:</I></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 43%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>with a copy
    (which will not constitute notice) to:</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 30%; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 59%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telephone No.:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I><U>The
Subject Party:</U></I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Lisa
Embree</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 41%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Number
    of Shares and Type of Purchaser Common Stock:</I></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Purchaser Common Stock:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Address
    for Notice:</I></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 43%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>with a copy
    (which will not constitute notice) to:</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 30%; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 59%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telephone No.:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 15; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>12
<FILENAME>ex10-5.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><BR>
Exhibit 10.5</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
6, 2021</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Data
Knights Acquisition Corp.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trident
Court, 1 Oakcroft Road&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chessington,
Surrey KT9 1BD&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">United
Kingdom</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Re:
Initial Public Offering</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladies
and Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
letter (this &ldquo;Letter Agreement&rdquo;) is being delivered to you in accordance with the Underwriting Agreement (the &ldquo;Underwriting
Agreement&rdquo;) to be entered into by and between Data Knights Acquisition Corp., a Delaware corporation (the &ldquo;Company&rdquo;)
and Kingswood Capital Markets, division of Benchmark Investments, Inc., as representative of the underwriters (each, an &ldquo;Underwriter&rdquo;
and collectively, the &ldquo;Underwriters&rdquo;), relating to an underwritten initial public offering (the &ldquo;Public Offering&rdquo;),
of up to 11,500,000 of the Company&rsquo;s units (including up to 1,500,000 units that may be purchased to cover over-allotments, if
any) (the &ldquo;Units&rdquo;), each comprised of one share of the Company&rsquo;s Class A common stock, par value $0.0001 per share
(the &ldquo;Common Stock&rdquo;), and one redeemable warrant. Each redeemable warrant (each, a &ldquo;Warrant&rdquo;) entitles the holder
thereof to purchase one share of Common Stock at a price of $11.50 per share, subject to adjustment. The Units shall be sold in the Public
Offering pursuant to a registration statement on Form S-1 and prospectus (the &ldquo;Prospectus&rdquo;) filed by the Company with the
Securities and Exchange Commission (the &ldquo;Commission&rdquo;) and the Units have been approved to be listed on the Nasdaq Capital
Market. Certain capitalized terms used herein are defined in paragraph 11 hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to induce the Company and the Underwriters to enter into the Underwriting Agreement and to proceed with the Public Offering and
for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Data Knights, LLC (the &ldquo;Sponsor&rdquo;)
and each of the undersigned individuals, each of whom is a member of the Company&rsquo;s board of directors and/or management team (each,
an &ldquo;Insider&rdquo; and collectively, the &ldquo;Insiders&rdquo;), hereby agrees with the Company as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
The Sponsor and each Insider agrees that if the Company seeks stockholder approval of a proposed Business Combination, then in connection
with such proposed Business Combination, it, he or she shall (i) vote any shares of Capital Stock owned by it, him or her in favor of
any proposed Business Combination and (ii) not redeem any shares of Common Stock owned by it, him or her in connection with such stockholder
approval. If the Company engages in a tender offer in connection with any proposed Business Combination, each Insider agrees that it,
he or she will not seek to sell its, his or her shares of Common Stock to the Company in connection with such tender offer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
The Sponsor and each Insider hereby agrees that in the event that the Company fails to consummate a Business Combination within 12 months
from the closing of the Public Offering (or up to 18 months from the closing of the Public Offering if the Company extends the period
of time to consummate a Business Combination, as described in more detail in the Prospectus) or such later period approved by the Company&rsquo;s
stockholders in accordance with the Company&rsquo;s amended and restated certificate of incorporation, the Sponsor and each Insider shall
take all reasonable steps to cause the Company to (i) cease all operations except for the purpose of winding up, (ii) as promptly as
reasonably possible but not more than 10 business days thereafter, subject to lawfully available funds therefor, redeem 100% of the Common
Stock sold as part of the Units in the Public Offering (the &ldquo;Offering Shares&rdquo;), at a per-share price, payable in cash, equal
to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account and not
previously released to the Company to pay its taxes (less up to $100,000 of interest to pay dissolution expenses), divided by the number
of then outstanding Offering Shares, which redemption will completely extinguish all Public Stockholders&rsquo; rights as stockholders
of the Company (including the right to receive further liquidation distributions, if any), subject to applicable law, and (iii) as promptly
as reasonably possible following such redemption, subject to the approval of the Company&rsquo;s remaining stockholders and the Company&rsquo;s
board of directors, dissolve and liquidate, subject in each case to the Company&rsquo;s obligations under Delaware law to provide for
claims of creditors and other requirements of applicable law. The Sponsor and each Insider agree not to propose any amendment to the
Company&rsquo;s amended and restated certificate of incorporation that would modify (i) the substance or timing of the Company&rsquo;s
obligation to redeem 100% of the Offering Shares if the Company does not complete a Business Combination within 12 months from the closing
of the Public Offering (or up to 18 months from the closing of the Public Offering if the Company extends the period of time to consummate
a Business Combination, as described in more detail in the Prospectus) or (ii) the other provisions relating to stockholders&rsquo; rights
or pre-initial business combination activities, unless the Company provides its Public Stockholders with the opportunity to redeem their
Offering Shares upon approval of any such amendment at a per-share price, payable in cash, equal to the aggregate amount then on deposit
in the Trust Account, including interest (which interest shall be net of amounts released for payment of taxes) divided by the number
of then outstanding Offering Shares. The Sponsor and each Insider agree to waive its redemption rights with respect to shares of Capital
Stock owned by it in connection with a stockholder vote to approve an amendment to the Company&rsquo;s amended and restated certificate
of incorporation (A) to modify the substance or timing of the Company&rsquo;s obligation to redeem 100% of the Offering Shares if the
Company does not complete a Business Combination within 12 months from the closing of the Public Offering (or up to 18 months from the
closing of the Public Offering if the Company extends the period of time to consummate a Business Combination, as described in more detail
in the Prospectus) or (B) with respect to any other provision relating to stockholders&rsquo; rights or pre-initial business combination
activity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
of the Sponsor and each Insider acknowledges that it, he or she has no right, title, interest or claim of any kind in or to any monies
held in the Trust Account or any other asset of the Company as a result of any liquidation of the Company with respect to the Founder
Shares held by it, him or her. The Sponsor and each Insider hereby further waives, with respect to any shares of Common Stock held by
it, him or her, if any, any redemption rights it, he or she may have in connection with the consummation of a Business Combination, including,
without limitation, any such rights available in the context of a stockholder vote to approve such Business Combination or in the context
of a tender offer made by the Company to purchase shares of Common Stock (although the Sponsor, the Insiders and their respective affiliates
shall be entitled to redemption and liquidation rights with respect to any Offering Shares it or they hold if the Company fails to consummate
a Business Combination within 12 months from the date of the closing of the Public Offering (or up to 18 months from the closing of the
Public Offering if the Company extends the period of time to consummate a Business Combination, as described in more detail in the Prospectus)).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
During the period commencing on the effective date of the Underwriting Agreement and ending 180 days after such date, the Sponsor and
each Insider shall not, without the prior written consent of the Representative, (i) sell, offer to sell, contract or agree to sell,
hypothecate, pledge, grant any option to purchase or otherwise dispose of or agree to dispose of, directly or indirectly, or establish
or increase a put equivalent position or liquidate or decrease a call equivalent position within the meaning of Section 16 of the Securities
Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), and the rules and regulations of the Commission promulgated thereunder,
with respect to any Units, shares of Common Stock, Warrants or any securities convertible into, or exercisable, or exchangeable for,
shares of Common Stock owned by it, him or her, (ii) enter into any swap or other arrangement that transfers to another, in whole or
in part, any of the economic consequences of ownership of any Units, shares of Common Stock, Warrants or any securities convertible into,
or exercisable, or exchangeable for, shares of Common Stock owned by it, him or her, whether any such transaction is to be settled by
delivery of such securities, in cash or otherwise, or (iii) publicly announce any intention to effect any transaction specified in clause
(i) or (ii). Each of the Insiders and the Sponsor acknowledges and agrees that, prior to the effective date of any release or waiver,
of the restrictions set forth in this paragraph 3 or paragraph 7 below, the Company shall announce the impending release or waiver by
press release through a major news service at least two business days before the effective date of the release or waiver. Any release
or waiver granted shall only be effective two business days after the publication date of such press release. The provisions of this
paragraph will not apply if the release or waiver is effected solely to permit a transfer not for consideration and the transferee has
agreed in writing to be bound by the same terms described in this Letter Agreement to the extent and for the duration that such terms
remain in effect at the time of the transfer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
In the event of the liquidation of the Trust Account, the Sponsor (which for purposes of clarification shall not extend to any other
stockholders, members or managers of the Sponsor) agrees to indemnify and hold harmless the Company against any and all loss, liability,
claim, damage and expense whatsoever (including, but not limited to, any and all legal or other expenses reasonably incurred in investigating,
preparing or defending against any litigation, whether pending or threatened, or any claim whatsoever) to which the Company may become
subject as a result of any claim by (i) any third party (other than the Company&rsquo;s independent accountants) for services rendered
or products sold to the Company or (ii) a prospective target business with which the Company has entered into a letter of intent, confidentiality
or other similar agreement for a Business Combination (a &ldquo;Target&rdquo;); provided, however, that such indemnification of the Company
by the Sponsor shall apply only to the extent necessary to ensure that such claims by a third party for services rendered (other than
the Company&rsquo;s independent public accountants) or products sold to the Company or a Target do not reduce the amount of funds in
the Trust Account to below (i) $10.20 per share of the Offering Shares or (ii) such lesser amount per share of the Offering Shares held
in the Trust Account due to reductions in the value of the trust assets as of the date of the liquidation of the Trust Account, in each
case, net of the amount of interest earned on the property in the Trust Account which may be withdrawn to pay taxes, except as to any
claims by a third party (including a Target) who executed a waiver of any and all rights to seek access to the Trust Account and except
as to any claims under the Company&rsquo;s indemnity of the Underwriters against certain liabilities, including liabilities under the
Securities Act. In the event that any such executed waiver is deemed to be unenforceable against such third party, the Sponsor shall
not be responsible to the extent of any liability for such third party claims. The Sponsor shall have the right to defend against any
such claim with counsel of its choice reasonably satisfactory to the Company if, within 15 days following written receipt of notice of
the claim to the Sponsor, the Sponsor notifies the Company in writing that it shall undertake such defense.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
To the extent that the Underwriters do not exercise their over-allotment option to purchase up to an additional 1,500,000 Units within
45 days from the date of the Prospectus (and as further described in the Prospectus), the Sponsor agrees to forfeit, at no cost, a number
of Founder Shares in the aggregate equal to the product of 375,000 multiplied by a fraction, (i) the numerator of which is 1,500,000
minus the number of Units purchased by the Underwriters upon the exercise of their over-allotment option, and (ii) the denominator of
which is 1,500,000. The forfeiture will be adjusted to the extent that the over-allotment option is not exercised in full by the Underwriters
so that the Initial Stockholders will own an aggregate of 20.0% of the Company&rsquo;s issued and outstanding shares of Common Stock
after the Public Offering (excluding the Private Placement Shares).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.
The Sponsor and each Insider hereby agrees and acknowledges that: (i) the Underwriters and the Company would be irreparably injured in
the event of a breach by such Sponsor or an Insider of its, his or her obligations under paragraphs 1, 2, 3, 4, 5, 6, 7(a), 7(b), and
9 of this Letter Agreement (ii) monetary damages may not be an adequate remedy for such breach and (iii) the non-breaching party shall
be entitled to injunctive relief, in addition to any other remedy that such party may have in law or in equity, in the event of such
breach.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.
(a) The Sponsor and each Insider agrees that it or he shall not Transfer any Founder Shares (or shares of Common Stock issuable upon
conversion thereof) until the earlier of (A) six months after the date of the Company&rsquo;s initial Business Combination or (B) subsequent
to the Company&rsquo;s initial Business Combination, (x)&nbsp;if the reported last sale price of the Common Stock equals or exceeds $12.00
per share (as adjusted for stock splits, stock dividends, right issuances, reorganizations, recapitalizations and the like) for any 20
trading days within any 30-trading day period commencing at least 150&nbsp;days after the Company&rsquo;s initial Business Combination,
or (y)&nbsp;the date on which the Company completes a liquidation, merger, capital stock exchange, reorganization or other similar transaction
that results in all of our stockholders having the right to exchange their shares of common stock for cash, securities or other property
(the &ldquo;Founder Shares Lock-up Period&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(b)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Sponsor and each Insider agrees that it, he or she
shall not Transfer any Private Placement Units, the Private Placement Shares, the Private Placement Warrants or shares of Common Stock
issued or issuable upon the exercise of the Private Placement Warrants, until 30 days after the completion of the initial Business Combination
(the &ldquo;Private Placement Units Lock-up Period&rdquo;, together with the Founder Shares Lock-up Period, the &ldquo;Lock-up Periods&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(c)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding the provisions set forth in paragraphs
7(a) and 7(b), Transfers of the Founder Shares, Private Placement Units, Private Placement Shares, Private Placement Warrants and shares
of Common Stock issued or issuable upon the exercise or conversion of the Private Placement Warrants or the Founder Shares that are held
by the Sponsor, any Insider or any of their permitted transferees (that have complied with this paragraph 7(c)), are permitted (i) to
the Company&rsquo;s officers or directors, any affiliate or family member of any of the Company&rsquo;s officers or directors or any
members of the Sponsor or any affiliates of the Sponsor; (b) in the case of an individual, by gift to a member of such individual&rsquo;s
immediate family or to a trust, the beneficiary of which is a member of such individual&rsquo;s immediate family, an affiliate of such
individual or to a charitable organization; (c) in the case of an individual, by virtue of laws of descent and distribution upon death
of such individual; (d) in the case of an individual, pursuant to a qualified domestic relations order; (e) by private sales or transfers
made in connection with the consummation of an initial Business Combination at prices no greater than the price at which the securities
were originally purchased; (f) in the event of the Company&rsquo;s liquidation prior to the completion of an initial Business Combination;
(g) by virtue of the laws of the State of Delaware or the Sponsor&rsquo;s limited liability company agreement upon dissolution of the
Sponsor; or (h) in the event of the Company&rsquo;s liquidation, merger, capital stock exchange, reorganization or other similar transaction
which results in all of the Company&rsquo;s stockholders having the right to exchange their shares of Common Stock for cash, securities
or other property subsequent to the Company&rsquo;s completion of an initial Business Combination; provided, however, that in the case
of clauses (a) through (e) or (g), these permitted transferees must enter into a written agreement with the Company agreeing to be bound
by the transfer restrictions herein and the other restrictions contained in this Agreement (including provisions relating to voting,
the Trust Account and liquidating distributions).&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.
Each of the Sponsor and the Insiders represents and warrants that it, he or she has never been suspended or expelled from membership
in any securities or commodities exchange or association or had a securities or commodities license or registration denied, suspended
or revoked. Each Insider&rsquo;s biographical information furnished to the Company (including any such information included in the Prospectus)
is true and accurate in all respects and does not omit any material information with respect to the Insider&rsquo;s background. The Sponsor
and each Insider&rsquo;s questionnaire furnished to the Company is true and accurate in all respects. The Sponsor and each Insider represents
and warrants that: it, he or she is not subject to or a respondent in any legal action for, any injunction, cease-and-desist order or
order or stipulation to desist or refrain from any act or practice relating to the offering of securities in any jurisdiction; it, he
or she has never been convicted of, or pleaded guilty to, any crime (i) involving fraud, (ii) relating to any financial transaction or
handling of funds of another person, or (iii) pertaining to any dealings in any securities and it, he or she is not currently a defendant
in any such criminal proceeding. The Company represents and warrants that, to its knowledge, (i) none of its advisors has been suspended
or expelled from membership in any securities or commodities exchange or association or had a securities or commodities license or registration
denied, suspended or revoked, (ii) each advisor&rsquo;s biographical information furnished to the Company (including any such information
included in the Prospectus) is true and accurate in all respects and does not omit any material information with respect to such advisor&rsquo;s
background and each advisor&rsquo;s questionnaire furnished to the Company is true and accurate in all respects, (iii) none of its advisors
is subject to or a respondent in any legal action for, any injunction, cease-and-desist order or order or stipulation to desist or refrain
from any act or practice relating to the offering of securities in any jurisdiction; and (iii) none of its advisors has been convicted
of, or pleaded guilty to, any crime (x) involving fraud, (y) relating to any financial transaction or handling of funds of another person,
or (z) pertaining to any dealings in any securities and none of its advisors is currently a defendant in any such criminal proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.
(a) Except as disclosed in the Prospectus and cash or other compensation to the Company&rsquo;s officers or advisors to be engaged subsequent
to the consummation of the Public Offering (which will be disclosed in the Company&rsquo;s other filings with the Securities and Exchange
Commission), neither the Sponsor nor any individual who is an officer, director or advisor of the Company as of the date hereof nor any
affiliate thereof shall receive from the Company any finder&rsquo;s fee, reimbursement, consulting fee, monies in respect of any repayment
of a loan or other compensation prior to, or in connection with any services rendered in order to effectuate the consummation of the
Company&rsquo;s initial Business Combination (regardless of the type of transaction that it is), other than the following, none of which
will be made from the proceeds held in the Trust Account prior to the completion of the initial Business Combination: repayment of a
loan and advances up to an aggregate of $300,000 made to the Company by Data Knights, LLC; reimbursement for any out-of-pocket expenses
related to identifying, investigating and consummating an initial Business Combination; payment to an affiliate of the Sponsor of $10,000
per month, for up to 18 months, for office space, utilities and secretarial and administrative support; and repayment of non-interest
bearing loans, if any, and on such terms as to be determined by the Company from time to time, made by the Sponsor or any of the Company&rsquo;s
officers or directors to finance transaction costs in connection with an intended initial Business Combination, provided, that, if the
Company does not consummate an initial Business Combination, a portion of the working capital held outside the Trust Account may be used
by the Company to repay such loaned amounts so long as no proceeds from the Trust Account are used for such repayment. Up to $1,500,000
of such loans may be convertible into units, at a price of $10.00 per unit at the option of the lender, upon consummation of the initial
Business Combination. The units would be identical to the Private Placement Units. Additionally, up to $2,000,000 (or $2,300,000 if the
underwriters&rsquo; over-allotment option is exercised in full) may be loaned by the Sponsor to fund up to two three-month extensions
on the period of time in which the Company has to consummate a Business Combination. Such loans may be convertible into units at a price
of $10.00 per unit, which units would be identical to the Private Placement Units.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.
Each of the Sponsor and each Insider has full right and power, without violating any agreement to which it is bound (including, without
limitation, any non-competition or non-solicitation agreement with any employer or former employer), to enter into this Letter Agreement
and, as applicable, to serve as an officer and/or a director on the board of directors of the Company and hereby consents to being named
in the Prospectus as an officer and/or a director of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.
As used herein, (i) &ldquo;Business Combination&rdquo; shall mean a merger, capital stock exchange, asset acquisition, stock purchase,
reorganization or similar business combination, involving the Company and one or more businesses; (ii) &ldquo;Capital Stock&rdquo; shall
mean, collectively, the Common Stock and the Founder Shares; (iii) &ldquo;Founder Shares&rdquo; shall mean the 2,875,000 shares of the
Company&rsquo;s Class B common stock, par value $0.0001 per share, initially held by the Sponsor (up to 375,000 Shares of which are subject
to complete or partial forfeiture by the Sponsor if the over-allotment option is not exercised in full by the Underwriters); (iv) &ldquo;Initial
Stockholders&rdquo; shall mean the Sponsor and any other holder of Founder Shares immediately prior to the Public Offering; (v) &ldquo;Private
Placement Shares&rdquo; shall mean the 525,275 shares of Common Stock comprising the Private Placement Units (or up to 585,275 shares
of Common Stock if the over-allotment option is exercised in full); (vi) &ldquo;Private Placement Units&rdquo; shall mean the 525,275
units to be purchased by the Sponsor, or up to 585,275 units if the over-allotment option is exercised in full, each comprised of one
share of Common Stock and one warrant to purchase one share of Common Stock, that the Sponsor has agreed to purchase for an aggregate
purchase price of $5,252,750 (or up to $5,852,750 if the over-allotment option is exercised in full), or purchase price of $10.00 per
Private Placement Unit, in a private placement that shall occur simultaneously with the consummation of the Public Offering; (vii) &ldquo;Private
Placement Warrants&rdquo; shall mean the Warrants to purchase up to 525,275 shares of Common Stock (or up to 585,275 shares of Common
Stock if the over-allotment option is exercised in full) comprising the Private Placement Units; (viii) &ldquo;Public Stockholders&rdquo;
shall mean the holders of securities issued in the Public Offering; (ix) &ldquo;Trust Account&rdquo; shall mean the trust fund into which
a portion of the net proceeds of the Public Offering and the sale of the Private Placement Units shall be deposited; and (x) &ldquo;Transfer&rdquo;
shall mean the (a) sale or assignment of, offer to sell, contract or agreement to sell, hypothecate, pledge, grant of any option to purchase
or otherwise dispose of or agreement to dispose of, directly or indirectly, or establishment or increase of a put equivalent position
or liquidation with respect to or decrease of a call equivalent position within the meaning of Section 16 of the Securities Exchange
Act of 1934, as amended, and the rules and regulations of the Commission promulgated thereunder with respect to, any security, (b) entry
into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of any
security, whether any such transaction is to be settled by delivery of such securities, in cash or otherwise, or (c) public announcement
of any intention to effect any transaction specified in clause (a) or (b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.
This Letter Agreement constitutes the entire agreement and understanding of the parties hereto in respect of the subject matter hereof
and supersedes all prior understandings, agreements, or representations by or among the parties hereto, written or oral, to the extent
they relate in any way to the subject matter hereof or the transactions contemplated hereby. This Letter Agreement may not be changed,
amended, modified or waived (other than to correct a typographical error) as to any particular provision, except by a written instrument
executed by all parties hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.
No party hereto may assign either this Letter Agreement or any of its rights, interests, or obligations hereunder without the prior written
consent of the other parties. Any purported assignment in violation of this paragraph shall be void and ineffectual and shall not operate
to transfer or assign any interest or title to the purported assignee. This Letter Agreement shall be binding on the Sponsor and each
Insider and their respective successors, heirs and assigns and permitted transferees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.
Nothing in this Letter Agreement shall be construed to confer upon, or give to, any person or corporation other than the parties hereto
any right, remedy or claim under or by reason of this Letter Agreement or of any covenant, condition, stipulation, promise or agreement
hereof. All covenants, conditions, stipulations, promises and agreements contained in this Letter Agreement shall be for the sole and
exclusive benefit of the parties hereto and their successors, heirs, personal representatives and assigns and permitted transferees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.
This Letter Agreement may be executed in any number of original or facsimile counterparts and each of such counterparts shall for all
purposes be deemed to be an original, and all such counterparts shall together constitute but one and the same instrument.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.
This Letter Agreement shall be deemed severable, and the invalidity or unenforceability of any term or provision hereof shall not affect
the validity or enforceability of this Letter Agreement or of any other term or provision hereof. Furthermore, in lieu of any such invalid
or unenforceable term or provision, the parties hereto intend that there shall be added as a part of this Letter Agreement a provision
as similar in terms to such invalid or unenforceable provision as may be possible and be valid and enforceable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.
This Letter Agreement shall be governed by and construed and enforced in accordance with the laws of the State of New York, without giving
effect to conflicts of law principles that would result in the application of the substantive laws of another jurisdiction. The parties
hereto (i) all agree that any action, proceeding, claim or dispute arising out of, or relating in any way to, this Letter Agreement shall
be brought and enforced in the courts of New York City, in the State of New York, and irrevocably submit to such jurisdiction and venue,
which jurisdiction and venue shall be exclusive and (ii) waive any objection to such exclusive jurisdiction and venue or that such courts
represent an inconvenient forum.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18.
Any notice, consent or request to be given in connection with any of the terms or provisions of this Letter Agreement shall be in writing
and shall be sent by express mail or similar private courier service, by certified mail (return receipt requested), by hand delivery
or facsimile transmission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.
This Letter Agreement shall terminate on the earlier of (i) the expiration of the Lock-up Periods or (ii) the liquidation of the Company;
provided, however, that this Letter Agreement shall earlier terminate in the event that the Public Offering is not consummated and closed
by July 31, 2021; provided further that paragraph 4 of this Letter Agreement shall survive such liquidation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sincerely,</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Data Knights
    Acquisition Corp.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 31%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Barry Anderson</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 18%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Barry Anderson</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: Chief Executive
    Officer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;/s/
    Barry Anderson</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Barry Anderson</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;/s/
    Firdauz Edmin Bin Mokhtar</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Firdauz Edmin Bin
    Mokhtar</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;/s/
    Syed Musheer Ahmed</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Syed Musheer Ahmed</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Julianne Huh</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Julianne Huh</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;/s/
    Annie Damit Undikai</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Annie Damit Undikai</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;/s/
    Barry Anderson</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Data Knights, LLC</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: Barry Anderson, Chief
    Executive Officer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Signature
Page to Letter Agreement]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 9; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.7
<SEQUENCE>13
<FILENAME>ex10-7.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;<B>Exhibit
10.7</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Execution
Version</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SUBSCRIPTION
ESCROW AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This&nbsp;<B>Subscription
Escrow Agreement</B>&nbsp;(the &ldquo;<B><I>Escrow Agreement</I></B>&rdquo;) is entered into and effective the 28th day of March 2024,
by and among&nbsp;<B>OneMedNet Corporation</B>, a corporation organized under the laws of the State of Delaware (&ldquo;<B><I>OneMedNet</I></B>&rdquo;);
each investor identified on the signature pages hereto (each, including his, her or theirs successors and assigns, each, an &ldquo;<B><I>Investor</I></B>,&rdquo;
and, collectively, the &ldquo;<B><I>Investors</I></B>&rdquo;), and&nbsp;<B>Rimon, P.C.</B>, a professional corporation incorporated in
the State of Delaware (the &ldquo;<B><I>Escrow Agent</I></B>&rdquo;). Terms not defined in this Escrow Agreement are defined in the executed
Securities Purchase Agreement, dated as of March 28, 2024, as amended, modified or supplemented from time to time in accordance with
its terms (the &ldquo;<B><I>PIPE SPA</I></B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>,
pursuant to the PIPE SPA, OneMedNet has offered to issue and sell to each Investor, and each Investor shall purchase from the Company
(the &ldquo;<B><I>Offering</I></B>&rdquo;), convertible promissory notes (each, a &ldquo;<B><I>Note</I></B>&rdquo; and together, the
&ldquo;<B><I>Notes</I></B>&rdquo;), in an amount up to the principal amount set forth on the signature page to the PIPE SPA executed
by such Investor and common stock purchase warrants (each, a &ldquo;<B><I>Warrant</I></B>&rdquo; and together, the &ldquo;<B><I>Warrants</I></B>&rdquo;),
which sale and purchase of Notes and Warrants shall be conducted in tranches (each, a &ldquo;<B><I>Tranche</I></B>&rdquo; and together,
the &ldquo;<B><I>Tranches</I></B>&rdquo;) consisting of (x) an initial tranche (the &ldquo;<B><I>Initial Tranche</I></B>&rdquo;) of (i)
an aggregate Principal Amount of Notes of up to Two Million and zero/100 Dollars ($2,000,000.00) and including an original issue discount
of up to an aggregate of Three Hundred Thousand and zero/100 Dollars ($300,000.00), and (ii) Warrants to purchase a number of shares
of Common Stock equal to the applicable Warrant Share Amounts with respect to such Tranche, (y) a second tranche (the &ldquo;<B><I>Second
Tranche</I></B>&rdquo; of (i) an aggregate Principal Amount of Notes of up to Three Hundred Fifty Thousand and zero/100 Dollars ($350,000.00)
and including an original issue discount of up to an aggregate of Fifty Two Thousand Five Hundred and zero/100 Dollars ($52,500.00),
and (ii) Warrants to purchase a number of shares of Common Stock equal to the applicable Warrant Share Amounts with respect to such Tranche
and (z) up to three subsequent Tranches each of which shall be in (i) an aggregate Principal Amount of Notes of up to One Million and
zero/100 Dollars ($1,000,000) each and each including an original issue discount of fifteen percent (15.0%) of the applicable Principal
Amount, and (ii) Warrants to purchase a number of shares of Common Stock equal to the applicable Warrant Share Amounts with respect to
such Tranches; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>,
the Offering of the Notes and Warrants in a Tranche shall occur in one or more closings (each, a &ldquo;<B><I>Closing</I></B>&rdquo;),
with the date upon which such Closing shall occur being referred to as, a &ldquo;<B><I>Closing Date</I></B>,&rdquo; with the payment
of a portion of the purchase price for the Notes and Warrants to be payable by the Investors to the escrow account maintained by the
Escrow Agent (the &ldquo;<B><I>Escrow Account</I></B>&rdquo;), as specifically provided in the PIPE SPA; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>,
the Offering is being made by OneMedNet pursuant to Regulation D under the Securities Act of 1933, as amended (the &ldquo;<B><I>Securities
Act</I></B>&rdquo;), to the Investors, who have represented in the PIPE SPA that each of whom is an accredited investor, as defined in
Rule 501 of Regulation D of the Securities Act; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>,
the parties hereto desire to provide for the safekeeping of any Escrow Deposit (as defined below) related to the PIPE SPA until such
time as the Escrow Deposit is released by the Escrow Agent in accordance with the terms and conditions of this Agreement; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>,
the parties acknowledge that the Escrow Agent is not a party to, and has no duties or obligations under, the PIPE SPA, that all references
in this Escrow Agreement to the PIPE SPA are for convenience only, and that the Escrow Agent shall have no implied duties beyond the
express duties set forth in this Escrow Agreement; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>,
the Escrow Agent has agreed to accept, hold, and disburse the Escrow Deposit deposited with it in accordance with the terms of this Escrow
Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOW
THEREFORE</B>, in consideration of the foregoing and of the mutual covenants hereinafter set forth, the parties hereto agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.&nbsp;<B>Appointment</B>.
OneMedNet and each Investor hereby appoint the Escrow Agent as their escrow agent for the purposes set forth herein, and the Escrow Agent
hereby accepts such appointment under the terms and conditions set forth herein. In connection with the Closings, and as further provided
in the PIPE SPA, OneMedNet and each Investor agree that the payment of a portion of the consideration for the Initial Tranche, all of
the Second Tranche and a portion of the proceeds of the Tranche following the Second Tranche (the &ldquo;<B><I>Third Tranche</I></B>&rdquo;)
shall require the payment to the Escrow Agent of the following escrow deposits (the &ldquo;<B><I>Escrow Deposit</I></B>&rdquo;): (a)
$1,350,000.00 of the net proceeds of the Initial Tranche will be paid into the Escrow Account; (b) 100% of the net proceeds of the Second
Tranche shall be paid into the Escrow Account for distribution in accordance with the terms of this Escrow Agreement, and (c) 75% of
the net proceeds of the Third Tranche shall be paid into the Escrow Account for distribution in accordance with the terms of this Escrow
Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.&nbsp;<B>Escrow
Account Wiring Instructions.&nbsp;</B>The Investors shall remit each Escrow Deposit by wire transfer of immediately available funds to
the account of the Escrow Agent, as governed by the PIPE SPA. All funds received from the Investors in connection with the sale of the
OneMedNet Notes and Warrants in the Offering shall be deposited with the Escrow Agent using the following wire instructions, to be held
by the Escrow Agent and disbursed as provided in this Escrow Agreement:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 144px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bank: JP Morgan Chase Bank N.A.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bank Address: 1500 Polk Street, San Francisco, CA 94109</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the name of: Rimon, PC</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Swift Code: CHASUUS33</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acct: 825-083-959</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABA Routing: 322271627</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reference: OneMedNet</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.&nbsp;<B>Maintenance
of Escrow Deposit.&nbsp;</B>During the term of this Escrow Agreement, the Escrow Deposit shall be maintained by the Escrow Agent in a
segregated account in order to provide readily available funds necessary to make required payment under Section 4 of this Escrow Agreement.
The Escrow Agent may earn compensation in the form of short-term interest from the Escrow Deposit from the time of receipt and the time
of liquidation of the Escrow Deposit and as provided in&nbsp;<U>Exhibit A</U>&nbsp;hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.&nbsp;<B>Disposition
and Termination; Security Interest.&nbsp;</B>OneMedNet agrees to notify the Escrow Agent in writing of either: (i) a Closing of a Tranche
under the Offering, or (ii) a termination of the PIPE SPA. Upon receipt of any such written notification, the following procedures will
take place, as applicable:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)&nbsp;<U>Release
of Escrow Deposit upon Closing of the Initial Tranche</U>. Following the Closing of the Initial Tranche, the Investors shall fund the
Escrow Deposit to the Escrow Account. To release funds, OneMedNet and the Investors shall deliver to the Escrow Agent joint written notice
executed by a duly authorized executive officer of OneMedNet and duly authorized signatory of the Investors (&ldquo;<B><I>Instructions</I></B>&rdquo;),
from time to time, which Instructions shall specify the amount, day, time and payment instructions, including the address, phone number
and account number of each payee from the Escrow Deposit in accordance with the PIPE SPA. The Escrow Agent shall, at the time and in
accordance with the payment instructions specified in the Instructions, deliver the Escrow Deposit (without interest) to OneMedNet in
accordance with the Instructions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)&nbsp;<U>Release
of Escrow Deposit upon certain Subsequent Closings</U>. Following the Closing of the Second Tranche and the Third Tranche, the Investors
shall fund the Escrow Deposit to the Escrow Account. To release funds, OneMedNet and the Investors shall deliver to the Escrow Agent
the Instructions, from time to time, in accordance with the PIPE SPA, which Instructions shall specify the amount, day, time and payment
instructions, including the address, phone number and account number of each payee from the Escrow Deposit. The Escrow Agent shall, at
the time and in accordance with the payment instructions specified in the Instructions, deliver the Escrow Deposit (without interest)
to OneMedNet in accordance with the Instructions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)&nbsp;<U>Release
of Escrow Deposit upon a Termination</U>. In the event OneMedNet and all of the Investors shall deliver Instructions to the Escrow Agent,
which Instructions shall announce the termination of the PIPE SPA, whether as a result of an Event of Default (as defined in the PIPE
SPA or Notes) or otherwise, and to terminate the Escrow Account and refund the Escrow Deposit to all of the Investors, the Escrow Agent
will wire the Escrow Deposit, without interest, to the Investors, and the parties hereto acknowledge and agree that as of such wire,
the Escrow Agent&rsquo;s duties have been fully satisfied.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)&nbsp;<U>Delivery
Pursuant to Court Order</U>. Notwithstanding any provision contained herein, upon receipt by the Escrow Agent of a final and non-appealable
judgment, order, decree or award of a court of competent jurisdiction (a &ldquo;<B><I>Court Order</I></B>&rdquo;), the Escrow Agent shall
deliver the Escrow Deposit in accordance with the Court Order. Any Court Order shall be accompanied by an opinion of counsel for the
party presenting the Court Order to the Escrow Agent (which opinion shall be satisfactory to the Escrow Agent) to the effect that the
court issuing the Court Order has competent jurisdiction and that the Court Order is final and non-appealable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)&nbsp;<U>Security
Interest</U>. As security for the payment and performance of the Obligations owing to each Investor now existing or in the future, OneMedNet
does hereby pledge, assign, transfer, deliver and grant to such Investor a continuing and unconditional first priority security interest
in the Escrow Deposit (all of which property, along with the products and proceeds therefrom, are individually and collectively referred
to as the &ldquo;Collateral&rdquo;) until such time as the Escrow Deposit is delivered in accordance with this Section 4. &ldquo;Obligations&rdquo;
shall mean, whether now existing or hereafter arising, created or incurred: (i) the loans evidenced by the Notes issued to such Investor;
(ii) all interest accrued thereon (including interest which would be payable as post-petition in connection with any bankruptcy or similar
proceeding, whether or not permitted as a claim thereunder); (iii) any and all fees, charges or other amounts due to such Investor under
the Notes or the PIPE SPA; (iv) any and all expenses incurred by such Investor under, or in connection with, the Notes or the PIPE SPA;
(v) any and all other liabilities and obligations of OneMedNet to such Investor under the Notes or PIPE SPA; and (vi) the performance
by OneMedNet of all covenants, agreements and obligations of every nature and kind on the part of any of OneMedNet to be performed under
the Notes or the PIPE SPA. Each of OneMedNet and the Investors agree that the right of the Investors to direct delivery of the Escrow
Agreement pursuant to this Section 4 shall constitute &ldquo;control&rdquo; for purposes of applicable uniform commercial code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
delivery of the Escrow Deposit by the Escrow Agent in accordance with Section 4(a), (b) or (c), as the case may be, this Escrow Agreement
shall terminate, subject to the provisions of Section 8.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.&nbsp;<B>Escrow
Agent.&nbsp;</B>The Escrow Agent undertakes to perform only such duties as are expressly set forth herein and no duties shall be implied.
The Escrow Agent shall have no liability under and no duty to inquire as to the provisions of any agreement other than this Escrow Agreement.
The Escrow Agent may rely upon and shall not be liable for acting or refraining from acting upon any written notice, instruction or request
furnished to it hereunder and believed by it to be genuine and to have been signed or presented by the proper party or parties. The Escrow
Agent shall be under no duty to inquire into or investigate the validity, accuracy or content of any such document except as provided
herein. The Escrow Agent shall have no duty to solicit any payments which may be due it or the Escrow Deposit. The Escrow Agent shall
not be liable for any action taken or omitted by it in good faith except to the extent that a court of competent jurisdiction determines
that the Escrow Agent&rsquo;s gross negligence or willful misconduct was the primary cause of any loss to OneMedNet or the Investors.
The Escrow Agent may execute any of its powers and perform any of its duties hereunder directly or through agents or attorneys (and shall
be liable only for the careful selection of any such agent or attorney) and may consult with counsel, accountants and other skilled persons
to be selected and retained by it. The Escrow Agent shall not be liable for anything done, suffered or omitted in good faith by it in
accordance with the advice or opinion of any such counsel, accountants or other skilled persons. In the event that the Escrow Agent shall
be uncertain as to its duties or rights hereunder or shall receive instructions, claims or demands from any party hereto which, in its
opinion, conflict with any of the provisions of this Escrow Agreement, it shall be entitled to refrain from taking any action and its
sole obligation shall be to keep safely all property held in escrow until it shall be directed otherwise in writing by all of the other
parties hereto or by a final order or judgment of a court of competent jurisdiction. Anything in this Escrow Agreement to the contrary
notwithstanding, in no event shall the Escrow Agent be liable for special, indirect or consequential loss or damage of any kind whatsoever
(including but not limited to lost profits), even if the Escrow Agent has been advised of the likelihood of such loss or damage and regardless
of the form of action.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.&nbsp;<B>Succession.&nbsp;</B>The
Escrow Agent may resign and be discharged from its duties or obligations hereunder by giving ten (10) business days advance notice in
writing of such resignation to the other parties hereto specifying a date when such resignation shall take effect. The Escrow Agent shall
have the right to withhold an amount equal to any amount due and owing to the Escrow Agent, plus any costs and expenses the Escrow Agent
shall reasonably believe may be incurred by the Escrow Agent in connection with the termination of the Escrow Agreement. Any corporation
or association into which the Escrow Agent may be merged or converted or with which it may be consolidated shall be the Escrow Agent
under this Escrow Agreement without further act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.&nbsp;<B>Fees.</B>&nbsp;The
Escrow Agent hereby forgoes reasonable compensation for the services to be rendered hereunder, as described in&nbsp;<U>Exhibit A</U>&nbsp;attached
hereto. OneMedNet hereby agrees to pay or reimburse the Escrow Agent upon request for all expenses, disbursements and advances, including
reasonable attorney&rsquo;s fees and expenses, incurred or made by it in connection with the preparation, execution, performance, delivery,
modification and termination of this Escrow Agreement. The Escrow Agent is authorized to deduct expenses from the Escrow Deposit at the
time of the Closing without prior authorization from OneMedNet or the Investors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.&nbsp;<B>Indemnity.&nbsp;</B>OneMedNet
shall indemnify, defend and save harmless the Escrow Agent and its directors, officers, agents and employees (the &ldquo;<B><I>indemnitees</I></B>&rdquo;)
from all loss, liability or expense (including the reasonable fees and expenses of in house or outside counsel) arising out of or in
connection with (i) the Escrow Agent&rsquo;s execution and performance of this Escrow Agreement, except in the case of any indemnitee
to the extent that such loss, liability or expense is due to the gross negligence or willful misconduct of such indemnitee, or (ii) its
following any instructions or other directions from OneMedNet, except to the extent that its following any such instruction or direction
is expressly forbidden by the terms hereof. The parties hereto acknowledge that the foregoing indemnities shall survive the resignation
or removal of the Escrow Agent or the termination of this Escrow Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.&nbsp;<B>Notices.</B>&nbsp;All
communications hereunder shall be in writing and shall be deemed to be duly given and received upon delivery if delivered personally
or upon confirmed transmittal if by facsimile or if sent by overnight courier. Notwithstanding the above, in the case of communications
delivered to or by the Escrow Agent or to or by any other party to this Agreement under this Section 9, such communications shall be
deemed to have been given on the date received. In the event that the Escrow Agent, in its sole discretion, shall determine that an emergency
exists, the Escrow Agent may use such other means of communication as the Escrow Agent deems appropriate. The appropriate address for
the Escrow Agent is set forth in&nbsp;<U>Exhibit A</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.&nbsp;<B>Security
Procedures.</B>&nbsp;In the event funds transfer Instructions are given (other than in writing at the time of execution of this Escrow
Agreement), whether in writing, by telecopier or otherwise, the Escrow Agent is authorized to seek confirmation of such instructions
by telephone call-back, and the Escrow Agent may rely upon the confirmation of anyone purporting to be the authorized representative
of the particular party. The persons and telephone numbers for call-backs may be changed only in a writing actually received and acknowledged
by the Escrow Agent. The Escrow Agent and the beneficiaries&rsquo; bank in any funds transfer may rely solely upon any account numbers
or similar identifying numbers provided by OneMedNet to identify (i) the beneficiary, (ii) the beneficiary&rsquo;s bank, or (iii) an
intermediary bank. The Escrow Agent may apply any of the escrowed funds for any payment order it executes using any such identifying
number, even where its use may result in a person other than the beneficiary being paid, or the transfer of funds to a bank other than
the beneficiary&rsquo;s bank or an intermediary bank designated. The parties to this Escrow Agreement acknowledge that these security
procedures are commercially reasonable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.&nbsp;<B>Miscellaneous.&nbsp;</B>The
provisions of this Escrow Agreement may be waived, altered, amended or supplemented, in whole or in part, only by a writing signed by
all of the parties hereto. Neither this Escrow Agreement nor any right or interest hereunder may be assigned in whole or in part by any
party, except as provided in Section 6, without the prior consent of the other parties, which consent shall not be unreasonably withheld.
This Escrow Agreement shall be governed by and construed under the laws of the State of New York. Each party hereto irrevocably waives
any objection on the grounds of venue,&nbsp;<I>forum non-conveniens</I>&nbsp;or any similar grounds and irrevocably consents to service
of process by mail or in any other manner permitted by applicable law and consents to the jurisdiction of the courts located in the State
of New York. The parties further hereby waive any right to a trial by jury with respect to any lawsuit or judicial proceeding arising
or relating to this Escrow Agreement. No party to this Escrow Agreement is liable to any other party for losses due to, or if it is unable
to perform its obligations under the terms of this Escrow Agreement because of, acts of God, fire, floods, strikes, equipment or transmission
failure, or other causes reasonably beyond its control. This Escrow Agreement may be executed in one or more counterparts, each of which
shall be deemed an original, but all of which together shall constitute one and the same instrument.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[<I>Remainder
of Page Intentionally Left Blank</I>]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IN
WITNESS WHEREOF</B>, the parties hereto have executed this Subscription Escrow Agreement as of the date set forth above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>RIMON P.C.,&nbsp;</B>as Escrow Agent</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 46%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Debbie
    A. Klis</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Debbie A. Klis</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Partner</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ONEMEDNET
    CORPORATION</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 46%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Paul
    J. Casey</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul J. Casey</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>THE
INVESTORS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 46%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 46%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 46%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 46%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 46%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>EXHIBIT A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>RIMON, P.C., AS ESCROW AGENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SCHEDULE OF FEES &amp; EXPENSES</B></P>

<P STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B><I>Exhibit&nbsp;B</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SPONSOR SUPPORT AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">This SPONSOR SUPPORT AGREEMENT, dated as of April&nbsp;25,
2022 (this &ldquo;<B><I>Agreement</I></B>&rdquo;), by and among Data Knights, LLC, a Delaware limited liability company (&ldquo;<B><I>Sponsor</I></B>&rdquo;),
Data Knights Acquisition Corp., a Delaware corporation (&ldquo;<B><I>Purchaser</I></B>&rdquo;), and OneMedNet Corporation, a Delaware
limited liability company (the &ldquo;<B><I>Company</I></B>&rdquo;). Terms used but not defined in this Agreement shall have the meanings
ascribed to them in the Merger Agreement (as defined below).</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">WHEREAS, contemporaneously herewith, the Purchaser,
Data Knights Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of the Purchaser (<I>&ldquo;<B>Merger Sub</B>&rdquo;),</I>&nbsp;Data
Knights, LLC, a Delaware limited liability company (the &ldquo;<B><I>Purchaser Representative</I></B>&rdquo;), Paul Casey (the &ldquo;<B><I>Seller
Representative</I></B>&rdquo;), and&nbsp;<B>OneMedNet Corporation</B>, a Delaware corporation (the &ldquo;<B><I>Company</I></B>&rdquo;),
entered into that certain Agreement and Plan of Merger (the &ldquo;<B><I>Merger Agreement</I></B>&rdquo;), pursuant to which Merger Sub
will merge with and into the Company, with the Company continuing as the surviving entity (the &ldquo;<B><I>Merger</I></B>&rdquo;), and
as a result of which the stockholders of the Company will receive shares of the Purchaser&rsquo;s Common Stock;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">WHEREAS, as of the date hereof, Sponsor owns 3,415,275
shares of Purchaser Common Stock (all such shares of Purchaser Common Stock and any shares of Purchaser Common Stock of which ownership
of record or the power to vote is hereafter acquired by Sponsor prior to the termination of this Agreement being referred to herein as
the &ldquo;<B><I>Shares</I></B>&rdquo;); and</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">WHEREAS, in order to induce the Company and Purchaser
to enter into the Merger Agreement, Sponsor is executing and delivering this Agreement to the Company.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">NOW, THEREFORE, in consideration of the foregoing and
of the mutual covenants and agreements contained herein, and intending to be legally bound hereby, Sponsor, the Company, and Purchaser
hereby agree as follows:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">1. Agreement to Vote. Sponsor, with respect to the Shares,
hereby agrees (and agrees to execute such documents or certificates evidencing such agreement as Purchaser and/or the Company may reasonably
request in connection therewith) to vote at any meeting of the stockholders of Purchaser, and in any action by written consent of the
stockholders of Purchaser, to approve the Merger Agreement, all of the Shares (a)&nbsp;in favor of the approval and adoption of the Merger
Agreement, the transactions contemplated by the Merger Agreement and this Agreement, (b)&nbsp;in favor of any other matter reasonably
necessary to the consummation of the transactions contemplated by the Merger Agreement and considered and voted upon by the stockholders
of Purchaser (including the Purchaser Stockholder Approval Matters), (c)&nbsp;in favor of the approval and adoption of the Incentive Plan,
(d)&nbsp;for the appointment, and designation of classes, of the members of the Post-Closing Purchaser Board and (e)&nbsp;against any
action, agreement or transaction (other than the Merger Agreement or the transactions contemplated thereby) or proposal that would result
in a breach of any covenant, representation or warranty or any other obligation or agreement of Purchaser or Merger Sub under the Merger
Agreement or that would reasonably be expected to result in the failure of the transactions contemplated by the Merger Agreement from
being consummated. Sponsor acknowledges receipt and review of a copy of the Merger Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">2. Transfer of Shares. Sponsor agrees that it shall
not, directly or indirectly, except as otherwise contemplated pursuant to the Merger Agreement, (a)&nbsp;sell, assign, transfer (including
by operation of law), redeem, lien, pledge, distribute, dispose of or otherwise encumber any of the Shares or otherwise agree to do any
of the foregoing (unless the transferee agrees to be bound by this Agreement), (b)&nbsp;deposit any Shares into a voting trust, enter
into a voting agreement or arrangement or grant any proxy or power of attorney with respect thereto that is inconsistent with this Agreement,
(c)&nbsp;enter into any contract, option or other arrangement or undertaking with respect to the direct or indirect acquisition or sale,
assignment, transfer (including by operation of law), redemption or other disposition of any Shares (unless the transferee agrees to be
bound by this Agreement) or (d)&nbsp;take any action that would have the effect of preventing or disabling Sponsor from performing its
obligations hereunder. From time to time, at the request of Purchaser, Sponsor shall take all such further actions as may be necessary
or appropriate to effect the purposes of this Agreement, and execute customary documents incident to the consummation of the Merger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">TABLE OF CONTENTS</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">3. Representations and Warranties. Sponsor represents
and warrants for and on behalf of itself to Purchaser and the Company as follows:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">(a) The execution, delivery and performance by Sponsor
of this Agreement and the consummation by Sponsor of the transactions contemplated hereby do not and will not (i)&nbsp;conflict with or
violate any Law or Order applicable to Sponsor, (ii)&nbsp;require any consent, approval or authorization of, declaration, filing or registration
with, or notice to, any person or entity, (iii)&nbsp;result in the creation of any Lien on any Shares (other than pursuant to this Agreement
or transfer restrictions under applicable securities laws or the Organizational Documents of Sponsor) or (iv)&nbsp;conflict with or result
in a breach of or constitute a default under any provision of Sponsor&rsquo;s Organizational Documents.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">(b) Sponsor owns of record and has good, valid and marketable
title to the Shares free and clear of any Lien (other than pursuant to this Agreement or transfer restrictions under applicable securities
Laws or the Organizational Documents of Sponsor) and has the sole power (as currently in effect) to vote and has the full right, power
and authority to sell, transfer and deliver such Shares. Sponsor does not own, directly or indirectly, any other shares of Purchaser capital
stock other than the Shares, or any options, warrants or other rights to acquire any additional shares of the capital stock of Purchase
or any security exercisable for or convertible into the capital stock of Purchaser.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">(c) Sponsor has the power, authority and capacity to
execute, deliver and perform this Agreement, and this Agreement has been duly authorized, executed and delivered by Sponsor.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">(d) There is no Action pending, or, to the knowledge
of Sponsor, threatened, against Sponsor that would reasonably be expected to materially impair or materially adversely affect the ability
of Sponsor to perform its obligations hereunder or to consummate the transactions contemplated by this Agreement.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">4. Other Covenants and Agreements.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">(a) At the Effective Time, Sponsor will deliver to Purchaser
a duly executed copy of the Lock-Up Agreement and the Registration Rights Agreement in substantially the forms attached as Exhibits&nbsp;C
and G to the Merger Agreement.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">(b) Sponsor agrees to and shall be bound by and subject
to Section&nbsp;5.15 (Confidential Information) and Section&nbsp;5.16 (Public Announcements), Section&nbsp;5.6. (No Solicitation), and
Section&nbsp;9.1 (Waiver of Claims Against Trust) of the Merger Agreement to the same extent as such provisions apply to the parties to
the Merger Agreement, as if Sponsor is directly party thereto.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">(c) Sponsor hereby waives, and agrees not to assert
or perfect, any rights of appraisal or rights to dissent from the Merger that Sponsor may have by virtue of ownership of the Shares and
agrees not to commence or participate in any claim, derivative or otherwise, against Purchaser relating to the negotiation, execution
or delivery of this Agreement or the Merger Agreement or the consummation of the Merger.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">5. Termination. This Agreement and the obligations of
Sponsor under this Agreement shall automatically terminate upon the earliest of: (a)&nbsp;the Effective Time; (b)&nbsp;the termination
of the Merger Agreement in accordance with its terms; or (c)&nbsp;the mutual written agreement of the Company and Purchaser. Upon termination
or expiration of this Agreement, no party shall have any further obligations or liabilities under this Agreement; provided, however, such
termination or expiration shall not relieve any party from liability for any willful breach of this Agreement occurring prior to its termination.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">6. Miscellaneous.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">(a) Except as otherwise provided herein or in the Merger
Agreement or any Ancillary Document, all costs and expenses incurred in connection with this Agreement and the transactions contemplated
hereby shall be paid by the party incurring such costs and expenses, whether or not the transactions contemplated hereby are consummated.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">(b) All notices, requests, claims, demands and other
communications hereunder shall be in writing and shall be given (and shall be deemed to have been duly given upon receipt) by delivery
in</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 8; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">TABLE OF CONTENTS</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">person, by telecopy or e-mail or by registered or certified mail (postage
prepaid, return receipt requested) to the respective parties at the following addresses (or at such other address for a party as shall
be specified in a notice given in accordance with this&nbsp;Section&nbsp;5(b)):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">If to the Purchaser, to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Data Knights Acquisition Corp.<BR>
Unit G6, Frome Business Park,<BR>
Manor Road, Frome, BA11 4FN,<BR>
United Kingdom<BR>
Tel: +44 203 833 4000<BR>
Email: barry@dataknightsacuk.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">with a copy to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Nelson Mullins Riley &amp; Scarborough LLP<BR>
101 Constitution Ave NW, Suite 900<BR>
Washington, DC 20001<BR>
Attention: Andy Tucker<BR>
Telephone: (202) 689-2987<BR>
E-mail: andy.tucker@nelsonmullins.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">If to the Sponsor, to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Data Knights, LLC<BR>
Unit G6, Frome Business Park,<BR>
Manor Road, Frome, BA11 4FN,<BR>
United Kingdom<BR>
Tel: +44 203 833 4000<BR>
Email: barry@dataknightsacuk.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">with a copy to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Nelson Mullins Riley &amp; Scarborough LLP<BR>
101 Constitution Ave NW, Suite 900<BR>
Washington, DC 20001<BR>
Attention: Andy Tucker<BR>
Telephone: (202) 689-2987<BR>
E-mail: andy.tucker@nelsonmullins.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">If to the Company, to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">OneMedNet Corporation<BR>
6385 Old Shady Oak Road<BR>
Suite 250 Eden Prairie, MN 55344<BR>
Attn: Paul Casey<BR>
Telephone No.: (808) 228-5998<BR>
E-mail: paul.casey@onemednet.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">with a copy to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Rim&ocirc;n, P.C.<BR>
1990 K Street NW, Suite 420<BR>
Washington, DC 20006<BR>
Attn: Debbie Klis; Debra Vernon<BR>
Telephone: (202) 971-9494; (650) 292-5910<BR>
E-mail: debbie.klis@rimonlaw.com; debra.vernon@rimonlaw.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 20pt">(c) If any term or other provision of this Agreement
is invalid, illegal or incapable of being enforced by any rule of law, or public policy, all other conditions and provisions of this Agreement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">TABLE OF CONTENTS</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">shall nevertheless remain in full force and effect so long as the economic
or legal substance of the transactions contemplated hereby is not affected in any manner materially adverse to any party. Upon such determination
that any term or other provision is invalid, illegal or incapable of being enforced, the parties hereto shall negotiate in good faith
to modify this Agreement so as to effect the original intent of the parties as closely as possible in a mutually acceptable manner in
order that the transactions contemplated hereby be consummated as originally contemplated to the fullest extent possible.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">(d) This Agreement, the Merger Agreement and the Ancillary
Documents constitute the entire agreement among the parties with respect to the subject matter hereof and supersede all prior agreements
and undertakings, both written and oral, among the parties, or any of them, with respect to the subject matter hereof. This Agreement
shall not be assigned (whether pursuant to a merger, by operation of law or otherwise).</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">(e) This Agreement shall be binding upon and inure solely
to the benefit of each party hereto, and nothing in this Agreement, express or implied, is intended to or shall confer upon any other
person any right, benefit or remedy of any nature whatsoever under or by reason of this Agreement.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">(f) The parties hereto agree that irreparable damage
may occur in the event any provision of this Agreement was not performed in accordance with the terms hereof and that the parties shall
be entitled to specific performance of the terms hereof, in addition to any other remedy at law or in equity. Each of the parties agrees
that it shall not oppose the granting of an injunction, specific performance and other equitable relief when expressly available pursuant
to the terms of this Agreement on the basis that the other parties have an adequate remedy at law or an award of specific performance
is not an appropriate remedy for any reason at law or equity. Any party seeking an injunction or injunctions to prevent breaches or threatened
breaches of, or to enforce compliance with this Agreement when expressly available pursuant to the terms of this Agreement shall not be
required to provide any bond or other security in connection with any such Order.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">(g) This Agreement shall be governed by, and construed
in accordance with, the Laws of the State of Delaware applicable to contracts executed in and to be performed in that State without giving
effect to principles or rules of conflict of laws to the extent such principles or rules would require or permit the application of Laws
of another jurisdiction. All actions, suits or proceedings (collectively, &ldquo;<B><I>Action</I></B>&rdquo;) arising out of or relating
to this Agreement shall be heard and determined exclusively in any federal or state court having jurisdiction within the State of Delaware.
The parties hereto hereby (i)&nbsp;submit to the exclusive jurisdiction of federal or state courts within the State of Delaware for the
purpose of any Action arising out of or relating to this Agreement brought by any party hereto, and (ii)&nbsp;irrevocably waive, and agree
not to assert by way of motion, defense, or otherwise, in any such Action, any claim that it is not subject personally to the jurisdiction
of the above-named courts, that its property is exempt or immune from attachment or execution, that the Action is brought in an inconvenient
forum, that the venue of the Action is improper, or that this Agreement or the transactions contemplated hereunder may not be enforced
in or by any of the above-named courts.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">(h) This Agreement may be executed and delivered (including
by facsimile or portable document format (pdf) transmission) in one or more counterparts, and by the different parties hereto in separate
counterparts, each of which when executed shall be deemed to be an original but all of which taken together shall constitute one and the
same agreement.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">(i) Without further consideration, each party shall
use commercially reasonable efforts to execute and deliver or cause to be executed and delivered such additional documents and instruments
and take all such further action as may be reasonably necessary or desirable to consummate the transactions contemplated by this Agreement.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">(j) This Agreement shall not be effective or binding
upon Sponsor until such time as the Merger Agreement is executed by each of the parties thereto.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">(k) If, and as often as, there are any changes in Purchaser
or the Purchaser Common Stock by way of stock split, stock dividend, combination or reclassification, or through merger, consolidation,
reorganization, recapitalization or business combination, or by any other means, equitable adjustment</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">shall be made to the provisions of this Agreement as may be required so
that the rights, privileges, duties and obligations hereunder shall continue with respect to Purchaser, Sponsor and the Shares as so changed.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">(l) Each of the parties hereto hereby waives to the
fullest extent permitted by applicable law any right it may have to a trial by jury with respect to any litigation directly or indirectly
arising out of, under or in connection with this Agreement. Each of the parties hereto (i)&nbsp;certifies that no representative, agent
or attorney of any other party has represented, expressly or otherwise, that such other party would not, in the event of litigation, seek
to enforce that foregoing waiver and (ii)&nbsp;acknowledges that it and the other parties hereto have been induced to enter into this
Agreement and the transactions contemplated hereby, as applicable, by, among other things, the mutual waivers and certifications in this
Paragraph&nbsp;(l).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">[Signature pages follow]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">TABLE OF CONTENTS</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">IN WITNESS WHEREOF, the parties have executed this Agreement as of the
date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-weight: bold">DATA KNIGHTS ACQUISITION CORP.</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 45%">&nbsp;</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>By:</TD>
    <TD>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>Name:</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>Title:</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-weight: bold">DATA KNIGHTS, LLC</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>By:</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>Name:</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>Title:</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-weight: bold">ONEMEDNET CORPORATION</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>By:</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>Name:</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>Title:</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>[Signature Page to Sponsor Support Agreement]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 11; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.8
<SEQUENCE>14
<FILENAME>ex10-8.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.8</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OneMedNet
Corporation</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
18, 2023</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dear
Aaron Green,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OneMedNet
Corp. (the &ldquo;Company&rdquo;) is pleased to offer you employment on the following terms:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
<B>Position.</B> Your title will be President and will have dual reporting to the CEO and the Chairman of the Board. This is a full-time,
exempt position. While you render services to the Company, you will not engage in any other employment, consulting or other business
activity (whether full-time or part-time) that would create a conflict of interest with the Company. By signing this letter agreement,
you confirm to the Company that you have no contractual commitments or other legal obligations that would prohibit you from performing
your duties for the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
<B>Cash Compensation.</B> The Company will pay you a starting salary at the rate of $350,000 USD per year, payable in accordance with
the Company&rsquo;s standard payroll schedule and subject to applicable deductions and withholdings. This salary will be subject to periodic
review and adjustments at the Company&rsquo;s discretion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
<B>Annual Bonus.</B> Beginning in fiscal year 2023, as pro-rated for the amount of the fiscal year that you are employed, you will also
be eligible to receive an annual cash performance bonus of $175,000 USD upon the achievement of the perfo1mance goals set by the Company&rsquo;s
CEO and Board of Directors (the <B>&ldquo;Target Bonus&rdquo;). </B>The Target Bonus, or any portion thereof, will be paid as soon as
practicable after the Company&rsquo;s CEO and Board of Directors determines that the applicable performance goals have been achieved,
provided that you must remain an employee of the Company through the date the Target Bonus is paid out in order to receive the Target
Bonus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
<B>Employee Benefits. </B>As an employee of the Company, you will be eligible to receive certain employee benefits. Refer to benefit
plan for further detail. You should note that the Company may modify job titles, salaries and benefits from time to time as it deems
necessary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
<B>Equity. </B>Subject to the approval of the Company&rsquo;s Board of Directors, you are eligible to receive 600,000 of the company&rsquo;s
outstanding shares at closing, as part of the Company&rsquo;s Restricted Stock Unit Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.
<B>Proprietary Information and Inventions Agreement. </B>Like all Company employees, you will be required, as a condition of your employment
with the Company, to sign the Company&rsquo;s standard Proprietary Information and Inventions Agreement, a copy of which is attached
hereto as <B>Exhibit A, </B>requires, among other provisions, the assignment of patent rights to any invention made during your employment
at the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aaron
Green</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page
2</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.
<B>Employment Relationship. </B>Employment with the Company is for no specific period of time. Your employment with the Company will
be &ldquo;at will,&rdquo; meaning that either you or the Company may terminate your employment at any time and for any reason, with or
without cause. Any contrary representations that may have been made to you are superseded by this letter agreement. This is the full
and complete agreement between you and the Company on this term. Although your job duties, title, compensation and benefits, as well
as the Company&rsquo;s personnel policies and procedures, may change from time to time, the &ldquo;at will&rdquo; nature of your employment
may only be changed in an express written agreement signed by you and a duly authorized officer of the Company (other than you).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.
<B>Termination.</B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 21.15pt 0pt 65.7pt; text-align: left; text-indent: 72.65pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.
In the event that your employment with the Company is terminated by the Company without Cause (as defined below)), or is terminated
by you for Good Reason (as defined below), after six months of employment, and you sign and do not revoke a standard release of claims
with the Company in a form reasonably satisfactory to the Company&rsquo;s Board of Directors (a <B>&ldquo;Release&rdquo;),</B> which
Release becomes irrevocable no later than sixty (60) days (the <B>&ldquo;Release Deadline&rdquo;) </B>after the date of your termination
of employment (the <B>&ldquo;Termination Date&rdquo;) </B>you will be entitled to the following severance payment (&ldquo;Severance&rdquo;):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.
If the Termination Date is after 6 months&rsquo; of employment, but before you have completed 12 months&rsquo; of employment, you will
receive 3 months&rsquo; salary;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.
If the Termination Date is after 12 months&rsquo; employment you will receive 6 months&rsquo; salary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the Release does not become effective and irrevocable by the Release Deadline, you will forfeit any right to Severance. In no event will
Severance be paid or provided hereunder until the Release actually becomes effective and irrevocable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following terms referred to in this offer letter shall have the following meanings:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&ldquo;Cause&rdquo;
</B>shall mean: (i) your material failure to perform your stated duties, and your continued failure to cure such failure to the reasonable
satisfaction of the Company within ten (10) days following written notice of such failure to you from the Company&rsquo;s Board of Directors;
(ii) your material violation of a written Company policy (including any insider trading policy) or any written agreement or covenant
with the Company; (iii) your conviction of, or entry of a plea of guilty or <I>nolo contendere </I>to, a felony (other than motor vehicle
offenses the effect of which do not materially impair your performance of your employment duties); (iv) a willful act by you that constitutes
gross misconduct and which is injurious to the Company; (v) your commission of any act of fraud, embezzlement, dishonesty or any other
willful misconduct that has caused or is reasonably expected to result in material injury to the Company; (vi) the unauthorized use or
disclosure by you of any proprietary information or trade secrets of the Company or any other party to whom you owe an obligation of
nondisclosure as a result of your relationship with the Company; or your willful failure to cooperate with an investigation by a governmental
authority.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aaron
Green</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page
3</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&ldquo;Good
Reason&rdquo; </B>shall mean your voluntary termination, within thirty (30) days following the expiration of any Company cure period
(discussed below) following the occurrence of one or more of the following, without your consent: (i) a material reduction of your duties,
authority, or responsibilities, relative to your title, duties, authority, or responsibilities as in effect immediately prior to such
reduction; provided that your title, duties, authority and responsibilities will not be deemed to be materially reduced if you have reasonably
comparable duties, authorities and responsibilities as an employee with respect to the Company&rsquo;s business following a Change of
Control, regardless of any change in title or whether you provide services to a subsidiary, affiliate, business unit, division or otherwise;
(ii) a material reduction by the Company of your annual base salary, except to the extent the base salaries of all other senior executives
of the Company are similarly reduced; (iii) a material change in the location of the performance of your work, required by the Company,
of more than fifty (50) miles from your principal place of residence. You may not resign for Good Reason without first providing the
Company with written notice within ninety (90) days of the initial existence of the condition that you believe constitutes Good Reason
specifically identifying the acts or omissions constituting the grounds for Good Reason and a reasonable cure period of not less than
thirty </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">(30) days following the date of such notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.
<B>Tax Matters.</B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.
<B>Withholding. </B>All forms of compensation referred to in this letter agreement are subject to reduction to reflect applicable withholding
and payroll taxes and other deductions required by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>b.
Tax Advice.</B> You are encouraged to obtain your own tax advice regarding your compensation from the Company. You agree that the Company
does not have a duty to design its compensation policies in a manner that minimizes your tax liabilities, and you will not make any claim
against the Company or its Board of Directors related to tax liabilities arising from your compensation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.6pt 0pt 73.55pt; text-align: justify; text-indent: 36.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.
<B>Interpretation, Amendment and Enforcement. </B>This letter agreement and Exhibit A constitute the complete agreement between you and
the Company, contain all of the terms of your employment with the Company and supersede any prior agreements, representations or understandings
(whether written, oral or implied) between you and the Company. This letter agreement may not be amended or modified, except by an express
written agreement signed by both you and a duly authorized officer of the Company. The terms of this letter agreement and the resolution
of any disputes as to the meaning, effect, performance or validity of this letter agreement or arising out of, related to, or in any
way connected with, this letter agreement, your employment with the Company or any other relationship between you and the Company (the
&ldquo;Disputes&rdquo;) will be governed by Delaware law, excluding laws relating to conflicts or choice of law. You and the Company
submit to the exclusive personal jurisdiction of the federal and state courts located in Delaware in connection with any Dispute or any
claim related to any Dispute.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aaron
Green</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page
4</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.
We also ask that, if you have not already done so, you disclose to the Company any and all agreements relating to your prior employment
that may affect your eligibility to be employed by the Company or limit the manner in which you may be employed. It is the Company&rsquo;s
understanding that any such agreements will not prevent you from performing the duties of your position and you represent that such is
the case. Moreover, you agree that, during the term of your employment with the Company, you will not engage in any other employment,
occupation, consulting or other business activity directly related to the business in which the Company is now involved or becomes involved
during the term of your employment, nor will you engage in any other activities that conflict with your obligations to the Company. Similarly,
you agree not to bring any third-party confidential information to the Company, including that of your former employer, and that in performing
your duties for the Company you will not in any way utilize any such information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.
As a condition of your employment, you are also required to sign and comply with the Company&rsquo;s standard Employee Non-Disclosure
Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
hope that you will accept our offer to join the Company. You may indicate your agreement with these terms and accept this offer by signing
and dating both the enclosed duplicate original of this letter agreement and the enclosed Proprietary Information and Inventions Agreement
and returning them to me. This offer, if not accepted, will expire at the close of business on April 30, 2023. As required by
law, your employment with the Company is contingent upon your providing legal proof of your identity and authorization to work in the
United States. Your employment is also contingent upon successful background check and your starting work with the Company on May 23,
2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you have any questions, please let me know.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very
truly yours,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-bottom: Black 1.5pt solid; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>/s/ <FONT STYLE="font-size: 10pt">Paul
  Casey</FONT></I></FONT></TD>
  <TD STYLE="padding-bottom: 1.5pt; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="padding-bottom: 1.5pt; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul Casey</FONT></TD>
  <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
have read and accept this employment offer:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>/s/ Aaron Green</I></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Aaron Green</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Dated: May 7, 2023</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Attachment</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
A: Proprietary Information and Inventions Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 169.05pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aaron
Green</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page
6</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Exhibit
A</U></B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proprietary
Information and Inventions Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aaron
Green</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page
7</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PROPRIETARY
INFORMATION AND INVENTIONS AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following confirms and memorializes an agreement that <B>COMPANY NAME INC, Inc., </B>a Delaware corporation (the &ldquo;Company&rdquo;)
and I have had since the commencement of my employment (which term, for purposes of this agreement, shall be deemed to include any relationship
of service to the Company that I may have had prior to actually becoming an employee) with the Company in any capacity and that is and
has been a material part of the consideration for my employment by Company:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
I have not entered into, and I agree I will not enter into, any agreement either written or oral in conflict with this Agreement or my
employment with Company. I will not violate any agreement with or rights of any third party or, except as expressly authorized by Company
in writing hereafter, use or disclose my own or any third party&rsquo;s confidential information or intellectual property when acting
within the scope of my employment or otherwise on behalf of Company. Further, I have not retained anything containing any confidential
information of a prior employer or other third party, whether or not created by me.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
Company shall own all right, title and interest (including patent rights, copyrights, trade secret rights, mask work rights, <I>sui generis
</I>database 1ights and all other intellectual property rights of any sort throughout the world) relating to any and all inventions (whether
or not patentable), works of authorship, mask works, designs, know-how, ideas and information made or conceived or reduced to practice,
in whole or in part, by me during the term of my employment with Company to and only to the fullest extent allowed (which is attached
as <B>Appendix A)</B> (collectively &ldquo;Inventions&rdquo;) and I will promptly disclose all Inventions to Company. Without disclosing
any third party confidential information, I will also disclose anything I believe is excluded so that the Company can make an independent
assessment. I hereby make all assignments necessary to accomplish the foregoing. I shall further assist Company, at Company&rsquo;s expense,
to further evidence, record and perfect such assignments, and to perfect, obtain, maintain, enforce, and defend any rights specified
to be so owned or assigned. I hereby irrevocably designate and appoint Company as my agent and attorney-in-fact, coupled with an interest
and with full power of substitution, to act for and in my behalf to execute and file any document and to do all other lawfully permitted
acts to further the purposes of the foregoing with the same legal force and effect as if executed by me. If I wish to clarify that something
created by me prior to my employment that relates to Company&rsquo;s actual or proposed business is not within the scope of the foregoing
assignment, I have listed it on <B>Appendix B</B> in a manner that does not violate any third party rights or disclose any confidential
information. Without limiting Section 1 or Company&rsquo;s other rights and remedies, if, when acting within the scope of my employment
or otherwise on behalf of Company, I use or (except pursuant to this Section 2) disclose my own or any third party&rsquo;s confidential
information or intellectual property (or if any Invention cannot be fully made, used, reproduced, distributed and otherwise exploited
without using or violating the foregoing), Company will have and I hereby grant Company a perpetual, i1Tevocable, worldwide, royalty-free,
non-exclusive, sublicensable right and license to exploit and exercise all such confidential information and intellectual property rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aaron
Green</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page
8</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
To the extent allowed by law, paragraph 2 includes all rights of paternity, integrity, disclosure and withdrawal and any other rights
that may be known as or referred to as &ldquo;moral rights,&rdquo; &ldquo;artist&rsquo;s rights,&rdquo; &ldquo;droit moral,&rdquo; or
the like (collectively &ldquo;Moral Rights&rdquo;). To the extent I retain any such Moral Rights under applicable law, I hereby ratify
and consent to any action that may be taken with respect to such Moral Rights by or authorized by Company and agree not to assert any
Moral Rights with respect thereto. I will confirm any such ratifications, consents and agreements from time to time as requested by the
Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
I agree that all Inventions and all other business, technical and financial information (including, without limitation, the identity
of and information relating to customers or employees) I develop, learn or obtain during the term of my employment that relate to Company
or the business or demonstrably anticipated business of Company or that are received by or for Company in confidence, constitute &ldquo;Proprietary
Information.&rdquo; I will hold in confidence and not disclose or, except within the scope of my employment, use any Proprietary Information.
However, I shall not be obligated under this paragraph with respect to information I can document is or becomes readily publicly available
without restriction through no fault of mine. Upon termination of my employment, I will promptly return to Company all items containing
or embodying Proprietary Information (including all copies), except that I may keep my personal copies of (i) my compensation records,
(ii) materials distributed to shareholders generally and (iii) this Agreement. I also recognize and agree that I have no expectation
of privacy with respect to Company&rsquo;s telecommunications, networking or infom1ation processing systems (including, without limitation,
stored computer files, embedded messages and voice messages) and that my activity and any files or messages on or using any of those
systems may be monitored at any time without notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
Until one year after the term of my employment, I will not encourage or solicit any employee or consultant of Company to leave
Company for any reason (except for the bona fide firing of Company personnel within the scope of my employment).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.
I agree that during the term of my employment with Company (whether or not during business hours), I will not engage in any activity
that is in any way competitive with the business or demonstrably anticipated business of Company, and I will not assist any other person
or organization in competing or in preparing to compete with any business or demonstrably anticipated business of Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.
I agree that this Agreement is not an employment contract for any particular term and that I have the right to resign and the Company
has the right to terminate my employment at will, at any time, for any or no reason, with or without cause. In addition, this Agreement
does not purport to set forth all of the terms and conditions of my employment, and, as an employee of Company, I have obligations to
Company which are not set forth in this Agreement. However, the terms of this Agreement govern over any inconsistent terms and can only
be changed by a subsequent written agreement signed by the President of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.
I agree that my obligations under paragraphs 2, 3, 4 and 5 of this Agreement shall continue in effect after termination of my employment,
regardless of the reason or reasons for termination, and whether such termination is voluntary or involuntary on my part, and that Company
is entitled to communicate my obligations under this Agreement to any future employer or potential employer of mine. My obligations under
paragraphs 2, 3 and 4 also shall be binding upon my heirs, executors, assigns, and administrators and shall insure to the benefit of
Company, its subsidiaries, successors and assigns.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aaron
Green</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page
9</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 74.4pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.
Any dispute in the meaning, effect or validity of this Agreement shall be resolved in accordance with the laws of the State of
Delaware without regard to the conflict of laws provisions thereof. I further agree that if one or more provisions of this Agreement
are held to be illegal or unenforceable under applicable law, such illegal or unenforceable portion(s) shall be limited or excluded
from this Agreement to the minimum extent required so that this Agreement shall otherwise remain in full force and effect and
enforceable in accordance with its te1ms. This Agreement is fully assignable and transferable by Company, but any purported
assignment or transfer by me is void. I also understand that any breach of this Agreement will cause irreparable harm to Company for
which damages would not be an adequate remedy, and, therefore, Company will be entitled to injunctive relief with respect thereto in
addition to any other remedies and without any requirement to post bond.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.
I acknowledge receipt of the following notice under 18 U.S.C <I>&sect; </I>1833(b)(l): &ldquo;An individual shall not be held criminally
or civilly liable under any Federal or State trade secret law for the disclosure of a trade secret that (A) is made (i) in confidence
to a Federal, State, or local government official, either directly or indirectly, or to an attorney; and (ii) solely for the purpose
of reporting or investigating a suspected violation of law; or (B) is made in a complaint or other document filed in a lawsuit or other
proceeding, if such filing is made under seal.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Remainder
of Page Intentionally Left Blank</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aaron
Green</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page
10</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
HAVE READ THIS AGREEMENT CAREFULLY AND I UNDERSTAND AND ACCEPT THE OBLIGATIONS WHICH IT IMPOSES UPON ME WITHOUT RESERVATION. NO PROMISES
OR REPRESENTATIONS HAVE BEEN MADE TO ME TO INDUCE ME TO SIGN THIS AGREEMENT. I SIGN THIS AGREEMENT VOLUNTARILY AND FREELY, IN
DUPLICATE, WITH THE UNDERSTANDING THAT THE COMPANY WILL RETURN ONE COUNTERPART AND THE OTHER COUNTERPART WILL BE RETAINED BYME.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employee</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-bottom: Black 1.5pt solid; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>/s/ Aaron Green</I></FONT></TD>
  <TD STYLE="padding-bottom: 1.5pt; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="padding-bottom: 1.5pt; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Signature</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">May 7, 2023</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Aaron Green</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accepted and Agreed to: OneMedNet Corp.</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 47%"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
                                            Paul Casey</I></FONT> </P></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 48%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Paul Casey</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 73.2pt"></P>


<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aaron
Green</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page
11</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>APPENDIX
A</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Application
of provision providing that employee shall assign or offer to assign rights in invention to employer.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Any provision in an employment agreement which provides that an employee shall assign, or offer to assign, any of his or her rights in
an invention to his or her employer shall not apply to an invention that the employee developed entirely on his or her own time without
using the employer&rsquo;s equipment, supplies, facilities, or trade secret information except for those inventions that either:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1<B>.
</B>Relate at the time of conception or reduction to practice of the invention to the employer&rsquo;s business, or actual or demonstrably
anticipated research or development of the employer; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
Result from any work performed by the employee for his employer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 58.3pt 0pt 146.35pt; text-align: left; text-indent: 36.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
To the extent a provision in an employment agreement purports to require an employee to assign an invention otherwise excluded from being
required to be assigned under subdivision (a), the provision is against the public policy of this state and is unenforceable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aaron
Green</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page
12</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>APPENDIX
B</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PRIOR
MATTER</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 11; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.9
<SEQUENCE>15
<FILENAME>ex10-9.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.9</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OneMedNet
Corporation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">October
19, 2023</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dear
Lisa Embree,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OneMedNet
Corp. (the &ldquo;Company&rdquo;) is pleased to offer you employment on the following terms:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
<B>Position. </B>Your title will be Chief Financial Officer, reporting to the CEO. This is a full-time, exempt position. While you render
services to the Company, you will not engage in any other employment, consulting or other business activity (whether full-time or part-time)
that would create a conflict of interest with the Company. By signing this letter agreement, you confirm to the Company that you have
no contractual commitments or other legal obligations that would prohibit you from performing your duties for the Company.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
<B>Cash Compensation.</B> The Company will pay you a starting salary at the rate of $225,000 USO per year, payable in accordance with
the Company&rsquo;s standard payroll schedule and subject to applicable deductions and withholdings. This salary will be subject to periodic
review and adjustments at the Company&rsquo;s discretion.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
<B>Annual Bonus.</B> You will also be eligible to receive an annual cash performance bonus of 25% of your annual salary based on achievement
of the performance goals set by the Company&rsquo;s CEO<B>. </B>The Target Bonus, or any portion thereof, will be paid as soon as practicable
after the Company&rsquo;s CEO and Board of Directors determines that the applicable performance goals have been achieved, provided that
you must remain an employee of the Company through the date the Target Bonus is paid out in order to receive the Target Bonus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
<B>Employee Benefits. </B>As an employee of the Company, you will be eligible to receive certain employee benefits. Refer to benefit
plan for further detail. You should note that the Company may modify job titles, salaries and benefits from time to time as it deems
necessary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
<B>Equity.</B> Subject to the approval of the Company&rsquo;s Board of Directors, you are eligible to receive 260,000 of the company&rsquo;s
outstanding shares at closing, as part of the Company&rsquo;s Restricted Stock Unit Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.
<B>Proprietary Information and Inventions Agreement. </B>Like all Company employees, you will be required, as a condition of your employment
with the Company, to sign the Company&rsquo;s standard Proprietary Information and Inventions Agreement, a copy of which is attached
hereto as <B>Exhibit A,</B> requires, among other provisions, the assignment of patent rights to any invention made during your employment
at the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lisa
Embree</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page
2</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.
<B>Employment Relationship.</B> Employment with the Company is for no specific period of time. Your employment with the Company will
be &ldquo;at will,&rdquo; meaning that either you or the Company may terminate your employment at any time and for any reason, with or
without cause. Any contrary representations that may have been made to you are superseded by this letter agreement. This is the full
and complete agreement between you and the Company on this term. Although your job duties, title, compensation and benefits, as well
as the Company&rsquo;s personnel policies and procedures, may change from time to time, the &ldquo;at will&rdquo; nature of your employment
may only be changed in an express written agreement signed by you and a duly authorized officer of the Company (other than you).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.
<B>Termination.</B></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event that your employment with the Company is terminated by the Company without Cause (as defined below) or is terminated by you
for Good Reason (as defined below). After the date of your termination of employment (the <B>&ldquo;Termination Date&rdquo;) </B>you
will receive 6 months&rsquo; salary as a Severance Payment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the Release does not become effective and irrevocable by the Release Deadline, you will forfeit any right to Severance. In no event will
Severance be paid or provided hereunder until the Release becomes effective and irrevocable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following terms referred to in this offer letter shall have the following meanings:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&ldquo;Cause&rdquo;
</B>shall mean: (i) your material failure to perform your stated duties, and your continued failure to cure such failure to the reasonable
satisfaction of the Company within ten (10) days following written notice of such failure to you from the Company&rsquo;s Board of Directors;
(ii) your material violation of a written Company policy (including any insider trading policy) or any written agreement or covenant
with the Company; (iii) your conviction of, or entry of a plea of guilty or <I>nolo contendere </I>to, a felony (other than motor vehicle
offenses the effect of which do not materially impair your performance of your employment duties); (iv) a willful act by you that constitutes
gross misconduct and which is injurious to the Company; (v) your commission of any act of fraud, embezzlement, dishonesty or any other
willful misconduct that has caused or is reasonably expected to result in material injury to the Company; (vi) the unauthorized use or
disclosure by you of any proprietary information or trade secrets of the Company or any other party to whom you owe an obligation of
nondisclosure as a result of your relationship with the Company; or your willful failure to cooperate with an investigation by a governmental
authority.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lisa
Embree</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page
3</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&ldquo;Good
Reason&rdquo; </B>shall mean your voluntary termination, within thirty (30) days following the expiration of any Company cure period
(discussed below) following the occurrence of one or more of the following, without your consent: (i) a material reduction of your duties,
authority, or responsibilities, relative to your title, duties, authority, or responsibilities as in effect immediately prior to such
reduction; provided that your title, duties, authority and responsibilities will not be deemed to be materially reduced if you have reasonably
comparable duties, authorities and responsibilities as an employee with respect to the Company&rsquo;s business following a Change of
Control, regardless of any change in title or whether you provide services to a subsidiary, affiliate, business unit, division or otherwise;
(ii) a material reduction by the Company of your annual base salary, except to the extent the base salaries of all other senior executives
of the Company are similarly reduced; (iii) a material change in the location of the performance of your work, required by the Company,
of more than fifty (50) miles from your principal place of residence. You may not resign for Good Reason without first providing the
Company with written notice within ninety (90) days of the initial existence of the condition that you believe constitutes Good Reason
specifically identifying the acts or omissions constituting the grounds for Good Reason and a reasonable cure period of not less than
thirty (30) days following the date of such notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36.65pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.
<B>Tax Matters.</B></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.
<B>Withholding.</B> All forms of compensation referred to in this letter agreement are subject to reduction to reflect applicable withholding
and payroll taxes and other deductions required by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.
<B>Tax Advice.</B> You are encouraged to obtain your own tax advice regarding your compensation from the Company. You agree that the
Company does not have a duty to design its compensation policies in a manner that minimizes your tax liabilities, and you will not make
any claim against the Company or its Board of Directors related to tax liabilities arising from your compensation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36.65pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.
<B>Interpretation, Amendment and Enforcement. </B>This letter agreement and Exhibit A constitute the complete agreement between you and
the Company, contain all of the terms of your employment with the Company and supersede any prior agreements, representations or understandings
(whether written, oral or implied) between you and the Company. This letter agreement may not be amended or modified, except by an express
written agreement signed by both you and a duly authorized officer of the Company. The terms of this letter agreement and the resolution
of any disputes as to the meaning, effect, performance or validity of this letter agreement or arising out of, related to, or in any
way connected with, this letter agreement, your employment with the Company or any 0th.er relationship between you and the Company (the
&ldquo;Disputes&rdquo;) will be governed by Delaware law, excluding laws relating to conflicts or choice of law. You and the Company
submit to the exclusive personal jurisdiction of the federal and state courts located in Delaware in connection with any Dispute or any
claim related to any Dispute.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lisa
Embree</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page
4</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36.65pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.
We also ask that, if you have not already done so, you disclose to the Company any and all agreements relating to your prior employment
that may affect your eligibility to be employed by the Company or limit the manner in which you may be employed. It is the Company&rsquo;s
understanding that any such agreement will not prevent you from performing the duties of your position and you represent that such is
the case. Moreover, you agree that, during the term of your employment with the Company, you will not engage in any other employment,
occupation, consulting or other business activity directly related to the business in which the Company is now involved or becomes involved
during the term of your employment, nor will you engage in any other activities that conflict with your obligations to the Company. Similarly,
you agree not to bring any third-party confidential information to the Company, including that of your former employer, and that in performing
your duties for the Company you will not in any way utilize any such information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36.65pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.
As a condition of your employment, you are also required to sign and comply with the Company&rsquo;s standard Employee Non-Disclosure
Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36.65pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
hope that you will accept our offer to join the Company. You may indicate your agreement with these terms and accept this offer by signing
and dating both the enclosed duplicate original of this letter agreement and the enclosed Proprietary Information and Inventions Agreement
and returning them to me. This offer, if not accepted, will expire at the close of business on October 31, 2023. As required by
law, your employment with the Company is contingent upon your providing legal proof of your identity and authorization to work in the
United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you have any questions, please let me know. Very truly</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">yours,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Paul Casey</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul
    Casey</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
have read and accept this employment offer:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Lisa Embree</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lisa
    Embree</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lisa
Embree</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page
5</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PROPRIETARY
INFORMATION AND INVENTIONS AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following confirms and memorializes an agreement that <B>COMPANY NAME INC, Inc., </B>a Delaware corporation (the &ldquo;Company&rdquo;)
and I have had since the commencement of my employment (which term, for purposes of this agreement, shall be deemed to include any relationship
of service to the Company that I may have had prior to actually becoming an employee) with the Company in any capacity and that is and
has been a material part of the consideration for my employment by Company:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
I have not entered into, and I agree I will not enter into, any agreement either written or oral in conflict with this Agreement or my
employment with Company. I will not violate any agreement with or rights of any third party or, except as expressly authorized by Company
in writing hereafter, use or disclose my own or any third party&rsquo;s confidential information or intellectual property when acting
within the scope of my employment or otherwise on behalf of Company. Further, I have not retained anything containing any confidential
information of a prior employer or other third party, whether or not created by me.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
Company shall own all right, title and interest (including patent rights, copyrights, trade secret rights, mask work rights, <I>sui generis
</I>database rights and all other intellectual property rights of any sort throughout the world) relating to any and all inventions (whether
or not patentable), works of authorship, mask works, designs, know-how, ideas and information made or conceived or reduced to practice,
in whole or in part, by me during the term of my employment with Company to and only to the fullest extent allowed (which is attached
as <B>Appendix A) </B>(collectively &ldquo;Inventions&rdquo;) and I will promptly disclose all Inventions to Company. Without disclosing
any third party confidential information, I will also disclose anything I believe is excluded so that the Company can make an independent
assessment. I hereby make all assignments necessary to accomplish the foregoing. I shall further assist Company, at Company&rsquo;s expense,
to further evidence, record and perfect such assignments, and to perfect, obtain, maintain, enforce, and defend any rights specified
to be so owned or assigned. I hereby irrevocably designate and appoint Company as my agent and attorney-in-fact, coupled with an interest
and with full power of substitution, to act for and in my behalf to execute and file any document and to do all other lawfully permitted
acts to further the purposes of the foregoing with the same legal force and effect as if executed by me. If I wish to clarify
that something created by me prior to my employment that relates to Company&rsquo;s actual or proposed business is not within the scope
of the foregoing assignment, I have listed it on <B>Appendix B</B> in a manner that does not violate any third party rights or disclose
any confidential information. Without limiting Section 1 or Company&rsquo;s other rights and remedies, if, when acting within the scope
of my employment or otherwise on behalf of Company, I use or (except pursuant to this Section 2) disclose my own or any third party&rsquo;s
confidential information or intellectual property (or if any Invention cannot be fully made, used, reproduced, distributed and otherwise
exploited without using or violating the foregoing), Company will have and I hereby grant Company a perpetual, irrevocable, worldwide,
royalty-free, non-exclusive, sublicensable right and license to exploit and exercise all such confidential information and intellectual
property rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lisa
Embree</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page
6</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
To the extent allowed by law, paragraph 2 includes all rights of paternity, integrity, disclosure and withdrawal and any other rights
that may be known as or referred to as &ldquo;moral rights,&rdquo; &ldquo;artist&rsquo;s rights,&rdquo; &ldquo;droit moral,&rdquo; or
the like (collectively &ldquo;Moral Rights&rdquo;). To the extent I retain any such Moral Rights under applicable law, I hereby ratify
and consent to any action that may be taken with respect to such Moral Rights by or authorized by Company and agree not to assert any
Moral Rights with respect thereto. I will confirm any such ratifications, consents and agreements from time to time as requested by the
Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
I agree that all Inventions and all other business, technical and financial information (including, without limitation, the identity
of and information relating to customers or employees) I develop, learn or obtain during the term of my employment that relate to Company
or the business or demonstrably anticipated business of Company or that are received by or for Company in confidence, constitute &ldquo;Proprietary
Information.&rdquo; I will hold in confidence and not disclose or, except within the scope of my employment, use any Proprietary Information.
However, I shall not be obligated under this paragraph with respect to information I can document is or becomes readily publicly available
without restriction through no fault of mine. Upon termination of my employment, I will promptly return to Company all items containing
or embodying Proprietary Information (including all copies), except that I may keep my personal copies of (i) my compensation records,
(ii) materials distributed to shareholders generally and (iii) this Agreement. I also recognize and agree that I have no expectation
of privacy with respect to Company&rsquo;s telecommunications, networking or information processing systems (including, without limitation,
stored computer files, embedded messages and voice messages) and that my activity and any files or messages on or using any of those
systems may be monitored at any time without notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
Until one year after the term of my employment, I will not encourage or solicit any employee or consultant of Company to leave Company
for any reason (except for the bona fide firing of Company personnel within the scope of my employment).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.
I agree that during the term of my employment with Company (whether or not during business hours), I will not engage in any activity
that is in any way competitive with the business or demonstrably anticipated business of Company, and I will not assist any other person
or organization in competing or in preparing to compete with any business or demonstrably anticipated business of Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.
I agree that this Agreement is not an employment contract for any particular term and that I have the right to resign a11d the Company
has the right to terminate my employment at will, at any time, for any or no reason, with or without cause. In addition, this Agreement
does not purport to set forth all of the terms and conditions of my employment, and, as an employee of Company, I have obligations to
Company which are not set forth in this Agreement. However, the terms of this Agreement govern over any inconsistent terms and can only
be changed by a subsequent written agreement signed by the President of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lisa
Embree</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page
7</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.
I agree that my obligations under paragraphs 2, 3, 4 and 5 of this Agreement shall continue in effect after termination of my employment,
regardless of the reason or reasons for termination, and whether such termination is voluntary or involuntary on my part, and that Company
is entitled to communicate my obligations under this Agreement to any future employer or potential employer of mine. My obligations under
paragraphs 2, 3 and 4 also shall be binding upon my heirs, executors, assigns, and administrators and shall insure to the benefit of
Company, its subsidiaries, successors and assigns.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.
Any dispute in the meaning, effect or validity of this Agreement shall be resolved in accordance with the laws of the State of Delaware
without regard to the conflict of laws provisions thereof. I further agree that if one or more provisions of this Agreement are held
to be illegal or unenforceable under applicable law, such illegal or unenforceable portion(s) shall be limited or excluded from this
Agreement to the minimum extent required so that this Agreement shall otherwise remain in full force and effect and enforceable in accordance
with its terms. This Agreement is fully assignable and transferable by Company, but any purported assignment or transfer by me is void.
I also understand that any breach of this Agreement will cause irreparable harm to Company for which damages would not be an adequate
remedy, and, therefore, Company will be entitled to injunctive relief with respect thereto in addition to any other remedies and without
any requirement to post bond.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.
I acknowledge receipt of the following notice under 18 U.S.C &sect; 1833(b)(l): &ldquo;An individual shall not be held criminally or
civilly liable under any Federal or State trade secret law for the disclosure of a trade secret that (A) is made (i) in confidence to
a Federal, State, or local government official, either directly or indirectly, or to an attorney; and (ii) solely for the purpose of
reporting or investigating a suspected violation of law; or (B) is made in a complaint or other document filed in a lawsuit or other
proceeding, if such filing is made under seal.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Remainder
of Page Intentionally Left Blank</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lisa
Embree</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page
8</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
HAVE READ THIS AGREEMENT CAREFULLY AND I UNDERSTAND AND ACCEPT THE OBLIGATIONS WHICH IT IMPOSES UPON ME WITHOUT RESERVATION. NO PROMISES
OR REPRESENTATIONS HAVE BEEN MADE TO ME TO INDUCE ME TO SIGN THIS AGREEMENT. I SIGN THIS AGREEMENT VOLUNTARILY AND FREELY, IN DUPLICATE,
WITH THE UNDERSTANDING THAT THE COMPANY WILL RETURN ONE COUNTERPART AND THE OTHER COUNTERPART WILL BE RETAINED BY ME.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employee</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Lisa Embree</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lisa
    Embree</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Paul Casey</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul
    Casey, CEO ONEMEDNET</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>APPENDIX
A</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Application
of provision providing that employee shall assign or offer to assign rights in invention to employer.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Any provision in an employment agreement which provides that an employee shall assign, or offer to assign, any of his or her rights in
an invention to his or her employer shall not apply to an invention that the employee developed entirely on his or her own time
without using the employer&rsquo;s equipment, supplies, facilities, or trade secret information except for those inventions that either:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1<B>.
</B>Relate at the time of conception or reduction to practice of the invention to the employer&rsquo;s business, or actual or demonstrably
anticipated research or development of the employer; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
Result from any work performed by the employee for his employer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
To the extent a provision in an employment agreement purports to require an employee to assign an invention otherwise excluded from being
required to be assigned under subdivision (a), the provision is against the public policy of this state and is unenforceable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<!-- Field: Page; Sequence: 9; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.10
<SEQUENCE>16
<FILENAME>ex10-10.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 90.45pt 0pt 89.7pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
10.10</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 90.45pt 0pt 89.7pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OneMedNet
Corporation</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
28, 2022</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul
Casey</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1010
Wilder Avenue</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Apt.
1301</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Honolulu,
HI 96822</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dear
Paul,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OneMedNet
Corp. (the &ldquo;Company&rdquo;) is pleased to offer you employment on the following terms:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
<B>Position</B>. Your title will be CEO and you will report to the Board of Directors. This is a full-time, exempt position. While you
render services to the Company, you will not engage in any other employment, consulting or other business activity (whether full-time
or part- time) that would create a conflict of interest with the Company. By signing this letter agreement, you confirm to the Company
that you have no contractual commitments or other legal obligations that would prohibit you from performing your duties for the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
<B>Cash Compensation</B>. The Company will pay you a starting salary at the rate of $144,000 per year, payable in accordance with the
Company&rsquo;s standard payroll schedule and subject to applicable deductions and withholdings. This salary will be subject to periodic
review and adjustments at the Company&rsquo;s discretion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
<B>Employee Benefits</B>. As an employee of the Company, you will be eligible to receive certain employee benefits. Refer to benefit
plan for further detail. You should note that the Company may modify job titles, salaries and benefits from time to time as it deems
necessary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
<B>Equity</B>. You will be awarded 147,000 shares of stock upon the successful fundraising of an amount equal to or greater than $5,000,000.
As part of the Company&rsquo;s Restricted Stock Unit Plan, further equity will be rewarded subject to the approval of the Company&rsquo;s
Board of Directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
<B>Proprietary Information and Inventions Agreement</B>. Like all Company employees, you will be required, as a condition of your employment
with the Company, to sign the Company&rsquo;s standard Proprietary Information and Inventions Agreement, a copy of which is attached
hereto as <B>Exhibit A</B>, requires, among other provisions, the assignment of patent rights to any invention made during your employment
at the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.
<B>Employment Relationship</B>. Employment with the Company is for no specific period of time. Your employment with the Company will
be &ldquo;at will,&rdquo; meaning that either you or the Company may terminate your employment at any time and for any reason, with or
without cause. Any contrary representations that may have been made to you are superseded by this letter agreement. This is the full
and complete agreement between you and the Company on this term. Although your job duties, title, compensation and benefits, as well
as the Company&rsquo;s personnel policies and procedures, may change from time to time, the &ldquo;at will&rdquo; nature of your employment
may only be changed in an express written agreement signed by you and a duly authorized officer of the Company (other than you).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul
Casey</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page
2</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">7.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Termination<FONT STYLE="font-weight: normal">.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.
In the event that your employment with the Company is terminated by the Company without Cause (as defined below)), or is terminated by
you for Good Reason (as defined below), after six months of employment, and you sign and do not revoke a standard release of claims with
the Company in a form reasonably satisfactory to the Company&rsquo;s Board of Directors (a &ldquo;<B>Release</B>&rdquo;), which Release
becomes irrevocable no later than sixty (60) days (the &ldquo;<B>Release Deadline</B>&rdquo;) after the date of your termination of employment
(the &ldquo;<B>Termination Date</B>&rdquo;) you will be entitled to the following severance payment (&ldquo;Severance&rdquo;):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.
If the Termination Date is after 6 months&rsquo; of employment, but before you have completed 12 months&rsquo; of employment, you will
receive 3 months&rsquo; salary;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 17.3pt 0pt 103.25pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.
If the Termination Date is after 12 months&rsquo; employment you will receive 6 months&rsquo; salary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the Release does not become effective and irrevocable by the Release Deadline, you will forfeit any right to Severance. In no event will
Severance be paid or provided hereunder until the Release actually becomes effective and irrevocable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following terms referred to in this offer letter shall have the following meanings:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Cause</B>&rdquo;
shall mean: (i) your material failure to perform your stated duties, and your continued failure to cure such failure to the reasonable
satisfaction of the Company within ten (10) days following written notice of such failure to you from the Company&rsquo;s Board of Directors;
(ii) your material violation of a written Company policy (including any insider trading policy) or any written agreement or covenant
with the Company; (iii) your conviction of, or entry of a plea of guilty or <I>nolo contendere</I> to, a felony (other than motor vehicle
offenses the effect of which do not materially impair your performance of your employment duties); (iv) a willful act by you that constitutes
gross misconduct and which is injurious to the Company; (v) your commission of any act of fraud, embezzlement, dishonesty or any other
willful misconduct that has caused or is reasonably expected to result in material injury to the Company; (vi) the unauthorized use or
disclosure by you of any proprietary information or trade secrets of the Company or any other party to whom you owe an obligation of
nondisclosure as a result of your relationship with the Company; or your willful failure to cooperate with an investigation by a governmental
authority.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Good
Reason</B>&rdquo; shall mean your voluntary termination, within thirty (30) days following the expiration of any Company cure period
(discussed below) following the occurrence of one or more of the following, without your consent: (i) a material reduction of your duties,
authority, or responsibilities, relative to your title, duties, authority, or responsibilities as in effect immediately prior to such
reduction; provided that your title, duties, authority and responsibilities will not be deemed to be materially reduced if you have reasonably
comparable duties, authorities and responsibilities as an employee with respect to the Company&rsquo;s business following a Change of
Control, regardless of any change in title or whether you provide services to a subsidiary, affiliate, business unit, division or otherwise;
(ii) a material reduction by the Company of your annual base salary, except to the extent the base salaries of all other senior executives
of the Company are similarly reduced; (iii) a material change in the location of the performance of your work, required by the Company,
of more than fifty (50) miles from your principal place of residence. You may not resign for Good Reason without first providing the
Company with written notice within ninety (90) days of the initial existence of the condition that you believe constitutes Good Reason
specifically identifying the acts or omissions constituting the grounds for Good Reason and a reasonable cure period of not less than
thirty (30) days following the date of such notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul
Casey</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page
3</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">8.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax Matters<FONT STYLE="font-weight: normal">.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.
<B>Withholding</B>. All forms of compensation referred to in this letter agreement are subject to reduction to reflect applicable withholding
and payroll taxes and other deductions required by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.
<B>Tax Advice</B>. You are encouraged to obtain your own tax advice regarding your compensation from the Company. You agree that the
Company does not have a duty to design its compensation policies in a manner that minimizes your tax liabilities, and you will not make
any claim against the Company or its Board of Directors related to tax liabilities arising from your compensation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.
<B>Interpretation, Amendment and Enforcement</B>. This letter agreement and Exhibit A constitute the complete agreement between you and
the Company, contain all of the terms of your employment with the Company and supersede any prior agreements, representations or understandings
(whether written, oral or implied) between you and the Company. This letter agreement may not be amended or modified, except by an express
written agreement signed by both you and a duly authorized officer of the Company. The terms of this letter agreement and the resolution
of any disputes as to the meaning, effect, performance or validity of this letter agreement or arising out of, related to, or in any
way connected with, this letter agreement, your employment with the Company or any other relationship between you and the Company (the
&ldquo;Disputes&rdquo;) will be governed by Delaware law, excluding laws relating to conflicts or choice of law. You and the Company
submit to the exclusive personal jurisdiction of the federal and state courts located in Delaware in connection with any Dispute or any
claim related to any Dispute.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.
For purposes of federal immigration law, you will be required to provide to the Company documentary evidence of your identity and eligibility
for employment in the United States. Such documentation must be provided to us within three (3) business days of your date of hire, or
our employment relationship with you may be terminated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.
We also ask that, if you have not already done so, you disclose to the Company any and all agreements relating to your prior employment
that may affect your eligibility to be employed by the Company or limit the manner in which you may be employed. It is the Company&rsquo;s
understanding that any such agreements will not prevent you from performing the duties of your position and you represent that such is
the case. Moreover, you agree that, during the term of your employment with the Company, you will not engage in any other employment,
occupation, consulting or other business activity directly related to the business in which the Company is now involved or becomes involved
during the term of your employment, nor will you engage in any other activities that conflict with your obligations to the Company. Similarly,
you agree not to bring any third-party confidential information to the Company, including that of your former employer, and that in performing
your duties for the Company you will not in any way utilize any such information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.
As a condition of your employment, you are also required to sign and comply with the Company&rsquo;s standard Employee Non-Disclosure
Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
* * * *</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul
Casey</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page
4</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
hope that you will accept our offer to join the Company. You may indicate your agreement with these terms and accept this offer by signing
and dating both the enclosed duplicate original of this letter agreement and the enclosed Proprietary Information and Inventions Agreement
and returning them to me.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you have any questions, please let me know.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very
truly yours,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%"><I>/s/ <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Jeffrey Yu</FONT></I></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Jeffrey Yu Chairman of the Board</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
have read and accept this employment offer:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Paul Casey</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul
    Casey</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">02-Nov-2023</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attachment</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
A: Proprietary Information and Inventions Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul
Casey</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page
5</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Exhibit
A</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proprietary
Information and Inventions Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul
Casey</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page
6</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROPRIETARY
INFORMATION AND INVENTIONS AGREEMENT</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following confirms and memorializes an agreement that <B>COMPANY NAME INC, Inc.</B>, a Delaware corporation (the &ldquo;Company&rdquo;)
and I have had since the commencement of my employment (which term, for purposes of this agreement, shall be deemed to include any relationship
of service to the Company that I may have had prior to actually becoming an employee) with the Company in any capacity and that is and
has been a material part of the consideration for my employment by Company:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
I have not entered into, and I agree I will not enter into, any agreement either written or oral in conflict with this Agreement or my
employment with Company. I will not violate any agreement with or rights of any third party or, except as expressly authorized by Company
in writing hereafter, use or disclose my own or any third party&rsquo;s confidential information or intellectual property when acting
within the scope of my employment or otherwise on behalf of Company. Further, I have not retained anything containing any confidential
information of a prior employer or other third party, whether or not created by me.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
Company shall own all right, title and interest (including patent rights, copyrights, trade secret rights, mask work rights, <I>sui generis
</I>database rights and all other intellectual property rights of any sort throughout the world) relating to any and all inventions (whether
or not patentable), works of authorship, mask works, designs, know-how, ideas and information made or conceived or reduced to practice,
in whole or in part, by me during the term of my employment with Company to and only to the fullest extent allowed (which is attached
as <B>Appendix A</B>) (collectively &ldquo;Inventions&rdquo;) and I will promptly disclose all Inventions to Company. Without disclosing
any third party confidential information, I will also disclose anything I believe is excluded so that the Company can make an independent
assessment. I hereby make all assignments necessary to accomplish the foregoing. I shall further assist Company, at Company&rsquo;s expense,
to further evidence, record and perfect such assignments, and to perfect, obtain, maintain, enforce, and defend any rights specified
to be so owned or assigned. I hereby irrevocably designate and appoint Company as my agent and attorney-in-fact, coupled with an interest
and with full power of substitution, to act for and in my behalf to execute and file any document and to do all other lawfully permitted
acts to further the purposes of the foregoing with the same legal force and effect as if executed by me. If I wish to clarify that something
created by me prior to my employment that relates to Company&rsquo;s actual or proposed business is not within the scope of the foregoing
assignment, I have listed it on <B>Appendix B </B>in a manner that does not violate any third party rights or disclose any confidential
information. Without limiting Section 1 or Company&rsquo;s other rights and remedies, if, when acting within the scope of my employment
or otherwise on behalf of Company, I use or (except pursuant to this Section 2) disclose my own or any third party&rsquo;s confidential
information or intellectual property (or if any Invention cannot be fully made, used, reproduced, distributed and otherwise exploited
without using or violating the foregoing), Company will have and I hereby grant Company a perpetual, irrevocable, worldwide, royalty-free,
non-exclusive, sublicensable right and license to exploit and exercise all such confidential information and intellectual property rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
To the extent allowed by law, paragraph 2 includes all rights of paternity, integrity, disclosure and withdrawal and any other rights
that may be known as or referred to as &ldquo;moral rights,&rdquo; &ldquo;artist&rsquo;s rights,&rdquo; &ldquo;droit moral,&rdquo; or
the like (collectively &ldquo;Moral Rights&rdquo;). To the extent I retain any such Moral Rights under applicable law, I hereby ratify
and consent to any action that may be taken with respect to such Moral Rights by or authorized by Company and agree not to assert any
Moral Rights with respect thereto. I will confirm any such ratifications, consents and agreements from time to time as requested by the
Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul
Casey</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page
7</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
I agree that all Inventions and all other business, technical and financial information (including, without limitation, the identity
of and information relating to customers or employees) I develop, learn or obtain during the term of my employment that relate to Company
or the business or demonstrably anticipated business of Company or that are received by or for Company in confidence, constitute &ldquo;Proprietary
Information.&rdquo; I will hold in confidence and not disclose or, except within the scope of my employment, use any Proprietary Information.
However, I shall not be obligated under this paragraph with respect to information I can document is or becomes readily publicly available
without restriction through no fault of mine. Upon termination of my employment, I will promptly return to Company all items containing
or embodying Proprietary Information (including all copies), except that I may keep my personal copies of (i) my compensation records,
(ii) materials distributed to shareholders generally and (iii) this Agreement. I also recognize and agree that I have no expectation
of privacy with respect to Company&rsquo;s telecommunications, networking or information processing systems (including, without limitation,
stored computer files, embedded messages and voice messages) and that my activity and any files or messages on or using any of those
systems may be monitored at any time without notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
Until one year after the term of my employment, I will not encourage or solicit any employee or consultant of Company to leave Company
for any reason (except for the bona fide firing of Company personnel within the scope of my employment).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.
I agree that during the term of my employment with Company (whether or not during business hours), I will not engage in any activity
that is in any way competitive with the business or demonstrably anticipated business of Company, and I will not assist any other person
or organization in competing or in preparing to compete with any business or demonstrably anticipated business of Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.
I agree that this Agreement is not an employment contract for any particular term and that I have the right to resign and the Company
has the right to terminate my employment at will, at any time, for any or no reason, with or without cause. In addition, this Agreement
does not purport to set forth all of the terms and conditions of my employment, and, as an employee of Company, I have obligations to
Company which are not set forth in this Agreement. However, the terms of this Agreement govern over any inconsistent terms and can only
be changed by a subsequent written agreement signed by the President of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.
I agree that my obligations under paragraphs 2, 3, 4 and 5 of this Agreement shall continue in effect after termination of my employment,
regardless of the reason or reasons for termination, and whether such termination is voluntary or involuntary on my part, and that Company
is entitled to communicate my obligations under this Agreement to any future employer or potential employer of mine. My obligations under
paragraphs 2, 3 and 4 also shall be binding upon my heirs, executors, assigns, and administrators and shall insure to the benefit of
Company, its subsidiaries, successors and assigns.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul
Casey</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page
8</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.
Any dispute in the meaning, effect or validity of this Agreement shall be resolved in accordance with the laws of the State of Delaware
without regard to the conflict of laws provisions thereof. I further agree that if one or more provisions of this Agreement are held
to be illegal or unenforceable under applicable law, such illegal or unenforceable portion(s) shall be limited or excluded from this
Agreement to the minimum extent required so that this Agreement shall otherwise remain in full force and effect and enforceable in accordance
with its terms. This Agreement is fully assignable and transferable by Company, but any purported assignment or transfer by me is void.
I also understand that any breach of this Agreement will cause irreparable harm to Company for which damages would not be an adequate
remedy, and, therefore, Company will be entitled to injunctive relief with respect thereto in addition to any other remedies and without
any requirement to post bond.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.
I acknowledge receipt of the following notice under 18 U.S.C &sect; 1833(b)(1): &ldquo;An individual shall not be held criminally or
civilly liable under any Federal or State trade secret law for the disclosure of a trade secret that (A) is made (i) in confidence to
a Federal, State, or local government official, either directly or indirectly, or to an attorney; and (ii) solely for the purpose of
reporting or investigating a suspected violation of law; or (B) is made in a complaint or other document filed in a lawsuit or other
proceeding, if such filing is made under seal.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Remainder
of Page Intentionally Left Blank</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul
Casey</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page
9</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
HAVE READ THIS AGREEMENT CAREFULLY AND I UNDERSTAND AND ACCEPT THE OBLIGATIONS WHICH IT IMPOSES UPON ME WITHOUT RESERVATION. NO PROMISES
OR REPRESENTATIONS HAVE BEEN MADE TO ME TO INDUCE ME TO SIGN THIS AGREEMENT. I SIGN THIS AGREEMENT VOLUNTARILY AND FREELY, IN DUPLICATE,
WITH THE UNDERSTANDING THAT THE COMPANY WILL RETURN ONE COUNTERPART AND THE OTHER COUNTERPART WILL BE RETAINED BY ME.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Employee</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Paul Casey</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Paul Casey</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul
    Casey</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accepted
and Agreed to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OneMedNet
Corp.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Dr. Jeffrey Yu</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Jeffrey Yu</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman
    of the Board</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul
Casey</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page
10</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>APPENDIX
A</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Application
of provision providing that employee shall assign or offer to assign rights in invention to employer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Any provision in an employment agreement which provides that an employee shall assign, or offer to assign, any of his or her rights in
an invention to his or her employer shall not apply to an invention that the employee developed entirely on his or her own time without
using the employer&rsquo;s equipment, supplies, facilities, or trade secret information except for those inventions that either:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
Relate at the time of conception or reduction to practice of the invention to the employer&rsquo;s business, or actual or demonstrably
anticipated research or development of the employer; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
Result from any work performed by the employee for his employer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
To the extent a provision in an employment agreement purports to require an employee to assign an invention otherwise excluded from being
required to be assigned under subdivision (a), the provision is against the public policy of this state and is unenforceable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul
Casey</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page
11</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>APPENDIX
B</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PRIOR MATTER</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 195.95pt 0pt 5pt; text-indent: 8.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.11
<SEQUENCE>17
<FILENAME>ex10-11.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.11</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECURITIES
PURCHASE AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Securities Purchase Agreement (as amended, supplemented, restated and/or modified from time to time, this &ldquo;<B>Agreement</B>&rdquo;)
is entered into as of March 28, 2024, by and between&nbsp;<B>ONEMEDNET CORPORATION</B>, a corporation organized under the laws of the
State of Delaware (the &ldquo;<B>Company</B>&rdquo;), and each investor identified on the signature pages hereto (each, including its
successors and assigns, an &ldquo;<B>Investor</B>&rdquo; and collectively, the &ldquo;<B>Investors</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BACKGROUND</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.
The board of directors (the &ldquo;<B>Board of Directors</B>&rdquo;) of the Company has authorized the issuance to each of the Investors
of certain Notes (as defined below) and Warrants (as defined below).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B
Each Investor desires to purchase certain Notes and Warrants on the terms and conditions set forth in this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOW
THEREFORE, in consideration of the foregoing recitals and the covenants and agreements set forth herein, and other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and each Investor hereby agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>1.&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>DEFINITIONS</U></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
As used in this Agreement, the following terms shall have the following meanings specified or indicated below, and such meanings shall
be equally applicable to the singular and plural forms of such defined terms:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>1933
Act</B>&rdquo; means the Securities Act of 1933, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>1934
Act</B>&rdquo; means the Securities Exchange Act of 1934, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Affiliate</B>&rdquo;
means a Person that directly, or indirectly through one or more intermediaries, controls or is controlled by, or is under common control
with, the Person specified.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Aggregate
Outstanding Amount</B>&rdquo; means the sum of (a) the outstanding Aggregate Principal Amount plus (b) the aggregate accrued and unpaid
interest and all other amounts owing to all Investors under the Notes as of the applicable measurement date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Aggregate
Principal Amount</B>&rdquo; has the meaning set forth in Section 2.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Agreement</B>&rdquo;
has the meaning set forth in the preamble.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Board
of Directors</B>&rdquo; has the meaning set forth in the recitals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Business
Day</B>&rdquo; means any day other than a Saturday, Sunday or any other day on which banks are permitted or required to be closed in
New York City.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Change
of Control</B>&rdquo; means, with respect to the Company:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 48px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">other than a shareholder
    that holds such a position at the date of this Agreement, if a Person comes to have beneficial ownership, control or direction over
    more than fifty percent (50%) of the voting rights attached to any class of voting securities of the Company; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the sale or other disposition
    in a single transaction, or in a series of transactions, of all or substantially all of the assets of the Company and its Subsidiaries,
    taken as a whole to any Person.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Closing</B>&rdquo;
has the meaning set forth in&nbsp;<U>Section 2.2</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Closing
Date</B>&rdquo; has the meaning set forth in&nbsp;<U>Section 2.2</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Closing
Equity Conditions</B>&rdquo; means, during the period in question, (a) there is a sufficient number of authorized but unissued and otherwise
unreserved Common Stock for the issuance of all of the shares then issuable pursuant to the Transaction Documents, (b) there has been
no Event of Default and no existing event which, with the passage of time or the giving of notice, would constitute an Event of Default,
and (c) the Common Stock shall be DWAC Eligible.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Code</B>&rdquo;
has the meaning set forth in&nbsp;<U>Section 2.1</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Common
Stock</B>&rdquo; means the Class A common stock of the Company having a par value per share of $0.0001.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Common
Stock Equivalent</B>&rdquo; means any convertible security or warrant, option or other right to subscribe for or purchase any Common
Stock or any convertible security convertible into Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Company</B>&rdquo;
has the meaning set forth in the preamble.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Company
Articles and Bylaws</B>&rdquo; means the Articles of Incorporation and the bylaws governing the Company duly authorized under the DGCL.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Conversion
Shares</B>&rdquo; means the Common Stock issuable upon the full or any partial conversion of a Note.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>DGCL</B>&rdquo;
means The Delaware General Corporation Law (Title 8, Chapter 1 of the Delaware Code).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>DWAC
Eligible</B>&rdquo; means that (a) the Common Stock is eligible at the Depository Trust Company (&ldquo;DTC&rdquo;) for full services
pursuant to DTC&rsquo;s Operational Arrangements, including, without limitation, transfer through DTC&rsquo;s Deposit and Withdrawal
at Custodian (&ldquo;DWAC&rdquo;) service, (b) the Transfer Agent is approved as an agent in DTC&rsquo;s Fast Automated Securities Transfer
Program, (c) the Conversion Shares are otherwise eligible for delivery via DWAC, and (d) the Transfer Agent does not have a policy prohibiting
or limiting delivery of the Conversion Shares via DWAC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Effectiveness
Date</B>&rdquo; has the meaning set forth in the Registration Rights Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Equity
Interests</B>&rdquo; means and includes the Common Stock and any Common Stock Equivalents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Escrow
Account</B>&rdquo; means the escrow account identified in and subject to the terms of the Escrow Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Escrow
Agent</B>&rdquo; means Rimon, P.C., a professional corporation incorporated in the State of Delaware, the escrow agent under the Escrow
Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Escrow
Agreement</B>&rdquo; means that certain Escrow Agreement, among the Company, the Lead Investor and the Escrow Agent, in a form acceptable
to the Lead Investor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Event
of Default</B>&rdquo; has the meaning set forth in&nbsp;<U>Section 7.1</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Exempted
Securities</B>&rdquo; means (a) equity securities issued by reason of a dividend, stock split, split-up or other distribution on Common
Stock, (b) Common Stock or rights, warrants or options to purchase Common Stock issued to employees or directors of, or consultants or
advisors to, the Company or any of its Subsidiaries pursuant to a plan, agreement or arrangement approved by the Board of Directors (&ldquo;<B>Equity
Plans</B>&rdquo;), or (c) securities issued upon the exercise or exchange of or conversion of any Securities issued hereunder and/or
rights or other securities exercisable or exchangeable for or convertible into Common Stock issued and outstanding on the date of this
Agreement as disclosed on&nbsp;<U>Schedule 1</U>&nbsp;hereto, provided that such rights and securities have not been amended since the
date of this Agreement to increase the number of such securities or to decrease the exercise price, exchange price or conversion price
of such securities or to extend the term of such securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Funding
Amount</B>&rdquo; shall mean, in respect of any Investor, the amount identified as such on the signature page hereto executed by such
Investor, but not to exceed an aggregate amount of Four Million Five Hundred Forty-Seven Thousand Five Hundred and zero/100 Dollars ($4,547,500.00).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Investor</B>&rdquo;
has the meaning set forth in the preamble.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Investor
Group</B>&rdquo; shall mean, in respect of each Investor, such Investor plus any other Person with which such Investor is considered
to be part of a group under Section 13 of the 1934 Act or with which the Investor otherwise files reports under Sections 13 and/or 16
of the 1934 Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Investor
Party</B>&rdquo; has the meaning set forth in&nbsp;<U>Section 5.12(a)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Investor
Shares</B>&rdquo; means the Conversion Shares and the Warrant Shares, and any other shares issued or issuable to the Investors pursuant
to this Agreement or the Notes or the Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>IP
Rights</B>&rdquo; has the meaning set forth in&nbsp;<U>Section 3.10</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Law</B>&rdquo;
means any law, rule, regulation, order, judgment or decree, including, without limitation, any federal and state securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&ldquo;Lead
Investor&rdquo;</B>&nbsp;means Helena Global Investment Opportunities 1 Ltd.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Losses</B>&rdquo;
has the meaning set forth in&nbsp;<U>Section 5.12(a)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Market
Capitalization</B>&rdquo; means, as of any date of determination, the product of (a) the number of issued and outstanding shares of the
Common Stock as of such date (exclusive of any Common Stock issuable upon the exercise of options or warrants or conversion of any convertible
securities), multiplied by (b) the closing price of the Common Stock on the Trading Market on the date of determination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Material
Adverse Effect</B>&rdquo; means any material adverse effect on (i) the businesses, properties, assets, operations, results of operations
or financial condition of the Company, or the Company and its Subsidiaries, taken as a whole, (ii) the ability of the Company to consummate
the transactions contemplated by this Agreement or to perform its obligations hereunder or under the Notes, or (iii) in the opinion of
the Company&rsquo;s auditor the Company is not a going concern or there is reasonable likelihood that the Company&rsquo;s auditor will
be unable to provide a going concern opinion;&nbsp;<I>provided, however</I>, that none of the following shall be deemed either alone
or in combination to constitute, and none of the following shall be taken into account in determining whether there has been or would
be, a Material Adverse Effect: (a) any adverse effect resulting from or arising out of general economic conditions; (b) any adverse effect
resulting from or arising out of general conditions in the industries in which the Company and the Subsidiaries operate; (c) any adverse
effect resulting from any changes to applicable Law; or (d) any adverse effect resulting from or arising out of any natural disaster
or any acts of terrorism, sabotage, military action or war or any escalation or worsening thereof;&nbsp;<I>provided</I>,&nbsp;<I>further</I>,
that any event, occurrence, fact, condition or change referred to in clauses (a) through (d) immediately above shall be taken into account
in determining whether a Material Adverse Effect has occurred or could reasonably be expected to occur to the extent that such event,
occurrence, fact, condition or change has a disproportionate effect on the Company and/or the Subsidiaries compared to other participants
in the industries in which the Company and the Subsidiaries operate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Maximum
Percentage</B>&rdquo; means 4.99%;&nbsp;<I>provided</I>, that if at any time after the date hereof an Investor Group beneficially owns
in excess of 4.99% of any class of Equity Interests in the Company that is registered under the 1934 Act (excluding any Equity Interests
deemed beneficially owned by virtue of a Note), then the Maximum Percentage shall automatically increase to 9.99% so long as the Investor
Group owns in excess of 4.99% of such class of Equity Interests (and shall, for the avoidance of doubt, automatically decrease to 4.99%
upon the Investor Group ceasing to own in excess of 4.99% of such class of Equity Interests).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Money
Laundering Laws</B>&rdquo; has the meaning set forth in&nbsp;<U>Section 3.25</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>New
Securities</B>&rdquo; means, collectively, equity or debt securities of the Company, whether or not currently authorized, as well as
rights, options, or warrants to purchase such equity or debt securities, or securities of any type whatsoever that are, or may become,
convertible or exchangeable into or exercisable for such equity or debt securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Note</B>&rdquo;
has the meaning set forth in&nbsp;<U>Section 2.1</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>OFAC</B>&rdquo;
has the meaning set forth in&nbsp;<U>Section 3.23</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Offer
Notice</B>&rdquo; has the meaning set forth in&nbsp;<U>Section 10.1</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Person</B>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Principal
Amount</B>&rdquo; means the principal amount of the Note(s) as of the applicable date of determination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Proceedings</B>&rdquo;
has the meaning set forth in&nbsp;<U>Section 3.6</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Prohibited
Transaction</B>&rdquo; means a transaction with a third party or third parties in which the Company issues or sells (or arranges or agrees
to issue or sell):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
any debt, equity or equity-linked securities (including options or warrants) that are convertible into, exchangeable or exercisable for,
or include the right to receive Common Stock:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
at a conversion, repayment, exercise or exchange rate or other price that varies over time based upon a discount to the future trading
prices of, or quotations for, Common Stock; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
at a conversion, repayment, exercise or exchange rate or other price that is subject to being reset at some future date after the initial
issuance of such debt, equity or equity-linked security or upon the occurrence of specified or contingent events, including but not limited
to, in connection with anti-dilution provisions or other similar price protection provisions; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
any securities in a capital or debt raising transaction or series of related transactions which grant to an investor the right to receive
additional securities based upon future transactions of the Company on terms more favorable than those granted to such investor in such
first transaction or series of related transactions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
the foregoing, and for the avoidance of doubt, rights issuances, shareholder purchase plans, or Equity Plans shall not be deemed to be
a Prohibited Transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Registration
Condition</B>&rdquo; means in respect of the Initial Tranche and in respect of the Second Tranche, the Investor Shares issuable pursuant
to the Notes and Warrants to be issued in in the Initial Tranche and the Second Tranche may be resold without a legend pursuant to an
effective registration statement pursuant to Rule 144 under the 1933 Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Registration
Rights Agreement</B>&rdquo; means a Registration Rights Agreement, in the form of&nbsp;<U>Exhibit C</U>&nbsp;hereto, among the Company
and the Investors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Required
Minimum</B>&rdquo; means, as of any date, two (2) times the maximum aggregate number of shares Common Stock then issued or potentially
issuable in the future pursuant to the Transaction Documents, including any Conversion Shares issuable upon conversion in full of the
Notes and Warrant Shares issuable upon exercise in full of the Warrants, ignoring any conversion or exercise limits set forth therein
based, as of the date of initial Closing, on a conversion price of $0.41 and an exercise price of $ $0.6821, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Requisite
Holder</B>&rdquo; means the Lead Investor or any successor in interest to the Lead Investor that is mutually agreed to by the Lead Investor
and the Company. For the purposes of clarity hereunder, only one entity shall serve as the Requisite Holder at any time hereunder and
the affirmative action or consent by the Requisite Holder shall bind all Investors hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>SEC</B>&rdquo;
means the United States Securities and Exchange Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>SEC
Documents</B>&rdquo; has the meaning set forth in&nbsp;<U>Section 3.5(a)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Securities</B>&rdquo;
means the Notes, the Warrants, and the Investor Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Securities
Termination Event</B>&rdquo; means either of the following has occurred:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
trading in securities generally in the United States has been suspended or limited for a consecutive period of greater than three (3)
Business Days; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
a banking moratorium has been declared by the United States or the New York State authorities and is continuing for a consecutive period
of greater than three (3) Business Days.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Shareholder
Approval</B>&rdquo; means the approval of the holders of the requisite number of the outstanding Common Stock to ratify and approve all
of the transactions contemplated by the Transaction Documents, including the issuance of all of Investor Shares (as such term is defined
in each of such documents) issued and potentially issuable to the Investor thereunder, all as may be required by the applicable rules
and regulations of the Trading Market (or any successor entity).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Subsidiaries</B>&rdquo;
and &ldquo;<B>Subsidiary</B>&rdquo; have the meaning set forth in&nbsp;<U>Section 3.4(b)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Subsidiary
Guarantee</B>&rdquo; means a guarantee, in the form of&nbsp;<U>Exhibit E</U>&nbsp;hereto issued by the Subsidiaries, of the Company&rsquo;s
obligations under this Agreement and the Notes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&ldquo;Trading
Day&rdquo;</B>&nbsp;means a day on which the Common Stock is traded on a Trading Market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Trading
Market</B>&rdquo; means whichever of the New York Stock Exchange, NYSE American, or the Nasdaq Stock Market (including the Nasdaq Capital
Market and the Nasdaq Global Market), on which the Common Stock is listed or quoted for trading on the date in question.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Tranche</B>&rdquo;
has the meaning set forth in&nbsp;<U>Section 2.1</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Transaction
Documents</B>&rdquo; means this Agreement, the Notes, the Registration Rights Agreement, the Subordination Agreement, the Subsidiary
Guarantee, the Transfer Agent Instruction Letter, the Escrow Agreement, and any other documents or agreements executed or delivered in
connection with the transactions contemplated hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Transfer
Agent</B>&rdquo; means Continental Stock Transfer &amp; Trust Co. having its offices at 1 State Street, 30<SUP>th</SUP>&nbsp;Floor, New
York, NY 10004.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Transfer
Agent Instruction Letter</B>&rdquo; means a letter of irrevocable instructions addressed by the Company to the Transfer Agent, acceptable
to the Investor in its sole discretion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>VWAP</B>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30
a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if the Common Stock is traded on OTCQB or OTCQX , the volume weighted
average sales price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common
Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock is then reported in the &ldquo;Pink
Sheets&rdquo; published by OTC Markets Group, Inc. (or a similar organization or agency succeeding to its functions of reporting prices),
the most recent bid price per share of the Common Stock so reported, or (d) in all other cases, the fair market value of a Share of Common
Stock as determined by an independent appraiser selected in good faith by the Lead Investor and reasonably acceptable to the Company,
the fees and expenses of which shall be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Warrant</B>&rdquo;
has the meaning set forth in&nbsp;<U>Section 2.1</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Warrant
Shares</B>&rdquo; means the Common Stock issuable upon the full or any partial exercise of a Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Warrant
Share Amount</B>&rdquo; means in respect of any Warrant issued in a Closing the initial amount of shares of Common Stock for which such
Warrant may be exercised and which shall be equal to the applicable Principal Amount of the Note issued to the applicable Investor in
such Closing multiplied by Fifty Percent (50%) and divided by the 95% of lowest VWAP over the ten Trading Day period immediately preceding
the applicable Closing Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>2.&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>PURCHASE
AND SALE OF THE NOTES</U></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.1&nbsp;</B><U>Purchase
and Sale of the Notes</U>. Subject to the terms and conditions set forth herein, the Company shall issue and sell to each Investor, and
each Investor shall purchase from the Company, convertible promissory notes, in the form attached hereto as&nbsp;<U>Exhibit A</U>&nbsp;(each,
a &ldquo;<B>Note</B>&rdquo; and together, the &ldquo;<B>Notes</B>&rdquo;), in an amount up to the principal amount set forth on the signature
page hereto executed by such Investor and common stock purchase warrants, in the form attached hereto as&nbsp;<U>Exhibit B</U>&nbsp;(each,
a &ldquo;<B>Warrant</B>&rdquo; and together, the &ldquo;<B>Warrants</B>&rdquo;). Subject to the terms and conditions set forth herein,
the sale and purchase of Notes and Warrants shall be conducted in tranches (each, a &ldquo;<B>Tranche</B>&rdquo; and together, the &ldquo;<B>Tranches</B>&rdquo;)
consisting of (x) an initial tranche (the &ldquo;<B>Initial Tranche</B>&rdquo;) of (i) an aggregate Principal Amount of Notes of up to
Two Million and zero/100 Dollars ($2,000,000.00) and including an original issue discount of up to an aggregate of Three Hundred Thousand
and zero/100 Dollars ($300,000.00), and (ii) Warrants to purchase a number of shares of Common Stock equal to the applicable Warrant
Share Amounts with respect to such Tranche, (y) a second tranche (the &ldquo;<B>Second Tranche</B>&rdquo;) of (i) an aggregate Principal
Amount of Notes of up to Three Hundred Fifty Thousand and zero/100 Dollars ($350,000.00) and including an original issue discount of
up to an aggregate of Fifty Two Thousand Five Hundred and zero/100 Dollars ($52,500.00), and (ii) Warrants to purchase a number of shares
of Common Stock equal to the applicable Warrant Share Amounts with respect to such Tranche and (z) up to three subsequent Tranches each
of which shall be in (i) an aggregate Principal Amount of Notes of up to One Million and zero/100 Dollars ($1,000,000) each and each
including an original issue discount of fifteen percent (15.0%) of the applicable Principal Amount, and (ii) Warrants to purchase a number
of shares of Common Stock equal to the applicable Warrant Share Amounts with respect to such Tranches. The purchase price of a Note and
its accompanying Warrant shall be computed by subtracting the portion of the OID represented by that such Note from the portion of the
Principal Amount represented by such Note (a &ldquo;<B>Purchase Price</B>&rdquo;). For purposes of this Agreement and the other Transaction
Documents, the aggregate Principal Amounts of all the Notes, shall be referred to together as, the &ldquo;<B>Aggregate Principal Amount</B>;
the aggregate original issue discounts of the Notes shall be referred to together as, the &ldquo;<B>OID</B>; and the aggregate Funding
Amounts of all of the Notes, shall be referred to together as, the &ldquo;<B>Aggregate Funding Amount</B>&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.2&nbsp;</B><U>Closings</U>.
Each sale of Notes and Warrants in a Tranche shall occur in one or more closings (each, a &ldquo;<B>Closing</B>&rdquo;) with the date
upon which such Closing shall occur being referred to as, a &ldquo;<B>Closing Date</B>&rdquo;, and more specifically as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;<U>Initial
Tranche</U>. Subject to the terms and conditions set forth herein, the Closing of the Initial Tranche shall occur no later than five
(5) Business Days following the date that the Registration Condition shall have been met in respect of the Investor Shares issuable in
respect of the Notes and Warrants to be issued in the Initial Tranche.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;<U>Second
Tranche</U>. Subject to the terms and conditions set forth herein, the Closing of the Second Tranche shall occur on the date that is
twenty (20) Trading Days following the Closing Date of the Initial Tranche; provided that the Registration Condition shall have been
met in respect of the Investor Shares underlying the Notes and Warrants to be issued in the Second Tranche as of the proposed Closing
Date for the Second Tranche.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&nbsp;<U>Subsequent
Tranches</U>. Subject to the terms and conditions set forth herein, the Closing of any subsequent Tranche (each, a &ldquo;<B>Subsequent
Tranche</B>&rdquo;) shall occur on the earlier of (i) such date as the Company and Lead Investor may agree and (ii) the date that is
sixty (60) Trading Days following the disbursement of the preceding Tranche; provided, that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
the closing price of the Common Stock on the Trading Market shall have been equal to or in excess of 200% of the Floor Price (as defined
in the Notes) on the Trading Day immediately preceding the applicable Closing Date; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
the Closing of any subsequent Tranche shall be for only one Tranche of Notes having an initial aggregate Principal Amount equal to up
to One Million and zero/100 Dollars ($1,000,000).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&nbsp;<U>Generally,
in Respect of Closings</U>. Subject to the terms and conditions set forth herein, each Closing, including payment for and delivery of
the Notes and Warrants in respect of such Closing, shall take place remotely via the exchange of documents and signatures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&nbsp;<U>Escrow
Agreement</U>. In connection with the Closings, each of the Company and the Lenders agree that the payment of consideration for the Initial
Tranche, the Second Tranche and of the Tranche following the Second Tranche (the &ldquo;<B>Third Tranche</B>&rdquo;) shall be made in
accordance with the following provisions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
$1,350,000.00 of the net proceeds of the Initial Tranche will be paid into the Escrow Account for distribution in accordance with Section
2.2(f) with the balance of the net proceeds of the Initial Tranche being paid in accordance with the flow of funds request relating to
such Initial Tranche;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
100% of the net proceeds of the Third Tranche shall be paid into the Escrow Account for distribution in accordance with Section 2.2(f);
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
75% of the net proceeds of the Third Tranche shall be paid into the Escrow Account for distribution in accordance with Section 2.2(f)
with the balance of the net proceeds of the Third Tranche being paid in accordance with the flow of funds request relating to such Third
Tranche.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)&nbsp;<U>Release
of the Proceeds of the Initial Tranche, the Second Tranche and the Third Tranche</U>. The Company and the Lead Investor agree that they
shall direct the Escrow Agent in writing to release the proceeds of the Initial Tranche, the Second Tranche and the Third Tranche (the
&ldquo;<U>Escrowed Proceeds</U>&rdquo;) from the Escrow Account as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
The Company and the Lead Investor shall direct the Escrow Agent to immediately release all Escrowed Proceeds held in the Escrow Account
to the Investors for payment on a pro rata basis of all amounts owing in respect of the Notes, (x) if the closing price of the Common
Stock on the Trading Market shall have been less than the then Floor Price (as defined in the Notes) for a period of ten (10) consecutive
Trading Days, or (y) an Event of Default shall have occurred;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
The Company and the Lead Investor shall direct the Escrow Agent to immediately release all Escrowed Proceeds held in the Escrow Account
to the Company if the Aggregate Outstanding amount is equal to zero;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
If on the date that is 20 Trading Days following the Closing Date of the Initial Tranche, the Aggregate Outstanding Amount is in excess
of zero but less than $1,700,000.00, then the Lead Investor shall direct the Escrow Agent to immediately release to the Company from
the Escrowed Proceeds an amount equal to the difference between $1,700,000.00 and such Aggregate Outstanding Amount; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
If on the date that is 40 Trading Days following the Closing Date of the Initial Tranche and every 20 Trading Days thereafter, the Aggregate
Outstanding Amount is in excess of zero but is less than $1,700,000.00&nbsp;<U>minus</U>&nbsp;the amount of any prior disbursement from
the Escrow Account pursuant to this Section 2.2(f)(iv) or Section 2.2(f)(iii) (&ldquo;<B>Adjusted Escrow Reference Amount</B>&rdquo;),
then the Lead Investor shall direct the Escrow Agent to immediately release to the Company from the Escrowed Proceeds an amount equal
to the difference between the Adjusted Escrow Reference Amount and such Aggregate Outstanding Amount.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.3&nbsp;</B><U>Priority
of Obligation</U>. As an inducement for the Investors to enter into this Agreement and to purchase the Notes, all obligations of the
Company pursuant to this Agreement and the Notes shall be senior in payment to any subsequent unsecured Indebtedness (as defined in the
Notes).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.4&nbsp;</B><U>Pro
Rata Payments</U>. The Company and each Investor hereby agree that, notwithstanding anything to the contrary contained herein or in the
Notes, to the extent the Company is obligated to make any payments hereunder or under the Notes to the Investors (or offers to make any
prepayments hereunder or thereunder), all such payments shall be applied to the outstanding principal amount of the Notes held by all
Investors on a pro rata basis based on the Aggregate Outstanding Amount at the time of such prepayment. If any Investor shall, by exercising
any right of setoff or counterclaim or otherwise, obtain payment in respect of any principal of or interest on any of outstanding amounts
under the Notes resulting in such Investor receiving payment of a proportion of the Aggregate Outstanding Amount at the time of such
prepayment greater than its pro rata share thereof as provided herein, then the Investor receiving such greater proportion shall (a)
notify the other Investors of such fact, and (b) purchase (for cash at face value) participations in the principal amount owing to the
other Investors under the applicable Notes, or make such other adjustments as shall be equitable, so that the benefit of all such payments
shall be shared by the Investors ratably in accordance with the aggregate amount of principal of and accrued interest on their respective
Notes and other amounts owing them. The Company consents to the foregoing and agrees, to the extent it may effectively do so under applicable
law, that any Investor acquiring a participation pursuant to the foregoing arrangement may exercise against the Company rights of setoff
and counterclaim with respect to such participation as fully as if such Investor were a direct creditor of the Company in the amount
of such participation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>3.&nbsp;</B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>REPRESENTATIONS
AND WARRANTIES OF THE COMPANY</U>. The Company represents and warrants to each Investor and covenants with each Investor that, the following
representations and warranties are true and correct as of the date hereof and as of each Closing Date:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.1&nbsp;</B><U>Organization
and Qualification</U>. The Company is a company duly incorporated and validly existing in good standing under the Laws of the State of
Delaware and has the requisite corporate power and authority to own its properties and to carry on its business as now being conducted.
The Company is duly qualified to do business and is in good standing in every jurisdiction in which the ownership of its property or
the nature of the business conducted by it makes such qualification necessary, except to the extent that the failure to be so qualified
or be in good standing would not have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.2&nbsp;</B><U>Authorization;
Enforcement; Compliance with Other Instruments</U>. The Company and each Subsidiary has the requisite corporate power and authority to
execute the Transaction Documents, and if applicable, to issue and sell the Notes and Warrants pursuant hereto, and to perform its obligations
under the Transaction Documents, including issuing the Investor Shares on the terms set forth in this Agreement. The execution and delivery
of the Transaction Documents by the Company, and the issuance and sale of the Securities by the Company pursuant hereto have been duly
and validly authorized by the Company&rsquo;s Board of Directors. The execution and delivery of each Transaction Document to be executed
by a Subsidiary has been duly and validly authorized by such Subsidiary&rsquo;s board of directors, shareholder(s), or member(s), as
applicable. No further consent or authorization is required by the Company, any Subsidiary, the Company&rsquo;s Board of Directors, their
respective shareholders or members or any other Person in connection therewith, except such as have been waived and other than such filings
as are required to be made under applicable Laws. Each Transaction Document has been duly and validly executed and delivered by the Company
and each Subsidiary to which it is a party and constitutes the valid and binding obligation of the Company and such Subsidiary, enforceable
against the Company and such Subsidiary in accordance with their respective terms, except as such enforceability may be limited by general
principles of equity or applicable bankruptcy, insolvency, reorganization, moratorium, liquidation or similar Laws relating to, or affecting
generally, the enforcement of creditors&rsquo; rights and remedies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.3&nbsp;</B><U>No
Conflicts</U>. The execution, delivery and performance of the Transaction Documents by the Company and each Subsidiary and the issuance
and sale of the Notes and Warrants hereunder by the Company will not (a) conflict with or result in a violation of the Company Articles
and Bylaws, (b) conflict with, or constitute a material default (or an event which, with notice or lapse of time or both, would become
a material default) under, or give to others any right of termination, amendment, acceleration or cancellation of, any material agreement
to which the Company or any of the Subsidiaries is a party, or (c) violate in any material respect any Law or any rule or regulation
of the Trading Market applicable to the Company or any of the Subsidiaries or by which any of their properties or assets are bound or
affected. Assuming the accuracy of each Investor&rsquo;s representations in&nbsp;<U>Section 4</U>&nbsp;and subject to the making of the
filings referred to in&nbsp;<U>Section 6</U>&nbsp;and receipt of the Shareholder Approval, (i) no approval or authorization will be required
from any governmental authority or agency, regulatory or self-regulatory agency or other third party (including the Trading Market) in
connection with the issuance of the Notes and the other transactions contemplated by this Agreement (including the issuance of the Conversion
Shares upon conversion of the Notes), (ii) the issuance of (x) the Notes, and the issuance of the Conversion Shares upon the conversion
of the Notes, and (y) the Warrants, and the issuance of the Warrant Shares upon the exercise of the Warrants, will be exempt from the
registration and qualification requirements under the 1933 Act and all applicable state securities Laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.4&nbsp;</B><U>Capitalization
and Subsidiaries</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
As of the date hereof, there are 23,572,232 shares of Common Stock issued and outstanding. The Conversion Shares, when issued upon conversion
of a Note in accordance with its terms, will be validly issued, fully paid and non-assessable and free from all taxes, liens and charges
with respect to the issuance thereof. The Warrant Shares, when issued upon exercise of a Warrant in accordance with its terms, will be
validly issued, fully paid and non-assessable and free from all taxes, liens and charges with respect to the issuance thereof. Other
than as provided in&nbsp;<U>Schedule 3.4(a)</U>, no Common Stock is subject to preemptive rights or any other similar rights or any liens
or encumbrances suffered or permitted by the Company. The Company Articles and Bylaws on file with the SEC are true and correct copies
of the Company Articles and Bylaws as in effect as of the date hereof. The Company is not in violation of any provision of the Company
Articles or Bylaws nor is any Subsidiary in violation of its organization documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;<U>Schedule
3.4(b)</U>&nbsp;lists each direct and indirect subsidiary of the Company (each, a &ldquo;Subsidiary&rdquo; and collectively, the &ldquo;Subsidiaries&rdquo;)
and indicates for each Subsidiary (i) the authorized capital stock or other Equity Interest of such Subsidiary as of the date hereof
, (ii) the number and kind of shares or other ownership interests of such Subsidiary that are issued and outstanding as of the date hereof
, and (iii) the owner of such shares or other ownership interests as of the date hereof . No Subsidiary has any outstanding stock options,
warrants or other instruments pursuant to which such Subsidiary may at any time or under any circumstances be obligated to issue any
shares of its capital stock or other Equity Interests. Each Subsidiary is duly organized and validly existing in good standing under
the laws of its jurisdiction of formation, except to the extent that the failure to be in good standing would not have a Material Adverse
Effect, and has all requisite power and authority to own its properties and to carry on its business as now being conducted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Other than as provided in&nbsp;<U>Schedule 3.4(c)</U>&nbsp;, neither the Company nor any Subsidiary is bound by any agreement or arrangement
pursuant to which it is obligated to register the sale of any securities under the 1933 Act. Other than as provided in&nbsp;<U>Schedule
3.4(c)</U>&nbsp;, there are no outstanding securities of the Company or any of the Subsidiaries which contain any redemption or similar
provisions, and there are no contracts, commitments, understandings or arrangements by which the Company or any Subsidiary is or may
become bound to redeem or purchase any security of the Company or any Subsidiary. Other than as provided in&nbsp;<U>Schedule 3.4(c)</U>,
there will be no outstanding securities or instruments containing anti-dilution or similar provisions that will be triggered by the issuance
of the Notes, the Warrants, or the Investor Shares. Neither the Company nor any Subsidiary has any stock appreciation rights or &ldquo;phantom
stock&rdquo; plans or agreements or any similar plan or agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
The issuance and sale of any of the Securities will not obligate the Company to issue Common Stock or other securities to any Person
other than the Investors and, other than as provided in&nbsp;<U>Schedule 3.4(d)</U>, will not result in the adjustment of the exercise,
conversion, exchange, or reset price of any outstanding securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.5&nbsp;</B><U>SEC
Documents; Financial Statements</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
As of the date hereof and each Closing Date and except as set forth on&nbsp;<U>Schedule 3.5(a)</U>, the Company has filed all reports,
schedules, forms, statements and other documents required to be filed by it with the SEC pursuant to the reporting requirements of the
1934 Act since August 9, 2023 (all of the foregoing filed prior to the date hereof, as they have been amended since the time of their
filing, and all exhibits included therein and documents incorporated by reference therein being hereinafter referred to as the &ldquo;<B>SEC
Documents</B>&rdquo;). As of their respective filing dates, the SEC Documents complied in all material respects with the requirements
of the 1934 Act and the rules and regulations of the SEC promulgated thereunder applicable to the SEC Documents, and none of the SEC
Documents, at the time they were filed with the SEC, contained any untrue statement of a material fact or omitted to state a material
fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made,
not misleading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
As of their respective dates, the financial statements of the Company included in the SEC Documents complied as to form in all material
respects with applicable accounting requirements and the published rules and regulations of the SEC with respect thereto. Such financial
statements have been prepared in accordance with generally accepted accounting principles consistently applied, and audited by a firm
that is a member of the Public Company Accounting Oversight Board, during the periods involved (except as may be otherwise indicated
in such financial statements or the notes thereto, except in the case of pro forma statements or, in the case of unaudited interim statements,
except to the extent they may exclude footnotes or may be condensed or summary statements) and fairly present in all material respects
the consolidated financial position of the Company as of the dates thereof and the consolidated results of its operations and consolidated
cash flows for the periods then ended (subject, in the case of unaudited statements, to normal year-end audit adjustments).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Except as disclosed in the SEC Documents, the Company and each of the Subsidiaries maintain a system of internal accounting controls
sufficient to provide reasonable assurance that (i) transactions are executed in accordance with management&rsquo;s general or specific
authorizations, (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with US generally
accepted accounting principles and to maintain asset accountability, (iii) reasonable controls to safeguard assets are in place and (iv)
the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with
respect to any differences.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.6&nbsp;</B><U>Litigation
and Regulatory Proceedings</U>. Except as disclosed in&nbsp;<U>Schedule 3.6</U>, there are no actions, causes of action, suits, claims,
proceedings, inquiries or investigations (collectively, &ldquo;Proceedings&rdquo;) (i) before or by any court, public board, government
agency, self-regulatory organization or body pending or, to the knowledge of the executive officers of the Company or any of the Subsidiaries,
threatened against or affecting the Company or any of the Subsidiaries, the Common Stock or any other class of issued and outstanding
shares of the Company, or any of the Company&rsquo;s or the Subsidiaries&rsquo; officers or directors in their capacities as such, which
adversely affects or challenges the legality, validity or enforceability of any of the Transaction Documents or the Securities or (ii)
that would, if there were an unfavorable decision, have or reasonably be expected to result in a Material Adverse Effect; and, to the
knowledge of the executive officers of the Company, there is no reason to believe that there is any basis for any such Proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.7&nbsp;</B><U>No
Undisclosed Events, Liabilities or Developments</U>. Except for the issuance of the Securities contemplated by this Agreement or as set
forth on&nbsp;<U>Schedule 3.7</U>, no event, development or circumstance has occurred or exists, or to the knowledge of the executive
officers of the Company is reasonably anticipated to occur or exist that (a) would reasonably be anticipated to have a Material Adverse
Effect or (b) would be required to be disclosed by the Company under applicable securities Laws and which has not been publicly announced.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.8&nbsp;</B><U>Compliance
with Law</U>. Except as disclosed in&nbsp;<U>Schedule 3.8</U>, the Company and each of the Subsidiaries have conducted and are conducting
their respective businesses in compliance in all material respects with all applicable Laws and are in compliance in all material respects
with the rules and regulations of the Trading Market. Except as disclosed in&nbsp;<U>Schedule 3.8</U>, the Company is not aware of any
facts which could reasonably be anticipated to lead to a delisting of the Common Stock by the Trading Market in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.9&nbsp;</B><U>Employee
Relations</U>. Neither the Company nor any Subsidiary is involved in any union labor dispute nor, to the knowledge of the Company, is
any such dispute threatened. Neither the Company nor any Subsidiary is a party to any collective bargaining agreement. No executive officer
(as defined in Rule 501(f) of the 1933 Act) has notified the Company that such officer intends to leave the Company&rsquo;s employ or
otherwise terminate such officer&rsquo;s employment with the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.10&nbsp;</B><U>Intellectual
Property Rights</U>. The Company and each Subsidiary owns or possesses or can acquire on reasonable terms adequate rights or licenses
to use all trademarks, trade names, service marks, service mark registrations, service names, patents, patent rights, copyrights, inventions,
licenses, approvals, governmental authorizations, trade secrets and other intellectual property rights (collectively, &ldquo;<B>IP Rights</B>&rdquo;)
used in or reasonably necessary to conduct their respective businesses as now conducted. None of the material IP Rights of the Company
or any of the Subsidiaries are expected to expire or terminate within three (3) years from the date of this Agreement. Neither the Company
nor any Subsidiary has received any notice alleging that it is infringing, misappropriating or otherwise violating any IP Rights of any
other Person. No written notice of a claim has been received by, and no Proceeding is pending against, the Company or any Subsidiary
alleging that the Company or any Subsidiary is infringing, misappropriating or otherwise violating the IP Rights of any other Person,
and, to the Company&rsquo;s knowledge, no such claim or Proceeding is threatened, and the Company is not aware of any facts or circumstances
which might give rise to any such claim or Proceeding. The Company and the Subsidiaries have taken commercially reasonable security measures
to protect the secrecy, confidentiality and value of all of their material IP Rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.11&nbsp;</B><U>Environmental
Laws</U>. Except, in each case, as would not be reasonably anticipated to have a Material Adverse Effect, the Company and the Subsidiaries
(a) are in compliance with any and all applicable Laws relating to the protection of human health and safety, the environment or hazardous
or toxic substances or wastes, pollutants or contaminants, (b) have received and hold all permits, licenses or other approvals required
of them under all such Laws to conduct their respective businesses and (c) are in compliance with all terms and conditions of any such
permit, license or approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.12&nbsp;</B><U>Title
to Assets</U>. The Company and the Subsidiaries have good and marketable title to all personal property (other than IP Rights, which
is addressed in&nbsp;<U>Section 3.10</U>) owned by them which is material to their respective businesses, in each case free and clear
of all liens, encumbrances and defects except those set forth on&nbsp;<U>Schedule 3.12</U>. Any real property and facilities held under
lease by the Company or any Subsidiary are held under valid, subsisting and enforceable leases with such exceptions as are not material
and do not interfere with the use made and proposed to be made of such property and buildings by the Company and the Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.13&nbsp;</B><U>Insurance</U>.
The Company and each of the Subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks
and in such amounts as management of the Company reasonably believes to be prudent and customary in the businesses in which the Company
and the Subsidiaries are engaged. Neither the Company nor any of the Subsidiaries has been refused any insurance coverage sought or applied
for, and the Company has no reason to believe that it will not be able to renew all existing insurance coverage as and when such coverage
expires or to obtain similar coverage from similar insurers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.14&nbsp;</B><U>Regulatory
Permits</U>. The Company and the Subsidiaries have in full force and effect all certificates, approvals, authorizations and permits from
all regulatory authorities and agencies necessary to own, lease or operate their respective properties and assets and conduct their respective
businesses, and neither the Company nor any Subsidiary has received any notice of Proceedings relating to the revocation or modification
of any such certificate, approval, authorization or permit, except for such certificates, approvals, authorizations or permits with respect
to which the failure to hold would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.15&nbsp;</B><U>No
Materially Adverse Contracts, Etc</U>. Neither the Company nor any of the Subsidiaries is (a) subject to any charter, corporate or other
legal restriction, or any judgment, decree or order which in the judgment of the Company&rsquo;s officers has or would reasonably be
expected in the future to have a Material Adverse Effect or (b) a party to any contract or agreement which in the judgment of the Company&rsquo;s
management has or would reasonably be anticipated to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.16&nbsp;</B><U>Taxes</U>.
Other than as provided on&nbsp;<U>Schedule 3.16</U>, the Company and the Subsidiaries each has made or filed, or caused to be made or
filed, all United States federal, and applicable state, local and non-U.S. tax returns, reports and declarations required by any jurisdiction
to which it is subject and has paid all taxes and other governmental assessments and charges that are material in amount, required to
be paid by it, regardless of whether such amounts are shown or determined to be due on such returns, reports and declarations, except
those being contested in good faith by appropriate proceedings and for which it has set aside on its books provision reasonably adequate
for the payment of all taxes for periods subsequent to the periods to which such returns, reports or declarations apply. There are no
unpaid taxes in any material amount claimed to be due by the taxing authority of any jurisdiction, and, to the knowledge of the Company,
there is no basis for any such claim.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.17&nbsp;</B><U>Solvency</U>.
After giving effect to the receipt by the Company of the proceeds from the transactions contemplated by this Agreement, (a) the Company&rsquo;s
book value of its assets exceeds the Company&rsquo;s book value of existing debts and other liabilities (ignoring any potential contingent
liabilities) as they mature; and (b) the current cash flow of the Company, together with the proceeds the Company would receive, were
it to liquidate all of its assets at book value, after taking into account all anticipated uses of the cash, would be sufficient to pay
all amounts on or in respect of its debt at book value when such amounts are required to be paid. The Company does not intend to incur
debts beyond its ability to pay such debts as they mature (taking into account the timing and amounts of cash to be payable on or in
respect of its debt). Except as disclosed as set forth in&nbsp;<U>Schedule 3.17</U>, the Company has no knowledge of any facts or circumstances
which lead it to believe that it will file for reorganization or liquidation under the bankruptcy or reorganization laws of any jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.18&nbsp;</B><U>Investment
Company</U>. The Company is not, and is not an Affiliate of, an &ldquo;investment company&rdquo; within the meaning of the Investment
Company Act of 1940, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.19&nbsp;</B><U>Certain
Transactions</U>. Other than as disclosed in&nbsp;<U>Schedule 3.19</U>, there are no contracts, transactions, arrangements or understandings
between the Company or any of its Subsidiaries, on the one hand, and any director, officer or employee thereof on the other hand, that
would be required to be disclosed pursuant to Item 404 of Regulation S-K promulgated by the SEC in the Company&rsquo;s Form&nbsp;<U>10-K</U>&nbsp;or
proxy statement pertaining to an annual meeting of shareholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.20&nbsp;</B><U>No
General Solicitation</U>. Neither the Company, nor any of its Affiliates, nor any person acting on its behalf, has engaged in any form
of general solicitation or general advertising (within the meaning of Regulation D) in connection with the offer or sale of the Notes
pursuant to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.21&nbsp;</B><U>Acknowledgment
Regarding the Investors&rsquo; Purchase of the Notes</U>. The Company&rsquo;s Board of Directors has approved the execution of the Transaction
Documents and the issuance and sale of the Notes and Warrants, based on its own independent evaluation and determination that the terms
of the Transaction Documents are reasonable and fair to the Company and in the best interests of the Company and its shareholders. The
Company is entering into this Agreement and is issuing and selling the Notes and Warrants voluntarily. The Company has had independent
legal counsel of its own choosing review the Transaction Documents and advise the Company with respect thereto. The Company acknowledges
and agrees that each Investor is acting solely in the capacity of an arm&rsquo;s length purchaser with respect to its Notes and Warrants
and the transactions contemplated hereby and that neither such Investor nor any person affiliated with such Investor is acting as a financial
advisor to, or a fiduciary of, the Company (or in any similar capacity) with respect to execution of the Transaction Documents or the
issuance of the Notes and Warrants or any other transaction contemplated hereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.22&nbsp;</B><U>No
Brokers&rsquo;, Finders&rsquo; or Other Advisory Fees or Commissions</U>. Except as set forth on&nbsp;<U>Schedule 3.22</U>, no brokers,
finders or other similar advisory fees or commissions will be payable by the Company or any Subsidiary or by any of their respective
agents with respect to the issuance of the Notes or the Warrants or any of the other transactions contemplated by this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.23&nbsp;</B><U>OFAC</U>.
None of the Company nor any of the Subsidiaries nor, to the best knowledge of the Company, any director, officer, agent, employee, affiliate
or person acting on behalf of the Company and/or any Subsidiary has been or is currently subject to any United States sanctions administered
by the Office of Foreign Assets Control of the United States Department of the Treasury (&ldquo;<B>OFAC</B>&rdquo;); and the Company
will not directly or indirectly use any proceeds received from any Investor, or lend, contribute or otherwise make available such proceeds
to its Subsidiaries or to any affiliated entity, joint venture partner or other person or entity, to finance any investments in, or make
any payments to, any country or person currently subject to any of the sanctions of the United States administered by OFAC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.24&nbsp;</B><U>No
Foreign Corrupt Practices</U>. None of the Company or any of the Subsidiaries has, directly or indirectly: (a) made or authorized any
contribution, payment or gift of funds or property to any official, employee or agent of any governmental authority of any jurisdiction
except as otherwise permitted under applicable Law; or (b) made any contribution to any candidate for public office, in either case,
where either the payment or the purpose of such contribution, payment or gift was, is, or would be prohibited under the Foreign Corrupt
Practices Act or the rules and regulations promulgated thereunder or under any other legislation of any relevant jurisdiction covering
a similar subject matter applicable to the Company or its Subsidiaries and their respective operations and the Company has instituted
and maintained policies and procedures designed to ensure, and which are reasonably expected to continue to ensure, continued compliance
with such legislation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.25&nbsp;</B><U>Anti-Money
Laundering</U>. The operations of each of the Company and the Subsidiaries are and have been conducted at all times in compliance with
all applicable anti-money laundering laws, regulations, rules and guidelines in its jurisdiction of incorporation and in each other jurisdiction
in which such entity, as the case may be, conducts business (collectively, the &ldquo;<B>Money Laundering Laws</B>&rdquo;) and no action,
suit or proceeding by or before any court or governmental authority involving the Company or its Subsidiaries with respect to any of
the Money Laundering Laws is, to the best knowledge of the Company, pending, threatened or contemplated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.26&nbsp;</B><U>Disclosure</U>.
The Company confirms that neither it, nor to its knowledge, any other Person acting on its behalf has provided any Investor or its agents
or counsel with any information that the Company believes constitutes material, non-public information. The Company understands and confirms
that the Investors will rely on the foregoing representations and covenants in effecting transactions in securities of the Company. All
disclosures provided to the Investors regarding the Company, its business and the transactions contemplated hereby, furnished by or on
behalf of the Company (including the Company&rsquo;s representations and warranties set forth in this Agreement) are true and correct
in all material respects and do not contain any untrue statement of a material fact or omit to state any material fact necessary in order
to make the statements made therein, in light of the circumstances under which they were made, not misleading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.27&nbsp;</B><U>Available
Common Stock</U>. As of the date hereof, the Company has capacity under the rules and regulations of the Trading Market to issue up to
6,452,668 shares of Common Stock (or securities convertible into or exercisable for Common Stock) without obtaining Shareholder Approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.28&nbsp;</B><U>Indebtedness</U>.
Except for as listed on&nbsp;<U>Schedule 3.28</U>, as of the date hereof the Company or any Subsidiary has no outstanding Indebtedness.
For the purposes of this Agreement, &ldquo;<B>Indebtedness</B>&rdquo; means (x) any liabilities for borrowed money or amounts owed in
excess of $100,000 (other than trade accounts payable incurred in the ordinary course of business), (y) all guaranties, endorsements
and other contingent obligations in respect of indebtedness of others, whether or not the same are or should be reflected in the Company&rsquo;s
consolidated balance sheet (or the notes thereto), except guaranties by endorsement of negotiable instruments for deposit or collection
or similar transactions in the ordinary course of business; and (z) the present value of any lease payments in excess of $100,000 due
under leases required to be capitalized in accordance with GAAP. Except as set forth on&nbsp;<U>Schedule 3.28</U>, neither the Company
nor any Subsidiary is in default with respect to any Indebtedness.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.29&nbsp;</B><U>No
Other Representations</U>. Except for the representations and warranties set forth in this Agreement and in the other Transaction Documents,
the Company makes no other representations or warranties to the Investors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>4.&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>REPRESENTATIONS
AND WARRANTIES OF EACH INVESTOR</U></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. Each Investor
represents and warrants to the Company as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.1&nbsp;</B><U>Organization
and Qualification</U>. Such Investor is either an individual or an entity duly incorporated or formed, validly existing and in good standing
under the laws of the jurisdiction of its incorporation or formation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.2&nbsp;</B><U>Authorization;
Enforcement; Compliance with Other Instruments</U>. Such Investor has the requisite power and authority to enter into the Transaction
Documents and to perform its obligations thereunder. The execution and delivery by such Investor of the Transaction Documents to which
it is a party have been duly and validly authorized by such Investor&rsquo;s governing body, as necessary, and no further consent or
authorization is required. The Transaction Documents to which it is a party have been duly and validly executed and delivered by such
Investor and constitute valid and binding obligations of such Investor, enforceable against such Investor in accordance with their terms,
except as such enforceability may be limited by general principles of equity or applicable bankruptcy, insolvency, reorganization, moratorium,
liquidation or similar Laws relating to, or affecting generally, the enforcement of creditors&rsquo; rights and remedies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.3&nbsp;</B><U>No
Conflicts</U>. The execution, delivery and performance of the Transaction Documents to which it is a party by such Investor and the purchase
of a Note by such Investor will not (a) conflict with or result in a violation of such Investor&rsquo;s organizational documents, if
applicable, (b) conflict with, or constitute a material default (or an event which, with notice or lapse of time or both, would become
a material default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, any material agreement,
contract, indenture mortgage, indebtedness or instrument to which such Investor is a party, or (c) violate any Law applicable to such
Investor or by which any of such Investor&rsquo;s properties or assets are bound or affected. No approval or authorization will be required
from any governmental authority or agency, regulatory or self-regulatory agency or other third party in connection with the purchase
of a Note and the other transactions contemplated by this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.4&nbsp;</B><U>Investment
Intent; Accredited Investor</U>. Each Investor is purchasing its Notes and Warrants for its own account, for investment purposes, and
not with a view towards distribution. Such Investor is an &ldquo;accredited investor&rdquo; as such term is defined in Rule 501(a) of
Regulation D of the 1933 Act. Such Investor has, by reason of its business and financial experience, such knowledge, sophistication and
experience in financial and business matters and in making investment decisions of this type that it is capable of (a) evaluating the
merits and risks of an investment in its Notes, Warrants and the Investor Shares and making an informed investment decision, (b) protecting
its own interests and (c) bearing the economic risk of such investment for an indefinite period of time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.5&nbsp;</B><U>Acknowledgement
of Risk; Opportunity to Discuss</U>. Each Investor acknowledges that an investment in the Company is speculative and subject to numerous
risks, including those risks described in the SEC Documents. Each Investor has reviewed and understands the risks related to the Company
and its business as described in the SEC Documents. Each Investor has received all materials relating to the business, finance and operations
of the Company and the Subsidiaries as it has requested and has had an opportunity to discuss the business, management and financial
affairs of the Company and the Subsidiaries with the Company&rsquo;s management. In making its investment decision, such Investor has
relied solely on its own due diligence performed on the Company by its own representatives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.6&nbsp;</B><U>Restricted
Securities</U>. Each Investor understands that its Notes, Warrants and the Investor Shares are being offered in a transaction not involving
any public offering within the meaning of the 1933 Act and that its Notes and the Investor Shares may not be registered under the 1933
Act except as otherwise required under the Transaction Documents. The Investor understands that its Notes, Warrants and the Investor
Shares may not be offered, resold, transferred, pledged or otherwise disposed of by the Investor absent an effective registration statement
under the 1933 Act, except (i) to the Company or a Subsidiary thereof, (ii) to non-U.S. persons pursuant to offers and sales that occur
outside the United States within the meaning of Regulation S under the 1933 Act or (iii) pursuant to an applicable exemption from the
registration requirements of the 1933 Act, and, in each of cases (ii) and (iii), in accordance with any applicable securities laws of
the states and other jurisdictions of the United States, and that any book-entry position or certificates representing its Notes, Warrants
or Investor Shares shall contain a notation or restrictive legend, as applicable, to such effect substantially in the form attached hereto
as&nbsp;<U>Exhibit A</U>, and as a result of these transfer restrictions, the Investor may not be able to readily offer, resell, transfer,
pledge or otherwise dispose of its Notes, Warrants or Investor Shares and may be required to bear the financial risk of an investment
in its Notes, Warrants and Investor Shares for an indefinite period of time. The Investor acknowledges and agrees that (i) its Notes,
Warrants and Investor Shares will not be eligible for offer, resale, transfer, pledge or disposition pursuant to Rule 144 promulgated
under the 1933 Act (&ldquo;<U>Rule 144</U>&rdquo;) until the date that is at least one year from the date that the Company filed &ldquo;Form
10 information&rdquo; with the SEC reflecting its status as an entity that is no longer an issuer described in Rule 144(i)(1)(i)) and
(ii) additional conditions to any such transaction may apply under Rule 144 and other applicable securities laws to the extent that the
Investor is at such time, or has been at any time in the immediately preceding three months, an &ldquo;affiliate&rdquo; of the Company
within the meaning of Rule 144. The Investor understands that it has been advised to consult legal counsel prior to making any offer,
resale, pledge or transfer of any of its Notes, Warrants or Investor Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.7&nbsp;</B><U>Exculpation
Among Investors</U>. Each Investor acknowledges that it is not relying upon any Person, other than the Company and its officers and directors,
in making its investment or decision to invest in the Company. Each Investor agrees that neither the Lead Investor, any Investor nor
the respective controlling Persons, officers, directors, partners, agents, or employees of any Investor shall be liable to any other
Investor for any action heretofore taken or omitted to be taken by any of them in connection with the purchase of the Notes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.8&nbsp;</B><U>No
Other Representations.</U>&nbsp;Except for the representations and warranties set forth in this Agreement and in other Transaction Documents,
such Investor makes no other representations or warranties to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>5.&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OTHER
AGREEMENTS OF THE PARTIES</FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.1&nbsp;</B><U>Restrictions
on Transfer</U>. The Investor Shares, when issued, will be restricted, and book-entry positions or certificates relating to the same
shall bear a restrictive legend unless sold pursuant to an effective registration statement or available for resale pursuant to Rule
144 under the 1933 Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.2&nbsp;</B><U>Furnishing
of Information</U>. As long as an Investor owns Securities, the Company covenants to timely file (or obtain extensions in respect thereof
and file within the applicable grace period) all reports required to be filed by the Company after the date hereof pursuant to the 1934
Act. As long as an Investor owns Securities, if the Company is not required to file reports pursuant to the 1934 Act, it will prepare
and furnish to such Investor and make publicly available in accordance with Rule 144(c) such information as is required for such Investor
to sell the Investor Shares under Rule 144. The Company further covenants that it will take such further action as any holder of Securities
may reasonably request, all to the extent required from time to time to enable such Person to sell such Investor Shares without registration
under the 1933 Act within the limitation of the exemptions provided by Rule 144 or other applicable exemptions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.3&nbsp;</B><U>Integration</U>.
The Company shall not, and shall use its commercially reasonable efforts to ensure that no Affiliate of the Company shall, sell, offer
for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined in Section 2 of the 1933 Act) that will
be integrated with the offer or sale of the Securities in a manner that would require the registration under the 1933 Act of the sale
of the Securities to any Investor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.4&nbsp;</B><U>Notification
of Certain Events</U>. The Company shall give prompt written notice to each Investor of (a) any notice or other communication from any
Person alleging that the consent of such Person is or may be required in connection with the consummation of the transactions contemplated
by this Agreement or any other Transaction Document, or (b) any Proceeding pending or, to the Company&rsquo;s knowledge, threatened against
a party relating to the transactions contemplated by this Agreement or any other Transaction Document.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.5&nbsp;</B><U>Available
Shares</U>. The Company shall at all times keep authorized and available for issuance, free of preemptive rights, the Required Minimum
of Common Stock. If the Company determines at any time that it does not have a sufficient number of authorized Common Stock to keep available
for issuance as described in this&nbsp;<U>Section 5.5</U>, the Company shall use all commercially reasonable efforts to increase the
number of authorized Common Stock by seeking approval from its shareholders for the authorization of such additional shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.6&nbsp;</B><U>Use
of Proceeds</U>. The Company will use the proceeds from the sale of the Notes to fund its general working capital.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.7&nbsp;</B><U>Repayment
of Notes</U>. If the Company issues any debt, including any subordinated debt or convertible debt (other than the Notes), then the Investors
will have the option (exercisable in writing by the Requisite Holder) to cause the Company to immediately utilize 30% of the aggregate
proceeds of such issuance to repay the Notes on a pro rata basis based on the Aggregate Principal Amount, and accrued, but unpaid, Interest
(as defined in the Notes) outstanding on the date of funding of such debt. If the Company issues any Equity Interests for cash as part
of a financing transaction (other than in connection with an &ldquo;at the market&rdquo; funding program), then the Investors will have
the option (exercisable in writing by the Requisite Holder) to cause the Company to direct 30% of such proceeds from such issuance to
repay the Notes on a pro rata basis based on the Aggregate Principal Amount outstanding on the date of closing of such issuance. The
Company will notify the Investors no later than two (2) Business Days prior to the public announcement of any such debt or Equity Interest
financing and provide the Investors (with the written approval of the Requisite Holder ) the opportunity to exercise the option set forth
in the preceding sentence; it being agreed, however, that, notwithstanding such notice to the Investors, the Company shall not be under
an obligation to make a public announcement regarding such debt or Equity Interest financing until it is legally required to do so.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.8&nbsp;</B><U>Shareholder
Approval; Exchange Cap</U>. To fulfill its obligations under the Transaction Documents, the Company shall be required to seek Shareholder
Approval, whether at its annual meeting of shareholders or by calling a special meeting of shareholders) on the earlier to occur of (i)
the Company&rsquo;s next annual meeting of shareholders or (ii) the date that is 45 days from the date hereof; and the Company shall
solicit proxies from its shareholders in connection therewith in the same manner as all other management proposals in such proxy statement
and all management-appointed proxyholders shall vote their proxies in favor of such proposal. If the Company does not obtain Shareholder
Approval at the first meeting, the Company shall call a meeting every four months thereafter to seek Shareholder Approval until the date
the Shareholder Approval is obtained. Notwithstanding anything to the contrary contained in this Agreement, the Notes or the other Transaction
Documents, the Investors and the Company agree that the total cumulative number of shares of Common Stock issued to the Investors under
the Transaction Documents may not exceed a number of shares equal to 19.99% of the outstanding Common Stock as of the date hereof (the
&ldquo;Exchange Cap&rdquo;), except that such limitation will not apply following Shareholder Approval or if the Common Stock is no longer
listed on the Trading Market. If the Company is unable to obtain Shareholder Approval to issue Common Stock to the Investor in excess
of the Exchange Cap, without limiting any rights of the Investor under Section 3.6 of the Notes, any remaining outstanding balance under
the Notes may be repaid in cash at the request of the Investor in accordance with the terms of the Notes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.9&nbsp;</B><U>Prohibited
Transactions; Limitation on At the Market Offerings</U>. The Company hereby covenants and agrees not to enter into any Prohibited Transactions
without the prior written consent of the Requisite Holder, until sixty (60) Trading Days after such time as each Note has been repaid
in full and/or has been converted into Conversion Shares. The Company hereby covenants and agrees, without the prior written consent
of the Requisite Holder, not to utilize any &ldquo;at the market&rdquo; offering program in respect of its Common Stock, except as permitted
hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.10&nbsp;</B><U>ELOC,
ATM or Similar Transactions</U>. The Company hereby covenants and agrees not to enter into any equity line of credit transactions, at-the-market
transaction or similar transaction without the prior written consent of the Requisite Holder, until each Note has been repaid in full
and/or has been converted into Conversion Shares. The Company hereby covenants and agrees, without the prior written consent of the Requisite
Holder, not to utilize any &ldquo;at the market&rdquo; offering program in respect of its Common Stock, except as permitted hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.11&nbsp;</B><U>Securities
Laws Disclosure; Publicity</U>. The Company shall, within one (1) Trading Day following the date hereof, file a Form 8-K report or other
public disclosure disclosing the material terms of the transactions contemplated hereby and including this Agreement as an exhibit thereto;
provided, that the Company may not issue such press release or file such Form 8-K or other public disclosure without the prior written
consent (including by electronic mail) of the Requisite Holder, which shall not be unreasonably withheld, conditioned or delayed. The
Company shall not issue any press release nor otherwise make any such public statement regarding the Investors or the Transaction Documents
without the prior written consent (including by electronic mail) of the Requisite Holder, except (i) if such disclosure is required by
Law, in which case the Company shall (a) ensure that such disclosure is restricted and limited in content and scope to the maximum extent
permitted by Law to meet the relevant disclosure requirement and (b) provide a copy of the proposed disclosure to the Requisite Holder
for review prior to release and the Company shall incorporate the reasonable comments of the Requisite Holder or (ii) to the extent such
press release or public statement contains only information previously disclosed in a press release or public statement previously approved
in accordance with the foregoing clause (i). Each Investor will promptly provide any information reasonably requested by the Company
or any of its Affiliates for any regulatory application or filing made or to be made or approval sought in connection with the transactions
contemplated by this Agreement (including filings with the SEC). Following the execution of this Agreement, each Investor and its Affiliates
and/or advisors may, upon receiving the prior written consent of the Requisite Holder, place announcements on their respective corporate
websites and in financial and other newspapers and publications (including, without limitation, customary &ldquo;tombstone&rdquo; advertisements)
describing such Investor&rsquo;s relationship with the Company under this Agreement and including the name and corporate logo of the
Company. Notwithstanding anything herein to the contrary, to comply with United States Treasury Regulations Section 1.6011-4(b)(3)(i),
each of the Company and each Investor, and each employee, representative or other agent of the Company or such Investor, may disclose
to any and all persons, without limitation of any kind, the U.S. federal and state income tax treatment, and the U.S. federal and state
income tax structure, of the transactions contemplated hereby and all materials of any kind (including opinions or other tax analyses)
that are provided to such party relating to such tax treatment and tax structure insofar as such treatment and/or structure relates to
a U.S. federal or state income tax strategy provided to such recipient.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.12&nbsp;</B><U>Indemnification
of the Investors</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
The Company will indemnify and hold each Investor, its Affiliates and their respective directors, officers, managers, shareholders, members,
partners, employees and agents and permitted successors and assigns (each, an &ldquo;<B>Investor Party</B>&rdquo;) harmless from any
and all losses, liabilities, obligations, claims, contingencies, damages, costs and expenses, including all judgments, amounts paid in
settlements, court costs and reasonable attorneys&rsquo; fees and costs of investigation and defense (collectively, &ldquo;<B>Losses</B>&rdquo;)
that any such Investor Party may suffer or incur as a result of or relating to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
any material breach or inaccuracy of any representation, warranty, covenant or agreement made by the Company in any Transaction Document;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
any material misrepresentation made by the Company in any Transaction Document or in any SEC Document;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
any material omission to state any material fact necessary in order to make the statements made in any SEC Document, in light of the
circumstances under which they were made, not misleading;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
any Proceeding before or by any court, public board, government agency, self-regulatory organization or body based upon, or resulting
from the execution, delivery, performance or enforcement of any of the Transaction Documents or the consummation of the transactions
contemplated thereby, and whether or not such Investor is party thereto by claim, counterclaim, crossclaim, as a defendant or otherwise,
or if such Proceeding is based upon, or results from, any of the items set forth in clauses (i) through (iii) above;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">except,
in the case of clauses (ii) and (iii) above, to the extent, but only to the extent, that such misrepresentation or omission is based
upon information regarding such Investor furnished in writing to the Company by or on behalf of such Investor expressly for use therein
or such Investor has made any untrue statement of a material fact or omitted to state a material fact in such information or otherwise
violated the 1933 Act, 1934 Act or any state securities law or any rule or regulation thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
If any action shall be brought against any Investor Party in respect of which indemnity may be sought pursuant to this Agreement, such
Investor Party shall promptly notify the Company in writing, and the Company shall have the right to assume the defense thereof with
counsel of its own choosing reasonably acceptable to the Investor Party. Any Investor Party shall have the right to employ separate counsel
in any such action and participate in the defense thereof, but the fees and expenses of such counsel shall be at the expense of such
Investor Party except to the extent that (i) the employment thereof has been specifically authorized by the Company in writing, (ii)
the Company has failed after a reasonable period of time to assume such defense and to employ counsel or (iii) in such action there is,
in the reasonable opinion of counsel, a material conflict on any material issue between the position of the Company and the position
of such Investor Party, in which case the Company shall be responsible for the reasonable fees and expenses of no more than one such
separate counsel. The Company will not be liable to any Investor Party under this Agreement (i) for any settlement by an Investor Party
effected without the Company&rsquo;s prior written consent, which shall not be unreasonably withheld or delayed; or (ii) to the extent,
but only to the extent that a loss, claim, damage or liability is attributable to any Investor Party&rsquo;s breach of any of the representations,
warranties, covenants or agreements made by such Investor Party in this Agreement or in the other Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
In addition to the indemnity contained herein, the Company will reimburse each Investor Party for its reasonable out-of-pocket legal
and other expenses (including the cost of any investigation, preparation and travel in connection therewith) incurred in connection therewith,
as such expenses are incurred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
The provisions of this&nbsp;<U>Section 5.12</U>&nbsp;shall survive the termination or expiration of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.13&nbsp;</B><U>Non-Public
Information</U>. Except to the extent necessary to fulfill its notice, disclosure or similar obligations hereunder or under any Transaction
Document, the Company covenants and agrees that neither it nor any other Person acting on its behalf will provide the Investors or their
agents or counsel with any information that the Company believes constitutes material, non-public information. Except in connection with
the fulfillment of its notice, disclosure or similar obligations hereunder or under any Transaction Document, to the extent the Company
provides an Investor with material, non-public information, the Company shall publicly disclose such information within forty-eight (48)
hours of providing the information to such Investor,&nbsp;<U>provided</U>&nbsp;that if the last day of any such time period is not a
Trading Day, such time period shall be extended to 9:30 a.m., New York City Time, on the next Trading Day following the day on which
it would otherwise end. The Company understands and confirms that the Investors shall be relying on the foregoing representation in effecting
transactions in securities of the Company. In the event that the Company fails to comply with its obligations under this Section 5.13,
a liquidated damages charge of 2% of the outstanding principal balance of each Note will be assessed and will become immediately due
and payable each month while such failure remains uncured to the Investors at their election in the form of a cash payment or added to
the balance of the respective Note.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.14&nbsp;</B><U>Share
Transfer Agent</U>. The Company&rsquo;s share transfer agent is Continental Stock Transfer and Trust. To the Company&rsquo;s knowledge,
such transfer agent participates in the Depository Trust Company Fast Automated Securities Transfer program. For so long as any Investor
holds Investor Securities, the Company shall not change its share transfer agent without the prior written consent of the Requisite Holder,
such consent not to be unreasonably withheld, conditioned or delayed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.15&nbsp;</B><U>Intended
Tax Treatment</U>. Each Investor and the Company agree that for U.S. federal income tax purposes, and applicable state, local and non-U.S.
income tax purposes, the Notes are not intended to be treated as indebtedness. No Investor nor the Company shall take any position on
any tax return, or in any audit, claim, investigation, inquiry or proceeding in respect of taxes inconsistent with such intentions, unless
otherwise required pursuant to a final determination within the meaning of Section 1313 of the Internal Revenue Code of 1986, as amended,
or any analogous provision of applicable state, local or non-U.S. law. Concurrently with the execution and delivery of this Agreement,
each Investor agrees to execute and deliver to the Company an IRS Form W-8 or W-9 (as applicable with respect to such Investor).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.16&nbsp;</B><U>Set-Off</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Each Investor may, subject to the provisions of Section 2.4 hereof, set off any of its obligations to the Company (whether or not due
for payment), against any of the Company&rsquo;s obligations to such Investor (whether or not due for payment) under this Agreement and/or
any other Transaction Document.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Each Investor may do anything necessary to effect any set-off undertaken in accordance with this&nbsp;<U>Section 5.16</U>&nbsp;(including
varying the date for payment of any amount payable by such Investor to the Company).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
The Company may set off any of its obligations to an Investor (whether or not due for payment), against any of such Investor&rsquo;s
obligations to the Company (whether or not due for payment) under this Agreement and/or any other Transaction Document.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
The Company may do anything necessary to effect any set-off undertaken in accordance with this&nbsp;<U>Section 5.16</U>&nbsp;(including
varying the date for payment of any amount payable by the Company to an Investor).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.17&nbsp;</B><U>No
Repricing</U>. The Company shall not, without the prior written consent of the Requisite Holder, (i) authorize the amendment of any outstanding
note, option, warrant, or other derivative security convertible, exercisable or exchangeable for Common Stock to reduce the conversion,
exercise or exchange price of any such security or (ii) grant a replacement note, option, warrant or other derivative security convertible,
exercisable or exchangeable for Common Stock for the purpose of reducing the conversion, exercise or exchange price of any such security
being replaced; provided that this&nbsp;<U>Section 5.17</U>&nbsp;shall not apply to amendments to or grants in respect of any option
granted pursuant to an Equity Plan that is outstanding as of the date of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.18&nbsp;</B><U>Commitment
Fee</U>. As consideration for entering into this Agreement, on the date of the initial Closing the Company shall pay to the Lead Investor
a commitment fee of One Hundred Sixty Thousand Five Hundred and zero/100 Dollars ($160,500.00), which will be deemed fully earned on
such date as such fee is paid. In its sole discretion in lieu of cash payment of the foregoing amount the Lead Investor may choose to
accept a convertible promissory note or notes substantially in the form of&nbsp;<U>Exhibit A</U>&nbsp;hereto having an initial principal
amount equal to the amount of the commitment fee required to be paid pursuant to this&nbsp;<U>Section 5.18</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>6.&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CLOSING
CONDITIONS</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6.1&nbsp;</B><U>Conditions
Precedent to the Obligations of each Investor</U>. The obligation of each Investor to fund its Note at each Closing is subject to the
satisfaction or waiver by such Investor, at or before such Closing, of each of the following conditions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;<U>General
Conditions Precedent</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&nbsp;<U>Required
Documentation</U>. The Company must have delivered to&nbsp;<U>such</U>&nbsp;Investor (i) a duly executed certificate of an officer of
the Company and each Subsidiary party to the Subsidiary Guarantee, appending thereto (A) copies of duly executed resolutions or consents
of the directors, members or manager, as applicable, of such party, approving and consenting to such party&rsquo;s execution, performance
of its obligations under the applicable Transaction Documents and the transactions contemplated thereby, (B) a certificate of good standing
or equivalent document dated no more than five days prior to the date hereof, in respect of such party, (C) true and correct copies of
the organizational documents of such party, and (D) incumbency signatures of such party, and (ii) copies of each Transaction Document,
duly executed by the Company, the applicable Subsidiaries or the Transfer Agent, as applicable;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)&nbsp;<U>Consents
and Permits</U>. The Company must have obtained and delivered to such Investor copies of all necessary permits, approvals, and registrations
necessary to effect this Agreement, the Transaction Documents and any of the transactions contemplated hereby or thereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)&nbsp;<U>No
Event(s) of Default</U>. No Event of Default has occurred and no Event of Default would result from the execution of this Agreement or
any of the Transaction Documents or the transactions contemplated hereby or thereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)&nbsp;<U>Representations
and Warranties</U>. The representations and warranties of the Company contained herein shall be true and correct in all material respects
as of the date when made and as of such Closing as though made on and as of such date;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)&nbsp;<U>Performance</U>.
The Company shall have performed, satisfied and complied in all material respects with all covenants, agreements and conditions required
by the Transaction Documents to be performed, satisfied or complied with by it at or prior to such Closing;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)&nbsp;<U>No
Injunction</U>. No statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated
or endorsed by any court or governmental authority of competent jurisdiction that prohibits the consummation of any of the transactions
contemplated by the Transaction Documents;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii)&nbsp;<U>No
Suspensions of Trading in the Common Stock; Listing</U>. Trading in the Common Stock shall not have been suspended by the SEC or any
Trading Market (except for any suspensions of trading of not more than one day on which the Trading Market is open solely to permit dissemination
of material information regarding the Company) at any time since the date of execution of this Agreement, and the Common Stock shall
have been at all times since such date listed for trading on a Trading Market;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(viii)&nbsp;<U>Limitation
on Beneficial Ownership</U>. The issuance of a Note or Warrant to such Investor shall not cause such Investor Group to become, directly
or indirectly, a &ldquo;beneficial owner&rdquo; (within the meaning of Section 13(d) of the 1934 Act and the rules and regulations promulgated
thereunder) of a number of Equity Interests of a class that is registered under the 1934 Act which exceeds the Maximum Percentage of
the Equity Interests of such class that are outstanding at such time; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ix)&nbsp;<U>Funds
Flow Request</U>. The Company shall have delivered to the Lead Investor a flow of funds request, substantially in the form set out in&nbsp;<U>Exhibit
D</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(x)&nbsp;<U>Non-Public
Information</U>. The Company shall, on or before 9:30 a.m., New York City Time, on or prior to the first business day after the date
of each Closing, release or file, as applicable, a press release or a Current Report on Form 8-K or other applicable public disclosure
describing the terms of the Closing (the &ldquo;Cleansing Release&rdquo;). From and after the filing of the Cleansing Release, the Company
shall have disclosed all material, non-public information (if any) provided up to such time to each Investor by the Company or any of
its officers, directors, employees or agents. In addition, upon the filing of the Cleansing Release, the Company acknowledges and agrees
that any and all confidentiality or similar obligations under any agreement with respect to the transactions contemplated hereby or as
otherwise disclosed in the Cleansing Release, whether written or oral, between the Company, or any of its officers, directors, affiliates,
employees or agents, on the one hand, and any of the Investors or any of their affiliates, on the other hand, shall terminate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xi)&nbsp;<U>Opinions
of Counsel</U>. The Lead Investor shall have received opinions from United States counsel to the Company and Subsidiaries in forms acceptable
to the Lead Investor in its sole discretion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xii)&nbsp;<U>Closing
Equity Conditions</U>. Each of the Closing Equity Conditions shall have been satisfied.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xiii)&nbsp;<U>Lock-Up
Agreements</U>. The directors, officers and major shareholders (holders of 4% or more of the Company&rsquo;s issued and outstanding Common
Stock) of the Company shall have entered into a lock-up agreement, solely with respect to the Common Stock, in a form acceptable to by
the Lead Investor, that shall provide that for a period of six months beginning on the Closing Date, such Persons shall not sell into
the market pursuant to Rule 144 or pursuant to a then effective registration statement any Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;<U>Specific
Closing Conditions</U>. The closing conditions set forth in Section 2.2 relating to the Tranche being funded on such Closing Date shall
be met.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6.2&nbsp;</B><U>Conditions
Precedent to the Obligations of the Company</U>. The obligation of the Company to issue a Note to an Investor at the Closing is subject
to the satisfaction or waiver by the Company, at or before such Closing, of each of the following conditions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;<U>Required
Documentation</U>. Such Investor must have delivered to the Company copies of each Transaction Document to which the Investor is a party,
duly executed by such Investor;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;<U>Representations
and Warranties</U>. The representations and warranties of such Investor contained herein shall be true and correct in all material respects
as of the date when made and as of such Closing Date as though made on and as of such date;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&nbsp;<U>Performance</U>.
The Investors shall have performed, satisfied and complied in all material respects with all covenants, agreements and conditions required
by the Transaction Documents to be performed, satisfied or complied with by it at or prior to such Closing; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&nbsp;<U>No
Injunction</U>. No statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated
or endorsed by any court or governmental authority of competent jurisdiction that prohibits the consummation of any of the transactions
contemplated by the Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>7.&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>EVENTS
OF DEFAULT</U></FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7.1&nbsp;</B><U>Events
of Default</U>. The occurrence of any of the following events shall be an &ldquo;<B>Event of Default</B>&rdquo; under this Agreement:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
an Event of Default under a Note;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
any of the representations or warranties made by the Company or any of its agents, officers, directors, employees or representatives
in any Transaction Document or public filing being inaccurate, false or misleading in any material respect, as of the date as of which
it is made or deemed to be made, or any certificate or financial or other written statements furnished by or on behalf of the Company
to the Investors or any of their representatives, is inaccurate, false or misleading, in any material respect, as of the date as of which
it is made or deemed to be made, or on any Closing Date; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
a failure by the Company to comply with any of its covenants or agreements set forth in this Agreement, including those set forth in&nbsp;<U>Section
5</U>&nbsp;in all material respects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7.2&nbsp;</B><U>Investor
Right to Investigate an Event of Default</U>. If in the reasonable opinion of the Requisite Holder, an Event of Default has occurred,
or is or may be continuing:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
the Requisite Holder may notify the Company that it wishes to investigate such purported Event of Default;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
the Company shall cooperate with the Requisite Holder in such investigation;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
the Company shall comply with all reasonable requests made by the Requisite Holder to the Company in connection with any investigation
by the Requisite Holder and shall (i) provide all information requested by the Requisite Holder in relation to the Event of Default to
the Requisite Holder; provided that the Requisite Holder agrees that any materially price sensitive information and/or non-public information
will be subject to confidentiality, and (ii) provide all such requested information within three (3) Business Days of such request.;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
the Company shall pay all reasonable out-of-pocket costs incurred by the Requisite Holder in connection with any such investigation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7.3&nbsp;</B><U>Remedies
Upon an Event of Default</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
If an Event of Default occurs pursuant to&nbsp;<U>Section 7.1(a)</U>, each Investor shall have such remedies as are set forth in their
Note.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
If an Event of Default occurs pursuant to&nbsp;<U>Section 7.1(b)</U>&nbsp;or&nbsp;<U>Section 7.1(c)</U>&nbsp;and is not remedied following
written notice provided by the Requisite Holder to the Company within (i) two (2) Business Days for an Event of Default occurring by
the Company&rsquo;s failure to comply with&nbsp;<U>Section 7.1(c)</U>, or (ii) ten (10) Business Days for an Event of Default occurring
pursuant to&nbsp;<U>Section 7.1(b)</U>, the Requisite Holder may declare, by written notice to the Company, effective immediately, all
outstanding obligations by the Company under the Transaction Documents to be immediately due and payable in immediately available funds
and the Investors shall have no obligation to consummate any Closing under this Agreement or to accept the conversion of any Note into
Conversion Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
If any Event of Default occurs and is not remedied following written notice provided by the Requisite Holder to the Company within (i)
two (2) Business Days for an Event of Default occurring by the Company&rsquo;s failure to comply with&nbsp;<U>Section 7.1(c)</U>, or
(ii) ten (10) Business Days for an Event of Default occurring pursuant to&nbsp;<U>Section 7.1(b)</U>, the Requisite Holder may, by written
notice to the Company, terminate this Agreement effective as of the date set forth in the Requisite Holder&rsquo;s notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>8.&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>TERMINATION</U></FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.1&nbsp;</B><U>Events
of Termination</U>. This Agreement:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
may be terminated:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
by the Requisite Holder on the occurrence or existence of a Securities Termination Event or a Change of Control;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
by either the Company or the Requisite Holder, by written notice to the other party, effective immediately, if the applicable Closing
has not occurred within thirty (30) Business Days of the date specified in Section 2.2 of this Agreement or such later date as the Company
and the Requisite Holder agree in writing, provided that the right to terminate this Agreement under this Section 8.1(a)(ii) is not available
to any party that is in material breach of or material default under this Agreement or whose failure to fulfill any obligation under
this Agreement has been the principal cause of, or has resulted in the failure of the applicable Closing to occur; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
by the Requisite Holder, in accordance with&nbsp;<U>Section 7.3(c)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
will automatically terminate, without further action by the parties, on the date that is twenty-four (24) months from the date of this
Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.2&nbsp;</B><U>Effect
of Termination</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Upon termination of this Agreement, no Investor will be required to fund any further amount after the date of termination of the Agreement,
provided that termination will not affect any undischarged obligation under this Agreement, and any obligation of the Company to pay
or repay any amounts owing to the Investor hereunder and which have not been repaid at the time of termination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Nothing in this Agreement will be deemed to release any party from any liability for any breach by such party of the terms and provisions
of this Agreement or to impair the right of any party to compel specific performance by any other Party of its obligations under this
Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>9.&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RESERVED</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>10.&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RIGHTS
TO FUTURE STOCK ISSUANCES.&nbsp;</FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject to the terms
and conditions of this&nbsp;<U>Section 10</U>&nbsp;and applicable securities laws, if at any time during the period ending 24 months
after the Closing Date of the initial Closing, the Company proposes to offer or sell any New Securities, the Company shall offer to the
Investors the opportunity to purchase up to twenty percent (20%) of such New Securities (such amount, the &ldquo;<B>Offered Securities</B>&rdquo;).
Such offer may only be accepted with the prior written approval of an Investor. If accepted by an Investor, it shall be afforded the
opportunity to purchase its Pro Rata Portion (as defined below). The Investors shall be entitled to apportion the right of first offer
hereby granted to them in such proportions as they deem appropriate among themselves and their Affiliates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10.1&nbsp;</B>The
Company shall give notice no fewer than ten (10) Business Days in advance of the proposed date of the sale of New Securities (the &ldquo;<B>Information
Notice</B>&rdquo;) to the Requisite Holder and each Investor, requesting if such Requisite Holder and Investors would desire to receive
further information regarding the proposed sale. In the event that any Investor does not affirmatively respond to the Information Notice
within two (2) Business Days of receipt thereof, the Company may proceed with the sale; provided that obligations and rights set forth
in this Section 10 shall not be in force and effective for a period with respect to any non-affirming Investor for a period of 45 days
following the delivery of the Information Notice; provided, further that the obligations and rights set forth in this Section 10 shall
automatically renew following the expiration of such period. If an Investor affirmatively responds to the Information Notice, such sale
shall be subject to the obligations and rights set forth in this Section 10.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10.2&nbsp;</B>The
Company shall give notice no fewer than two (2) Business Days following receipt of an affirmative response to the Information Notice
(the &ldquo;<B>Offer Notice</B>&rdquo;) to the Requisite Holder and each Investor, stating (a) its bona fide intention to offer such
New Securities, (b) the number of such New Securities to be offered, and (c) the price and terms, if any, upon which it proposes to offer
such New Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10.3&nbsp;</B>By
notification to the Company within five (5) days after the Offer Notice is given, the Requisite Holder and each Investor may elect to
purchase or otherwise acquire, at the price and on the terms specified in the Offer Notice, up to their Pro Rata Portion of the Offered
Securities. &ldquo;<B>Pro Rata Portion</B>&rdquo; means the ratio of (x) Securities purchased by an Investor participating under this
Section 10.3 and (y) the sum of the aggregate Securities purchased by all Investors participating under this 10.3. The closing of any
sale pursuant to this&nbsp;<U>Section 10</U>&nbsp;shall occur within the later of ninety (90) days of the date that the Offer Notice
is given and the date of initial sale of New Securities pursuant to&nbsp;<U>Section 10.4</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10.4&nbsp;</B>The
Company may, during the ninety (90) day period following the expiration of the period provided in&nbsp;<U>Section 10.3</U>, offer and
sell the remaining portion of such New Securities to any Person or Persons at a price not less than, and upon terms no more favorable
to the offeree than, those specified in the Offer Notice. If the Company does not enter into an agreement for the sale of the New Securities
within such period, or if such agreement is not consummated within thirty (30) days of the execution thereof, the right provided hereunder
shall be deemed to be revived and such New Securities shall not be offered unless first reoffered to the Investors in accordance with
this&nbsp;<U>Section 10</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10.5&nbsp;</B>The
right of first offer in this&nbsp;<U>Section 10</U>&nbsp;shall not be applicable to offers, issuances, sales or other transactions related
to Exempted Securities, or any New Securities registered for sale under the 1933 Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>11.&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>GENERAL
PROVISIONS</U></FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.1&nbsp;</B><U>Fees
and Expenses</U>. Prior to the date of this Agreement, the Company has paid the Lead Investor $20,000 as an advance the expenses payable
under this Section 11.1. At the initial Closing, the Company shall reimburse the Lead Investor up to an additional $30,000 (equal to
an aggregate of $50,000 in total fees and expenses, inclusive of the initial $20,000 paid in accordance with the foregoing sentence)
for actual and reasonably documented due diligence, travel and legal fees and expenses related to the preparation and negotiation of
the Transaction Documents and disbursements of its counsel, Lucosky Brookman LLP it being understood that Lucosky Brookman LLP has not
rendered any legal advice to the Company in connection with the transactions contemplated hereby and that the Company has relied for
such matters on the advice of its own counsel; provided that the foregoing cap maybe be increased if in the reasonable discretion of
the Lead Investor the legal services required to draft and negotiate the Transaction Documents exceeds those initially contemplated by
the Parties. In the event that this Agreement is terminated prior to the occurrence of the initial Closing, the Company shall reimburse
the Lead Investor for all actual and reasonably documented due diligence and legal fees and expenses, including the reasonable and documented
fees and disbursements of its counsel, Lucosky Brookman LLP. Except as specified above, each party shall pay the fees and expenses of
its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to the negotiation,
preparation, execution, delivery and performance of the Transaction Documents. The Company shall pay all stamp and other taxes and duties
levied in connection with the sale of the Notes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.2&nbsp;</B><U>Notices</U>.
Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall
be deemed given and effective on the earliest of (a) the date of transmission, if such notice or communication is delivered via email
at the email address specified in this Section prior to 5:00 p.m. (New York time) on a Business Day, (b) the next Business Day after
the date of transmission, if such notice or communication is delivered via email at the email address specified in this Section on a
day that is not a Business Day or later than 5:00 p.m. (New York time) on any date and earlier than 11:59 p.m. (New York time) on such
date, (c) the Business Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service, or (d) upon
actual receipt by the party to whom such notice is required to be given. The address for such notices and communications shall be as
follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    to the Company:</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 96px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 48px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OneMedNet
    Corporation</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">6385
    Old Shady Oak Rd Ste 250</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Eden
    Prairie, MN 55344</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:
    aaron.green@onemednet.com</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:
    Aaron Green</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
    a copy (which shall not constitute notice) to:</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 96px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 48px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rimon,
    P.C.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1909
    K. Street, NW, Suite 420</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Washington,
    DC 20006</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:
    Debbie A. Klis, Esq.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phone:
    (202) 935-3390</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:
    debbie.klis@rimonlaw.com</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    to an Investor, such address set forth on the signature page hereto executed by such Investor;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">or
such other address as may be designated in writing hereafter, in the same manner, by such Person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.3&nbsp;</B><U>Severability</U>.
If any provision of this Agreement is held by a court of competent jurisdiction to be excessive in scope or otherwise invalid or unenforceable,
such provision shall be adjusted rather than voided, if possible, so that it is enforceable to the maximum extent possible, and the validity
and enforceability of the remaining provisions of this Agreement will not in any way be affected or impaired thereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.4&nbsp;</B><U>Governing
Law</U>. This Agreement shall be governed by and construed in accordance with the Laws of the State of Delaware, without reference to
principles of conflict of laws or choice of laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.5&nbsp;</B><U>Jurisdiction
and Venue</U>. Any action, proceeding or claim arising out of, or relating in any way to this Agreement shall be brought and enforced
in the New York Supreme Court, County of New York (Commerical Division), or in the United States District Court for the Southern District
of New York. The Company and the Investors irrevocably submit to the jurisdiction of such courts, which jurisdiction shall be exclusive,
and hereby waive any objection to such exclusive jurisdiction or that such courts represent an inconvenient forum. The prevailing party
in any such action shall be entitled to recover its reasonable and documented attorneys&rsquo; fees and out-of-pocket expenses relating
to such action or proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.6&nbsp;</B><U>WAIVER
OF RIGHT TO JURY TRIAL</U>. THE COMPANY AND THE INVESTORS HEREBY IRREVOCABLY WAIVE, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW,
ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE OTHER TRANSACTION DOCUMENTS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.7&nbsp;</B><U>Survival</U>.
The representations, warranties, agreements and covenants contained herein shall survive the Closing and the delivery of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.8&nbsp;</B><U>Entire
Agreement</U>. The Transaction Documents, together with the Exhibits and Schedules thereto, contain the entire understanding of the parties
with respect to the subject matter hereof and supersede all prior agreements and understandings, oral or written, with respect to such
matters, which the parties acknowledge have been merged into such documents, exhibits and schedules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.9&nbsp;</B><U>Amendments;
Waivers</U>. No provision of this Agreement may be waived or amended except in a written instrument signed by the Company and the Requisite
Holder. No waiver of any default with respect to any provision, condition or requirement of this Agreement shall be deemed to be a continuing
waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall
any delay or omission of either party to exercise any right hereunder in any manner impair the exercise of any such right.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.10&nbsp;</B><U>Construction</U>.
The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any
of the provisions hereof. The language used in this Agreement will be deemed to be the language chosen by the parties to express their
mutual intent, and no rules of strict construction will be applied against any party. This Agreement shall be construed as if drafted
jointly by the parties, and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship
of any provisions of this Agreement or any of the Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.11&nbsp;</B><U>Successors
and Assigns</U>. This Agreement shall be binding upon, and inure to the benefit of and be enforceable by, the Company and the Investors
and their respective successors and assigns. The Company may not assign this Agreement or any rights or obligations hereunder without
the prior written consent of the Requisite Holder. Subject to Section 5.1 of this Agreement, each Investor may assign any or all of its
rights under this Agreement to any Person to whom such Investor assigns or transfers any Securities, provided such transferee agrees
in writing to be bound, with respect to the transferred Securities, by the provisions hereof that apply to the &ldquo;Investor&rdquo;
and such transferee is an accredited investor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.12&nbsp;</B><U>Further
Assurances</U>. Each party hereto shall do and perform, or cause to be done and performed, all such further acts and things, and shall
execute and deliver all such other agreements, certificates, instruments and documents, as the other party may reasonably request in
order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.13&nbsp;</B><U>Counterparts</U>.
This Agreement may be executed in identical counterparts, each of which shall be considered one and the same agreement and shall become
effective when counterparts have been signed by each party and delivered to the other parties. Signature pages delivered by facsimile
or e-mail shall have the same force and effect as an original signature.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.14&nbsp;</B><U>Specific
Performance</U>. The Company acknowledges that monetary damages alone would not be adequate compensation to the Investors for a breach
by the Company of this Agreement and the Requisite Holder may seek an injunction or an order for specific performance from a court of
competent jurisdiction if (a) the Company fails to comply or threatens not to comply with this Agreement or (b) the Requisite Holder
has reason to believe that the Company will not comply with this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Signature
Page Follows]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the undersigned have executed this Securities Purchase Agreement as of the date first set forth above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>COMPANY:</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ONEMEDNET
    CORPORATION</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 46%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Paul
    J. Casey</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul J. Casey</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 34 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories
as of the date first indicated above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Investor:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature
of Authorized Signatory of Investor: _________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Authorized Signatory:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
of Authorized Signatory: Authorized Signatory</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email
Address of Authorized Signatory:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Facsimile
Number of Authorized Signatory: N/A</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address
for Notice to Investor:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address
for Delivery of Securities to Investor (if not same as address for notice):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Funding
Amount:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal
amount of Note:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>[Investor
Signature Page to the Securities Purchase Agreement]</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<!-- Field: Page; Sequence: 35; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.12
<SEQUENCE>18
<FILENAME>ex10-12.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.12</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>REGISTRATION
RIGHTS AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This&nbsp;<B>REGISTRATION
RIGHTS AGREEMENT</B>&nbsp;(this &ldquo;<B>Agreement</B>&rdquo;), dated as of March 28, 2024, is by and among OneMedNet Corporation, a
Delaware corporation (the &ldquo;<B>Company</B>&rdquo;), and each of the investors to the Securities Purchase Agreement (as defined below)
(collectively, the &ldquo;<B>Investors</B>&rdquo; and, together with the Company, the &ldquo;<B>Parties</B>&rdquo; and each, a &ldquo;<B>Party</B>&rdquo;).
Certain capitalized terms used herein are defined in&nbsp;<U>Section 1</U>. Except as otherwise defined herein, capitalized terms have
the meanings given to them in the Securities Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>RECITALS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.
The Company and the Investors have entered into that certain Securities Purchase Agreement, dated as of the date hereof (the &ldquo;<B>Securities
Purchase Agreement</B>&rdquo;), pursuant to which, among other things, the Investors have agreed to purchase, and the Company has agreed
to issue and sell, (a) convertible promissory notes in the aggregate original principal amount of up to $5,350,000, which are being issued
with a fifteen percent (15%) original issue discount, in substantially the form attached as Exhibit A to the Securities Purchase Agreement
(collectively, the &ldquo;<B>Notes</B>&rdquo;), and (b) common stock purchase warrants, which shall be exercisable for shares of the
Company&rsquo;s common stock, $0.0001 par value per share (&ldquo;<B>Common Stock</B>&rdquo;), in substantially the form attached as
Exhibit B to the Securities Purchase Agreement (collectively, the &ldquo;<B>Warrants</B>,&rdquo; and together with the Notes, the &ldquo;<B>Purchased
Securities</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.
The Purchased Securities are being offered and sold in reliance upon the exemption from securities registration afforded by Section 4(a)(2)
of the 1933 Act, and Rule 506(b) of Regulation D as promulgated by the SEC under the 1933 Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.
The Notes shall be convertible into shares of Common Stock in certain circumstances in accordance with the terms of the Notes at an initial
conversion price of ninety-five percent (95%) of the average of the lowest VWAP of the Common Stock over the ten (10) trading days immediately
preceding the delivery of the applicable conversion notice (the &ldquo;<B>Conversion Price</B>&rdquo;), subject to adjustment as set
forth in the Notes, and an initial floor price of $0.41 (the shares of Common Stock issuable pursuant to the terms of the Notes, the
&ldquo;<B>Note Conversion Shares</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.
The Warrants shall initially be exercisable for an aggregate number of shares of Common Stock equal to 50% of the aggregate principal
amount of the Notes issued in conjunction with such Warrants divided by ninety-five percent (95%) of the average of the lowest VWAP of
the Common Stock over the ten (10) trading days immediately preceding the issuance of the Warrants and which for purposes of this Agreement,
shall be deemed $0.6821 (the &ldquo;<B>Warrant Shares</B>&rdquo; and, together with the Note Conversion Shares, the &ldquo;<B>Conversion
Shares</B>&rdquo;). The Notes, the Warrants, and the Conversion Shares shall sometimes be collectively referred to herein as the &ldquo;<B>Securities</B>.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">E.
Pursuant to the terms of, and in consideration for the Investors entering into, the Securities Purchase Agreement, and to induce the
Investors to execute and deliver the Securities Purchase Agreement, the Company has agreed to provide the Investors with certain resale
registration rights with respect to the Registrable Securities (as defined herein) upon the terms and subject to the conditions as set
forth herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOW,
THEREFORE, in consideration of the representations, warranties, covenants and agreements contained herein and in the Securities Purchase
Agreement, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, intending to be
legally bound hereby, the Company and the Investors hereby agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.</B>&nbsp;<B>DEFINITIONS.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
used in this Agreement, the following terms shall have the following meanings:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
&ldquo;<B>Closing Date</B>&rdquo; shall mean the date of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
&ldquo;<B>Effective Date</B>&rdquo; means the date that the applicable Registration Statement has been declared effective by the SEC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
&ldquo;<B>Effectiveness Deadline</B>&rdquo; means: (i) with respect to the Initial Registration Statement required to be filed pursuant
to&nbsp;<U>Section 2(a)</U>, the Forty-Fifth (45th) calendar day after the date of this Agreement; and (ii) with respect to any Subsequent
Registration Statements that may be required to be filed by the Company pursuant to this Agreement, the earlier of the (A) Forty-Fifty
(45th) calendar day following the date on which such Subsequent Registration Statement was initially filed by the Company, and (B) fifth
(5th) Business Day after the date on which the Company is notified (orally or in writing, whichever is earlier) by the SEC that such
Subsequent Registration Statement will not be reviewed or will not be subject to further review.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
&ldquo;<B>Filing Deadline</B>&rdquo; means: (i) with respect to the Initial Registration Statement required to be filed pursuant to&nbsp;<U>Section
2(a)</U>, the thirtieth (30th) calendar day after the date of this Agreement; and (ii) with respect to any Subsequent Registration Statements
that may be required to be filed by the Company pursuant to this Agreement, the thirtieth (30th) calendar day following the sale of substantially
all of the Registrable Securities included in the Initial Registration Statement or the most recent prior Subsequent Registration Statement,
as applicable, or such other date as permitted by the SEC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
&ldquo;<B>Person</B>&rdquo; means an individual, a limited liability company, a partnership, a joint venture, a corporation, a trust,
an unincorporated organization, any other entity and any governmental authority or any department or agency thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
&ldquo;<B>Prospectus</B>&rdquo; means (i) the prospectus included in any Registration Statement, as amended or supplemented by any prospectus
supplement, with respect to the terms of the offering of any portion of the Registrable Securities covered by such Registration Statement
and by all other amendments and supplements to the prospectus, including post-effective amendments and all material incorporated by reference
in such prospectus, and (ii) any &ldquo;free writing prospectus&rdquo; as defined in Rule 405 under the 1933 Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
&ldquo;<B>Prospectus Supplement</B>&rdquo; means any prospectus supplement to a Prospectus filed with the SEC from time to time pursuant
to Rule 424(b) under the 1933 Act, including the documents incorporated by reference therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
&ldquo;<B>register</B>,&rdquo; &ldquo;<B>registered</B>,&rdquo; and &ldquo;<B>registration</B>&rdquo; refer to a registration effected
by preparing and filing one or more Registration Statements in compliance with the 1933 Act and pursuant to Rule 415 and the declaration
of effectiveness of such Registration Statement(s) by the SEC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
&ldquo;<B>Registrable Securities</B>&rdquo; means the Conversion Shares and any other securities issued or issuable with respect to or
in exchange for Registrable Securities, whether by merger, charter amendment, or as a result of a stock split, stock dividend, recapitalization,
exchange or similar event or otherwise, provided that, a security shall cease to be a Registrable Security upon (A) sale pursuant to
a Registration Statement or Rule 144, or (B) such security becoming eligible for sale without restriction on the Investors who are not
affiliates pursuant to Rule 144.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)
&ldquo;<B>Registration Statement</B>&rdquo; means a registration statement or registration statements of the Company filed under the
1933 Act covering the resale by the Investors of Registrable Securities, as such registration statement or registration statements may
be amended and supplemented from time to time, including all documents filed as part thereof or incorporated by reference therein. Registration
Statement includes the Initial Registration Statement and any Subsequent Registration Statement that may be filed pursuant to the terms
of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)
&ldquo;<B>Rule 415</B>&rdquo; means Rule 415 promulgated by the SEC under the 1933 Act, as such rule may be amended from time to time,
or any other similar or successor rule or regulation of the SEC providing for offering securities on a delayed or continuous basis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)
&ldquo;<B>Subsequent Registration Statement</B>&rdquo; means any Registration Statement filed subsequent to the Initial Registration
Statement that relates to the registration of the Registrable Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.</B>&nbsp;<B>REGISTRATION.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;<U>Mandatory
Registration</U>. The Company shall prepare and, as soon as practicable, but in no event later than the Filing Deadline, file with the
SEC an initial Registration Statement on Form S-1 (or any successor form) covering the resale by the Investors of such number of Registrable
Securities equal to the Conversion Shares and Warrant Shares (the &ldquo;<B>Initial Registration Statement</B>&rdquo;) that would result
from the conversion of the principal amount of the Convertible Notes then outstanding (to the extent determinable) and the exercise of
the Warrants then outstanding. The Initial Registration Statement shall also cover, to the extent allowable under the 1933 Act, such
indeterminate number of additional shares of Common Stock resulting from stock splits, stock dividends, reclassifications, or similar
transactions with respect to the Registrable Securities. The Initial Registration Statement shall not include any shares of Common Stock
for the account of any person other than the Investors without the prior written consent of the Investors. The Initial Registration Statement
shall contain the &ldquo;Selling Stockholder&rdquo; and &ldquo;Plan of Distribution&rdquo; sections in substantially the form attached
hereto as&nbsp;<U>Exhibit B</U>. The Initial Registration Statement (and each amendment or supplement thereto, and each request for acceleration
of effectiveness thereof) shall be provided in accordance with&nbsp;<U>Section 2(d)</U>&nbsp;to the Investors prior to its filing or
submission. The Company shall use its commercially reasonable efforts to have the Initial Registration Statement declared effective by
the SEC as soon as reasonably practicable following the filing thereof with the SEC, but in no event later than the applicable Effectiveness
Deadline.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;<U>Filing
and Effectiveness Failures</U>. If (i) the Initial Registration Statement is not filed on or prior to its Filing Deadline (if the Company
files the Initial Registration Statement without affording the Investors the opportunity to review and comment on the same as required
by&nbsp;<U>Section 3(e)</U>&nbsp;herein, the Company shall be deemed to have not satisfied this clause (b)(i)), or (ii) the Company fails
to file with the SEC a request for acceleration of a Registration Statement in accordance with Rule 461 promulgated by the SEC pursuant
to the 1933 Act, within five (5) Trading Days of the date that the Company is notified (orally or in writing, whichever is earlier) by
the SEC that such Registration Statement shall not be &ldquo;reviewed&rdquo; or shall not be subject to further review, or (iii) prior
to the Effective Date of a Registration Statement, the Company fails to file a pre-effective amendment and otherwise respond in writing
to comments made by the SEC in respect of such Registration Statement within twenty (20) calendar days after the receipt of comments
by or notice from the SEC that such amendment is required in order for such Registration Statement to be declared effective, or (iv)
a Registration Statement registering for resale all of the Registrable Securities included in such Registration Statement is not declared
effective by the SEC by the Effectiveness Date of the Initial Registration Statement, or (v) after the effective date of a Registration
Statement, such Registration Statement ceases for any reason to remain continuously effective as to all Registrable Securities included
in such Registration Statement, or the Investors are otherwise not permitted to utilize the Prospectus therein to resell such Registrable
Securities, for more than ten (10) consecutive calendar days or more than an aggregate of fifteen (15) calendar days (which need not
be consecutive calendar days) during any 12-month period (any such failure or breach being referred to as an &ldquo;<B>Event</B>,&rdquo;
and for purposes of clauses (i) and (iv), the date on which such Event occurs, and for purpose of clause (ii) the date on which such
five (5) Trading Day period is exceeded, and for purpose of clause (iii) the date which such ten (10) calendar day period is exceeded,
and for purpose of clause (v) the date on which such ten (10) or fifteen (15) calendar day period, as applicable, is exceeded being referred
to as &ldquo;<B>Event Date</B>&rdquo;), then, in addition to any other rights the Investors may have hereunder or under applicable law,
on each such Event Date and on each monthly anniversary of each such Event Date (if the applicable Event shall not have been cured by
such date) until the applicable Event is cured, the Company shall pay to each Investor an amount in cash, as liquidated damages and not
as a penalty, equal to the product of two percent (2.0%) multiplied by the aggregate Purchase Price paid by such Investor pursuant to
the Securities Purchase Agreement. If the Company fails to pay any liquidated damages pursuant to this Section in full within seven (7)
days after the date payable, the Company will pay interest thereon at a rate of ten percent (10%) per annum (or such lesser maximum amount
that is permitted to be paid by applicable law) to the Investor, accruing daily from the date such partial liquidated damages are due
until such amounts, plus all such interest thereon, are paid in full. The partial liquidated damages pursuant to the terms hereof shall
apply on a daily pro rata basis for any portion of a month prior to the cure of an Event.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&nbsp;<U>Offering</U>.
If the Staff of the SEC (the &ldquo;<B>Staff</B>&rdquo;) or the SEC seeks to characterize any offering pursuant to a Registration Statement
filed pursuant to this Agreement as constituting an offering of securities that does not permit such Registration Statement to become
effective and be used for resales by the Investors on a delayed or continuous basis under Rule 415 at then-prevailing market prices (and
not fixed prices), or if after the filing of any Registration Statement pursuant to&nbsp;<U>Section 2(a)</U>, the Company is otherwise
required by the Staff or the SEC to reduce the number of Registrable Securities included in such Registration Statement, then the Company
shall reduce the number of Registrable Securities to be included in such Registration Statement (after consultation with the Investors
as to the specific Registrable Securities to be removed therefrom) until such time as the Staff and the SEC shall so permit such Registration
Statement to become effective and be used as aforesaid. Notwithstanding anything in this Agreement to the contrary, if after giving effect
to the actions referred to in the immediately preceding sentence, the Staff or the SEC does not permit such Registration Statement to
become effective and be used for resales by the Investors on a delayed or continuous basis under Rule 415 at then-prevailing market prices
(and not fixed prices), the Company shall not request acceleration of the Effective Date of such Registration Statement, but instead
the Company shall promptly (but in no event later than 48 hours from the time that the decision of the Staff or the SEC becomes known
to the Company) request the withdrawal of such Registration Statement pursuant to Rule 477 under the 1933 Act, and the Effectiveness
Deadline shall automatically be deemed to have elapsed with respect to such Registration Statement at such time as the Staff or the SEC
has made a final and non-appealable determination that the SEC will not permit such Registration Statement to be so utilized (unless
prior to such time the Company has received assurances from the Staff or the SEC that a Subsequent Registration Statement filed by the
Company with the SEC promptly thereafter may be so utilized). In the event of any reduction in Registrable Securities pursuant to this
paragraph, the Company shall use its commercially reasonable efforts to file one or more Subsequent Registration Statements with the
SEC until such time as all Registrable Securities have been included in Registration Statements that have been declared effective and
the Prospectuses contained therein are available for use by the Investors. Notwithstanding any provision herein or in the Securities
Purchase Agreement to the contrary, the Company&rsquo;s obligations to register Registrable Securities (and any related conditions to
the Investors&rsquo; obligations) shall be qualified as necessary to comport with any requirement of the Staff or the SEC as addressed
in this&nbsp;<U>Section 2(c)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&nbsp;<U>Registrable
Securities</U>. Any Registrable Security shall cease to be a &ldquo;Registrable Security&rdquo; at the earliest of the following: (i)
when a Registration Statement covering such Registrable Security becomes or has been declared effective by the SEC and such Registrable
Security has been sold or disposed of pursuant to such effective Registration Statement; (ii) when such Registrable Security is held
by the Company or one of its subsidiaries; and (iii) the date that is the later of (A) the first (1st) anniversary of the date of termination
of the Securities Purchase Agreement in accordance with Article VIII of the Securities Purchase Agreement and (B) the first (1st) anniversary
of the date of the last sale of any Registrable Securities by the Company to the Investors pursuant to the Securities Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.</B>&nbsp;<B>COMPANY
OBLIGATIONS.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company shall use its commercially reasonable efforts to effect the registration of the Registrable Securities in accordance with the
intended method of disposition thereof, and, pursuant thereto, the Company shall have the following obligations:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
The Company shall promptly prepare and file with the SEC the Initial Registration Statement pursuant to&nbsp;<U>Section 2(a)</U>&nbsp;with
respect to the Registrable Securities, but in no event later than the applicable Filing Deadline therefor, and the Company shall use
its commercially reasonable efforts to cause each such Registration Statement to become effective as soon as practicable after such filing,
but in no event later than the applicable Effectiveness Deadline therefor. Subject to Allowable Grace Periods, the Company shall keep
each Registration Statement effective (and the Prospectus contained therein available for use) pursuant to Rule 415 for resales by the
Investors on a continuous basis at then-prevailing market prices (and not fixed prices) at all times until the earlier of (i) the date
on which the Investors shall have sold all of the Registrable Securities covered by such Registration Statement and (ii) the date of
termination of the Securities Purchase Agreement if, as of such termination date, the Investors hold no Registrable Securities (or, if
applicable, the date on which such Securities cease to be Registrable Securities after the date of termination of the Securities Purchase
Agreement) (the &ldquo;<B>Registration Period</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
The Company shall ensure that, when filed and at all times while effective, each Registration Statement (including, without limitation,
all amendments and supplements thereto) and the Prospectus (including, without limitation, all amendments and supplements thereto) used
in connection with such Registration Statement shall not contain any untrue statement of a material fact or omit to state a material
fact required to be stated therein, or necessary to make the statements therein (in the case of Prospectuses, in the light of the circumstances
in which they were made) not misleading and disclose (whether directly or through incorporation by reference to other SEC filings to
the extent permitted) all material information regarding the Company and its Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
The Company shall use its commercially reasonable efforts to prepare and file with the SEC such amendments (including, without limitation,
post-effective amendments) and supplements to each Registration Statement and the Prospectus used in connection with each such Registration
Statement, which Prospectus is to be filed pursuant to Rule 424 promulgated under the 1933 Act, as may be necessary to keep each such
Registration Statement effective (and the Prospectus contained therein current and available for use) at all times during the Registration
Period for such Registration Statement, and, during such period, comply with the provisions of the 1933 Act with respect to the disposition
of all Registrable Securities of the Company required to be covered by such Registration Statement until such time as all of such Registrable
Securities shall have been disposed of in accordance with the intended methods of disposition by the Investors as set forth in such Registration
Statement. Without limiting the generality of the foregoing, the Company covenants and agrees that at or before 8:30 a.m. (New York City
time) on the Trading Day immediately following the Effective Date of the Initial Registration Statement and any Subsequent Registration
Statement (or any post-effective amendment thereto), the Company shall file with the SEC in accordance with Rule 424(b) under the 1933
Act the final Prospectus to be used in connection with sales pursuant to such Registration Statement (or post-effective amendment thereto).
In the case of amendments and supplements to any Registration Statement on Form S-1 or Prospectus related thereto which are required
to be filed pursuant to this Agreement (including, without limitation, pursuant to this&nbsp;<U>Section 3(c)</U>) by reason of the Company
filing a report on Form 8-K, Form 10-Q, or Form 10-K or any analogous report under the 1934 Act, the Company shall have incorporated
such report by reference into such Registration Statement and Prospectus, if applicable, or shall file such amendments or supplements
to the Registration Statement or Prospectus with the SEC on the same day on which the 1934 Act report which created the requirement for
the Company to amend or supplement such Registration Statement or Prospectus is filed, for the purpose of including or incorporating
such report into such Registration Statement and Prospectus. The Company consents to the use of the Prospectus (including, without limitation,
any supplement thereto) included in each Registration Statement in accordance with the provisions of the 1933 Act and with the securities
or &ldquo;Blue Sky&rdquo; laws of the jurisdictions in which the Registrable Securities may be sold by the Investors, in connection with
the resale of the Registrable Securities and for such period of time thereafter as such Prospectus (including, without limitation, any
supplement thereto) (or in lieu thereof, the notice referred to in Rule 173(a) under the 1933 Act) is required by the 1933 Act to be
delivered in connection with resales of Registrable Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
The Company shall (i) permit the Investors an opportunity to review and comment upon (A) each Registration Statement at least two (2)
Business Days prior to its filing with the SEC and (B) all amendments and supplements to each Registration Statement (including, without
limitation, the Prospectus contained therein) (except for Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports
on Form 8-K, and any similar or successor reports or Prospectus Supplements the contents of which are limited to that set forth in such
reports) within a reasonable number of days prior to their filing with the SEC, and (ii) shall reasonably consider any comments of the
Investors on any such Registration Statement or amendment or supplement thereto or to any Prospectus contained therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
Without limiting any obligation of the Company under the Securities Purchase Agreement, the Company shall promptly furnish to the Investors
(but not later than one (1) Business Day after the filing date, receipt date, or sending date, as the case may be), without charge, (i)
after the same is prepared and filed with the SEC, at least one (1) electronic copy of each Registration Statement and any amendment(s)
and supplement(s) thereto, including, without limitation, financial statements and schedules, all documents incorporated therein by reference,
if requested by the Investors, all exhibits thereto (or such other number of copies as the Investors may reasonably request from time
to time), (ii) upon the effectiveness of each Registration Statement, one (1) electronic copy of the Prospectus included in such Registration
Statement and all amendments and supplements thereto (or such other number of copies as the Investors may reasonably request from time
to time), (iii) electronic or digital copies of any correspondence from the SEC or the Staff to the Company or its representatives relating
to each Registration Statement (which correspondence shall be redacted to exclude any material, non-public information regarding the
Company or any of its Subsidiaries), and (iv) such other documents, including, without limitation, copies of any final Prospectus and
any Prospectus Supplement thereto, as the Investors may reasonably request from time to time in order to facilitate the disposition of
the Registrable Securities owned by the Investors;&nbsp;<U>provided</U>,&nbsp;<U>however</U>, the Company shall not be required to furnish
any document to the Investors to the extent such document is available on EDGAR).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
The Company shall submit to the SEC, within two (2) Business Days after the date that the Company learns that no review of a particular
Registration Statement shall be made by the Staff or that the Staff has no further comments on a particular Registration Statement (as
the case may be), a request for acceleration of effectiveness of such Registration Statement to a time and date not later than three
(3) Business Days after the submission of such request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
Within one (1) Business Day after each Registration Statement which covers Registrable Securities is declared effective by the SEC, the
Company shall deliver, and shall cause its legal counsel to deliver, to the transfer agent for such Registrable Securities (with copies
to the Investors) confirmation that such Registration Statement has been declared effective by the SEC in the form attached hereto as&nbsp;<U>Exhibit
A</U>, or in such other form as requested by the Company&rsquo;s transfer agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
The Company shall take such action as is reasonably necessary to (i) register and qualify, unless an exemption from registration and
qualification applies, the resale by the Investors of the Registrable Securities covered by a Registration Statement under such other
securities or &ldquo;Blue Sky&rdquo; laws of all applicable jurisdictions in the United States, (ii) prepare and file in those jurisdictions,
such amendments (including, without limitation, post-effective amendments) and supplements to such registrations and qualifications as
may be necessary to maintain the effectiveness thereof during the Registration Period, (iii) take such other actions as may be reasonably
necessary to maintain such registrations and qualifications in effect at all times during the Registration Period, and (iv) take all
other actions reasonably necessary or advisable to qualify the Registrable Securities for sale in such jurisdictions;&nbsp;<U>provided</U>,&nbsp;<U>however</U>,
the Company shall not be required in connection therewith or as a condition thereto to (A) qualify to do business in any jurisdiction
where it would not otherwise be required to qualify but for this&nbsp;<U>Section 3(h)</U>, (B) subject itself to general taxation in
any such jurisdiction, or (C) file a general consent to service of process in any such jurisdiction. The Company shall promptly notify
the Investors of the receipt by the Company of any notification with respect to the suspension of the registration or qualification of
any of the Registrable Securities for sale under the securities or &ldquo;Blue Sky&rdquo; laws of any jurisdiction in the United States
or its receipt of actual notice of the initiation or threatening of any proceeding for such purpose.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
The Company shall notify the Investors in writing of the happening of any event, as promptly as reasonably practicable after becoming
aware of such event, as a result of which the Prospectus included in a Registration Statement, as then in effect, includes an untrue
statement of a material fact or omission to state a material fact required to be stated therein or necessary to make the statements therein,
in the light of the circumstances under which they were made, not misleading (provided that in no event shall such notice contain any
material, non-public information regarding the Company or any of its Subsidiaries), and promptly prepare a supplement or amendment to
such Registration Statement and such Prospectus contained therein to correct such untrue statement or omission and deliver one (1) electronic
copy of such supplement or amendment to the Investors (or such other number of copies as the Investors may reasonably request) upon its
filing with the SEC. The Company shall also promptly notify the Investors in writing (i) when a Prospectus or any Prospectus Supplement
or post-effective amendment has been filed, when a Registration Statement or any post-effective amendment has become effective (notification
of such effectiveness shall be delivered to the Investors by e-mail on the same day of such effectiveness, and by overnight delivery),
and when the Company receives written notice from the SEC that a Registration Statement or any post-effective amendment will be reviewed
by the SEC, (ii) of any request by the SEC for amendments or supplements to a Registration Statement or related Prospectus or related
information, and (iii) of the Company&rsquo;s reasonable determination that a post-effective amendment to a Registration Statement would
be appropriate and (iv) of the receipt of any request by the SEC or any other federal or state governmental authority for any additional
information relating to the Investors or the transactions contemplated by the Transaction Documents in the Registration Statement or
any amendment or supplement thereto or any related Prospectus. The Company shall respond in writing to any comments received from the
SEC with respect to a Registration Statement or any amendment thereto as promptly as reasonably practicable, but in no event later than
ten (10) calendar days after the receipt of such comments by or notice from the SEC that an amendment is required in order for a Registration
Statement to be declared effective. Nothing in this&nbsp;<U>Section 3(i)</U>&nbsp;shall limit any obligation of the Company under the
Securities Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)
The Company shall (i) use its commercially reasonable efforts to prevent the issuance of any stop order or other suspension of effectiveness
of a Registration Statement or the use of any Prospectus contained therein, or the suspension of the qualification, or the loss of an
exemption from qualification, of any of the Registrable Securities for sale in any jurisdiction and, if such an order or suspension is
issued, to obtain the withdrawal of such order or suspension at the earliest possible time, and (ii) notify the Investors of the issuance
of such order and the resolution thereof or its receipt of actual notice of the initiation or threat of any proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)
The Company shall hold in confidence and not make any disclosure of information concerning the Investors provided to the Company unless
(i) disclosure of such information is necessary to comply with federal or state securities laws, (ii) the disclosure of such information
is necessary to avoid or correct a misstatement or omission in any Registration Statement or is otherwise required to be disclosed in
such Registration Statement pursuant to the 1933 Act, (iii) the release of such information is ordered pursuant to a subpoena or other
order from a court or governmental body of competent jurisdiction, or (iv) such information has been made generally available to the
public other than by disclosure in violation of this Agreement or any other Transaction Document. The Company agrees that it shall, upon
learning that disclosure of such information concerning the Investors is sought in or by a court or governmental body of competent jurisdiction
or through other means, to the extent legally permissible, the Company shall give prompt written notice (email being sufficient) to the
Investors and allow the Investors, at the Investors&rsquo; expense, to undertake appropriate action to seek prevention of disclosure
of, or to seek a protective order for, such information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)
Without limiting any obligation of the Company under the Securities Purchase Agreement, the Company shall use its commercially reasonable
efforts either to (i) cause all of the Registrable Securities covered by each Registration Statement to be listed on the Trading Market
or other market on which the Common Stock is then listed, (ii) secure designation and quotation of all of the Registrable Securities
covered by each Registration Statement on another Trading Market, or (iii) if, despite the Company&rsquo;s commercially reasonable efforts
to satisfy the preceding clauses (i) or (ii), the Company is unsuccessful in satisfying the preceding clauses (i) or (ii), without limiting
the generality of the foregoing, use its commercially reasonable efforts to arrange for at least two (2) market makers to register with
the Financial Industry Regulatory Authority (&ldquo;<B>FINRA</B>&rdquo;) as such with respect to such Registrable Securities. In addition,
the Company shall reasonably cooperate with the Investors and any Broker-Dealer through which an Investor proposes to sell its Registrable
Securities in effecting a filing with the FINRA pursuant to FINRA Rule 5110 as requested by the Investor. The Company shall pay all fees
and expenses in connection with satisfying its obligation under this&nbsp;<U>Section 3(l)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)
The Company shall cooperate with the Investors and, to the extent applicable, facilitate the timely preparation and delivery of Registrable
Securities, as DWAC Shares, to be offered pursuant to a Registration Statement and enable such DWAC Shares to be in such denominations
or amounts (as the case may be) as the Investor may reasonably request from time to time and registered in such names as the Investor
may request. Each Investor hereby agrees that it shall cooperate with the Company, its counsel and transfer agent in connection with
any issuances of the DWAC Shares, and hereby represents, warrants and covenants to the Company that it will resell such shares only pursuant
to the Registration Statement in which such DWAC Shares are included, in a manner described under the caption &ldquo;Plan of Distribution&rdquo;
in such Registration Statement, and in a manner in compliance with all applicable U.S. federal and state securities laws, rules and regulations,
including, without limitation, any applicable prospectus delivery requirements of the 1933 Act. DWAC Shares shall be free from all restrictive
legends may be transmitted by the transfer agent to the Investor by crediting an account at DTC as directed in writing by the Investor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)
Upon the written request of any Investor, the Company shall as soon as reasonably practicable after receipt of notice from the Investor,
(i) incorporate in a Prospectus Supplement or post-effective amendment such information as the Investor reasonably requests to be included
therein relating to the sale and distribution of Registrable Securities, including, without limitation, information with respect to the
number of Registrable Securities being offered or sold, the purchase price being paid therefor and any other terms of the offering of
the Registrable Securities to be sold in such offering; (ii) make all required filings of such Prospectus Supplement or post-effective
amendment after being notified of the matters to be incorporated in such Prospectus Supplement or post-effective amendment; and (iii)
supplement or make amendments to any Registration Statement or Prospectus contained therein if reasonably requested by the Investor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(o)
The Company shall use its commercially reasonable efforts to cause the Registrable Securities covered by a Registration Statement to
be registered with or approved by such other governmental agencies or authorities in the United States as may be necessary to consummate
the disposition of such Registrable Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(p)
The Company shall make generally available to its security holders (which may be satisfied by making such information available on EDGAR)
as soon as practical, but not later than ninety (90) days after the close of the period covered thereby, an earnings statement (in form
complying with, and in the manner provided by, the provisions of Rule 158 under the 1933 Act) covering a twelve (12)-month period beginning
not later than the first day of the Company&rsquo;s fiscal quarter next following the applicable Effective Date of each Registration
Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(q)
The Company shall otherwise use its commercially reasonable efforts to comply with all applicable rules and regulations of the SEC in
connection with any registration hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.</B>&nbsp;<B>OBLIGATIONS
OF THE INVESTORS.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
At least five (5) Business Days prior to the first anticipated filing date of each Registration Statement (or such shorter period to
which the Parties agree), the Company shall notify the Investors in writing of the information the Company requires from the Investors
with respect to such Registration Statement. It shall be a condition precedent to the obligations of the Company to complete the registration
pursuant to this Agreement with respect to the Registrable Securities of the Investors that each Investor shall furnish to the Company
such information regarding itself, the Registrable Securities held by it and the intended method of disposition of the Registrable Securities
held by it, as shall be reasonably required to effect and maintain the effectiveness of the registration of such Registrable Securities
and shall execute such documents in connection with such registration as the Company may reasonably request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Each Investor, by acceptance of the Registrable Securities, agrees to cooperate with the Company as reasonably requested by the Company
in connection with the preparation and filing of each Registration Statement hereunder, unless the Investor has notified the Company
in writing of the Investor&rsquo;s election to exclude all of its Registrable Securities from such Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Each Investor agrees that, upon receipt of any notice from the Company of the happening of any event of the kind described in&nbsp;<U>Section
3(i)</U>, the Investor shall immediately discontinue disposition of Registrable Securities pursuant to any Registration Statement(s)
covering such Registrable Securities until the Investor&rsquo;s receipt of the copies of the supplemented or amended Prospectus contemplated
by&nbsp;<U>Section 3(i)</U>&nbsp;or receipt of notice that no supplement or amendment is required. Notwithstanding anything to the contrary
in this&nbsp;<U>Section 4(c)</U>, the Company shall cause its transfer agent to deliver DWAC Shares to a transferee of such Investor
in accordance with the terms of the Securities Purchase Agreement in connection with any sale of Registrable Securities with respect
to which the Investor has entered into a contract for sale prior to the Investor&rsquo;s receipt of a notice from the Company of the
happening of any event of the kind described in&nbsp;<U>Section 3(i)</U>&nbsp;and for which the Investor has not yet settled.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Each Investor covenants and agrees that it shall comply with the prospectus delivery and other requirements of the 1933 Act as applicable
to it in connection with sales of Registrable Securities pursuant to a Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.</B>&nbsp;<B>EXPENSES
OF REGISTRATION.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company shall pay all expenses associated with the registration of the Registrable Securities, including costs to prepare the Registration
Statements, filing and printing fees, fees and expenses of the Company&rsquo;s counsel, accounting fees and expenses, costs associated
with clearing the Registrable Securities for sale under applicable state securities laws, listing fees, reasonable out of pocket fees
and expenses of one counsel to the lead Investor, and such lead Investor&rsquo;s reasonable expenses. All registration, listing and qualification
fees, printers and accounting fees incurred by the Company, and fees and disbursements of counsel for the Company, shall be paid by the
Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6.</B>&nbsp;<B>INDEMNIFICATION.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
In the event any Registrable Securities are included in any Registration Statement under this Agreement, to the fullest extent permitted
by law, the Company shall, and hereby does, indemnify, hold harmless and defend each Investor, each of its respective directors, officers,
shareholders, members, partners, employees, and authorized representatives, agents and financial, accounting and legal advisors (and
any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding the lack of such title or any other
title), and each Person, if any, who controls the Investor within the meaning of the 1933 Act or the 1934 Act and each of the directors,
officers, shareholders, members, partners, employees, and authorized representatives, agents and financial, accounting and legal advisors
(and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding the lack of such title or
any other title) of such controlling Persons (each, an &ldquo;<B>Investor Party</B>&rdquo; and collectively, the &ldquo;<B>Investor Parties</B>&rdquo;),
against any losses, obligations, claims, damages, liabilities, contingencies, judgments, fines, penalties, charges, costs (including,
without limitation, court costs, attorneys&rsquo; fees, costs of defense and investigation), amounts paid in settlement or expenses,
joint or several, (collectively, &ldquo;<B>Claims</B>&rdquo;) reasonably incurred in investigating, preparing or defending any action,
claim, suit, inquiry, proceeding, investigation or appeal taken from the foregoing by or before any court or governmental, administrative
or other regulatory agency, body or the SEC, whether pending or threatened, whether or not an Investor Party is or may be a party thereto
(&ldquo;<B>Indemnified Damages</B>&rdquo;), to which any of them may become subject insofar as such Claims (or actions or proceedings,
whether commenced or threatened, in respect thereof) arise out of or are based upon: (i) any untrue statement or alleged untrue statement
of a material fact in a Registration Statement or any post-effective amendment thereto or in any filing made in connection with the qualification
of the offering under the securities or other &ldquo;Blue Sky&rdquo; laws of any jurisdiction in which Registrable Securities are offered
(&ldquo;<B>Blue Sky Filing</B>&rdquo;), or the omission or alleged omission to state a material fact required to be stated therein or
necessary to make the statements therein not misleading, or (ii) any untrue statement or alleged untrue statement of a material fact
contained in any Prospectus (as amended or supplemented) or in any Prospectus Supplement or the omission or alleged omission to state
therein any material fact necessary to make the statements made therein, in light of the circumstances under which the statements therein
were made, not misleading (the matters in the foregoing clauses (i) and (ii) being, collectively, &ldquo;<B>Violations</B>&rdquo;). Subject
to&nbsp;<U>Section 6(c)</U>, the Company shall reimburse the Investor Parties, promptly as such expenses are incurred and are due and
payable, for any reasonable legal fees or other reasonable out of pocket expenses incurred by them in connection with investigating or
defending any such Claim. Notwithstanding anything to the contrary contained herein, the indemnification agreement contained in this&nbsp;<U>Section
6(a)</U>: (i) shall not apply to a Claim by an Investor Party arising out of or based upon a Violation which occurs in reliance upon
and in conformity with information furnished in writing to the Company by such Investor Party for such Investor Party expressly for use
in connection with the preparation of such Registration Statement, Prospectus or Prospectus Supplement or any such amendment thereof
or supplement thereto (it being hereby acknowledged and agreed that the written information set forth on&nbsp;<U>Exhibit B</U>&nbsp;attached
hereto is the only written information furnished to the Company by or on behalf of the Investor expressly for use in any Registration
Statement, Prospectus or Prospectus Supplement); (ii) shall not be available to the Investor to the extent such Claim is based on a failure
of the Investor to deliver or to cause to be delivered the Prospectus (as amended or supplemented) made available by the Company (to
the extent applicable), including, without limitation, a corrected Prospectus, if such Prospectus (as amended or supplemented) or corrected
Prospectus was timely made available by the Company pursuant to&nbsp;<U>Section 3(d)</U>&nbsp;and then only if, and to the extent that,
following the receipt of the corrected Prospectus no grounds for such Claim would have existed; and (iii) shall not apply to amounts
paid in settlement of any Claim if such settlement is effected without the prior written consent of the Company, which consent shall
not be unreasonably withheld or delayed. Such indemnity shall remain in full force and effect regardless of any investigation made by
or on behalf of the Investor Party and shall survive the transfer of any of the Registrable Securities by the Investor pursuant to&nbsp;<U>Section
9</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
In connection with any Registration Statement in which the Investors are participating, each Investor agrees to severally and not jointly
indemnify, hold harmless and defend, to the same extent and in the same manner as is set forth in&nbsp;<U>Section 6(a)</U>, the Company,
each of its directors, each of its officers who signs the Registration Statement and each Person, if any, who controls the Company within
the meaning of the 1933 Act or the 1934 Act (each, a &ldquo;<B>Company Party</B>&rdquo; and collectively, the &ldquo;<B>Company Parties</B>&rdquo;),
against any Claim or Indemnified Damages to which any of them may become subject, under the 1933 Act, the 1934 Act or otherwise, insofar
as such Claim or Indemnified Damages arise out of or are based upon any Violation, in each case, to the extent, and only to the extent,
that such Violation occurs in reliance upon and in conformity with written information relating to the Investor furnished to the Company
by the Investor expressly for use in connection with such Registration Statement, the Prospectus included therein or any Prospectus Supplement
thereto (it being hereby acknowledged and agreed that the written information set forth on&nbsp;<U>Exhibit B</U>&nbsp;attached hereto
is the only written information furnished to the Company by or on behalf of the Investor expressly for use in any Registration Statement,
Prospectus or Prospectus Supplement); and, subject to&nbsp;<U>Section 6(c)</U>&nbsp;and the below provisos in this&nbsp;<U>Section 6(b)</U>,
the Investor shall reimburse a Company Party any legal or other expenses reasonably incurred by such Company Party in connection with
investigating or defending any such Claim;&nbsp;<U>provided</U>,&nbsp;<U>however</U>, the indemnity agreement contained in this&nbsp;<U>Section
6(b)</U>&nbsp;and the agreement with respect to contribution contained in&nbsp;<U>Section 7</U>&nbsp;shall not apply to amounts paid
in settlement of any Claim if such settlement is effected without the prior written consent of the Investor, which consent shall not
be unreasonably withheld or delayed; and&nbsp;<U>provided, further</U>&nbsp;that the Investor shall be liable under this&nbsp;<U>Section
6(b)</U>&nbsp;for only that amount of a Claim or Indemnified Damages as does not exceed the net proceeds to the Investor as a result
of the applicable sale of Registrable Securities pursuant to such Registration Statement, Prospectus or Prospectus Supplement. Such indemnity
shall remain in full force and effect regardless of any investigation made by or on behalf of such Company Party and shall survive the
transfer of any of the Registrable Securities by the Investor pursuant to&nbsp;<U>Section 9</U>&nbsp;hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Promptly after receipt by an Investor Party or Company Party (as the case may be) under this&nbsp;<U>Section 6</U>&nbsp;of notice of
the commencement of any action or proceeding (including, without limitation, any governmental action or proceeding) involving a Claim,
such Investor Party or Company Party (as the case may be) shall, if a Claim in respect thereof is to be made against any indemnifying
party under this&nbsp;<U>Section 6</U>, deliver to the indemnifying party a written notice of the commencement thereof, and the indemnifying
party shall have the right to participate in, and, to the extent the indemnifying party so desires, jointly with any other indemnifying
party similarly noticed, to assume control of the defense thereof with counsel mutually satisfactory to the indemnifying party and the
Investor Party or the Company Party (as the case may be);&nbsp;<U>provided</U>,&nbsp;<U>however</U>, an Investor Party or Company Party
(as the case may be) shall have the right to retain its own counsel with the fees and expenses of such counsel to be paid by the indemnifying
party if: (i) the indemnifying party has agreed in writing to pay such fees and expenses; (ii) the indemnifying party shall have failed
promptly to assume the defense of such Claim and to employ counsel reasonably satisfactory to such Investor Party or Company Party (as
the case may be) in any such Claim; or (iii) the named parties to any such Claim (including, without limitation, any impleaded parties)
include both such Investor Party or Company Party (as the case may be) and the indemnifying party, and such Investor Party or such Company
Party (as the case may be) shall have been advised by counsel that a conflict of interest is likely to exist if the same counsel were
to represent such Investor Party or such Company Party and the indemnifying party (in which case, if such Investor Party or such Company
Party (as the case may be) notifies the indemnifying party in writing that it elects to employ separate counsel at the expense of the
indemnifying party, then the indemnifying party shall not have the right to assume the defense thereof on behalf of the indemnified party
and such counsel shall be at the expense of the indemnifying party,&nbsp;<U>provided further</U>&nbsp;that in the case of clause (iii)
above the indemnifying party shall not be responsible for the reasonable fees and expenses of more than one (1) separate legal counsel
for all Investor Parties or Company Parties (as the case may be). The Company Party or Investor Party (as the case may be) shall reasonably
cooperate with the indemnifying party in connection with any negotiation or defense of any such action or Claim by the indemnifying party
and shall furnish to the indemnifying party all information reasonably available to the Company Party or Investor Party (as the case
may be) which relates to such action or Claim. The indemnifying party shall keep the Company Party or Investor Party (as the case may
be) reasonably apprised at all times as to the status of the defense or any settlement negotiations with respect thereto. No indemnifying
party shall be liable for any settlement of any action, claim or proceeding effected without its prior written consent;&nbsp;<U>provided</U>,&nbsp;<U>however</U>,
the indemnifying party shall not unreasonably withhold, delay or condition its consent. No indemnifying party shall, without the prior
written consent of the Company Party or Investor Party (as the case may be), consent to entry of any judgment or enter into any settlement
or other compromise which does not include as an unconditional term thereof the giving by the claimant or plaintiff to such Company Party
or Investor Party (as the case may be) of an unconditional release from all liability in respect to such Claim or litigation, and such
settlement shall not include any admission as to fault on the part of the Company Party. For the avoidance of doubt, the immediately
preceding sentence shall apply to&nbsp;<U>Sections 6(a)</U>&nbsp;and&nbsp;<U>6(b)</U>. Following indemnification as provided for hereunder,
the indemnifying party shall be subrogated to all rights of the Company Party or Investor Party (as the case may be) with respect to
all third parties, firms or corporations relating to the matter for which indemnification has been made. The failure to deliver written
notice to the indemnifying party within a reasonable time of the commencement of any such action shall not relieve such indemnifying
party of any liability to the Investor Party or Company Party (as the case may be) under this&nbsp;<U>Section 6</U>, except to the extent
that the indemnifying party is materially and adversely prejudiced in its ability to defend such action.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
No Person involved in the sale of Registrable Securities who is guilty of fraudulent misrepresentation (within the meaning of Section
11(f) of the 1933 Act) in connection with such sale shall be entitled to indemnification from any Person involved in such sale of Registrable
Securities who is not guilty of fraudulent misrepresentation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
The indemnification required by this&nbsp;<U>Section 6</U>&nbsp;shall be made by periodic payments of the amount thereof during the course
of the investigation or defense, as and when bills are received or Indemnified Damages are incurred;&nbsp;<U>provided</U>&nbsp;that any
Person receiving any payment pursuant to this&nbsp;<U>Section 6</U>&nbsp;shall promptly reimburse the Person making such payment for
the amount of such payment to the extent a court of competent jurisdiction determines that such Person receiving such payment was not
entitled to such payment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
The indemnity and contribution agreements contained herein shall be in addition to (i) any cause of action or similar right of the Company
Party or Investor Party against the indemnifying party or others, and (ii) any liabilities the indemnifying party may be subject to pursuant
to the law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7.</B>&nbsp;<B>CONTRIBUTION.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent any indemnification by an indemnifying party is prohibited, limited by law, or unavailable to an indemnified party or insufficient
to hold it harmless, then the indemnifying party agrees to make the maximum contribution with respect to any amounts for which it would
otherwise be liable under&nbsp;<U>Section 6</U>&nbsp;to the fullest extent permitted by law;&nbsp;<U>provided</U>,&nbsp;<U>however</U>:
(i) no contribution shall be made under circumstances where the maker would not have been liable for indemnification under the fault
standards set forth in&nbsp;<U>Section 6</U>&nbsp;of this Agreement, (ii) no Person involved in the sale of Registrable Securities which
Person is guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the 1933 Act) in connection with such sale shall
be entitled to contribution from any Person involved in such sale of Registrable Securities who was not guilty of fraudulent misrepresentation;
and (iii) contribution by any seller of Registrable Securities shall be limited in amount to the amount of net proceeds received by such
seller from the applicable sale of such Registrable Securities pursuant to such Registration Statement. Notwithstanding the provisions
of this&nbsp;<U>Section 7</U>, an Investor shall not be required to contribute, in the aggregate, any amount in excess of the amount
by which the net proceeds actually received by the Investor from the applicable sale of the Registrable Securities subject to the Claim
exceeds the amount of any damages the Investor has otherwise been required to pay, or would otherwise be required to pay under&nbsp;<U>Section
6(b)</U>, by reason of such untrue or alleged untrue statement or omission or alleged omission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.</B>&nbsp;<B>EXCHANGE
ACT REPORTS.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
a view to making available to the Investors the benefits of Rule 144 (or its successor rule), the Company agrees to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
use its reasonable best efforts to make and keep public information available, as those terms are understood and defined in Rule 144,
until the earlier of (i) six (6) months after such date as all of the Registrable Securities may be sold without restriction by the holders
thereof pursuant to Rule 144 or any other rule of similar effect, or (ii) such date as all of the Registrable Securities shall have been
resold;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
use its reasonable best efforts to file with the SEC in a timely manner all reports and other documents required of the Company under
the 1933 Act and the 1934 Act so long as the Company remains subject to such requirements (it being understood that nothing herein shall
limit any of the Company&rsquo;s obligations under the Securities Purchase Agreement) and the filing of such reports and other documents
is required for the applicable provisions of Rule 144;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
furnish to the Investors (so long as the Investors own Registrable Securities), promptly upon request, (i) a written statement by the
Company, if true, that it has complied with the reporting, submission, and posting requirements of Rule 144 and the 1934 Act, (ii) a
copy of the most recent annual or quarterly report of the Company and such other reports and documents so filed by the Company with the
SEC if such reports are not publicly available via EDGAR, and (iii) such other information as may be reasonably requested to permit the
Investors to sell such Securities pursuant to Rule 144 without registration; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
take such additional action as is reasonably requested by the Investors to enable the Investors to sell the Registrable Securities pursuant
to Rule 144, including, without limitation, delivering all such legal opinions, consents, certificates, resolutions and instructions
to the Company&rsquo;s Transfer Agent as may be reasonably requested from time to time by the Investors and otherwise fully cooperate
with the Investors and any broker of an Investor to effect such sale of Securities pursuant to Rule 144.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>9.</B>&nbsp;<B>ASSIGNMENT
OF REGISTRATION RIGHTS.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
Investor may transfer or assign, in whole or from time to time in part, to one or more persons its rights hereunder in connection with
the transfer of Registrable Securities by such Investor to such person, provided that the Investor complies with all laws applicable
thereto and provides written notice of assignment to the Company promptly after such assignment is effected. This Agreement may not be
assigned by the Company (whether by operation of law or otherwise) without the prior written consent of the Investors, provided that
in the event that the Company is a party to a merger, consolidation, share exchange or similar business combination transaction in which
the Common Stock is converted into the equity securities of another entity, from and after the effective time of such transaction, such
entity shall, by virtue of such transaction, be deemed to have assumed the obligations of the Company hereunder, the term &ldquo;Company&rdquo;
shall be deemed to refer to such entity and the term &ldquo;Registrable Securities&rdquo; shall be deemed to include the securities received
by the Investors in connection with such transaction unless such securities are otherwise freely tradable by the Investors after giving
effect to such transaction. This Agreement shall inure to the benefit of and be binding upon the Parties and their respective successors
and permitted assigns. This Agreement is not for the benefit of, nor may any provision hereof be enforced by, any Person, other than
the Parties, their respective successors and permitted assigns.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10.</B>&nbsp;<B>AMENDMENT
OR WAIVER.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
provision of this Agreement may be amended or waived by the Parties from and after the date that is one (1) Trading Day immediately preceding
the date on which the Initial Registration Statement is filed with the SEC. Subject to the immediately preceding sentence, no provision
of this Agreement may be (a) amended other than by a written instrument signed by the Parties or (b) waived other than in a written instrument
signed by the Party against whom enforcement of such waiver is sought. Failure of any Party to exercise any right or remedy under this
Agreement or otherwise, or delay by a Party in exercising such right or remedy, shall not operate as a waiver thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.</B>&nbsp;<B>MISCELLANEOUS.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Solely for purposes of this Agreement, a Person is deemed to be a holder of Registrable Securities whenever such Person owns or is deemed
to own of record such Registrable Securities. If the Company receives conflicting instructions, notices or elections from two (2) or
more Persons with respect to the same Registrable Securities, the Company shall act upon the basis of instructions, notice or election
received from such record owner of such Registrable Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Any notices, consents, waivers or other communications required or permitted to be given under the terms of this Agreement shall be given
in accordance with Section 9(f) of the Securities Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Failure of any Party to exercise any right or remedy under this Agreement or otherwise, or delay by a Party in exercising such right
or remedy, shall not operate as a waiver thereof. The Company and the Investors acknowledge and agree that irreparable damage would occur
in the event that any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise
breached. It is accordingly agreed that either Party shall be entitled to an injunction or injunctions to prevent or cure breaches of
the provisions of this Agreement by the other Party and to enforce specifically the terms and provisions hereof (without the necessity
of showing economic loss and without any bond or other security being required), this being in addition to any other remedy to which
either Party may be entitled by law or equity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by the internal
laws of the State of New York, without giving effect to any choice of law or conflict of law provision or rule (whether of the State
of New York or any other jurisdictions) that would cause the application of the laws of any jurisdictions other than the State of New
York. Each Party hereby irrevocably submits to the jurisdiction of the state and federal courts sitting in The City and State of New
York, New York County, for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby
or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is
not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is brought in an inconvenient forum
or that the venue of such suit, action or proceeding is improper. Each Party hereby irrevocably waives personal service of process and
consents to process being served in any such suit, action or proceeding by mailing a copy thereof to such Party at the address for such
notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof.
Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. If any provision
of this Agreement shall be invalid or unenforceable in any jurisdiction, such invalidity or unenforceability shall not affect the validity
or enforceability of the remainder of this Agreement in that jurisdiction or the validity or enforceability of any provision of this
Agreement in any other jurisdiction.&nbsp;<B>EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE TO, AND AGREES NOT TO REQUEST,
A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION HEREWITH OR ARISING OUT OF THIS AGREEMENT OR ANY TRANSACTION
CONTEMPLATED HEREBY.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
The Transaction Documents set forth the entire agreement and understanding of the Parties solely with respect to the subject matter thereof
and supersedes all prior and contemporaneous agreements, negotiations and understandings between the Parties, both oral and written,
solely with respect to such matters. There are no promises, undertakings, representations or warranties by either Party relative to the
subject matter hereof not expressly set forth in the Transaction Documents. Notwithstanding anything in this Agreement to the contrary
and without implication that the contrary would otherwise be true, nothing contained in this Agreement shall limit, modify or affect
in any manner whatsoever any of the Company&rsquo;s obligations under the Securities Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
The headings in this Agreement are for convenience of reference only and shall not limit or otherwise affect the meaning hereof. Unless
the context clearly indicates otherwise, each pronoun herein shall be deemed to include the masculine, feminine, neuter, singular and
plural forms thereof. The terms &ldquo;including,&rdquo; &ldquo;includes,&rdquo; &ldquo;include&rdquo; and words of like import shall
be construed broadly as if followed by the words &ldquo;without limitation.&rdquo; The terms &ldquo;herein,&rdquo; &ldquo;hereunder,&rdquo;
&ldquo;hereof&rdquo; and words of like import refer to this entire Agreement instead of just the provision in which they are found.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
This Agreement may be executed in two or more identical counterparts, all of which shall be considered one and the same agreement and
shall become effective when counterparts have been signed by each Party and delivered to the other Party; provided that a facsimile signature
or signature delivered by e-mail in a &ldquo;.pdf&rdquo; or comparable commercially recognized electronic or digital format, including
any electronic signature complying with the U.S. Electronic Signatures in Global and National Commerce Act of 2000 shall be considered
due execution and shall be binding upon the signatory thereto with the same force and effect as if the signature were an original signature.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
Each Party shall do and perform, or cause to be done and performed, all such further acts and things, and shall execute and deliver all
such other agreements, certificates, instruments and documents as any other Party may reasonably request in order to carry out the intent
and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
The language used in this Agreement will be deemed to be the language chosen by the Parties to express their mutual intent and no rules
of strict construction will be applied against any Party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[<I>Signature
Page Follows</I>]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IN
WITNESS WHEREOF,</B>&nbsp;each Investor and the Company have caused their respective signature page to this Agreement to be duly executed
as of the date first above written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>COMPANY:</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 46%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ONEMEDNET CORPORATION</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Paul
    J. Casey</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul J. Casey</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[<I>Signature
page to Registration Rights Agreement</I>]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IN
WITNESS WHEREOF,</B>&nbsp;each Investor and the Company have caused their respective signature page to this Agreement to be duly executed
as of the date first above written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INVESTOR:</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 8%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 52%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[_____]</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[<I>Signature
page to Registration Rights Agreement</I>]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
A</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>FORM
OF NOTICE OF EFFECTIVENESS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>OF
REGISTRATION STATEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Company
Transfer Agent]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 48px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 48px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Re:</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>OneMedNet Corporation</I></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladies
and Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are counsel to OneMedNet Corporation, a Delaware corporation (the &ldquo;<B>Company</B>&rdquo;), and have represented the Company in
connection with that certain Securities Purchase Agreement, dated as of March [&#9679;], 2024 (the &ldquo;<B>Securities Purchase Agreement</B>&rdquo;),
entered into by and among the Company and the investors named therein (the &ldquo;<B>Investors</B>&rdquo;), pursuant to which the Company
may issue to the Investors from time to time convertible promissory notes and common stock purchase warrants, convertible or exercisable,
as applicable, into common stock, $0.0001 par value per share of the Company (the &ldquo;<B>Common Stock</B>&rdquo;). Pursuant to the
Purchase Agreement, the Company also has entered into a Registration Rights Agreement, dated as of March [&#9679;], 2024, with the Investor
(the &ldquo;<B>Registration Rights Agreement</B>&rdquo;), pursuant to which the Company agreed, among other things, to register the resale
by the Investor of the Registrable Securities (as defined in the Registration Rights Agreement) under the 1933 Act of 1933, as amended
(the &ldquo;<B>1933 Act</B>&rdquo;). In connection with the Company&rsquo;s obligations under the Registration Rights Agreement, on [&#9679;],
202[&#9679;], the Company filed a Registration Statement on Form S-1 (File No. 333-[&#9679;]) (the &ldquo;<B>Registration Statement</B>&rdquo;)
with the Securities and Exchange Commission (the &ldquo;<B>SEC</B>&rdquo;) relating to the Registrable Securities which names the Investor
as a selling stockholder thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the foregoing, based solely on our review of the SEC&rsquo;s EDGAR website, we advise you that the Registration Statement
became effective under the 1933 Act on [&#9679;], 202[&#9679;]. In addition, based solely on our review of the information made available
by the SEC at http://www.sec.gov/litigation/stoporders.shtml, we confirm that the SEC has not issued any stop order suspending the effectiveness
of the Registration Statement. To our knowledge, based solely on our participation in the conferences mentioned above regarding the Registration
Statement and our review of the information made available by the SEC at http://www.sec.gov/litigation/stoporders.shtml, no proceedings
for that purpose are pending or have been instituted or threatened by the SEC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
letter shall serve as our standing opinion to you that the shares of Common Stock are freely transferable by the Investor pursuant to
the Registration Statement, provided the Registration Statement remains effective.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
opinion letter is limited to the federal securities laws of the United States of America. We express no opinion as to matters relating
to state securities laws or Blue Sky laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
assume no obligation to update or supplement this opinion letter to reflect any facts or circumstances which may hereafter come to our
attention with respect to the opinion and statements expressed above, including any changes in applicable law that may hereafter occur.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 16; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
opinion letter is being delivered solely for the benefit of the person to whom it is addressed; accordingly, it may not be quoted, filed
with any governmental authority or other regulatory agency or otherwise circulated or utilized for any purposes without our prior written
consent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very
truly yours,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">[COMPANY
    COUNSEL]</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cc: [____]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
B</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SELLING
STOCKHOLDER</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus relates to the possible resale from time to time by [____], of any or all of the shares of common stock that may be issued
by us to [____] under the Securities Purchase Agreement. For additional information regarding the issuance of common stock covered by
this prospectus, see the section titled &ldquo;<I>The [____] Financing</I>&rdquo; above. We are registering the shares of common stock
pursuant to the provisions of the Registration Rights Agreement we entered into with [____] on March [&#9679;], 2024, in order to permit
the selling stockholder to offer the shares for resale from time to time. Except for the transactions contemplated by the Securities
Purchase Agreement and the Registration Rights Agreement, [____] has not had any material relationship with us within the past three
years. As used in this prospectus, the term &ldquo;selling stockholder&rdquo; means [____].</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below presents information regarding the selling stockholder and the shares of common stock that it may offer from time to time
under this prospectus. This table is prepared based on information supplied to us by the selling stockholder, and reflects holdings as
of [&#9679;], 202[&#9679;]. The number of shares in the column &ldquo;Maximum Number of Shares of Common Stock to be Offered Pursuant
to this Prospectus&rdquo; represents all of the shares of common stock that the selling stockholder may offer under this prospectus.
The selling stockholder may sell some, all or none of its shares in this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not know how long the selling stockholder will hold the shares before selling them, and we are not currently aware of any existing
agreements, arrangements or understandings between the selling stockholder and any other stockholder, broker, dealer, underwriter or
agent relating to the sale or distribution of the shares of our common stock offered by this prospectus by the selling stockholder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beneficial
ownership is determined in accordance with Rule 13d-3(d) promulgated by the SEC under the 1934 Act, and includes shares of common stock
with respect to which the selling stockholder has voting and investment power. The percentage of shares of common stock beneficially
owned by the selling stockholder prior to the offering shown in the table below is based on an aggregate of [&#9679;] shares of our common
stock outstanding on [&#9679;], 202[&#9679;]. The fourth column assumes the sale of all of the shares offered by the selling stockholder
pursuant to this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 18; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of Shares of Common Stock Owned Prior to Offering</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maximum
    Number of Shares of Common Stock to be Offered Pursuant to this Prospectus</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maximum Number of Shares of Common Stock Owned After Offering</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    of Selling Stockholder</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number(1)</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Percent(2)</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number(3)</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Percent(2)</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[____]4)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;]</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;]</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;]</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;]</FONT></TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents less than 1.0%.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In accordance with Rule
    13d-3(d) under the 1934 Act, we have excluded from the number of shares beneficially owned prior to the offering all of the shares
    that [____], may be required to purchase under the Securities Purchase Agreement, because the issuance of such shares is solely at
    our discretion and is subject to conditions contained in the Securities Purchase Agreement, the satisfaction of which are entirely
    outside of [____]&rsquo;s control, including the registration statement that includes this prospectus becoming and remaining effective.
    Furthermore, the issuances of common stock are subject to certain agreed upon maximum amount limitations set forth in the Securities
    Purchase Agreement. Also, the Securities Purchase Agreement prohibits us from issuing and selling any shares of our common stock
    to [____] to the extent such shares, when aggregated with all other shares of our common stock then beneficially owned by [____],
    would cause [____]&rsquo;s beneficial ownership of our common stock to exceed the 4.99% Beneficial Ownership Cap or 9.99% Beneficial
    Ownership Cap has been so increased.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Applicable percentage ownership
    is based on [&#9679;] shares of our common stock outstanding as of [&#9679;], 202[&#9679;].</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assumes the sale of all
    shares being offered pursuant to this prospectus.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The business address of
    [____] is [Address]. [____]&rsquo;s principal business is that of a private investor. [____] is the manager [____] has sole voting
    control and investment discretion over securities beneficially owned directly by [____]. We have been advised that none of [____]
    is a member of the Financial Industry Regulatory Authority, or FINRA, or an independent broker-dealer, or an affiliate or associated
    person of a FINRA member or independent broker-dealer. The foregoing should not be construed in and of itself as an admission by
    [____] as to beneficial ownership of the securities beneficially owned directly by [____].</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>PLAN
OF DISTRIBUTION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
shares of common stock offered by this prospectus are being offered by the selling stockholder, [____]. The shares may be sold or distributed
from time to time by the selling stockholder directly to one or more purchasers or through brokers, dealers, or underwriters who may
act solely as agents at market prices prevailing at the time of sale, at prices related to the prevailing market prices, at negotiated
prices, or at fixed prices, which may be changed. The sale of the ordinary shares offered by this prospectus could be effected in one
or more of the following methods:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 48px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ordinary brokers&rsquo; transactions;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">transactions involving cross or block trades;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">through brokers, dealers, or underwriters who may act
    solely as agents;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;at the market&rdquo; into an existing market
    for the ordinary shares;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in other ways not involving
    market makers or established business markets, including direct sales to purchasers or sales effected through agents;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in privately negotiated transactions; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any combination of the foregoing.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to comply with the securities laws of certain states, if applicable, the shares may be sold only through registered or licensed
brokers or dealers. In addition, in certain states, the shares may not be sold unless they have been registered or qualified for sale
in the state or an exemption from the state&rsquo;s registration or qualification requirement is available and complied with.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[____]
has informed us that it intends to use one or more registered broker-dealers to effectuate all sales, if any, of our common stock that
it has acquired and may in the future acquire from us pursuant to the Purchase Agreement. Such sales will be made at prices and at terms
then prevailing or at prices related to the then current market price. Each such registered broker-dealer will be an underwriter within
the meaning of Section 2(a)(11) of the 1933 Act. [____] has informed us that each such broker-dealer will receive commissions from [____]
that will not exceed customary brokerage commissions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brokers,
dealers, underwriters or agents participating in the distribution of the shares of our common stock offered by this prospectus may receive
compensation in the form of commissions, discounts, or concessions from the purchasers, for whom the broker-dealers may act as agent,
of the shares sold by the selling stockholder through this prospectus. The compensation paid to any such particular broker-dealer by
any such purchasers of shares of our common stock sold by the selling stockholder may be less than or in excess of customary commissions.
Neither we nor the selling stockholder can presently estimate the amount of compensation that any agent will receive from any purchasers
of shares of our common stock sold by the selling stockholder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
know of no existing arrangements between the selling stockholder or any other stockholder, broker, dealer, underwriter or agent relating
to the sale or distribution of the shares of our common stock offered by this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may from time to time file with the SEC one or more supplements to this prospectus or amendments to the registration statement of which
this prospectus forms a part to amend, supplement or update information contained in this prospectus, including, if and when required
under the 1933 Act, to disclose certain information relating to a particular sale of shares offered by this prospectus by the selling
stockholder, including the names of any brokers, dealers, underwriters or agents participating in the distribution of such shares by
the selling stockholder, any compensation paid by the selling stockholder to any such brokers, dealers, underwriters or agents, and any
other required information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will pay the expenses incident to the registration under the 1933 Act of the offer and sale of the shares of our common stock covered
by this prospectus by the selling stockholder, and have agreed to reimburse [____] for the fees and disbursements of its counsel incurred
in connection therewith, in an amount not to exceed $[_____]. We also have agreed to reimburse [____] for the fees and disbursements
of its counsel, payable upon execution of the Securities Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also have agreed to indemnify [____] and certain other persons against certain liabilities in connection with the offering of shares
of our common stock offered hereby, including liabilities arising under the 1933 Act or, if such indemnity is unavailable, to contribute
amounts required to be paid in respect of such liabilities. [____] has agreed to indemnify us against liabilities under the 1933 Act
that may arise from certain written information furnished to us by [____] specifically for use in this prospectus or, if such indemnity
is unavailable, to contribute amounts required to be paid in respect of such liabilities. Insofar as indemnification for liabilities
arising under the 1933 Act may be permitted to our directors, officers, and controlling persons, we have been advised that in the opinion
of the SEC this indemnification is against public policy as expressed in the 1933 Act and is therefore, unenforceable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
estimate that the total expenses for the offering will be approximately $[&#9679;].</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[____]
has represented to us that at no time prior to the date of the Securities Purchase Agreement has [____] or its agents, representatives
or affiliates engaged in or effected, in any manner whatsoever, directly or indirectly, any short sale (as such term is defined in Rule
200 of Regulation SHO of the 1934 Act) of our common stock or any hedging transaction, which establishes a net short position with respect
to our common stock. [____] has agreed that during the term of the Purchase Agreement, neither [____], nor any of its agents, representatives
or affiliates will enter into or effect, directly or indirectly, any of the foregoing transactions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have advised the selling stockholder that it is required to comply with Regulation M promulgated under the 1934 Act. With certain exceptions,
Regulation M precludes the selling stockholder, any affiliated purchasers, and any broker-dealer or other person who participates in
the distribution from bidding for or purchasing, or attempting to induce any person to bid for or purchase any security which is the
subject of the distribution until the entire distribution is complete. Regulation M also prohibits any bids or purchases made in order
to stabilize the price of a security in connection with the distribution of that security. All of the foregoing may affect the marketability
of the securities offered by this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
offering will terminate on the date that all shares of our common stock offered by this prospectus have been sold by the selling stockholder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is currently listed on The Nasdaq Capital Market under the symbol &ldquo;<FONT STYLE="background-color: white">ONMD</FONT>.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 21; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.13
<SEQUENCE>19
<FILENAME>ex10-13.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.13</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Execution
Version</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SUBSCRIPTION
ESCROW AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This&nbsp;<B>Subscription
Escrow Agreement</B>&nbsp;(the &ldquo;<B><I>Escrow Agreement</I></B>&rdquo;) is entered into and effective the 28th day of March 2024,
by and among&nbsp;<B>OneMedNet Corporation</B>, a corporation organized under the laws of the State of Delaware (&ldquo;<B><I>OneMedNet</I></B>&rdquo;);
each investor identified on the signature pages hereto (each, including his, her or theirs successors and assigns, each, an &ldquo;<B><I>Investor</I></B>,&rdquo;
and, collectively, the &ldquo;<B><I>Investors</I></B>&rdquo;), and&nbsp;<B>Rimon, P.C.</B>, a professional corporation incorporated in
the State of Delaware (the &ldquo;<B><I>Escrow Agent</I></B>&rdquo;). Terms not defined in this Escrow Agreement are defined in the executed
Securities Purchase Agreement, dated as of March 28, 2024, as amended, modified or supplemented from time to time in accordance with
its terms (the &ldquo;<B><I>PIPE SPA</I></B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>,
pursuant to the PIPE SPA, OneMedNet has offered to issue and sell to each Investor, and each Investor shall purchase from the Company
(the &ldquo;<B><I>Offering</I></B>&rdquo;), convertible promissory notes (each, a &ldquo;<B><I>Note</I></B>&rdquo; and together, the
&ldquo;<B><I>Notes</I></B>&rdquo;), in an amount up to the principal amount set forth on the signature page to the PIPE SPA executed
by such Investor and common stock purchase warrants (each, a &ldquo;<B><I>Warrant</I></B>&rdquo; and together, the &ldquo;<B><I>Warrants</I></B>&rdquo;),
which sale and purchase of Notes and Warrants shall be conducted in tranches (each, a &ldquo;<B><I>Tranche</I></B>&rdquo; and together,
the &ldquo;<B><I>Tranches</I></B>&rdquo;) consisting of (x) an initial tranche (the &ldquo;<B><I>Initial Tranche</I></B>&rdquo;) of (i)
an aggregate Principal Amount of Notes of up to Two Million and zero/100 Dollars ($2,000,000.00) and including an original issue discount
of up to an aggregate of Three Hundred Thousand and zero/100 Dollars ($300,000.00), and (ii) Warrants to purchase a number of shares
of Common Stock equal to the applicable Warrant Share Amounts with respect to such Tranche, (y) a second tranche (the &ldquo;<B><I>Second
Tranche</I></B>&rdquo; of (i) an aggregate Principal Amount of Notes of up to Three Hundred Fifty Thousand and zero/100 Dollars ($350,000.00)
and including an original issue discount of up to an aggregate of Fifty Two Thousand Five Hundred and zero/100 Dollars ($52,500.00),
and (ii) Warrants to purchase a number of shares of Common Stock equal to the applicable Warrant Share Amounts with respect to such Tranche
and (z) up to three subsequent Tranches each of which shall be in (i) an aggregate Principal Amount of Notes of up to One Million and
zero/100 Dollars ($1,000,000) each and each including an original issue discount of fifteen percent (15.0%) of the applicable Principal
Amount, and (ii) Warrants to purchase a number of shares of Common Stock equal to the applicable Warrant Share Amounts with respect to
such Tranches; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>,
the Offering of the Notes and Warrants in a Tranche shall occur in one or more closings (each, a &ldquo;<B><I>Closing</I></B>&rdquo;),
with the date upon which such Closing shall occur being referred to as, a &ldquo;<B><I>Closing Date</I></B>,&rdquo; with the payment
of a portion of the purchase price for the Notes and Warrants to be payable by the Investors to the escrow account maintained by the
Escrow Agent (the &ldquo;<B><I>Escrow Account</I></B>&rdquo;), as specifically provided in the PIPE SPA; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>,
the Offering is being made by OneMedNet pursuant to Regulation D under the Securities Act of 1933, as amended (the &ldquo;<B><I>Securities
Act</I></B>&rdquo;), to the Investors, who have represented in the PIPE SPA that each of whom is an accredited investor, as defined in
Rule 501 of Regulation D of the Securities Act; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>,
the parties hereto desire to provide for the safekeeping of any Escrow Deposit (as defined below) related to the PIPE SPA until such
time as the Escrow Deposit is released by the Escrow Agent in accordance with the terms and conditions of this Agreement; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>,
the parties acknowledge that the Escrow Agent is not a party to, and has no duties or obligations under, the PIPE SPA, that all references
in this Escrow Agreement to the PIPE SPA are for convenience only, and that the Escrow Agent shall have no implied duties beyond the
express duties set forth in this Escrow Agreement; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>,
the Escrow Agent has agreed to accept, hold, and disburse the Escrow Deposit deposited with it in accordance with the terms of this Escrow
Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOW
THEREFORE</B>, in consideration of the foregoing and of the mutual covenants hereinafter set forth, the parties hereto agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.&nbsp;<B>Appointment</B>.
OneMedNet and each Investor hereby appoint the Escrow Agent as their escrow agent for the purposes set forth herein, and the Escrow Agent
hereby accepts such appointment under the terms and conditions set forth herein. In connection with the Closings, and as further provided
in the PIPE SPA, OneMedNet and each Investor agree that the payment of a portion of the consideration for the Initial Tranche, all of
the Second Tranche and a portion of the proceeds of the Tranche following the Second Tranche (the &ldquo;<B><I>Third Tranche</I></B>&rdquo;)
shall require the payment to the Escrow Agent of the following escrow deposits (the &ldquo;<B><I>Escrow Deposit</I></B>&rdquo;): (a)
$1,350,000.00 of the net proceeds of the Initial Tranche will be paid into the Escrow Account; (b) 100% of the net proceeds of the Second
Tranche shall be paid into the Escrow Account for distribution in accordance with the terms of this Escrow Agreement, and (c) 75% of
the net proceeds of the Third Tranche shall be paid into the Escrow Account for distribution in accordance with the terms of this Escrow
Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.&nbsp;<B>Escrow
Account Wiring Instructions.&nbsp;</B>The Investors shall remit each Escrow Deposit by wire transfer of immediately available funds to
the account of the Escrow Agent, as governed by the PIPE SPA. All funds received from the Investors in connection with the sale of the
OneMedNet Notes and Warrants in the Offering shall be deposited with the Escrow Agent using the following wire instructions, to be held
by the Escrow Agent and disbursed as provided in this Escrow Agreement:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 144px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bank: JP Morgan Chase Bank N.A.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bank Address: 1500 Polk Street, San Francisco, CA 94109</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the name of: Rimon, PC</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Swift Code: CHASUUS33</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acct: 825-083-959</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABA Routing: 322271627</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reference: OneMedNet</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.&nbsp;<B>Maintenance
of Escrow Deposit.&nbsp;</B>During the term of this Escrow Agreement, the Escrow Deposit shall be maintained by the Escrow Agent in a
segregated account in order to provide readily available funds necessary to make required payment under Section 4 of this Escrow Agreement.
The Escrow Agent may earn compensation in the form of short-term interest from the Escrow Deposit from the time of receipt and the time
of liquidation of the Escrow Deposit and as provided in&nbsp;<U>Exhibit A</U>&nbsp;hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.&nbsp;<B>Disposition
and Termination; Security Interest.&nbsp;</B>OneMedNet agrees to notify the Escrow Agent in writing of either: (i) a Closing of a Tranche
under the Offering, or (ii) a termination of the PIPE SPA. Upon receipt of any such written notification, the following procedures will
take place, as applicable:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)&nbsp;<U>Release
of Escrow Deposit upon Closing of the Initial Tranche</U>. Following the Closing of the Initial Tranche, the Investors shall fund the
Escrow Deposit to the Escrow Account. To release funds, OneMedNet and the Investors shall deliver to the Escrow Agent joint written notice
executed by a duly authorized executive officer of OneMedNet and duly authorized signatory of the Investors (&ldquo;<B><I>Instructions</I></B>&rdquo;),
from time to time, which Instructions shall specify the amount, day, time and payment instructions, including the address, phone number
and account number of each payee from the Escrow Deposit in accordance with the PIPE SPA. The Escrow Agent shall, at the time and in
accordance with the payment instructions specified in the Instructions, deliver the Escrow Deposit (without interest) to OneMedNet in
accordance with the Instructions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)&nbsp;<U>Release
of Escrow Deposit upon certain Subsequent Closings</U>. Following the Closing of the Second Tranche and the Third Tranche, the Investors
shall fund the Escrow Deposit to the Escrow Account. To release funds, OneMedNet and the Investors shall deliver to the Escrow Agent
the Instructions, from time to time, in accordance with the PIPE SPA, which Instructions shall specify the amount, day, time and payment
instructions, including the address, phone number and account number of each payee from the Escrow Deposit. The Escrow Agent shall, at
the time and in accordance with the payment instructions specified in the Instructions, deliver the Escrow Deposit (without interest)
to OneMedNet in accordance with the Instructions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)&nbsp;<U>Release
of Escrow Deposit upon a Termination</U>. In the event OneMedNet and all of the Investors shall deliver Instructions to the Escrow Agent,
which Instructions shall announce the termination of the PIPE SPA, whether as a result of an Event of Default (as defined in the PIPE
SPA or Notes) or otherwise, and to terminate the Escrow Account and refund the Escrow Deposit to all of the Investors, the Escrow Agent
will wire the Escrow Deposit, without interest, to the Investors, and the parties hereto acknowledge and agree that as of such wire,
the Escrow Agent&rsquo;s duties have been fully satisfied.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)&nbsp;<U>Delivery
Pursuant to Court Order</U>. Notwithstanding any provision contained herein, upon receipt by the Escrow Agent of a final and non-appealable
judgment, order, decree or award of a court of competent jurisdiction (a &ldquo;<B><I>Court Order</I></B>&rdquo;), the Escrow Agent shall
deliver the Escrow Deposit in accordance with the Court Order. Any Court Order shall be accompanied by an opinion of counsel for the
party presenting the Court Order to the Escrow Agent (which opinion shall be satisfactory to the Escrow Agent) to the effect that the
court issuing the Court Order has competent jurisdiction and that the Court Order is final and non-appealable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)&nbsp;<U>Security
Interest</U>. As security for the payment and performance of the Obligations owing to each Investor now existing or in the future, OneMedNet
does hereby pledge, assign, transfer, deliver and grant to such Investor a continuing and unconditional first priority security interest
in the Escrow Deposit (all of which property, along with the products and proceeds therefrom, are individually and collectively referred
to as the &ldquo;Collateral&rdquo;) until such time as the Escrow Deposit is delivered in accordance with this Section 4. &ldquo;Obligations&rdquo;
shall mean, whether now existing or hereafter arising, created or incurred: (i) the loans evidenced by the Notes issued to such Investor;
(ii) all interest accrued thereon (including interest which would be payable as post-petition in connection with any bankruptcy or similar
proceeding, whether or not permitted as a claim thereunder); (iii) any and all fees, charges or other amounts due to such Investor under
the Notes or the PIPE SPA; (iv) any and all expenses incurred by such Investor under, or in connection with, the Notes or the PIPE SPA;
(v) any and all other liabilities and obligations of OneMedNet to such Investor under the Notes or PIPE SPA; and (vi) the performance
by OneMedNet of all covenants, agreements and obligations of every nature and kind on the part of any of OneMedNet to be performed under
the Notes or the PIPE SPA. Each of OneMedNet and the Investors agree that the right of the Investors to direct delivery of the Escrow
Agreement pursuant to this Section 4 shall constitute &ldquo;control&rdquo; for purposes of applicable uniform commercial code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
delivery of the Escrow Deposit by the Escrow Agent in accordance with Section 4(a), (b) or (c), as the case may be, this Escrow Agreement
shall terminate, subject to the provisions of Section 8.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.&nbsp;<B>Escrow
Agent.&nbsp;</B>The Escrow Agent undertakes to perform only such duties as are expressly set forth herein and no duties shall be implied.
The Escrow Agent shall have no liability under and no duty to inquire as to the provisions of any agreement other than this Escrow Agreement.
The Escrow Agent may rely upon and shall not be liable for acting or refraining from acting upon any written notice, instruction or request
furnished to it hereunder and believed by it to be genuine and to have been signed or presented by the proper party or parties. The Escrow
Agent shall be under no duty to inquire into or investigate the validity, accuracy or content of any such document except as provided
herein. The Escrow Agent shall have no duty to solicit any payments which may be due it or the Escrow Deposit. The Escrow Agent shall
not be liable for any action taken or omitted by it in good faith except to the extent that a court of competent jurisdiction determines
that the Escrow Agent&rsquo;s gross negligence or willful misconduct was the primary cause of any loss to OneMedNet or the Investors.
The Escrow Agent may execute any of its powers and perform any of its duties hereunder directly or through agents or attorneys (and shall
be liable only for the careful selection of any such agent or attorney) and may consult with counsel, accountants and other skilled persons
to be selected and retained by it. The Escrow Agent shall not be liable for anything done, suffered or omitted in good faith by it in
accordance with the advice or opinion of any such counsel, accountants or other skilled persons. In the event that the Escrow Agent shall
be uncertain as to its duties or rights hereunder or shall receive instructions, claims or demands from any party hereto which, in its
opinion, conflict with any of the provisions of this Escrow Agreement, it shall be entitled to refrain from taking any action and its
sole obligation shall be to keep safely all property held in escrow until it shall be directed otherwise in writing by all of the other
parties hereto or by a final order or judgment of a court of competent jurisdiction. Anything in this Escrow Agreement to the contrary
notwithstanding, in no event shall the Escrow Agent be liable for special, indirect or consequential loss or damage of any kind whatsoever
(including but not limited to lost profits), even if the Escrow Agent has been advised of the likelihood of such loss or damage and regardless
of the form of action.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.&nbsp;<B>Succession.&nbsp;</B>The
Escrow Agent may resign and be discharged from its duties or obligations hereunder by giving ten (10) business days advance notice in
writing of such resignation to the other parties hereto specifying a date when such resignation shall take effect. The Escrow Agent shall
have the right to withhold an amount equal to any amount due and owing to the Escrow Agent, plus any costs and expenses the Escrow Agent
shall reasonably believe may be incurred by the Escrow Agent in connection with the termination of the Escrow Agreement. Any corporation
or association into which the Escrow Agent may be merged or converted or with which it may be consolidated shall be the Escrow Agent
under this Escrow Agreement without further act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.&nbsp;<B>Fees.</B>&nbsp;The
Escrow Agent hereby forgoes reasonable compensation for the services to be rendered hereunder, as described in&nbsp;<U>Exhibit A</U>&nbsp;attached
hereto. OneMedNet hereby agrees to pay or reimburse the Escrow Agent upon request for all expenses, disbursements and advances, including
reasonable attorney&rsquo;s fees and expenses, incurred or made by it in connection with the preparation, execution, performance, delivery,
modification and termination of this Escrow Agreement. The Escrow Agent is authorized to deduct expenses from the Escrow Deposit at the
time of the Closing without prior authorization from OneMedNet or the Investors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.&nbsp;<B>Indemnity.&nbsp;</B>OneMedNet
shall indemnify, defend and save harmless the Escrow Agent and its directors, officers, agents and employees (the &ldquo;<B><I>indemnitees</I></B>&rdquo;)
from all loss, liability or expense (including the reasonable fees and expenses of in house or outside counsel) arising out of or in
connection with (i) the Escrow Agent&rsquo;s execution and performance of this Escrow Agreement, except in the case of any indemnitee
to the extent that such loss, liability or expense is due to the gross negligence or willful misconduct of such indemnitee, or (ii) its
following any instructions or other directions from OneMedNet, except to the extent that its following any such instruction or direction
is expressly forbidden by the terms hereof. The parties hereto acknowledge that the foregoing indemnities shall survive the resignation
or removal of the Escrow Agent or the termination of this Escrow Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.&nbsp;<B>Notices.</B>&nbsp;All
communications hereunder shall be in writing and shall be deemed to be duly given and received upon delivery if delivered personally
or upon confirmed transmittal if by facsimile or if sent by overnight courier. Notwithstanding the above, in the case of communications
delivered to or by the Escrow Agent or to or by any other party to this Agreement under this Section 9, such communications shall be
deemed to have been given on the date received. In the event that the Escrow Agent, in its sole discretion, shall determine that an emergency
exists, the Escrow Agent may use such other means of communication as the Escrow Agent deems appropriate. The appropriate address for
the Escrow Agent is set forth in&nbsp;<U>Exhibit A</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.&nbsp;<B>Security
Procedures.</B>&nbsp;In the event funds transfer Instructions are given (other than in writing at the time of execution of this Escrow
Agreement), whether in writing, by telecopier or otherwise, the Escrow Agent is authorized to seek confirmation of such instructions
by telephone call-back, and the Escrow Agent may rely upon the confirmation of anyone purporting to be the authorized representative
of the particular party. The persons and telephone numbers for call-backs may be changed only in a writing actually received and acknowledged
by the Escrow Agent. The Escrow Agent and the beneficiaries&rsquo; bank in any funds transfer may rely solely upon any account numbers
or similar identifying numbers provided by OneMedNet to identify (i) the beneficiary, (ii) the beneficiary&rsquo;s bank, or (iii) an
intermediary bank. The Escrow Agent may apply any of the escrowed funds for any payment order it executes using any such identifying
number, even where its use may result in a person other than the beneficiary being paid, or the transfer of funds to a bank other than
the beneficiary&rsquo;s bank or an intermediary bank designated. The parties to this Escrow Agreement acknowledge that these security
procedures are commercially reasonable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.&nbsp;<B>Miscellaneous.&nbsp;</B>The
provisions of this Escrow Agreement may be waived, altered, amended or supplemented, in whole or in part, only by a writing signed by
all of the parties hereto. Neither this Escrow Agreement nor any right or interest hereunder may be assigned in whole or in part by any
party, except as provided in Section 6, without the prior consent of the other parties, which consent shall not be unreasonably withheld.
This Escrow Agreement shall be governed by and construed under the laws of the State of New York. Each party hereto irrevocably waives
any objection on the grounds of venue,&nbsp;<I>forum non-conveniens</I>&nbsp;or any similar grounds and irrevocably consents to service
of process by mail or in any other manner permitted by applicable law and consents to the jurisdiction of the courts located in the State
of New York. The parties further hereby waive any right to a trial by jury with respect to any lawsuit or judicial proceeding arising
or relating to this Escrow Agreement. No party to this Escrow Agreement is liable to any other party for losses due to, or if it is unable
to perform its obligations under the terms of this Escrow Agreement because of, acts of God, fire, floods, strikes, equipment or transmission
failure, or other causes reasonably beyond its control. This Escrow Agreement may be executed in one or more counterparts, each of which
shall be deemed an original, but all of which together shall constitute one and the same instrument.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[<I>Remainder
of Page Intentionally Left Blank</I>]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IN
WITNESS WHEREOF</B>, the parties hereto have executed this Subscription Escrow Agreement as of the date set forth above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>RIMON P.C.,&nbsp;</B>as Escrow Agent</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 46%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Debbie
    A. Klis</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Debbie A. Klis</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Partner</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ONEMEDNET
    CORPORATION</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 46%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Paul
    J. Casey</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul J. Casey</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>THE
INVESTORS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 46%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 46%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 46%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 46%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 46%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
A</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>RIMON,
P.C., AS ESCROW AGENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SCHEDULE
OF FEES &amp; EXPENSES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<!-- Field: Page; Sequence: 7; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-14.1
<SEQUENCE>20
<FILENAME>ex14-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 14.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex14-1_001.jpg" ALT="" STYLE="height: 87px; width: 232px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ONEMEDNET
CORPORATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>CODE
OF ETHICS AND BUSINESS CONDUCT POLICY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Adopted
November 8, 2023)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INTRODUCTION</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board of Directors (the &ldquo;<U>Board</U>&rdquo;) of OneMedNet Corporation (the &ldquo;<U>Company</U>&rdquo;) has adopted this code
of ethics and business conduct policy (this &ldquo;<U>Code</U>&rdquo;), as amended from time to time by the Board, and which is applicable
to all of the Company&rsquo;s directors, officers and employees (to the extent that employees are hired in the future) to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">promote
    honest and ethical conduct, including the ethical handling of actual or apparent conflicts of interest between personal and professional
    relationships;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">promote
    the full, fair, accurate, timely and understandable disclosure in reports and documents that the Company files with, or submits to,
    the Securities and Exchange Commission (the &ldquo;<U>SEC</U>&rdquo;), as well as in other public communications made by or on behalf
    of the Company;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">promote
    compliance with applicable governmental laws, rules and regulations;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">deter
    wrongdoing; and</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">require
    prompt internal reporting of breaches of, and accountability for adherence to, this Code.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to following this Code in all aspects of business activities, the Company&rsquo;s directors, officers and employees are expected
to seek guidance in any situation where there is a question regarding compliance issues, whether with the letter or the spirit of the
Company&rsquo;s policies and applicable laws. Cooperation with this Code is essential to the continued success of the Company&rsquo;s
business and the cultivation and maintenance of its reputation as a good corporate citizen. Misconduct is never justified, even where
sanctioned or ordered by an officer or other individual in a position of higher management. No individual, regardless of stature or position,
can authorize actions that are illegal, or that jeopardize or violate Company standards. This Code sets forth general principles of conduct
and ethics and is intended to work in conjunction with the policies and procedures that are covered in the Company&rsquo;s specific policy
statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nothing
in this Code prohibits the Company&rsquo;s directors, officers or employees from reporting possible violations of federal law or regulation
to any governmental agency or entity, including but not limited to the Department of Justice, the SEC, the Congress, and any agency Inspector
General, or making other disclosures that are protected under the whistleblower provisions of U.S. federal law or regulation. No prior
authorization from the Company is needed to make any such reports or disclosures and there is no duty to notify the Company that any
such reports or disclosures have been made. The Company has a no-tolerance policy for retaliation against persons who raise good faith
compliance, ethics or related issues.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Code may be amended and modified by the Board. In this Code, references to the &ldquo;<U>Company</U>&rdquo; mean OneMedNet Corporation,
Inc. and, in appropriate context, the Company&rsquo;s subsidiaries, if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify">II. </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>HONEST,
    ETHICAL AND FAIR CONDUCT</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
person owes a duty to the Company to act with integrity. Integrity requires, among other things, being honest, fair and candid. Deceit,
dishonesty and subordination of principle are inconsistent with integrity. Service to the Company should never be subordinated to violations
of laws or regulations, unscrupulous dealings or to personal gain and advantage.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
person must:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">act
    with integrity, including being honest and candid while still maintaining the confidentiality of the Company&rsquo;s information
    where required or when in the Company&rsquo;s interests;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">observe
    all applicable governmental laws, rules and regulations;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">comply
    with the requirements of applicable accounting and auditing standards, as well as Company policies, in order to maintain a high standard
    of accuracy and completeness in the Company&rsquo;s financial records and other business-related information and data;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">adhere
    to a high standard of business ethics and not seek competitive advantage through unlawful or unethical business practices;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">deal
    fairly with the Company&rsquo;s customers, suppliers, competitors, employees and independent contractors;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">refrain
    from taking advantage of anyone through manipulation, concealment, abuse of privileged information, misrepresentation of material
    facts or any other unfair-dealing practice;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">protect
    the assets of the Company and ensure their proper use;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">h.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">until
    the earliest of (i) the Company&rsquo;s liquidation, or (ii) such time that such person ceases to be an officer or director of the
    Company, in each case, to first present to the Company for the Company&rsquo;s consideration, prior to presentation to any other
    entity, any business opportunity, but only if such opportunity is suitable for the Company, subject to the Company&rsquo;s certificate
    of incorporation and bylaws in effect at such time and subject to any other fiduciary or contractual obligations such officer or
    director may have; and</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">avoid
    actual or apparent conflicts between personal, private interests and the interests of the Company, wherever possible, including receiving
    improper personal benefits as a result of his or her position, except as may be allowed under guidelines or resolutions approved
    by the Board (or the appropriate committee of the Board) or as disclosed in the Company&rsquo;s public filings with the SEC. Anything
    that would be a conflict for a person subject to this Code will also be a conflict for a member of his or her immediate family or
    any other close relative.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Examples
of conflict of interest situations include, but are not limited to, the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    significant ownership interest in any supplier or customer;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    consulting or employment relationship with any supplier or customer;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    receipt of any money, non-nominal gifts or excessive entertainment from any entity with which the Company has current or prospective
    business dealings;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">selling
    anything to the Company or buying anything from the Company, except on the same terms and conditions as a third party would buy or
    sell a comparable item in an arm&rsquo;s-length transaction;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    other financial transaction, arrangement or relationship (including any indebtedness or guarantee of indebtedness) involving the
    Company; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    other circumstance, event, relationship or situation in which the personal interest of a person subject to this Code interferes,
    or even appears to interfere, with the interests of the Company as a whole.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
material transaction or relationship that reasonably could be expected to give rise to a conflict of interest shall be disclosed to the
Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">III. </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONFIDENTIALITY</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s directors, officers and employees must maintain and protect the confidentiality of information entrusted to them by the
Company, or that otherwise comes into their possession, while carrying out their duties and responsibilities, except when disclosure
is authorized by the Company or legally mandated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential
information encompasses all non-public information (including, for example, &ldquo;<U>inside information</U>&rdquo; or information that
third-parties have entrusted to the Company) that may be of use to competitors or may otherwise be harmful to the Company or its key
stakeholders, if disclosed. Financial information is of special sensitivity and should under all circumstances be considered confidential,
except where its disclosure is approved by the Company or when the information has been publicly disseminated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IV. </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DISCLOSURE</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company strives to ensure that the contents of and the disclosures in the reports and documents that the Company files with the SEC and
other public communications shall be full, fair, accurate, timely and understandable in accordance with applicable disclosure standards,
including standards of materiality, where appropriate. Each person must:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">not
    knowingly misrepresent, or cause others to misrepresent, facts about the Company to others, whether within or outside the Company,
    including to the Company&rsquo;s independent registered public accountants, governmental regulators, self-regulating organizations
    and other governmental officials, as appropriate; and</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    relation to his or her area of responsibility, properly review and critically analyze proposed disclosure for accuracy and completeness.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the foregoing, the Chief Executive Officer and Chief Financial Officer of the Company and the Chief Executive Officer and
the Chief Financial Officer of each subsidiary of the Company (or persons performing similar functions), if any, and each other person
that typically is involved in the financial reporting of the Company must familiarize himself or herself with the disclosure requirements
applicable to the Company as well as the business and financial operations of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
person must promptly bring to the attention of the Board of Directors any information he or she may have concerning (a) significant deficiencies
in the design or operation of internal and/or disclosure controls that could adversely affect the Company&rsquo;s ability to record,
process, summarize and report financial data or (b) any fraud that involves management or other employees who have a significant role
in the Company&rsquo;s financial reporting, disclosures or internal controls.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">V. </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>COMPLIANCE</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is the Company&rsquo;s obligation and policy to comply with all applicable governmental laws, rules and regulations. All directors, officers
and employees of the Company are expected to understand, respect and comply with all of the laws, regulations, policies and procedures
that apply to them in their positions with the Company. Employees are responsible for talking to their supervisors to determine which
laws, regulations and Company policies apply to their position and what training is necessary to understand and comply with them.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors,
officers and employees are directed to specific policies and procedures available to persons they supervise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">VI. </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REPORTING
    AND ACCOUNTABILITY</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board is responsible for applying this Code to specific situations in which questions are presented to it and has the authority to interpret
this Code in any particular situation. Any person who becomes aware of any existing or potential breach of this Code is required to notify
the Board promptly. Failure to do so is, in and of itself, a breach of this Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Specifically,
each person must:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notify
    the Board promptly of any existing or potential violation of this Code.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
    retaliate against any other person for reports of potential violations that are made in good faith.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company will follow the following procedures in investigating and enforcing this Code and in reporting on this Code:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Board will take all appropriate action to investigate any breaches reported to it.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
    determination by the Board that a breach has occurred, the Board (by majority decision) will take or authorize such disciplinary
    or preventive action as it deems appropriate, after consultation with the Company&rsquo;s internal or external legal counsel, up
    to and including dismissal or, in the event of criminal or other serious violations of law, notification of the SEC or other appropriate
    law enforcement authorities.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
person following the above procedure shall, as a result of following such procedure, be subject by the Company or any officer or employee
thereof to discharge, demotion suspension, threat, harassment or, in any manner, discrimination against such person in terms and conditions
of employment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">VII. </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WAIVERS
    AND AMENDMENTS</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
waiver (defined below) or an implicit waiver (defined below) from a provision of this Code for the principal executive officer, principal
financial officer, principal accounting officer or controller, and persons performing similar functions or any amendment (as defined
below) to this Code is required to be disclosed in a Current Report on Form 8-K filed with the SEC. In lieu of filing a Current Report
on Form 8-K to report any such waivers or amendments, the Company may provide such information on its website, in the event that it establishes
one in the future, and if it keeps such information on the website for at least 12 months and discloses the website address as well as
any intention to provide such disclosures in this manner in its most recently filed Annual Report on Form 10-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
&ldquo;<U>waiver</U>&rdquo; means the approval by the Board of a material departure from a provision of this Code. An &ldquo;<U>implicit
waiver</U>&rdquo; means the Company&rsquo;s failure to take action within a reasonable period of time regarding a material departure
from a provision of this Code that has been made known to an executive officer of the Company. An &ldquo;<U>amendment</U>&rdquo; means
any amendment to this Code other than minor technical, administrative or other non-substantive amendments hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
request for a waiver of any provision of this Code must be in writing and addressed to the Board. All persons should note that it is
not the Company&rsquo;s intention to grant or to permit waivers from the requirements of this Code. The Company expects full compliance
with this Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">VIII. </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INSIDER
    INFORMATION AND SECURITIES TRADING</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s directors, officers or employees who have access to material, non-public information are not permitted to use that information
for security trading purposes or for any purpose unrelated to the Company&rsquo;s business. It is also against the law to trade or to
&ldquo;tip&rdquo; others who might make an investment decision based on inside company information. For example, using non-public information
to buy or sell the Company securities, options in the Company securities or the securities of any Company supplier, customer, competitor
or potential target is prohibited. The consequences of insider trading violations can be severe. These rules also apply to the use of
material, non-public information about other companies (including, for example, the Company&rsquo;s customers, competitors, potential
business partners and potential targets). In addition to directors, officers or employees, these rules apply to such person&rsquo;s spouse,
children, parents and siblings, as well as any other family members living in such person&rsquo;s home.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IX. </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FINANCIAL
    STATEMENTS AND OTHER RECORDS</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of the Company&rsquo;s books, records, accounts and financial statements must be maintained in reasonable detail, must appropriately
reflect the Company&rsquo;s transactions and must both conform to applicable legal requirements and to the Company&rsquo;s system of
internal controls. Unrecorded or &ldquo;off the books&rdquo; funds or assets should not be maintained unless permitted by applicable
law or regulation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Records
should always be retained or destroyed according to the Company&rsquo;s record retention policies. In accordance with those policies,
in the event of litigation or governmental investigation, please consult the Board or the Company&rsquo;s internal or external legal
counsel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
and all reports received by the Company of questionable accounting, violations of internal accounting controls, or any other auditing
or financial matters, or the reporting of fraudulent financial information or other questionable conduct that are submitted to an officer
of the Company will be handled as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    reports received will be logged and include, among other things: (1) the date the report was received, (2) a description of the report,
    (3) the reporting party (if provided), and (4) the status and disposition of an investigation of the report.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Secretary of the Company will promptly submit to the Audit Committee of the Board (the &ldquo;<U>Audit Committee</U>&rdquo;) all
    reports received. The Audit Committee shall direct and oversee an investigation of all reports as it determines to be appropriate.
    The Audit Committee may also delegate the oversight and investigation of reports to the appropriate members of the Company&rsquo;s
    management. The Audit Committee may request special treatment for any report and may re-assume the direction and oversight of an
    investigation of any report delegated to members of our management.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">X. </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IMPROPER
    INFLUENCE ON CONDUCT OF AUDITS</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
director or officer, or any other person acting under the direction thereof, shall directly or indirectly take any action to coerce,
manipulate, mislead or fraudulently influence any public or certified public accountant engaged in the performance of an audit or review
of the financial statements of the Company or take any action that such person knows or should know that if successful could result in
rendering the Company&rsquo;s financial statements materially misleading. Any person who believes such improper influence is being exerted
should report such action to such person&rsquo;s supervisor, or if that is impractical under the circumstances, to any of the Company&rsquo;s
directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Types
of conduct that could constitute improper influence include, but are not limited to, directly or indirectly:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Offering
    or paying bribes or other financial incentives, including future employment or contracts for non-audit services;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Providing
    an auditor with an inaccurate or misleading legal analysis;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Threatening
    to cancel or canceling existing non-audit or audit engagements if the auditor objects to the Company&rsquo;s accounting;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Seeking
    to have a partner removed from the audit engagement because the partner objects to the Company&rsquo;s accounting;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Blackmailing;
    and</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Making
    physical threats.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XI. </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ANTI-CORRUPTION
    LAWS</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company complies with the anti-corruption laws of the countries in which it does business, including the U.S. Foreign Corrupt Practices
Act of 1977 (&ldquo;<U>FCPA</U>&rdquo;). Directors, officers, employees and agents, such as third-party sales representatives, shall
not take or cause to be taken any action that would reasonably result in the Company not complying with such anti-corruption laws, including
the FCPA. If you are authorized to engage agents on the Company&rsquo;s behalf, you are responsible for ensuring they are reputable and
for obtaining a written agreement for them to uphold the Company&rsquo;s standards in this area. The Company will comply with the Policy
Statement Regarding Compliance and Ethics attached hereto as <U>Schedule A</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XII. </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>VIOLATIONS</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board will investigate any reported violations and will oversee an appropriate response, including corrective action and preventative
measures. Any director, officer or employee who violates this Code will face appropriate, case specific disciplinary action, which may
include demotion or discharge. Such action is in addition to any civil or criminal liability which might be imposed by any court or regulatory
agency.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XIII. </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OTHER
    POLICIES AND PROCEDURES</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
other policy or procedure set out by the Company in writing or made generally known to employees, officers or directors of the Company
prior to the date hereof or hereafter are separate requirements and remain in full force and effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XIV. </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INQUIRIES</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
inquiries and questions in relation to this Code or its applicability to particular people or situations should be addressed to the Board,
or such other compliance officer as shall be designated from time to time by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B><U>Policy
Statement Regarding Compliance &amp; Ethics</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>I.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INTRODUCTION</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OneMedNet
Corporation, Inc. (the &ldquo;<U>Company</U>&rdquo;) is committed to the highest ethical standards, and expects the same of its directors,
officers and employees (to the extent that employees are hired in the future), Third Party (as defined below) representatives, and joint
venture partners. Consistent with this commitment, all Company employees are expected to understand and comply with all applicable laws,
rules, and regulations applicable to their job responsibilities at the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Policy Statement sets forth the Company&rsquo;s general requirements and expectations relating to several key areas of business conduct
and ethics. At the same time, this Policy Statement is not intended to be a comprehensive rulebook and cannot address every situation
that a Company director, officer and employee (to the extent that employees are hired in the future) may face. If any Company director,
officer or employee (to the extent that employees are hired in the future) feels uncomfortable about a situation or has any doubts about
whether a situation or course of conduct is consistent with the Company&rsquo;s ethical standards, such individuals are advised to seek
help from the Company&rsquo;s Chief Financial Officer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>II.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>COMPLIANCE
    WITH ALL LAWS INCLUDING BRIBERY AND OTHER CORRUPT PAYMENTS LAWS</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company shall comply with all applicable laws, including applicable laws governing bribery, extortion, kickbacks, and the giving or receiving
of gifts or hospitality to &ldquo;<U>Government Officials</U>.&rdquo;<SUP>1</SUP> Consistent with this commitment, Company directors,
officers or employees (to the extent that employees are hired in the future) are prohibited from offering, promising, giving, soliciting,
accepting or authorizing another to offer, promise, give, solicit or accept anything of value, either directly or indirectly, for the
purpose of corruptly influencing the decision of any person, or to otherwise obtain or retain business or a business advantage in connection
with the Company. This includes all local, state and federal corruption laws, as well as international laws such as the Foreign Corrupt
Practices Act, to the extent the Company is conducting business outside of the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>III.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FACILITATION
    PAYMENTS</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is the Company&rsquo;s policy not to make or authorize anyone to make any small, unofficial payment to secure or expedite the performance
of a routine or necessary action by a Government Official (a &ldquo;<U>Facilitation Payment</U>&rdquo;)<SUP>2</SUP> in connection with
the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IV.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>GIFTS
    &amp; HOSPITALITY</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company requires that all gifts and hospitality promised, offered or provided on behalf of the Company be reasonable, related to a legitimate
business purpose, and lawful under applicable laws and regulations, including those relating to the nature and amount of gifts and hospitality
that can be provided to Government Officials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>1
</SUP>&ldquo;<U>Government Official</U>&rdquo; means: (i) any person who is an officer, officeholder, full or part-time employee or representative
of: (1) a national, state, regional, provincial, city, county or other local government; (2) independent agencies of any government;
or (3) state-owned businesses or state-controlled businesses (e.g., a representative of a sovereign wealth fund or public pension fund,
an affiliate of a state-owned company owning distressed assets); (ii) political party officials and candidates for political office;
and (iii) any employees of quasi-public or non-governmental international organizations (sometimes called &ldquo;<U>NGOs</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>2
</SUP>A &ldquo;<U>Facilitation Payment</U>&rdquo; may take the form of any kind of advantage, and is not limited to cash or cash equivalents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
Company employee or Third Party may offer, promise, give, solicit, accept or authorize another to offer, promise, give, solicit or accept
any gift or hospitality for the purpose of corruptly influencing the decision of any person, or to otherwise obtain or retain business
or a business advantage on behalf of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
gifts and hospitality are required to be approved by appropriate Company personnel before being provided to any external party, and shall
be documented fairly and accurately in the Company&rsquo;s books and records.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>V.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>POLITICAL
    AND CHARITABLE CONTRIBUTIONS</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is the policy of the Company that its funds or assets not be used to make a political or charitable contribution,<SUP>3</SUP> unless
prior approval has been given by the Company&rsquo;s Chief Financial Officer. The Company shall not reimburse any Company employee or
Third Party for their own personal political or charitable contributions. When Company employees participate in private political affairs,
those employees should be careful to make it clear that their views and actions are their own, and not made on behalf of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company
employees are prohibited from making or authorizing any person to make a political or charitable contribution on behalf of the Company
for the purpose of corruptly influencing the decision of any person, or to otherwise obtain or retain business or a business advantage.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>VI.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>RELATIONSHIPS
    WITH THIRD PARTIES</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company shall conduct reasonable commercial and risk-based due diligence on all third party vendors, suppliers, agents, representatives,
and intermediaries (each a &ldquo;<U>Third Party</U>&rdquo; and collectively &ldquo;<U>Third Parties</U>&rdquo;) working on behalf of
the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
agreements with Third Parties relating to the Company shall be reduced to writing, accurately reflect the actual goods or services to
be provided by the Third Party, and include appropriate anti-corruption compliance representations and warranties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
payments to Third Parties made by or on behalf of the Company shall be made transparently, consistent with applicable written agreements,
and reflected accurately in the Company&rsquo;s books and records.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>VII.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DISCRIMINATION
    &amp; HARASSMENT</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company
employees shall not discriminate, harass, or authorize any discrimination or harassment on the basis of race, color, religion, sex, sexual
orientation, gender identity or expression, age, disability, marital status, citizenship, genetic information, or any other characteristic
protected by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company will not tolerate or authorize any unwelcome sexual advances, requests for sexual favors, or any other verbal or physical conduct
of a sexual nature by any Company employee or Third Party in connection with the Company if and when: (i) submission to such conduct
was made either explicitly or implicitly a term or condition of an individual&rsquo;s employment; (ii) submission to or rejection of
such conduct by an individual is used as the basis for employment decisions affecting such individual; or (iii) such conduct has the
purpose or effect of unreasonably interfering with an individual&rsquo;s work performance or creating an intimidating, hostile, or offensive
working environment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>3
</SUP>For purposes of this provision, the term &ldquo;<U>political contribution</U>&rdquo; refers to any contribution of something of
value to an incumbent elected official, a candidate for elected office, a political party, a political committee, a political organization,
a ballot measure committee, an inaugural committee, or a member of the transition team of a successful candidate. The term &ldquo;<U>charitable
contribution</U>&rdquo; refers to any contribution of something of value to a charitable or philanthropic cause, including, but not limited
to donations of cash or cash equivalents to registered charities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>VIII.</B></FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MONEY
    LAUNDERING</B></FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is the policy of the Company to prohibit and actively prevent money laundering and any activity that could conceivably facilitate money
laundering, the funding of terrorism, or other criminal activity. Consistent with this policy, the local Company partner shall develop
appropriate procedures to help ensure that the Company does not facilitate or engage in any money laundering activities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IX.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>HEALTH,
    SAFETY, AND ENVIRONMENT</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is committed to conducting all business activities in a responsible manner, which helps ensure the health, safety, and security
of people, preservation of the environment, quality of our business offerings, security, legal, quality, and regulatory requirements
in all our business activities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>X.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>RECORDKEEPING</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company shall make and maintain records that fairly and accurately reflect the business transactions of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>XI.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>COOPERATION
    WITH AUDITS AND INSPECTIONS</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company, including each Company employee and Third Party, shall cooperate fully with any and all requests made by its shareholders relating
to the review and/or inspection of books and records relating to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>XII.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REPORTED
    CONCERNS</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company encourages reporting of suspected violations of this policy statement, violations of law, and perceived incidents of discrimination
or harassment. The Company will not tolerate actions by Company directors, officers or employees (to the extent that employees are hired
in the future) or Third Parties to discourage or authorize discouragement of any kind against any individual who reports a perceived
incident of discrimination or harassment in relation to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Retaliation
of any kind against any individual who reports any perceived incident of discrimination or harassment, or who cooperates with any investigation
relating to such reports in good faith is prohibited. Engaging in any form of retaliation may subject Company personnel to discipline,
up to and including termination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>XIII.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ACCOUNTABILITY</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Failure
to comply with the guidelines and requirements set forth in this Policy Statement is a serious matter. Violating applicable laws, regulations,
or the policies set forth in this document, or otherwise engaging in illegal, improper, or unethical conduct may result in appropriate
remedial action.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>21
<FILENAME>ex21-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
21.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Subsidiaries</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Data
    Knights Merger Sub, Inc.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delaware</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>22
<FILENAME>ex23-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
23.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>INDEPENDENT
REGISTERED PUBLIC ACCOUNTING FIRM&rsquo;S CONSENT</U></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
hereby consent to the incorporation in this Form S-1 of our report dated December 31, 2023, relating to the financial statements
of OneMedNet Corporation as of December 31, 2023 and 2022 and to all references to our firm included in this registration
statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex23-1_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BF
Borgers CPA PC</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certified
Public Accountants</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lakewood,
CO</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> April 16, 2024 </P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>23
<FILENAME>ex107.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
107</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Calculation
of Filing Fee Tables</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FORM
S-1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Form
Type)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ONEMEDNET
CORPORATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
Name of Registrant as Specified in its Charter)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Table
1: Newly Registered Securities</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Security
    Type</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
    of each Class of Securities to be Registered</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Fee
                                            calculation</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>rule</B></FONT></P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount<BR>
    Registered(1)</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proposed<BR>
    Maximum<BR> Offering<BR> Price Per<BR> Share</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 0.07in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maximum<BR>
    Aggregate<BR> Offering<BR> Price</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fee
    Rate</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount
    of<BR> Registration<BR> Fee(2)</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 0.07in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    Stock, $0.0001 par value, each underlying the warrants (Primary Offering)<SUP>(2)</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">457</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,085,275</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.50</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0.07in; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(3)</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">138,980,662.5</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.00014760</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20,513.55</FONT></TD><TD STYLE="padding-bottom: 0.07in; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    Stock, $0.0001 par value (Secondary Offering)<SUP>(4)</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">457</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19,683,367</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.59</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0.07in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(5)</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,613,186.53</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.00014760</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,714.11</FONT></TD><TD STYLE="padding-bottom: 0.07in; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
    to purchase Common Stock, $0.0001 par value (Secondary Offering)<SUP>(6)</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">457</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">681,019</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">--</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0.07in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">--</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">--</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">--</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0.07in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(7)</SUP></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registration
    Fee Previously Paid</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">--</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">--</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">--</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0.07in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">--</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">---</FONT></TD><TD STYLE="padding-bottom: 0.07in; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total
                                            Offering Amounts</B></FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0.07in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">152,068,297.11</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22,227.66</FONT></TD><TD STYLE="padding-bottom: 0.07in; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total
                                            Fees Previously Paid</B></FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0.07in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">--</FONT></TD><TD STYLE="padding-bottom: 0.07in; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Net
                                            Fees Due</B></FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0.07in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22,227.66</FONT></TD><TD STYLE="padding-bottom: 0.07in; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
                                            to Rule 416(a) promulgated under the U.S. Securities Act of 1933, as amended (the &ldquo;<B>Securities
                                            Act</B>&rdquo;), there are also being registered an indeterminable number of additional securities
                                            as may be issued to prevent dilution resulting from stock splits, stock dividends, or similar
                                            transactions.</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reflects
                                            up to 11,500,000 shares of Common Stock issuable upon the exercise of 11,500,000 warrants
                                            (the &ldquo;Public Warrants&rdquo;) originally issued in the initial public offering of Data
                                            Knights Acquisition Corp, a Delaware corporation (&ldquo;DKAC&rdquo;), and (ii)&nbsp;up to
                                            an aggregate of 585,275 shares of Common Stock issuable upon the exercise of 585,275 warrants
                                            (the &ldquo;Private Warrants&rdquo; and, together with the Public Warrants, the &ldquo;Warrants&rdquo;)
                                            that made up a part of the private units originally issued in a private placement in DKAC&rsquo;s
                                            initial public offering.</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reflects
                                            the shares of Common Stock that may be issued upon exercise of the Warrants at an exercise
                                            price of $11.50 per share of Common Stock.</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents
    the resale of the selling shareholders named in this prospectus (including their permitted transferees, donees, pledgees and other
    successors-in-interest) (collectively, the &ldquo;Selling Shareholders&rdquo;) of up to an aggregate of 19,683,367 shares of Common
    Stock consisting of (i)&nbsp;797,872 shares of Common Stock upon conversion of up to $1,595,744.70 of OneMedNet Senior Secured Convertible
    Notes (the &ldquo;Pre-Closing PIPE Notes&rdquo;) issued at the closing of the Business Combination (as defined below) subject to
    a floor price of $2.00 per share pursuant to the terms of the Securities Purchase Agreement dated June 28, 2023, by and among Data
    Knights Acquisition Corp, a Delaware corporation (&ldquo;Data Knights&rdquo;) and the named investors (the &ldquo;Pre-Closing PIPE&rdquo;),
    (ii) 95,744 shares underlying 95,744 warrants related to the Pre-Closing PIPE and the Warrant Agreements executed at the closing
    of the Business Combination, (iii) 7,312,817 shares of Common Stock upon conversion (the &ldquo;Conversion Shares) of up to $4,547,500
    of funding to the Company pursuant to the Securities Purchase Agreement and convertible promissory notes <FONT STYLE="background-color: white">dated
    </FONT>March 28, 2024 <FONT STYLE="background-color: white">(the &ldquo;PIPE Notes Financing&rdquo;) with Helena Global Investment
    Opportunities 1 Ltd. (the &ldquo;Notes Investor&rdquo;),</FONT> (iv) 3,656,408 shares underlying 3,656,408 warrants related to the
    <FONT STYLE="background-color: white">PIPE Notes Financing</FONT> with the Notes Investor, (v) 277,778 shares of Common Stock issued
    pursuant to the terms of the Satisfaction and Discharge Agreement at $10.88 per share dated as of June 28, 2023, by and among the
    Company, Data Knights, and EF Hutton LLC (&ldquo;EF Hutton&rdquo;), (vi) 1,315,840 shares of Common Stock issuable pursuant to the
    outstanding loans converted to equity for Data Knights to fund its extension payments prior to the Business Combination
    by certain of the Selling Securityholders named in this prospectus, (vii) 1,439,563 shares of Common Stock issued upon the closing
    of the Business Combination to ARC Group Limited, as consideration for its financial advisory services, (viii) 1,327,070 shares of
    Common Stock at $0.7535 (95% of VWAP 10-day average $0.7932) for $1,000,000 investment by Dr. Thomas Kosasa, and (ix)&nbsp;3,609,859
    shares of Common Stock issued to Data Knights LLC (the &ldquo;Sponsor&rdquo;) and its affiliates, including 2,875,000 shares of Common
    Stock originally issued as share of Class B Stock in connection with the initial public offering of DKAC for aggregate consideration
    of $25,000, or approximately $0.009 per share, and 585,275 shares of Common Stock originally issued to Sponsor as part of the Placement
    Units issued to the Sponsor in connection with DKAC&rsquo;s initial public offering at $10.00 per unit, and which are subject to
    six month lock-up restrictions set forth herein; and (b)&nbsp;the selling warrant holders.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Estimated
    solely for the purpose of calculating the registration fee pursuant to Rule 457(c) under the Securities Act, as amended, based on
    the average of the high and low reported trading prices of the Registrant&rsquo;s shares of Common Stock as reported on the Nasdaq
    Capital Market on April 11, 2024, such date being within five business days of the date that this Registration Statement was filed
    with the SEC.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents
    the resale of the selling warrant holders named in this prospectus (including their permitted transferees, donees, pledgees and other
    successors-in-interest) of up to an aggregate of 585,275 Private Warrants.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    accordance with Rule 457(i), the entire registration fee for the Private Warrants is allocated to the Common Shares underlying such
    warrants, and no separate fee is payable for the Private Warrants.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>forms-1_001.jpg
<TEXT>
begin 644 forms-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" !? .H# 2(  A$! Q$!_\0
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M/K2U!&C12$'E3SG/3L!BIZQ:.A.X4444AA1110 4444 %%%% !1110 4444
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MI5N"#@CI7)_ G_D#ZS_U^_\ LM<EX8U+PMIWC#Q*?%<<+H]RPA\V R<[VSC
M..U 'K^G>/O#6KW\5E8:M#-<RDA(U5@6.,]QZ"M&_P!>TW3+A(+V[2&5QN56
M!Y&<5RWA/4O >K:R$\.6UI]OA0RADM2A5> 2"0/[U9OQ(YUZW_Z]Q_Z$U=>"
MP\<15]G)Z'+C*\J%+GB>E A@"""#T(JEJ&LV&EE!?7*0E\E0<G/Y5SO@OQ&D
MVD2V][)B2R3=D]3&/\.GY5QNMZI)K.IRWCA@C';&#_"HZ#_/K730RV4ZTJ<]
M$OZ1S8C,HPHQG#5O^F>J7FLV.GPPS74XCCF^X<$[N,U4'BS1CTO5_P"^6_PK
MG?&G_("T?_=_]E%4=.?PT+&(7L=P;G;^\*YQFG3P5-TE4=WJ]C&OCZL:SIQY
M5HGK<[R+6+&:Q>\2<&WC.&?!P#_DU /$FDGI>I^1_P *S+J&RB\%7#:<KK!*
M-XWGGJ!_2L[PMHMIJEI.]TKED<*"K8XQ64</1Y)5)-V3L.IC,2JD*5-1;DK]
M;'86M_:WH/V:=),=0#S^55=9\0Z7X>BBEU>\CM4E;8C.#@G\!7,ZKIS:!J$4
MEI*P5OF0GJ,=0?6N;^.$GVSPSH3]/-N,_3*UA7HQ@E.#NF;X+&SK3G1JQM./
MW'K2.LB*Z,&1@"K \$5G6WB+2[S6;C2;>\CDO[<;I8 #E1Q[8[C\Z\[^'?B:
M\\,ZM_PAGB9MKK@V,['Y64\A<^A[?E2^$O\ DN_B;_KBW\XZYCT3M]5\<>'=
M$OFLM2U2&WN4 +1LK$@'D=!51/B;X1=U5=;MRS' &U_\*\[\57>CV7QO>;Q$
ML;:>MNN\21EQG9QP/>NETS6/AEJ>IVUG86ED]U,X6)?L3#+=N2O% '4:EX\\
M-Z/?R66H:M#!<Q8WQLK$KD9'0>A%5?\ A9_A#_H.6_\ WR_^%:6H>%=#U":6
MZO-*LY[AQ\TDD0+' QUKS3X.^'M)U:SUHZAIUM<F*["H98PVT8/ H ];T[4;
M75K"*]L)EFMIAE)%SAAG'?Z59J&TL[>PM8[:TA2&",82-!A5'L*FH *S;RPC
MD2\-]=O]CG5049MHC([ANW.*TJBN;:&\MI(+B,212##*>A%7"7*[D3BI*Q@7
M4J#5U\FZO(SIT&Z6(IN6>/'4>I]Z=HU^DT$#V\UQ>RW"';+*"B[0W*G' 89/
MUJQJ5PT!CT>Q$MO-+ 1;W&S<BE?X2?H*SV\Z'4K.TEU&&*7[*WVFRA7:),@_
M,F /FKNBE.%G_25^R[^?EV.1WC.Z_IZ>?;R.H5PQ(!!P2..U>=?%3PYJ,USI
MGB;18S/>:6X+0*N2RAMP('?!ZCT-=?H^J0WEC'/;^9]BCB.Z:5OG#+P0P^G.
M:U8I5EC1T(974,&7D$?6N*I3<&TSKA-25T<!9?&KPS-8"6\:XM;D#Y[<Q%B#
MZ C@_I6'H?V_XD_$:U\1-:26FC:8/]',@YD(R0/<Y.3CIC%>G3:!I-Q/YT^F
M64DO)WO I)S[XJ\B)$@2-51%& JC %9EGE?BP_\ %]O#/_7$?S>K?Q,\&71N
M$\5^&RT6JVGS2K&.95 ^]CN0.W<5Z')86DMVEU):P/<1C"2M&"Z_0]1UJQ0!
MY3\!&+Z%JS-U-V"?^^:YGPEKOAS1?&'B9O$BQ,DMRPB\R#S.0[9['':O=;6Q
MM;%76TMH8 YW,(HPNX^IQ55_#VCRNSR:38.['+,ULA)/J3B@#EM"\<^")M6A
MM='\F.\N6$2>7:E"V>V<50^(AQXDM/\ KBO_ *$:[J'0=)MIEE@TNQBE0Y5T
MMT5E/L0*GGL+2ZD#W%M#*X& SH"0*ZL'B%AZO.U<YL50=>GR)V.!\4^%KJ/6
M!-I<$KQ7?WEC'"-WSZ ]:A\7Z7'H]GI5I'C*QN7;^\W&37IE0SVEO<D&X@BE
M*]-Z!L?G733S*<7#G5U'\>AS5<MA)3Y79R_#J<3XR/\ Q3^B_P"X/_0!533=
M8T."PABN=*\V95P\F!\QKT&6TMYD598(G5/NAD! ^E1_V98_\^=O_P!^E_PI
M0QL%25.47NWH[$5<!4E5=2$ELEJKG/SZE:ZCX.O39P&"&+"!#CCD'^M9?ASQ
M!%H]M-')"\AD?<"I'I7<+:6ZQ-$L$0C;DH$&#^%-_L^S'_+I!_W[%1'$TE"4
M'%V;ON*I@:\JD*L9I2BK;?H<=<7-UXFU!!%#M1>%'4*.Y)KG_C?$MMX?T&('
MB.ZVY^BUZND:1+MC147T48%0W=A:7ZHMY:P7 0Y42QAPI]1FL*U?VB48JR1M
M@\#["4JLY<TY;LY/QUX(C\7^'H6M]L6J6R![:;H<X^Z3Z']#7!_"*YO[KXF:
MK)J^\7_V1EFWC#;@R#D>O%>W@   # %0)8VL5V]U';0K<R##RK& [#W;J>@K
MG/0/&_$NHZ5I?QS>YUP(;%;=0X>/>,F/CCZUTL/Q"^'5O,DL MXY4.5=+(@J
M?8[:[FYT73+R8S76G6<\IZO+ K,?Q(J+_A&]$_Z ^G?^ R?X4 7V<26Y=3E6
M3(/MBO,/@8?]!U[_ *_1_(UZEM&W;@8QC%06MA:6"NMG:P6X<Y811A=Q]3CK
M0!8HHHH **** "N;%B=/:XU'Q!/!*+9]UM=;"'C4\8('N?>NDJ.>"*Y@>&=%
MDB<;65AD$5K2J<FG1[]_D9SAS:]4<:EU/:Z?!J&O7C^5!<@V]S:8*SHW7>HX
MQ^M;L>HM#!<7]Y&%MH\"![=BZR1-C#;?49JEKVD7L.F6MOH<,+VL1(ELY "L
MBGW/X_G59_L,7CFT@BN)[.XB@">3M_=2K@X4<\8_I7>U"M'F7F].B7DMK_-:
MG(N:F[>F_=_G;Y,ZE+B-W"+*C.$#$9YP>AQZ5*#D GK7+076IQ6&H75S9VNH
M7,3>4CV[#=+'GE3CT]*T;>YAAO=/M5T^Y0-;%HG.2L?&2C>AX[UR3P[5[:_=
MVO\ UH=$:U]S7WCMR<9P.])(^Q20"S8)"CJ?I6;;:A=3VUL]OIKQ+YQCFCE.
MUHU'\0]14BK%:SP#4;J.6Y:5_LS. K8/\(]>*S=)IV9?/=:%UV9(6=(V=L9V
M C)]N:<BJB!5&T#H/2L^Q:74)%N;JVN+.:W=XQ&7^5QZ^XK2J9KE]TJ+OJ%%
M%%04%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4$
MMC;3W,5Q+!&\T7^KD*_,OT-3T4TVMA-)[G.P^$4LGU-K&]G@%\A 53_JVSG<
M#UJJ^F^)X/#\$<-\DE_;S$]>)8^P)(KK**Z5BZE[RL_5=M#%X>'33T9B_8]7
M?65F>Y7[!-!LF@SS&^.JGZ]Z6Q\.10V$5KJ$K7X@E\R%YA\R>G-;-%9NO.UE
MIZ>12I1O=ZA1116)J%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
&4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>forms-1_002.jpg
<TEXT>
begin 644 forms-1_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  U G # 2(  A$! Q$!_\0
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MSR*N^"O'^@>(;33M-M]82ZU;[(K31X;<6"C>22,=: .SHHHH **** "BBB@
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M2Z/ID]^E]-IUI)=IC;.\*EQCIAL9J[110 4444 %%%% !1110 4444 %%%%
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0 ^E:  4    < "BB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>forms-1_003.jpg
<TEXT>
begin 644 forms-1_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" "- F\# 2(  A$! Q$!_\0
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MZ.X(&?H*V= U&_O(98=9M;>UU"!L/'!,)%93]UQW4'G //% &O1110 4444
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MLO%/B2YL+76-.L+'3X;J.YG:*Y,K2!#N5,8'5L9^E ';T444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 52OM'T[4W1[^QMKED!"F6(,5'MFKM% &1_PB>@_] ;3_ /P'7_"C
M_A$]!_Z VG_^ Z_X5KT4 5;'3;+3(VCL+2"V1VW,L,84$],G'TJU110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MHKFM/U"Z@\+Z<5>-KFYF\GS')9%)=N>N2..!GTJE:ZK<VF\220M<$R*),22
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M6A65HY1*,OY;!>5QQDGCGIUQ6AHVKIJ\,S!45X9-C>7)YB'@$%6P,C!].N:
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MT\UQ)<^>-LNU0O[Q@R%0@8MM&,C& />H8M#OM:EFO;W:DJR(8A- 45@$*ME
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/>BP>]^>2<DEFD)PD7(SG) +8]2*[:B@#A=6U!X[0KIMQJ<B".62"61Y '8
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/[LC(QR3[@_3%:M% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>forms-1_004.jpg
<TEXT>
begin 644 forms-1_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" $" I\# 2(  A$! Q$!_\0
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M@=:89/2LZE6%/XF:0I2G\*'T5&'(Z\T\,#4T\13GLRIT)PW0M%%%;&(4444
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MDP$<X&0?7FO<]A#O^1YIZE_PD&C_ /05LO\ O^O^-*NOZ2S!5U2R)/0>>O\
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MRLWS*"=FWISU"\4_84^WXB.T;XL6Z.R-I%P&4D$><O!'X4G_  MJU_Z!,_\
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M6Z*FI1A55IH=.K.F[Q9GVFB6EKABGFN/XGY_2M"BBJITH4ERP5A5*DZCO-W
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M-D7Y@V>!GIQCK5*[UO5+O2]HD9Y)81).D-N\;6;B1/DSWSEAZ\9Z4!9LU?\
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ML+(C^SP_\\8O^^!3U14&$55'HHQ2T47"P4444@"BBB@ HJC_ &YI?_00M?\
MOX*/[<TO_H(6O_?P57)+L3SQ[AI&CVNB6C6UEYWEM(TA\V4R')Z\FKX."#Z5
M0_MS2_\ H(6O_?P4?VYI?_00M?\ OX*.278.>/<SM(\*PV&G6\=R[3W,#-(A
M:5VB1RS%6"$XXSZ5ECP5>R1R+-/9CS+3[/($4A7/F(^[ 4 #"D8YQGJ:Z7^W
M-+_Z"%K_ -_!1_;FE_\ 00M?^_@I>SEV'[1=S*N_"B3ZN\\<5DMH\UO*8_+P
M?W6[*X P0<@_A5:Y\'SO(&BF@,2RW#);ME8U60@@CY3@C!&,=^"*WO[<TO\
MZ"%K_P!_!1_;FE_]!"U_[^"CV<NP>T7<IZ%X>&D7,\TC1S2O'#&DI!+@)&%.
M2>>2,]:KR:+JAAU>SBELEMM2FD<RL7+QJZA2-N,$X![XK4_MS2_^@A:_]_!1
M_;FE_P#00M?^_@I^SEV#VD>YBR^%;J358;@36WDPW4<RG;AS&H V'"\G /).
M#Z"JDO@N]?28[!9;!42VD@5@F"&9B0^=I/0C@$<CJ:Z7^W-+_P"@A:_]_!1_
M;FE_]!"U_P"_@I>SEV#VJ[EJVC:*UAC<[G2-58^I P34E4?[<TO_ *"%K_W\
M%']N:7_T$+7_ +^"GR2["YX]R]15'^W-+_Z"%K_W\%']N:7_ -!"U_[^"CDE
MV#GCW+U%4?[<TO\ Z"%K_P!_!1_;FE_]!"U_[^"CDEV#GCW+U%4?[<TO_H(6
MO_?P5H*C.H95+*1D$<@TFFMQII[#:*?Y4G]QORH\J3^XWY4KHJS&44_RI/[C
M?E1Y4G]QORHN@LQE%/\ *D_N-^5'E2?W&_*BZ"S&44_RI/[C?E1Y4G]QORHN
M@LQE%/\ *D_N-^5'E2?W&_*BZ"S&44_RI/[C?E1Y4G]QORHN@LQE%/\ *D_N
M-^5'E2?W&_*BZ"S&44_RI/[C?E1Y4G]QORHN@LQE%/\ *D_N-^5'E2?W&_*B
MZ"S&44_RI/[C?E1Y4G]QORHN@LQE%/\ *D_N-^5'E2?W&_*BZ"S&44_RI/[C
M?E1Y4G]QORHN@LQE+3_+V(TDS".-1DLW%8M[XICA)CTZ(,?^>LG3\!7-B,72
MH*\V;T<+4K/W461X9LI+DW)MR)2V_>9&'/KUJW-<V5M_Q\7L2GT!R:XZZU.\
MO2?M%Q(P/\(.%_(55QBO&GFZC?V,+'K++G.WM9MV.Q?7])CZ2RR?[J&H'\46
M"_ZNUF?ZD#^M<KD>M/2&63[D4C?[JDUSO-<3+9_@:K+Z$=T=$WBV(?<T_P#.
M3_ZU1MXL+ C^SXB#V+9_I6.NFWK?=L[@_P#;,T_^R-0_Y\I_^^*7US&RZO[O
M^ 5]6PRZ+[R]!XACMI7D@TRVC:3&XH<9_#%6!XN/\5A$?H__ -:LK^Q]1_Y\
MI_\ OFFG2K\=;*X_[X-2L5C([-_=_P  IT,-)W=OO_X)KR^)K6YA:*YTT/&W
MWE$G!_2I;?Q#I<*!$L'A7TC K :PNU^]:SC_ +9FHFBD3[\;K]5(I_VABHN[
M?X"^J4)+E2T]3KDU[29.LLL?^\AJU%<V5S_J+V%CZ%L&N$R/6C&:VAG%9?$D
MS&664GM='H36\@YQD>U9]]I5KJ!7[9$7V?=&XC'X"N6MM0N[0YM[B1!Z!LC\
MJVK/Q63A-1A#K_STC&"/P_PKNIYM1J^[55OQ1RSRZK2?-2E^C-2TM(;&W6"W
M7;&O09S4U/01W$*S6KB6)NA%'E2?W&_*O6@X\JY=CS)J?,^;<913_*D_N-^5
M59KZUMI_)GNH(I>/DDE56YZ<$U2U)LR>BD+*)UA+#S74LJ9Y('4@>G(J3RI/
M[C?E0%F,HI_E2?W&_*CRI/[C?E1=!9C**?Y4G]QORH\J3^XWY47068RBG^5)
M_<;\J/*D_N-^5%T%F,HI_E2?W&_*CRI/[C?E1=!9C**?Y4G]QORH\J3^XWY4
M7068RBG^5)_<;\J/*D_N-^5%T%F,HI_E2?W&_*CRI/[C?E1=!9C**?Y4G]QO
MRH\J3^XWY47068RBG^5)_<;\J/*D_N-^5%T%F>-T445[IX84444 %%:/V*VM
M=-MKN\,SM=%C''$0N%4X))(/?MBGPZ=9SFYN(KF5K.VB620; ) 2<!/3.>_2
MHYT7[-F716DME:WEC<SV9FC>U"N\<I#!D)QD$ <@GH16A=^&8H=:MX()WELW
MN%MY7XWQ,>Q^H.0:3JQ6C&J4FKHYVBM>SL]/FCOO,2ZWV<32$K*H#X8#'W>.
MM+:Z5;7EFEQ&9D#WT=L%9@2%8<G..M#J);@J;>QCT5T!\.1C65A29Y+&3S0D
MRXW!D4DHWH01^(YK+U"S2TM;"5&8FYMA,P/8Y(P/;BB-2,G9!*G**NRG16Y=
MZ);6<UY)++,;6U$0PN-[NZY ST Z\U#;Z9;7\"SVK31JEQ%#-'(02 YP&4@#
M\B*/:QM</92O8R:*U+;2XI]?GL&=Q'&90&&,G8"1_*IK#2+>[L+>9%N+N23/
MFI;R(&AYZ;3RQ[T.I% J<F8M%2W,0AN98U+E48J"Z;6Q[CL?:HJLC8*W_#OB
MRZT-A%)F>S)YC)Y3W4_TK HJ9PC-<LD5"<H/FBSVK3]2M=4M5N+.421GTZJ?
M0CL:M5XOIFJW>CW0N+.4HW\2GE7'H17IOA_Q1::[&$'[F[4?-"Q_5?45Y.(P
MLJ6JU1[&'Q<:ONRT9MT445R'6%<P;^6[U'5DN]7.F"SD"11#RQ\FP-YK;@=P
M))]!\N.N:Z>L\7&E:CJ,MIOM+F\M,&2,[6>+/(R.HH YJV\9:D=,DNI[*W M
M;6"XN SLC-YA8?*N..%R,GOBIE\97$][+ EGY<1EGMT8L-Z-&&^8@]0=O3L"
M#5B3Q+^YOKN71BVGV\[P7$X=6;"-M+%.I Y/7..U:$NJ:/#J#AP@NGW1[O(;
M,A"Y*AL88X'0'M0!Q\OBK5U\)QP"\']JQ+'<37&Q>;=MK*V,8RVX)T[-Z5L-
MXWF6^F7^SF:".>: *&_>DQACNQWSMZ=<$&K\'B+19M)MKZ=/(AN+=),26[82
M/L&(&  <]>.]3ZWJ-KHC0W9LXWGG?RA,VV-5X)^>0_='&!ZG H YF^\2ZM<N
MZ6U]:6S2VEO+&;<B81M)<*N3D<_*<>_M4\_C.\L[^Y6ZMR)[.S'GVB\+YIE5
M%D#$9V$'.?3.>16U;:GI<5G'/<VD-K)<.0J1HLIEVG.Y?+SN'?/;OBIWUW16
MEC)N()&GC3#JA8;'.%W,!@ GIDB@#'B\3ZA=ZEI\"I;P*;XV\Y8Y$@\EG 7N
MIXZ'OCL:M:[XGGTK4KJWBBM#':V0O&\Z<H\@W,"BC'7Y>OJ15QM4T&UL(92]
MM':E7N(\184"/[S 8XQFLZ[UC1DU=;R2U:>>1K>U5O+9F7<SE3L(RO.[GJ:
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M+]GNO/#>>2.?E'*X]ZT:IV^KV%UJ-S86]U%)=VH!FA5OF3/3-9&IYUJ'B6Z
MUFYN_$LNFZK9SR)9Z4L:;9%4_NQL*EI-_'(/?VJ.Y\8:_9>)M3\UW\F1;>SA
MM=H(M[J:%67G&<;@P.?6NGF\8PJ]Q,UC;2-;7+VPC6Y!N7VOM)2/;D^N,UK2
M>(-'2[DA:53*LA0L(F(,BC.T-C!< '@<]J /.].\2>*%&A^5=M?3HU\UU P
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M%9ZAYJO!+ +EKE1+$Q=&))X.['!/!VYKI:SG*UN5C2[A1116104444 %%%%
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MH **** )K7_7#Z&N&U08U6[Q_P ]F_G7<6Q F&>_%<=K5G/!JMPSQ/MD<LK
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M]G\+&ICAXN,7?>WX_P!?\,!Z3138BYAC,O\ K"@W_7'/ZTZN, HHHH ****
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M"DL9PR[&./TH2E-VBKC;A25Y.WJ:E&#Z&N%\:>)UN]'C@T*ZE\]I07>/*%5
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M9./1O:M^BBF#"BBB@04444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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; HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>forms-1_005.jpg
<TEXT>
begin 644 forms-1_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" #7 I\# 2(  A$! Q$!_\0
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M*QNKQ]3A6WM)_L\SG.%D_N].3]*UTGCD("NI8KN"YYQZXKSB#X57*G9/?PO
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M.H6FD2V\=W:"2>2$3(5W(\<8/JO#$G.=IZ8)/6D_X5SJ4>E6MJ+G3[EH[.>
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M0#QD$9H ]$JB^LZ>FL)I+748OY(S*L&?F*#O46E+J$45S!/# D4!$5GMRN]
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MYZ':#UZUTM% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MA"-@P5'0?2K-% $ LK8"8"","?\ UOR_?^OK3WMXI(/(>)&BQMV$9&/I4E%
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MBBB@ HHHH S;ZWD@NX[ZU4LXPDR#^-/\16B#D9I:*!)6"BBB@84444 %%%%
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M&<53\4W.HV\>G_V6S"5[KYE"@AU$;L5/H"5 S]*W:Q_$.MG0DM)F4-"\K";
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MIZ*S/09'#)YT*2;&3<H.UQ@CV-<_XBU;4--U.,V:^8GV1F\MD)0OYL2@G'/
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M*/J:]%^!S!!K3,0% B))Z#[U=O:ZYK&LVWVO3-)M&L)21"]S=%&E3.-VT(<
M]N>E<M2O*,VDM$;1IIJY\WYHKWU_"\DCL[^#_#A9CDGSSR?^_59VM^ [G5-*
MEM;7PYH-C.^-EQ%.VY,'/:,?3\::Q,?ZL+V3/%**EN[9[.\GMI"C/#(T;%&R
MI(.#@]Q45=)D>I?![Q=]GN&\/7DG[N4E[1F/W6ZLGX]1[Y]:]BKY-AFDMYHY
MH7:.6-@Z.IY4CD&OI'P1XHC\5^'8KO*BYC_=W*#^%QW^AZBO/Q5*SYT=-&=U
M9G0UGZM<QP&S0VZ3SSSB.$.!A3M8LV>V%#?R[UH5E:_<:=;6]M+J=S]FVSJ8
M)!][S #@ 8.<C<,=P37(E<V,0>+_  ]8VPN$L)8H KS6\BVR@3[2$8Q\]><<
MXR.E4M3U32HKU9TT:Z:XM9K>-XY55(K8N0J@X)P=K9 &1R,X)J\__"$(U\KF
MP!"$W ).%7<"V!T'S$9"]^M2WEQX/OI3J=T]K)*)5C+?-N+K\RY0<D@<@XZ>
MU;6CV9%WW*@\8^%YXIS'I[RK&R*H6T4B7YO+7;]"<<X.#Z5=M=8T2[UV/36T
MEH;M%"KYULBA<+G:#GL"1QQU&:IWM_X*TNWN)2()!M2Z:. ,^1NWJ5 X W<]
MAFKL7_"+ZOK#>0T+:E(C$$;@R%DY(!X#[3]<4.,>S"[[EK6;RQT9[**2S@,-
MQ(^X",<;(F)(&,9VKCZ<5EV?BK08Y(WATBXM\F%O,^RHNP2_+&Q(.0#DCUZ\
M8J[X@GTK2+?2H+^TDNSN,%N6=00?+()9G91RN1DGO6<FI>&SJ-IIUQIAA>\@
M1E9F1XPD)/E@LKD<$'&,^]$8IK8&W<F;QCX?G:[MGLI79'1_+-NI\]V?8I7G
MEB<#G!J.X\9^&[65?.T^9;F!WA\O[*IDB"8ST/0;L<>^!6(;[PGJ=AY%CI=W
M;&\$B!T>*)E6-U;@R/@#+ @#WZ5LZ9I?A>+PO!J5R':VFD:82W?RR%G(!7"X
MSDJ/E&0<=ZIP@MTQ7;-'3-;T2;6SI=G9&*:-BZ.;=40L%ZKW^Z>N.F:W(+"T
MMIGE@M8(I'^\Z1@$\YY(]ZY(WWA"\$]_(4M))9)K99VRISPK.O4+G(^;CWK4
MMO&.AI;3AKMHH[.8VK-,K9+*.2/4>]9RAV3*4NYT-%4[34[>\N)(8B2R(DH/
M9T;[K*>XX(_"KE9E!1110 5QWC'5_,D&GPM\J?-*1W/8?UKH=;U1=*TYYN#(
M?EC4]VKS=W:1V=V+.QRQ/<U<5U.7$U++E0VBB@8R,\CO6AQ&G%ID$%K'<ZG,
M\22C,<,8S(X]>>@I5&B3'9F]MB>DC%7 ^H%/\3 MJ:SKS;RQ(82.FW'05D5*
MU-)-1=K%J_T^73YE20JZ.-T<B'*NOJ*JUL:@K0^'-.AGXF+O(BGJJ&L>FB9J
MS"BBBF2=]X7U?^T;#R96S<0 !L_Q+V-;E>8:9?R:9?QW,?.TX9?[R]Q7I=O/
M'<P)-"VZ-U#*?:LI*QZ%"IS1L]T25GW]U:1W,<5S;^:X0R!O+#!%'4Y/2M"L
MB_U;3+/5U@O1MF-LS^8RDJ(]P!!/89QUX]ZDVDFUH1#5-,O$<K;.99_W6%B
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MA,<$YR<D].@!-5'66B$]CDHO$6N"[M(Y+U9I]ML(XX(@8[L-N\Y\XS\N.H(
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MVQ<I^Z;IU6@"]1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*%3F&..W#"7YWSO)^[QMQR/7GI4%I=>(;O4[);N*X%NLL,K-Y93!*R!U;@9
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MTQVL+EM+G8D*-]NY_BC]/J.GY4 :U%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !3719$9'4,C#!4C((HHH @T
M^PATRQBM+4,L$0VHI8G:/3)[59HHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH *BN;>.[MWAF7<CC!%%% #T78BK
MDG QDTZBB@ J.2"*;;YL:/M.1N4'%%% "^5'M"^6FU3D#' /K33;0,,-#&1C
M&"@]<_SHHH"PL4,4"E88TC!.2%4"I*** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "H+FSBNFB>0'?"VY&!P0:** )Z*** "BBB@ HHH
<H **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>forms-1_006.jpg
<TEXT>
begin 644 forms-1_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" #_ E,# 2(  A$! Q$!_\0
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MES'< E#E=I!VX! /3J1F@#5M]>TZ[7?#<H4WNA<L  5X/6K<EW;PEA+<1(5
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M;M3H3K7F1"Z>[^P;W^:%,3#@;0>Y7KS@'IFIM6\0WT%CJ?V>"!+BQB#.[2Y
M+<C:".>/7%6;?Q!*;Z*WNK80)(XC221B/,.,Y7 V\^F<T <_8VVOV>FVZ6T-
MPA%N=^Y5WC,Y+8_VMG.*UKMK[;;QV9U+[.7<R22J=PX&!@#=C.:Z>B@#A;&V
MUN\N4:_MYUDN;-+>:5EV[0)6)SCOMQ^==PJA%"J,*!@ =J=10 4444 %%%%
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M5P.02>V:])TN^74M+MKM1@31AL>A[T1;ORL=2$>55(;;6[,N44E+5F 4444
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M@Y55*LQ('KD"M#P1H\.E?#RRG@>4F\FBF=';*JV['RCMG%+M\4[54KXA*KC
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M/W$C/;.IEL7<Y.WNGX4M8O4IJ-2+<59HT-1UR2TUM+!6M8E:W\[S)V/)W8P
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MA0037,U^V8H]D\B7)+LF>C8.2,FIDTC0,_:$\D)&R$CS?D4[-B@C..5.,>]
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M!T:\L+XS3MLC\@1F,."';/WL #\SSS0!ONZQHSNP55&23T I(I4FB62)@Z.
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MK'B\/^(],CO5L[ZWNY+I0OVFX9EE0 8&#R.,TS3/!VK)!/;7FJM#9SR>9)%
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MBXMJ6YT/P:LHM0MO$=O. 4>WCZ]B"Q!KT3P]XSL8M$MHM1GD$\0*,PB9@<'
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M6\;F1E95.78';DX!P!U_&NONK"VO2IN(@Y7[I.1C\JEBA2")8XD5(U&%51@
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MIL^EW>H!;V-@\:0*9)$D'(X ING:UXH;P=<7UW81"Y2WW6^T,9';I\R8X]:
M,;P^=1L[.]U&P(:XL;AH;RW08CN5'\8'9L>E>B:9J,&JZ?#>6K;HI5R/4>H/
MN*XWP7K>A:9I8MKO41'J-RYEN1=*8B9&ZCD8Q6CX0Q9ZQK>FQ$&WBF$T6#D
M.,\5'PO3J=%_:TVWNOQ1UE%)15G.+124M !1110 44E+0 4444 %%%% !111
M0 4444 %%%% !36IU-:@!****0!3J;3J8"T444 %%%% !1110 4444 %%%%
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MMHX+= D4:A54= !4+WG?H=#_ '4'%[O\$97BR[GLO#\LMK(\<OF1J&0@'!<
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>S1F@!U%-S1F@!U%-S1F@!U-:C-!.: $HHHI ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>forms-1_007.jpg
<TEXT>
begin 644 forms-1_007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" %. G # 2(  A$! Q$!_\0
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METZW$9MS:E=G'E$[BGT).:;<>%](N89HVL8T$WEEFC^1LI]PY'=<#'TK6HH
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MK</M,G[N!3W<]_PZT =&"#T(-+7EWPD\9/?K+HVHS[[E,RPNYY<$Y(_#->H
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ME@ &;J<=:?0 4444 %177_'K-_N-_*I:ANO^/2;_ '&_E0!R_P ,/^1(MO\
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MW"LLA154%BV ">!]: *>@Z-)I@E,R-YAC"%_,R'QGG&.*RK#1]0DT^*2"&*
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MI)UG8PL3(IR">>A]NE &7\,/^1(MO^NLO_H9KKJY'X8?\B1;?]=9?_0S774
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MCYP&R,>E1Z-:W4>JQM<1"/R;;RW*C"L2V0/J .?K714P,5O#T92)1(3Y;RN
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MLA_Y:I_B*]"P#7S/X:OFT'QE9S0S+(L5P(RZ?==2<$_3FOI=3D9'>FBA<"C
MI:*8"8%&!2T4 )@4;1Z4M% "8%&!2T4 )@4M%% !1110 4444 %%%% !1110
M!R?BJRN+_4+2,Z$NIVJ(S;C-L*OVK5TJWFM/#,<%Q#'#*D+!HXSD+UXS67XL
MNM0%[:6FEZA#:M,CB4NX4HO'SC/4BM'1)Y;GPK%+/.+B0Q-F7.=^,C- &7\,
M/^1(MO\ KK+_ .AFNNKD?AA_R)%M_P!=9?\ T,UUU !1110 4444 %%%% 'F
MOQM_Y%NQ_P"OK_V4UY!I.H'2=6MKY8]YMWWA<XS7U%<65O>*%NH(IE!R%D0,
M ?QJO_86E?\ 0-L_^_*_X4K":/GC3_%'E3:B=5MI-1COHQ&ZO*5( ;<.>M63
MXZO(TN3:6T,$DOEHAV[A'$G1 #_.O?O["TK_ *!MG_WY7_"C^PM*_P"@;9_]
M^5_PHL%CYQUW5;367>]^S-%?S2 RX/R8"X)QZD\U=E\5Q2Z9IUL]A)Y]CY86
M43MM8*V>4Z<^M>YZSH]O#I%R^FZ/9S7@0B)/*09;ZD5@?#[1KH:&T7B+1[=9
MD<F.22-"SJ?7Z&BP6/,SX]F;R]UFN5,VYMW+!P0H/^[N-10^.9X((;);2+^S
MH[4VS0$#+9'+;L9Y/->_?V%I7_0-L_\ ORO^%']A:5_T#;/_ +\K_A18+'S9
MX:A2X\3:="^X)).JG!(.#[U[EX7\!0>&-;O+VVN998[@?(CDY3UR>]=$FBZ;
M&ZO'I]HKJ<AEA4$'\JN@8HL,QM/LK"XU*XOK=K@S12M$X:5MN[O\O2K/]C6W
M]I_;\S^?UQYK;>F/N]*J^&_^8I_U_P O]*VZ8&;)HMK+J2WS&?SE(.!*P7C_
M &>E5K_3[6YU%;HF;S4Q]V5@O'^STK0NI\?(IY[FJM-(12NM*MKRXCGF\WS(
M_N[)64?B!UHN]*MKZ:.6?SM\?W=DK*/Q ZU=HI@4[W3+?4#&;CS?W?W=DA3\
M\=:2]TNVU!(UN/.Q']W9*R_GCK5VB@"G=:7;WEO'!-YOEQ_=VRLI_$CK1<Z7
M;W=K';R^;Y:8QMD*GCU(Y-7** *<NEV\UBMF_F^2N,8E(;_OKK2MIMNU@+,^
M;Y(&/]8V[_OKK5NB@"FNF6ZZ>;(>;Y)ZYE.[_OKK2Q:;;PV+6:>;Y+ @YD);
MG_:ZU;HH IV^EV]K:26T7F^7)G=NE9FY]">11::9;V,,D,'F[).N^1F/X$]*
MN44 4[/2[>PCD2#S<2?>WRL_Y9Z4ECI5MIQ<V_G?/U\R5G_G5VB@"G9Z7;6$
MLDD'F[I/O;Y6<?@#TI+;2K:TNGN(?.\Q\[M\K,/P!X%7:* *=MIEO:7SW<)F
M$SYSNE8KS['BK5MI]J-2-[F87#=096*?]\]*=10 _P#L2U.I?;LS^=G./-;;
M_P!\]*631K:74EOF,WG+C $K!>/]GI4L%UCY9.G8U;!STJ1F=<:):W5^MY(9
M_-7& LK!>/8<4MYHUM?7D=S,9Q)'C;LE95]>0.#6C10!FW^BVNI3QRW!G#(,
M#RY60?D*=J&CVVI-$UP9@8ON^7*R?GCK6A10!GZAI%OJ4<<=P9@(_N^7*4/X
MXI+W2+:_MXH)C,(XL;=DK*>F.2.M3:I.]KI=U/'C?'$S+GU K-M['4YK:*4Z
MQ(/,0-CREXR*:6EQV+UUI-O>64=K*9A$F,;)"K<>XYI)M'MI].2R<S>2F,$2
ML&X_VNM9VH1WVFVWGS:O.R[@H"0*22>G%-LA=WUL)X]9E12Q7;)"JG(.",4^
M72X6-(Z1;'3!89F\@=_-;=US][K7,_$/2%A^'%];VOF%8<2?.Q8X!YY-;*F^
ML-8L89KXW,5P7#*R 8P,CI6M>6L5[9S6TZAHID*.I[@TF@:/F7PW>PZ=XDTZ
M\N6*PP3AW(&<"M_6/%<&J6D<T<PM[JROS-'%''M2X0MD.<?Q#WK&\5>'+GPQ
MK4UG<(?*)+0R=G3M6/4$GI4OC+0GUZ.%6?\ L>:%VN/D_P"6K,&Z?4"JFD^+
M[9H]<:?4OL%Q>W2RQ2-;^:-@!&,?3%<!29HN!JV-NVH>*X(89//,MVN'"[=P
MW9SCM7T\@VJ!Z#%>-_"'PE+-J']O7D16"(8MMP^^QZL/85[**:!"T444QA11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 <)X_6T2^T][B"P5G#J;B
M[C9PH'\.%]?6NDT<HWA>$Q- R>0<&!"J$8/0'D5S_CR^GA-HUE<Q'R9<RPB=
M8V)X(SGMC/%;^CM,WA>)KB5)96A8LR-N'?N.M(#)^&'_ ")%M_UUE_\ 0S77
M5R/PP_Y$BV_ZZR_^AFNNI@%%%% !1110 4444 %%%% !1110 U^%)]*H:'>3
M:CI4=S=0^5*Q(*8(Q@XJ^QPI/H*H:'J3:MI4=VT7EER1M';!Q0!HT444 %%%
M% &)X;_YBG_7_+_2M:>411Y[GI63X<Z:I_U_R_TJU/)YDA]!P*: CSGD]311
M13$%%%% !1110 444A.* %HKSOQ?\3DTV=['15CGG7AYVY1#Z#U-><WOBG6K
M^0O<:G<DGLKE0/P%)R ^BJ,U\Z6GB?6;&0/;ZG<@CLSE@?P->A^$OB@+V=++
M75CAD?A+A1A6/^T.U)2 ](HI 0<8Y![TM4 4444 %%%% !1110 5+#<&+@\K
M_*HJ* --'#@%3D&G5F12M$V5_$5?BF65<CKZ4FADE%%%("AKG_(#O?\ KBW\
MJR1XA:V$5J+5F1$BC:4..&9<CBMO4K=[O3KB"/ >2-E!/3)%<V=+U$KE["(G
M,;$BXP,H,#M5QM;4J-NIGB6X*6WFW,\PD$4I$CY ;?VK9TK2+/5;62[O8_.F
MED?(R0(\'H!VK#DNDBGAA,5N3''E2+OC"-G!XZYJS!Y^KR-<6,:1/,N^2."\
MVY]R,<&M))V+9:LG<:W9VQD:6.VN98XW8Y)79TS[=*ZW%<UI&B7-G>6QF0"W
MBWR(H?)C8\$$_P 0/6NE%93M?0B1D^(/#6G>); VNHP!QU20?>0^H->3:S\&
MM7M96.DS17D/8.0CC^E>X45-B3YXC^%OBJ1]O]GJO^TTJ@5V'AKX-)#*MQX@
MG$I'(MX?N_B>]>KT4K!8BM[>*V@CAAC6..-0JHHP%%2T44P"BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** .+\8RR6&H6\[#1Q:R*P87B\L_
M8]*V]&S_ ,(K#NEAF)A8[X5VH>O0>E8WCI(97M8?LS274B.(W,ZQ+&!@DY;C
M/ P*TO#=Q;2^$85MI&8+ <J[AG!YZXH H_##_D2+;_KK+_Z&:ZZN1^&'_(D6
MW_767_T,UUU !1110 4444 %%%% !1110 4444 -?A2?2J.AZ@FJ:7'=QQ>4
MKDX3TP<5>?A#]*HZ'>6]_I<=Q:1>5"Q.$P!C!Q0!H4444 %%%% '/Z(^R'5<
M=3?RC^56ZS=';+ZFOI?R_P!*TJ:$%%%%, HHHH **** "N.^)/B)M$\/^3;M
MMNKP^6I[JO\ $:[&O(?C%(S:[81G[JVY(^I:D]@//>G>BO1? VCVM]X6\YK'
M3KB=K_RF:[)'[O:"0OOZ5%;Z'I6LX_LVVV0V.J$3%Q\S08W8;_ODBHL!Y_F@
MX->B:EHVEVD>I:K%:1&TOC;K8J>B;S\V/IBI=0L-+U36];T4:3;6@L;=I8;J
M $,I4 _-V(-%@L=#\,/$4FL:&UG<MNN++"[CU9.W^%=M7C?P@E9?$UQ&/NO;
M'=^!XKV2KCL 4444P"BBB@ HHHH **** "A6*'<IP:** +T%R),!N&_G4]95
M6(;LKQ)R/6E8!FMZHFC:3<7LB[_+'RIG&YCP!^)K'B\;V/\ 9EI<744RS7.]
M?(B7S"K)]X<>E:FLZ';>((((;MF-O'*)3&IXDQT!]JS;7P-I]G?BYMI)HU5Y
M'2$'Y4+KM;%(8DOB/0(GL@T2[+T*8I/)&WYNF3VJOIWB[3XQ<M=P):RQ-+@Q
MIPR(V.OK[4O_  KK3O-@?[3<_N5C !(YV'(/3BHM2\%BYELK6)<VD=XUY-,[
M_-R<E /0G%%V!9G\<636MXUF)#):J"YDC(4'(X/OS6C8>)+34-4ET^#S6GA'
M[QMGR XSC/XU0NO MG>WEW<SW5P7N4V$# "C(/8<].]6[7PK;VVOG5OM$SS!
M"BJ<!0,8[=?QH W!TI:0<"EH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@#C-=UBS?6C8:OX>N+N./+0S+#Y@(QVK:TRRT^
M#2)+C3K!;-9XR2GE[&Z=Q5'Q;IM]?FU-K ]U;Q[O,MTN#"22/E;</3TK2TRW
MNK7PU'#?R>9<I"1(V<\X/?O]: ,;X8?\B1;?]=9?_0S775R/PP_Y$BV_ZZR_
M^AFNNH **** "BBB@ HHHH **** "BBB@!K?=.>E4]&FL[C38Y-.0);$G:H&
M._/ZU<?&TYZ52T8V)TV/^S,?9<G;C..O/ZT 7Z*** "BBB@#E]&_UNJ_]?\
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M>_<FO4*J:9IMOI.G0V5F@2&%0H&.ON?<U;JTK %%%%, HHHH **** "BBB@
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M%% !1110 4444 %%%% !1110 4^'_7)]:93X?]<GUH TJ***D84444 %%%%
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MHHH **** "BBB@ HHHH **** "BBB@ J*Z_X])O]QOY5+45U_P >LW^XW\J
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MQPG_  J#2?\ G_U#_O[1_P *@TG_ )_]0_[^UWN[VH#9&1TH X+_ (5!I/\
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MRK%-)#;;%V%%)#')W X_K4&EPW$$=G%<G4!"H;=@L3YN[H3_ '<?A74/,D9
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/ **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>forms-1_008.jpg
<TEXT>
begin 644 forms-1_008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" #- I8# 2(  A$! Q$!_\0
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MSU%9UGK]IJ=M;W&G;KJ&=]FY"!Y;8SA@2"#P:O?:K?S_ "//B\[IY>\;ORH
M?^\]11^\]14#:E9([HUY;*Z,%93*H*D] 1G@FJ4_B?38K34+B*;[0-/!,Z0X
M+#'7&<9Q0!J?O/44?O/456L-3M=2AC>VF1F>-9/+W#>H(R,@'BK,DBQ1M)(P
M5%&6)["@ _>>HH_>>HJEH^M6>NZ<+VQD+1;F4AAAE(/(([5*FJ6$I01WUJQ<
MD*%F4[B.H'- %C]YZBC]YZBHXKRVGB:6&XADC0D,Z2 A<=<GM36O[1(#.UU
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M'/;R++#(H9'4Y# ]Z '?O/44H+CN*6B@!5DS142?>;ZT4 $?WVJ2HX_OM4E
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HI<'THP?2@!**
M,$44 %%%% ',^-/$]SX9@M'M8893.S*PESQ@#I@UR?\ PM75/^?&R_\ '_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%<SJ/C_2-+U">RN5NO.A;:VR,$9]CFJC%RV1,YQ@KR=CIJ*Y#
M_A9VA?W;W_OR/\:FL_B)HU]>PVL*W?F3.$7=$ ,GUYJO93[&:Q%)_:.IHHHK
M,V"LWQ&2/#6ID$@BVDY'TK2K-\2?\BSJ?_7K)_Z#51^)$S^%GA0GFQ_KI/\
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M>7#XD>\GJ:*#U-%>.?1D:?>;ZT4)]YOK10 1_?:I*CC^^U24 %%%% !1110
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M7_UQ_J:\0KV_P9_R)VE_]<?ZFL\7\*-<O^-^AMT445P'K!7B'C/_ )''4_\
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M!_,UX=7N/@__ )%#3/\ K@/YFL\7\*-<O^-^ALT445P'K!7A_C'_ )&_5/\
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MP'K!7A_C'_D;]4_Z[G^0KW"O#_&/_(WZI_UW/\A75A/B9P9A\"]3%K4\,_\
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M[?7B'C/_ )''4_\ KM_05U83XF<&8?PUZF)6GX;_ .1ETW_KY3^=9E:?AO\
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MN",=12[AZBOH$V%BN,VMJ,],QKS^E!L+$,%-K:@GH#&N3^E=GUM=CS?[.?\
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M=ST.5P /8#'UK;P?2D!!S@@X.#@]#0!':QO%:0QRE2Z(%8J.,@5+1@^E!."
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M 4444 %%%% !1110 4444 %9<FF79F9X[S:!.9(QR=JL.0?4^G85J44 9/\
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? !1110 4444 %%%% !1110!&GWF^M%"?>;ZT4 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>forms-1_009.jpg
<TEXT>
begin 644 forms-1_009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" #Z G0# 2(  A$! Q$!_\0
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MS_A)=7_Y_I/^^5_PJO[/J=T2\WI+>+_#_,],HKS/_A)=7_Y_I/\ OE?\*/\
MA)=7_P"?Z3_OE?\ "C^SZG=!_;%'^5_A_F>F45YG_P )+J__ #_2?]\K_A1_
MPDNK_P#/])_WRO\ A1_9]3N@_MBC_*_P_P STRBO,_\ A)=7_P"?Z3_OE?\
M"C_A)=7_ .?Z3_OE?\*/[/J=T']L4?Y7^'^9Z917F?\ PDNK_P#/])_WRO\
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MF58D"X!C!ZJ#2V5[XIU"V6XMC&T3$X)5!FNKZI+E4VTDS@>84^=TU%MKLO\
M@G9T5R?_ !5__3'_ ,<K(E\5:W!*\4LZJZ,593$O!%..#E/X9)_,4\QA3^.$
ME\O^">AT5YS_ ,)=K'_/PG_?I:/^$NUC_GX3_OTM7_9]7NC/^UZ'9_A_F>C4
M5YS_ ,)=K'_/PG_?I:/^$NUC_GX3_OTM']GU>Z#^UZ'9_A_F>C45YS_PEVL?
M\_"?]^EH_P"$NUC_ )^$_P"_2T?V?5[H/[7H=G^'^9Z-17G/_"7:Q_S\)_WZ
M6C_A+M8_Y^$_[]+1_9]7N@_M>AV?X?YGHU%><_\ "7:Q_P _"?\ ?I:/^$NU
MC_GX3_OTM']GU>Z#^UZ'9_A_F>C45YS_ ,)=K'_/PG_?I:/^$NUC_GX3_OTM
M']GU>Z#^UZ'9_A_F>C45YS_PEVL?\_"?]^EKI_">J76J6MP]Y('9) JX4#C'
MM6=7"3I1YI6-:&8TJ\U"*=_Z\S?HHHKE.\**** $S6;XB_Y%Z^_ZY&K^ZL[Q
M"V?#]]_UR-:4OCCZHRK_ ,*7H_R.8\/I;:=%!?7!B,TTH5!(?N1\@N/?(KH(
MIIH-9G5=A@GNA&PVL6!\H'.>@%4M/G#^%+6-E/V5T>&>5.6B.>#C'3UJ[IS7
M,]W)>VC(UK++Y;QMD$A1CS,^O'3TQ796?,Y2?FO\CS</%1C",?)_AKZ_UV(K
M[0'O-'>VG"--;#%K,OWF4#@-_+]:X"O8*\MUFP?3=5G@?D;MR'U4\BM<#5<K
MQ9SYKAU!1G%>7^11HHK2TE$>#4RZ*Q2S9ER,X.1R*[Y2Y5<\B$>>5C-HK9_L
M&/?Y7]H1B?R1.4,9P$QDY/J!VJ!]*C#V[)>QFVG1G$SJ4V[>HQZ^@[U*JP9H
M\/473\49M%:G]B^:;4VER)8KAF7>Z%-FT9)(/;'-20:3$WV>XL[Z.93=) -T
M)&&/<@]1_.AU8@L/4;V_+^F8]%:R:1$\<4MQ?)";B9XT7RB<L&QVZ"HQI B2
M1KZZ2V"S- OR%]S+UZ= /6CVL0]A/M^*_I&;15G4;,Z??S6S.',1 W 8!X!_
MK6O]CB.C_8?+7[8+?[;OQ\W7[N?]WG%$JB23[A&C*3E'9K\^QS]%:,Z(/#MG
M(%7>T\@+8Y(P.]9U5&7,9SCRNWI^(Y/OK]17KN:\B7[Z_45ZUNKSLQ^S\_T/
M:R;[?R_4?FC-,W4;J\P]P?FBF;J4-0 ^DI,TFZ@!V:,TS=1NH ?FC-,W4!N1
M0!Y3=_\ '[<?]=7_ /0C4-37?_'[<?\ 75_YFI=,LCJ.I06HZ2-\WLO4_I7T
METHW9\5RN4^5;MG4Z?&FB^#)KF9 9+A2VUN^[A1^7-<77HVK6HO_ /0)% B.
MT1@+T_VL]L>G^->>SPO;7$D,@P\;%6^HKDPDU+F;W>IWYC3<.2*^%*WSZD=%
M7-(B2;6+..50Z/*H92."*T9;"W'B0$(/L)3[3MQQL R5_,8KIE4479]KG'"B
MYQYEWL85%;-_I:'4K]_-AL[2&;RPS@XR1G: !5?^QI$DG^T3PPPPA29B25;=
MRNW')R*%5BU<)4)IVM_7](SJ*TM<MH[2>VCB$?\ QZHS-'T<\Y;\:LWUU%IX
MLXTT^RD5K6.1R\668D<\YI>TNE9;C]C9R4G:QB45L7>CH+V=HI4M[-427?+D
M[0XR%XY)ZU7ETB6))W$L;K%$LRE<XDC)QN'T[YIJK%]12H3C?0SZ*TAILL-E
M*Y\EBT"2E2I+J&?"X]"?Y&B?1GA611<P27$6/,@0G<N>.O0GD=*/:1[B]C.V
MW]?TC-HK1N-'>".?;<P2RVXS-$F=R#H><8.#UQ6=51DI;$3A*#M(*])\+?\
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MHKM:35F>9&3B[HUGU6%M0DG"2;6LS;@8&=VS;GZ9IUEJUO;PV22QR$P)*I<
M$H6.0R@]2/>L>BLW2BU8U6(FG?\ K=/]#I8=76[N+*WA-Q<2+(X8W+!?,5EP
M0.P/H*"+?1].MSY5VG^G)+MG4*[*HYPOH.F?6N;I6=G.79F/JQS4>P738T6+
M=KM:_P##?Y&A-J,4D5DH5\P3R2MGN&8$8_*M'"ZU;R,UM=20B[D>/[. S#=R
M5<=A[_6N<IRNR9VLRYZX.,U4J2^SN1&N[OFU3_0T=9>"3Q'<,Q)@$JAMG/
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M)Y[81&"5I  SJP.X@#IUX'M6+14^P@BGBJC6O]:W]#6?5D:;4I0"#,(Q N.
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MU.DL-:L;3[,4DDAC2,+) ENO+8P6+]2,\XKFZ**(4U!MKJ*I6E423Z!7:^!
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ME_7R(]C@[7Y';7KT6[W*TO@=((FDFU-8XUY+-'@#\<TX> ]R@KJ((/((B_\
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ME=Q_%_YG)_\ "!'_ *"'_D'_ .O1_P ($?\ H(?^0?\ Z]=C11]<K?S?D/\
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M4 %17'_'N_TJ6HKC_CW?Z4 4!TJY:?Z@?4U3'2KEI_J!]30!/2TE+0 4444
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M'X5I*H1 JC"J, >@HKU8U+.(82A.BFI;?UY(=1117.=@4444 %%%% !1110
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M;)'!Y<$$#HP,FXH6.<9ZFJ<6CZA!8V1$ >6WO6F,?F 94YQ@]*<84>_X^O\
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M>IC5H1JR3ELK_B<G?100:CJ0U"U>7S8E6T(B+C 7&U<=#FJEY;2VZVK7:DW
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ML%AG&<5FR^'+6._EM[N^E%O.JF&!2"6(RI<_+V,@[XZ9Z5.?!^G69GN5FFC
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MI'23=JLIFD4QF3R4_P!68]FW'K@ Y]?;B@#2G\2Z5;SK"UXC2F5(=B?,0S'
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MS"+E[81O,L[ DA)E"YQT^=.?;VI)/$.KV*L'>9[AKJ1C"UMD*N4Q'NST 8]
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M>*-1@L(7@GDN9B2Q(L&16(VY3)/;)Z#/'L: -!]$U0>,!JD30&(N%9F?K#M
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M>.] %"U\9V-W?VUHL4RO.%!+;?D9@2%(SGMR1D<CFD7Q#*?&)TTM"MGM**[
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M.WJO'/-=3UK,D\-Z5+&(WM 5"A?OMR!G@G/(^8YSUSS6F    , =J %HHHH
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MAC5A%$K"/E..O[O)X'7VY .IFO[>W>)))5#2R>4N.?FVEL'TX4]:F+JH)9E
M'4D]*Y%O",B7%U+.83:/*\K0Q*6=P5E!P<9S^\&!D\YP>U2OI-\WA*WBGACN
M-0FN89[E9!\K-YBD[AZ  #OT[T =1YB$ [UP?>D$\1Z2(>-W##ITS7(GP=?
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M,L)DC9XDBPK[?,YVX Y\P=<].IJ;2O"=SI^I6,TC6<BVQW--M/G?ZGR]@/\
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M*6IMI@#,\)E9E5=RG'!)Y/MUJJOC>*2-S%83221LVY$DC(VA-^=V<'C/ [T
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M30Y5B=^>=F200O.1VX(-.OWU]]+N;:X?4'22!L216JL[R-"I"$!>%W%QG'&
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MRV0 .>-WY4 7=)\/:I!J5C<7:IM@<YS)N*KF;:/P$BCK_*H]3\.ZO<ZG<S0
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MW/E3H"Y^;;Y7/"9VYZ<8XX- $DOA"\:\B:.:S2&.Z\\;8L/_ *\R]<9Y!QU
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M;[N2.O3I6;<MKL\VHV]K<F1K4(Q,38W&0J70<Y!55?'.?G6H-OB<260$=YE
M-S^8-I0E^&7/W@"O)R?IS0!//X)FEMVMUDLT0Q8\P1'?GR/*V?\ 7/\ BQ^G
M>M/6="M]8V0PM: 06T\*1E0?+9P K #I@K4=S;:C%X?TV/=?RNNTWGDRCSVR
MAZ,2!]\C..WM6=;:5K!O@CBZMK>:9FF:*50V"7/WA[[>E "_\(A=?:KR2"]M
MY&9V/[Q0Q;=(LA#C'! & 3NQP<"M'P[X=.AAOM,T+S21K"CJN&&"[8!/^]T]
MJSH(=?#0O>1WK A"5MY$1C+Y<7+G^YD29Z\]NE&F6VMSZU!+?6]RMNDZRXFD
M#[&V3*V#GIRG0 >@ZT .B\&^2(GO7L/)MT"%1%A9 L<BB1\\;R9 3].M;VD:
M<=(M(XY[V69F2./$CC8K!<80=1GTYKGY]*U476J_9S>JK&XEC'F@I(["/9@$
M],;^.GZ4V*UURZUC==6UR+5;J*0++('"E9&R0<]-I'0 ?4T =K1110 4444
M<1!XON;>U_?)!/Y18'S),2N3O(95Q]T!<$^Q].9[CQC>VT<R2V]BD\"-,Q>=
ME1U"(P53C._Y_P!/?C2/B#0 2[/$#'&"283E5<,<=/\ 8;(_/K574[O0M5@@
M:[^TK%YOENJQ.H5OE7;(,<=5'.#@\<9H @M/%%S'K$D-PT M#,L0,CX9,R3@
ML3TQ^[  [9%4KKQC=W5M!<1&""+:2\238E?_ $<R9''W,D8/M6W;ZS9:AHE]
M>K9Q2/:QR&6/;E=REFV;L8SD D=LBFWFOZ;;C/V(O<HL:[#;D%D+JC;#M^8
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MT@>-G &1]W@ GU!]*NCQ)>77A6XOH?LT5W#,D;!LE%RR9S_P%NH)'?-=&;6
MNCF"(N@VJVP94>@/:D6U@2W,"01+"<YC" +SUXZ4 <C;>*[VUMC'=FV:20L8
M)&9CN'FNN" .N!QC\35O2?%%S>66I:A-'$T$-K%<Q01GYQNCW$$^F<X-=&]G
M;R)L>WB9.FTH".N?Y\TY((HSF.)%) 7*J!P.@_4T <I+XQNHG>,IISM"KR.Z
MW!V2A1&VV,XY;#XQZ@>M)'XSN[FZ>"&RC5GF$47FL5V_O-GS\=>_'TKH_P"R
M++[3!.+:,- K+&H4!5W%22!TSE1S5@6L"R-((8P[D,S!!EB.A)H Y^Z\23_V
M#97,26T,]WO4M-*5BC*JQ/S8[[>*S[;QI<Q6,)DCMY28UCRTV) ^Q29'&,!#
MNSGTP>_'8/;0R0^4\,;1YSL901^5(+6 ,S""+<R[&.P9*^GT]J ,71]?NM3U
M/[*8K8)$CF62.0L'(<J-G'3CO[BLZR\27MK(R71MYB;@E@92'97F:-5B7'.W
M;DUUL4$4( BB1 HV@*H&!Z?2D-M"71S#'OCSL;:,KGK@]LT 5=$O)]1T>UO+
ME(D>XC$H6)B0 PR!D]^:OTBJJ*%50J@8  P *6@ J*X_X]W^E2U%<?\ 'N_T
MH H#I5RT_P!0/J:ICI5RT_U ^IH GI:2EH **** "BBB@ HHHH J6VEVEI=2
MW,$(6:7[S;B>^2!D\#/.!5NBB@ J*VMHK2!8;= D:DD*.V3D_J:EHH ****
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2444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>forms-1_010.jpg
<TEXT>
begin 644 forms-1_010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" $A G # 2(  A$! Q$!_\0
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M1_\ G^C_ "/^%>:T4?V?3[L/[8K?RK\?\STK_A*-'_Y_H_R/^%'_  E&C_\
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M5LR#*ZL,!<9S_P#6]JUH)DN8(YHCE)%#*?8T2A.*NQPJ4YMJ/0/L\7_/)/\
MOD4?9XO^>2?]\BL*=+R_\1W=K%J$]M'%"CJ(P",GZTEEKTL%DT5VIN+Q+EK5
M0F%\PCG)SP.*OV,K:.^WXF/UF%[25EKKZ&]]GB_YY)_WR*/L\7_/)/\ OD5E
M_P#"11&U5UMY#<M/]G%N",[_ $STQCO23>(&@MHG>PN%EDG^S^4< [O8]"/>
MI]E4+^L4>_X?U]QJ_9XO^>2?]\BC[/%_SR3_ +Y%9-QXB^S.Z-92%H$#W 5U
M/E ]O]HXYXI^H:_]A3S5M)9;8(KF;<J@@_W0>2:?LJFGF#Q%%)N^WD:?V>+_
M )Y)_P!\BC[/%_SR3_OD5ES>( MVT%M:2W!1%=]K*#AAD8!.3QZ47OB%+2XE
MC6VEE6! \[ @>6#[$\G'84O95&#KT5=WV\C4^SQ?\\D_[Y%'V>+_ )Y)_P!\
MBJ.L7\EMH<UY9@,WE[E;C@$?>YZ_2J$>L/$\3W"3B1; SM'YBE&P>O3J:<:4
MY*Z"=>G"7*S>6&-3E8T!]0*?6$GB5Y'CC73;CS)HO-A7<OSKW/7BI/\ A(XY
M8+1K:VDFFN4+K%N"[0.#DGCK0Z-3J@6)H]'^#_KJC9HJM87T6HV4=S#D(XZ-
MU!'!!JS6333LS>,E))K8****0SD'TO5-4CU*<>5%'=OCRYHSYFU/NX]*E5IV
MN+&_OK">5/LAA=!$69),\Y7W'>NJHKI^LMZ6_K8XE@DM5)W_ .#?_/[SEV@-
MM>6=U)I<OV7[*T0MT7S#$Q.<$>X[U!=6<Z7%M.MI-;6YM3$(HX1.8CG)4@],
MCO77U#<7<%J8A/($,KB-,_Q,>U$<0[Z(4L)&SO+\O+^K','2[E7M8;=9R!IT
ML:R2)@@D\ ]@>U1V-A*T98I=K+#9O%Y9M0B\K]W(^\<]*[&BCZS*UK!]1A>]
M_P"M/\CEW@N+3P_I20V?(*F9O(\QXCCJ%]<U3CL[A-+8O:W#&/4UF*F+YRG<
MX']*[2H;>[ANQ(8) _EN8WQV8=136(=M@E@XMI<W2WX')3Z?/+>WD<RW:)<S
MB6-HK8/QP5^8\KCIBMKQ/;R7.C"*)'D8RQY"#)QNY-;-%0Z[<HRML7'"1491
MO\7]?J8K:#;65M=S0^?-</ Z!I7+MC'05C2PWHLK6W^R2J#8! Z6X=V;NA)^
MZ*[.BG'$26^H5,'"7PZ>ARMA;RP7NCRS6LQ06?DL?+)VMD?>]/QJ&WL+B/2=
M-DDM)'2WN7>:'9\Q&3@[>^*["HY)XHGC21U5I#M0$\L?:G]8;Z?UK_F1]3BE
MK+^M/\CD;NPGNH[N:.SECM[B\A*0E,' X9BO;-7[RP,FN7S_ &8M'_9Y6,[.
M-V3P/>NCHI?6'V_K3_(I8./?^M?\SEM,L98+S0F%LZ!+9Q*=F,$C^+WS74T4
M5G4J.H[O^M3:C15)-+^M$OT"BBBLS8*KWO\ J/Q%6*KWO^H_$4 43TK2C_U:
M_05FGI6E'_JU^@H DHHHH *Q6T1+GQ!<W5Y;Q2V[Q(L>\ X8=>*VJ*N$W"]C
M.I3C4MS=-3*N=.<ZSIL\$:+;VRR*P'&W(P,"J$^A7DLM_*GEJ[7<=Q &/#;1
MT/I7245<:TH[?UK<SGA83O?O?\+',WVCZAJ4=_<2Q113S0I#'"),C 8$DM6A
M/I\[ZMIDZJOE6\;K(<\@E<#%:U%#KR>G];6$L+!.^O3\'<Y:UT74(8=/B>&/
M%G<M)N$GWE.3GVZU)8:;J/GW;W]JAFO 4><3 ^6A&  N/ZUO7EU'8VDMS-GR
MXEW-M&3BJ%IXCL[NZCM]EQ$\H_=^=$5#_0UI[6I--J/];F+H4:<HQ<M>VGIV
M^13T?19K6YMS=6HS;J0LWVIF!.,<)T&15O5=/NVO[?4=/,;3PJ4:.0X#J??L
M:UZ@O+N&QM7N+AML:#DXS6?MIRGS=3;ZO3A3<;V6]_0Q#I.H7GV^[O!$MS-;
M-;PPHV0H/J?K3FTB[,^FMM7$%H\,GS=&*X'ZUO@Y /K2T_;R_KTL+ZI#S_IW
M.9L](U)K;3+.ZBACALY!*TBR9+8SA<8]^M"Z)?FRCTIEA^R)/YGV@/\ ,5W;
ML;<=:Z:BF\1*_P#6_<2P=-*UWV^6FGX>IRESHNISW?F2JLQ2Z$JRM.?]6#]T
M)T%75T6>6PUBVE*H;R=WC8'/!QC/Y5O44GB)M#6#IIMZZG.)I^IW%]:S7,$,
M:PVSP_+)NR2,9Z=#2Z7H]W:W.E/*J!;:W>.3#9P2>*Z*BAUY-6M_6O\ F"PD
M$^:[O_PW^2.0-I-HT.G2SO D\-Q*5CDDVJZM_M= ?K6CX69Y5U&=MA\V[9@R
M'*G@=#W%;CQI(NV159?1AD4JJJ*%50JCH ,"G.OSQ::U?^=R:>%]G-23T73Y
M6%HHHKG.P2JM[T3ZU:JK>]$^M %5ONUJ+]T?2LMONUJ+]T?2@!:9*GF1.FYD
MW*1N4X(]Q3Z* W.>.@ZA<R6Z7U]%+!!('#B+$K8Z M4\.DWUI<2):WD<=I).
M9V_=Y<9Y*CM@UM45LZ\WI^AS+"TUJKW]6<RWA>Y-SYGGV[8N1.)&0^8PSG:6
M]*EF\-/-'+F2%G-XUS&'4E"",;6%=#13^LU.XOJ5'70HZ58FQMV5H[9'9LD6
M\>Q?;ZUE77AV\E%W#%<PBWN+@7&&0[@<@XSZ<5T=4]3U.#2K833G.Y@JJ",D
MFE"I/GO'=CJT:7L[3T2,,65]=:IK45M*D,<S(CF2,G(*]5/K6Y9VL]FR0B1#
M9QQ*B+@[\CN34S7=NFS=/$OF?<RX&[Z>M2.ZQH7=@JJ,DL< 43J2DK6_K8=*
MC"#;OK_FVS&N=+U(:Q/>V%Q;QB:-4(E0L1BH7\+YL8E\Y);I)C.[2IE)&/4$
M>E;7VVVV,_VB'8IPS;Q@'WIXGB9D42H6<94!AEAZCUIJM45K$O#T97OK?S[O
M_,QCH,HMH&B-I!=03><GDQ%8SQC!&<GCO4DFDWUS]E>ZNHY)(;H3D!,*%Q]U
M?_KUJ-=0*CNT\05#M8EQA3Z'WH:YA159IHPK_=)88;Z4O:U!_5Z7],QK_P /
M-/J<MW"+-_. #+<Q%]I'&5Y]*AU#PQ-=S3F.6V"2Q+&OF1DF' QA.> :WQ=0
M&-9!/$48[5;>,$^@-+Y\67'F)F/[XW#Y?KZ4U7J1MY$RPM"5[]==S U#PY<W
MNT&6V(\I4#/&=T1 P2A&#^=.N?#;M>-/$;6;S$57^U1%R"HQN'/<5O131SIO
MAD21?[R,"*?1]8J+0?U2C+6VY3O; 76D2V*%8P\7E@A>%X]/2LQM!NYOFEF@
MW_86M?E!QDG@_E6_141JRBK(TGAX3=V8\.C2QWEE,94(M[3[.PP>3QR/:J0\
M+2+:V0W6TLULKHRS(6C<%B>G7(S72T52KS77^M?\R'A*3W7]:?Y(K:?:_8[-
M(=L*L.6$*;5S["K-%%9-MN[.B,5%)(****0PHHHH 9(Q2)V49(!('K7&*[W,
M&C7<][)--/> O$S#:IR>@[8_K7;52&CZ>)O.%G")-X?<$&=P[UO1JJ%[G+B*
M$JK5G_5U_E^)SUG>:I=70N(S,2+HQNC3((P@."NTG.<=ZDCNKPZBNC&>;S4N
MS(TF[YC!C<!G\<5OG2[(W?VHVL)GSGS-@SGU^M2BU@%T;D1)YY789,<X]*MU
MX/:/_#F4<+42UEU_#K]YR]E>ZI=W0N8S,3]J*.C3((P@."H0G.<=Z9%<2Q*\
M$<S01W.JR1R3*<%1UP#VS73'2[(W?VHVL/GYSYFP9SZ_6G'3K-H986MHC'*Y
M=U*\,Q[_ %I_6(=B5A*EOBU_K[K]3F+V^NK6WU&WBOI62VN(0DY;+ -]Y2>^
M*74KNYL/[1M[>^FF1;=)ED9\M&Q<# (]16W?Z'#<:8+*T6.W02+)@)P<')JP
MNDV*02P+:0K%*<NH7AOK5*O323M_6A+PM9MJ]M-[OST_%?<<]*MVEY?6XU*\
MV168N =XSOQZXZ>U-EU"_O9;:)9)P38K-^YD6/+GJQ)Z@>E=.;&V:220PH7D
MC\MSC[R^GTJ.;2;">***6TA=(AM0%?NCT%2J\.J+EA*FO++\7W,3??W>I6EM
M<W4UNS6)>40N.6#=01Q^54HGDU ^'YKBXF\QFD1F#X^[GGZGH?6NM6RMEE25
M84#HGEJ0,87T'M41TFQ:".$VL1BB;<B[>%/J*%B(KI_6O^:"6$F^M_7U7^3^
M\N4445R'H!1110 4444 %5[W_4?B*L57O?\ 4?B* *)Z5I1_ZM?H*S3TK2C_
M -6OT% $E%%% !1110 4444 %%%% &9XC_Y%V^_ZY&J5EI%Q+]BO+V^:=+=
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M:H7/@J2W@9-)NG22X#)/-(X4[2JJ<!4P?N@]CGOR:FUK0-4U#7TNK66"")
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MD0>'5+\7%U>B6-0)B<H8T1P">3@(#[9J.W\'3QS1/(UB[( V[R/XQ"8Q\O3
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M;[0T?D7.P3BV$WE_(S[@I .<\$\\=CC.*A7Q7:2)*\=O=.D04LVU0,DD 9+
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MR[-2LOEOO<CSOWPC_=CGD Y(R>H]<U+IGB^^U2Z@@CM8(VFF49<G]VI61BI
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MS:_C=)PNT[Q@L < G\*V:\J2L['H)W5PHHHI#"BBB@ HHHH **** .?\9_\
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M /7J[Y=IZK_WU1Y=IZK_ -]4.38XTXQ=T4]L/]]_^^?_ *]&V'^^_P#WS_\
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M1=6(_#_[&EL;RVBU2WN)KNV5$E5VVD\ 'L,5;'PUOQ_R_6O_ 'RU.'PVO_\
MG^MO^^6K3V>$_G_K[C'DK+[)HS7_ (;N)"\FJ$DC;PK@8^E,-SX98D_VI)SU
MQYE4A\.+_P#Y_;;_ +Y:E'PYOA_R^VW_ 'RU3['"?SO^OD4YXG^3^OO+J3^&
MD# :I(=PP<^8>*DAO/#L#[X]4?.,?,'8?K5 ?#N^_P"?VV_[Y:E'P\OO^?RV
M_P"^6H]EA/YW_7R)=3%_\^U_7S-=M8T-CG^TQ_W[;_"J\MSX>GE\R34V+8 P
M%< X]JI#X?7W_/Y;_P#?+4H\ 7O_ #^6_P#WRU'LL+_._P"OD0ZN,_Y]K^OF
M6,^'#M_XFDHVC:,%QQ_DU/;W6@VV[R]4<[CD[P[?EFJ7_" WO_/Y;_\ ?+4H
M\!WO_/W;_P#?+4O987^=_P!?(EUL=_S[7]?,U$U71D)_XF0.?^F;?X4_^V-'
M_P"@@/\ OVW^%90\"7@_Y>[?_OEJ4>!KS_G[@_(T>RPO\[_KY$_6,P6U)?U\
MS5_M?1_^@@/^_;?X4?VMI'_00'_?L_X5F#P/=_\ /U!^1I1X)N_^?J#\C1[+
M"_SO^OD2\3F7_/I?U\S3_M323_R_C_OV?\*7^T])_P"?\?\ ?L_X5FCP7=_\
M_4'Y&G#P9=?\_,/Y&E[+"_SO^OD2\5F?_/I?U\S1_M+2O^?X?]\'_"C^T=+_
M .?X?]\&L\>#KK_GYA_(TX>#[G_GYA_(T>RPW\_]?<3];S7_ )\K^OF;VFWM
MI/NBM9Q*R_,?E(XJ_6+HFBS:7/(\DL;ADV@*#ZUM5QU5!2M!W1Z^#G6G24J\
M;2[?U<*KWO\ J/Q%6*KWG^H_$5F=12/2M&/_ %:_05G$<5I1_P"K7Z"@!]%%
M% "44M% "44M% "5C>+[2ZOO"U_;V/,[Q\#U&>1^6:VJ*<79W%)<R:,SP[91
MZ=X?L;6':R1PK\RKM!/4G'N<UI4M%#=W<$K*PE%+12&)12T4 )2<Y.<8[4ZB
M@!**6B@!*3:-V[ W8QG'.*=10!7N+.*Z>)I@6$3;U7)VD]B1WQVS4]+10 44
M44 )56]Z)]:M55O/NI]: *K?=K47[H^E9C=*TQT% "T444 %%%% !1110 44
M44 %%%% &?J&@Z;JLRRWUG'/(B[59L\"JG_"':#_ - N#\C_ (UMT52G);,7
M*GT,_3]"TW2I6EL+..!W7:S+GD5H444FV]P22V"BBBD,**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *@N_]3^(HHH IGI6A'_JU^@HHH ?1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% "56N_NI]:** *QZ5I#H*** %H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
$B@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>forms-1_011.jpg
<TEXT>
begin 644 forms-1_011.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" $8 0L# 2(  A$! Q$!_\0
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MY?HJA]KO_P#H&_\ D=:/M=__ - W_P CK18+E^BJ'VN__P"@;_Y'6C[7?_\
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MR"*L?VUIIM/M7V^V\C?Y?F>:,;_[N?7VH NT5GS:_I-NL;3:G9QK*ADC+3J
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M/<"9LG>K,G"D#')P._-065SJFF6-_%I=K/&\NH7LL8:U8J1UCY(X#=N.?44
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MG_(*NO\ KDW\JJ/Q(3V+2_='TKG+N.0?$&QFCAN/+^Q2QR2B-S&&+*5!/3.
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MP]X)LB1I(XTW#&,815'3VJ7[;<_] VY_[[B_^*IDVI300O+)IUR$12S'=&<
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M_H&W/_?<7_Q5'VVY_P"@;<_]]Q?_ !5%@+M%4OMMS_T#;G_ON+_XJC[;<_\
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M+_A.K-XI)8+.[DCBLQ?.<*N(]Q4\$]05;CVXH Z>BFHP=%9>C#(IU !1110
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M_P#@,W_Q= %F*)((DBC4*B *H'84^J?E:C_S]6O_ (#-_P#%T>5J/_/U:_\
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(H **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>ex3-2_001.jpg
<TEXT>
begin 644 ex3-2_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !. +\# 2(  A$! Q$!_\0
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M*XY''(JS\0M3O=.\7VLMK<RQ^7;HX4.=I.YNHJOI/C'P9!JUJVG^ M3M+II
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LGVHQ2USRFY/4VC%1V%HHHI%!1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>ex14-1_001.jpg
<TEXT>
begin 644 ex14-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" !7 .@# 2(  A$! Q$!_\0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
?%%%% !1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>ex23-1_001.jpg
<TEXT>
begin 644 ex23-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  B *,# 2(  A$! Q$!_\0
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M6\L9&=$F4$ E6*L.>>H->8S1?V+X-\=^)GTM?#%OJ=E'#%9,H0J51H_-=5&
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;J** &_Q4M%% "?Q4OI110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>38
<FILENAME>onmd-20231231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWaCLWbP9z5Z8WekhvWB0bXnqDywld635pSgEciGG0eoE -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ONMD="http://onemednet.com/20231231" elementFormDefault="qualified" targetNamespace="http://onemednet.com/20231231">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://onemednet.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://onemednet.com/role/BalanceSheets" id="BalanceSheets">
          <link:definition>00000002 - Statement - Consolidated Balance Sheets</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://onemednet.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
          <link:definition>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://onemednet.com/role/StatementsOfOperations" id="StatementsOfOperations">
          <link:definition>00000004 - Statement - Consolidated Statements of Operations</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://onemednet.com/role/StatementsOfStockholdersEquityDeficit" id="StatementsOfStockholdersEquityDeficit">
          <link:definition>00000005 - Statement - Consolidated Statements of Stockholders Equity (Deficit)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://onemednet.com/role/StatementsOfStockholdersEquityDeficitParenthetical" id="StatementsOfStockholdersEquityDeficitParenthetical">
          <link:definition>00000006 - Statement - Consolidated Statements of Stockholders Equity (Deficit) (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://onemednet.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
          <link:definition>00000007 - Statement - Consolidated Statements of Cash Flows</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://onemednet.com/role/OrganizationAndOperations" id="OrganizationAndOperations">
          <link:definition>00000008 - Disclosure - Organization and Operations</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://onemednet.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
          <link:definition>00000009 - Disclosure - Summary of Significant Accounting Policies</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://onemednet.com/role/BusinessCombination" id="BusinessCombination">
          <link:definition>00000010 - Disclosure - Business Combination</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://onemednet.com/role/GoingConcern" id="GoingConcern">
          <link:definition>00000011 - Disclosure - Going Concern</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://onemednet.com/role/PropertyAndEquipment" id="PropertyAndEquipment">
          <link:definition>00000012 - Disclosure - Property and Equipment</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://onemednet.com/role/IncomeTaxes" id="IncomeTaxes">
          <link:definition>00000013 - Disclosure - Income Taxes</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://onemednet.com/role/ConvertiblePromissoryNotesHeldByRelatedParty" id="ConvertiblePromissoryNotesHeldByRelatedParty">
          <link:definition>00000014 - Disclosure - Convertible Promissory Notes held by Related Party</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://onemednet.com/role/CanadianEmergencyBusinessLoanActCeba" id="CanadianEmergencyBusinessLoanActCeba">
          <link:definition>00000015 - Disclosure - Canadian Emergency Business Loan Act (CEBA)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://onemednet.com/role/ShareholdersEquity" id="ShareholdersEquity">
          <link:definition>00000016 - Disclosure - Shareholders&#8217; Equity</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://onemednet.com/role/StockOptions" id="StockOptions">
          <link:definition>00000017 - Disclosure - Stock Options</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://onemednet.com/role/StockWarrants" id="StockWarrants">
          <link:definition>00000018 - Disclosure - Stock Warrants</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://onemednet.com/role/FairValueMeasures" id="FairValueMeasures">
          <link:definition>00000019 - Disclosure - Fair Value Measures</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://onemednet.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
          <link:definition>00000020 - Disclosure - Related Party Transactions</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://onemednet.com/role/CommitmentsContingenciesAndConcentrationsOperatingLease" id="CommitmentsContingenciesAndConcentrationsOperatingLease">
          <link:definition>00000021 - Disclosure - Commitments, Contingencies, and Concentrations Operating lease</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://onemednet.com/role/SubsequentEvents" id="SubsequentEvents">
          <link:definition>00000022 - Disclosure - Subsequent Events</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
          <link:definition>00000023 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
          <link:definition>00000024 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://onemednet.com/role/PropertyAndEquipmentTables" id="PropertyAndEquipmentTables">
          <link:definition>00000025 - Disclosure - Property and Equipment (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://onemednet.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
          <link:definition>00000026 - Disclosure - Income Taxes (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://onemednet.com/role/ShareholdersEquityTables" id="ShareholdersEquityTables">
          <link:definition>00000027 - Disclosure - Shareholders&#8217; Equity (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://onemednet.com/role/StockOptionsTables" id="StockOptionsTables">
          <link:definition>00000028 - Disclosure - Stock Options (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://onemednet.com/role/FairValueMeasuresTables" id="FairValueMeasuresTables">
          <link:definition>00000029 - Disclosure - Fair Value Measures (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://onemednet.com/role/OrganizationAndOperationsDetailsNarrative" id="OrganizationAndOperationsDetailsNarrative">
          <link:definition>00000030 - Disclosure - Organization and Operations (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://onemednet.com/role/ScheduleOfAggregatePercentageRevenueAndAccountsReceivableDetails" id="ScheduleOfAggregatePercentageRevenueAndAccountsReceivableDetails">
          <link:definition>00000031 - Disclosure - Schedule Of Aggregate Percentage Revenue and Accounts Receivable (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" id="SummaryOfSignificantAccountingPoliciesDetailsNarrative">
          <link:definition>00000032 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://onemednet.com/role/GoingConcernDetailsNarrative" id="GoingConcernDetailsNarrative">
          <link:definition>00000033 - Disclosure - Going Concern (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://onemednet.com/role/ScheduleOfPropertyAndEquipmentDetails" id="ScheduleOfPropertyAndEquipmentDetails">
          <link:definition>00000034 - Disclosure - Schedule of Property And Equipment (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://onemednet.com/role/PropertyAndEquipmentDetailsNarrative" id="PropertyAndEquipmentDetailsNarrative">
          <link:definition>00000035 - Disclosure - Property and Equipment (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://onemednet.com/role/ScheduleOfDeferredIncomeTaxesDetails" id="ScheduleOfDeferredIncomeTaxesDetails">
          <link:definition>00000036 - Disclosure - Schedule of Deferred Income Taxes (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://onemednet.com/role/IncomeTaxesDetailsNarrative" id="IncomeTaxesDetailsNarrative">
          <link:definition>00000037 - Disclosure - Income Taxes (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://onemednet.com/role/ConvertiblePromissoryNotesHeldByRelatedPartyDetailsNarrative" id="ConvertiblePromissoryNotesHeldByRelatedPartyDetailsNarrative">
          <link:definition>00000038 - Disclosure - Convertible Promissory Notes held by Related Party (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://onemednet.com/role/CanadianEmergencyBusinessLoanActCebaDetailsNarrative" id="CanadianEmergencyBusinessLoanActCebaDetailsNarrative">
          <link:definition>00000039 - Disclosure - Canadian Emergency Business Loan Act (CEBA) (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://onemednet.com/role/ScheduleOfCommonStockActivitiesDetails" id="ScheduleOfCommonStockActivitiesDetails">
          <link:definition>00000040 - Disclosure - Schedule of Common Stock Activities (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://onemednet.com/role/ShareholdersEquityDetailsNarrative" id="ShareholdersEquityDetailsNarrative">
          <link:definition>00000041 - Disclosure - Shareholders&#8217; Equity (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://onemednet.com/role/ScheduleOfOptionsOutstandingDetails" id="ScheduleOfOptionsOutstandingDetails">
          <link:definition>00000042 - Disclosure - Schedule of Options Outstanding (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://onemednet.com/role/ScheduleOfFairValueOfStockOptionsDetails" id="ScheduleOfFairValueOfStockOptionsDetails">
          <link:definition>00000043 - Disclosure - Schedule of Fair Value of Stock Options (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://onemednet.com/role/StockOptionsDetailsNarrative" id="StockOptionsDetailsNarrative">
          <link:definition>00000044 - Disclosure - Stock Options (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://onemednet.com/role/StockWarrantsDetailsNarrative" id="StockWarrantsDetailsNarrative">
          <link:definition>00000045 - Disclosure - Stock Warrants (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://onemednet.com/role/ScheduleOfFinancialAssetsDetails" id="ScheduleOfFinancialAssetsDetails">
          <link:definition>00000046 - Disclosure - Schedule of Financial Assets (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://onemednet.com/role/RelatedPartyTransactionsDetailsNarrative" id="RelatedPartyTransactionsDetailsNarrative">
          <link:definition>00000047 - Disclosure - Related Party Transactions (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://onemednet.com/role/CommitmentsContingenciesAndConcentrationsOperatingLeaseDetailsNarrative" id="CommitmentsContingenciesAndConcentrationsOperatingLeaseDetailsNarrative">
          <link:definition>00000048 - Disclosure - Commitments, Contingencies, and Concentrations Operating lease (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://onemednet.com/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
          <link:definition>00000049 - Disclosure - Subsequent Events (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="onmd-20231231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="onmd-20231231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="onmd-20231231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="onmd-20231231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
    <import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
    <import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
    <import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
    <import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
    <element id="ONMD_SeriesATwoPreferredStockMember" name="SeriesATwoPreferredStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ONMD_SeriesAOnePreferredStockMember" name="SeriesAOnePreferredStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ONMD_CommonClassAOneMember" name="CommonClassAOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ONMD_DataKnightsAcquisitionCorpMember" name="DataKnightsAcquisitionCorpMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ONMD_CommitmentMember" name="CommitmentMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ONMD_SecuritiesPurchaseAgreementMember" name="SecuritiesPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ONMD_OneCustomerMember" name="OneCustomerMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ONMD_TwoCustomersMember" name="TwoCustomersMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ONMD_ThreeCustomersMember" name="ThreeCustomersMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ONMD_CustomerOneMember" name="CustomerOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ONMD_CustomerTwoMember" name="CustomerTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ONMD_CustomersMember" name="CustomersMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ONMD_CustomerThreeMember" name="CustomerThreeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ONMD_CustomerFourMember" name="CustomerFourMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ONMD_CustomerFiveMember" name="CustomerFiveMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ONMD_ConvertiblePromissoryNotesMember" name="ConvertiblePromissoryNotesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ONMD_CEBALoanMember" name="CEBALoanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ONMD_BoardOfDirectorsMember" name="BoardOfDirectorsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ONMD_EmployeesDirectorsAndConsultantsMember" name="EmployeesDirectorsAndConsultantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ONMD_NewEquityIncentivePlanMember" name="NewEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ONMD_TwentyTwentyOneServiceMember" name="TwentyTwentyOneServiceMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ONMD_TwentyTwentyTwoServiceMember" name="TwentyTwentyTwoServiceMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ONMD_ConvertiableNotesMember" name="ConvertiableNotesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ONMD_WarrantOneMember" name="WarrantOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ONMD_PubliclyTradedWarrantsMember" name="PubliclyTradedWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ONMD_PrivateWarrantsMember" name="PrivateWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ONMD_InvestmentsHeldInTrustMember" name="InvestmentsHeldInTrustMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ONMD_ManagementAndDirectorsMember" name="ManagementAndDirectorsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ONMD_SeniorConvertibleNotesMember" name="SeniorConvertibleNotesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ONMD_EFHuttonMember" name="EFHuttonMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ONMD_KingwoodCapitalPartnersLLCMember" name="KingwoodCapitalPartnersLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ONMD_LoanExtensionsCurrent" name="LoanExtensionsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ONMD_DeferredUnderwriterFeePayableCurrent" name="DeferredUnderwriterFeePayableCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ONMD_AccruedInterestRelatedParty" name="AccruedInterestRelatedParty" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ONMD_WarrantLiabilityNonCurrent" name="WarrantLiabilityNonCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ONMD_DeferredUnderwriterFeePayableNonCurrent" name="DeferredUnderwriterFeePayableNonCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ONMD_WorkingCapitalLoan" name="WorkingCapitalLoan" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ONMD_UnrealizedGainLoss" name="UnrealizedGainLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ONMD_CommonStockSubjectToPossibleRedemptionValue" name="CommonStockSubjectToPossibleRedemptionValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ONMD_StockIssuedDuringPeriodValueConvertibleNotesToCommonStock" name="StockIssuedDuringPeriodValueConvertibleNotesToCommonStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ONMD_StockIssuedDuringPeriodSharesConvertibleNotesToCommonStock" name="StockIssuedDuringPeriodSharesConvertibleNotesToCommonStock" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ONMD_StockIssuedDuringPeriodValueStockOptionsToCommonStock" name="StockIssuedDuringPeriodValueStockOptionsToCommonStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ONMD_StockIssuedDuringPeriodSharesStockOptionsToCommonStock" name="StockIssuedDuringPeriodSharesStockOptionsToCommonStock" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ONMD_StockIssuedDuringPeriodValueConvertingOfWarrantsToCommonStock" name="StockIssuedDuringPeriodValueConvertingOfWarrantsToCommonStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ONMD_StockIssuedDuringPeriodSharesConvertingOfWarrantsToCommonStock" name="StockIssuedDuringPeriodSharesConvertingOfWarrantsToCommonStock" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ONMD_StockIssuedDuringPeriodValueConvertingDataKnightsCommonShares" name="StockIssuedDuringPeriodValueConvertingDataKnightsCommonShares" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ONMD_StockIssuedDuringPeriodSharesConvertingDataKnightsCommonShares" name="StockIssuedDuringPeriodSharesConvertingDataKnightsCommonShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ONMD_RetainedEarningsAdjustment" name="RetainedEarningsAdjustment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ONMD_BusinessCombinationCost" name="BusinessCombinationCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ONMD_CashHeldInTrustAccount" name="CashHeldInTrustAccount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ONMD_IncreaseDecreaseInExerciseTaxLiability" name="IncreaseDecreaseInExerciseTaxLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ONMD_IncreaseDecreaseInExtensionLoan" name="IncreaseDecreaseInExtensionLoan" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ONMD_IncreaseDecreaseFranchiseTaxPayable" name="IncreaseDecreaseFranchiseTaxPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ONMD_IncreaseDecreaseInWorkingCapitalLoan" name="IncreaseDecreaseInWorkingCapitalLoan" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ONMD_ProceedsFromIssuanceOfCommonStockOne" name="ProceedsFromIssuanceOfCommonStockOne" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ONMD_ProceedsFromBusinessLoan" name="ProceedsFromBusinessLoan" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ONMD_ProceedsFromCommonStockSubjectToRedemption" name="ProceedsFromCommonStockSubjectToRedemption" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ONMD_ProceedsFromDeferredUnderwritingFee" name="ProceedsFromDeferredUnderwritingFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ONMD_ProceedsFromWarrantLiability" name="ProceedsFromWarrantLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ONMD_ProceedsFromIssuanceOfCommonStockTwo" name="ProceedsFromIssuanceOfCommonStockTwo" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ONMD_ClassBCommonStock" name="ClassBCommonStock" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ONMD_ProccedsFromRetainedEarningsAdjustment" name="ProccedsFromRetainedEarningsAdjustment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ONMD_DisclosureStockWarrantsAbstract" name="DisclosureStockWarrantsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ONMD_StockWarrantsDisclosureTextBlock" name="StockWarrantsDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ONMD_OperatingSegmentsPolicyTextBlock" name="OperatingSegmentsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ONMD_PatentsAndTrademarksPolicyTextBlock" name="PatentsAndTrademarksPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ONMD_EmergingGrowthCompanyPolicyTextBlock" name="EmergingGrowthCompanyPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ONMD_AccountingPronouncementsNotYetAdoptedPolicyTextBlock" name="AccountingPronouncementsNotYetAdoptedPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ONMD_EquityFinancingDescription" name="EquityFinancingDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ONMD_EquitySecuritiesFvNiMeasurementTerm" name="EquitySecuritiesFvNiMeasurementTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="ONMD_ExtensionLoan" name="ExtensionLoan" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ONMD_StockIssuedDuringPeriodValueIssuanceOfPipeWarrants" name="StockIssuedDuringPeriodValueIssuanceOfPipeWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ONMD_StockIssuedDuringPeriodSharesIssuanceOfPipeWarrants" name="StockIssuedDuringPeriodSharesIssuanceOfPipeWarrants" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ONMD_StockIssuedDuringPeriodValueCommonStockRedemption" name="StockIssuedDuringPeriodValueCommonStockRedemption" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>39
<FILENAME>onmd-20231231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://onemednet.com/role/Cover" xlink:href="onmd-20231231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/BalanceSheets" xlink:href="onmd-20231231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/BalanceSheetsParenthetical" xlink:href="onmd-20231231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/StatementsOfOperations" xlink:href="onmd-20231231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/StatementsOfStockholdersEquityDeficit" xlink:href="onmd-20231231.xsd#StatementsOfStockholdersEquityDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/StatementsOfStockholdersEquityDeficitParenthetical" xlink:href="onmd-20231231.xsd#StatementsOfStockholdersEquityDeficitParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/StatementsOfCashFlows" xlink:href="onmd-20231231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/OrganizationAndOperations" xlink:href="onmd-20231231.xsd#OrganizationAndOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="onmd-20231231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/BusinessCombination" xlink:href="onmd-20231231.xsd#BusinessCombination" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/GoingConcern" xlink:href="onmd-20231231.xsd#GoingConcern" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/PropertyAndEquipment" xlink:href="onmd-20231231.xsd#PropertyAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/IncomeTaxes" xlink:href="onmd-20231231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/ConvertiblePromissoryNotesHeldByRelatedParty" xlink:href="onmd-20231231.xsd#ConvertiblePromissoryNotesHeldByRelatedParty" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/CanadianEmergencyBusinessLoanActCeba" xlink:href="onmd-20231231.xsd#CanadianEmergencyBusinessLoanActCeba" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/ShareholdersEquity" xlink:href="onmd-20231231.xsd#ShareholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/StockOptions" xlink:href="onmd-20231231.xsd#StockOptions" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/StockWarrants" xlink:href="onmd-20231231.xsd#StockWarrants" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/FairValueMeasures" xlink:href="onmd-20231231.xsd#FairValueMeasures" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/RelatedPartyTransactions" xlink:href="onmd-20231231.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/CommitmentsContingenciesAndConcentrationsOperatingLease" xlink:href="onmd-20231231.xsd#CommitmentsContingenciesAndConcentrationsOperatingLease" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/SubsequentEvents" xlink:href="onmd-20231231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="onmd-20231231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="onmd-20231231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/PropertyAndEquipmentTables" xlink:href="onmd-20231231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/IncomeTaxesTables" xlink:href="onmd-20231231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/ShareholdersEquityTables" xlink:href="onmd-20231231.xsd#ShareholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/StockOptionsTables" xlink:href="onmd-20231231.xsd#StockOptionsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/FairValueMeasuresTables" xlink:href="onmd-20231231.xsd#FairValueMeasuresTables" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/OrganizationAndOperationsDetailsNarrative" xlink:href="onmd-20231231.xsd#OrganizationAndOperationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/ScheduleOfAggregatePercentageRevenueAndAccountsReceivableDetails" xlink:href="onmd-20231231.xsd#ScheduleOfAggregatePercentageRevenueAndAccountsReceivableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="onmd-20231231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/GoingConcernDetailsNarrative" xlink:href="onmd-20231231.xsd#GoingConcernDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:href="onmd-20231231.xsd#ScheduleOfPropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/PropertyAndEquipmentDetailsNarrative" xlink:href="onmd-20231231.xsd#PropertyAndEquipmentDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/ScheduleOfDeferredIncomeTaxesDetails" xlink:href="onmd-20231231.xsd#ScheduleOfDeferredIncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/IncomeTaxesDetailsNarrative" xlink:href="onmd-20231231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/ConvertiblePromissoryNotesHeldByRelatedPartyDetailsNarrative" xlink:href="onmd-20231231.xsd#ConvertiblePromissoryNotesHeldByRelatedPartyDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/CanadianEmergencyBusinessLoanActCebaDetailsNarrative" xlink:href="onmd-20231231.xsd#CanadianEmergencyBusinessLoanActCebaDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/ScheduleOfCommonStockActivitiesDetails" xlink:href="onmd-20231231.xsd#ScheduleOfCommonStockActivitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/ShareholdersEquityDetailsNarrative" xlink:href="onmd-20231231.xsd#ShareholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/ScheduleOfOptionsOutstandingDetails" xlink:href="onmd-20231231.xsd#ScheduleOfOptionsOutstandingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/ScheduleOfFairValueOfStockOptionsDetails" xlink:href="onmd-20231231.xsd#ScheduleOfFairValueOfStockOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/StockOptionsDetailsNarrative" xlink:href="onmd-20231231.xsd#StockOptionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/StockWarrantsDetailsNarrative" xlink:href="onmd-20231231.xsd#StockWarrantsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/ScheduleOfFinancialAssetsDetails" xlink:href="onmd-20231231.xsd#ScheduleOfFinancialAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="onmd-20231231.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/CommitmentsContingenciesAndConcentrationsOperatingLeaseDetailsNarrative" xlink:href="onmd-20231231.xsd#CommitmentsContingenciesAndConcentrationsOperatingLeaseDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/SubsequentEventsDetailsNarrative" xlink:href="onmd-20231231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://onemednet.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://onemednet.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsHeldInTrustCurrent" xlink:label="loc_us-gaapAssetsHeldInTrustCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapAssetsHeldInTrustCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivables" xlink:label="loc_us-gaapOtherReceivables" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapOtherReceivables" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherShortTermBorrowings" xlink:label="loc_us-gaapOtherShortTermBorrowings" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOtherShortTermBorrowings" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesAndExciseTaxPayableCurrent" xlink:label="loc_us-gaapSalesAndExciseTaxPayableCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapSalesAndExciseTaxPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_LoanExtensionsCurrent" xlink:label="loc_ONMDLoanExtensionsCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_ONMDLoanExtensionsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaapDeferredRevenueCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapDeferredRevenueCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayable" xlink:label="loc_us-gaapLoansPayable" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapLoansPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="loc_us-gaapConvertibleDebtCurrent" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapConvertibleDebtCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnsecuredDebtCurrent" xlink:label="loc_us-gaapUnsecuredDebtCurrent" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapUnsecuredDebtCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="loc_us-gaapAccruedIncomeTaxesCurrent" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedIncomeTaxesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:label="loc_us-gaapAccrualForTaxesOtherThanIncomeTaxesCurrent" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNotesPayableCurrent" xlink:label="loc_us-gaapOtherNotesPayableCurrent" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOtherNotesPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_DeferredUnderwriterFeePayableCurrent" xlink:label="loc_ONMDDeferredUnderwriterFeePayableCurrent" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_ONMDDeferredUnderwriterFeePayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="loc_us-gaapConvertibleDebtNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapConvertibleDebtNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnsecuredDebt" xlink:label="loc_us-gaapUnsecuredDebt" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapUnsecuredDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_AccruedInterestRelatedParty" xlink:label="loc_ONMDAccruedInterestRelatedParty" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_ONMDAccruedInterestRelatedParty" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaapOtherLiabilitiesNoncurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOtherLiabilitiesNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_WarrantLiabilityNonCurrent" xlink:label="loc_ONMDWarrantLiabilityNonCurrent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_ONMDWarrantLiabilityNonCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_DeferredUnderwriterFeePayableNonCurrent" xlink:label="loc_ONMDDeferredUnderwriterFeePayableNonCurrent" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_ONMDDeferredUnderwriterFeePayableNonCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_WorkingCapitalLoan" xlink:label="loc_ONMDWorkingCapitalLoan" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_ONMDWorkingCapitalLoan" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermLoansPayable" xlink:label="loc_us-gaapLongTermLoansPayable" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLongTermLoansPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://onemednet.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://onemednet.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaapCostOfRevenue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapCostOfRevenue" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherGeneralExpense" xlink:label="loc_us-gaapOtherGeneralExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapOtherGeneralExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaapSellingAndMarketingExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapSellingAndMarketingExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaapAssetImpairmentCharges" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapAssetImpairmentCharges" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="loc_us-gaapOtherNonoperatingExpense" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapOtherNonoperatingExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionPlanExpense" xlink:label="loc_us-gaapStockOptionPlanExpense" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapStockOptionPlanExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_UnrealizedGainLoss" xlink:label="loc_ONMDUnrealizedGainLoss" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_ONMDUnrealizedGainLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://onemednet.com/role/StatementsOfStockholdersEquityDeficit" xlink:title="00000005 - Statement - Consolidated Statements of Stockholders Equity (Deficit)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://onemednet.com/role/StatementsOfStockholdersEquityDeficitParenthetical" xlink:title="00000006 - Statement - Consolidated Statements of Stockholders Equity (Deficit) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://onemednet.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_BusinessCombinationCost" xlink:label="loc_ONMDBusinessCombinationCost" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_ONMDBusinessCombinationCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_CashHeldInTrustAccount" xlink:label="loc_ONMDCashHeldInTrustAccount" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_ONMDCashHeldInTrustAccount" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentAssets" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaapIncreaseDecreaseInContractWithCustomerLiability" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:label="loc_us-gaapIncreaseDecreaseInDueToRelatedParties" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInDueToRelatedParties" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_IncreaseDecreaseInExerciseTaxLiability" xlink:label="loc_ONMDIncreaseDecreaseInExerciseTaxLiability" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_ONMDIncreaseDecreaseInExerciseTaxLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_IncreaseDecreaseInExtensionLoan" xlink:label="loc_ONMDIncreaseDecreaseInExtensionLoan" />
      <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_ONMDIncreaseDecreaseInExtensionLoan" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_IncreaseDecreaseFranchiseTaxPayable" xlink:label="loc_ONMDIncreaseDecreaseFranchiseTaxPayable" />
      <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_ONMDIncreaseDecreaseFranchiseTaxPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedIncomeTaxesPayable" />
      <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_IncreaseDecreaseInWorkingCapitalLoan" xlink:label="loc_ONMDIncreaseDecreaseInWorkingCapitalLoan" />
      <link:calculationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_ONMDIncreaseDecreaseInWorkingCapitalLoan" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_ProceedsFromIssuanceOfCommonStockOne" xlink:label="loc_ONMDProceedsFromIssuanceOfCommonStockOne" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_ONMDProceedsFromIssuanceOfCommonStockOne" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRepaymentsOfNotesPayable" xlink:label="loc_us-gaapProceedsFromRepaymentsOfNotesPayable" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromRepaymentsOfNotesPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaapProceedsFromConvertibleDebt" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromConvertibleDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRelatedPartyDebt" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromRelatedPartyDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_ProceedsFromBusinessLoan" xlink:label="loc_ONMDProceedsFromBusinessLoan" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_ONMDProceedsFromBusinessLoan" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_ProceedsFromCommonStockSubjectToRedemption" xlink:label="loc_ONMDProceedsFromCommonStockSubjectToRedemption" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_ONMDProceedsFromCommonStockSubjectToRedemption" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_ProceedsFromDeferredUnderwritingFee" xlink:label="loc_ONMDProceedsFromDeferredUnderwritingFee" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_ONMDProceedsFromDeferredUnderwritingFee" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_ProceedsFromWarrantLiability" xlink:label="loc_ONMDProceedsFromWarrantLiability" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_ONMDProceedsFromWarrantLiability" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromContributedCapital" xlink:label="loc_us-gaapProceedsFromContributedCapital" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromContributedCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_ProceedsFromIssuanceOfCommonStockTwo" xlink:label="loc_ONMDProceedsFromIssuanceOfCommonStockTwo" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_ONMDProceedsFromIssuanceOfCommonStockTwo" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_ClassBCommonStock" xlink:label="loc_ONMDClassBCommonStock" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_ONMDClassBCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_ProccedsFromRetainedEarningsAdjustment" xlink:label="loc_ONMDProccedsFromRetainedEarningsAdjustment" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_ONMDProccedsFromRetainedEarningsAdjustment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://onemednet.com/role/OrganizationAndOperations" xlink:title="00000008 - Disclosure - Organization and Operations" />
    <link:calculationLink xlink:type="extended" xlink:role="http://onemednet.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000009 - Disclosure - Summary of Significant Accounting Policies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://onemednet.com/role/BusinessCombination" xlink:title="00000010 - Disclosure - Business Combination" />
    <link:calculationLink xlink:type="extended" xlink:role="http://onemednet.com/role/GoingConcern" xlink:title="00000011 - Disclosure - Going Concern" />
    <link:calculationLink xlink:type="extended" xlink:role="http://onemednet.com/role/PropertyAndEquipment" xlink:title="00000012 - Disclosure - Property and Equipment" />
    <link:calculationLink xlink:type="extended" xlink:role="http://onemednet.com/role/IncomeTaxes" xlink:title="00000013 - Disclosure - Income Taxes" />
    <link:calculationLink xlink:type="extended" xlink:role="http://onemednet.com/role/ConvertiblePromissoryNotesHeldByRelatedParty" xlink:title="00000014 - Disclosure - Convertible Promissory Notes held by Related Party" />
    <link:calculationLink xlink:type="extended" xlink:role="http://onemednet.com/role/CanadianEmergencyBusinessLoanActCeba" xlink:title="00000015 - Disclosure - Canadian Emergency Business Loan Act (CEBA)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://onemednet.com/role/ShareholdersEquity" xlink:title="00000016 - Disclosure - Shareholders&#8217; Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://onemednet.com/role/StockOptions" xlink:title="00000017 - Disclosure - Stock Options" />
    <link:calculationLink xlink:type="extended" xlink:role="http://onemednet.com/role/StockWarrants" xlink:title="00000018 - Disclosure - Stock Warrants" />
    <link:calculationLink xlink:type="extended" xlink:role="http://onemednet.com/role/FairValueMeasures" xlink:title="00000019 - Disclosure - Fair Value Measures" />
    <link:calculationLink xlink:type="extended" xlink:role="http://onemednet.com/role/RelatedPartyTransactions" xlink:title="00000020 - Disclosure - Related Party Transactions" />
    <link:calculationLink xlink:type="extended" xlink:role="http://onemednet.com/role/CommitmentsContingenciesAndConcentrationsOperatingLease" xlink:title="00000021 - Disclosure - Commitments, Contingencies, and Concentrations Operating lease" />
    <link:calculationLink xlink:type="extended" xlink:role="http://onemednet.com/role/SubsequentEvents" xlink:title="00000022 - Disclosure - Subsequent Events" />
    <link:calculationLink xlink:type="extended" xlink:role="http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000023 - Disclosure - Summary of Significant Accounting Policies (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000024 - Disclosure - Summary of Significant Accounting Policies (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://onemednet.com/role/PropertyAndEquipmentTables" xlink:title="00000025 - Disclosure - Property and Equipment (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://onemednet.com/role/IncomeTaxesTables" xlink:title="00000026 - Disclosure - Income Taxes (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://onemednet.com/role/ShareholdersEquityTables" xlink:title="00000027 - Disclosure - Shareholders&#8217; Equity (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://onemednet.com/role/StockOptionsTables" xlink:title="00000028 - Disclosure - Stock Options (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://onemednet.com/role/FairValueMeasuresTables" xlink:title="00000029 - Disclosure - Fair Value Measures (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://onemednet.com/role/OrganizationAndOperationsDetailsNarrative" xlink:title="00000030 - Disclosure - Organization and Operations (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://onemednet.com/role/ScheduleOfAggregatePercentageRevenueAndAccountsReceivableDetails" xlink:title="00000031 - Disclosure - Schedule Of Aggregate Percentage Revenue and Accounts Receivable (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000032 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://onemednet.com/role/GoingConcernDetailsNarrative" xlink:title="00000033 - Disclosure - Going Concern (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://onemednet.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:title="00000034 - Disclosure - Schedule of Property And Equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://onemednet.com/role/PropertyAndEquipmentDetailsNarrative" xlink:title="00000035 - Disclosure - Property and Equipment (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://onemednet.com/role/ScheduleOfDeferredIncomeTaxesDetails" xlink:title="00000036 - Disclosure - Schedule of Deferred Income Taxes (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaapDeferredTaxAssetsOther" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsOther" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://onemednet.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000037 - Disclosure - Income Taxes (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://onemednet.com/role/ConvertiblePromissoryNotesHeldByRelatedPartyDetailsNarrative" xlink:title="00000038 - Disclosure - Convertible Promissory Notes held by Related Party (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://onemednet.com/role/CanadianEmergencyBusinessLoanActCebaDetailsNarrative" xlink:title="00000039 - Disclosure - Canadian Emergency Business Loan Act (CEBA) (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://onemednet.com/role/ScheduleOfCommonStockActivitiesDetails" xlink:title="00000040 - Disclosure - Schedule of Common Stock Activities (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://onemednet.com/role/ShareholdersEquityDetailsNarrative" xlink:title="00000041 - Disclosure - Shareholders&#8217; Equity (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://onemednet.com/role/ScheduleOfOptionsOutstandingDetails" xlink:title="00000042 - Disclosure - Schedule of Options Outstanding (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://onemednet.com/role/ScheduleOfFairValueOfStockOptionsDetails" xlink:title="00000043 - Disclosure - Schedule of Fair Value of Stock Options (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://onemednet.com/role/StockOptionsDetailsNarrative" xlink:title="00000044 - Disclosure - Stock Options (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://onemednet.com/role/StockWarrantsDetailsNarrative" xlink:title="00000045 - Disclosure - Stock Warrants (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://onemednet.com/role/ScheduleOfFinancialAssetsDetails" xlink:title="00000046 - Disclosure - Schedule of Financial Assets (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://onemednet.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000047 - Disclosure - Related Party Transactions (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://onemednet.com/role/CommitmentsContingenciesAndConcentrationsOperatingLeaseDetailsNarrative" xlink:title="00000048 - Disclosure - Commitments, Contingencies, and Concentrations Operating lease (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://onemednet.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000049 - Disclosure - Subsequent Events (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>40
<FILENAME>onmd-20231231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://onemednet.com/role/Cover" xlink:href="onmd-20231231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/BalanceSheets" xlink:href="onmd-20231231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/BalanceSheetsParenthetical" xlink:href="onmd-20231231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/StatementsOfOperations" xlink:href="onmd-20231231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/StatementsOfStockholdersEquityDeficit" xlink:href="onmd-20231231.xsd#StatementsOfStockholdersEquityDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/StatementsOfStockholdersEquityDeficitParenthetical" xlink:href="onmd-20231231.xsd#StatementsOfStockholdersEquityDeficitParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/StatementsOfCashFlows" xlink:href="onmd-20231231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/OrganizationAndOperations" xlink:href="onmd-20231231.xsd#OrganizationAndOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="onmd-20231231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/BusinessCombination" xlink:href="onmd-20231231.xsd#BusinessCombination" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/GoingConcern" xlink:href="onmd-20231231.xsd#GoingConcern" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/PropertyAndEquipment" xlink:href="onmd-20231231.xsd#PropertyAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/IncomeTaxes" xlink:href="onmd-20231231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/ConvertiblePromissoryNotesHeldByRelatedParty" xlink:href="onmd-20231231.xsd#ConvertiblePromissoryNotesHeldByRelatedParty" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/CanadianEmergencyBusinessLoanActCeba" xlink:href="onmd-20231231.xsd#CanadianEmergencyBusinessLoanActCeba" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/ShareholdersEquity" xlink:href="onmd-20231231.xsd#ShareholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/StockOptions" xlink:href="onmd-20231231.xsd#StockOptions" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/StockWarrants" xlink:href="onmd-20231231.xsd#StockWarrants" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/FairValueMeasures" xlink:href="onmd-20231231.xsd#FairValueMeasures" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/RelatedPartyTransactions" xlink:href="onmd-20231231.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/CommitmentsContingenciesAndConcentrationsOperatingLease" xlink:href="onmd-20231231.xsd#CommitmentsContingenciesAndConcentrationsOperatingLease" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/SubsequentEvents" xlink:href="onmd-20231231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="onmd-20231231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="onmd-20231231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/PropertyAndEquipmentTables" xlink:href="onmd-20231231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/IncomeTaxesTables" xlink:href="onmd-20231231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/ShareholdersEquityTables" xlink:href="onmd-20231231.xsd#ShareholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/StockOptionsTables" xlink:href="onmd-20231231.xsd#StockOptionsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/FairValueMeasuresTables" xlink:href="onmd-20231231.xsd#FairValueMeasuresTables" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/OrganizationAndOperationsDetailsNarrative" xlink:href="onmd-20231231.xsd#OrganizationAndOperationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/ScheduleOfAggregatePercentageRevenueAndAccountsReceivableDetails" xlink:href="onmd-20231231.xsd#ScheduleOfAggregatePercentageRevenueAndAccountsReceivableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="onmd-20231231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/GoingConcernDetailsNarrative" xlink:href="onmd-20231231.xsd#GoingConcernDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:href="onmd-20231231.xsd#ScheduleOfPropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/PropertyAndEquipmentDetailsNarrative" xlink:href="onmd-20231231.xsd#PropertyAndEquipmentDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/ScheduleOfDeferredIncomeTaxesDetails" xlink:href="onmd-20231231.xsd#ScheduleOfDeferredIncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/IncomeTaxesDetailsNarrative" xlink:href="onmd-20231231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/ConvertiblePromissoryNotesHeldByRelatedPartyDetailsNarrative" xlink:href="onmd-20231231.xsd#ConvertiblePromissoryNotesHeldByRelatedPartyDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/CanadianEmergencyBusinessLoanActCebaDetailsNarrative" xlink:href="onmd-20231231.xsd#CanadianEmergencyBusinessLoanActCebaDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/ScheduleOfCommonStockActivitiesDetails" xlink:href="onmd-20231231.xsd#ScheduleOfCommonStockActivitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/ShareholdersEquityDetailsNarrative" xlink:href="onmd-20231231.xsd#ShareholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/ScheduleOfOptionsOutstandingDetails" xlink:href="onmd-20231231.xsd#ScheduleOfOptionsOutstandingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/ScheduleOfFairValueOfStockOptionsDetails" xlink:href="onmd-20231231.xsd#ScheduleOfFairValueOfStockOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/StockOptionsDetailsNarrative" xlink:href="onmd-20231231.xsd#StockOptionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/StockWarrantsDetailsNarrative" xlink:href="onmd-20231231.xsd#StockWarrantsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/ScheduleOfFinancialAssetsDetails" xlink:href="onmd-20231231.xsd#ScheduleOfFinancialAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="onmd-20231231.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/CommitmentsContingenciesAndConcentrationsOperatingLeaseDetailsNarrative" xlink:href="onmd-20231231.xsd#CommitmentsContingenciesAndConcentrationsOperatingLeaseDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/SubsequentEventsDetailsNarrative" xlink:href="onmd-20231231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://onemednet.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesLineItems" xlink:label="loc_deiEntityAddressesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesTable" xlink:label="loc_deiEntityAddressesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_deiEntityAddressesAddressTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_deiEntityAddressesTable" xlink:to="loc_deiEntityAddressesAddressTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain" xlink:label="loc_deiAddressTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiEntityAddressesAddressTypeAxis" xlink:to="loc_deiAddressTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain" xlink:label="loc_deiAddressTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiEntityAddressesAddressTypeAxis" xlink:to="loc_deiAddressTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_BusinessContactMember" xlink:label="loc_deiBusinessContactMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiAddressTypeDomain" xlink:to="loc_deiBusinessContactMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentType_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAmendmentFlag_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAmendmentDescription_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentRegistrationStatement_30" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentAnnualReport_30" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentQuarterlyReport_30" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentTransitionReport_30" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentShellCompanyReport_30" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate_30" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentPeriodStartDate_30" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentPeriodEndDate_30" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus_30" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentFiscalYearFocus_30" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate_30" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityFileNumber_30" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityRegistrantName_30" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCentralIndexKey_30" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityPrimarySicNumber_30" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber_30" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode_30" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine1_30" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine2_30" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine3_30" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressCityOrTown_30" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressStateOrProvince_30" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressCountry_30" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressPostalZipCode_30" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCountryRegion_30" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCityAreaCode_30" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiLocalPhoneNumber_30" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="loc_deiExtension_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiExtension_30" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiWrittenCommunications_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSolicitingMaterial_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiPreCommencementTenderOffer_30" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer_30" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurity12bTitle_30" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiNoTradingSymbolFlag_30" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiTradingSymbol_30" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurityExchangeName_30" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurity12gTitle_30" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurityReportingObligation_30" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAnnualInformationForm_30" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements_30" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer_30" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityVoluntaryFilers_30" xlink:type="arc" order="44" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCurrentReportingStatus_30" xlink:type="arc" order="45" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent_30" xlink:type="arc" order="46" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityFilerCategory_30" xlink:type="arc" order="47" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntitySmallBusiness_30" xlink:type="arc" order="48" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany_30" xlink:type="arc" order="49" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityExTransitionPeriod_30" xlink:type="arc" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentAccountingStandard_30" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber_30" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityShellCompany_30" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityPublicFloat_30" xlink:type="arc" order="54" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent_30" xlink:type="arc" order="55" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding_30" xlink:type="arc" order="56" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock_30" xlink:type="arc" order="57" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelName" xlink:label="loc_deiContactPersonnelName_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiContactPersonnelName_30" xlink:type="arc" order="58" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://onemednet.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_SeriesATwoPreferredStockMember" xlink:label="loc_ONMDSeriesATwoPreferredStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ONMDSeriesATwoPreferredStockMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_SeriesAOnePreferredStockMember" xlink:label="loc_ONMDSeriesAOnePreferredStockMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ONMDSeriesAOnePreferredStockMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaapCommonClassAMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassAMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_CommonClassAOneMember" xlink:label="loc_ONMDCommonClassAOneMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ONMDCommonClassAOneMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsCurrentAbstract_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_130" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsHeldInTrustCurrent" xlink:label="loc_us-gaapAssetsHeldInTrustCurrent_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_130" xlink:to="loc_us-gaapAssetsHeldInTrustCurrent_130" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_130" xlink:to="loc_us-gaapAccountsReceivableNetCurrent_130" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_130" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent_130" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivables" xlink:label="loc_us-gaapOtherReceivables_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_130" xlink:to="loc_us-gaapOtherReceivables_130" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_130" xlink:to="loc_us-gaapAssetsCurrent_130" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_130" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssets_130" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract_130" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_130" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent_130" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherShortTermBorrowings" xlink:label="loc_us-gaapOtherShortTermBorrowings_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_130" xlink:to="loc_us-gaapOtherShortTermBorrowings_130" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesAndExciseTaxPayableCurrent" xlink:label="loc_us-gaapSalesAndExciseTaxPayableCurrent_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_130" xlink:to="loc_us-gaapSalesAndExciseTaxPayableCurrent_130" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_LoanExtensionsCurrent" xlink:label="loc_ONMDLoanExtensionsCurrent_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_130" xlink:to="loc_ONMDLoanExtensionsCurrent_130" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaapDeferredRevenueCurrent_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_130" xlink:to="loc_us-gaapDeferredRevenueCurrent_130" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayable" xlink:label="loc_us-gaapLoansPayable_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_130" xlink:to="loc_us-gaapLoansPayable_130" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="loc_us-gaapConvertibleDebtCurrent_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_130" xlink:to="loc_us-gaapConvertibleDebtCurrent_130" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnsecuredDebtCurrent" xlink:label="loc_us-gaapUnsecuredDebtCurrent_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_130" xlink:to="loc_us-gaapUnsecuredDebtCurrent_130" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="loc_us-gaapAccruedIncomeTaxesCurrent_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_130" xlink:to="loc_us-gaapAccruedIncomeTaxesCurrent_130" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:label="loc_us-gaapAccrualForTaxesOtherThanIncomeTaxesCurrent_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_130" xlink:to="loc_us-gaapAccrualForTaxesOtherThanIncomeTaxesCurrent_130" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNotesPayableCurrent" xlink:label="loc_us-gaapOtherNotesPayableCurrent_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_130" xlink:to="loc_us-gaapOtherNotesPayableCurrent_130" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_DeferredUnderwriterFeePayableCurrent" xlink:label="loc_ONMDDeferredUnderwriterFeePayableCurrent_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_130" xlink:to="loc_ONMDDeferredUnderwriterFeePayableCurrent_130" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_130" xlink:to="loc_us-gaapLiabilitiesCurrent_130" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaapLiabilitiesNoncurrentAbstract_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_130" xlink:to="loc_us-gaapLiabilitiesNoncurrentAbstract_130" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="loc_us-gaapConvertibleDebtNoncurrent_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract_130" xlink:to="loc_us-gaapConvertibleDebtNoncurrent_130" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnsecuredDebt" xlink:label="loc_us-gaapUnsecuredDebt_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract_130" xlink:to="loc_us-gaapUnsecuredDebt_130" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_AccruedInterestRelatedParty" xlink:label="loc_ONMDAccruedInterestRelatedParty_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract_130" xlink:to="loc_ONMDAccruedInterestRelatedParty_130" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaapOtherLiabilitiesNoncurrent_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract_130" xlink:to="loc_us-gaapOtherLiabilitiesNoncurrent_130" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_WarrantLiabilityNonCurrent" xlink:label="loc_ONMDWarrantLiabilityNonCurrent_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract_130" xlink:to="loc_ONMDWarrantLiabilityNonCurrent_130" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_DeferredUnderwriterFeePayableNonCurrent" xlink:label="loc_ONMDDeferredUnderwriterFeePayableNonCurrent_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract_130" xlink:to="loc_ONMDDeferredUnderwriterFeePayableNonCurrent_130" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_WorkingCapitalLoan" xlink:label="loc_ONMDWorkingCapitalLoan_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract_130" xlink:to="loc_ONMDWorkingCapitalLoan_130" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermLoansPayable" xlink:label="loc_us-gaapLongTermLoansPayable_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract_130" xlink:to="loc_us-gaapLongTermLoansPayable_130" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_130" xlink:to="loc_us-gaapLiabilities_130" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_130" xlink:to="loc_us-gaapStockholdersEquityAbstract_130" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_130" xlink:to="loc_us-gaapPreferredStockValue_130" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_130" xlink:to="loc_us-gaapCommonStockValue_130" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_130" xlink:to="loc_us-gaapCommitmentsAndContingencies_130" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_130" xlink:to="loc_us-gaapAdditionalPaidInCapital_130" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_130" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_130" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_130" xlink:to="loc_us-gaapStockholdersEquity_130" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_130" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity_130" xlink:type="arc" order="40" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://onemednet.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_SeriesATwoPreferredStockMember" xlink:label="loc_ONMDSeriesATwoPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ONMDSeriesATwoPreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_SeriesAOnePreferredStockMember" xlink:label="loc_ONMDSeriesAOnePreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ONMDSeriesAOnePreferredStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaapCommonClassAMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassAMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_CommonClassAOneMember" xlink:label="loc_ONMDCommonClassAOneMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ONMDCommonClassAOneMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_110" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_110" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_110" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://onemednet.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations" />
    <link:definitionLink xlink:type="extended" xlink:role="http://onemednet.com/role/StatementsOfStockholdersEquityDeficit" xlink:title="00000005 - Statement - Consolidated Statements of Stockholders Equity (Deficit)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapPreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_CommitmentMember" xlink:label="loc_ONMDCommitmentMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_ONMDCommitmentMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_SeriesATwoPreferredStockMember" xlink:label="loc_ONMDSeriesATwoPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ONMDSeriesATwoPreferredStockMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_SeriesAOnePreferredStockMember" xlink:label="loc_ONMDSeriesAOnePreferredStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ONMDSeriesAOnePreferredStockMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaapCommonClassAMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassAMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaapCommonClassBMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassBMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_DataKnightsAcquisitionCorpMember" xlink:label="loc_ONMDDataKnightsAcquisitionCorpMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_ONMDDataKnightsAcquisitionCorpMember_20" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_100" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_100" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_100" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_100" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_100" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_100" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions_100" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_100" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_CommonStockSubjectToPossibleRedemptionValue" xlink:label="loc_ONMDCommonStockSubjectToPossibleRedemptionValue_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ONMDCommonStockSubjectToPossibleRedemptionValue_100" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_100" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_100" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_100" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_100" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_StockIssuedDuringPeriodValueConvertibleNotesToCommonStock" xlink:label="loc_ONMDStockIssuedDuringPeriodValueConvertibleNotesToCommonStock_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ONMDStockIssuedDuringPeriodValueConvertibleNotesToCommonStock_100" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_StockIssuedDuringPeriodSharesConvertibleNotesToCommonStock" xlink:label="loc_ONMDStockIssuedDuringPeriodSharesConvertibleNotesToCommonStock_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ONMDStockIssuedDuringPeriodSharesConvertibleNotesToCommonStock_100" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_StockIssuedDuringPeriodValueStockOptionsToCommonStock" xlink:label="loc_ONMDStockIssuedDuringPeriodValueStockOptionsToCommonStock_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ONMDStockIssuedDuringPeriodValueStockOptionsToCommonStock_100" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_StockIssuedDuringPeriodSharesStockOptionsToCommonStock" xlink:label="loc_ONMDStockIssuedDuringPeriodSharesStockOptionsToCommonStock_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ONMDStockIssuedDuringPeriodSharesStockOptionsToCommonStock_100" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_StockIssuedDuringPeriodValueConvertingOfWarrantsToCommonStock" xlink:label="loc_ONMDStockIssuedDuringPeriodValueConvertingOfWarrantsToCommonStock_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ONMDStockIssuedDuringPeriodValueConvertingOfWarrantsToCommonStock_100" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_StockIssuedDuringPeriodSharesConvertingOfWarrantsToCommonStock" xlink:label="loc_ONMDStockIssuedDuringPeriodSharesConvertingOfWarrantsToCommonStock_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ONMDStockIssuedDuringPeriodSharesConvertingOfWarrantsToCommonStock_100" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther_100" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_100" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued_100" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_StockIssuedDuringPeriodValueConvertingDataKnightsCommonShares" xlink:label="loc_ONMDStockIssuedDuringPeriodValueConvertingDataKnightsCommonShares_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ONMDStockIssuedDuringPeriodValueConvertingDataKnightsCommonShares_100" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_StockIssuedDuringPeriodSharesConvertingDataKnightsCommonShares" xlink:label="loc_ONMDStockIssuedDuringPeriodSharesConvertingDataKnightsCommonShares_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ONMDStockIssuedDuringPeriodSharesConvertingDataKnightsCommonShares_100" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_RetainedEarningsAdjustment" xlink:label="loc_ONMDRetainedEarningsAdjustment_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ONMDRetainedEarningsAdjustment_100" xlink:type="arc" order="25" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://onemednet.com/role/StatementsOfStockholdersEquityDeficitParenthetical" xlink:title="00000006 - Statement - Consolidated Statements of Stockholders Equity (Deficit) (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://onemednet.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Consolidated Statements of Cash Flows" />
    <link:definitionLink xlink:type="extended" xlink:role="http://onemednet.com/role/OrganizationAndOperations" xlink:title="00000008 - Disclosure - Organization and Operations" />
    <link:definitionLink xlink:type="extended" xlink:role="http://onemednet.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000009 - Disclosure - Summary of Significant Accounting Policies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://onemednet.com/role/BusinessCombination" xlink:title="00000010 - Disclosure - Business Combination" />
    <link:definitionLink xlink:type="extended" xlink:role="http://onemednet.com/role/GoingConcern" xlink:title="00000011 - Disclosure - Going Concern" />
    <link:definitionLink xlink:type="extended" xlink:role="http://onemednet.com/role/PropertyAndEquipment" xlink:title="00000012 - Disclosure - Property and Equipment" />
    <link:definitionLink xlink:type="extended" xlink:role="http://onemednet.com/role/IncomeTaxes" xlink:title="00000013 - Disclosure - Income Taxes" />
    <link:definitionLink xlink:type="extended" xlink:role="http://onemednet.com/role/ConvertiblePromissoryNotesHeldByRelatedParty" xlink:title="00000014 - Disclosure - Convertible Promissory Notes held by Related Party" />
    <link:definitionLink xlink:type="extended" xlink:role="http://onemednet.com/role/CanadianEmergencyBusinessLoanActCeba" xlink:title="00000015 - Disclosure - Canadian Emergency Business Loan Act (CEBA)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://onemednet.com/role/ShareholdersEquity" xlink:title="00000016 - Disclosure - Shareholders&#8217; Equity" />
    <link:definitionLink xlink:type="extended" xlink:role="http://onemednet.com/role/StockOptions" xlink:title="00000017 - Disclosure - Stock Options" />
    <link:definitionLink xlink:type="extended" xlink:role="http://onemednet.com/role/StockWarrants" xlink:title="00000018 - Disclosure - Stock Warrants" />
    <link:definitionLink xlink:type="extended" xlink:role="http://onemednet.com/role/FairValueMeasures" xlink:title="00000019 - Disclosure - Fair Value Measures" />
    <link:definitionLink xlink:type="extended" xlink:role="http://onemednet.com/role/RelatedPartyTransactions" xlink:title="00000020 - Disclosure - Related Party Transactions" />
    <link:definitionLink xlink:type="extended" xlink:role="http://onemednet.com/role/CommitmentsContingenciesAndConcentrationsOperatingLease" xlink:title="00000021 - Disclosure - Commitments, Contingencies, and Concentrations Operating lease" />
    <link:definitionLink xlink:type="extended" xlink:role="http://onemednet.com/role/SubsequentEvents" xlink:title="00000022 - Disclosure - Subsequent Events" />
    <link:definitionLink xlink:type="extended" xlink:role="http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000023 - Disclosure - Summary of Significant Accounting Policies (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000024 - Disclosure - Summary of Significant Accounting Policies (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://onemednet.com/role/PropertyAndEquipmentTables" xlink:title="00000025 - Disclosure - Property and Equipment (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://onemednet.com/role/IncomeTaxesTables" xlink:title="00000026 - Disclosure - Income Taxes (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://onemednet.com/role/ShareholdersEquityTables" xlink:title="00000027 - Disclosure - Shareholders&#8217; Equity (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://onemednet.com/role/StockOptionsTables" xlink:title="00000028 - Disclosure - Stock Options (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://onemednet.com/role/FairValueMeasuresTables" xlink:title="00000029 - Disclosure - Fair Value Measures (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://onemednet.com/role/OrganizationAndOperationsDetailsNarrative" xlink:title="00000030 - Disclosure - Organization and Operations (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_SecuritiesPurchaseAgreementMember" xlink:label="loc_ONMDSecuritiesPurchaseAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ONMDSecuritiesPurchaseAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_DataKnightsAcquisitionCorpMember" xlink:label="loc_ONMDDataKnightsAcquisitionCorpMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_ONMDDataKnightsAcquisitionCorpMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentIssuedPrincipal" xlink:label="loc_us-gaapDebtInstrumentIssuedPrincipal_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapDebtInstrumentIssuedPrincipal_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaapPaymentsToAcquireBusinessesGross_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapPaymentsToAcquireBusinessesGross_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentDescription" xlink:label="loc_us-gaapDebtInstrumentDescription_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapDebtInstrumentDescription_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Investments" xlink:label="loc_us-gaapInvestments_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapInvestments_30" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://onemednet.com/role/ScheduleOfAggregatePercentageRevenueAndAccountsReceivableDetails" xlink:title="00000031 - Disclosure - Schedule Of Aggregate Percentage Revenue and Accounts Receivable (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaapProductInformationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaapScheduleOfProductInformationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapScheduleOfProductInformationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="loc_us-gaapRevenueFromContractWithCustomerMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapRevenueFromContractWithCustomerMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaapAccountsReceivableMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapAccountsReceivableMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaapCustomerConcentrationRiskMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapCustomerConcentrationRiskMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="loc_srtMajorCustomersAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtMajorCustomersAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_CustomerOneMember" xlink:label="loc_ONMDCustomerOneMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_ONMDCustomerOneMember_0" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_CustomerTwoMember" xlink:label="loc_ONMDCustomerTwoMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_ONMDCustomerTwoMember_20" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_CustomersMember" xlink:label="loc_ONMDCustomersMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_ONMDCustomersMember_40" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_CustomerThreeMember" xlink:label="loc_ONMDCustomerThreeMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_ONMDCustomerThreeMember_100" xlink:type="arc" order="103" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_CustomerFourMember" xlink:label="loc_ONMDCustomerFourMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_ONMDCustomerFourMember_120" xlink:type="arc" order="123" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_CustomerFiveMember" xlink:label="loc_ONMDCustomerFiveMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_ONMDCustomerFiveMember_140" xlink:type="arc" order="143" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1_190" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000032 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaapProductInformationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaapScheduleOfProductInformationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapScheduleOfProductInformationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="loc_us-gaapRevenueFromContractWithCustomerMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapRevenueFromContractWithCustomerMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaapAccountsReceivableMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapAccountsReceivableMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaapCustomerConcentrationRiskMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapCustomerConcentrationRiskMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="loc_srtMajorCustomersAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtMajorCustomersAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_OneCustomerMember" xlink:label="loc_ONMDOneCustomerMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_ONMDOneCustomerMember_20" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_TwoCustomersMember" xlink:label="loc_ONMDTwoCustomersMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_ONMDTwoCustomersMember_30" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_ThreeCustomersMember" xlink:label="loc_ONMDThreeCustomersMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_ONMDThreeCustomersMember_40" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivableCurrent_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivableCurrent_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="loc_us-gaapImpairmentOfLongLivedAssetsToBeDisposedOf_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapImpairmentOfLongLivedAssetsToBeDisposedOf_80" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://onemednet.com/role/GoingConcernDetailsNarrative" xlink:title="00000033 - Disclosure - Going Concern (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://onemednet.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:title="00000034 - Disclosure - Schedule of Property And Equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_70" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://onemednet.com/role/PropertyAndEquipmentDetailsNarrative" xlink:title="00000035 - Disclosure - Property and Equipment (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://onemednet.com/role/ScheduleOfDeferredIncomeTaxesDetails" xlink:title="00000036 - Disclosure - Schedule of Deferred Income Taxes (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://onemednet.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000037 - Disclosure - Income Taxes (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaapOperatingLossCarryforwardsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaapOperatingLossCarryforwardsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwardsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaapDomesticCountryMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapDomesticCountryMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaapStateAndLocalJurisdictionMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapStateAndLocalJurisdictionMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_DataKnightsAcquisitionCorpMember" xlink:label="loc_ONMDDataKnightsAcquisitionCorpMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_ONMDDataKnightsAcquisitionCorpMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards_70" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://onemednet.com/role/ConvertiblePromissoryNotesHeldByRelatedPartyDetailsNarrative" xlink:title="00000038 - Disclosure - Convertible Promissory Notes held by Related Party (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonrelatedPartyMember" xlink:label="loc_us-gaapNonrelatedPartyMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapNonrelatedPartyMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_ConvertiblePromissoryNotesMember" xlink:label="loc_ONMDConvertiblePromissoryNotesMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_ONMDConvertiblePromissoryNotesMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_SeriesATwoPreferredStockMember" xlink:label="loc_ONMDSeriesATwoPreferredStockMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ONMDSeriesATwoPreferredStockMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_DataKnightsAcquisitionCorpMember" xlink:label="loc_ONMDDataKnightsAcquisitionCorpMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_ONMDDataKnightsAcquisitionCorpMember_100" xlink:type="arc" order="102" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaapConvertibleNotesPayable_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapConvertibleNotesPayable_120" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_120" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_120" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_120" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_EquityFinancingDescription" xlink:label="loc_ONMDEquityFinancingDescription_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_ONMDEquityFinancingDescription_120" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="loc_us-gaapPreferredStockConvertibleConversionPrice_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapPreferredStockConvertibleConversionPrice_120" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrentAndNoncurrent_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapAccruedLiabilitiesCurrentAndNoncurrent_120" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_120" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_120" xlink:type="arc" order="8" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://onemednet.com/role/CanadianEmergencyBusinessLoanActCebaDetailsNarrative" xlink:title="00000039 - Disclosure - Canadian Emergency Business Loan Act (CEBA) (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_CEBALoanMember" xlink:label="loc_ONMDCEBALoanMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_ONMDCEBALoanMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" xlink:label="loc_us-gaapProceedsFromIssuanceOfUnsecuredDebt_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfUnsecuredDebt_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentDecreaseForgiveness" xlink:label="loc_us-gaapDebtInstrumentDecreaseForgiveness_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentDecreaseForgiveness_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="loc_us-gaapDebtConversionOriginalDebtAmount1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtConversionOriginalDebtAmount1_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaapDebtInstrumentTerm_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentTerm_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_40" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://onemednet.com/role/ScheduleOfCommonStockActivitiesDetails" xlink:title="00000040 - Disclosure - Schedule of Common Stock Activities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="loc_srtBoardOfDirectorsChairmanMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtBoardOfDirectorsChairmanMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharesOutstanding_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_StockIssuedDuringPeriodSharesConvertibleNotesToCommonStock" xlink:label="loc_ONMDStockIssuedDuringPeriodSharesConvertibleNotesToCommonStock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ONMDStockIssuedDuringPeriodSharesConvertibleNotesToCommonStock_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_StockIssuedDuringPeriodSharesStockOptionsToCommonStock" xlink:label="loc_ONMDStockIssuedDuringPeriodSharesStockOptionsToCommonStock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ONMDStockIssuedDuringPeriodSharesStockOptionsToCommonStock_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_StockIssuedDuringPeriodSharesConvertingOfWarrantsToCommonStock" xlink:label="loc_ONMDStockIssuedDuringPeriodSharesConvertingOfWarrantsToCommonStock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ONMDStockIssuedDuringPeriodSharesConvertingOfWarrantsToCommonStock_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_StockIssuedDuringPeriodSharesConvertingDataKnightsCommonShares" xlink:label="loc_ONMDStockIssuedDuringPeriodSharesConvertingDataKnightsCommonShares_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ONMDStockIssuedDuringPeriodSharesConvertingDataKnightsCommonShares_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_40" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://onemednet.com/role/ShareholdersEquityDetailsNarrative" xlink:title="00000041 - Disclosure - Shareholders&#8217; Equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapScheduleOfStockByClassTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_SeriesATwoPreferredStockMember" xlink:label="loc_ONMDSeriesATwoPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ONMDSeriesATwoPreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_SeriesAOnePreferredStockMember" xlink:label="loc_ONMDSeriesAOnePreferredStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ONMDSeriesAOnePreferredStockMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_BoardOfDirectorsMember" xlink:label="loc_ONMDBoardOfDirectorsMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_ONMDBoardOfDirectorsMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPreferredStock" xlink:label="loc_us-gaapDividendsPreferredStock_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapDividendsPreferredStock_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:label="loc_us-gaapConvertiblePreferredStockTermsOfConversion_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapConvertiblePreferredStockTermsOfConversion_110" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_110" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharePrice_110" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://onemednet.com/role/ScheduleOfOptionsOutstandingDetails" xlink:title="00000042 - Disclosure - Schedule of Options Outstanding (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://onemednet.com/role/ScheduleOfFairValueOfStockOptionsDetails" xlink:title="00000043 - Disclosure - Schedule of Fair Value of Stock Options (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaapMeasurementInputExpectedTermMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedTermMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaapMeasurementInputExpectedDividendRateMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedDividendRateMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_EquitySecuritiesFvNiMeasurementTerm" xlink:label="loc_ONMDEquitySecuritiesFvNiMeasurementTerm_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_ONMDEquitySecuritiesFvNiMeasurementTerm_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiMeasurementInput" xlink:label="loc_us-gaapEquitySecuritiesFvNiMeasurementInput_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapEquitySecuritiesFvNiMeasurementInput_90" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://onemednet.com/role/StockOptionsDetailsNarrative" xlink:title="00000044 - Disclosure - Stock Options (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_EmployeesDirectorsAndConsultantsMember" xlink:label="loc_ONMDEmployeesDirectorsAndConsultantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_ONMDEmployeesDirectorsAndConsultantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_NewEquityIncentivePlanMember" xlink:label="loc_ONMDNewEquityIncentivePlanMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_ONMDNewEquityIncentivePlanMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_10" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_110" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_110" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_110" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_110" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_110" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_110" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_110" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_110" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_110" xlink:type="arc" order="11" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://onemednet.com/role/StockWarrantsDetailsNarrative" xlink:title="00000045 - Disclosure - Stock Warrants (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_TwentyTwentyOneServiceMember" xlink:label="loc_ONMDTwentyTwentyOneServiceMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ONMDTwentyTwentyOneServiceMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_TwentyTwentyTwoServiceMember" xlink:label="loc_ONMDTwentyTwentyTwoServiceMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ONMDTwentyTwentyTwoServiceMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_ConvertiableNotesMember" xlink:label="loc_ONMDConvertiableNotesMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_ONMDConvertiableNotesMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_WarrantOneMember" xlink:label="loc_ONMDWarrantOneMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ONMDWarrantOneMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_PubliclyTradedWarrantsMember" xlink:label="loc_ONMDPubliclyTradedWarrantsMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ONMDPubliclyTradedWarrantsMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_PrivateWarrantsMember" xlink:label="loc_ONMDPrivateWarrantsMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ONMDPrivateWarrantsMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_us-gaapWarrantMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_170" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_170" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants_170" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_170" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilities" xlink:label="loc_us-gaapOtherLiabilities_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapOtherLiabilities_170" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://onemednet.com/role/ScheduleOfFinancialAssetsDetails" xlink:title="00000046 - Disclosure - Schedule of Financial Assets (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaapFairValueByMeasurementFrequencyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaapFairValueMeasurementsRecurringMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:to="loc_us-gaapFairValueMeasurementsRecurringMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaapFairValueByAssetClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByAssetClassAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByAssetClassAxis" xlink:to="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByAssetClassAxis" xlink:to="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_InvestmentsHeldInTrustMember" xlink:label="loc_ONMDInvestmentsHeldInTrustMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="loc_ONMDInvestmentsHeldInTrustMember_0" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsHeldInTrustCurrent" xlink:label="loc_us-gaapAssetsHeldInTrustCurrent_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapAssetsHeldInTrustCurrent_160" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://onemednet.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000047 - Disclosure - Related Party Transactions (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_DataKnightsAcquisitionCorpMember" xlink:label="loc_ONMDDataKnightsAcquisitionCorpMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_ONMDDataKnightsAcquisitionCorpMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_ManagementAndDirectorsMember" xlink:label="loc_ONMDManagementAndDirectorsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_ONMDManagementAndDirectorsMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_SecuritiesPurchaseAgreementMember" xlink:label="loc_ONMDSecuritiesPurchaseAgreementMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ONMDSecuritiesPurchaseAgreementMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_SeniorConvertibleNotesMember" xlink:label="loc_ONMDSeniorConvertibleNotesMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_ONMDSeniorConvertibleNotesMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_70" xlink:type="arc" order="72" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaapConvertibleNotesPayable_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapConvertibleNotesPayable_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_ExtensionLoan" xlink:label="loc_ONMDExtensionLoan_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_ONMDExtensionLoan_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaapProceedsFromConvertibleDebt_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapProceedsFromConvertibleDebt_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrentAndNoncurrent_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapAccruedLiabilitiesCurrentAndNoncurrent_110" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_110" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentDescription" xlink:label="loc_us-gaapDebtInstrumentDescription_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtInstrumentDescription_110" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_110" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotesCurrent" xlink:label="loc_us-gaapSeniorNotesCurrent_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapSeniorNotesCurrent_110" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://onemednet.com/role/CommitmentsContingenciesAndConcentrationsOperatingLeaseDetailsNarrative" xlink:title="00000048 - Disclosure - Commitments, Contingencies, and Concentrations Operating lease (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://onemednet.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000049 - Disclosure - Subsequent Events (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSubsequentEventTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_srtStatementScenarioAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember" xlink:label="loc_srtScenarioForecastMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_srtScenarioForecastMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_EFHuttonMember" xlink:label="loc_ONMDEFHuttonMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_ONMDEFHuttonMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_KingwoodCapitalPartnersLLCMember" xlink:label="loc_ONMDKingwoodCapitalPartnersLLCMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_ONMDKingwoodCapitalPartnersLLCMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MajorityShareholderMember" xlink:label="loc_us-gaapMajorityShareholderMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapMajorityShareholderMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="loc_srtBoardOfDirectorsChairmanMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtBoardOfDirectorsChairmanMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaapBusinessCombinationConsiderationTransferred1_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapBusinessCombinationConsiderationTransferred1_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodShares_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodShares_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaapRelatedPartyTransactionAmountsOfTransaction_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionAmountsOfTransaction_80" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRelatedPartyDebt_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapProceedsFromRelatedPartyDebt_80" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement_80" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSharePrice_80" xlink:type="arc" order="6" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>41
<FILENAME>onmd-20231231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="dei_EntityAddressesAddressTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_EntityAddressesAddressTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesAddressTypeAxis_lbl" xml:lang="en-US">Entity Addresses, Address Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_BusinessContactMember" xlink:label="dei_BusinessContactMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_BusinessContactMember" xlink:to="dei_BusinessContactMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_BusinessContactMember_lbl" xml:lang="en-US">Business Contact [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyMember_lbl" xml:lang="en-US">Related Party [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_SeriesATwoPreferredStockMember" xlink:label="ONMD_SeriesATwoPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_SeriesATwoPreferredStockMember" xlink:to="ONMD_SeriesATwoPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ONMD_SeriesATwoPreferredStockMember_lbl" xml:lang="en-US">Series A-2 Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_SeriesAOnePreferredStockMember" xlink:label="ONMD_SeriesAOnePreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_SeriesAOnePreferredStockMember" xlink:to="ONMD_SeriesAOnePreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ONMD_SeriesAOnePreferredStockMember_lbl" xml:lang="en-US">Series A-1 Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonClassAMember" xlink:to="us-gaap_CommonClassAMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonClassAMember_lbl" xml:lang="en-US">Common Class A [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_CommonClassAOneMember" xlink:label="ONMD_CommonClassAOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_CommonClassAOneMember" xlink:to="ONMD_CommonClassAOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ONMD_CommonClassAOneMember_lbl" xml:lang="en-US">Common Class A One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xml:lang="en-US">Business Acquisition [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_DataKnightsAcquisitionCorpMember" xlink:label="ONMD_DataKnightsAcquisitionCorpMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_DataKnightsAcquisitionCorpMember" xlink:to="ONMD_DataKnightsAcquisitionCorpMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ONMD_DataKnightsAcquisitionCorpMember_lbl" xml:lang="en-US">Data Knights Acquisition Corp [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonClassBMember" xlink:to="us-gaap_CommonClassBMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonClassBMember_lbl" xml:lang="en-US">Common Class B [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_CommitmentMember" xlink:label="ONMD_CommitmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_CommitmentMember" xlink:to="ONMD_CommitmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ONMD_CommitmentMember_lbl" xml:lang="en-US">Commitment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_SecuritiesPurchaseAgreementMember" xlink:label="ONMD_SecuritiesPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_SecuritiesPurchaseAgreementMember" xlink:to="ONMD_SecuritiesPurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ONMD_SecuritiesPurchaseAgreementMember_lbl" xml:lang="en-US">Securities Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="us-gaap_RevenueFromContractWithCustomerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerMember" xlink:to="us-gaap_RevenueFromContractWithCustomerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerMember_lbl" xml:lang="en-US">Revenue from Contract with Customer Benchmark [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MajorCustomersAxis_lbl" xml:lang="en-US">Customer [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_OneCustomerMember" xlink:label="ONMD_OneCustomerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_OneCustomerMember" xlink:to="ONMD_OneCustomerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ONMD_OneCustomerMember_lbl" xml:lang="en-US">One Customer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_TwoCustomersMember" xlink:label="ONMD_TwoCustomersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_TwoCustomersMember" xlink:to="ONMD_TwoCustomersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ONMD_TwoCustomersMember_lbl" xml:lang="en-US">Two Customers [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableMember_lbl" xml:lang="en-US">Accounts Receivable [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_ThreeCustomersMember" xlink:label="ONMD_ThreeCustomersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_ThreeCustomersMember" xlink:to="ONMD_ThreeCustomersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ONMD_ThreeCustomersMember_lbl" xml:lang="en-US">Three Customers [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_CustomerOneMember" xlink:label="ONMD_CustomerOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_CustomerOneMember" xlink:to="ONMD_CustomerOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ONMD_CustomerOneMember_lbl" xml:lang="en-US">Customer One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_CustomerTwoMember" xlink:label="ONMD_CustomerTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_CustomerTwoMember" xlink:to="ONMD_CustomerTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ONMD_CustomerTwoMember_lbl" xml:lang="en-US">Customer Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_CustomersMember" xlink:label="ONMD_CustomersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_CustomersMember" xlink:to="ONMD_CustomersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ONMD_CustomersMember_lbl" xml:lang="en-US">Customers [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_CustomerThreeMember" xlink:label="ONMD_CustomerThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_CustomerThreeMember" xlink:to="ONMD_CustomerThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ONMD_CustomerThreeMember_lbl" xml:lang="en-US">Customer Three [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_CustomerFourMember" xlink:label="ONMD_CustomerFourMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_CustomerFourMember" xlink:to="ONMD_CustomerFourMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ONMD_CustomerFourMember_lbl" xml:lang="en-US">Customer Four [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_CustomerFiveMember" xlink:label="ONMD_CustomerFiveMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_CustomerFiveMember" xlink:to="ONMD_CustomerFiveMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ONMD_CustomerFiveMember_lbl" xml:lang="en-US">Customer Five [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US">Computer Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonrelatedPartyMember" xlink:label="us-gaap_NonrelatedPartyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonrelatedPartyMember" xlink:to="us-gaap_NonrelatedPartyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonrelatedPartyMember_lbl" xml:lang="en-US">Nonrelated Party [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_ConvertiblePromissoryNotesMember" xlink:label="ONMD_ConvertiblePromissoryNotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_ConvertiblePromissoryNotesMember" xlink:to="ONMD_ConvertiblePromissoryNotesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ONMD_ConvertiblePromissoryNotesMember_lbl" xml:lang="en-US">Convertible Promissory Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_CEBALoanMember" xlink:label="ONMD_CEBALoanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_CEBALoanMember" xlink:to="ONMD_CEBALoanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ONMD_CEBALoanMember_lbl" xml:lang="en-US">CEBA Loan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_BoardOfDirectorsMember" xlink:label="ONMD_BoardOfDirectorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_BoardOfDirectorsMember" xlink:to="ONMD_BoardOfDirectorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ONMD_BoardOfDirectorsMember_lbl" xml:lang="en-US">Board Of Directors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="srt_BoardOfDirectorsChairmanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_BoardOfDirectorsChairmanMember" xlink:to="srt_BoardOfDirectorsChairmanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_BoardOfDirectorsChairmanMember_lbl" xml:lang="en-US">Board of Directors Chairman [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_EmployeesDirectorsAndConsultantsMember" xlink:label="ONMD_EmployeesDirectorsAndConsultantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_EmployeesDirectorsAndConsultantsMember" xlink:to="ONMD_EmployeesDirectorsAndConsultantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ONMD_EmployeesDirectorsAndConsultantsMember_lbl" xml:lang="en-US">Employees Directors and Consultants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_NewEquityIncentivePlanMember" xlink:label="ONMD_NewEquityIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_NewEquityIncentivePlanMember" xlink:to="ONMD_NewEquityIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ONMD_NewEquityIncentivePlanMember_lbl" xml:lang="en-US">New Equity Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_TwentyTwentyOneServiceMember" xlink:label="ONMD_TwentyTwentyOneServiceMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_TwentyTwentyOneServiceMember" xlink:to="ONMD_TwentyTwentyOneServiceMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ONMD_TwentyTwentyOneServiceMember_lbl" xml:lang="en-US">2021 Service [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_TwentyTwentyTwoServiceMember" xlink:label="ONMD_TwentyTwentyTwoServiceMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_TwentyTwentyTwoServiceMember" xlink:to="ONMD_TwentyTwentyTwoServiceMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ONMD_TwentyTwentyTwoServiceMember_lbl" xml:lang="en-US">2022 Service [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_ConvertiableNotesMember" xlink:label="ONMD_ConvertiableNotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_ConvertiableNotesMember" xlink:to="ONMD_ConvertiableNotesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ONMD_ConvertiableNotesMember_lbl" xml:lang="en-US">Convertiable Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_WarrantOneMember" xlink:label="ONMD_WarrantOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_WarrantOneMember" xlink:to="ONMD_WarrantOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ONMD_WarrantOneMember_lbl" xml:lang="en-US">Warrant One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_PubliclyTradedWarrantsMember" xlink:label="ONMD_PubliclyTradedWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_PubliclyTradedWarrantsMember" xlink:to="ONMD_PubliclyTradedWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ONMD_PubliclyTradedWarrantsMember_lbl" xml:lang="en-US">Publicly Traded Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_PrivateWarrantsMember" xlink:label="ONMD_PrivateWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_PrivateWarrantsMember" xlink:to="ONMD_PrivateWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ONMD_PrivateWarrantsMember_lbl" xml:lang="en-US">Private Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xml:lang="en-US">Asset Class [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_InvestmentsHeldInTrustMember" xlink:label="ONMD_InvestmentsHeldInTrustMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_InvestmentsHeldInTrustMember" xlink:to="ONMD_InvestmentsHeldInTrustMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ONMD_InvestmentsHeldInTrustMember_lbl" xml:lang="en-US">Investments Held in Trust [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_ManagementAndDirectorsMember" xlink:label="ONMD_ManagementAndDirectorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_ManagementAndDirectorsMember" xlink:to="ONMD_ManagementAndDirectorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ONMD_ManagementAndDirectorsMember_lbl" xml:lang="en-US">Management and Directors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_SeniorConvertibleNotesMember" xlink:label="ONMD_SeniorConvertibleNotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_SeniorConvertibleNotesMember" xlink:to="ONMD_SeniorConvertibleNotesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ONMD_SeniorConvertibleNotesMember_lbl" xml:lang="en-US">Senior Convertible Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioForecastMember_lbl" xml:lang="en-US">Forecast [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_EFHuttonMember" xlink:label="ONMD_EFHuttonMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_EFHuttonMember" xlink:to="ONMD_EFHuttonMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ONMD_EFHuttonMember_lbl" xml:lang="en-US">EF Hutton [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_KingwoodCapitalPartnersLLCMember" xlink:label="ONMD_KingwoodCapitalPartnersLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_KingwoodCapitalPartnersLLCMember" xlink:to="ONMD_KingwoodCapitalPartnersLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ONMD_KingwoodCapitalPartnersLLCMember_lbl" xml:lang="en-US">Kingwood Capital Partners LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MajorityShareholderMember" xlink:label="us-gaap_MajorityShareholderMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MajorityShareholderMember" xlink:to="us-gaap_MajorityShareholderMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MajorityShareholderMember_lbl" xml:lang="en-US">Majority Shareholder [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesTable" xlink:label="dei_EntityAddressesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesTable" xlink:to="dei_EntityAddressesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesTable_lbl" xml:lang="en-US">Entity Addresses [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesLineItems" xlink:label="dei_EntityAddressesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesLineItems" xlink:to="dei_EntityAddressesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesLineItems_lbl" xml:lang="en-US">Entity Addresses [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelName" xlink:label="dei_ContactPersonnelName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_ContactPersonnelName" xlink:to="dei_ContactPersonnelName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_ContactPersonnelName_lbl" xml:lang="en-US">Contact Personnel Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsHeldInTrustCurrent" xlink:label="us-gaap_AssetsHeldInTrustCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsHeldInTrustCurrent" xlink:to="us-gaap_AssetsHeldInTrustCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsHeldInTrustCurrent_lbl" xml:lang="en-US">Investments held in Trust</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable, net of allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivables" xlink:label="us-gaap_OtherReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivables" xlink:to="us-gaap_OtherReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivables_lbl" xml:lang="en-US">Receivable from SPAC</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and Equipment, Net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accounts payable &amp; accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherShortTermBorrowings" xlink:label="us-gaap_OtherShortTermBorrowings" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherShortTermBorrowings" xlink:to="us-gaap_OtherShortTermBorrowings_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherShortTermBorrowings_lbl" xml:lang="en-US">Loan Amount due to related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesAndExciseTaxPayableCurrent" xlink:label="us-gaap_SalesAndExciseTaxPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesAndExciseTaxPayableCurrent" xlink:to="us-gaap_SalesAndExciseTaxPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesAndExciseTaxPayableCurrent_lbl" xml:lang="en-US">Excise tax</link:label>
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_LoanExtensionsCurrent" xlink:label="ONMD_LoanExtensionsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_LoanExtensionsCurrent" xlink:to="ONMD_LoanExtensionsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ONMD_LoanExtensionsCurrent_lbl" xml:lang="en-US">Loan Extensions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US">Deferred revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayable" xlink:label="us-gaap_LoansPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansPayable" xlink:to="us-gaap_LoansPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansPayable_lbl" xml:lang="en-US">Loan Payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="us-gaap_ConvertibleDebtCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtCurrent" xlink:to="us-gaap_ConvertibleDebtCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtCurrent_lbl" xml:lang="en-US">Convertible promissory notes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnsecuredDebtCurrent" xlink:label="us-gaap_UnsecuredDebtCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnsecuredDebtCurrent" xlink:to="us-gaap_UnsecuredDebtCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnsecuredDebtCurrent_lbl" xml:lang="en-US">Canada Emergency Business Loan Act</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedIncomeTaxesCurrent" xlink:to="us-gaap_AccruedIncomeTaxesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_lbl" xml:lang="en-US">Income tax payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:label="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:to="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent_lbl" xml:lang="en-US">Franchise tax payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNotesPayableCurrent" xlink:label="us-gaap_OtherNotesPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNotesPayableCurrent" xlink:to="us-gaap_OtherNotesPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNotesPayableCurrent_lbl" xml:lang="en-US">Pipe Notes, net of discount including interest</link:label>
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_DeferredUnderwriterFeePayableCurrent" xlink:label="ONMD_DeferredUnderwriterFeePayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_DeferredUnderwriterFeePayableCurrent" xlink:to="ONMD_DeferredUnderwriterFeePayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ONMD_DeferredUnderwriterFeePayableCurrent_lbl" xml:lang="en-US">Deferred underwriter fee payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">Long Term Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="us-gaap_ConvertibleDebtNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtNoncurrent" xlink:to="us-gaap_ConvertibleDebtNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtNoncurrent_lbl" xml:lang="en-US">Convertible promissory note</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnsecuredDebt" xlink:label="us-gaap_UnsecuredDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnsecuredDebt" xlink:to="us-gaap_UnsecuredDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_UnsecuredDebt_lbl" xml:lang="en-US">Canada Emergency Business Loan Act</link:label>
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_AccruedInterestRelatedParty" xlink:label="ONMD_AccruedInterestRelatedParty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_AccruedInterestRelatedParty" xlink:to="ONMD_AccruedInterestRelatedParty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ONMD_AccruedInterestRelatedParty_lbl" xml:lang="en-US">Accrued interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US">Loan, related party of OMN</link:label>
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_WarrantLiabilityNonCurrent" xlink:label="ONMD_WarrantLiabilityNonCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_WarrantLiabilityNonCurrent" xlink:to="ONMD_WarrantLiabilityNonCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ONMD_WarrantLiabilityNonCurrent_lbl" xml:lang="en-US">Warrant liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_DeferredUnderwriterFeePayableNonCurrent" xlink:label="ONMD_DeferredUnderwriterFeePayableNonCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_DeferredUnderwriterFeePayableNonCurrent" xlink:to="ONMD_DeferredUnderwriterFeePayableNonCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ONMD_DeferredUnderwriterFeePayableNonCurrent_lbl" xml:lang="en-US">Deferred underwriter fee payable</link:label>
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_WorkingCapitalLoan" xlink:label="ONMD_WorkingCapitalLoan" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_WorkingCapitalLoan" xlink:to="ONMD_WorkingCapitalLoan_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ONMD_WorkingCapitalLoan_lbl" xml:lang="en-US">Working capital Loan</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermLoansPayable" xlink:label="us-gaap_LongTermLoansPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermLoansPayable" xlink:to="us-gaap_LongTermLoansPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermLoansPayable_lbl" xml:lang="en-US">Extension loans</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; Equity (Deficit)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders&#8217; equity (deficit)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders&#8217; equity (deficit)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US">Revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">Cost of Revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">Gross Margin</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherGeneralExpense" xlink:label="us-gaap_OtherGeneralExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherGeneralExpense" xlink:to="us-gaap_OtherGeneralExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherGeneralExpense_lbl" xml:lang="en-US">Operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="us-gaap_SellingAndMarketingExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpense" xlink:to="us-gaap_SellingAndMarketingExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingAndMarketingExpense_lbl" xml:lang="en-US">Sales &amp; Marketing</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total Operating Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other Expense (income)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xml:lang="en-US">Impairment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax provision</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xml:lang="en-US">Other expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US">Change in FV of Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionPlanExpense" xlink:label="us-gaap_StockOptionPlanExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionPlanExpense" xlink:to="us-gaap_StockOptionPlanExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionPlanExpense_lbl" xml:lang="en-US">Stock Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_UnrealizedGainLoss" xlink:label="ONMD_UnrealizedGainLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_UnrealizedGainLoss" xlink:to="ONMD_UnrealizedGainLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ONMD_UnrealizedGainLoss_lbl" xml:lang="en-US">Unrealized gain or loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Other Expense (income)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Loss per share of Common Stock:(1)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_lbl" xml:lang="en-US">Weighted-average shares of Common Stock outstanding:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Beginning balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US">Issuance of common shares in exchange for services</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US">Issuance of common shares in exchange for services, share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance Public Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance public shares, share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xml:lang="en-US">Issuance of Data Knights Acquisition Corp. Class B Common Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xml:lang="en-US">Issuance of common class B stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_CommonStockSubjectToPossibleRedemptionValue" xlink:label="ONMD_CommonStockSubjectToPossibleRedemptionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_CommonStockSubjectToPossibleRedemptionValue" xlink:to="ONMD_CommonStockSubjectToPossibleRedemptionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ONMD_CommonStockSubjectToPossibleRedemptionValue_lbl" xml:lang="en-US">Common stock redemption</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Stock-based compensation expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Preferred Stock to Common Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Preferred stock to common stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_StockIssuedDuringPeriodValueConvertibleNotesToCommonStock" xlink:label="ONMD_StockIssuedDuringPeriodValueConvertibleNotesToCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_StockIssuedDuringPeriodValueConvertibleNotesToCommonStock" xlink:to="ONMD_StockIssuedDuringPeriodValueConvertibleNotesToCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ONMD_StockIssuedDuringPeriodValueConvertibleNotesToCommonStock_lbl" xml:lang="en-US">Convertible Notes to Common Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_StockIssuedDuringPeriodSharesConvertibleNotesToCommonStock" xlink:label="ONMD_StockIssuedDuringPeriodSharesConvertibleNotesToCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_StockIssuedDuringPeriodSharesConvertibleNotesToCommonStock" xlink:to="ONMD_StockIssuedDuringPeriodSharesConvertibleNotesToCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ONMD_StockIssuedDuringPeriodSharesConvertibleNotesToCommonStock_lbl" xml:lang="en-US">Convertible notes to common stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_StockIssuedDuringPeriodValueStockOptionsToCommonStock" xlink:label="ONMD_StockIssuedDuringPeriodValueStockOptionsToCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_StockIssuedDuringPeriodValueStockOptionsToCommonStock" xlink:to="ONMD_StockIssuedDuringPeriodValueStockOptionsToCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ONMD_StockIssuedDuringPeriodValueStockOptionsToCommonStock_lbl" xml:lang="en-US">Stock Options to Common Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_StockIssuedDuringPeriodSharesStockOptionsToCommonStock" xlink:label="ONMD_StockIssuedDuringPeriodSharesStockOptionsToCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_StockIssuedDuringPeriodSharesStockOptionsToCommonStock" xlink:to="ONMD_StockIssuedDuringPeriodSharesStockOptionsToCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ONMD_StockIssuedDuringPeriodSharesStockOptionsToCommonStock_lbl" xml:lang="en-US">Stock issued during period shares options to common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_StockIssuedDuringPeriodValueConvertingOfWarrantsToCommonStock" xlink:label="ONMD_StockIssuedDuringPeriodValueConvertingOfWarrantsToCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_StockIssuedDuringPeriodValueConvertingOfWarrantsToCommonStock" xlink:to="ONMD_StockIssuedDuringPeriodValueConvertingOfWarrantsToCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ONMD_StockIssuedDuringPeriodValueConvertingOfWarrantsToCommonStock_lbl" xml:lang="en-US">Converting of Warrants to Common Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_StockIssuedDuringPeriodSharesConvertingOfWarrantsToCommonStock" xlink:label="ONMD_StockIssuedDuringPeriodSharesConvertingOfWarrantsToCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_StockIssuedDuringPeriodSharesConvertingOfWarrantsToCommonStock" xlink:to="ONMD_StockIssuedDuringPeriodSharesConvertingOfWarrantsToCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ONMD_StockIssuedDuringPeriodSharesConvertingOfWarrantsToCommonStock_lbl" xml:lang="en-US">Converting of warrants to common stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Private OneMedNet to ONMD Public Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Stock issued during period shares other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xml:lang="en-US">Issuance of PIPE Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_StockIssuedDuringPeriodValueConvertingDataKnightsCommonShares" xlink:label="ONMD_StockIssuedDuringPeriodValueConvertingDataKnightsCommonShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_StockIssuedDuringPeriodValueConvertingDataKnightsCommonShares" xlink:to="ONMD_StockIssuedDuringPeriodValueConvertingDataKnightsCommonShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ONMD_StockIssuedDuringPeriodValueConvertingDataKnightsCommonShares_lbl" xml:lang="en-US">Converting Data Knights Common Shares (A and B) to ONMD Public Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_StockIssuedDuringPeriodSharesConvertingDataKnightsCommonShares" xlink:label="ONMD_StockIssuedDuringPeriodSharesConvertingDataKnightsCommonShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_StockIssuedDuringPeriodSharesConvertingDataKnightsCommonShares" xlink:to="ONMD_StockIssuedDuringPeriodSharesConvertingDataKnightsCommonShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ONMD_StockIssuedDuringPeriodSharesConvertingDataKnightsCommonShares_lbl" xml:lang="en-US">Converting Data Knights Common Shares (A and B) to ONMD Public Shares, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_RetainedEarningsAdjustment" xlink:label="ONMD_RetainedEarningsAdjustment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_RetainedEarningsAdjustment" xlink:to="ONMD_RetainedEarningsAdjustment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ONMD_RetainedEarningsAdjustment_lbl" xml:lang="en-US">Retained earnings adjustment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Ending Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Ending balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Share Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flow from Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_3_lbl" xml:lang="en-US">Net Loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash flows from operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_BusinessCombinationCost" xlink:label="ONMD_BusinessCombinationCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_BusinessCombinationCost" xlink:to="ONMD_BusinessCombinationCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ONMD_BusinessCombinationCost_lbl" xml:lang="en-US">Business combination cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_CashHeldInTrustAccount" xlink:label="ONMD_CashHeldInTrustAccount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_CashHeldInTrustAccount" xlink:to="ONMD_CashHeldInTrustAccount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ONMD_CashHeldInTrustAccount_lbl" xml:lang="en-US">Cash Held in Trust Account</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US">Prepaid Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xml:lang="en-US">Other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable and accrued Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Accounts receivable, net of allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US">Deferred Revenue &amp; Customer Deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedParties_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties_lbl" xml:lang="en-US">Amount due to related party</link:label>
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_IncreaseDecreaseInExerciseTaxLiability" xlink:label="ONMD_IncreaseDecreaseInExerciseTaxLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_IncreaseDecreaseInExerciseTaxLiability" xlink:to="ONMD_IncreaseDecreaseInExerciseTaxLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ONMD_IncreaseDecreaseInExerciseTaxLiability_lbl" xml:lang="en-US">Exercise tax liability</link:label>
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_IncreaseDecreaseInExtensionLoan" xlink:label="ONMD_IncreaseDecreaseInExtensionLoan" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_IncreaseDecreaseInExtensionLoan" xlink:to="ONMD_IncreaseDecreaseInExtensionLoan_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ONMD_IncreaseDecreaseInExtensionLoan_lbl" xml:lang="en-US">Extension loan</link:label>
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_IncreaseDecreaseFranchiseTaxPayable" xlink:label="ONMD_IncreaseDecreaseFranchiseTaxPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_IncreaseDecreaseFranchiseTaxPayable" xlink:to="ONMD_IncreaseDecreaseFranchiseTaxPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ONMD_IncreaseDecreaseFranchiseTaxPayable_lbl" xml:lang="en-US">Franchise tax payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_lbl" xml:lang="en-US">Income Tax Payable</link:label>
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_IncreaseDecreaseInWorkingCapitalLoan" xlink:label="ONMD_IncreaseDecreaseInWorkingCapitalLoan" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_IncreaseDecreaseInWorkingCapitalLoan" xlink:to="ONMD_IncreaseDecreaseInWorkingCapitalLoan_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ONMD_IncreaseDecreaseInWorkingCapitalLoan_lbl" xml:lang="en-US">Working capital loan</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash flows used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash used for Investing Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flow from Financing Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_ProceedsFromIssuanceOfCommonStockOne" xlink:label="ONMD_ProceedsFromIssuanceOfCommonStockOne" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_ProceedsFromIssuanceOfCommonStockOne" xlink:to="ONMD_ProceedsFromIssuanceOfCommonStockOne_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ONMD_ProceedsFromIssuanceOfCommonStockOne_lbl" xml:lang="en-US">Class B Common Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRepaymentsOfNotesPayable" xlink:label="us-gaap_ProceedsFromRepaymentsOfNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRepaymentsOfNotesPayable" xlink:to="us-gaap_ProceedsFromRepaymentsOfNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRepaymentsOfNotesPayable_lbl" xml:lang="en-US">Proceeds (repayment) from issuance of convertible promissory note payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US">Proceeds from issuance of PIPE Convertible Notes and Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xml:lang="en-US">Proceed from related party loan</link:label>
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_ProceedsFromBusinessLoan" xlink:label="ONMD_ProceedsFromBusinessLoan" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_ProceedsFromBusinessLoan" xlink:to="ONMD_ProceedsFromBusinessLoan_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ONMD_ProceedsFromBusinessLoan_lbl" xml:lang="en-US">Proceeds from Canada Emergency Business Loan Act</link:label>
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_ProceedsFromCommonStockSubjectToRedemption" xlink:label="ONMD_ProceedsFromCommonStockSubjectToRedemption" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_ProceedsFromCommonStockSubjectToRedemption" xlink:to="ONMD_ProceedsFromCommonStockSubjectToRedemption_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ONMD_ProceedsFromCommonStockSubjectToRedemption_lbl" xml:lang="en-US">Common Stock Subject to Redemption</link:label>
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_ProceedsFromDeferredUnderwritingFee" xlink:label="ONMD_ProceedsFromDeferredUnderwritingFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_ProceedsFromDeferredUnderwritingFee" xlink:to="ONMD_ProceedsFromDeferredUnderwritingFee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ONMD_ProceedsFromDeferredUnderwritingFee_lbl" xml:lang="en-US">Deferred underwriting fee</link:label>
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_ProceedsFromWarrantLiability" xlink:label="ONMD_ProceedsFromWarrantLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_ProceedsFromWarrantLiability" xlink:to="ONMD_ProceedsFromWarrantLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ONMD_ProceedsFromWarrantLiability_lbl" xml:lang="en-US">Warrant liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromContributedCapital" xlink:label="us-gaap_ProceedsFromContributedCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromContributedCapital" xlink:to="us-gaap_ProceedsFromContributedCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromContributedCapital_lbl" xml:lang="en-US">Additional Paid-in Capital</link:label>
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_ProceedsFromIssuanceOfCommonStockTwo" xlink:label="ONMD_ProceedsFromIssuanceOfCommonStockTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_ProceedsFromIssuanceOfCommonStockTwo" xlink:to="ONMD_ProceedsFromIssuanceOfCommonStockTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ONMD_ProceedsFromIssuanceOfCommonStockTwo_lbl" xml:lang="en-US">Class A Common Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_ClassBCommonStock" xlink:label="ONMD_ClassBCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_ClassBCommonStock" xlink:to="ONMD_ClassBCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ONMD_ClassBCommonStock_lbl" xml:lang="en-US">Class B Common Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_ProccedsFromRetainedEarningsAdjustment" xlink:label="ONMD_ProccedsFromRetainedEarningsAdjustment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_ProccedsFromRetainedEarningsAdjustment" xlink:to="ONMD_ProccedsFromRetainedEarningsAdjustment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ONMD_ProccedsFromRetainedEarningsAdjustment_lbl" xml:lang="en-US">Retained Earnings adjustment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash flows from financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net change in cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Cash and Cash Equivalents, Beginning</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xml:lang="en-US">Cash and Cash Equivalents, Ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Organization and Operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_lbl" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xml:lang="en-US">Business Combination</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" xml:lang="en-US">Going Concern</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">Property and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="us-gaap_LongTermDebtTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtTextBlock" xlink:to="us-gaap_LongTermDebtTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtTextBlock_lbl" xml:lang="en-US">Convertible Promissory Notes held by Related Party</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">Canadian Emergency Business Loan Act (CEBA)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Shareholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Stock Options</link:label>
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_DisclosureStockWarrantsAbstract" xlink:label="ONMD_DisclosureStockWarrantsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_DisclosureStockWarrantsAbstract" xlink:to="ONMD_DisclosureStockWarrantsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ONMD_DisclosureStockWarrantsAbstract_lbl" xml:lang="en-US">Stock Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_StockWarrantsDisclosureTextBlock" xlink:label="ONMD_StockWarrantsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_StockWarrantsDisclosureTextBlock" xlink:to="ONMD_StockWarrantsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ONMD_StockWarrantsDisclosureTextBlock_lbl" xml:lang="en-US">Stock Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">Fair Value Measures</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">Related Party Transactions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments, Contingencies, and Concentrations Operating lease</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xml:lang="en-US">Basis of Presentation and Foreign Currency Translation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="us-gaap_BusinessCombinationsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsPolicy" xlink:to="us-gaap_BusinessCombinationsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BusinessCombinationsPolicy_lbl" xml:lang="en-US">Business Combination</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_OperatingSegmentsPolicyTextBlock" xlink:label="ONMD_OperatingSegmentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_OperatingSegmentsPolicyTextBlock" xlink:to="ONMD_OperatingSegmentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ONMD_OperatingSegmentsPolicyTextBlock_lbl" xml:lang="en-US">Operating Segments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xml:lang="en-US">Accounts Receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_PatentsAndTrademarksPolicyTextBlock" xlink:label="ONMD_PatentsAndTrademarksPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_PatentsAndTrademarksPolicyTextBlock" xlink:to="ONMD_PatentsAndTrademarksPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ONMD_PatentsAndTrademarksPolicyTextBlock_lbl" xml:lang="en-US">Patents and Trademarks</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US">Stock-based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xml:lang="en-US">General, and Administrative Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_EmergingGrowthCompanyPolicyTextBlock" xlink:label="ONMD_EmergingGrowthCompanyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_EmergingGrowthCompanyPolicyTextBlock" xlink:to="ONMD_EmergingGrowthCompanyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ONMD_EmergingGrowthCompanyPolicyTextBlock_lbl" xml:lang="en-US">Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_AccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:label="ONMD_AccountingPronouncementsNotYetAdoptedPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_AccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:to="ONMD_AccountingPronouncementsNotYetAdoptedPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ONMD_AccountingPronouncementsNotYetAdoptedPolicyTextBlock_lbl" xml:lang="en-US">Accounting Pronouncements Not Yet Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently adopted accounting pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl" xml:lang="en-US">Schedule Of Aggregate Percentage Revenue and Accounts Receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of Property And Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Deferred Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_lbl" xml:lang="en-US">Schedule of Common Stock Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Options Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US">Schedule of Fair Value of Stock Options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xml:lang="en-US">Schedule of Financial Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentIssuedPrincipal" xlink:label="us-gaap_DebtInstrumentIssuedPrincipal" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentIssuedPrincipal" xlink:to="us-gaap_DebtInstrumentIssuedPrincipal_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentIssuedPrincipal_lbl" xml:lang="en-US">Debt Instrument, Issued, Principal</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross_lbl" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentDescription" xlink:label="us-gaap_DebtInstrumentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentDescription" xlink:to="us-gaap_DebtInstrumentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentDescription_lbl" xml:lang="en-US">Debt Instrument, Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Investments" xlink:label="us-gaap_Investments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Investments" xlink:to="us-gaap_Investments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Investments_lbl" xml:lang="en-US">Investments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="us-gaap_ScheduleOfProductInformationTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfProductInformationTable" xlink:to="us-gaap_ScheduleOfProductInformationTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfProductInformationTable_lbl" xml:lang="en-US">Schedule of Product Information [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductInformationLineItems" xlink:label="us-gaap_ProductInformationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductInformationLineItems" xlink:to="us-gaap_ProductInformationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductInformationLineItems_lbl" xml:lang="en-US">Product Information [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US">Aggregate Percent of Revenue and Accounts Receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConcentrationRiskPercentage1_2_lbl" xml:lang="en-US">Concentration Risk, Percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl" xml:lang="en-US">Impairment of Long-Lived Assets to be Disposed of</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Total Property and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less: accumulated depreciation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xml:lang="en-US">Net Property and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xml:lang="en-US">Deferred Tax Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carry forward</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US">Stock Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Gross deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Less valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Net deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Operating Loss Carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="us-gaap_ScheduleOfShortTermDebtTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ScheduleOfShortTermDebtTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShortTermDebtTable_lbl" xml:lang="en-US">Schedule of Short-Term Debt [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="us-gaap_ShortTermDebtLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ShortTermDebtLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtLineItems_lbl" xml:lang="en-US">Short-Term Debt [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="us-gaap_ConvertibleNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayable" xlink:to="us-gaap_ConvertibleNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayable_lbl" xml:lang="en-US">Convertible Notes Payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_EquityFinancingDescription" xlink:label="ONMD_EquityFinancingDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_EquityFinancingDescription" xlink:to="ONMD_EquityFinancingDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ONMD_EquityFinancingDescription_lbl" xml:lang="en-US">[custom:EquityFinancingDescription]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleConversionPrice" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice_lbl" xml:lang="en-US">Preferred Stock, Convertible, Conversion Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Accrued Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfUnsecuredDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfUnsecuredDebt_lbl" xml:lang="en-US">Proceeds from Issuance of Unsecured Debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentDecreaseForgiveness" xlink:label="us-gaap_DebtInstrumentDecreaseForgiveness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentDecreaseForgiveness" xlink:to="us-gaap_DebtInstrumentDecreaseForgiveness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentDecreaseForgiveness_lbl" xml:lang="en-US">Debt Instrument, Decrease, Forgiveness</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionOriginalDebtAmount1" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1_lbl" xml:lang="en-US">Debt Conversion, Original Debt, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xml:lang="en-US">Debt Instrument, Term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_2_lbl" xml:lang="en-US">Preferred Stock to Common Stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_StockIssuedDuringPeriodSharesConvertibleNotesToCommonStock" xlink:to="ONMD_StockIssuedDuringPeriodSharesConvertibleNotesToCommonStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ONMD_StockIssuedDuringPeriodSharesConvertibleNotesToCommonStock_2_lbl" xml:lang="en-US">Convertible Notes to Common Stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_StockIssuedDuringPeriodSharesStockOptionsToCommonStock" xlink:to="ONMD_StockIssuedDuringPeriodSharesStockOptionsToCommonStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ONMD_StockIssuedDuringPeriodSharesStockOptionsToCommonStock_2_lbl" xml:lang="en-US">Stock Options to Common Stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_StockIssuedDuringPeriodSharesConvertingOfWarrantsToCommonStock" xlink:to="ONMD_StockIssuedDuringPeriodSharesConvertingOfWarrantsToCommonStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ONMD_StockIssuedDuringPeriodSharesConvertingOfWarrantsToCommonStock_2_lbl" xml:lang="en-US">Converting of Warrants to Common Stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_2_lbl" xml:lang="en-US">Private OneMedNet to ONMD Public Shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_StockIssuedDuringPeriodSharesConvertingDataKnightsCommonShares" xlink:to="ONMD_StockIssuedDuringPeriodSharesConvertingDataKnightsCommonShares_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ONMD_StockIssuedDuringPeriodSharesConvertingDataKnightsCommonShares_2_lbl" xml:lang="en-US">Converting Data Knights Common Stock (A and B) to ONMD Public Shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Issuance Public Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Class of Stock [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Shares Issued, Price Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPreferredStock" xlink:label="us-gaap_DividendsPreferredStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPreferredStock" xlink:to="us-gaap_DividendsPreferredStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsPreferredStock_lbl" xml:lang="en-US">Dividends, Preferred Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xml:lang="en-US">Proceeds from Issuance of Preferred Stock and Preference Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:label="us-gaap_ConvertiblePreferredStockTermsOfConversion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:to="us-gaap_ConvertiblePreferredStockTermsOfConversion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockTermsOfConversion_lbl" xml:lang="en-US">Preferred Stock, Convertible, Terms</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_2_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Options outstanding, ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, begining balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic value, begining balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Options, Granted - under the Plan</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Options, Granted - under the Plan</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US">Options, cancelled</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted average exercise price, ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xml:lang="en-US">Aggregate Intrinsic value, ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xml:lang="en-US">Options, Granted - under the Plan</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Options outstanding, ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Options exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Aggregate Intrinsic value, exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_EquitySecuritiesFvNiMeasurementTerm" xlink:label="ONMD_EquitySecuritiesFvNiMeasurementTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_EquitySecuritiesFvNiMeasurementTerm" xlink:to="ONMD_EquitySecuritiesFvNiMeasurementTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ONMD_EquitySecuritiesFvNiMeasurementTerm_lbl" xml:lang="en-US">[custom:EquitySecuritiesFvNiMeasurementTerm]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiMeasurementInput" xlink:label="us-gaap_EquitySecuritiesFvNiMeasurementInput" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesFvNiMeasurementInput" xlink:to="us-gaap_EquitySecuritiesFvNiMeasurementInput_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquitySecuritiesFvNiMeasurementInput_lbl" xml:lang="en-US">Equity Securities, FV-NI, Measurement Input</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_3_lbl" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US">Proceeds from Issuance of Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilities" xlink:label="us-gaap_OtherLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilities" xlink:to="us-gaap_OtherLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilities_lbl" xml:lang="en-US">Other Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsHeldInTrustCurrent" xlink:to="us-gaap_AssetsHeldInTrustCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetsHeldInTrustCurrent_2_lbl" xml:lang="en-US">Assets measured and recorded fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_ExtensionLoan" xlink:label="ONMD_ExtensionLoan" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_ExtensionLoan" xlink:to="ONMD_ExtensionLoan_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ONMD_ExtensionLoan_lbl" xml:lang="en-US">[custom:ExtensionLoan-0]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromConvertibleDebt_2_lbl" xml:lang="en-US">Proceeds from Convertible Debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_2_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Acquisitions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotesCurrent" xlink:label="us-gaap_SeniorNotesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeniorNotesCurrent" xlink:to="us-gaap_SeniorNotesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeniorNotesCurrent_lbl" xml:lang="en-US">Senior Notes, Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating Lease, Cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesRentExpenseNet" xlink:to="us-gaap_OperatingLeasesRentExpenseNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_lbl" xml:lang="en-US">Operating Leases, Rent Expense, Net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xml:lang="en-US">Stock Repurchased During Period, Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xml:lang="en-US">Related Party Transaction, Amounts of Transaction</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_2_lbl" xml:lang="en-US">Proceeds from Related Party Debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US">Proceeds from Issuance of Private Placement</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_SecuritiesPurchaseAgreementMember" xlink:to="ONMD_SecuritiesPurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ONMD_SecuritiesPurchaseAgreementMember_doc" xml:lang="en-US">Securities Purchase Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_DataKnightsAcquisitionCorpMember" xlink:to="ONMD_DataKnightsAcquisitionCorpMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ONMD_DataKnightsAcquisitionCorpMember_doc" xml:lang="en-US">Data Knights Acquisition Corp [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_OperatingSegmentsPolicyTextBlock" xlink:to="ONMD_OperatingSegmentsPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ONMD_OperatingSegmentsPolicyTextBlock_doc" xml:lang="en-US">Operating Segments [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_CustomerOneMember" xlink:to="ONMD_CustomerOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ONMD_CustomerOneMember_doc" xml:lang="en-US">Customer One [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_CustomerTwoMember" xlink:to="ONMD_CustomerTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ONMD_CustomerTwoMember_doc" xml:lang="en-US">Customer Two [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_CustomerThreeMember" xlink:to="ONMD_CustomerThreeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ONMD_CustomerThreeMember_doc" xml:lang="en-US">Customer Three [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_CustomerFourMember" xlink:to="ONMD_CustomerFourMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ONMD_CustomerFourMember_doc" xml:lang="en-US">Customer Four [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_CustomerFiveMember" xlink:to="ONMD_CustomerFiveMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ONMD_CustomerFiveMember_doc" xml:lang="en-US">Customer Five [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_DeferredUnderwriterFeePayableNonCurrent" xlink:to="ONMD_DeferredUnderwriterFeePayableNonCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ONMD_DeferredUnderwriterFeePayableNonCurrent_doc" xml:lang="en-US">Deferred underwriter fee payable noncurrent.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_DeferredUnderwriterFeePayableCurrent" xlink:to="ONMD_DeferredUnderwriterFeePayableCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ONMD_DeferredUnderwriterFeePayableCurrent_doc" xml:lang="en-US">Deferred underwriter fee payable current.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_WorkingCapitalLoan" xlink:to="ONMD_WorkingCapitalLoan_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ONMD_WorkingCapitalLoan_doc" xml:lang="en-US">Working capital loan.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_LoanExtensionsCurrent" xlink:to="ONMD_LoanExtensionsCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ONMD_LoanExtensionsCurrent_doc" xml:lang="en-US">Loan extensions current.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_PatentsAndTrademarksPolicyTextBlock" xlink:to="ONMD_PatentsAndTrademarksPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ONMD_PatentsAndTrademarksPolicyTextBlock_doc" xml:lang="en-US">Patents And Trademarks [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_EmergingGrowthCompanyPolicyTextBlock" xlink:to="ONMD_EmergingGrowthCompanyPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ONMD_EmergingGrowthCompanyPolicyTextBlock_doc" xml:lang="en-US">Emerging Growth Company [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_AccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:to="ONMD_AccountingPronouncementsNotYetAdoptedPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ONMD_AccountingPronouncementsNotYetAdoptedPolicyTextBlock_doc" xml:lang="en-US">Accounting Pronouncements Not Yet Adopted [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_SeriesATwoPreferredStockMember" xlink:to="ONMD_SeriesATwoPreferredStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ONMD_SeriesATwoPreferredStockMember_doc" xml:lang="en-US">Series A Two Preferred Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_SeriesAOnePreferredStockMember" xlink:to="ONMD_SeriesAOnePreferredStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ONMD_SeriesAOnePreferredStockMember_doc" xml:lang="en-US">Series A One Preferred Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_IncreaseDecreaseFranchiseTaxPayable" xlink:to="ONMD_IncreaseDecreaseFranchiseTaxPayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ONMD_IncreaseDecreaseFranchiseTaxPayable_doc" xml:lang="en-US">Increase decrease franchise tax payable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_ProceedsFromIssuanceOfCommonStockOne" xlink:to="ONMD_ProceedsFromIssuanceOfCommonStockOne_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ONMD_ProceedsFromIssuanceOfCommonStockOne_doc" xml:lang="en-US">Proceeds from issuance of common stock one.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_ProceedsFromIssuanceOfCommonStockTwo" xlink:to="ONMD_ProceedsFromIssuanceOfCommonStockTwo_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ONMD_ProceedsFromIssuanceOfCommonStockTwo_doc" xml:lang="en-US">Proceeds from issuance of common stock two.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_CommonClassAOneMember" xlink:to="ONMD_CommonClassAOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ONMD_CommonClassAOneMember_doc" xml:lang="en-US">Common Class A One [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_ProccedsFromRetainedEarningsAdjustment" xlink:to="ONMD_ProccedsFromRetainedEarningsAdjustment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ONMD_ProccedsFromRetainedEarningsAdjustment_doc" xml:lang="en-US">Procceds from retained earnings adjustment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_ProceedsFromBusinessLoan" xlink:to="ONMD_ProceedsFromBusinessLoan_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ONMD_ProceedsFromBusinessLoan_doc" xml:lang="en-US">Proceeds from business loan.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_ProceedsFromDeferredUnderwritingFee" xlink:to="ONMD_ProceedsFromDeferredUnderwritingFee_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ONMD_ProceedsFromDeferredUnderwritingFee_doc" xml:lang="en-US">Proceeds from deferred under writing fee.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_ProceedsFromCommonStockSubjectToRedemption" xlink:to="ONMD_ProceedsFromCommonStockSubjectToRedemption_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ONMD_ProceedsFromCommonStockSubjectToRedemption_doc" xml:lang="en-US">Proceeds from common stock subject to redemption.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_BusinessCombinationCost" xlink:to="ONMD_BusinessCombinationCost_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ONMD_BusinessCombinationCost_doc" xml:lang="en-US">Business combination cost.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_CashHeldInTrustAccount" xlink:to="ONMD_CashHeldInTrustAccount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ONMD_CashHeldInTrustAccount_doc" xml:lang="en-US">Cash held in trust account.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_UnrealizedGainLoss" xlink:to="ONMD_UnrealizedGainLoss_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ONMD_UnrealizedGainLoss_doc" xml:lang="en-US">Unrealized gain loss.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_IncreaseDecreaseInExtensionLoan" xlink:to="ONMD_IncreaseDecreaseInExtensionLoan_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ONMD_IncreaseDecreaseInExtensionLoan_doc" xml:lang="en-US">Increase decrease in extension loan.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_IncreaseDecreaseInWorkingCapitalLoan" xlink:to="ONMD_IncreaseDecreaseInWorkingCapitalLoan_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ONMD_IncreaseDecreaseInWorkingCapitalLoan_doc" xml:lang="en-US">Increase decrease in working capital loan.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_IncreaseDecreaseInExerciseTaxLiability" xlink:to="ONMD_IncreaseDecreaseInExerciseTaxLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ONMD_IncreaseDecreaseInExerciseTaxLiability_doc" xml:lang="en-US">Increase decrease in exercise tax liability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_ClassBCommonStock" xlink:to="ONMD_ClassBCommonStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ONMD_ClassBCommonStock_doc" xml:lang="en-US">Class B common stock.</link:label>
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_StockIssuedDuringPeriodValueIssuanceOfPipeWarrants" xlink:label="ONMD_StockIssuedDuringPeriodValueIssuanceOfPipeWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_StockIssuedDuringPeriodValueIssuanceOfPipeWarrants" xlink:to="ONMD_StockIssuedDuringPeriodValueIssuanceOfPipeWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ONMD_StockIssuedDuringPeriodValueIssuanceOfPipeWarrants_doc" xml:lang="en-US">Stock issued during period value issuance of pipe warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_CustomersMember" xlink:to="ONMD_CustomersMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ONMD_CustomersMember_doc" xml:lang="en-US">Customers [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_StockIssuedDuringPeriodValueStockOptionsToCommonStock" xlink:to="ONMD_StockIssuedDuringPeriodValueStockOptionsToCommonStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ONMD_StockIssuedDuringPeriodValueStockOptionsToCommonStock_doc" xml:lang="en-US">Stock issued during period value stock options to common stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_StockIssuedDuringPeriodValueConvertingOfWarrantsToCommonStock" xlink:to="ONMD_StockIssuedDuringPeriodValueConvertingOfWarrantsToCommonStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ONMD_StockIssuedDuringPeriodValueConvertingOfWarrantsToCommonStock_doc" xml:lang="en-US">Stock issued during period value converting of warrants to common stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_StockIssuedDuringPeriodValueConvertingDataKnightsCommonShares" xlink:to="ONMD_StockIssuedDuringPeriodValueConvertingDataKnightsCommonShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ONMD_StockIssuedDuringPeriodValueConvertingDataKnightsCommonShares_doc" xml:lang="en-US">Stock issued during period value converting data knights common shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_StockIssuedDuringPeriodSharesStockOptionsToCommonStock" xlink:to="ONMD_StockIssuedDuringPeriodSharesStockOptionsToCommonStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ONMD_StockIssuedDuringPeriodSharesStockOptionsToCommonStock_doc" xml:lang="en-US">Stock issued during period shares stock options to common stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_StockIssuedDuringPeriodSharesConvertingOfWarrantsToCommonStock" xlink:to="ONMD_StockIssuedDuringPeriodSharesConvertingOfWarrantsToCommonStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ONMD_StockIssuedDuringPeriodSharesConvertingOfWarrantsToCommonStock_doc" xml:lang="en-US">Stock issued during period shares converting of warrants to common stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_StockIssuedDuringPeriodSharesConvertingDataKnightsCommonShares" xlink:to="ONMD_StockIssuedDuringPeriodSharesConvertingDataKnightsCommonShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ONMD_StockIssuedDuringPeriodSharesConvertingDataKnightsCommonShares_doc" xml:lang="en-US">Stock Issued During Period shares converting data knights common shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_EquityFinancingDescription" xlink:to="ONMD_EquityFinancingDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ONMD_EquityFinancingDescription_doc" xml:lang="en-US">Equity financing description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_CEBALoanMember" xlink:to="ONMD_CEBALoanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ONMD_CEBALoanMember_doc" xml:lang="en-US">CEBA Loan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_BoardOfDirectorsMember" xlink:to="ONMD_BoardOfDirectorsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ONMD_BoardOfDirectorsMember_doc" xml:lang="en-US">Board Of Directors [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_EmployeesDirectorsAndConsultantsMember" xlink:to="ONMD_EmployeesDirectorsAndConsultantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ONMD_EmployeesDirectorsAndConsultantsMember_doc" xml:lang="en-US">Employees Directors and Consultants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_NewEquityIncentivePlanMember" xlink:to="ONMD_NewEquityIncentivePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ONMD_NewEquityIncentivePlanMember_doc" xml:lang="en-US">New Equity Incentive Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_EquitySecuritiesFvNiMeasurementTerm" xlink:to="ONMD_EquitySecuritiesFvNiMeasurementTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ONMD_EquitySecuritiesFvNiMeasurementTerm_doc" xml:lang="en-US">Equity securities FvNi measurement term.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_StockWarrantsDisclosureTextBlock" xlink:to="ONMD_StockWarrantsDisclosureTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ONMD_StockWarrantsDisclosureTextBlock_doc" xml:lang="en-US">Stock warrants disclosure text block.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_TwentyTwentyOneServiceMember" xlink:to="ONMD_TwentyTwentyOneServiceMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ONMD_TwentyTwentyOneServiceMember_doc" xml:lang="en-US">Twenty Twenty One Service [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_TwentyTwentyTwoServiceMember" xlink:to="ONMD_TwentyTwentyTwoServiceMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ONMD_TwentyTwentyTwoServiceMember_doc" xml:lang="en-US">Twenty Twenty Two Service [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_ConvertiableNotesMember" xlink:to="ONMD_ConvertiableNotesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ONMD_ConvertiableNotesMember_doc" xml:lang="en-US">Convertiable Notes [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_ExtensionLoan" xlink:to="ONMD_ExtensionLoan_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ONMD_ExtensionLoan_doc" xml:lang="en-US">Extension loan.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_WarrantOneMember" xlink:to="ONMD_WarrantOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ONMD_WarrantOneMember_doc" xml:lang="en-US">Warrant One [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_PubliclyTradedWarrantsMember" xlink:to="ONMD_PubliclyTradedWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ONMD_PubliclyTradedWarrantsMember_doc" xml:lang="en-US">Publicly Traded Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_PrivateWarrantsMember" xlink:to="ONMD_PrivateWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ONMD_PrivateWarrantsMember_doc" xml:lang="en-US">Private Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_SeniorConvertibleNotesMember" xlink:to="ONMD_SeniorConvertibleNotesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ONMD_SeniorConvertibleNotesMember_doc" xml:lang="en-US">Senior Convertible Notes [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_ManagementAndDirectorsMember" xlink:to="ONMD_ManagementAndDirectorsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ONMD_ManagementAndDirectorsMember_doc" xml:lang="en-US">Management and Directors [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_EFHuttonMember" xlink:to="ONMD_EFHuttonMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ONMD_EFHuttonMember_doc" xml:lang="en-US">EF Hutton [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_KingwoodCapitalPartnersLLCMember" xlink:to="ONMD_KingwoodCapitalPartnersLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ONMD_KingwoodCapitalPartnersLLCMember_doc" xml:lang="en-US">Kingwood Capital Partners LLC [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_ConvertiblePromissoryNotesMember" xlink:to="ONMD_ConvertiblePromissoryNotesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ONMD_ConvertiblePromissoryNotesMember_doc" xml:lang="en-US">Convertible Promissory Notes [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_WarrantLiabilityNonCurrent" xlink:to="ONMD_WarrantLiabilityNonCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ONMD_WarrantLiabilityNonCurrent_doc" xml:lang="en-US">Warrant liability non current.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_StockIssuedDuringPeriodSharesConvertibleNotesToCommonStock" xlink:to="ONMD_StockIssuedDuringPeriodSharesConvertibleNotesToCommonStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ONMD_StockIssuedDuringPeriodSharesConvertibleNotesToCommonStock_doc" xml:lang="en-US">Stock issued during period shares convertible notes to common stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_OneCustomerMember" xlink:to="ONMD_OneCustomerMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ONMD_OneCustomerMember_doc" xml:lang="en-US">One Customer [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_TwoCustomersMember" xlink:to="ONMD_TwoCustomersMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ONMD_TwoCustomersMember_doc" xml:lang="en-US">Two Customers [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_ThreeCustomersMember" xlink:to="ONMD_ThreeCustomersMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ONMD_ThreeCustomersMember_doc" xml:lang="en-US">Three Customers [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_StockIssuedDuringPeriodSharesIssuanceOfPipeWarrants" xlink:label="ONMD_StockIssuedDuringPeriodSharesIssuanceOfPipeWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_StockIssuedDuringPeriodSharesIssuanceOfPipeWarrants" xlink:to="ONMD_StockIssuedDuringPeriodSharesIssuanceOfPipeWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ONMD_StockIssuedDuringPeriodSharesIssuanceOfPipeWarrants_doc" xml:lang="en-US">Stock issued during period shares issuance of pipe warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_ProceedsFromWarrantLiability" xlink:to="ONMD_ProceedsFromWarrantLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ONMD_ProceedsFromWarrantLiability_doc" xml:lang="en-US">Proceeds from warrant liability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_InvestmentsHeldInTrustMember" xlink:to="ONMD_InvestmentsHeldInTrustMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ONMD_InvestmentsHeldInTrustMember_doc" xml:lang="en-US">Investments Held In Trust [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_AccruedInterestRelatedParty" xlink:to="ONMD_AccruedInterestRelatedParty_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ONMD_AccruedInterestRelatedParty_doc" xml:lang="en-US">Accrued interest related party.</link:label>
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_StockIssuedDuringPeriodValueCommonStockRedemption" xlink:label="ONMD_StockIssuedDuringPeriodValueCommonStockRedemption" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_StockIssuedDuringPeriodValueCommonStockRedemption" xlink:to="ONMD_StockIssuedDuringPeriodValueCommonStockRedemption_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ONMD_StockIssuedDuringPeriodValueCommonStockRedemption_doc" xml:lang="en-US">Stock issued during period value common stock redemption.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_CommonStockSubjectToPossibleRedemptionValue" xlink:to="ONMD_CommonStockSubjectToPossibleRedemptionValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ONMD_CommonStockSubjectToPossibleRedemptionValue_doc" xml:lang="en-US">Common stock subject to possible redemption value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_StockIssuedDuringPeriodValueConvertibleNotesToCommonStock" xlink:to="ONMD_StockIssuedDuringPeriodValueConvertibleNotesToCommonStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ONMD_StockIssuedDuringPeriodValueConvertibleNotesToCommonStock_doc" xml:lang="en-US">Stock issued during period value convertible notes to common stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_RetainedEarningsAdjustment" xlink:to="ONMD_RetainedEarningsAdjustment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ONMD_RetainedEarningsAdjustment_doc" xml:lang="en-US">Retained earnings adjustment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_CommitmentMember" xlink:to="ONMD_CommitmentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ONMD_CommitmentMember_doc" xml:lang="en-US">Commitment [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnsecuredDebt" xlink:to="us-gaap_UnsecuredDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnsecuredDebt_2_lbl" xml:lang="en-US">Unsecured Debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_DeferredUnderwriterFeePayableNonCurrent" xlink:to="ONMD_DeferredUnderwriterFeePayableNonCurrent_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ONMD_DeferredUnderwriterFeePayableNonCurrent_3_lbl" xml:lang="en-US">DeferredUnderwriterFeePayableNonCurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Equity, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_UnrealizedGainLoss" xlink:to="ONMD_UnrealizedGainLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ONMD_UnrealizedGainLoss_3_lbl" xml:lang="en-US">UnrealizedGainLoss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Current Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_IncreaseDecreaseFranchiseTaxPayable" xlink:to="ONMD_IncreaseDecreaseFranchiseTaxPayable_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ONMD_IncreaseDecreaseFranchiseTaxPayable_3_lbl" xml:lang="en-US">IncreaseDecreaseFranchiseTaxPayable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_ProceedsFromWarrantLiability" xlink:to="ONMD_ProceedsFromWarrantLiability_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ONMD_ProceedsFromWarrantLiability_3_lbl" xml:lang="en-US">ProceedsFromWarrantLiability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_ClassBCommonStock" xlink:to="ONMD_ClassBCommonStock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ONMD_ClassBCommonStock_3_lbl" xml:lang="en-US">ClassBCommonStock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ONMD_StockWarrantsDisclosureTextBlock" xlink:to="ONMD_StockWarrantsDisclosureTextBlock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ONMD_StockWarrantsDisclosureTextBlock_3_lbl" xml:lang="en-US">StockWarrantsDisclosureTextBlock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsPolicy" xlink:to="us-gaap_BusinessCombinationsPolicy_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationsPolicy_2_lbl" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_2_lbl" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_2_lbl" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_2_lbl" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>42
<FILENAME>onmd-20231231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://onemednet.com/role/Cover" xlink:href="onmd-20231231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/BalanceSheets" xlink:href="onmd-20231231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/BalanceSheetsParenthetical" xlink:href="onmd-20231231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/StatementsOfOperations" xlink:href="onmd-20231231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/StatementsOfStockholdersEquityDeficit" xlink:href="onmd-20231231.xsd#StatementsOfStockholdersEquityDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/StatementsOfStockholdersEquityDeficitParenthetical" xlink:href="onmd-20231231.xsd#StatementsOfStockholdersEquityDeficitParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/StatementsOfCashFlows" xlink:href="onmd-20231231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/OrganizationAndOperations" xlink:href="onmd-20231231.xsd#OrganizationAndOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="onmd-20231231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/BusinessCombination" xlink:href="onmd-20231231.xsd#BusinessCombination" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/GoingConcern" xlink:href="onmd-20231231.xsd#GoingConcern" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/PropertyAndEquipment" xlink:href="onmd-20231231.xsd#PropertyAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/IncomeTaxes" xlink:href="onmd-20231231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/ConvertiblePromissoryNotesHeldByRelatedParty" xlink:href="onmd-20231231.xsd#ConvertiblePromissoryNotesHeldByRelatedParty" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/CanadianEmergencyBusinessLoanActCeba" xlink:href="onmd-20231231.xsd#CanadianEmergencyBusinessLoanActCeba" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/ShareholdersEquity" xlink:href="onmd-20231231.xsd#ShareholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/StockOptions" xlink:href="onmd-20231231.xsd#StockOptions" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/StockWarrants" xlink:href="onmd-20231231.xsd#StockWarrants" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/FairValueMeasures" xlink:href="onmd-20231231.xsd#FairValueMeasures" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/RelatedPartyTransactions" xlink:href="onmd-20231231.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/CommitmentsContingenciesAndConcentrationsOperatingLease" xlink:href="onmd-20231231.xsd#CommitmentsContingenciesAndConcentrationsOperatingLease" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/SubsequentEvents" xlink:href="onmd-20231231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="onmd-20231231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="onmd-20231231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/PropertyAndEquipmentTables" xlink:href="onmd-20231231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/IncomeTaxesTables" xlink:href="onmd-20231231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/ShareholdersEquityTables" xlink:href="onmd-20231231.xsd#ShareholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/StockOptionsTables" xlink:href="onmd-20231231.xsd#StockOptionsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/FairValueMeasuresTables" xlink:href="onmd-20231231.xsd#FairValueMeasuresTables" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/OrganizationAndOperationsDetailsNarrative" xlink:href="onmd-20231231.xsd#OrganizationAndOperationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/ScheduleOfAggregatePercentageRevenueAndAccountsReceivableDetails" xlink:href="onmd-20231231.xsd#ScheduleOfAggregatePercentageRevenueAndAccountsReceivableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="onmd-20231231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/GoingConcernDetailsNarrative" xlink:href="onmd-20231231.xsd#GoingConcernDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:href="onmd-20231231.xsd#ScheduleOfPropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/PropertyAndEquipmentDetailsNarrative" xlink:href="onmd-20231231.xsd#PropertyAndEquipmentDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/ScheduleOfDeferredIncomeTaxesDetails" xlink:href="onmd-20231231.xsd#ScheduleOfDeferredIncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/IncomeTaxesDetailsNarrative" xlink:href="onmd-20231231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/ConvertiblePromissoryNotesHeldByRelatedPartyDetailsNarrative" xlink:href="onmd-20231231.xsd#ConvertiblePromissoryNotesHeldByRelatedPartyDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/CanadianEmergencyBusinessLoanActCebaDetailsNarrative" xlink:href="onmd-20231231.xsd#CanadianEmergencyBusinessLoanActCebaDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/ScheduleOfCommonStockActivitiesDetails" xlink:href="onmd-20231231.xsd#ScheduleOfCommonStockActivitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/ShareholdersEquityDetailsNarrative" xlink:href="onmd-20231231.xsd#ShareholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/ScheduleOfOptionsOutstandingDetails" xlink:href="onmd-20231231.xsd#ScheduleOfOptionsOutstandingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/ScheduleOfFairValueOfStockOptionsDetails" xlink:href="onmd-20231231.xsd#ScheduleOfFairValueOfStockOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/StockOptionsDetailsNarrative" xlink:href="onmd-20231231.xsd#StockOptionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/StockWarrantsDetailsNarrative" xlink:href="onmd-20231231.xsd#StockWarrantsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/ScheduleOfFinancialAssetsDetails" xlink:href="onmd-20231231.xsd#ScheduleOfFinancialAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="onmd-20231231.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/CommitmentsContingenciesAndConcentrationsOperatingLeaseDetailsNarrative" xlink:href="onmd-20231231.xsd#CommitmentsContingenciesAndConcentrationsOperatingLeaseDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://onemednet.com/role/SubsequentEventsDetailsNarrative" xlink:href="onmd-20231231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://onemednet.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesTable" xlink:label="loc_deiEntityAddressesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesLineItems" xlink:label="loc_deiEntityAddressesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesTable" xlink:to="loc_deiEntityAddressesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_deiEntityAddressesAddressTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesTable" xlink:to="loc_deiEntityAddressesAddressTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain" xlink:label="loc_deiAddressTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesAddressTypeAxis" xlink:to="loc_deiAddressTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_BusinessContactMember" xlink:label="loc_deiBusinessContactMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiAddressTypeDomain" xlink:to="loc_deiBusinessContactMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelName" xlink:label="loc_deiContactPersonnelName" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiContactPersonnelName" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://onemednet.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_SeriesATwoPreferredStockMember" xlink:label="loc_ONMDSeriesATwoPreferredStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ONMDSeriesATwoPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_SeriesAOnePreferredStockMember" xlink:label="loc_ONMDSeriesAOnePreferredStockMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ONMDSeriesAOnePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaapCommonClassAMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassAMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_CommonClassAOneMember" xlink:label="loc_ONMDCommonClassAOneMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ONMDCommonClassAOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsHeldInTrustCurrent" xlink:label="loc_us-gaapAssetsHeldInTrustCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsHeldInTrustCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivables" xlink:label="loc_us-gaapOtherReceivables" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapOtherReceivables" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherShortTermBorrowings" xlink:label="loc_us-gaapOtherShortTermBorrowings" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOtherShortTermBorrowings" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesAndExciseTaxPayableCurrent" xlink:label="loc_us-gaapSalesAndExciseTaxPayableCurrent" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapSalesAndExciseTaxPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_LoanExtensionsCurrent" xlink:label="loc_ONMDLoanExtensionsCurrent" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_ONMDLoanExtensionsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaapDeferredRevenueCurrent" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapDeferredRevenueCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayable" xlink:label="loc_us-gaapLoansPayable" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLoansPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="loc_us-gaapConvertibleDebtCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapConvertibleDebtCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnsecuredDebtCurrent" xlink:label="loc_us-gaapUnsecuredDebtCurrent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapUnsecuredDebtCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="loc_us-gaapAccruedIncomeTaxesCurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedIncomeTaxesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:label="loc_us-gaapAccrualForTaxesOtherThanIncomeTaxesCurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNotesPayableCurrent" xlink:label="loc_us-gaapOtherNotesPayableCurrent" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOtherNotesPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_DeferredUnderwriterFeePayableCurrent" xlink:label="loc_ONMDDeferredUnderwriterFeePayableCurrent" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_ONMDDeferredUnderwriterFeePayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaapLiabilitiesNoncurrentAbstract" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="loc_us-gaapConvertibleDebtNoncurrent" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapConvertibleDebtNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnsecuredDebt" xlink:label="loc_us-gaapUnsecuredDebt" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapUnsecuredDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_AccruedInterestRelatedParty" xlink:label="loc_ONMDAccruedInterestRelatedParty" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_ONMDAccruedInterestRelatedParty" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaapOtherLiabilitiesNoncurrent" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapOtherLiabilitiesNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_WarrantLiabilityNonCurrent" xlink:label="loc_ONMDWarrantLiabilityNonCurrent" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_ONMDWarrantLiabilityNonCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_DeferredUnderwriterFeePayableNonCurrent" xlink:label="loc_ONMDDeferredUnderwriterFeePayableNonCurrent" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_ONMDDeferredUnderwriterFeePayableNonCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_WorkingCapitalLoan" xlink:label="loc_ONMDWorkingCapitalLoan" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_ONMDWorkingCapitalLoan" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermLoansPayable" xlink:label="loc_us-gaapLongTermLoansPayable" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapLongTermLoansPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://onemednet.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_SeriesATwoPreferredStockMember" xlink:label="loc_ONMDSeriesATwoPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ONMDSeriesATwoPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_SeriesAOnePreferredStockMember" xlink:label="loc_ONMDSeriesAOnePreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ONMDSeriesAOnePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaapCommonClassAMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassAMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_CommonClassAOneMember" xlink:label="loc_ONMDCommonClassAOneMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ONMDCommonClassAOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://onemednet.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaapCostOfRevenue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapCostOfRevenue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherGeneralExpense" xlink:label="loc_us-gaapOtherGeneralExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOtherGeneralExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaapSellingAndMarketingExpense" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapSellingAndMarketingExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaapAssetImpairmentCharges" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapAssetImpairmentCharges" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="loc_us-gaapOtherNonoperatingExpense" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapOtherNonoperatingExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionPlanExpense" xlink:label="loc_us-gaapStockOptionPlanExpense" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapStockOptionPlanExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_UnrealizedGainLoss" xlink:label="loc_ONMDUnrealizedGainLoss" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_ONMDUnrealizedGainLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasicAbstract" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://onemednet.com/role/StatementsOfStockholdersEquityDeficit" xlink:title="00000005 - Statement - Consolidated Statements of Stockholders Equity (Deficit)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="90" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_CommitmentMember" xlink:label="loc_ONMDCommitmentMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_ONMDCommitmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="90" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_SeriesATwoPreferredStockMember" xlink:label="loc_ONMDSeriesATwoPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_ONMDSeriesATwoPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_SeriesAOnePreferredStockMember" xlink:label="loc_ONMDSeriesAOnePreferredStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_ONMDSeriesAOnePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaapCommonClassAMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapCommonClassAMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaapCommonClassBMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapCommonClassBMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" order="90" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_DataKnightsAcquisitionCorpMember" xlink:label="loc_ONMDDataKnightsAcquisitionCorpMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_ONMDDataKnightsAcquisitionCorpMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_CommonStockSubjectToPossibleRedemptionValue" xlink:label="loc_ONMDCommonStockSubjectToPossibleRedemptionValue" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ONMDCommonStockSubjectToPossibleRedemptionValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_StockIssuedDuringPeriodValueConvertibleNotesToCommonStock" xlink:label="loc_ONMDStockIssuedDuringPeriodValueConvertibleNotesToCommonStock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ONMDStockIssuedDuringPeriodValueConvertibleNotesToCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_StockIssuedDuringPeriodSharesConvertibleNotesToCommonStock" xlink:label="loc_ONMDStockIssuedDuringPeriodSharesConvertibleNotesToCommonStock" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ONMDStockIssuedDuringPeriodSharesConvertibleNotesToCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_StockIssuedDuringPeriodValueStockOptionsToCommonStock" xlink:label="loc_ONMDStockIssuedDuringPeriodValueStockOptionsToCommonStock" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ONMDStockIssuedDuringPeriodValueStockOptionsToCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_StockIssuedDuringPeriodSharesStockOptionsToCommonStock" xlink:label="loc_ONMDStockIssuedDuringPeriodSharesStockOptionsToCommonStock" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ONMDStockIssuedDuringPeriodSharesStockOptionsToCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_StockIssuedDuringPeriodValueConvertingOfWarrantsToCommonStock" xlink:label="loc_ONMDStockIssuedDuringPeriodValueConvertingOfWarrantsToCommonStock" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ONMDStockIssuedDuringPeriodValueConvertingOfWarrantsToCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_StockIssuedDuringPeriodSharesConvertingOfWarrantsToCommonStock" xlink:label="loc_ONMDStockIssuedDuringPeriodSharesConvertingOfWarrantsToCommonStock" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ONMDStockIssuedDuringPeriodSharesConvertingOfWarrantsToCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_StockIssuedDuringPeriodValueConvertingDataKnightsCommonShares" xlink:label="loc_ONMDStockIssuedDuringPeriodValueConvertingDataKnightsCommonShares" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ONMDStockIssuedDuringPeriodValueConvertingDataKnightsCommonShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_StockIssuedDuringPeriodSharesConvertingDataKnightsCommonShares" xlink:label="loc_ONMDStockIssuedDuringPeriodSharesConvertingDataKnightsCommonShares" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ONMDStockIssuedDuringPeriodSharesConvertingDataKnightsCommonShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_RetainedEarningsAdjustment" xlink:label="loc_ONMDRetainedEarningsAdjustment" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ONMDRetainedEarningsAdjustment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://onemednet.com/role/StatementsOfStockholdersEquityDeficitParenthetical" xlink:title="00000006 - Statement - Consolidated Statements of Stockholders Equity (Deficit) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://onemednet.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_BusinessCombinationCost" xlink:label="loc_ONMDBusinessCombinationCost" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_ONMDBusinessCombinationCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_CashHeldInTrustAccount" xlink:label="loc_ONMDCashHeldInTrustAccount" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_ONMDCashHeldInTrustAccount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentAssets" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaapIncreaseDecreaseInContractWithCustomerLiability" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:label="loc_us-gaapIncreaseDecreaseInDueToRelatedParties" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInDueToRelatedParties" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_IncreaseDecreaseInExerciseTaxLiability" xlink:label="loc_ONMDIncreaseDecreaseInExerciseTaxLiability" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_ONMDIncreaseDecreaseInExerciseTaxLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_IncreaseDecreaseInExtensionLoan" xlink:label="loc_ONMDIncreaseDecreaseInExtensionLoan" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_ONMDIncreaseDecreaseInExtensionLoan" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_IncreaseDecreaseFranchiseTaxPayable" xlink:label="loc_ONMDIncreaseDecreaseFranchiseTaxPayable" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_ONMDIncreaseDecreaseFranchiseTaxPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedIncomeTaxesPayable" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_IncreaseDecreaseInWorkingCapitalLoan" xlink:label="loc_ONMDIncreaseDecreaseInWorkingCapitalLoan" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_ONMDIncreaseDecreaseInWorkingCapitalLoan" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_ProceedsFromIssuanceOfCommonStockOne" xlink:label="loc_ONMDProceedsFromIssuanceOfCommonStockOne" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_ONMDProceedsFromIssuanceOfCommonStockOne" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRepaymentsOfNotesPayable" xlink:label="loc_us-gaapProceedsFromRepaymentsOfNotesPayable" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromRepaymentsOfNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaapProceedsFromConvertibleDebt" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromConvertibleDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRelatedPartyDebt" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromRelatedPartyDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_ProceedsFromBusinessLoan" xlink:label="loc_ONMDProceedsFromBusinessLoan" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_ONMDProceedsFromBusinessLoan" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_ProceedsFromCommonStockSubjectToRedemption" xlink:label="loc_ONMDProceedsFromCommonStockSubjectToRedemption" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_ONMDProceedsFromCommonStockSubjectToRedemption" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_ProceedsFromDeferredUnderwritingFee" xlink:label="loc_ONMDProceedsFromDeferredUnderwritingFee" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_ONMDProceedsFromDeferredUnderwritingFee" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_ProceedsFromWarrantLiability" xlink:label="loc_ONMDProceedsFromWarrantLiability" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_ONMDProceedsFromWarrantLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromContributedCapital" xlink:label="loc_us-gaapProceedsFromContributedCapital" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromContributedCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_ProceedsFromIssuanceOfCommonStockTwo" xlink:label="loc_ONMDProceedsFromIssuanceOfCommonStockTwo" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_ONMDProceedsFromIssuanceOfCommonStockTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_ClassBCommonStock" xlink:label="loc_ONMDClassBCommonStock" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_ONMDClassBCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_ProccedsFromRetainedEarningsAdjustment" xlink:label="loc_ONMDProccedsFromRetainedEarningsAdjustment" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_ONMDProccedsFromRetainedEarningsAdjustment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://onemednet.com/role/OrganizationAndOperations" xlink:title="00000008 - Disclosure - Organization and Operations">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapOrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://onemednet.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000009 - Disclosure - Summary of Significant Accounting Policies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://onemednet.com/role/BusinessCombination" xlink:title="00000010 - Disclosure - Business Combination">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_us-gaapBusinessCombinationDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapBusinessCombinationDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://onemednet.com/role/GoingConcern" xlink:title="00000011 - Disclosure - Going Concern">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="loc_us-gaapSubstantialDoubtAboutGoingConcernTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapSubstantialDoubtAboutGoingConcernTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://onemednet.com/role/PropertyAndEquipment" xlink:title="00000012 - Disclosure - Property and Equipment">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://onemednet.com/role/IncomeTaxes" xlink:title="00000013 - Disclosure - Income Taxes">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://onemednet.com/role/ConvertiblePromissoryNotesHeldByRelatedParty" xlink:title="00000014 - Disclosure - Convertible Promissory Notes held by Related Party">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="loc_us-gaapLongTermDebtTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapLongTermDebtTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://onemednet.com/role/CanadianEmergencyBusinessLoanActCeba" xlink:title="00000015 - Disclosure - Canadian Emergency Business Loan Act (CEBA)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaapDebtDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://onemednet.com/role/ShareholdersEquity" xlink:title="00000016 - Disclosure - Shareholders&#8217; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://onemednet.com/role/StockOptions" xlink:title="00000017 - Disclosure - Stock Options">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://onemednet.com/role/StockWarrants" xlink:title="00000018 - Disclosure - Stock Warrants">
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_DisclosureStockWarrantsAbstract" xlink:label="loc_ONMDDisclosureStockWarrantsAbstract" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_StockWarrantsDisclosureTextBlock" xlink:label="loc_ONMDStockWarrantsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ONMDDisclosureStockWarrantsAbstract" xlink:to="loc_ONMDStockWarrantsDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://onemednet.com/role/FairValueMeasures" xlink:title="00000019 - Disclosure - Fair Value Measures">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaapFairValueDisclosuresTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueDisclosuresTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://onemednet.com/role/RelatedPartyTransactions" xlink:title="00000020 - Disclosure - Related Party Transactions">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://onemednet.com/role/CommitmentsContingenciesAndConcentrationsOperatingLease" xlink:title="00000021 - Disclosure - Commitments, Contingencies, and Concentrations Operating lease">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://onemednet.com/role/SubsequentEvents" xlink:title="00000022 - Disclosure - Subsequent Events">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000023 - Disclosure - Summary of Significant Accounting Policies (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="loc_us-gaapBusinessDescriptionAndBasisOfPresentationTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="loc_us-gaapBusinessCombinationsPolicy" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBusinessCombinationsPolicy" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_OperatingSegmentsPolicyTextBlock" xlink:label="loc_ONMDOperatingSegmentsPolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_ONMDOperatingSegmentsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="loc_us-gaapTradeAndOtherAccountsReceivablePolicy" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapTradeAndOtherAccountsReceivablePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaapRevenueRecognitionPolicyTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRevenueRecognitionPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_PatentsAndTrademarksPolicyTextBlock" xlink:label="loc_ONMDPatentsAndTrademarksPolicyTextBlock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_ONMDPatentsAndTrademarksPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaapCompensationRelatedCostsPolicyTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCompensationRelatedCostsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpensesPolicyTextBlock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_EmergingGrowthCompanyPolicyTextBlock" xlink:label="loc_ONMDEmergingGrowthCompanyPolicyTextBlock" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_ONMDEmergingGrowthCompanyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_AccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:label="loc_ONMDAccountingPronouncementsNotYetAdoptedPolicyTextBlock" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_ONMDAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000024 - Disclosure - Summary of Significant Accounting Policies (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="loc_us-gaapSchedulesOfConcentrationOfRiskByRiskFactorTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://onemednet.com/role/PropertyAndEquipmentTables" xlink:title="00000025 - Disclosure - Property and Equipment (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://onemednet.com/role/IncomeTaxesTables" xlink:title="00000026 - Disclosure - Income Taxes (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://onemednet.com/role/ShareholdersEquityTables" xlink:title="00000027 - Disclosure - Shareholders&#8217; Equity (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" xlink:label="loc_us-gaapScheduleOfCommonStockOutstandingRollForwardTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfCommonStockOutstandingRollForwardTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://onemednet.com/role/StockOptionsTables" xlink:title="00000028 - Disclosure - Stock Options (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://onemednet.com/role/FairValueMeasuresTables" xlink:title="00000029 - Disclosure - Fair Value Measures (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://onemednet.com/role/OrganizationAndOperationsDetailsNarrative" xlink:title="00000030 - Disclosure - Organization and Operations (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_SecuritiesPurchaseAgreementMember" xlink:label="loc_ONMDSecuritiesPurchaseAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ONMDSecuritiesPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_DataKnightsAcquisitionCorpMember" xlink:label="loc_ONMDDataKnightsAcquisitionCorpMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_ONMDDataKnightsAcquisitionCorpMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentIssuedPrincipal" xlink:label="loc_us-gaapDebtInstrumentIssuedPrincipal" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapDebtInstrumentIssuedPrincipal" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaapPaymentsToAcquireBusinessesGross" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapPaymentsToAcquireBusinessesGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentDescription" xlink:label="loc_us-gaapDebtInstrumentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapDebtInstrumentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Investments" xlink:label="loc_us-gaapInvestments" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapInvestments" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://onemednet.com/role/ScheduleOfAggregatePercentageRevenueAndAccountsReceivableDetails" xlink:title="00000031 - Disclosure - Schedule Of Aggregate Percentage Revenue and Accounts Receivable (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaapScheduleOfProductInformationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfProductInformationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaapProductInformationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapProductInformationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="loc_us-gaapRevenueFromContractWithCustomerMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapRevenueFromContractWithCustomerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaapAccountsReceivableMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapAccountsReceivableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaapCustomerConcentrationRiskMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapCustomerConcentrationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="loc_srtMajorCustomersAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtMajorCustomersAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_CustomerOneMember" xlink:label="loc_ONMDCustomerOneMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_ONMDCustomerOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_CustomerTwoMember" xlink:label="loc_ONMDCustomerTwoMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_ONMDCustomerTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_CustomersMember" xlink:label="loc_ONMDCustomersMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_ONMDCustomersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_CustomerThreeMember" xlink:label="loc_ONMDCustomerThreeMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_ONMDCustomerThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_CustomerFourMember" xlink:label="loc_ONMDCustomerFourMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_ONMDCustomerFourMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_CustomerFiveMember" xlink:label="loc_ONMDCustomerFiveMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_ONMDCustomerFiveMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000032 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaapScheduleOfProductInformationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfProductInformationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaapProductInformationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapProductInformationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="loc_us-gaapRevenueFromContractWithCustomerMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapRevenueFromContractWithCustomerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaapAccountsReceivableMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapAccountsReceivableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaapCustomerConcentrationRiskMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapCustomerConcentrationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="loc_srtMajorCustomersAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtMajorCustomersAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_OneCustomerMember" xlink:label="loc_ONMDOneCustomerMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_ONMDOneCustomerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_TwoCustomersMember" xlink:label="loc_ONMDTwoCustomersMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_ONMDTwoCustomersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_ThreeCustomersMember" xlink:label="loc_ONMDThreeCustomersMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_ONMDThreeCustomersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivableCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="loc_us-gaapImpairmentOfLongLivedAssetsToBeDisposedOf" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://onemednet.com/role/GoingConcernDetailsNarrative" xlink:title="00000033 - Disclosure - Going Concern (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://onemednet.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:title="00000034 - Disclosure - Schedule of Property And Equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://onemednet.com/role/PropertyAndEquipmentDetailsNarrative" xlink:title="00000035 - Disclosure - Property and Equipment (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://onemednet.com/role/ScheduleOfDeferredIncomeTaxesDetails" xlink:title="00000036 - Disclosure - Schedule of Deferred Income Taxes (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="loc_us-gaapDeferredTaxAssetsNetAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsNetAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaapDeferredTaxAssetsOther" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://onemednet.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000037 - Disclosure - Income Taxes (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaapOperatingLossCarryforwardsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapOperatingLossCarryforwardsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaapOperatingLossCarryforwardsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapOperatingLossCarryforwardsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaapDomesticCountryMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapDomesticCountryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaapStateAndLocalJurisdictionMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapStateAndLocalJurisdictionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_DataKnightsAcquisitionCorpMember" xlink:label="loc_ONMDDataKnightsAcquisitionCorpMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_ONMDDataKnightsAcquisitionCorpMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://onemednet.com/role/ConvertiblePromissoryNotesHeldByRelatedPartyDetailsNarrative" xlink:title="00000038 - Disclosure - Convertible Promissory Notes held by Related Party (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapShortTermDebtLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonrelatedPartyMember" xlink:label="loc_us-gaapNonrelatedPartyMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapNonrelatedPartyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_ConvertiblePromissoryNotesMember" xlink:label="loc_ONMDConvertiblePromissoryNotesMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_ONMDConvertiblePromissoryNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_SeriesATwoPreferredStockMember" xlink:label="loc_ONMDSeriesATwoPreferredStockMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ONMDSeriesATwoPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_DataKnightsAcquisitionCorpMember" xlink:label="loc_ONMDDataKnightsAcquisitionCorpMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_ONMDDataKnightsAcquisitionCorpMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaapConvertibleNotesPayable" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapConvertibleNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_EquityFinancingDescription" xlink:label="loc_ONMDEquityFinancingDescription" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_ONMDEquityFinancingDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="loc_us-gaapPreferredStockConvertibleConversionPrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapPreferredStockConvertibleConversionPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrentAndNoncurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapAccruedLiabilitiesCurrentAndNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://onemednet.com/role/CanadianEmergencyBusinessLoanActCebaDetailsNarrative" xlink:title="00000039 - Disclosure - Canadian Emergency Business Loan Act (CEBA) (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapShortTermDebtLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_CEBALoanMember" xlink:label="loc_ONMDCEBALoanMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_ONMDCEBALoanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" xlink:label="loc_us-gaapProceedsFromIssuanceOfUnsecuredDebt" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfUnsecuredDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentDecreaseForgiveness" xlink:label="loc_us-gaapDebtInstrumentDecreaseForgiveness" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentDecreaseForgiveness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="loc_us-gaapDebtConversionOriginalDebtAmount1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtConversionOriginalDebtAmount1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaapDebtInstrumentTerm" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://onemednet.com/role/ScheduleOfCommonStockActivitiesDetails" xlink:title="00000040 - Disclosure - Schedule of Common Stock Activities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_srtTitleOfIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="loc_srtBoardOfDirectorsChairmanMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtBoardOfDirectorsChairmanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_StockIssuedDuringPeriodSharesConvertibleNotesToCommonStock" xlink:label="loc_ONMDStockIssuedDuringPeriodSharesConvertibleNotesToCommonStock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ONMDStockIssuedDuringPeriodSharesConvertibleNotesToCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_StockIssuedDuringPeriodSharesStockOptionsToCommonStock" xlink:label="loc_ONMDStockIssuedDuringPeriodSharesStockOptionsToCommonStock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ONMDStockIssuedDuringPeriodSharesStockOptionsToCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_StockIssuedDuringPeriodSharesConvertingOfWarrantsToCommonStock" xlink:label="loc_ONMDStockIssuedDuringPeriodSharesConvertingOfWarrantsToCommonStock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ONMDStockIssuedDuringPeriodSharesConvertingOfWarrantsToCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_StockIssuedDuringPeriodSharesConvertingDataKnightsCommonShares" xlink:label="loc_ONMDStockIssuedDuringPeriodSharesConvertingDataKnightsCommonShares" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ONMDStockIssuedDuringPeriodSharesConvertingDataKnightsCommonShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://onemednet.com/role/ShareholdersEquityDetailsNarrative" xlink:title="00000041 - Disclosure - Shareholders&#8217; Equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockByClassTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapClassOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_SeriesATwoPreferredStockMember" xlink:label="loc_ONMDSeriesATwoPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ONMDSeriesATwoPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_SeriesAOnePreferredStockMember" xlink:label="loc_ONMDSeriesAOnePreferredStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ONMDSeriesAOnePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtTitleOfIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_BoardOfDirectorsMember" xlink:label="loc_ONMDBoardOfDirectorsMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_ONMDBoardOfDirectorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPreferredStock" xlink:label="loc_us-gaapDividendsPreferredStock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapDividendsPreferredStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:label="loc_us-gaapConvertiblePreferredStockTermsOfConversion" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapConvertiblePreferredStockTermsOfConversion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://onemednet.com/role/ScheduleOfOptionsOutstandingDetails" xlink:title="00000042 - Disclosure - Schedule of Options Outstanding (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://onemednet.com/role/ScheduleOfFairValueOfStockOptionsDetails" xlink:title="00000043 - Disclosure - Schedule of Fair Value of Stock Options (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaapMeasurementInputExpectedTermMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedTermMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaapMeasurementInputExpectedDividendRateMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedDividendRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_EquitySecuritiesFvNiMeasurementTerm" xlink:label="loc_ONMDEquitySecuritiesFvNiMeasurementTerm" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_ONMDEquitySecuritiesFvNiMeasurementTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiMeasurementInput" xlink:label="loc_us-gaapEquitySecuritiesFvNiMeasurementInput" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapEquitySecuritiesFvNiMeasurementInput" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://onemednet.com/role/StockOptionsDetailsNarrative" xlink:title="00000044 - Disclosure - Stock Options (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtTitleOfIndividualAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_EmployeesDirectorsAndConsultantsMember" xlink:label="loc_ONMDEmployeesDirectorsAndConsultantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_ONMDEmployeesDirectorsAndConsultantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_NewEquityIncentivePlanMember" xlink:label="loc_ONMDNewEquityIncentivePlanMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_ONMDNewEquityIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://onemednet.com/role/StockWarrantsDetailsNarrative" xlink:title="00000045 - Disclosure - Stock Warrants (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_DisclosureStockWarrantsAbstract" xlink:label="loc_ONMDDisclosureStockWarrantsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ONMDDisclosureStockWarrantsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_TwentyTwentyOneServiceMember" xlink:label="loc_ONMDTwentyTwentyOneServiceMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ONMDTwentyTwentyOneServiceMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_TwentyTwentyTwoServiceMember" xlink:label="loc_ONMDTwentyTwentyTwoServiceMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ONMDTwentyTwentyTwoServiceMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_ConvertiableNotesMember" xlink:label="loc_ONMDConvertiableNotesMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_ONMDConvertiableNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_WarrantOneMember" xlink:label="loc_ONMDWarrantOneMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ONMDWarrantOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_PubliclyTradedWarrantsMember" xlink:label="loc_ONMDPubliclyTradedWarrantsMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ONMDPubliclyTradedWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_PrivateWarrantsMember" xlink:label="loc_ONMDPrivateWarrantsMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ONMDPrivateWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilities" xlink:label="loc_us-gaapOtherLiabilities" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapOtherLiabilities" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://onemednet.com/role/ScheduleOfFinancialAssetsDetails" xlink:title="00000046 - Disclosure - Schedule of Financial Assets (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaapFairValueByMeasurementFrequencyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByMeasurementFrequencyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaapFairValueMeasurementsRecurringMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:to="loc_us-gaapFairValueMeasurementsRecurringMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaapFairValueByAssetClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByAssetClassAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByAssetClassAxis" xlink:to="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_InvestmentsHeldInTrustMember" xlink:label="loc_ONMDInvestmentsHeldInTrustMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="loc_ONMDInvestmentsHeldInTrustMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsHeldInTrustCurrent" xlink:label="loc_us-gaapAssetsHeldInTrustCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapAssetsHeldInTrustCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://onemednet.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000047 - Disclosure - Related Party Transactions (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_DataKnightsAcquisitionCorpMember" xlink:label="loc_ONMDDataKnightsAcquisitionCorpMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_ONMDDataKnightsAcquisitionCorpMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_srtTitleOfIndividualAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_ManagementAndDirectorsMember" xlink:label="loc_ONMDManagementAndDirectorsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_ONMDManagementAndDirectorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_SecuritiesPurchaseAgreementMember" xlink:label="loc_ONMDSecuritiesPurchaseAgreementMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ONMDSecuritiesPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_SeniorConvertibleNotesMember" xlink:label="loc_ONMDSeniorConvertibleNotesMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_ONMDSeniorConvertibleNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaapConvertibleNotesPayable" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapConvertibleNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_ExtensionLoan" xlink:label="loc_ONMDExtensionLoan" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_ONMDExtensionLoan" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaapProceedsFromConvertibleDebt" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapProceedsFromConvertibleDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrentAndNoncurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapAccruedLiabilitiesCurrentAndNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentDescription" xlink:label="loc_us-gaapDebtInstrumentDescription" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtInstrumentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotesCurrent" xlink:label="loc_us-gaapSeniorNotesCurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapSeniorNotesCurrent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://onemednet.com/role/CommitmentsContingenciesAndConcentrationsOperatingLeaseDetailsNarrative" xlink:title="00000048 - Disclosure - Commitments, Contingencies, and Concentrations Operating lease (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaapOperatingLeaseCost" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaapOperatingLeasesRentExpenseNet" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeasesRentExpenseNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://onemednet.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000049 - Disclosure - Subsequent Events (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_srtStatementScenarioAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember" xlink:label="loc_srtScenarioForecastMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_srtScenarioForecastMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_EFHuttonMember" xlink:label="loc_ONMDEFHuttonMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_ONMDEFHuttonMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="onmd-20231231.xsd#ONMD_KingwoodCapitalPartnersLLCMember" xlink:label="loc_ONMDKingwoodCapitalPartnersLLCMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_ONMDKingwoodCapitalPartnersLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MajorityShareholderMember" xlink:label="loc_us-gaapMajorityShareholderMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapMajorityShareholderMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_srtTitleOfIndividualAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="loc_srtBoardOfDirectorsChairmanMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtBoardOfDirectorsChairmanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaapBusinessCombinationConsiderationTransferred1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapBusinessCombinationConsiderationTransferred1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodShares" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaapRelatedPartyTransactionAmountsOfTransaction" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionAmountsOfTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRelatedPartyDebt" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapProceedsFromRelatedPartyDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>93
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MD#2MS:-B,ERR[71:%_/ (RN?>:]DSKZ2I618-K=ICDM_''>]EX6XN.1J)V!
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MO*P/,V I"#- ?[_B7#V=F-V9;C=N]A]02P,$%     @ +:ZF6)PQ/47P!0
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M/#R"EG1HB1/M7T)#@GY;73:F#C*/!!&D:!_M4!!C+PKB> QOQXG823U[':2
M3F=%Z0][5^+' 1G"M$A"KI PB,9P=AR& W>GTVLF'Z.)CO**R^V['"<;?F^[
M>RIKAVYW!(G=#/FFW-!<CJ:[A?6\T M\,JA.YS0_ZD;'HMA-H\W62],'M)%B
MEYN/$:M#3C-VF,BZ;$/")3A(PK%NU!$N=A(<>*(93*T1JU/1ZD4\F#P.4C)L
M0D.YP/-]+QX!V=$D=O-D72PNA#9N)&'4!S@4"Z)DC!AQQXS838V+->4KAG*.
M7G\R^[_/5$H*'S-6J$,*/#8@2!^K32Y(4FB4=KBD(TOR%;+48GGWV'ML&,F0
M^_PP)L3O@W1/](-E2#HJ)6XJ_<@EHT7^'WQ!KBA$7\C1KN^V]!V52(9,>XS]
M&$=).K(N'=<2-]=^.R<0"X$&B8^)UT]YB^1QB--P/^$.X7942]Q4^X[I\7#[
M@R^L8T@?+PP&16D3C0A)(W\LH!W)$C?)_FD^=F!#@-2:2F8J<R'*4G!45<#L
M"-N#^Z2$^U36#D/0$2YQ$^XK*CGLAA2Z@C!<FS"\0)=YL=7]$Y'*VL57K'W!
MUJ.%1BO97T+O)$WZ*_TS2)MTI$TB9S9\KH[B6'9,=[!'A'Y=987JIP426ZTT
M;,XA;#.KMS] ZH[\>")KAT'I^)^X^?\Q*.B\"<J[;7D#J0)!N:[#\[X+ARMU
M%F3(_F2$-7[&-S<QNXG#D8Z_B9N_(:U-JWC6M8J<UR?;YH1X317B0J,;QCBJ
M$'$3,! PO247&?08N$BD!8(.CBZV"NQ#YX&LNLEY;>0(C&3L%EYD9I_P3FB&
M_!=VV<?!9WN#-L^G>Z>O)9.KZA1;H:78<ET?I[6C[4GY174^W!M?X-DEMHR?
MDV2V@,#:WJ3PICITGW93UT?V]>F20@6[!1C>20QE+^M3\/I!BTUU+GPCM!9E
M=;MF-&/2",#[6P'1:1[,!.U_$?/_ 5!+ P04    "  MKJ98_S\+1,(*  !)
M8@  &    'AL+W=O<FMS:&5E=',O<VAE970U+GAM;*V=;7.;.A;'OPKCW=EI
M9ZYK)/'833+3&(QAIVVFN0\O=O8%L96$K0V^0)+>;W\%QL9(0@;WO&EB]^AW
M9/37L= ?R-5;EG\OGBDMM1_;35I<3Y[+<O=Q-BM6SW0;%Q^R'4W9_SQF^38N
MV<O\:5;L<AJOZT;;S0SKNC7;QDDZN;FJW[O+;ZZREW*3I/0NUXJ7[3;._[JE
MF^SM>H(FAS>^)4_/9?7&[.9J%S_1>UK^MKO+V:O9D;).MC0MDBS5<OIX/?F$
M/D;$K!K4$;\G]*TX^5VK/LI#EGVO7H3KZXE>]8ANZ*JL$#'[\4KG=+.I2*P?
M?S;0R3%GU?#T]P-]47]X]F$>XH+.L\T?R;I\OIXX$VU-'^.73?DM>UO2Y@/5
M'5QEFZ+^5WO;Q]HL>/52E-FV:<QZL$W2_<_X1W,@3AI8J*<!;AK@H0U(TX!P
M#1R]IX'1-#"X!H;5T\!L&IA#,UA- XMK@/L:V$T#FVM ^KKD- T</H/=T\!M
M&KA< T3Z!DX_C)Q>*V@_Y+5>O+B,;Z[R[$W+JWC&JWZI15>W9S))TFI^W)<Y
M^]^$M2MOYEE:9)MD'9=TK=V7[ <3?UEHV2-[E:V^/V>;-<T+S?_S)2G_TMYY
M]#%9)>5[;:K]=N]I[_[Y_FI6LGY4M-FJR7F[SXE[<MZQ*4#SO$[(4FC__4RW
M#S3_GW9/\X06VJ<IUOIB)-GF/YL-C<GFJ;/-L^V637LN5?/N?!,7+&'[?C5D
MVG_2:@ZS]U?L&!=)73;F6;Y3]<('[(4$O_AI_"W APS.]R(I*[FJ($LUY--Z
M77<FWFAW<;*>)JQ;\2XIV6L%-%1#O]&2?3,Q-?EQGB;I4Z%B16K6KQGK2[?9
MC,WQXT3'QXF.:X[1P[FE3TE:=89]G6SB=$6UN-0\NOJ@$?2+AG6,9!-YSS1K
M9O55^WI#'/-J]GHZ_20Q6._&>&*,Z79#?#'$($8W9B'&8,?IQ@2R&-O4$>+Z
MM!0#D6OI-K))-S 4 Z>$N%BW^?Y%$J1A$$<G[3'K#!XY#AX9-WB_:,5SG+/J
M-600]VRK.XC$=FUN("5Q6#=TG1],,<YT3&QSNO#%,#:@V+(L;E#%N'K ^+2!
M\A!5Z\B/Q2Y>T>L)6R@6-'^EDYM__0-9^K]E50$2%D+"(B!81V?&46>&4F=A
M4;S4M8%]_:_VY;S1&:N+],?J.4Z?J,96Y5J5.5G10J8W98Z1AV,."?,@8;XA
M%AI.L@O(?,$%,$TF?4.8;\AU78?K>PC9]TC,R4[@3J=X1Z[F4:XFL%R;NBE3
MK3+56-5"PCQ(F&^>&XF]<B%S!I"P)20LA(1%0+#.5+".4\$:-A7N7AXVR4J[
MK^>!3.=*SEB=0\(\2)AOB4LQ3N*0Z8(+8-+B; G3TS9<;JD<0O8\DF0T^PJS
M?52C/4R-N[T:]U5947R5N+&BA(1YD##?5A_KO2XA,P:0L"4D+(2$14"PCMB=
MH]B=P:L0Y5['A^/>R.D&BFPZ*!..G0Z0, \2YD/"%HY8\ EWAAM<D%!:I1W)
M*2LV'<SO'$!^P$B>U+5Z:K5[E*\[=A&]:F1:5/H\;#7(=*HDC]4I),R#A/F0
ML(4KGGX1VS$1KU7(I$M(6 @)BX!@'>DCO74_=*7XFT)<"UW+Z9IN=U6YEGH:
M2M)8L8/2/%":#TI;@-*"2VC2$@[:K;"AG<[J*2&F:[K<64<T)+(KYA,K#RG%
M7"\GII5;O*XJ^8ZF15PO/NB/ZG?IPEN-'*UJ2)H'2O-!:0M06G )3:YJ)/EV
M<;'N<)ON(6C_HP%INYIN72NDMJV^T%+;9(5T]:%N.ORHS:% 'A3(OP2D$"M0
MMP(HT!+T\X4-K5-3+8Q=B[A\]1T0V55J:]$AM4?GI^O*H+N5NZM8*F RP%Z5
M!0G^JB1(,%@E,8;)95O(@C 7%* >RT[T6&61ADZP:2&^((F14X.8NNM:O,LJ
M"76QS8+[OD%;^PNI_:]F#,^8K/*Q%"T.N<LJ"Y3:K)) J<\JB6/CJB/!:)4%
M8I.(IQ[JHS3VW .4%H+2(BA:5V^M?X4&&EAG=^W5H-'K-%!_"I3F-[3.1@Z_
M=0^:,;B$)O]6$\TUA)!K"(LO4-NI)ZMI]U3#UE)" SVEH;OX:MYHD8*:2Z T
M'XFN"7?,&Z&"FDR@M"4H+02E15"TKO);^PJI_:LQVT*@UA4HS0.E^:"T!2@M
M0**S-NU;DH*Z6*"T:-#'Z&JZ=:F0VJ:Z:'<(U(@"I7F@-!^4M@"E!:"T)1)]
M).14YT_"&1FH>S4@;5?8K7^%U :6<HOH GM!OD4$!/*@0/XE((5B(6D!*&T)
M2@N1:,!-,3L#-PW3XC<:AH1VK\9OG2>L=I[X6T[*[.Q5 0VQ>R&Z>#F^+$J\
M(!_4,9+DM'5^^P$T97 )37K2AD5#QM9-6^>=FQ"T_U%O6MRCK-8&PFH;J%56
M<5#6ZF0]J_+SL;B//Y7O8DDCI=M8ZMZ.5IJ8MSIL0@<7H&D#4-H2E!:"TB(H
M6E>\K=^#U7[//$M?:5XF#QNJ?<E*6@PJC)!NPAR4YH'2?"S>860AAY<^9,K@
M$IJ\T(K>BX5LR^)W]T+0_D?RM#;&/8X/;AT?K'9\3K6:'K0ZN-1"WC0T!Z5Y
MH#0?BW8-/P"-;B'3!J"T)2@M!*5%4+3N-&A-,ZPVS?;KUZ_U#MFP<@UIX<Q!
M:1XHS6]HW7+-JQXR8W )35ZM1;/00MC2^7L10+L?]62U>W:_<.NT8;73MA=I
M4A0O;%V\?LDKFW='\R1;'TS>K!7P:0V7"AC4C .E>: T'XO>$C<>C8A!#3E0
MVA*4%H+2(BA:=U:T#A]6.WR'%0R;#-FC]D><YW'U\(\A-1S4Z@.E>: T'XMW
MDA'^<KH%:,K@$IJ\B(LV)3N==W7;X:LXJ'O7D]8XN9*G*]C6F,/GC+E3P;Z=
M"';PNAO4KP.E>: T'XMF$C\*C7A!K3A0VA*4%H+2(BA:=RZTAAY6&WIW>?(:
MEU3[FM+/=%VY(&P:?/WRV3M_-9&:/'H2@/IZH#0?B[>%33$6RC>H7W<)35Z^
M1<^,==ZT$;_)&H)^@*@O+\%]MD=KUF&U63=@'5X^TUPJ6M"[S4!I'BC-QS+?
MB3O^C7!!;3M0VA*4%H+2(BA:]VE.K?E'U.;?Z3V7=^&=?UQZRW2O9HW5/2C-
M Z7YH+0%*"VXA"8MZD0T_I".=)O?!0?M?G0^:U?*K=M(U&[CR8J\<_/[X01R
M7]3??=+B=*W=OA^^1E'G'2U[T#O3&EIG52'<;R$)(OREP L92;SAXI+>R\4G
MVJ<6,1#OU8>@ARN29B6NY?2(KW4+R3"W\*?$ISI;5.<?+4)09Y%([F62/XA/
M#&1"U(7 A8PHOT,$]),L06DA*"V"HG45?O+@1[7'>'R4*#T\2C1>__^EJ!][
M*A4LJ*T(2O- :3XH;0%*"RZAR>LU[',J12<6(8M4]\YQ5[X-B>PJNK4+B=HN
M5-\G2:2B%FTT[@1X?C[$.Q_B2T(P$6[J. \*SH<L)2$&QI@MR0S^RUB,G)JF
M[F#+MOEQDX0B[%1/B>DY=2>MA4;4%MJPFR/E RC:2,( G@WQSH?XDI!J #$F
MF!_$L[! ?3Q&?\F!VE"@M B*ME?6[.1Q]-4?6?@<YT])6F@;^LCP^@>;9<OW
M?[=@_Z+,=O43ZA^RLLRV]:_/-%[3O I@__^89>7A1?70^^-?C[CY&U!+ P04
M    "  MKJ98K_(N#0X"   \!   &    'AL+W=O<FMS:&5E=',O<VAE970V
M+GAM;'U446_3,!#^*U9 L$FH3A.ZH9)$6EO0>$"J5@$/B <WN316G3BSK\WV
M[SD[:510MY?:9]_WW?>Y=TDZ;?:V D#V5*O&ID&%V,XYMWD%M; 3W4)#-Z4V
MM4 *S8[;UH H/*A6/ K#&UX+V019XL_6)DOT 95L8&V8/=2U,,\+4+I+@VEP
M.GB0NPK= <^25NQ@ _BC71N*^,A2R!H:*W7##)1I<#>=+V*7[Q-^2NCLV9XY
M)UNM]R[X5J1!Z 2!@AP=@Z#E"$M0RA&1C,>!,QA+.N#Y_L3^U7LG+UMA8:G5
M+UE@E0:? E9 *0X*'W1W#X.?F>/+M;+^EW5][FT<L/Q@4=<#F!34LNE7\32\
MPQD@FKT B 9 Y'7WA;S*E4"1)49WS+AL8G,;;]6C29QLW)^R04.WDG"8+75C
MM9*%0"C8!FFA%T?+=$F1SO>55@48R[X\'B0^LZL5E#*7>,VNUL)09@4H<Z&N
M$XZDQG'R?*B\Z"M'+U1>03YA\?0#B\(H8F\99[8B2OLO$R<_HZEH-!5YZO@%
MZM''_S;>GWS\OMM:--02?RX)[]D_7F9W8S*WK<@A#6@.+)@C!-F[-].;\/,K
MVN-1>_P:>[9QC\#61N9P25H/GGFP&[AC-DWX\;P>/VL&-U??A=G)QC(%)6'"
MR2V!3=^K?8"Z]?VQU4C=YK<5C3<8ET#WI=9X"ES+C1^,["]02P,$%     @
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MU0-I!B'>E&SZ8A]5B*>-!9&D^,405WOQ5KD5-M_5BW%RF^S DO<1G]#>;6@
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M1J1;&CY52)O8[\[8Y/2PH/PJ,H/\TRDE)(4A%PV&J[8-PDTG@H*530&Z$0^
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M8!:[E&W!9HP-2T[GAQ,L.!<O-"S1$KE6B0_W'FJ1@ML1+M$L^8S@11WLZT3
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MI94#?N9X[^QH[Y**##$X/PSJ0JE]XA1K. Z-7#APLE0\K_A:#0?1"&$J!'M
M8]OO;#U4CH5NZ2A^Y_)M3>,--P"UI[""N>N332*^0B<QY81YLC??[)4AUYA
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MSB*CHQ?P_;IINO"!-H@_>OGL7U!+ P04    "  MKJ985J5'?]$#  !+"0
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M0Y!![#R"I-\>5I!E'HC<^-I@!JU)KW@Z/J _<.P4RT8BK$SVATI<.@MN Y'
M5I:9^VBJ7Z&)Y\;CQ29#_HJJEKV9!"(NT9F\428/<J7KO_S6\'"B<#N\H! U
M"A'[71MB+]]))^=3:RIAO32A^0&'RMKDG-(^*6MG:5>1GILO2Z051+$R^49I
MZ:F:AHZ0_7X8-RC+&B6Z@#**Q*/1+D7QBTX@.0<(R:76K^C@US*ZBO@.XH$8
MC_HB&D;C*WCC-LXQXXW_1YQ"ZD0L$*GT%_'74J'BU3\7&W26RN6O+B)J,Y-N
M,_X(W6$A8Y@%=$80[!Z"^>M7HS?#^RM!3-H@)M?0_W.RKJ)T^S@>]#HI^I1"
M]T8ED8Y4;$KM(!%T.PB_0.=T#Q:!_K$LE).9^J?A&L4'#8^0_$YTKXPMC#T"
M)># 4G43DC-B \*E<$!7>D=#2H\%VRNIO*QX("=TK&1&>6MEUH[2*6V"8FGH
M]_K5;31Z>X_B)S^*AO</B_62AZ/[G[OU5B916Q77;AW4%NM5J_7)%"H6M\.;
M?B<G.""ZU#&:8WR%573EJ>R%;Y!$T'(W&;')21:]7YX"HW?&C^D.K@50F"WO
MQ&P6DAY0%.ZEWXW7DH"@%:4HEYIN6KI3W:DE@I19QK _RGUGC_6D)H/^\/@=
M0C&VAZFTD)J,TL,^'MTQE>84$NC?QI*O!\B]8?X+4U%*OS=3AS7@1-F$Y#(R
MR55VS%Q14J (V&?5[:$H>NBD8^=_8*N!%67!7&MN14Q\(]A9ZA;XG'"A2Z]&
MULLSM=:V.-KNG;%P5O'*I:R6@]U1[!O@?%-/90O(>T 5OY=9DX(CD$(LO3AU
MAOB9&?'2FG:DO\DX9-\)Q&_:-R3LO=?QH,^T^<0ILK!YX8-Z?D 'XL.QR#BG
M_BA>Y(2R+4Y8\3Y3*L2EF'M*BVWI2NMO!EJ\F)J!Z+HGPY,&QZ3Y-HZ"*Z'N
M=>UJ^U)8U WR*%X_,QZEW2D*,8,MJ0X';V\"8>O674^<*;A=;HRCYLO#E%X[
M8+T [6^-<8>)-]"^G^;_ E!+ P04    "  MKJ98O[CCZ;X$  #N"@  &0
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M9_[#5GOS, K=ZQ )<XDCW2/G\TH/]_?#86T,; ZKPA]L\NB&*;:2%G<:UU3
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M#?TJ4)H VE\)H?<+<T#[\YG^!5!+ P04    "  MKJ983[#)\?P'  #K$P
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MIDU=,7649>5Z>T\V,/"N(2GL/H>=V+LFZC)Y8MX/BZ:'!,)C#N:<JA<)H!A
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M,#VI,1/.$<P<_B.#O^FS.4E[=$:X8[*_%^]-=W_FK=R:DG':[E)8+Y$6D3:
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M!OWC%6 +<G[,?HV"&K9?"%8-P=?AEPQ_L<DO% <V9,LW8-1!D H'/T,:U&R
M-V=@G+9 )7!4+=LS+BF@<^YJ<5;MIK8@S%S$ K86J.DW&QO#:0BX+_=65LG*
M\*GUJJ17P!=18)#AS-3@.BCYRB#-\H;*['9U=2NN*@:[K*\^2Y]0NN*V^"^,
M*S!$!E _O7Q]J5^7E.\H<MA[>KZ$%-Y>6T[I)J2_*_W29G:[!,7SA;4)E2?
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M915H?RFEJ1?60?/+,_T-4$L#!!0    ( "VNIEA[?""MY0(  /H&   9
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M5'EW* =&YJ[]GDM#S;Q[3.B^A<HNH/=WDD[W>F =5#>XT3]02P,$%     @
M+:ZF6%.=>4![!   ^!X  !D   !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL
MO5G;;N,V$/T50@6*%F@CB_(UM0TD3A<-T&"-I)>'11]D:6P)D427I.TMT(\O
M=;%HNC)]P>R^V+IPSG .#P<'XGC'^+N( 23YG*6YF#BQE.M[UQ5A#%D@[M@:
M<O5FR7@62'7+5ZY8<PBB,BA+7=KI]-TL2')G.BZ?S?ETS#8R37*8<R(V61;P
M?QXA9;N)XSG[!Z_)*I;% W<Z7@<K> /Y^WK.U9W;H$1)!KE(6$XX+"?.@W<_
MHZ,BH!SQ1P([<7!-BE(6C+T7-\_1Q.D4,X(40EE !.IO"S-(TP))S>/O&M1I
M<A:!A]=[] ]E\:J812!@QM(_DTC&$V?HD B6P2:5KVSW"]0%]0J\D*6B_"6[
M>FS'(>%&2);5P6H&69)7_\'GFHB# *]_(H#6 ?0XH'LBP*\#_++0:F9E64^!
M#*9CSG:$%Z,56G%1<E-&JVJ2O%C&-\G5VT3%R>F;TD6T28%\7)*'U8K#*I!
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M.<><E!\@WC"R=CTXEP8[VBU+G+F@K .>+Z0T&\,&Z*9X]AM02P,$%     @
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M7"]0]Y>,R:>!WJ ^1AK_ U!+ P04    "  MKJ98:LR9MFP'   90@  &0
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MW4C%BR98]Z#(ROHO_=Z\$8<$!$U \"3 'S\3,&H"1H<&C)N \:$!DR9@<FC
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M%^#WC<02T@SL!NW=*_X74$L#!!0    ( "VNIECHK;WO^P,  "L2   9
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M1331T [E%U#>20- +76_3-T_M$!NJ7B$&4=U]8E$Q;:$6R*QM51:G1PJA8[
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M^?[]]+XAV3I_Q3MG4K(TOUP!B8'K#NK[!6/RT-!OC<O_$@A_ %!+ P04
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M5)$8E@;9.1V:+Y$L%B 6&UJL\Q5V"V$N[9+\[0IX"#([P'R^%$(_;60#5,M
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M>TJ2),O""&!A!4F"(? TX@BF #1@2)*X<W#O/(K7YU2\^05H]!M02P,$%
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M"-+R009!5C[((<C+!PTA:%@^: 1!H_)!+Q#T4C[H%8)>RP>-(6A</D@&*..
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MYY3_,CMN[X=QR^X\/.MNU^_QUS,^UK^P#P'2AP3I0X'T<0/2QPBDCUN0/NY
M^K@'Z8,/41I!$96CD,I13.4HJ'(453D*JQS%58X"*T>15:#(*E!D%2BR"A19
M!8JL D56@2*K0)%5H,@J4&25*+)*%%DEBJP215:)(JM$D56BR"I19)4HLDH4
M616*K I%5H4BJT*15:'(JE!D52BR*A19%8JLZC]E?3=F^=>_ MM[6NNR.>2S
M[G_K]!-02P$"% ,4    "  MKJ98!T%-8H$   "Q    $
M@ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( "VNIEB:?B#R[P
M "L"   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4
M Q0    ( "VNIEB97)PC$ 8  )PG   3              "  <T!  !X;"]T
M:&5M92]T:&5M93$N>&UL4$L! A0#%     @ +:ZF6'L2KTSW!   '14  !@
M             ("!#@@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4
M Q0    ( "VNIEB_ O@.=0@  "XO   8              " @3L-  !X;"]W
M;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    "  MKJ98'6DXR*4#  "9
M$P  &               @('F%0  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL
M4$L! A0#%     @ +:ZF6)PQ/47P!0  EQ@  !@              ("!P1D
M 'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( "VNIEC_/PM$
MP@H  $EB   8              " @><?  !X;"]W;W)K<VAE971S+W-H965T
M-2YX;6Q02P$"% ,4    "  MKJ98K_(N#0X"   \!   &
M@('?*@  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ +:ZF
M6*.T@:WJ!P  ?B$  !@              ("!(RT  'AL+W=O<FMS:&5E=',O
M<VAE970W+GAM;%!+ 0(4 Q0    ( "VNIEC%][BY?@L  ",>   8
M      " @4,U  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4
M"  MKJ98U\/V*6H<    4P  &               @('W0   >&PO=V]R:W-H
M965T<R]S:&5E=#DN>&UL4$L! A0#%     @ +:ZF6%:E1W_1 P  2PD  !D
M             ("!EUT  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"
M% ,4    "  MKJ98O[CCZ;X$  #N"@  &0              @(&?80  >&PO
M=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( "VNIECHB *^[0(
M (@&   9              " @91F  !X;"]W;W)K<VAE971S+W-H965T,3(N
M>&UL4$L! A0#%     @ +:ZF6$^PR?'\!P  ZQ,  !D              ("!
MN&D  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    "  MKJ98
M$QHCA 8)  #J&0  &0              @('K<0  >&PO=V]R:W-H965T<R]S
M:&5E=#$T+GAM;%!+ 0(4 Q0    ( "VNIEA5L53^[0,  .0(   9
M      " @2A[  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%
M  @ +:ZF6,T4&(./!@  VQ4  !D              ("!3'\  'AL+W=O<FMS
M:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    "  MKJ98?@5!+5D)  #]%P
M&0              @($2A@  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+
M 0(4 Q0    ( "VNIEA>8$BO[ ,  !(*   9              " @:*/  !X
M;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ +:ZF6$=#X[CR
M!   J@P  !D              ("!Q9,  'AL+W=O<FMS:&5E=',O<VAE970Q
M.2YX;6Q02P$"% ,4    "  MKJ98Y:CU%@ '  #6$   &0
M@('NF   >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( "VN
MIEB$A?XOM@(  %@&   9              " @26@  !X;"]W;W)K<VAE971S
M+W-H965T,C$N>&UL4$L! A0#%     @ +:ZF6)BJ01CQ!0  _ X  !D
M         ("!$J,  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4
M    "  MKJ98C@0W9.8=  #/70  &0              @($ZJ0  >&PO=V]R
M:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( "VNIE@? '-^)0,  %4(
M   9              " @5?'  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL
M4$L! A0#%     @ +:ZF6,RBNDN= @  S04  !D              ("!L\H
M 'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    "  MKJ9840,P
M:-H"   J!@  &0              @(&'S0  >&PO=V]R:W-H965T<R]S:&5E
M=#(V+GAM;%!+ 0(4 Q0    ( "VNIEC\_'MV'@,   X'   9
M  " @9C0  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @
M+:ZF6"17XKS' P  _@@  !D              ("![=,  'AL+W=O<FMS:&5E
M=',O<VAE970R."YX;6Q02P$"% ,4    "  MKJ98>WP@K>4"  #Z!@  &0
M            @('KUP  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4
M Q0    ( "VNIEAD)CGX4 0  ,T-   9              " @0?;  !X;"]W
M;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ +:ZF6%.=>4![!
M^!X  !D              ("!CM\  'AL+W=O<FMS:&5E=',O<VAE970S,2YX
M;6Q02P$"% ,4    "  MKJ98#)K3,> #   S$P  &0              @(%
MY   >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( "VNIEC>
M89*P4P(  $ %   9              " @5?H  !X;"]W;W)K<VAE971S+W-H
M965T,S,N>&UL4$L! A0#%     @ +:ZF6(F3\+8, P  TPL  !D
M     ("!X>H  'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( "VNIEC7:_8?'@,  (D)   9              "
M@8W_  !X;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ +:ZF
M6-(TQ#IG P  APD  !D              ("!X@(! 'AL+W=O<FMS:&5E=',O
M<VAE970T,"YX;6Q02P$"% ,4    "  MKJ98Z*V][_L#   K$@  &0
M        @(& !@$ >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0
M   ( "VNIE@#UWF+O ,  -(.   9              " @;(* 0!X;"]W;W)K
M<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @ +:ZF6.'_K=*/ P  X0\
M !D              ("!I0X! 'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q0
M2P$"% ,4    "  MKJ988/SX *D&  !7-   &0              @(%K$@$
M>&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( "VNIEB'FFX#
MK04  $HL   9              " @4L9 0!X;"]W;W)K<VAE971S+W-H965T
M-#4N>&UL4$L! A0#%     @ +:ZF6._!9-8Q!   ,2   !D
M ("!+Q\! 'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"% ,4    "  M
MKJ98X(=1?8('  !8.@  &0              @(&7(P$ >&PO=V]R:W-H965T
M<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( "VNIECWF6H]D@(  +<&   9
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M 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  MKJ98CF$X^KT!  !Z'0
M&@              @ &5/ $ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-0
M2P$"% ,4    "  MKJ98G"O3#[T!  !W'0  $P              @ &*/@$
I6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     .0 Y (8/  !X0 $    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>164</ContextCount>
  <ElementCount>245</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>63</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onemednet.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onemednet.com/role/BalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onemednet.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onemednet.com/role/StatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Consolidated Statements of Stockholders Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onemednet.com/role/StatementsOfStockholdersEquityDeficit</Role>
      <ShortName>Consolidated Statements of Stockholders Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Consolidated Statements of Stockholders Equity (Deficit) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onemednet.com/role/StatementsOfStockholdersEquityDeficitParenthetical</Role>
      <ShortName>Consolidated Statements of Stockholders Equity (Deficit) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onemednet.com/role/StatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - Organization and Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onemednet.com/role/OrganizationAndOperations</Role>
      <ShortName>Organization and Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onemednet.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - Business Combination</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onemednet.com/role/BusinessCombination</Role>
      <ShortName>Business Combination</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - Going Concern</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onemednet.com/role/GoingConcern</Role>
      <ShortName>Going Concern</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onemednet.com/role/PropertyAndEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onemednet.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - Convertible Promissory Notes held by Related Party</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://onemednet.com/role/ConvertiblePromissoryNotesHeldByRelatedParty</Role>
      <ShortName>Convertible Promissory Notes held by Related Party</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - Canadian Emergency Business Loan Act (CEBA)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onemednet.com/role/CanadianEmergencyBusinessLoanActCeba</Role>
      <ShortName>Canadian Emergency Business Loan Act (CEBA)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - Shareholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onemednet.com/role/ShareholdersEquity</Role>
      <ShortName>Shareholders??? Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - Stock Options</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onemednet.com/role/StockOptions</Role>
      <ShortName>Stock Options</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - Stock Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onemednet.com/role/StockWarrants</Role>
      <ShortName>Stock Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - Fair Value Measures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onemednet.com/role/FairValueMeasures</Role>
      <ShortName>Fair Value Measures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onemednet.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - Commitments, Contingencies, and Concentrations Operating lease</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onemednet.com/role/CommitmentsContingenciesAndConcentrationsOperatingLease</Role>
      <ShortName>Commitments, Contingencies, and Concentrations Operating lease</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onemednet.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://onemednet.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://onemednet.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onemednet.com/role/PropertyAndEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://onemednet.com/role/PropertyAndEquipment</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onemednet.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://onemednet.com/role/IncomeTaxes</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - Shareholders??? Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onemednet.com/role/ShareholdersEquityTables</Role>
      <ShortName>Shareholders??? Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://onemednet.com/role/ShareholdersEquity</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - Stock Options (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onemednet.com/role/StockOptionsTables</Role>
      <ShortName>Stock Options (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://onemednet.com/role/StockOptions</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - Fair Value Measures (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onemednet.com/role/FairValueMeasuresTables</Role>
      <ShortName>Fair Value Measures (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://onemednet.com/role/FairValueMeasures</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - Organization and Operations (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onemednet.com/role/OrganizationAndOperationsDetailsNarrative</Role>
      <ShortName>Organization and Operations (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://onemednet.com/role/OrganizationAndOperations</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - Schedule Of Aggregate Percentage Revenue and Accounts Receivable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onemednet.com/role/ScheduleOfAggregatePercentageRevenueAndAccountsReceivableDetails</Role>
      <ShortName>Schedule Of Aggregate Percentage Revenue and Accounts Receivable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>Summary of Significant Accounting Policies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - Going Concern (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onemednet.com/role/GoingConcernDetailsNarrative</Role>
      <ShortName>Going Concern (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://onemednet.com/role/GoingConcern</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - Schedule of Property And Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onemednet.com/role/ScheduleOfPropertyAndEquipmentDetails</Role>
      <ShortName>Schedule of Property And Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - Property and Equipment (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onemednet.com/role/PropertyAndEquipmentDetailsNarrative</Role>
      <ShortName>Property and Equipment (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://onemednet.com/role/PropertyAndEquipmentTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - Schedule of Deferred Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onemednet.com/role/ScheduleOfDeferredIncomeTaxesDetails</Role>
      <ShortName>Schedule of Deferred Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>00000037 - Disclosure - Income Taxes (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onemednet.com/role/IncomeTaxesDetailsNarrative</Role>
      <ShortName>Income Taxes (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://onemednet.com/role/IncomeTaxesTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>00000038 - Disclosure - Convertible Promissory Notes held by Related Party (Details Narrative)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://onemednet.com/role/ConvertiblePromissoryNotesHeldByRelatedPartyDetailsNarrative</Role>
      <ShortName>Convertible Promissory Notes held by Related Party (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://onemednet.com/role/ConvertiblePromissoryNotesHeldByRelatedParty</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>00000039 - Disclosure - Canadian Emergency Business Loan Act (CEBA) (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onemednet.com/role/CanadianEmergencyBusinessLoanActCebaDetailsNarrative</Role>
      <ShortName>Canadian Emergency Business Loan Act (CEBA) (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://onemednet.com/role/CanadianEmergencyBusinessLoanActCeba</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>00000040 - Disclosure - Schedule of Common Stock Activities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onemednet.com/role/ScheduleOfCommonStockActivitiesDetails</Role>
      <ShortName>Schedule of Common Stock Activities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>00000041 - Disclosure - Shareholders??? Equity (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onemednet.com/role/ShareholdersEquityDetailsNarrative</Role>
      <ShortName>Shareholders??? Equity (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://onemednet.com/role/ShareholdersEquityTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>00000042 - Disclosure - Schedule of Options Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onemednet.com/role/ScheduleOfOptionsOutstandingDetails</Role>
      <ShortName>Schedule of Options Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>00000043 - Disclosure - Schedule of Fair Value of Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onemednet.com/role/ScheduleOfFairValueOfStockOptionsDetails</Role>
      <ShortName>Schedule of Fair Value of Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>00000044 - Disclosure - Stock Options (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onemednet.com/role/StockOptionsDetailsNarrative</Role>
      <ShortName>Stock Options (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://onemednet.com/role/StockOptionsTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>00000045 - Disclosure - Stock Warrants (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onemednet.com/role/StockWarrantsDetailsNarrative</Role>
      <ShortName>Stock Warrants (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://onemednet.com/role/StockWarrants</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>00000046 - Disclosure - Schedule of Financial Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onemednet.com/role/ScheduleOfFinancialAssetsDetails</Role>
      <ShortName>Schedule of Financial Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>00000047 - Disclosure - Related Party Transactions (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onemednet.com/role/RelatedPartyTransactionsDetailsNarrative</Role>
      <ShortName>Related Party Transactions (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://onemednet.com/role/RelatedPartyTransactions</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>00000048 - Disclosure - Commitments, Contingencies, and Concentrations Operating lease (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onemednet.com/role/CommitmentsContingenciesAndConcentrationsOperatingLeaseDetailsNarrative</Role>
      <ShortName>Commitments, Contingencies, and Concentrations Operating lease (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://onemednet.com/role/CommitmentsContingenciesAndConcentrationsOperatingLease</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>00000049 - Disclosure - Subsequent Events (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onemednet.com/role/SubsequentEventsDetailsNarrative</Role>
      <ShortName>Subsequent Events (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://onemednet.com/role/SubsequentEvents</ParentRole>
      <Position>49</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="S-1/A" isDefinitelyFs="true" isUsgaap="true" original="forms-1a.htm">forms-1a.htm</File>
    <File>onmd-20231231.xsd</File>
    <File>onmd-20231231_cal.xml</File>
    <File>onmd-20231231_def.xml</File>
    <File>onmd-20231231_lab.xml</File>
    <File>onmd-20231231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>forms-1_001.jpg</File>
    <File>forms-1_002.jpg</File>
    <File>forms-1_003.jpg</File>
    <File>forms-1_004.jpg</File>
    <File>forms-1_005.jpg</File>
    <File>forms-1_006.jpg</File>
    <File>forms-1_007.jpg</File>
    <File>forms-1_008.jpg</File>
    <File>forms-1_009.jpg</File>
    <File>forms-1_010.jpg</File>
    <File>forms-1_011.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="526">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="26">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>99
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "forms-1a.htm": {
   "nsprefix": "ONMD",
   "nsuri": "http://onemednet.com/20231231",
   "dts": {
    "inline": {
     "local": [
      "forms-1a.htm"
     ]
    },
    "schema": {
     "local": [
      "onmd-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "onmd-20231231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "onmd-20231231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "onmd-20231231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "onmd-20231231_pre.xml"
     ]
    }
   },
   "keyStandard": 206,
   "keyCustom": 39,
   "axisStandard": 24,
   "axisCustom": 0,
   "memberStandard": 31,
   "memberCustom": 31,
   "hidden": {
    "total": 80,
    "http://fasb.org/us-gaap/2023": 61,
    "http://onemednet.com/20231231": 16,
    "http://xbrl.sec.gov/dei/2023": 3
   },
   "contextCount": 164,
   "entityCount": 1,
   "segmentCount": 63,
   "elementCount": 454,
   "unitCount": 5,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 526,
    "http://xbrl.sec.gov/dei/2023": 26
   },
   "report": {
    "R1": {
     "role": "http://onemednet.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "dei:AmendmentDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "dei:AmendmentDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1a.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://onemednet.com/role/BalanceSheets",
     "longName": "00000002 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1a.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://onemednet.com/role/BalanceSheetsParenthetical",
     "longName": "00000003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "AsOf2022-12-31",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-12-31",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1a.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://onemednet.com/role/StatementsOfOperations",
     "longName": "00000004 - Statement - Consolidated Statements of Operations",
     "shortName": "Consolidated Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1a.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://onemednet.com/role/StatementsOfStockholdersEquityDeficit",
     "longName": "00000005 - Statement - Consolidated Statements of Stockholders Equity (Deficit)",
     "shortName": "Consolidated Statements of Stockholders Equity (Deficit)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesATwoPreferredStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesATwoPreferredStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1a.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://onemednet.com/role/StatementsOfStockholdersEquityDeficitParenthetical",
     "longName": "00000006 - Statement - Consolidated Statements of Stockholders Equity (Deficit) (Parenthetical)",
     "shortName": "Consolidated Statements of Stockholders Equity (Deficit) (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "AsOf2022-12-31",
      "name": "us-gaap:SharePrice",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1a.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R7": {
     "role": "http://onemednet.com/role/StatementsOfCashFlows",
     "longName": "00000007 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1a.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://onemednet.com/role/OrganizationAndOperations",
     "longName": "00000008 - Disclosure - Organization and Operations",
     "shortName": "Organization and Operations",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1a.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://onemednet.com/role/SummaryOfSignificantAccountingPolicies",
     "longName": "00000009 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1a.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://onemednet.com/role/BusinessCombination",
     "longName": "00000010 - Disclosure - Business Combination",
     "shortName": "Business Combination",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1a.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://onemednet.com/role/GoingConcern",
     "longName": "00000011 - Disclosure - Going Concern",
     "shortName": "Going Concern",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1a.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://onemednet.com/role/PropertyAndEquipment",
     "longName": "00000012 - Disclosure - Property and Equipment",
     "shortName": "Property and Equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1a.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://onemednet.com/role/IncomeTaxes",
     "longName": "00000013 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1a.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://onemednet.com/role/ConvertiblePromissoryNotesHeldByRelatedParty",
     "longName": "00000014 - Disclosure - Convertible Promissory Notes held by Related Party",
     "shortName": "Convertible Promissory Notes held by Related Party",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:LongTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:LongTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1a.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://onemednet.com/role/CanadianEmergencyBusinessLoanActCeba",
     "longName": "00000015 - Disclosure - Canadian Emergency Business Loan Act (CEBA)",
     "shortName": "Canadian Emergency Business Loan Act (CEBA)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1a.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://onemednet.com/role/ShareholdersEquity",
     "longName": "00000016 - Disclosure - Shareholders\u2019 Equity",
     "shortName": "Shareholders\u2019 Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1a.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://onemednet.com/role/StockOptions",
     "longName": "00000017 - Disclosure - Stock Options",
     "shortName": "Stock Options",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1a.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://onemednet.com/role/StockWarrants",
     "longName": "00000018 - Disclosure - Stock Warrants",
     "shortName": "Stock Warrants",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "ONMD:StockWarrantsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "ONMD:StockWarrantsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1a.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://onemednet.com/role/FairValueMeasures",
     "longName": "00000019 - Disclosure - Fair Value Measures",
     "shortName": "Fair Value Measures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1a.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://onemednet.com/role/RelatedPartyTransactions",
     "longName": "00000020 - Disclosure - Related Party Transactions",
     "shortName": "Related Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1a.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://onemednet.com/role/CommitmentsContingenciesAndConcentrationsOperatingLease",
     "longName": "00000021 - Disclosure - Commitments, Contingencies, and Concentrations Operating lease",
     "shortName": "Commitments, Contingencies, and Concentrations Operating lease",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1a.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://onemednet.com/role/SubsequentEvents",
     "longName": "00000022 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1a.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "00000023 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "23",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1a.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "longName": "00000024 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:TradeAndOtherAccountsReceivablePolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:TradeAndOtherAccountsReceivablePolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1a.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://onemednet.com/role/PropertyAndEquipmentTables",
     "longName": "00000025 - Disclosure - Property and Equipment (Tables)",
     "shortName": "Property and Equipment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1a.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://onemednet.com/role/IncomeTaxesTables",
     "longName": "00000026 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1a.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://onemednet.com/role/ShareholdersEquityTables",
     "longName": "00000027 - Disclosure - Shareholders\u2019 Equity (Tables)",
     "shortName": "Shareholders\u2019 Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1a.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://onemednet.com/role/StockOptionsTables",
     "longName": "00000028 - Disclosure - Stock Options (Tables)",
     "shortName": "Stock Options (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1a.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://onemednet.com/role/FairValueMeasuresTables",
     "longName": "00000029 - Disclosure - Fair Value Measures (Tables)",
     "shortName": "Fair Value Measures (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1a.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://onemednet.com/role/OrganizationAndOperationsDetailsNarrative",
     "longName": "00000030 - Disclosure - Organization and Operations (Details Narrative)",
     "shortName": "Organization and Operations (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "From2023-11-012023-11-30_custom_SecuritiesPurchaseAgreementMember",
      "name": "us-gaap:DebtInstrumentDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-06-282023-06-28_custom_SecuritiesPurchaseAgreementMember_custom_DataKnightsAcquisitionCorpMember",
      "name": "us-gaap:DebtInstrumentIssuedPrincipal",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1a.htm",
      "unique": true
     }
    },
    "R31": {
     "role": "http://onemednet.com/role/ScheduleOfAggregatePercentageRevenueAndAccountsReceivableDetails",
     "longName": "00000031 - Disclosure - Schedule Of Aggregate Percentage Revenue and Accounts Receivable (Details)",
     "shortName": "Schedule Of Aggregate Percentage Revenue and Accounts Receivable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "From2023-01-012023-12-31_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerOneMember",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "us-gaap:TradeAndOtherAccountsReceivablePolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-012023-12-31_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerOneMember",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "us-gaap:TradeAndOtherAccountsReceivablePolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1a.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "longName": "00000032 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)",
     "shortName": "Summary of Significant Accounting Policies (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:TradeAndOtherAccountsReceivablePolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:TradeAndOtherAccountsReceivablePolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1a.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://onemednet.com/role/GoingConcernDetailsNarrative",
     "longName": "00000033 - Disclosure - Going Concern (Details Narrative)",
     "shortName": "Going Concern (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1a.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R34": {
     "role": "http://onemednet.com/role/ScheduleOfPropertyAndEquipmentDetails",
     "longName": "00000034 - Disclosure - Schedule of Property And Equipment (Details)",
     "shortName": "Schedule of Property And Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1a.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://onemednet.com/role/PropertyAndEquipmentDetailsNarrative",
     "longName": "00000035 - Disclosure - Property and Equipment (Details Narrative)",
     "shortName": "Property and Equipment (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:DepreciationAndAmortization",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:DepreciationAndAmortization",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1a.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://onemednet.com/role/ScheduleOfDeferredIncomeTaxesDetails",
     "longName": "00000036 - Disclosure - Schedule of Deferred Income Taxes (Details)",
     "shortName": "Schedule of Deferred Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1a.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://onemednet.com/role/IncomeTaxesDetailsNarrative",
     "longName": "00000037 - Disclosure - Income Taxes (Details Narrative)",
     "shortName": "Income Taxes (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1a.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://onemednet.com/role/ConvertiblePromissoryNotesHeldByRelatedPartyDetailsNarrative",
     "longName": "00000038 - Disclosure - Convertible Promissory Notes held by Related Party (Details Narrative)",
     "shortName": "Convertible Promissory Notes held by Related Party (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "AsOf2022-12-31",
      "name": "us-gaap:ConvertibleNotesPayable",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:LongTermDebtTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-12-31_custom_ConvertiblePromissoryNotesMember",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:LongTermDebtTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1a.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://onemednet.com/role/CanadianEmergencyBusinessLoanActCebaDetailsNarrative",
     "longName": "00000039 - Disclosure - Canadian Emergency Business Loan Act (CEBA) (Details Narrative)",
     "shortName": "Canadian Emergency Business Loan Act (CEBA) (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "From2020-12-012020-12-31_custom_CEBALoanMember",
      "name": "us-gaap:ProceedsFromIssuanceOfUnsecuredDebt",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2020-12-012020-12-31_custom_CEBALoanMember",
      "name": "us-gaap:ProceedsFromIssuanceOfUnsecuredDebt",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1a.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://onemednet.com/role/ScheduleOfCommonStockActivitiesDetails",
     "longName": "00000040 - Disclosure - Schedule of Common Stock Activities (Details)",
     "shortName": "Schedule of Common Stock Activities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "AsOf2022-12-31_us-gaap_CommonStockMember_srt_BoardOfDirectorsChairmanMember",
      "name": "us-gaap:SharesOutstanding",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-12-31_us-gaap_CommonStockMember_srt_BoardOfDirectorsChairmanMember",
      "name": "us-gaap:SharesOutstanding",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1a.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://onemednet.com/role/ShareholdersEquityDetailsNarrative",
     "longName": "00000041 - Disclosure - Shareholders\u2019 Equity (Details Narrative)",
     "shortName": "Shareholders\u2019 Equity (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ConvertiblePreferredStockTermsOfConversion",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ConvertiblePreferredStockTermsOfConversion",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1a.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://onemednet.com/role/ScheduleOfOptionsOutstandingDetails",
     "longName": "00000042 - Disclosure - Schedule of Options Outstanding (Details)",
     "shortName": "Schedule of Options Outstanding (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "AsOf2021-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2020-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1a.htm",
      "unique": true
     }
    },
    "R43": {
     "role": "http://onemednet.com/role/ScheduleOfFairValueOfStockOptionsDetails",
     "longName": "00000043 - Disclosure - Schedule of Fair Value of Stock Options (Details)",
     "shortName": "Schedule of Fair Value of Stock Options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "From2022-01-012022-12-31_us-gaap_MeasurementInputExpectedTermMember",
      "name": "ONMD:EquitySecuritiesFvNiMeasurementTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-01-012022-12-31_us-gaap_MeasurementInputExpectedTermMember",
      "name": "ONMD:EquitySecuritiesFvNiMeasurementTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1a.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://onemednet.com/role/StockOptionsDetailsNarrative",
     "longName": "00000044 - Disclosure - Stock Options (Details Narrative)",
     "shortName": "Stock Options (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "AsOf2022-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-01-012022-12-31",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1a.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://onemednet.com/role/StockWarrantsDetailsNarrative",
     "longName": "00000045 - Disclosure - Stock Warrants (Details Narrative)",
     "shortName": "Stock Warrants (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "AsOf2022-12-31",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:LongTermDebtTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-01-012022-12-31",
      "name": "us-gaap:ProceedsFromIssuanceOfWarrants",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "ONMD:StockWarrantsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1a.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://onemednet.com/role/ScheduleOfFinancialAssetsDetails",
     "longName": "00000046 - Disclosure - Schedule of Financial Assets (Details)",
     "shortName": "Schedule of Financial Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "AsOf2022-12-31",
      "name": "us-gaap:AssetsHeldInTrustCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-12-31_us-gaap_FairValueMeasurementsRecurringMember",
      "name": "us-gaap:AssetsHeldInTrustCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1a.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://onemednet.com/role/RelatedPartyTransactionsDetailsNarrative",
     "longName": "00000047 - Disclosure - Related Party Transactions (Details Narrative)",
     "shortName": "Related Party Transactions (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "AsOf2022-12-31",
      "name": "us-gaap:ConvertibleNotesPayable",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:LongTermDebtTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:SeniorNotesCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1a.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://onemednet.com/role/CommitmentsContingenciesAndConcentrationsOperatingLeaseDetailsNarrative",
     "longName": "00000048 - Disclosure - Commitments, Contingencies, and Concentrations Operating lease (Details Narrative)",
     "shortName": "Commitments, Contingencies, and Concentrations Operating lease (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1a.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://onemednet.com/role/SubsequentEventsDetailsNarrative",
     "longName": "00000049 - Disclosure - Subsequent Events (Details Narrative)",
     "shortName": "Subsequent Events (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ProceedsFromRelatedPartyDebt",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31_us-gaap_SubsequentEventMember",
      "name": "us-gaap:ProceedsFromIssuanceOfPrivatePlacement",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-4",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1a.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ONMD_AccountingPronouncementsNotYetAdoptedPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://onemednet.com/20231231",
     "localname": "AccountingPronouncementsNotYetAdoptedPolicyTextBlock",
     "presentation": [
      "http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Pronouncements Not Yet Adopted",
        "documentation": "Accounting Pronouncements Not Yet Adopted [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://onemednet.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://onemednet.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable &amp; accrued expenses",
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_AccountsReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableMember",
     "presentation": [
      "http://onemednet.com/role/ScheduleOfAggregatePercentageRevenueAndAccountsReceivableDetails",
      "http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable [Member]",
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold."
       }
      }
     },
     "auth_ref": [
      "r558"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://onemednet.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://onemednet.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts receivable, net of allowance",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r226",
      "r227"
     ]
    },
    "us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccrualForTaxesOtherThanIncomeTaxesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://onemednet.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://onemednet.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Franchise tax payable",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for real and property taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r67",
      "r564"
     ]
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedIncomeTaxesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://onemednet.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://onemednet.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income tax payable",
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r133"
     ]
    },
    "ONMD_AccruedInterestRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://onemednet.com/20231231",
     "localname": "AccruedInterestRelatedParty",
     "crdr": "credit",
     "calculation": {
      "http://onemednet.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://onemednet.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued interest",
        "documentation": "Accrued interest related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://onemednet.com/role/ConvertiblePromissoryNotesHeldByRelatedPartyDetailsNarrative",
      "http://onemednet.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://onemednet.com/role/ScheduleOfPropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://onemednet.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r158",
      "r448"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "presentation": [
      "http://onemednet.com/role/ScheduleOfCommonStockActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r170",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "presentation": [
      "http://onemednet.com/role/ScheduleOfCommonStockActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r170",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://onemednet.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://onemednet.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r585",
      "r693"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://onemednet.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r343",
      "r344",
      "r345",
      "r471",
      "r632",
      "r633",
      "r634",
      "r674",
      "r695"
     ]
    },
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://onemednet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://onemednet.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation expense",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r66",
      "r310"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "crdr": "credit",
     "presentation": [
      "http://onemednet.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of PIPE Warrants",
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r52",
      "r124"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://onemednet.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash flows from operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://onemednet.com/role/StockOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r346"
     ]
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r230",
      "r235"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://onemednet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://onemednet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://onemednet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r612"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://onemednet.com/role/OrganizationAndOperationsDetailsNarrative",
      "http://onemednet.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r372"
     ]
    },
    "us-gaap_AssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetImpairmentCharges",
     "crdr": "debit",
     "calculation": {
      "http://onemednet.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://onemednet.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment",
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r49"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://onemednet.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://onemednet.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r159",
      "r179",
      "r209",
      "r217",
      "r221",
      "r232",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r373",
      "r375",
      "r395",
      "r441",
      "r507",
      "r585",
      "r597",
      "r641",
      "r642",
      "r679"
     ]
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://onemednet.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://onemednet.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r165",
      "r179",
      "r232",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r373",
      "r375",
      "r395",
      "r585",
      "r641",
      "r642",
      "r679"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://onemednet.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsHeldInTrustCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsHeldInTrustCurrent",
     "crdr": "debit",
     "calculation": {
      "http://onemednet.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://onemednet.com/role/BalanceSheets",
      "http://onemednet.com/role/ScheduleOfFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments held in Trust",
        "verboseLabel": "Assets measured and recorded fair value",
        "documentation": "The amount of cash, securities, or other assets held by a third-party trustee pursuant to the terms of an agreement which assets are available to be used by beneficiaries to that agreement only within the specific terms thereof and which agreement is expected to terminate within one year of the balance sheet date (or operating cycle, if longer) at which time the assets held-in-trust will be released or forfeited."
       }
      }
     },
     "auth_ref": [
      "r626"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://onemednet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r612"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://onemednet.com/role/StockOptionsDetailsNarrative",
      "http://onemednet.com/role/StockWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338"
     ]
    },
    "srt_BoardOfDirectorsChairmanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "BoardOfDirectorsChairmanMember",
     "presentation": [
      "http://onemednet.com/role/ScheduleOfCommonStockActivitiesDetails",
      "http://onemednet.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Board of Directors Chairman [Member]"
       }
      }
     },
     "auth_ref": [
      "r637"
     ]
    },
    "ONMD_BoardOfDirectorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://onemednet.com/20231231",
     "localname": "BoardOfDirectorsMember",
     "presentation": [
      "http://onemednet.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Board Of Directors [Member]",
        "documentation": "Board Of Directors [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://onemednet.com/role/ConvertiblePromissoryNotesHeldByRelatedPartyDetailsNarrative",
      "http://onemednet.com/role/IncomeTaxesDetailsNarrative",
      "http://onemednet.com/role/OrganizationAndOperationsDetailsNarrative",
      "http://onemednet.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://onemednet.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "auth_ref": [
      "r369",
      "r580",
      "r581"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://onemednet.com/role/ConvertiblePromissoryNotesHeldByRelatedPartyDetailsNarrative",
      "http://onemednet.com/role/IncomeTaxesDetailsNarrative",
      "http://onemednet.com/role/OrganizationAndOperationsDetailsNarrative",
      "http://onemednet.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://onemednet.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r73",
      "r369",
      "r580",
      "r581"
     ]
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationConsiderationTransferred1",
     "crdr": "credit",
     "presentation": [
      "http://onemednet.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Consideration Transferred",
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r3",
      "r12"
     ]
    },
    "ONMD_BusinessCombinationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://onemednet.com/20231231",
     "localname": "BusinessCombinationCost",
     "crdr": "debit",
     "calculation": {
      "http://onemednet.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://onemednet.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business combination cost",
        "documentation": "Business combination cost."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationDisclosureTextBlock",
     "presentation": [
      "http://onemednet.com/role/BusinessCombination"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination",
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r370"
     ]
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationsPolicy",
     "presentation": [
      "http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Business Combination",
        "label": "Business Combinations Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "dei_BusinessContactMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "BusinessContactMember",
     "presentation": [
      "http://onemednet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Contact [Member]",
        "documentation": "Business contact for the entity"
       }
      }
     },
     "auth_ref": [
      "r611",
      "r612"
     ]
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "presentation": [
      "http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation and Foreign Currency Translation",
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r110",
      "r112"
     ]
    },
    "ONMD_CEBALoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://onemednet.com/20231231",
     "localname": "CEBALoanMember",
     "presentation": [
      "http://onemednet.com/role/CanadianEmergencyBusinessLoanActCebaDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CEBA Loan [Member]",
        "documentation": "CEBA Loan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://onemednet.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://onemednet.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r156",
      "r563"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://onemednet.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and Cash Equivalents, Beginning",
        "periodEndLabel": "Cash and Cash Equivalents, Ending",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r107",
      "r175"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://onemednet.com/role/StatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://onemednet.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net change in cash and cash equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r107"
     ]
    },
    "ONMD_CashHeldInTrustAccount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://onemednet.com/20231231",
     "localname": "CashHeldInTrustAccount",
     "crdr": "debit",
     "calculation": {
      "http://onemednet.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://onemednet.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Held in Trust Account",
        "documentation": "Cash held in trust account."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://onemednet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "ONMD_ClassBCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://onemednet.com/20231231",
     "localname": "ClassBCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://onemednet.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://onemednet.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Class B Common Stock",
        "documentation": "Class B common stock.",
        "label": "ClassBCommonStock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://onemednet.com/role/BalanceSheets",
      "http://onemednet.com/role/BalanceSheetsParenthetical",
      "http://onemednet.com/role/ConvertiblePromissoryNotesHeldByRelatedPartyDetailsNarrative",
      "http://onemednet.com/role/ShareholdersEquityDetailsNarrative",
      "http://onemednet.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r160",
      "r161",
      "r162",
      "r179",
      "r199",
      "r200",
      "r202",
      "r204",
      "r207",
      "r208",
      "r232",
      "r242",
      "r244",
      "r245",
      "r246",
      "r249",
      "r250",
      "r278",
      "r279",
      "r283",
      "r286",
      "r293",
      "r395",
      "r462",
      "r463",
      "r464",
      "r465",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r494",
      "r516",
      "r539",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r618",
      "r627",
      "r636"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://onemednet.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r161",
      "r162",
      "r207",
      "r278",
      "r279",
      "r281",
      "r283",
      "r286",
      "r291",
      "r293",
      "r462",
      "r463",
      "r464",
      "r465",
      "r575",
      "r618",
      "r627"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://onemednet.com/role/StockWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://onemednet.com/role/StockWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://onemednet.com/role/ConvertiblePromissoryNotesHeldByRelatedPartyDetailsNarrative",
      "http://onemednet.com/role/StockWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r294"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://onemednet.com/role/ConvertiblePromissoryNotesHeldByRelatedPartyDetailsNarrative",
      "http://onemednet.com/role/StockWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r294"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://onemednet.com/role/StockWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://onemednet.com/role/OrganizationAndOperationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r372"
     ]
    },
    "ONMD_CommitmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://onemednet.com/20231231",
     "localname": "CommitmentMember",
     "presentation": [
      "http://onemednet.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitment [Member]",
        "documentation": "Commitment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://onemednet.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://onemednet.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r85",
      "r442",
      "r493"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://onemednet.com/role/CommitmentsContingenciesAndConcentrationsOperatingLease"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments, Contingencies, and Concentrations Operating lease",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r236",
      "r237",
      "r559",
      "r640"
     ]
    },
    "us-gaap_CommonClassAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonClassAMember",
     "presentation": [
      "http://onemednet.com/role/BalanceSheets",
      "http://onemednet.com/role/BalanceSheetsParenthetical",
      "http://onemednet.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Class A [Member]",
        "documentation": "Classification of common stock representing ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r695"
     ]
    },
    "ONMD_CommonClassAOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://onemednet.com/20231231",
     "localname": "CommonClassAOneMember",
     "presentation": [
      "http://onemednet.com/role/BalanceSheets",
      "http://onemednet.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Class A One [Member]",
        "documentation": "Common Class A One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonClassBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonClassBMember",
     "presentation": [
      "http://onemednet.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Class B [Member]",
        "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r695"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://onemednet.com/role/ScheduleOfCommonStockActivitiesDetails",
      "http://onemednet.com/role/StatementsOfStockholdersEquityDeficit",
      "http://onemednet.com/role/StockWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r587",
      "r588",
      "r589",
      "r591",
      "r592",
      "r593",
      "r594",
      "r632",
      "r633",
      "r674",
      "r691",
      "r695"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://onemednet.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://onemednet.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r494"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://onemednet.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r93",
      "r494",
      "r513",
      "r695",
      "r696"
     ]
    },
    "ONMD_CommonStockSubjectToPossibleRedemptionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://onemednet.com/20231231",
     "localname": "CommonStockSubjectToPossibleRedemptionValue",
     "crdr": "debit",
     "presentation": [
      "http://onemednet.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock redemption",
        "documentation": "Common stock subject to possible redemption value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://onemednet.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://onemednet.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock value",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r444",
      "r585"
     ]
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "presentation": [
      "http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based Compensation",
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://onemednet.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computer Equipment [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://onemednet.com/role/ScheduleOfAggregatePercentageRevenueAndAccountsReceivableDetails",
      "http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r44",
      "r76",
      "r77",
      "r225",
      "r558"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://onemednet.com/role/ScheduleOfAggregatePercentageRevenueAndAccountsReceivableDetails",
      "http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r44",
      "r76",
      "r77",
      "r225",
      "r459",
      "r558"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://onemednet.com/role/ScheduleOfAggregatePercentageRevenueAndAccountsReceivableDetails",
      "http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r44",
      "r76",
      "r77",
      "r225",
      "r558",
      "r622"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://onemednet.com/role/ScheduleOfAggregatePercentageRevenueAndAccountsReceivableDetails",
      "http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Percent of Revenue and Accounts Receivable",
        "verboseLabel": "Concentration Risk, Percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r44",
      "r76",
      "r77",
      "r225"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://onemednet.com/role/ScheduleOfAggregatePercentageRevenueAndAccountsReceivableDetails",
      "http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r44",
      "r76",
      "r77",
      "r225",
      "r558"
     ]
    },
    "dei_ContactPersonnelName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ContactPersonnelName",
     "presentation": [
      "http://onemednet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Name",
        "documentation": "Name of contact personnel"
       }
      }
     },
     "auth_ref": []
    },
    "ONMD_ConvertiableNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://onemednet.com/20231231",
     "localname": "ConvertiableNotesMember",
     "presentation": [
      "http://onemednet.com/role/StockWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertiable Notes [Member]",
        "documentation": "Convertiable Notes [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertibleDebtCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleDebtCurrent",
     "crdr": "credit",
     "calculation": {
      "http://onemednet.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://onemednet.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible promissory notes",
        "documentation": "The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "us-gaap_ConvertibleDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleDebtNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://onemednet.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://onemednet.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible promissory note",
        "documentation": "Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_ConvertibleNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleNotesPayable",
     "crdr": "credit",
     "presentation": [
      "http://onemednet.com/role/ConvertiblePromissoryNotesHeldByRelatedPartyDetailsNarrative",
      "http://onemednet.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Notes Payable",
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r134",
      "r688"
     ]
    },
    "us-gaap_ConvertiblePreferredStockTermsOfConversion": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertiblePreferredStockTermsOfConversion",
     "presentation": [
      "http://onemednet.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Convertible, Terms",
        "documentation": "Description of conversion terms for preferred stock."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r56",
      "r59",
      "r92",
      "r122",
      "r123"
     ]
    },
    "ONMD_ConvertiblePromissoryNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://onemednet.com/20231231",
     "localname": "ConvertiblePromissoryNotesMember",
     "presentation": [
      "http://onemednet.com/role/ConvertiblePromissoryNotesHeldByRelatedPartyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Promissory Notes [Member]",
        "documentation": "Convertible Promissory Notes [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfRevenue",
     "crdr": "debit",
     "calculation": {
      "http://onemednet.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://onemednet.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of Revenue",
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r179",
      "r232",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r395",
      "r641"
     ]
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CountryRegion",
     "presentation": [
      "http://onemednet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://onemednet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://onemednet.com/role/ScheduleOfAggregatePercentageRevenueAndAccountsReceivableDetails",
      "http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r225"
     ]
    },
    "ONMD_CustomerFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://onemednet.com/20231231",
     "localname": "CustomerFiveMember",
     "presentation": [
      "http://onemednet.com/role/ScheduleOfAggregatePercentageRevenueAndAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer Five [Member]",
        "documentation": "Customer Five [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ONMD_CustomerFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://onemednet.com/20231231",
     "localname": "CustomerFourMember",
     "presentation": [
      "http://onemednet.com/role/ScheduleOfAggregatePercentageRevenueAndAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer Four [Member]",
        "documentation": "Customer Four [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ONMD_CustomerOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://onemednet.com/20231231",
     "localname": "CustomerOneMember",
     "presentation": [
      "http://onemednet.com/role/ScheduleOfAggregatePercentageRevenueAndAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer One [Member]",
        "documentation": "Customer One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ONMD_CustomerThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://onemednet.com/20231231",
     "localname": "CustomerThreeMember",
     "presentation": [
      "http://onemednet.com/role/ScheduleOfAggregatePercentageRevenueAndAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer Three [Member]",
        "documentation": "Customer Three [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ONMD_CustomerTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://onemednet.com/20231231",
     "localname": "CustomerTwoMember",
     "presentation": [
      "http://onemednet.com/role/ScheduleOfAggregatePercentageRevenueAndAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer Two [Member]",
        "documentation": "Customer Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ONMD_CustomersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://onemednet.com/20231231",
     "localname": "CustomersMember",
     "presentation": [
      "http://onemednet.com/role/ScheduleOfAggregatePercentageRevenueAndAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customers [Member]",
        "documentation": "Customers [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ONMD_DataKnightsAcquisitionCorpMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://onemednet.com/20231231",
     "localname": "DataKnightsAcquisitionCorpMember",
     "presentation": [
      "http://onemednet.com/role/ConvertiblePromissoryNotesHeldByRelatedPartyDetailsNarrative",
      "http://onemednet.com/role/IncomeTaxesDetailsNarrative",
      "http://onemednet.com/role/OrganizationAndOperationsDetailsNarrative",
      "http://onemednet.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://onemednet.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Data Knights Acquisition Corp [Member]",
        "documentation": "Data Knights Acquisition Corp [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtConversionOriginalDebtAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtConversionOriginalDebtAmount1",
     "crdr": "credit",
     "presentation": [
      "http://onemednet.com/role/CanadianEmergencyBusinessLoanActCebaDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Conversion, Original Debt, Amount",
        "documentation": "The amount of the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r40"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://onemednet.com/role/CanadianEmergencyBusinessLoanActCeba"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Canadian Emergency Business Loan Act (CEBA)",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r177",
      "r251",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r267",
      "r274",
      "r275",
      "r276"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://onemednet.com/role/CanadianEmergencyBusinessLoanActCebaDetailsNarrative",
      "http://onemednet.com/role/ConvertiblePromissoryNotesHeldByRelatedPartyDetailsNarrative",
      "http://onemednet.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://onemednet.com/role/StockWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r90",
      "r91",
      "r132",
      "r134",
      "r183",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r258",
      "r263",
      "r264",
      "r265",
      "r266",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r404",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r628"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "presentation": [
      "http://onemednet.com/role/ConvertiblePromissoryNotesHeldByRelatedPartyDetailsNarrative",
      "http://onemednet.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Convertible, Conversion Price",
        "documentation": "The price per share of the conversion feature embedded in the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r254"
     ]
    },
    "us-gaap_DebtInstrumentDecreaseForgiveness": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentDecreaseForgiveness",
     "crdr": "debit",
     "presentation": [
      "http://onemednet.com/role/CanadianEmergencyBusinessLoanActCebaDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Decrease, Forgiveness",
        "documentation": "Decrease for amounts of indebtedness forgiven by the holder of the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r628"
     ]
    },
    "us-gaap_DebtInstrumentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentDescription",
     "presentation": [
      "http://onemednet.com/role/OrganizationAndOperationsDetailsNarrative",
      "http://onemednet.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Description",
        "documentation": "Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r56",
      "r86",
      "r90",
      "r132",
      "r134"
     ]
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://onemednet.com/role/ConvertiblePromissoryNotesHeldByRelatedPartyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Face Amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r80",
      "r252",
      "r404",
      "r571",
      "r572"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://onemednet.com/role/CanadianEmergencyBusinessLoanActCebaDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r253"
     ]
    },
    "us-gaap_DebtInstrumentIssuedPrincipal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentIssuedPrincipal",
     "crdr": "credit",
     "presentation": [
      "http://onemednet.com/role/OrganizationAndOperationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Issued, Principal",
        "documentation": "Amount of principal of debt issued."
       }
      }
     },
     "auth_ref": [
      "r462"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://onemednet.com/role/CanadianEmergencyBusinessLoanActCebaDetailsNarrative",
      "http://onemednet.com/role/ConvertiblePromissoryNotesHeldByRelatedPartyDetailsNarrative",
      "http://onemednet.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://onemednet.com/role/StockWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r183",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r258",
      "r263",
      "r264",
      "r265",
      "r266",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r404",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r628"
     ]
    },
    "us-gaap_DebtInstrumentTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentTerm",
     "presentation": [
      "http://onemednet.com/role/CanadianEmergencyBusinessLoanActCebaDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Term",
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredRevenueCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredRevenueCurrent",
     "crdr": "credit",
     "calculation": {
      "http://onemednet.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://onemednet.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred revenues",
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r623"
     ]
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://onemednet.com/role/ScheduleOfDeferredIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://onemednet.com/role/ScheduleOfDeferredIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross deferred tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r357"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://onemednet.com/role/ScheduleOfDeferredIncomeTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://onemednet.com/role/ScheduleOfDeferredIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax assets",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r672"
     ]
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNetAbstract",
     "presentation": [
      "http://onemednet.com/role/ScheduleOfDeferredIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://onemednet.com/role/ScheduleOfDeferredIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://onemednet.com/role/ScheduleOfDeferredIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net operating loss carry forward",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r673"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration",
     "crdr": "debit",
     "presentation": [
      "http://onemednet.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://onemednet.com/role/ScheduleOfDeferredIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://onemednet.com/role/ScheduleOfDeferredIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r673"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://onemednet.com/role/ScheduleOfDeferredIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://onemednet.com/role/ScheduleOfDeferredIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Compensation",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r673"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://onemednet.com/role/ScheduleOfDeferredIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://onemednet.com/role/IncomeTaxesDetailsNarrative",
      "http://onemednet.com/role/ScheduleOfDeferredIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r358"
     ]
    },
    "ONMD_DeferredUnderwriterFeePayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://onemednet.com/20231231",
     "localname": "DeferredUnderwriterFeePayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://onemednet.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://onemednet.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred underwriter fee payable",
        "documentation": "Deferred underwriter fee payable current."
       }
      }
     },
     "auth_ref": []
    },
    "ONMD_DeferredUnderwriterFeePayableNonCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://onemednet.com/20231231",
     "localname": "DeferredUnderwriterFeePayableNonCurrent",
     "crdr": "credit",
     "calculation": {
      "http://onemednet.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://onemednet.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deferred underwriter fee payable",
        "documentation": "Deferred underwriter fee payable noncurrent.",
        "label": "DeferredUnderwriterFeePayableNonCurrent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "presentation": [
      "http://onemednet.com/role/PropertyAndEquipmentDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r50"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://onemednet.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://onemednet.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation and amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r213"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://onemednet.com/role/StockOptions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Options",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r308",
      "r312",
      "r340",
      "r341",
      "r342",
      "r583"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ONMD_DisclosureStockWarrantsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://onemednet.com/20231231",
     "localname": "DisclosureStockWarrantsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DividendsPreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DividendsPreferredStock",
     "crdr": "debit",
     "presentation": [
      "http://onemednet.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends, Preferred Stock",
        "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK)."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r124"
     ]
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://onemednet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r611"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://onemednet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r609",
      "r611",
      "r612"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://onemednet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://onemednet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://onemednet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://onemednet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://onemednet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r610"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://onemednet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r598"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://onemednet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r611"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://onemednet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r611"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://onemednet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r613"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://onemednet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://onemednet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r601"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://onemednet.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Domestic Tax Authority [Member]",
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "ONMD_EFHuttonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://onemednet.com/20231231",
     "localname": "EFHuttonMember",
     "presentation": [
      "http://onemednet.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "EF Hutton [Member]",
        "documentation": "EF Hutton [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://onemednet.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss per share of Common Stock:(1)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://onemednet.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r173",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r199",
      "r202",
      "r203",
      "r204",
      "r205",
      "r385",
      "r386",
      "r437",
      "r451",
      "r566"
     ]
    },
    "ONMD_EmergingGrowthCompanyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://onemednet.com/20231231",
     "localname": "EmergingGrowthCompanyPolicyTextBlock",
     "presentation": [
      "http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Emerging Growth Company",
        "documentation": "Emerging Growth Company [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://onemednet.com/role/StockOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r671"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://onemednet.com/role/StockOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "ONMD_EmployeesDirectorsAndConsultantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://onemednet.com/20231231",
     "localname": "EmployeesDirectorsAndConsultantsMember",
     "presentation": [
      "http://onemednet.com/role/StockOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employees Directors and Consultants [Member]",
        "documentation": "Employees Directors and Consultants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://onemednet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://onemednet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://onemednet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://onemednet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://onemednet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://onemednet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://onemednet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://onemednet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressesLineItems",
     "presentation": [
      "http://onemednet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressesTable",
     "presentation": [
      "http://onemednet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Table]",
        "documentation": "Container of address information for the entity"
       }
      }
     },
     "auth_ref": [
      "r600"
     ]
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://onemednet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r604"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://onemednet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r600"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://onemednet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://onemednet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityDomain",
     "presentation": [
      "http://onemednet.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://onemednet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r600"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://onemednet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r617"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://onemednet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://onemednet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r600"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://onemednet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://onemednet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r614"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://onemednet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r612"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://onemednet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://onemednet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r600"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://onemednet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r600"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://onemednet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r600"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://onemednet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r600"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://onemednet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://onemednet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r615"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://onemednet.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://onemednet.com/role/ScheduleOfCommonStockActivitiesDetails",
      "http://onemednet.com/role/StatementsOfStockholdersEquityDeficit",
      "http://onemednet.com/role/StockWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r152",
      "r169",
      "r170",
      "r171",
      "r184",
      "r185",
      "r186",
      "r188",
      "r194",
      "r196",
      "r206",
      "r233",
      "r234",
      "r295",
      "r343",
      "r344",
      "r345",
      "r362",
      "r363",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r384",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r406",
      "r454",
      "r455",
      "r456",
      "r471",
      "r539"
     ]
    },
    "ONMD_EquityFinancingDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://onemednet.com/20231231",
     "localname": "EquityFinancingDescription",
     "presentation": [
      "http://onemednet.com/role/ConvertiblePromissoryNotesHeldByRelatedPartyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:EquityFinancingDescription]",
        "documentation": "Equity financing description."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquitySecuritiesFvNiMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquitySecuritiesFvNiMeasurementInput",
     "presentation": [
      "http://onemednet.com/role/ScheduleOfFairValueOfStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Securities, FV-NI, Measurement Input",
        "documentation": "Value of input used to measure investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r392"
     ]
    },
    "ONMD_EquitySecuritiesFvNiMeasurementTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://onemednet.com/20231231",
     "localname": "EquitySecuritiesFvNiMeasurementTerm",
     "presentation": [
      "http://onemednet.com/role/ScheduleOfFairValueOfStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:EquitySecuritiesFvNiMeasurementTerm]",
        "documentation": "Equity securities FvNi measurement term."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Extension",
     "presentation": [
      "http://onemednet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "ONMD_ExtensionLoan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://onemednet.com/20231231",
     "localname": "ExtensionLoan",
     "crdr": "credit",
     "presentation": [
      "http://onemednet.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:ExtensionLoan-0]",
        "documentation": "Extension loan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://onemednet.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://onemednet.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in FV of Warrants",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r8"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://onemednet.com/role/ScheduleOfFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r388",
      "r389",
      "r393"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://onemednet.com/role/ScheduleOfFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r388",
      "r389",
      "r393"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "presentation": [
      "http://onemednet.com/role/ScheduleOfFairValueOfStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "presentation": [
      "http://onemednet.com/role/ScheduleOfFairValueOfStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "presentation": [
      "http://onemednet.com/role/StockOptionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Fair Value of Stock Options",
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "presentation": [
      "http://onemednet.com/role/FairValueMeasuresTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Financial Assets",
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r129"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "presentation": [
      "http://onemednet.com/role/ScheduleOfFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByAssetClassAxis",
     "presentation": [
      "http://onemednet.com/role/ScheduleOfFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Axis]",
        "documentation": "Information by class of asset."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r75"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://onemednet.com/role/ScheduleOfFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r265",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r389",
      "r418",
      "r419",
      "r420",
      "r571",
      "r572",
      "r577",
      "r578",
      "r579"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://onemednet.com/role/ScheduleOfFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r388",
      "r389",
      "r391",
      "r392",
      "r394"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://onemednet.com/role/FairValueMeasures"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measures",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r387"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://onemednet.com/role/ScheduleOfFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r265",
      "r299",
      "r304",
      "r389",
      "r418",
      "r577",
      "r578",
      "r579"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://onemednet.com/role/ScheduleOfFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r265",
      "r299",
      "r304",
      "r389",
      "r419",
      "r571",
      "r572",
      "r577",
      "r578",
      "r579"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://onemednet.com/role/ScheduleOfFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r265",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r389",
      "r420",
      "r571",
      "r572",
      "r577",
      "r578",
      "r579"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://onemednet.com/role/ScheduleOfFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://onemednet.com/role/ScheduleOfFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r265",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r418",
      "r419",
      "r420",
      "r571",
      "r572",
      "r577",
      "r578",
      "r579"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://onemednet.com/role/ScheduleOfFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r387",
      "r394"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r19"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://onemednet.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://onemednet.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://onemednet.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r518"
     ]
    },
    "us-gaap_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GrossProfit",
     "crdr": "credit",
     "calculation": {
      "http://onemednet.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://onemednet.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross Margin",
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r179",
      "r209",
      "r216",
      "r220",
      "r222",
      "r232",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r395",
      "r568",
      "r641"
     ]
    },
    "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf",
     "crdr": "debit",
     "presentation": [
      "http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of Long-Lived Assets to be Disposed of",
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r115"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of Long-Lived Assets",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r117"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://onemednet.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Axis]",
        "documentation": "Information by tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://onemednet.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://onemednet.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r180",
      "r349",
      "r353",
      "r354",
      "r360",
      "r364",
      "r366",
      "r367",
      "r368",
      "r467"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://onemednet.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://onemednet.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income tax provision",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r150",
      "r195",
      "r196",
      "r214",
      "r352",
      "r365",
      "r452"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r350",
      "r351",
      "r354",
      "r355",
      "r359",
      "r361",
      "r461"
     ]
    },
    "ONMD_IncreaseDecreaseFranchiseTaxPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://onemednet.com/20231231",
     "localname": "IncreaseDecreaseFranchiseTaxPayable",
     "crdr": "debit",
     "calculation": {
      "http://onemednet.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://onemednet.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Franchise tax payable",
        "documentation": "Increase decrease franchise tax payable.",
        "label": "IncreaseDecreaseFranchiseTaxPayable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://onemednet.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://onemednet.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable and accrued Expenses",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://onemednet.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://onemednet.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable, net of allowance",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
     "crdr": "debit",
     "calculation": {
      "http://onemednet.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://onemednet.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Payable",
        "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "crdr": "debit",
     "calculation": {
      "http://onemednet.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://onemednet.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Revenue &amp; Customer Deposits",
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r423",
      "r625"
     ]
    },
    "us-gaap_IncreaseDecreaseInDueToRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInDueToRelatedParties",
     "crdr": "debit",
     "calculation": {
      "http://onemednet.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://onemednet.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount due to related party",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "ONMD_IncreaseDecreaseInExerciseTaxLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://onemednet.com/20231231",
     "localname": "IncreaseDecreaseInExerciseTaxLiability",
     "crdr": "debit",
     "calculation": {
      "http://onemednet.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://onemednet.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise tax liability",
        "documentation": "Increase decrease in exercise tax liability."
       }
      }
     },
     "auth_ref": []
    },
    "ONMD_IncreaseDecreaseInExtensionLoan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://onemednet.com/20231231",
     "localname": "IncreaseDecreaseInExtensionLoan",
     "crdr": "debit",
     "calculation": {
      "http://onemednet.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://onemednet.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension loan",
        "documentation": "Increase decrease in extension loan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherCurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://onemednet.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://onemednet.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other current assets",
        "label": "Increase (Decrease) in Other Current Assets",
        "documentation": "Amount of increase (decrease) in current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r625"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "crdr": "credit",
     "calculation": {
      "http://onemednet.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://onemednet.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid Expenses",
        "label": "Increase (Decrease) in Prepaid Expense",
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "ONMD_IncreaseDecreaseInWorkingCapitalLoan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://onemednet.com/20231231",
     "localname": "IncreaseDecreaseInWorkingCapitalLoan",
     "crdr": "debit",
     "calculation": {
      "http://onemednet.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://onemednet.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Working capital loan",
        "documentation": "Increase decrease in working capital loan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://onemednet.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://onemednet.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest expense",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r137",
      "r172",
      "r212",
      "r403",
      "r524",
      "r595",
      "r694"
     ]
    },
    "us-gaap_Investments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Investments",
     "crdr": "debit",
     "presentation": [
      "http://onemednet.com/role/OrganizationAndOperationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments."
       }
      }
     },
     "auth_ref": [
      "r440"
     ]
    },
    "ONMD_InvestmentsHeldInTrustMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://onemednet.com/20231231",
     "localname": "InvestmentsHeldInTrustMember",
     "presentation": [
      "http://onemednet.com/role/ScheduleOfFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments Held in Trust [Member]",
        "documentation": "Investments Held In Trust [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ONMD_KingwoodCapitalPartnersLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://onemednet.com/20231231",
     "localname": "KingwoodCapitalPartnersLLCMember",
     "presentation": [
      "http://onemednet.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Kingwood Capital Partners LLC [Member]",
        "documentation": "Kingwood Capital Partners LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://onemednet.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://onemednet.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://onemednet.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r179",
      "r232",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r374",
      "r375",
      "r376",
      "r395",
      "r492",
      "r567",
      "r597",
      "r641",
      "r679",
      "r680"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://onemednet.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://onemednet.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 equity (deficit)",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r135",
      "r446",
      "r585",
      "r629",
      "r638",
      "r676"
     ]
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://onemednet.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://onemednet.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r155",
      "r179",
      "r232",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r374",
      "r375",
      "r376",
      "r395",
      "r585",
      "r641",
      "r679",
      "r680"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://onemednet.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://onemednet.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long Term Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ONMD_LoanExtensionsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://onemednet.com/20231231",
     "localname": "LoanExtensionsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://onemednet.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://onemednet.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan Extensions",
        "documentation": "Loan extensions current."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LoansPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LoansPayable",
     "crdr": "credit",
     "calculation": {
      "http://onemednet.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://onemednet.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan Payable",
        "documentation": "Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r134",
      "r688"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://onemednet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtTextBlock",
     "presentation": [
      "http://onemednet.com/role/ConvertiblePromissoryNotesHeldByRelatedParty"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Promissory Notes held by Related Party",
        "documentation": "The entire disclosure for long-term debt."
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "us-gaap_LongTermLoansPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermLoansPayable",
     "crdr": "credit",
     "calculation": {
      "http://onemednet.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://onemednet.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension loans",
        "documentation": "Carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://onemednet.com/role/ScheduleOfAggregatePercentageRevenueAndAccountsReceivableDetails",
      "http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]"
       }
      }
     },
     "auth_ref": [
      "r225",
      "r576",
      "r644",
      "r689",
      "r690"
     ]
    },
    "us-gaap_MajorityShareholderMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MajorityShareholderMember",
     "presentation": [
      "http://onemednet.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Majority Shareholder [Member]",
        "documentation": "Owner that controls more than 50 percent of the voting interest in the entity through direct or indirect ownership."
       }
      }
     },
     "auth_ref": []
    },
    "ONMD_ManagementAndDirectorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://onemednet.com/20231231",
     "localname": "ManagementAndDirectorsMember",
     "presentation": [
      "http://onemednet.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Management and Directors [Member]",
        "documentation": "Management and Directors [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://onemednet.com/role/StockOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r238",
      "r239",
      "r240",
      "r241",
      "r306",
      "r422",
      "r453",
      "r483",
      "r484",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r560",
      "r561",
      "r569",
      "r575",
      "r582",
      "r586",
      "r643",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686"
     ]
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputExpectedDividendRateMember",
     "presentation": [
      "http://onemednet.com/role/ScheduleOfFairValueOfStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Expected Dividend Rate [Member]",
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year."
       }
      }
     },
     "auth_ref": [
      "r675"
     ]
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputExpectedTermMember",
     "presentation": [
      "http://onemednet.com/role/ScheduleOfFairValueOfStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Expected Term [Member]",
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date."
       }
      }
     },
     "auth_ref": [
      "r675"
     ]
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputPriceVolatilityMember",
     "presentation": [
      "http://onemednet.com/role/ScheduleOfFairValueOfStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Price Volatility [Member]",
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r675"
     ]
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://onemednet.com/role/ScheduleOfFairValueOfStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r675"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://onemednet.com/role/ScheduleOfFairValueOfStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r390"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://onemednet.com/role/ScheduleOfFairValueOfStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": []
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://onemednet.com/role/ScheduleOfAggregatePercentageRevenueAndAccountsReceivableDetails",
      "http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "auth_ref": [
      "r225",
      "r576",
      "r644",
      "r689",
      "r690"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://onemednet.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://onemednet.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash flows from financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r174"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://onemednet.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flow from Financing Activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://onemednet.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash used for Investing Activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://onemednet.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://onemednet.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash flows used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r108",
      "r109"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://onemednet.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flow from Operating Activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://onemednet.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://onemednet.com/role/StatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://onemednet.com/role/StatementsOfCashFlows",
      "http://onemednet.com/role/StatementsOfOperations",
      "http://onemednet.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "label": "Net loss",
        "verboseLabel": "Net Loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r109",
      "r136",
      "r153",
      "r166",
      "r167",
      "r171",
      "r179",
      "r187",
      "r189",
      "r190",
      "r191",
      "r192",
      "r195",
      "r196",
      "r201",
      "r209",
      "r216",
      "r220",
      "r222",
      "r232",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r386",
      "r395",
      "r450",
      "r515",
      "r537",
      "r538",
      "r568",
      "r595",
      "r641"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recently adopted accounting pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ONMD_NewEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://onemednet.com/20231231",
     "localname": "NewEquityIncentivePlanMember",
     "presentation": [
      "http://onemednet.com/role/StockOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Equity Incentive Plan [Member]",
        "documentation": "New Equity Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://onemednet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://onemednet.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://onemednet.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Other Expense (income)",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r104"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://onemednet.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Expense (income)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonrelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonrelatedPartyMember",
     "presentation": [
      "http://onemednet.com/role/ConvertiblePromissoryNotesHeldByRelatedPartyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonrelated Party [Member]",
        "documentation": "Party not related to reporting entity."
       }
      }
     },
     "auth_ref": [
      "r630",
      "r631"
     ]
    },
    "ONMD_OneCustomerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://onemednet.com/20231231",
     "localname": "OneCustomerMember",
     "presentation": [
      "http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "One Customer [Member]",
        "documentation": "One Customer [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://onemednet.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://onemednet.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Operating Expenses",
        "label": "Operating Expenses [Default Label]",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://onemednet.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://onemednet.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://onemednet.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating loss",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r216",
      "r220",
      "r222",
      "r568"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://onemednet.com/role/CommitmentsContingenciesAndConcentrationsOperatingLeaseDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r405",
      "r584"
     ]
    },
    "us-gaap_OperatingLeasesRentExpenseNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasesRentExpenseNet",
     "crdr": "debit",
     "presentation": [
      "http://onemednet.com/role/CommitmentsContingenciesAndConcentrationsOperatingLeaseDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Leases, Rent Expense, Net",
        "documentation": "Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income."
       }
      }
     },
     "auth_ref": [
      "r141"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://onemednet.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsLineItems",
     "presentation": [
      "http://onemednet.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsTable",
     "presentation": [
      "http://onemednet.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Table]",
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "ONMD_OperatingSegmentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://onemednet.com/20231231",
     "localname": "OperatingSegmentsPolicyTextBlock",
     "presentation": [
      "http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Segments",
        "documentation": "Operating Segments [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
     "presentation": [
      "http://onemednet.com/role/OrganizationAndOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization and Operations",
        "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r111",
      "r112",
      "r128"
     ]
    },
    "us-gaap_OtherGeneralExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherGeneralExpense",
     "crdr": "debit",
     "calculation": {
      "http://onemednet.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://onemednet.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operations",
        "documentation": "Amount of general expenses not normally included in Other Operating Costs and Expenses."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "us-gaap_OtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://onemednet.com/role/StockWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities",
        "documentation": "Amount of liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r439",
      "r487",
      "r488",
      "r597",
      "r692"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://onemednet.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://onemednet.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan, related party of OMN",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_OtherNonoperatingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingExpense",
     "crdr": "debit",
     "calculation": {
      "http://onemednet.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://onemednet.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other expense",
        "documentation": "Amount of expense related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r105"
     ]
    },
    "us-gaap_OtherNotesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNotesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://onemednet.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://onemednet.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pipe Notes, net of discount including interest",
        "documentation": "Amount of long-term notes classified as other, payable within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_OtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherReceivables",
     "crdr": "debit",
     "calculation": {
      "http://onemednet.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://onemednet.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivable from SPAC",
        "documentation": "Amount due from parties in nontrade transactions, classified as other."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r502"
     ]
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://onemednet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r611"
     ]
    },
    "us-gaap_OtherShortTermBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherShortTermBorrowings",
     "crdr": "credit",
     "calculation": {
      "http://onemednet.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://onemednet.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan Amount due to related parties",
        "documentation": "Amount of borrowings classified as other, maturing within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r491"
     ]
    },
    "ONMD_PatentsAndTrademarksPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://onemednet.com/20231231",
     "localname": "PatentsAndTrademarksPolicyTextBlock",
     "presentation": [
      "http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patents and Trademarks",
        "documentation": "Patents And Trademarks [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireBusinessesGross",
     "crdr": "credit",
     "presentation": [
      "http://onemednet.com/role/OrganizationAndOperationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Businesses, Gross",
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r371"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://onemednet.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://onemednet.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r106"
     ]
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://onemednet.com/role/StockOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://onemednet.com/role/StockOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://onemednet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r605"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://onemednet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r606"
     ]
    },
    "us-gaap_PreferredStockConvertibleConversionPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockConvertibleConversionPrice",
     "presentation": [
      "http://onemednet.com/role/ConvertiblePromissoryNotesHeldByRelatedPartyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Convertible, Conversion Price",
        "documentation": "Per share conversion price of preferred stock."
       }
      }
     },
     "auth_ref": [
      "r280"
     ]
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://onemednet.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock [Member]",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r587",
      "r588",
      "r591",
      "r592",
      "r593",
      "r594",
      "r691",
      "r695"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://onemednet.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r278"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://onemednet.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r494"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://onemednet.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r494",
      "r513",
      "r695",
      "r696"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://onemednet.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://onemednet.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred value",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r443",
      "r585"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://onemednet.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://onemednet.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses and other assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r624"
     ]
    },
    "ONMD_PrivateWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://onemednet.com/20231231",
     "localname": "PrivateWarrantsMember",
     "presentation": [
      "http://onemednet.com/role/StockWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Warrants [Member]",
        "documentation": "Private Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ONMD_ProccedsFromRetainedEarningsAdjustment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://onemednet.com/20231231",
     "localname": "ProccedsFromRetainedEarningsAdjustment",
     "crdr": "debit",
     "calculation": {
      "http://onemednet.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://onemednet.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings adjustment",
        "documentation": "Procceds from retained earnings adjustment."
       }
      }
     },
     "auth_ref": []
    },
    "ONMD_ProceedsFromBusinessLoan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://onemednet.com/20231231",
     "localname": "ProceedsFromBusinessLoan",
     "crdr": "debit",
     "calculation": {
      "http://onemednet.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://onemednet.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Canada Emergency Business Loan Act",
        "documentation": "Proceeds from business loan."
       }
      }
     },
     "auth_ref": []
    },
    "ONMD_ProceedsFromCommonStockSubjectToRedemption": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://onemednet.com/20231231",
     "localname": "ProceedsFromCommonStockSubjectToRedemption",
     "crdr": "debit",
     "calculation": {
      "http://onemednet.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://onemednet.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Subject to Redemption",
        "documentation": "Proceeds from common stock subject to redemption."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromContributedCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromContributedCapital",
     "crdr": "debit",
     "calculation": {
      "http://onemednet.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://onemednet.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital",
        "documentation": "The cash inflow associated with the amount received by a corporation from a shareholder during the period."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromConvertibleDebt",
     "crdr": "debit",
     "calculation": {
      "http://onemednet.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://onemednet.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://onemednet.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of PIPE Convertible Notes and Warrants",
        "verboseLabel": "Proceeds from Convertible Debt",
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "ONMD_ProceedsFromDeferredUnderwritingFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://onemednet.com/20231231",
     "localname": "ProceedsFromDeferredUnderwritingFee",
     "crdr": "debit",
     "calculation": {
      "http://onemednet.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://onemednet.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred underwriting fee",
        "documentation": "Proceeds from deferred under writing fee."
       }
      }
     },
     "auth_ref": []
    },
    "ONMD_ProceedsFromIssuanceOfCommonStockOne": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://onemednet.com/20231231",
     "localname": "ProceedsFromIssuanceOfCommonStockOne",
     "crdr": "debit",
     "calculation": {
      "http://onemednet.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://onemednet.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class B Common Stock",
        "documentation": "Proceeds from issuance of common stock one."
       }
      }
     },
     "auth_ref": []
    },
    "ONMD_ProceedsFromIssuanceOfCommonStockTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://onemednet.com/20231231",
     "localname": "ProceedsFromIssuanceOfCommonStockTwo",
     "crdr": "debit",
     "calculation": {
      "http://onemednet.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://onemednet.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class A Common Stock",
        "documentation": "Proceeds from issuance of common stock two."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock",
     "crdr": "debit",
     "presentation": [
      "http://onemednet.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Preferred Stock and Preference Stock",
        "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "crdr": "debit",
     "presentation": [
      "http://onemednet.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Private Placement",
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfUnsecuredDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfUnsecuredDebt",
     "crdr": "debit",
     "presentation": [
      "http://onemednet.com/role/CanadianEmergencyBusinessLoanActCebaDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Unsecured Debt",
        "documentation": "The cash inflow from the issuance of long-term debt that is not secured by collateral. Excludes proceeds from tax exempt unsecured debt."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://onemednet.com/role/StockWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Warrants",
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "crdr": "debit",
     "presentation": [
      "http://onemednet.com/role/ConvertiblePromissoryNotesHeldByRelatedPartyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance or Sale of Equity",
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r462"
     ]
    },
    "us-gaap_ProceedsFromRelatedPartyDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromRelatedPartyDebt",
     "crdr": "debit",
     "calculation": {
      "http://onemednet.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://onemednet.com/role/StatementsOfCashFlows",
      "http://onemednet.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceed from related party loan",
        "verboseLabel": "Proceeds from Related Party Debt",
        "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_ProceedsFromRepaymentsOfNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromRepaymentsOfNotesPayable",
     "crdr": "debit",
     "calculation": {
      "http://onemednet.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://onemednet.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds (repayment) from issuance of convertible promissory note payable",
        "documentation": "Amount of cash inflow (outflow) from long-term debt supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": []
    },
    "ONMD_ProceedsFromWarrantLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://onemednet.com/20231231",
     "localname": "ProceedsFromWarrantLiability",
     "crdr": "credit",
     "calculation": {
      "http://onemednet.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://onemednet.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Warrant liability",
        "documentation": "Proceeds from warrant liability.",
        "label": "ProceedsFromWarrantLiability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProductInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProductInformationLineItems",
     "presentation": [
      "http://onemednet.com/role/ScheduleOfAggregatePercentageRevenueAndAccountsReceivableDetails",
      "http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://onemednet.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://onemednet.com/role/PropertyAndEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r145",
      "r148",
      "r149"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://onemednet.com/role/ScheduleOfPropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://onemednet.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Property and Equipment",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r157",
      "r449"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://onemednet.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://onemednet.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://onemednet.com/role/ScheduleOfPropertyAndEquipmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://onemednet.com/role/BalanceSheets",
      "http://onemednet.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment, Net",
        "totalLabel": "Net Property and Equipment",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r438",
      "r449",
      "r585"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r145",
      "r148",
      "r447"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://onemednet.com/role/PropertyAndEquipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Property And Equipment",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://onemednet.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r116"
     ]
    },
    "ONMD_PubliclyTradedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://onemednet.com/20231231",
     "localname": "PubliclyTradedWarrantsMember",
     "presentation": [
      "http://onemednet.com/role/StockWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Publicly Traded Warrants [Member]",
        "documentation": "Publicly Traded Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://onemednet.com/role/StockOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r238",
      "r239",
      "r240",
      "r241",
      "r298",
      "r306",
      "r335",
      "r336",
      "r337",
      "r421",
      "r422",
      "r453",
      "r483",
      "r484",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r560",
      "r561",
      "r569",
      "r575",
      "r582",
      "r586",
      "r589",
      "r639",
      "r643",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://onemednet.com/role/StockOptionsDetailsNarrative"
     ],
     "auth_ref": [
      "r238",
      "r239",
      "r240",
      "r241",
      "r298",
      "r306",
      "r335",
      "r336",
      "r337",
      "r421",
      "r422",
      "r453",
      "r483",
      "r484",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r560",
      "r561",
      "r569",
      "r575",
      "r582",
      "r586",
      "r589",
      "r639",
      "r643",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://onemednet.com/role/BalanceSheets",
      "http://onemednet.com/role/ConvertiblePromissoryNotesHeldByRelatedPartyDetailsNarrative",
      "http://onemednet.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://onemednet.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r305",
      "r410",
      "r411",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r512",
      "r514",
      "r546"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://onemednet.com/role/BalanceSheets",
      "http://onemednet.com/role/ConvertiblePromissoryNotesHeldByRelatedPartyDetailsNarrative",
      "http://onemednet.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r181",
      "r182",
      "r410",
      "r411",
      "r412",
      "r413",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r512",
      "r514",
      "r546"
     ]
    },
    "us-gaap_RelatedPartyTransactionAmountsOfTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionAmountsOfTransaction",
     "crdr": "debit",
     "presentation": [
      "http://onemednet.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction, Amounts of Transaction",
        "documentation": "Amount of transactions with related party during the financial reporting period."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r410"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://onemednet.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r519",
      "r520",
      "r523"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://onemednet.com/role/BalanceSheets",
      "http://onemednet.com/role/ConvertiblePromissoryNotesHeldByRelatedPartyDetailsNarrative",
      "http://onemednet.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://onemednet.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party, Type [Axis]",
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r305",
      "r410",
      "r411",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r512",
      "r514",
      "r546",
      "r678"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://onemednet.com/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r407",
      "r408",
      "r409",
      "r411",
      "r414",
      "r468",
      "r469",
      "r470",
      "r521",
      "r522",
      "r523",
      "r543",
      "r545"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://onemednet.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://onemednet.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r348",
      "r687"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r347"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://onemednet.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://onemednet.com/role/BalanceSheets",
      "http://onemednet.com/role/GoingConcernDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "negatedLabel": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r124",
      "r445",
      "r457",
      "r458",
      "r466",
      "r495",
      "r585"
     ]
    },
    "ONMD_RetainedEarningsAdjustment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://onemednet.com/20231231",
     "localname": "RetainedEarningsAdjustment",
     "crdr": "credit",
     "presentation": [
      "http://onemednet.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained earnings adjustment",
        "documentation": "Retained earnings adjustment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://onemednet.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r184",
      "r185",
      "r186",
      "r188",
      "r194",
      "r196",
      "r233",
      "r234",
      "r343",
      "r344",
      "r345",
      "r362",
      "r363",
      "r377",
      "r379",
      "r380",
      "r382",
      "r384",
      "r454",
      "r456",
      "r471",
      "r695"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://onemednet.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://onemednet.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r211",
      "r215",
      "r218",
      "r219",
      "r223",
      "r224",
      "r225",
      "r296",
      "r297",
      "r424"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerMember",
     "presentation": [
      "http://onemednet.com/role/ScheduleOfAggregatePercentageRevenueAndAccountsReceivableDetails",
      "http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer Benchmark [Member]",
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r225",
      "r621"
     ]
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Recognition",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r517",
      "r562",
      "r565"
     ]
    },
    "us-gaap_SalesAndExciseTaxPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SalesAndExciseTaxPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://onemednet.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://onemednet.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Excise tax",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred through that date and payable for statutory sales and use taxes, including value added tax. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "srt_ScenarioForecastMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioForecastMember",
     "presentation": [
      "http://onemednet.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]"
       }
      }
     },
     "auth_ref": [
      "r307",
      "r635"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://onemednet.com/role/SubsequentEventsDetailsNarrative"
     ],
     "auth_ref": [
      "r197",
      "r307",
      "r619",
      "r635"
     ]
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://onemednet.com/role/OrganizationAndOperationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r372"
     ]
    },
    "us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCommonStockOutstandingRollForwardTableTextBlock",
     "presentation": [
      "http://onemednet.com/role/ShareholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Common Stock Activities",
        "documentation": "Tabular disclosure of the change in common stock outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://onemednet.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Income Taxes",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r126"
     ]
    },
    "us-gaap_ScheduleOfProductInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfProductInformationTable",
     "presentation": [
      "http://onemednet.com/role/ScheduleOfAggregatePercentageRevenueAndAccountsReceivableDetails",
      "http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Product Information [Table]",
        "documentation": "Schedule detailing quantitative information concerning products or product lines by product or product line."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://onemednet.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://onemednet.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r82",
      "r519",
      "r520",
      "r523"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://onemednet.com/role/StockOptionsDetailsNarrative",
      "http://onemednet.com/role/StockWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r309",
      "r311",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://onemednet.com/role/StockOptionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Options Outstanding",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r18",
      "r64"
     ]
    },
    "us-gaap_ScheduleOfShortTermDebtTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShortTermDebtTable",
     "presentation": [
      "http://onemednet.com/role/CanadianEmergencyBusinessLoanActCebaDetailsNarrative",
      "http://onemednet.com/role/ConvertiblePromissoryNotesHeldByRelatedPartyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Short-Term Debt [Table]",
        "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://onemednet.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock by Class [Table]",
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r54",
      "r55",
      "r56",
      "r57",
      "r58",
      "r59",
      "r122",
      "r123",
      "r124",
      "r160",
      "r161",
      "r162",
      "r207",
      "r278",
      "r279",
      "r281",
      "r283",
      "r286",
      "r291",
      "r293",
      "r462",
      "r463",
      "r464",
      "r465",
      "r575",
      "r618",
      "r627"
     ]
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "presentation": [
      "http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Aggregate Percentage Revenue and Accounts Receivable",
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r42",
      "r44",
      "r45",
      "r76",
      "r130"
     ]
    },
    "ONMD_SecuritiesPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://onemednet.com/20231231",
     "localname": "SecuritiesPurchaseAgreementMember",
     "presentation": [
      "http://onemednet.com/role/OrganizationAndOperationsDetailsNarrative",
      "http://onemednet.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Purchase Agreement [Member]",
        "documentation": "Securities Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://onemednet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r599"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12gTitle",
     "presentation": [
      "http://onemednet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r603"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://onemednet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r602"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://onemednet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r607"
     ]
    },
    "us-gaap_SellingAndMarketingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SellingAndMarketingExpense",
     "crdr": "debit",
     "calculation": {
      "http://onemednet.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://onemednet.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sales &amp; Marketing",
        "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock",
     "presentation": [
      "http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General, and Administrative Expenses",
        "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "ONMD_SeniorConvertibleNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://onemednet.com/20231231",
     "localname": "SeniorConvertibleNotesMember",
     "presentation": [
      "http://onemednet.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Convertible Notes [Member]",
        "documentation": "Senior Convertible Notes [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeniorNotesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeniorNotesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://onemednet.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Notes, Current",
        "documentation": "Carrying value as of the balance sheet date of the portion of long-term notes having the highest claim on the assets of the issuer in case of bankruptcy or liquidation, due within one year or the normal operating cycle, if longer. Senior note holders are paid off in full before any payments are made to debt holders having a lesser priority of repayment."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r585"
     ]
    },
    "ONMD_SeriesAOnePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://onemednet.com/20231231",
     "localname": "SeriesAOnePreferredStockMember",
     "presentation": [
      "http://onemednet.com/role/BalanceSheets",
      "http://onemednet.com/role/BalanceSheetsParenthetical",
      "http://onemednet.com/role/ShareholdersEquityDetailsNarrative",
      "http://onemednet.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A-1 Preferred Stock [Member]",
        "documentation": "Series A One Preferred Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ONMD_SeriesATwoPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://onemednet.com/20231231",
     "localname": "SeriesATwoPreferredStockMember",
     "presentation": [
      "http://onemednet.com/role/BalanceSheets",
      "http://onemednet.com/role/BalanceSheetsParenthetical",
      "http://onemednet.com/role/ConvertiblePromissoryNotesHeldByRelatedPartyDetailsNarrative",
      "http://onemednet.com/role/ShareholdersEquityDetailsNarrative",
      "http://onemednet.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A-2 Preferred Stock [Member]",
        "documentation": "Series A Two Preferred Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://onemednet.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://onemednet.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://onemednet.com/role/StockOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r583"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription",
     "presentation": [
      "http://onemednet.com/role/StockOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Description",
        "documentation": "Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r62"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://onemednet.com/role/StockOptionsDetailsNarrative",
      "http://onemednet.com/role/StockWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r309",
      "r311",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://onemednet.com/role/ScheduleOfOptionsOutstandingDetails",
      "http://onemednet.com/role/StockOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Options exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r318"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://onemednet.com/role/ScheduleOfOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Weighted average exercise price, exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r318"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "presentation": [
      "http://onemednet.com/role/ScheduleOfOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Options, cancelled",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired."
       }
      }
     },
     "auth_ref": [
      "r651"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://onemednet.com/role/ScheduleOfOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options, Granted - under the Plan",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r320"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://onemednet.com/role/ScheduleOfOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Aggregate Intrinsic value, begining balance",
        "periodEndLabel": "Aggregate Intrinsic value, ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://onemednet.com/role/ScheduleOfOptionsOutstandingDetails",
      "http://onemednet.com/role/StockOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Options outstanding, ending balance",
        "periodEndLabel": "Options outstanding, ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r317"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://onemednet.com/role/ScheduleOfOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted average exercise price, begining balance",
        "periodEndLabel": "Weighted average exercise price, ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r317"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://onemednet.com/role/StockOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r332"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://onemednet.com/role/StockOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r332"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://onemednet.com/role/StockOptionsDetailsNarrative",
      "http://onemednet.com/role/StockWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharePrice",
     "presentation": [
      "http://onemednet.com/role/ShareholdersEquityDetailsNarrative",
      "http://onemednet.com/role/StatementsOfStockholdersEquityDeficitParenthetical",
      "http://onemednet.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://onemednet.com/role/ScheduleOfOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Aggregate Intrinsic value, exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://onemednet.com/role/StockOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://onemednet.com/role/StockOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://onemednet.com/role/ShareholdersEquityDetailsNarrative",
      "http://onemednet.com/role/StockOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Issued, Price Per Share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://onemednet.com/role/ScheduleOfCommonStockActivitiesDetails",
      "http://onemednet.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance, shares",
        "periodEndLabel": "Ending balance, shares",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermDebtLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermDebtLineItems",
     "presentation": [
      "http://onemednet.com/role/CanadianEmergencyBusinessLoanActCebaDetailsNarrative",
      "http://onemednet.com/role/ConvertiblePromissoryNotesHeldByRelatedPartyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://onemednet.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r176"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://onemednet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r608"
     ]
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://onemednet.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://onemednet.com/role/BalanceSheets",
      "http://onemednet.com/role/BalanceSheetsParenthetical",
      "http://onemednet.com/role/ConvertiblePromissoryNotesHeldByRelatedPartyDetailsNarrative",
      "http://onemednet.com/role/ShareholdersEquityDetailsNarrative",
      "http://onemednet.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r160",
      "r161",
      "r162",
      "r179",
      "r199",
      "r200",
      "r202",
      "r204",
      "r207",
      "r208",
      "r232",
      "r242",
      "r244",
      "r245",
      "r246",
      "r249",
      "r250",
      "r278",
      "r279",
      "r283",
      "r286",
      "r293",
      "r395",
      "r462",
      "r463",
      "r464",
      "r465",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r494",
      "r516",
      "r539",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r618",
      "r627",
      "r636"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://onemednet.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://onemednet.com/role/ScheduleOfCommonStockActivitiesDetails",
      "http://onemednet.com/role/StatementsOfStockholdersEquityDeficit",
      "http://onemednet.com/role/StockWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r34",
      "r152",
      "r169",
      "r170",
      "r171",
      "r184",
      "r185",
      "r186",
      "r188",
      "r194",
      "r196",
      "r206",
      "r233",
      "r234",
      "r295",
      "r343",
      "r344",
      "r345",
      "r362",
      "r363",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r384",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r406",
      "r454",
      "r455",
      "r456",
      "r471",
      "r539"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://onemednet.com/role/BalanceSheets",
      "http://onemednet.com/role/BalanceSheetsParenthetical",
      "http://onemednet.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r184",
      "r185",
      "r186",
      "r206",
      "r424",
      "r460",
      "r482",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r494",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r503",
      "r504",
      "r505",
      "r506",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r514",
      "r517",
      "r518",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r539",
      "r590"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://onemednet.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r197",
      "r307",
      "r619",
      "r620",
      "r635"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://onemednet.com/role/BalanceSheets",
      "http://onemednet.com/role/BalanceSheetsParenthetical",
      "http://onemednet.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r184",
      "r185",
      "r186",
      "r206",
      "r424",
      "r460",
      "r482",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r494",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r503",
      "r504",
      "r505",
      "r506",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r514",
      "r517",
      "r518",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r539",
      "r590"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "presentation": [
      "http://onemednet.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://onemednet.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common class B stock, shares",
        "verboseLabel": "Stock Issued During Period, Shares, Acquisitions",
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r93",
      "r124"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://onemednet.com/role/ScheduleOfCommonStockActivitiesDetails",
      "http://onemednet.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock to common stock, shares",
        "verboseLabel": "Preferred Stock to Common Stock",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r33",
      "r56",
      "r124",
      "r268"
     ]
    },
    "ONMD_StockIssuedDuringPeriodSharesConvertibleNotesToCommonStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://onemednet.com/20231231",
     "localname": "StockIssuedDuringPeriodSharesConvertibleNotesToCommonStock",
     "presentation": [
      "http://onemednet.com/role/ScheduleOfCommonStockActivitiesDetails",
      "http://onemednet.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible notes to common stock, shares",
        "verboseLabel": "Convertible Notes to Common Stock",
        "documentation": "Stock issued during period shares convertible notes to common stock."
       }
      }
     },
     "auth_ref": []
    },
    "ONMD_StockIssuedDuringPeriodSharesConvertingDataKnightsCommonShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://onemednet.com/20231231",
     "localname": "StockIssuedDuringPeriodSharesConvertingDataKnightsCommonShares",
     "presentation": [
      "http://onemednet.com/role/ScheduleOfCommonStockActivitiesDetails",
      "http://onemednet.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Converting Data Knights Common Shares (A and B) to ONMD Public Shares, shares",
        "verboseLabel": "Converting Data Knights Common Stock (A and B) to ONMD Public Shares",
        "documentation": "Stock Issued During Period shares converting data knights common shares."
       }
      }
     },
     "auth_ref": []
    },
    "ONMD_StockIssuedDuringPeriodSharesConvertingOfWarrantsToCommonStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://onemednet.com/20231231",
     "localname": "StockIssuedDuringPeriodSharesConvertingOfWarrantsToCommonStock",
     "presentation": [
      "http://onemednet.com/role/ScheduleOfCommonStockActivitiesDetails",
      "http://onemednet.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Converting of warrants to common stock, shares",
        "verboseLabel": "Converting of Warrants to Common Stock",
        "documentation": "Stock issued during period shares converting of warrants to common stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "presentation": [
      "http://onemednet.com/role/ShareholdersEquityDetailsNarrative",
      "http://onemednet.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common shares in exchange for services, share",
        "verboseLabel": "Stock Issued During Period, Shares, Issued for Services",
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://onemednet.com/role/ScheduleOfCommonStockActivitiesDetails",
      "http://onemednet.com/role/StatementsOfStockholdersEquityDeficit",
      "http://onemednet.com/role/StockOptionsDetailsNarrative",
      "http://onemednet.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance public shares, share",
        "verboseLabel": "Issuance Public Shares",
        "terseLabel": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r92",
      "r93",
      "r124",
      "r462",
      "r539",
      "r553"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesOther",
     "presentation": [
      "http://onemednet.com/role/ScheduleOfCommonStockActivitiesDetails",
      "http://onemednet.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock issued during period shares other",
        "verboseLabel": "Private OneMedNet to ONMD Public Shares",
        "documentation": "Number of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://onemednet.com/role/ScheduleOfOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Options, Granted - under the Plan",
        "negatedLabel": "Options, Granted - under the Plan",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r92",
      "r93",
      "r124",
      "r321"
     ]
    },
    "ONMD_StockIssuedDuringPeriodSharesStockOptionsToCommonStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://onemednet.com/20231231",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsToCommonStock",
     "presentation": [
      "http://onemednet.com/role/ScheduleOfCommonStockActivitiesDetails",
      "http://onemednet.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock issued during period shares options to common stock",
        "verboseLabel": "Stock Options to Common Stock",
        "documentation": "Stock issued during period shares stock options to common stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "crdr": "credit",
     "presentation": [
      "http://onemednet.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of Data Knights Acquisition Corp. Class B Common Stock",
        "documentation": "Value of stock issued pursuant to acquisitions during the period."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r34",
      "r124"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://onemednet.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock to Common Stock",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r34",
      "r124"
     ]
    },
    "ONMD_StockIssuedDuringPeriodValueConvertibleNotesToCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://onemednet.com/20231231",
     "localname": "StockIssuedDuringPeriodValueConvertibleNotesToCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://onemednet.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Notes to Common Stock",
        "documentation": "Stock issued during period value convertible notes to common stock."
       }
      }
     },
     "auth_ref": []
    },
    "ONMD_StockIssuedDuringPeriodValueConvertingDataKnightsCommonShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://onemednet.com/20231231",
     "localname": "StockIssuedDuringPeriodValueConvertingDataKnightsCommonShares",
     "crdr": "credit",
     "presentation": [
      "http://onemednet.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Converting Data Knights Common Shares (A and B) to ONMD Public Shares",
        "documentation": "Stock issued during period value converting data knights common shares."
       }
      }
     },
     "auth_ref": []
    },
    "ONMD_StockIssuedDuringPeriodValueConvertingOfWarrantsToCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://onemednet.com/20231231",
     "localname": "StockIssuedDuringPeriodValueConvertingOfWarrantsToCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://onemednet.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Converting of Warrants to Common Stock",
        "documentation": "Stock issued during period value converting of warrants to common stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "crdr": "credit",
     "presentation": [
      "http://onemednet.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common shares in exchange for services",
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://onemednet.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance Public Shares",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r92",
      "r93",
      "r124",
      "r471",
      "r539",
      "r553",
      "r596"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueOther",
     "crdr": "credit",
     "presentation": [
      "http://onemednet.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private OneMedNet to ONMD Public Shares",
        "documentation": "Value of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "ONMD_StockIssuedDuringPeriodValueStockOptionsToCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://onemednet.com/20231231",
     "localname": "StockIssuedDuringPeriodValueStockOptionsToCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://onemednet.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Options to Common Stock",
        "documentation": "Stock issued during period value stock options to common stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockOptionPlanExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockOptionPlanExpense",
     "crdr": "debit",
     "calculation": {
      "http://onemednet.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://onemednet.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Expense",
        "documentation": "Amount of noncash expense for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockRepurchasedDuringPeriodShares",
     "presentation": [
      "http://onemednet.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Repurchased During Period, Shares",
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r92",
      "r93",
      "r124",
      "r465",
      "r539",
      "r555"
     ]
    },
    "ONMD_StockWarrantsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://onemednet.com/20231231",
     "localname": "StockWarrantsDisclosureTextBlock",
     "presentation": [
      "http://onemednet.com/role/StockWarrants"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock Warrants",
        "documentation": "Stock warrants disclosure text block.",
        "label": "StockWarrantsDisclosureTextBlock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://onemednet.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://onemednet.com/role/BalanceSheets",
      "http://onemednet.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity (deficit)",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending Balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r96",
      "r97",
      "r113",
      "r496",
      "r513",
      "r540",
      "r541",
      "r585",
      "r597",
      "r629",
      "r638",
      "r676",
      "r695"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://onemednet.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity (Deficit)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://onemednet.com/role/ShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders\u2019 Equity",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r178",
      "r277",
      "r279",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r292",
      "r295",
      "r383",
      "r542",
      "r544",
      "r557"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://onemednet.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r402",
      "r416"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://onemednet.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r402",
      "r416"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://onemednet.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued."
       }
      }
     },
     "auth_ref": [
      "r402",
      "r416"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://onemednet.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r402",
      "r416"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://onemednet.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r402",
      "r416"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://onemednet.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r415",
      "r417"
     ]
    },
    "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubstantialDoubtAboutGoingConcernTextBlock",
     "presentation": [
      "http://onemednet.com/role/GoingConcern"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Going Concern",
        "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "ONMD_ThreeCustomersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://onemednet.com/20231231",
     "localname": "ThreeCustomersMember",
     "presentation": [
      "http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Three Customers [Member]",
        "documentation": "Three Customers [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://onemednet.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://onemednet.com/role/ScheduleOfCommonStockActivitiesDetails",
      "http://onemednet.com/role/ShareholdersEquityDetailsNarrative",
      "http://onemednet.com/role/StockOptionsDetailsNarrative",
      "http://onemednet.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r637",
      "r677"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://onemednet.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://onemednet.com/role/ScheduleOfCommonStockActivitiesDetails",
      "http://onemednet.com/role/ShareholdersEquityDetailsNarrative",
      "http://onemednet.com/role/StockOptionsDetailsNarrative",
      "http://onemednet.com/role/SubsequentEventsDetailsNarrative"
     ],
     "auth_ref": []
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "presentation": [
      "http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable",
        "documentation": "Disclosure of accounting policy for accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r139",
      "r140",
      "r228",
      "r229",
      "r231"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://onemednet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ONMD_TwentyTwentyOneServiceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://onemednet.com/20231231",
     "localname": "TwentyTwentyOneServiceMember",
     "presentation": [
      "http://onemednet.com/role/StockWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2021 Service [Member]",
        "documentation": "Twenty Twenty One Service [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ONMD_TwentyTwentyTwoServiceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://onemednet.com/20231231",
     "localname": "TwentyTwentyTwoServiceMember",
     "presentation": [
      "http://onemednet.com/role/StockWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2022 Service [Member]",
        "documentation": "Twenty Twenty Two Service [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ONMD_TwoCustomersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://onemednet.com/20231231",
     "localname": "TwoCustomersMember",
     "presentation": [
      "http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Customers [Member]",
        "documentation": "Two Customers [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://onemednet.com/role/OrganizationAndOperationsDetailsNarrative",
      "http://onemednet.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r372"
     ]
    },
    "ONMD_UnrealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://onemednet.com/20231231",
     "localname": "UnrealizedGainLoss",
     "crdr": "credit",
     "calculation": {
      "http://onemednet.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://onemednet.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Unrealized gain or loss",
        "documentation": "Unrealized gain loss.",
        "label": "UnrealizedGainLoss"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnsecuredDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnsecuredDebt",
     "crdr": "credit",
     "calculation": {
      "http://onemednet.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://onemednet.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Canada Emergency Business Loan Act",
        "label": "Unsecured Debt",
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of uncollateralized debt obligations (with maturities initially due after one year or beyond the operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r134",
      "r688"
     ]
    },
    "us-gaap_UnsecuredDebtCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnsecuredDebtCurrent",
     "crdr": "credit",
     "calculation": {
      "http://onemednet.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://onemednet.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Canada Emergency Business Loan Act",
        "documentation": "Carrying value as of the balance sheet date of the portion of long-term, uncollateralized debt obligations due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r132"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r47",
      "r48",
      "r143",
      "r144",
      "r146",
      "r147"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://onemednet.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r356"
     ]
    },
    "ONMD_WarrantLiabilityNonCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://onemednet.com/20231231",
     "localname": "WarrantLiabilityNonCurrent",
     "crdr": "credit",
     "calculation": {
      "http://onemednet.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://onemednet.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant liabilities",
        "documentation": "Warrant liability non current."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantMember",
     "presentation": [
      "http://onemednet.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://onemednet.com/role/StockWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r587",
      "r588",
      "r591",
      "r592",
      "r593",
      "r594"
     ]
    },
    "ONMD_WarrantOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://onemednet.com/20231231",
     "localname": "WarrantOneMember",
     "presentation": [
      "http://onemednet.com/role/StockWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant One [Member]",
        "documentation": "Warrant One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://onemednet.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r204"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract",
     "presentation": [
      "http://onemednet.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average shares of Common Stock outstanding:"
       }
      }
     },
     "auth_ref": []
    },
    "ONMD_WorkingCapitalLoan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://onemednet.com/20231231",
     "localname": "WorkingCapitalLoan",
     "crdr": "credit",
     "calculation": {
      "http://onemednet.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://onemednet.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Working capital Loan",
        "documentation": "Working capital loan."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://onemednet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r616"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "13",
   "SubTopic": "10",
   "Topic": "480",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481766/480-10-25-13"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "7",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-7"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "8",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-8"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "SubTopic": "405",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481071/942-405-45-2"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "35",
   "Topic": "720",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483406/720-35-50-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "60",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-16"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-21"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-4"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-2"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(CFRR 211.02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b),(f(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "720",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483384/720-30-45-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "05",
   "Paragraph": "4",
   "Subparagraph": "(a)-(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479515/805-10-05-4"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.15)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205/tableOfContent"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205-40/tableOfContent"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "250",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//250/tableOfContent"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//360/tableOfContent"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-15"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//470/tableOfContent"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-5"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//805/tableOfContent"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//810/tableOfContent"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11B",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-11B"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-15"
  },
  "r140": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-6"
  },
  "r141": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481501/840-20-50-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(210.5-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-1"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//850/tableOfContent"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482312/912-310-45-11"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(h))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(5)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-8"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3"
  },
  "r621": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r622": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r623": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r626": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r633": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r634": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r635": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r636": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55"
  },
  "r637": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13"
  },
  "r638": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r639": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r640": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r641": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r642": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r643": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r644": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r645": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r646": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r647": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r648": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r649": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r650": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r651": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r652": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r653": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r654": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r655": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r656": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r657": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r658": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r659": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r660": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r661": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r662": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r663": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r664": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r665": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r666": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r667": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r668": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r669": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r670": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r671": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r672": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r673": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r674": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r676": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r677": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r678": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r679": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r680": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r681": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r682": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r683": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r684": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r685": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r686": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r687": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r690": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r691": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r692": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r695": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r696": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>100
<FILENAME>0001493152-24-017983-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-24-017983-xbrl.zip
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M[;:KW/S@GV6'9F;5D+W 7\@[@;D/=C#XXD<-_'T&*FX&3W:/-R7;:E?CL5:
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M X**1G]]*RD9U1FI-\5 I8X,G>&;9MHU3GJE(W.[YT&C_<%O00%.=&9R/HI
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MY?T<W"I<?C ;$-=*"2.0S'+0>\RQ,=6,H661PW?LBXY6.W#F?8,!ROZTBZ"
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M/C]+U4 [(YNA=WX='-#$N%_!AE49YY=6N]]\5/76[!L=9=X8QBWL#,]P'.
MN6WJ3W:_85-'^_X=//M,C\GWQST\/.$>3KB'$^[A8UM09$)]H$^26\Z/]S/"
M3 NL\[.I/O0?W3899SE=F0(W1+2=N9*C.@94/0KX36.C*66 ;^/B>%NLHY&S
MEGUS;OG7<.@_'+W)Y\G,<%:ACHMBPS[#R9B->(I!/\EEN=)\K\6VA/>^:+LL
M&'!4CZLCYQRF(OOQ[.8\P&P_-#!AS>F![L;$X$AXVJYF(B*!-2I@-:RN- 3Z
M%,.#(56]@5;J^"0D2>^F6(D*LQ?+,J!V,E,?I5$3MHS>R.>:K.&33,VK/)DY
MU:B14-X%=9?C#4@:>KP/]XC!'3/ZE  8I?2_)(OF"-W[\ 'W:^-I?MHVNUZ8
MYWU559@GH-@CB*O)1(SS]*9S*V(9FE:S[+'YG?O:.MA)U))T7" '*DF:N=:H
M*P6\Q85W)#]2KRR,^:[A!4E)/R8(DQ@^<2P1;5O+_YV@ O/9':UWC"?KDY1Z
MGI_]\KE;4^IY?C;Q[G'E9Y3-E6;<=ZO:/)")'44Y/M-M?>0>?D@P#=@L8#AL
M$-O"*7?7/-ULZ"\Z4I>&9KQ)Z 9RM4GFN)LN5<J$729<DMIAIP*&C2 O)EFR
MWVD2DQIT"YVY% $A?:9N@IRIZ:0))>\@Z8*-^1:ST-EXG8]](7P&(3!QTVF.
MD@T+.#EI?\O)&H($EQ\PLI&-OP?FEF>4Q-]_R^/A,9^IAOA@L,;S(%CFQ8:T
M\BMOEQU8AR.VDCE0,7.NR P^^@E)GMMS@CE ;!"-M]HA&?MO-BBQK1%7.YF@
MH[WV)REZ#80N"+7%9@"34&JY9UTV:S0]M*YPXM;#[;:\Z(ENZ9 H,PB5<[L2
ML0XN@5T+-R[8G],ZKUTOI#%V/H/K_M*"D0Q#X/&\!5'!\0C7;0TN8BWC2UW8
MPW?:J@>\*@Q!TZQNL<66XR\V%R$',\SU:;NEL[6I!9VRM/V2?BPQP(4F5O]#
MHLB.FQAB<]OYO1C0HM2<H"!-%BQ'M$>WYM81Q<Z%")T8\=B&!"PYT[,08]E4
M:X_UHSW"J3#CM);.>QVVG6<_O*AYI7?L%R; U HKU^(0DGC+W+&'(,U=*^6/
MIIB:&%V+KH%/:43X-UJS8!-<"'=:ZPC,T".=!?S%10]S116X-64UW*U\BR6Y
M#?=2B>^C-^JPRG%'S])_KKOV!O31Q8::J/""%30^^!%\"5-)_,5THVNY#W^^
M[=I597XG?_,=GYR?7>C/9?ZQ+PS_9/J=K_U0$7&2R;#Z@*+.%0F[+N"Y(%1H
M]'U?XNHNBBVL3YUC?$,@!_H1L7>C<898@*+61^NS*4JR@D4\^%3_9NZ:'#S$
MLK1_XV2R?61CDTXHI?C?/=._B0Q7!J>C6X&L*DQ,B[#EEUE7P$; K"2B#PLY
M :.7X,Z0]BUH"J)=YUM.T%0QE>Y\,(A]DHAW,B@GD<F5S3,E[(;-6EI.*-G:
MX'/#:?LO^A!N^RZ0,[^#L0D1*=H>?^3"C%V[1 KH:QPGS2E_K=\+^HU[X$TO
M*&8T<]T/3NX8'XQS:_%*O$8S?HP^IWR'"A&Y?;IU.? 8= N885^GADU+J2\)
M+KSPL</_\35.-.%  :W1>3RDS)B17OV);$3^LIIE-VWWED65A<6.4V?<O3=B
M9L"L:C?50M.:Q1)$%W^M/\9]U2 @DR, ;4U?NNG )8=9AQFAZ_E+MR@H<_(1
MC(UD2TX#KDP;Z#/^A4Z9MIDZ/Z-EIB_U.W2PP+BHBUVS(/NJ@;,:)@@)"V06
MS3361'8/RXBTB3R#-(6^1>#H._A2GH&M!NK2@9<Z5/@[1K_A0V5A^44$:B2O
M^LZ]2#_8^7=3"AI8V<SI:LHRRT^2\DZ\,U9:0.^^HWD&@46BDC4<'6C+"N%_
M[^IH1#T(>\([68@MQ<Z\=,".0'L.K_*O30=VUV*LIF?F*W,VNW!NTOP0XV G
MM@%ZD7.PF'>#G$H8Z;X6SGSR-5D@.5PU;2.,3033U5@ AS=7:)G+H>\,!;0%
MC"5[U T/E6&-8=)8#2F]@1F#[$D3!7,];Z\G#'>9,FIPT7E,0S0;A7@9)885
MVQUU=N!+JIXY$[=ER8N(;3(0S4WA/.+\)Z0['H9HF&$/7K!4WR4R0-/9'WS!
M/AN]8!\,^QH&T^YZ5J4.- $/PQV2Y$&[DMD,X@]RC#*;B6/D63JRGR"Z$IJA
MBZL*E(S:H4'LB_R6<:E;:D4\4EK@S+C#BG57;*]X.TQ;WI2HXQ,<YGE3HJ,*
MFVS$D,0$/5'Q-.8S*+E!0N@"4H3AW)K""9R$GSHXZJHMGNS:^/4OEY<_N7:O
M*-7\T&*);DJY9-H16_N V1!EK,/DXCO^)Y5V#[C>/B3#/Z.\E/LEMU2@$#$^
M^HMR[HZ!A3PZP4).L) 3+.03T6&T2\\G'X71)*B1BJ @.SJ?-?_B(FQ*$DNZ
MCS4E&P1+I86'=5[L3()^?*K00349[G,'E)"*D_Q)M,PT3Y>\%L-^W?FSJ+K%
M;H,X#X'E7C/.'@;>+L!3Z[/EKF,VO.3#?6)P[-Y.1C/(PR96D/(> D][&ZQ
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MI6GM$TQ+!89<7[>+B'/*KZ(K !2C=WIT 1M:LH.?%$Y(1UT8%'?!L*Z&?UY
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M&Y.+RP<T^P'Y[U6UZ<OZRXI)'2/[K9-]?PB#T+#GS,60N@U^\.IKJKD2,W"
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M/->WISS7*<_UZ\]S_8IVU3''SXZ#CR_>H:=6]D^ROV!T!"3M#<*Q.9#[U[+
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M^"0[%++\]PC"?9SPY"<)S,7B +?[ZNF/S__G3_B/O[[Y_KL__?]02P,$%
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M-\*'4LWL?-OJ\\30-#1LMY/K%+RMT/F9&=$J[-@6T7KUW&E6*IV>1J=:F93
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M1!XV]# N_D[&^V<F!-W8/)R@%>X]<IT0)1]FLTL.4$W%DV$/UKR?]6/*35G
MSBGFDH?(O#0=GH18724WLOOUB/UBZ*CT%%2<G'+M0_Z%IF1<P'))Q2 H?.KQ
M#Q+)*\(*DD;C^#UO3HF,#82)P@Z5,UA;'IL75H?G.B5$.*J?8?<D(%*NLH)'
MSOV0+MK$HP2LR:8S#1FG_B015U*$WLY-5<AD,4,/8S=(MN39)Y-GEU@HD0+B
M-[5RG4GYMK90)Y=$T_NM<<=?RI%Y^Y.&W>/HLKPVL'=^_.;M3S&W65!]("T!
MJ67F++U-BA.;1B;CJBPY/$U;A*I(+F<B8G39F$LG%K*>&U_,6X-K;"NNMK""
M"Q^]OC3"+.RS Y',1?(>G R$8>H9BL(C] -=&[0UP]/"VQX;H"+AA!')2.BB
M2P Z?"&)F@9&5"ZSN5?X]"4)ZOY+IY,[O]6KHBK[#.1,B\@<0Y^XH(A_M A"
MZ@-?^,2"BHU %*]#T\GP,.DR(C0#(7>\*CGODNN7M/?3/S9=^!L*8L/@TJQ.
MZ@8S[@2S \>6[V-3527\;AE'=0*V':C?< 6B!$@J>DHX-N V5;B/J<$>2.P7
M)?1)4^<K4R[ZNYLVM?UTT5;X)'V(YS=I^*U7A)LLYW 55V@^Q=$"FH]]25?)
M3,'8%]!OQC+AAL^3%B2KZ".<"HFSEBVII%9C,(]_5EZ9FW8Y5CP:W.8;=S)M
M?>EPRFH&<E=9.;+&ALQGC/=Q5^E9]8(3#J7Q #<\ [!"=YH"JB=-]+%PFX!^
MCFCGQK]Y.COU&Q&(P6:=X_<RC^R\ISQWK/)38)GY>S@(HY*S;4/QE)S/V;)=
M3B<?F7$=SGY?OWFV]_WW_[GA3//F13IX/L,-M!PEBT:N;U)Z62@@&,;&DBE&
M[G'%PT$IKPO>;HB=82IW:MBJZTKP+K1\-JU/9;554ZA'>)ECWB9&PSU]P@:Z
MV<8@/1U_U'WI="*W:[>/K-I<9573&L?_L!LSPQXV(7,:N2D5F9-P(C3Z4N!=
M#@M71M_30.LRRA%M+N9W!U% $Q0-SP\)C\T3M$-.<^Q#;.D"DZLR2Y4O,"W;
M&8+=@PXZ_%W)+4TGUN#J+.0<GI-:<-#+/]3)$;2T=4-Q4@+4Q?5T\BZA<X0+
M_:Y#N/.%P;W#YZ._:!N'8E<<?G,C"CXF1S*GU6-Y4P'$4TAOUFPNOA%;E0H>
M16N,]9PF8%DB+]2U08E9*[I:R=[8%K2.'1_HSAK4IH[0[\)^T66Q7AGH4]+4
M)1I??'E0"AC694U0?\/Z)J"3^3CM+I2;E$CZT,&]%T3#?U.7QOV_;4-Q^[]L
M1D;21[R^']X<'?_Q]84+[.FXP-LX%+? "R(7>D^4TG]84SG8'T_R_> -GHUX
M@WO%&SP;\08CWN !B1XKF#F-81 YB$Y&3)AMDYQ=J9:V(2:GI*TFV"#U7AQR
M.5#4*/@DJ>MRGLGO_U&"CAZA>[5%Y9[0A?!,GDFL"_5[L5#X44[8M1\R/2S%
ML7;("4Z\$/.U%-O"?E-L63S@NRX;%//+.):&]L8G&.-XFVS;4-SNU +W0^F%
M#A>_TL>\I#Z-5N[4NP)H(#>;"^:, ( ',11O+Y28Q E*XI^ 1SW=>S$JD-LX
M%'^9B?P3D^:\.C@#, \?[<!9<@EB'*J4;J<U(PGTSXV1,L)'U>R-RO.:KQ-F
M0J!/B2*AIG08>E2?W'W,A;8?Y%!VDEVL0K0FOY[O ^5_/<FSXI,)J!-V;*+#
M$$QMUWH?>Z00<>AO[+L:8T%^$)<E[3=;#*,R<X-0.A^J-NZE/S>4@WO>2=DN
ML3(G'DP106"K9,TT5(.<)14I%*IG,BR1=M"5A-_)H8T!V5E2*P,* 088TR,H
MA$5++ <-HQ:G$WJ198(! =@(1 NW6;"+@E+:#W?V']$VNM]]E-4^>^+,4/EU
M@_H. E;*I=T[I-JZJ'^&N3JH0_LUZ1C>>Q=)2=_84+/#PM!;5F;.=!V,Z47T
M$QIEA)RIO4PRR\8AIAY>J#%#XXK"^'<XO.-)FN7,O43@AEHELV2SPAOR1&<&
MGFCD]^[A\21LV]VP,Y/+V6>"0O$W9PB\C<=5"4/F?.6.5"ZML5T91K0&6%?6
MZRXJY;="YX5 (H8N7V308OQ6DOL]\@2S$\.NE0X %T\$T9<N2WARD5R5%>--
MX1S#_Y1PKJE'C.:B V=[!6-GOII%5M7-EXUVM%ZV;"CORP9EER97, 8:W;@$
M-F:,[TU 'R'V4O$,+5%ZQF69(T[*1M21LXT#YX+6(;XU03,Q YB"D.E^@%T>
M.7/*KRHZ[J!M&XJU?_WR!IB7(SC3OOT;4M<P"HSN>5KH.6XUHM/O/G6&8.U4
M'XI#_-B98XH(*M-:HE0F?Z *)A[H8V8TSR@K%/\WU)M^^P+JP$[";K?IYDF4
MFPLDA0M8"PN%;*/]5/EU("@%G=S!_@].B5OOV;,0</AT9+[9QJ%L. '="A]#
MCJ ;2X+$NB$ISZ5<6)_@R6>2C-%QGWRQ1S/,Y8T#JI1Q!VW;4+P=!/<CT6[]
M"K;/LEW>FED)8O"ZC'8.=\E %X>R (<=9:!'D<ER,D@W;+2F-UM#JQ*S"0BH
M+)87>X]\(_^.A;^=%<7)EUT6H# #TTNMS HIF2=IGCWI/?P&:Y:&O[<B'WIT
M4925=LC/Y:S<C\G2JSU_/ 7C,CC3I&;'7EA&8S%BJ492\SV.R$/2I1*5XL+/
M#H3FJ,-&2E_C R^^.SR(]?HC9.1X9O\L<.3Y"!RY5^#(\Q$X,@)''I#H">_8
M.L/,XU_(3AT.S8>5&21?L6[GF([";I!,4D[T#@Q_H8[/)5R8E 9#\3@V<-?]
MYYV>)HK;'G+X,DB@K59ES5Z5>9Z08]-F.>--@PE%A5& "%O5M:FP,B&/Q0XY
MXA$'258!#SE[ )+%(JLP@0=?87T[F/R+AHITO_=228C,\&K+<X^:S[8PWF+;
M-A1[*LY.C@>P5+C.OQ7DA*'B-G7D\=CCACU1WS\JE!D5RAD7>=N&XB_R=&+5
M\S^1=_5\9.K9TJ&XM1Y*NO+/M3!BA.91UUD@9M:XSMLVE(%UGD[.'1XPHH)#
M?=5&2#YZG!T^_\ (ZMBRH1! 2' 5%(!SE[!0CE >^,!U;1E5ZK9><8$5K4MM
M.+23L%XW;TG;6T$/2JJ7 ]IJPG%XB@F"[AKM/(5NO!+VH>AULOYJX>IQL]P6
ML(YF2?$)M\L24>QEE;5+MQE2@W:$*Y(4[AEERX86_UY6GZ2LH:356LV/RP0T
M6=$2;\R&G43$_<-;*0IVTGC#;-M0W WC0KK3R1'5UTKR8:,YD6_U?N%?66]I
M94U&YY F:(['[Q=ZIDL$%<%HV6'*M;W0NK0%(6XA#KN#9YJ 1AZ^*&&W<3>R
MN*-E?:C2$^S^U"Q@^Z9,-8+U-RPV25O9]3D,/:_Z1A9[=C2+74],'[4+,W)D
M0(?EY0,@0W;-_@-'DVWGO$,BN-/S9+#;8*3-V+JAN /H<2$%RCPN^<!CG9H;
M5^9+3+MG<'^,IMTV#F5@H:>3G]N$D%H#=$M)=*%?WAI*/NF&DKU"E%TZKK@#
M)U,:0Y#)'@^C(A<"ZD8U+\GV''?8E@W%$>V?*X8;5+,--/M)E":$) PR4WQR
M74*"4]U(>#B\AL:EW[:A6.%BEYY7JB]6:+V)XT:3%9VA@ NO+N$X>O_WLY/H
M: E-SK$+:E<D=9K\4QY6K214Q^01(9G6KCCIP5]+A0?^<C>^>2_F2.&6:B*"
MV+YJ4OO,RB H_]F"-C9ZLK=P*/XN11#>2*WSN)=8#+<-00NU.[, --?Q;=\"
ML1/EIJQ2=9SVO^PK6[$S+1<@"(\H=>1M >VTO+W>F:8Q4B'VI)Y7Y;7_WK#(
MF;47;=8F_V5+Q%*&09Y=$04EPI"ZJ2<W&\)C^/7N0_EW[6LB%:)MT]_0Q^16
M0\;/7.XON]'^*UFN7L*?,-/PV!X:=^02)@+F!:7;)4UT("Z[LP;V$FRWI_L_
MGOWV\:?F\L=O\+\\@6_R$M/PWB-!'][>>%TC@&7_V5^U31[FCOBJXL]MDP'I
M,F3QY?0-(1*KRER5<\%NVM_"0VE:8?4 :]MYM/Q]J18CI[59-0E5M^CZJQ %
M@TC)$FDI,I!S9M2;[@.L^&($*]XK6/'%"%8<P8H/2/386^!_?S_ZV,=O,/NV
MEP)PJ0ARY01RTIW3-'OQ?JUSP$P1&$PP-9?3R 8*$F4U)PFP%4T4$6)&#SAW
M8C&F8>C159F#;AM=&U2\,1("VQ4WT.;:1Y;NEBLXB=.@, E!+5>8!TMMX=>[
MT)--I9)N<$NYD7C^@$0+D?/4O0+U"$-4%]&[O8][T0XGV :C?9VLN5[&]S\\
MW9].DKTE/&>=(<>(Q6Q@G7>)]_R'_<-HM>F)W9AJCFR:>>M&^W!^_#^OL,_X
MC_\OXHGN3#%T1.:X3K"Z^CW-]$#S6#7"1J%B*E(2C& ZL4/ ',_A:>^X8;I-
M8*!Y$0F3A&:B#BZH73SQ=,L9^I@5G[ V-2C"M2I+JW8&_;CDA8:&9-?43$(?
M@WHSW^- F4W9+ZN+I)!J9VRF$6D;1=%XEM!E#J]8M(7+N>8^V5I?]6[,^-IE
M63>4T8UHVBQ50@ M>#VX6G5IAQAK*1?,0\=H)9F1\Z16FW>19$@Z34?A"O4(
M+C!PIB\/UR>I.V*#&?0,X44*D@Z8VVZ(/H@+D$##%UC1"!H"\W,(SQQQ.-*6
M+W%:I.J9RN0M2<=&< 58Y*00M#.?85MH995D7:5U5#6W;2CVZA)0X>BB>_1+
MC/(5+XUA3,@M)1<Y38^U&>([PZI<7AG&1-&IXS[8MJ%LV ?1)L;+,*4?%UR3
M.5T.?J(IE#X!D,>.Z<I_]G09N2V(G$1?+.@9W5 ,Q>E<*V -0A-R*WFX&LOA
M*0/RR3FUQ_U?>;Z1Z834*QU06 WT3;9 (@RN[1/M/-__SUWJ'#'7.O7]^^=4
M\P:T=E3*T!P0.BYT^8+:XRNC M[T2Y59+4X2>UP_M5>OQ\):7]%Y*6\GYSUB
M,WX P0C+B+H<Q>,/]W14KW[2D;VZSY#_;S]]_.WT^)>CLY/IY.C]Z^CLZ-U)
M].%-=/[+2?3^P_G)&5[!=D[OL^G1S7SGHW+/[%RTKPZ\C06;0*AZ&%-VEN3&
MEW8UZ6$8"E,.-Q8_2"&%SWOU+IU&QSGS<>!B9IG+=*142PR+\\#K"#^IDC/F
M1,3@,_FE910BN]NW(@*FRQ5\FR&X<8V6IZE#^%/2-/!J"8PA.TO=@T,=.3C4
M#O8C1D3UQJHN#$PH+Z@@4>Q;G_*LKQGM4F>0]YLOE7:E\]DC@W9S*;I2#7L$
MJW#",J'_40=@ X6S-1OT@1$VYWN2><CM!%X[1H0OFYI7-T]-7^N_<78T\\B?
MH#^XT?B&0Z<'XVUUI+"/![A_[.V/KVS5J&T85E!'/+3('UD?<G#CR.3Q8&04
MN:VSFEP"6/3\\RX;VZSE2.O13OBF#A^1_T)Z2;;+-/)*]C&DM_ ,P#]HNTTG
MY]=E]&N6YVAGX2C^9:KRFX/]_>@U>J KF(#_.(SW]_?Q__?V]W>%DLFQ>8#*
MGH$02_0T6S)0;2/L$WQZ3L#_7]HBQ3#V^679UG3.-S3_U#7. 7.J*OW[4,&N
MI,]OTM4/-^EX@YIKS5%UU565 L\23^VL=]$UQ'10&Q8M)(NZ^YHI7WQ_T3H3
MR/JC3N.F17SZ_ \M(59H'%I#:?2Z= V_P60/[=2&7CP_C)__T:4DI/^7K&5T
M]Z7DSOQKUPIAG."ZG=44(&KTL9KN)^I(QW3(BC]R_*(/A;GM]!WHZ=OERY%<
M8]2+NY["!:P5)ONLU,0X>+Z'1D:_H$"WQW==))J1/W;@OF"1ZCW8;,8C$U2'
M-E=,964!7:]8?)F4 9P;;<>3\\N5NR1G<&SGC9J94O18I^;#V]?H:T6&VL)F
MDFAI96K3JA_A+Z>3WN)WWN->L>/?+:I^X5($9:9VF0;"IX#8 *EF)_ P:(KO
MILU;M-:\%P\[92?.+Y"MEQTH!MW[[FCCVW$X+\7^=,)D>./6@=KYQ9V E:/6
M[*RX!M^T0G'9&;+?WI\9M;R_[_SX*L;U@^#SO1L6XML1"W&O6(AO1RS$B(5X
M*(*'7!6'@:M"')?LDYA.3E [JL5A,6#H91*R)WV/Q3OQ'. 7R)J$Y7F1!7LN
MKQTR_:3)0(NWP%L,CTM%<^>!MNY5OT4EOG<W"UXH PV14]9KC14RZJ;PUG-E
M]:061$?]52@;'L0E<Z>!_ 6$#=9Q\E:+&%A;\$_ZTF2/;.!.]C=<44:YR[Q?
M$'_\SO-.YKT'"K)),*3N]M#SEM-9&J'44B(46$)/AVB=-Y S8VBD\^S R>W2
M,P^,]NOH5H_(L?P7D$_X<?RR2/^J?=]AX_:WO9_.)31\8'Y<PXC7T<XA6-1>
MT*R[_7T)O.&(O>1Z'1BD^\)S@O"]NQP4RM;(US8=[FYGHS,CCJ06NHO68ZJ#
MP[3.QE@X5?B[\4AMV5!VYMZ1LKXI>ZS^?&S&G2LFANBZOX8THH&.!-K1P'$T
M295G[-E#GYE#'B86)T(Q(NQT""7#(#[E13F_5/]\U]EG/-XO;C[>:5;/VJIF
MUXD]'HIT[!WPF-[_=92KQW,D#O^"(F>X<**RWP!Q'48'=[47ZZODC!;S&9E1
M\'V'8!;J>RE?BOUSQ 7CT[]8(;W;;1%A&8-XC*Y?U+]WR'WU"!;J$>TXW7*W
M"TOK0<3KU7+SZK?61I7,/2_Z=T,$P6[0=D4Y6%\4/_@J%_JCV4GW?YVG[CK_
M6<G[8A(CITXK#)P<?_!RI[B1+4C@PD92Q$]R2%+-+5Y3W&^#OAGJK+Z'0WWF
M3?*)"CW-T7>^+$G:764)7_W*$DR5HS3;F0 @BFCX.FPPC^B2O?^-:MQ&Y11V
M3$6UQ6QP7[[M5T'TA&0=6UZTKG['Z0(%<<.Q9F<M*=V=2':.8 EXAJTJ-5>Z
M_I1XT/@I4H\ C3X*%<'.\YWH_3F57]ZLV,ZPR$K*C@P,.U9<&,W.@&O+E78<
MM<BMNE)(BX1KTB$D=,,4!K.?J&9[O<G+=IUY*2E86#E@>IAS$!YW;(IN@6S&
M14'1%]W9+9+L,)T<[AWN+#RW\BS)E9'PKIUB_[)TJ=<2[4O8E80-:(NT)DY!
M0YE(R!E(.4P"6>YZ/![!>G_-$.9W8PCS7D.8WXTAS#&$^5 $#QN/!YXK84B6
M!QI')^7Q'NZ7B*\7Y@Q]!)/ZF'8';H]OGV_![IA.OD3["/MT#[J'H/[PM5:Y
M'YT76Z7]PR:Q-N&IR0UEC,A^^'BS=KK13.OM);8MSP=-QB##/# <UZ"ZTKE(
MLXI\)=Z)( (EV);7R%_/>ZWBWFM\['YZ3F;D=*)VI-K-)K630\D3:DM:%&GG
MY'YM6,=H,]YD,]Z^,6_>AT@4X44$="/B3WK;);H$+4WCN^$NZ9%Q,3^&=9\@
M[ DV-O+G8S&(.K.(UT0!L-=23F0(BA%3<HKP>=P0:%$2B;M%6G(,K$@9"#I[
MQ::X2A2&5;B^A*M.@JFO.P?[NW[)";HT;."/23+6!,ZG6CCXL]=FD;1YT"\M
M>O,8]N<C.FC;>-*T+W(J'/;[@U>_0G+WX+C9J V&9Q[#JCRF[87[Z^UB""H4
M'>[_28!0?,/V.++;PT::28/"/1*!HNZ)R/\XB+^U27 Q2\M[.@*=#8V*"(=^
M^N?"9:H&*3UIMEB8BMPN,]-<HW /^LO1'53H;YJ',=*]90/9R:XV'XQG?_9@
M<!8;Q1J[APSS:TRRL*3)=M=,)[<<G\@_/<CT/GR K-VRS(JV=DG,A,.PB7K$
M0@-*1A4BA;H'Q*KJ*WBD30H)S69UQZ+&Z40]I/LI0IAVO"RB%!<73IV\_=3H
MV>IE$PF%V%\I":(["0)[*PY( EK 6\9T-P$QVO];!-"G9(RG(6\$GI6L6=,=
M]L&6?V$3_J@6*KEV;BSB(#19D+T @P+JQ>JG-GIYIYYQ0NA"K]J,YE_J/NZ=
MRPTU:)POK39%QO@O-:$H_SG ^+1D:V#NQEN8X1GL;D+1]\V6Z83MEC'W[\\%
MSKX? V?W&CC[?@R<C8&SAR)XZ+IYUKENRNGD%#U:'UE(U\/.XI ["%7+V=KS
M%\=("X2!"6>U%VNX)M@U3!XOZ$R5@)Z*_TA(LC.L3C#"3L;'^A.8";HU?$=!
MK9<4I_LM$2/'1(?<>U>; ]^K)=/T;NHY^)"3MD1MJ_;?-IVL*C/\QL;^M<MW
M)BE<]EE[^3$!M*6S\^MQ]EB)@H0M\IK@W&))3M?1(>^C95"^U3@6)%@#V\.B
M#=T0]Z*WK*>'BF^,W1">/\IQP4<JY$2F=Y@&)@ZGA/1V>"I/LB7^3;P)UUD-
M5GLYPZ6V]W^?KM#-1;G@C0!OPB@6X7#7]&G/%03V?7=AX3?(!2C%G /&)L2'
M9U<^3).8+BB%)R"I^-(9]'=)6)$7N3/L6C$!,>T;;+AVN4Y>SD@1[$NOSS06
M?;G79]YH5,8:3A[6<Z5MALUXVUO7>I',E8-DMNO4OQU4'^=)?8G#6R#0E+B-
M=YDV%->%=4%QXO4W[K4[X*"O=AIW:^2A\N6$4P[*)\.]XQ\F9-X(D-4[25BF
MM6%"[+ITJ,:9*4!!;-0%'QQ##5S-#,^^Y7YTG<.EF7&-[Z'0JH..NS,:[%5B
M")K/*\X6<YL6?IQ5NLO)A>ZPOS+.(%@ 'RU#:4O^=\E(8^0C]*1DD9JRR.V)
MR(QY.0U(,FH5!I:6.%V\!F[^IY,\N>8<G/#$)W.LADNMA*O?4?R#_B"4^8)M
M &I>26:3BP0+I 22N^)"459R,$U5(#L&.6O"SF @KY5$[6S1.>G7L I819'M
M]3FL>]:4E1==X2N$-S,O Q/N]-H9K8PMXB&]C='SZ0"CYWW2>9Z>?#P].3MY
M?WYT_O;#^S-F]?S]Z/3TZ/WYVY,SY?8\_O#KQZ/W?^^K3Y:PB*7 M9=Q&FI5
M?""N3)%8!J?P =:T C@TIGW+ZT58>VU097F\?"IAAP1!1V?#9;*2.U+OIB*5
M;_Q$!W(_?I6P^<@W>H,B_[3#-_K!JZ? LO5_6N@2$ELX_]%YJ$HGD?![16E+
M=R'L#U P2+G&-X VD*4Y"G9A6-0J!58[<G?\N^3:;BHNEH;)+Z\-W#>X!?%U
MRE7OBM;;]J)5>6WX!"1M<TD>,,H?O+;:U K-4;E)X9LY;'&JEHM?SY1^(<'*
M&->"G;)$E'MAY!-+S>-X_\D3Q%IZ6GIO05Z_NC]:])"3K_T?;975:397%)@K
MC0(=!F/B,EM1Q3#7<^AJQ?YNSL[1J;)M.M9,T%7H/O^$SC2\FO[I+V14&/31
M@R45D[M^U?3,)=&0%DF68TN<V0[*@!TOE9MALKUP@-=E"]8'*)0<R4^B7U'O
MQ'C#40H#AZO]A%2,\7[<HH&0, @9?8[X#+$T>#F=G!1P<;++^"4=@SQS^NX'
MT=NQHMUM'@!7N_,/G.;I1'AU%=BBQ'J1QZLG!6K\.CA:.]TC.+X<S*FSJBJ3
M[<;6WVTJ(N.EJH[.Q^V;D1MZXW+\L <:F.NR2X@)SEF$?@6.CJ><)Y4G03--
M-5?0HOX&>](ITA);GSLQP.!2TMQX+--GZ%?/2&)VJA)V9LD#$Z%4Y+M#);\L
MW[]ZM0VU1'WTJDPJ A"])K4;;*N;1FF5BZ%1BJ12\N7I!-T@W2UG.QIM[B=)
M3?<[V]>9]C75OL9L(%Z6.6R$G7J7+5.#7)ST5P*;Q&W%/=AT8']4=&#$3J-*
M&_YQPYN#SD35F[28;"[7L?B.,QJS66DI?I @UNMW[3I=:^$/MC4_PB=\0WE9
MA>2*P)-O+Q":KZ3V=L)U FVDGM5*?@WV)60YIB+"O+!R:<?*JT=9?%VSD[2#
MO>ADX\IO7EE+Q>UMH][$\J;M2BCH$%_,6</:#MIX:TWS!<G<M.04O#3<&GTS
MR_@J=')B*-VRL\-@)EG"LHT]9/\._&J#\R'P'[!0L2N5B$I@FX/%@"%)48X\
M6V:B05QP(C3ZJ,AKD3/5*3E3UK1)W.+,DN)3U:Z:^1H%7EWF5UB**X9>^$6Z
M8J1+2V [9NTRAJ;@36FBU;NTJA=I@1X"G<Y3PFX)-%8N;'XVJRSN7J+T5#'9
M:SD+ZC3@RE<8:O]:6<T/0?6X6P#P8'^, -YK!/!@?PP!CB' AR)ZR%@($2?O
M2T1Y% NX#GS=WRIPL=/>J P$*]-^,M-=5-9!&Z*KQ?(]7G>+I81:OHO'=5J@
M%'(T7K'HZEQ&Q-<JQ50P1,3LI5=9F0_>[4>XWW/DR,<F7ZUSN,^XE&CPOICC
M7JI#P!N7:BBG HBG:I?D+X"[C=20F+N"X9HYL:32::0>4%0)QE/BJ]D(GYEY
MN<0)Z;UZE]4KZL,%J0@E*VEU%$3HN "EW-T@M(IT:<N/Y\H!00$@F/G<S@<K
MJ;;11(T7@J<%-6!IQE3?%*M#US8C=DK5N3AU8+XK$V^X8(O7BGK]\4/0(?2M
M59L;7KN+-A?7EMMS?EZ$I\YT '@W=+"D+<1C<L]DE>]NPI_7-=8R165W5K:H
M$H,JSDJ-21&45;=+2T"%R0_)W!DZ:BM:];[KKQVHT_C,@2E9;0S(:I;))\?:
M.)V(/AZPX Z\\T7X3HHPKFSL^<Q9$]'1"B.421X3JUQ14KE2_*!OZBAI@]H
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MUPRD7Y7$7<!V[QR1SE2]PD1$'6-]XLS'FZ187;'Q.0- 2T4404V45JT4,&Y
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M5)FK<FYQC<LRM43:K/=89X.;7S>]G=EU?*@V"6Q!N5;A[V]<'_N*D"ZV4T#
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M7-I=B^QAT 4MA%7U2E7C4/L3Z&"<FWVH.)J91L"@KPKG(E^7[7-7/U/5+?5
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M,XAU=S&&,9A1&2XQB+G,F<*%[7@M'JP_SHTGG4LS8C^]&LU8:!$9+*JR@->
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MR4=45W#/6L)4Z,F26'5<\J#J3: ,4ITDI-;#FH]$-.!!?6(T+;-E3?X=5']
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MO3&&U8PCQK-E&/6@*V)!R?$-,]P3+7\W9ZE3]93Q65F#:1W''@%Y!Q26V+R
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M>"DP#LZYQ]("7%A=&C)7?"<"DUVVCD9]!P-%@EBCYG# Q99.V_,F0EO4'18
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MO*NE)(K;M^E]"@W&9WX<!8/J)P;"TR8?8)1AALQG.!:/\3<EA.8<GB7&@@
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MJ>DW?>V=^&E6%YM^2^SVP:*6/T[48?#/W_2//V&^X_GO9^]/?OM_4$L#!!0
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MZ7]6<HT,+'Z=W..1WNPXBV%?,VO<?X[K=MPY (JHY\*8I;44%IR+D%DE)%H
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MFE]+S%Q8)EU1'\3G0M1)+5'IBC^@FNK55AN"=]6?J!#!Z]JA DGBFK=A] O
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M-5ESJF:;N, ?AO0TXX/H62G-YR&$=H/C$%^+[VZ;+],=.(AN'3VN+,ME=;$
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M6DW\%I5/"]0**':>!3L&H0S%UV!4?#N$&F#^L^[X*.YP#BH\S($:D#W4+$T
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M.O+(THS7G(X]11UAOG[/+)J:[D^ 2Q25)5AU-O!$R8J\9#\/&?U\1<SLVL@
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MM,W&3_!HBWW_&@29[/N]';0JMI_$OA= (J$?G>I'#P=B'Y-Z2'ON/SN<EE^
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M/!U^]O!$ L;X?QX]BMZD*IL\C3[" CR#!_QC >N 7XP>/1*$U?/71_^MA]%
M9?R,9O^H*&$-S<]>9N"@13M;CV$6%5S^$YC)V<'+=X?1J\-W[SX>O'Y]=/SK
M?_RP_0/]^_3CP2O];WF'/ ^ST,F\@K'HOST#8V927^"LMO\]Y!"<G>AG7"KP
M",=)I@6V+N:^!&=J2M]XK;_A/-HNV-EKQ)6=X']P!O GK$5@64:E2CX_&BGP
M>V T<UI+%]'R,PWOH[^* FK1[_KH/]W9FY]P<W@_'H)@_8OH&C1I3S% W'W+
MA<+),48C*-BAHK]L;VWC_W80[\&W6MQ.GFNT"3_M9?MIPT'GXT*IJPRS; 9I
M B<:$V#6D(8GIA3DGZ08[LLG=+5-,&B7CA:<(R(4B@R*DGGT/,QN&=^+_1N)
MT$OLD4,U[F_<>WQ"GD.1X]G$-$/S'0]/A?YK2#JC$1I7JI-/D/S(''3<#.-W
MK2#S>N/N8>->JQDE>MT,4U-3^9NH(6*[6[M;.^L]N[<] U4W'&CTW7K#ON4-
M,PA6=GU?2VQ2MHLPM1VA2=281SE<N.!;>$G@4PQ]V.3KDVW,J249W,-@-DR2
M:R<83=G?-,._XINC#;IG.6&B+C' AG\+/YTS*I<$(94I31=9!C^^3-65EK?1
MM4;2&.\(_[VSBZ/J'<PF1QY#$=EDPE"3SIE78BC,X 4CS/V B8*X A?9)+)?
MH?"3A;2[M1=8L>&@/4I$,2 ^5Q)'^?(!X;DSHV!4P33-)%% 4=5G.CLZB:.+
MX@I6OXPYY\^WXW!@-\1:=O#8O*@YC-5::OZZ&VP06RX9%9==VUHQ2 J>RBN'
MF\F&%;UK.$#C#XU#"_^9+DKR=/G#@@.;Z;0ONK&ND+.D(8Q*3+R.%0/[#L8Q
MDOQ).H4]T2$B>,3U<-"W)ZU5J@J[4.F47TQ?F:,83U1E'E(Y(4*S9;1B[A;)
MG"FYB!F =-HUTRE,H\*1)=%I4B]*$"?0#;#GR;4?*, ?B'VKIYZ %WD.0G6!
M7JY\GC[G3=3N.%E5R:*^*$K*2!6EG0*(1Y9<14[:%$0LYRBZG 38D3%8RJIS
MU_P],>OO[LOZ%KG_6^0C?*>8-*]^WCR3DI1$I(_6LP;!SM;.>B?O82?%E1T.
M#L;-S$<4C$*Z,4)4\#M/]O;];(AV_\M%)E'+4ITOLJ36*,O&M0%:;K;(SAT4
M+MU0# 75^%=XNE4'(#F*1#!*^(9:9U'N27[8@+*&9$M\OL:0M)>((PSXM;U^
MVQ)MIYI1-9B;S2?A!/N?;,ZII,S@H-3#P1PSNQBT768MS!'.5M=\:SHGX]=%
MRG!EM'K ?F,[8KGU1Q VI0&7UJ7&8(<]RITFH#$O7%O]%NR*X6!5PR*Z1;O"
MG02-"(O1UA;%-Z9'BG(V')P^VELU@+"_WJ9[V2;2QDM@X%UVA ,H[_U^[.'V
MWX.:^)GJ '=BK\(6#,]P52!5X;%?**_C%'W!%2[F6VL1ND\1LA=16%[P[O *
M)F9TQU$.B60 ?V_M4LG#I'C'4>X&X0U?5#E.*[KW$,#;\3BXEU1F AH&'9X8
M8]7X.WR+M$J1UX)T?X+4E!X-G@B4Y;Y,RO(Z.J!O863P30I6S.*?T2'"(Z*7
M\/_WQ>>+.@%U<GH-^N?]HKI06$AV,4,;Z3\769KDN8K>+KB4[R#/4Q0)L-VB
M3_DD_9RD(II8Q&>K]B,J*,)2HZKF.B)=;M2P3-=%!-^$9 53&>L,XC>_;T?P
MEEE.05>LD"_K9A:XPYK<W]I;[]<][M<UA1#6&_8 -HS"-@WSW\0=NN.'R^(\
M;HHJ$&6)'F2ZN!^/N+O&(Z[QB-^M)F$3:SAPKNSH1A?  ]0'_P+;]C[YDLX6
ML^'@>$%4"N ):QZ/57$_Z\#=O6R<9K *[I:]J,,1DC;$-ZVJA89I5%P%+:D=
M76C?9/7ARC]^T'#0I&A9"\4]",5Q 5=X2QJ:CJXEXEL;W?>Q2Q_3\_/K1R_!
MYOLZ;.S>^JZ\GWTK"]BPI$[6=^,WOE&6074=\7M86\?ZT.Y<;+8N^#'5 JDY
M9 /N1\,:%LVD*/$)@1B'Q+@$$(YY0B66Q!@CT)C&%RH3_2ALY>ZD&"\8MYL3
M/R@F&ER6.@F4,#A%C#&_A-/"KAP..X/ PD(G"\%R %>1A[<BKIKQ1=> B<.7
M. AU/FPM]/<F](3F69Y%119JDA9+544D(V$[W\V#!AFSTME,39#1)'.P5PS@
M'TMAG8BG@=0XY?7".<N,U-?155*6":&V[7!\0CQ;XFZ%O5UN..8H(O*8P/'D
M<>-7=3JM59@7:\>%00:)J1RT+W3+!UNY.BI;,&6 S U%/P(%D"5C.BU$'T*G
MB9=^*SJH=)Z/Z)W&"SSY86B69ENQLV8LU5@EE9)H:?B;2$0"<KF1P!)[85>L
M_=0'.03)JY*,,MOA%Q.,ESF\[>D7MIA /;G1),T'#0?R))5C[!+IKHA>294E
MIEAAU><%$AHA:T'I,2&VV#M[P/S/HHW19L],$ $& [# >V\0.1Q+!(ZD4U"C
M"-"?<GG\3*H41,4CIDT1N!4E94SL+KHT03_/7SUXY41EL'",8^-CXY?-(H<K
MA8B1#WT$>MP71);]F3P6AR,W@Z^RN_8%UF7<6A=BGM"#) '3\?AB48/RI_JN
M9[@=&Y--+YK?D#PLC9V"-02J 86)?LTC.8%[*-K9WZ>-@Z=&ET4&]QV38_.E
MM+Y)[O$F:>B'#CQ.EUG :1NY-:PXN[3&!M89-F].'6'4ZJ,;01XV7^B4)OK4
M%*"CC"6F55NK<ISN ?=J$>T/NAN><B[O<U%$CE+2J*+8J0(WZ*,X4*:^40A#
M5-N*=(Q")%LM9]'IHWT81:G_\4LL'!UIZ;6#$.1MQ\.0XY!6H<@SOV*^+%C/
M\D&7J[!YI[DZ E^$I#5,>Y7S5)B+>MTHX3[.;N/,K%2[84LV]FZM9,/U(,#9
M69=L?/."$TH!N)1#;7);!Q:YQJ;=[^Y]PDVX@@T(A*NDX ;L:G;/V 2<+TK4
M]54;MHH]/IQ+8:(2;!N"C7LT"UE%MTN7O8?W2)J/TSGX:VB@B^&)HZL5\2<Z
MES :J_@-<'V,F\%O-&3FL-2?5?UHEGRF+Z&/\4 %K1_ZL;>&?JRA'TL$JY=\
M^%]&N?7.<G<K^O'??MG=>_),_O@S")?='G/# 3>9(^;E!Z=S'N+^XR;O^)O\
M!_\@ T=E4S]7NL5WY7I'VSNZ<^O[N;4S''P@>M(Y=>? =@[8WL,IQ(P;L0)V
M$SA_HG3V1 5#"$D7F-0XNYPP0:>?8K#XY*)D@V/&^*5H7I1N2X > \>MS#T]
M?&5+<C=T\:R4S(8FA)S2$YCU.<6#P?^!UW(0>')98&PQ.$-MN#4;3]!$>@?<
MT>/('3?X:):16X?C;!R.Y_$^R;%% M7*83@%K,F#RR3-Z'UG*E/S"Z1Y.<*:
M%M@T">%%K[=VGVQRG1]N(UI\1#]:FO0;U0_G-H+<A23F8$YNPS@<IZ#VG20#
MTB&K6%31**E2'VY$X<;]G<=;T6'23?C2(,318="1<F(P.]&&^C)6<);2-@**
M)Z=@>U/)".N)TO!9!/NVR[YG+VXGWH(#VFOL,0X?=W%S"QN.M9ND!6S^+D'%
M3J/$HU..4_@9!I62JL@YS>3(+E.E=QY#WJF)&F<);O@JR0(.Z<V1L)W^SE7S
MN%@V<Z.SJ;5N\S9:U.QT7 MUE%$VC21HFU=&,IVKS#QR)OY9J3EM4Z?46JF$
MAZPP\P5\/*-SW2$AI--8^;32'6Y"IYE400(F)B_ ?S?#[O3;/ <_H)@^(B$U
M.0R*KS:/TL[^?FR>T4A'(R]2V9 I"2J&8[TPM]));Z0YVGV\D,YC&XD#BE9-
M%+?]L<'F<;'(*Y7!"YNY%'<.220>:53,TQQ?E*FZYG'2JO).Q4BL4"(U-K=W
M@5,&!]^%-I[IK,[!N6X&0+*F(0"2,1T.>CH'DQ!JPIQ&OUGJI= \FK6H6_2X
M2#3!BZQJ*UWT0&I%$!;*X8#K6!\_W=Z.YENS+;K,_UZ4GZ-7&*#&.!SK5(\$
M(3@6<TR)V\I/$\.6*'#=4W-'*9\DJ&>(D73[HXBA.PJ^2QK"Y:\''+EIBIK.
M7Y# O4I3<FK&>4XQS"5"M@P)S-,X%'87]$=B-9$]UQ,I!N[)1,9LR"3P!_)U
M?"P+2KHN*J>'F6O<5![1!5]DNVM8V)V9KKO1<5'CSNC$)[(":F83TRLR=*VF
M4[J+/!N1\B5,=I4X1I:6]]R Z#O4O[$^0;T53$7C65(A($'C:&U([,V=4^A8
M41LA;:M&7::J:<VXDJV*^3A8(#I<CL4=GNQFO-J:T$(0GDFOA#&3X!^+L5X:
M7I\2C#(L!&<C<43);=U;M$"<R=+W:4@,'7*M[#:X&3IFT<I:$^&5BA$$.$1I
MR)14S<Z+<*42)+2I^H]X4&S*D*ZDV=":-5B0FEKY/+UT>]PQCZ5&['">QUA#
M,:9?,C!OT/Z%KVT\WO3T7"5FE+XQ<X*(NQ3<=.\FV=ADAQQJ11Z CN=*_I+&
M86*\,."B)KPD*D,Q^DBW,E;&/3[$ !D) :1CT37A*U7!1HWC(($5D:3$-[?(
MK:AT,2&%UY4U]TILFR&_"T9OL+U1H^"?SK-#*[Y6\'>EX/>& W(*!25&G?4J
M817-T^I"VWH.+(?-6(46'G961Z%Z?J+SK]<70A9P\B+Z+[3,8+_S!!$YN-\@
M&.%C%J83;?&*1.Y8-;C(:1?H-"\4@IVT=L!!(^G_E9E,?PXFEF#>*IX+N)DR
MDXBGHJ'.7;8:W16\1L::80@<.NLZ>XQN1=6C5C%&D(OUN<@S,A$='0(>#2K4
M&C;%\)AU[ GY<B!$-]L>T+A3!RSHC=-%5<H@<,%NLOG67)RH9 )?4T[K-(LE
MOTPQ@E%ANRB,S?BSU & &[BH=?)9D\2-C79.2H?##CZ44V+>66M7'**V-/"E
MWRT.A&@LU2-K&&/HKZAJYR>$-)@)H3#WM,QI,!R,4MC<ER_ +S5^2F)'^$G,
M^^B/338Q?-4GGGW1,50J9@=H =#PO\F^6LH\)N(-WANYYC*V2[[Z5>(D;]W[
MP5,$K@+@V][5 #@DUZN6];J9ZF*#BHS"%K#+BB^8G]KBZQ42'*+T.L5>J81B
ME_VFC=4V-<TX,/;P8]>7YEVE:':CGOX,ZVVX&]L%K)>(,)L4 .*X6VLOH@/G
M7J4\2MEH-AAQYSCG@@J:'K$7W,%?7\%/KQ^1.8,I6G(N=Q__^Z;ID]FA=C$0
M.<-[R<;A)B1*$B5? ;?L>)0:/\)0R(Y+.]88-$PDZTCH1N+[8BS/C25LNF4'
ML);.:),H\"U1^WR_"ZK;NI6VM*'+R?>QF!2PU:%%9 U#A%XT4_5%,=FH-KGY
MH ,)EX!X(V"'X:4LTS8H[QULU_8FLJZV:RB,>Z;;5LL'0K.5V!]!QJUXA"=G
M9(/7D /OE R\"!E>?AT#NDS5!5OGVDPP<04GGD"WQH7G>G8.1RZ4T+PV:%S.
MPR*;*%NZB=J@<,4YCH(2YW5+\>5-2U+A!EA]1#5. $[0QH[>2GN0]=[)A6U7
MF 22'7E6!^Y3MX:#3_."$RDR!5(PL;-0N 1:%9AHB^M9:);WM*N@Q1AP4?<.
M8 ],F\-RJ7_VS8'@$%Q1A6GDL=1Y)QRZ%J-,<-T\:@&DY@5WJV!@-IB[R3EH
MP7.C%K'W^L;>9FC(E5%9KK>/H^!J( Y1B/8*K\S#NS[[P6W[:W#;&MSV?=EE
M9!X?AC$-8I7Y=HYI>8,)S)K][]"5Q/GA'L>*,0RA3%*XO6'H)1AID=JT5LY>
MJUVK3?'3G-;5+Y:H*T8HW*H9JQB' V-5-D*W[.#WM"*:QFYPN&,1>B; EYA&
MD9 UTF6%>0GCT#JE%9.X3BGI0!,A-NIKK%6=1Z1[N ST]T4^=N%%SK9PN 0&
M4OO<];9A+Q43+4JY?SNFW(J =VVN]N0GN/X,PM;7-2[9<!!:,X['T>:3!,94
M1<SAB*ZI4OYC!O/A=NCCE,Q6KP$Z9^^Y3[JM X83_'N!T0@XH8\T2ZZQ&]OV
M!PD-"X7*9/J"NU#>;H?:)X4R7]WV 9XNK-^7?'#'7@B(HSL@E3@BR@<VK?CD
MZU!L:.>X Y9=LX=G)SQ4=;X7N7465,GP062*M3E%CD-B&W5*+9CT+*VF,OK"
M_B:97*8ZI&Y#W%7#US6#6>:/^DJO!5#H47R=:L0MXR(T%K5KH$I K^8C</CL
MD>.$JQG7O$PYQV="V=>1^C)G* U:YU_&"L^NO-(8Y7'TE\?;$6QOAJ .I! 4
M%,^E"5N4R/K-A8HFCNTXD7A5W<"/L[-'-4#Q6QCA IVF@.LY''!2/IV;$"9]
MRBR3+H@)1S]7\F/UFGC/] +HV'Q&UI]3T6"#P!S:@LG1!_F^"2PL<>; )RH6
MYQ>!B?%283Z#.RAC>+HQ=6,+($ ,SC2<RY("WC-KR#A53J@(G7^BYY>QC)@8
MN?=\XH#HO5/TR4N)S;;6*;B W*]U[EWIW'T.;0KB@;:JI7-QD^!YR3GN6)^$
M=$?JV*H4$$FG\B*=<UX4D^%@FH!(QJ*AJZ:*EE/</E7P?7,LM?J;H#-:8NN2
M!>?-5H\1#@>V25+[91-58=(&];="0!LF 6&JQ;DB(],:Z?3/+H;' --*H%L5
MWC[XMDJ_SBQ"5ZL.QD7% A/A1Y9!_T,"3PT*:+TY:.,A,AB!Z7.BQ!L1)9[W
MK)([R6C,CC-C)U39"*I=%*T5Y*NG$HGCDH'6]NE?\#8RW0NO 7>Z >G2X5Q]
M!YB[3X-I0:Y@4(HP,&1^BRXR,6'_MN3;K4YG)*0D5&XHF(/$,>%NY"FC9)1F
MF,WE^V4L8%%_-!M>;<22B5IY;4&+6JC7'KI8+_ 9,?@K#UKFYM8.7,U/R3.9
MIF75\)?:E1QX%['T]3K!5@@EC-H^;QL:Q=55;]$ZV"00)KQ,#3,K>:GS/N4%
M20/A9+1_RDDF>QA\DY9\&\OF=VVVA)(!J"B$+.U:]&3/HN:6/6-_C7VAV+<V
MK)+K^C;-E7TL6F08'MI07'@A%J4Z+W 0X(\BX@$VMG=+X=%Z0X2@0V8 9HNH
M ;<B8XD]DX!YX)[8FZZ-^+-$MI667[\^PDSD+5 46A]F]M)N='P3M1[P@1M*
M7< -7[\@:\/IK@RGQV@X_0:;,RF3JR0C8PE\HFELZV&X=,8TX[8X2M'5TFA3
MKAD-Z=*JF<KX#,ZK6L#7)>Y1B0W.9?MD_;=T%H9/;N8IPXT&0RRQ8[A\QE0R
MH3?GV?IHYTFAF9N-\I*%XCYW03]U#9&U_>0RO,F8,<-L@E%7LAF<:_-O6B3]
M.D\OR03P$;9MB)O857V&KHD-Z*H0]_5>/52S7*07KM,?55XE[NC8ZRNLHTZ'
M5F;P%2]>$C"$J+>I^*O=X8]N-WYYV-WQG:=,Z_<OW(;D\3I=MT[7?<-7YI^
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MSN&@6SKC&W-$.GQT-[NH=)V;9F&WU11@+&*%37(3E@DLE?$KS]*2RVET$"W
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M['&?':!AH%H>X\A*H^4M K]IJB@>BD'!4F'TV7(QW-PHZ<\%.!.-Z31:!6A
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M2ZIZK6&7:=B'H0/O(K'^Y^N0GUY^>/UWM%Q^>GOV_MV+_P]02P,$%     @
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M%4WYC\BRFFQFOV>7VTO@/?-T!62#R6@$]Z#J[KE_)JYC5&)M6S2*VGFF73=
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MY3G[@*IK=0 /T#8/W"A>O#")@N^/V[];,+Z51_46O^N3WI5^=^A)L*EWMM[
MZD%G<AU86J]Y>-H21ZW3TXOF\7&[\_&?/VW_1)^[%\TC^]F\U#QO &="CB,
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MSD3G;N.-6<A%LXY\)B=92X[)3,JY\<>IN9_6W!6L_7N!M:H$<K ^[+%-8<9
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M3'-Z']+^<F:G-3D0KB"T")ZBI0*=VE0R2NH20Q=VN5[[(W&NM:GEYZDL/:
MA:5=:_=.OYPLG3R6(IUWA^JE;U!H7I*=1GT7<%\?G90VWQMO!-Y: #M/G<:0
M3 \64.2M.TBW'(NQ F/-43HW:.T9&T[KD%!9+<*A]YPJ7.AW139Z\6 ]A!Y*
MLBM:X $:AK"+0Q.Q4-Z0\)^GT ;>F/H5;($)6?B#8&RR&W3VAH':)K(;C&JR
MRX6,I>.$>%VAP4(N)V-W8[A9-&ZF_;\:\Y+\/=KY8@J8ACD.0N5.X:TIOIV_
MIQJW.7N@/YE*D5]Y4Z#*"Z*4"J"<S\WV[SI\_.O5Y1?1NVPW3S4%M9I'G_![
MC,I>-"\II(QAV=XY_77X1="]71NY/;DZ/6UU>Z+U?WL8_KUH79YAW);"Y<V+
MB]/V$5DGI\W/HMGY(B[;'S_U1+M7KYTUOXA/S=];^*"FA@#O(7@P9(S!] L3
M5\<[FQ16%\?M2_CR](LXOQ3M3OJI>=GN@J4C,-!\?M(05QV,)],UXNB\TVGI
MN^G!%,5/(];U&ER%*Z%@?=,$[^&>7NOLXI2B\GKA9F]P4[[8+4&UP.0#X)9\
M:O9$YSS+&FCV8*MP-W$!YQA1M[<W"[D%#=@^_- ]_4+@T*6?V]U60S^38NWY
M^S^?7YT>PZMZ#5P@0M_Z';??O$JO LB@U?H-]Z_5.3F_/&KIAV'-_\=SW"Q#
M!9@60"I#\^BWSOGGT];QQU87&P0T$5-IUD#V_CQ-( 8/6ZT.(N/J"/,&\'6]
M%NX\D4A^KP'!#9/$H)\&/W<^=AOT_+.KWA70@ :J2Z_-4BT0*?4:K;5-&0OX
M#;.:$B^(4@. U;31VA]CK#]O4H'<=6-/I2V%S*?Y!4"4K3ZT;4Y02T/MP/>T
MJ42I[%J;[6>=9TRYI3:C0"2:0E<#B_9A%PJ0,/MQ6MPGOD?R69M.N%NY5#',
MQG=!+NM*9N-$]H/$OV\5QMK3^0G*/#5$AW:@PP<C&0T2#ZRE!EA$(_2T:_W;
M5PE6_&*.691EJZ+!D&!-.7Z/DAS?#;\;*,R5H'OT;8PY]V;0SCPJ-Z)K4-M"
M\U4>:$9@*YEL)H4M8:(,3#)!"7!4I&ZSCH&%NU2:=80_1[FL#&N:4K4)8097
M8ZI1,!YALT>H;E9798^QM,0Q!0SDF=2?LL:$6;9LYBW%PD+*$90Z>[9O,_:R
M"HH[,*S3]I4&LGHM:WIC5G%@"HEG;M'1@H;=H-RW<9!^B[#E?NE/\C]HO4H_
M%!5#TR@ TVG#F&S@^\SL>U89JJ$*YYCGE%6CXT?X7FL &O7/'1 M149AS(J>
MDS[V,8JT)CV=@7U@[,W;S9D:O2"TJ]0$8+Z&ZU^F/VE.D,9ZT+.M87''I('_
M$<")]=*>3+ZZ!NM4FN9#Z%X(Y9#.\@Q@6]3-C%R"5%-OGJ!NM0M'R%'?O:;H
M%ZR4JFJ,(:KKTD6>6<C41*?63U/&>-ZH,BX;W>Z&@,LMPE!<,;+5,+A "@=#
M)^U!T$]"X,H($!QG) NMP",,8BAO@]"<!<>-[$==0J]5>7C7K1O&F=TJ$R#M
MM&R_&/&:W;P5$D.K)U>'6JZ"J0=LVP2UFKK('+]HI/9TPV3=1/EZ9NS!DOB8
M+YU&\'6P.:5CC#*'Q)GG,M5\"*I><Q),58*W8&A:^=;<50X)10Q2FW)6DBM
MED,Y(!:G,A:C/& Z(+3<@685IB<CENJ%(RUBT'&I/VAZI4K#<6R:@.JRBL,$
M)"**ZV.,Z5*WE[XB(:&#YT/Z!\(0JG$2H[W:P*I;UWBFTAH/V"IR":.!C'XH
MEWH_D$_"=&L@=H?U'ECY:=];K\&+H\*;1Q(6ZDR]^QK+\TQ>@<E>5PY=BK);
MO=#MXV#G@3\DH6_7FE7_-698?M%?H*/GJ2,A2U(W?@2LKZ>:&RT^C;/$^!BH
M#,5Z(O+9\JD/"A;AN5^5H;?-E4]D?SCT]XJC?,N-\KWB*%_Z__(%8T9E>:J:
MIKKO7DV!Z.XESI]H(W,D^/@7S"'6GRQ:,@)]_/.FZ3Q=PANBX\6U8VQ_: \U
MG#.]0C2]ZA(]W;(,L[WV==C*H*UW7)%5ZF)TA-0XP6&Y&R97..V10RJT&V-8
M-9,NQ=72>2\MF2SQ@"X6T\L%='V0A.WG-6@/#)8H/08[RHO0ID;@SA+/<\$R
MN 35=2)^EB.0^MV!#(%K8\A4@"183U1?^3A5"$'[^+8A3D)LE)S:'!<R_-JH
M *9WMG<T9$>6U2*=-BG&W1"=SW!GX@+[W=O>7D\LGTD?&PTA;)>!= RB&^*P
MN;,C7I]TJH#DSS*Z,4DS&L+CK:,ML;N]O;VSGDC%HXL)1<2G86><8+0\-"['
M_EWTEC3CV-_'N4%@]M^)LRW12P9?,9NE%?U9]/^)Q?VWW+TA<VRMZ+JGO'T-
MVO]Y_1H.^"OQ[M4K\7J[R+Q+"OQ)Z@GL!%O[8F-W>W=3O'VW]V+WW=LU%3XM
M] (:C/9E&$[^Y8!^^55KEG*0?-T:+)-S+9(NU?@FP,P\A&\:OWOO?EE/_%;&
MI%L.24O?F6S%)&?^Y9/),=+&1H&LJT,8N59HRWINV;=@F9XP.^YJ(RNSSS72
MG6[GO[ELYQ@[Q)A[LD/L6VM/QQA:-T-NEB$CKL2(>_OJW1L-VKGGB.Z-=";B
M7'XE+T@%4'?ICGX.!FXX.+!.CXNMHZWU1"6Y\#1LNV^J8 KN[.UM&^^,Z,:A
M4G'.%?EZ=UVM04<9G_Q%*-W050UQYOJ^BH)8BC=O7KU^70'4WN^+?+N>6#6.
M-T)K.D&X HC,P7VL^GU7B=\\-SK #Z$4OZO0+XKX]<'H7&_'N^UWFV)W]]V+
M-WM[[RJ WG01!L?:7;/WR\Z+O==[KP_$QMLWV["@O5U8T,ZZ,N07.6?&& [O
M%B;@3?X%NS92CJ_BBKCG"NMPZ#!O?87#_*_0'04^UO#!.@[PEU!NW=+)+OPT
M'_LF!XN;&CP9^,9E,G]\3QR@IV!?YX;.%)#2[-7[Q]\(K,*VA;[8\ 6'TRC*
MG)NM+.!T\1(O:.-:IXLW<;25F2WB.^*SS@PWV>/8T$SI(J*IHA%3&FX&8Z6U
M1T$?$Z+SO5X?OI\2T9UZ;<,,^C+5/G;VH<DX-C4HV',)'ZW3ULT=H8K#0%+C
M+WW7. QL)S!OLJG+P=+N&)C 'BL_ZU$VU4 VFV<TU:JL$X@A\$8D=MWV35(Q
MA<PZ/*F_5#AP(]MD7-=13Z?18R4X]7*BFAO=^])VV,!WF,1\JJBA7@4X)8L2
M\DU)#FYG(YMUUC KOJ]B(VW,0/,%0C$*:"RSWD>@CCE)_'W;ND07K= T;YE.
M@#%=35P_H9(MO0*#ZK3HZEX >2IAF3C C>$ 5 )D1M,B;S],.QD4SD96HFE+
ME>3@JQ_<T736K(6(;CGA3W5 !/K0'0BRCC-ZG$?:;FU.29ON(&([-]J>,00G
MUJX,S#^R&:?YE<QOEECLU%!87ZY#=+VF>U[8EH8S4W7S;21#/#FX'?.;,UKZ
MM]M@S_C,L+<Y/32#8<,6DD6!APP.3B?.1@$Q+K\JWW1N,<O6-1@C^0=\B-.!
MHP[R)"PLB?18+4>-%1%4-O/KWN'!HA]@QQYLS)E>; IB;<U<V@XE%X+)6F$*
M)U"ZY0O5!IG^2#EX<G/'HD!X >Y1-*<S^ UU'9[@**^1Z369;]\Y?^N+8-VY
M'C6O&(VQZDZ.QUA_1XQQ;G^^8M7@Y[G%J;F>GN[,IF U87ZJF)QN=HX]-2([
M!DUO0SJ2K2&PW4@P46H.?:/ O=;B2\.1+=(,BS%=0P=)&)JJQ6%"FEI^_)EO
M1.CL;ONF=4D&OR9"C40-!>J2ZJ\QZ8^8&>?20$U'-Q[50_5&0*.F9#=W=!\X
M@M\!_GU(J]<*C7:F.G(U<U?;H[<FP\RJO* -5XNJ+DZ'E7T7R\&U.&K[NMBM
M6+GZ0''TC?)HN"" CP5S'O6TH3.6^*;1$76L(>4SW^>H89I;96])GSD*'%T"
M9SH"4RV>3/L6%7I:P:L#[Q8O(,VTV)Z^,'DO5(:IF>[K!F0-L%94<P!G]?]T
M'1U/NM2UXPO3BUTO)QXR?CHC>W+Q9J-%WAFMG_H%T7KIW$LW5&8F;%\S#WWG
M?=!0X]%I8&SG([.Y^=?8)Q<Z#N5W=:M>NQI3WWIX1I'9&%9L#9'<@'I+*]%\
M<@!E0(Z)%  X7;9I&V$U"@7;)%>H8SX%Y.LU.['K$526@2&IAY9NZX3(^M-^
MRBZAI0QPC#*\%801B<RA#'-#(;]%(PBWJ62GULA9TSG:NN^!F!EFB1>T\8=A
MF+HZ=X#3)K =")I]II]3KE5<IL9'66.];ZE7U%\E\=T_L4 @K9$V3=BI1%L_
MK&$4>ZL;Z9&U(=4IS[%71Z"0@<B6(WEMSQ;5GH/2^V>BVR#;\=/V1Q\4#OLK
M*>-4XIQ.Y=:=\&R/8] H8-5$ROHEXBY(0"0$ ] VYFIQ*:M\<&[VG3+M9L9Z
MI^_MT(GS:".+%CU1 ^=@X.U9#QF]/\K9 HT%GP#<![M5:)\=6@_4+=[R1XU&
M-#3DU.@0ZN_L:<.>^AG^D?BVD0>-Q04CS&C3=L ?:'2T>@/"W!GAOI,?!6A7
M(^VP$#,G!!G,C#V3MGG1PH=:Y>B&&?CN(-([W@_\;  ;-A])M,))@&AF?.],
M-=/!+DQIX5:Z'B%\OI6@:46S?##\J/?]RC.WAXO77W/Q^G*+UU]S\?I*1W.6
M+-V_:NG> NX.8B/E97/[4F>IHMJO,K33;I6^FYABSD_G9./&A1P%Q@.6*;MS
M9K7:=KXC'-<;IIR^V(K5NMYI<  V&$O?,MUY=>[CP$1R([JJK^([''.0 PM4
MC,@Z([!Q+ I<D'H'V S5=INU\VE!(TF;+A<FT^6FTF7SQ#(32*:SS^^?(5.<
M7Y.D]ML9S5D1,YZ)IC\ '0;MO6,S0>*;LV/\J4ZNTR8N.:ATRR=KX6EHK4 D
MXR',ZS53<W!FFU&9E>0ZZ*8OM<B8=FX9+:U>F_'MY >S!G82,#TKZQ$T?V!&
MZB>RS;'2G9@#62/_HH;I\I>^*K=7XD>W:IXVP0&.,K%)3[/)$Q.[:D91$E+@
M2S-*K.#57FID/"Y6\Y+";SP$A;BW:;(D;*-#U&!M3,RVEM0.AXT^_"0S_59%
MVE\\_3R)?:!1*QT$YKG P+"U^J:98*RU>DVI9J2+Z9U/Q\3,63$J,':4-BQ$
M,Z:8?*_DF8#+#*C %TQ?^=1CD (R*7J?<%'):(2G]#N[83^M[LPGX*$3,-(G
MX"A(J&DA4%1T(-("RRT\!]/Z DV^\B(*!*>3A')TIU&>M6O+LD!T8WKT)WK4
MX2T(M0?+$B9YQD:2O(GQ79#&HP<YZ SM [O-E[QD 6J)"H1[C>WL&X).FN=E
M5\?!M9YM9@8G954R&.9)91*Y4S-IL/+&WH\OZ'X+C[Z;M8T6FL9$TSG^\Y(\
MU YR+T TF2!M<F':!GVG8+*A=>E_!1LVI<8+<B"=4).[_[(C/9X&TXO?BA^P
MX=^P#;]<&_[-.MOPS\T8[$*?ZD@_T6A96%F[4Z]];O<ZK6Y7?-:#[W&9Q9@3
M!>)3Z4SZEYTK76CL;'- 4(T;NF#FIV8X#=6Y7_+-.S$+I1%N6?@TF>]/56A[
M=([;W/GG3[O?O:>+UQEHPJ<INT@=$/NH[<XH J4K5%A.I\6%UDA;$$L/X>ME
M@U@FTEF_DW[<[#5->6@'YP=U1?/H/Z[:W3;-]#DZO[S8*O-9+^GI61NP%OLG
M4]FS@74XV7\0IF\9L8]7;5F:K!#9D$'/A,.$\[U@]3"G:M4H9P%ENL_J%%H]
MS_?_;Z;!O7HM=6Q'MOSV))W?0J[N_UZXC[N$Z%Q1GTYY3*HIYTDAJ:/@0!&E
MX\KE%HOL-5FHZVG9WK&EDDYYCCL=]$/9E^+<5Z*=#E]7HA<F44R! T><R7!P
M(W;?-L3N]N[.M$N%#S_KQ!4":U7I8E6<(*78S/4A&W*"&$C*AH7#4#J>FICN
MHSBQ>C$-\9A2?MSK45)2(75%J=+!M62/R_R<E:6EISR74;XFEG<G&?5U.Z7N
MC41/#V:L8A(:?I454AP%HU'@BVX<#+[NSTMH*#WE/S]C3,EK]]U3&[OVQ;O_
M6-2DB)4PBLWSQEC1X%^G>BIIJ,^CF^:ZPDT=N;^A9B\*YW/WB257V207NY.;
MN0'R'9I5PC+K;S+Z)Q=9W^]"WBT]B"LA+9_CD)@#S=ZFJM+.'/&P2'0M0K_A
MW>7=+1W?BTW1(7,^II[O7JF>=\F4P^8IFZ<E,4_UK$TA<=#FQ,[8I*:"_MP1
MFPN=(UIA+OJW\+?F^@MKA[R[O+N\NXMS!NZ\7J@?B\;Y/9&:FJ[AU5MV%Y:)
MN!::F3$[!9&M("8CMI_+2SG+GMA8BOY8;[D_UG+[8[U=Y_Y84_3/OJ**^XIR
ME7$/%,55BLL_OW[ -7%LH93OH-,1#\8W7!)7%=N@,BIV2<%:5;K@DC@FFQ\M
MB5M4B9.I8;/E:XL35$P?S^;1I$*X11&(K5Q;3\K@5(W'FM]K8F-S#=S3F]]<
M U<N!'(-W.-VDVO@*B&YV'',-7!< U=&$%="6C['(>$:N(JS'<YEY-VMZNX^
M)]_C&CBF'L[AJP#EL'G*YNDCS%.N@7M:LW7!U1K+, JY&(.U8]Y=WEW>W;)+
ME:K6_954O##A<'T?DQ'[!E:><E:DOF])T/^1@,T[G"RK?*A>>T3]4-46N%S\
M+!@5OZKA,,2Q$E^2>9M>Y52^A7/**LVC?[U7>A!W_O'41W')C'\5',"E]/(^
MD4S2Z;8:XN?+N7W60_'\>G0^$?<9MF(!<%<BU6GMJ6S)R\_E"B.(B\L7KKQA
MMV)"?U4CP150!$SKEN7D)VMXEY6DO/;LUU#:VW\L%Z6/X%O3K_\!>_!U^0/9
M+/*72VB/2H*>)366]A4CNJ7&?)^=%S)6&:NK@]5R"8C'98NSB&"R>^)0,I,<
M^R#*Z8.H6C;Z\N,4.D5= _L\>>I/L49+;T60GUH#+,V.K KCJ[;BSHAEQ#)B
M&;&,V(57@2U]*WB0SWP0.2JP].5S20#SO2==/A</K*I_I[B<9W'Z/#Q&Z!<>
M([3<,4*_\!BA]/]5<'"NJ1>S4 &$$"]YBM#:JQSI:*%J&<B5FC>T:D16<@Z2
M\H[+J9E$P5#\JL)P(LZVQ"=7QL4I13N_-,3.WA[\*2,!TA6T)X?Y3$5,F\J4
M%U=I"]>*@M9^"A(3V+SEDYWU=QE*4>HL!4VYED 5V%4]&VC^1OSML0YV5-"3
M;3.G[;!5^VVK]ME']C"#G^<JS0_W>:BOVN)G\3P$#O61>&*>_C<9[U,6SE9D
MR X+$18B7():/4%Q3PEJN?T67'-:+2);=F(3S]Y905;&.9*,6$9LE1!;MN7S
M;"*F,TXV7 ,:8X?"8QT*7$S*Q:2<.K,RC(^U<T8L(Y81RXA=1<3^L*+'Q:3L
M[E]=<YN+29GOL7]GG6CLB8I)E^_@J0SX/)^J-&69@(H+F7CUVI&,U(3G4WV'
M)E9:7EH299&G/SU3TMVK\KE$ES?]J52J8KGF*BT^T_J)F1_G:J].KG959<ZJ
MQFK7-"#+R=^<_/THL#GYNQ)$QLG?J^Z>XY@F(Y81N^:(+=OR.?F;Z8R#@VM
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MKO I84":2QZXY.%Q8'/)0R6(C$L>5MTIS9%\1BPC=LT16[;E<\D#TQF'Q->
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M+8C'2[,/+_+)@1?4LV<VO/ONJ/NKFY[A?C:,TC2:O%6OIND^*+8Q,/+\NX-
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MW@MR5\1ZOD=>7%.PA(*6N_R#6W&^K!%YU5GZ]$#PP%NV;AXA=K7S@LB50N3
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MKECA:2^K?#K7!9/7- -*4_@/8) D<_BU,T3):KM%3/"J>O^(5GA^L<PMO@P
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MUEQC063_HPDHGI1MSL9%%4 +%GG<@TBR)3?GV9F)I9/)3Y)W4^EM1A8@.GO
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M;$DL.8[A.EM^Q:N&96#2& Z.:[A?6^L;^&IKK\ZTU=KHM\/S)4[?'*>GNB
MB6DP,:4M2+T5<N4);:G'YL*8J3 HT/N=S6O73(&Z XD,T&-DTOQJ%3 O)5-6
M5UT&@FE3XBFP"C1/P:OX0&=$0$48P0#5=U19M8CRO%&+GF&;%NO=&> P(*68
M6V% ;V9;TMT[N)5K<53'%UE^E9H$#3!(M^81@HVSFEX!A,E9&$<36 ;(7=,P
M@-#Y"':E&3&(,$<=\QD-CT(."38&T OH[D);;Q>]43K'>T.VKLSBZR">H>V;
M#"&]2V>9BN@U+-5.0.@'K)<EC\R,E&842\R?2,U+]U-CJ5JTO"7A;7GAW%#_
MY^%#T+]-FKQ01_K,O(3G46^-<04OU3]T6L-?F^KA0PEP>+6[_P\W.X_Y<)17
M53YYH9Y.X9!'0(=,X;][DP*ZJHVU+9BVS%.;P-2GVV_>[:F=O7?OCK9W=_</
M?OW;@_4']!FP9L=]ECED//2=Z&D):W%_H<2<5.>X^_6_]-VATV,W!EE:0?QT
M<*KR:1MPJ1G3&[ONC7G/:VLZ>#8X-W=B+]7I; KS;Q=Z9..7Z@#D&#[5@QP/
M<"-\Z9%["W]Y]>AT%_]SC/_!TX%_X9Q[CGQ4&'WQ<&0 UV'L*4%,P "[(AC<
MCQ-NG:;#\FM/(3P\/%3&R:5/^ILRH1:Q1H:BD;ZRPAO'9EI%ZCQ/$R;QB2U'
MH B8/J$FX7_A51)8["?$&">W\"@@_#NROO3$?5\4.3C\.!R<(IZ\/3S>8X\T
M0)(\%D!6=&B\0*)UEK/9,7%?3NJJ)K<UR ADN$ 9W&9Z#(!OV'JD>L1TPCT4
MFL= L?*K\L4R6N6;@'UCS4<C;$^G -#*!::L#0>-$6#>A8IPPS@2?FE>^F/]
MQQ;>+$7?.MUK6A= ,UK"'N.*$RC;HPT';CHB3"4;[W2SX, 8T:LK=:=9@XW@
M[QD&<:!)T)$HL>N5D02)J'%=H(_/&[M$:.[W3,\?$^.U%Y#%(*CZ[('M>^9.
MJN/XBTB&S\<2_\&N)V<_I27/F1F+/ :R[L-SW,-\T? &]XPT;ZXY/;=%LLC]
M.!RPL%^ ($3:=K!5425:R.&)B%N"((EPDK[PC3;/Z2[@!>CJL(K_V(@:%Y>;
M)4,C5N<0.J<*\&</SE1;":<*U\P&T9=J9;1*4LYU(W><?8USZ+JA"=K 8JO"
MCFH)][DQ!PWC;,A1$Z^J7[;^XI&D;Y4M:'Z#-7YS+K^T4-QX*YL-"_# $I!_
MM&0=WL\ ZC51RM(]#)?OM.6%<!1@8L7\VI$2@7I?$6T I"O'["VTDXE)K*Y,
M"J3]4MN4'!QC(.8E^?W(6QA['V:7CI#]]@RDC:+Q<GBZO*:V83T\5F%B8R]]
M&%EKW;:?$5!0"<\9,L)^%U;+ENYO4T<NGJ."=>FH;T,(Z8AL<-Z1>'_.05NB
M6)QY3AN(Y\2RVGZ9'CIQZ\(5_Q<1\SN)W(V6'&K%7:WYLS?94IH7*M</2*T-
M5.B;3]"C;#]P2G*C8'_^@I\\F?[Y%4_]=/?+%WF;RWJCLXL7ZC^/U'L*2E8[
MY$_%;]7!VO9:N%XR1MP1./TDD%';28*&7?AN"\2QHSR]4"<5T" @W"< K;<H
M?F"(2J1VMM7S)QOKSY<0^V[+VF<VEND)\KT7R@6G[RQA\MV6=7)EQYB/D< W
M.[]MGWSX</+X\1(>WVU9(!?#G,\VMQZN/WO\\/G6DEY]1UB\V88G:XRD?J$>
M;VYN_K+Q=/.7)4"^V[*.G6/YA0I2O/K (2ZAI87_F^KYCQL]_SW&!J*-/C84
MF]A6U0,5?[<NG(Z*9IUK+$\]?B&O",^%(LX'O0P'I9&0Z<2K_!@#6I!=MXG>
M*8Q.;(^Y !1X$#5U@3$2,.&%<<;(Q%LBV49\(IK^DX6;61L.3KMKG.B9,KI
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M1P-:K/,,CVTJC!XD391HZ7MT J%O$;Z&E=N8&PJ2="?M= OQZ43<&]@M)E3
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M9#A!4?D<5)]+5'Z0/ /M#<-'6\OBJ?'2P@6S1E; RR(*T42ZCT4U1=D%]/G
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M%&*HZ.TM?OLZ@WF!O15B,)V'I2"$&:Y*'!2'.%( 59'EFB4S5'18..O#><)
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M@V;SHK=?9.@!'8*NV; VC3/8"G$C04/#\\$+GVK)IC@FWY7+U&B<=JN T"N
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MKS:Z"YZDR!]8<RI-=C,H&R# _ ^^8ID7H 7QK)+$;>"1$V_'(<8;H2B(T46
MT=>P7%TT[8H(PIQH(1+L3<Q,?2K82H7999[PXB]AT5=@K[-G(N]>[W1V=[\.
MM7;V.J\>6_3=HLO$O&2BV\-Z)I-<%D:5[0+IC,>V+,PQ&JDC+[NL/Y_2XJ,V
M'\L3_US2XOTQR[5:$U3*A:XF2?@L;++O<XZ_8B9DCNM0F !K8W1'[<!-3EIK
M/68[0S=Y#*^85$I0(%R=&",MH_Z*:9TY.E- RHTW[PN\-N';,_MD9?@!%C-
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M=)6H2A/]K?G,2C[$O>'1CCJ=T:G3_ZF:+O/\84U )$I_IB.OU2+,]?O,T!3
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MX!JEF12%D%H+J( GC<)T(L1F5DKA D2DT>U)Y):LBU!LW_^84,JJ,ZG5[&0
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MYO(AC/+9%BROAG7^W0KU.Y0=7R?#[U7S_/"___'+K_^XK:'?\6"7L.&S0O(
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MRV4N$<$K;+X,OH3Q51(H8HP6NC3L5)0IBJ5CD\1RQD,K0UH9LK\R9+8C,L1
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M*3.9L<.@3>-+.)<"+"X<8XQZ;R&:K(OAUO-#/$T>6H]]Q%__CGI0Y#F>LG\
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MTWR(V;W6/EX%A!:C=R;H8!;%YE_0H ?:*N8RXW?1$$%3Q2' \"D_DND(]U/
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MRLC9*QTS],H4Y\P1P[>!66X1VT>_9M?F 576E%))!4K?KHQ-:9;$FNPTDAV
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M)\U@S.L489UTIC57PH/\9#*[,^%=+5NG95L:(F=F#X#,WF4:G.?&A=[VF8;
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M/LOTFE?%N^\>2]4GC$&?!1V3B_$(0]'0XH+B][1:\DG";M#.A..#UEB5@>D
M$] NYILE8S+4;T+2B=XF$+.?,K0VFK8N$%VT KV@+?C6)'UX.B68RP7%\;&)
M2<Y -M.G;%(LR:%[O@A&+-/23$%Z9T)KY3>#8K,Z614"U%5,01<1C="LAP8(
MTVE)WM[[#HO=Y/19]&O+G;F6^ #^C:-FS4.&.<,-" /D^]3\M3M0^.IFB2_Y
M7O,3-"MLW!COC&"G,L7SR6:#'0%F26$!7%.<X!RNM08#@[.<P>;7[CM\VF4?
M^X5YR-<6W:GTMZ+NO"*?[,VKG<+XS!5PA&EN-*&E-SOD]S<6>$$9'[CZ#KA(
M)XP(UBC Z<\K"@P6:2@92K.+56KIHR?C$9TL60;V5?C'G>*$5[VZ$^4<>1W*
M/\^A^YXNM1+H94T*A,]-1A'@7D;\B^IR0=ZFH*&VOIS*#G*C\%T(4##^B7"M
M[X3B<<<3]KY%:D)WFPISS9;<YU39CG C,SE*ZMS6W)#?PP-W5AIDXG'.#^H8
M.<?^:O(&N\VIQD<J_C!.TU$10$E_V)<*_\L^';R;E6PBB*QRHK,BTR@BJ%UV
M4$L%- O2F+KFH'V>)R* [_'8M@#K]N:7@/OVW0@F_!HXX4AP<LX&[TO.UGB9
MC%I%EA[>\"6AD<Q?3<M=\\VA3CKD1MVD-9=WUS/8C&\ A2R(<\[&DPQ/,HEX
M8M(^Q9:G$D"GUXJ2=BBB2RGT(;] X%3KR,1 O63B!%$-243>9RQQVJ&3Z$]/
MAQQ#Z"[".,Y6 'Z@JR%F"\$'K G9+F:PQZ]Z /R=>'L.V&@"8:_[J5= 923P
M0O MT(3T8WXJ!C8A0Z#A)3)32.T+D%OWT.ZQA@[.V<X9CC*([)'4$#DD<781
M-T6[!G@GKKJWP ;</V ##MB O[8&]1UJ4.Q^$94#!<8CN8P.>8.W;B2:-]@A
MC:5<3W-ILB<.[$6G5XA*%FH2CC!I6&,V]$J!CD)*EE+0%\>&RN!]T1@IM0\%
MN$6CX.B%M[3'(_$R47Y1P-,AU*1]7M+.B+>VKSSAE,"T]0M(W+'E$]UTDEA>
MYYMC;]??5"D(/C@>=9A>\=\PFX8%05;"Q5KGE,O.R1L!/\%WPD2H;(X]-4-T
ML)X?9#A]9$O/Z2M'USP1C"."X]'-<8%>@SFP0<>*!P-L[3U95);:@# 'G)JX
M?=@2:*)815:#$41I,^IG+2L:LDR@<[<0&8=&VO:@Z46]>)BG-[*C!H@C[Y]\
M0YU6< 9B3F%YZU[_.@Z50UC[5@&60,0_#:LH>')7$Z&S_+?,9>LD])$1V[)'
MH:7FV-GB<?'8NP_(F1](H[2/A")P#AFK8BS"^);7>E@UQH%V/WW6Q3<0IZ/G
MRV.[R8RR%##4/H@T)WH)SB%M242T8S0*&C]  ?2.-TET,=VB8$0=0*>'3(2+
MSNFU-!UT-Y4YYEE(>78FN:*AG'_)C+B;]IH[!F&I?A'E[R#88=;J,I.46A*7
MH<V7Y3_\\)7DBR/92)[5(%;-:Y@'*7=#]\6O[WW5SS2'/0*=JQN:#"NEBM4J
MGQ7L UGC@&<LT[>I&%NR\Z-YO9W6Q -,$M3Y-[2S4=Y+3H/0RT<'(CXS6?,(
M;-6NJEO4IH*+;XEML*,.+KKNY ZN271J[3T866#^$1I#96%;Z^/1#UM:1WWF
M>GL#((SD?9_(P)?2=:*P@RA?8^5=D(ER5_?7;%[4#7(GS]Q<!^G.&! ;:!QE
ME'$@(?I->"KM$^$'R2W#)P9=FYSP2MX@\N-*X AU41#LN7!=FC\=.S7':U%;
M90;E^373NICT&0_([@+Y<P $?TI \'DE4:S(I73#"R'IW@>!0W?P*N9KS2NP
MG('-;E8/@.E?M]AA@EFB1**D]&'+X^CT&'-4:^2EYPVYMM:-+^D ?U3.AW@U
MAUAU"UPF@_J%7G%LQ8_=(>6#YQE5K[SWC8YHQIS.JK1*5G\Y"R^"4#<05I!&
M- +J :X ,B@F;9_?<)F5%YO,T]KHI_D-E"#'EM\Z(RU?>D6844TJL"Q_L?DY
M>L3RE:A1.&I-1I,2K:@W-M!:E'P%WN%>F*<90U#FH! @J7]U5>)%J:$9C@F3
M<@2RKK,D>$>"I(5./5:A'P8UZ+;IQJPK1Y\H/NHH[0^ETN)5>T6Q,]?!)6MR
MWG:=7,<'+.)_]]#0PMXVMB>XU3N;G' 4S(0C92+J9%.BVB%V(*H*[17&6 97
MH]>S\>@FL^ZXDX= V^$A*6I:?I /!2*CRU)T5F<#:_M,FQ%LQ<@4P[R<'3.N
M"E4'' 2B=&H!H^P_Z*&=QA=\;]":DAV4.SOZY9C0&1(*-#NHUP_R"R7_@2/%
M3B7[TF4>Z_HQ,I;BY<V(H?4:-+%AMHF(K'3BM#.IMZ&BS?N^ ^_074Z7^<+2
M(,HUW2T/L\7)8^# %+%N8)<US,O:,7_EEB:^)]WS?,.+!1)<\46/MXR8U;"#
MU'I7FD:VM5,^:',;JK7&78:N(^31Q8LCU+9+\:3Y\.7+S1(4_ ?9%]\;!RQQ
MS;":BP;[L8I[F*]-35A'I$1F-/#IE,3'US_<?T !;F4L[G/3Z2OC$;P3+^?3
M._S$/L?./Y/^W5U/>HU&PLY+$*(!@-C+I-(G1R&9,F,$A*UN%K$_R*;G-"H'
M8G,Y8.'LADYV3QKAR$3BLJ;O'V5J8"]U=OJM(U%ID<0W](WZ;*P4$1S6 J^P
M:<_2I8S^-_"N1WJIBR/=))M[P!&KIE+TD/(Q8%(X1'UN.)LH[FQWH)F 6#CP
M\,= /YUR$HGE$7/T+#W='!.(^)B[RW!@J1@:OTL\4><PY,(0-9_?9EF%MYHL
MLRKG_K!D4Y1>CW9J#V&9(M>-/5XQ4F9Q.&?.W=S?&CV7/#WCI?B^L\/J6%?,
M[M8?.F\<^SD2W6&ODQOUS!D!'=@8WD5H9M"2?P=3Z4-U,6+FS(NFHG3&9Y@\
MP:PW'D;4=4%:E\OGKPN\!0+DP0$!<D" _&54Y<M^7.DFUU#'*Z99"LM&(K7B
M!Y.,CEB0R@7M SW2>5LPPTQ<)1?$8D,IS:B-DLG><[.12:95E)RN@\\7I6>>
M'=1]8!5A5!&M(B."-_92N;31+N,]C@N-Z$#OU#NQV0:"Z&NB)IAK-',>-+9B
MI^N Q[E5(U$NQ&X5U3@@YP5B!T+W0MQDR+K%2_MIOXWE?<+K?3P:+L+;RT+>
M"YV#A\A9L[2_Q645@ FD19>91B5LV/.UUT 4Q>TSDS-'S4(?R6=OUWV$P2RO
M=V E#E&83\[9QW&^4Q/GX]/RBRW*QU>'=><';H9(L+#C;)#C@JD.9"XN*V)I
M1LN)G $-9FDAX[;F!'D]^4EUE?ROJN3181R/"%32Y+1IJFE!\)_?V$U?TU68
MU73U\<')L/S'5:.T*UPT!#W5U71#$4ON.M)V,]]=Q!]A*?#4%X,7I;L8'E<K
M9=.PVUWV>I-\?3^%6P6__?4W1S/GV@GN8?$$D7EG74%84? N[+>[<W)"#._W
M)[#\='?@LH9EO,\[/@U;J)Y<;SN$<Y J%ZUZ#7N*:X61K3RAXF&TE>#>X/16
M3B&=;S0T-VW=_ANHHXV:UT M[>0(C/T%9TTM<LOOHM?',1(;I<G->L0!_:%O
MXKO;_EZ(W\!0E9&:BT(!Z;7;/7J=W+S3;AK]=[BGP>\(J-OMGBGZH\E89K%=
M+G=0FIMW$Q?R[E0L5@"1JO(H7 W8= VF;</!7=J $MGV_!5=9TS#",8^1ZOO
MXE!2V/;LO1..%9@L>JRYSM,1MS\4^#'U1RQ TO35,E=Q%BT*G$LP"FJ\)5Q)
M04T))[ )F1 8\F[H!Q7U(2_'E@ZB]]T7CC>GJ#L-6\@5M$HMZ9)DBU$"&D4N
ME7:4Z6XE?Y'Y"B*5T%*-3A#VQ?0[#3O-.8/JJ>;VQJ-91>8C^]FGF!#>N$/Q
MYV9VH0@?)H62L:7*/Z#S[-9,H!WQI9/"'_W.$6VN]4]K<F=LFIG:VD%]=N6.
M<K%X\EFGCA^8N ,S7WS. :Y^'(^0/9^V"MB+$R15M""GB[R<9<1;48N;VYD5
M.@6N! X8*F8#F;G')U=90>59&!M&8:[@5'E(1)/-<\WBKAKG[X7VI\=F((0B
MX_IUY//.&*B%' D(<50R#7N2(E4PPCS^QUWJ&LR^[_#4":V,XS93%ZD>(2OR
M&I>9N96=PKG\88R@.6'D'"D?9*=0!<GZNE.6Q5$M2YF(,%U1(6B6 H2I!8[R
MWB2Z-H@$0*B/R/7 3]327-LPS9).<8F$ ;\S=9 <5R-R^K1'6\,@?O\.L5 Y
MSS59?[:$C);Q& B"\)Y$VQ*!DQA')$B5VZ!2Q<(6Q+JA$F-*<+<!;.L=;ES7
M""HK: <4Z)IO3>--9:Y1?MLQHPQ=3EK)YJU[DR@57[]'1'YB/T[X$;MG+:D,
MQ;=9,?"<@DVW*MF=SQ_]+$<26@<_D'70D/L5-OLS87@4,X&M!!$3\3+')'JW
MEC#VS.Y!%0GXZF:%J".L.8_BOD""'(7U5L@B1A#%P(Y_(;^.(06N-9[8$2^4
MZJ_E/'H,#T8L!+G6G/%O6F5-5//D]FVSAUYHTK"-7A6 E!,(\'=<TDLQP^7,
M/(RZKQ0[U=(#GG(E17\W=8!]WB0TA/&RXN^F7E<.N5G\_0H2P/('Q5D-^'XJ
M4344;(TI=D=" !9VM5D9_" SUW"58Z7V+'-T*61\4WKJ7;QOH+<24O;AXAB/
MWW+9+>G:Z^05TFZXZKA"+S&SJ?GDZ%? ?M^92"):'J"N8G$$4^].V'7DUGC5
MRH%XDB^S*ZJPB,]OJ5\F>T[:J3V1=2R,+%,^!;E1S9S0G535:T^T1_=D/M,[
M>9@ELM:T/:R5\$1'J.1'0SY5/W2\+FCL;AXG&%HN9X*L8U:D(I>JY6[&L$0?
MJM<M&@H4@%ZW&CR!KGQ(@3M%($+]7D7K'? 5;X^(?W.(B!\BXG\95>D,A2 3
M7&/NAUZT*N(R26T6*>_K!E3]4J>4L8Q/-.HN8OY=3N1*ACXAU<1 &A-LJ-7*
ME+W"0HX6F*4UQKB%&98="85/<).+@C/1FI;Z/W-?]M=?6*%>E2JQ4@K2]UT*
M!H5!_O'X6>2R2+N#:XS&D8%^A/=&@9_V*L(@MX_.028*+-Y;VR[L9-_[>N\K
M>N"&=N:2_?BGOZ&#:KR'&_HCR*8/H%4\^OGTY?G3Q\_.QJ.G3Y]^:*:9#S*
M)T]?GCT^?_'RU5WAR;D[EYSU!]P_^?HD^0TY89N'R7,2QSY0&.3J9/-Y5D3Q
MK5Z^P->S"Y;SFE?%%V:4127U%C;BW?-ZBJX&Y^\GIMKH][ [-C( @GR^64J
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M]AWM]2ORO4562X@#&.+*I>YH4O@.8+44OG=(14YSH, "]<"H])SK$^;R;\N
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MZ$XV8#.4>O==,N]'?TU$W1HV U,9GX *HCU+=]B*'@M'3A6W.GV;^TX8DG=
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MO>1'HT[64BHP'3VBV1G6:8/OE8-J[3OTX+'V(*,3)0N,->#,Q\J\O:KJU]#
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MV3:3.'FU8 7V%<(M3EEU$CLY0H*C::63ZQ"88]1+:\RZHJ*8%7O=KTV%<=H
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M9_3P>$RQH\DV7YMM:M7GI(K%)&^O<LU BH\-C!7I)(< [AWC@-B8<?1+^*J
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M_WA1Y'-8:T$2C4<OM-X&/O@;G&H4$ZTL+SW\2U'"9\$,3()GSVLVF&O59?_
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M$P]<"X<=3A7%5]\4^#%-)@B0_@X_( FW39>;DTXD%P>4^(8IVU#91-;J*HX
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M^:I!"1#CJ7 #ZS]8,8X5CI%=<+4;G,;GE$ Q/2#<,$ZE+45!D88EC"C*9_;
MB0/& T8DI8G":2B1#&.^'##8;07>*[YJJ="0;Q=RON"D3N!I9PB8 V/F'KSV
MGO0W,859_$,A-*RC+V_DN9[;8DQSQ_@U;5DX:M;K2<.GLK2L]JUW8HP**\CE
M>'!_E_N"V5=1P('!6^ F8#;&@;M&Y=#NDH!2PGO9/119<B1,.N_[3#J@D[6U
M@XH$$^=LS!/#]%=3@?]4HKJP(+9*9EA^U+2[?MGLK,!3HNTLM' V2!UK%Y/
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M/)X+&&Q>0QKNG*"\^OC?@>_*X 3>BM%M6,^U7+QHQ14<6_16,I8%Y2!/VPN
M$B@C*UT71N.;[4#CHZ!/K#4U8%0^08A-T5@I'Z0C]<IH_NH\_S]L"]>OM7#]
MAVWA^C<7]UN>:F>>_S=$3LCW#MU%+BB<M?L?I-BHLXQSR_BY(:<\Z>Q3.9Q]
MO&P6)0N5>^,4KX>0@U)2Z[%FTJG?U5HN'VIXV!O\>,0W,U&F&IR7,V.%C\1H
M*ZE9#A7>%R'-[160PUF76"B2DT4=6!>?V)4J$I&@E1X%EG(FS)2+O#NK9XGK
M\9C$.A933J7LU(WK>:3M1<N>G(@ 12VG3)$[-2ERODR]U*YO2^P[MD3?KF#3
M0ZR#R):/1[$]UQBJ-QHG=XA)N\R&\/SEDQPG-5S/9K,&KWA;26THCS1>67GF
MN(G&I#:'09VD9A(2'S8=Q5Q\);7%,,930]/#\TJ5,AT<?>D&@06]RL< 7P+W
MQ#:**//3K!34!K5;$_2!78AM+<<-G]+#O<>BAI-7MA6D6X,7MB^F4)N:VI:)
MW 1S;9S"1FS  F[60ZV.&5]L&U$.5N%%U9+3"C;6==-1GSUOI.<B6!7PK1IN
M1M8H=3/SIO_)%;MN7NTJN*E--[<'^"H'^ <ZP*\D0>%93B=.YD)EN,(B:^&3
M9N\?)7J:K2SJS#DTO?-B#@N'4YR:+90>O!X,[[1W]M:.V=-B;T;?<%.K@#ZZ
M2B]VY#_LM .!8TL9S#568XE(]R9A=-0P6,<]ASAZE\\(WB@<'CEE+YJ<8_7$
M380H<!-4H9L[W('H\XGVQ2$(B  0G9O7$LQT;D6TJZLZBZC3O:%8!26-6A!1
MG//%&6?7N?^,24#1XPFJ4U?29<?+%YM>R1+BN""5) V!W(P9MJ.H5<RVNN2&
M3^GAWA/2)6]))EZ>&_9Q@V]V#&ZZO\D %L'4T*>#Y3$Y^PJI5,4,#>-T7H,2
MBV>6<*O/<H%,HATHC$XB=UJ&@VDN?I.V9N+NWU%&"\:&AMA")-IHA,X?X];9
M>4VM@D&ES;AHOH!Y33N-VWK848HJL]6]4BV'U[MX;9+^27HSTHK^0DE?)(P=
M,P1@(,ME7> C$^Y(@1BG6;[,21Y,.P_.!.'0\+GGN1:@9M4'20(++ ^435:T
M8(CHT]"3.*U (&9.BEK.?.J6?HI3A$JP7H*^-3!$U2=UPQK+OTPTW]"'N4HJ
MUZT KG(,QR('#3I3L:7E5,G@VN+*:P_9M<W@)-)IP1V8^[K4EY'@)HM=&!AH
MS;3C6U4'@"V#;[:S<XM*-AJD>T_(1R5Q],%K6GJ9J>_IP'VC+&Q1>)IR;6DU
M0/B.R.8YZ'S*Y00(-@O1.\(0>O+<0TRDR.YR__[]_5@D.^5,ID_)?=)S&7A(
MFP]R!DH5%J"1G2E:32;EVIDKD$R4_(5@"A77*9*]O;5N4#>)1]P=PS0:0@7P
MTL*2C!!L>V;<,+E[)'T7.'IE 72ZD]9?B34H;23FI0E3*1?H=?1)537&C%5+
MC] /I8F'K:W% Q=>053RVJ!.QVMDKAW?4@<B5<WJIE7$$5K>6;>BNBKSE=-5
MAK_*!=&,5SBJ/.&B=[V"HH+56TELTQV6Q$@-]-0.-X.[[<),Q>L+C] R1 +
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MM E31239JCNK&XKB4[\ \Q*.E\/?Q'%._>;MMB+*B:NZR=+ *7=UJXD-I$%
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M+6N[;4;T.C*BCSXW(_J5<Y9?^R1]__SMBW^@8OC^EY/??_OY_P=02P,$%
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M3\("" 3S*EL-Q=>,Z4*>>(N66#&QAB3B4T8?9WVJO,G (\>CE*W9R0*L:]?
MM(@3!B?/B+7KBETH.ZEXT(>MK%XKS>R6_R*/M93#>N%1%RT=Y-&28F:E.,C=
MCPD @38F7GRJUXQQC @$FFLPC2ZNNC?8;FMW!TY/I-="!+?,CSQ0&US#<P;D
MD[4"G'PI8:_X-#K (]@JNM :7P8XQEB-1E2(KSS^P.JEM:5G0%\5[LFWT2J'
MD21QK\ G(1O@A1C5'FQAITK\I 0RMP92%$H+!<&$9*)=/5Q>O::CK2;8CZ28
M%R<K1:;X!P*U76NS@U/+XZW'B8CZ[Z =<6:G&"!%C/-#"_[_Q ]#1$T$BP]A
M_''V$Z4*6V]FDN17')$/K>04RX%DP7 A!,0_,+@4ZHS)6I-4=:5%)L3:YH9)
M^N(M8$['>*0P![L&Z15!A1MFM/-.T%7 9^1K2ZD;!4\EF($88Y<2\W@NB'OA
M0GHO4Q70JM".NRI>IN"/^W/S5$)0.X!*,]#B:99[8EK4O0SQ(L^ H5C^"0/5
M!A"_?&<*[*@M;+N")RQ"<#O#BC<E&9$G2>.,T$3KH8M]HZ=BIS)^DX2X !+&
MSK+T)]K8\3 S[<(68S'FL4=V#-HC!$MZLZQZ8VW#ZA_Y*FS5CNHKBOI11QHY
M%[L/<[&>PX]VG[CL_;+QIF1IN71_-37^FPW3^'UQ[ONQQP_Y-'^Z?9QQ5[.=
MM\NU6Y+<VY^>>XKR@*2.;Q:>7RSD[<&73^#N/AGDF!J&:1I.]]G0YUB0Z2@E
M";$V+);?J@BN:"H/2+\]X1+Q=O ('3Q$4(H1.REV&ZRO/?O7.P4J['.%WGYC
MEF+_Q]86)B=\;Y]=\+$X0%O:PK@T?[:U58BI8_UZ^U2^5/G;*"U]5?'N6,.@
MN3<#0L5E5EWDO N]#:LO?=^<C_SR!.]>;"T\AIJ!^9[#8!KN2S07^C[<AGP6
MB&H8"_YQ:RBP!02'D9)O+CYPHV3W,B3S>"E4<+5-P-)8>C9NUQ;R5 ZB[D^.
MK_D@;-TQ7?Y2!IX@@JWFG@STIKF(=W62)HL#F4R*4*Q><R<@J_94@E+VZDPB
MWU%=3T)8>;&; B,<GQ'4Z0Q+GEX(KQ$-8W<M=.Q,6],&@CB!S09Y&[UMU9G2
M*]&@4PY 5$8J6]+(\S24ZYEEN".A_'&L]81Q%&.N2HO@J<B4H"7D,@L3[PCO
MV:<,@E(!KN;-1ZB?%@^@ F)IC!"47JA3FB3#<',SV*:&BJ$U1J.+5?CM@#,*
M*6E%22H^A,>[DH74KB<BJ-<R2@_FN309)&XL=?I0YR1I\R46928:LVU&N;.@
M! KA<:SV$X J1%_NYD.=F5:G.GKWD>?<>11A[T I 3K%N4ZT-L>9K_G<_\::
M>DE[B0=B)<>D.IES]BKP>#(Y6!R#W4^"-"P"E:^#,O4)Z%/H7/:L$W9JG3CL
MW.HQH^VPK<5E1>7N:'=^C7U4E/STG54;6 D]>4?(NJK(?>7;'-*UB>^KT76>
M?Z*CQUC0"<_R\?LB#3Y>"YNDAM?WJN"^Y7HU4-@\ET$8+^9BK<K\E\-(G\_3
MY1^AI'.17*,JZZ/60K4:9_&5O KC9"*CIZCVS4.B4R<IE*JBXQ9V*D<ZI:T$
M^C"8GIW+V&TMEWW8_7EA4>DM22(@H73MTIYP/DC?6XZ5'Q[DQ'#3I0:LK#!/
M\IEE F<E9'9V02?B'BW_):&=:J'T T)90\[B>2]7Y.%4IG4U+FZQC-:1_?BF
M,2], ##26P]F5(-;=+S1I\6(3U6$F\>EL%R5_Z;5C _#*X&-Q(L[49H3\Z%U
M=!(656=%.4+COE) ?7B(13T1OK^9O%;E3> :/^H-5W[.1,]9D(:'V]9*-]7K
MP\G&T477-&R363W;',#:^FW+Z#+;;%\.+.<#ZP]8WSDS!^M4RJZ:E-5!^&6=
M?*"2WM[E^;$YH&)>P[:MTYYI;MJOUSGX"][#W'?31&7EYA:=\J,*9N[^3$FS
M56? YZ+_!SBX8]5\$H?/\N7SN<3;6<]6^9C/9_:BF,'7R/1MYH9\,;"P:L)N
MG0\7YGL8L<EZQKFI"N !WH%IVPU8>[M[24"NU_YC76!![IB-.7-;J;W=GQ5\
MP>;V\]O51'EO'HQ>L6II.JH85*\PCSNS64)DWSB;JV;Y19FK/G)'$-*NIM-H
MW?5"IA=FQ"@QHIF0TF(W.L$FTXQJ8JF,)HIH*[?J1?GO=*8^!^J]U8!Z;WE0
M&Q@E#L3-4W"]&MA1I5I1+J1*$[GT\L+K/+4[#,./19U'O99C,N!3X<T?-N ?
M=4*@4P5##49=,IE7)XJI3 1EU:VO8%1_'V2^67R)=0Y2'57S. ^ENVC^N%Q^
M86\]>^E5)&G_<E4+A\='O1 TQ?Z#UX,7F^/]J=I)I61-UP-35;_:D:E#NBF5
M8+HA5H0D"O-B2&5W9*R4B"K.6(KK,)53&W&[U#"@>P'Q37Z E_D\GM5S<1^+
M8GE1100^'2GJ4\)8E6KF]?S7$Y "E>;SRHV^6L7-_=*W"\G39O<TXU2,*H2W
M_[0JH6?O(9Y?^[,:=IZ"XS.34;AM.)<#BKB9?=:_[';8L<E.+PVZI6J:>/J
MT)V97>O4(K>=?T%\CQV[8SF7ZC;WYK'1>X>X7MUU/1[TWYD#>C)^A3>W5>C?
M[8,*PGO:WZM;Z>IM>V!V+(==]M2;]Y9SQLY-VGO;9]@6T$D3_EY<#/J_@I.2
MUQE[:-TQNEUB 8U.!\9Y@UU<#NQ+?&5.G]E-L]ENLL$E.-_YT?"V=O9>-Y^+
ME'5$N%^YHO^>"O;RF#B_,T@%H^6M&<06@5<<1@AUPZ&X$*%.#/P;.B2N7K2<
MW:M)564Z$4! @R@YCT7TO:<[;K3Y\E,F/>WCR%E2U;#T<[=+878VG:JK9XMO
MYM%=DE&U9#\1XF.2]R6[8C1[M*(*B'P^-,M;$ZA,3,]3IO6:\MPE _F5,57"
M<"<CJGT@W-F=01([EY6K.\E==]H,:I$7!@^$*@?QJML154%A!96[I4T\TK4R
M7=WARMC-IHFZB9#D*JZ(9<*OA%HQ\@.F6-<64S$_7;+$AX\R4%4'LPLP,W6N
M-1O[5_RU!D_Y=0_W% ;N'K!^I&LG6)=#J/^O$WQ"G>!:*N06ZW]MR)IS_MOT
M6Y^.U*^!HM\6]3]02P,$%     @ *ZZF6.'GK",<#P  &TP   D   !E>#0M
M,RYH=&WM7&U3VT@2_NXJ_X<Y:I,B5\8QD&0WP%)E; &Z&)NS1%+<UM756!K;
ML\B2HA<(^^OOZ1G)%L;&!NQDV5HJ%9 \+SW=3_=T]_3XX-0^:QV62P>G1KV)
MWXQ^#FS3;AF'!V_U;WSZ-OOXX*C3O&26?=DR?MWH!WZRQ[9K8<)L.1(Q:XL;
MU@U&W*_H%Q5FB4CV-] 17<\?VV^?C7@TD/X>J^VS1'Q+MK@G!WB,Y&"8;!P>
M''?:=CZH)Y)$1%MQR!WI#_;85JVZ$U*CH\/7?B\.]P_>'F%%U 6_SG\P2<:W
MH>S)A+VK[OZIZ)K/*KM^U#)8PVBUK/-ZPVR?_+I1VU#/Y_5F,W^^2_;.8K)O
MI)L,:86U5_NL%T0N"',"S^-A+/98_M>&0N:!W<T0>F W\ZFN191(AWOY@I,@
MW&<A=UTL;:L7)$DPVF,[U8]A,GGMB3[(^T"O%O&*5K(5RS^$EH)BTD7;M*T[
M/+*;!<(:'6)1^]>-]QMC?J(!_NOFRWB ^(W[2\S)5O1E="]8BB-\B'C16BS#
M8%WCL]&U#';<Z6)I!T==I>Y'APVC:]?--FL:QR;6:W;:UH+E[FZLG6!0V*S;
M=?:I;9Z<VA:K-_Y]85J*.M#1/:\N(96=59 Y1Z[W99?A>^?=JSN=YK7;KBW7
M[MW.DNV6G';)9A]?S5GZ6V4>#M=BNH#%"\L\9[_]\[]:O&LSDG?MW\JG&6,\
M,R' 9-LR+1O&DW6.6:=M,.NTWC7HH=&J6\ WFIR===KEDF5W&I]8O=U4S;[4
MN]UZVUX_G6OEQ^]IG,C^[<:A?6J"&3 XYK%I6,P^K=OL?VO]6>=J<IZM;P89
MLV0H6'#CBX@%_37S*OLIERY\F<35E\TZ@SM#1@MAFZ\]]VL:[-/#ZTC]^08.
MAQ_+.(F)JX$O6#SDD2B7\-3P>!Q#(9U@- I\%B>!<U6!^Y(,&<>N$;%K[J6"
M_52KUFJU;19",JKS>)Y\@(8>P*(!\GDK-%^3)YQ]\LD6H9WS-96Q3"2:-H(H
MK%88+Y>:PN,W-*B#5T'$U<>;A(5\DF 4<O]V,B[W7;602+A"C'C/$PP#1-R?
M,."+?L[[5)GB4:%#UH#!+,C$$W&Y1#,. P_.&@$Q$J ^"5B81LZ0QV+".59@
M7''=C"?$M4@ZJLE/V]O5]S7%LW[J>3GCXK3WNW 2&IJ[),$1*,":TA#C8-YR
MR>,)D1"PP'%2I0J;\@W;K3&7W\:,]Q--(!NS):8EQB3$$%XP<0]].!N):""B
M2C:Q^(9E^ ,![L6Q *436>1-\J56P">'AS(!SOY0XJB42^!'-.!^]H(%((RX
MQ&(YDAZ0TDMCZ8M8D=&3OFZED$2,0_-1@"GR5D [7BG>2_R]R7-9'^7#-";#
MC($<1.72I@0S:,A;@5G[43!2S'"\ !T'M/)9O)'0!\D]++'G20>M^M L?U!E
M]C"3:CQ?K$!;AA;-Y$C25!HPRGR 7R%&H!W&9;U;4 !CYI ;W(<CG A&W/4#
M"!V#Q)A:(3 6T#!\ZMT2: (E<AJR+_O)[58LH+8NVWR_X[MO2/0%R;LT9K;2
M, KB$(!*8Y(1L$-<R$9:D@L G^\1SS_A(;X) I<UM/C9&8^N1 )+Y,IKK%I#
MZTCXSA VZ8J9_K70"$83TW>J8_T;#Y4+KUQR!>@?D71!'.F*SR!"3V)1:D'@
M&7<<$2;$G0J@DH!@L(V):TP +$&)DD>*JR>(YR[$,N%VN90"=UZ10^ Y&*#A
M2J\M <W3T*3AC$QWU$0RCJ<-E&4TQACE#%TC(AB@"*($6&7'031BOVQ]8C=#
M"2LD?<=+73(Y8 %/7:E@PSWN.[0Z(:AOWX-0E2R'9.@<(;%/*&Q-J,X@,  $
M8@*"(X0;:YT@5,X1=S9_/G;>C^"#6:YS"!>8DRN9^"8B1\9C[ 4(]; 9>8&"
M  M"I?3*>"9!A<F'6D':^7!NE9FSFF*+NM]VH1I@_Q(:+"140AG'8*Z:.].+
ML3R@=)SYV';';\CB1\&U= 4L,DW@8A@?D@$CRR7I]]%0VS:TS*2T/&^J[$M&
M&_?B( <"P;Q(5D71-2$ZYR?>HB5V3.PAL?B:TH>3/D7:I.^2X5'"UN2D/O:U
M&V!:1#&#D6=$VDU!+Y2>%"SH8BTKE\9J=L=^D<5:RF"]<*^+M@ZR:'&^LC$[
MR-P/" "^5B:>?U0NU0<1/!!(KL(TNKCJ7F$[M9UM&#V1W CAWU$_LD -4 W+
MZ9--U@*PLZV$O>:C<!^/("OO0GO\V,&I#]1L- K1E?D?V+VTM/0*Z%.%>[)M
MM,MA)DG4*_!)\ 9X(4*U!9O9J> _*89,[8'DA=)&03 AGFA3#Y-7+FEOJPKR
M0RFFV<G&+%/T X%:K[7:P:AE_M;C6$3]M]&.*+,23)# Q]FMP?X?>T$ KXE@
M<1E$5Y._*)]7>S?A)+_F\'QH)R=?#D/F!.=,@/\#A4L@SHBT-4Y45]ID NQM
M3A G:]4 >UH">"0G!#Z]=/,MWPE2BHMC=!70Z,SRCSFGP*/([HH!8HB(1U,N
MU@M7XB\R4>ZF<KRXH[Q9<LVX-[5.Q03EGQ>:82R>I)F=I"W73>'-\102CN0?
M4!\-S^CEFSI@1P68C0*>L$7 */0*MHYX1'J>1"FAB78K!U&=JSR;L7<E"7$^
M.(RX;ZSM6A7Q,%&\7%,B,>"12UJ&L?MP970HJWICY\'>''K*J=1FY#NR^L]Q
M?K!DXGV<+'XW)NGQR>K?+*C&?XO9Z*<? 63+_&6Y/.W.DOG<)8?[L#LO[;OL
M,A9PZNAV9LY^)FT+7SZ!NH=XD&$J/TGJ>1S;Y3: &0?8&V;S;U4#KF@I"[C?
M&'();]A_A P6#2A%GQWGL0#K:,L^6Q/6<7(P?4JS B.W,4F _V-K"XL3GKO'
MSOE [*,M!1@.K9]M;>5L:IJ?YXC\2(N\^CX7>C[/N,4'==@U,9E%$SEM0N_.
M<=_V3=G(^V=J#V+K+F/I5(QZ-.=;Q3O3W4=S+N^#M^#/+%9%@E]M]00"-% 8
M*OYFS $U+X@SC^=" 5=O"5@:2\_&[=I<GL(QT<.IZS4?4ZW;I\M>2M\5-&"M
M^E[Z.J3-_5V=0DDC7\;#W!4KEYPAAE41CZ"$NCHQR.*=FV$ S<]C'1#"\3&<
M.IW_R(+_X ;>,&)?H7UG"APK<.($@@VR-CJHU'G,:U&A,PA 5(8JEU')LBB4
MB9GDGT.A['&DY81Y%&&.2EK@*<]CH"7X,G$3Y[CW[&L*1BD'5]/FP=5/\@>,
M@L&2""XHO5!G*'&*Z:96\)8:*H+6Z(W.%N&/ TX_H)02I9!X#Q;O6N9<NQD*
MOUQ**7F79;JD'SN1U,D]G3&DX$O,RAM4)F'&.+*@] ;A<:#B"4 5K!_'VH'.
M&ZLS%QU]9!EQ'H:('2A@IS.6FUA+<Y!ZFLZ]'RRIEQ1++/"5;(,J5\[8:]_E
M\7!_M@_V\! D8>&K;!J$J<\GGS+.1=L\9B?FL<W.S#:K-VRVM70IS5.\Y*='
M5@U@)7#E')=U59[[RL,<DK6!SU<CZRS_1 >#D:#SE^7]]UD2?+P4-DD,;QX4
MP8+2J15 8?-,^D$TFXJU"O-?-B-Y/D^6OP>23BTRB:JLC]H+U6Z<1M?R.HCB
MH0R?(MIWBUBGSCDH546'(>Q$]G7"63%T,9B>G<O87K*$;??G5XM60@X)I6N7
MMH33I'Q8DI2%E-2=Y!DVJ; %+2!HR7&69/'VSZ_NU\QNTWJ69,H:<A;/>[DB
M"Z<RK:LQ<=^O;O*'^KQ0 <!(AQZL7G1NT?%6G^7"/U4>;N:70G-5_IMV,]X+
MK@4"B36?]ZR>"U-L/C /CX.\)BPO%J@\5*BGC_:PJ<?"\S;C-ZKX"%3C3QUP
M9>=,])SZ27#PUEQI4+T^G&P<GK>,NF4PLVT976A;IV'66\PR&A==T[YDG2[K
MV*=&=YU"V5&+,IMPO\SC2RJX;5^<'1E=*K6M6Y9YTC:,3>O-.B=_P3',U*ZC
M$G'SMZ["S%EE_;VVV<>ZR'ZU&? I6A=0,'<#?0*%*[7E"]"S^BS:9J:DYUT3
M.R)TTKX\-[Y 00W6KI\9JO0<P.P:EE6!)C=:%P32<ND_YCDVVZ91F5*EE>K2
MC\[K[_R=U_\[K__GSNN_X/UD413S<7>Y,&9QH BW3(^C:I&U"_6X0\DE6/:#
MCRO4*N]56>N:$GC9C6*^F!Q+-V#:\X03'L%=#RCO>ZLSR#))J22;JKC"D'(5
MJ_8Z_TI%(X\$]9(U&A^7!W4=,T:^N'T*KE<#.RJ4S.OA5&4LEVY6]Y^=7?2"
MX"HO9"J7,DSZ?"3<Z=,T_*>.P'0NK*?!J"MVL^)8,9*QH&,C\SLHU5\ F<LG
MU"#*IBJYG8;20Z9W"3"__["69-$J3B'^=&4Y!T>'[0!CBKWYEYIG>&L3=7SX
M+&)8J,G4Y>ATJ42E'-0I](@J@)T .T(<!EDMKM([4E;*M.:'B/EMK,*QI+A;
M2^O3M93H-CNA3CT>30H6N8=-<7Q/2O@>G9GK8_!(50IGUTENAA@*HU2?5T_W
MW4K*%ER\SSE/V9R3E%,MM!#NWM/*X)X=)#^_N&TUY#P%QZ<&HYBS;E]T*>QD
MUFGGHM5D1P8[N:C3)6G#P-,EXE=FM,P3D\QV]@F"7+-MV:9]H;Y 8/.HWOZ$
MX%9=M3[J=CX977JJ?X8UMU3\V^I@%,2XE,!2WXB@WC:Z1M.TV45;O?EBVJ?L
MS*#DDG6*V)B.4O'O_+S;^0Q*QK1.R$/K9KW5(A+0Z*1;/ZNP\XNN=8%/F=UA
M5M6H-JJL>P'*MW^NNUO;[]]4GXN4=7BXW_E"R0,7*,9U$-F55:J('E_:@F_A
MN_EIFU 7;/+[..I(S+NE*HCB/=_)M:Y$78R@ >#0P$O.?!%][6[.A4I/?DVE
MJVT<&4LJBY=>9G;)S4Y'(W7S<?;%4+K*U"_>&(F%N(JSOJ17C%:/5E3BDZV'
M5GEG 86%Z77*I%Q2EGM,0'9C4=7HS"5$M?>%,[FR2FSGLG!S+)YWI;).+;+*
M]ZY0]4YN,1Q1)4*F7[C:7,4CW6K4Y4N.C)QT%*N+,'$FX@);AOQ:J!TC.T&-
M=/$\W26A.[[XX$KZJJQF<O]J(LYU'#?HW,':E.&17^TSZTM]'DAY[>ZS3JBK
M?5B+@TLS,V#W\UOW4JOWLF(O(\^SF@S86G(_,RE_[A<\J6_]Z30O#]6W?=&7
M@OT?4$L#!!0    ( "NNIEB9[XW7\!$  .&6   )    97@T+30N:'1M[1UK
M<]LV\KMF]!]PGE['GI$5NTG:N<3U#"W1-B>*I).HI)E./T D)+&A2)4/.[Y?
M?[L+@*2>MA,YD1+V0VJ3!+!O["YVX;-K^VWKO%HYNS:-)OR?X7]GMF6WS/.S
M9_+_\/:9>GUVT6E^8'W[0\O\_6 4!LDK=GHR2YCM347,VN*6]<(I#VKR08WU
M1>2-#F @#.WJ<5,>C;W@%8.!K]E#)WG-$O$I.>:^-X:AC@@2$1V<GUUVVG81
MGN,1GWK^W:O[)J-O8^]_0JX-,UV<_QP,X]GKLV<7@#G."__K+H#^<&CGD"R"
M'GGC2;)ER,U/$V_H)=7*B_J+C? OT_ Q') X'2?A3.&E'@S#) FG]&R;B&E^
M/!TOGD2,+L-H6JV$(_:>1Q$/$M804>*-/(<GXJF%:X_UXDE __/2:)A_[1_H
M3R_Z?Z<Q".7=-H%NI].AB+8&]$8[L_\,>!)Y5R8G+B7^*Q'<OK;ZU<I[H]<S
M<-)KH]5B%R9[U[&:S+ID[8[-S#_,7L/JFTW6[5F='K,[^\<=PM2L5LP_NE;/
ML*U.FW4N&3S*L&-=$[!#'#OOK"8@>]GI[26>5KM:0<0T3XVKGFF^->&GIMEO
M]*P+P.W";'7>[Q]V>ZIC3<,VJI4W;>OJVNXSH_'?@=6W2 8;G5ZWOG]\.+/.
MK< )HUD8@4_H5BN#P!412R:"M?AMS,!WQ)_[";S%7YK"Y[<\ N_1VC-,GU[B
MMAY.-09]JUNM_"E!_[Q_V5^E%_3MO:!J9:\CKZ\6 ZB''A@AG/*D_M(+MHF(
M/?%B\)&6HV$@&OT,LR43GK :"R,6B;$7 RF%RW@< YPPLQ>302R\FH0^FDPP
MCK=RWL/XB(D;#U!P\#5\-+QCASCJ9]_])PU?@UR W<T=9#2E$-M&]+):X8'+
M!'<F-<97CE@8<,22D,W2R)GP6+!X M:9[';#!Z"9P9QP.@T#%B>A\['&?CJI
MGYR<G+(9C]@-]U/!9@ \C6*'<ZLU:%RUTL>!BVO6:#/@"6=O C1[L)#S3^K%
M7N+!6@W84.H(OMXNF-YB\.TR*6"I&0_N%A>I,Q/(P#(= IGP$E](#DBRUU@Z
M@RG%)Q$Y'J#OII$7C.D#P,L+71:+!.0@2B;,"^BYYKXQCH28PIS S)&(D)5
MR*'PP]L:_A0)1W@W@HVB<$H#%935"DE(0"$FDF&4^OX=$-0#,0'6!6%P#)07
M<<R'_AQ#)".(GB!0!<C4HC KKI,A,XL\1ZP@EZD^J%:Z^,62/,#<K@#AG'H!
M( 6B$:>(,."T$O\:P'Y'L *%@%^ #P- !0AMB*Y %*;CB8; X?$$6!!G4.9B
M&P/ (<J]BVBM)?>1=BH&@0<NA_0MB$#&%%CF<,G2. 66!$JS$M#;54DL(CA
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M@@.$  "PX#?YIW>OIO\!4$L#!!0    ( "NNIEB:M=E<<T   -M"   /
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M9_?/WO[9^<7EU?7-W]N[_^!" E"0_G?Z;^(B^(<+&145!17T'UQ(R%[_:4"
MBD;'C4XHI0$RA[ZDYPG"()*&YU1W88)Y-4^)/[A-8)% ^-9?G_T'VG\A^_\&
M+/A_"-G_ >S_Q+4 8*,@_5,>"@$@ 5S;,^4&8OU?F85B8&%FU&Z2G-%[TT8_
M#[&'0;[ NS2;;/\$F>;+T%Q%+)@,WX6%5?XVZZAU:;>5)UM\@% ^04*ZB)#V
MZ[1U&[E7#&7<,1F88Q6^?@\)YA$2C4S\OP_PWV))J3]2=[J,D1X^;'P^<AF"
M#^^H>EU+WUI_6.*F -W3IG:?%AS8+914VQX[?;P='B$T-E2DWDO5"^CH>?)9
MV[P;![G+\E-9RGK/\7#U6PFC:A4#N9%,_X]<WJ[6*V"H,NQY@[R^ \<.HFOT
M41V'QM=1NCEH-A\<"+D\F#;<,%$S3*6Q!!SDCJ/^/$V8?P;&,BN>@>!_A;^I
M$NNLM<] EMC[9P#M7^&,/^D9P/P2^R =T[/GG#5?1A:XY Z'5O6_%$8(X(W6
M'7TR+S09L\)6$;A?C*C('?:^W1A]N,/%94*^3BHWLC^0F/^R/RZD2&AKR* I
M:=X#^!+H'9#*/P.Q3S^?@?<$ 7^^5)0"3+F1_QVN]3CRG.U9,#)=/C%ODB?2
MB![C"_LJ2S7 AU0@"]W_Y%/,N&#QAB.Y8M#PW0_>H#_'&.1W6//C_!3W_59A
M!O6-]=.TCJ*N[R"Z6C?&7NH^G:)GDJ\N-60!HO\.0R7P+]D_K!D<K%"U)'A0
ML;JS-[C%T]WWN+C'#$-GB1-L_,!V$W_'5*8*[M'.GX'>S7>6_8ZNUE'4^6:[
M]SU+>B:5WK!-N588V4<J/0T]E1UEA=\)J@H+;O*B-F>E^-XSQP9YWYX(J#[S
M>[YHSI8LQ=S_[/P=:7)^Q6B?Q'5Y?C#>:#AG$XXK@Z(U*Y+G[;LK.>L<4+L=
M9>LE.>AD)-R8)GKKWR (@?5"9UI8_KO"8XX+LS5^VP5AD:XF!ZZ%BB8DJ:U<
M<'Z'18K.?'W]FW24T/C%2^=&7A]R,GAZ* C&]>:ENEK1?N*"I8#O!&FPL'D0
M&<I'#N3;87TY,N[UL)S-A=9G@/#/KNGX;K4,<O^VDNC$B0XM#'H0%8.H^D2W
M_@R M9*T'3#*XU]*5XE5*2)=I(>![@L44.9PIY'*UNX=ROP)N?DBKJUU!&)?
M6*!(44^<\\2INF<6-A;_OQC1+Y=;:O S4.4>\.=716FO&P@&'D!Y>CTR^]3"
M#KC].-UX#-D'Z4'+&PH>L^$^18=I/6?G1Z.>T*P]K;U,K!EV444+T21#/[M$
MTEE!#52\7:YD0=!?;S;6@M_:)L8]E(GQ;?9+RMA-",D!\,-EP01-OV[#/='U
MP-!Q0H_E&<(6J47B(>SJ&;C[^^T9>/O:29<C2FKVZH'R&<B7?09R"1O^^T99
MJ7DKEW,FHM*0EESW**X\-WW)PQO>U5>%$U/AX3'L':/\6\NT>I:/S*FH)92<
MW2;8!_N#PEPHF2.U#$? *Z#K;\89UD6/UN*?!3:T*Y%>[!IX;&"U1IW7!ZEK
MZDM36[>_:MVO5+8:"15+C?;5C9>'C>-%^KN%D<00LYW7R)7&>,0F*UT^[NOL
MN$9I 5<\[2NF$CGS<-7FFC.U" Y'=H_H-]U]:J'[(BD+K/&L"OC'V@B0+N+S
M=Z3%"5DB0.-_$NNP'M&H3B]3/R$6MF/Q"_5#B*GGR^K4T>4?Z'WQ'I'JGH$'
MT/O3O"<",=!3X$+ $\J/O[KM1$BZ?2HU4V#;0W;:!GFGX2H$T<LI1AJE^O_1
MB1@O75_?4#.KU7 +J@_6&(^./55XFDG_//$ -RB*PG5ZDWPMW\09&BORC127
M)B7\SJ?MC9)&IU.\-$7GC00.F"K]>F9KWZ\N&_//)PHV!,V(I4G'44!0^@?0
MB_=.S%T*YO<YCN]:?;YV<U^\_LY*&MUW(P6"A2 'OKECA=7.>CC4!W,*"*VL
MK]/K1F.J[V\%EN[&?#?+^ES7T-)^LO!K>-96RL@[4RR;41"/@FLWZNNC_U?
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M#G98FN?HT+#]R6):TH_BW@[<@NY)4A40]PO\+$XFV&QIL&F5WL]\_^ +9V'
M$SW=HMR$_]5Y!HCL3M5R6$WEJ7HG1)5>?R3?>8L3\VX<)"4+#3%MG2IH47:P
MC9M<+HH40LXMO;57 .,T[9*#762.XNY+3M(T&O4]'.R*@LE71Q2\41R=ZJ(V
MSR[%V\9!YK)N[T]C]^E4KO]DXG%;D S1, ILO&]/WX7VJ280W;6/VXHNAO^(
M,C59J&.ML\K[?KB6*:XN_^D5<%A<J<%?=B$J$+! 4NF,JG9='^7TS;=Y,6IM
MUPP1T+X2+6'ZL^D>PJ.,';="L*WXREQ!D4Q)7F(92_Y^&NGWA#&LM5@A]6\+
MC"(I3&F^0Z%SKG7LQ,L]$\SB^PJVJ=[1//VA*72').7S#%T]YF#R7_+=]*"Q
M^QXBI'D-8X]G()+#<.#XL$B#@JT1'XFPX4\LTQ")&7+BJ-\YMY;*#WLNGUF_
MC3CB5(7$)?DQ?'*DY?1=,-4;&D-@_T^EW(G1-'LJA?Z/M98XE4F^\=XL6BPR
M9NQUGU'W]".::/WJ61>;WT>ZVWD*',BE^>:6ZCOLV\KH@PWNTTZL,'=)*GYB
MV7IRV=7XQPQO/<]5/M3YJ_OYOG6]8B#?&JL@.3#;,GY<<^9]^+I?-*$E3."[
MLYSWM&4+"&T:]U9=3F0<;4CY7OG*PL8=>QV7K'>]^E:[PQ[SK='L,&L3AT]?
MI<2K+><KQJ:.3 <\MH5P.*2EX>N,OL4%J5N<-R-:# IKB'K:M[@C-O=E_I:R
M7..U%/&QG5_-00A5] ?J)O*;;-P1FPCXO)5T=1QE*)GFF]TI8JK*'#L_@KC)
M??)Q@>6))O,L59%9,7/*E]Y&.KKW)B-U\2,7+#MZTKY15]=7?9]FW!H7K C;
M^Q;,83O3:7_H;%^8)SNZ"D$LW;AOJJ"25+]Y% G)%A1--/"M4F  =?XLCD/Q
MJHD*O;R[=P37EVH.@XFH_7+Q/QB+BFAZM!JE:D+5;?5M;>WZ%K -$;=F"]XP
M6E;*3ZL<W)G9\8NT**V% VQ0-)XWV=98@I26F<%-:2.:-_=*9TZ%+3+;2SF:
MVY'$TNI?%NM]R+7B]#W*2'-R?Z_59QY?98JT!M0BYJWB1(.'^R@?%IN/ L6S
MJ:+UG*0G.$DF*G-(V7CH>7!V3P]4+EPDZC[]J)6_%DNY>#A)\RH<_G@S8K8X
M9N=L\V]F/C^VIK'+:!+=;N.9:<6XRF#NB"4_=9 \SC I:K@U3!I@=$ )=$-Z
MQ-M6-;"P,^7WX*%%^TXM*<8C@6+L$=Z2:*3,+3;-)4+KPLKB*MLENAF5\'XR
MC?AQ4QZT6%F96\^,T93B5IY'>!$K-,1B&>.<DHT['8L$6<.*,I;692#,>1E0
M)A(VAO"^6GMI[&[OQ5EF"'%_3[ C3U&^5>(]+WX6Q<&E>-^[*PJ=K%P>\7!:
M-X$L\L'[V6&>,#GV])@';SQ$X)M4UA@9?SM/8]/WP]5JA%\L6MW:##YSCXF)
MX;W3$6%7W3?94&ZMJPF@V_FN,'H6LN-\VQ!=Y"K9Y6U\G8V[I12JA>]Q@1S*
MFBDIW-6W%L#B#R7QTFO\YO!J9:5.LS_<ZKY2;R2=,MW5M11O?3*O:=IYXY^S
M5?S9'JG075!M_'3_LJ;A6%A$>E<,YK<3*-+"5!XM+1O3FZJ[BU7(?)>.MY:-
MX\L:^9MC.T:GJ2UFR*K:+T(3/S""W#P\E'':^6#/\$XNS\/=X7/2),$6\+:3
MX8%X;%G.'+XX;7$&K.0V*5/$YS%Q4<BP-0QJ'J]\F% J?/M>0%LTE*(V/?V<
M5_<'?UJK2)+^3O"Q:PG> C@<G:)@L1^"'?,N*&LP4.05*^S-4^GX$&,:=H!E
MT+;K1!FY9[]>1KGT%JZK*MZVYK+#3971F%NC[G:F7JC(>S:7;XZY8O-+O(%N
M[D']6U[_\=AOWN/ONR[F]?\I0QG8%9A;'BPQ)I%\P%404:3=A$%U'V2<KD>\
MU*1POJ\9O5MTP<2\R=LRH_9Y^H@TI6'<UI(QFE6Z8%=57R,Y#J)_/=BK8W1C
M\?A@Y3Y/L5"*1["O:(<<L=X<MR_B1=CSZFEKH!6,%BCA%97Y>*<.LI&%UMC?
M?5W^/L+;"0Y=XD58Z!(*IN[%R> +J;MB[K:#O9.TF3WHOTB^[="':Q%\CZ5=
M$]@Y&)7LZE,"#O]4&ER92'%85<>K-WS-\5%LB2,(Q:JNTFSN>Z@3OC8L7Q@Y
M?]%8E[C M*9XK(]1NY,03W;0"2XYD*1*(!XUW+^)=_#\,\OEPSLF*C?-.!HL
MNK8KO MDBL3TY64C1S)E8Q6]JQ8,L!?01>R*M)TP>^T6>EGPW3H>58+CA"O6
MX1"1#!,D;'\%,5^\P6PG!U6CGS7UA\B;GF-L3<NM4\3Q7E /P4B&!@,/.BS(
M:]GBF ^)['';H7ZX&<4H_NPY,"F(*Z(27[Y9&Z7N(_GE=6%!0IT7IUOB:?DQ
MU^07I&2_S/JQ'J@_$?<^PY,=RCZ.\_4QJ74/=Y13)RI!U\%"1J[WE_=_@X^7
MEG^QN9W8TFORXD<W<(D].5.D LN1W9/8MP)5\DD7X@J=MS_;KVYRZNX%4<7R
ML;&^TR)PM=/AEXSINM0Y&ZQ?&MH7[<?I;T^[H&W<//35]TUK5$74FP7B 23R
M=OYB;>/,!)#H^^:$]$/@/.]XMT'57S(;)\2*4'+/OLQQ&ZL<3A^<<KE)Y5,T
MO_#+P@:G#H6@-XA4/+B:\T&#(Z5&9)%LO<GLI+I2;D86Y;4197H#T+E%#1TQ
M;?D]3SAVZ#D"95\@)R!O:Z,%XA2I?%"HB^H!PQC5VDAA"]CD,J'+56DU$]X5
MV>Y948^=BS,0BI&'A4&!CXT2=7F'-UB%]^UZT3_GL!=*@%6F*(0R#)=!$W4%
M&!D7 VV3$!KR#JC/@$U47APEQ5<0W75&"'F \2DWS/T7X!1@->>?D7V/TQ@W
MTM:WS3&YTH3@U47E#M,CR/8PR:GNI\Y2!6T;3V>RQW69N-!]&=I9(J;V5O\0
M?7T&'Z(.].K3,&QXU=Q.ZDXF6F;D26?)&?<7B&^D=+5%GJ^JLR-8F$'^LR-K
M0398O=]YS3B3SFZF/^R *D7>F(#!920\*N8^ZI#9<!:W0N^?.6&9J!LSI)-.
M$ ;!Z:-A)MMRGXV:AGN7VM'JO;% C\5C1NU,%+<-#^DC8\,0ZRM2 E::ZH./
MD/]E:H/Y7(2T9G@_Q/:^F=O&0\H<@$3^.1B87.<25%7YV8705-[WF)TG\?J"
M?YC:MIO(:D"W;^0\$T3E\\N@Z4QI<9_'\#%IF*6&2+\ #TQLLI2]!T]WS[('
M?C\-5=WS&CU&+O9;+UF<)]F)_Q.-FA^% 0-,K^%K03@ LT#-OA8K0_7.%\7\
M6)4"P#0U5\SI!:9H($?+B&= 4@X/%#D_68]4,O=Z,+SS@_SQ%B%S%T(&-^]<
M/%L=;?!?#DM+XMD)L*\#3!I?J)#Z:21]B'4/WM8V&T,4D>QT%5\Q3?,EF\TQ
M4O63G_QR/_V;<0R9>:M7_?-.=,JPU(+KUD FZ\?@TEUJO,8,YWI;;2)K,/ND
MA\$XD\BX;/-]0!W> WK@&ZOJ>CWXS +^9.PD5Y15_];+ \V!5TII$%D/(2%S
M>!]]LVV]W]XG*7J?W<,??I106HT83LOLB^.)G0:/;XMI8*MKJ^@OC:R4K8MD
M[PBA7;N10!,[^Z\AXQ?>7PY;#4U"H-1?KGX)L+Y0P(<(5,GE"6&2 38_=F$.
M5)_4Z/1E[ YK3$K;4V_S;G+":;C[!B5I,]M\,UDP157X>/]M<=(]9(JT[.=]
MC*G:U6:8BU&4FT7VP)_$&32 C0 @X^K&Q2 #'<#$O\\Y.CDAZ!I"N7\.=\N!
M1@[Z GP'.WY7TLA5M=5*[:A!"0\-B$/0'0F:+"V6M$E-V4D2)Y3Y2YF'RHMG
ML<B(_:/P+3C',P,M.KRS<5C;"1<V!BJRM>MU [C;BN.Q Q8T,5QZ?34-;&/U
MAYPGVJ(:)L@VY!!$U4."JD4Q+E+:E6U:5/FJDT89$TD&1/V -(2@4O4-MYG[
MG'7!M]XJ@1"/DOYD(\W! XIC73#9PI(E)<S[D0G%J/^;X[=MAGGW'9P\/'A(
MEBESA(4#55>FB*WN!RY+_4Y'"RK?RW+(F<4HLI$!Y"*$UBP)/-1=VB"SF1[:
MI_HSX\U[8KKF8-0(8F>-=X[6Z)*&/&O?R3<;%"FOZ0,%WJO6PND5V=GGZ9\!
MW8I7L5FJ0B4D"VB(.0LRIQXL(2'$YZ:-YN)/,E[7K$@^Y(U)CKP*BR&W\ 21
MB,ZU;1^4:7<M@[_M+L$%[:4#4&8U9A)7[5#LS];_U*,%'W.T#A3X67.(\W/^
MZ9?3EO/J]JURHU<E=]3]=/#HG/%COE$OXV+CR)R@Q908U,#PTT+",Q"6ERA,
MR(J(DURQ[5>G"A6Z[*3Y*L7YS:(^[I:#%LL)J9\G\- +#;4$!>M7$#8/]RP1
MTH2&\<29.Q_:6HU!!FH%PP"B$XS56V:QTP^%@40IM<LV^._?O7>2L0S?:K;3
M+NPA.1V&WGF*]6?C!D?"5C98BPG]? CU\RG@XUM<5^BE#KP^)$C7H8\/K,$*
M!_2POI5 S@E]7X8?'OY>4!??ZE\LQ7!\.AH.A7['!(^]"^0WE\015B7[54RM
M?N%%YT<$VX2LG]:&-P$;8/.G&(@(:7'"^#K^A\GJ?J9QXI:1PA0+#5/E2'3=
MI][UVI!Q;+]I07'::?:.*8%%^:]63:%,G4[K>7*NP^Y3VUUDQ[BV*$6YS2$_
M[!5+ONE&0,Y3B1+R@AJJXRE#E[]B8:SM"HD)E3_R&DRSL>=^U3IZ1^S,&, \
MEFP)#Q4DZ3;CU(KU-5,'N<BZ@XVG@_/'KK4(C%)2= 66:Q@ )I&."]_K2WZJ
MK' /D:+@Y=Q(9F<EHE0% PTIO0\"B4/^PRBQN/[%**6YS142ZBTAW7=0O>A*
M9^OS3WVOX8J>NY4*FT%92@4.I4L++H2*+XQ?TD=P0P*KFSVZLT5/A6@JT0!/
M;;W7SP"F0!Y'%ML$>[Z;8??Y((,<M37D(X"SRKD$.?>AU6ZD!O^LN["&LV>2
M^(5OJ),1<W>,Z^_FG 0AF%"*<YL=EOVT:W@[-5<,V+-N:N5?<"U6<8GK._54
M8E)4=_7QFZHX[\SL;*QGLB80OANW<?MB C?SZ*(1<(\Q! [MV[>_"XZ'[^)\
M-1O4&.2!+^%+$0V!FBP3.'8:$FU7[6R14,A0K12%1"\'-D'M1MD8%16YM8T*
M[.,0!:Y2EA<9+)/'VS:I C8F;2"SBKIM+R8A1VHY6>/<0*P?'N9VGXA,#;M<
M7R80(FAHWOV.1)QA-U:_"*AY+.L?(G]"%$\AQ7P/7);S7;,I:@?L"@K:],^/
M-MYAXQ2C"Z'< A)(RBX.:.FF)N4$,M3N#7Q8O =!^@V9M&"5E2T3/NA;A ZU
MZ?DYCUN^E<)B_U5_T3/0+2/\Y5V+'YEU_%"#B]#GLT8GBE!QC>F;-=\SR5=0
MNQG7VPZ=@A:?U0-/!/HS\(/RB0]'?,3\7'<2B60D#=7">6F7K._==;E##,D+
MY=[ZEGK]0O502][@H>;(Z! :B7?7FZN1:G^5 V%GT=GH\]T)/ \#B:PIZ#PA
M':[_$DWTC;F%_,^&B](O;9+JY+@;[YLNK[/G%E)>QR[*=)@WZ)XCC'U?+OG;
MUQF._+@V)IW5_.5"V6E65SJ494U)G?!>Y[?&@P34I] X+X$E5Z'?#'<-[R+[
MQ>I\@ZFQQB-LU9+QH_(V!_Y=<1_-US<':K4=B]=#"AP"-BYI9/[-!U$S;$^,
M31';\X6D;R\&&S/1UU\XN4=!CPY6J>R<18UP*BYDV%BW4:W1K'$8!]-NI<;Q
M,<B%Q^R!V3=._X(FHH90/EI7>% 4-K+0T>)D7MW$807?NF7B>)T(L3&?P_TP
MP--#QA@YF-7KWGG,<9@?K.S>#&?0)<1CD$= GQ B[D<SVF?$/8/L ;75OJ,"
MO3842M^7FQJ$UBS(#F!+X^B=M0T$MQ]6\-.DG3"XZSZ275)_7ZTR](D;N-87
M'(KA;JM.ZGN7>1518G]A[!V@VA9V)(#8MPW)IQ6-+!+6Z!HH]5Q8_MUF?5;)
MF*1F4! A/AE9(P!FQ 90S2<"^T%9!8 'X=S"$C)#0ZBDL8(, F]8")3Y=%DX
MN70R3$"U%GH+&L:#T!C/T@F4E,H7^:<J]Y%Z%@^YLY0&Z_='AA6"!H<#L%:J
M_+ZIV#N).Y1PY)Z3>*^HMT[ML&C'HLL#,#%;I-,_7++E KF3 Y"4#T$)GXU/
M/YL)4@L!\9'3Y>2BJH2CPK_R&OZ^<D0?':\L&06II4$V _&(B9XX]-G9*['Q
M>=[Q>"Z7]"\W;O6M7AW]I69"R<MM7HPA\4\PM7-,-B1.R/NNQ/-DA+8-12AN
M9F9 #5\)5*:V\7)IZX6J1&\/[-"MX>M4\7#YO]D)Y"O%.**///<K (UDZ+S/
MY&KNHXDH/7?0U7A/(0__$GC$..045-WJ?&CA*8QP5RYR($FM/*D126<9N$ ,
M-!L=5_63@T#_ JP?-&'LX*SAB\J,M]$\;R\(X:V$RFA70Y0V0F68^89]5)%R
MY;E]CXH@^'E"UU4_/\7!-2:VFT_Y6W@$/INC,G*7'#IOG )9OCCM5-<W'@71
M3MQW:O=5BAH_8^)CY86V7@$5H%!S3L^;&$CFIWB>[-A#*08I6D^G(O*[N^FB
MGE=^[XXW;.1X:)@+1$B'09]!'8I/^F6"=[\RT^@+AJ/(OS<O1"T2N1I4B>O<
M\,ORSV>IS3CW(NGV]E>SEC'[?XM3%(NXS,94"ZW >@8JVRXB1(I(L2&NDFC*
MON;RVYEM$Q5V6J8RCFP-K)T*: 7><\A-ZTF,^]QCQ:(SOMZ).\+!"HX<2?8*
MDX;]"M'O(K\(FKK.4_[;?DLVSR@GC8VEV6-Y5MBX,OIVH^)>9!4.2-!)DC@]
M"#O@)B=63I*\(+'29>G*4R\=^O-90R6M>X:W<C;NS[$:A\QN@Q7%-YR^#DS&
ML\N-[*GZUAUES'HRI\25)[&S-K;YJ$/.4-"/03SPU$K)P$99G5&$VK4O!HG@
M/6__V\ECV4^</T>"^C0D7YW_]9S4]20TD1L^WNKC9>Y9:]D*P 0+7>U%MKI8
MH)6[Y=M[*FTO<8\JKCT#+/WB]"G.[/0">RD<^:$!:8^&H7,5?Q/5AG\+GNGT
M++%@U@WQ>;=M";IQ<13*Z_2I]F,^ [Z!_&NG5P4=(S]<-P3EHA1YN:(X/(M!
M50// 'UVV^D2X7P?6JVH%;FD!1TJ9VJ- ,9)PMKOLF53,?&-0>:)\.;5%AV0
MI;D>%')-J9UHV%YPIS3>BL>$#J7GP<^W%"!#"7[S"@@2%;.$*V2UNPB0T\%3
MI0UZTJL9IS<KN/Y:]R[Q-3=UV;@&6V.5[\O@@Z3=U*KW(C.GC&O:N<--W_5W
M:7UZUUI3$$1.A:$IM:=1%'ZYQP#C3QB(I0,-.I6UQ:8(=0Z@8M]DH_\(8YOF
MYG2;$CB:(H])5EP<75]R-/9GV?[ZY8U'<R35KGL*U7+-:%\)XTQ)WX83C_[R
MC U6B"L#(P7BZ"<GC>"PY*8H_%WSF6R4P CD@X\E@2)C7%7'>NT).MFMJP+E
MW3CZ"/_L)\<4L"N8=BW2JJY[9X$YN"8"7V"&# S^SS$SK_6XHTU-0[VE.7&=
MM=!U X;F5PS&#JF'4[OW,K7>$^3&7WAHVGQ6"HPD@O+#WE=E7)?UXZIS_$WQ
M"A/120+'JD'5!S:,A$[R@WJ#F3:][!H$QG6NB?<&QE!F M%/1^"AD.AC.FZ,
M;E&WV)X/-3\DY!SO=BHZDB@38Z78IOK-8A7B:A_N@X[]KL![.OEGXFE$K)"X
MP>;5YD])2VG</UT1>A1!PH?NJL_ E\C.;DO=C'[_-!(09[KSZ)(-A8+P7B00
M_8G;#%X3(B%+\)*; 2ABP7\&,$ /;[3ZPAPGQ:K;N\6Y=\I[A46^D8RY*0H_
MM&B!S]CS!H3FN16&/P@HI+0][K4Y I9G#[6*/AM&"HE(C@B;E'44C$5MD:\4
M,*ZB2J3+[!=V>0M]-B[VI2O&A!%).\(<%)Z*)W&*_)J;W=>D#"J(];<YO4&O
M62#8VZ>?HWIC*E2N#UK]6?S2_JX%*XR1L0W!A(5V2_@I,YFFZ./>VC$,N@S@
M"]. G=QPA;%\,Z>1^%*IOM>L*/3?GPB0DPFC$MT7^&,(B7H174XZ(3+8OQ<:
M;":)6RC367_PVVULX(Z"OG/R[19)"E4TP$)GD(O^$L T!,QUT;K/Y+XGW#NN
MJ%LB)T[ ?F\3/PPI,?^*4!OD_;?!T(U7Y%IYQFW8$0FMLA4D'P,T$[+2F:15
M,(5YE4YM2RA-JN>Q#@89;-<6N5*E=$'&BG@^MDW+B<#'7K]?31+82LVQVO S
M.&+?SO(E3SZO;M9&&V2VB$F">&5C.CWPFSM&YHW&,G1V.!94%6/H[/[U$?4;
M[Z"HT\>6-JH-+A3DK;;UW+65620'KXKNY(3T7I^C)WIX@]&2+!!/YN:<B5S<
M_8S4M_Q\'8Q3M(T&^8F2!0;)/ASOS%5G5K@3NC8S+Y&\U*K#5&I@,ZL!B2E@
M/Q)&2'R<[[F*5E)/@]886RWYU@J%?5WY6]EP2-&-JJ3HQSZRDGHJZS$E)H[E
MZ1:^$$?'.1W$CA (L+3\;7/V.K8WV"RV\!D0'([N 4HI:"T*,<0W"P EOA?O
MV<ICH*Q$<0(^K]F&*8&E1R(+*A;9B0J2(P[D:C@&F+T/L[9HLFQ@0X0/688S
MB>BS3?KKB-^S]J%[,=)X8E(;F2OT5?K*M<,8L0B+<YIA5)R^;02T+B3= E4=
M/1E)$@! YBJ)9+LJ<;DM6P(8Q[A2#QCH:4Y0JN5R/7R!/P62?^80VE$A.AYE
M>Y>/_$7U7U28XO@QC,B7UM4DH@%EN\+YN;88.R<B=N:A[\8V#UM3>HI5;^$D
MD_@UCZ>DH;?? GC4-@U4-O\9T+H2MWZB=($)IEL8SGE(PFYS9R=#R(9!.N)L
M 0G%<(0[@-]H1SK;+%@&)3-O]D#RU>E>@ZNIHA=.N2*4<Q6NC2[>=G]S5=JP
M0E,=[-"<2;:=N+W46H-]]+GL\DC;J4W*N]#(YQ"2N2-L0B0]=)'+<NP>'S2$
M*_9+:84Q4IO3";7">4ZV>=,6'N]60C[FR@LK(D(JXDBQXE_2TUSHOO@5&$=,
M;OSQH=57BT9N*B/;IB8H^N==KOJG]-V8OJP*:U/[6=>]%KY!5PZL^N$\E\%@
MGJ/ @&4Q$9L.YMW>7D>9(N-O$4H^&B3O6CJ.*M+7_*=B?8B0*J@2VF2QI"/5
MN8QQ@V!&%_1E'"'_0O!8]J]-D7+8@_AF\*GSHSUU^X6[/2U'!\6=1<Q,&?+W
M<!3 %QX_)J5NXIWCQ Y)=2#7R(''Z=A9J*=)NK09H<9V!@H?[$F^RIIO"# C
MD;#Z=AAH)E/GA/(#.?<-2;+30TQ5U[:%K7H@(.C\#(Q'2!CFKS!HL'ZI;O).
MB'*@90V#TB038>\FG!S\,OIFV)#XHBR0XO!ZHCR:08BV\$D\4GY7DNB*!LOP
MO0\W@CYX&0G]=9":5ISV/P\N=O?(.V)/]68B]-4"/<\NFA2-Q.K#Q8AY4;@S
MVD.6?6-30X0G3T^U03+9MOMXUC%N^M:'K'^???TYEY/6/S1\6/TCBV0&0%;P
M7_0+BMK]9X[H\'&^6L?$G>ZE[B@3[>RUS**S$M6D#]9Q6G:8/DBX2GC)^$2[
MI\!GXHQ_W:A4M]1%F\?V>!+]XM@><C;IP<SH]1Q],\V\26''IKEN9F85*T^8
MDH<$FUQJ.&0&*$/Z1;VR<5J56?TP4 5B\[F#5:?)=F>*2A?\+]]D?!'TW$HN
M,(ZZHLZ[*./[7X_DV664PS2X1=HF5$@^-9O'YA6+R<E;!'5=$GN6[+^JJ$Q^
M><1V^RFVA$*X<]\528AJ!- .P-87"L<3(R;6+AWN5*QO#%XI@C**[WS_:]^;
M@FM# ?O3^7T#I17*_+B:C'+W<2.+,;SN;WZ"9<*T'&Q[6*7J*[FC )<"Y9KV
M=6I%Q:&6XLLJ_'0%B)QTFXT0+26^U B@^Q[7(!_>(C98LSG<>RBZ05;%^7BL
M* %[ U7\YT^V"V]I1EL)!3&>_)S#;3R)KLD/W?<F$S[)FTV('*<36VF0!_5T
M'"8L- V,XJG)[*F^Q]\;8;.M%:"2<3F?8]FR1'<T5T5:VPADGS?H*5IXW=Y$
MSS>PM16GJL@X':?"?I2N=QWC),0@B'!U]19^2OB/)HGKHI$",V(8YK&+)Q)4
M8.NGG:Z>'GLSZ:+R1<D)/2J)< MM+B%/-DQC#MY@HEA?5UMDW0EV2GR=T[>#
MGRTFM9(>?7UU##YQ6J]8R%DN>=7(0Z(^X/;K1!A?Q*H&O-/PV/@FXFUE.[EA
M+=VD\Q5Q:DS' KT %/8>[0]?M1>,'!@BCG:0.PFCB"/3N73!J"&S5$PH+#W=
MS\#KKNGE?)_P=1N;SO,%B39)QC#G)>CTA=:^[TNE(3$8&F(;4E<>AE4@1^X.
MPQ.EO'>5#3LCR:#J'6^KK,!T/?S@E)/@Q7.,P%P<!=F_/2/)/'^;MHUNTE;'
M@7PL9-)'PW$\C[!%<KS4SY[\>,^<_'.N@:<*8I7T<_);-#+BSY)/\;WS:Y@/
MD3"*KP4J[GPG:)9H8D-%&#YOF= 02X3QGF<K5@!ZX8;W[K*HLMWL7#H"7/T=
M!?X2/^6UW.8_;T4P*HP>^"(#??3/*F\$\8DTI@%ER+G_I!B+$0X'E=@VW-2N
M, EI.U7Z4'(4W0\IOO.*7_]O\((MBL&Q#[7"9M0;'M"**QFAL#&Z,/7WBPTJ
ML7?-"9TQ$MS157_-BLS[1D)IH9DJP-M,\IKHC#R_ K8"K9=5YT%F?]74_FM)
M)C^]G%K&2FRFF"XOL*8=261/O!*)D(@I,/RF!W-(TXDV&FQ>":Q)L(+[L$CM
M=;H,UMFBI'_KP6$H8$OZBE/(@$GIUH&7W!E'=!H6=:HF&O6QHHR"J"H"#DG5
M]5P:X_LZEYFA5D7%,D*$%"$>PM;H=M2B4Y<(=9NX]0G@8@*<QY;[087^^Z,9
M!13D>>Y,_HE0(PMGWEH)P<W,!(_C[*@FGSS-$'?D-2?JHLG0YJ\"+JG\%^([
M^CBK:H; ;M_72M%XHB3/<T2L?R8D;I%%S]LE:V?K+"K*HKAX+$20[-M2'_-<
M"6<:A3@1+Q=FXA]!I]M&5[2/I$FG!D9\YP);I@/!:K0!O(H>)?/S/:*U2W)E
M /K[9"O>*7 ]H/G[H]V/HCAEAX*PL4:!J="8SUJ0;1\R\_A9<&:ZUL_J@ V-
M8OWRSA<_!1V<[H,0H,]00^0=PN%<VQN68[!K/_5/)<(-\I<?W>6&,IIU46TF
M WD*3\_)G7'J(E"]=!'DF_I_;6C<I(Z%J3>IOR<^4>*;V%VD!2,FYW.AC8\.
M\)ZKS1.)QRM#0=_H]OC>N,8QMF^OLL$2W)U"EP,'FH^%.#6"&=1S$814/1C^
MCTPHZ)RXINT)]17+E^Q4^0Q,;]43!EAKW:U@JI-+V&[V(ZMAX&;!42J+3#M"
M(Y^W%A]QPW,4Q&Y-TUT5*C@;I5\D>2A,Z+3-F!&$V) )7S_:J6PI3-Z6T^O/
M<=R8(4&0N<=^^@+]3:>+Q@TE="V8KP^5JA-4Z5R%S<>$S8I.BS*HKV?V7D\5
MU>F05"\F9)*X-!FAFH?=_%2:O=BX^&)J[U.4ZTS^4.RS$?V;^JVN,[$RH#9U
MGHW]:*3@I"M$O*.]0/6Z^W'[(\O<;LBHO*$1CL .N4WF^1Y#4R+?%SZHHX[.
M,@Q3&%+-6&]R;](4#;G8F*?K%C@+%0^\*2;5"=K,B!7FZI\@6N,E1D#CIU*!
M_KK3D9'$V>!CU#CAQ+=O \,_'[!2I35!)$YCA2BU=3]3M\&VCZBAUWRP.9'D
MYN0<-L_TA[8UZH[?D]_"#99)](=HAX >%K%_N9]^(>SC*G8$_3/@HT\@2?DK
M)NQ'I2.[Z?GVA\PYZ_E/65<VPW@7%Q?^XT)]Y"=Z'TX/OU;F-[7HIAZ36R3$
MB0+O76AMLK% [<X3DO@+?1"!V#Y>5H5PXA1T)%I/8E;L$B!685]$<T*2LOWG
METHSS[2CB7K$W!GX;9\?)*U'7#].3298K-3EKYPS=U8C8[)R<P#CW^%NG7]]
M@E&]J'XY?RO&?5 C.!^=O>T;],<KD/$I-9R;IRBQTJ*>'*H*-@ZH/9 DM^F)
M5[E.L6F5@;IC#]#IGV;W%^>AB %17CMQ]SV:RX.'2?8$<Z31XPEF^)RT7 -D
M_6.4EQ5BREHQRD$%J<PFTL>/<ZA9*=JX"EN)U+]-Q3Z_]&ZH731>5!TM)=0Q
MC:( L2@@U&,JF5#XV\!T#9&<=;_HOKS5^B2/%L=+/DKF*B_Z4;P>8DJ:.D_(
MZM 4AVYKZG$N?B'7U6'Z61T*<Y\ZT.V+.%1)6RI.SAV!0!RWONM^\+WLWJ*!
M:LTY<*\L85 O[,SHQHS(9DBNM%D&Y\-X>'@S90&54@,J>=74:?$>6L2A#>5N
M@<W/L/F-C_>2%+DM,2(2N[7'8Z;+8@?&8_CP/)["2XH4+^R@??D"ON7%\'>%
MWFW9GDDK O]"7PE#8.=$E)%M:@3Z>BQ38*A>^NDLA$X]Z)L363\"N"G^,'Y2
M7V+=WKX05Q[^X:6DACXJR[SD+67ZKI?&GHG14@\%3]M$&<NQF3XRJ.2Z]'Q_
M!CY<51YLD,G-DHNOS+#6&B:$4 %TG8ASI]B<CAA@PN7)HLX?;C$7M+>E*/'[
M<C9J(:=?ATNPAHHA:0(-AN#SIN_]2M%S%+4AL6J4>LK7X8K0G;[D?EQ!O"0Q
MWCT50<\-2.P8:>*N?<-_K?QL;*O3K2R[BU=[2N6MTQBW?5D[:Q>SQ>5'[Q5^
M-CH4'Z+&\=\IP39H!P6%S3"7!.!-YVX81W 3V?HM+[D 3M=S*VZ!=9B<A*I]
M8=[&"QP!LM>)5A^3JZ2C\LVEV-S4I&!+UWEFI%J3JMF]$5]\ZE(7CW<?K5<"
M<'Y6:':<#IDJ\K[([O@ O^&-ZGTYN\A?8%,JY67;R(9-4(WT:48C/5!>6MXW
MQ85>XE-X1"PB9PZGU]=]]2(;.UJ^Q\E?;#IXBS'K9W0*XD^"6,#\V*:Z_36I
MI]=8L0&F9:J-2S-&O!EWZ5KE^G0V[?7)KX^LHFK,T58R]%$)V#P@U>\1[JAE
M+<)Y5EW"NJAF'GQ(Z/$NKS-CK%P$1.>RWW[R_0I,G1Q.J=?Z>7E)]N+_D=NF
M#<88HY(L X*10+27]#FM3215/F$VJV]O%U%VS#K",FU1Q$1%4#65)HR7Y2"K
M]19F'086B;1!F1WY0?&_>#BQ#7]MP_EN<<<8EY$UA\O=D->P<R_[ @R]'B +
M/C_CT#*PH6\G%3E42;%)46!NJD+'W)H_P^N:-B+EVV0-I%AC?5%"^_O(&-,O
M3R0)1M;_Y#<EVAX?9\?)6R^_9%H@ P9Y\$#V6>KR9/G4Y+7RR,*,RJXR_AGZ
MCBNDMLXI_8 70E)H1,9KH]7!]H>)>N/<<.F^%[JU9-$VF3"-H.GO#YSX"Z];
MQ"Y/I8\/ \&\N-QQ;ME1EC:T2*E U9U*6V)#XKFS;47H;]3']:I"O#5$F=%?
M3XS7D;I-S:D*D8YV^H3$,FBFP.:.^&YS[D7O@E.^H-HNN>&\\AOZ.%4,+1B7
MJP*(2F1J+)S-G&9/CT"V14ZVB_&K$.3L_(I\#$7,%EGY\=6J>IQ>2CZZ C;(
M#F6;#:_(E*7^))3=I2A.-]5[Q>1^D/C/?JEDO]!]"'S,U+Y_MFX*RD?C&*6(
M84$KC.3Y>.P+7=*NVD_T(G$SZ7MS2V S;#UXV&?2>2[Q"BA/A0B<E80/GA!U
MK\MP4:3+;P>JOK&X*MQ[Q6/PAP&Q3A01DA++#=YE9,U<0R;R0U(3!T_.(/&:
M  6#9GG.2^@; IMBPGM3J5:SX>793?7!S)IVSI!H'>VS^CO*32KA/J@D]K<>
M]3ZZ..6A^?S!]16I)G,J= P42N'=2I_"@&YF1YYGP*[I7EG8'?IER2U' ;'<
M#NR2]X_:C_2%LSF>%#4TP_.X(,[#ZFLG$(!+6)A*;.^@<J^"K]J_DFN"5>2X
M'^!<V3I#^/S3/'' .DD=J<.;,3>!_CC')6$KD^Q$Q'%((333=RI@G;AA2&%6
MD-V]6=]8H'O3EM9FN\>U[W40XVR!4@>DVN\+)BT7GR-")E8GA/[K@IR;5\S4
MS'_B<+0O[ZJ7EGHHRP]SM!/)<+4@FS Y7&]0U#C:@;)5;3T,U<8JVI5\5/\^
M7DN'J?X;YLG"(.MW!WCK%G#1>&)V*=0/HF(Y^J^;_\09Q7LW@J1<2_/&!6UG
M>;T&FRL"#9B;X%AM D-^HJ071/U1&-B8J_"@*(_=E4#A@0>PV*_AFH'/E"W#
M02L\QA'XE9C+41S> &Y"98M%><NWBAZP*4MI#<R"3F#+[Z;,P>M?"NKFG;:]
MVA-R?CDV&5._>(BW^ZNN87P1@;D74P&X7V<2-]?&+LG[8+3@4.2<ZU=NZVFU
MLBDN4=ZL_8[/-OF9192:^(=CVK_L1E*D8:3(;I0('T3&"&N;&5R2WOJ:R"/C
M2,NUWB[>,4T1+E-*KN4>1^R%74T%O<S&=<,#E79.C/#IFU='<1.S91H50:IW
M=\>*J%C\!7L8$+8%=F:<E*6K+>&5V]H>Y$,OL[+$0ZHJG&340U3J?8XIL+(S
MLJ-'8J16$G<UZNHB?1B;HDF6!0<%L7/OX)*4#Y\)FA1?)_R8V+$=Q'S%P-8W
MK(>]U2CA149&>1;96.1MY\AOX=5!(GG^!HE\-0F27OV!B\<7Z>2D)HEK@#::
M(3J]\C0G2,0?NJ=ALB]P[29#69'"X!KY+>HB$[K79PCTO"+>OE\MZ!TBKOYG
MK[&_+@@G#G'2SW]R"R'\]W_WA6VE>KWX6.;@^L$A?-CG@P5"H,$;!%#CJ;(:
M4B3O?(6@<CQ\*I>3 @L)B=G>FS1'*5Z'-[QL]#R+NK,.Y"H\_35\K6$XXD\)
M-R2^YR%3>)\$WNVQ3*=TE:^@_ZLSJ<P V\ 8Z<#TSF%:.V'K4G!IF>_":9TM
MJ6AVR8[V N'F7 O+T;0*#2R/D?7-),[<+9S/B'SS@6_$(I?C&5\^^! A!=&$
M,4Z-+8#A$&8H92X&F*D(-=2IF98;V]?,52B7$\1&[9N?^(O<Q.*"_29=!)WN
M? [<"-CLL^;9;1@D,L!183S%^I8QY@H<V5:>!ANL-!PR49R?_9E0L*BHSP?8
MUD*EP$;DE<3)5.&_E/(M(!EYT).%%M3E[1\IT7\IJJ?X<1(.]<Y$8RU+%2:V
M;EA<%:XWRM619(G409REMJ2D>%ZB7"7PD[SDHSE#_1E^XT\]E%RC%#")5XB?
MM4]C(8>- A,J4%&-<(NXMZM(%\GKDBAB\AA"B[!D_C]\DZ7ZW.I*EY"/V;BZ
M)HR:R>&?^XGI+KH'=GZ<"(["N-[$?*?<;==)DYPN2CW*1'!FDL_:<G_QM"-.
MHNEUKSO?+?G#VI ;*'3?CGZ^S0%6QIB4$^2AB#Y(T7UK5IWYX*SNWCG'K3O3
MS;W1?W24^+I!86;'-OXO1%U#B(J'0N)ZM,50$H $\OAF_0M>ZJFH]YWL"I29
MM@E-9'B6D]3-=0#BKMUJ,.4G1&UY&W^ "Y9/(D*-5AH2D4G;*$+!2"$Y5LSA
MI@:::?5E0HG)DFKYKD@[]44)(0!C]0&+FXHN/50*"*Z2@U#B0WZQ^;Z^U)07
M&\U 6RA&JDCX3B>NQ+!& <.JVJW>:+EC0HFK/?V]W-([1NGD0=6+<QTHY?0-
M*P]?30@$IMI;" L]/AXNW"K,$803.8B&ARN^) &C!)UO'IB8$!V#B$O_^CXI
M5)K5UX3_8EP0K>C09WE/=C^_4(3ZD"=\6?+Z]"EGUYX0XTON:97Z\<_F'F8*
M_[3T^R"3:*+$0&A+8L3K^C1C,O,H]&:_4 @>MZ'9?KG\!W2QVA%;;U/U9\ I
M;F'@0V/F6;*/<X$>0?88)67LYV,Y=Q,\4QRL'"*60**/P,=LM/_\HI+O>"0"
M38>F&C*A1-2>'MV_*]P?Y(OZ!J7_?,B@:3(2V*Y'WO5!\42U[?1H+G)?Z'*N
MDL2<7K+@MVR'M0VJ339=T&9Z,?&"AB09-632V4/@?6U?\Z>PJ(Q[!0:%M)!+
MN=V%TF5;KX;5!6D$K^LQN*D^U>Z;$)Q"7,,:<G0LL6*_;YN-J_D>UP0\1L3R
MP^4Q79.W"7M4:VCOZ0_E_>][,D[G>@KAX_*%21$1SR@0W"#?>C&K10% N]H5
M_]TL"T!].^*A5(79)S9D!(^E7JTKO#QOQ%_>K_9F[P95?8BX?#&P993LB-:&
M+/GY%WE$[7U[Z^F\ZM^K/C'ORN% .8Q^OCJD_AB\Y<6Y=R23S$7FCFGI><UO
M-5K1JC!1H>FX;[2YO3\_TD4;CG@];(K$,XF/U^ F4U9ZHY!73D8"FS0]27%=
M6Q1DWQ%1<4/M 9,W2M'QJ[EQ7EY"1*D_PG[D&S4Y.>9R#4XE-]SZ: X&^A]^
MU92Q0?%TJ,L-%-[C^S;?)E%JB"TO-E3+."R,IA?L<Q#,*O)$,%3BE.51Q#%9
M!;,@T>,ZI*3%XIG;RTSAG]>0I$Q/I1K6PV.>,F_[<J+3:*V>7:?!]-F[DZGS
MIFN37_>BQ_!+>=\ QX]=6H4%B=C:+0%C2FPO&J[.M5DG6<!-D/I5BW?!N7DT
MQ^O$/W6M@6R5^1P*NZ"8 H&[7PO*EI$(''&C <.ESJC65'2-'>X7?10@U;DQ
MAE:L=]@A0?"50'"CM:UV&P,ACP A+B!$);0W(E.RP'^5_)6,^<+B4Y:LA\4=
M5N._<6J\3>_TXS YV'MUJS&.!D&Z3C7@RG,,\+'9VOV]]H2WO4?P[L?8\B22
MJ=Y.WB8<.F.J846A%P./K/G_Y-(:@VNB\GKL9!V3?A#_(BL#W_V2*>!-K&W2
M]4W<TH*:([5U@M&PIG1>PYKDL;PH-1YUPO@_N91GDDU;)WHEGC-:A]I.I*3O
M^K$R+V:4HB_AYZWDQ_<TSK?8VC3@^-;\$KB"T(N\3+@",X9T;4ZVV#.A9 ;@
M#)KI?XGE*6_$BR"JJ8K%1Z*T^<'/7PGW1P_SLN7H=1^)QUR:#/<&@)$+ZI3=
M0N\]HX_J(.$B;]_]A4?GHE3P_<[W8B\W7OQWSH[Q_:-VB1V4'75&^H1^UHV*
MM*F:@XLW<J7YG(Y4V1=3J7O%V=A^R_1^&0;.A I?A(/"'8_1!2WZG&4^)Z1!
MU_WN6YNI_?H'X5RZK^?6^UG/7]9+=J+B=M3__@=Q>3;LY.I%/^<Q8X/RD-D(
M$"70^ZF0]W%-NDKXZ8:*N:\G"9WUUT4NCJCJMZZUNC'&<S,)K#_%V;A*W2L/
M]GM$W$C$J4NW3GRJ;:W(K6DY)S?N\(&NC98%IO^Z]HM<]4DY?\D^E!M;F3X<
M$AW"1>.3)[0[K^+R;V#3LNSZ@M \U\38W..6V(3.QT5I24I/QL9-W8I+YL)I
MBV8! D.I'1+](-WSN;?:XB!R""PCD'\Z%J.+'#V-;:*+^C9# PG%G1([/N@N
M%=C*&7>)6_VDR[6X9+@H5RQ8R6$MATT!SA8",V:E3UF=CNPO2]6;],CC6LI%
M^3A7F@RPO<!.9-P^&-^L\-1.2_)<BIX;Y1UE0DD[8XAW]X/R_K*@6DN=D_Z:
MH==OUINX.PLN$M;0YOB(H[1S?322+F4)VQ,Z[Q9X!IJ?)D;1E:GQI"(/,V:8
MYK?,BK,3K84 W]0*E]*YY4'ZQM90 ZQ0K$I,!&]6?\QHH/"]$\O#7]B+OAJ%
M#XKS ^_9@%#Z/(C5-QO@ B8THNB3MRQ>9VE$MHWCG81\V!(<#EYLI/*]W@N]
MJLR,!+9(>[QVEHQPX'*.,LY+XD8_6 >/%BEW9S(*O7T]6AL3-Z8<%87<*0O9
M..@]L(D!*GW<W4#O7QYUZB JB_7[N4)9@6"1CZF\$:\$')%H)7B"FN76HWN\
M&/F..%4__BYG?R6TJ5^1E[J/W_D]D4L#C_+3?/\SX*IG (G 5H.4$^"36%L$
M OLJ@J-?+657@K;)-3+?4V?6(8W:^^H\CH7';8AH<[_N)<34&R+7 7MN?/X$
M<T5'ER#0L3C]/=)>D0T;I <W?%'#L$*V5D0A%HM J*J15PY& D.GC_D-OI\B
M^&L629L29;_JXT>.*NSUR1A^UY!$(\I@TL7.^1Z,T0]N!]B)_O/F?S*[=S T
MZ[NPY24>GZ\P1EH\1;>R;3HOK=DT]Y5LMG_4>;GX]H9[="#E@ZZVXR5.U#-
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MF<4''E,X)J>J\P,9J\(YUG?[/PC80+8-\HN_H/V-['\&S/?_%;)_ ?M/7(L
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MF 6$Y/\<;,VY' HZ5C-41?[V=:^%^^"//X=P+":&!,")HB0"!$P7,N4]4,-
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M AN' >:B,U!K*&<NDE,QED7B3+0[_G2_0D,:K*"^3#$7+TMG/*')H4"N0LL
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M>4-;?ULSPFYY7DLRY8+#.;J?CG$-[W>@*_^@3S^EA6:XCU!],B:P>'0BXG<
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M;8M?W]^J?PX+V-P?O%[S]&T.HY_HW.^''H;$." R7?GKW"*72YG>YK1F@,G
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MNQ,)Y1**32Y7]YI^M?]Z(=&GN\IDZ=('R]R/13_;F(263VM3SV8J,\5@3Z;
M9!?9E+_?I]+Z\>%SGH:\;&*>3D12]O2S-%^/\Q%P_Q+Z%Z^0.#1EG?A+S289
MB<1>IM@\@7\0$/KH<@J\01FAP<@P90X\85AC0BE1):"Z.720XV_!G#VPH4/=
M(0FS'JROET-CL9OPNY?+?@7$>+USB+IJ[TFW^/W9]%NN11S:F)8P$_-<NI+
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MMX>%/&Q9VH*MIG*H%ZL:[9V+41)!I(/<LKD.8949G34=C!LZ>X]EZ(_62Y_
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MQ;2#!WT97[AY58L-GG\C2Y</S@[YQCQ$7V*#FG&L4UY&L=" ?#YQD5XHI-'
M$]$O'"LX\>8 S_?G>QX_"_"HBT$6FU? !.4!%P/SN#ZDCA-#FU5Z?PB5:#9,
MK2\(D%M*!0K'C-(PE]%*U6QP\I<#N&A<?=^FH(CN?9851H"L)WCA%$8!-@*2
M'OJ8^4RK0FL^?2C D:7[4.M=((>0EEGF?- S<V[+GVCT>,+<6Q\Y(X;+!TPZ
M+[G/Q&<:/@&>M!X@>*[5,)AS!3S;ZGN6HO43GXP+$;^6C6OK99Z0;0A=AARP
MA)..5*9/MCK!&BS\6<[^/H.O(PG/5RA_E4K)^#V6HOZ6YA@&81-M*-3A?&E
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M";=>TH?[T>! Z3%K9/[4VK3IX.S'"O!LN]O=F+*">XRGXG#TWL"3>LF^"J/
M@?&B+^4/%#9_YB*.&C3T\Q:P5*K$:7H[/6AZMJL@OM9+TWGS\6!W8#UON>9Z
M0=_]7E)P(2EC[?8+B^N-IE2#.T[<U=GW18S+0R.F7R(PYH+8ITNX(/(;NN /
MA8F.WOYK1V#*L\*CGH>:NRK+^VCMYC]D8N1H30^7%";NS_ZB1]6]H\^9]V_T
M#+34#S[.FLZKW8RIUB%W2S=UZZ>1#>>6C5' 59=O[@+F$#8Y(B(+2Q81L:&5
M, LO^(,<E>%#>V;C/E??"_%5XEGZ*+)-.ROL"EZE"R*GJP3&*ZF-8:Z;S<Z;
M9\X7M>(=.%,)YHG:K$L)#AO9U*I:YEB/@*!30Z>K/$7B6C83L\@N^N% U4N[
MW,X9_OW 9PL(1*^#E\/2,\I=^@9;I1$V9J.$W(7UQD\6K>Z/ !ZR5O_/0CYY
M:38X#!O4)HEZI<.BWC%-4E?$_G:P:*FC#+W#\=\')>/K6+?[\Y0!1KK4V^-C
MUIED_"M*AQ:Z*BYP!F#8!--3!8T/=I7&IO+OS7$F&BK28;AD;YT*MS%0/&[=
M)WX::+7]>@H+?)#IH'X$U)P^ @H03?N9G3-( 0>@K H6N4?XT=#KA04'8RBO
M$O7Y]WGQ)"6CCW\,_Y_!#$I>26_96*D*<?N%R&M/R[[J'^&273O9<T]V0P94
MYTJ;&I*06-YU@+ZE2^^XSTP)\^>P-M/GB-5?<(/L%T:1#I^R4O7>@3UPLU'?
MA3P"U%4,?6^GS9L2%;:5R_3XV>!.O02RMU!\6SE;-<B.4>[>\WE52M?E%?DN
M Z[#!!QO:P9W8<I</-N@^3OYXZ46^ O%N:,Z>3-[U5=2PO0@>NH,(_?M)JMC
M"^*CP@F@+UDJ?RK:*Q5EZ%X05 B-Q"@T]IF(G^;S] &!G&7A9CL=JX4W*6H=
MJZ0[K*)G133TK&+WNJK2A,JCCM759D&*&3PJV[6Z(GM90C2JR3YS<[6>[B !
MR !;G_U!S_H6[:F^(@WS4FC0@/A&D_"8>N!+O0K9LF60IQ+?$GM3WQ1NHOQA
M99C(1II1B )ZZ2/@4].8P$MK!LVB*-YN%@K5-'H@%#41_6<B+SHH>$*N:E]'
ME*C.<, -3 \G0*8NY E 8Q(FX1\*V>(T=3/_Z*FNM2/RO=<[^._&43*]C9.9
M:KSIH ]ONB3$M$=4R>0S+3P-BK_.=6^D2M,%J=\U=0,LLL_Z?6:FKCH0[\NI
M8-,?IA4 41[9:;A:A^/+?J7BQXJ!KVKW#(IRL6//DX9G(,]^= V 5D(\@/2Q
M/I3NW;OZ=7:9:PDH>ENQ=%;X+I.;]9R"@"?4F$PYA<(#5&=;Q_Y5,G07EZSC
MXU#*@D\6#E5MT0Y,$@!QB-?Q^Z^\QM$U/&\Y).=Q@E9U> N34J_#1:W2.^3?
M][=7TW=',BJE'3S82UF+T7B;<L<E9P-4-9KIVPU(;EIE<>%"!')H\ZX,=1R?
M@8[DJ2]^.BFM!)\^#S2 TT17Y=[I7[M6>O>LQ&%8%.$G![D&?< !DE6*AG]M
M]3](?018M.84--UJQ1 O,WC3GM,SA79]EI0G6-[G:2H,)*RO9T4@HY#84?6]
M5*6,7B)=NS,W.O#(WX<'17#(R+@IMP@O@^$\/2D:TOYE+KK(@+H*$Z1JHR-D
MF2&6R2U6A"@IU0G[KF4997 3DF^W(6<H#!; )$=EI_BFB,((+1% @0/S JM!
MZ$7$-TV=$I_FJ\F9PBETB=<L'P%Z$W'\KA/4*ZR*X'.<FN>@:)=+[%UWYQW#
M:)?:;_F4KTU)S>3Q&39S>2"=^-&TK:G,#O:')<T)1:8<'DYJ;"^;FS!?A6-*
MSKY.6T>MM)4G=5C0SQ*N+DR)1/O-SBWO==LY@4CW@Y!?U)<O[O$JF"<117Z3
M(15B#XX;E<96ZMH?WJ#:K;=%]# NO67PG0&%+/I#D[4U/+B3H)MFYV+U04_U
MZX\99Q!AL_4+@^.<%N&KI)!#2^BSPU%#U-]XPGNB4QC1P.:V%WUHB0.L<A=>
M,^;R"="LY,T?#B<3FS[?G^3,U50H;.&H1($Y##08VGSYR.(V!]4$LS<OEP94
M?<SW?=9'S,%T?DJ4ENN0A7 7HY  RX=#+#*-CG.P%+D"J64;/ 'LM]@5IAQ2
MV[_DHB0\\45\-GA]R3-\V\N!BP$>#+1*9@9<0ZH*T78*<1.%MX.N7]ADYA8[
M5ZDX^M3Q>\6'?+%7/%I0<T%!B_.8,(+\LJW.*ANHT.?X]N830[50I5GH7A&D
M4>M3#X3YL_0_;TQ0'*XNUGM26B:Q:_,979QG*.<7+-N:?KKTM,C01NUY;1E&
MS6DY<[&%I'7C8.X<%CHU(_VR?^"WF<+@/[N[Q#=+OF&$6KJZ:@N((5=WVEC2
M-->6 Y;(5,A&BGQA^>JJK0%QL3=:52?P&0T6]6J 1B]:KK]M8"W(](S%Y!&P
MEO((6-^[EJK9#9Y5-_+3?!U=Q;A)_J$06'R-"W\SD/(LH;$I7$)DB&A>@4Z%
M7(D"0P$E)?A'Z.3,L"#*C+J<XE\)*51F=T07;^XW"RUNA.$2B>#1P(OXK29.
M/DUU=7ZX0-$*HB5ZG3_!/-QK90:UMJF61GF'"JU*?T;,TXI,*L<C,ZP34645
MW6)4,^/"EO9EC39UQ?DT9DF)-E$,UWU_<GY\FW^+?+<4[#AQ4WMHMD.F4:];
MJS <1W8R37,(467ENM[.NQR$[9# R&@LX0OR%V2DXH'G YLLNDATF3Z. IZ<
ML7[7 =7!AY2A@YV[B6.A[8B3FJ[N$^ C(!?T"/"#B*<_ G8R ]?HJI810[8_
M%/,]+8+P?&>(QG<T.,?J+3$%W!*"R[OHVLS0B?KE7!$<I4ON^VQ&%DI.%0$9
M.V=$"W8OP,&,5&H_[I]97F%/C!]_-I<T=$]4'?C\X'YY[<&U9$8O>*X\,1NH
M>'73[%BY42%M?S _\8"USU1>4?N+F.+K4*%OA/AASLA#!*1>Y^4A]KH:-.]K
MM?MPT8_V^8_T$&%=>\6R#@@WRXRZH;VKD-._)P&>L%66V<,L6UKB%7"5C9?/
M #KO1%,;R_J9:J<=D,AT*SY?-@SG!:2:Q\[R])V^[7PN16L8M8!KXZ3B3]D4
MLR47?V=(?>&^A\%6P0205P3@G;"S#;WA1AHPVISJ85^T+H^4*93NS>4!6])?
MXA3^AMB[8R\_]X\LM95D_#)M8K,P)OZ%\UH#0?\*ZE-+R;5NQV?<2CZ7;_VQ
MZ$NNK\C#-'_Y<&\#)8N$$,&;/@L;:JPO<_S"-33J,V_AM%G)2D'45DX_H#XW
M<Y#G</Z&%SY<)+9ICCB&B[N#8""?(>*]4\^Z37_ Q^ &:PS O$+!WN2^CY;0
M17<* P;KBG9P-\8ON^RVHX9,R00QN9IE6: CS@]QGOJ"C<.J]$&,29^Y^4^P
MCJ&?$KQ\SZ.^AEF9N@Y)P5@AE/#(L9>!I"[%>4X.S=WB.T0:#U1"&@N."EFU
M+IU\>'@2F!>5#UK>3.:;V3M4>TQUP3-Q'+H2,\"[LVI'?WN;]CS#]-W/7MX>
MR74X#1\50>BS&VO!@S ;3HX?]?<CW"$ 0KQ  -_<'WM-$?R$!B033[IZ>!()
M,P_S*&.PH.29X!?1\OUROY;^91G6[\%#"P@43<RL+2#0EDG=#Y[+>6^"B$?Z
M/_ECS;3_R/.@I+UD$#P9X[E?MM&?, %LUZXW3"*G59M57+>60R_D' ZBTT?\
MRCZ0;&%\.2M'BDM9E]C,&WADAF-6HT5L>_CQ05\.C:G'=3?-'8%"5EY!?/G9
M&/)5?[OBR/L>CU@?%4G@J(%$215#^@@R"/C(57B6*TAYPY[6?>;&0(UE,0M5
MF/WIV72RF&G=?+O@GH;.>^N:I[ZKA]'K.3=&!!6L_9#K7M@XDQ"7_/:YX-Q*
MO*1L,/3$9T<@P!0=R_X5W/!3V"PX5:D@#F_5PWFB2<&DN4@J SP@,\7AUA#G
MQM='Z-PS+;Y(*H-)MA)V'21,2E:.X*#V=]#E:3R#<%ZP1]@AA?&TJ*H4JOD&
M&BVY0HM/BKD$.C/'L+#%QPI')D3&I:^;:9VG,]N*O0+\11\0VTH_T@?L+WY'
M-N5:K IN3.=/F#3T;ALZ\"DN417V@=_RM%:Q7[/&75XQY5\6A7[XKD5FSC/X
M,<&*M[$[OI+YE9+YP&>FT &!+-^?6:F=7[_",VE?GU+VEWDJ&O!F>0]BE([R
M[$)*\4/!G/PCEKDJODKFC2$OB+Y::D.X'5?-3@<'J$3$IT[P,^"2204J**F6
MH4/)'3NGPT59XWH$%+A8!UX5EX^ !4$8(8G.C]J.4SHH"V/I4IL+]&S@I_;G
MH^2Y$_9=QJ)IQY1,LJE<FAPM"XL=IZ7Y#E7E1"DL?E?ZAJ8=^VTS-+$W--8G
M3AA@[QLU&CXY^[,6SO561+3X-R,Z_F)/0<E'0%HV\8"?55E[1PS,+HY]^G?6
M@?.WN=$M27FKC]DOLD\$LR_.RZKNV 3BWYZR;VND_ERUP1&W8L"Y[?#" ,O[
M$/C,>AXUS(G:]W"G\=['8IJ?J&$1VZ0G.RFADM%+7'V6M/HQ>09OX>-HO8X6
M'951[-;1[J>P$7X6)*;!%>'6"/W<8-SF$=S>H=X92'D<O@DLM<U2JG60^J!8
M;':)]PY.@'*Y!4R5RMA8P&YYI\NRM"NH4\\P)1NEUD+ 5R]H2A'%D.C:X'Y6
M,*U45YLHPF'V@M\IVKV7YMPLD81L!RWWZZDN\V<Y,C<5+"4K>&^&@<.O@RJJ
M<-)PM!?QZ K*UA?H&5_H%@N>:FDO**<LYC33;KYH/A'9G(LAU//D(^G--)"I
M+:Z5T]@D3)GM<$U[&CR$=B(MP#-U(%Y>0#Q<SB/O5!2K!OCTW(N6N5^"%4FH
MQREM#73\^%+!CKK/DU>((14X&R6>=&CK\R_+]K^"GHG (R!!9__^UR/@3 "&
MZ#FNN8/ 37\K/ +R8<9242AVNC.E#;G#X\/"JX?'BVK#BF^Q>4>=AVZPXZCI
M..H]$@$[XTM,DDNN _,"UMK?D[1"N"V]F,*^Q:O2K$;=^P^4_=;&OHI]>ROB
M+TH_N?IZ7?'\12ZJ_P>62KTG:YI)&I/G7)*,D.V%]VC#,2G+)!5Y,L^ 5^3]
M>OJ<J>.&=OIN5UI\7^CT41B^D$G(2[!Y@;[LFE"W-L&7>X=2<I:WBLR+4IEF
M,ONOG,N6]ZC)Z;9Z<;S%T[]\_O@$BN]34\MI'+3/7%9M?2O0IK(U],HDBGPK
MQGQQSV?L=H@<(6??M2F^UXNS@+(\S[[7_TSN<&QW,D6QA8VAK3Z@?,7V0M#:
M?IXGXF$]9S001?L14%O4LJ/>V9P=.,$O:1 @F]EB5XK0QS4T'*!IK9'*,] M
MYTAI#QP*3'>9BD5VOI<B>9"30JJ,U%P=35L@?)1<_!KO6F='!-KTLI!U;T]>
M)FRQH"B42MCV$<X*M7EB:#N0%G72['_O-LK99+&$U0W"-M.69<Y9[:JJ8-8J
MOA<01>5P-5FPA)SW=1B6=DF+-L+: Z_AHY3WK]$DQJP6/O]B_0]][_)2G.-.
M6& 7+[[E@? PAT\ I,BKN:2E/5Q#4),V0[:+*CU&IFK=GNR#@:'_6 Z^\BDU
M<<W) \W1A]G(TKNUN#M4NOW!DTG9[7"T0P+KSFNZBKF#&__[;_(B%D$AW5$[
M(OU\VIU?. -WBDPS'@'8/278;9YJ#QVG-N;EC%70J(V7;X[SUDE+_$3K6 *K
MC+DW>;])G='?L]G=/MEY\)&[SCNJO.%,N4]!^Z6<E@MD<[A!N6=;&&YOQ'9G
MGHE)JC>M.=_T3C__4*PX&SK[.F_WYG[KVE*1#F0I_);,'-VK%+&&,*FYX?CF
M<LOF>NU>#GS_-;?18%^Q]JM82=/[/S&A:4K$.MM4PUPM_/S>0[BE?$3)=#8P
M[8Y@BRCM/L/7[A% +9J<I:!XJ)#>F6?P5Y;$].I^.F/&/7$6'G>[>:K0"/^6
M>1?XRA?/,43I ?_XGM-673]JG4-@,U9*O%+1X^=,]?3OW)127;+^0)R6E\6B
M@>0VS$R I$E7.?I'0*7CI>I)!9](#3[HR*[)#F9;RSC;-\WW-C%F",TLOJ+"
MBTI$PNXSO*ZQ@=T!EO\)CC9 :O2@G?2CYOIEP]K-=N 9O6%*L?QU)FK>RQ5;
M\I2YO$)^'6*/N*;UGW1/<S6'M$RRK5-%RMW6<*LSRH=\J8O]Z4<]WU,08K$,
M:.0K2*X7'I4:VSWTN 8JKY6R"'=H84BL.[#VG"B^GG7W1M+BH3F32+\4_N6D
MP+0O=W>3%C[E^/JK@^P''1S1$?*J6A;AU>(W:+@GF%6/ )(KNL#GQL6SQ?OL
M84%>):Y;%<'0,M10G?,<'K>XB-:4S F)GN*V/%Z/Y0'Q\TJ=!NW?F_0E:,\Q
M13#B;<I@@1OC^#>;>8-:C4%_M@M%_YF_03=N,$#\@H.\74&OBWI4Z12?%W#1
MO)8^?&:I+X>KMMB8FU/V3$=X(MT"[W-';Y[ !!Z.S\MQS.H2"+M8=JCI_@0X
M9$X%[@GADMBNQS9+'@Y.D4>7_WZ]#T7-]#_9ZP1'662>*#K46+QU_Q1PC(M6
M_8,$S9'1%1H@/J\OQ_9T7'G.WYT]TV@TSYK8CNH+W+B:3'-L@FR#8_(8XH9H
M:N7X 4&L>G:H-GIW([]$@'^S;7=A2'%R>U=70]A)1)S+]FI'J8F_MM0JT?*J
M<)0L<JM@:3&K*:*"?CA/O*Y<L47LZJ82MNG=W0:3XVA0S7"?#+"NR#MADCT<
M]7D0MA1TNY(8*1W23B_FY\#0NFL^1O].7G#"I(RG +_9P_#ILZLLJZZ9[KW0
M=6*89.!1X'\7M5.?L%TF0<C%<"\\YN'6PJ_'Z?I 'O);.75#N25X#L']NB%I
ME#>F-%QF$T_68F.JO3( PA**S5P0_']UVD':UQH]WYH#]MTQ7!LQDAW0T2A!
MV+5)GVOW_L-%_R/@6QHQ")5K$=HC/D1FTI;AW;U>Y5^]]!"A.H=_!$M+M1KR
M=1;$\8/1K.R@HIVO0VL';M#,CCX0 C&FXV!2CB331X^ (-!!D>LPP^QYV+3Y
M?+5CPR7<NM7& Y<RB+ UEF^"RJXJ!!.6KV@6 XPA9*V  I[JZ&^]KZ2JJ$A9
M=L*&WKA5<K<I$=2SZ$A(%^VQ_(I*IM1>N&$N2/C'-7X:(-[DS 7@0*Z"0234
MO9+P.;YZ9JZLJJU.<?D%U^?B+JJR37R;R+?V_A5R;SH-W(F469YO+ZC+$0[^
M59ME60$1"]5?S^OLLZ?WZ^6FV#(GDJ8*S]LR=U&'Y,@I?])L-4C=^Z DU_Y<
M35X:([\ 4H#);F\V;5_0T"@3_Y8;\L&)+[<S1J^D-34FQ1!$&]0+;]>R8Z$8
M>=5#2!G&<"A"^1">7'1KU-PGL1+I9LQKS'<K.^;FV+ JT8.<P%[HDKS32=&\
M9?_A5X<TPV3'&CF=N0D@K+'CRUGU(-VA?1DZC7HFE<,D(F$OJ?@(X &7V341
MV+82(:'LY8S?Y 6L?V&=EW^-BDA_7H&NADYZ5V1=2B3^\9,M94B7BX*K-IG8
M<AIA:Q0VZ0\(W]!;;09?7,U?!2$R_U=W.?Z_!?B/B_\+4$L#!!0    ( "NN
MIE@-(/F"R%(  /)6   /    9F]R;7,M,5\P,#4N:G!GW+QE4%S1NBVZ&G<+
M$!P"'5R"NP=I(+B[NP3W0-"$0&,!@A/<G<;=W5V"NVN"WNQS[MG[G%O[5;UW
M?[[9/:J^JK7ZZSGF)VN.V57]LO"R#N#(24.D 1 (!!C_?0$ORX D@(:,C(J,
MA(:*@HJ.CH:!38R#C86%34'X&H\83$7[EH:*AIJ>A?\=/2,/$S4-QWL.'D%A
M,3$QVG?2\E(B<ORB8L+_< )"1T?'QL0FQ\$A%V:@81#^_SQ>.@!<%& >+A,>
M1 W X8+@<4$O/0 E ( 00?\Q@/\]0'#P"(A(R"BH:.A_;ZC# >! \/!P"/"(
MB @(?Z_Z_[T.(. BXKUA%T=ZI6*"3.V,S_$Y]B<*C415)X'JY#F8T]0E"!6-
M\#41,<E;6CIZ!D8N;AY>/GX!R?=2TC*R$#DU=0U-+6T=73-S"TLK:QM;5S=W
M#T\O;Y_@D-"P\"]?(^+BOR<D)OU(3LG.R<W++R@L*JZNJ:V#U3<T-G5U]_3V
M]0\,#DU-S\S.S2\L+FUL;FWO[.[M'QQ>7%Y=W]S>_?YS_P]>(  >]%_CW_+"
M_<L+#@$!'@'Y'[Q <)[_N $7 ?$-.Q*>N JRB?,K:H[/*/@2L3^K.E%I.%7/
M"4Q=)M$(P5P;;R_^0>T_F/V_(Q;T?\7LG\3^Q6L)P( '_0T>/"X@"MS:TF<'
MHOT[C,X\BN?OC\7^6F5VD45GMBT]57<75'\5_2DA3W]T+;1$?%-^54NVH7K5
M'^%C^U+LUV#+CVKDXF-R:2X"$TC')*%YLZ5:[_2[P7B%;K'Z!":'F(KFXE21
M3>$T;UP'*>7663\1OY[>JX5NKBDW>577>4\[2]N@C[XAA\?SZE= 2VZC7,7&
MA^4G#5V OW&1#OXBUKXM=GMHW+X:H(->@R8@6\)P3*0E_3,;>KZ0YW'.M WS
MYS-%I:FZ*:]M*J8BT^:@O32?S99-[% M1@^E /0.W37I+PQ]Y_@*+X FFL0]
M$K?O,\'.P07B\\^GHJI\[YTP]_&4*&H"9:^'8NQR/C(TX*B">Y2G2PIZ>$F_
M&B<#S__'C-CU[\3D'3P_M/A*P9JADMZH&4#CGRVB85]W<KN(\(W67TD,'M,.
MZ<?952^ E#0H1I9$T_[&0R7RX4I-_GS)F; .$Y9-';2#X(&2%5W39WYE'OD"
M5(_VDR/OB)'7WB>DUSI#A&?HX_F@'&/OCA4!B@*N90/5H1OBDU/<! MK5"&_
MPX]#G//($5O'GRCE[7@2P&56''J&@YY"K+GE.G!1:0![Y#601C$K^E4(5Z2F
M9%G)UMXDC K_M<0VYD,:/K_F>,60M$\*<.3H]*9&>^2L5IZZYX>JR\A'9(($
M[,A:IF^A84PWS",#N7T;.DG\H"^=0A2@DP\72%^]BW_93.N.8T!,:1,TQ10M
MV1,B+Q;E7^D(B :*5K^="E]:.ER:6TV4=01[J/^(OJG"BH"PQ/A2\&=A!;'A
MV7".FV%X3G+57Q"7Q:<-!)K75_97Y*G']U-01)E9SL3;Q_X9&B:-W3EE:HGA
MTP\>W(K8,?ZMY]'DF(G?E/U4SB_4G!JB2GK<C&%*](0TY7UC:J<8@'*X^0)H
M$7(>W-[Z1+(OT1!8^EKCHIU('61HWYR=B)$[]#[5E7UM252Y_0COI*R-XV-&
M/.8BH#[,['@<<:CSZ3)XX'X.*V\CL7'JVH%C2D->$'7#$\\\&>_-907Y)^/<
M)\;HT!9*]^RC)('0X<63!"*$4'GRX^7D^OH1T/,!R\UFH, X-T*0\-$N;DSC
M'J5<A56QCE&/15TC]#T>EPXRL85#+L;-MFDCL1]!\>CF51G$V]RO,2^1BF:I
MGSWA"P_2)_VKP?&\M]'=^6%(\M]^1,8>V%G8<>3K$F/MQJED["S3D%V(D5>F
M4$=NOF<,"1,,0Q+8#182)QCY0C"&?THD*G=U9!0N$)H?R]+BZ1$$V0Y1"/6D
MZ2<2*>G&<TTOR$<5MA'=T#]4.="$9>\I-5H?[P66C=BK,IB[K-D;NPE]GC C
M4T;V-"M>M-64.!W;Y7<8<Z;B(\,3? B66BNR,A.NY=5"Q4]2T"1PVJ(R?PYJ
M,!#MC!/]&C<]E"*,-C:WR$KX?HG-*ORC@D_6@-FA6%D H9?B0P])J18N+./V
M0A?B&&O0-X:[O9$+.,< '??765B5 Q&'D8?$;?MT\=>%U#,LEMX)M/H=N_R\
M%F+&(!JZ"@2W<H8V,J6G5AL7]U?<I:CVQ>9THTI@4"C?,S6'HHQ:VH0(Q>HP
MX='@<3F=GB_,8+]79%9P>T#\L+@!4$;VF)9.]93]UH#'T6&NFJ2,GPBP=^R5
M>8L4K#_\<2*5B>B2+S2'3DT8K$B^ !07TL@_)ML^@O:$L13?V35<4(0&%*[9
M<![$ZTHW^<IN,LQ&G#'4$9D]- KY3B!=-'Q!I%4'05_ODF6**UZ]&KF\*W^T
M<O3N+V<:/Q4A,Q!NBW?"F-.SSY)-T<%-BV]V*S 9@FW%8?^CR-(_41H&=$&\
M"].5G%+!4]T<>Z.1300:!W=:(@U\9%BUH 5(L8Z4KY/E'?M3]GI3+Q$_L[I%
MDUO'33:+ZIB#M"_**6[Y.IKY-Z%"8]DG1)<U@O/W33PU6#^]4GQ:6[_4BEM'
M\L)<IOB%M===;PJ5@BH"-JB2-%KB1F=L*9<HS-G9&Y>^U;U1>UH!91I*T\/7
MX_4M?SST?%JA:)<K;\I+7=-?^A9R=:)!XB[D;5)33U? QSWDA=W-2^A FU,D
M?7'L;3KML -PUV*^L8]=7*81"00I'[:!9K@)&QH>W&B]ZUXW>2U0LDP;R\YL
M4ZAC7-. GZSA&VW,5#_G*AN=!GVZFRI9.TST\2EJ;I"]DXT%%"&6?"J?Q\'S
MF,[G:_=Z43QL]7K<"3'U&BOAHVC1C3,\J-O7_$0'JA6!3GTEF"MQ!V.W=UJO
M;5Q46@YRC=>479]FP!]%F]@C@).L&0='4PXICN\8@XE_O)&1*]J)BU*L)V$M
M7\HBURN1R3D-_>FZ&2RF=NJ\3PS%"SK-$*"A+>T_6LZBS]CID.L)("W<OH6_
M:Z584TX<G@I9MUL:P_&8V0N7B?QBE!.(X.=CZ.&G"EJ#YJRI4SY4"!)$&J?%
M<'Q*P[J^$)(A2L!2G PC]V=*OM *K:A[&'P;=$JD;'.I*T&$I[)C#/XDND!$
ML5L3WOUE6N7J)V%,#]O)KL9[?MDW"HS!B\EAD%-Z^ :\'-F!\KSY,WJAZ*ZL
MAAD'%@?SQD3W2S.#D>$KYS0W8KJ4J]1Q.#O"2MNDZ57F>5[".,GGSUCDZ=NJ
M(UH[6]:=Q&#7R)DEMN *;F+6\MTJV-1ZQNTRSS"NV-SYXP+ZC*.?%=^ +G#M
MGL)C7'RH_0)@>3\6ZN1X+%73D,4&=M?KKH//R6?3:SW;;.L>5=9&A>:^/AQ8
M_<#)<Y%!0^T NR"*=AA2-@;K)JDV39M60=?Z!.GA>LPXTD[C) K2XO#-;^[Z
MK.%;_WLA,"!,QFS+AM!AAE&RS4\U;)]++<Y6E+]MK!VY'.?2RN;A=4Z2*/Y9
M#:@C?Q[X^U =C]X8O;MU&&U?8G9(L>,[)M*C04R #XN3H8NG <2N![<GD+-0
M-]^*)7#TA)*&@]U[I=P+=1?E'0A&ALF25+V5B\8,*A61US&=FZ*[HVM_A[(Z
M6$9@"GD+FHC792VX>!@'X';2T:3M<5=L*F']LA.(Y.6I5Y:\M8/$@:@)>Z9,
M/'$G IO#']$">=BX]<A%>L]8R\WDO1:8(&F!$ !+</OS[]E@9[0^,$<?;A.[
M2?#O^0SQ\RWEH-X-G6/2D;:P75D#I>\'>"9F5*#91CIRX$BIY;>K/T^2@QW^
M+2A.9W=0&A5^:/$-#;^F&!^:F) Y;@IP+9=]/Y:1TF7#XD[4'L?)V)GY(^M,
MQ4:^4(I@Y%4WG!0(5^=DZ$PLT"),4<1^B[PDM>:<)\>A=-&.T[9$)(LU9?-$
M]QUNL+1R,9EC!ZD8PE;P6J# ,HOTO HOW)1%TO$5%][)^-#1; #&S)J?- U=
M2H;VX7(8\I9^#P5><W@'KP!5&^ZOE:\4>KD(2+$K-;[K>T[EC)$9B(T\YT+.
M-B@'GK=?F?'H]'3$HDW#R+8KUL:0E%3^AAAFDRV%,46ERH%J$D1_E4/:[I7)
MT.W7':R/\ NS/&_:K,ZW&=+R#74]>"3R!&J3R=KIW55\GE,G7O2;\'#MA,5M
MGRIN[?)T-8TCD\&D/C+F[:E\N]KXEAA%A.,;7%2%0AIARH_]>W+3TJ7PLH%I
MQJ^.IEKN'S;6\D1BF->;IR<@++T]L=ZBS6$0/A4BJL=BSG[B,:^BTT]DPDL*
M-1\<=T+36U3?O=VL#[<Q+JBI0L[T 4Y>*\-LRJFO GU=L@TZ IO#9.BBA_)M
MS+34K91'[]0SE*8:6-0V3IZS\HWJQ:SB[C</M9=%]/X$,KHC?]> +W"=+I-=
M QH-S!33+>M\?<%A')=,$'!L'\=K.W/XC,A<W'UG,?(= B5(W+T!!_(L=013
M'\) K)7M5<>AK]E%R7= 10K__P:@/4V!T^HUYJ9DBI.RO'8W7XB#D;E';)],
M2KD7L4D'.:2X9!/[U=+!!<_@SX8&&&_LF]HX5V?.QF5DNCL3+6MA@;V(ZWMZ
M^/'V#:9YUD<IX=981).VL$6'Q)FFZL!V:\ND+#3Y3Y+EML*B.O,G-[B?N@Y]
MF0[.6#_DZ'$**;]O-D./[V:'1^_S)#DK8RXK-7.K"WVC%9MK'$R:#(6(;,]<
M@W9A(DP7'U;+EL R8XF^V@X6<2.!81(*D3)W&LB?PAM+Z@7J(Y"*;V_CD;ZR
MK5?+Q T_.6JY39'AA@+K9@U'!B?XH%W>9_8+%E@PO QFM\'@[5>S&.W,->ER
MS7<REGPKT@*>Y/?1KXY\H D_%[EP(;?+B>J>8?#4TAX[;<E](*HK ^Z_'DXV
MG0CDL\LZ)#$F;*0/]75>V]!:4=-WW?+!>^;;<)_8]=2KZA_$#+*D#P\B9LL@
MYJ1OS/H-AK3BP^F17=1GU!UP*2,S;)99*4\YVI<YD&BSI*""?7_:SC./!3I\
M 4W ((/7Y:;#>A>A7Z8=A)*\RVF@.RE>JR$53(EN8UB]4AW]1$=3K7(1P$;N
M!?87,P=M[IH_NFJ*)W0QKFY8?E\F_%&8NR>P;@B3BGX'8:K.RV= :*R%0NGG
MXA18):ELS&T@70!$9;"3+-C@!A_4XR5J=$%143;4E%<8M$"33&V=K(!%BI(5
M.R;M.GA#INY)LO?EE'LJT9&JQA]29J;#/&Q*M#D2ESA^UV!DY'.ZGX7]KO4B
M.N+-I-L+P+KD=(+ZAI/W'G>9R@8M2R2$%1T4:<5?YCDO),,*PZ!B2;4=MHQ)
M58M'8[6(J3>)\<C<,^C]FW*P->9YI[*6W@@O#(]Z3T]0:2I#V#*&?.P5KRNT
M+AVK9-, PV;)3\G?W9<M]NU,DC)GB5 I+[#(]YX8F?2CO]W,?A86GBC.4<W*
MH8+?0%23?F95><:(F3K"^R[);D$<%'BJX&6"=+M-(UQ=FQ)'BLW3B^,WUAEZ
M/$\[(U/&:5L@,S+7B.LA>OB0]KE')?*V>G_+#'-"3R8[)W@]\C% !=QSPXAJ
M^D[0$W^55_=")'O)/P<7E"+_%=STP$ W( ;W48STVZMH9<Z(,^LL+,ZNI=N:
MHM_00_2N4<LOQZ6P*!*VT5!5;23LR&T<\3T$3<<"[XKN"EN?--[7 69!ITPH
MXJ&1'Z75N>+_V#W7()P@9TZU$OZ-K+U[)MXAA\VMM8*(?V\G;[5.C.XBL+"#
MC3:B%^B+L55G=WB7TOT[8EAAFJP?IRYN\] CV.,8IS!":8@H[9E@<E*,PL)N
MBY*P+O1FYI8^STQEIZYY=TDZAA7H8"60Q^-0@J\J(<Q@F3/4D5OA'HT[C%U$
MSZLT[B1 '])!D@7'!$><L5T??5!=6/ZUW.N,^@8FVTA,CCV7V-<U_Z%.SX[4
M:ST4\H9&'R.CX$B,[-71_4[7P7Q-IT\)OI9N9(PD/)R:(-77,.FM*T>JV*GB
M:!RO3.6I9'"&KQ&G6M"B8TZ-8(A]<ZZ]V>DUL-6&>F:8*05\Y,E@F&^OX]7O
MI)$AU2<M83<?OO7*01XVH;NHB6F ISK=(BJTNG@=P>7+@N;;SGIYI!F50_@-
MB!Y._D[4R3^&+!A=Y_-6PX%G] 8\0[%$V_*>/;?79:B@$+D.,+6[#RO+L=;U
MTGF?A"<7:VB85^6,%N,I2V/H$XB<+VV7V3[G)_/--U6[W-&R:GJGD>G6,]3*
MTS\V/)HN06Q,2]B?:=(Z"YL[OG>-)O@])IB3JWKL6:K'(R0Q2AD/A0J0Q\,_
MX>_?TBI[E-QDR.%])7W1:Y;7[>I*QF.QYKU"2!\8VP&88[GX:GE+ =YCR9M&
M^&M=$R$4]O/G>MV"2S$$:*\3OFPQ H!OFF6:WX?--V8.>UPQ,ESS>JSSBC9@
M=^EE/&_)'%$Z.GCXBXKWV8%\Q(]2FPD7"H2B9E*A"J15\ [I<L%,P<&1+L X
M@FO:[#CJ4=-82<6:I)].&2[Q3%F.#,GC@L:P23!H!N=3=C,C/7QP4F]*_R.M
MY1J3W>?\7G )1^M/2K!S(C-IG#P.S]5XGF9T3P9K7<W#^[G-0[7<IZH-/6D5
M_,AUZFV7'E9Y-J.DM7_DYY80@W.Q+07-C&,%6SEK*8LQE-2#Y\2QAM/O=!E;
ME4_9#DV)PFXR2O/H^#*O6E=P.?<VC]B2@_%]QDG\P.#)5*M$5E-U?5L435,H
M[7OW6(T^,0M^Y$-,P/OZF76>Q6%5X=GT@[>3DY/''$9X HL(]>'09Y^'C(:2
M.9+QK^[$7 ]@5YR,S8VHXT1S1Y@8'+MD5PWA%M^Z%<'BJ(6#LZN3,Q?*E5Z<
MB0<Q>]P[V>N!S8(L+'2Y^4?Y0EL;5-4X65;"3>0:<SV6K"^I(T+\ILCP5$$^
MICE*!%X11MCY>2RY<VO6$7-\O4665^T[I2,"Q>8$AMA%R-2M2!' E37W&8[1
MLDW2:W1G!-CMO);+"Y S0 #=(D.GSAH\U/Z\8$4PY46C-G/S06330,O;/,F4
M4WPG;-V\:,ME[^<2MF'=U*08(K[*_T^A9AYK&I4;&Y0=--*S#@BD #_+['#W
MYZH:HPHR;!"4Q4*0$L9-,@(QXGQ!ZNVPNLS[U^8O0$?#(2PB:A-3H^XHE'I5
M'-K%0^DA<A:MU?<I4/.TP(=KE?7T)J8!%KK#* ";4!25:R5,I/-7:#\ILWH.
M710]9Q40_9>G(ZQ????I8QG93/1&*M[9*F@Y?E4M%G?&E:L=?)U[$VZ%29OO
MOWD=&H?9:=;*!%EW,\1MS#.F*HG)4ODS/J4UHR=["E#^>\>L1J\/Y=<%'4P%
M!3UG:-/$MQT%>8GE/OK<%I=<L" ^0F\;IPD7.)K@S+VK(Y2QTCA#[X,E0C*5
MCLZP+%;6GI?F O8-XE\ N*V<!SN=%^"GA](C.K10?FLAHW=M7+'9-R_()H58
MHB"QZES>/#(R=IHV7NFB6;^X[]:!>Z4:_+$;Z;7S.^:R*TY0(-&]ZK9_>T4+
M:W,*Y;+N^!-Z=<"ZOEN @YWH->O@"_#9>=8WFDRWLZC3Y%;G<1%6?OQ3>]N"
MF:!2D8_RN4GIMQRK4JB;@=; M]$9VOJH:3K;KT3PT?G6.__I,C'@7Y3W_]NL
M2R<O\!:6DU^ ZK.6*GC]TQ&_GHJJU#,/X::4E( O) ZP'&<'9EY2J@@=H1VT
MH37=H [C/:&[)_KMI,L7P,C+P)/UOTUP\JFN] 68:*9[1NQ7'X_RM'VGDTI<
MMLOY/JZT66_'S9.(<6$,+R=ZDSQ53X:KR?]8PM>MH1ZS,CF83PR)-+@Q7-]Y
ME"SNV>CH#+U\MRVA//7HH)2->;NJ]2M"$-W'+MEQTN]0+&SDZ8LRG^U3R_B>
MCZ/>^<N#=B7[\XBX%DQ7L E##O48C<_]\\AU3@<"N21CJ9@G;1(#_-(/ ]UA
MJH(X+I@*.0YR"LU2^.H8]-D1P/]$=F,C=&IQ[_L&SM]%"@6TVF:D<F-[8KFF
M(7&XLD3PC87MM16B^\1L3X^ZC@D.8.C=O.3=M!OEBF'W^0M ,I,OUSPS^CS5
M\@)DF;??75C_R[23:TBMH!BW=T<)#:Z%+67K@(/HWGVWC+3(S')*N[B^R27T
M'XM_D+MZ_ASW OSJS?F76>XO0M63^($Y46U%GHSWM>H7N$(H4:[YZA4O.';"
MZCQ_^?>?);U8D4RJ\).P.=2)J.9("2DLSK0,%[&.S<":4S>C):W,:XRDYV<6
MRG]:)@<90A&[<UV")1"DG][DS?T87CW9RA"+P8>2NIJ,'W<ENN7M?BF/*9KI
MMR@DZ!I-B;Z[QKF<!&A99@W;>Y%0_BSFAY1_Y]?U-A/W>'?RE,VR)IUD;I;5
MXCVC^"J-3"@X\C(\@P.E\,;H*XX>N1RZ((1B<X[X+12"P@[9J=0D5LLH> %F
MQ73N!)1.F,;OD>1?@ #"Z'^9C;Z_R&V9 LCSHB(Y.(U6]+BB.Z0BWNU%+=(A
M7/4K)@@G]?@R%%3!XN9.\C+H#75,0WYLVF@Q8H,G_JYJ^+]=U5('TCZGLJ,Y
MCPGM%AXM#Q<#*>;2YERTPZQ U Y^(3**A-F_GQV"\0[[1%]RN?0MFT<U%95H
M)!7VS7FB%XGE'I-:B3_:'-V0V\GQ$VK/R2YPO!N@:<AZM=__5V7AXZM( ?\3
MZNYZ5Q;V"%3<(_WF<O[^2I5'8KCC)=5KPJUE)2NU7FL:@6C^_&<?GJ=;_^:+
M>N;=C:T#8X^.;B#$AG374A@B%&=[ UB\ #9K?RN+4>GAOC;@GV8=;4T :Z8-
M64QV<TL)!0I=T3592NX:5>+88FY[W4=/GM%@&S?XM["J@2QTT27/]FNT^.?G
M,LI_6AHO0$BZJDY/8K6]5A3U<M"8CJ>+H+,J[]>?*/JZ*_BR<Q L8($H=B)3
M1>Q5P+_[_MH!]Z]YTW6DB?4H#A12RGIO8- ;!)*;(:D]0]W,-[%HU6\4FG'@
MHE9];@[$"-MKSP+V">B>GG1%_VG9'AV][5J6L>'43W2SOLRQ448='!/ 5:>^
M>'^V#6$I[@5%0/(<EJ&S?'^D ](!Z_^'5<#(H*+V^JGG 56C+LD-(6-B>D<5
M'+V1^ZVGBM0\4=;<F!I":PZ@=)_ST=&=CP)*3P6^+X!8D>C9X11/D4^QTJUZ
M"\8%XUP9/@@Q?45KKL@9=8AOWR=XA=)9;8[S!>A)5;\2T#& 44[Q"U+^W/>_
MT./ZMQI;B[-";FDWOXVRGFY &3Q#%N!:W'OC6/"4669S=-\P>7W&P77EF&="
M4"MZ-24YX2\8OP"O<'X:^Y1@\K!WY9AOQM+3XTJ347 /6@"IUVJ]FI=4I$\D
M2N0"&",!AI&?WTL <2*JN[SL7$NK1QH?OAH[\;S%I_3,$?8_3+7UY>QS^<]]
MTY)AA(2=GZ,^XV*A^7>_ *!QB@2/"+_QAM*(8/DJPJIE=-GWN VQ- L\)4@K
M1-CZ5S>%8^%YU?@"_D6JY;G>DD26*]T70ID^[;+2TO3-Y%""%O$-XNNB#'^:
M)Z0.3M8C=9-A!RH HJIDV2EL9T?QNJGV<D03&R$)%5<STGBTTH&H?VTYNBL[
MOL/'[9<-YXKAT'3'W$.&U$JA-N_:<B(_/&*]6Q%IY]^"\YY:_26;O^&80>N^
M<!FZW!#8N.T.;!WHUF-%Q5I:\51M8)\0$-YZU Q])66>E/BL[AW$W<FWKVU&
MWN2C^7-6B*-2.%5?&\7MF/_+EKT@%@B^ !D>&E92$%A[<QF\^FN@LI^,G6F@
M(0I/*E;=KZT8F9\O[UN'K@*FAQDG?:.6OE]F\\IR*K*CDN@:W538QFIXBU%5
M]40=$^[;A++<N5%2\<L^]DJ8#CLT>3O";XUTRI*3=X$*8JFIF<B%]@)PG-B_
MV\;#%'T_:3QAG[*T!,G5C!E0*(N/WP< + $ T7K.47=_2+XQ.,>+4W82=/G&
M)JVZTGO -$]<HY_,^-79J';;>5]"0 %W_%*N"M&G,0PJ&K WLC5-U@"99AV^
MZ]!=@PYQ$T6PU<8#A*H:^RN80U!VT=(>=+V/+#?<_ )$F!D^N%SD':HB-)%G
MI9U7^R)M*+5ANLUB[N3RWKKJKDJ#@\SI]WUPK%7GE>M-;9DRST]6;N-'LPXY
M_H9+>4)NU9%JO^SY_*'L+'BM">V#3I G&GUV3%<$?1;<?Z%JATYK)L1NM*S&
MQ5?P!0A\#I#+U&SVBF4I&[]7>&2@[&A=?A0^[(W*UM'-E67_K)!44F4,9($F
M5">EJ(.JW<TGK]-I3P_OEW!MP:\Y080GE^8.]I[VH?UM3+K%MBD.L*K\43.?
MT/7DCQUX*'M400(X8E0/RLCDA?M+2$TF'_049[C<0UM^)'3UQ24O)R#*,X!O
M^E!&[>KV0DZVY6GMR$]<ELT6XRS%<#(RO>! (@G,:[C0P]6MYEEW^7 .*6:7
M08Y=PJAZ!F5\5M=YJKW6M^%!Q\RLHT/ZAA!!U#NA.(QX=M4]*BR7'*(#,6*6
MDM^2BC,L-]JGCWVPQ8).?!H&>S#?'W4L$/K\!)G&JHSF>4:9#<;2TD(U,1CZ
MQJUX;]NTU&OL-4W\=+Y-XB\LMV'97.WRL\=^+\I1UM39GZ8J;:>H>VG!&3=,
M7LB*E[!>=W]TC@_XT63?FK1W7$ZC$OHXO&@0?"80[#-0X^XQV3>GP0U?GC*(
MTN$=QD=P\(0OD7=4[.HIB"9N-.H:)_'L4@>6I"_+)DY5.WA5T?&\&1N%K AR
M*(.N!SY2<V:S7&L-_>R#[_N,[_;0H-)OY!-O=)Y7\&6,C94UCI,R\4+ZJ&J>
M?[]C_06H;7#R <8_>'9]X+Z&PBZXHY;[F0:11'T.PFDBTPJI,LV6:KBQ7WOQ
M0F;4RS-J(&9.KZ2$6ZNKB^MQB\F@_=!N83O3JPY=_^TDQ/*S./Z]!\FN:H8/
M#T(UG6IIA>2N01SL<AEPTWB#)^_G,_2Z[5!%C,>6/58I'1N/CD[$2'0-H_+T
M.'XM'"3>UHRD?F.6*X<WCI&]*Y.CST*@PA'?MV.=> $L?OF'O@!;:Z:Z*YD;
MPM/W$;/%\[=V_K:3K^K"1Z ")5@ARK1-V:,$\@HM=H4ZM"!'$\&W1@$JQSZS
M2R#!T+\2Y;]G,-(@M20IA ;Q/6)RM!@3I6+4#5/_C)4J?E3ESV?\%^#5S#/%
M=UL.G@*_)C^9._:8Z=B5&_0GI0W=BS[J2.IK?.">/CN0F)E]!%\N8D/[W0IG
MD  )='-HZ<QIR1AJT+C<*M[G,W.MC*@YS9PI6&8B&*CVG>SS]&7>\WCMPO"M
M-:PZA,:X4V7"GW$4'P14P^",J2)17X"YQ_: HR,E7Z_<X &OV.R^U1!SLP-5
M%3&"S2I8X,^(-2[V/1,->$>?9[?8@SEG/+.Z4 @"&=6^3W1?Z:08@=FT_:9R
MU5)7,>E'$#(RT?BV]?-H]8C,<>4N%8*5\1^Q@XBZ_]QO2+H[D._4QBC\C.U#
MX9:!-,827S_DTVZN^)4&[.3ZIQXMO  W1ZHU[G;\8.W3DW>L96/;+X"UI]JQ
M-;Q<1(6%-_E-KB>NE1U4_+"@062S5!DDA?\O?/#4GDQ?8"P<!*^#%,OM>O#:
MZ@K9PD\@EU_P;+':NRFMKPY77X!%Y+D4+5/';BYW)US;T7*%@N/88/(@WCO1
M" 4?&-\+8(ZM>\C(9R+[1GM+N3@' *DJKRZ\-<Z.8/@WF_)_H>^"(HE[&]?0
M9INUP+1/ST,(^?G:ZBF1[)-,G<W2R#QAE=P%%^LANO23\AWR@9J*XKVVYO_H
M;-D-#="YU=T??[?W*8E5>W2:,R%,+P %;#1)./VO* H0S8.S_Y3D!)YJ?9K:
MU/ETF+ENV/UX5Z8K!A>(#*A.H.H@_A]9]G\"8_G(FZH9>C\KS]>E$/Q[^E'*
M.C@V19<>[Q_S^!SZ7U):9=8I*J$2%YC'2X]EN+D1Z2XJB9.MDIZ2[521ULX(
MU!3))#WT+"M4S*7EZ0K_K?:HI/9;&;&5L4-'#R-NBG=DQ"?.&_QD^X3_/R/S
M;X"D[G%Y<-]HC5-7-L]!_P(D.CV=]?]\9-*,H >R(R3$$.(#!>+%B#+8+L B
MA.>/=Y<F>7T#-*+];_9%TL<K*S)_]3Z_B9/VF#N[8P>?I <^(GF5.7UY9A&A
MOT!G:8XO6(PG ]Q<'Y5^W]["-9)<[ZNH0$LT76;2U\+J']]F4/W=RZ[E_-6$
MF,]< 5TZF]CWF(>BOW%^;>EP::Y4'5N-C#K]EO<3?P'$6V7^RE#21UOZ%IG2
M3G"<9/%:SM!RKD7R9]=I\-V!SHS*4#/B8MD+@&KU172?M_ %6)<,B/*5Z:9\
MG8FW'V#9$N^18PDWI'U%_0*@OP"29S<5H#(CC-]! 1A'<_<);;*1)PFB>]F4
M+>U[#00)NHS.U2L-'PJ*KI\X=(0*#3]$/N##9HCIR,-;I4S\D0I,$'=R@V3I
MQ/:[&[A-6UJA-8*2LWJZ4U,7I8ZEW^*$4G,7MI")>]4N/HSE.%%D/B6.O/6M
M2)8((G_OV*N4]59L?*K>CK)'8'$B;LI2>:*EE+9CV$$[_=G(KS#_#AY/">]7
M?@[+B$E;OS,&I@-9E8DRIRPO^Q9"**57I/DGMIH+S2)/QZM46153;<^"Q.U&
M[Q2>SF- >17;J*\B$U_T-H2'TICV4O5=]D=E>%(^P:KG3J+^ D=;E$<[\MY:
MK7>+[8MK[T-J9'\F+/(^K:W#\8\?R*(W\=1X%PYZ5"\SIK[9'L+';7..D]C[
M[7$B>LYF._ZM9QX*2QTM1NU*3NNE94'%\&CGHZ-B4QEW_&YM2*,5)^AL1H:C
M1'<::8^L36BJ[9.^6E2QI=50%70Z-H%"8@[5C.U;5_AD O(]EQ'-Y\]"J+O@
M*7--LN/[*<Z,:\_>:+;K;NS:049F5H!,H#G?NQ3),X?*;.-,P]*0'FFA$QD5
M1F7UVW<=YYV+E'7O%M_S&"MMG3D,BYHC&9]\32RUP"0X<J^BCJ7@&\6=3EV5
MGAHZ5^];/*NW"@J'6@7NIP)N66CW5E^Y(5-T<4OL.(E+M*K1+7^R'.WW?D.N
M'XOM1G6?AWM?)?G/H<Q=)-!+]%6TN\:O[*B[=HPJ\7Y#T'(18U[]TLP3F[ZX
M=IBZL XGUC^S5^]C_XD]3!Y2WIN6O;0HGE93W!275XG_=+KZ9YPX"V-5U&CF
M!M-CIBI.T,92@[XJIMEC?"7RJ@I[Y\B@S/77><*[UOIJ'KH3S@0JU,_*D=#U
M1/(+4@RSZ3I1N0N$I?PB#%,$Z)0O6]U[SS 7=( #61%;\5,MJ/6?%4M WG.Q
M+':EL&P6)<]^FX41\.H(^4,5KL1"8VHH33%TMV'\Q$'R.<!1]&PC=^9L^^^[
M,3ZJ'ZU]U;"K>*Y(A\)!M]RE::'^J:PP8/RD_^F1*\#.EO+JP?FOB,94STZ/
M_)/I\NL6]O,%$*VGO#N?IIYA>V-09:#P;;]<2BO[&S+GJ<$'*Q6HE+,O/Z-K
MF(OX_?Q/FY00G_003_:+!I.DA[(5K1^:OT)OG(Z/7@!:S=Z6;?C,#<?^>_5!
M:P>)DLC26ZL 94/]5'FM'Y+@7N252(OHJ8+L&F$D&8P,-P;:O@]#6/-$- OS
MHILL>LK3[GRC*7^^WDH[L<1\9]OMR4IS[; \,WAK9:O;=%#=5X8N4+DRA@*2
M=A[?$TM5T;(2]=UD,9RZ57@?]\V]08F!FDIA>(? L9$(JQ^>'RT F3?"74A.
M=>W7< 3IUY;-D-(@;@F@&X??%)NN8$,/>Y,H(>T/JQG&?BF11;(X'33+>2XK
M4_]! DQIKGDUQ"1]3&S(BQRM<#$Q74.W]+[ 85-8^O!T"D5U27O/?-653*G2
MDLXEZ]4, 3S_\YL83#4C?-MYYPZ_[W5(VKIF-;0X%FB3]2+A14M>0IYEN?-=
MIZCV"U#.A[P^2>3%0-?I\_P/F_SO2(C4K.+!D?)!D@Q][%(_6DL5%OSTB@9K
M_".=PZGD=" /=&.O64&#6Z*K!P<#2^>S.[TWH3WU'%]_&"@4'J:J9YF^AI^F
M-"HJB'+@9+"NPN?7=*6N&'DMC#K&6'E!*COI[;& 9$:6FIJUW!S=]8W]03:U
M5I/9$ S)P8!5!QV7$)D"#HO]PDT:H[0W9R>&.@0:(>4_U#) O82(?/7FAG\?
MO(3__;0B2E&8[D/BH:)<Y-^6ZMV,!NP]6E0,V@^:6##)L&$S_>Q46;"Z*5=[
ML%)] 3(?*A[N;6NO!EV%XA66<V._L=]PDP,&SXLS[7O/1\_/*:(P=[8_+T#3
M"]">7Z0B1I@[R[8;V<]RTIWCKAD38S-<<HCRKGZ>R@<54RT[D-OM!<#]M?A+
MBBM);90D,X/711+KYJ!2B7P$=Q0="2J%D>N)U.+1C U_)$AV$%^/F1B2:7CT
M%"  G!27W1Q4:W^!902P=VV^'?OEJEF8I<"4TMZ>P"TL(;B\_(UH0YWGDRK\
M;E!6'!+657-4NR)_>6+E:8O$K6[H#-ZRD^R(#47?G^1489D"RCTNC-PUZEE#
MS8BE*;K,T5C$FARFXNQM0;(MS$#D9J@BIE9J[WTP];B3:9$#EQ-+LT+(:S0Q
M-'$:#$4E8KY^Y)3%\!ZFCQ>E'F.H8I?>T*)*0J:5JP%N35%\+@\(]VS1V\E5
M!?MWRWK(P=.%66@U7DEJ$7-Z26%+]'.;UBTPM19&*P2X#G:1P&C[.6B.I\^5
M3=C,0.P("01')LR>=;U F'/Z2%&$:ID?9B?]6L*(^4VLQ]/JXNITGCCVUSDM
M#VU(5$O>5Q^\\087UTB_5FM0[.^PX^+FY1R9'R/E7]8EB"N'7&<^'_SY&SS'
M7PK33QDH,.D:@9J<QTX4^*M1N37Z2)J3.@^OV#5E S&# F3D'-<#!2?\4O$K
M)W#%[CL-\4C&0CJZBRR4O'DVB\;/$MY,>_T_@M@])!KI^/HX^RL(L!_!)%$C
MO@EFH9K:D  6J,K7,1D8_W-""5([V5*<[@^*=X\TC?#.R\U$9;; KI9!:\02
MARDQ$PU2K/:?7'[0:W(L85N3<B.D*W"=RNLE$KS/V@U=I^/7!P:(^* 17;ND
M^?K$PL&=BHR?$6^Z?TH+[?%U$DQ/_F?R$NRU$_H9/$7G8M*.*1C^8EA3OR(S
M0+W/R$SW:.HK<?AYP"L0NN40AL#LKY1%L7UAQ&GGTSO67JI_J!7.,;;8;VXX
M)!Q8GL;-ZNTJ')N@LZC]4UZ*X( LKU50=H;;TVW:OIPUA3T)IT_/^JY7N^6\
MK[Y@N:YW-]X7@>DNUTN;_C[EVNCS"(Z=0@\B'#5D7^3&X[9IMZITV;]"8<J!
MI$OU/9NKFTJ>PI;'1#APNY?G,E-!/YI;*SV9G])X]<FZPC\ ?9"FICWXD4\'
M"KD:IWM^TO2H7Q=,5Y-+G)OO3L&,/(M*PE5<CD<6SJ%4ZDOIZ;^O;(T74HU(
M/%T\/J.#Q>0(<7#9JU3G!@<'KZAK3)G[)'6>O?;/V&@1]J8[W7E[0AR]ZEB:
M&:UREJE[R_B'ASBW/H7_IP=4>T% ($,=*EZ1ZX>[^>51:V.A_#)[5W1U)>OY
M-?ES>&&%*('<>#HYEY6[I1MW9HE^/ZA&TC%^7&B33_)SJ*!VC14,G_?R3)<@
MH6+%9F[N=NK04]1R6> 'F-)W!%@'!:=%=9-W<@\DC$:*;[X V-K+Z"&5B?1P
M+7.7+-6?1:9P(_UN]LBV:/)49VX^,#+-IG/9Y3?4I:SQ0C74(Q8:T;+6T\C+
M8I!D:/AH*T0?WZ#,#^UVX(2LP"D2>,(MD"./2$O<':FNZ7N)W*L5K0J7QGW5
MY/C%LWETQ:KL(DL6#,V8K<M9C/5<*10RV_#>3.LO:"DAI2[4DZ(V2ATV:)=P
M'L/"SC.HF^.2;_40YJY-##O!9_PS-_#S8^,2EB^<#)D[<;%G_3/:U,GI6VI4
MI)DFZW6,/Z3U1<I\\)["8;;'1N??#N^[O3'1;55I<*37!W3XJ2C@3T3UE;<H
M1E@?$NM2A\F)C[/CQN Q>Z(;4/I)J4UEB?H\RD72- TR(VJ)MJ,VIEA9+DV<
M.(\+FQ':F>UE^8'M:,,6T_+?0?Y,LO536>VU<<>G[_02W1$HF8-TTK^[-!+3
MM5K1YFW4%"[9S).8A)Y126M:RD2"P7^,JQO)<)PC'R:)\F%(JX.I?2*4Z>4G
M&4-:YFX!S,M%5ZN9I@E[B73P:230K;Y/I'4)?B<B?\MWC9+MN-C\"RWGQ#5I
M57\;HBGI&>JA!X44-,G3W@GA"SD%?;(FK^;ZP&]X9A3X7WGV!RE&H9OG+20)
M QZP%.D?\IZ7 SH#B!\;QN2BOYN3>19_#%IE-ZB149B[AM35Y"TN$N5'?<M)
M=7_/_+KX[J&@7,"RGJJR%I:\$S2'DAO0<D"$<)4A>U<N^\M+XEPIX(T\Y&V<
MG45Z=8$0D\ ->EIT:K3/#.P"&I8X'=9LG5/S8ZE&H2QNB)]FQG?.)=Q\2/74
MC4M#\(/BVN6FK"FXFEH.VTKZH;2@83VZJUS3XC^TEO,:^^SC(%(FNE_1E9R,
MZT* [KY[JXI;&?_N^L G[9D[VRM/C]C%U6^"9%7"H_I::DFO5(<3,+,CD#@X
M!\YTR:33=,UQ=/M=BT8NP#GLW40C4&'O?09UZWCRY%8876ZD1L?]9Z6+=RQ%
MI4>C+55O0J"ISA.:4G(S4Q^DEGI+GD0,1"P@:$U\JV1?7,K;LHOG^K+*L,.Y
M]JTV3<^H&0X+[2A2:&U'_FI;\_2[T)N $U)L6LW1'@!I_(+-3"]AE\3B,<7B
MT9/]JG8CZ6%X12MO>9Q\!)6+I8E7><B_A(&)(A0M;;)F%4_3_VDVUY.]U]5I
MMT&2RHGYG12YHI+<1.FW)SV%FMDY]$F8F?WX+D=<MG 'CI))FOO66NX2I.XG
MSBS7<(\+;,PB\TY;.] 3 UOR&KF5!9:3+V.[RV1:!(<JRQYY+K=WU)GK?8W"
M$NA-I9TBK>SRZ9*\ !F&38!+00E3<^"J:OQ2S7.<GN.A>/P18.870BO#^&.U
MK9@2%8\7;4W4+(LUT$FJ_MA;<S/*S6W Z#7Q-MFY 6RSC>5I56!/IM%,>3Q<
M]-;NK<R[YKYC_'5V4;[!]4O^HIRIXXWEG8X<.V3#%MQIRG2FK)VDV SW*);/
M&?*F>3D#'B$6?1XQHA0,2$7YWI+#5:9PR7*EZ)>AZ_'7H]8O@(6./>JMVU*Q
M.K:8HM+1*.,!+ (%AXU^,FTO05AF2VK"97Q@V$"SAV7 010'E>!O&GQ%):V6
M<>HK;\NQL7"PV>[J/W&J)C)51N=!IUC' "#@VR+%>//EZ,5YELCUV GC3]]K
M;!+CEZ4<S]D24#&)](LD!'!DJ)Z$K2VD(,(*3VP]=%JS5D%+JZ&U[YC#9*C8
M74;RG)<145X H>GI1ZO;&(K=+NTWE\8):1RP<>Y%).^#!'+.^3K')9M$#PS=
MN57JMX0<ZNX:X,]_JAX/46K)>8@R^$YP:$(P.)10>K^[[Z."59G#Y2]8H!4?
MW]1Q6,0,1(IU%_+1!3G/?/SXT<ZP:,E&TX,CF24+MPI1&K4KR$4"&L&Y8%K^
MGR+#T&%SU.I!395=8A%6_U:+G+@Y\\! ]-M-Q?&)Z/$$C)45!$"+6\>O*P2S
MX"*83+O??].8EE_4/VV/?GNR8L;T/'@F1G3CJ3#E6&<SXC'PKJ4EJBOKCMM5
MX?PZ"73*3<CCH9RY)A2,$+N 5D>;1UB0SJ:40<ZI)$7G5H!D5'1WG87EHWZ9
MY[7X_3L8KX#J"9.7ZJZ\;5 QTY+JF_K$]OM!Q'E7BB=7;0%HO4@>7"\7ST#Q
M<@V^K]*>&/',_K:7!83&M#R$H_)8BB<"N#' UOA@I@#=^ BF9(X0#0W7G:S@
M..^K=HM2\([Z9E-9[>O#NV'X X6&)L8:9$O,?))O:>.PZ6%2FR@&H4C@%KN;
MJQK?%AYA8N^X7!(CS4A3!NS+4H=7G5 OVW:5_3*5Y-2L[(?PEWLTQ %\(N#2
M5M.X6.<+&A)$&)$%D'R;U](94OE^8X"E$;0B(V'-DWA<6H8@I8UHK&S\>8(R
M3[8\NMF,R4%0#YE/Y'LK/5SH;KB9_PZJ2<=7N>*?C("P-*(V#V$9D30L-(9\
M@1YE7.')UMP]EF RF DC#)DJPAUXSV+\RKL+):25-X2T72#Q/TYL_@GX5[W/
MY-&]%&0-T^DPV6X_MJ=%Y%6ZY?HM(V[]Y0\6[BQU(Y;\&RYQ;PY+^:C;*BO
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M3,/>"'AN=?E#40O4JIK[3&W[3/RORLTKJ@EM6\,!%! IHI30P20F$+KTCI
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MM4LE#^Q&3@#\1X-B,6H:TG F2"Z=703AK]M )&5"(CS/[BO]J[/9' \OOQ)
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MZ/M=C6(K8@I/H%W1JDXW8$LKSF/$BWRV/@/U:JR8VC]FK-T:;7P -JV.7]T
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M1J09=*Y^.'_^+>#@1KS,F(Q7(!.%;H$_?*#0+33%D)4N'*.K$M38' ]@X<[
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MBQ.1_G1>Z%$0E\^<SB69!87B:P?W%1G=:TE=]S6]J*K+>LTRC<)-:^<:-SK
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MR;<L[SD&+YE27X6LW@@CF)EZK/2V-CX T,<E50;OGR--/P":GFXY,J!7BP]
M,)_$WV;Y5O5;D_U5WO4984-7QN4'(- 54Y/Q P#?E-=U<G>Z<Q>7+ES#.?^2
M?M?S ?"&>U:>8.HYV_E;N ?QI1\QF[QH5-+@\<.'>[XJWKS1,]FB#L"IQ*@M
M9)8AV_% '8-_E>.+QG,BP(S9Q=NAW ^R_XEP3/3^I5:,6S@&?+_QN@TSBL'<
MAIA0+O>*\9UY5)?-9RG326(QT!)P4@C';V;:#X1%<?"A.S=5+))ARAMKE(\:
MI_R),6+(&N5]Z8<8;F,MN[YDMTA$E6QC)Q,J$:6()A7EW.&XX".,:#%=DR'?
M!UF+FV]83$K\FOBLIG2<6HHU-(FM%CO<Y+/5DWFTG)T3PG4X^*RUCQT)1#16
MIYDSJ;?#(SV*8;\K>2+"<:_[>3BMH9TE/QN.+!NB[@G@<AZASM08=C4WU8!)
M_0/P)-$9;IFS@SFKTXGZ,H)+*H3DWU]W5'*JP;$F!6[K2/[%*L5.)L'<?,GB
MF[27OSQ9W$70HCN=%T$O_M,MARQ(&2DG18'UCZ9)&WA.QZTEC3P8@NJ(!TI0
MZEA[)G#I$F+)51@T7<DY]GNO!?HL*C-F_4J\HX&0U_[/F;80Y4P_/;V51H^6
MB9EHI@_?@N9545@FY4K2LQ0!]VUA[65HJNEG44!<[.ZW"<N!PI5^(3F+H1V5
ME@E07I/\Z_DS;O%@4^4'@/@>/WA+VO%U@OL=/5K6_O%NVEPH5!OR T!JG:]E
MK-@:(128(T5_P6P)TR",\S>K/11N$%!V?*]6J/,GOA@?>E:)-,!2?*]7:O0G
M>3J"%YYL]:+9OT&U>9;PV3IR3A4B7"B&.^=[6Q+\XJ'\K"J 0;[R^Z'IAHMX
M<E>4FG"ORKJ4<]RJ9BS7FEJG,;J@X2=T1[BD]*V#8-O\*!VC#/Y<R<G G+U/
MJY5CJW"437LLIG3*EV1*0Y$RU)2A7Q35#%I'B^6Z'JVX[_B@("NA&>B3VF$*
M1<8Z7W,EC]_20QWN^)K!MT6U"P=SQ>+$=7)XY-&2W<[=0TN%0D?=;IJ^N/C
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M#WR?EI8+G%,#0G_K?@#:EM]H^[07;'GF.;1U49\LS78EA -Z*L^4(V) MK_
M3?9[FJ_O-\@>54LDG-D%Q2]%,S?2WR6<'0="(_UH!?%-T9@/Y>TP!KX9>/3)
M-;3)\1Q8EP_9ED)#.6,<9R=E+9Z5.(V\Q'5-O>.&-T1KZ@A?\;2"K%47%Z=S
M,E9RJ@] *6X.6FM [%H&96H(-4--QEU4G)-5E'BJ8J%0]$4V*+M,'+P+D0\
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M=OC5ZN;1[H(B0T_BZFT%]L2RJ5&L%'=07F(#?=]KUMY IVK5MQ$>V%&>NY\
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M^;%^X-D^\+;<,S]F8W%W;VR%!.E][7ON-9U<%A.UZWP[IR,A3E2@,6).@JM
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M[)^WX/4)F.R@?[2SI4\U+[L6K>Q@O0QYB(;XG%Q@O$;6\?]LPR#HPK-TV#V
MRREK$48N<C)\E.\@V9VOP4#8>'P/>'W!1",42AGW-'97<J#' T,&W22Y@!A\
MHT@%K]#Q[7735C>%OTL5)TK/6_V!EUX$KJ4Q?<0\V.%?3&L5:_39A4>:)B]^
M:DC'W7]L;C0'4>@R;*U1H/3OBJ-RFKZDHF'56/:QLYU1^W7)Y+<KK(DQIUD8
MKYN7_, H8AUC/'GZV&.0M3_L!'YZ9K>1BRCUDK"-JXZ5@O_VB):SN24H6M^)
MAD9:/%5=OS,4BW57  ^"5O!J"DWE';\;=Z.XKXEUWOXZ>5'UF:.$GA7,CNLW
M'X6F%GD:B R[![2%:G9GBH%"RQ,N3 (RU^I;$28P=NL42J5TLV?_U \&DX /
M4?(Y"8+ <U+0FZ/!ESTTQ%6\;>38F+?*B#^GF>1\ING2\E%F%AG4#7D6NMN[
M>F6"ZG)=?#5E,2T+;4!E#P4:S?<G%*VY?VN88#EL@;?Q(NV4I:H1/DLG$9>/
M/(6V#M]$[=)VK!!$GQ6^:&@),%Y,@Y#(FM'S*K!_6*6@B[(355]X\S<U^+#C
M(]BP2.1, X.K[@$$3K7B-H:6FA2]/I:.AP$U]P LY'H35 /!\$!3<V*'W8&M
M]/&[_U!_84=F?\+%)BD5BP\2=;3H.%)TO\W-57+<?YJ9G LAG=./)NDB@/!4
M3NCN-'P^++^=EIRX!ZAL:,J98B(YJT.J^#\\96[Z<@OZ<DRY6_W8_00YLX9F
M?<NZRZ7QX;;QQ[&8EGW9ZS<33=I<F8FU1)R6=UM;AU$V/QI.!8NY_#59N8H<
M1NTJ0?S6ARR(='1'^F-%.R;G/U%H_+B5,%_0(-\Z0\=!=>!WEEPIEL9QF.#@
M*[#]]9R,_U0H!AC3J?MG[[758L>XF,1H1,C8T<+9O%U-"DMXS^/0YQ.3"EP@
M!</F<M0$%V)ACQS.LH7DH/9P-%1^-KJ/ML=7!0^4T[?WO&QXI9),?BH0;"P+
M*K2&C99):.;/F4>;]X$V"A)_D7Z6MWXBW<'GYZ?OZ\E H;RR4;9[TO@I+\\<
M!!(/YM8\].R6O>6HSTGFV#.L#CUZW7,S]&&+@73[545(I&*8B-7AKS\JKK/C
M%(%J![MEF?RF5<J>?HM^*^[UK22R)Z4?M=B_<TVE.PCVTU$EG[KR:A-QO)/.
MX%I^ZGDL]&@Q75->.T[/ ?X\GG.WLNVS?_YO^N9B.U2(8G0&VW2.:%3E9ZUK
M/[U$+5P&:]3QP-W;-]9_<Q/[[SU9QSP3D"*?[QM9\106OIMNA5/1*\)F>8 B
M,2FHH/>E$J9L0@M_4^>_+LW\+U35M@!!JS3K:N>KAJ(3O/BCHFSS"W5Q6!9_
MHFMG_&3)7@V4^[Z$UK^_=%'"%T%6+76L: H=!D!8JBX9G;Y^:81+I8L9&BK9
MXZ304W"Y80(===U8CQ4F7P5=OGLH\O%LV 0QWE'DX+K.N01'P2EIQ1N=N'Y)
M)VF;B>O50/HC+:HYQSYDHR7O 8QOO$*8_:RISU=2/[8P1H4ZB^Z1J[S7O2MM
MV"54;EM_UG8U@E<6G4U')K/XP?CISJC,; (^>^Q#T?--8[>+@"/C[$H++D[X
M;1E*],&0FQ(N<#U3L_O[W P8H]WTB&X.?21+RQ/KD:B4M\HJR3^.$X%8E&VZ
MP]22,:_TT-T._&!+/(AJ9<<779\)XKX'=%!*=7*9[//VX,9V=!E5ACS[U6]=
MF$5=0A,:;#7!)%X608&*>%[<3"BTU).1L5@JQHQN729/X6<]BVA$ON]=T)(&
MG@P-A:(KS<=U8_2;ZRJ_:)&JQ2K^49MVR4J?6G?=GL4?"Q)\>5#[>KD)OJ;6
M[U(E1+Y<6Z0E9<O::F+MHZ/8'&'7_,"JZ=IHP,YU^R@S%> ^09CMZ(!4AH %
M5\S%3!94U]Z7J]GRHB32HJ>!ZPM(!QQ3,]O!LF#,] +KM5)"DN&J<^"/5X L
M?+DE# K&2['!&4O[L9('CT\9B <\/I%*8FIYXEP^-VTRCW0Q#;L9YJ/;(03@
MC<>U]\B--;P;@P?1?"'$S^H2^Y<=5X  ]!_B50I$ZATE##6E-S7Z*!X*7Q#^
MR//Q!_6?[:IW+12R<C$2_T7.:=DIPB*GUAESR89X#5V-8!T>/SRG@OCUKN.Y
M#PD."PSCL&P!_*=*8[C1) 40M*OIT,YFZIFV%FS7[!X0-V%5=WFC7+3=@+QR
M#C%@6T6)V[5\>Z]WQ;9O@+CNVLG7B"RTC KLF;X'$*X)&%F-6C4?[$<8J++M
MFZK2=8@2]HS[7!D4LD^V?MUS=H1+ZIHU-#P/86B(EI'*76,*\*2XBUL1E_?E
M%/2<T&40S-_A",?/>D[8[+I,)W2N6EGIP'T3:8%@4?U,<)5QJFL>*CLN^$P0
MJG)F5%BK5=%9E9E))V5^0MPQZOFC4HXEMT".R:"\95Y.W3KS^3T *ME<,N)8
MQMB 4EZV'.W-3H0M86B72OE6]HX-T#]*!TBW;"Y=RK>^KC/I.[ZVR%1 -8PZ
M6D)2>YW,GN/O%=M]ULQ"@O06$\16J<*"[\9N&EOE?J %&]4I%P<; D!?HWV]
MI8(,)2G_CBEERTZ>_NV6A;PS[-M["P5E#O34@=7IBL:Q\^8H:>%Y34MQ0Q4
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M#FY+3\)L'23JSG:CE;"\3MJ[E\<K*$K^R^K\_Y7)Q6V/-:'KKN 0M,5>GRL
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MR*RNQ'ZCPN8'P$(AO\9WA/KL.O5PUBQVU3S5G5!&=R,C4D9$6SYTJ[:C9XA
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M4ND%E)!)!'G*'6+W.H[SM-21@8.]!E>?.LKZQH UPU2=)#_B8SR:KWV@G(,
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M9F9F9HY!9L;G=/?M_OK.W+7ZS;P_7DFU2E5UM,_^;=ZGI->%UPT JKBPF#
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M)N(U.TF=9UX==#<9F*L:WFVQC!*5BV3F:W&XZG52]AB3]S)_BF1'P<+M8KP
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MKC-[8GEBY'?L/R(G$&W8ARQL-CK2I'6QU'+KC%8C"Y3!%TP%'_DE]V>7+)8
MTWO<C9V6I/>>U!]JYK^WU$6/_OIV7FCG P,@O1XH3%'QKS5)%Z-,7_CV/3X7
MP%P"U>#-Y;CAKDR'Q=<%5Q!2.-<^5W_%FJ$LG"(?!XG4Q0BY[8W6"7BPH9['
M:7)>VITANS1HC.X)QBC'_C@ /!GG6U?OS\ZHBI0Y>OC55LG>?MU^GW*[M&+?
M;2=_ Q[9\/>)HNE/;[3>PO(1PI+-SRP-+E%6TMK!.B#&EO5@-Q(]7G] JV"O
M$#NK> IU @G_T:_M'DFW=D%6["L [\&K</8?%H.U0R+,KO<@5X,\<_A5 #6P
MH#]@O%8)16&9\.2)"E+KOZSI_7\9&,0^,1WN.=$8?U/& UQYT\G<W9J:MFHN
MLKY/CF%\R'5_YDVY2._Z!>/**^#O(U P#LC6>.=#<JF&XCD)/6FG2_..#QI*
M#AZ(B8FF;Z[C=BW=EXWZ71]NGQ[>RO?UO;?.=X='<=ZRN*@M@FKW(@!:4E6?
M<JY"VRQG,.#B0>.&73"= YQ[,<4*"W#/4)]L/*O->_9N5#MIV0MB8JFR[L?K
M'#=37#$1$S=;RSC;+L\+\?-G6ZV=K;AXEL8/H:J0/?-]J[ 1;VZ[WA-OK1)_
M2Q:+GBDB]T9V?3)E&9ZM:V=>J?[%R&5\2AA/"N+*$?KJ:UJ^%U(:&WIL9GH[
M%Z6^]-49+UZ_T52+;>=[)N!Q(R+>]3K%^B/NTI[:B+/<:$9UT S5F(#<6N,2
MC:$PD[-1=,\8S<"$^8(D?K;'8E.T.A\W+&6&]'M5KK3VFQ_,D(_HPP/\]-QU
M6$]5YL0A5G$ZUQ<4*C'UU[/M,P>?6$L(9*HQ8T3U1;L&(34JZ,*PZ6?"+D/V
M?F<'*<A:EF<7J2NARV2JF&\(O ]?$WFJ?<LRMDK++B@O/%:O@*/"-YV;(UF?
MJ<TG@%HJ,G8<"7"FPD,/I+-;OA["'.N(4\_(0BC5(C*"=%E+. 5IP)]@R4HG
MI=C2)O*P@-.<_'<"F7^6(MI/?42>2)5? 9>/[,]GM*7937SU&O<1_,=/[!=>
MQF_-'QPFR>7SVZT_:R$(*/<O*2]W6'-R(G-'( :0\69[[.5_(R4+&K]:O^TH
MKPKY0\COD?_]4T;2X%M/\P[VZ14@]0KP0.#?A/1[ >6_ MK>.<;)73>MCY L
MWEGO/(W)O*!2\>\_6#]NR/UKXC>>(LOF7KZ_C'>#*/?L0&<^@F\MW#1H'3+R
M7Q-K&6)Z6M5?PMYX$=SS,\?^BU=,T%\F/J+*.7)L_\E??;8^>)^:\4]F<_XY
MKXJ:$(E&V5/G<T; B\S(+JSW!C1)W6CG^ K6[*20H7SIH8?5WI7-U>_UQ1)-
MJNR0D04:[LAKE*LB&MK(NUM0'D!^',MJ9@_MFE74H20AXQ!V9@+ZJB:N!O!6
M"4$,C&XH?+H0NWFRMENX:#+8G\NQAH26'RWT5\(#]G:0I#DI!6\U=UKG_/1#
MG?]$-H!'2M)B>U4^Y))\&1,"\N596B"DX^!L +\YT$BO7R>C9@_03TE,]LH@
M[*U,SE+,./,A>8 #[9"\M'Z.+^XNR*\@BC(* #Y^0SA4J8/KW"^G%:9->:1E
M:TE^X(XW5V"/&8"RZO/2!+VWY(J?OFM'N8/EY>(0$V)'T6 WG&Y,>9/_&]G,
MP)<W81]-L?M 4AO-",@RB846'*DS:NDLJ7HVF?\NQP)+KDE00;,QL6W7ERE7
MM\WDA]UO;6FX@K72=GZ0Y5@.+(G(>A[0U%Y['#W<OY_H,FE-:;Y\!?@JAW8<
M\$@ U9.;&(:J>J- ZLY/I"(OOB3WL*^ "LGJ&6OL<9FJ6M-)Y1%Q2=1@O& .
MO'&SML3DM+VL@F4QYL6:NI%+*L&HCNVP"&8EZGF9K9>VK0\2\,!VI],"E;DU
M+\,WDXQ\AN:_0'D%:$>Y8*DEJ<C+#]]ZAT8_S%R:L]NNBP!QY,>AM.!D3B![
MP[8!UY3K>2H:)6ETCL%9:6M?G3X0Q!%+\UFX;8<Y9,F@OLQOO@( 1#SX(*AZ
M+8^*E;_R*O*7SQI<%*-7B3AH6GG=7S)9Y,=1A?DR?7H5&AIG/L[4JFZV7Y#7
M"$7CZ*4^-9XNAXPJ5XQLC]2\-..WL*$)2BRV.JS/CP_D_9O8)__M;':8^Q&L
M(%\GU&CNDC[ZF4@.<[?:%T;$+?110Y;+W.P58 J![9EAN,!8[[1B7'Y881K4
MVIAX?4&^L 'V$K%TN])H'9JZ(R(-SDU14-W6EF!Q@3H?Y7!!L?-M"B*]@'MK
M"BND9\NM3J]&C90;X:'1<87:.@>@[60T9VMFK.0]Q2D2T987<J/#4.+KK@O
MM!?K*3IWUO2,[H24K(TLUUY>7D+T?Q%ZD]3G28<ROK7!?.0A..@P[)WTC'#]
M3D]0H9BQ.='^XL(B8F#B=XJ%\_4P!6+N8 ^I/)9$GQT&1CHX FFN[87;TD-W
M\="$W):W4O']@3L^?7H8<9W&K?G(X9O/;?(*Y"<[LDS V+ :C3R_!9;B"O%J
MPU< '3\"H%X(4Q;B;8=E+[D3/4R.2P197-QZL]V[]L%P[16!NJ!!OS^\ J)
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M6&%KC";$C1NC&3W[<D^\6.Q,C%Y5ERQ67DLIQ[:%U##^4]'*XNIW[@;$>BW
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M@/!^3F 760?L;CZJ:'V(*X6G^%KY71^U"Q9CM3DQV>?]7.571_094DGF2BY
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MK2)A%>,#$[")"3EK;%]9Q LBD(YDQG2FFB$!P:#X:-**6 .0"NH8$>R%>H9
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M^"T#YK!'(&AS)_.W=PY.FVQ8R!>U7@<DH?@369J8)([!0B4E\>VFW$WY*O;
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M_B.,68%JP[;W8\[UG% ?:?;NQ+9WA?U[,4.J1U8]'1<MJ[7[,VN%A"]JRBX
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M$EA6]DUVFWF/@S$&!<[.=1] _@\ _;S._C/<-VK>$/H'8&U'^"100A;*P7!
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M_Z$W8JU9:.^8JV_[^10ZWW6$2<S(]_>C;6>K.*MD[5?:7)\7WNK6^O:V7BL
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M#0;*Y5[UB+%@C^!QB!!S@C>KA=F?O@/.XC4JVR">[O8HO=+H5,ORO8FFVG\
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M['//?O>^^^0?_V3,L<;LV5W=7U7U5U7T?)E[605>R4A(2P!04%# )\@?\+(
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M?4-C1V=7=T]O7__ Q.34],SLW._YM?6-S:WMG=V]_;/SB\NKZYO;N_L_N*
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M$9SG>]8S?:S$7MPL*_,/HRMW^FEK^2L+M*[C MG9!G>$:<9>:EY7A@5ZSB^
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M0*)GAA>4TL<YF -E53Q)*)\:8.+*Q+GT?%'==Y<.RAP2X!G)ND'GS$M/>"_
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MIQ@PF3*4A(T&D)ER_9VR)L%V%^>7+P#7K& 8%X82Q)B,N>O(?PP*L646)-J
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M(U[.5MGB$)(POPG4:'X!E&[#*M5.0%,^%+[TK[LM))_+?/RK%63&HY^TG^
MZ3^D+(XSLK+/M;+@QOG30'N^&UMF=:2A7_"NI$!N^#>!6G$1U8I*=O9/IB\?
M(POF!3:5"8ZY C45Z\X+"&"62R7+1#%;X[;7FNM)- S#+3Y((O/P1:K\8)\'
M7U5B=BO'R0GM_P'$^.X9BXBCKCY5A-UT!5YJF;4<:M=A3^F[A4E#'?WU5VE<
M"4QVX@%L,_*=:#MMF6\/V&?8#R^ 1F6EN%,=X6-2C)8T(SL:1WNT>3##1CK@
MU#L[4R&^CF+V2U8R:)M 3Q:*R4L8P)*^7D\OE.?53#8JDJ;U'I9AY!W5K?GU
MW2A\6'FUQOHL 0MJJDC DD1#L4GGP5M( 3,\]%N3-/E =K3M=ES>6UN-'_+-
MV!Z3C><<NZ5\-OK; _O[L^KG2S^^+C+]+.?*.N@MDR,+8;9UDT1(K<+7UHR(
MC2&&FO*<=#9M1#*R:%G*M,VOQ0G,N0WC*[%B;URF3?\DE"AFO>Q[.:QM\$J+
MHRV$@#.%_P=GYU;2Y9)8X3!G*6;7Q#?5!C#[;NGLK(UQTSF)&<SP^9=)S-^M
MD^SA%=KL-YCKGYC#D4SH7&E65!Z+O.BO&1<F%U((G34$^85G><N:%9$H_5;C
M)"Z,WD0AP)H5%F6=P35JSR,16H7:4K*^B4+%:W_>'6'XCE2>.7L9HEDL#V%4
M;5!*K;@IB<_@H:)N46S741V[&/5<5 [IM&!F47M1:9E=*Z9@SW*3O"4)3YYK
M)(ZEHR7]OFYV& ,:;#$XTT6PUK)X^6GJ?@S.E%\]>9>1^=>1Y3M(%0UHT^7+
MZ!DZX:.NR8]Y94S!D$D-X!OZDE]3-#!3*M5G7./43^=&'?ZBJ<E@+O9.K)W5
MOWB;\J8J0]8EK<]B$A;^I%<70WO9F1K/[N",QV)];X3+TT<HX05XK7!X!AJE
M@@17<3*S\&</VJ=S1E8;K\/9?M1KQ][7PYNEI8/]5POI&\O%V@?*.M0KF=NZ
M,K,GL)C^"(8]"@"R3,1\_3)%G"O7KU&\QW.%ATVE:_?6G3C0"D7)7F.8)8O4
M!W9'L6T>2B,D==*-,I6D+GJ<O*GMI3YPPP,/4?"0(SQ(.T'>9@ZL'A<6[TF8
M^=<2Z![X#2[ZA4YBM;A(WYC;OJ.,ZK!0'PI@+$&%ZW%Z 6:NR\QI9),I4RF_
MQ8K27[/+O YK(F902;,4@/FO:)"=FUO/2)9*M;]>CW<C\X:T4=(>2'^ND(6+
M%W?-7S][JSW]P?!+!T__*$Q8JS&C^0EXW?@J67]"7?M@U\X[X]W=9N9-7\Y_
MB/W\ G2(8]9JZ'B@#2I<.]@BCD"RV\L>O@FY=7C_>5HOE,!$Z>?1+6*8IKE+
MRN6"WZKO#K"]GLEF%RV?_HLLDT7W\,.1W1EE7#^813@7046!UGGNG3"?'Q5/
M@?S3-8DZG\*V;0:R I[&/&@RJXH*DOG%L=-^+4MD_EZ'9'32D!0M3/ OK:OK
M+I.CN([I:,O:*^&L6-%Q&\;ZRBN0?M._#61^2QUIDY?P2?CB)[G'IX?7_;V&
MLK]5/QV,:[@M]$W]2]&2_Y:94VK0;_-CV,,4ABNI02<*BLPKHU7F!^G/,WX%
M^_A0W+:1\;LPI9^>E_L6/=\VR_U=]CIT2Y<UC542(J&NH#,UI=<U8C<BG1>B
M6<V;YS0<'P\6K]9S7X"O43R?:JRL+&A2MU!*=?R/8 +BW ]$<U2*X4)SQI\Q
M[O<C4QEJ R^U([^YO=^DC(J<PFR'+YV18S\<WJ"F2IVCRPX3Y4&8N))3%I!Q
MV!(G6=@83&7;ME%HBI9)T':MKVS]]3-#]>%-X)B85MS'BX0;DH/B[$:?JN7$
MYSKN1"1FU>\OP.K*X_-%DCE:[=;WJ53=UL\/C&+,XU\Z7[].QSSFF\)3=\KK
MKCFPX*AMJ&5!S/DJ;\33KXSQ,>IJ=HH+SUX[^>LY+&M])-OC1R\E8M%?(<H=
M$B/GC\VM)<3M$\=J1X9@K3Y"Y\K2.!I$JE.,3UZJKIQ8-9_#]$I__F[6UZI%
M;*Y8ZGOH%6"LS(XN'9CYZ2V!U_("E GU;2VCA"M@[$FC99(7I31'LZQS[^/-
M<LCS\7V=F&LIZ\2_XD@N"M^A7UP%R1PQ$'G5VW8%(<'<V1I_<36<4M$,MO'7
MY*Y+XI+U0: 6S.0'@V.'P.9);*'&YF4!9^T&R>?U>V'S9P+-2;SOPZ@\\ =)
M/Z"FVV[.#..@-SE&E%4Z=(A+*+5V/_GD,YISSJC/.HGN#-N?\L(G#-:QC*FS
M_UP.9]0!5<EDS<&B)ZXMI35B^>R6CX0Y=$G;%:JV=QB@9P0S&MHQX37R5VL/
M*6K=,7VI<JV37+Y\M"3R0@FY_,XIS4SE#&YP2R7)9"'@YO-:;T*.DEX/W9 F
M4<OE4WP]2&8)TK0KN*JXB[WBSBMMA6ACT_:0MC'JV/QP*VIY_1PKYEM[VUIR
MA?7TPR ,3<.7%\"4F>S:0W-DA,OD5. @)SMIALSN0.&<_M/&GWI_1.=C92+*
M,%)@=9:L&=;WY';*VY8+/3EL=1<&WJB3^ZGY2!QI]M8RK"?H,+K28?^2Y1>@
M\%%<L_BF=5\(4QA;06;B'_':-",AC^R^]AX9B NCRX*NU!&3S7RENZ2OT\W<
MU!5.>HJ.[[)>5UCR=?&=,>^W#>7%)0[6<N<=WI$T?LSLA06FL#8',"4,=*'"
M#WU9YL>BK9+:1;=7\/R<XV/W&M+BNE8R?"#MQ1%W3?F;$U!'+YMWSC[A-[<;
MK&YLE6%D46**CQ'PL''3/P0S^?;G3?9+MG1Z#MZ,DB>T=5LIB5;0%ES5?OWY
M4_[^\I%D1'M6?.I-L$+H6C2N&S/-&NVR2GRF;2UU4%KAW8T=R#+(JDUIYS7,
MU@]\X*U0F9V^GJ2Q!?/0[_-UO>$:D_5";?>HD>-]/N\D3/Z<&Q]G<=$G-(LC
M2SG.G"=;HUVE KKN0?UY3]<[[$MO7"N=-"<72S;;7*852U/8#6):D5CU*SW!
MHXJC*Q+^GLF./$(>=)BBFT,K_:SFIJ">Z>.W1-;F/-S#9D<%]!<NG/<MW"H.
M+8DWERSH\87ZWK^.3\7 ;#H<S>]S3.@$"P[D;2@.1_/KIKMPHU$SN208_>YG
M;GF ^XG)Z_/G%J9WQ:*C]VX\:0*4RE8VK"/[=,9!(R*,4E4F=6R!/0+W8XW4
M=U71,I^##T.%4JY]7P 6O85*,(E5?G9:EPPD3#QU_72>J%VQ2TSU(2V@=\K>
M=UJZBRL>4MZ5J:K9>=(4<J85T= 0S]!!,YI7+K2C=8OT&T7 ']W2F5)V#ZWA
M",A/\]QW"BW8=\.;J=9M1[5"J^X\[V^BBC K$)7-V[UQ!?.J#!3BSB]MQ*.E
M8[F7AX61>'!8@;1?@&0FJM?;3:V/7'>4,9SQYF-[$R.G5*>+,NH\5//E9<^S
MPCZU.6NF'AI*W^O(.(^268F+5IT%NFWY+2B.8M62QH/$&8JS ]60<[)@H-,/
M+KKS:T$[CA9KWNE3\>/.=YK:=-D-(^T,92=B]]/%)5[C@C50:G]E"8-V3=KA
M-Y(3OK@I#!ZQO+8FB[FV*OX"W8)A,$X9O.@_G*@;#0S$F5Y)$7.'8]7Q0D_S
M\\I=Y76%6GD0N\;)F]DM;?5X,/!]FIG&J:[@*MAU8F+F*&YYTAH"!Q[+C:;L
M+-2]%5N7$-U^/^*:>%ED>CHY3-P0A^OD/LL2K*SHSU(;Z,RN<C\LOWZ?0.),
MMZ=.T[.4D%,G:=J/>W9H8%?V6<_=]5S)#57C?;A7N)]#D&@]<4#$O8,>B<K4
M%3=[B2'[#E\R0R$E5:IBD:!7KRMOC847GX)8!,MG;Y=B*R4=F9A>-@J>.%9'
MY"N5 YU$U^K?51^H1,V(94+J^<[YXE4XEAJME_AEM[V'ZHE^9=12-O8$+OD7
M1\3U DJ\<7&UK67!,A'D"[]:MQ=8RIU;I*Q>+\_IZO301"J&*E;B%QITW%6&
M?ME,W*-A:Y))D<:_@O54GUVPJ6-[RB8)LQ]N_D3FZ9Y!8Z+$@.N0 !6DZ1FM
M;5DK;H5U>OG9ZP D>/(X9)PUP)QE'IF+IRBW0QN/J3F*WT[0O]$B31/O[72M
MT=@8)?VF\77,:V0\,A?0_57AK"(#7\T9G&AMJ$.@8/!R4$,@CE9^!./3A*;A
MKV\M92)/^DF70U8O  ;[?3K8/ISKPA<5S((W+TF@[\U (MKY6F^8)TKG4UQ7
M944* 0TQJB'/*N$*GB+^C B_./Z1^O)[A2SV7U^T'+9IC!\V[.]\?GV;]HP%
MQ[)VC"6<S.H-H8EV)G$UB23.1=,KLO6XB0FWTTE@[,@WG"[4;BA@UJ8-B6L\
MJ(KW,;#4.RVJ7ZI(\MH%B<6"FB,0"\:OPL)%GI0C:NNV^!:@7')EC0*-,? 2
M$?7QHA5DAFS@C^U2M;)6KG%K[T1ZI%>?U5K%Q2P'&/HFW-WEEI)/=R=Z/3ZS
M)""":Q[X4$D5B*,M<_F9*>9_H\U,#%N71U2_,5_$I2W0C9B5%5>NX)B%L'J?
MNXR"RY/%LU19P?Q3U/";!>2?6U_I:YT.&8:QU>7JCD="NL6I( 5S[OOL,#JH
M.!:I[]],?*5(:WL86X8(.19OJN38;WR;/W9:IF<$U F5N4Y+F=^[IXW@VH=R
M!2^^,K,_T1DO_N&57A^&53R=>>7R;! ZJK5LF:3Q89V-A6*W9W>2/(*<F[$F
M?8=D7^JX CV[D27#CN/M4"3-27)[9)O96;?=][=]2T^%\QUF(U^& WBN[J>R
M9Z"<;<6D=Q+F3'JY+TM<5J^C'WF^V==BS>B!T%L]!G_K[R>Y?=AF8Q&RI/NG
M?(97$/E[L;JR6,V80V.23L7]Q/'T[4JSP/6P<Z]L%1?(DO/GW=UHRD\SP59M
MA\G2>0)#*_,(QP8WY68VTC\5AV:PD3I6WB]F4$7CD[S1]?W^S(H2..Q>7=8J
MY(.\#A.,]Q;M+WH7QJ8TC",B+Z^]?'&P=*+$EQIK751H 7&;E5W[10O_@7%C
ML A%OV\Z,7'JST:Y,!$F% OD;OK!0GVB ]6226E(X,(ZK4VSO)[T:A40PKDA
MOBQQ34J:V5!N_HV37(_@/O+HN5%0RZGWX?E:QSQ1NIV3D>O81/-\IP3+TV]/
MCZ>RSH(JIB-P,WK0*;KY5Z9,E U-AWMVF(Z4'@61(LY#SIAJ\>E^>")6?G/5
MHX'3:^^GY3P+&R<7CB:.4 ^QMSR?ED2(?=1D:.,5!<E2U]?M6%+%3#&BFS)\
M"GY<E==:ER6J)A@*[V9HQ[ $7I).8TY8:R.N<5;B9]OT-;FK[--IAI1GSK1N
M^VM*_P)?71EL/I]O82OI!F?].?3Z<^/HWSQ)KC-T:[3\HYP'LCW5OX'V9W<9
MV2_+Z%Z Z8HQ1=AO?_7]UVWJ'OTLOG!ROVF9D!CK\&ZNXIU=JC-8^$PL%JY]
MX6 9_%NT2!T(F,(4!@"@#:?4LKXS@?BBL\>%9VOKEB]=,-,YNLQB4B<A>B2A
MLR)]] WQT^.I0"#MW"<[N$'W 7W0^\>MT+:5Z"V]UGA\'LQ\IR8^20-M6//7
MG\010<'$ZB<XQ1:N!_,OP+9C*7RD](KD9*/V,P+==1W8,V^=$K<N6D$CA"K8
M[@MI\S17AD[RY9H;DX^LUF=MCU2.=^FO8Z=]NUW7Z6:/LZ,X3_D\%0TC8]Y$
M(D?Y%K;E5G+NJOYD/H10#U]Z64M1\XSSG%T^'J"9:"K)9])I[V5:HBU'3#CT
M.5FW;U9<M+0T_JV"A.BTN&L:GKU-CCT^ O%Z_( "FT_WRM.AT]W$_<B-Z'WB
ML("==PO"^'_^W !)S<Z3=J9,36<Y]"H+N>S&2LEG]UY=QWM^ZL^9,5#S-V7C
MA*[7?VP4-L2,R>WK1:GWR["R#6MTVHQ+,N:M><HEYDM/&! &>P8L_>YG7>SP
M'RJE#EIJ=78X3W]BE'!_2WFJTVE/< Q7/D,B[S !IBLC\5J0*[O%ET1.XFPJ
MN#VX..=A?("!RX@Z^U!D&Y[2:F\"%1;!1K=Y<Z],Q,-48^7UH$(U:F4_D9W\
MT<S8?@"OG&]63UQC1B\.?/7$JH_,92-T2P2*[=6UF)R?VU.@V.)J!L/]8 UT
M(X"+<;F\SI/CMYF@?+/CN]2TMDJ'([57<TE0WA$&*7Q_O0"SC]U7^"L^*X&M
M?>L[=>YE%6*N)YOMQ4P_E#"0%OWV+O.:I2N":IEKV*SCI(C0".#&7#9:)YIX
MZ33S:\%7!7=(JRJ3:0JW+O?)@B1^ZMO'[EM,<39PN%,=*21MD+1/2=Q0^<MY
MPZQ,:@&ZVI./H3BV*B'<W[_WP%9Q?7<CN26,GIU6ZPU'I#&F"%.8?VAP',;Y
M+BL+04EN_I=_9/C3^)_WE:!&(0;.BK\WW_VSMXC$]"4VL$_?A/>0_:_F[##@
MS]$V0\O)?7276EB%UW/.&3:4V+]VD[K%GK;2"U!BD)6%1/=77[J_Y@!<L)=*
M=ND@<_B2B',9O0#./JK6!B+_6B-DDG^WV_RSO?)O[??(?RURKG4)V]K@.'H
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M1=F^)1XTW@-U-5WH.$&JHB*G<.^#*';,;8%"IEW23NP% 6)@2 !L0#.$:AA
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M1FP^TWG1O,(L%#:JI[IIT>I!VM.'?=74:5QC2J2P3.YC-2*DO>JMQV@%==J
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M$\S75=ODIKDT1$ER851"T_$_2<.<[GO!J.:<^7QGTT44JV(G6'-]7.7LD%
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MIMF=%*FELXS53S>S)!UR6L2$P"!XJ/!>Y4_#L>3/@UA&Q+"_HQ=*)\9K\QX
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MM'M#DLQ\&".T[Q<'1&RN7,,;2UGUU';DJ/FE5MFK@CATV1&L&J3@1?$OT?G
M$):$P"N(<K36P=$&BQ#\].KS2GQ\G\!&VFY>2)2T]9[33,_@MZT=K^FJTMU
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M\EX^  )4-^>]*AYQAINP*M3DV4[]9P*_*>_/N^=9,YE69[)/J0OC) &]\@^
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M:[&O]]FM'1^X(?@HJ0P> %#.<N8?0N*( LP^-BP%-T!;6OBK!H^.A:<U37T
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MMS].F3'[:5_!)^S \/_;@</_FQ[F_@]02P,$%     @ *ZZF6!4^SK+ (
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M$"_?7.5V+Z@2W35S(6P2# <D%VZBJG:1KUA"H/MP8),"#L1,1%<OP(%O@G"
MMI08,W&SB-JV%0YD.L)D=<7_-D2;PRB[T.\C'( %MEY26ET;P(%;1/"1R+!Q
MO7]8UEDC'+A"@0.K+W/V/.# "38<^+(C';3V_[&;_-$RF2QSRK;(G%DYEDY\
M-#JJ].5PD$484RY(FE#YAZ XE,(!:A&C6W_<6Q)Z:\U?5343#*;L=Y_#\HJW
M)Y*IXIT+M_$OW2=VZF?(Q - V_((%>N'+MI=YLY%VOHZT/DOY3V\\?81"VY"
MJ*P9/92'DI381!DHS7D&^I@^?@HC\DE)2-8\"6PB$9:%)X6.OH_MD2/.B1^]
M1'U%L50;KWC:0R;>I(Q23=2O>(CX7 F%,W3ES;(VKC8A+K><D/%C(5(X@*L[
M53U1RA V.93 ZO5=Q>"!EY8_1<&&)#F?EH3?"B:K@4N/XFO,#V64*VI884]$
M.!1JA8ETAWHT)R'ZT-NP96P99'P_B$OA2#<X$L>I_X0/-#:LGJ)5'B83YM/H
MN?&4DTY&I1X@$[["L:'@Q+-.?A-V5=T\0D&H:1%W0*0ES'@T %@/:VL:TOM)
MO7@N,ZG0!.E3)F>D\/A2D(,TZ'RU4FT5::1DF\0^<38[0$J_@H_='U5/-;>)
ML$84)ZJ2%8_%'RE:;!S$07 _%>?V"TT)V-XZ?W3/R+'F2/#2WS*9N_6Z_O0L
M$[-*TQ<*BW4HKX*FI=JRD-&RBP1LB\0,/5";U!TU7)2L/2OE)D.C5U4BV\IX
MX1\'<@_;6#K,C_>< !O'&;"/#]=HRFBTD_7_$4KG/"-F^]2V08< KQ : [ S
M'VNM HNQ0P YT"JM7C%NQ\_PLKRYMIX)D2M,<@HU:Z6\V U0D28$-"U#P*N8
M)-='=U'472KR]6#_)M $#O@;W9*.76%^*) F5"7]87<GH)1B<,]@(APP>@4'
MI'MU-?Y!5Y\*NHLUGJC*7%U;Z//NE$(90^B2>QTJZM@]O\? A#Z,@/RUN\!5
M?A;_7%Y<.)LSH?I\_[EBS'GY)G?ZZ;"Z:Z,L4E213KP\@ 5QWIH/$*8 ARBW
M%\JZO61>,+^9[!*M)O,B9,6*FKJO?B4;^,>WW>#FR&]8 72NHAAF:-2>JG/=
MLM5*2VEJ&LW-R6(*C/=2/-?#9 )ZCN^'J&U%X B+GO+'V-L7>"6?0]VN>ZPY
MIDM?:QZ]Q;BTAI5^XCYVV'A@R0=RV5^:BSO3':@2=)5,K@J2#RID)5NL:?_F
M0,N0&])6\TI#[Y+#_]LZ4W8\_5L=^?#O7-2?V\"1RI5COBIFR>9O,LDL[STU
M=*P0:TNJ\"CF<<K%<G%Z=*RLH[^=;!YYHVM0<MC4$+Q;_J;:)/=E-$0(>R;*
M3QJPAOI*! VN*'F^Q(SF?)[NM:><G5;*H8@BU(^CE&?8=!"<7O"'*4[FNEX*
MB5;0%B%M/MI*5"<6WGSA 'A9GN"6C)M^+EO),<67C0?'++)WU9+6P6<]Z<..
M]S84,YS")]@K$[+,1%=%]T%9H+O30T*0=*BN"] +:3OCVB&IG?D:=&21!GFJ
MR=W(,<$TIT53ND5%6C,JRM: -,(_]_YMEK@Q$"?\1>AJ0LU6][JFE(]X=\O*
ME$OJ3 9%PPSY0)XB##*+4]=EM:6E>[>3A.Q3#V"[2X5;TU7Y^+O?-,9?"HD=
M,"$8,$IFR%8&=2^H)948?^Z.)D]$$^& K1P,/AK'!(.@>H9=?!YJE^['0ZZ.
M9(BK$)4W=*?&/$X2HJ-\BHK"?/U"'_<<)]65(YV.V(+4'G0O&V61G7>S5$'W
M0Q.Z"J*F6T8>)N77V,K0S(T14(V(P^00(S:$5PA!6AH']\_\T2N&JYPX\FH:
MHAZS!>(U?;K^PMC*7TP=:#_>M3##2 (''$5"DC6<Z%AK*41,':F:C]47#"9H
MQNQ++1HPSTKY/X[1A_/F!F1.:8GQ*"F+5TN<]82FB)MGQ'CF4R9D(QQ^)>4X
M7@?CH#OF#T_R 3L2(1.:@MY/O\WV]>>_+;\?6D+/L^'O)W* JN!Z04ZP+/<R
MME"!?'YU5I8D(8N0"*H5X1QUZU]-2%[3R)#L0,]!N4\^2S/U"1HX8Q?"^( (
M<Q!MO9 A9UEX84_PK0AB[D"*J=4 P>!'&8P5T0#<E2[ J.;"S]'1,5^*.$<X
MY$633]UC:6$.>1:E L9D.R,<MJ5*XEX_Y[4N2_[X%@U70A>(GL2\Z,%S5)V)
MKNQP'YDW3ZN"][*((RN6^FXVE6XJVU?NFY;Q7?MYZ%S;) U_!4,C[4R)'5!C
M:FF>SP]T>Y,#40MMM2+Z:KUY.P32[F=.TSV,<:],NF5PI=)YTX6';'9-L<H+
M8VJ% %Y3,O&J;28@.XP)*!G"N3NIB#G/U^# <*3NRZ2EA4N$+MA-ZQ7WAQ,2
MM1=W^P77#[L[0134A /1:9RP5E18.*2JF%?'D?UD2T<_U^-Q:A$Q5+26K.V<
M]O@#N,8.#K1RWEZ #_)I3HEDKRV&?NQ="R%P $/B[WW97STX5=1_,L[YV9#M
M\]HV2_390,8/7*VX,$*PW?2//>_Z  XL2;_7;Y96@4U7WL$\7X(#GZ/W4B3V
M^^_ZJ6^8*C$3"XLD9@3 "XFP&XD+E=M*R]M+\'X'' @F_L/E'_#(3.RJ*/)!
M6 (ASSB VQ]C-__Y6+4"78'LVO5Y7O="4YWR8^2=6O%XBT(X\!,RV9\0ZP3W
MCVE0_X3L)\#A7/7>83D_34_]=Z<6)/\WZZ*33@D'WK$9_7":0Y[WD\^<@ZN*
MS4\AFJJZ,AW,J,A34;CE.9D-R>HJT@^#"54DD7\GZN.MJWAW:8V^WJ5&PX>B
MNXAAV(?5U1X517>^/F-7'<$)2LC]XR\IS+\D&OQ&E\AW&=4D TS#H<@FXPBC
M 0Y\?'Y3E'/X4"Q<\5QVI+Z_;I7ZGIU%%$4TYZYJ#UVV(/<;MKS'8KP!X\.,
MLT9Y(KF6"'Q[9E-2E'$>>#8[V&W-:179,@_V.JA($]I5Q3<IBZ:&(V\JV9L\
M!+Q=]#IWH_%N5[<[WRD?S1I3JT6]8*W,#A#:@(T-VY_LLW0O7_>%EMC2$IMW
M ]C1*\9*7_TUNA^MGB&^X^'>4Y0&"%5^(QJ4+[9]7*T2YK5]WG;JY:H^B2R9
M;J.]KFHQS(,#$L3@\Z76BP9WA#TBQ?ZQUHWE(=C-7=Y)(IOX 3S4E7%[X0CC
M". 85F]J5H3YL\&!_0[PH9N7=^+-C<Y="+R! \N;_\^&CALHP1Y[&)WVML;S
M_FRE,JN[+4A\]&12($ N3YYXKQN\Z#81H61R ]Z>W&0>ES89BY>\EBY A'G^
ML%9<VS8Z/K2\B\J[G#<\E^??D.@_#$W6F)UT&CH+I$["VB<V14*L.FUG" =Y
M_Z_3<J9,+/"%?*EY:V-E>=#ZF9XXA_A@0(G][6PY4/MI0+[@(E9^G,VTL:8E
MI"]6:'Z&%*\=Z?X]:=7J@Z_0%WD?YJS.WV)LJWJ-=(F*&\MS!_5)X;2$\$?X
MD[;?&T4NW88#67Y9<P4!<I80\P[N=L 4$<  ]K#'&R[U"D*]6K>/5C:NO"<T
MHL/9.'VE7+/CTN>OYD0_QS*!)J/4@QYOLZ+,+!4]X3L4.VA0U..OM%J+#.(I
MWM<$Z1,Y=D8A6RU<\&U[1^:==FW$.]NZC!3/=*LW/:NS2F'S%+I_ZV>%\#UF
M>4!"IW',N(;@P6B&V='7K'O4IJDK$1M$WM>:5:,GZ\T0#:L@$H.H>B>4%[/O
MT+M<U'R%((LVR\_5.<\B9STR&@,"HD(>*@T<<]92%G7>U0[#:V%Z/N^-S6O3
MYW*XJF*6U1+,L2ZQTR_7 ]@S0LF?6N?W.]4JZVXS45$DT2+0#TGNHD-=>_@K
M48JQBIV.:6=DD=)UO/J*RD^1"'IH*JJ&T-D3DE 2/=@$&WS=389S(/=)R ;E
M!R64NBL7EF;E\Z=T9K8)+MT%'9WQAQ*124W[[;CH0&W"RP$BX#T?Q ^10@:?
M';'\K5X+S=5.$BFL= EPV7@(8%0^=[4).Z93P&0REON\X>HD\9J\(.]"A)*Q
M$\]&LZ([M$;1PKY3%F"F(S+IC*K;$!,9%95=K&N2.Z*H9Q_<]5)- 2_HX8BO
M!KR:3'>5I"2!+AXG4(M(""<ZA7Z:EQTMM;2",8Y6%_,Z8[4HO#4+MUNEQ0_!
M#DR7++'VI\Y-SM&/?*+$7K;<^BB69_\IE.3KT)SX^U/*[>;:CMH:/0;R"'O^
MM+FNOO*:2^UGN3PQC36>PC=,B!\2#48?UM?60F!3BDZ83UN,+P.V_=-/$D3F
MTL[2D->/'>^OOM:+H,7'$;&$UI>R+FV<Z0S/.8[(\\U8VU=,W"A\E$>EJ'N0
M ?Y<K.?+=2T>C_U^K./]KL4GMK-+ PBWR79CBQ;93KKG<L CBS%V?#6".<D*
M!,*L=XBQWTS2:Y5%UY'3:7F.3'$$<3M*G:ZB.VB]Z(>C5=4).NPQJA*N5Q^C
M(U'.O%$T35[X=-!;?HC5D.K!\E9@A0TO"Y,VU7>#;O'P1FCHKHIJ_NNYH.--
M/=L"!\JFP6DVFH8AYYRM.V=&&TJ9D0I_^<<A_/C7S>G!Q-U:KVZHKS@41DI^
MT?(["?\\X%3Q@=Y%#$"7)2^AV+2PLC1M3(T'T*:U?/7M%@>7/XDZE-.B;HPF
M1,[+OX,S8<F!Q/4FJT79+W1;&G#4HBC5G\>EU&LO$NNDHA;(R_%49!&]W*+E
MI(T*>(?;;*_G629;]ZFJ47!8BG(*A9L7R:&N'35KB%HWJK^+N*++_7S]D43E
M7*\-HGRC?QOZ'SU90]6 I9%-64YST@A4QV[?0;3>X2-F/U%VT6%4");G3L0X
MIA'ISOFD"'O%UMF$JXW R)?E=6&TR+%W:6AM=I:HR=MYASCQ&%]'C&:*VHJ.
M(#<TM7-T5U3=&:X?K6NB>IU]L)YE>/(:1_%FY*-MU%@A1E4?3I1QE-$G55?7
M>;YT+FA2EEGZZB-O[0H!C)POU<]:>"<8&[571R%<G_<'(KJO2SJ-MJ%2J5R.
M=CX6M6S4'5#IT\W*^MJPY64I]B_7C^WJ*6KOR0/O>$]*,>U-E9JJD]>A1V1_
MO!*WS4$@0&043U5&I;=?P3:[,!S2:GC3ZS\QW/DPBDRQ>^V]P%(J*$#D':JP
M&$MU8OCI@*82EL)P7IQ@F5-MIEXCDMMUYNHJRB#XP\>B4</TJV[6'7L.CZKW
MK$]GQN3ZE+ K/_6(N4:-6U?/<9M!!%IK-2-U4GA  :V>&S.M>8"3KD3XJ:T]
M_NQM*NRPC ZRO*KX .=U7(39*O%>[&B^]55!)[M[_P!K7@=%?@KV0@R;*LFQ
M3AR?#I(+B'U4/+M1Z4+^Q$2./.V#<>,7? 3WPV/3T9BAYA=7$VGW8W+F9][$
M,2NE&G^_;CK9J"T%>)]/LIT^2MHSCFD9=0@=R9(AQ>+ADFNG5A@N*3PM)19F
M@+#.&.Q.Q<2WTP?.1+NF<S\#$UD_66-?:7J;"YG[J/*VTX=PA?X*!QR3B1W&
M^NC:Y3,3^_SZ$50@F=_YK4N=&)J#$&.6T( P?[. 8D9EWFGC\W52]Q"D?41Z
M_[H]29+-[#" Z4Y8.:6N$Q=.KSF/2Q7ZO\'6SF_]^V^V3O ^_.Y*(*.H@R_2
MG.Y>4E-X("W+)U2'[OMF@>/!$GNU$B?8]7"@9?GN_/P0VBBM>FT_=(OH -ZO
M:[TH$I]QA0.2,QG7WSEA+.%8C<]?SD?4TSIURZIH_-(573,+![X);,"NP^%
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M]N156V\FMLA=8O?7N"1KJ+WQW0*?7DB<Z,?GZ?RB/0^].P*EN)N4EN5\^?_
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M'+M[^WM0S#I5*^T@E6Z9QU\D HE(X@OAP-!X&0SQS_OB7S1)?-VI&1VO#/-
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MPHT!^<M8[2Z67J;XM:0U"_0J\R@G%*7C3.F^GRY&_QT$%S[]'U!+ P04
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MO?&A4S[S46 1N8GOQ?WUL1.&+ J_ @(=>U=!'$;[<1# F&LI$#OA^6 "6)L
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M>)5[H/YJ#LG)&N\RG_B<=?VWX8Z<$GW./?9&T:=DY17Z3(4^GWTKL,\'!T[
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M"EGG.F"T.\N/E%AQYWS0P10A<>!ZH^L'%OZ2J)"M_O^4@NYXJLG<LZ_^7XI
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M_/W9'OW\O/TGN_O[<+[[TZH_X!AIM==;K=W7OJ3_BL/(&8Q73'M]R55U1J/
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M%=[,.*=EL>Z;5[U1YWEQ6F[H9V]/;KCG[)=L]X0$$0Q,;\!_:SIACAS90&T
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M$:;V8RUM$;\KE \1,5(6+5)22@(=H31+X1R&S.W@0W-'I.9LE<4+R)@@*D'
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M JH"154S?43'F"F-I71@JDPC"CP)9<?C:7EX#9<Z8-1,#S)IM ^E>'28-#A
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M7^?;(82=^4HZ$]5U(R?I<!63-D:Z&&",V<@]I>JZ,:788W9D&ZUG3%;+2_*
MET"91IE2@&%F(GY5AGA@]$"Y]5C5.,>(0%E,OJ?B'1R!#X,$UZ^TM!ZC'+VR
M\7*:R3(%,:VJAT?&%0=1SIUJ-)$>0H7::1$6M_7QQ"&]:+S,'2\SCIN3C..5
MA+K "^JXH8\AVQF7\N&1^34&&<;#V#9E04M-2W#9K"]"NCYR=N$"'UK;4Y^+
MG5)A47>6@]$OO[1J]2;9B"3A_+(IGQC$?&VL7A;(HI;YD'%@BN3FC22;GL(8
M74O1C&5VX6DX$-H61?4Y8?\&0VJTH!_CV*,(\X ;K))6%U-\K.\C=LL:11C/
MKVG61+?3+-= '5O$V!-S)P^9[[%UNIYH#,T0\HO,P,O<8=I&_2JB@Y-W1X&/
MLV&S;71,)Z$$:6.GPI96G6-+TE&#EWP2K4@XIQMBF?S0N8?+P8MNW''2<QM^
M3'9'\ ]^[RJ+WR\[K5JKU=IHM6@K&+?G4LU^([44X7V#]32WMVO;VSN:"SQ5
M_ST31Y4IAJ*,MTE4(4]-W=E-?#3<C*GG QJWJ+H1P JO*Z:WP LZ]XPN$B,)
M<,V&'D>C76V(5*K)Q'[">5+!O(?["E<*\K6+!&?=-F\D&>(4 A_X]^,D:_R#
M5I\+RS?XP=#LKF^F #A(HH4O\.O72?&L\.]QEZZJ"<0=K? 75:*"O$(*-R6+
MU8_\$N]<"D%G26!0N];8;M9VMUN/X'S&),ZG)[)E@W+Q[ZJT-/#Q6S)S\ZNF
M*Q3 4\8B$F?/M3))VP4A:P:%)B::XY!_*'UJ>FY6FO2T'Q34VMV*']/>B<8C
MVKC=TC%%01,!O#YLDM62R "ET=WRRLR'$'<*=TGP'ATLW'_#"G\RT>])%!C'
MK;_UD_I_P") S[9<D,0169V!DTCC6=[PJ[E9V]JMU]I;[;(0,3IU%3!/0QD\
M>0A-^K JSJ**S[K&RT:0>Q*5<TPN &TVB(>4O"<&Y:&"Z#,1H*<CHU^;<;V=
MH-27"F:6Y=A,1?UW(AZY0&X?86\Q'A8/=.MCL7$5:$]U10$'D_P%GM1@F^DT
MA@>23\QW5)(H@"EXSDIA?LQ[D0+Q0$&S*?(B9-2FK'1AJ,0'\S&)#P\!\NAL
MB'2GO70VA/GX; C>XRW%$K6T8.17>420^IBT+^23;L0-D\KBHA52P#+\A2I7
MP1NYQ*-\NI%*FT@NV]3&&#W6I]$RKRQ43;NWS+%FN:"+#.JES'AY/*17*)]>
M7L6<ZF1(2Y&](=6K(448^4PI($9M6,U>$O*;\=[!1"Y@6;\TDSYE&^9QL6"2
MNYAE;SJ1\%XD^UPRM,6C!;90LL*_4^9P;:M>KVUO-LI$B%15(R<PJ8T04FA
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MIC5\HO&"I*.![P)VPQ)XC3P0YQ(Q64*.[3;TVCQ(C;)QF5BO6I2LXR&R^P2
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MIGZ%L.I4&K!G 3\VL0VE-S]$NK<0TT)V!!'BKM1$@40K>3,#U#CQBGZ]L)1
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ML7Y$CJJ9W2AEZIV.^F:6]&I7]3'=U;<R3BPME)\AJ!>MSE3*T@HF*YO,\T*
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MFYT-_*BLPG/@#E .#-,(8U8IS*M":S+SZVRDL#)9^.#H\"#\7;]^%:W*,%F
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MP9M2'<RN,O>QH,^V](T'_7(8XW6#2X1S9%K@8B]Y]^H@)";*BN\5-C2%?C6
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MHIZ9>_3Y:9WPQUL0+2[J\^I$4FE;"^(/"2?:_N Q2?TQ\6]*=.F%_U5"@.Z
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MYL TE9XP J4# BM,3'/M$4TOB1]>I;\>O#]0_!8G0<-]XX:/WGQE96LM>0>
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M>-WX/_25!1!8NXM=YFK75GNA!,@UQ$U)(<&M'$LK#GST+KGCB0:G-92-)O#
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MHVH6@2Z/P@]!& ,1X]&'(K!A?==D6-A%HM.VUI_4+O5AL_AK(S&[UT+Q^>(
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MF"YM%^B$235,JF%2#9^K&NCT=39*[LO1F!_IW#L#,S@M)P!0-/;W"[,TWKN
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M'C0Q(4W<</?K9KCY[*A;E7H?U,M]4J5D2/P,Z''RL\<IOW55L22;;P5KX Y
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M?^1J!YI:M),[>X4</\Z>/SW,#H\.$Q7+"[8E5YN;AKP BRF=90/H#&,*%'+
M=+UKK,+1-]G7SQ]GC[]^MB.2FZS[!E_2-DG!OBJ)<,-6,#?)V=$!9U&4O>U:
M[9ATPE 7C%M.?<!RB.+*R3"NW-;<#&$X$B7)7C;&:(->SD<C](9:8X02:">=
MB;WL&_8#R%+7U@D@H>:FS\PFZ(T/=-Y(S$?(+0L/K']=J%-3,A.6FY*+:TL?
M-AO8BUL2IYJ<7+&([/K"JW^^>#E9 I\SUT\WX[GZ*_TU6YH)J[ Q+>>Y.?4C
M$2E;E.X85:8AP_66]HL3W(D<CXCE^L;Z[NVE.-Q(;R8PP6+O+WV!_H?VG0M=
MD2X^4RJ=4%J27=2OK9--^UYNWJR^OF\A)6_&S:KOY?""V(L7W+72,8JO6L"'
MNTW8ZB/VUT!.Y2]>_E=P^]+C<?FVT>U[5Z3D;LG\>Y_23<)F/PJ(M'<U6DZ9
MQ4 (N(VB<F@SUUF95Q4,+!<("S$\]AH/RYE5T(N??WOUU[9?_^V7'V$ST5^\
M.1JWH!?)%KL1!T:8,?-5%O=H]TWR;$,\M!QOZWG!\55)\KE(ZK"?YD'R2YTV
M.7PJ70<7^^##,9=SV0I*B9: TS8P86)@J-(2\U%*XZ-45]SV0%KX-7G5YFKO
MY%T0FDV8)&N%56U@*BX,V>NK FN\E2[DAA#GYDI&F 6UBN@I,3-AY)TM1.$5
M];TI96<.TO=>\V&]6/'X\(NC6/ZDE2FAYXKDV(=[17N>((YEJ]!(@Y*@F,K&
MLFGMSHK2H)<E6;E!OSJ'5!A1K7?E+-\MS73Y%O!?3QP[]AO7P['S>.+8N:TM
MX&_)8;U;JN>=1E&2.)/HL@''A\?'Z?=R:[ZI<,Z0A'Q7XM&<0104Z#(,$S3#
MGI2K5=%U!F&>-.^[T[JA 7"U]4GC\'5)O=:$<2V@I-6ZK#?&;&&1@CZ>Z)V*
M7L6E[6:WRC\6JWZ5YB<G2'9V9C1B&#D[;,5K%PG.-RZBR%(KL:MS[C#M(S&[
MEP63/,J^?OXT>_[\:,=+#](7SOZT0W<#378,%,&L!B0Y\%]<P.Q20V+3EE:>
M)(*/>[D)^G96Z7_G58]Z]R.\W>1DU6P,,OTS0Q+*/";AAS*\Z:G="IC$ ELG
M.3TY53R#-82C+ST^YD##TS_;R-,P+.DF'O>V":.5],-79LZ]?-/'1PX, (B.
M=/<F<PSMP'4&00^3W M'50$1YU=@2>,[/#S$_[<V3.,7B+"ER)S3>[<&'-BJ
M"B_=/A4'Z:]5:9/R(X?&@!^@9:2!M/V5L7G)2/S[XKH6]5#D* 6[MQ7*84S>
M:/+1FJ@6VK?5P8S70!,T=;HD"9).Y&'<-DS3NT4,K?.+_ 1T4?]=Z:#4FD6;
M>0GE2KM>4])H9H9;N."C6<(95W;27,94^IBT?[S!R$ ]?Z%[Y=ZQQ>TO,=S>
M<L!=!P[9YUBXS[176*1]1#M$X1)4Y^4;&R8AVQ$HJL4@$)>Q EL8T8SCJ/H_
M@I.<3OQTXJ<3_Y^>>-<0]JS6 %=CJA.)9K)1@@1 4?=MN=E./V]9"I+!G2%J
MSUWD3\UB=XW =.BG0S\=^B]QZ(>H%V_W[_!A]0:/NQU?TUF>XD-7,9LW51*:
M8)H;XER'H+.+KATD?.9U52FI'6>??#-)C@WE<_+^VD+1X[]$Y>YQ&IJC,?$3
M$WYB7@4/'3S3.J_T]*[H^BYJ=ZE%!BX <6JJ1^%M- C25)L='F[R'\]X -(=
M<<)M "P"(MT5<;I;AT/0-L!2]%5.ODS'U3 UPZCRH(ZBJ/@GR@7%+5 7C'\K
M.%R(H$]! CC/;>7.N47!:O6F?]2Z5C'W!1EI5)"1G/M&KZBUF? V-SCH/RP*
M"EFT4=ZR[ 4&> 8X3D.;CTNU*@6MIZ)3<7UBWA0<UK5BE/PQ,4H'8D1_DZ*P
M[[1D"+IR5DBUHWR".?E,YV&G@'FVB0[)+&Y"B=U["70JJ3$)RT=ZTN<(#1OC
M8%,H.L6/6DD,&+(6.?NAI3%U94A]TE\W-F1<D(MVCF[8$L&6? -BWBPT[FFV
M%S<HTGF[KT/Q7/UBV7W>2S4)C6,^FF8."(\'8$:[3'+PU='1P=-#'W[;SDBQ
MR*0[1>:=P(9^NT!R$I8<#,)A48HFH"00G$LNA=59/,0Q0;L9HX=_2#K*X*''
MSU@L[K<*(9/?FJ621?+JPC0F,,L%I<[D#[C4-!>9V\][K@F2D>X<5\1+3AC2
M3^@*$B/_%R#"EJ:1E?H?^8I\[%\:FI3-1&<)28Q_(GU7Y(B1Z.P^;+^.+EZ$
MD%LOODY9;4F=5U@.E8_/P'_0>#3 \6*'(_DU9TPH\/)T_9UP'HL3W@TR>?R+
MA5EJ#3:/H^5UG#':GYEJ6^'X E[TC-9AMAFBMFC,I<G;CCV7N/H 'DL2>BS#
M<\FM5C_("+6FF%F;R)N9TR#Q'62<K1^'F5^P0!$H3^I>))>JZU$L/V/<Z47C
MEN60* +S+F!DV$P:>(EM.3D=EONZP2?C@V=7;+B7?V"(!0  9;&";0?:H!SF
M3FM'G+@16R"TE2SY65=G<'21P^9MZ4[I'8(:]:G>@28?S"@3.CA3#3[+5:+2
MP%2>E42  I<VEM7BMNB.)B!?+FE!78L3AQQM;<W^KE .F:,D62U'+OLU_=B-
MAZNV=,R3S7=C-M^;I2M]O@ !*J#9/.*WBJ,B15P)70@ZI@*<A@0&/@;IY1UE
M;SB,%Y6 @4H(I]L.D):"1B,A$:$WB,;5U'-C%NU-NK W&#?8:[OS!9? 62]/
M]I[]5Z&1Z-ML5$"8@3C,]-!W9J:LS\E"/3PX/ P3Q$HSE;>^/'A@P):DKI(7
MNPKQ8)<R.LQBWEU9G@X$?![L.]=-EKY",Z9_5@JVUDJ7B#Y#Y_ONS;OOK5+D
ME\$HD(.71#V?AU%!O/)=8QZ]+,GYQOV"!WF&"E:_B*O&[P9EB7LW;C(R;+0P
M4"VQKK9U>^_I;(,"0>L$-X$>>%N9'\WB)]H+5M8,HEMI'$*78\RS/TC_49_#
MS,_L'%UY0@@M.C^M^4S'9;G)-M".+4BZ=DE2&8:FMXA'3@5[XC"(+8UX:X_2
M'WYXF6EK[:8X@Q"NRWQN#4#U03"*L4?NDHP'6&5\ZOCPV]>U&+3O>4[\PZ-O
M'P)S&/'A'&?/GSUE[)C=)"9^ZN)$9Q(_31;"SQYE196BE\1R5(G["J?BF_!8
M6':>H^S)XV^RIU\_OO"]NP!MMDCTQ<\OT[^3MENG/XAE8YM_!)8][ 74BMGR
M5G_((X^ #@-?#]5 3)>,Z6K.N-2#]@2[F.@N#LS20&"UO&O<^! #BZ^RX8VE
M%5J#LRNU6BU#^/"/2O5-(NQVN(70A(T4W.!N;$S7-Y76H)Q*O9D,KVZC$A-^
M@XQ+Z8+T@4ZTQ>Z[Z;#^]=4IW*OA[J'E^:7M&ZXQ]0=$H)NL:<UB3)?L*MCG
MBM.J0^V )37;D;+SRE'*LJQK%MJS.\I8PVK2D3K6';7.8T:N+W4.%4FYN18K
M]DOO\?79L#<0.2W:)!*_DOU>RSX'016/!2I_JPC1QFW4YDI';"Y'9D$C]A4)
M@)L/R2VVZ"3X!K7L#>F#XJ$L]+-OGI&U<;SK6K2F74#P) /XZBA[^LW3[-F3
M)P?/#F-S\+V@K7GX9D$FFR^@_*G&>H0FT9;YRA^QII$U!#3F-M</JGDRFCAZ
MP*6>2\'.PP]XR,<QP<T=UG(RB^RN-@^=M\N] <Z >F:Q@CX)%D5.KJ#-=:_I
MO1(IH84.')$DL+@>%/2K;XX/?/4"OM1VEO/PW,">P>3I/5!5$?N@B\DC>//@
MZ/"A^_4BWY UNEJ912',*[Z60<IQ[+@3,IO,H*)A6=: SCI;\3CRH+90=3%C
MRB#F%W"+O%.S-'WA(JH++B;^[[XRR?%SK@!YS,4<[+1P5"NRS5\$>(R7=;.F
M-4Q?T?DZEWUMUK7:A@]4L,)O.W&RRKS*5WQCV*V%1"8[)-)^.=,=8Z&WDL,6
M>+G!9_4708[$^E(CLD1"&A:,A]9M8G=V\)4 GZ+.Z/C9L6ZN1AG]DJMM+=S,
MGSQ427"H>.HT]V?9XR-R3HYV,>ALJ8OPI'O!4X_E8:!-GF1/GSS+GHK+L^SE
M(N[J)*23&0K;Q?*EU43NO)->7A7PV)A\D[YS.4(B%E/+1?1C3J])55R?7/()
MD;9SNY2^MFZZER_=D-!3^_K8G[ZA2L\D"/ /TDM5GOZ]K&<D2F^\E+Q=(PS7
M5[)$1^D/W>(@VA$9R!N5,#<.G2SM^=G#]''V]=.OLR>'S^V]$DB\_]T.H8]?
M<)'0.W5VN37%.B:#=;3#=D'Z^.TDPS2=XV?/LF?/GN^27QW^Q6J-!MPN\[DE
M-$Q>%2T)7W,225_'6O_Y\]T)4M6 0F(%/9CNT(/!&1@&E?"A[U^G_^B[CA3'
M#S^\=.K/_3107V=TA(_H"#_-GC_9KDL+ED **P:+$)K(99U7K3U>LM]:@44W
M[5='6Y?&T)R-5#NB33W )_1W,M!,)9>JE&^T4?9W!U9D$X:2 A-J*VQE]?YV
M:)$6AU?'1D N%A#6<Y>T2)#BVXJ)9-CW[1. )?"0FGQQ5K#"<K&.RYT.L>S$
M2D&QC./%^2H.B-H3LZ57L!@B*\?/LL-G.V4%4GYX\.SIXZ>7')DS@7:\.GWP
MC9A#__NW%^_(JGZT0$I1[1^\ZIO'QP]YI;[R!9;!Q4B2\*I!#I?L]3;]9]WF
M;6ZMK8]J\9+6.OPF>_[TFUUEL5Z'#:.#D?9\+S'$R+; _OG\5UB1Y&-Z.^M!
M70C3&KWM(#"=?N?IE(:AX$\$IY';%E8WYS7$1@<;>SQ =FAC[KYAR-!IZZ6&
M(!WE'ZW!T^=/L^-G3W?)S/8\::%U+9&81R#4!<9=^/77JMBZ7?1+8ZN!Z7XR
M,JLZ6D\$[DF>0"+F$Z89F,9M\1$X)GJV[7L1,>VUPLE-OQ;DW;<B=#.5.0X@
MJ%MGP06?TDG)@ZB%5]%@F%SVOA#6&X0]N)B]KOC/=6D6)T;3KAH:[.<2IFX?
M%=4CVVK@8?H I1H2&+;5XE:J=91J/>H@5<@1VZ1/UR>&G^X$SWFLV'([K[AN
M^\(9C+Q_H+G=*:N7R;@';,7.RXQ-LU]I3'2*VOV!@(@2&D51$0>'5\9 ZQ*H
M[ZS<G4?P#4;5Y]!L<5=SB![PWT^<J1K9Y3$PPTO;ME*.<QF?3@ON\F(3>+'Z
M(K:,4ZR2/(1AN8,2!/&!G'>K"HY'>;F[-^"9@[*79(75?'*6N:R._QE'BT"X
M%5]%(J4OXF@ ZYW*PZ<>\//BM44/GZ(K%;)D05#"W(J=M@FLD7>FP]<-)A3C
M$1_J$?+!%AGSA=KC(I-@MW19U3,N6EOZ*+.[OJU(9:T2]\E0,VX)I_*,+# J
MK$1P<=K\9<_7YK84[TARCA3&7/8FW1*MX%(5-ME@P=TF^^^03_+T.'OV])"9
M[\\E?<8 CD0F), -B9KB)(0;@$\X4!7>!K/W2M7^+=3P>T%Y>WD>LF<3#]GU
M\I ]F7C(;BL/V5X<Y3U06U>#(K#__W)V\R6A<-HFJ]. /_+&ES,%(S-*=Q3I
M(Z[6D-05$"U):-K&V:<Z:HG*H+5AO/ 3T8B#])5IUS0<F6>Q=%2D:E/K"Y.=
M79\TEW/Q "-"*+PWVQ$KW$JW6@8W)3X#[B:Q#,\*$9+9SXS+Y;OZ)D>)I75Q
M9X;[^^&=BO]1.S+"^Y@0OK;HC5W*>'7$((I,**0\VWE3S+Q+XK-^9!CF)TV^
M/G5+IENRM6+Q"@]:/MA0I_UTLH53D CCTV<:T_Z1EN)84B69-YQW<81GZ8/\
MX7C>ZX)D5S*RWMQLB!N4MH$_^=71P9/'(>KMP>RARL_@39=/00Q3.39/=/E!
MD:7\-!K4_*$/Z'/(\3,F>'CP^"C,,C]8/(P"91<\BE3+LNC\#@;1^VHDTN<[
MLNX>6>)']DVT]/:1V_Z'#2,^,#)PCEKNRCMPED"'LWLHR=:"#Z1@^3"(SO\G
M*Z0.YLG#[=#SX'G)A8)P]/R*P7M?_AZ[CMJ'+S^K[\\,=# 7$ 4HV8$Z+1@W
M&O?]+C<*3;^45\W/R:*CXG45:FD29JVPO)SV;HJN(W:D!8UJ!;A23)K]7  ^
ML<@/BU\+KZ/HRF.\J[])/$I]$N&]F-5OIT4I@97W%@D_%@W23<VVT"LNP7"1
M\70I,V@&X4JLB3%ZDNJHJY [-K'Q$)@U[<A8 *".QF/;G<;#22YKE8W8JT.+
MS!I;HY.:SLGX<T>'/SK5JRYYWRHK<P'%&&9\<?7"Y1#'[-XP5?%V7<58_QK7
MZ6RG0RAUR[M0S)^%E XSO\ESBT\<@*2'?-/%DAEUHT!LWO@P^2*[T-<2:I#Z
MO.(XL7OR7V=.KF9_.SK.#B^,TF=^%E+]%**-GAX>//OS[K7?8BYP?HJ=UA!W
MGNQ>S?\4$AZ0.$45(X-NR+'WENS$C4<ZYK:%:FY/2<9>S'(/@F]7R18QAFZ)
M.OV )QY\_KGVTL$'?C3-"9DD'H07IN%^";[M(7$CY<TCID98<\+A>#[UC)?^
M 6"07]?!2\,PF,3EV()@*HFPLG/0J;'R<UP*<EP,[JOMM;,7^W^?9!V6!QO7
M_S][;][<-I;DB_Z/3X%7K^J&= -2D=1>55T1LBQ7:=K;M5SCJ7CQ8@(D#R6T
M28 -D)(YG_[F=C80T&*1-"EC8KK;(L&#LV3FR?67%T:YMOT7YEQ>=*-R_)Q(
M2> _I/><3DNHR$VO=Z!I-95G8>YNN(H-8XT83EN4:Z/X*$K*@J<N)YSLIA7>
MJJ7PN^[)V,Y5\-6KLXLQ:^!$$YH3:/<9:B!47TK;..#.@?KF_C*#XX2G<2(_
M.S=YX+Y9*C1K&G!<VF0Q]G,Z:<*H1XS'L'\4!BOA;/"T+:J1M<@YT<R@T!0!
M->S*>7OB;G8C[@&9DIN<6@Z/WWWZH7_ZNG&=WQ;"U)0$KOY;(@/]8396J52V
MP=8HI74H5H;XC$4T8\=P7L Y\%FB7\<M1T/LVXS58#II@I()+&RF@W[7B,>O
MLA]7!";R206,RD&=I9$:IBGC<_5MXLP<TI<0L>V8J<NN^TD1]V]B,JDREA"E
MQ,J(&;]+';)-"J+-_W)1P19=;+CV99$;0>E ,J8ABX/2)"3DFF_F4&,&S")2
MT0W:%7I=>]G("%Z2:-+PL!98SJ0TZ<1Y"JWH-T4:$:QO++MPB"A08()F5!+!
M5E[9@V5-<BH7).A#[+F-J4T_MH_]P@G=A;O3"KSB/E2)R4C<:VDKD!+E!;9)
MF<9&I%)>)WE?LI#M('Y5!3D5J/VEKH_+)C)OW.S16-<QX'<E-J/6F;B9M]<"
M(W5K'2>TZWQ>M.F4XVFPP@Q[)W1;ZQ=Q?TJ$ DS1KR 7]C3%$;S[&!: FPA4
M)_+$: 2.PDY8$7A;"98<8A79JY@N???Q87Q;E)T;*1C?DUFP==*2'$(Z!4->
M<PMVR,RL58@67[^%R&WHD+30$?#QMJ:2.KHF&@P<&N2+/@ZQGP%VH8+?[[7L
M!,5ZD9.^S3'O.JT\6=QECO'IID=@7O4%79KRX$F7253_EP!S<JN)7?L]OY+8
ML6Y7H^?U49B(KXV3% HXL0FH8_R7Z>>"+I\LOXK3Y']BZ9F;*VD[JS_2SIAA
M\EEM.X;6':P@2^"]^C6PR:/58<M;U^-%.<ZP?Q8[!99,@'FFXK*(1R9YHY@[
M\U(N,E42!%1_:>; L)H>O LSA2B01I6%B=QP,,E+M;X[O;6L.NKE$;));/S9
MY4)W>0NJVH[B*%W<- CB7LN55,Q"=Y-F$5[!^E($R0E40D&''M@-D?O079S#
MKC6@)!AZEDUMY3LUSY65SCQ02KH:XIF?YRN]RG"!))>-1D)R+S$=_\J*"3Z,
M[\6@01866>3D(NN07>GU C")4/)ZL[T.Y_1&').;DE,DYA;G"/]UC2\BX"1_
M4)B%2T-P1#UT30J=CS ]V-U1ID[R7YBZ5-&_5% MH; .&^28<9'KL2)**@+F
M&]+MW56N8QP^LU(07R(+-1A5N JCLWT?'LWOR?]A; .&!<^SN(\<U ,IPGCF
M?+-;890JB^*G,922PDE%E\04O%\E"CZR8G*1F"D;L;_?$RV] TD!SX'<I:OO
M&N[6.H(2#="]/.XA++>6$\M46/L'4388)+T$W^>@%ESEV2T#$\(J,\31PS W
MT2;*1K \/W-K45)4Z/,KE:J<JN(9RL*B\[-C3=1(N'%3 F;E8+Q$E,R\R2JX
MC6=D(@0V+=2#UL,;"EU*N^$+/P5$\%WQ=3=QGFB3"Q$98NXIRHA[Z!TR'4II
M_+L8-"CM(]M:T^&$8HST4US9#79U]6\&#9&6Y X2'18Q$K8R_) C=0/0-=!3
M)*!H#@G@-0<G/>-M"O"$"E<8B'( ^N>(NZA*^?9N^%Z,*)EL815YV7@"'?7W
M75"-:8_ZF>)6"O!(?]JC-%(T#3(L=D+(8.J[0+><QNMX."9J&?*R<7P]N[7R
MO8@23=-D.,KZ:HBZE(@-*N=-B^1&>1)"H )9^09C.2;_F0.[(4*'<(S 8&#S
M@1 N.(P_06O4[]O;50'W$I(T,Q=P$,W_6U3]4GQS[>M(9TV!63 5@)();&,0
M=L6P->% 7>L>2]*;1-#"A[,@)@Y>9#^(C:")[XG^02,$BD(JP*RMGF",2'=P
M)D)X*891W2P;H2GLVOP%N\6KPB#P\_W*C23MG9VCDVG*Q<AD*O,/@7KA0@':
M?G>#U:DP51+_/!6Y!*5(,96H[ASATV7C:0W2S[QLB3-P2B3_NZ.C5@2^WITX
MOJF '!D\2-;%Q9,2 9866)]T5[I-@;A7&?&7 *R4*_<9'!<FF(RQPS;\*>Z;
M80)3Z=.DLO0J8X=0P7@SL\#-3)FFXR'>>GUN2M930]QDU3?[SZ(IA7,GYX2Z
M2GIN+S,J]A31T54F-$X[7"5$RG&IX'XIYH@=7Z2%=2*-YXR[8_?3.,2BZN9&
MD973CY1FH2/-O@?._IZDF+%N^YG)0.4(,:9TQ=+V8[X[=899;(H#KQ0%;6ZZ
M9[M62QUXB:$L!J.(R8/]&3,&<;)4(@Z^NG8,]42$V(\%U?U.*&?3Y&F WAB8
MBPQEDBD2,'E(NNZ'/+;BNQYCC5DB 3/7B,&+5#(;M8,;.\RA84IO$%AL6!K/
M++P"J8])4 &_S-X0C5!\=FMU^\F)CI=FV"9FFI-*Y*E7CB5#S0!G7@\>4@;[
MH*\4TB$<;M8X[YL8U-NXZ,?_;H3GLUWKNW)+"%*^RHV@<D4D8DM9F2Z<]+1B
M-NIFPT)G)+U[^^:E@>9)^^['G^3SR&EY-)SM!A<NQ8'\QA<6Y9)E=FA)Z!&]
MD81XR-%!\@QJ5Q;VW%)*T@KFJ%NL?5P7W1O"(/A@0'XIM^H94^JY5H?A"%'5
M=])9Y>VN?5,>PJBP_YYFLHEP?&@M[<"X.SULM:QRD^QU,6"/'X'-(I 37P2W
MRJC5GC=2XG-QS^_48QHLZR9A/7UW<<F-6%6_?!]T7L73%E+#A= H0VP\>C\\
MA(U:)(X?J+>ZA=MXZ/@_/*$%O<RLM=LY0("]U6[YI/^$F5>"D:QZ.2>'1R?+
M7,^2%Q#3=(>ZI0Q[ $R 0ESD**'$J8CBU!>_WN()U67U-+SI1-M0Z=T+R!5&
M>_I"J^)&6TM:;,CN&9%=23B.4"5#L9BJ6^G""7K?K)!\,,+M@D^_.0TV\O#[
M($S=1;;OIG%3M8KKY7>MEEPB'%Y$Q30VU"XN[1NM(&/!:WN^)H%7&_U]6$&P
MY ])\;D(/NC*KBQ\!]>JMO2_GYWXGGP\5>5#MG3HTT)*AWRT\\9A^&S7B@[#
M*O^@FZUO:X1(;_=PJ$O=+^[ GZ;0=GWYDI=$_:FJ?.E!Q4FA5YSTZ2N*D^8:
MQ3VJ,"FL*TS:\2HL:@N3#(K%U]4DS?.N#K_S\@W4(]<-^%4M(_96>L5+P:='
M%R^A85<N7BJJJY>\.N:'5"\%7U>]A&CRG*90KC]R 5HH.&<;5U ]L9DW/BA;
M2JWS;)&!78K9 G?4)F+W[-;ZP=8 5E3:?*JJM"DQ)56-^023Y([8JRVX"6L*
M;H*["VXHZ]^ON#'X>.5WWU-M8T3#K++<)M#E-J5A=;U-^*12F^J-KB^U"6P4
MYU9';1Y3;>,O8C=\B[=?J:? >*ZA@0G56F$9<#>/(@N'V,(L%APUG+GN$SYQ
MD$FE]55E>YA5"91:CF((]J5A%CT9)TU#Q#]@859NK;O JH6L T.@JX:)$L6*
M"LN2ZRP37:?<78E(LT;N&,@2DC"BJ!G?F;1.DPQ_DY4@2%W4FB(*T)Q0F#&J
M=#UN7<)^'6S()UTV[?W(>(SK^I%X?>=1\^2#->B_X1883<FNVHW0F/%N:.)"
M"6EC:JSP-XRN9A8:B?-YDHD F1JI5 5&#ONBST3V/_#VOXM:@RT!K#F.)U?W
M?353+ :O\'&O7#=-9 U6\O!F(<=-LQ#]B^4T"SEHFH6L:[.0-6#4%?6H6U!'
MCP4-LW2EL"N#)?U__!#_=ZMU8B3B7Y?GP;M7X?L/[\[.SU]>+A:K:/DK6S:Y
MF!DO"0Q+/DQ(R\.,G8,D76B[E^%0&]9U35,%:U:;334PNGX+%A_A5RMBU*OE
M[G%T!_HD=Y(<T8I%U5B@AG53=BZ"PLH_5HG)+V@L1K^<VH#?+A#]>E,</=^6
MPCXRP+4],7U:U=T02]U_VWO'NR>\#_#Z(36KEA.M;<,744;W2$//Z,>"!'X[
MA0D(LG)M\SZ/R-BE09$:P72H+-=W9D,YK+?NJ.P"EC+[8+[,GM[(P#KSZ>B.
M-W1NRFQA#J6PQ\:=D ]RO4AO/O J\G$'U.U\XAFN)=AL2K;5QAIN#)E]W;A(
MG#:2\V9KV5"M/B]O4H&4]7.DGC$;+4#C2VHO9-!V'"!/<7"_D_K^>JC&T(%J
M1"]XG.L*^[ 2WZ61"ZN1"[68[-0T!/NO R53^ &!FO#) ;>=3@J^$,B+HKM;
M(RY!4A049$D8!(NN&Z*UNE<E:0"CC1F=M!KZ& %CO?9B'US JP_27E<CI48:
M@LQ*O*Z*A1LE%D0%K0/=+UL7K 9FTHF!UQ(J]2"VJE#.*+E*W](E%XG)6(],
M23*E:^F('LED.SYA;0E&+6^W5!;H:@ S\;D5D!" @X$3D1[<UD/E="Z6**C<
MZJO@OF43\\K4S*6I_.V64?E?7KS^Z^/%N[>-KK]\O/E!@&!J NR"T6(O53=B
M)#5$Q,Z+ZV1,"#0(WFY4:BHDYW0DOF+I5M<-.TRG&'AT<JM46MWHR39NJZSJ
MU$#-V"E<PR.B#@2<RY#)W2S[+($<I]-:57VHAG&FVG/&L'0 >G9#/SJQGN;W
M!ESH2Y_RKZ%$1KKHWM1=0U^"QD<P3GMMZKVXAQK:=8S(C7#,DRQ'1U<MZ6 Z
MR5:[$QT?G$2'K8-M:F7RXQ;(ZH-MGZZ8I@+IO$)MG%!9[>Q%!T>=J+/7J;5E
MG9 FZ+US\UUH:Z2&:BJ4OBQPQ!09'PRKFHT-8&JU-1()DH?[<)PK SQ/.2HH
M<!C+Q&E.AS A1$NW:B[Q-_#:T7JYO8+A;23M8)J3]L;0'9S_8\O8QW$N%?0F
M2=@3;!<VG=CDQ?2N,P3UGV1!+721TRA/8G1.(A$AU&ID$ZQ13/H&$\1- K(Q
M2XXC4F98"3V.#-6 <>,X$0%+0KE"WD+;X%8:V*7:2;MH,[J5D9Q*EDL'S0EQ
M?PEEAK8\< %JQ'%3+@BUW8JJ3J5<Y]EP]4K[(-T5/#MI@F?+#9X=-L&S=0V>
MK4'RSS,P4]O63#V_//MP\1XM58Q079Z?_?7AXN/%^67XZ3P\_7 >OGOUZOS#
MQ=L_-LV.76QYS2I"5ZLIQ7#5_G"Y>]/<Z]I%V_>][W,FO0-D(AV6Q'-?<MN?
MB7)(O])>^HINH GY;G6(I!^B#IZDF--)#:CP-FOTN>7SF@XQ!0V?K:K,[ ^)
M#^Z$N@;LH]<8!9,APVZ>*(R>C4:(68WN=HU;B?B3Y*IS+42_BT:I%R_E20N.
MM7F+P^^885I(9[DDE3A!8<*A$F:_20K3%A,FHKO24AXI-88Q;8N\#RG%T]C6
M"2:4Q]Q7Y,MUTDU,K,6+3-CF(F:(LOS %^!&H4'>"(J5$.[+J1,X.M=!WO?D
M6?:)V;8$$1*4+FE$!^26B--R%0:Z!?^___W_N]5MWE":AAS?<E!NMB7E&C:T
M[1:[X?V4.RV5DC0A1%\S#RH'(P I>K)K,[8'R8W:F5%T+TT3!(L2KD0_AF[G
MH_T9/&]_=<RQ#'Y/[%J;=%W9)8<:)-G>CY0[ >/2?,E3C[P2"#^B1X@89ZZ1
MD=?GJ-S6B-Q,TK&>AB@$-I9$2;GO\WQA!COH<!(HJ@AC2_HKC0B:L6'2E3#I
MN68)*@8-:OA2'YK71DR24#*CRZD8!"\[US"Z#)(X0R\?@F>2W(WP:D$<.MT
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M@ZB1S\LST>PN4-4-":^$A+D\+L#8;DAB6FY?2\OG[$J&)ZPKQ_@W?4\&!:-
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MNUAR2OZSW/VM=FLSU+&+M#><]B7YL!T='1U%)YW[];"RH>BF*0ZS.-6FD8@
M]>]I,IEA:-#/"IID]%ZT2"E>2%XH$EOC>,8</LX3^)6\IMK!1LF,.=E>3N8C
M6.Y93\N@2] .<&YBT,ZN09!B]E.N!BK';&_6!.&W*JE1FM: /IW<ZP435#FK
M>TT6O-7&?.+%+_?\"U-]V&ZC5X0\SY)&8VZP DBDG',C26>5>3=HL?>N?;I_
MEZHWJO]63>RPC[JH5J"T<QG%NE?>+'O.OW5AIMU'%.7L-44Y2RW*.6PU13D;
M492S L[4JROSYU.GKO^S@B6\?WWZ-GCW*GQY<?GQP\6+OSY>O'N[Z@7I;7SR
MJRHO5?DP2='AM@27Q7G<NPZJU3A]B18V6D$.OW0FWR1Y.!ZJ_I7"%\1% ?-6
M\E Q[7%B?@%3W[&9]*-X%DG&.\R+]$_XWPC>,1P&-').=2[F!<[+>QFP,R@
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M-,\1I%KH>$2.$NLF&]YPBQQ=HU)B<:F7Z2,T15]T"JP;[K1^=5#\"_JH_6N
MK"AB;J3BU*D%]E5NOH]]\<_!#=:]+E+^4]W C"-:CJ-S:3V,F&:>)4@GD[7J
MS0!2'R037;4D*8'S(EIG%YJ&/I4;8%:.ZW/GY>J"09VYL1MBU5>-^ OA[; Y
MU#JE[Z'8L6B=A/T,AD%-BQNFP#<XDXEBZ9ACTJ/!LLMRGH5&,8BD_\IPQC>J
M_BOB$Z"-HMY)N%"3F%66^[O/@H6>Q2)0#F@"20I]1_79J)G93CRZ,%!]&:NT
M(%T$3C,GUN\QFIB 47@6\QR#\,VMWWA-Y@H06S^ 7^,B1RDL^DZ]++Z*\7HR
M4P,EI, 5,KHK$&@\ M;EV8*VWL54>[)W$L+T("@.^W&E31\@DVW<O;3AE/A)
M!4P*2$B?E1K/J1@*%)T>Z58@'A,NTU!Q/DS8MMU*MGDC; &J*YE)VG455E,B
MA,4=N@Q*?]]#5">)?==1;GZ#"EH"VQ#G,ND(9J>G1^JYW IS4_'>2[<AZM=P
MRX(R3UIF#'=>OI,-=N@"0GLF3R1K#K^'U^CW)!/B+UKRY#8+9[!7CH-!XTZ]
M!!V6N5(N-6?/L#HFT-/,4L1\E7 B<SGIG:CE)SV4"GWM&Z%[3-2&9&"EBN [
M6S]J054PSAN'\2W?WA@0P&61YT!X/:#'B\B]@NL+C'&+\9K3\Y]R$T#:?DL,
M_D+^/06BIYP)*C_&%X@V8B?-L^"C+[L+YP6@&;/''\A>T.T*5&>\ANR@*,3)
M !/ LV^$T(J%T%](H(%#H$[B.)>"7&&6#.EJ5BB<ZX Z^H)=)4C[&86&O$QU
MD5#S9"QT&X $F0Y![U+9M!C.'">!%,B/XL^$R(LB4;.KWW&2)&!-USIQ#[I+
M%5FB*/Z19-3%)N@K, MY"1_,XL,WD8] A3HL I'H)(7R:DLL?=?]3A5YR+/3
M[K]TYTS+>R"E;Q+1E0=SFV]@0N\X-G+^T-FY*H&_-NNB&6+['2[3@W^Q-6(K
MB @JP7/65._V/7YF[Q9ATMD-/RG>"CAFW-]QHM_B7XI&@ 0&G+K>JB.QYQH'
M(P/0+!>O]O?$^,I9U0L1MXS,#^M8CNDB)(+0LX#=LN81$OB6W>ON;,Z5ZEQ[
M1YW:ZW:1SH)5(ITL _KIGKG?#]6TWT UZ5\L!ZJIW4 U;014TXK@@?"HE@ZH
M]/K\C]/7@3?D4$W@/3MR[+^$.ZW=-CU-#R7]?_P0_W>KO?^#!EUZ<_KQX_F'
M2R.M%HO&M+&X6#\L8_W56NW>WN[Q@3VB1;EY;N"E?4)#XFN94$M1(MVMNY #
MM"?]F0G046,V.H&'J02GG&[P@5;DQG%1Z*:*J';"L_"+#PF^XOWNV6X4?HJ+
M:_@%]C!]>;;0._X;;??B+_QOM)"W:HAVS)LIZI0%'-H0C.?_%8] ME_VXAPN
M#O(&O'[]/MRRIQC!,6ZS<P_-B8":84[30@V-W>'Z_JM\^<:[IZYBU($G$\:E
M=>"S'5IK:.;!"UF*'%L.\JAW01V8"^K\O]Z??_AXV=Q,=T]\5:RPE)"$#463
MLXTQK^%FLLC!9UD^SL3)MO5;\OO@<QS^]G/R.[HS#9#V:>_?TT2P>O 'VY'T
MW'ZI>MSU9*_-?;>YVUZKTR&;'J44&;ER-;+K=()0?!S1!F-6WL_WGP',-M?@
M!]<+>*D7$>&(&HO(MZO1*"\P)RG.)U'@>JO%3<%.&!"!;#>;2"3B#N&P+UZ%
M+[+\"N7DV?O3\/T9NJ(HJ#)6=%:NKU-0F@6VA, 2DWP4H:L%UHI_@^17M^@K
M"72VS%5R@T%"\8=.)]=9+NI$$2=]&@"W%T-$^82D>CSM<XQ3*Q'\KI6+:TVC
M&\L3WT:A6-"VB8=@WE)=Z24R^ORO_VZUVHZ=\_;TC_,WYV\_"HSY9?#RXO+L
MK\O+BW=OP].W+^$_IZ__OKRX#-^]PER_T[=G%Z>OP[-W;U]>?-3/?#B__.OU
M1WKD'5Q+I_C%@J^F9T%POX:UO=P6>MX260[>W6!#=76[Z*-8P2J^62!E):M[
M14U>^YAHW&FU3J+PECHDWB1]O#O33&?/9<.I]M?'$XS=H2U*9BHL@\)I<*'=
MH ,3;0>T%21FII,DP6!!?U288#I B+T38=R"LR;CX>0:S!<))Z![?#<\'XV'
M&1FXV#T-OX#+SNH;R8=/+T%0[!]W?C63H\E3Y$8-9V%?[5 B!,8/"X1$QG?B
MOZ@AY!1U!;S?^]CI0Z838B^.X7 6!5V\<^FFA#%Q>CA1REA-!84,5I;W=U [
MX'P\Z@:9>?TR,6G#+NC%#*RG&\R8YK2LQ#02@1</%#PDY=[\BS!5D]LL_QP%
MD^R*:T?)$@,2 9+)<3!&59ZHWG4*U'$UDZ3JG>L,(8W-CK,"D!0J<O9/$*4'
M4^P<.E**TW##45: 7I)<H2$)2M.GE^'K9*# N$Q0FPJ<:.EBBR8VDH]7(T)!
MF=9]-P*G[P8JUXTT73-I^BX-WH*@(E/FB"T9$DK7:MBO:J@RSM5-PO'D&(3M
M%%O\ #>BU1!NX0.2FOF&/I*DS.WP5E(JO"Y%_ S& :/@(NWM1CQ07Z<"]CGS
MVHJ 2R/3/>.-HI$YS"B-,2I9:>)M2X+A/8-A10 8&%,2I"Q@BBGH 3=DT,!7
MDYD.[H((G0XG;%,Y"4/2S1AG[S9OZL7C9$+6*%Y#GB%:/9&NHE=*;%K228R#
MU4G+U#UT*GH64QQ5H57HE=K@Q[+WMNGP%H9L.#L*LS&=H\3:@*H^.OIP.?='
M!J1USR?(TQU,Z?Z8!A3.DURY\55Y?A'<'I3CYU$0;0[N$R)HXNGCSV7:E60@
M<S9A_JY>E[^G8#CW:+32(V;,H/+0EIUM\\VDQ/.6@>^%]DSJ ;&,4,0\(=(C
M&3)S#WM@DAJ42&AB4M=,C9-(AG-(=15",SASA[4B%+WA8U"VOH!"B@!XX8^@
M_X:PY*'.CZDJ9[I$$!^8ZQO0F"C_6CO&Q8%CR@*=>7Q0F&R.(1@2)O*(F<DU
M=\L,V]%AJQ4=[;?K(C^Z57=?ZGMRY%HNYL 72+X]_Q9W#^OI,BQ^+6-A!]C)
MKN!+"6Z1,Q+2V#U\*&_ZB%LZ@'/BT,+''$A*,S.Y[";XB5+AEBS1&<*L2T0C
M/:J=3:$J,(Z<%-=L<I2WV!5'(HEK&YFY6\PS/.676$EZ;C)4YT5DQ:L"5-Q!
M#"HJ&)"N)6POJ/F1CO5(1HR9NZ/'Q\:W4U== 6?I'BARC[R-BW[\[_"/8=9%
M:N(,,@K"!'1+SD;=;&AD[]LW+\NBUD3]'CE\6#W\IUUYP7.52L];YIX602PJ
M5$G2:GJI$J.1$5?H@O<T 9> XRE6_%(VR7!F2W6\9]S;/"*??=W0ML5@];!.
M.-MM3,@%15W4 %FI"MFX1P.7;IC=\'3B)E('=_0LC$C%M&+6FZ!I6,SR'FX/
MS./N<8-FT=WOB,T[7PUC,-E>>!NEU=U;Q3$*2J=DS7B0,8/R !@:\3;(=FPD
M-1YSG3&3V063,V^>DTB!.\W($,5[::_T?AA+KN@GO?OZ<G VX9X9F8-#MX>D
M9%(Q)LT+IA6X.J2S:P\XV^?*MYOJD_BGFE&94I;J2"!J69B&2"K9I1\D'(OR
M56R@OX(=,/J<-M+EPDOX@*674[6,-3QOCEJGU;GE@5<J5>S$SOEHI>3E-H-7
MY2H>%;^$6^UM\I2'6^AVY\1Z$*J?LARD.]YZVW(?B=>YT*GY60XOP&X]H?XA
M><VU2QF=YH$H^.]!O(_@_IB2P ;%6MT@8.F;.)T.P"R;YJ1$GWUX9]1C'.KT
M0NHF^,^MSG;XXOSTC4P'*W% @^G3RRYD!J:R8 P31"\5Z+Z36Z72X,^L('_0
MSW^:4$)X.0,+!0L0]<_/*)X)'[R_GA4)6''2/NP]R";R9_-.)84NKX(I<$_!
M 5@ZW1BN?_QO=KE0CKZY>6D[V'C05VL/'>D(VDKQ!?R."XLGDB^EPR($IP*/
MH:<LC[&86!B5RS][V54*Y]_GOH-4QH'CP7=2&:"SK^Q0N\$+.'Q#%+@>+@V@
MNJ@=7H+^UFRW\RJT&+M847RCS07G]U*+XB]&] 0S@] K8TUO,NS"2%XEFII^
MKL!:+% @<BY?CM-T2HH%N@#[-W['B+F-FE<@4T6=&FU=F?E10&Y$I*D>CCJ4
MRI(T@Q^K1KG8R-6Y)*9THW3!"&/:GL1?J J1'+'(QOAE;"G)P"9@0FPA& %Q
M>(5TGX[8'V+3:LB!#AJ/"  2AQD77:>3@'WL&N.YI^>P W*U/^V5@&K8Q>M"
M'#'&LW9Y\8\P98?)6#BH+U!08.DP=\"$$RHNXH4'#FL0]@G8%[DXSQWVC@N'
M^S&#*L[!X-D%N2W/ZV_%Y"$=;AS/6)\S=IK#I/B]RE$BXY\.3H(5:I?HF])(
M5C@[OKW$\JN8FA$^>@RT=5CV^#7K,J'"3I'WPL@8%GCDP7?'DJT+B]ZUZD\)
MI$+\1WJ15+(AHC'ONS+8>-Y\EV47'AQ1#3M\SK5U\7 W>,\3TX[0M'R><,BS
ML99B#&Z&E/H_*L_P'2<MD/FS0B(N\JCUJN[QUYL6C7TV>O497/3H:UBB?KV*
MM?AGL5%S?S?- U*WLH&K]6")!$OK :60],E]TYNXLBK,NG";Q1-=P'J=%>S6
M'\9=<G@@Y!8J7#C^IK'8*IT+]]<W'OP:OF/ \U_P79?L]C=%CX>=IU4]-D6.
M5.3864F1(TS.$))7DV6K\Y9<*+BA#%2I0*_LJOJ#=2[VSY_V1V#,<TK\S>K<
M0LVQ/6(E<F!T7K%W7N$ E$R!=91RA$(  U7$55I1>#V%EV!8"*Z_GLY\9+@!
M5EB=U$'$"LSR">G6A3.\'IUNP"+@_JH*<V!(HR\032#.J7<-#-Z%"0^T&\3%
M3TC5<$<'[&FD"/87\REIQAPX0;1"2M5$;#=%"&R@Z!+4%16 ?)'L2UY=8.L7
M(N=UJ)%/AQ2G*3#EV*R[K\8YQNYIX0*;M7C37]O![<[NR0%F]6\DO:],(IG0
M0* /:T/UYXT\ QN8"8RM/\X3F$0RI#HBTH+9E4EXVZ!%9^8W0/#Q"":56>>Q
M/D0T6_%A8X0WJO.WO?D_2((ZW20OP48:9F/T2337_CJNY(RN6@?142-3<9$!
MWV;F#+5]:[R&Z%Z3"XY<:GH@#"W4#$%7LKGJS94=&9<BC&2O4TR8RY-X:#0*
MAATUHU@06L96QA*1JEFGL"-VUJG["ICV+;7-*[1-'BSCSMY(LER9U+A$**V
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M^2.X7_J&VP7V2;DN!4Z/<DYZHW;K7L[1CQ6#CT6.3'I]TQX2XO[W_ZJJ4OD
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M>Y)SALMC54"M@W[0)-RYQTI$(QP*PKT5]%]18MF7;KLDYB6T^*>^!>-.T&M
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MTE$X@VJ4DR(8@CX>S!$30"7'F>\8 H);!S5)TV <F#VE/6B&&31GF=RTS3K
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MO:Y#2)0G/?J8[T_1 A$G2Y>L57$X/^R2=27.A:.UZ'ZP7-7_R3LV*$#G_HO
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M\UC6.N T,G.L>.$N0G $:C+?$7Q]X+*J#)QNB-* !9T#'70_=TLB7K=)O7R
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MD[,"L% KW[:Q4"GHV0GYI>!?97E>F(3.7 %A3;9+>3S=CV-;/'4V5 7DT2-
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M$^K19V+JI]:-,W ]KDJ,\]_#'_=/?]IZ72.%3"A+2[+B26B=6@_$S]CK4C!
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M2?5QL.<:M0M0$IGV*_'%2BK#.T2F_3HR[=?%4Y>?^9DJ3\U<=KUHTI$]!Y:
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M8P0B]'(1),O?EA@Q23_Z=C:%SD?)!=CR K5_+MTC->\F4O5*<KZJRN5*FI6
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M&Y?8OJ?8_LK)V'F9C"V3L27]OC[]3D[&+LAD[)G)V(E4['R^82 PL[ELKM'
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M]N+FR>_EUVO\RIJ-5V-)8UBP)/]Y>9_*PIKG=TH&%&= U5=B0%I28S+"!*M
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M%*"R+Z5^!A3J/5J/:&K#^S)T48[H,6("<G%"O&[U/?BJIYA4G#<9J\)NZ@I
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MMVH)"?;BK>;^/7EP[?K]_2HE)!XM0\^&3",\G1([WK9+R;TT(.B]/-)[ 2O
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M#W,!<D65DT28MV]UQ6,9?F$M"R=@\A2#64L5#AD;C($<=^AWQ,@(JF#0]/W
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M.W@M_6Z?90%CMI@!YG&2D*K9;*(D'?L9$/-4]U"0^[7H^1/V>,.Z.F^85L-
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M8<M-V 2[9. ]M"!7"#M:7\L'XR8&'L.?V87C7])!C\?"MD6T'!DNJ EX3X+
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M_5;CO;=*P#UEE\Y#*?[<=RD1=Q#Y]Y28@3.0_;OV7)'S'YS-[_45>EL!.]*
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MY[\&ZGLEC["F(?R\<9J$0M%-\__=]J8(A8-S76HLE;$^M_6&1< 9JAERAI,
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MI& L3V'3&QEWRZ]Y ]=<7N":>7N;V%73[?HC+.>[6B;]5,W8 Q&' C7@/>2
M8$('FU@X !*]"UACNKX\0>$>2!FJE?/:J&RX.CS"I@1V/7@X/'UR<F,Y?FT
MORH+LI&P4L"&NH80@#^=HNS^$1>=N?DZ,=H\-JDQ838C#6-,&_IXFC[T<>92
M=X^GU8.C=V?#ZLGIBIT!G\[2"H:P$XY&AM?&1SF"ZJ* OB]$GB/P5>4#8T7_
ME8B-@LXSV9^,B>J7+L8M$WZWK7NN+\O8OJUGV>2;7<3=*K\D>P1,#OC:>?6,
M-*K)N8ZG=X_J5>VH_T/Y5JVO8ZZCCP.,2C)WW24!:4TS(N?K@K(]TQ^39_IE
M,KMPN5F)D_,,*Q,]9M8[T/"'!EK:"38Z?)IAD=DW-5\%/1(WO#C6;!)A2M6%
M$6997/FW_79"H#"'[F:!\(SA77X2>&\7D6X]#]_P3%JRK.15Q])N>MCO3@-[
MUR8K[S2P*SFP-P%L:KB<@SKGV'\DL'..G7/L/PW83\BQ=V]T9LJAF!/N]?(F
MU6IX,N][5K=_UV16Y\?/CY\??ZW'3YS ]JPADA\_/_Z:C[\CPU9YF*U\^'?2
MZ( SFJC$DF'[FD%%.K>VY[C+@TZ\\._D:UUVO5+B_O_R]^G7C!R&FU<QY>T]
MG.S,I'.U/-N&TZ9U._,3%([&H0F-IS8;*C&.U8_XOP[]UO%3&7A92>+B_C_?
MB\1)LHO2UJ<1D0[]I#1M63HN5;Y$2^Y"UQR"A:A[.?E\VO_\:WS6O7@AN[J+
MUY.*%TO()GZ!M;\3Q50DK+WG:)T]_6&OKZNJ!K^!"RWK#VW;*#8:!XA/E!JT
M\N#*J2BU*NMX<OP__J/QOYP]_G_Z[ZQ65MH#[^?/;2: PYP YB. UA]- )7L
M"<#Z\N/3Z+%]]5^QL;4$4"H6BSD!S$< E1T@@.4P]?O1^>G)Z.##@[:]K!HP
MM9QC:O:Z2KS">_M9]1IT]?NS=[UC7?OY^])X"@*8/A\ZY0+G*HZ?ZWXF?IP
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MX6N-Q5'P=$&H)7[V5$R25,V A>TQWI:*M*?*P4=L@\IP:.@=R@$)J!P]F@#
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MR=\3*RA@G128#^*2]7-XAWG8D4V&O_#W&J545N"BL(J2:47U<SNO*N4#IG[
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M:7$[*I@=E6 YT5:GX#!K?CA&]Y>F4!D-0-.V!@5)6"T!$-,L%SEFN7!,GF;
M%"8MF +QBZ@)4Y#(7DE4[*<:+Z%MS&G&()D0FDY:,_M2!OZZ68R4.)S@IL03
M1G&V)^&Y0]>1S/D(/B&HT*6G,27\-8(-1Y(H/D*2A0E'[BKW<7)!RR-@6[A:
M:$,Y[TKC7=/XCKPBWY$6XSO,!1"U3R."E[G-5W#G+,Z&"NE\"+TG,32;QH:D
MM;"AL#M#GLL/(6W #X%_>+ YX7N8\!I(4:\!NX2PVV!.3T$AJI\D> '"H<^(
M*V ?1XN'HP#46P6MJ9Y%%Y_@*(FQ.>0 ! 18&#;CD'^)!^RQQX;K^!0W(E(+
M-DO\LQW23AF&>Z"-+B6S%Q7!A,9X^OV@C'J +*)-K8<4ZB#'&';HP%11"Z:&
MC;&DZ$ULQ"^R$[;-#D:/OVD2472D7:ZC@4!!]2%.27Z72X>Q4!%SBUA5/'=>
MM!P2]A6@&_XZ=4G>6E<C/H\6#S=D /-1&26Q&'UT#H,-HWEDY"VE+$F+*$L^
M]8K^6D:X0#VN5Y-EIQ@LWC$U5"%QP4S<F@UHG7(M0EL3G0$Y1;/XLAT)-8>Y
M# >E'A)HINHO8FOZH.W9#ML/<7@4@2 QT2N+B:F,21*7U2.Z%PJR,&\._\3?
M/V,N(&8-G4VE7^3:I)5TW)QY[3;SHIY<Q,$4N<?37H*H Q"D9U-SD*$%N#5F
M:-JQ[M'?(X29^#G+L(OQ,=\[Q+E<.+ZB@!9-OAF/B)0(U F2]T N.UQ99OTF
MN*VCVY%@IQ/.D[$#=IDCYNXBII^(5]L'AH,.6OE&,1A^?3&#/B%RT" Z[U:S
M1BQ=OU?;E#YXIB;:DE>BLPA>8N-0C6*7CGRLN(K\T41_AR,W.[\]G<7D*5OO
M%4O-]%N:WUB&QP+3D>;FX?4F^Y]KKZ38](.I?<BC'<NOFM&^Y()+BC[A8)%@
M;$B,W(LX.M&R0(.7):SP%<4+;;]%-P5GK\ZN3L1H6>"AW VD]&!7/5+&;+U'
MOK2A#8:,/D2O&NE(2$-_E0JU1JU0KU;WZT4_'=K/C1O:.FLC_E=IOR::EJ^[
M,?@VT];:-^RW+97TP4!3L2N]@8EUV,2=ZY8M,4S/A%6&+FL#6A?DHOBJJ\K5
M0<I4O6HF3JS%&W>POPEFHG(;!'\6X!KH[K()VX=_<[D^5TMY'VEM;4]LF# U
MTF.^P+TC+-TR6(<93]3M5XJ/&>.>R6"'LF9PBYRG?.$ZE(7(T%?[[:'3B0'/
MH.0O6!-[O_Y5*NX7B[+?,;@@^I^^DAOE_=K? AKXD.-*]\!#!IH\TI#E(/#@
M/1@G=6V%W KL=4+7!QM*?EDJOI)O^=?'RA@TE\BM@D13Q63[5K!OX&P:1<8P
M:8+GME+)0H'Z9E&T+=+D'VV!4'D#\R.!Y3@ U*;NP9'>*"&T")YILN1<6P,M
MSF2MV'GF@EQ]6?;[N@=/2/ $9O\(I\JUUO-X%NTQ,Q \N,E:\0#Q<> 9/3(6
MR&E"&\")H_C[>W)UN:'17&AO8HHMHBCSX '/M R660?,J0T:*(,'?++SR23;
MS8] 'J\\)X0?FLZ<.DU(>L)A(#(;!A*9A7'&Q73 JIYD4H@4F8WSA.-"I$G>
M'AT7(O-=)PQ\B+\%_Z:'HS*)!<3(B<ZYM;@$:C:(GG.4 )*/'B/%QAZ#T5U]
MXQ_ZB*!T;,M!UZSAZD.#V+5)*>'AIV[YA_Y3-/W8<?G46IIC!;B"@H3]4@H_
M?<:_XZN$AV%0CW$SI(]-J&%_E<4X/11&#$%\3[49Z&\,,J()H_Q23+8X._;U
M00S[#460,-  07^K!&\8&IXC"RA1C- GMU A7,J0SX@P#3F:^'HRM>B7^(A#
M^271-WH0-9"AKYC3#9#+0D63P2I.V?A5'(S\+AQ^$U-@"3\@Q()_2 P2?U5J
MZ; %V,D^S/ZJE0NUX(<90TB*0$@6$(I'OTF4\_,S<$TW.6AFPV!H4!],S'?!
M2)"8$286<H1N)_%@E(AHZ>;\\!10\H<_LD7)1\W\T9. !;.]Z&M1(5C$WU-8
M!\3EV1"78A#/TEF4Q>B$9ZQX8-?:23M4(71DA(S5=)T.DQV(=N*Z?>S&[SP>
MOP"B<&E2"->V4?KK?M8#X:NM@4+N:*:?HL8=\1*]TA_"$7MR@F1BRQ!ZT0HO
ME;@E+]/@E4""SB1WB?%3)P6U!YK"G*."H?"(A_@U-_HH*T(892Q:P<170/0I
ME)8@9R4VE,7GU:A5A$+>XM4#9<QM$ARLPRW/&#=*H^,DKB14"'XF*:XP^ D5
M_)A<^O,8<0VX$FZ U0CZ&8D-9O(Q<T_^^JUY):.'VS?G0I8<&HVZI2;;<U+L
M  +69-?E'&9+.,R9*24IJAQC"/E)L''9@*K]!.VS$9]^*D)?,XB\- =TSE&$
M7$[HHZ >V+-1'T:9#^8\C_(")K*?A02\*F;<PCNCEAC1,34H(+W:/X#?Z_LU
M=W(40BH0W[D)UIN_>Y[Y%5-B_4/Q2"JG,+%!UI:1R%T-]8I/VQ38^AJO$/+?
MB[J>SBS^,*2NV4^EEO\UAQKIOI[C^/ID(5@?S+NP=1$Y'QU .,^XK4%)-8+O
M"2;A1W&99X*JSR2>)QF!#9_5@[GU4R *_%RW?6TV5*N[/$"#!NH<2G( I?#T
MGGIM[1N34FYZ<F/SW5+BUE@.\*P+E*9=(%?PPLL^9P_V;A<]^/'  TRZXO7A
MB/:G+  ").I/W)-OL"F!9V0:$F2%07346$%6WJ3EJ9?.$LM.OK\_.SJ[E<XN
MCD^^YZ-IYIP4L:YN6U/&1BS;B&NRYU:L!+.=-LA@R29?H59=]8Q;=2&^,F9(
M9[JP]B,8NU+_KK1>BOYA2MF>9>%>@YG>DSC=^L48S7>EHV'/&:OCH<B*7YOH
M(B9E@N +D!X:AWM(S;!ETQK9RC"E<5UV,"GOETC/KV;4[#5M$,QVMJ:=6?.[
M!BP,W$JB$_"5H9!Q>Z[9/8S0,N.S.;1U0R[7R.PL%UAX5N79Q>$LG )_4+[Q
MVO#:(>C^6++C!PR9FS<8>9K<,6^3J/YT8W.V8X=/ O2GX2^5_5)&+2W_6,ZB
MR'T;9VUK#Y6]TG[?S?1,S )?N'8 /TC,. B8AY(SD)R!;(*!E',&,C\#*6?-
M0*;5#.5,(F<26\$DJKF6L3'[)<1NJD)?$5%I/(AOWPA#YEP9RP=DQ91\*Z:M
MN2.L/VY9.!0%?DPN9 QV8[# Z8(U\W^4 1SFELK_1?B!9B1/*T#89RPGMV]R
MSK,ISI.K)W.K)]7LU9.;H=:!7YCR%U-WXR;-+%:1*RE/OL-GQ2HJ.:N8GU54
MUL8J6H;B #^()MEEP#K6-&MG&[JKEO-&JADW4BWGC50WT4AU15K<^(2KC<3<
MLY>3:PRS5_>K:Q6;3QE47[L0K:Y-B(H4\USESE7NK56Y2T#3__?_R97N.?E%
MJ9A] /+4L@>I@0)*;9!/@$NXV)\093]6IF-"Q';PBJ=!VW4BPA^#MCF'S(A#
MY@[,)PB= *OEOE#!(*_#S4*NN0+E%R2UQWXKHX"3:HQQ\@ES>>QC&W;XO'A'
M[M%\&M[!G:.?K,XO;YBSB9Q-;#>;6*\'YP]@$Q'B7H/3AG+"9607>V%^L1U&
M5LX+GA,OJ.6\8 %>4,N:%WS2:$K&0EE:T6J3<.\2WC[.5R[\9J9^XVG6\",T
M29V&D(46S'G0-NSP>?&@@YP';=ILZ;ONT'G]SS^CT6@?N,9^S[K_IVEW^OJ]
MYORCJ3W%_@<8D?)/Z;#:J!P6_RD6BZ52L7I0:Y3+Q6KCX+#ZCSLHETN5:JVJ
MENZTAS+W58MM[L&J>W 8[#?U6M989>Z+MU\MZD@1F$BZ7^?"6A!1!VB*O;N6
M3,Z8P[V/<E<W)FKP>.<DW>%=UUB'F.:0AAP^R$U<@%<$R^7]<FYH;<,.GQ=C
MJ^>,;0'EJKXN0^O&HT:W*0VEHEPEUW^V88?/BTT<YD'Q1?C$8=9\XH2&9Q)C
M"/ENN;65'"FG05"*#?]Z!P_ *ZYLS='5W(FS)3M\7@RDD3.011A(8TL8R"?=
M4>2301N>*,BMOJYU0RW<+IG+)F<GV[##Y\5.2D5^]O^;LY-YDO2*F1LN4]O=
M,^,E,B&,=1==I/I_>[MIA:H+LL>\M2R>CBCQ2HEEH)X"IA6N8EVU <@ZLJK\
MWX4J@'EX0^89O--Y0W2T4$+#[(EH4KIZPB=:B&;R:-RP >-\-+D#!U=<S]:H
MV,EA8ZU<*TN-)6/<WTY$>HZ[^C-Q AE@-OF[VXD3\[&\S+L*3,_%31\.$.O2
M.(/3\6!X,)J4-UN?RG!S9I?OZADSNVP2CK<3)^9C=MGW1?#:3L?6A\2<)B:A
M:&(T[A*LKK"L1L=:UE[K USC:K^U7Q!3F?W]36.%FS4UMQ.9MG57$P;JUOJX
MUFFWKKMAW6Z8L\OYOZK9%ZFV+)6JUT_<OMYQ<@?X%NQPRYE#EH<OE_+VE?/3
M?[F4/?VC"J2KNF*CS<7-,F$#SDH9]#/^X!9CX[)PLD*I_L9A:84W>Z TL;Q"
M?S37S4F+S7P?NAK-6\7L:_2OO\K#<-NPP^?$A?)6_9M*BYXV&33$Z/QQ "W+
MQ-&VR)F.3N4C"Z=].'+KJBE?M;8CRSCOD_&GX^Q.<L=R]<^(ZOI<X7\/+>6N
M].+ME35BP]F;L!_;U,;R2[\F ?2)J%M%9DZ55_N[TTOGCP[);S'<2\7ZNE)P
MGHIDT&O*$_U/=0-K@4XU3;[%3HZ3]" ZN*[<P/6)1G]OI$%E\M'6T+DR\UC$
M:KA-" 0,%MDI6G!;%FKQKZGR=Y9HEE&B+]];HY[IYLY,E5I/.K0Q!6C0!(%'
M@0O+!OP;X&1J!43D6!Y&FLIMU<UERQ4RG.:X9HW2'Q5-.R3?B>Z(TDVYK]SC
M*'+-E*V![J+K9>C9CH<.&?@I#J26#XJEE^U7+\NO)AIHW>Q]W)=OHVX<I%L,
M6F%LBX+M7<\V=:</>-.QAF/:!*R#@T;$&QVQ0S\V?]*2O2&\P,:.S8Z;C%&9
MB9%MZP->R?N 9]P'O)+W =]$'_ 5*7'=>MMZ^,0ZU\X,'/^VWR(OETKU??F+
MJ6+WLE^ C<YZQ[]OAID^YWL%X2MY>)_HC !1:D\(8H_?MN:\SB]ZRD6OWZC;
M$@,ME+50SCCC(DOG:V23:\>VEZ57.Z',WUJT-0QP%F35L]'3@JKT$'YO87T
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M7)_<K+=9F[_Y78#+YAA]9EN^$ED(?@8<A=!8WN+4)BV4TT9)VPE*#JHKJF>
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M DJ( B3>.KD2(JK:&U+E#0VP@?)&@U1,7[!!\M5NF^2*!M0(?1MT #HXF:3
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M9$9,7-AN\*%>#GK^+-%:=#E*,\*1-)-8G3?6;AB>M1 _Q_.IT_D!4$L#!!0
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MN;;$2U"[%(I47>\$*FW63OH2%"W&E:LTK*!I[>QMK3>Y73!GSQ/1MA5&\S[
M8<7ZLRJCK4IH#+P8@_4K"F?JMJJ[>DTZ=^O)4+'CV%OMA*PCP_%3HF#CU:#4
M2\^G6A2GE[BDXM_"@SP,BK&1>KI'[!#+A,U3O(F0W#YP Q-SJL-<U;XL:>1
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M%G$:TWQU^T(EE\:IF0A=#W@E&EO]"F@!GX9XN4!4R6T$2MK8]7"'@J/1U"=
M;G&2\,B01I\1^88;BFG*HQH:US44*#QFO7U"Z0NFF$G"+[@X8V$DR<I#E$:@
M#&2NJRE0K$#:^P376K'5%L\KEB   FJSL3<A2-1@.PA)TA\O)]MPE=3]TJ><
M[3I+L[9*1G^@(7%X[<#EXA[%A _ITSDB,UWRJ6KO>K@8L9#=5*#4VZMNMMZE
M7FETPE(:;<U 2>#: =B"9-#<,Y166^*,+D!HZ#IALT=%JJE7:%2G!S:*P:8Z
M4@K729HM/B;=O0)J?6/L<?1[0<L5U?%T^_T_(EH&,M<K7K:0@:S@%6Z-"W3Y
MU3+F&:NBO>OMG;9(Z?7N$B+%KL*O*<$HB?_$T2<4IXJ)#6\I:^AZ"R?8VBH%
M_)MI7K,T$C#'W&KF/%V62:V:A$E:>CF_A"AE[H$^+>#:O4:WM1#Z!KX0VN0<
MK%@'+RKF@RWL6KY?MZ7K#QWIZFI16WQ+;TN]MW#U.*=@Q<J5-^0BW)#L(6;&
M.%E^I?RTT-J5;%X=H7658![_]_E6[M$2FVW?*?6O'L7B,WQ/<!B7MF#?)[BT
M;1H=+S*25Z\?4\,%H_8@R#T/11LC]7](1O+F:KY8K\AIE:V=UU!V1D6KEG]#
MK'RSS@EBVC%A>>)D&%2J]LZ+*L\=1GI#]#]PN/2-*]RK:S85XT;5V'F=Y%G#
M1F\"GT8-"YMD]5J5U=?+M'U3N+:6;Z!T7D%Y[DB"&L>K^I<H=%EVK0Z9FB[S
MAE$[K]9TCZS:2)ZC"[G&V 9O&#_7IX![Z $VAO3;A8NOZ-BE S2I79\U[A%N
MT4B>#WC9-N[U+0\V0!L8.;]%KP?00;;S>W"?%?@N:UQO8^G>I>3.+]_K 6J-
MG?J? XGBG#]A4EV"KANLG!I*[/R6ON=-DNQLY :SZB)US14I1BH@2KY6@(!6
M&1Z>"X+2<-YZK0 0(BDE$"8?ZSY@'?\*X4V\V-AX/8X5$R#./E:6=E'7G?,$
M7S(%(P7BYF,U":ZD?P-4H77U'NUG+9M*>739)]D#0XPCRL^^7E):\$/BXVGC
M_IIQJ@H9,%)/UTTUX#2[I(UY?.J23;F_X'NTK/8J-*_D5G=&&+6G:ZD 9*W4
M]!O<K<N+89@*1)XNP.X&I<(DOB+8O(47#J%(Y>F:[*[#46Z4_I.TIA3URKXF
M,5,W]W1U=H? )S/#L$ T NYM,?D=ASDO6T5X<:_8O["M@HF!I\NP.X %,]6P
M\ F7^S*-+C DKU12>KJZN@-@!N,,B]3VA=@ B$023]<]=\!&90ZO5K^V<I^<
MQ)."Q4[C+9$F.D_7,W=."A6&&7: 22>1=X_9KG/LDM375<BN)MD-^PRP-2]!
ME)XTGJZ 1M+.UR5"( Y*S8<9(N$Z]]^Z1W1]JE(S2"#$OJX%6@P3N(U\FNYR
MI?D_?F+G 26XW%%"F3\.2W=,^<TT[0\:+6\PB;-(K U7=_*=/X5SE,[P%S9?
M/)].6;ZKCGA#R^&Z]NG&[N*Y$]LU 8^Z[DU5%;S+CD-F&X*9'DSR?,G/#^?\
MM>WLTWN%<ZKS$ L>KHNJ7G09>Z,#$_*AZYI>6'.'J./3*=HQF:&T.MG$S&6Z
M0OC'8!2<Q31,,EH0S'YHT@<HC9HW!_=Y0I3W$+(<3V_C61I/XY#WW-5V2F;S
MFRR)6Z\;:.GP;EN'BEEY!';#+MCP"S8,^U-)<M!)*O_!JVWY:\J@1=J?I)\R
MOFJ<L7D$48AXL"UB21*L:?J3K?9E4C?6DO%P6\::M.S&DJ#1O;"-[1)R&8^V
M95Q1!!5)?Y(U5GF8618QI1E9EBMW_%#1R5+Z<L.6Z*^W16^P##8\@Y)I,&=<
M@\DRJ/@&6V]\[$%!E*(H1NGY A/^<I)ELPS/?/8IGB"Y8F\$Q2I6P9K79D1R
M;LR1Y,&+T_.3XWX/S?-#=_)[]UOR_R"XOP;A/[_[\?#@[4_!]CL6^CCCO[XL
M1M'YWPJ"<I)@3=.S;,(50RWAA$"X$DZ\9JE[Z=87(GUF&0M[N$)"(<QQNJ D
M##:4_8G9=!%WS"@4A6JP#X6@UO($09M!GWYO_>ZBUHN+5B\R"G&:5\G->H)U
MQ=-&N4Y"%&QP_SYH\?^^##KM1P3K9P3)ZB%]YE,3BO\H^,6U#UC5Z0^%D+DA
M"VHZUSF?-O<[% (J//<+7M3?]>O&05K>\=TS"AV%R&NCXXIQKQK*4C2=/D+
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M6)T\S76T>EY_Z=#@7G>L\OXQ&P^Q:N]Z%\@SG4%3::_AT4Z&Y*V]\]/J[-"
MHL_ \/+=RJ9)DCWR[=46.,F(O7.7%K"IC>%7OBXFLX8T72B12Q/8@9)SF^T9
M,/6$2KK]=HW!C0#8P@%37BC+6VSI<#<O:QPEV&PRU,W,7@ME^^;,;,6N6D'9
M,!RH3BTL5X&0>RV6Y34+5ZZ JI:CQD5.<S:G9S,/+4IBG;V!4KVTU6 V$$)K
M==8K7M6+22J1M#J)Z^X-G1J+8/5;2#9+>(/H)JIAZ'=BE5TJ]5!=K;E?"::
M4'5J[U]R-UBJC=,H6>43VEZEK32M&04K3L-T)=6N)Q@J0I*AW@4U?,JQT\XH
MF-Z2[.,Y.Z4&[[U;NZ=@2DOVH6_MIE+K467+_+\)4YA]\C]02P,$%     @
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MV:6[A3';K7W-/3D1-,*F'<!3]BD%JH='-]%@%EQW>EIX-BX,9U^LZ&*+!]%
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M@<(YAO,_1"TM5S?(,JCUGG:?N^5MKK5FSX>U9L\UUNR>=I\;IK)$?S;W)K/
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M:)6-'AS$T>8WNV&4_^)ARUP%DL) RAN+VAX^W _B&GIW89]C:UY=D*BR/!,
M":!)T.&+"TT @AZH*K^2"+S'D'=2IX]6@=5ZGT&.#VDL"0BP#5""#PH(!#7T
MBD-SE<.8]?.T0__@6/GD0W< ]O .Q*$8@L]""(3*GUH0#;XNO3GU_(!Q*+ ,
MSB5C"]UV*1\'*(KRUT#E)DI"8K=%4LK:40W^)K@4652M<:*V9@R06L-$R;E]
M]N8P+&RV-X?CU8UYJ3XD.KGY>OYPARE_$?7^F4QI_@)\R@IH0#B5G.A!E/G:
M@R61C'Q2BW=(]XT32^6ZGX2XONX!HH>/ ]"]C'=(]Q^-F?,L])H*.%*Y5=6V
M#Y]M!43.,H3#YY;G0/'S;%Q(A[ZP+5LM;=6P@F<X!&-LK&=OEN?G/J,9+^_J
MBH["\O;"Y@\G?<>%Z\;")&Q#F)ASE%"TX.^5L_^[^"/QGU# 3Q=&\1A1NO;#
M^2\H2"2!2RUR8XBI@2!-I;$N_)7)^A,.O*OPGB91#!\TE[13I1@,7'(!K-L?
MYKE2T2UV,1M;;--[@S50DE -!RFE$.!^Q!1:S(-<(=^[>%FQC1MFJT*:7E42
M' 9-@W@PV&G+ FYK3$&8)\1MAIPD/K;?<C#@B!F'D&@EE^9@OT_3WQL,!C6F
M0BO),LU6,[+"-%Y/ \1?<O2X>[/BOBQ;AV7+&$QEOQNNYAZ"J97TF.;S1#5!
M[%=]D4]PIV]*R=<^FOD!TQ36WXG"-/:#H>(= JB56RN'.,I3M.9&C4U=]AN:
M8*\JB=IOUNC$&(2:R(A]:6W!X#B04<?L;D%H?(_I\HQ02IYY9K#"01-0# LZ
MN10@3N9.FA%S*;GE?'']"-^CEWS,*2>?@G!8J&D) X+7--P Q+.O"0JW-4TE
MJR!O+&P[$-TK^ ?5;2Q><)X?.-WB)QPFZBDB;C\0=#1D !$R%@[@PVEC-26>
M7J'5L-"H<@YB8"P0,";A$]N3^8S%<SQ31S_%[8>%BTP&$"%CD8*?PX@7),.>
M%CZBUL-"!Y8 Q,9<>"!S]/G=GR5W1/2V06*28:&D$ .$REB0(648!9>$IMRF
MGO_] H6UL=/J8X!@UI +1-=8A")E^8;$.-+=$4$4PT).+@5XXMIR3N'&[?R9
M5_1^IGZ,Z27&2B0XK0[I0""I)PZ(C;'@0IU@WM!C=G5#<^T\#'@@*C<D=!O$
MQZMD@\4*$@6$S5CT86^/L6-<>VNU([$!+H7FI1NL?4E M(Q%(DI[#LW-U>!0
M$7 /(M$T'@$X"-O= K.'.(J+-[L OT!",1S%:PD"8F LXI ZE4)A%>ZTD&8X
M<&F* @+6- P!3)I?$:6(GR9GG*P9'W)?&B88#@8Z<H  - TN--G6*-'0I!X6
M-+6$ G%J&B: )@JAO_/J56CEQRC@47=H@E0:#DO[$/^0HLU=3;\FX9P?J>L>
M\51;#P<9I1 @/#9L];6VD#: T6C#J # V*X^O42V( %C(^)ID/%:O:6':88%
MCTH.$"V35P\*EU<5-[ $C0VF)&JING*_0"P "(RQ?7NA2J+J7MQ>RV%!(N8>
MQ,-@-L%RZ<=I/41^;8^DA:AQZ$KMC(1H>"A)!0$!,[;5'WE>JD@43)'O786Y
M:RDY A43# LHJ1 @2,:R#&YQS#2!O0M$0YZ=.G+=9)FD<22V'^.O3<-XJ6F'
M!9VN/""*QA(0JN+6<?6&A1+$/XB*L<2!@@?+UNPZ&*DHA^64ZTD#X5<L &2N
MDNX4<6$7./;=G0DKE]5]KU]6U_EKJ;__.);9;<#UL<RNG65VCR4+[:R9>RQ9
M>"Q9>"Q9V$/)0C.N62L5"SLH=M1CO4)#58=;J5=H9_GA ^L56EM 4LXRA$/C
MNI&=U2NTMB"DG&5(P8T+0K9\#,-V9Q.:6C(OC8E/^4UNMF/3/9F!Z!].VK?<
M;==1T9<#0M&85U5F/GO;:I3$"T+]?V'1JYQ"H??IA@::F'_KMB,BIN4OL$FD
M+;Y@-DBX*@* OH %YZ'UET<-8OMQTQ8"W+Q8@)W^JB@A&A16]=9#&_(-:BR&
MTK<<AX>2]C+XP="AP%8TYOY.5IBB]/T?\8' =[(#@5U'#GETBEV]ZX/WZBG,
MWG%O690/^J(4>W:RKIV_YIT?#SJ.!QV"96#H!QW9*.<O@;-9QS-T] X[Q&0#
M.?"0R6S1+F./356L'6AN^.A#JFNB(X!])R!M #.(<Y!#P;/T@4#-J+UPRVOT
MG$0^0V0[]>[.2-K</.B%Z2TX-JD#A)CIUL]+)''Z+/E6&:(O-GOX8+%B08;!
M'9>YUT[$*;6J@2XE,W4T56?0JP5H_:"J]7QB]=NQHO8/G^Q'1\(Y!,NGXS.R
M=N9DF0NJ'W.RK-F1''.RCCE9 \O):KG>>!<Y68:.(%K)R9*>FQL^B&V<DV5M
MDIR<97 *V(##60T<\K8/AF[P-,&AR#)H!(SA<)9$S ]GH\5EWGN4:4_JV8($
M=ONU"CDM2C<0<<I_I!BK'"L-4C,^KTK[:JR$&K#) >X2-IO=XY:A[=57/D<Q
M^F?HSQ=QD:$QH2NITZ8B,^4EZ,\;4E,8<+H96R4/O;1MZ*GZ&J?Z8IZM.SRI
MD6XER%*R'@8QR]:%PM+A<A5%"?;.$\KXG++-&<G2*[-?7Q+*-FQ/OBNK^%*K
MFP&@5U\<Z]Q!0(9L8!X.+=#/8+&5R@.!:RQM539 ;_!S^I>&TW5+/E@H16*
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M=+OU%2/^;8#!BG'C=$Y*Z.PH.^.RN#C<,Y5$R(61/JV8LM(:X)0[Z'#!V[[
M7'I^.7N.V66_S_V9W+,)Y]=,D5@L4L7V%7K_FU/J_V^IK2E_PME^PPFRCW3H
M0LTB_$?""UD^86C GU8,Y8[,V= 9]O*DWMYIQ8SJ>WML Y'_U.GRK25D6C\
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M<LFTP%-"*?,$?_7CQ3B)8K+$5/VVJ@:YJ9?Q=*?<_J.KFB)9M]A6_5KEF29
M8>KIXH:02<6 8#+W@+%@A>$GLK7]F1W1:W!E]E5@40B@PBWGM;8-+!)9X[M4
MM*[ J2JYU1[+@4 -S$]I#J:EWLG&Z%8X5SZ&*2>TQ2,1S"925XY^5LN(Q@7
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M$E ,G?,8+6([XEHZ6)'ZPEGG)<"B:IP":!&;.;:I@X8FCG8?XW0-I)7AM3[
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M# ] , API+Q;%R80W\PNLSX*O>P7F/U1@5RS_@8!["&B]>-EULIZ+[P45)2
MWX6,-GDW1?=;6EM:T<<@\*TK#NB%6'G6E?W^DE"V,WUB)J/IF5>EGT%@VT0D
M<']NU,]1U%[=M1D&+GOL0CHO) X8NC*=9RX5TE6E]Z5/9?>E\[Z<0F>%N]([
M2;N3YA+Y]!<4))O82<Z15*3W,I%XAT[:(_]7=A-\(Z;A:^!;64=1A..(F>A"
M =BO&'%IO$EXR]-+^=*0%8.EFW^>H<B/.'VZ?;K'[B+T_TBPSK7Q[K]L9B'J
M2"[%87"W7[7F-+FOX;JW$O>!J?4GV[F<676/51+?LV_)#[9A"F-A\5Z0))I:
ML&[#*V)5=28KHS%S3JY4N!H?>X_+VX7(R@!YVS!:>K=^G^&+EQ5V8^SQ';7J
MLKV:UM#1N\9DDL,FEL3ZE?+6CWZ_I!@7ZU[5!1'NX\%0=?F#T52(!"ZOUN"Z
M&8Z;P'437.$^3*5IM#9+ 9%ZRMXX -<TK/(+X<=^S/=;UX542&[J;>*#T82E
M@8#\V'(*5)9,OKO$>OETXQ>X!&I=[IZ0DE(^?#&#2]^;U3KJL.X85,%X.D[A
M^:E#_6<9!G55HN%;]1M6KL9<%?=5OJL$7X4A5N-75-* /L,3>_PN$MLFH6S@
M413.4U#.UKLF4[1.:^<_(^IIA%/;Z-OXY1>5#!$D1(U78P[\A#6AT/8&D^0Y
MFE;P,!/9_%.D]K8$4.-$8+/9V,=$X&,B\#$1V'0B\,5R%9 UQM$V(99YL&/&
M%E,*+VLA30S6(QY>P;5ZLED7WIP&*.2O"\G/]\JM7I\]%(H)+J*FL5*= NVW
M,W,X)U2F6-_V'L(U4[F51J@I++V:F!O\G(4SKD+^A@C;P7-FI(9%1F+H; P8
MUT2?Z7[6'H7_=LL74WBW5/CSZ[,(9?G X=\['+):MJ4&_>]FJOHB8M;LV)W4
M4:>5"[J^RBVJT?P5O?C+!$Y[8&U*33K0O')'(!JL1,(>Z-0;NP.1K6O*M+V]
M9J]O%1?+"1Y:&[W2T$CJG62AI^NK=O,U,YL,,;*"VQ4=:=>FO<KP1Y&59M;P
M2+,TIW$3\BJ<X:I2:T 24^?UG2X,I(;L$+Q?S!43Z*=@J*G+>=T=J=:0&T+=
M7@,BG0Z_X"C>"BQY6;K-K[S" =2Z=JP[<G@5A4JZ'0#UJYJ8?;JGB2*J5XEO
M$KD#T?JG7NGH:5]%_<0_ZXZZF5K.F5K.7S$OXHZ]T1.F:(YO,0>0_7[,-@@4
MN7&" IY,>ZH8E_TR\TI'K@DE#B\:I)C#%R^8NG[$XV%=KZB53[W2<=F^BJ!1
MU_1M$.,K:D%.S?FGVB/TR\PK';DFE B-;7//GQPXA_FVB@D?>ML[JX3_JD?7
M59>#5SJ*>],<-'0_O=ZANS>W\UFO56'+&%_'8=Z%/J'!_WEP@_\<1R[U4\UT
M,(0+O1\'(JP5\%3#6%9$D/:+/;&,?.:$D63-TZ-_?4.BCMQ@M-G\2656UE(L
MPPVO:IJNH%PAT3V)45#\^YA$\0V)_P?'M]@E\]#_5UX5-5]^-4X]N_S\ZQMS
M/:H-'+)&[T5OWHK5NQC]07PQ>M/)\6;T\6;T\6;TG^YF]#%CM..,4;-GZ(/.
M]3MFC!XS1H\9H\/)& 4N[-T_,X;6V7\GX<9=EU[8DY&8JG_81RJHENS@(M%R
M';8B(_?/I"YN^R0/HG'U2G$3R@[.-V,NPCF>Q5=AQ)S*5&:I6R=J^VI].U@Q
M%J75E9G4,:\PA1E'2Z)F&1YV>TSMP6*SYW(P=+VZ()L7J](4&Q)C>1T:H+6I
M KW*P4_T6 >SV(S9G_P!I#P$.:&W_/A1;H8D)*_6&BG59%'6K9!7U0(H)3)C
MFM0ZU\#(7B/5-DPVFZH6H>S5:&T8".5[KOUF#Y^-OF8GG0%$P3:87M+RUG::
MS +?#=;W%'G8VQR!2=4L(V'#8A Z5\L 'T6TC0#UGU",]50O:OMP8B@.5%?G
M,/.@LLT]>9&SJ;JG76KV<&+(,:Z!!,PW"((YM_@N9@.&F[2L_A=W)4G(G4>Y
M:ZP@>[7NL9:Z++J\L\>FRNL"FIMQB_5T+7I\ )#7)J>X#6!L=H1; \_2@B.,
MRR4)T[0FE0&K-#558$0^.?;?71<Q#>%@KC*(T"YG5RB8#=@^0C)&08"]L_7&
M-<H;U@W^Z'?\</+)TB.HIDE(K2@$&D!V!2=*EQ&V?]R*(KDIV*B[/\E8T5,#
MZ",;J[E,B8NQ%UTR[?$Z&"@L<@\/!3G=Z\-<1U[KSC6% [5P2ZGF3"]0OCZ
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MXR,A,92 I="V$AM[TZ_:A,=*L]PNA)8F8>WQJTK&$C9_$+'?Q].@RNDBQ:;
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M5I&E>5WLU@FV1/:%WZ^670K1B3,%Y9@^3 VU>@,*,4TX%DG:%ISZ[L!/(^_
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M54(:3(JUDQ2*9&A>&*".J3$2 \4./38C07KQN!QY)$E9Y\R .4FBB@;?;AC
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M9*)SZK5J1.*@SZ1K$8?(.<_I5OMP):"Y=L)CJ7XJ41GFF&)!/Y,Z :0/R4Y
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M2HC>/I[)133 WF87S^*.B!L'F%]:CAS?!#-ND1UG&,_BCI(LV\PQNL3G&K(
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MX[8(YE-M"T%=*2<\1QY=LG:^/%[4<4>) S&Q7AA-$>(ZI6-Y! M(^YN!:1_
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M7]95B/=5K%@#X]Y7(-2.KJFZ@#IR,F3-;E+>Y0\W^2?P^E<<)S,WHKL_3;*
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M$WTTTOD@7X/&X,-6,AAIW>M,^5?7]"?ZZ^Y7]#^LCO0W_QM02P,$%     @
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MJ<YUR2HT,U4/0[O/:?C[C"81-S47?RSC?'5.'N,PSEU&:NWDD -W4H?V/?;
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M2"WCIHSO1?[ZU;MOOT61,U=P<I63>0:2=:4UOKQ-&J,7>X6%4O3OD41?_O#
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M-3=RBX[%*,AFXAU6_C_BD>JG(!$NY&$^"AA;Q>E4OJ1L,$ P<G#A])[ ,F-
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M5:X&,D' L$!6VF!G2;@NA WVG"(]R[^(_TSX.LI_\_\!4$L! A0#%     @
M*ZZF6&<12[].<P  17T"  H              ( !     &5X,3 M,2YH=&U0
M2P$"% ,4    "  KKJ98JNQ%QD0F  !?! $ "P              @ %V<P
M97@Q,"TQ,"YH=&U02P$"% ,4    "  KKJ98F%(B,AF4  "?%@0 "P
M        @ 'CF0  97@Q,"TQ,2YH=&U02P$"% ,4    "  KKJ98)Q^I%I)E
M  "_PP( "P              @ $E+@$ 97@Q,"TQ,BYH=&U02P$"% ,4
M"  KKJ98R.^N8UX@  #)YP  "P              @ '@DP$ 97@Q,"TQ,RYH
M=&U02P$"% ,4    "  KKJ98/SJEM4%1  #%"0( "@              @ %G
MM $ 97@Q,"TR+FAT;5!+ 0(4 Q0    ( "NNIEBV/'Z\?2P  )"@ @ *
M          "  = % @!E>#$P+3,N:'1M4$L! A0#%     @ *ZZF6"ZO3U$!
M+   T< "  H              ( !=3(" &5X,3 M-"YH=&U02P$"% ,4
M"  KKJ98M"PH76\H  "C# $ "@              @ &>7@( 97@Q,"TU+FAT
M;5!+ 0(4 Q0    ( "NNIE@R*XY=>S@  #QE 0 *              "  36'
M @!E>#$P+3<N:'1M4$L! A0#%     @ *ZZF6$1JKL.M)P  [@<!  H
M         ( !V+\" &5X,3 M."YH=&U02P$"% ,4    "  KKJ98T&+TS?4C
M  !QV@  "@              @ &MYP( 97@Q,"TY+FAT;5!+ 0(4 Q0    (
M "NNIEAE&%CM_@X  (3,   )              "  <H+ P!E>#$P-RYH=&U0
M2P$"% ,4    "  KKJ98%X]M9GXS   EN0$ "@              @ 'O&@,
M97@Q-"TQ+FAT;5!+ 0(4 Q0    ( "NNIE@EERJW"0(  )H(   *
M      "  95. P!E>#(Q+3$N:'1M4$L! A0#%     @ *ZZF6& Q;?#] @
MR@\   H              ( !QE # &5X,C,M,2YH=&U02P$"% ,4    "  K
MKJ98ZGH<!PLL  "/)0$ "0              @ 'K4P, 97@S+3$N:'1M4$L!
M A0#%     @ *ZZF6&IVU1AP9   KFP"  D              ( !'8 # &5X
M,RTR+FAT;5!+ 0(4 Q0    ( "NNIEB@ZK18)EH  "<M @ )
M  "  ;3D P!E>#0M,2YH=&U02P$"% ,4    "  KKJ98>W.^EPD/   T2@
M"0              @ $!/P0 97@T+3(N:'1M4$L! A0#%     @ *ZZF6.'G
MK",<#P  &TP   D              ( !,4X$ &5X-"TS+FAT;5!+ 0(4 Q0
M   ( "NNIEB9[XW7\!$  .&6   )              "  71=! !E>#0M-"YH
M=&U02P$"% ,4    "  KKJ98",HS_,0.  #8#P  #P              @ &+
M;P0 9F]R;7,M,5\P,#$N:G!G4$L! A0#%     @ *ZZF6#.Y!1+ $P  @A4
M  \              ( !?'X$ &9O<FUS+3%?,# R+FIP9U!+ 0(4 Q0    (
M "NNIEB:M=E<<T   -M"   /              "  6F2! !F;W)M<RTQ7S P
M,RYJ<&=02P$"% ,4    "  KKJ98&Y2]HAYM    =0  #P
M@ $)TP0 9F]R;7,M,5\P,#0N:G!G4$L! A0#%     @ *ZZF6 T@^8+(4@
M\E8   \              ( !5$ % &9O<FUS+3%?,# U+FIP9U!+ 0(4 Q0
M   ( "NNIEC4J_.ZW%\  +MB   /              "  4F3!0!F;W)M<RTQ
M7S P-BYJ<&=02P$"% ,4    "  KKJ98![=H!A5&  #\3@  #P
M    @ %2\P4 9F]R;7,M,5\P,#<N:G!G4$L! A0#%     @ *ZZF6./E/!2_
M+   ,C@   \              ( !E#D& &9O<FUS+3%?,# X+FIP9U!+ 0(4
M Q0    ( "NNIEA*<@L4''T  #2#   /              "  8!F!@!F;W)M
M<RTQ7S P.2YJ<&=02P$"% ,4    "  KKJ98UK1J)_5M  !#=0  #P
M        @ ')XP8 9F]R;7,M,5\P,3 N:G!G4$L! A0#%     @ *ZZF6!4^
MSK+ (   T"@   \              ( !ZU$' &9O<FUS+3%?,#$Q+FIP9U!+
M 0(4 Q0    ( "NNIECH'=RT]@L# $/+'@ ,              "  =AR!P!F
M;W)M<RTQ82YH=&U02P$"% ,4    "  KKJ98RT62%A4.  !^GP  $0
M        @ 'X?@H ;VYM9"TR,#(S,3(S,2YX<V102P$"% ,4    "  KKJ98
MV6W(:S<2  !QYP  %0              @ $\C0H ;VYM9"TR,#(S,3(S,5]C
M86PN>&UL4$L! A0#%     @ *ZZF6"[OX::+,P  ZW8# !4
M ( !II\* &]N;60M,C R,S$R,S%?9&5F+GAM;%!+ 0(4 Q0    ( "NNIEBN
M/=CZW%@  (<C!0 5              "  633"@!O;FUD+3(P,C,Q,C,Q7VQA
M8BYX;6Q02P$"% ,4    "  KKJ98JAIU_'M   "^3@0 %0
M@ %S+ L ;VYM9"TR,#(S,3(S,5]P<F4N>&UL4$L%!@     G "< \0@  "%M
$"P    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>forms-1a_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:ONMD="http://onemednet.com/20231231"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="onmd-20231231.xsd" xlink:type="simple"/>
    <context id="From2023-01-01to2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_dei_BusinessContactMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_SeriesATwoPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ONMD:SeriesATwoPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_SeriesATwoPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ONMD:SeriesATwoPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_SeriesAOnePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ONMD:SeriesAOnePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_SeriesAOnePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ONMD:SeriesAOnePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_CommonClassAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CommonClassAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_CommonClassAOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ONMD:CommonClassAOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_CommonClassAOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ONMD:CommonClassAOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesATwoPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ONMD:SeriesATwoPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesAOnePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ONMD:SeriesAOnePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember_custom_DataKnightsAcquisitionCorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ONMD:DataKnightsAcquisitionCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassBMember_custom_DataKnightsAcquisitionCorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ONMD:DataKnightsAcquisitionCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_CommitmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ONMD:CommitmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesATwoPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ONMD:SeriesATwoPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesAOnePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ONMD:SeriesAOnePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember_custom_DataKnightsAcquisitionCorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ONMD:DataKnightsAcquisitionCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassBMember_custom_DataKnightsAcquisitionCorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ONMD:DataKnightsAcquisitionCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_CommitmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ONMD:CommitmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_PreferredStockMember_custom_SeriesATwoPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ONMD:SeriesATwoPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_PreferredStockMember_custom_SeriesAOnePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ONMD:SeriesAOnePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember_custom_DataKnightsAcquisitionCorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ONMD:DataKnightsAcquisitionCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassBMember_custom_DataKnightsAcquisitionCorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ONMD:DataKnightsAcquisitionCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_CommitmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ONMD:CommitmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_SeriesATwoPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ONMD:SeriesATwoPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_SeriesAOnePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ONMD:SeriesAOnePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember_custom_DataKnightsAcquisitionCorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ONMD:DataKnightsAcquisitionCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassBMember_custom_DataKnightsAcquisitionCorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ONMD:DataKnightsAcquisitionCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_CommitmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ONMD:CommitmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesATwoPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ONMD:SeriesATwoPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesAOnePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ONMD:SeriesAOnePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember_custom_DataKnightsAcquisitionCorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ONMD:DataKnightsAcquisitionCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassBMember_custom_DataKnightsAcquisitionCorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ONMD:DataKnightsAcquisitionCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_CommitmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ONMD:CommitmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-06-282023-06-28_custom_SecuritiesPurchaseAgreementMember_custom_DataKnightsAcquisitionCorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ONMD:DataKnightsAcquisitionCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ONMD:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-28</startDate>
            <endDate>2023-06-28</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-28_custom_SecuritiesPurchaseAgreementMember_custom_DataKnightsAcquisitionCorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ONMD:DataKnightsAcquisitionCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ONMD:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-28</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_CustomerConcentrationRiskMember_custom_OneCustomerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ONMD:OneCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_CustomerConcentrationRiskMember_custom_TwoCustomersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ONMD:TwoCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_ThreeCustomersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ONMD:ThreeCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_TwoCustomersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ONMD:TwoCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ONMD:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ONMD:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ONMD:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ONMD:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ONMD:CustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ONMD:CustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ONMD:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ONMD:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ONMD:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ONMD:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ONMD:CustomerThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ONMD:CustomerThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ONMD:CustomerFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ONMD:CustomerFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ONMD:CustomerFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ONMD:CustomerFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ONMD:CustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ONMD:CustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_StateAndLocalJurisdictionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_DataKnightsAcquisitionCorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ONMD:DataKnightsAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_DataKnightsAcquisitionCorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ONMD:DataKnightsAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_NonrelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_NonrelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-11-11_us-gaap_RelatedPartyMember_custom_ConvertiblePromissoryNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ONMD:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-11</instant>
        </period>
    </context>
    <context id="From2022-11-102022-11-11_us-gaap_RelatedPartyMember_custom_ConvertiblePromissoryNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ONMD:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-10</startDate>
            <endDate>2022-11-11</endDate>
        </period>
    </context>
    <context id="AsOf2022-11-11_us-gaap_RelatedPartyMember_custom_SeriesATwoPreferredStockMember_custom_ConvertiblePromissoryNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ONMD:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ONMD:SeriesATwoPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-11</instant>
        </period>
    </context>
    <context id="AsOf2019-11-30_us-gaap_RelatedPartyMember_custom_ConvertiblePromissoryNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ONMD:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-30</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_ConvertiblePromissoryNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ONMD:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-11-30_us-gaap_RelatedPartyMember_custom_DataKnightsAcquisitionCorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ONMD:DataKnightsAcquisitionCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="From2020-12-012020-12-31_custom_CEBALoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ONMD:CEBALoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_CEBALoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ONMD:CEBALoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_CEBALoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ONMD:CEBALoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_SeriesATwoPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ONMD:SeriesATwoPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_SeriesAOnePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ONMD:SeriesAOnePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_BoardOfDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ONMD:BoardOfDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_BoardOfDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ONMD:BoardOfDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_BoardOfDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ONMD:BoardOfDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CommonStockMember_srt_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_CommonStockMember_srt_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_CommonStockMember_srt_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_EmployeesDirectorsAndConsultantsMember_custom_NewEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ONMD:EmployeesDirectorsAndConsultantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ONMD:NewEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_EmployeesDirectorsAndConsultantsMember_custom_NewEquityIncentivePlanMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ONMD:EmployeesDirectorsAndConsultantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ONMD:NewEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_EmployeesDirectorsAndConsultantsMember_custom_NewEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ONMD:EmployeesDirectorsAndConsultantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ONMD:NewEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-11-07">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
        </entity>
        <period>
            <instant>2023-11-07</instant>
        </period>
    </context>
    <context id="From2023-10-172023-10-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
        </entity>
        <period>
            <startDate>2023-10-17</startDate>
            <endDate>2023-10-17</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_TwentyTwentyOneServiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ONMD:TwentyTwentyOneServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_TwentyTwentyTwoServiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ONMD:TwentyTwentyTwoServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_ConvertiableNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ONMD:ConvertiableNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_ConvertiableNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ONMD:ConvertiableNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_WarrantOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ONMD:WarrantOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_PubliclyTradedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ONMD:PubliclyTradedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_PubliclyTradedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ONMD:PubliclyTradedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_PrivateWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ONMD:PrivateWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_PrivateWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ONMD:PrivateWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member_custom_InvestmentsHeldInTrustMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ONMD:InvestmentsHeldInTrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member_custom_InvestmentsHeldInTrustMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ONMD:InvestmentsHeldInTrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member_custom_InvestmentsHeldInTrustMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ONMD:InvestmentsHeldInTrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_custom_InvestmentsHeldInTrustMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ONMD:InvestmentsHeldInTrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member_custom_InvestmentsHeldInTrustMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ONMD:InvestmentsHeldInTrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member_custom_InvestmentsHeldInTrustMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ONMD:InvestmentsHeldInTrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member_custom_InvestmentsHeldInTrustMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ONMD:InvestmentsHeldInTrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueMeasurementsRecurringMember_custom_InvestmentsHeldInTrustMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ONMD:InvestmentsHeldInTrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_DataKnightsAcquisitionCorpMember_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ONMD:DataKnightsAcquisitionCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RelatedPartyMember_custom_ManagementAndDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ONMD:ManagementAndDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-11-012023-11-30_custom_SecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ONMD:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="From2023-11-012023-11-30_custom_SeniorConvertibleNotesMember_custom_SecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ONMD:SeniorConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ONMD:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-11-30_us-gaap_RelatedPartyMember_custom_SecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ONMD:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="From2023-11-012023-11-30_custom_SecuritiesPurchaseAgreementMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ONMD:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-11-30_custom_SecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ONMD:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_srt_ScenarioForecastMember_custom_EFHuttonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ONMD:EFHuttonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_srt_ScenarioForecastMember_custom_KingwoodCapitalPartnersLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ONMD:KingwoodCapitalPartnersLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_srt_ScenarioForecastMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_SubsequentEventMember_us-gaap_MajorityShareholderMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-03-262024-03-27_srt_ScenarioForecastMember_srt_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-26</startDate>
            <endDate>2024-03-27</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-27_srt_ScenarioForecastMember_srt_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-27</instant>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="Integer">
        <measure>ONMD:Integer</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2023-01-01to2023-12-31" id="Fact000003">true</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="From2023-01-01to2023-12-31" id="Fact000004">0001849380</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl0012">S-1/A</dei:DocumentType>
    <us-gaap:AssetsHeldInTrustCurrent
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0042"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SalesAndExciseTaxPayableCurrent
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0073"
      unitRef="USD"
      xsi:nil="true"/>
    <ONMD:LoanExtensionsCurrent
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0076"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LoansPayable
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0082"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ConvertibleDebtCurrent
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0084"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:UnsecuredDebtCurrent
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0088"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0093"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherNotesPayableCurrent
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0097"
      unitRef="USD"
      xsi:nil="true"/>
    <ONMD:DeferredUnderwriterFeePayableCurrent
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0100"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="AsOf2022-12-31_us-gaap_RelatedPartyMember"
      id="xdx2ixbrl0118"
      unitRef="USD"
      xsi:nil="true"/>
    <ONMD:DeferredUnderwriterFeePayableNonCurrent
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0123"
      unitRef="USD"
      xsi:nil="true"/>
    <ONMD:WorkingCapitalLoan
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0126"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LongTermLoansPayable
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0129"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-12-31_custom_SeriesATwoPreferredStockMember"
      id="xdx2ixbrl0138"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-12-31_custom_SeriesAOnePreferredStockMember"
      id="xdx2ixbrl0145"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-12-31_custom_SeriesAOnePreferredStockMember"
      id="xdx2ixbrl0152"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommonStockValue
      contextRef="AsOf2023-12-31_us-gaap_CommonClassAMember"
      id="xdx2ixbrl0162"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommonStockValue
      contextRef="AsOf2023-12-31_custom_CommonClassAOneMember"
      id="xdx2ixbrl0169"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommonStockValue
      contextRef="AsOf2023-12-31_custom_CommonClassAOneMember"
      id="xdx2ixbrl0176"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0179"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl0230"
      unitRef="USD"
      xsi:nil="true"/>
    <ONMD:UnrealizedGainLoss
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl0245"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2022-01-012022-12-31_custom_CommitmentMember"
      id="xdx2ixbrl0288"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-12-31_custom_CommitmentMember"
      id="xdx2ixbrl0300"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2022-01-012022-12-31_custom_CommitmentMember"
      id="xdx2ixbrl0313"
      unitRef="USD"
      xsi:nil="true"/>
    <ONMD:CommonStockSubjectToPossibleRedemptionValue
      contextRef="From2022-01-012022-12-31_custom_CommitmentMember"
      id="xdx2ixbrl0325"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-12-31_custom_CommitmentMember"
      id="xdx2ixbrl0335"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_custom_SeriesATwoPreferredStockMember"
      id="xdx2ixbrl0340"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_custom_SeriesAOnePreferredStockMember"
      id="xdx2ixbrl0341"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember_custom_DataKnightsAcquisitionCorpMember"
      id="xdx2ixbrl0342"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassBMember_custom_DataKnightsAcquisitionCorpMember"
      id="xdx2ixbrl0343"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_custom_CommitmentMember"
      id="xdx2ixbrl0345"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2023-01-012023-12-31_custom_CommitmentMember"
      id="xdx2ixbrl0405"
      unitRef="USD"
      xsi:nil="true"/>
    <ONMD:StockIssuedDuringPeriodValueConvertibleNotesToCommonStock
      contextRef="From2023-01-012023-12-31_custom_CommitmentMember"
      id="xdx2ixbrl0421"
      unitRef="USD"
      xsi:nil="true"/>
    <ONMD:StockIssuedDuringPeriodValueStockOptionsToCommonStock
      contextRef="From2023-01-012023-12-31_custom_CommitmentMember"
      id="xdx2ixbrl0433"
      unitRef="USD"
      xsi:nil="true"/>
    <ONMD:StockIssuedDuringPeriodValueConvertingOfWarrantsToCommonStock
      contextRef="From2023-01-012023-12-31_custom_CommitmentMember"
      id="xdx2ixbrl0445"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-01-012023-12-31_custom_CommitmentMember"
      id="xdx2ixbrl0457"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2023-01-012023-12-31_custom_CommitmentMember"
      id="xdx2ixbrl0469"
      unitRef="USD"
      xsi:nil="true"/>
    <ONMD:StockIssuedDuringPeriodValueConvertingDataKnightsCommonShares
      contextRef="From2023-01-012023-12-31_custom_CommitmentMember"
      id="xdx2ixbrl0479"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_custom_CommitmentMember"
      id="xdx2ixbrl0505"
      unitRef="USD"
      xsi:nil="true"/>
    <ONMD:RetainedEarningsAdjustment
      contextRef="From2023-01-012023-12-31_custom_CommitmentMember"
      id="xdx2ixbrl0517"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_SeriesATwoPreferredStockMember"
      id="xdx2ixbrl0522"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_SeriesAOnePreferredStockMember"
      id="xdx2ixbrl0523"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember_custom_DataKnightsAcquisitionCorpMember"
      id="xdx2ixbrl0524"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_SeriesATwoPreferredStockMember"
      id="xdx2ixbrl0532"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_SeriesAOnePreferredStockMember"
      id="xdx2ixbrl0533"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember_custom_DataKnightsAcquisitionCorpMember"
      id="xdx2ixbrl0534"
      unitRef="USD"
      xsi:nil="true"/>
    <ONMD:BusinessCombinationCost
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0595"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl0597"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl0606"
      unitRef="USD"
      xsi:nil="true"/>
    <ONMD:ProceedsFromIssuanceOfCommonStockOne
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl0648"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0658"
      unitRef="USD"
      xsi:nil="true"/>
    <ONMD:ProceedsFromDeferredUnderwritingFee
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0667"
      unitRef="USD"
      xsi:nil="true"/>
    <ONMD:ProceedsFromIssuanceOfCommonStockTwo
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0676"
      unitRef="USD"
      xsi:nil="true"/>
    <ONMD:ClassBCommonStock
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0679"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-01-012023-12-31_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerTwoMember"
      id="xdx2ixbrl0725"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-01-012023-12-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerOneMember"
      id="xdx2ixbrl0733"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-01-012022-12-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerTwoMember"
      id="xdx2ixbrl0737"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-01-012022-12-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerThreeMember"
      id="xdx2ixbrl0740"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-01-012023-12-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerFourMember"
      id="xdx2ixbrl0742"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-01-012022-12-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerFiveMember"
      id="xdx2ixbrl0746"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0821"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0830"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0831"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0917"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:AssetsHeldInTrustCurrent
      contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member_custom_InvestmentsHeldInTrustMember"
      id="xdx2ixbrl0996"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsHeldInTrustCurrent
      contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member_custom_InvestmentsHeldInTrustMember"
      id="xdx2ixbrl0998"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsHeldInTrustCurrent
      contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member_custom_InvestmentsHeldInTrustMember"
      id="xdx2ixbrl1000"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsHeldInTrustCurrent
      contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_custom_InvestmentsHeldInTrustMember"
      id="xdx2ixbrl1002"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsHeldInTrustCurrent
      contextRef="AsOf2022-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member_custom_InvestmentsHeldInTrustMember"
      id="xdx2ixbrl1006"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsHeldInTrustCurrent
      contextRef="AsOf2022-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member_custom_InvestmentsHeldInTrustMember"
      id="xdx2ixbrl1008"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsHeldInTrustCurrent
      contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl1012"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsHeldInTrustCurrent
      contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1014"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsHeldInTrustCurrent
      contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl1016"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsHeldInTrustCurrent
      contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember"
      id="xdx2ixbrl1018"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsHeldInTrustCurrent
      contextRef="AsOf2022-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1022"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsHeldInTrustCurrent
      contextRef="AsOf2022-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1024"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:AmendmentDescription contextRef="From2023-01-01to2023-12-31" id="Fact000011">Amendment No. 2</dei:AmendmentDescription>
    <dei:EntityRegistrantName contextRef="From2023-01-01to2023-12-31" id="Fact000013">ONEMEDNET CORPORATION</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2023-01-01to2023-12-31" id="Fact000014">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2023-01-01to2023-12-31" id="Fact000015">86-2049355</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2023-01-01to2023-12-31" id="Fact000016">6385 Old Shady Oak Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2023-01-01to2023-12-31" id="Fact000017">Suite 250</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2023-01-01to2023-12-31" id="Fact000018">Eden Prairie</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2023-01-01to2023-12-31" id="Fact000019">MN</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2023-01-01to2023-12-31" id="Fact000020">55344</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2023-01-01to2023-12-31" id="Fact000021">800</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2023-01-01to2023-12-31" id="Fact000022">918-7189</dei:LocalPhoneNumber>
    <dei:ContactPersonnelName
      contextRef="From2023-01-012023-12-31_dei_BusinessContactMember"
      id="Fact000023">Debbie A. Klis, Esq.</dei:ContactPersonnelName>
    <dei:EntityAddressAddressLine1
      contextRef="From2023-01-012023-12-31_dei_BusinessContactMember"
      id="Fact000024">1990 K. Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="From2023-01-012023-12-31_dei_BusinessContactMember"
      id="Fact000025">NW, Suite 420</dei:EntityAddressAddressLine2>
    <dei:EntityAddressAddressLine3
      contextRef="From2023-01-012023-12-31_dei_BusinessContactMember"
      id="Fact000026">Washington</dei:EntityAddressAddressLine3>
    <dei:EntityAddressStateOrProvince
      contextRef="From2023-01-012023-12-31_dei_BusinessContactMember"
      id="Fact000027">DC</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="From2023-01-012023-12-31_dei_BusinessContactMember"
      id="Fact000028">20006</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="From2023-01-012023-12-31_dei_BusinessContactMember"
      id="Fact000029">(202)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="From2023-01-012023-12-31_dei_BusinessContactMember"
      id="Fact000030">935-3390</dei:LocalPhoneNumber>
    <dei:EntityFilerCategory contextRef="From2023-01-01to2023-12-31" id="Fact000031">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2023-01-01to2023-12-31" id="Fact000032">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2023-01-01to2023-12-31" id="Fact000033">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="From2023-01-01to2023-12-31" id="Fact000034">false</dei:EntityExTransitionPeriod>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000039"
      unitRef="USD">47008</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000040"
      unitRef="USD">301730</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AssetsHeldInTrustCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000043"
      unitRef="USD">29029415</us-gaap:AssetsHeldInTrustCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000045"
      unitRef="USD">151640</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000046"
      unitRef="USD">18975</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000048"
      unitRef="USD">165538</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000049"
      unitRef="USD">100945</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:OtherReceivables
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000052"
      unitRef="USD">900152</us-gaap:OtherReceivables>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000054"
      unitRef="USD">364186</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000055"
      unitRef="USD">30351217</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000057"
      unitRef="USD">98871</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000058"
      unitRef="USD">83097</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Assets
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000060"
      unitRef="USD">463057</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000061"
      unitRef="USD">30434314</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000066"
      unitRef="USD">4184398</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000067"
      unitRef="USD">2814570</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:OtherShortTermBorrowings
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000069"
      unitRef="USD">11200</us-gaap:OtherShortTermBorrowings>
    <us-gaap:OtherShortTermBorrowings
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000070"
      unitRef="USD">11500</us-gaap:OtherShortTermBorrowings>
    <us-gaap:SalesAndExciseTaxPayableCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000072"
      unitRef="USD">113353</us-gaap:SalesAndExciseTaxPayableCurrent>
    <ONMD:LoanExtensionsCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000075"
      unitRef="USD">2991679</ONMD:LoanExtensionsCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000078"
      unitRef="USD">253997</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000079"
      unitRef="USD">183683</us-gaap:DeferredRevenueCurrent>
    <us-gaap:LoansPayable
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000081"
      unitRef="USD">38921</us-gaap:LoansPayable>
    <us-gaap:ConvertibleDebtCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000085"
      unitRef="USD">8490000</us-gaap:ConvertibleDebtCurrent>
    <us-gaap:UnsecuredDebtCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000087"
      unitRef="USD">44673</us-gaap:UnsecuredDebtCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000090"
      unitRef="USD">120017</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000091"
      unitRef="USD">214850</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000094"
      unitRef="USD">69966</us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent>
    <us-gaap:OtherNotesPayableCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000096"
      unitRef="USD">1549820</us-gaap:OtherNotesPayableCurrent>
    <ONMD:DeferredUnderwriterFeePayableCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000099"
      unitRef="USD">3525000</ONMD:DeferredUnderwriterFeePayableCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000102"
      unitRef="USD">12833058</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000103"
      unitRef="USD">11784569</us-gaap:LiabilitiesCurrent>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000109"
      unitRef="USD">1500000</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:UnsecuredDebt
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000112"
      unitRef="USD">44144</us-gaap:UnsecuredDebt>
    <ONMD:AccruedInterestRelatedParty
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000115"
      unitRef="USD">690772</ONMD:AccruedInterestRelatedParty>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact000117"
      unitRef="USD">465023</us-gaap:OtherLiabilitiesNoncurrent>
    <ONMD:WarrantLiabilityNonCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000120"
      unitRef="USD">24582</ONMD:WarrantLiabilityNonCurrent>
    <ONMD:WarrantLiabilityNonCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000121"
      unitRef="USD">362558</ONMD:WarrantLiabilityNonCurrent>
    <ONMD:DeferredUnderwriterFeePayableNonCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000124"
      unitRef="USD">4025000</ONMD:DeferredUnderwriterFeePayableNonCurrent>
    <ONMD:WorkingCapitalLoan
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000127"
      unitRef="USD">207081</ONMD:WorkingCapitalLoan>
    <us-gaap:LongTermLoansPayable
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000130"
      unitRef="USD">2545839</us-gaap:LongTermLoansPayable>
    <us-gaap:Liabilities
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000132"
      unitRef="USD">13322663</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000133"
      unitRef="USD">21159963</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31_custom_SeriesATwoPreferredStockMember"
      decimals="INF"
      id="Fact000140"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2022-12-31_custom_SeriesATwoPreferredStockMember"
      decimals="INF"
      id="Fact000141"
      unitRef="Shares">4200000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2023-12-31_custom_SeriesATwoPreferredStockMember"
      decimals="INF"
      id="Fact000142"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2022-12-31_custom_SeriesATwoPreferredStockMember"
      decimals="INF"
      id="Fact000143"
      unitRef="Shares">3853797</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2022-12-31_custom_SeriesATwoPreferredStockMember"
      decimals="0"
      id="Fact000139"
      unitRef="USD">385</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31_custom_SeriesAOnePreferredStockMember"
      decimals="INF"
      id="Fact000147"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2022-12-31_custom_SeriesAOnePreferredStockMember"
      decimals="INF"
      id="Fact000148"
      unitRef="Shares">4400000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2023-12-31_custom_SeriesAOnePreferredStockMember"
      decimals="INF"
      id="Fact000149"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2022-12-31_custom_SeriesAOnePreferredStockMember"
      decimals="INF"
      id="Fact000150"
      unitRef="Shares">3204000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2022-12-31_custom_SeriesAOnePreferredStockMember"
      decimals="0"
      id="Fact000146"
      unitRef="USD">320</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2022-12-31_custom_SeriesAOnePreferredStockMember"
      decimals="0"
      id="Fact000153"
      unitRef="USD">320</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact000157"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact000158"
      unitRef="Shares">30000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000159"
      unitRef="Shares">23572232</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact000160"
      unitRef="Shares">4550166</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000155"
      unitRef="USD">2357</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000156"
      unitRef="USD">455</us-gaap:CommonStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact000164"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2022-12-31_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact000165"
      unitRef="Shares">4200000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact000166"
      unitRef="Shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact000167"
      unitRef="Shares">3853797</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2022-12-31_us-gaap_CommonClassAMember"
      decimals="0"
      id="Fact000163"
      unitRef="USD">59</us-gaap:CommonStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31_custom_CommonClassAOneMember"
      decimals="INF"
      id="Fact000171"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2022-12-31_custom_CommonClassAOneMember"
      decimals="INF"
      id="Fact000172"
      unitRef="Shares">4200000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2023-12-31_custom_CommonClassAOneMember"
      decimals="INF"
      id="Fact000173"
      unitRef="Shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2022-12-31_custom_CommonClassAOneMember"
      decimals="INF"
      id="Fact000174"
      unitRef="Shares">3853797</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2022-12-31_custom_CommonClassAOneMember"
      decimals="0"
      id="Fact000170"
      unitRef="USD">425</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2022-12-31_custom_CommonClassAOneMember"
      decimals="0"
      id="Fact000177"
      unitRef="USD">425</us-gaap:CommonStockValue>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000180"
      unitRef="USD">28750110</us-gaap:CommitmentsAndContingencies>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000182"
      unitRef="USD">42220714</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000183"
      unitRef="USD">24032561</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000185"
      unitRef="USD">-55082677</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000186"
      unitRef="USD">-43509964</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000188"
      unitRef="USD">-12859606</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000189"
      unitRef="USD">9274351</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000191"
      unitRef="USD">463057</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000192"
      unitRef="USD">30434314</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000194"
      unitRef="USD">1021651</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000195"
      unitRef="USD">1152738</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfRevenue
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000197"
      unitRef="USD">1149551</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000198"
      unitRef="USD">1513428</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000200"
      unitRef="USD">-127900</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000201"
      unitRef="USD">-360690</us-gaap:GrossProfit>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000206"
      unitRef="USD">5273503</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000207"
      unitRef="USD">8755620</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralExpense
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000209"
      unitRef="USD">226257</us-gaap:OtherGeneralExpense>
    <us-gaap:OtherGeneralExpense
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000210"
      unitRef="USD">398760</us-gaap:OtherGeneralExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000212"
      unitRef="USD">1114977</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000213"
      unitRef="USD">957690</us-gaap:SellingAndMarketingExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000215"
      unitRef="USD">1631613</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000216"
      unitRef="USD">952701</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000218"
      unitRef="USD">8246350</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000219"
      unitRef="USD">11064771</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000221"
      unitRef="USD">-8374250</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000222"
      unitRef="USD">-11425461</us-gaap:OperatingIncomeLoss>
    <us-gaap:AssetImpairmentCharges
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000227"
      unitRef="USD">10504327</us-gaap:AssetImpairmentCharges>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000231"
      unitRef="USD">214850</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:InterestExpense
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000233"
      unitRef="USD">749213</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000234"
      unitRef="USD">403307</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000236"
      unitRef="USD">52256</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000237"
      unitRef="USD">46820</us-gaap:OtherNonoperatingExpense>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000239"
      unitRef="USD">-46822</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000240"
      unitRef="USD">-4489110</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:StockOptionPlanExpense
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000242"
      unitRef="USD">3572232</us-gaap:StockOptionPlanExpense>
    <ONMD:UnrealizedGainLoss
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000246"
      unitRef="USD">1371689</ONMD:UnrealizedGainLoss>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000248"
      unitRef="USD">-14831206</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000249"
      unitRef="USD">5195822</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000251"
      unitRef="USD">-23205456</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000252"
      unitRef="USD">-6229639</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact000256"
      unitRef="USDPShares">-0.98</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact000260"
      unitRef="Shares">23572232</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesATwoPreferredStockMember"
      decimals="INF"
      id="Fact000273"
      unitRef="Shares">3853797</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesATwoPreferredStockMember"
      decimals="0"
      id="Fact000263"
      unitRef="USD">385</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesAOnePreferredStockMember"
      decimals="INF"
      id="Fact000275"
      unitRef="Shares">3204000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesAOnePreferredStockMember"
      decimals="0"
      id="Fact000264"
      unitRef="USD">320</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember_custom_DataKnightsAcquisitionCorpMember"
      decimals="INF"
      id="Fact000277"
      unitRef="Shares">585275</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember_custom_DataKnightsAcquisitionCorpMember"
      decimals="0"
      id="Fact000265"
      unitRef="USD">59</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassBMember_custom_DataKnightsAcquisitionCorpMember"
      decimals="INF"
      id="Fact000279"
      unitRef="Shares">2875000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassBMember_custom_DataKnightsAcquisitionCorpMember"
      decimals="0"
      id="Fact000266"
      unitRef="USD">288</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact000281"
      unitRef="Shares">4342666</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember"
      decimals="0"
      id="Fact000267"
      unitRef="USD">434</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_custom_CommitmentMember"
      decimals="0"
      id="Fact000268"
      unitRef="USD">28750110</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000269"
      unitRef="USD">19607173</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000270"
      unitRef="USD">-33920734</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact000271"
      unitRef="USD">14438035</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact000293"
      unitRef="Shares">200000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember"
      decimals="0"
      id="Fact000287"
      unitRef="USD">20</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000289"
      unitRef="USD">199980</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000291"
      unitRef="USD">200000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:SharePrice
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact000304"
      unitRef="USDPShares">1.00</us-gaap:SharePrice>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact000306"
      unitRef="Shares">7500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember"
      decimals="0"
      id="Fact000299"
      unitRef="USD">1</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000301"
      unitRef="USD">7499</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000303"
      unitRef="USD">7500</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassBMember_custom_DataKnightsAcquisitionCorpMember"
      decimals="INF"
      id="Fact000318"
      unitRef="Shares">1378517</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassBMember_custom_DataKnightsAcquisitionCorpMember"
      decimals="0"
      id="Fact000311"
      unitRef="USD">137</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000314"
      unitRef="USD">2825823</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000316"
      unitRef="USD">2825960</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <ONMD:CommonStockSubjectToPossibleRedemptionValue
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000327"
      unitRef="USD">-3359591</ONMD:CommonStockSubjectToPossibleRedemptionValue>
    <ONMD:CommonStockSubjectToPossibleRedemptionValue
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000328"
      unitRef="USD">-3359591</ONMD:CommonStockSubjectToPossibleRedemptionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000336"
      unitRef="USD">1392086</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000338"
      unitRef="USD">1392086</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000347"
      unitRef="USD">-6229639</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000348"
      unitRef="USD">-6229639</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesATwoPreferredStockMember"
      decimals="INF"
      id="Fact000360"
      unitRef="Shares">3853797</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesATwoPreferredStockMember"
      decimals="0"
      id="Fact000350"
      unitRef="USD">385</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesAOnePreferredStockMember"
      decimals="INF"
      id="Fact000362"
      unitRef="Shares">3204000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesAOnePreferredStockMember"
      decimals="0"
      id="Fact000351"
      unitRef="USD">320</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember_custom_DataKnightsAcquisitionCorpMember"
      decimals="INF"
      id="Fact000364"
      unitRef="Shares">585275</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember_custom_DataKnightsAcquisitionCorpMember"
      decimals="0"
      id="Fact000352"
      unitRef="USD">59</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassBMember_custom_DataKnightsAcquisitionCorpMember"
      decimals="INF"
      id="Fact000366"
      unitRef="Shares">4253517</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassBMember_custom_DataKnightsAcquisitionCorpMember"
      decimals="0"
      id="Fact000353"
      unitRef="USD">425</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact000368"
      unitRef="Shares">4550166</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember"
      decimals="0"
      id="Fact000354"
      unitRef="USD">455</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_custom_CommitmentMember"
      decimals="0"
      id="Fact000355"
      unitRef="USD">28750110</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000356"
      unitRef="USD">24032561</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000357"
      unitRef="USD">-43509964</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000358"
      unitRef="USD">9274351</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesATwoPreferredStockMember"
      decimals="INF"
      id="Fact000380"
      unitRef="Shares">3853797</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesATwoPreferredStockMember"
      decimals="0"
      id="Fact000370"
      unitRef="USD">385</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesAOnePreferredStockMember"
      decimals="INF"
      id="Fact000382"
      unitRef="Shares">3204000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesAOnePreferredStockMember"
      decimals="0"
      id="Fact000371"
      unitRef="USD">320</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember_custom_DataKnightsAcquisitionCorpMember"
      decimals="INF"
      id="Fact000384"
      unitRef="Shares">585275</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember_custom_DataKnightsAcquisitionCorpMember"
      decimals="0"
      id="Fact000372"
      unitRef="USD">59</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassBMember_custom_DataKnightsAcquisitionCorpMember"
      decimals="INF"
      id="Fact000386"
      unitRef="Shares">4253517</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassBMember_custom_DataKnightsAcquisitionCorpMember"
      decimals="0"
      id="Fact000373"
      unitRef="USD">425</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact000388"
      unitRef="Shares">4550166</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember"
      decimals="0"
      id="Fact000374"
      unitRef="USD">455</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_custom_CommitmentMember"
      decimals="0"
      id="Fact000375"
      unitRef="USD">28750110</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000376"
      unitRef="USD">24032561</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000377"
      unitRef="USD">-43509964</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000378"
      unitRef="USD">9274351</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000396"
      unitRef="USD">1892741</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000398"
      unitRef="USD">1892741</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_SeriesATwoPreferredStockMember"
      decimals="INF"
      id="Fact000410"
      unitRef="Shares">-3853797</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_SeriesATwoPreferredStockMember"
      decimals="0"
      id="Fact000400"
      unitRef="USD">-385</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_SeriesAOnePreferredStockMember"
      decimals="INF"
      id="Fact000412"
      unitRef="Shares">-3204000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_SeriesAOnePreferredStockMember"
      decimals="0"
      id="Fact000401"
      unitRef="USD">-320</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact000414"
      unitRef="Shares">7057797</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember"
      decimals="0"
      id="Fact000404"
      unitRef="USD">706</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000406"
      unitRef="USD">7057091</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000408"
      unitRef="USD">7057092</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <ONMD:StockIssuedDuringPeriodSharesConvertibleNotesToCommonStock
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact000426"
      unitRef="Shares">6177229</ONMD:StockIssuedDuringPeriodSharesConvertibleNotesToCommonStock>
    <ONMD:StockIssuedDuringPeriodValueConvertibleNotesToCommonStock
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember"
      decimals="0"
      id="Fact000420"
      unitRef="USD">618</ONMD:StockIssuedDuringPeriodValueConvertibleNotesToCommonStock>
    <ONMD:StockIssuedDuringPeriodValueConvertibleNotesToCommonStock
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000422"
      unitRef="USD">6176611</ONMD:StockIssuedDuringPeriodValueConvertibleNotesToCommonStock>
    <ONMD:StockIssuedDuringPeriodValueConvertibleNotesToCommonStock
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000424"
      unitRef="USD">6177229</ONMD:StockIssuedDuringPeriodValueConvertibleNotesToCommonStock>
    <ONMD:StockIssuedDuringPeriodSharesStockOptionsToCommonStock
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact000438"
      unitRef="Shares">612670</ONMD:StockIssuedDuringPeriodSharesStockOptionsToCommonStock>
    <ONMD:StockIssuedDuringPeriodValueStockOptionsToCommonStock
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember"
      decimals="0"
      id="Fact000432"
      unitRef="USD">61</ONMD:StockIssuedDuringPeriodValueStockOptionsToCommonStock>
    <ONMD:StockIssuedDuringPeriodValueStockOptionsToCommonStock
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000434"
      unitRef="USD">612609</ONMD:StockIssuedDuringPeriodValueStockOptionsToCommonStock>
    <ONMD:StockIssuedDuringPeriodValueStockOptionsToCommonStock
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000436"
      unitRef="USD">612670</ONMD:StockIssuedDuringPeriodValueStockOptionsToCommonStock>
    <ONMD:StockIssuedDuringPeriodSharesConvertingOfWarrantsToCommonStock
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact000450"
      unitRef="Shares">3859464</ONMD:StockIssuedDuringPeriodSharesConvertingOfWarrantsToCommonStock>
    <ONMD:StockIssuedDuringPeriodValueConvertingOfWarrantsToCommonStock
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember"
      decimals="0"
      id="Fact000444"
      unitRef="USD">386</ONMD:StockIssuedDuringPeriodValueConvertingOfWarrantsToCommonStock>
    <ONMD:StockIssuedDuringPeriodValueConvertingOfWarrantsToCommonStock
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000446"
      unitRef="USD">3859078</ONMD:StockIssuedDuringPeriodValueConvertingOfWarrantsToCommonStock>
    <ONMD:StockIssuedDuringPeriodValueConvertingOfWarrantsToCommonStock
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000448"
      unitRef="USD">3859464</ONMD:StockIssuedDuringPeriodValueConvertingOfWarrantsToCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact000462"
      unitRef="Shares">-2257326</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember"
      decimals="0"
      id="Fact000456"
      unitRef="USD">-226</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000458"
      unitRef="USD">-2257100</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000460"
      unitRef="USD">-2257326</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000470"
      unitRef="USD">101071</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000472"
      unitRef="USD">101071</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <ONMD:StockIssuedDuringPeriodSharesConvertingDataKnightsCommonShares
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember_custom_DataKnightsAcquisitionCorpMember"
      decimals="INF"
      id="Fact000484"
      unitRef="Shares">-585275</ONMD:StockIssuedDuringPeriodSharesConvertingDataKnightsCommonShares>
    <ONMD:StockIssuedDuringPeriodValueConvertingDataKnightsCommonShares
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember_custom_DataKnightsAcquisitionCorpMember"
      decimals="0"
      id="Fact000476"
      unitRef="USD">-59</ONMD:StockIssuedDuringPeriodValueConvertingDataKnightsCommonShares>
    <ONMD:StockIssuedDuringPeriodSharesConvertingDataKnightsCommonShares
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassBMember_custom_DataKnightsAcquisitionCorpMember"
      decimals="INF"
      id="Fact000486"
      unitRef="Shares">-4253517</ONMD:StockIssuedDuringPeriodSharesConvertingDataKnightsCommonShares>
    <ONMD:StockIssuedDuringPeriodValueConvertingDataKnightsCommonShares
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassBMember_custom_DataKnightsAcquisitionCorpMember"
      decimals="0"
      id="Fact000477"
      unitRef="USD">-425</ONMD:StockIssuedDuringPeriodValueConvertingDataKnightsCommonShares>
    <ONMD:StockIssuedDuringPeriodSharesConvertingDataKnightsCommonShares
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact000488"
      unitRef="Shares">3460275</ONMD:StockIssuedDuringPeriodSharesConvertingDataKnightsCommonShares>
    <ONMD:StockIssuedDuringPeriodValueConvertingDataKnightsCommonShares
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember"
      decimals="0"
      id="Fact000478"
      unitRef="USD">346</ONMD:StockIssuedDuringPeriodValueConvertingDataKnightsCommonShares>
    <ONMD:StockIssuedDuringPeriodValueConvertingDataKnightsCommonShares
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000480"
      unitRef="USD">634106</ONMD:StockIssuedDuringPeriodValueConvertingDataKnightsCommonShares>
    <ONMD:StockIssuedDuringPeriodValueConvertingDataKnightsCommonShares
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000482"
      unitRef="USD">633968</ONMD:StockIssuedDuringPeriodValueConvertingDataKnightsCommonShares>
    <ONMD:CommonStockSubjectToPossibleRedemptionValue
      contextRef="From2023-01-012023-12-31_custom_CommitmentMember"
      decimals="0"
      id="Fact000495"
      unitRef="USD">-28750110</ONMD:CommonStockSubjectToPossibleRedemptionValue>
    <ONMD:CommonStockSubjectToPossibleRedemptionValue
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000498"
      unitRef="USD">-28750110</ONMD:CommonStockSubjectToPossibleRedemptionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact000510"
      unitRef="Shares">111957</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember"
      decimals="0"
      id="Fact000504"
      unitRef="USD">11</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000506"
      unitRef="USD">111946</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000508"
      unitRef="USD">111957</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <ONMD:RetainedEarningsAdjustment
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000519"
      unitRef="USD">11632743</ONMD:RetainedEarningsAdjustment>
    <ONMD:RetainedEarningsAdjustment
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000520"
      unitRef="USD">11632743</ONMD:RetainedEarningsAdjustment>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000529"
      unitRef="USD">-23205456</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000530"
      unitRef="USD">-23205456</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000539"
      unitRef="USD">-23205456</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000540"
      unitRef="USD">-23205456</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesATwoPreferredStockMember"
      decimals="INF"
      id="Fact000552"
      unitRef="Shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesATwoPreferredStockMember"
      decimals="0"
      id="Fact000542"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesAOnePreferredStockMember"
      decimals="INF"
      id="Fact000554"
      unitRef="Shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesAOnePreferredStockMember"
      decimals="0"
      id="Fact000543"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember_custom_DataKnightsAcquisitionCorpMember"
      decimals="INF"
      id="Fact000556"
      unitRef="Shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember_custom_DataKnightsAcquisitionCorpMember"
      decimals="0"
      id="Fact000544"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassBMember_custom_DataKnightsAcquisitionCorpMember"
      decimals="INF"
      id="Fact000558"
      unitRef="Shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassBMember_custom_DataKnightsAcquisitionCorpMember"
      decimals="0"
      id="Fact000545"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact000560"
      unitRef="Shares">23572232</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember"
      decimals="0"
      id="Fact000546"
      unitRef="USD">2357</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_custom_CommitmentMember"
      decimals="0"
      id="Fact000547"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000548"
      unitRef="USD">42220714</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000549"
      unitRef="USD">-55082677</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000550"
      unitRef="USD">-12859606</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesATwoPreferredStockMember"
      decimals="INF"
      id="Fact000572"
      unitRef="Shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesATwoPreferredStockMember"
      decimals="0"
      id="Fact000562"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesAOnePreferredStockMember"
      decimals="INF"
      id="Fact000574"
      unitRef="Shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesAOnePreferredStockMember"
      decimals="0"
      id="Fact000563"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember_custom_DataKnightsAcquisitionCorpMember"
      decimals="INF"
      id="Fact000576"
      unitRef="Shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember_custom_DataKnightsAcquisitionCorpMember"
      decimals="0"
      id="Fact000564"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassBMember_custom_DataKnightsAcquisitionCorpMember"
      decimals="INF"
      id="Fact000578"
      unitRef="Shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassBMember_custom_DataKnightsAcquisitionCorpMember"
      decimals="0"
      id="Fact000565"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact000580"
      unitRef="Shares">23572232</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember"
      decimals="0"
      id="Fact000566"
      unitRef="USD">2357</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_custom_CommitmentMember"
      decimals="0"
      id="Fact000567"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000568"
      unitRef="USD">42220714</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000569"
      unitRef="USD">-55082677</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000570"
      unitRef="USD">-12859606</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000585"
      unitRef="USD">-23205456</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000586"
      unitRef="USD">-6229639</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000591"
      unitRef="USD">27983</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000592"
      unitRef="USD">24807</us-gaap:DepreciationDepletionAndAmortization>
    <ONMD:BusinessCombinationCost
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000594"
      unitRef="USD">900152</ONMD:BusinessCombinationCost>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000598"
      unitRef="USD">1599586</us-gaap:ShareBasedCompensation>
    <ONMD:CashHeldInTrustAccount
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000600"
      unitRef="USD">29029416</ONMD:CashHeldInTrustAccount>
    <ONMD:CashHeldInTrustAccount
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000601"
      unitRef="USD">88291558</ONMD:CashHeldInTrustAccount>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000603"
      unitRef="USD">64594</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000607"
      unitRef="USD">875803</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000609"
      unitRef="USD">1369825</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000610"
      unitRef="USD">1929787</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000612"
      unitRef="USD">132665</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000613"
      unitRef="USD">-72767</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000615"
      unitRef="USD">70314</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000616"
      unitRef="USD">-458667</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInDueToRelatedParties
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000618"
      unitRef="USD">-300</us-gaap:IncreaseDecreaseInDueToRelatedParties>
    <us-gaap:IncreaseDecreaseInDueToRelatedParties
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000619"
      unitRef="USD">11500</us-gaap:IncreaseDecreaseInDueToRelatedParties>
    <ONMD:IncreaseDecreaseInExerciseTaxLiability
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000621"
      unitRef="USD">113353</ONMD:IncreaseDecreaseInExerciseTaxLiability>
    <ONMD:IncreaseDecreaseInExtensionLoan
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000624"
      unitRef="USD">445840</ONMD:IncreaseDecreaseInExtensionLoan>
    <ONMD:IncreaseDecreaseInExtensionLoan
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000625"
      unitRef="USD">2545838</ONMD:IncreaseDecreaseInExtensionLoan>
    <ONMD:IncreaseDecreaseFranchiseTaxPayable
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000627"
      unitRef="USD">-69966</ONMD:IncreaseDecreaseFranchiseTaxPayable>
    <ONMD:IncreaseDecreaseFranchiseTaxPayable
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000628"
      unitRef="USD">-94043</ONMD:IncreaseDecreaseFranchiseTaxPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000630"
      unitRef="USD">-94833</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000631"
      unitRef="USD">214850</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <ONMD:IncreaseDecreaseInWorkingCapitalLoan
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000633"
      unitRef="USD">-168159</ONMD:IncreaseDecreaseInWorkingCapitalLoan>
    <ONMD:IncreaseDecreaseInWorkingCapitalLoan
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000634"
      unitRef="USD">207081</ONMD:IncreaseDecreaseInWorkingCapitalLoan>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000636"
      unitRef="USD">8220910</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000637"
      unitRef="USD">87239622</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000642"
      unitRef="USD">43757</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000643"
      unitRef="USD">58137</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <ONMD:ProceedsFromIssuanceOfCommonStockOne
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000649"
      unitRef="USD">137</ONMD:ProceedsFromIssuanceOfCommonStockOne>
    <us-gaap:ProceedsFromRepaymentsOfNotesPayable
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000651"
      unitRef="USD">-10680772</us-gaap:ProceedsFromRepaymentsOfNotesPayable>
    <us-gaap:ProceedsFromRepaymentsOfNotesPayable
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000652"
      unitRef="USD">5543162</us-gaap:ProceedsFromRepaymentsOfNotesPayable>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000654"
      unitRef="USD">1549820</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000657"
      unitRef="USD">465024</us-gaap:ProceedsFromRelatedPartyDebt>
    <ONMD:ProceedsFromBusinessLoan
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000660"
      unitRef="USD">529</ONMD:ProceedsFromBusinessLoan>
    <ONMD:ProceedsFromBusinessLoan
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000661"
      unitRef="USD">-2754</ONMD:ProceedsFromBusinessLoan>
    <ONMD:ProceedsFromCommonStockSubjectToRedemption
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000663"
      unitRef="USD">-28750109</ONMD:ProceedsFromCommonStockSubjectToRedemption>
    <ONMD:ProceedsFromCommonStockSubjectToRedemption
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000664"
      unitRef="USD">-88549890</ONMD:ProceedsFromCommonStockSubjectToRedemption>
    <ONMD:ProceedsFromDeferredUnderwritingFee
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000666"
      unitRef="USD">-500000</ONMD:ProceedsFromDeferredUnderwritingFee>
    <ONMD:ProceedsFromWarrantLiability
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000669"
      unitRef="USD">337976</ONMD:ProceedsFromWarrantLiability>
    <ONMD:ProceedsFromWarrantLiability
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000670"
      unitRef="USD">4489110</ONMD:ProceedsFromWarrantLiability>
    <us-gaap:ProceedsFromContributedCapital
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000672"
      unitRef="USD">18189350</us-gaap:ProceedsFromContributedCapital>
    <us-gaap:ProceedsFromContributedCapital
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000673"
      unitRef="USD">2825823</us-gaap:ProceedsFromContributedCapital>
    <ONMD:ProceedsFromIssuanceOfCommonStockTwo
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000675"
      unitRef="USD">-59</ONMD:ProceedsFromIssuanceOfCommonStockTwo>
    <ONMD:ClassBCommonStock
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000678"
      unitRef="USD">-425</ONMD:ClassBCommonStock>
    <ONMD:ProccedsFromRetainedEarningsAdjustment
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000681"
      unitRef="USD">11632743</ONMD:ProccedsFromRetainedEarningsAdjustment>
    <ONMD:ProccedsFromRetainedEarningsAdjustment
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000682"
      unitRef="USD">-3359594</ONMD:ProccedsFromRetainedEarningsAdjustment>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000684"
      unitRef="USD">-8431875</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000685"
      unitRef="USD">-88032226</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000687"
      unitRef="USD">-254722</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000688"
      unitRef="USD">-850741</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000690"
      unitRef="USD">301730</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact000691"
      unitRef="USD">1152471</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000693"
      unitRef="USD">47008</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000694"
      unitRef="USD">301730</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000696">&lt;p id="xdx_809_eus-gaap--OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_zV9YseO4iab1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;1.
&lt;span id="xdx_82A_zfz7jzRiBva7"&gt;Organization and Operations&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;OneMedNet
Corporation (the &#x201c;Company&#x201d;) is a healthcare software company with solutions focused on digital medical image management,
exchange, and sharing. The Company was incorporated in Delaware on September 20, 2006. The Company has been solely focused on creating
solutions that simplify digital medical image management, exchange, and sharing. The Company has one wholly-owned subsidiary, OneMedNet
Technologies (Canada) Inc., incorporated on October 16, 2015 under the provisions of the Business Corporations Act of British Columbia
whose functional currency is the Canadian dollar. The Company&#x2019;s headquarters location is Eden Prairie, Minnesota.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 12.95pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 7, 2023, as contemplated by the Company, Data Knights Merger Sub, Inc., a Delaware corporation (&#x201c;Merger Sub&#x201d;), and
Data Knights, LLC, the Merger Sub&#x2019;s sponsor merged with and into OneMedNet Corporation, with OneMedNet Corporation surviving the
merger. The Business Combination is further described in Note 3, &lt;span style="background-color: white"&gt;&lt;i&gt;Business Combination.&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 12.95pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;i&gt;Data
Knights Acquisition Corp Merger&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;On
November 7, 2023, we consummated a merger (the &#x201c;Merger&#x201d;) &lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;following
the approval at the special meeting of the shareholders of Data Knights Acquisition Corp., a Delaware corporation held on October 17,
2023 (the &#x201c;Special Meeting&#x201d;), Data Knights Merger Sub, Inc., a Delaware corporation (&#x201c;Merger Sub&#x201d;) and a wholly-owned
subsidiary of Data Knights Acquisition Corp., a Delaware corporation (&#x201c;Data Knights&#x201d;), consummated a merger (the &#x201c;Merger&#x201d;)
with and into OneMedNet Solutions Corporation (formerly named OneMedNet Corporation), a Delaware corporation (&#x201c;OneMedNet&#x201d;)
pursuant to an agreement and plan of merger, dated as of April 25, 2022 (the &#x201c;Merger Agreement&#x201d;), by and among Data Knights,
Merger Sub, OneMedNet, Data Knights, LLC, a Delaware limited liability company (&#x201c;Sponsor&#x201d; or &#x201c;Purchaser Representative&#x201d;)
in its capacity as the representative of the stockholders of Data Knights, and Paul Casey in his capacity as the representative of the
stockholders of OneMedNet (&#x201c;Seller Representative&#x201d;). Accordingly, the Merger Agreement was adopted, and the Merger and other
transactions contemplated thereby (collectively, the &#x201c;Business Combination&#x201d;) were approved and completed.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
Business Combination was accounted for as a &lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;as
a reverse recapitalization with OneMedNet as the accounting acquirer &lt;span style="background-color: white"&gt;under the accounting principles
generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;). Accordingly, the financial statements of the combined company
represent a continuation of the financial statements of OneMedNet.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;On
June 28, 2023, the Company and Data Knights entered into a Securities Purchase Agreement (the &#x201c;SPA&#x201d;) with certain investors
(collectively referred to herein as the &#x201c;Purchasers&#x201d;) for PIPE financing in the aggregate original principal amount of $&lt;span id="xdx_902_eus-gaap--DebtInstrumentIssuedPrincipal_pp2d_c20230628__20230628__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--BusinessAcquisitionAxis__custom--DataKnightsAcquisitionCorpMember_zd35VsLoAFv9"&gt;1,595,744.70
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;and the purchase
price of $&lt;span id="xdx_904_eus-gaap--PaymentsToAcquireBusinessesGross_pn5n6_c20230628__20230628__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--BusinessAcquisitionAxis__custom--DataKnightsAcquisitionCorpMember_zLfq0MnZLOhi"&gt;1.5
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;million. &lt;span id="xdx_90A_eus-gaap--DebtInstrumentDescription_c20230628__20230628__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--BusinessAcquisitionAxis__custom--DataKnightsAcquisitionCorpMember_zcrEXy9YpNK3"&gt;Pursuant
to the Securities Purchase Agreement, Data Knights will issue and sell to each of the Purchasers, a new series of senior secured convertible
notes (the &#x201c;PIPE Notes&#x201d;), which are convertible into shares of Common Stock at the Purchasers election at a conversion price
equal to the lower of (i) $10.00 per share, and (ii) 92.5% of the lowest volume weighted average trading price for the ten (10) Trading
Days immediately preceding the Conversion Date.&lt;/span&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
Purchasers&#x2019; $&lt;span id="xdx_904_eus-gaap--Investments_iI_pn5n6_c20230628__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--BusinessAcquisitionAxis__custom--DataKnightsAcquisitionCorpMember_z2iQWtEALUT4"&gt;1.5
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;million investment
in the PIPE Notes closed and funded contemporaneous to the Closing of the Business Combination.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Effective
immediately prior to the Closing, OneMedNet, Inc. issued the PIPE Notes to the Purchasers under the private offering exemptions under
Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Risks
and Uncertainties&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is subject to risks common to companies in the markets it serves, including, but not limited to, global economic and financial
market conditions, fluctuations in customer demand, acceptance of new products, development by its competitors of new technological innovations,
dependence on key personnel, and protection of proprietary technology.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
previously reported on Form 8-K on February 9, 2024, the Company received written notice (the &#x201c;Nasdaq Notice&#x201d;), dated February
7, 2024, from the Nasdaq Stock Market (&#x201c;Nasdaq&#x201d;) indicating that for the preceding 30 consecutive business days, the market
value of the Company&#x2019;s listed securities (&#x201c;MVLS&#x201d;) did not maintain a minimum market value of $50,000,000 (the &#x201c;Minimum
MVLS Requirement&#x201d;) as required by Nasdaq Listing Rule 5450(b)(2)(A). In accordance with Nasdaq Listing Rule 5810(c)(3)(C), the
Company has a compliance period of 180 calendar days, or until August 5, 2024, to regain compliance with the Minimum MVLS Requirement.
Compliance may be achieved if the Company&#x2019;s MVLS closes at $50,000,000 or more for a minimum of ten consecutive business days at
any time during the 180-day compliance period, in which case Nasdaq will notify the Company of its compliance and the matter will be
closed.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 12.95pt; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;If
the Company does not regain compliance with the Minimum MVLS Requirement by August 5, 2024, Nasdaq will provide written notification
to the Company that its common stock is subject to delisting. At that time, the Company may appeal the relevant delisting determination
to a hearings panel pursuant to the procedures set forth in the applicable Nasdaq Listing Rules. However, there can be no assurance,
if the Company does appeal the delisting determination by Nasdaq to the hearings panel, that such appeal would be successful. In such
event, the Company may also seek to apply for a transfer to The Nasdaq Global Market if it meets the requirements for continued listing
thereon. The Nasdaq Notice received have no immediate effect on the Company&#x2019;s continued listing on the Nasdaq Global Market or
the trading of Company&#x2019;s common stock, subject to the Company&#x2019;s compliance with the other continued listing requirements.
The Company is presently evaluating potential actions to regain compliance with all applicable requirements for continued listing on
the Nasdaq Global Market. There can be no assurance that the Company will be successful in maintaining the listing of its common stock
on the Nasdaq Global Market.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
    <us-gaap:DebtInstrumentIssuedPrincipal
      contextRef="From2023-06-282023-06-28_custom_SecuritiesPurchaseAgreementMember_custom_DataKnightsAcquisitionCorpMember"
      decimals="2"
      id="Fact000697"
      unitRef="USD">1595744.70</us-gaap:DebtInstrumentIssuedPrincipal>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="From2023-06-282023-06-28_custom_SecuritiesPurchaseAgreementMember_custom_DataKnightsAcquisitionCorpMember"
      decimals="-5"
      id="Fact000698"
      unitRef="USD">1500000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:DebtInstrumentDescription
      contextRef="From2023-06-282023-06-28_custom_SecuritiesPurchaseAgreementMember_custom_DataKnightsAcquisitionCorpMember"
      id="Fact000699">Pursuant
to the Securities Purchase Agreement, Data Knights will issue and sell to each of the Purchasers, a new series of senior secured convertible
notes (the &#x201c;PIPE Notes&#x201d;), which are convertible into shares of Common Stock at the Purchasers election at a conversion price
equal to the lower of (i) $10.00 per share, and (ii) 92.5% of the lowest volume weighted average trading price for the ten (10) Trading
Days immediately preceding the Conversion Date.</us-gaap:DebtInstrumentDescription>
    <us-gaap:Investments
      contextRef="AsOf2023-06-28_custom_SecuritiesPurchaseAgreementMember_custom_DataKnightsAcquisitionCorpMember"
      decimals="-5"
      id="Fact000700"
      unitRef="USD">1500000</us-gaap:Investments>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000702">&lt;p id="xdx_802_eus-gaap--SignificantAccountingPoliciesTextBlock_zGbBSfC6KOC7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2.
&lt;span id="xdx_820_zKg7KUIVwbK9"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zvzejhltBzmk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span id="xdx_86A_zHiorFzUGPkd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Basis
of Presentation and Foreign Currency Translation&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 12.95pt; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
consolidated financial statements have been prepared in U.S. dollars, in accordance with accounting principles generally accepted in
the United States of America (&#x201c;GAAP&#x201d;). The accompanying consolidated financial statements include the accounts of the Company
and its wholly owned subsidiaries. The consolidated financial statements include 100% of the accounts of wholly-owned subsidiaries. All
intercompany balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--BusinessCombinationsPolicy_zndaSaMzFgIb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span id="xdx_868_z9lk6RJzb8ma" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Business
Combination&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
account for business acquisitions under ASC Topic 805, Business Combinations (&#x201c;ASC Topic 805&#x201d;). The total purchase consideration
for an acquisition is measured as the fair value of the assets given, equity instruments issued, and liabilities assumed at the acquisition
date. Costs that are directly attributable to the acquisition are expensed as incurred. Identifiable assets (including intangible assets)
and liabilities assumed (including contingent liabilities) are measured initially at their fair values at the acquisition date. We recognize
goodwill if the fair value of the total purchase consideration is in excess of the net fair value of the identifiable assets acquired
and the liabilities assumed. We recognize a bargain purchase gain within Other income (expense), net, in the consolidated statement of
operations if the net fair value of the identifiable assets acquired and the liabilities assumed is in excess of the fair value of the
total purchase consideration. We include the results of operations of the acquired business in the consolidated financial statements
beginning on the acquisition date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 12.95pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--UseOfEstimates_zjt1UdiaaVH7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span id="xdx_869_zIt7XWTLer6d" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Use
of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of consolidated financial statements in conformity with GAAP requires management to make estimates, judgments, and assumptions
that affect the reported amounts of assets, liabilities, revenue, and expenses, and the amounts disclosed in the related notes to the
consolidated financial statements. Actual results and outcomes may differ materially from management&#x2019;s estimates, judgments, and
assumptions. Significant estimates, judgments, and assumptions used in these financial statements include, but are not limited to, those
related to revenue, useful lives and realizability of long-lived assets, accounting for income taxes and related valuation allowances,
and unit and stock-based compensation. Estimates are periodically reviewed in light of changes in circumstances, facts, and experience.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_843_ecustom--OperatingSegmentsPolicyTextBlock_zACDXJyzWbLk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span id="xdx_862_zQstZ0yF89o" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Operating
Segments&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company operates as one operating segment. Operating segments are defined as components of an enterprise for which separate financial
information is regularly evaluated by the chief operating decision maker (&#x201c;CODM&#x201d;), which is the Company&#x2019;s Chief Executive
Officer, in deciding how to allocate resources and assess performance. The Company&#x2019;s CODM evaluates the Company&#x2019;s financial
information and resources and assesses the performance of these resources on a consolidated basis. The Company is not organized by market
and is managed and operated as one business. A single management team that reports to the chief executive officer comprehensively manages
the entire business. Accordingly, the Company does not accumulate discrete financial information with respect to separate divisions and
does not have separate operating or reportable segments. Since the Company operates in one operating segment, all required financial
segment information can be found in the consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zMlRvLLBGcYl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span id="xdx_867_zKdmKLGHFwQ8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Cash
and Cash Equivalents&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash
and cash equivalents consist of highly liquid, short-term investments with a maturity of three months or less when purchased. Cash equivalents
consist of money market funds and are carried at cost, which approximates fair value. The balances, at times, may exceed FDIC Insured
limits. The Company believes that, as of December 31, 2023, its risk relating to deposits exceeding federally insured limits was not
significant.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zHSkOZjoaDAg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span id="xdx_863_zDnAqV8hKKmb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Accounts
Receivable&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accounts
receivable are unsecured, recorded at net realizable value, and do not bear interest. Accounts receivable are considered past due if
not paid within the terms established between the Company and the customer. Amounts are only written off after all attempts at collections
have been exhausted. The Company determines the need for an allowance for doubtful accounts based upon factors surrounding the credit
risk of specific customers, historical trends and other information. As of December 31, 2023 and 2022, the Company established allowances
of $&lt;span id="xdx_90D_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20231231_zsgeggHAEi86"&gt;0&lt;/span&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;and
$&lt;span id="xdx_904_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20221231_zELlL3nc7kY7"&gt;102,700&lt;/span&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;respectively.
The net receivable balances outstanding are fully collectible.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company believes its credit policies are prudent and reflect normal industry terms and business risk. The Company generally does not
require collateral from its customers and generally requires payment from 0 to 90 days from the invoice date. For the year ended December
31, 2023, there was 1 customer that accounted for &lt;span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneCustomerMember_zYlEzIbkEdmk"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%
or more of total revenue, and there were 2 customers that accounted for &lt;span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--TwoCustomersMember_zWk6srTqOOyb"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%
or more of total revenue for the years ended December 31, 2022 . The following table represents these customers&#x2019; aggregate percent
of total revenue:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_zQi7JmXQvsj9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B2_zGLv6h4dCOii"&gt;Schedule
Of Aggregate Percentage Revenue and Accounts Receivable&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20230101__20231231_zUGdB37NKUn6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December
    31, 2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20220101__20221231_zcYb7a6l5vo2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December
    31, 2022&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Year Ended&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zEHO2Q3PAb9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 56%"&gt;Customer 1&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"&gt;52&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"&gt;31&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_zZGLElbzyVq4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;Customer 2&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0725"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;22&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomersMember_z5Y4MjatHXV" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Aggregate Percent of Total Revenue&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;52&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;53&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 12.95pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2023, three customers accounted for more than &lt;span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--ThreeCustomersMember_zaeCBpShTQP9"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%
of the Company&#x2019;s accounts receivable balance, and two customers accounted for over &lt;span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--TwoCustomersMember_z1pBVCbDsh6b"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%
of the Company&#x2019;s accounts receivable balance at December 31, 2022. The following table represents these customers&#x2019; aggregate
percent of total accounts receivable:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 12.95pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20230101__20231231_zFefwqYRVOU8" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December
    31, 2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20220101__20221231_z2cFFNbI99Sb" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December
    31, 2022&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Year Ended&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zUQw8G4cVKZe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%"&gt;Customer 1&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0733"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;40&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_zbivTlCYEB3g" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Customer 2&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;36&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0737"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerThreeMember_zUf1RqDmH0z5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Customer 3&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;33&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0740"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerFourMember_zMcJm0AG6jMd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Customer 4&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0742"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;32&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerFiveMember_zXVSrVaFghWj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;Customer 5&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;27&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0746"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomersMember_zdgdbAAO0zIb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Aggregate Percent of Total Accounts Receivable&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;96&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;72&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomersMember_zg1FiXjCH2xe" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Aggregate Percent of Revenue and Accounts Receivable&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;96&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;72&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A5_zHDNCw2Iq6Qc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 12.95pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zoEI6ToaNBQc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span id="xdx_868_z4IcW1vRIm1b" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Property
and Equipment&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment are recorded at cost. The straight-line method is used for computing depreciation and amortization. Assets are depreciated
over their estimated useful lives ranging from three to five years. Cost of maintenance and repairs are charged to expense when incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zqQEFN1kkqcg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span id="xdx_862_zNNfTwY6IbVa" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Impairment
of Long-Lived Assets&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company reviews long-lived assets, including property and equipment, for impairment whenever events or changes in business circumstances
indicate that the carrying amount of an asset may not be fully recoverable. An impairment loss would be recognized when the estimated
future undiscounted net cash flows from the use of the asset are less than the carrying amount of that asset. There have been &lt;span id="xdx_90A_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_do_c20220101__20221231_zU0HgIgIqy09"&gt;no
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;losses during the years ended December
31, 2023 or December 31, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zDiDCTuKvzr" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span id="xdx_865_zS2oqDkolOjj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Fair
Value of Financial Instruments&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fair
value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between
market participants at the measurement date. To increase the comparability of fair value measures, the following hierarchy prioritizes
the inputs to valuation methodologies used to measure fair value:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 12.95pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Level
1&lt;/b&gt; &#x2014; Valuations based on quoted prices for identical assets and liabilities in active markets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Level
2&lt;/b&gt; &#x2014; Valuations based on observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets
and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, or other
inputs that are observable or can be corroborated by observable market data.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Level
3&lt;/b&gt; &#x2014; Valuations based on unobservable inputs reflecting our own assumptions, consistent with reasonably available assumptions
made by other market participants. These valuations require significant judgment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 12.95pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
measure the fair value of money market funds and certain marketable equity securities based on quoted prices in active markets for identical
assets or liabilities. Other marketable securities were valued either based on recent trades of securities in inactive markets or based
on quoted market prices of similar instruments and other significant inputs derived from or corroborated by observable market data. We
did not hold significant amounts of marketable securities categorized as Level 3 assets as of the years ended December 31, 2022 and December
31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s financial instruments consist of cash and cash equivalents, accounts receivable, accounts payable, convertible notes
payable and certain privately issued warrants. The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable
financial instruments approximate their fair value due to their short-term nature. The Company&#x2019;s Private Warrants estimated fair
values are provided by a third party pricing vendor and are reviewed by the Company&#x2019;s management. The Private Warrants valuations
are based on unobservable inputs reflecting the vendor&#x2019;s assumptions, consistent with reasonably available assumptions made by
other market participants and thus are classified as Level 3.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--RevenueRecognitionPolicyTextBlock_z8kXah7HUIp5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span id="xdx_860_zetssCGQ3aL3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Revenue
Recognition&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Revenue
is recognized in accordance with the five-step model set forth by Accounting Standards Update (&#x201c;ASU&#x201d;) 2014-09, Revenue from
Contracts with Customers (&#x201c;Topic 606&#x201d;), which involves identification of the contract, identification of performance obligations
in the contract, determination of the transaction price, allocation of the transaction price to the previously identified performance
obligations, and revenue recognition as the performance obligations are satisfied.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 12.95pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Revenue
from all customers is recognized when a performance obligation is satisfied by transferring control of a distinct good or service to
a customer. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit
of account under Topic 606. A contract&#x2019;s transaction price is allocated to each distinct performance obligation in proportion to
the standalone selling price for each and recognized as revenue when, or as, the performance obligation is satisfied.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 12.95pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Individual
promised goods and services in a contract are considered a performance obligation and accounted for separately if the good or service
is distinct. A good or service is considered distinct if the customer can benefit from the good or service on its own or with other resources
that are readily available to the customer and the good or service is separately identifiable from other promises in the arrangement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 12.95pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
transaction price for the products is the invoiced amount. Advanced billings from contracts are deferred and recognized as revenue when
earned. Revenue is recognized only to the extent that it is probable that a significant reversal of revenue will not occur and when collection
is considered probable The Company excludes from revenue taxes collected from a customer that are assessed by a governmental authority
and imposed on and concurrent with a specific revenue-producing transaction. Deferred revenue consists of payments received in advance
of performance under the contract. Such amounts are generally recognized as revenue over the contractual period. The Company receives
payments from customers based upon contractual billing schedules. Accounts receivable is recorded when the right to consideration becomes
unconditional. Payment terms on invoiced amounts typically range from zero to 90 days, with typical terms of 30 days.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 12.95pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company generates revenue from two streams: (1) iRWD (imaging Real World Data) which provides regulatory grade imaging and clinical data
in the Pharmaceutical, Device Manufacturing, CRO&#x2019;s and AI markets and (2) BEAM which is a Medical Imaging Exchange platform between
Hospital/Healthcare Systems, Imaging Centers, Physicians and Patients. iRWD is sold on a fixed fee basis based on the number of data
units and the cost per data unit committed to in the customer contract. Revenue is recognized when the data is delivered to the customer.
Beam revenue is subscription-based revenue which is recognized ratably over the subscription period committed to by the customer. The
Company invoices its Beam customers quarterly or annually in advance with the customer contracts automatically renewing unless the customer
issues a cancellation notice.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--IncomeTaxPolicyTextBlock_zJ6mvQ9t6Vg8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span id="xdx_86A_zWc184B7YKG7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Income
Taxes&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is subject to U.S. federal, state and local income taxes. The Company accounts for income taxes in accordance with ASC Topic
740, Accounting for Income Taxes (&#x201c;ASC Topic 740&#x201d;), which requires the recognition of tax benefits or expenses on temporary
differences between the financial reporting and tax bases of its assets and liabilities by applying the enacted tax rates in effect for
the year in which the differences are expected to reverse. Such net tax effects on temporary differences are reflected on the Company&#x2019;s
consolidated balance sheets as deferred tax assets and liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ASC
Topic 740 prescribes a two-step approach for the recognition and measurement of tax benefits associated with the positions taken or expected
to be taken in a tax return that affects amounts reported in the financial statements. The Company has reviewed and will continue to
review the conclusions reached regarding uncertain tax positions, which may be subject to review and adjustment at a later date based
on ongoing analyses of tax laws, regulations and interpretations thereof. To the extent that the Company&#x2019;s assessment of the conclusions
reached regarding uncertain tax positions changes as a result of the evaluation of new information, such change in estimate will be recorded
in the period in which such determination is made. The Company reports income tax-related interest and penalties relating to uncertain
tax positions, if applicable, as a component of income tax expense&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
tax assets are reduced by a valuation allowance when the Company believes that it is more-likely-than-not that some portion or all of
the deferred tax assets will not be realized. The Company provides deferred taxes at the enacted tax rate that is expected to apply when
the temporary differences reverse. The Company has recorded a full valuation allowance against the net deferred tax asset due to the
uncertainty of realizing the related benefits.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_843_ecustom--PatentsAndTrademarksPolicyTextBlock_zllmj1Dmzjha" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span id="xdx_866_zbuYUjfdq4qd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Patents
and Trademarks&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Costs
associated with the submission of a patent application are expensed as incurred given the uncertainty of the patents resulting in probable
future economic benefits to the Company and are included in research and development expenses on the consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 30pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--ResearchAndDevelopmentExpensePolicy_zqccu0sxztVd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span id="xdx_86F_zoLfadaIiS4e" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Research
and Development&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 30pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company account for its research and development cost in accordance with ASC Topic 730, Research and Development (&#x201c;ASC Topic 730&#x201d;).
ASC Topic 730 requires that all R&amp;amp;D costs be recognized as an expense as incurred. However, some costs associated with R&amp;amp;D activities
that have an alternative future use (e.g., materials, equipment, facilities) may be capitalizable. For the years ended December 31, 2023
and December 31, 2022 research and development expenditures were charged to operating expense as incurred..&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 30pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zY1upFaeMacf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span id="xdx_869_z2L8cRNHHXpg" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Stock-based
Compensation&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has a stock-based compensation plan, which is described in more detail in Note 8. The fair value of stock option and warrant
grants are determined on the date of grant using the Black Scholes valuation model. Forfeitures of stock based awards are recorded as
the actual forfeitures occur. Stock based compensation expense is recognized over the service period, net of estimated forfeitures, using
the straight-line method. The Company converted all unvested stock based compensation awards to common shares in the year ended December
31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--SellingGeneralAndAdministrativeExpensesPolicyTextBlock_zob83QmMzd2g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span id="xdx_862_zp3OEq1qEjda" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;General,
and Administrative Expenses&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;General
and administrative expenses include all costs that are not directly related to satisfaction of customer contracts. General, and administrative
expenses include items for the Company&#x2019;s selling and administrative functions, such as sales, finance, legal, human resources,
and information technology support. These functions include costs for items such as salaries and benefits and other personnel-related
costs, maintenance and supplies, professional fees for external legal, accounting, and other consulting services, intangible asset amortization,
and depreciation expense.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_ecustom--EmergingGrowthCompanyPolicyTextBlock_zSv3ZJ534jDd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span id="xdx_861_zPmGBlQam70g" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Emerging
Growth Company&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is an emerging growth company, as defined in Section 2(a) of the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;),
as modified by the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;). Section 102(b)(1) of the JOBS Act exempts
emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that
is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered
under the Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;)) are required to comply with the new or revised
financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply
with the requirements that apply to non-emerging growth companies but any such an election to opt out is irrevocable. The Company has
not elected to opt out of such extended transition period which means that when a standard is issued or revised and it has different
application dates for public or private companies, the Company, as an emerging growth company , can adopt the new or revised standard
at the time private companies adopt the new or revised standard.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_845_ecustom--AccountingPronouncementsNotYetAdoptedPolicyTextBlock_zkriRDHeinT3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span id="xdx_86B_zXnyAgn1N81h" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Accounting
Pronouncements Not Yet Adopted&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2023, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued ASU No. 2023-07, Improvements to Reportable Segment
Disclosures (Topic 280). This ASU updates reportable segment disclosure requirements by requiring disclosures of significant reportable
segment expenses that are regularly provided to the Chief Operating Decision Maker (&#x201c;CODM&#x201d;) and included within each reported
measure of a segment&#x2019;s profit or loss. This ASU also requires disclosure of the title and position of the individual identified
as the CODM and an explanation of how the CODM uses the reported measures of a segment&#x2019;s profit or loss in assessing segment performance
and deciding how to allocate resources. The ASU is effective for annual periods beginning after December 15, 2023, and interim periods
within fiscal years beginning after December 15, 2024. Adoption of the ASU should be applied retrospectively to all prior periods presented
in the financial statements. Early adoption is also permitted. This ASU will likely result in us including the additional required disclosures
when adopted. We are currently evaluating the provisions of this ASU and expect to adopt them for the year ending December 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
December 2023, the Financial Accounting Standards Board issued an Accounting Standards Update (&#x201c;ASU&#x201d;) amending existing income
tax disclosure guidance, primarily requiring more detailed disclosure for income taxes paid and the effective tax rate reconciliation.
The ASU is effective for annual reporting periods beginning after December 15, 2024, with early adoption permitted and can be applied
on either a prospective or retroactive basis. We are currently evaluating the ASU to determine its impact on our income tax disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zMFQj8yXoSH2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span id="xdx_86F_zcTBCyVWS00i" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Recently
adopted accounting pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
October 2021, the FASB issued ASU No. 2021-08, Accounting for Contract Assets and Contract Liabilities from Contracts with Customers
(ASC Topic 805). This ASU requires an acquirer in a business combination to recognize and measure contract assets and contract liabilities
(deferred revenue) from acquired contracts using the revenue recognition guidance in Topic 606. At the acquisition date, the acquirer
applies the revenue model as if it had originated the acquired contracts. The ASU is effective for annual periods beginning after December
15, 2022, including interim periods within those fiscal years. We adopted this ASU prospectively on January 1, 2023. This ASU has not
and is currently not expected to have a material impact on our consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_85B_zXwne0u5Kej2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000704">&lt;p id="xdx_842_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zvzejhltBzmk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span id="xdx_86A_zHiorFzUGPkd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Basis
of Presentation and Foreign Currency Translation&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 12.95pt; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
consolidated financial statements have been prepared in U.S. dollars, in accordance with accounting principles generally accepted in
the United States of America (&#x201c;GAAP&#x201d;). The accompanying consolidated financial statements include the accounts of the Company
and its wholly owned subsidiaries. The consolidated financial statements include 100% of the accounts of wholly-owned subsidiaries. All
intercompany balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:BusinessCombinationsPolicy contextRef="From2023-01-01to2023-12-31" id="Fact000706">&lt;p id="xdx_840_eus-gaap--BusinessCombinationsPolicy_zndaSaMzFgIb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span id="xdx_868_z9lk6RJzb8ma" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Business
Combination&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
account for business acquisitions under ASC Topic 805, Business Combinations (&#x201c;ASC Topic 805&#x201d;). The total purchase consideration
for an acquisition is measured as the fair value of the assets given, equity instruments issued, and liabilities assumed at the acquisition
date. Costs that are directly attributable to the acquisition are expensed as incurred. Identifiable assets (including intangible assets)
and liabilities assumed (including contingent liabilities) are measured initially at their fair values at the acquisition date. We recognize
goodwill if the fair value of the total purchase consideration is in excess of the net fair value of the identifiable assets acquired
and the liabilities assumed. We recognize a bargain purchase gain within Other income (expense), net, in the consolidated statement of
operations if the net fair value of the identifiable assets acquired and the liabilities assumed is in excess of the fair value of the
total purchase consideration. We include the results of operations of the acquired business in the consolidated financial statements
beginning on the acquisition date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 12.95pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:UseOfEstimates contextRef="From2023-01-01to2023-12-31" id="Fact000708">&lt;p id="xdx_843_eus-gaap--UseOfEstimates_zjt1UdiaaVH7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span id="xdx_869_zIt7XWTLer6d" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Use
of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of consolidated financial statements in conformity with GAAP requires management to make estimates, judgments, and assumptions
that affect the reported amounts of assets, liabilities, revenue, and expenses, and the amounts disclosed in the related notes to the
consolidated financial statements. Actual results and outcomes may differ materially from management&#x2019;s estimates, judgments, and
assumptions. Significant estimates, judgments, and assumptions used in these financial statements include, but are not limited to, those
related to revenue, useful lives and realizability of long-lived assets, accounting for income taxes and related valuation allowances,
and unit and stock-based compensation. Estimates are periodically reviewed in light of changes in circumstances, facts, and experience.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <ONMD:OperatingSegmentsPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000710">&lt;p id="xdx_843_ecustom--OperatingSegmentsPolicyTextBlock_zACDXJyzWbLk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span id="xdx_862_zQstZ0yF89o" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Operating
Segments&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company operates as one operating segment. Operating segments are defined as components of an enterprise for which separate financial
information is regularly evaluated by the chief operating decision maker (&#x201c;CODM&#x201d;), which is the Company&#x2019;s Chief Executive
Officer, in deciding how to allocate resources and assess performance. The Company&#x2019;s CODM evaluates the Company&#x2019;s financial
information and resources and assesses the performance of these resources on a consolidated basis. The Company is not organized by market
and is managed and operated as one business. A single management team that reports to the chief executive officer comprehensively manages
the entire business. Accordingly, the Company does not accumulate discrete financial information with respect to separate divisions and
does not have separate operating or reportable segments. Since the Company operates in one operating segment, all required financial
segment information can be found in the consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</ONMD:OperatingSegmentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000712">&lt;p id="xdx_84C_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zMlRvLLBGcYl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span id="xdx_867_zKdmKLGHFwQ8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Cash
and Cash Equivalents&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash
and cash equivalents consist of highly liquid, short-term investments with a maturity of three months or less when purchased. Cash equivalents
consist of money market funds and are carried at cost, which approximates fair value. The balances, at times, may exceed FDIC Insured
limits. The Company believes that, as of December 31, 2023, its risk relating to deposits exceeding federally insured limits was not
significant.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="From2023-01-01to2023-12-31" id="Fact000714">&lt;p id="xdx_84D_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zHSkOZjoaDAg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span id="xdx_863_zDnAqV8hKKmb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Accounts
Receivable&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accounts
receivable are unsecured, recorded at net realizable value, and do not bear interest. Accounts receivable are considered past due if
not paid within the terms established between the Company and the customer. Amounts are only written off after all attempts at collections
have been exhausted. The Company determines the need for an allowance for doubtful accounts based upon factors surrounding the credit
risk of specific customers, historical trends and other information. As of December 31, 2023 and 2022, the Company established allowances
of $&lt;span id="xdx_90D_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20231231_zsgeggHAEi86"&gt;0&lt;/span&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;and
$&lt;span id="xdx_904_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20221231_zELlL3nc7kY7"&gt;102,700&lt;/span&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;respectively.
The net receivable balances outstanding are fully collectible.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company believes its credit policies are prudent and reflect normal industry terms and business risk. The Company generally does not
require collateral from its customers and generally requires payment from 0 to 90 days from the invoice date. For the year ended December
31, 2023, there was 1 customer that accounted for &lt;span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneCustomerMember_zYlEzIbkEdmk"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%
or more of total revenue, and there were 2 customers that accounted for &lt;span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--TwoCustomersMember_zWk6srTqOOyb"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%
or more of total revenue for the years ended December 31, 2022 . The following table represents these customers&#x2019; aggregate percent
of total revenue:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_zQi7JmXQvsj9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B2_zGLv6h4dCOii"&gt;Schedule
Of Aggregate Percentage Revenue and Accounts Receivable&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20230101__20231231_zUGdB37NKUn6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December
    31, 2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20220101__20221231_zcYb7a6l5vo2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December
    31, 2022&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Year Ended&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zEHO2Q3PAb9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 56%"&gt;Customer 1&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"&gt;52&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"&gt;31&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_zZGLElbzyVq4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;Customer 2&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0725"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;22&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomersMember_z5Y4MjatHXV" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Aggregate Percent of Total Revenue&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;52&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;53&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 12.95pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2023, three customers accounted for more than &lt;span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--ThreeCustomersMember_zaeCBpShTQP9"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%
of the Company&#x2019;s accounts receivable balance, and two customers accounted for over &lt;span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--TwoCustomersMember_z1pBVCbDsh6b"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%
of the Company&#x2019;s accounts receivable balance at December 31, 2022. The following table represents these customers&#x2019; aggregate
percent of total accounts receivable:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 12.95pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20230101__20231231_zFefwqYRVOU8" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December
    31, 2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20220101__20221231_z2cFFNbI99Sb" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December
    31, 2022&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Year Ended&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zUQw8G4cVKZe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%"&gt;Customer 1&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0733"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;40&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_zbivTlCYEB3g" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Customer 2&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;36&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0737"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerThreeMember_zUf1RqDmH0z5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Customer 3&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;33&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0740"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerFourMember_zMcJm0AG6jMd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Customer 4&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0742"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;32&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerFiveMember_zXVSrVaFghWj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;Customer 5&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;27&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0746"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomersMember_zdgdbAAO0zIb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Aggregate Percent of Total Accounts Receivable&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;96&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;72&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomersMember_zg1FiXjCH2xe" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Aggregate Percent of Revenue and Accounts Receivable&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;96&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;72&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A5_zHDNCw2Iq6Qc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 12.95pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000715"
      unitRef="USD">0</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000716"
      unitRef="USD">102700</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-01-012023-12-31_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_CustomerConcentrationRiskMember_custom_OneCustomerMember"
      decimals="INF"
      id="Fact000717"
      unitRef="Pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-01-012022-12-31_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_CustomerConcentrationRiskMember_custom_TwoCustomersMember"
      decimals="INF"
      id="Fact000718"
      unitRef="Pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000720">&lt;p id="xdx_899_eus-gaap--SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_zQi7JmXQvsj9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B2_zGLv6h4dCOii"&gt;Schedule
Of Aggregate Percentage Revenue and Accounts Receivable&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20230101__20231231_zUGdB37NKUn6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December
    31, 2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20220101__20221231_zcYb7a6l5vo2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December
    31, 2022&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Year Ended&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zEHO2Q3PAb9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 56%"&gt;Customer 1&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"&gt;52&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"&gt;31&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_zZGLElbzyVq4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;Customer 2&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0725"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;22&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomersMember_z5Y4MjatHXV" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Aggregate Percent of Total Revenue&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;52&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;53&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 12.95pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2023, three customers accounted for more than &lt;span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--ThreeCustomersMember_zaeCBpShTQP9"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%
of the Company&#x2019;s accounts receivable balance, and two customers accounted for over &lt;span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--TwoCustomersMember_z1pBVCbDsh6b"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%
of the Company&#x2019;s accounts receivable balance at December 31, 2022. The following table represents these customers&#x2019; aggregate
percent of total accounts receivable:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 12.95pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20230101__20231231_zFefwqYRVOU8" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December
    31, 2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20220101__20221231_z2cFFNbI99Sb" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December
    31, 2022&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Year Ended&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zUQw8G4cVKZe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%"&gt;Customer 1&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0733"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;40&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_zbivTlCYEB3g" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Customer 2&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;36&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0737"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerThreeMember_zUf1RqDmH0z5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Customer 3&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;33&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0740"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerFourMember_zMcJm0AG6jMd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Customer 4&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0742"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;32&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerFiveMember_zXVSrVaFghWj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;Customer 5&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;27&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0746"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomersMember_zdgdbAAO0zIb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Aggregate Percent of Total Accounts Receivable&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;96&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;72&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomersMember_zg1FiXjCH2xe" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Aggregate Percent of Revenue and Accounts Receivable&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;96&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;72&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-01-012023-12-31_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerOneMember"
      decimals="INF"
      id="Fact000722"
      unitRef="Pure">0.52</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-01-012022-12-31_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerOneMember"
      decimals="INF"
      id="Fact000723"
      unitRef="Pure">0.31</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-01-012022-12-31_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerTwoMember"
      decimals="INF"
      id="Fact000726"
      unitRef="Pure">0.22</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-01-012023-12-31_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomersMember"
      decimals="INF"
      id="Fact000728"
      unitRef="Pure">0.52</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-01-012022-12-31_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomersMember"
      decimals="INF"
      id="Fact000729"
      unitRef="Pure">0.53</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-01-012023-12-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_ThreeCustomersMember"
      decimals="INF"
      id="Fact000730"
      unitRef="Pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-01-012022-12-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_TwoCustomersMember"
      decimals="INF"
      id="Fact000731"
      unitRef="Pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-01-012022-12-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerOneMember"
      decimals="INF"
      id="Fact000734"
      unitRef="Pure">0.40</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-01-012023-12-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerTwoMember"
      decimals="INF"
      id="Fact000736"
      unitRef="Pure">0.36</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-01-012023-12-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerThreeMember"
      decimals="INF"
      id="Fact000739"
      unitRef="Pure">0.33</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-01-012022-12-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerFourMember"
      decimals="INF"
      id="Fact000743"
      unitRef="Pure">0.32</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-01-012023-12-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerFiveMember"
      decimals="INF"
      id="Fact000745"
      unitRef="Pure">0.27</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-01-012023-12-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomersMember"
      decimals="INF"
      id="Fact000748"
      unitRef="Pure">0.96</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-01-012022-12-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomersMember"
      decimals="INF"
      id="Fact000749"
      unitRef="Pure">0.72</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-01-012023-12-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomersMember"
      decimals="INF"
      id="Fact000751"
      unitRef="Pure">0.96</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-01-012022-12-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomersMember"
      decimals="INF"
      id="Fact000752"
      unitRef="Pure">0.72</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000754">&lt;p id="xdx_846_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zoEI6ToaNBQc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span id="xdx_868_z4IcW1vRIm1b" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Property
and Equipment&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment are recorded at cost. The straight-line method is used for computing depreciation and amortization. Assets are depreciated
over their estimated useful lives ranging from three to five years. Cost of maintenance and repairs are charged to expense when incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000756">&lt;p id="xdx_841_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zqQEFN1kkqcg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span id="xdx_862_zNNfTwY6IbVa" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Impairment
of Long-Lived Assets&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company reviews long-lived assets, including property and equipment, for impairment whenever events or changes in business circumstances
indicate that the carrying amount of an asset may not be fully recoverable. An impairment loss would be recognized when the estimated
future undiscounted net cash flows from the use of the asset are less than the carrying amount of that asset. There have been &lt;span id="xdx_90A_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_do_c20220101__20221231_zU0HgIgIqy09"&gt;no
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;losses during the years ended December
31, 2023 or December 31, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000757"
      unitRef="USD">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2023-01-01to2023-12-31" id="Fact000759">&lt;p id="xdx_845_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zDiDCTuKvzr" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span id="xdx_865_zS2oqDkolOjj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Fair
Value of Financial Instruments&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fair
value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between
market participants at the measurement date. To increase the comparability of fair value measures, the following hierarchy prioritizes
the inputs to valuation methodologies used to measure fair value:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 12.95pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Level
1&lt;/b&gt; &#x2014; Valuations based on quoted prices for identical assets and liabilities in active markets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Level
2&lt;/b&gt; &#x2014; Valuations based on observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets
and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, or other
inputs that are observable or can be corroborated by observable market data.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Level
3&lt;/b&gt; &#x2014; Valuations based on unobservable inputs reflecting our own assumptions, consistent with reasonably available assumptions
made by other market participants. These valuations require significant judgment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 12.95pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
measure the fair value of money market funds and certain marketable equity securities based on quoted prices in active markets for identical
assets or liabilities. Other marketable securities were valued either based on recent trades of securities in inactive markets or based
on quoted market prices of similar instruments and other significant inputs derived from or corroborated by observable market data. We
did not hold significant amounts of marketable securities categorized as Level 3 assets as of the years ended December 31, 2022 and December
31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s financial instruments consist of cash and cash equivalents, accounts receivable, accounts payable, convertible notes
payable and certain privately issued warrants. The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable
financial instruments approximate their fair value due to their short-term nature. The Company&#x2019;s Private Warrants estimated fair
values are provided by a third party pricing vendor and are reviewed by the Company&#x2019;s management. The Private Warrants valuations
are based on unobservable inputs reflecting the vendor&#x2019;s assumptions, consistent with reasonably available assumptions made by
other market participants and thus are classified as Level 3.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000761">&lt;p id="xdx_848_eus-gaap--RevenueRecognitionPolicyTextBlock_z8kXah7HUIp5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span id="xdx_860_zetssCGQ3aL3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Revenue
Recognition&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Revenue
is recognized in accordance with the five-step model set forth by Accounting Standards Update (&#x201c;ASU&#x201d;) 2014-09, Revenue from
Contracts with Customers (&#x201c;Topic 606&#x201d;), which involves identification of the contract, identification of performance obligations
in the contract, determination of the transaction price, allocation of the transaction price to the previously identified performance
obligations, and revenue recognition as the performance obligations are satisfied.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 12.95pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Revenue
from all customers is recognized when a performance obligation is satisfied by transferring control of a distinct good or service to
a customer. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit
of account under Topic 606. A contract&#x2019;s transaction price is allocated to each distinct performance obligation in proportion to
the standalone selling price for each and recognized as revenue when, or as, the performance obligation is satisfied.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 12.95pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Individual
promised goods and services in a contract are considered a performance obligation and accounted for separately if the good or service
is distinct. A good or service is considered distinct if the customer can benefit from the good or service on its own or with other resources
that are readily available to the customer and the good or service is separately identifiable from other promises in the arrangement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 12.95pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
transaction price for the products is the invoiced amount. Advanced billings from contracts are deferred and recognized as revenue when
earned. Revenue is recognized only to the extent that it is probable that a significant reversal of revenue will not occur and when collection
is considered probable The Company excludes from revenue taxes collected from a customer that are assessed by a governmental authority
and imposed on and concurrent with a specific revenue-producing transaction. Deferred revenue consists of payments received in advance
of performance under the contract. Such amounts are generally recognized as revenue over the contractual period. The Company receives
payments from customers based upon contractual billing schedules. Accounts receivable is recorded when the right to consideration becomes
unconditional. Payment terms on invoiced amounts typically range from zero to 90 days, with typical terms of 30 days.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 12.95pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company generates revenue from two streams: (1) iRWD (imaging Real World Data) which provides regulatory grade imaging and clinical data
in the Pharmaceutical, Device Manufacturing, CRO&#x2019;s and AI markets and (2) BEAM which is a Medical Imaging Exchange platform between
Hospital/Healthcare Systems, Imaging Centers, Physicians and Patients. iRWD is sold on a fixed fee basis based on the number of data
units and the cost per data unit committed to in the customer contract. Revenue is recognized when the data is delivered to the customer.
Beam revenue is subscription-based revenue which is recognized ratably over the subscription period committed to by the customer. The
Company invoices its Beam customers quarterly or annually in advance with the customer contracts automatically renewing unless the customer
issues a cancellation notice.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000763">&lt;p id="xdx_846_eus-gaap--IncomeTaxPolicyTextBlock_zJ6mvQ9t6Vg8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span id="xdx_86A_zWc184B7YKG7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Income
Taxes&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is subject to U.S. federal, state and local income taxes. The Company accounts for income taxes in accordance with ASC Topic
740, Accounting for Income Taxes (&#x201c;ASC Topic 740&#x201d;), which requires the recognition of tax benefits or expenses on temporary
differences between the financial reporting and tax bases of its assets and liabilities by applying the enacted tax rates in effect for
the year in which the differences are expected to reverse. Such net tax effects on temporary differences are reflected on the Company&#x2019;s
consolidated balance sheets as deferred tax assets and liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ASC
Topic 740 prescribes a two-step approach for the recognition and measurement of tax benefits associated with the positions taken or expected
to be taken in a tax return that affects amounts reported in the financial statements. The Company has reviewed and will continue to
review the conclusions reached regarding uncertain tax positions, which may be subject to review and adjustment at a later date based
on ongoing analyses of tax laws, regulations and interpretations thereof. To the extent that the Company&#x2019;s assessment of the conclusions
reached regarding uncertain tax positions changes as a result of the evaluation of new information, such change in estimate will be recorded
in the period in which such determination is made. The Company reports income tax-related interest and penalties relating to uncertain
tax positions, if applicable, as a component of income tax expense&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
tax assets are reduced by a valuation allowance when the Company believes that it is more-likely-than-not that some portion or all of
the deferred tax assets will not be realized. The Company provides deferred taxes at the enacted tax rate that is expected to apply when
the temporary differences reverse. The Company has recorded a full valuation allowance against the net deferred tax asset due to the
uncertainty of realizing the related benefits.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <ONMD:PatentsAndTrademarksPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000765">&lt;p id="xdx_843_ecustom--PatentsAndTrademarksPolicyTextBlock_zllmj1Dmzjha" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span id="xdx_866_zbuYUjfdq4qd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Patents
and Trademarks&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Costs
associated with the submission of a patent application are expensed as incurred given the uncertainty of the patents resulting in probable
future economic benefits to the Company and are included in research and development expenses on the consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 30pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</ONMD:PatentsAndTrademarksPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2023-01-01to2023-12-31" id="Fact000767">&lt;p id="xdx_84F_eus-gaap--ResearchAndDevelopmentExpensePolicy_zqccu0sxztVd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span id="xdx_86F_zoLfadaIiS4e" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Research
and Development&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 30pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company account for its research and development cost in accordance with ASC Topic 730, Research and Development (&#x201c;ASC Topic 730&#x201d;).
ASC Topic 730 requires that all R&amp;amp;D costs be recognized as an expense as incurred. However, some costs associated with R&amp;amp;D activities
that have an alternative future use (e.g., materials, equipment, facilities) may be capitalizable. For the years ended December 31, 2023
and December 31, 2022 research and development expenditures were charged to operating expense as incurred..&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 30pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000769">&lt;p id="xdx_845_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zY1upFaeMacf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span id="xdx_869_z2L8cRNHHXpg" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Stock-based
Compensation&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has a stock-based compensation plan, which is described in more detail in Note 8. The fair value of stock option and warrant
grants are determined on the date of grant using the Black Scholes valuation model. Forfeitures of stock based awards are recorded as
the actual forfeitures occur. Stock based compensation expense is recognized over the service period, net of estimated forfeitures, using
the straight-line method. The Company converted all unvested stock based compensation awards to common shares in the year ended December
31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000771">&lt;p id="xdx_846_eus-gaap--SellingGeneralAndAdministrativeExpensesPolicyTextBlock_zob83QmMzd2g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span id="xdx_862_zp3OEq1qEjda" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;General,
and Administrative Expenses&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;General
and administrative expenses include all costs that are not directly related to satisfaction of customer contracts. General, and administrative
expenses include items for the Company&#x2019;s selling and administrative functions, such as sales, finance, legal, human resources,
and information technology support. These functions include costs for items such as salaries and benefits and other personnel-related
costs, maintenance and supplies, professional fees for external legal, accounting, and other consulting services, intangible asset amortization,
and depreciation expense.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
    <ONMD:EmergingGrowthCompanyPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000773">&lt;p id="xdx_84B_ecustom--EmergingGrowthCompanyPolicyTextBlock_zSv3ZJ534jDd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span id="xdx_861_zPmGBlQam70g" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Emerging
Growth Company&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is an emerging growth company, as defined in Section 2(a) of the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;),
as modified by the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;). Section 102(b)(1) of the JOBS Act exempts
emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that
is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered
under the Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;)) are required to comply with the new or revised
financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply
with the requirements that apply to non-emerging growth companies but any such an election to opt out is irrevocable. The Company has
not elected to opt out of such extended transition period which means that when a standard is issued or revised and it has different
application dates for public or private companies, the Company, as an emerging growth company , can adopt the new or revised standard
at the time private companies adopt the new or revised standard.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</ONMD:EmergingGrowthCompanyPolicyTextBlock>
    <ONMD:AccountingPronouncementsNotYetAdoptedPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000775">&lt;p id="xdx_845_ecustom--AccountingPronouncementsNotYetAdoptedPolicyTextBlock_zkriRDHeinT3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span id="xdx_86B_zXnyAgn1N81h" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Accounting
Pronouncements Not Yet Adopted&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2023, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued ASU No. 2023-07, Improvements to Reportable Segment
Disclosures (Topic 280). This ASU updates reportable segment disclosure requirements by requiring disclosures of significant reportable
segment expenses that are regularly provided to the Chief Operating Decision Maker (&#x201c;CODM&#x201d;) and included within each reported
measure of a segment&#x2019;s profit or loss. This ASU also requires disclosure of the title and position of the individual identified
as the CODM and an explanation of how the CODM uses the reported measures of a segment&#x2019;s profit or loss in assessing segment performance
and deciding how to allocate resources. The ASU is effective for annual periods beginning after December 15, 2023, and interim periods
within fiscal years beginning after December 15, 2024. Adoption of the ASU should be applied retrospectively to all prior periods presented
in the financial statements. Early adoption is also permitted. This ASU will likely result in us including the additional required disclosures
when adopted. We are currently evaluating the provisions of this ASU and expect to adopt them for the year ending December 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
December 2023, the Financial Accounting Standards Board issued an Accounting Standards Update (&#x201c;ASU&#x201d;) amending existing income
tax disclosure guidance, primarily requiring more detailed disclosure for income taxes paid and the effective tax rate reconciliation.
The ASU is effective for annual reporting periods beginning after December 15, 2024, with early adoption permitted and can be applied
on either a prospective or retroactive basis. We are currently evaluating the ASU to determine its impact on our income tax disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</ONMD:AccountingPronouncementsNotYetAdoptedPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000777">&lt;p id="xdx_840_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zMFQj8yXoSH2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span id="xdx_86F_zcTBCyVWS00i" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Recently
adopted accounting pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
October 2021, the FASB issued ASU No. 2021-08, Accounting for Contract Assets and Contract Liabilities from Contracts with Customers
(ASC Topic 805). This ASU requires an acquirer in a business combination to recognize and measure contract assets and contract liabilities
(deferred revenue) from acquired contracts using the revenue recognition guidance in Topic 606. At the acquisition date, the acquirer
applies the revenue model as if it had originated the acquired contracts. The ASU is effective for annual periods beginning after December
15, 2022, including interim periods within those fiscal years. We adopted this ASU prospectively on January 1, 2023. This ASU has not
and is currently not expected to have a material impact on our consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000779">&lt;p id="xdx_80D_eus-gaap--BusinessCombinationDisclosureTextBlock_z4vKWwQH9wHb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;3.
&lt;span id="xdx_82B_zeoEFUOzArqf"&gt;Business Combination&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Business Combination was accounted for as a reverse recapitalization as OneMedNet Corporation was determined to be the accounting acquirer
under Financial Accounting Standards Board&#x2019;s (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 805,
Business Combinations. This determination was primarily based on OneMedNet Corporation comprising the ongoing operations of the combined
entity, OneMedNet Corporation&#x2019;s senior management comprising of all the senior management of the combined company, and the prior
shareholders of OneMedNet owning a majority of the voting power of the combined entity. Accordingly, for accounting purposes, the financial
statements of the combined entity upon consummation of the Business Combination represented a continuation of the financial statements
of OneMedNet Corporation with the merger being treated as the equivalent of OneMedNet issuing stock for the net assets of Data Knights
Inc., accompanied by a recapitalization. Operations prior to the Business Combination are presented as those of OneMedNet Corporation
in future reports of the combined entity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:SubstantialDoubtAboutGoingConcernTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000781">&lt;p id="xdx_80C_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_z9GQMeGj2eO9" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.
&lt;span id="xdx_820_zNMLide1oM86"&gt;Going Concern&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets
and satisfaction of liabilities and commitments in the normal course of business. The Company does not have adequate liquidity to fund
its operations through at least twelve months from the date these financial statements were available for issuance. The Company has an
accumulated deficit &lt;span id="xdx_900_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_di_c20231231_zLT6O9l1Mpdd"&gt;55,082,677&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;as of year-end December 31, 2023 and $&lt;span id="xdx_90A_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_di_c20221231_zFrRkvZ0DDf6"&gt;43,509,964&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;,
as of year-end December 31, 2022 and has had negative cash flows from operating activities for the year ended December 31, 2023. These
conditions raise substantial doubt about the Company&#x2019;s ability to continue as a going concern. To continue in existence and expand
its operations, the Company will be required to, and management plans to, raise additional working capital through an equity or debt
offering and ultimately attain profitable operations. If the Company is not able to raise additional working capital, it would have a
material adverse effect on the operations of the Company and continuing research and development of its product. The consolidated financial
statements do not include any adjustments relating to the recoverability and classification of assets and liabilities that might be necessary
should the Company be unable to continue as a going concern. The Company&#x2019;s continuation as a going concern is dependent upon its
ability to continue receiving working capital cash payments and generating cash flow from operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SubstantialDoubtAboutGoingConcernTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000782"
      unitRef="USD">-55082677</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000783"
      unitRef="USD">-43509964</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000785">&lt;p id="xdx_80B_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_z2S0u7LSVuZ2" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.
&lt;span id="xdx_822_zswcSU5RuXy"&gt;Property and Equipment&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment are summarized as of December 31:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--PropertyPlantAndEquipmentTextBlock_zAazqlokgi91" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B2_z8Gw2Lkw6J59"&gt;Schedule
of Property And Equipment &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%; margin-left: 0.75in"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20231231_zxbghYXtYgG" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20221231_zt0fc4NDUIdi" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_ziE4TvzcdXC8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%"&gt;Computers&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;246,578&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;259,207&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zo9jdq1Pm0n1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Furniture and equipment&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;35,708&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;3,785&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzSdJ_zRVEXvJRbLte" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Total Property and Equipment&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;282,286&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;262,992&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzSdJ_zESw8MyMt588" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Less: accumulated depreciation&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(183,415&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(179,895&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzSdJ_zkzCLNMdEYJ2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;Net Property and Equipment&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;98,871&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;83,097&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_z2Z5jWJEfOhc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Depreciation
and amortization expense was $&lt;span id="xdx_905_eus-gaap--DepreciationAndAmortization_c20230101__20231231_z4c8S5We6ZWd"&gt;27,983&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;and $&lt;span id="xdx_901_eus-gaap--DepreciationAndAmortization_c20220101__20221231_zRDHKmXJDHP7"&gt;24,807
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;for the years ended December 31, 2023
and 2022, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000787">&lt;p id="xdx_89A_eus-gaap--PropertyPlantAndEquipmentTextBlock_zAazqlokgi91" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B2_z8Gw2Lkw6J59"&gt;Schedule
of Property And Equipment &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%; margin-left: 0.75in"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20231231_zxbghYXtYgG" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20221231_zt0fc4NDUIdi" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_ziE4TvzcdXC8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%"&gt;Computers&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;246,578&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;259,207&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zo9jdq1Pm0n1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Furniture and equipment&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;35,708&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;3,785&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzSdJ_zRVEXvJRbLte" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Total Property and Equipment&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;282,286&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;262,992&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzSdJ_zESw8MyMt588" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Less: accumulated depreciation&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(183,415&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(179,895&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzSdJ_zkzCLNMdEYJ2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;Net Property and Equipment&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;98,871&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;83,097&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-12-31_us-gaap_ComputerEquipmentMember"
      decimals="0"
      id="Fact000789"
      unitRef="USD">246578</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2022-12-31_us-gaap_ComputerEquipmentMember"
      decimals="0"
      id="Fact000790"
      unitRef="USD">259207</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-12-31_us-gaap_FurnitureAndFixturesMember"
      decimals="0"
      id="Fact000792"
      unitRef="USD">35708</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2022-12-31_us-gaap_FurnitureAndFixturesMember"
      decimals="0"
      id="Fact000793"
      unitRef="USD">3785</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000795"
      unitRef="USD">282286</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000796"
      unitRef="USD">262992</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000798"
      unitRef="USD">183415</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000799"
      unitRef="USD">179895</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000801"
      unitRef="USD">98871</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000802"
      unitRef="USD">83097</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000803"
      unitRef="USD">27983</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000804"
      unitRef="USD">24807</us-gaap:DepreciationAndAmortization>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000806">&lt;p id="xdx_80C_eus-gaap--IncomeTaxDisclosureTextBlock_zQGKlG3kSa4g" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6.
&lt;span id="xdx_828_zYHZpHPvRJn6"&gt;Income Taxes&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has generated both federal and state net operating losses (NOL) of approximately $&lt;span id="xdx_90E_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_iI_pn6n6_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zrJBbv8G4Dve"&gt;21
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million and $&lt;span id="xdx_905_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_iI_pn6n6_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_z5CpxqCHQ7id"&gt;23
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million, respectively, which if not used,
will begin to expire in 2030. The Company believes that its ability to fully utilize the existing NOL carryforwards could be restricted
on a portion of the NOL by changes in control that may have occurred or may occur in the future and by its ability to generate net income.
The Company has not yet conducted a formal study of whether, or to what extent, past changes in control of the Company impairs its NOL
carryforwards because such NOL carryforwards cannot be utilized until the Company achieves profitability.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zOTyCca4QW1c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Components
of deferred income taxes are as follows as of December 31:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span id="xdx_8B6_zo03RUu2UEKe" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Schedule
of Deferred Income Taxes&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20231231_zuzdypJa1VJe" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20221231_zvNXwFlUwyx6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredTaxAssetsNetAbstract_iB_z1AfkgxFsRQc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Deferred Tax Assets&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzqvH_z5F5Wc4Dlonj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;Net operating loss carry forward&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6,823,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;6,973,587&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTAGzqvH_znQ6MjBxc6q2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Stock Compensation&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,035,947&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;481,144&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredTaxAssetsOther_iI_maDTAGzqvH_zYoSYWKgPhFb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; padding-bottom: 1.5pt"&gt;Other&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0821"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;53,268&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzqvH_maDTANzhf6_zP6nBXkfV5Hc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Gross deferred tax assets&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;7,859,732&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;7,507,999&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzhf6_zvM5foPdYXh1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Less valuation allowance&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(7,859,732&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(7,507,999&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzhf6_zpjeP5OEWge3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Net deferred tax assets&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0830"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0831"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_z2sdkuOVvkC" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
change in the valuation allowance was $&lt;span id="xdx_901_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_c20230101__20231231_z0SoQZV1P5eh"&gt;351,734
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;and $&lt;span id="xdx_907_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_c20220101__20221231_zDJsXDusfHxb"&gt;1,384,220
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;for the years ended December 31, 2023
and 2022, respectively. The effective tax rate for the years ended December 31, 2023 and 2022 differs from the federal and state statutory
rates due to the full valuation allowance. The Company recognizes the financial statement benefit of a tax position only after determining
that the relevant tax authority would more likely than not sustain the position following an audit. The tax years from inception through
December 31, 2023 remain subject to examination by all major taxing authorities due to the net operating loss carryovers. The Company
is not currently under examination by any taxing jurisdiction. The Company did not incur any interest or penalties during the years ended
December 31, 2023 or 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
a result of the Business Combination, the Company was appointed as the sole managing member of Data Knights. The Company is subject to
U.S. federal income taxes, in addition to state and local income taxes. The Company accounts for income taxes using the asset and liability
method, which requires the recognition of deferred tax assets and liabilities for the estimated future tax consequences attributable
to temporary differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective
tax base. Deferred tax assets and liabilities are determined on the basis of the differences between the consolidated financial statements
and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the temporary differences are expected
to be settled or recovered. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. In assessing
the realizability of deferred tax assets, the Company considers whether it is more likely than not that some portion or all of the deferred
tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income
during the periods in which those temporary differences become deductible. The Company considers the scheduled reversal of deferred tax
liabilities, projected future income, and tax planning strategies in making this assessment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has established a valuation allowance related deferred tax assets on deductible temporary differences, tax losses, and tax credit
carryforwards. The valuation allowance as of December 31, 2023 was $&lt;span id="xdx_90C_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_pn5n6_c20231231__us-gaap--BusinessAcquisitionAxis__custom--DataKnightsAcquisitionCorpMember_zc9I8GCxiNOl"&gt;168.3&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;.
The increase in the valuation allowance in fiscal year 2023 of $&lt;span id="xdx_90C_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn5n6_c20230101__20231231__us-gaap--BusinessAcquisitionAxis__custom--DataKnightsAcquisitionCorpMember_zAXOyzAGvkna"&gt;155.7
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million primarily relates to the Company&#x2019;s
investment in Data Knights, and tax carryforward attributes.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2023, the Company had a U.S. federal net operating loss carryforwards of $&lt;span id="xdx_903_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_z3uZn3tL8Luk"&gt;10.3
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million and gross state net operating
loss carryforwards of $&lt;span id="xdx_903_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zW99MiPyTjFe"&gt;8.9
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
      contextRef="AsOf2023-12-31_us-gaap_DomesticCountryMember"
      decimals="-6"
      id="Fact000807"
      unitRef="USD">21000000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
      contextRef="AsOf2023-12-31_us-gaap_StateAndLocalJurisdictionMember"
      decimals="-6"
      id="Fact000808"
      unitRef="USD">23000000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000810">&lt;p id="xdx_897_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zOTyCca4QW1c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Components
of deferred income taxes are as follows as of December 31:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span id="xdx_8B6_zo03RUu2UEKe" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Schedule
of Deferred Income Taxes&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20231231_zuzdypJa1VJe" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20221231_zvNXwFlUwyx6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredTaxAssetsNetAbstract_iB_z1AfkgxFsRQc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Deferred Tax Assets&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzqvH_z5F5Wc4Dlonj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;Net operating loss carry forward&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6,823,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;6,973,587&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTAGzqvH_znQ6MjBxc6q2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Stock Compensation&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,035,947&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;481,144&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredTaxAssetsOther_iI_maDTAGzqvH_zYoSYWKgPhFb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; padding-bottom: 1.5pt"&gt;Other&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0821"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;53,268&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzqvH_maDTANzhf6_zP6nBXkfV5Hc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Gross deferred tax assets&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;7,859,732&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;7,507,999&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzhf6_zvM5foPdYXh1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Less valuation allowance&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(7,859,732&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(7,507,999&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzhf6_zpjeP5OEWge3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Net deferred tax assets&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0830"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0831"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000815"
      unitRef="USD">6823785</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000816"
      unitRef="USD">6973587</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000818"
      unitRef="USD">1035947</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000819"
      unitRef="USD">481144</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000822"
      unitRef="USD">53268</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000824"
      unitRef="USD">7859732</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000825"
      unitRef="USD">7507999</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000827"
      unitRef="USD">7859732</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000828"
      unitRef="USD">7507999</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000832"
      unitRef="USD">351734</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000833"
      unitRef="USD">1384220</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2023-12-31_custom_DataKnightsAcquisitionCorpMember"
      decimals="-5"
      id="Fact000834"
      unitRef="USD">168300000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="From2023-01-012023-12-31_custom_DataKnightsAcquisitionCorpMember"
      decimals="-5"
      id="Fact000835"
      unitRef="USD">155700000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2023-12-31_us-gaap_DomesticCountryMember"
      decimals="-5"
      id="Fact000836"
      unitRef="USD">10300000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2023-12-31_us-gaap_StateAndLocalJurisdictionMember"
      decimals="-5"
      id="Fact000837"
      unitRef="USD">8900000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:LongTermDebtTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000839">&lt;p id="xdx_804_eus-gaap--LongTermDebtTextBlock_zs77GuAQ061c" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;7.
&lt;span id="xdx_822_zC14DSedB2je"&gt;Convertible Promissory Notes held by Related Party&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
2023, the Company entered various Convertible Promissory Notes (&#x201c;Note&#x201d;) with related party investors totaling $&lt;span id="xdx_90E_eus-gaap--ConvertibleNotesPayable_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zJ0A9yJtOCIj"&gt;2,300,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2022 - $&lt;span id="xdx_909_eus-gaap--ConvertibleNotesPayable_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zvGkZMJNdQSf"&gt;4,700,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)
and unrelated party investors of $&lt;span id="xdx_90B_eus-gaap--ConvertibleNotesPayable_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_ze08HTFx5wN"&gt;1,875,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2022 - $&lt;span id="xdx_909_eus-gaap--ConvertibleNotesPayable_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zO5hNPsSKwdd"&gt;440,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;).
The Notes issued are unsecured and bear an interest rate of six percent annually from the date of issuance until the outstanding principal
is paid or converted. On November 11, 2022 the Convertible note agreement was amended and restated in order to (i) provide for the sale
and issuance to Purchasers from the effective date of January 1, 2022 and after the date of this Agreement of up to an additional $&lt;span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_c20221111__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNotesMember_ze3YghPcbhM5"&gt;5,000,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;aggregate principal amount of Notes and
warrants to purchase shares of the Company&#x2019;s capital stock, (ii) provide for the sale and issuance to Purchasers who purchased
Notes under the Prior Agreement between the Effective Date and the date of this Agreement of warrants to purchase shares of the Company&#x2019;s
common stock at an exercise price of $&lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221111__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z0g21z8lG49c"&gt;1.00
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per share; (iii) extend the maturity date
of all outstanding Notes from December 31, 2022 to November 7, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
principal and unpaid accrued interest on each Note will convert: (i) automatically, upon the Company&#x2019;s issuance of equity securities
(the &#x201c;Next Equity Financing&#x201d;) in a single transaction, or series of related transactions, with aggregate gross proceeds to
the Company of at least $&lt;span id="xdx_907_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_c20221110__20221111__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNotesMember_zAHMpalxTCIi"&gt;5,000,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;,
into shares of the Company&#x2019;s capital stock issued to investors in the Next Equity Financing, at a conversion price equal to the
lesser of (A) &lt;span id="xdx_906_ecustom--EquityFinancingDescription_c20221110__20221111__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNotesMember_zP3bi3FMTxA8"&gt;a
20% discount to the lowest price per share of shares sold in the Next Equity Financing, or (B) $2.50 per share; (ii) at the noteholder&#x2019;s
option, in the event of a defined Corporate Transaction while such Note remains outstanding, into shares of the Company&#x2019;s Series
A-2 Preferred Stock at a conversion price equal to $&lt;/span&gt;&lt;/span&gt;&lt;span id="xdx_907_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_c20221111__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__us-gaap--StatementClassOfStockAxis__custom--SeriesATwoPreferredStockMember__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNotesMember_zzxoqgGTU0af" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.50
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per
share; and (iii) at the noteholder&#x2019;s option, on or after the Maturity Date while such Note remains outstanding, into shares of
the Company&#x2019;s Series A-2 Preferred Stock at a conversion price equal to $&lt;/span&gt;&lt;span id="xdx_901_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_c20221111__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__us-gaap--StatementClassOfStockAxis__custom--SeriesATwoPreferredStockMember__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNotesMember_zwlO38ap7fT2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.50
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per
share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;If
a Corporate Transaction occurs before the repayment or conversion of the Notes, the Company will pay at the closing of the Corporate
Transaction to each noteholder that elects not to convert its Notes in connection with such Corporate Transaction an amount equal to
the outstanding principal amount of such noteholder&#x2019;s Note plus a 20% premium. &#x201c;Corporate Transaction&#x201d; means (a) a
sale by the Company of all or substantially all of its assets, (b) a merger of the Company with or into another entity (if after such
merger the holders of a majority of the Company&#x2019;s voting securities immediately prior to the transaction do not hold a majority
of the voting securities of the successor entity) or (c) the transfer of more than 50% of the Company&#x2019;s voting securities to a
person or group.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
November 2019, the Company entered into a Convertible Promissory Note (&#x201c;Note&#x201d;) agreement with a related party investor. The
total amount of the Note is $&lt;span id="xdx_90B_eus-gaap--ConvertibleNotesPayable_iI_c20191130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNotesMember_zv56oApNNbeh"&gt;1,500,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;.
The Note is unsecured and bears interest at a rate of four percent annually from the date of issuance until the outstanding principal
is paid or converted. The Note matures on January 1, 2025. The Note shall automatically convert into the next offering of preferred stock
upon closing of such next equity financing. The number of shares of preferred stock to be issued upon conversion shall be equal to the
number obtained by dividing the outstanding principal and unpaid accrued interest owed on the date of conversion, by the conversion price.
The conversion price is 100 percent of the lowest price per share paid for the next equity preferred stock by other investors in the
next equity financing. In the event that prior to the conversion or repayment of amounts owed, the Company completes a financing transaction
in which the Company sells equity securities but such transaction does not qualify as next equity financing (i.e., an &#x201c;alternative
financing&#x201d;), then the principal and unpaid accrued interest may (upon written election of the purchaser holding the Note) convert
into the securities issued by the Company in the alternative financing. The number of alternative financing equity securities to be issued
upon such conversion shall be equal to the number obtained by dividing the outstanding principal and unpaid accrued interest owed by
an amount equal to 100 percent multiplied by the lowest price per share at which the alternative financing equity securities are sold
and issued for cash in the alternative financing.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2022 there was $&lt;span id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20221231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNotesMember_zzQfngxlNZv"&gt;9.9
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million outstanding principal balance
on the Notes and $&lt;span id="xdx_90D_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_c20221231_zdNy3XL0rF12"&gt;690,771&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;in accrued interest, all included in long-term liabilities
on the balance sheet. There were no payments of principal or interest during 2022. In connection with the $&lt;span id="xdx_909_eus-gaap--ConvertibleNotesPayable_iI_c20221231_zHeJIptueIbd"&gt;5,140,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;in convertible notes issued in 2022, &lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231_ztjzjo3Remni"&gt;2,056,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;in warrants were issued.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2023, the Business Combination between Data Knights and the Company triggered the Notes&#x2019; conversion to common stock. Approximately
$&lt;span id="xdx_90F_eus-gaap--ConvertibleNotesPayable_iI_pn5n6_c20231130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__us-gaap--BusinessAcquisitionAxis__custom--DataKnightsAcquisitionCorpMember_zWFSXJD2XsXd"&gt;15.4
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million of the total outstanding Notes
plus accrued interest were converted at $&lt;span id="xdx_900_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20231130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__us-gaap--BusinessAcquisitionAxis__custom--DataKnightsAcquisitionCorpMember_z22nSokD3835"&gt;2.50
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per share of common stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 29.95pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LongTermDebtTextBlock>
    <us-gaap:ConvertibleNotesPayable
      contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact000840"
      unitRef="USD">2300000</us-gaap:ConvertibleNotesPayable>
    <us-gaap:ConvertibleNotesPayable
      contextRef="AsOf2022-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact000841"
      unitRef="USD">4700000</us-gaap:ConvertibleNotesPayable>
    <us-gaap:ConvertibleNotesPayable
      contextRef="AsOf2023-12-31_us-gaap_NonrelatedPartyMember"
      decimals="0"
      id="Fact000842"
      unitRef="USD">1875000</us-gaap:ConvertibleNotesPayable>
    <us-gaap:ConvertibleNotesPayable
      contextRef="AsOf2022-12-31_us-gaap_NonrelatedPartyMember"
      decimals="0"
      id="Fact000843"
      unitRef="USD">440000</us-gaap:ConvertibleNotesPayable>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2022-11-11_us-gaap_RelatedPartyMember_custom_ConvertiblePromissoryNotesMember"
      decimals="0"
      id="Fact000844"
      unitRef="USD">5000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-11-11_us-gaap_RelatedPartyMember_custom_ConvertiblePromissoryNotesMember"
      decimals="INF"
      id="Fact000845"
      unitRef="USDPShares">1.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2022-11-102022-11-11_us-gaap_RelatedPartyMember_custom_ConvertiblePromissoryNotesMember"
      decimals="0"
      id="Fact000846"
      unitRef="USD">5000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <ONMD:EquityFinancingDescription
      contextRef="From2022-11-102022-11-11_us-gaap_RelatedPartyMember_custom_ConvertiblePromissoryNotesMember"
      id="Fact000847">a
20% discount to the lowest price per share of shares sold in the Next Equity Financing, or (B) $2.50 per share; (ii) at the noteholder&#x2019;s
option, in the event of a defined Corporate Transaction while such Note remains outstanding, into shares of the Company&#x2019;s Series
A-2 Preferred Stock at a conversion price equal to $</ONMD:EquityFinancingDescription>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="AsOf2022-11-11_us-gaap_RelatedPartyMember_custom_SeriesATwoPreferredStockMember_custom_ConvertiblePromissoryNotesMember"
      decimals="INF"
      id="Fact000848"
      unitRef="USDPShares">2.50</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="AsOf2022-11-11_us-gaap_RelatedPartyMember_custom_SeriesATwoPreferredStockMember_custom_ConvertiblePromissoryNotesMember"
      decimals="INF"
      id="Fact000849"
      unitRef="USDPShares">2.50</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:ConvertibleNotesPayable
      contextRef="AsOf2019-11-30_us-gaap_RelatedPartyMember_custom_ConvertiblePromissoryNotesMember"
      decimals="0"
      id="Fact000850"
      unitRef="USD">1500000</us-gaap:ConvertibleNotesPayable>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2022-12-31_custom_ConvertiblePromissoryNotesMember"
      decimals="-5"
      id="Fact000851"
      unitRef="USD">9900000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000852"
      unitRef="USD">690771</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:ConvertibleNotesPayable
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000853"
      unitRef="USD">5140000</us-gaap:ConvertibleNotesPayable>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact000854"
      unitRef="Shares">2056000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ConvertibleNotesPayable
      contextRef="AsOf2023-11-30_us-gaap_RelatedPartyMember_custom_DataKnightsAcquisitionCorpMember"
      decimals="-5"
      id="Fact000855"
      unitRef="USD">15400000</us-gaap:ConvertibleNotesPayable>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2023-11-30_us-gaap_RelatedPartyMember_custom_DataKnightsAcquisitionCorpMember"
      decimals="INF"
      id="Fact000856"
      unitRef="USDPShares">2.50</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000858">&lt;p id="xdx_80B_eus-gaap--DebtDisclosureTextBlock_zoh1A7v8pgNb" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;8.
&lt;span id="xdx_823_z8QgZaljwfyc"&gt;Canadian Emergency Business Loan Act (CEBA)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
December 2020, the Company applied for and received a $&lt;span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOfUnsecuredDebt_c20201201__20201231__us-gaap--DebtInstrumentAxis__custom--CEBALoanMember_z9FBa1FDxqQ1"&gt;44,673
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;USD CEBA loan. The loan was provided by
the Government of Canada to provide capital to organizations to see them through the current challenges and better position them to return
to providing services and creating employment. The loan is unsecured. The loan was interest free through December 31, 2023. If the loan
is paid back by January 18, 2024, $&lt;span id="xdx_90B_eus-gaap--DebtInstrumentDecreaseForgiveness_c20200101__20201231__us-gaap--DebtInstrumentAxis__custom--CEBALoanMember_zHgzJPz57Uf1"&gt;14,742
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;of the loan will be forgiven. If the loan
is not paid back by January 18, 2023, the full $&lt;span id="xdx_90F_eus-gaap--DebtConversionOriginalDebtAmount1_c20200101__20201231__us-gaap--DebtInstrumentAxis__custom--CEBALoanMember_zezZ4lDkBQNf"&gt;44,673
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;loan will be converted to loan repayable
over &lt;span id="xdx_90A_eus-gaap--DebtInstrumentTerm_dc_c20200101__20201231__us-gaap--DebtInstrumentAxis__custom--CEBALoanMember_z527KNug8vY8"&gt;three
years&lt;/span&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;with a &lt;span id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20201231__us-gaap--DebtInstrumentAxis__custom--CEBALoanMember_z3pHMKrhHD42"&gt;5%
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;interest rate. The loan was paid back
prior January 18, 2024. At December 31, 2023 the loans is classified as Canada Emergency Business Loan Act under Current Liabilities
on the Consolidated Balance Sheet.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounted for the loan as debt in accordance with FASB Accounting Standards Codification 470 Debt and accrued interest in accordance
with the interest method under FASB ASC 835-30.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ProceedsFromIssuanceOfUnsecuredDebt
      contextRef="From2020-12-012020-12-31_custom_CEBALoanMember"
      decimals="0"
      id="Fact000859"
      unitRef="USD">44673</us-gaap:ProceedsFromIssuanceOfUnsecuredDebt>
    <us-gaap:DebtInstrumentDecreaseForgiveness
      contextRef="From2020-01-012020-12-31_custom_CEBALoanMember"
      decimals="0"
      id="Fact000860"
      unitRef="USD">14742</us-gaap:DebtInstrumentDecreaseForgiveness>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="From2020-01-012020-12-31_custom_CEBALoanMember"
      decimals="0"
      id="Fact000861"
      unitRef="USD">44673</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:DebtInstrumentTerm
      contextRef="From2020-01-012020-12-31_custom_CEBALoanMember"
      id="Fact000862">P3Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2020-12-31_custom_CEBALoanMember"
      decimals="INF"
      id="Fact000863"
      unitRef="Pure">0.05</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000865">&lt;p id="xdx_802_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zwIUK3ZPhU96" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;9.
&lt;span id="xdx_82C_zMJnazzhoipg"&gt;Shareholders&#x2019; Equity&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Series
A-2 Preferred Stock&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s previously issued and outstanding Series A-2 preferred stock included a $&lt;span id="xdx_909_eus-gaap--SharesIssuedPricePerShare_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesATwoPreferredStockMember_zq4f8awROcvj"&gt;0.15
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per share annual noncumulative dividend
when and if declared by the board of directors. &lt;span id="xdx_90A_eus-gaap--DividendsPreferredStock_do_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesATwoPreferredStockMember_zfb2qGerALUh"&gt;No
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;dividends were declared in the years ended
December 31, 2023 or December 31 2022. The Series A-2 preferred stock also includes a liquidation preference of 1.25 times the original
issue price plus any declared but unpaid dividends upon the liquidation, dissolution, merger or sale of substantially all the assets
of the Company and have a preference upon liquidation over Series A-1 preferred stock and common stock. Each share of Series A-2 preferred
stock may be converted into equal shares of common stock at the option of the holder at any time. In addition, the Series A-2 preferred
stock shares are automatically convertible into common shares upon the sale of shares of common stock to the public at the then applicable
conversion price in a firm commitment underwritten public offering pursuant to an effective registration statement under the Securities
Act of 1933, as amended, resulting in at least $&lt;span id="xdx_900_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_pn5n6_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesATwoPreferredStockMember_z2VdHHmRJnT"&gt;20
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million in proceeds, net of underwriting
discounts and commissions. Each share of Series A-2 preferred stock has voting rights equal to the number of shares of common stock then
issuable upon conversion of such share of preferred stock. The Company is obligated to redeem shares of Series A-2 Preferred Stock in
the occurrence of a Deemed Liquidation Event unless a majority of the holders of Series A-2 Preferred Stock and a majority of the Series
A-1 Preferred Stock consent otherwise.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2023, the Business Combination between Data Knights and the Company triggered the &lt;span id="xdx_90A_eus-gaap--ConvertiblePreferredStockTermsOfConversion_c20230101__20231231_zq6xgWTwPSXg"&gt;Series
A-2 Preferred Stock and Series A-1 Preferred Stock convert 1-1 to commons stock&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Series
A-1 Preferred Stock&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s previously issued and outstanding Series A-1 preferred stock included a $&lt;span id="xdx_909_eus-gaap--SharesIssuedPricePerShare_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember_zPFWdKqH8CR2"&gt;0.15
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per share annual noncumulative dividend
when and if declared by the board of directors. &lt;span id="xdx_905_eus-gaap--DividendsPreferredStock_do_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember_zcOAGK1oCteb"&gt;No
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;dividends were declared in the years ended
December 31, 2023 or December 31 2022. The Series A-1 preferred stock also includes a liquidation preference of 1.25 times the original
issue price plus any declared but unpaid dividends upon the liquidation, dissolution, merger or sale of substantially all the assets
of the Company and have a preference upon liquidation over common stock. Each share of Series A-1 preferred stock may be converted into
equal shares of common stock at the option of the holder at any time. In addition, the Series A-1 preferred stock shares are automatically
convertible into common shares upon the sale of shares of common stock to the public at the then applicable conversion price in a firm
commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended,
resulting in at least $&lt;span id="xdx_909_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_pn5n6_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember_ziTTDyaYppZj"&gt;20
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million in proceeds, net of underwriting
discounts and commissions. Each share of Series A-1 preferred stock has voting rights equal to the number of shares of common stock then
issuable upon conversion of such share of preferred stock. The Company is obligated to redeem shares of Series A-1 Preferred Stock in
the occurrence of a Deemed Liquidation Event unless a majority of the holders of Series A-1 Preferred Stock consent otherwise.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2023, the Business Combination between Data Knights and the Company triggered the &lt;span id="xdx_90A_eus-gaap--ConvertiblePreferredStockTermsOfConversion_c20230101__20231231_zPmigUwb7mv3"&gt;Series
A-2 Preferred Stock and Series A-1 Preferred Stock convert 1-1 to commons stock&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Common
Stock&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
2023, in connection with services performed by the Board of Directors common shares of &lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230101__20231231__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_zUbEE9Udi2H9"&gt;100,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(&lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20220101__20221231__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_zvCTDm0x78h6"&gt;100,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-
2022) were issued at $&lt;span id="xdx_902_eus-gaap--SharePrice_iI_c20231231__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_zoQnKnHOJV64"&gt;1.00
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per share. These were expensed as general
and administrative expenses in the Statement of Operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_893_eus-gaap--ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_z57uq3swwTu3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;The
table below summarizes the Common Stock activities during the year ended December 31, 2023.&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span id="xdx_8B9_z64bu48q1ymf" style="font: normal 10pt Times New Roman, Times, Serif"&gt;Schedule
of Common Stock Activities&lt;/span&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 1in"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_z2msICVrt1Qb" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;Common
    Stock&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--SharesOutstanding_iS_zLHH8ANuCOvi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 80%"&gt;Balances, December 31, 2022&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;4,550,166&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--SharesOutstanding_iS_zW2yvdRyeAgd" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;Balance&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;4,550,166&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_z2wlaGxg9Xb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Preferred Stock to Common Stock&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;7,057,797&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--StockIssuedDuringPeriodSharesConvertibleNotesToCommonStock_zJwjfDx64uRl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Convertible Notes to Common Stock&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;6,177,229&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--StockIssuedDuringPeriodSharesStockOptionsToCommonStock_z3uhYW1PO4Ql" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Stock Options to Common Stock&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;612,670&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--StockIssuedDuringPeriodSharesConvertingOfWarrantsToCommonStock_z3UmWOkuvHcd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Converting of Warrants to Common Stock&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;3,859,464&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--StockIssuedDuringPeriodSharesOther_zuvjfYqYrP3e" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Private OneMedNet to ONMD Public Shares&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(2,257,326&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--StockIssuedDuringPeriodSharesConvertingDataKnightsCommonShares_zO0iuFy9if3i" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Converting Data Knights Common Stock (A and B) to ONMD Public Shares&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;3,460,275&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_z2eiIknVjv5e" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;Issuance Public Shares&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;111,957&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--SharesOutstanding_iE_zyOXDTAsVnxi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;Balances, December 31, 2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;23,572,232&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--SharesOutstanding_iE_zOLEX9Io8sth" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;Balance&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;23,572,232&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A0_z6jRMRei6Rl1" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2023-12-31_custom_SeriesATwoPreferredStockMember"
      decimals="INF"
      id="Fact000866"
      unitRef="USDPShares">0.15</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="From2023-01-012023-12-31_custom_SeriesATwoPreferredStockMember"
      decimals="-5"
      id="Fact000868"
      unitRef="USD">20000000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:ConvertiblePreferredStockTermsOfConversion contextRef="From2023-01-01to2023-12-31" id="Fact000869">Series
A-2 Preferred Stock and Series A-1 Preferred Stock convert 1-1 to commons stock</us-gaap:ConvertiblePreferredStockTermsOfConversion>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2023-12-31_custom_SeriesAOnePreferredStockMember"
      decimals="INF"
      id="Fact000870"
      unitRef="USDPShares">0.15</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="From2023-01-012023-12-31_custom_SeriesAOnePreferredStockMember"
      decimals="-5"
      id="Fact000872"
      unitRef="USD">20000000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:ConvertiblePreferredStockTermsOfConversion contextRef="From2023-01-01to2023-12-31" id="Fact000873">Series
A-2 Preferred Stock and Series A-1 Preferred Stock convert 1-1 to commons stock</us-gaap:ConvertiblePreferredStockTermsOfConversion>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2023-01-012023-12-31_custom_BoardOfDirectorsMember"
      decimals="INF"
      id="Fact000874"
      unitRef="Shares">100000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2022-01-012022-12-31_custom_BoardOfDirectorsMember"
      decimals="INF"
      id="Fact000875"
      unitRef="Shares">100000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:SharePrice
      contextRef="AsOf2023-12-31_custom_BoardOfDirectorsMember"
      decimals="INF"
      id="Fact000876"
      unitRef="USDPShares">1.00</us-gaap:SharePrice>
    <us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000878">&lt;p id="xdx_893_eus-gaap--ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_z57uq3swwTu3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;The
table below summarizes the Common Stock activities during the year ended December 31, 2023.&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span id="xdx_8B9_z64bu48q1ymf" style="font: normal 10pt Times New Roman, Times, Serif"&gt;Schedule
of Common Stock Activities&lt;/span&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 1in"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_z2msICVrt1Qb" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;Common
    Stock&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--SharesOutstanding_iS_zLHH8ANuCOvi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 80%"&gt;Balances, December 31, 2022&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;4,550,166&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--SharesOutstanding_iS_zW2yvdRyeAgd" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;Balance&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;4,550,166&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_z2wlaGxg9Xb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Preferred Stock to Common Stock&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;7,057,797&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--StockIssuedDuringPeriodSharesConvertibleNotesToCommonStock_zJwjfDx64uRl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Convertible Notes to Common Stock&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;6,177,229&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--StockIssuedDuringPeriodSharesStockOptionsToCommonStock_z3uhYW1PO4Ql" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Stock Options to Common Stock&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;612,670&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--StockIssuedDuringPeriodSharesConvertingOfWarrantsToCommonStock_z3UmWOkuvHcd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Converting of Warrants to Common Stock&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;3,859,464&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--StockIssuedDuringPeriodSharesOther_zuvjfYqYrP3e" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Private OneMedNet to ONMD Public Shares&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(2,257,326&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--StockIssuedDuringPeriodSharesConvertingDataKnightsCommonShares_zO0iuFy9if3i" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Converting Data Knights Common Stock (A and B) to ONMD Public Shares&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;3,460,275&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_z2eiIknVjv5e" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;Issuance Public Shares&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;111,957&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--SharesOutstanding_iE_zyOXDTAsVnxi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;Balances, December 31, 2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;23,572,232&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--SharesOutstanding_iE_zOLEX9Io8sth" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;Balance&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;23,572,232&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember_srt_BoardOfDirectorsChairmanMember"
      decimals="INF"
      id="Fact000880"
      unitRef="Shares">4550166</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember_srt_BoardOfDirectorsChairmanMember"
      decimals="INF"
      id="Fact000882"
      unitRef="Shares">4550166</us-gaap:SharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember_srt_BoardOfDirectorsChairmanMember"
      decimals="INF"
      id="Fact000884"
      unitRef="Shares">7057797</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <ONMD:StockIssuedDuringPeriodSharesConvertibleNotesToCommonStock
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember_srt_BoardOfDirectorsChairmanMember"
      decimals="INF"
      id="Fact000886"
      unitRef="Shares">6177229</ONMD:StockIssuedDuringPeriodSharesConvertibleNotesToCommonStock>
    <ONMD:StockIssuedDuringPeriodSharesStockOptionsToCommonStock
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember_srt_BoardOfDirectorsChairmanMember"
      decimals="INF"
      id="Fact000888"
      unitRef="Shares">612670</ONMD:StockIssuedDuringPeriodSharesStockOptionsToCommonStock>
    <ONMD:StockIssuedDuringPeriodSharesConvertingOfWarrantsToCommonStock
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember_srt_BoardOfDirectorsChairmanMember"
      decimals="INF"
      id="Fact000890"
      unitRef="Shares">3859464</ONMD:StockIssuedDuringPeriodSharesConvertingOfWarrantsToCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember_srt_BoardOfDirectorsChairmanMember"
      decimals="INF"
      id="Fact000892"
      unitRef="Shares">-2257326</us-gaap:StockIssuedDuringPeriodSharesOther>
    <ONMD:StockIssuedDuringPeriodSharesConvertingDataKnightsCommonShares
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember_srt_BoardOfDirectorsChairmanMember"
      decimals="INF"
      id="Fact000894"
      unitRef="Shares">3460275</ONMD:StockIssuedDuringPeriodSharesConvertingDataKnightsCommonShares>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember_srt_BoardOfDirectorsChairmanMember"
      decimals="INF"
      id="Fact000896"
      unitRef="Shares">111957</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember_srt_BoardOfDirectorsChairmanMember"
      decimals="INF"
      id="Fact000898"
      unitRef="Shares">23572232</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember_srt_BoardOfDirectorsChairmanMember"
      decimals="INF"
      id="Fact000900"
      unitRef="Shares">23572232</us-gaap:SharesOutstanding>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000902">&lt;p id="xdx_806_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zAjaUuhHpcC9" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;10.
&lt;span id="xdx_828_zssYNJtF6ti3"&gt;Stock Options&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
2020, the Company adopted a new equity incentive plan (the Plan), which provides for the granting of incentive and nonqualified stock
options to employees, directors, and consultants. As of December 31, 2020, the Company has reserved &lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20200101__20201231__srt--TitleOfIndividualAxis__custom--EmployeesDirectorsAndConsultantsMember__us-gaap--PlanNameAxis__custom--NewEquityIncentivePlanMember_zOPY3Epoom39"&gt;3,000,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of common stock under the Plan.
The Company believes that such awards better align the interests of its employees with those of its stockholders. Option awards are generally
granted with an exercise price equal to the fair market value of the Company&#x2019;s stock at the date of grant; those option awards
generally vest with a range of one
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;to &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc_c20200101__20201231__srt--TitleOfIndividualAxis__custom--EmployeesDirectorsAndConsultantsMember__us-gaap--PlanNameAxis__custom--NewEquityIncentivePlanMember__srt--RangeAxis__srt--MaximumMember_zana3dh21Z82"&gt;four
years&lt;/span&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;of continuous service and have ten-year
contractual terms. As there is no public data available for the share price valuation, the Company considers the Fair Market Value of
$&lt;span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_c20201231__srt--TitleOfIndividualAxis__custom--EmployeesDirectorsAndConsultantsMember__us-gaap--PlanNameAxis__custom--NewEquityIncentivePlanMember_zuowjumEyy9k"&gt;1
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;to be on the conservative side and similar
to the exercise price. Certain option awards provide for accelerated vesting if there is a change in control, as defined in the Plan.
The Plan also permits the granting of restricted stock and other stock-based awards. Unexercised options are cancelled upon termination
of employment and become available under the Plan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zOOwKvbrQpb1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Information
with respect to options outstanding is summarized as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span id="xdx_8B8_zQRZFYMZHvh1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Schedule
of Options Outstanding&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Options Outstanding&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Weighted- Average Exercise Price&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Aggregate Intrinsic Value&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 52%"&gt;Outstanding as of December 31, 2020&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210101__20211231_zadM3myKcRSg" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Options outstanding, begining balance"&gt;1,995,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231_zP106pErband" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Weighted average exercise price, begining balance"&gt;1.00&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20210101__20211231_z121yn1pvKH9" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Aggregate Intrinsic value, begining balance"&gt;1,995,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Granted - under the Plan&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210101__20211231_zXHo6mISQpKb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options, Granted - under the Plan"&gt;25,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Exercised&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20210101__20211231_zyywVTg5nGIa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options, Granted - under the Plan"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0917"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;Cancelled&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20210101__20211231_zSn9l0NAWEk4" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options, cancelled"&gt;(1,072,816&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Outstanding as of December 31, 2021&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220101__20221231_zaCQmCo4rgci" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options outstanding, ending balance"&gt;947,184&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210101__20211231_zXDcIpQgUsAi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, ending balance"&gt;1.00&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20210101__20211231_zhXfMFmK7TH1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic value, ending balance"&gt;947,184&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Granted - under the Plan&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231_z3d4RVyP48Li" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options, Granted - under the Plan"&gt;577,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Exercised&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20220101__20221231_z3Cg4GHDeiCb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options, Granted - under the Plan"&gt;(7,500&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;Cancelled&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20220101__20221231_z6qJl1wVmuyk" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options, cancelled"&gt;(485,684&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Outstanding as of December 31, 2022&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20220101__20221231_zS1IVj8CRw3j" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options outstanding, ending balance"&gt;1,031,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231_zX1i6YPg8JM9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, ending balance"&gt;1.00&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20220101__20221231_zM05DsMkmdHa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic value, ending balance"&gt;1,031,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;Options exercisable as of December 31, 2022&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20220101__20221231_ztwl4L855yl8" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options exercisable"&gt;567,581&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20220101__20221231_zYrTENj4cnQg" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, exercisable"&gt;1.00&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_c20220101__20221231_zj3Qf8Lulmh7" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic value, exercisable"&gt;567,581&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_z8EfnFrKpN6b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2022 and 2021, there were &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20221231_zCusyY0Eadkf"&gt;1,031,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;and &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20211231_z60y0LjYvs75"&gt;947,184
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;common stock options outstanding with
a weighted average remaining contractual life of &lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231_zTZjpFpO9Ie2"&gt;7.11
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;years and &lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231_zCiL8vS0y486"&gt;6.01
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;years, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2022 and 2021, there were &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20221231_zQD82gnRuEM2"&gt;567,581
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;and &lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20211231_zX6RDBNpqYZi"&gt;723,431
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;common stock options exercisable at a
weighted average remaining contractual life of &lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231_zCQqssRftxz1"&gt;5.56
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;years and &lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20210101__20211231_zoakaW2uUSNa"&gt;5.27
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;years, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 7, 2023, the Company issued shares of common stock for &lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_pid_c20231107_zC2U5iJKuiKl"&gt;692,153
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;vested options less an exercise price
of $&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_pid_c20231107_zIYsl5WuH4K1"&gt;1.00&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;At
the Special Meeting &lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;held on October 17, 2023&lt;span style="background-color: white"&gt;,
Data Knights shareholders considered and approved the OneMedNet Corporation 2022 Equity Incentive Plan (the &#x201c;Plan&#x201d;) and reserved
an amount of shares of &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_pid_c20231017__20231017_zIGkitfX4Hnb"&gt;common
stock equal to 10% of the number of shares of common stock of OneMedNet following the Business Combination for issuance thereunder&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;.
The Plan was approved by the OneMedNet pre-Closing board of directors on October 17, 2023. The Plan became effective immediately upon
the Closing of the Business Combination.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;Black
Scholes Assumptions&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
determination of the fair value of stock options using an option valuation model is affected by the Company&#x2019;s stock price valuation,
as well as assumptions regarding a number of complex and subjective variables. The volatility assumption is based on volatilities of
similar companies over a period of time equal to the expected term of the stock options. The volatilities of similar companies are used
in conjunction with the Company&#x2019;s historical volatility because of the lack of sufficient relevant history for the Company&#x2019;s
common stock equal to the expected term. The expected term of the employee stock options represents the weighted average period for which
the stock options are expected to remain outstanding. The expected term assumption is estimated based primarily on the options&#x2019;
vesting terms and remaining contractual life and employees&#x2019; expected exercise and post- vesting employment termination behavior.
The risk-free rate for periods within the contractual life of the option is based on the U.S. Treasury yield curve in effect at the time
of grant. The dividend yield assumption is based on the expectation of no future dividend payouts by the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_898_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zay0AEYnB9Ej" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value of the Company&#x2019;s previous stock options was estimated assuming no expected dividends and the following weighted average
assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"&gt;&lt;span id="xdx_8B6_zJo0ngyYGTwc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Schedule
of Fair Value of Stock Options&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;Expected life in years&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span id="xdx_901_ecustom--EquitySecuritiesFvNiMeasurementTerm_dtY_c20220101__20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zoolrrCQTN9h"&gt;5.89&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span id="xdx_905_ecustom--EquitySecuritiesFvNiMeasurementTerm_dtY_c20210101__20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zyneyj3ZuwJ"&gt;6.08&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z9y58LCpnxXh"&gt;0.55&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zWq5I7FYdBS2"&gt;0.49&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Expected dividend yield&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z69uRpV0a13b"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z4ohD9teCjj4"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zY9O0q7FP8Pk"&gt;32&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zSQ9xugXtAYb"&gt;60&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_zPAh7czH2RHd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
total expense recognized for share-based payments was $&lt;span id="xdx_903_eus-gaap--AllocatedShareBasedCompensationExpense_c20220101__20221231_zs5NCE7xjYwb"&gt;45,584
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;and $&lt;span id="xdx_906_eus-gaap--AllocatedShareBasedCompensationExpense_c20210101__20211231_zh4A4jq44eFh"&gt;47,071
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;for the years ended December 31, 2022
and 2021, respectively. These costs are included in the statements of operations. As of December 31, 2022, there was $&lt;span id="xdx_909_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_c20221231_z0GkDmV9WgF7"&gt;75,987
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;of unrecognized compensation costs related
to stock option grants which will be recognized over the next four years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
2023, the Company issued common stock to employees and extinguished all outstanding stock options. The &lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zyhahePb5iy"&gt;612,720
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares outstanding were recorded as stock
expense in the Consolidated Statement of Operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2020-01-012020-12-31_custom_EmployeesDirectorsAndConsultantsMember_custom_NewEquityIncentivePlanMember"
      decimals="INF"
      id="Fact000903"
      unitRef="Shares">3000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="From2020-01-012020-12-31_custom_EmployeesDirectorsAndConsultantsMember_custom_NewEquityIncentivePlanMember_srt_MaximumMember"
      id="Fact000904">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2020-12-31_custom_EmployeesDirectorsAndConsultantsMember_custom_NewEquityIncentivePlanMember"
      decimals="INF"
      id="Fact000905"
      unitRef="USDPShares">1</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000907">&lt;p id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zOOwKvbrQpb1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Information
with respect to options outstanding is summarized as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span id="xdx_8B8_zQRZFYMZHvh1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Schedule
of Options Outstanding&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Options Outstanding&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Weighted- Average Exercise Price&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Aggregate Intrinsic Value&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 52%"&gt;Outstanding as of December 31, 2020&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210101__20211231_zadM3myKcRSg" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Options outstanding, begining balance"&gt;1,995,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231_zP106pErband" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Weighted average exercise price, begining balance"&gt;1.00&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20210101__20211231_z121yn1pvKH9" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Aggregate Intrinsic value, begining balance"&gt;1,995,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Granted - under the Plan&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210101__20211231_zXHo6mISQpKb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options, Granted - under the Plan"&gt;25,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Exercised&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20210101__20211231_zyywVTg5nGIa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options, Granted - under the Plan"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0917"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;Cancelled&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20210101__20211231_zSn9l0NAWEk4" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options, cancelled"&gt;(1,072,816&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Outstanding as of December 31, 2021&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220101__20221231_zaCQmCo4rgci" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options outstanding, ending balance"&gt;947,184&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210101__20211231_zXDcIpQgUsAi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, ending balance"&gt;1.00&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20210101__20211231_zhXfMFmK7TH1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic value, ending balance"&gt;947,184&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Granted - under the Plan&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231_z3d4RVyP48Li" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options, Granted - under the Plan"&gt;577,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Exercised&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20220101__20221231_z3Cg4GHDeiCb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options, Granted - under the Plan"&gt;(7,500&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;Cancelled&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20220101__20221231_z6qJl1wVmuyk" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options, cancelled"&gt;(485,684&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Outstanding as of December 31, 2022&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20220101__20221231_zS1IVj8CRw3j" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options outstanding, ending balance"&gt;1,031,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231_zX1i6YPg8JM9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, ending balance"&gt;1.00&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20220101__20221231_zM05DsMkmdHa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic value, ending balance"&gt;1,031,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;Options exercisable as of December 31, 2022&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20220101__20221231_ztwl4L855yl8" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options exercisable"&gt;567,581&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20220101__20221231_zYrTENj4cnQg" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, exercisable"&gt;1.00&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_c20220101__20221231_zj3Qf8Lulmh7" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic value, exercisable"&gt;567,581&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2020-12-31"
      decimals="INF"
      id="Fact000909"
      unitRef="Shares">1995000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-12-31"
      decimals="INF"
      id="Fact000911"
      unitRef="USDPShares">1.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="Fact000913"
      unitRef="USD">1995000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      id="Fact000915"
      unitRef="Shares">25000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      id="Fact000919"
      unitRef="Shares">1072816</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2021-12-31"
      decimals="INF"
      id="Fact000921"
      unitRef="Shares">947184</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31"
      decimals="INF"
      id="Fact000923"
      unitRef="USDPShares">1.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact000925"
      unitRef="USD">947184</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact000927"
      unitRef="Shares">577000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact000929"
      unitRef="Shares">7500</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact000931"
      unitRef="Shares">485684</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact000933"
      unitRef="Shares">1031000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact000935"
      unitRef="USDPShares">1.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000937"
      unitRef="USD">1031000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact000939"
      unitRef="Shares">567581</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact000941"
      unitRef="USDPShares">1.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000943"
      unitRef="USD">567581</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact000944"
      unitRef="Shares">1031000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2021-12-31"
      decimals="INF"
      id="Fact000945"
      unitRef="Shares">947184</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2022-01-012022-12-31" id="Fact000946">P7Y1M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2021-01-012021-12-31" id="Fact000947">P6Y3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact000948"
      unitRef="Shares">567581</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2021-12-31"
      decimals="INF"
      id="Fact000949"
      unitRef="Shares">723431</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2022-01-012022-12-31" id="Fact000950">P5Y6M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2021-01-012021-12-31" id="Fact000951">P5Y3M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="AsOf2023-11-07"
      decimals="INF"
      id="Fact000952"
      unitRef="Shares">692153</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-11-07"
      decimals="INF"
      id="Fact000953"
      unitRef="USDPShares">1.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription contextRef="From2023-10-172023-10-17" id="Fact000954">common
stock equal to 10% of the number of shares of common stock of OneMedNet following the Business Combination for issuance thereunder</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000956">&lt;p id="xdx_898_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zay0AEYnB9Ej" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value of the Company&#x2019;s previous stock options was estimated assuming no expected dividends and the following weighted average
assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"&gt;&lt;span id="xdx_8B6_zJo0ngyYGTwc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Schedule
of Fair Value of Stock Options&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;Expected life in years&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span id="xdx_901_ecustom--EquitySecuritiesFvNiMeasurementTerm_dtY_c20220101__20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zoolrrCQTN9h"&gt;5.89&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span id="xdx_905_ecustom--EquitySecuritiesFvNiMeasurementTerm_dtY_c20210101__20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zyneyj3ZuwJ"&gt;6.08&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z9y58LCpnxXh"&gt;0.55&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zWq5I7FYdBS2"&gt;0.49&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Expected dividend yield&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z69uRpV0a13b"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z4ohD9teCjj4"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zY9O0q7FP8Pk"&gt;32&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zSQ9xugXtAYb"&gt;60&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <ONMD:EquitySecuritiesFvNiMeasurementTerm
      contextRef="From2022-01-012022-12-31_us-gaap_MeasurementInputExpectedTermMember"
      id="Fact000957">P5Y10M20D</ONMD:EquitySecuritiesFvNiMeasurementTerm>
    <ONMD:EquitySecuritiesFvNiMeasurementTerm
      contextRef="From2021-01-012021-12-31_us-gaap_MeasurementInputExpectedTermMember"
      id="Fact000958">P6Y29D</ONMD:EquitySecuritiesFvNiMeasurementTerm>
    <us-gaap:EquitySecuritiesFvNiMeasurementInput
      contextRef="AsOf2022-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember"
      decimals="INF"
      id="Fact000959"
      unitRef="Pure">0.55</us-gaap:EquitySecuritiesFvNiMeasurementInput>
    <us-gaap:EquitySecuritiesFvNiMeasurementInput
      contextRef="AsOf2021-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember"
      decimals="INF"
      id="Fact000960"
      unitRef="Pure">0.49</us-gaap:EquitySecuritiesFvNiMeasurementInput>
    <us-gaap:EquitySecuritiesFvNiMeasurementInput
      contextRef="AsOf2022-12-31_us-gaap_MeasurementInputExpectedDividendRateMember"
      decimals="INF"
      id="Fact000961"
      unitRef="Pure">0.00</us-gaap:EquitySecuritiesFvNiMeasurementInput>
    <us-gaap:EquitySecuritiesFvNiMeasurementInput
      contextRef="AsOf2021-12-31_us-gaap_MeasurementInputExpectedDividendRateMember"
      decimals="INF"
      id="Fact000962"
      unitRef="Pure">0.00</us-gaap:EquitySecuritiesFvNiMeasurementInput>
    <us-gaap:EquitySecuritiesFvNiMeasurementInput
      contextRef="AsOf2022-12-31_us-gaap_MeasurementInputPriceVolatilityMember"
      decimals="INF"
      id="Fact000963"
      unitRef="Pure">32</us-gaap:EquitySecuritiesFvNiMeasurementInput>
    <us-gaap:EquitySecuritiesFvNiMeasurementInput
      contextRef="AsOf2021-12-31_us-gaap_MeasurementInputPriceVolatilityMember"
      decimals="INF"
      id="Fact000964"
      unitRef="Pure">60</us-gaap:EquitySecuritiesFvNiMeasurementInput>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000965"
      unitRef="USD">45584</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      id="Fact000966"
      unitRef="USD">47071</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000967"
      unitRef="USD">75987</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact000968"
      unitRef="Shares">612720</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <ONMD:StockWarrantsDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000970">&lt;p id="xdx_806_ecustom--StockWarrantsDisclosureTextBlock_z8PGkPv4zKwa" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;11.
&lt;span id="xdx_82B_zW0uKdrIgtgh"&gt;Stock Warrants&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
2021, there were &lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20211231_zVMpckQCE4Bf"&gt;174,102
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;OneMedNet Corporation outstanding common
stock warrants issued for service at a weighted average exercise price of $&lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20211231_zc6DmaF0LKM7"&gt;0.10&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;.
In 2022 for the exercise price of $&lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231_zgf5jJhyAZkb"&gt;1.00&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;,
the OneMedNet Corporation issued &lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__us-gaap--AwardTypeAxis__custom--TwentyTwentyOneServiceMember_zx0H5C9JD5ok"&gt;145,746
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;warrants for 2021 service and &lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__us-gaap--AwardTypeAxis__custom--TwentyTwentyTwoServiceMember_zF9lMoCrpHyc"&gt;294,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;warrants for 2022 service, &lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--ConvertiableNotesMember_zo7PsnZa1bXl"&gt;2,056,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;in warrants were issued attached to convertible
notes. The Company expensed $&lt;span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfWarrants_c20220101__20221231_ziimEIM50841"&gt;1,346,288&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;in 2022 in relation to the issuance of the Warrants. In 2023
for the exercise price of $&lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231_zwObMnOHBCT1"&gt;1.00&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;,
the OneMedNet issued &lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--ConvertiableNotesMember_zbfmaPMF2PY9"&gt;1,670,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;in warrants attached to convertible notes.
OneMedNet Corporation converted &lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantOneMember_zYX8MxovCp9d"&gt;4,165,746
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;warrants outstanding to common stock at
an exercise price of $&lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantOneMember_zDVAXmd1vmK9"&gt;1.00
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;and converted &lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zy008UtCDFD9"&gt;174,102
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;warrants outstanding to common stock at
an exercise price of $&lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zGTMTgjKR4f3"&gt;0.10&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2023 and December 31, 2022, the Company had &lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--PubliclyTradedWarrantsMember_zlBN1dUU6NMh"&gt;11,500,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;of publicly traded warrants. The warrants
trade on the Nasdaq had closing price of $&lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PubliclyTradedWarrantsMember_zYDKyHofnc49"&gt;.0149
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;and $&lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--PubliclyTradedWarrantsMember_z3715RMmux9c"&gt;.0400
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;at December 31, 2023 and December 31,
2022 respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2023 and December 31, 2022, the Company had &lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivateWarrantsMember_zGRZgpppUqL1"&gt;681,019
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;and &lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivateWarrantsMember_zoyczQ9iZHv2"&gt;585,275
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;of private warrants outstanding. These
warrants are classified as liability on the Consolidated Balance Sheet. Changes in the warrant liabilities are recorded in the Statement
of Operations. As of December 31, 2023 and December 31, 2022, the warrant liabilities were $&lt;span id="xdx_907_eus-gaap--OtherLiabilities_iI_pn5n6_c20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_ztu26qdbHEN6"&gt;0.6
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million and $&lt;span id="xdx_906_eus-gaap--OtherLiabilities_iI_pn5n6_c20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z5jxlvTWlcW8"&gt;0.4
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</ONMD:StockWarrantsDisclosureTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2021-12-31"
      decimals="INF"
      id="Fact000971"
      unitRef="Shares">174102</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2021-12-31"
      decimals="INF"
      id="Fact000972"
      unitRef="USDPShares">0.10</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact000973"
      unitRef="USDPShares">1.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2022-12-31_custom_TwentyTwentyOneServiceMember"
      decimals="INF"
      id="Fact000974"
      unitRef="Shares">145746</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2022-12-31_custom_TwentyTwentyTwoServiceMember"
      decimals="INF"
      id="Fact000975"
      unitRef="Shares">294000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2022-12-31_custom_ConvertiableNotesMember"
      decimals="INF"
      id="Fact000976"
      unitRef="Shares">2056000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000977"
      unitRef="USD">1346288</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000978"
      unitRef="USDPShares">1.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-12-31_custom_ConvertiableNotesMember"
      decimals="INF"
      id="Fact000979"
      unitRef="Shares">1670000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2023-12-31_custom_WarrantOneMember"
      decimals="INF"
      id="Fact000980"
      unitRef="Shares">4165746</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-12-31_custom_WarrantOneMember"
      decimals="INF"
      id="Fact000981"
      unitRef="USDPShares">1.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000982"
      unitRef="Shares">174102</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000983"
      unitRef="USDPShares">0.10</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2022-12-31_custom_PubliclyTradedWarrantsMember"
      decimals="INF"
      id="Fact000984"
      unitRef="Shares">11500000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-12-31_custom_PubliclyTradedWarrantsMember"
      decimals="INF"
      id="Fact000985"
      unitRef="USDPShares">0.0149</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-12-31_custom_PubliclyTradedWarrantsMember"
      decimals="INF"
      id="Fact000986"
      unitRef="USDPShares">0.0400</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2023-12-31_custom_PrivateWarrantsMember"
      decimals="INF"
      id="Fact000987"
      unitRef="Shares">681019</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2022-12-31_custom_PrivateWarrantsMember"
      decimals="INF"
      id="Fact000988"
      unitRef="Shares">585275</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:OtherLiabilities
      contextRef="AsOf2023-12-31_us-gaap_WarrantMember"
      decimals="-5"
      id="Fact000989"
      unitRef="USD">600000</us-gaap:OtherLiabilities>
    <us-gaap:OtherLiabilities
      contextRef="AsOf2022-12-31_us-gaap_WarrantMember"
      decimals="-5"
      id="Fact000990"
      unitRef="USD">400000</us-gaap:OtherLiabilities>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000992">&lt;p id="xdx_803_eus-gaap--FairValueDisclosuresTextBlock_zR5YrFIBCSuh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;12.
&lt;span id="xdx_829_zGhU1cTHD9La"&gt;Fair Value Measures&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value measurement accounting standards establish a framework for measuring fair value and expand disclosures about fair value measurements.
The standard does not require any new fair value measurements; rather, it applies to other accounting pronouncements that require or
permit fair value measurements. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability
in the principal or most advantageous market in an orderly transaction between market participants on the measurement date. This pronouncement
also establishes a three-level hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable
inputs when measuring fair value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
valuation hierarchy is based upon the transparency of inputs to the valuation of an asset or liability on the measurement date. The three
levels are defined as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
1&#x2014;inputs to the valuation methodology are quoted prices (unadjusted) for an identical asset or liability in an active market&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
2&#x2014;inputs to the valuation methodology include quoted prices for a similar asset or liability in an active market or model-derived
valuations in which all significant inputs are observable for substantially the full term of the asset or liability&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
3&#x2014;inputs to the valuation methodology are unobservable and significant to the fair value measurement of the asset or liability&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89F_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisTextBlock_zF46BGIp4EFd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents the Company&#x2019;s financial assets measured and recorded at fair value on a recurring basis using the above
input categories as of December 31, 2023 and December 31, 2022 (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span id="xdx_8BF_zdP5BhYaW47c" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Schedule
of Financial Assets&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="30" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Year Ended&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;December 31, 2023&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;December 31, 2022&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;Assets:&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 28%; text-align: left"&gt;Investments held in Trust&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AssetsHeldInTrustCurrent_iI_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByAssetClassAxis__custom--InvestmentsHeldInTrustMember_zEQFhQkyIfN" style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right" title="Investments held in Trust"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0996"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AssetsHeldInTrustCurrent_iI_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByAssetClassAxis__custom--InvestmentsHeldInTrustMember_zLZI52abmujj" style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right" title="Investments held in Trust"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0998"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AssetsHeldInTrustCurrent_iI_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByAssetClassAxis__custom--InvestmentsHeldInTrustMember_zoUYLwzbPZ09" style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right" title="Investments held in Trust"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1000"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AssetsHeldInTrustCurrent_iI_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--InvestmentsHeldInTrustMember_zXBMFEw6Jxej" style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right" title="Investments held in Trust"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1002"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AssetsHeldInTrustCurrent_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByAssetClassAxis__custom--InvestmentsHeldInTrustMember_zvIGgDiejqOl" style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right" title="Investments held in Trust"&gt;29,029,416&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AssetsHeldInTrustCurrent_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByAssetClassAxis__custom--InvestmentsHeldInTrustMember_zcCKPwhX93uc" style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right" title="Investments held in Trust"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1006"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AssetsHeldInTrustCurrent_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByAssetClassAxis__custom--InvestmentsHeldInTrustMember_zvXhmGsmuOr7" style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right" title="Investments held in Trust"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1008"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AssetsHeldInTrustCurrent_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--InvestmentsHeldInTrustMember_zrAoAx5qHUz5" style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right" title="Investments held in Trust"&gt;29,029,416&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Total Assets&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AssetsHeldInTrustCurrent_iI_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zmIvjjLwQdvj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Assets measured and recorded fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1012"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AssetsHeldInTrustCurrent_iI_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zVtsygBqkh22" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Assets measured and recorded fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1014"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AssetsHeldInTrustCurrent_iI_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zUnskt8YvWJ7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Assets measured and recorded fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1016"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AssetsHeldInTrustCurrent_iI_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zYdjoewzQqGk" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Assets measured and recorded fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1018"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AssetsHeldInTrustCurrent_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zJDtEWqItAIb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Assets measured and recorded fair value"&gt;29,029,416&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AssetsHeldInTrustCurrent_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zWmgRXu5v5Aj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Assets measured and recorded fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1022"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AssetsHeldInTrustCurrent_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zMRKEoTtJrC9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Assets measured and recorded fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1024"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AssetsHeldInTrustCurrent_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_ziDpKsUYsNjf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Assets measured and recorded fair value"&gt;29,029,416&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000994">&lt;p id="xdx_89F_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisTextBlock_zF46BGIp4EFd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents the Company&#x2019;s financial assets measured and recorded at fair value on a recurring basis using the above
input categories as of December 31, 2023 and December 31, 2022 (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span id="xdx_8BF_zdP5BhYaW47c" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Schedule
of Financial Assets&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="30" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Year Ended&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;December 31, 2023&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;December 31, 2022&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;Assets:&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 28%; text-align: left"&gt;Investments held in Trust&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AssetsHeldInTrustCurrent_iI_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByAssetClassAxis__custom--InvestmentsHeldInTrustMember_zEQFhQkyIfN" style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right" title="Investments held in Trust"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0996"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AssetsHeldInTrustCurrent_iI_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByAssetClassAxis__custom--InvestmentsHeldInTrustMember_zLZI52abmujj" style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right" title="Investments held in Trust"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0998"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AssetsHeldInTrustCurrent_iI_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByAssetClassAxis__custom--InvestmentsHeldInTrustMember_zoUYLwzbPZ09" style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right" title="Investments held in Trust"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1000"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AssetsHeldInTrustCurrent_iI_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--InvestmentsHeldInTrustMember_zXBMFEw6Jxej" style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right" title="Investments held in Trust"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1002"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AssetsHeldInTrustCurrent_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByAssetClassAxis__custom--InvestmentsHeldInTrustMember_zvIGgDiejqOl" style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right" title="Investments held in Trust"&gt;29,029,416&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AssetsHeldInTrustCurrent_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByAssetClassAxis__custom--InvestmentsHeldInTrustMember_zcCKPwhX93uc" style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right" title="Investments held in Trust"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1006"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AssetsHeldInTrustCurrent_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByAssetClassAxis__custom--InvestmentsHeldInTrustMember_zvXhmGsmuOr7" style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right" title="Investments held in Trust"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1008"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AssetsHeldInTrustCurrent_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--InvestmentsHeldInTrustMember_zrAoAx5qHUz5" style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right" title="Investments held in Trust"&gt;29,029,416&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Total Assets&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AssetsHeldInTrustCurrent_iI_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zmIvjjLwQdvj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Assets measured and recorded fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1012"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AssetsHeldInTrustCurrent_iI_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zVtsygBqkh22" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Assets measured and recorded fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1014"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AssetsHeldInTrustCurrent_iI_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zUnskt8YvWJ7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Assets measured and recorded fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1016"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AssetsHeldInTrustCurrent_iI_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zYdjoewzQqGk" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Assets measured and recorded fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1018"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AssetsHeldInTrustCurrent_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zJDtEWqItAIb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Assets measured and recorded fair value"&gt;29,029,416&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AssetsHeldInTrustCurrent_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zWmgRXu5v5Aj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Assets measured and recorded fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1022"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AssetsHeldInTrustCurrent_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zMRKEoTtJrC9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Assets measured and recorded fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1024"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AssetsHeldInTrustCurrent_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_ziDpKsUYsNjf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Assets measured and recorded fair value"&gt;29,029,416&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:AssetsHeldInTrustCurrent
      contextRef="AsOf2022-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member_custom_InvestmentsHeldInTrustMember"
      decimals="0"
      id="Fact001004"
      unitRef="USD">29029416</us-gaap:AssetsHeldInTrustCurrent>
    <us-gaap:AssetsHeldInTrustCurrent
      contextRef="AsOf2022-12-31_us-gaap_FairValueMeasurementsRecurringMember_custom_InvestmentsHeldInTrustMember"
      decimals="0"
      id="Fact001010"
      unitRef="USD">29029416</us-gaap:AssetsHeldInTrustCurrent>
    <us-gaap:AssetsHeldInTrustCurrent
      contextRef="AsOf2022-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      id="Fact001020"
      unitRef="USD">29029416</us-gaap:AssetsHeldInTrustCurrent>
    <us-gaap:AssetsHeldInTrustCurrent
      contextRef="AsOf2022-12-31_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="Fact001026"
      unitRef="USD">29029416</us-gaap:AssetsHeldInTrustCurrent>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001028">&lt;p id="xdx_805_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zVfbIOnskmzk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;13.
&lt;span id="xdx_829_z8h35XY0FX7d"&gt;Related Party Transactions&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Loan
Extensions&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Data
Knights closed its initial public offering in May 2021 and had 12 months to complete a business combination. Alternatively, the Data
Knight could extend the period up to two times for an additional three months each time with an extension costing $&lt;span id="xdx_908_eus-gaap--ConvertibleNotesPayable_iI_pn5n6_c20231231__us-gaap--BusinessAcquisitionAxis__custom--DataKnightsAcquisitionCorpMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z0CG6fi9Tq7i"&gt;1.2
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million. Data Knights received a total
of $&lt;span id="xdx_90D_ecustom--ExtensionLoan_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__srt--TitleOfIndividualAxis__custom--ManagementAndDirectorsMember_zA1fifUXV765"&gt;300,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;from members of the Company&#x2019;s Management
and Directors. As of December 31, 2023 and December 31, 2022 the total extension loan including interest outstanding was $&lt;span id="xdx_905_ecustom--ExtensionLoan_iI_pn5n6_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zO7QOwXdAHNg"&gt;3.0
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million and $&lt;span id="xdx_90C_ecustom--ExtensionLoan_iI_pn5n6_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zn10KaDPlSY"&gt;2.5
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;PIPE
Convertible Notes and Warrants&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2023, the Company entered into a Securities Purchase Agreement (SPA) in which the Company was required to sell senior secured
convertible notes and warrants to Directors of the Company. The SPA stipulates a collateral security agreement between the Company and
the Directors for punctual payment and performance by the Company on its Obligations to the Directors. The Intellectual Property of the
Company serves as the collateral for the Directors. The senior secured convertible notes and warrants were issued through a private issuance
of a public entity (PIPE) transaction, which is a form of debt and equity offering under an exception in the securities law for qualifying
private placements by issuers of publicly traded securities. The Company received a total of $&lt;span id="xdx_909_eus-gaap--ProceedsFromConvertibleDebt_pn5n6_c20231101__20231130__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zHfl035q52V8"&gt;1.5
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million from the director in exchange
for senior convertible notes of $&lt;span id="xdx_901_eus-gaap--ProceedsFromConvertibleDebt_pn5n6_c20231101__20231130__us-gaap--DebtInstrumentAxis__custom--SeniorConvertibleNotesMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zBMVzI03gT53"&gt;1.6
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million (plus accrued interest of $&lt;span id="xdx_902_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_pn5n6_c20231130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zWkuosgJLyol"&gt;0.1
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million) and &lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20231101__20231130__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z3r0Tli7e5mb"&gt;95,745
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;warrants to acquire common stock. &lt;span id="xdx_909_eus-gaap--DebtInstrumentDescription_c20231101__20231130__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z4uH06NxL485"&gt;The
senior secured notes are convertible to the conversion rate of $&lt;/span&gt;&lt;/span&gt;&lt;span id="xdx_904_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20231130__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zo5virPJQB77" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;10.00
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per
share, and 92.5% of the lowest VWAP for the ten (10) trading days immediately preceding the conversion Date, subject to the floor price
of $1.14 (representing 20% of the closing price on the last trading day before the closing of the Business Combination), or the alternative
conversion ratio the greater of the floor price and the lesser of 80% of the VWAP of the common stock as of the trading day and 80% of
the price computed as the quotient of the sum of the VWAP of the Common Stock for each of the three Trading Days with the lowest VWAP
of the Common Stock during the fifteen consecutive trading day period ending and including the trading day immediately preceding the
delivery or deemed delivery of the applicable Conversion Notice, divided by three&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;.
All such determinations to be appropriately adjusted for any stock dividend, stock split, stock combination, reclassification or similar
transaction that proportionately decreases or increases the common stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
warrants are classified as equity and the total proceeds received from the Directors are allocated based on the relative fair values
of the convertible notes and the warrants at the issued date. The portion allocable to warrants is accounted for as paid-in capital.
The senior secured convertible notes are classified as long term debt in the Consolidated Balance Sheet. The estimate fair value of the
senior secured convertible notes at December 31, 2023 was $&lt;span id="xdx_90A_eus-gaap--SeniorNotesCurrent_iI_pn5n6_c20231231_z2qCGfNbO6v4"&gt;1.2
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:ConvertibleNotesPayable
      contextRef="AsOf2023-12-31_custom_DataKnightsAcquisitionCorpMember_us-gaap_RelatedPartyMember"
      decimals="-5"
      id="Fact001029"
      unitRef="USD">1200000</us-gaap:ConvertibleNotesPayable>
    <ONMD:ExtensionLoan
      contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember_custom_ManagementAndDirectorsMember"
      decimals="0"
      id="Fact001030"
      unitRef="USD">300000</ONMD:ExtensionLoan>
    <ONMD:ExtensionLoan
      contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember"
      decimals="-5"
      id="Fact001031"
      unitRef="USD">3000000.0</ONMD:ExtensionLoan>
    <ONMD:ExtensionLoan
      contextRef="AsOf2022-12-31_us-gaap_RelatedPartyMember"
      decimals="-5"
      id="Fact001032"
      unitRef="USD">2500000</ONMD:ExtensionLoan>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2023-11-012023-11-30_custom_SecuritiesPurchaseAgreementMember"
      decimals="-5"
      id="Fact001033"
      unitRef="USD">1500000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2023-11-012023-11-30_custom_SeniorConvertibleNotesMember_custom_SecuritiesPurchaseAgreementMember"
      decimals="-5"
      id="Fact001034"
      unitRef="USD">1600000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent
      contextRef="AsOf2023-11-30_us-gaap_RelatedPartyMember_custom_SecuritiesPurchaseAgreementMember"
      decimals="-5"
      id="Fact001035"
      unitRef="USD">100000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="From2023-11-012023-11-30_custom_SecuritiesPurchaseAgreementMember_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001036"
      unitRef="Shares">95745</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:DebtInstrumentDescription
      contextRef="From2023-11-012023-11-30_custom_SecuritiesPurchaseAgreementMember"
      id="Fact001037">The
senior secured notes are convertible to the conversion rate of $</us-gaap:DebtInstrumentDescription>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2023-11-30_custom_SecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact001038"
      unitRef="USDPShares">10.00</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:SeniorNotesCurrent
      contextRef="AsOf2023-12-31"
      decimals="-5"
      id="Fact001039"
      unitRef="USD">1200000</us-gaap:SeniorNotesCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001041">&lt;p id="xdx_808_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zwxSvY1JlXvj" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;14.
&lt;span id="xdx_826_zgUaC2z4h9U3"&gt;Commitments, Contingencies, and Concentrations Operating lease&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has a month-to-month lease for a suite at a cost of $&lt;span id="xdx_905_eus-gaap--OperatingLeaseCost_c20230101__20231231_zPWRhci46SQk"&gt;575
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per month. The Company incurred $&lt;span id="xdx_908_eus-gaap--OperatingLeasesRentExpenseNet_c20230101__20231231_zin38NTu1i35"&gt;7,695
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;and $&lt;span id="xdx_909_eus-gaap--OperatingLeasesRentExpenseNet_c20220101__20221231_zCwDNKWtXxr1"&gt;7,694
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;of rent expense, including common tenant
costs and cancellation costs, during the years ended December 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact001042"
      unitRef="USD">575</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeasesRentExpenseNet
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact001043"
      unitRef="USD">7695</us-gaap:OperatingLeasesRentExpenseNet>
    <us-gaap:OperatingLeasesRentExpenseNet
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001044"
      unitRef="USD">7694</us-gaap:OperatingLeasesRentExpenseNet>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001046">&lt;p id="xdx_80F_eus-gaap--SubsequentEventsTextBlock_zJvyAX1Zop84" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;15.
&lt;span id="xdx_82C_zUZBTByM5AI1"&gt;Subsequent Events&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has evaluated subsequent events occurring through April 9, 2024, the date the financial statements were available for issuance,
for events requiring recording or disclosure in the Company&#x2019;s financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
2024, through to the date of this report, the Company issued &lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20241231__srt--StatementScenarioAxis__srt--ScenarioForecastMember__dei--LegalEntityAxis__custom--EFHuttonMember_zaAfsIKOPiMl"&gt;256,944
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;and &lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20241231__srt--StatementScenarioAxis__srt--ScenarioForecastMember__dei--LegalEntityAxis__custom--KingwoodCapitalPartnersLLCMember_zuM3Moi0ltog"&gt;20,834
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of Common Stock to EF Hutton LLC
and Kingwood Capital Partners, LLC, respectively, as consideration for $&lt;span id="xdx_903_eus-gaap--BusinessCombinationConsiderationTransferred1_pn5n6_c20240101__20241231__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zuOa4HNu8XSg"&gt;3.0
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million owed by the Company for underwriting
commission due at the closing of the Business Combination.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
2024, through to the date of this report, the Company bought back &lt;span id="xdx_907_eus-gaap--StockRepurchasedDuringPeriodShares_c20240101__20241231__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zotKVRYt0Kbh"&gt;187,745
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of Common Stock from a convertible
note holder.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
2024, through to the date of this report, the Company received $&lt;span id="xdx_902_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20240101__20241231__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--MajorityShareholderMember_z3LcYbfqQwm3"&gt;1,000,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;from a majority shareholder for the purchase
of shares, and an additional $&lt;span id="xdx_90A_eus-gaap--ProceedsFromRelatedPartyDebt_c20240101__20241231__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zz1aR5stuiD7"&gt;300,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;treated as a shareholder loan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
2024, through to the date of this report, the Company entered into a definitive securities purchase agreement with an institutional investor
providing up to&#160;$&lt;span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn4n6_c20240101__20241231__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z10C4pdnNwd9"&gt;4.54
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million&#160;in funding through a private
placement for the issuance of senior convertible notes.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;As previously announced
on Form 8-K, on March 28, 2024, OneMedNet Corporation (the &#x201c;Company&#x201d;) &lt;span style="background-color: white"&gt;entered into
a definitive securities purchase agreement (the &#x201c;Securities Purchase Agreement&#x201d;) with Helena Global Investment Opportunities
1 Ltd., an affiliate of Helena Partners Inc., a Cayman-Islands based advisor and investor providing for up to USD$&lt;/span&gt;4.54 million
&lt;span style="background-color: white"&gt;in funding through a private placement for the issuance of senior secured convertible notes (the
&#x201c;Notes&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;As previously announced
on Form 8-K, on March 27, 2024, Paul J. Casey, Chief, Chief Executive Officer of the Company, notified the Company of his intention to
retire as Chief Executive Officer of the Company effective March 29, 2024. Mr. Casey will continue to serve as a member of the Board
of Directors (the &#x201c;Board&#x201d;) of the Company. In connection with Mr. Casey&#x2019;s service on the Advisory Board of the Company,
the Board approved a Stock Option Grant (the &#x201c;Option Grant&#x201d;) providing for the grant of &lt;span id="xdx_901_eus-gaap--StockRepurchasedDuringPeriodShares_c20240326__20240327__srt--StatementScenarioAxis__srt--ScenarioForecastMember__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zuUqsqqUT0Ph"&gt;147,000
&lt;/span&gt;five-year options exercisable at $&lt;span id="xdx_90A_eus-gaap--SharePrice_iI_c20240327__srt--StatementScenarioAxis__srt--ScenarioForecastMember__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zm1HBlB7Oone"&gt;1.00
&lt;/span&gt;per share adviser to Mr. Casey. Also on March 27, 2024, Scott Holbrook, a member of the Board of the Company and a member
of the Company&#x2019;s Audit Committee, notified the Company of his intention to retire from the Company&#x2019;s Board effective March
29, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Effective March 29, 2024,
the Board (i) appointed Mr. Aaron Green, to serve as Chief Executive Officer of the Company to fill the vacancy created by the retirement
of Paul Casey; (ii) appointed Mr. Aaron Green, to serve as a member of the Board to fill the vacancy created by the retirement of Scott
Holbrook; and (iii) appointed Board member, Dr. Thomas Kosasa, to serve on the Company&#x2019;s Audit Committee, also to fill the vacancy
created by the retirement of Scott Holbrook.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-01-012024-12-31_srt_ScenarioForecastMember_custom_EFHuttonMember"
      decimals="INF"
      id="Fact001047"
      unitRef="Shares">256944</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-01-012024-12-31_srt_ScenarioForecastMember_custom_KingwoodCapitalPartnersLLCMember"
      decimals="INF"
      id="Fact001048"
      unitRef="Shares">20834</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="From2024-01-012024-12-31_srt_ScenarioForecastMember"
      decimals="-5"
      id="Fact001049"
      unitRef="USD">3000000.0</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="From2024-01-012024-12-31_srt_ScenarioForecastMember"
      decimals="INF"
      id="Fact001050"
      unitRef="Shares">187745</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2024-01-012024-12-31_us-gaap_SubsequentEventMember_us-gaap_MajorityShareholderMember"
      decimals="0"
      id="Fact001051"
      unitRef="USD">1000000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="From2024-01-012024-12-31_srt_ScenarioForecastMember"
      decimals="0"
      id="Fact001052"
      unitRef="USD">300000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="From2024-01-012024-12-31_us-gaap_SubsequentEventMember"
      decimals="-4"
      id="Fact001053"
      unitRef="USD">4540000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="From2024-03-262024-03-27_srt_ScenarioForecastMember_srt_BoardOfDirectorsChairmanMember"
      decimals="INF"
      id="Fact001054"
      unitRef="Shares">147000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:SharePrice
      contextRef="AsOf2024-03-27_srt_ScenarioForecastMember_srt_BoardOfDirectorsChairmanMember"
      decimals="INF"
      id="Fact001055"
      unitRef="USDPShares">1.00</us-gaap:SharePrice>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fact000256"
          xlink:label="Fact000256"
          xlink:type="locator"/>
        <link:footnote id="Footnote000261" xlink:label="Footnote000261" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Loss
    per share information has not been presented for periods prior to the Business Combination (as defined in Note 3, <xhtml:i>Business Combination</xhtml:i>),
    as it resulted in values that would not be meaningful to the users of these consolidated financial statements. Refer to Note 3, <xhtml:i>Business
    Combination</xhtml:i> for further information. This has been indicated on these statements of operations as &#x201c;N/M&#x201d;.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000256"
          xlink:to="Footnote000261"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140069379518496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressesLineItems', window );"><strong>Entity Addresses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">S-1/A<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentDescription', window );">Amendment Description</a></td>
<td class="text">Amendment No. 2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ONEMEDNET
CORPORATION<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001849380<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">86-2049355<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">6385
Old Shady Oak Road<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Eden Prairie<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MN<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">55344<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">918-7189<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Elected Not To Use the Extended Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember', window );">Business Contact [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressesLineItems', window );"><strong>Entity Addresses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1990
K. Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">NW, Suite 420<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine3', window );">Entity Address, Address Line Three</a></td>
<td class="text">Washington<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">DC<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">20006<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(202)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">935-3390<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_ContactPersonnelName', window );">Contact Personnel Name</a></td>
<td class="text">Debbie
A. Klis, Esq.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of changes contained within amended document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of contact personnel</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 3 such as an Office Park</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140069378746960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 47,008<span></span>
</td>
<td class="nump">$ 301,730<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsHeldInTrustCurrent', window );">Investments held in Trust</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">29,029,415<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net of allowance</a></td>
<td class="nump">151,640<span></span>
</td>
<td class="nump">18,975<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other assets</a></td>
<td class="nump">165,538<span></span>
</td>
<td class="nump">100,945<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivables', window );">Receivable from SPAC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,152<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">364,186<span></span>
</td>
<td class="nump">30,351,217<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and Equipment, Net</a></td>
<td class="nump">98,871<span></span>
</td>
<td class="nump">83,097<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">463,057<span></span>
</td>
<td class="nump">30,434,314<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable &amp; accrued expenses</a></td>
<td class="nump">4,184,398<span></span>
</td>
<td class="nump">2,814,570<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherShortTermBorrowings', window );">Loan Amount due to related parties</a></td>
<td class="nump">11,200<span></span>
</td>
<td class="nump">11,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesAndExciseTaxPayableCurrent', window );">Excise tax</a></td>
<td class="nump">113,353<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ONMD_LoanExtensionsCurrent', window );">Loan Extensions</a></td>
<td class="nump">2,991,679<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenues</a></td>
<td class="nump">253,997<span></span>
</td>
<td class="nump">183,683<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansPayable', window );">Loan Payable</a></td>
<td class="nump">38,921<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtCurrent', window );">Convertible promissory notes</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">8,490,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnsecuredDebtCurrent', window );">Canada Emergency Business Loan Act</a></td>
<td class="nump">44,673<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income tax payable</a></td>
<td class="nump">120,017<span></span>
</td>
<td class="nump">214,850<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent', window );">Franchise tax payable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">69,966<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNotesPayableCurrent', window );">Pipe Notes, net of discount including interest</a></td>
<td class="nump">1,549,820<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ONMD_DeferredUnderwriterFeePayableCurrent', window );">Deferred underwriter fee payable</a></td>
<td class="nump">3,525,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">12,833,058<span></span>
</td>
<td class="nump">11,784,569<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Long Term Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnsecuredDebt', window );">Canada Emergency Business Loan Act</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,144<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ONMD_AccruedInterestRelatedParty', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">690,772<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ONMD_WarrantLiabilityNonCurrent', window );">Warrant liabilities</a></td>
<td class="nump">24,582<span></span>
</td>
<td class="nump">362,558<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ONMD_DeferredUnderwriterFeePayableNonCurrent', window );">Deferred underwriter fee payable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">4,025,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ONMD_WorkingCapitalLoan', window );">Working capital Loan</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">207,081<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermLoansPayable', window );">Extension loans</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,545,839<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">13,322,663<span></span>
</td>
<td class="nump">21,159,963<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; Equity (Deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock value</a></td>
<td class="nump">2,357<span></span>
</td>
<td class="nump">455<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">28,750,110<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid in capital</a></td>
<td class="nump">42,220,714<span></span>
</td>
<td class="nump">24,032,561<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(55,082,677)<span></span>
</td>
<td class="num">(43,509,964)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity (deficit)</a></td>
<td class="num">(12,859,606)<span></span>
</td>
<td class="nump">9,274,351<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity (deficit)</a></td>
<td class="nump">463,057<span></span>
</td>
<td class="nump">30,434,314<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ONMD_SeriesATwoPreferredStockMember', window );">Series A-2 Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; Equity (Deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred value</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">385<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ONMD_SeriesAOnePreferredStockMember', window );">Series A-1 Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; Equity (Deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred value</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">320<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; Equity (Deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock value</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ONMD_CommonClassAOneMember', window );">Common Class A One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; Equity (Deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock value</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">425<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Long Term Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Loan, related party of OMN</a></td>
<td class="nump">$ 465,023<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ONMD_AccruedInterestRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued interest related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ONMD_AccruedInterestRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ONMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ONMD_DeferredUnderwriterFeePayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred underwriter fee payable current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ONMD_DeferredUnderwriterFeePayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ONMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ONMD_DeferredUnderwriterFeePayableNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred underwriter fee payable noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ONMD_DeferredUnderwriterFeePayableNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ONMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ONMD_LoanExtensionsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loan extensions current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ONMD_LoanExtensionsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ONMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ONMD_WarrantLiabilityNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant liability non current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ONMD_WarrantLiabilityNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ONMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ONMD_WorkingCapitalLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Working capital loan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ONMD_WorkingCapitalLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ONMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for real and property taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483384/720-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsHeldInTrustCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash, securities, or other assets held by a third-party trustee pursuant to the terms of an agreement which assets are available to be used by beneficiaries to that agreement only within the specific terms thereof and which agreement is expected to terminate within one year of the balance sheet date (or operating cycle, if longer) at which time the assets held-in-trust will be released or forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsHeldInTrustCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLoansPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermLoansPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term notes classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from parties in nontrade transactions, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowings classified as other, maturing within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(13)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a)(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesAndExciseTaxPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred through that date and payable for statutory sales and use taxes, including value added tax. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesAndExciseTaxPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnsecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of uncollateralized debt obligations (with maturities initially due after one year or beyond the operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnsecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnsecuredDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term, uncollateralized debt obligations due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnsecuredDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ONMD_SeriesATwoPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ONMD_SeriesATwoPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ONMD_SeriesAOnePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ONMD_SeriesAOnePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ONMD_CommonClassAOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ONMD_CommonClassAOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140069379460864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding</a></td>
<td class="nump">23,572,232<span></span>
</td>
<td class="nump">4,550,166<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ONMD_SeriesATwoPreferredStockMember', window );">Series A-2 Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,853,797<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ONMD_SeriesAOnePreferredStockMember', window );">Series A-1 Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,204,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,853,797<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ONMD_CommonClassAOneMember', window );">Common Class A One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,853,797<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ONMD_SeriesATwoPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ONMD_SeriesATwoPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ONMD_SeriesAOnePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ONMD_SeriesAOnePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ONMD_CommonClassAOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ONMD_CommonClassAOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140069377884928">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,021,651<span></span>
</td>
<td class="nump">$ 1,152,738<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,149,551<span></span>
</td>
<td class="nump">1,513,428<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross Margin</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(127,900)<span></span>
</td>
<td class="num">(360,690)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating Expenses</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,273,503<span></span>
</td>
<td class="nump">8,755,620<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherGeneralExpense', window );">Operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">226,257<span></span>
</td>
<td class="nump">398,760<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Sales &amp; Marketing</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,114,977<span></span>
</td>
<td class="nump">957,690<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,631,613<span></span>
</td>
<td class="nump">952,701<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total Operating Expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,246,350<span></span>
</td>
<td class="nump">11,064,771<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(8,374,250)<span></span>
</td>
<td class="num">(11,425,461)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other Expense (income)</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10,504,327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">214,850<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">749,213<span></span>
</td>
<td class="nump">403,307<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">Other expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">52,256<span></span>
</td>
<td class="nump">46,820<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in FV of Warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(46,822)<span></span>
</td>
<td class="num">(4,489,110)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockOptionPlanExpense', window );">Stock Expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,572,232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ONMD_UnrealizedGainLoss', window );">Unrealized gain or loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="num">(1,371,689)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other Expense (income)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">14,831,206<span></span>
</td>
<td class="num">(5,195,822)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (23,205,456)<span></span>
</td>
<td class="num">$ (6,229,639)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Loss per share of Common Stock:(1)</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings Per Share, Diluted</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (0.98)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract', window );"><strong>Weighted-average shares of Common Stock outstanding:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted Average Number of Shares Outstanding, Diluted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">23,572,232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Loss
    per share information has not been presented for periods prior to the Business Combination (as defined in Note 3, <i>Business Combination</i>),
    as it resulted in values that would not be meaningful to the users of these consolidated financial statements. Refer to Note 3, <i>Business
    Combination</i> for further information. This has been indicated on these statements of operations as &#8220;N/M&#8221;.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ONMD_UnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrealized gain loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ONMD_UnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ONMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherGeneralExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of general expenses not normally included in Other Operating Costs and Expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherGeneralExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockOptionPlanExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockOptionPlanExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140069378971376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders Equity (Deficit) - USD ($)<br></strong></div></th>
<th class="th">
<div>Preferred Stock [Member] </div>
<div>Series A-2 Preferred Stock [Member]</div>
</th>
<th class="th">
<div>Preferred Stock [Member] </div>
<div>Series A-1 Preferred Stock [Member]</div>
</th>
<th class="th">
<div>Common Stock [Member] </div>
<div>Common Class A [Member] </div>
<div>Data Knights Acquisition Corp [Member]</div>
</th>
<th class="th">
<div>Common Stock [Member] </div>
<div>Common Class A [Member]</div>
</th>
<th class="th">
<div>Common Stock [Member] </div>
<div>Common Class B [Member] </div>
<div>Data Knights Acquisition Corp [Member]</div>
</th>
<th class="th"><div>Commitment [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 385<span></span>
</td>
<td class="nump">$ 320<span></span>
</td>
<td class="nump">$ 59<span></span>
</td>
<td class="nump">$ 434<span></span>
</td>
<td class="nump">$ 288<span></span>
</td>
<td class="nump">$ 28,750,110<span></span>
</td>
<td class="nump">$ 19,607,173<span></span>
</td>
<td class="num">$ (33,920,734)<span></span>
</td>
<td class="nump">$ 14,438,035<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2021</a></td>
<td class="nump">3,853,797<span></span>
</td>
<td class="nump">3,204,000<span></span>
</td>
<td class="nump">585,275<span></span>
</td>
<td class="nump">4,342,666<span></span>
</td>
<td class="nump">2,875,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common shares in exchange for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">199,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common shares in exchange for services, share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance Public Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">7,499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance public shares, share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Issuance of Data Knights Acquisition Corp. Class B Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 137<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,825,823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,825,960<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of common class B stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,378,517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ONMD_CommonStockSubjectToPossibleRedemptionValue', window );">Common stock redemption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,359,591)<span></span>
</td>
<td class="num">(3,359,591)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,392,086<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,392,086<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,229,639)<span></span>
</td>
<td class="num">(6,229,639)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 385<span></span>
</td>
<td class="nump">$ 320<span></span>
</td>
<td class="nump">$ 59<span></span>
</td>
<td class="nump">$ 455<span></span>
</td>
<td class="nump">$ 425<span></span>
</td>
<td class="nump">28,750,110<span></span>
</td>
<td class="nump">24,032,561<span></span>
</td>
<td class="num">(43,509,964)<span></span>
</td>
<td class="nump">9,274,351<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Dec. 31, 2022</a></td>
<td class="nump">3,853,797<span></span>
</td>
<td class="nump">3,204,000<span></span>
</td>
<td class="nump">585,275<span></span>
</td>
<td class="nump">4,550,166<span></span>
</td>
<td class="nump">4,253,517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance Public Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">111,946<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111,957<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance public shares, share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111,957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ONMD_CommonStockSubjectToPossibleRedemptionValue', window );">Common stock redemption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28,750,110)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28,750,110)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,892,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,892,741<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,205,456)<span></span>
</td>
<td class="num">(23,205,456)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Preferred Stock to Common Stock</a></td>
<td class="num">$ (385)<span></span>
</td>
<td class="num">$ (320)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 706<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">7,057,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,057,092<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Preferred stock to common stock, shares</a></td>
<td class="num">(3,853,797)<span></span>
</td>
<td class="num">(3,204,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,057,797<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ONMD_StockIssuedDuringPeriodValueConvertibleNotesToCommonStock', window );">Convertible Notes to Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 618<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,176,611<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,177,229<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ONMD_StockIssuedDuringPeriodSharesConvertibleNotesToCommonStock', window );">Convertible notes to common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,177,229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ONMD_StockIssuedDuringPeriodValueStockOptionsToCommonStock', window );">Stock Options to Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">612,609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">612,670<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ONMD_StockIssuedDuringPeriodSharesStockOptionsToCommonStock', window );">Stock issued during period shares options to common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">612,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ONMD_StockIssuedDuringPeriodValueConvertingOfWarrantsToCommonStock', window );">Converting of Warrants to Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 386<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,859,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,859,464<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ONMD_StockIssuedDuringPeriodSharesConvertingOfWarrantsToCommonStock', window );">Converting of warrants to common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,859,464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Private OneMedNet to ONMD Public Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (226)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,257,100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,257,326)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Stock issued during period shares other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,257,326)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of PIPE Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">101,071<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,071<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ONMD_StockIssuedDuringPeriodValueConvertingDataKnightsCommonShares', window );">Converting Data Knights Common Shares (A and B) to ONMD Public Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (59)<span></span>
</td>
<td class="nump">$ 346<span></span>
</td>
<td class="num">$ (425)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">634,106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">633,968<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ONMD_StockIssuedDuringPeriodSharesConvertingDataKnightsCommonShares', window );">Converting Data Knights Common Shares (A and B) to ONMD Public Shares, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(585,275)<span></span>
</td>
<td class="nump">3,460,275<span></span>
</td>
<td class="num">(4,253,517)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ONMD_RetainedEarningsAdjustment', window );">Retained earnings adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,632,743<span></span>
</td>
<td class="nump">11,632,743<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,357<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 42,220,714<span></span>
</td>
<td class="num">$ (55,082,677)<span></span>
</td>
<td class="num">$ (12,859,606)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Dec. 31, 2023</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">23,572,232<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ONMD_CommonStockSubjectToPossibleRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock subject to possible redemption value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ONMD_CommonStockSubjectToPossibleRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ONMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ONMD_RetainedEarningsAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Retained earnings adjustment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ONMD_RetainedEarningsAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ONMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ONMD_StockIssuedDuringPeriodSharesConvertibleNotesToCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares convertible notes to common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ONMD_StockIssuedDuringPeriodSharesConvertibleNotesToCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ONMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ONMD_StockIssuedDuringPeriodSharesConvertingDataKnightsCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period shares converting data knights common shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ONMD_StockIssuedDuringPeriodSharesConvertingDataKnightsCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ONMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ONMD_StockIssuedDuringPeriodSharesConvertingOfWarrantsToCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares converting of warrants to common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ONMD_StockIssuedDuringPeriodSharesConvertingOfWarrantsToCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ONMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ONMD_StockIssuedDuringPeriodSharesStockOptionsToCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares stock options to common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ONMD_StockIssuedDuringPeriodSharesStockOptionsToCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ONMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ONMD_StockIssuedDuringPeriodValueConvertibleNotesToCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value convertible notes to common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ONMD_StockIssuedDuringPeriodValueConvertibleNotesToCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ONMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ONMD_StockIssuedDuringPeriodValueConvertingDataKnightsCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value converting data knights common shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ONMD_StockIssuedDuringPeriodValueConvertingDataKnightsCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ONMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ONMD_StockIssuedDuringPeriodValueConvertingOfWarrantsToCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value converting of warrants to common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ONMD_StockIssuedDuringPeriodValueConvertingOfWarrantsToCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ONMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ONMD_StockIssuedDuringPeriodValueStockOptionsToCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value stock options to common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ONMD_StockIssuedDuringPeriodValueStockOptionsToCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ONMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481284/470-20-25-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140069389850016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders Equity (Deficit) (Parenthetical)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price</a></td>
<td class="nump">$ 1.00<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140069378700368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flow from Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">$ (23,205,456)<span></span>
</td>
<td class="num">$ (6,229,639)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">27,983<span></span>
</td>
<td class="nump">24,807<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ONMD_BusinessCombinationCost', window );">Business combination cost</a></td>
<td class="nump">900,152<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,599,586<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ONMD_CashHeldInTrustAccount', window );">Cash Held in Trust Account</a></td>
<td class="nump">29,029,416<span></span>
</td>
<td class="nump">88,291,558<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid Expenses</a></td>
<td class="num">(64,594)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Other current assets</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(875,803)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued Expenses</a></td>
<td class="nump">1,369,825<span></span>
</td>
<td class="nump">1,929,787<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, net of allowance</a></td>
<td class="num">(132,665)<span></span>
</td>
<td class="nump">72,767<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred Revenue &amp; Customer Deposits</a></td>
<td class="nump">70,314<span></span>
</td>
<td class="num">(458,667)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueToRelatedParties', window );">Amount due to related party</a></td>
<td class="num">(300)<span></span>
</td>
<td class="nump">11,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ONMD_IncreaseDecreaseInExerciseTaxLiability', window );">Exercise tax liability</a></td>
<td class="nump">113,353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ONMD_IncreaseDecreaseInExtensionLoan', window );">Extension loan</a></td>
<td class="nump">445,840<span></span>
</td>
<td class="nump">2,545,838<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ONMD_IncreaseDecreaseFranchiseTaxPayable', window );">Franchise tax payable</a></td>
<td class="num">(69,966)<span></span>
</td>
<td class="num">(94,043)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income Tax Payable</a></td>
<td class="num">(94,833)<span></span>
</td>
<td class="nump">214,850<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ONMD_IncreaseDecreaseInWorkingCapitalLoan', window );">Working capital loan</a></td>
<td class="num">(168,159)<span></span>
</td>
<td class="nump">207,081<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash flows used in operating activities</a></td>
<td class="nump">8,220,910<span></span>
</td>
<td class="nump">87,239,622<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash used for Investing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(43,757)<span></span>
</td>
<td class="num">(58,137)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flow from Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ONMD_ProceedsFromIssuanceOfCommonStockOne', window );">Class B Common Stock</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">137<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfNotesPayable', window );">Proceeds (repayment) from issuance of convertible promissory note payable</a></td>
<td class="num">(10,680,772)<span></span>
</td>
<td class="nump">5,543,162<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of PIPE Convertible Notes and Warrants</a></td>
<td class="nump">1,549,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceed from related party loan</a></td>
<td class="nump">465,024<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ONMD_ProceedsFromBusinessLoan', window );">Proceeds from Canada Emergency Business Loan Act</a></td>
<td class="nump">529<span></span>
</td>
<td class="num">(2,754)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ONMD_ProceedsFromCommonStockSubjectToRedemption', window );">Common Stock Subject to Redemption</a></td>
<td class="num">(28,750,109)<span></span>
</td>
<td class="num">(88,549,890)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ONMD_ProceedsFromDeferredUnderwritingFee', window );">Deferred underwriting fee</a></td>
<td class="num">(500,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ONMD_ProceedsFromWarrantLiability', window );">Warrant liability</a></td>
<td class="num">(337,976)<span></span>
</td>
<td class="num">(4,489,110)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromContributedCapital', window );">Additional Paid-in Capital</a></td>
<td class="nump">18,189,350<span></span>
</td>
<td class="nump">2,825,823<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ONMD_ProceedsFromIssuanceOfCommonStockTwo', window );">Class A Common Stock</a></td>
<td class="num">(59)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ONMD_ClassBCommonStock', window );">Class B Common Stock</a></td>
<td class="num">(425)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ONMD_ProccedsFromRetainedEarningsAdjustment', window );">Retained Earnings adjustment</a></td>
<td class="nump">11,632,743<span></span>
</td>
<td class="num">(3,359,594)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash flows from financing activities</a></td>
<td class="num">(8,431,875)<span></span>
</td>
<td class="num">(88,032,226)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash and cash equivalents</a></td>
<td class="num">(254,722)<span></span>
</td>
<td class="num">(850,741)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and Cash Equivalents, Beginning</a></td>
<td class="nump">301,730<span></span>
</td>
<td class="nump">1,152,471<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and Cash Equivalents, Ending</a></td>
<td class="nump">$ 47,008<span></span>
</td>
<td class="nump">$ 301,730<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ONMD_BusinessCombinationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business combination cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ONMD_BusinessCombinationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ONMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ONMD_CashHeldInTrustAccount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash held in trust account.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ONMD_CashHeldInTrustAccount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ONMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ONMD_ClassBCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class B common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ONMD_ClassBCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ONMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ONMD_IncreaseDecreaseFranchiseTaxPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease franchise tax payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ONMD_IncreaseDecreaseFranchiseTaxPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ONMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ONMD_IncreaseDecreaseInExerciseTaxLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in exercise tax liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ONMD_IncreaseDecreaseInExerciseTaxLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ONMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ONMD_IncreaseDecreaseInExtensionLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in extension loan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ONMD_IncreaseDecreaseInExtensionLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ONMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ONMD_IncreaseDecreaseInWorkingCapitalLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in working capital loan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ONMD_IncreaseDecreaseInWorkingCapitalLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ONMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ONMD_ProccedsFromRetainedEarningsAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Procceds from retained earnings adjustment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ONMD_ProccedsFromRetainedEarningsAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ONMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ONMD_ProceedsFromBusinessLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from business loan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ONMD_ProceedsFromBusinessLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ONMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ONMD_ProceedsFromCommonStockSubjectToRedemption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from common stock subject to redemption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ONMD_ProceedsFromCommonStockSubjectToRedemption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ONMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ONMD_ProceedsFromDeferredUnderwritingFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from deferred under writing fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ONMD_ProceedsFromDeferredUnderwritingFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ONMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ONMD_ProceedsFromIssuanceOfCommonStockOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ONMD_ProceedsFromIssuanceOfCommonStockOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ONMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ONMD_ProceedsFromIssuanceOfCommonStockTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock two.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ONMD_ProceedsFromIssuanceOfCommonStockTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ONMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ONMD_ProceedsFromWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ONMD_ProceedsFromWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ONMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482312/912-310-45-11<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromContributedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received by a corporation from a shareholder during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromContributedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from long-term debt supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140069389787344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Operations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock', window );">Organization and Operations</a></td>
<td class="text"><p id="xdx_809_eus-gaap--OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_zV9YseO4iab1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.
<span id="xdx_82A_zfz7jzRiBva7">Organization and Operations</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">OneMedNet
Corporation (the &#8220;Company&#8221;) is a healthcare software company with solutions focused on digital medical image management,
exchange, and sharing. The Company was incorporated in Delaware on September 20, 2006. The Company has been solely focused on creating
solutions that simplify digital medical image management, exchange, and sharing. The Company has one wholly-owned subsidiary, OneMedNet
Technologies (Canada) Inc., incorporated on October 16, 2015 under the provisions of the Business Corporations Act of British Columbia
whose functional currency is the Canadian dollar. The Company&#8217;s headquarters location is Eden Prairie, Minnesota.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 12.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 7, 2023, as contemplated by the Company, Data Knights Merger Sub, Inc., a Delaware corporation (&#8220;Merger Sub&#8221;), and
Data Knights, LLC, the Merger Sub&#8217;s sponsor merged with and into OneMedNet Corporation, with OneMedNet Corporation surviving the
merger. The Business Combination is further described in Note 3, <span style="background-color: white"><i>Business Combination.</i></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 12.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i>Data
Knights Acquisition Corp Merger</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
November 7, 2023, we consummated a merger (the &#8220;Merger&#8221;) </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">following
the approval at the special meeting of the shareholders of Data Knights Acquisition Corp., a Delaware corporation held on October 17,
2023 (the &#8220;Special Meeting&#8221;), Data Knights Merger Sub, Inc., a Delaware corporation (&#8220;Merger Sub&#8221;) and a wholly-owned
subsidiary of Data Knights Acquisition Corp., a Delaware corporation (&#8220;Data Knights&#8221;), consummated a merger (the &#8220;Merger&#8221;)
with and into OneMedNet Solutions Corporation (formerly named OneMedNet Corporation), a Delaware corporation (&#8220;OneMedNet&#8221;)
pursuant to an agreement and plan of merger, dated as of April 25, 2022 (the &#8220;Merger Agreement&#8221;), by and among Data Knights,
Merger Sub, OneMedNet, Data Knights, LLC, a Delaware limited liability company (&#8220;Sponsor&#8221; or &#8220;Purchaser Representative&#8221;)
in its capacity as the representative of the stockholders of Data Knights, and Paul Casey in his capacity as the representative of the
stockholders of OneMedNet (&#8220;Seller Representative&#8221;). Accordingly, the Merger Agreement was adopted, and the Merger and other
transactions contemplated thereby (collectively, the &#8220;Business Combination&#8221;) were approved and completed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Business Combination was accounted for as a </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">as
a reverse recapitalization with OneMedNet as the accounting acquirer <span style="background-color: white">under the accounting principles
generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;). Accordingly, the financial statements of the combined company
represent a continuation of the financial statements of OneMedNet.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
June 28, 2023, the Company and Data Knights entered into a Securities Purchase Agreement (the &#8220;SPA&#8221;) with certain investors
(collectively referred to herein as the &#8220;Purchasers&#8221;) for PIPE financing in the aggregate original principal amount of $<span id="xdx_902_eus-gaap--DebtInstrumentIssuedPrincipal_pp2d_c20230628__20230628__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--BusinessAcquisitionAxis__custom--DataKnightsAcquisitionCorpMember_zd35VsLoAFv9">1,595,744.70
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">and the purchase
price of $<span id="xdx_904_eus-gaap--PaymentsToAcquireBusinessesGross_pn5n6_c20230628__20230628__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--BusinessAcquisitionAxis__custom--DataKnightsAcquisitionCorpMember_zLfq0MnZLOhi">1.5
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">million. <span id="xdx_90A_eus-gaap--DebtInstrumentDescription_c20230628__20230628__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--BusinessAcquisitionAxis__custom--DataKnightsAcquisitionCorpMember_zcrEXy9YpNK3">Pursuant
to the Securities Purchase Agreement, Data Knights will issue and sell to each of the Purchasers, a new series of senior secured convertible
notes (the &#8220;PIPE Notes&#8221;), which are convertible into shares of Common Stock at the Purchasers election at a conversion price
equal to the lower of (i) $10.00 per share, and (ii) 92.5% of the lowest volume weighted average trading price for the ten (10) Trading
Days immediately preceding the Conversion Date.</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Purchasers&#8217; $<span id="xdx_904_eus-gaap--Investments_iI_pn5n6_c20230628__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--BusinessAcquisitionAxis__custom--DataKnightsAcquisitionCorpMember_z2iQWtEALUT4">1.5
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">million investment
in the PIPE Notes closed and funded contemporaneous to the Closing of the Business Combination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Effective
immediately prior to the Closing, OneMedNet, Inc. issued the PIPE Notes to the Purchasers under the private offering exemptions under
Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Risks
and Uncertainties</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is subject to risks common to companies in the markets it serves, including, but not limited to, global economic and financial
market conditions, fluctuations in customer demand, acceptance of new products, development by its competitors of new technological innovations,
dependence on key personnel, and protection of proprietary technology.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
previously reported on Form 8-K on February 9, 2024, the Company received written notice (the &#8220;Nasdaq Notice&#8221;), dated February
7, 2024, from the Nasdaq Stock Market (&#8220;Nasdaq&#8221;) indicating that for the preceding 30 consecutive business days, the market
value of the Company&#8217;s listed securities (&#8220;MVLS&#8221;) did not maintain a minimum market value of $50,000,000 (the &#8220;Minimum
MVLS Requirement&#8221;) as required by Nasdaq Listing Rule 5450(b)(2)(A). In accordance with Nasdaq Listing Rule 5810(c)(3)(C), the
Company has a compliance period of 180 calendar days, or until August 5, 2024, to regain compliance with the Minimum MVLS Requirement.
Compliance may be achieved if the Company&#8217;s MVLS closes at $50,000,000 or more for a minimum of ten consecutive business days at
any time during the 180-day compliance period, in which case Nasdaq will notify the Company of its compliance and the matter will be
closed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 12.95pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the Company does not regain compliance with the Minimum MVLS Requirement by August 5, 2024, Nasdaq will provide written notification
to the Company that its common stock is subject to delisting. At that time, the Company may appeal the relevant delisting determination
to a hearings panel pursuant to the procedures set forth in the applicable Nasdaq Listing Rules. However, there can be no assurance,
if the Company does appeal the delisting determination by Nasdaq to the hearings panel, that such appeal would be successful. In such
event, the Company may also seek to apply for a transfer to The Nasdaq Global Market if it meets the requirements for continued listing
thereon. The Nasdaq Notice received have no immediate effect on the Company&#8217;s continued listing on the Nasdaq Global Market or
the trading of Company&#8217;s common stock, subject to the Company&#8217;s compliance with the other continued listing requirements.
The Company is presently evaluating potential actions to regain compliance with all applicable requirements for continued listing on
the Nasdaq Global Market. There can be no assurance that the Company will be successful in maintaining the listing of its common stock
on the Nasdaq Global Market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 250<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//250/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140069385403488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p id="xdx_802_eus-gaap--SignificantAccountingPoliciesTextBlock_zGbBSfC6KOC7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.
<span id="xdx_820_zKg7KUIVwbK9">Summary of Significant Accounting Policies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p id="xdx_842_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zvzejhltBzmk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span id="xdx_86A_zHiorFzUGPkd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Basis
of Presentation and Foreign Currency Translation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 12.95pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements have been prepared in U.S. dollars, in accordance with accounting principles generally accepted in
the United States of America (&#8220;GAAP&#8221;). The accompanying consolidated financial statements include the accounts of the Company
and its wholly owned subsidiaries. The consolidated financial statements include 100% of the accounts of wholly-owned subsidiaries. All
intercompany balances and transactions have been eliminated in consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p id="xdx_840_eus-gaap--BusinessCombinationsPolicy_zndaSaMzFgIb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span id="xdx_868_z9lk6RJzb8ma" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Business
Combination</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
account for business acquisitions under ASC Topic 805, Business Combinations (&#8220;ASC Topic 805&#8221;). The total purchase consideration
for an acquisition is measured as the fair value of the assets given, equity instruments issued, and liabilities assumed at the acquisition
date. Costs that are directly attributable to the acquisition are expensed as incurred. Identifiable assets (including intangible assets)
and liabilities assumed (including contingent liabilities) are measured initially at their fair values at the acquisition date. We recognize
goodwill if the fair value of the total purchase consideration is in excess of the net fair value of the identifiable assets acquired
and the liabilities assumed. We recognize a bargain purchase gain within Other income (expense), net, in the consolidated statement of
operations if the net fair value of the identifiable assets acquired and the liabilities assumed is in excess of the fair value of the
total purchase consideration. We include the results of operations of the acquired business in the consolidated financial statements
beginning on the acquisition date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 12.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_843_eus-gaap--UseOfEstimates_zjt1UdiaaVH7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span id="xdx_869_zIt7XWTLer6d" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Use
of Estimates</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of consolidated financial statements in conformity with GAAP requires management to make estimates, judgments, and assumptions
that affect the reported amounts of assets, liabilities, revenue, and expenses, and the amounts disclosed in the related notes to the
consolidated financial statements. Actual results and outcomes may differ materially from management&#8217;s estimates, judgments, and
assumptions. Significant estimates, judgments, and assumptions used in these financial statements include, but are not limited to, those
related to revenue, useful lives and realizability of long-lived assets, accounting for income taxes and related valuation allowances,
and unit and stock-based compensation. Estimates are periodically reviewed in light of changes in circumstances, facts, and experience.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_843_ecustom--OperatingSegmentsPolicyTextBlock_zACDXJyzWbLk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span id="xdx_862_zQstZ0yF89o" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Operating
Segments</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company operates as one operating segment. Operating segments are defined as components of an enterprise for which separate financial
information is regularly evaluated by the chief operating decision maker (&#8220;CODM&#8221;), which is the Company&#8217;s Chief Executive
Officer, in deciding how to allocate resources and assess performance. The Company&#8217;s CODM evaluates the Company&#8217;s financial
information and resources and assesses the performance of these resources on a consolidated basis. The Company is not organized by market
and is managed and operated as one business. A single management team that reports to the chief executive officer comprehensively manages
the entire business. Accordingly, the Company does not accumulate discrete financial information with respect to separate divisions and
does not have separate operating or reportable segments. Since the Company operates in one operating segment, all required financial
segment information can be found in the consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84C_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zMlRvLLBGcYl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span id="xdx_867_zKdmKLGHFwQ8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cash
and Cash Equivalents</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
and cash equivalents consist of highly liquid, short-term investments with a maturity of three months or less when purchased. Cash equivalents
consist of money market funds and are carried at cost, which approximates fair value. The balances, at times, may exceed FDIC Insured
limits. The Company believes that, as of December 31, 2023, its risk relating to deposits exceeding federally insured limits was not
significant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84D_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zHSkOZjoaDAg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span id="xdx_863_zDnAqV8hKKmb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Accounts
Receivable</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
receivable are unsecured, recorded at net realizable value, and do not bear interest. Accounts receivable are considered past due if
not paid within the terms established between the Company and the customer. Amounts are only written off after all attempts at collections
have been exhausted. The Company determines the need for an allowance for doubtful accounts based upon factors surrounding the credit
risk of specific customers, historical trends and other information. As of December 31, 2023 and 2022, the Company established allowances
of $<span id="xdx_90D_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20231231_zsgeggHAEi86">0</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and
$<span id="xdx_904_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20221231_zELlL3nc7kY7">102,700</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">respectively.
The net receivable balances outstanding are fully collectible.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company believes its credit policies are prudent and reflect normal industry terms and business risk. The Company generally does not
require collateral from its customers and generally requires payment from 0 to 90 days from the invoice date. For the year ended December
31, 2023, there was 1 customer that accounted for <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneCustomerMember_zYlEzIbkEdmk">10</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
or more of total revenue, and there were 2 customers that accounted for <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--TwoCustomersMember_zWk6srTqOOyb">10</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
or more of total revenue for the years ended December 31, 2022 . The following table represents these customers&#8217; aggregate percent
of total revenue:</span></p>

<p id="xdx_899_eus-gaap--SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_zQi7JmXQvsj9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B2_zGLv6h4dCOii">Schedule
Of Aggregate Percentage Revenue and Accounts Receivable</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20230101__20231231_zUGdB37NKUn6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December
    31, 2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20220101__20221231_zcYb7a6l5vo2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December
    31, 2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year Ended</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31, 2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31, 2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zEHO2Q3PAb9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 56%">Customer 1</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right">52</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right">31</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_405_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_zZGLElbzyVq4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Customer 2</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0725">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">22</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr id="xdx_40F_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomersMember_z5Y4MjatHXV" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Aggregate Percent of Total Revenue</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">52</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">53</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 12.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023, three customers accounted for more than <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--ThreeCustomersMember_zaeCBpShTQP9">10</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
of the Company&#8217;s accounts receivable balance, and two customers accounted for over <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--TwoCustomersMember_z1pBVCbDsh6b">10</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
of the Company&#8217;s accounts receivable balance at December 31, 2022. The following table represents these customers&#8217; aggregate
percent of total accounts receivable:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 12.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20230101__20231231_zFefwqYRVOU8" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December
    31, 2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20220101__20221231_z2cFFNbI99Sb" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December
    31, 2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year Ended</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31, 2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31, 2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zUQw8G4cVKZe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%">Customer 1</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0733">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">40</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_400_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_zbivTlCYEB3g" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">Customer 2</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">36</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0737">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerThreeMember_zUf1RqDmH0z5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Customer 3</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">33</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0740">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerFourMember_zMcJm0AG6jMd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">Customer 4</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0742">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">32</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr id="xdx_404_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerFiveMember_zXVSrVaFghWj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Customer 5</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">27</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0746">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomersMember_zdgdbAAO0zIb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Aggregate Percent of Total Accounts Receivable</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">96</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">%</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">72</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr id="xdx_40F_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomersMember_zg1FiXjCH2xe" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Aggregate Percent of Revenue and Accounts Receivable</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">96</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">%</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">72</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">%</td></tr>
</table>

<p id="xdx_8A5_zHDNCw2Iq6Qc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 12.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_846_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zoEI6ToaNBQc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span id="xdx_868_z4IcW1vRIm1b" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Property
and Equipment</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are recorded at cost. The straight-line method is used for computing depreciation and amortization. Assets are depreciated
over their estimated useful lives ranging from three to five years. Cost of maintenance and repairs are charged to expense when incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_841_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zqQEFN1kkqcg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span id="xdx_862_zNNfTwY6IbVa" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Impairment
of Long-Lived Assets</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company reviews long-lived assets, including property and equipment, for impairment whenever events or changes in business circumstances
indicate that the carrying amount of an asset may not be fully recoverable. An impairment loss would be recognized when the estimated
future undiscounted net cash flows from the use of the asset are less than the carrying amount of that asset. There have been <span id="xdx_90A_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_do_c20220101__20221231_zU0HgIgIqy09">no
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">losses during the years ended December
31, 2023 or December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_845_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zDiDCTuKvzr" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span id="xdx_865_zS2oqDkolOjj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Fair
Value of Financial Instruments</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between
market participants at the measurement date. To increase the comparability of fair value measures, the following hierarchy prioritizes
the inputs to valuation methodologies used to measure fair value:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 12.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level
1</b> &#8212; Valuations based on quoted prices for identical assets and liabilities in active markets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level
2</b> &#8212; Valuations based on observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets
and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, or other
inputs that are observable or can be corroborated by observable market data.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level
3</b> &#8212; Valuations based on unobservable inputs reflecting our own assumptions, consistent with reasonably available assumptions
made by other market participants. These valuations require significant judgment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 12.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
measure the fair value of money market funds and certain marketable equity securities based on quoted prices in active markets for identical
assets or liabilities. Other marketable securities were valued either based on recent trades of securities in inactive markets or based
on quoted market prices of similar instruments and other significant inputs derived from or corroborated by observable market data. We
did not hold significant amounts of marketable securities categorized as Level 3 assets as of the years ended December 31, 2022 and December
31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s financial instruments consist of cash and cash equivalents, accounts receivable, accounts payable, convertible notes
payable and certain privately issued warrants. The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable
financial instruments approximate their fair value due to their short-term nature. The Company&#8217;s Private Warrants estimated fair
values are provided by a third party pricing vendor and are reviewed by the Company&#8217;s management. The Private Warrants valuations
are based on unobservable inputs reflecting the vendor&#8217;s assumptions, consistent with reasonably available assumptions made by
other market participants and thus are classified as Level 3.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_848_eus-gaap--RevenueRecognitionPolicyTextBlock_z8kXah7HUIp5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span id="xdx_860_zetssCGQ3aL3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Revenue
Recognition</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue
is recognized in accordance with the five-step model set forth by Accounting Standards Update (&#8220;ASU&#8221;) 2014-09, Revenue from
Contracts with Customers (&#8220;Topic 606&#8221;), which involves identification of the contract, identification of performance obligations
in the contract, determination of the transaction price, allocation of the transaction price to the previously identified performance
obligations, and revenue recognition as the performance obligations are satisfied.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 12.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue
from all customers is recognized when a performance obligation is satisfied by transferring control of a distinct good or service to
a customer. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit
of account under Topic 606. A contract&#8217;s transaction price is allocated to each distinct performance obligation in proportion to
the standalone selling price for each and recognized as revenue when, or as, the performance obligation is satisfied.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 12.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Individual
promised goods and services in a contract are considered a performance obligation and accounted for separately if the good or service
is distinct. A good or service is considered distinct if the customer can benefit from the good or service on its own or with other resources
that are readily available to the customer and the good or service is separately identifiable from other promises in the arrangement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 12.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
transaction price for the products is the invoiced amount. Advanced billings from contracts are deferred and recognized as revenue when
earned. Revenue is recognized only to the extent that it is probable that a significant reversal of revenue will not occur and when collection
is considered probable The Company excludes from revenue taxes collected from a customer that are assessed by a governmental authority
and imposed on and concurrent with a specific revenue-producing transaction. Deferred revenue consists of payments received in advance
of performance under the contract. Such amounts are generally recognized as revenue over the contractual period. The Company receives
payments from customers based upon contractual billing schedules. Accounts receivable is recorded when the right to consideration becomes
unconditional. Payment terms on invoiced amounts typically range from zero to 90 days, with typical terms of 30 days.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 12.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company generates revenue from two streams: (1) iRWD (imaging Real World Data) which provides regulatory grade imaging and clinical data
in the Pharmaceutical, Device Manufacturing, CRO&#8217;s and AI markets and (2) BEAM which is a Medical Imaging Exchange platform between
Hospital/Healthcare Systems, Imaging Centers, Physicians and Patients. iRWD is sold on a fixed fee basis based on the number of data
units and the cost per data unit committed to in the customer contract. Revenue is recognized when the data is delivered to the customer.
Beam revenue is subscription-based revenue which is recognized ratably over the subscription period committed to by the customer. The
Company invoices its Beam customers quarterly or annually in advance with the customer contracts automatically renewing unless the customer
issues a cancellation notice.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p id="xdx_846_eus-gaap--IncomeTaxPolicyTextBlock_zJ6mvQ9t6Vg8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span id="xdx_86A_zWc184B7YKG7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Income
Taxes</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is subject to U.S. federal, state and local income taxes. The Company accounts for income taxes in accordance with ASC Topic
740, Accounting for Income Taxes (&#8220;ASC Topic 740&#8221;), which requires the recognition of tax benefits or expenses on temporary
differences between the financial reporting and tax bases of its assets and liabilities by applying the enacted tax rates in effect for
the year in which the differences are expected to reverse. Such net tax effects on temporary differences are reflected on the Company&#8217;s
consolidated balance sheets as deferred tax assets and liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC
Topic 740 prescribes a two-step approach for the recognition and measurement of tax benefits associated with the positions taken or expected
to be taken in a tax return that affects amounts reported in the financial statements. The Company has reviewed and will continue to
review the conclusions reached regarding uncertain tax positions, which may be subject to review and adjustment at a later date based
on ongoing analyses of tax laws, regulations and interpretations thereof. To the extent that the Company&#8217;s assessment of the conclusions
reached regarding uncertain tax positions changes as a result of the evaluation of new information, such change in estimate will be recorded
in the period in which such determination is made. The Company reports income tax-related interest and penalties relating to uncertain
tax positions, if applicable, as a component of income tax expense</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
tax assets are reduced by a valuation allowance when the Company believes that it is more-likely-than-not that some portion or all of
the deferred tax assets will not be realized. The Company provides deferred taxes at the enacted tax rate that is expected to apply when
the temporary differences reverse. The Company has recorded a full valuation allowance against the net deferred tax asset due to the
uncertainty of realizing the related benefits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p id="xdx_843_ecustom--PatentsAndTrademarksPolicyTextBlock_zllmj1Dmzjha" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span id="xdx_866_zbuYUjfdq4qd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Patents
and Trademarks</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs
associated with the submission of a patent application are expensed as incurred given the uncertainty of the patents resulting in probable
future economic benefits to the Company and are included in research and development expenses on the consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 30pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84F_eus-gaap--ResearchAndDevelopmentExpensePolicy_zqccu0sxztVd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span id="xdx_86F_zoLfadaIiS4e" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Research
and Development</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 30pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company account for its research and development cost in accordance with ASC Topic 730, Research and Development (&#8220;ASC Topic 730&#8221;).
ASC Topic 730 requires that all R&amp;D costs be recognized as an expense as incurred. However, some costs associated with R&amp;D activities
that have an alternative future use (e.g., materials, equipment, facilities) may be capitalizable. For the years ended December 31, 2023
and December 31, 2022 research and development expenditures were charged to operating expense as incurred..</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 30pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_845_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zY1upFaeMacf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span id="xdx_869_z2L8cRNHHXpg" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stock-based
Compensation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has a stock-based compensation plan, which is described in more detail in Note 8. The fair value of stock option and warrant
grants are determined on the date of grant using the Black Scholes valuation model. Forfeitures of stock based awards are recorded as
the actual forfeitures occur. Stock based compensation expense is recognized over the service period, net of estimated forfeitures, using
the straight-line method. The Company converted all unvested stock based compensation awards to common shares in the year ended December
31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p id="xdx_846_eus-gaap--SellingGeneralAndAdministrativeExpensesPolicyTextBlock_zob83QmMzd2g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span id="xdx_862_zp3OEq1qEjda" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>General,
and Administrative Expenses</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses include all costs that are not directly related to satisfaction of customer contracts. General, and administrative
expenses include items for the Company&#8217;s selling and administrative functions, such as sales, finance, legal, human resources,
and information technology support. These functions include costs for items such as salaries and benefits and other personnel-related
costs, maintenance and supplies, professional fees for external legal, accounting, and other consulting services, intangible asset amortization,
and depreciation expense.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84B_ecustom--EmergingGrowthCompanyPolicyTextBlock_zSv3ZJ534jDd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span id="xdx_861_zPmGBlQam70g" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Emerging
Growth Company</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is an emerging growth company, as defined in Section 2(a) of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;),
as modified by the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;). Section 102(b)(1) of the JOBS Act exempts
emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that
is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered
under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;)) are required to comply with the new or revised
financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply
with the requirements that apply to non-emerging growth companies but any such an election to opt out is irrevocable. The Company has
not elected to opt out of such extended transition period which means that when a standard is issued or revised and it has different
application dates for public or private companies, the Company, as an emerging growth company , can adopt the new or revised standard
at the time private companies adopt the new or revised standard.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_845_ecustom--AccountingPronouncementsNotYetAdoptedPolicyTextBlock_zkriRDHeinT3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span id="xdx_86B_zXnyAgn1N81h" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Accounting
Pronouncements Not Yet Adopted</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU No. 2023-07, Improvements to Reportable Segment
Disclosures (Topic 280). This ASU updates reportable segment disclosure requirements by requiring disclosures of significant reportable
segment expenses that are regularly provided to the Chief Operating Decision Maker (&#8220;CODM&#8221;) and included within each reported
measure of a segment&#8217;s profit or loss. This ASU also requires disclosure of the title and position of the individual identified
as the CODM and an explanation of how the CODM uses the reported measures of a segment&#8217;s profit or loss in assessing segment performance
and deciding how to allocate resources. The ASU is effective for annual periods beginning after December 15, 2023, and interim periods
within fiscal years beginning after December 15, 2024. Adoption of the ASU should be applied retrospectively to all prior periods presented
in the financial statements. Early adoption is also permitted. This ASU will likely result in us including the additional required disclosures
when adopted. We are currently evaluating the provisions of this ASU and expect to adopt them for the year ending December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2023, the Financial Accounting Standards Board issued an Accounting Standards Update (&#8220;ASU&#8221;) amending existing income
tax disclosure guidance, primarily requiring more detailed disclosure for income taxes paid and the effective tax rate reconciliation.
The ASU is effective for annual reporting periods beginning after December 15, 2024, with early adoption permitted and can be applied
on either a prospective or retroactive basis. We are currently evaluating the ASU to determine its impact on our income tax disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p id="xdx_840_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zMFQj8yXoSH2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span id="xdx_86F_zcTBCyVWS00i" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Recently
adopted accounting pronouncements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2021, the FASB issued ASU No. 2021-08, Accounting for Contract Assets and Contract Liabilities from Contracts with Customers
(ASC Topic 805). This ASU requires an acquirer in a business combination to recognize and measure contract assets and contract liabilities
(deferred revenue) from acquired contracts using the revenue recognition guidance in Topic 606. At the acquisition date, the acquirer
applies the revenue model as if it had originated the acquired contracts. The ASU is effective for annual periods beginning after December
15, 2022, including interim periods within those fiscal years. We adopted this ASU prospectively on January 1, 2023. This ASU has not
and is currently not expected to have a material impact on our consolidated financial statements.</span></p>

<p id="xdx_85B_zXwne0u5Kej2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140069381749088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combination<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Business Combination</a></td>
<td class="text"><p id="xdx_80D_eus-gaap--BusinessCombinationDisclosureTextBlock_z4vKWwQH9wHb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.
<span id="xdx_82B_zeoEFUOzArqf">Business Combination</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Business Combination was accounted for as a reverse recapitalization as OneMedNet Corporation was determined to be the accounting acquirer
under Financial Accounting Standards Board&#8217;s (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) Topic 805,
Business Combinations. This determination was primarily based on OneMedNet Corporation comprising the ongoing operations of the combined
entity, OneMedNet Corporation&#8217;s senior management comprising of all the senior management of the combined company, and the prior
shareholders of OneMedNet owning a majority of the voting power of the combined entity. Accordingly, for accounting purposes, the financial
statements of the combined entity upon consummation of the Business Combination represented a continuation of the financial statements
of OneMedNet Corporation with the merger being treated as the equivalent of OneMedNet issuing stock for the net assets of Data Knights
Inc., accompanied by a recapitalization. Operations prior to the Business Combination are presented as those of OneMedNet Corporation
in future reports of the combined entity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//805/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140069389754544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Going Concern<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock', window );">Going Concern</a></td>
<td class="text"><p id="xdx_80C_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_z9GQMeGj2eO9" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
<span id="xdx_820_zNMLide1oM86">Going Concern</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets
and satisfaction of liabilities and commitments in the normal course of business. The Company does not have adequate liquidity to fund
its operations through at least twelve months from the date these financial statements were available for issuance. The Company has an
accumulated deficit <span id="xdx_900_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_di_c20231231_zLT6O9l1Mpdd">55,082,677</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">as of year-end December 31, 2023 and $<span id="xdx_90A_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_di_c20221231_zFrRkvZ0DDf6">43,509,964</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
as of year-end December 31, 2022 and has had negative cash flows from operating activities for the year ended December 31, 2023. These
conditions raise substantial doubt about the Company&#8217;s ability to continue as a going concern. To continue in existence and expand
its operations, the Company will be required to, and management plans to, raise additional working capital through an equity or debt
offering and ultimately attain profitable operations. If the Company is not able to raise additional working capital, it would have a
material adverse effect on the operations of the Company and continuing research and development of its product. The consolidated financial
statements do not include any adjustments relating to the recoverability and classification of assets and liabilities that might be necessary
should the Company be unable to continue as a going concern. The Company&#8217;s continuation as a going concern is dependent upon its
ability to continue receiving working capital cash payments and generating cash flow from operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205-40/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubstantialDoubtAboutGoingConcernTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140069385454832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p id="xdx_80B_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_z2S0u7LSVuZ2" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
<span id="xdx_822_zswcSU5RuXy">Property and Equipment</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are summarized as of December 31:</span></p>

<p id="xdx_89A_eus-gaap--PropertyPlantAndEquipmentTextBlock_zAazqlokgi91" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B2_z8Gw2Lkw6J59">Schedule
of Property And Equipment </span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%; margin-left: 0.75in">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20231231_zxbghYXtYgG" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20221231_zt0fc4NDUIdi" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_ziE4TvzcdXC8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%">Computers</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">246,578</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">259,207</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zo9jdq1Pm0n1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Furniture and equipment</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">35,708</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3,785</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzSdJ_zRVEXvJRbLte" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Total Property and Equipment</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">282,286</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">262,992</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzSdJ_zESw8MyMt588" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Less: accumulated depreciation</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(183,415</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(179,895</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzSdJ_zkzCLNMdEYJ2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Net Property and Equipment</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">98,871</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">83,097</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A2_z2Z5jWJEfOhc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
and amortization expense was $<span id="xdx_905_eus-gaap--DepreciationAndAmortization_c20230101__20231231_z4c8S5We6ZWd">27,983</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_901_eus-gaap--DepreciationAndAmortization_c20220101__20221231_zRDHKmXJDHP7">24,807
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for the years ended December 31, 2023
and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140069389824896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_80C_eus-gaap--IncomeTaxDisclosureTextBlock_zQGKlG3kSa4g" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.
<span id="xdx_828_zYHZpHPvRJn6">Income Taxes</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has generated both federal and state net operating losses (NOL) of approximately $<span id="xdx_90E_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_iI_pn6n6_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zrJBbv8G4Dve">21
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million and $<span id="xdx_905_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_iI_pn6n6_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_z5CpxqCHQ7id">23
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million, respectively, which if not used,
will begin to expire in 2030. The Company believes that its ability to fully utilize the existing NOL carryforwards could be restricted
on a portion of the NOL by changes in control that may have occurred or may occur in the future and by its ability to generate net income.
The Company has not yet conducted a formal study of whether, or to what extent, past changes in control of the Company impairs its NOL
carryforwards because such NOL carryforwards cannot be utilized until the Company achieves profitability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_897_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zOTyCca4QW1c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Components
of deferred income taxes are as follows as of December 31:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span id="xdx_8B6_zo03RUu2UEKe" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
of Deferred Income Taxes</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_490_20231231_zuzdypJa1VJe" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20221231_zvNXwFlUwyx6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsNetAbstract_iB_z1AfkgxFsRQc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Deferred Tax Assets</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzqvH_z5F5Wc4Dlonj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Net operating loss carry forward</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,823,785&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">6,973,587</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTAGzqvH_znQ6MjBxc6q2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Stock Compensation</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,035,947</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">481,144</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsOther_iI_maDTAGzqvH_zYoSYWKgPhFb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; padding-bottom: 1.5pt">Other</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0821">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">53,268</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzqvH_maDTANzhf6_zP6nBXkfV5Hc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Gross deferred tax assets</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,859,732</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">7,507,999</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzhf6_zvM5foPdYXh1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Less valuation allowance</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(7,859,732</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(7,507,999</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzhf6_zpjeP5OEWge3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Net deferred tax assets</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0830">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0831">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A1_z2sdkuOVvkC" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
change in the valuation allowance was $<span id="xdx_901_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_c20230101__20231231_z0SoQZV1P5eh">351,734
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_907_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_c20220101__20221231_zDJsXDusfHxb">1,384,220
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for the years ended December 31, 2023
and 2022, respectively. The effective tax rate for the years ended December 31, 2023 and 2022 differs from the federal and state statutory
rates due to the full valuation allowance. The Company recognizes the financial statement benefit of a tax position only after determining
that the relevant tax authority would more likely than not sustain the position following an audit. The tax years from inception through
December 31, 2023 remain subject to examination by all major taxing authorities due to the net operating loss carryovers. The Company
is not currently under examination by any taxing jurisdiction. The Company did not incur any interest or penalties during the years ended
December 31, 2023 or 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the Business Combination, the Company was appointed as the sole managing member of Data Knights. The Company is subject to
U.S. federal income taxes, in addition to state and local income taxes. The Company accounts for income taxes using the asset and liability
method, which requires the recognition of deferred tax assets and liabilities for the estimated future tax consequences attributable
to temporary differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective
tax base. Deferred tax assets and liabilities are determined on the basis of the differences between the consolidated financial statements
and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the temporary differences are expected
to be settled or recovered. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. In assessing
the realizability of deferred tax assets, the Company considers whether it is more likely than not that some portion or all of the deferred
tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income
during the periods in which those temporary differences become deductible. The Company considers the scheduled reversal of deferred tax
liabilities, projected future income, and tax planning strategies in making this assessment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has established a valuation allowance related deferred tax assets on deductible temporary differences, tax losses, and tax credit
carryforwards. The valuation allowance as of December 31, 2023 was $<span id="xdx_90C_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_pn5n6_c20231231__us-gaap--BusinessAcquisitionAxis__custom--DataKnightsAcquisitionCorpMember_zc9I8GCxiNOl">168.3</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
The increase in the valuation allowance in fiscal year 2023 of $<span id="xdx_90C_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn5n6_c20230101__20231231__us-gaap--BusinessAcquisitionAxis__custom--DataKnightsAcquisitionCorpMember_zAXOyzAGvkna">155.7
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million primarily relates to the Company&#8217;s
investment in Data Knights, and tax carryforward attributes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023, the Company had a U.S. federal net operating loss carryforwards of $<span id="xdx_903_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_z3uZn3tL8Luk">10.3
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million and gross state net operating
loss carryforwards of $<span id="xdx_903_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zW99MiPyTjFe">8.9
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140069385405328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Promissory Notes held by Related Party<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">Convertible Promissory Notes held by Related Party</a></td>
<td class="text"><p id="xdx_804_eus-gaap--LongTermDebtTextBlock_zs77GuAQ061c" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.
<span id="xdx_822_zC14DSedB2je">Convertible Promissory Notes held by Related Party</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2023, the Company entered various Convertible Promissory Notes (&#8220;Note&#8221;) with related party investors totaling $<span id="xdx_90E_eus-gaap--ConvertibleNotesPayable_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zJ0A9yJtOCIj">2,300,000
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2022 - $<span id="xdx_909_eus-gaap--ConvertibleNotesPayable_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zvGkZMJNdQSf">4,700,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)
and unrelated party investors of $<span id="xdx_90B_eus-gaap--ConvertibleNotesPayable_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_ze08HTFx5wN">1,875,000
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2022 - $<span id="xdx_909_eus-gaap--ConvertibleNotesPayable_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zO5hNPsSKwdd">440,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">).
The Notes issued are unsecured and bear an interest rate of six percent annually from the date of issuance until the outstanding principal
is paid or converted. On November 11, 2022 the Convertible note agreement was amended and restated in order to (i) provide for the sale
and issuance to Purchasers from the effective date of January 1, 2022 and after the date of this Agreement of up to an additional $<span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_c20221111__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNotesMember_ze3YghPcbhM5">5,000,000
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">aggregate principal amount of Notes and
warrants to purchase shares of the Company&#8217;s capital stock, (ii) provide for the sale and issuance to Purchasers who purchased
Notes under the Prior Agreement between the Effective Date and the date of this Agreement of warrants to purchase shares of the Company&#8217;s
common stock at an exercise price of $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221111__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z0g21z8lG49c">1.00
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share; (iii) extend the maturity date
of all outstanding Notes from December 31, 2022 to November 7, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
principal and unpaid accrued interest on each Note will convert: (i) automatically, upon the Company&#8217;s issuance of equity securities
(the &#8220;Next Equity Financing&#8221;) in a single transaction, or series of related transactions, with aggregate gross proceeds to
the Company of at least $<span id="xdx_907_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_c20221110__20221111__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNotesMember_zAHMpalxTCIi">5,000,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
into shares of the Company&#8217;s capital stock issued to investors in the Next Equity Financing, at a conversion price equal to the
lesser of (A) <span id="xdx_906_ecustom--EquityFinancingDescription_c20221110__20221111__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNotesMember_zP3bi3FMTxA8">a
20% discount to the lowest price per share of shares sold in the Next Equity Financing, or (B) $2.50 per share; (ii) at the noteholder&#8217;s
option, in the event of a defined Corporate Transaction while such Note remains outstanding, into shares of the Company&#8217;s Series
A-2 Preferred Stock at a conversion price equal to $</span></span><span id="xdx_907_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_c20221111__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__us-gaap--StatementClassOfStockAxis__custom--SeriesATwoPreferredStockMember__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNotesMember_zzxoqgGTU0af" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.50
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per
share; and (iii) at the noteholder&#8217;s option, on or after the Maturity Date while such Note remains outstanding, into shares of
the Company&#8217;s Series A-2 Preferred Stock at a conversion price equal to $</span><span id="xdx_901_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_c20221111__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__us-gaap--StatementClassOfStockAxis__custom--SeriesATwoPreferredStockMember__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNotesMember_zwlO38ap7fT2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.50
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per
share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a Corporate Transaction occurs before the repayment or conversion of the Notes, the Company will pay at the closing of the Corporate
Transaction to each noteholder that elects not to convert its Notes in connection with such Corporate Transaction an amount equal to
the outstanding principal amount of such noteholder&#8217;s Note plus a 20% premium. &#8220;Corporate Transaction&#8221; means (a) a
sale by the Company of all or substantially all of its assets, (b) a merger of the Company with or into another entity (if after such
merger the holders of a majority of the Company&#8217;s voting securities immediately prior to the transaction do not hold a majority
of the voting securities of the successor entity) or (c) the transfer of more than 50% of the Company&#8217;s voting securities to a
person or group.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
November 2019, the Company entered into a Convertible Promissory Note (&#8220;Note&#8221;) agreement with a related party investor. The
total amount of the Note is $<span id="xdx_90B_eus-gaap--ConvertibleNotesPayable_iI_c20191130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNotesMember_zv56oApNNbeh">1,500,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
The Note is unsecured and bears interest at a rate of four percent annually from the date of issuance until the outstanding principal
is paid or converted. The Note matures on January 1, 2025. The Note shall automatically convert into the next offering of preferred stock
upon closing of such next equity financing. The number of shares of preferred stock to be issued upon conversion shall be equal to the
number obtained by dividing the outstanding principal and unpaid accrued interest owed on the date of conversion, by the conversion price.
The conversion price is 100 percent of the lowest price per share paid for the next equity preferred stock by other investors in the
next equity financing. In the event that prior to the conversion or repayment of amounts owed, the Company completes a financing transaction
in which the Company sells equity securities but such transaction does not qualify as next equity financing (i.e., an &#8220;alternative
financing&#8221;), then the principal and unpaid accrued interest may (upon written election of the purchaser holding the Note) convert
into the securities issued by the Company in the alternative financing. The number of alternative financing equity securities to be issued
upon such conversion shall be equal to the number obtained by dividing the outstanding principal and unpaid accrued interest owed by
an amount equal to 100 percent multiplied by the lowest price per share at which the alternative financing equity securities are sold
and issued for cash in the alternative financing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022 there was $<span id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20221231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNotesMember_zzQfngxlNZv">9.9
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million outstanding principal balance
on the Notes and $<span id="xdx_90D_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_c20221231_zdNy3XL0rF12">690,771</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in accrued interest, all included in long-term liabilities
on the balance sheet. There were no payments of principal or interest during 2022. In connection with the $<span id="xdx_909_eus-gaap--ConvertibleNotesPayable_iI_c20221231_zHeJIptueIbd">5,140,000
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in convertible notes issued in 2022, <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231_ztjzjo3Remni">2,056,000
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in warrants were issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2023, the Business Combination between Data Knights and the Company triggered the Notes&#8217; conversion to common stock. Approximately
$<span id="xdx_90F_eus-gaap--ConvertibleNotesPayable_iI_pn5n6_c20231130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__us-gaap--BusinessAcquisitionAxis__custom--DataKnightsAcquisitionCorpMember_zWFSXJD2XsXd">15.4
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million of the total outstanding Notes
plus accrued interest were converted at $<span id="xdx_900_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20231130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__us-gaap--BusinessAcquisitionAxis__custom--DataKnightsAcquisitionCorpMember_z22nSokD3835">2.50
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 29.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//470/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140069389778144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Canadian Emergency Business Loan Act (CEBA)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Canadian Emergency Business Loan Act (CEBA)</a></td>
<td class="text"><p id="xdx_80B_eus-gaap--DebtDisclosureTextBlock_zoh1A7v8pgNb" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.
<span id="xdx_823_z8QgZaljwfyc">Canadian Emergency Business Loan Act (CEBA)</span></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
December 2020, the Company applied for and received a $<span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOfUnsecuredDebt_c20201201__20201231__us-gaap--DebtInstrumentAxis__custom--CEBALoanMember_z9FBa1FDxqQ1">44,673
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">USD CEBA loan. The loan was provided by
the Government of Canada to provide capital to organizations to see them through the current challenges and better position them to return
to providing services and creating employment. The loan is unsecured. The loan was interest free through December 31, 2023. If the loan
is paid back by January 18, 2024, $<span id="xdx_90B_eus-gaap--DebtInstrumentDecreaseForgiveness_c20200101__20201231__us-gaap--DebtInstrumentAxis__custom--CEBALoanMember_zHgzJPz57Uf1">14,742
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of the loan will be forgiven. If the loan
is not paid back by January 18, 2023, the full $<span id="xdx_90F_eus-gaap--DebtConversionOriginalDebtAmount1_c20200101__20201231__us-gaap--DebtInstrumentAxis__custom--CEBALoanMember_zezZ4lDkBQNf">44,673
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">loan will be converted to loan repayable
over <span id="xdx_90A_eus-gaap--DebtInstrumentTerm_dc_c20200101__20201231__us-gaap--DebtInstrumentAxis__custom--CEBALoanMember_z527KNug8vY8">three
years</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">with a <span id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20201231__us-gaap--DebtInstrumentAxis__custom--CEBALoanMember_z3pHMKrhHD42">5%
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">interest rate. The loan was paid back
prior January 18, 2024. At December 31, 2023 the loans is classified as Canada Emergency Business Loan Act under Current Liabilities
on the Consolidated Balance Sheet.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounted for the loan as debt in accordance with FASB Accounting Standards Codification 470 Debt and accrued interest in accordance
with the interest method under FASB ASC 835-30.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//470/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140069389847168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders&#8217; Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Shareholders&#8217; Equity</a></td>
<td class="text"><p id="xdx_802_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zwIUK3ZPhU96" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.
<span id="xdx_82C_zMJnazzhoipg">Shareholders&#8217; Equity</span></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Series
A-2 Preferred Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s previously issued and outstanding Series A-2 preferred stock included a $<span id="xdx_909_eus-gaap--SharesIssuedPricePerShare_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesATwoPreferredStockMember_zq4f8awROcvj">0.15
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share annual noncumulative dividend
when and if declared by the board of directors. <span id="xdx_90A_eus-gaap--DividendsPreferredStock_do_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesATwoPreferredStockMember_zfb2qGerALUh">No
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">dividends were declared in the years ended
December 31, 2023 or December 31 2022. The Series A-2 preferred stock also includes a liquidation preference of 1.25 times the original
issue price plus any declared but unpaid dividends upon the liquidation, dissolution, merger or sale of substantially all the assets
of the Company and have a preference upon liquidation over Series A-1 preferred stock and common stock. Each share of Series A-2 preferred
stock may be converted into equal shares of common stock at the option of the holder at any time. In addition, the Series A-2 preferred
stock shares are automatically convertible into common shares upon the sale of shares of common stock to the public at the then applicable
conversion price in a firm commitment underwritten public offering pursuant to an effective registration statement under the Securities
Act of 1933, as amended, resulting in at least $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_pn5n6_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesATwoPreferredStockMember_z2VdHHmRJnT">20
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million in proceeds, net of underwriting
discounts and commissions. Each share of Series A-2 preferred stock has voting rights equal to the number of shares of common stock then
issuable upon conversion of such share of preferred stock. The Company is obligated to redeem shares of Series A-2 Preferred Stock in
the occurrence of a Deemed Liquidation Event unless a majority of the holders of Series A-2 Preferred Stock and a majority of the Series
A-1 Preferred Stock consent otherwise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2023, the Business Combination between Data Knights and the Company triggered the <span id="xdx_90A_eus-gaap--ConvertiblePreferredStockTermsOfConversion_c20230101__20231231_zq6xgWTwPSXg">Series
A-2 Preferred Stock and Series A-1 Preferred Stock convert 1-1 to commons stock</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Series
A-1 Preferred Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s previously issued and outstanding Series A-1 preferred stock included a $<span id="xdx_909_eus-gaap--SharesIssuedPricePerShare_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember_zPFWdKqH8CR2">0.15
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share annual noncumulative dividend
when and if declared by the board of directors. <span id="xdx_905_eus-gaap--DividendsPreferredStock_do_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember_zcOAGK1oCteb">No
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">dividends were declared in the years ended
December 31, 2023 or December 31 2022. The Series A-1 preferred stock also includes a liquidation preference of 1.25 times the original
issue price plus any declared but unpaid dividends upon the liquidation, dissolution, merger or sale of substantially all the assets
of the Company and have a preference upon liquidation over common stock. Each share of Series A-1 preferred stock may be converted into
equal shares of common stock at the option of the holder at any time. In addition, the Series A-1 preferred stock shares are automatically
convertible into common shares upon the sale of shares of common stock to the public at the then applicable conversion price in a firm
commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended,
resulting in at least $<span id="xdx_909_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_pn5n6_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember_ziTTDyaYppZj">20
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million in proceeds, net of underwriting
discounts and commissions. Each share of Series A-1 preferred stock has voting rights equal to the number of shares of common stock then
issuable upon conversion of such share of preferred stock. The Company is obligated to redeem shares of Series A-1 Preferred Stock in
the occurrence of a Deemed Liquidation Event unless a majority of the holders of Series A-1 Preferred Stock consent otherwise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2023, the Business Combination between Data Knights and the Company triggered the <span id="xdx_90A_eus-gaap--ConvertiblePreferredStockTermsOfConversion_c20230101__20231231_zPmigUwb7mv3">Series
A-2 Preferred Stock and Series A-1 Preferred Stock convert 1-1 to commons stock</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common
Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2023, in connection with services performed by the Board of Directors common shares of <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230101__20231231__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_zUbEE9Udi2H9">100,000
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20220101__20221231__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_zvCTDm0x78h6">100,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-
2022) were issued at $<span id="xdx_902_eus-gaap--SharePrice_iI_c20231231__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_zoQnKnHOJV64">1.00
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share. These were expensed as general
and administrative expenses in the Statement of Operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_893_eus-gaap--ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_z57uq3swwTu3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font: normal 10pt Times New Roman, Times, Serif">The
table below summarizes the Common Stock activities during the year ended December 31, 2023.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span id="xdx_8B9_z64bu48q1ymf" style="font: normal 10pt Times New Roman, Times, Serif">Schedule
of Common Stock Activities</span><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 1in">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_z2msICVrt1Qb" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">Common
    Stock</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--SharesOutstanding_iS_zLHH8ANuCOvi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 80%">Balances, December 31, 2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">4,550,166</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--SharesOutstanding_iS_zW2yvdRyeAgd" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif">Balance</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">4,550,166</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_z2wlaGxg9Xb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Preferred Stock to Common Stock</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">7,057,797</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--StockIssuedDuringPeriodSharesConvertibleNotesToCommonStock_zJwjfDx64uRl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Convertible Notes to Common Stock</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">6,177,229</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--StockIssuedDuringPeriodSharesStockOptionsToCommonStock_z3uhYW1PO4Ql" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Stock Options to Common Stock</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">612,670</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--StockIssuedDuringPeriodSharesConvertingOfWarrantsToCommonStock_z3UmWOkuvHcd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Converting of Warrants to Common Stock</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,859,464</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--StockIssuedDuringPeriodSharesOther_zuvjfYqYrP3e" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Private OneMedNet to ONMD Public Shares</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(2,257,326</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_407_ecustom--StockIssuedDuringPeriodSharesConvertingDataKnightsCommonShares_zO0iuFy9if3i" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Converting Data Knights Common Stock (A and B) to ONMD Public Shares</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,460,275</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_z2eiIknVjv5e" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Issuance Public Shares</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">111,957</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--SharesOutstanding_iE_zyOXDTAsVnxi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif">Balances, December 31, 2023</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">23,572,232</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--SharesOutstanding_iE_zOLEX9Io8sth" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif">Balance</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">23,572,232</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8A0_z6jRMRei6Rl1" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140069389748336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Options<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock Options</a></td>
<td class="text"><p id="xdx_806_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zAjaUuhHpcC9" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.
<span id="xdx_828_zssYNJtF6ti3">Stock Options</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2020, the Company adopted a new equity incentive plan (the Plan), which provides for the granting of incentive and nonqualified stock
options to employees, directors, and consultants. As of December 31, 2020, the Company has reserved <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20200101__20201231__srt--TitleOfIndividualAxis__custom--EmployeesDirectorsAndConsultantsMember__us-gaap--PlanNameAxis__custom--NewEquityIncentivePlanMember_zOPY3Epoom39">3,000,000
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock under the Plan.
The Company believes that such awards better align the interests of its employees with those of its stockholders. Option awards are generally
granted with an exercise price equal to the fair market value of the Company&#8217;s stock at the date of grant; those option awards
generally vest with a range of one
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc_c20200101__20201231__srt--TitleOfIndividualAxis__custom--EmployeesDirectorsAndConsultantsMember__us-gaap--PlanNameAxis__custom--NewEquityIncentivePlanMember__srt--RangeAxis__srt--MaximumMember_zana3dh21Z82">four
years</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of continuous service and have ten-year
contractual terms. As there is no public data available for the share price valuation, the Company considers the Fair Market Value of
$<span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_c20201231__srt--TitleOfIndividualAxis__custom--EmployeesDirectorsAndConsultantsMember__us-gaap--PlanNameAxis__custom--NewEquityIncentivePlanMember_zuowjumEyy9k">1
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to be on the conservative side and similar
to the exercise price. Certain option awards provide for accelerated vesting if there is a change in control, as defined in the Plan.
The Plan also permits the granting of restricted stock and other stock-based awards. Unexercised options are cancelled upon termination
of employment and become available under the Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zOOwKvbrQpb1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
with respect to options outstanding is summarized as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span id="xdx_8B8_zQRZFYMZHvh1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
of Options Outstanding</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Options Outstanding</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Weighted- Average Exercise Price</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Aggregate Intrinsic Value</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 52%">Outstanding as of December 31, 2020</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210101__20211231_zadM3myKcRSg" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Options outstanding, begining balance">1,995,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231_zP106pErband" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Weighted average exercise price, begining balance">1.00</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20210101__20211231_z121yn1pvKH9" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Aggregate Intrinsic value, begining balance">1,995,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Granted - under the Plan</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210101__20211231_zXHo6mISQpKb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options, Granted - under the Plan">25,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Exercised</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20210101__20211231_zyywVTg5nGIa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options, Granted - under the Plan"><span style="-sec-ix-hidden: xdx2ixbrl0917">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Cancelled</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20210101__20211231_zSn9l0NAWEk4" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options, cancelled">(1,072,816</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Outstanding as of December 31, 2021</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220101__20221231_zaCQmCo4rgci" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options outstanding, ending balance">947,184</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210101__20211231_zXDcIpQgUsAi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, ending balance">1.00</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20210101__20211231_zhXfMFmK7TH1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic value, ending balance">947,184</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Granted - under the Plan</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231_z3d4RVyP48Li" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options, Granted - under the Plan">577,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Exercised</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20220101__20221231_z3Cg4GHDeiCb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options, Granted - under the Plan">(7,500</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Cancelled</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20220101__20221231_z6qJl1wVmuyk" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options, cancelled">(485,684</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Outstanding as of December 31, 2022</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20220101__20221231_zS1IVj8CRw3j" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options outstanding, ending balance">1,031,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231_zX1i6YPg8JM9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, ending balance">1.00</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20220101__20221231_zM05DsMkmdHa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic value, ending balance">1,031,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Options exercisable as of December 31, 2022</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20220101__20221231_ztwl4L855yl8" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options exercisable">567,581</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20220101__20221231_zYrTENj4cnQg" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, exercisable">1.00</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_c20220101__20221231_zj3Qf8Lulmh7" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic value, exercisable">567,581</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A8_z8EfnFrKpN6b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022 and 2021, there were <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20221231_zCusyY0Eadkf">1,031,000
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20211231_z60y0LjYvs75">947,184
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">common stock options outstanding with
a weighted average remaining contractual life of <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231_zTZjpFpO9Ie2">7.11
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">years and <span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231_zCiL8vS0y486">6.01
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">years, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022 and 2021, there were <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20221231_zQD82gnRuEM2">567,581
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20211231_zX6RDBNpqYZi">723,431
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">common stock options exercisable at a
weighted average remaining contractual life of <span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231_zCQqssRftxz1">5.56
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">years and <span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20210101__20211231_zoakaW2uUSNa">5.27
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">years, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 7, 2023, the Company issued shares of common stock for <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_pid_c20231107_zC2U5iJKuiKl">692,153
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">vested options less an exercise price
of $<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_pid_c20231107_zIYsl5WuH4K1">1.00</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">At
the Special Meeting </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">held on October 17, 2023<span style="background-color: white">,
Data Knights shareholders considered and approved the OneMedNet Corporation 2022 Equity Incentive Plan (the &#8220;Plan&#8221;) and reserved
an amount of shares of <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_pid_c20231017__20231017_zIGkitfX4Hnb">common
stock equal to 10% of the number of shares of common stock of OneMedNet following the Business Combination for issuance thereunder</span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">.
The Plan was approved by the OneMedNet pre-Closing board of directors on October 17, 2023. The Plan became effective immediately upon
the Closing of the Business Combination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font: normal 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Black
Scholes Assumptions</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
determination of the fair value of stock options using an option valuation model is affected by the Company&#8217;s stock price valuation,
as well as assumptions regarding a number of complex and subjective variables. The volatility assumption is based on volatilities of
similar companies over a period of time equal to the expected term of the stock options. The volatilities of similar companies are used
in conjunction with the Company&#8217;s historical volatility because of the lack of sufficient relevant history for the Company&#8217;s
common stock equal to the expected term. The expected term of the employee stock options represents the weighted average period for which
the stock options are expected to remain outstanding. The expected term assumption is estimated based primarily on the options&#8217;
vesting terms and remaining contractual life and employees&#8217; expected exercise and post- vesting employment termination behavior.
The risk-free rate for periods within the contractual life of the option is based on the U.S. Treasury yield curve in effect at the time
of grant. The dividend yield assumption is based on the expectation of no future dividend payouts by the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_898_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zay0AEYnB9Ej" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of the Company&#8217;s previous stock options was estimated assuming no expected dividends and the following weighted average
assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span id="xdx_8B6_zJo0ngyYGTwc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
of Fair Value of Stock Options</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2021</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Expected life in years</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span id="xdx_901_ecustom--EquitySecuritiesFvNiMeasurementTerm_dtY_c20220101__20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zoolrrCQTN9h">5.89</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span id="xdx_905_ecustom--EquitySecuritiesFvNiMeasurementTerm_dtY_c20210101__20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zyneyj3ZuwJ">6.08</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Risk-free interest rate</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z9y58LCpnxXh">0.55</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90C_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zWq5I7FYdBS2">0.49</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Expected dividend yield</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_900_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z69uRpV0a13b">0.00</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90A_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z4ohD9teCjj4">0.00</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Expected volatility</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90D_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zY9O0q7FP8Pk">32</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zSQ9xugXtAYb">60</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  </table>

<p id="xdx_8AF_zPAh7czH2RHd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
total expense recognized for share-based payments was $<span id="xdx_903_eus-gaap--AllocatedShareBasedCompensationExpense_c20220101__20221231_zs5NCE7xjYwb">45,584
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_906_eus-gaap--AllocatedShareBasedCompensationExpense_c20210101__20211231_zh4A4jq44eFh">47,071
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for the years ended December 31, 2022
and 2021, respectively. These costs are included in the statements of operations. As of December 31, 2022, there was $<span id="xdx_909_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_c20221231_z0GkDmV9WgF7">75,987
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of unrecognized compensation costs related
to stock option grants which will be recognized over the next four years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2023, the Company issued common stock to employees and extinguished all outstanding stock options. The <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zyhahePb5iy">612,720
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares outstanding were recorded as stock
expense in the Consolidated Statement of Operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140069389847168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Warrants<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ONMD_DisclosureStockWarrantsAbstract', window );"><strong>Stock Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ONMD_StockWarrantsDisclosureTextBlock', window );">Stock Warrants</a></td>
<td class="text"><p id="xdx_806_ecustom--StockWarrantsDisclosureTextBlock_z8PGkPv4zKwa" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.
<span id="xdx_82B_zW0uKdrIgtgh">Stock Warrants</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2021, there were <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20211231_zVMpckQCE4Bf">174,102
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">OneMedNet Corporation outstanding common
stock warrants issued for service at a weighted average exercise price of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20211231_zc6DmaF0LKM7">0.10</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
In 2022 for the exercise price of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231_zgf5jJhyAZkb">1.00</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
the OneMedNet Corporation issued <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__us-gaap--AwardTypeAxis__custom--TwentyTwentyOneServiceMember_zx0H5C9JD5ok">145,746
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warrants for 2021 service and <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__us-gaap--AwardTypeAxis__custom--TwentyTwentyTwoServiceMember_zF9lMoCrpHyc">294,000
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warrants for 2022 service, <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--ConvertiableNotesMember_zo7PsnZa1bXl">2,056,000
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in warrants were issued attached to convertible
notes. The Company expensed $<span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfWarrants_c20220101__20221231_ziimEIM50841">1,346,288</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in 2022 in relation to the issuance of the Warrants. In 2023
for the exercise price of $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231_zwObMnOHBCT1">1.00</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
the OneMedNet issued <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--ConvertiableNotesMember_zbfmaPMF2PY9">1,670,000
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in warrants attached to convertible notes.
OneMedNet Corporation converted <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantOneMember_zYX8MxovCp9d">4,165,746
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warrants outstanding to common stock at
an exercise price of $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantOneMember_zDVAXmd1vmK9">1.00
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and converted <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zy008UtCDFD9">174,102
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warrants outstanding to common stock at
an exercise price of $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zGTMTgjKR4f3">0.10</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023 and December 31, 2022, the Company had <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--PubliclyTradedWarrantsMember_zlBN1dUU6NMh">11,500,000
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of publicly traded warrants. The warrants
trade on the Nasdaq had closing price of $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PubliclyTradedWarrantsMember_zYDKyHofnc49">.0149
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--PubliclyTradedWarrantsMember_z3715RMmux9c">.0400
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">at December 31, 2023 and December 31,
2022 respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023 and December 31, 2022, the Company had <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivateWarrantsMember_zGRZgpppUqL1">681,019
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivateWarrantsMember_zoyczQ9iZHv2">585,275
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of private warrants outstanding. These
warrants are classified as liability on the Consolidated Balance Sheet. Changes in the warrant liabilities are recorded in the Statement
of Operations. As of December 31, 2023 and December 31, 2022, the warrant liabilities were $<span id="xdx_907_eus-gaap--OtherLiabilities_iI_pn5n6_c20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_ztu26qdbHEN6">0.6
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million and $<span id="xdx_906_eus-gaap--OtherLiabilities_iI_pn5n6_c20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z5jxlvTWlcW8">0.4
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ONMD_DisclosureStockWarrantsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ONMD_DisclosureStockWarrantsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ONMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ONMD_StockWarrantsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock warrants disclosure text block.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ONMD_StockWarrantsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ONMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140069389820960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measures</a></td>
<td class="text"><p id="xdx_803_eus-gaap--FairValueDisclosuresTextBlock_zR5YrFIBCSuh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>12.
<span id="xdx_829_zGhU1cTHD9La">Fair Value Measures</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value measurement accounting standards establish a framework for measuring fair value and expand disclosures about fair value measurements.
The standard does not require any new fair value measurements; rather, it applies to other accounting pronouncements that require or
permit fair value measurements. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability
in the principal or most advantageous market in an orderly transaction between market participants on the measurement date. This pronouncement
also establishes a three-level hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable
inputs when measuring fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
valuation hierarchy is based upon the transparency of inputs to the valuation of an asset or liability on the measurement date. The three
levels are defined as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1&#8212;inputs to the valuation methodology are quoted prices (unadjusted) for an identical asset or liability in an active market</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2&#8212;inputs to the valuation methodology include quoted prices for a similar asset or liability in an active market or model-derived
valuations in which all significant inputs are observable for substantially the full term of the asset or liability</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3&#8212;inputs to the valuation methodology are unobservable and significant to the fair value measurement of the asset or liability</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89F_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisTextBlock_zF46BGIp4EFd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the Company&#8217;s financial assets measured and recorded at fair value on a recurring basis using the above
input categories as of December 31, 2023 and December 31, 2022 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span id="xdx_8BF_zdP5BhYaW47c" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
of Financial Assets</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="30" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year Ended</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><b>December 31, 2023</b></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><b>December 31, 2022</b></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level 1</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level 2</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level 3</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level 1</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level 2</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level 3</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Assets:</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 28%; text-align: left">Investments held in Trust</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--AssetsHeldInTrustCurrent_iI_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByAssetClassAxis__custom--InvestmentsHeldInTrustMember_zEQFhQkyIfN" style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right" title="Investments held in Trust"><span style="-sec-ix-hidden: xdx2ixbrl0996">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--AssetsHeldInTrustCurrent_iI_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByAssetClassAxis__custom--InvestmentsHeldInTrustMember_zLZI52abmujj" style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right" title="Investments held in Trust"><span style="-sec-ix-hidden: xdx2ixbrl0998">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--AssetsHeldInTrustCurrent_iI_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByAssetClassAxis__custom--InvestmentsHeldInTrustMember_zoUYLwzbPZ09" style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right" title="Investments held in Trust"><span style="-sec-ix-hidden: xdx2ixbrl1000">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--AssetsHeldInTrustCurrent_iI_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--InvestmentsHeldInTrustMember_zXBMFEw6Jxej" style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right" title="Investments held in Trust"><span style="-sec-ix-hidden: xdx2ixbrl1002">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--AssetsHeldInTrustCurrent_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByAssetClassAxis__custom--InvestmentsHeldInTrustMember_zvIGgDiejqOl" style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right" title="Investments held in Trust">29,029,416</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--AssetsHeldInTrustCurrent_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByAssetClassAxis__custom--InvestmentsHeldInTrustMember_zcCKPwhX93uc" style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right" title="Investments held in Trust"><span style="-sec-ix-hidden: xdx2ixbrl1006">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--AssetsHeldInTrustCurrent_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByAssetClassAxis__custom--InvestmentsHeldInTrustMember_zvXhmGsmuOr7" style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right" title="Investments held in Trust"><span style="-sec-ix-hidden: xdx2ixbrl1008">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--AssetsHeldInTrustCurrent_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--InvestmentsHeldInTrustMember_zrAoAx5qHUz5" style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right" title="Investments held in Trust">29,029,416</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Total Assets</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_eus-gaap--AssetsHeldInTrustCurrent_iI_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zmIvjjLwQdvj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Assets measured and recorded fair value"><span style="-sec-ix-hidden: xdx2ixbrl1012">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98A_eus-gaap--AssetsHeldInTrustCurrent_iI_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zVtsygBqkh22" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Assets measured and recorded fair value"><span style="-sec-ix-hidden: xdx2ixbrl1014">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98F_eus-gaap--AssetsHeldInTrustCurrent_iI_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zUnskt8YvWJ7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Assets measured and recorded fair value"><span style="-sec-ix-hidden: xdx2ixbrl1016">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98B_eus-gaap--AssetsHeldInTrustCurrent_iI_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zYdjoewzQqGk" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Assets measured and recorded fair value"><span style="-sec-ix-hidden: xdx2ixbrl1018">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98A_eus-gaap--AssetsHeldInTrustCurrent_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zJDtEWqItAIb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Assets measured and recorded fair value">29,029,416</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98A_eus-gaap--AssetsHeldInTrustCurrent_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zWmgRXu5v5Aj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Assets measured and recorded fair value"><span style="-sec-ix-hidden: xdx2ixbrl1022">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98C_eus-gaap--AssetsHeldInTrustCurrent_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zMRKEoTtJrC9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Assets measured and recorded fair value"><span style="-sec-ix-hidden: xdx2ixbrl1024">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_986_eus-gaap--AssetsHeldInTrustCurrent_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_ziDpKsUYsNjf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Assets measured and recorded fair value">29,029,416</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140069381734816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><p id="xdx_805_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zVfbIOnskmzk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>13.
<span id="xdx_829_z8h35XY0FX7d">Related Party Transactions</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Loan
Extensions</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Data
Knights closed its initial public offering in May 2021 and had 12 months to complete a business combination. Alternatively, the Data
Knight could extend the period up to two times for an additional three months each time with an extension costing $<span id="xdx_908_eus-gaap--ConvertibleNotesPayable_iI_pn5n6_c20231231__us-gaap--BusinessAcquisitionAxis__custom--DataKnightsAcquisitionCorpMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z0CG6fi9Tq7i">1.2
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million. Data Knights received a total
of $<span id="xdx_90D_ecustom--ExtensionLoan_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__srt--TitleOfIndividualAxis__custom--ManagementAndDirectorsMember_zA1fifUXV765">300,000
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">from members of the Company&#8217;s Management
and Directors. As of December 31, 2023 and December 31, 2022 the total extension loan including interest outstanding was $<span id="xdx_905_ecustom--ExtensionLoan_iI_pn5n6_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zO7QOwXdAHNg">3.0
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million and $<span id="xdx_90C_ecustom--ExtensionLoan_iI_pn5n6_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zn10KaDPlSY">2.5
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>PIPE
Convertible Notes and Warrants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2023, the Company entered into a Securities Purchase Agreement (SPA) in which the Company was required to sell senior secured
convertible notes and warrants to Directors of the Company. The SPA stipulates a collateral security agreement between the Company and
the Directors for punctual payment and performance by the Company on its Obligations to the Directors. The Intellectual Property of the
Company serves as the collateral for the Directors. The senior secured convertible notes and warrants were issued through a private issuance
of a public entity (PIPE) transaction, which is a form of debt and equity offering under an exception in the securities law for qualifying
private placements by issuers of publicly traded securities. The Company received a total of $<span id="xdx_909_eus-gaap--ProceedsFromConvertibleDebt_pn5n6_c20231101__20231130__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zHfl035q52V8">1.5
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million from the director in exchange
for senior convertible notes of $<span id="xdx_901_eus-gaap--ProceedsFromConvertibleDebt_pn5n6_c20231101__20231130__us-gaap--DebtInstrumentAxis__custom--SeniorConvertibleNotesMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zBMVzI03gT53">1.6
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million (plus accrued interest of $<span id="xdx_902_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_pn5n6_c20231130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zWkuosgJLyol">0.1
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million) and <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20231101__20231130__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z3r0Tli7e5mb">95,745
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warrants to acquire common stock. <span id="xdx_909_eus-gaap--DebtInstrumentDescription_c20231101__20231130__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z4uH06NxL485">The
senior secured notes are convertible to the conversion rate of $</span></span><span id="xdx_904_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20231130__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zo5virPJQB77" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.00
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per
share, and 92.5% of the lowest VWAP for the ten (10) trading days immediately preceding the conversion Date, subject to the floor price
of $1.14 (representing 20% of the closing price on the last trading day before the closing of the Business Combination), or the alternative
conversion ratio the greater of the floor price and the lesser of 80% of the VWAP of the common stock as of the trading day and 80% of
the price computed as the quotient of the sum of the VWAP of the Common Stock for each of the three Trading Days with the lowest VWAP
of the Common Stock during the fifteen consecutive trading day period ending and including the trading day immediately preceding the
delivery or deemed delivery of the applicable Conversion Notice, divided by three</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
All such determinations to be appropriately adjusted for any stock dividend, stock split, stock combination, reclassification or similar
transaction that proportionately decreases or increases the common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
warrants are classified as equity and the total proceeds received from the Directors are allocated based on the relative fair values
of the convertible notes and the warrants at the issued date. The portion allocable to warrants is accounted for as paid-in capital.
The senior secured convertible notes are classified as long term debt in the Consolidated Balance Sheet. The estimate fair value of the
senior secured convertible notes at December 31, 2023 was $<span id="xdx_90A_eus-gaap--SeniorNotesCurrent_iI_pn5n6_c20231231_z2qCGfNbO6v4">1.2
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140069389866032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments, Contingencies, and Concentrations Operating lease<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments, Contingencies, and Concentrations Operating lease</a></td>
<td class="text"><p id="xdx_808_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zwxSvY1JlXvj" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.
<span id="xdx_826_zgUaC2z4h9U3">Commitments, Contingencies, and Concentrations Operating lease</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has a month-to-month lease for a suite at a cost of $<span id="xdx_905_eus-gaap--OperatingLeaseCost_c20230101__20231231_zPWRhci46SQk">575
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per month. The Company incurred $<span id="xdx_908_eus-gaap--OperatingLeasesRentExpenseNet_c20230101__20231231_zin38NTu1i35">7,695
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_909_eus-gaap--OperatingLeasesRentExpenseNet_c20220101__20221231_zCwDNKWtXxr1">7,694
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of rent expense, including common tenant
costs and cancellation costs, during the years ended December 31, 2023 and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140069389857232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p id="xdx_80F_eus-gaap--SubsequentEventsTextBlock_zJvyAX1Zop84" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.
<span id="xdx_82C_zUZBTByM5AI1">Subsequent Events</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has evaluated subsequent events occurring through April 9, 2024, the date the financial statements were available for issuance,
for events requiring recording or disclosure in the Company&#8217;s financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2024, through to the date of this report, the Company issued <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20241231__srt--StatementScenarioAxis__srt--ScenarioForecastMember__dei--LegalEntityAxis__custom--EFHuttonMember_zaAfsIKOPiMl">256,944
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20241231__srt--StatementScenarioAxis__srt--ScenarioForecastMember__dei--LegalEntityAxis__custom--KingwoodCapitalPartnersLLCMember_zuM3Moi0ltog">20,834
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of Common Stock to EF Hutton LLC
and Kingwood Capital Partners, LLC, respectively, as consideration for $<span id="xdx_903_eus-gaap--BusinessCombinationConsiderationTransferred1_pn5n6_c20240101__20241231__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zuOa4HNu8XSg">3.0
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million owed by the Company for underwriting
commission due at the closing of the Business Combination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2024, through to the date of this report, the Company bought back <span id="xdx_907_eus-gaap--StockRepurchasedDuringPeriodShares_c20240101__20241231__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zotKVRYt0Kbh">187,745
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of Common Stock from a convertible
note holder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2024, through to the date of this report, the Company received $<span id="xdx_902_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20240101__20241231__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--MajorityShareholderMember_z3LcYbfqQwm3">1,000,000
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">from a majority shareholder for the purchase
of shares, and an additional $<span id="xdx_90A_eus-gaap--ProceedsFromRelatedPartyDebt_c20240101__20241231__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zz1aR5stuiD7">300,000
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">treated as a shareholder loan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2024, through to the date of this report, the Company entered into a definitive securities purchase agreement with an institutional investor
providing up to&#160;$<span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn4n6_c20240101__20241231__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z10C4pdnNwd9">4.54
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million&#160;in funding through a private
placement for the issuance of senior convertible notes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">As previously announced
on Form 8-K, on March 28, 2024, OneMedNet Corporation (the &#8220;Company&#8221;) <span style="background-color: white">entered into
a definitive securities purchase agreement (the &#8220;Securities Purchase Agreement&#8221;) with Helena Global Investment Opportunities
1 Ltd., an affiliate of Helena Partners Inc., a Cayman-Islands based advisor and investor providing for up to USD$</span>4.54 million
<span style="background-color: white">in funding through a private placement for the issuance of senior secured convertible notes (the
&#8220;Notes&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">As previously announced
on Form 8-K, on March 27, 2024, Paul J. Casey, Chief, Chief Executive Officer of the Company, notified the Company of his intention to
retire as Chief Executive Officer of the Company effective March 29, 2024. Mr. Casey will continue to serve as a member of the Board
of Directors (the &#8220;Board&#8221;) of the Company. In connection with Mr. Casey&#8217;s service on the Advisory Board of the Company,
the Board approved a Stock Option Grant (the &#8220;Option Grant&#8221;) providing for the grant of <span id="xdx_901_eus-gaap--StockRepurchasedDuringPeriodShares_c20240326__20240327__srt--StatementScenarioAxis__srt--ScenarioForecastMember__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zuUqsqqUT0Ph">147,000
</span>five-year options exercisable at $<span id="xdx_90A_eus-gaap--SharePrice_iI_c20240327__srt--StatementScenarioAxis__srt--ScenarioForecastMember__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zm1HBlB7Oone">1.00
</span>per share adviser to Mr. Casey. Also on March 27, 2024, Scott Holbrook, a member of the Board of the Company and a member
of the Company&#8217;s Audit Committee, notified the Company of his intention to retire from the Company&#8217;s Board effective March
29, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Effective March 29, 2024,
the Board (i) appointed Mr. Aaron Green, to serve as Chief Executive Officer of the Company to fill the vacancy created by the retirement
of Paul Casey; (ii) appointed Mr. Aaron Green, to serve as a member of the Board to fill the vacancy created by the retirement of Scott
Holbrook; and (iii) appointed Board member, Dr. Thomas Kosasa, to serve on the Company&#8217;s Audit Committee, also to fill the vacancy
created by the retirement of Scott Holbrook.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140069379476880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Basis of Presentation and Foreign Currency Translation</a></td>
<td class="text"><p id="xdx_842_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zvzejhltBzmk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span id="xdx_86A_zHiorFzUGPkd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Basis
of Presentation and Foreign Currency Translation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 12.95pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements have been prepared in U.S. dollars, in accordance with accounting principles generally accepted in
the United States of America (&#8220;GAAP&#8221;). The accompanying consolidated financial statements include the accounts of the Company
and its wholly owned subsidiaries. The consolidated financial statements include 100% of the accounts of wholly-owned subsidiaries. All
intercompany balances and transactions have been eliminated in consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business Combination</a></td>
<td class="text"><p id="xdx_840_eus-gaap--BusinessCombinationsPolicy_zndaSaMzFgIb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span id="xdx_868_z9lk6RJzb8ma" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Business
Combination</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
account for business acquisitions under ASC Topic 805, Business Combinations (&#8220;ASC Topic 805&#8221;). The total purchase consideration
for an acquisition is measured as the fair value of the assets given, equity instruments issued, and liabilities assumed at the acquisition
date. Costs that are directly attributable to the acquisition are expensed as incurred. Identifiable assets (including intangible assets)
and liabilities assumed (including contingent liabilities) are measured initially at their fair values at the acquisition date. We recognize
goodwill if the fair value of the total purchase consideration is in excess of the net fair value of the identifiable assets acquired
and the liabilities assumed. We recognize a bargain purchase gain within Other income (expense), net, in the consolidated statement of
operations if the net fair value of the identifiable assets acquired and the liabilities assumed is in excess of the fair value of the
total purchase consideration. We include the results of operations of the acquired business in the consolidated financial statements
beginning on the acquisition date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 12.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p id="xdx_843_eus-gaap--UseOfEstimates_zjt1UdiaaVH7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span id="xdx_869_zIt7XWTLer6d" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Use
of Estimates</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of consolidated financial statements in conformity with GAAP requires management to make estimates, judgments, and assumptions
that affect the reported amounts of assets, liabilities, revenue, and expenses, and the amounts disclosed in the related notes to the
consolidated financial statements. Actual results and outcomes may differ materially from management&#8217;s estimates, judgments, and
assumptions. Significant estimates, judgments, and assumptions used in these financial statements include, but are not limited to, those
related to revenue, useful lives and realizability of long-lived assets, accounting for income taxes and related valuation allowances,
and unit and stock-based compensation. Estimates are periodically reviewed in light of changes in circumstances, facts, and experience.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ONMD_OperatingSegmentsPolicyTextBlock', window );">Operating Segments</a></td>
<td class="text"><p id="xdx_843_ecustom--OperatingSegmentsPolicyTextBlock_zACDXJyzWbLk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span id="xdx_862_zQstZ0yF89o" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Operating
Segments</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company operates as one operating segment. Operating segments are defined as components of an enterprise for which separate financial
information is regularly evaluated by the chief operating decision maker (&#8220;CODM&#8221;), which is the Company&#8217;s Chief Executive
Officer, in deciding how to allocate resources and assess performance. The Company&#8217;s CODM evaluates the Company&#8217;s financial
information and resources and assesses the performance of these resources on a consolidated basis. The Company is not organized by market
and is managed and operated as one business. A single management team that reports to the chief executive officer comprehensively manages
the entire business. Accordingly, the Company does not accumulate discrete financial information with respect to separate divisions and
does not have separate operating or reportable segments. Since the Company operates in one operating segment, all required financial
segment information can be found in the consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zMlRvLLBGcYl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span id="xdx_867_zKdmKLGHFwQ8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cash
and Cash Equivalents</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
and cash equivalents consist of highly liquid, short-term investments with a maturity of three months or less when purchased. Cash equivalents
consist of money market funds and are carried at cost, which approximates fair value. The balances, at times, may exceed FDIC Insured
limits. The Company believes that, as of December 31, 2023, its risk relating to deposits exceeding federally insured limits was not
significant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zHSkOZjoaDAg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span id="xdx_863_zDnAqV8hKKmb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Accounts
Receivable</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
receivable are unsecured, recorded at net realizable value, and do not bear interest. Accounts receivable are considered past due if
not paid within the terms established between the Company and the customer. Amounts are only written off after all attempts at collections
have been exhausted. The Company determines the need for an allowance for doubtful accounts based upon factors surrounding the credit
risk of specific customers, historical trends and other information. As of December 31, 2023 and 2022, the Company established allowances
of $<span id="xdx_90D_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20231231_zsgeggHAEi86">0</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and
$<span id="xdx_904_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20221231_zELlL3nc7kY7">102,700</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">respectively.
The net receivable balances outstanding are fully collectible.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company believes its credit policies are prudent and reflect normal industry terms and business risk. The Company generally does not
require collateral from its customers and generally requires payment from 0 to 90 days from the invoice date. For the year ended December
31, 2023, there was 1 customer that accounted for <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneCustomerMember_zYlEzIbkEdmk">10</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
or more of total revenue, and there were 2 customers that accounted for <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--TwoCustomersMember_zWk6srTqOOyb">10</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
or more of total revenue for the years ended December 31, 2022 . The following table represents these customers&#8217; aggregate percent
of total revenue:</span></p>

<p id="xdx_899_eus-gaap--SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_zQi7JmXQvsj9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B2_zGLv6h4dCOii">Schedule
Of Aggregate Percentage Revenue and Accounts Receivable</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20230101__20231231_zUGdB37NKUn6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December
    31, 2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20220101__20221231_zcYb7a6l5vo2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December
    31, 2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year Ended</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31, 2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31, 2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zEHO2Q3PAb9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 56%">Customer 1</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right">52</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right">31</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_405_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_zZGLElbzyVq4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Customer 2</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0725">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">22</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr id="xdx_40F_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomersMember_z5Y4MjatHXV" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Aggregate Percent of Total Revenue</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">52</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">53</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 12.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023, three customers accounted for more than <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--ThreeCustomersMember_zaeCBpShTQP9">10</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
of the Company&#8217;s accounts receivable balance, and two customers accounted for over <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--TwoCustomersMember_z1pBVCbDsh6b">10</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
of the Company&#8217;s accounts receivable balance at December 31, 2022. The following table represents these customers&#8217; aggregate
percent of total accounts receivable:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 12.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20230101__20231231_zFefwqYRVOU8" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December
    31, 2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20220101__20221231_z2cFFNbI99Sb" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December
    31, 2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year Ended</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31, 2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31, 2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zUQw8G4cVKZe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%">Customer 1</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0733">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">40</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_400_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_zbivTlCYEB3g" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">Customer 2</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">36</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0737">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerThreeMember_zUf1RqDmH0z5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Customer 3</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">33</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0740">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerFourMember_zMcJm0AG6jMd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">Customer 4</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0742">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">32</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr id="xdx_404_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerFiveMember_zXVSrVaFghWj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Customer 5</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">27</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0746">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomersMember_zdgdbAAO0zIb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Aggregate Percent of Total Accounts Receivable</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">96</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">%</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">72</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr id="xdx_40F_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomersMember_zg1FiXjCH2xe" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Aggregate Percent of Revenue and Accounts Receivable</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">96</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">%</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">72</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">%</td></tr>
</table>

<p id="xdx_8A5_zHDNCw2Iq6Qc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 12.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p id="xdx_846_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zoEI6ToaNBQc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span id="xdx_868_z4IcW1vRIm1b" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Property
and Equipment</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are recorded at cost. The straight-line method is used for computing depreciation and amortization. Assets are depreciated
over their estimated useful lives ranging from three to five years. Cost of maintenance and repairs are charged to expense when incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p id="xdx_841_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zqQEFN1kkqcg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span id="xdx_862_zNNfTwY6IbVa" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Impairment
of Long-Lived Assets</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company reviews long-lived assets, including property and equipment, for impairment whenever events or changes in business circumstances
indicate that the carrying amount of an asset may not be fully recoverable. An impairment loss would be recognized when the estimated
future undiscounted net cash flows from the use of the asset are less than the carrying amount of that asset. There have been <span id="xdx_90A_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_do_c20220101__20221231_zU0HgIgIqy09">no
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">losses during the years ended December
31, 2023 or December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p id="xdx_845_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zDiDCTuKvzr" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span id="xdx_865_zS2oqDkolOjj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Fair
Value of Financial Instruments</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between
market participants at the measurement date. To increase the comparability of fair value measures, the following hierarchy prioritizes
the inputs to valuation methodologies used to measure fair value:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 12.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level
1</b> &#8212; Valuations based on quoted prices for identical assets and liabilities in active markets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level
2</b> &#8212; Valuations based on observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets
and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, or other
inputs that are observable or can be corroborated by observable market data.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level
3</b> &#8212; Valuations based on unobservable inputs reflecting our own assumptions, consistent with reasonably available assumptions
made by other market participants. These valuations require significant judgment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 12.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
measure the fair value of money market funds and certain marketable equity securities based on quoted prices in active markets for identical
assets or liabilities. Other marketable securities were valued either based on recent trades of securities in inactive markets or based
on quoted market prices of similar instruments and other significant inputs derived from or corroborated by observable market data. We
did not hold significant amounts of marketable securities categorized as Level 3 assets as of the years ended December 31, 2022 and December
31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s financial instruments consist of cash and cash equivalents, accounts receivable, accounts payable, convertible notes
payable and certain privately issued warrants. The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable
financial instruments approximate their fair value due to their short-term nature. The Company&#8217;s Private Warrants estimated fair
values are provided by a third party pricing vendor and are reviewed by the Company&#8217;s management. The Private Warrants valuations
are based on unobservable inputs reflecting the vendor&#8217;s assumptions, consistent with reasonably available assumptions made by
other market participants and thus are classified as Level 3.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p id="xdx_848_eus-gaap--RevenueRecognitionPolicyTextBlock_z8kXah7HUIp5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span id="xdx_860_zetssCGQ3aL3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Revenue
Recognition</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue
is recognized in accordance with the five-step model set forth by Accounting Standards Update (&#8220;ASU&#8221;) 2014-09, Revenue from
Contracts with Customers (&#8220;Topic 606&#8221;), which involves identification of the contract, identification of performance obligations
in the contract, determination of the transaction price, allocation of the transaction price to the previously identified performance
obligations, and revenue recognition as the performance obligations are satisfied.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 12.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue
from all customers is recognized when a performance obligation is satisfied by transferring control of a distinct good or service to
a customer. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit
of account under Topic 606. A contract&#8217;s transaction price is allocated to each distinct performance obligation in proportion to
the standalone selling price for each and recognized as revenue when, or as, the performance obligation is satisfied.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 12.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Individual
promised goods and services in a contract are considered a performance obligation and accounted for separately if the good or service
is distinct. A good or service is considered distinct if the customer can benefit from the good or service on its own or with other resources
that are readily available to the customer and the good or service is separately identifiable from other promises in the arrangement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 12.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
transaction price for the products is the invoiced amount. Advanced billings from contracts are deferred and recognized as revenue when
earned. Revenue is recognized only to the extent that it is probable that a significant reversal of revenue will not occur and when collection
is considered probable The Company excludes from revenue taxes collected from a customer that are assessed by a governmental authority
and imposed on and concurrent with a specific revenue-producing transaction. Deferred revenue consists of payments received in advance
of performance under the contract. Such amounts are generally recognized as revenue over the contractual period. The Company receives
payments from customers based upon contractual billing schedules. Accounts receivable is recorded when the right to consideration becomes
unconditional. Payment terms on invoiced amounts typically range from zero to 90 days, with typical terms of 30 days.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 12.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company generates revenue from two streams: (1) iRWD (imaging Real World Data) which provides regulatory grade imaging and clinical data
in the Pharmaceutical, Device Manufacturing, CRO&#8217;s and AI markets and (2) BEAM which is a Medical Imaging Exchange platform between
Hospital/Healthcare Systems, Imaging Centers, Physicians and Patients. iRWD is sold on a fixed fee basis based on the number of data
units and the cost per data unit committed to in the customer contract. Revenue is recognized when the data is delivered to the customer.
Beam revenue is subscription-based revenue which is recognized ratably over the subscription period committed to by the customer. The
Company invoices its Beam customers quarterly or annually in advance with the customer contracts automatically renewing unless the customer
issues a cancellation notice.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_846_eus-gaap--IncomeTaxPolicyTextBlock_zJ6mvQ9t6Vg8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span id="xdx_86A_zWc184B7YKG7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Income
Taxes</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is subject to U.S. federal, state and local income taxes. The Company accounts for income taxes in accordance with ASC Topic
740, Accounting for Income Taxes (&#8220;ASC Topic 740&#8221;), which requires the recognition of tax benefits or expenses on temporary
differences between the financial reporting and tax bases of its assets and liabilities by applying the enacted tax rates in effect for
the year in which the differences are expected to reverse. Such net tax effects on temporary differences are reflected on the Company&#8217;s
consolidated balance sheets as deferred tax assets and liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC
Topic 740 prescribes a two-step approach for the recognition and measurement of tax benefits associated with the positions taken or expected
to be taken in a tax return that affects amounts reported in the financial statements. The Company has reviewed and will continue to
review the conclusions reached regarding uncertain tax positions, which may be subject to review and adjustment at a later date based
on ongoing analyses of tax laws, regulations and interpretations thereof. To the extent that the Company&#8217;s assessment of the conclusions
reached regarding uncertain tax positions changes as a result of the evaluation of new information, such change in estimate will be recorded
in the period in which such determination is made. The Company reports income tax-related interest and penalties relating to uncertain
tax positions, if applicable, as a component of income tax expense</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
tax assets are reduced by a valuation allowance when the Company believes that it is more-likely-than-not that some portion or all of
the deferred tax assets will not be realized. The Company provides deferred taxes at the enacted tax rate that is expected to apply when
the temporary differences reverse. The Company has recorded a full valuation allowance against the net deferred tax asset due to the
uncertainty of realizing the related benefits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ONMD_PatentsAndTrademarksPolicyTextBlock', window );">Patents and Trademarks</a></td>
<td class="text"><p id="xdx_843_ecustom--PatentsAndTrademarksPolicyTextBlock_zllmj1Dmzjha" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span id="xdx_866_zbuYUjfdq4qd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Patents
and Trademarks</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs
associated with the submission of a patent application are expensed as incurred given the uncertainty of the patents resulting in probable
future economic benefits to the Company and are included in research and development expenses on the consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 30pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><p id="xdx_84F_eus-gaap--ResearchAndDevelopmentExpensePolicy_zqccu0sxztVd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span id="xdx_86F_zoLfadaIiS4e" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Research
and Development</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 30pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company account for its research and development cost in accordance with ASC Topic 730, Research and Development (&#8220;ASC Topic 730&#8221;).
ASC Topic 730 requires that all R&amp;D costs be recognized as an expense as incurred. However, some costs associated with R&amp;D activities
that have an alternative future use (e.g., materials, equipment, facilities) may be capitalizable. For the years ended December 31, 2023
and December 31, 2022 research and development expenditures were charged to operating expense as incurred..</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 30pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-based Compensation</a></td>
<td class="text"><p id="xdx_845_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zY1upFaeMacf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span id="xdx_869_z2L8cRNHHXpg" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stock-based
Compensation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has a stock-based compensation plan, which is described in more detail in Note 8. The fair value of stock option and warrant
grants are determined on the date of grant using the Black Scholes valuation model. Forfeitures of stock based awards are recorded as
the actual forfeitures occur. Stock based compensation expense is recognized over the service period, net of estimated forfeitures, using
the straight-line method. The Company converted all unvested stock based compensation awards to common shares in the year ended December
31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">General, and Administrative Expenses</a></td>
<td class="text"><p id="xdx_846_eus-gaap--SellingGeneralAndAdministrativeExpensesPolicyTextBlock_zob83QmMzd2g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span id="xdx_862_zp3OEq1qEjda" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>General,
and Administrative Expenses</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses include all costs that are not directly related to satisfaction of customer contracts. General, and administrative
expenses include items for the Company&#8217;s selling and administrative functions, such as sales, finance, legal, human resources,
and information technology support. These functions include costs for items such as salaries and benefits and other personnel-related
costs, maintenance and supplies, professional fees for external legal, accounting, and other consulting services, intangible asset amortization,
and depreciation expense.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ONMD_EmergingGrowthCompanyPolicyTextBlock', window );">Emerging Growth Company</a></td>
<td class="text"><p id="xdx_84B_ecustom--EmergingGrowthCompanyPolicyTextBlock_zSv3ZJ534jDd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span id="xdx_861_zPmGBlQam70g" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Emerging
Growth Company</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is an emerging growth company, as defined in Section 2(a) of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;),
as modified by the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;). Section 102(b)(1) of the JOBS Act exempts
emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that
is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered
under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;)) are required to comply with the new or revised
financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply
with the requirements that apply to non-emerging growth companies but any such an election to opt out is irrevocable. The Company has
not elected to opt out of such extended transition period which means that when a standard is issued or revised and it has different
application dates for public or private companies, the Company, as an emerging growth company , can adopt the new or revised standard
at the time private companies adopt the new or revised standard.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ONMD_AccountingPronouncementsNotYetAdoptedPolicyTextBlock', window );">Accounting Pronouncements Not Yet Adopted</a></td>
<td class="text"><p id="xdx_845_ecustom--AccountingPronouncementsNotYetAdoptedPolicyTextBlock_zkriRDHeinT3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span id="xdx_86B_zXnyAgn1N81h" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Accounting
Pronouncements Not Yet Adopted</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU No. 2023-07, Improvements to Reportable Segment
Disclosures (Topic 280). This ASU updates reportable segment disclosure requirements by requiring disclosures of significant reportable
segment expenses that are regularly provided to the Chief Operating Decision Maker (&#8220;CODM&#8221;) and included within each reported
measure of a segment&#8217;s profit or loss. This ASU also requires disclosure of the title and position of the individual identified
as the CODM and an explanation of how the CODM uses the reported measures of a segment&#8217;s profit or loss in assessing segment performance
and deciding how to allocate resources. The ASU is effective for annual periods beginning after December 15, 2023, and interim periods
within fiscal years beginning after December 15, 2024. Adoption of the ASU should be applied retrospectively to all prior periods presented
in the financial statements. Early adoption is also permitted. This ASU will likely result in us including the additional required disclosures
when adopted. We are currently evaluating the provisions of this ASU and expect to adopt them for the year ending December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2023, the Financial Accounting Standards Board issued an Accounting Standards Update (&#8220;ASU&#8221;) amending existing income
tax disclosure guidance, primarily requiring more detailed disclosure for income taxes paid and the effective tax rate reconciliation.
The ASU is effective for annual reporting periods beginning after December 15, 2024, with early adoption permitted and can be applied
on either a prospective or retroactive basis. We are currently evaluating the ASU to determine its impact on our income tax disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently adopted accounting pronouncements</a></td>
<td class="text"><p id="xdx_840_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zMFQj8yXoSH2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span id="xdx_86F_zcTBCyVWS00i" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Recently
adopted accounting pronouncements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2021, the FASB issued ASU No. 2021-08, Accounting for Contract Assets and Contract Liabilities from Contracts with Customers
(ASC Topic 805). This ASU requires an acquirer in a business combination to recognize and measure contract assets and contract liabilities
(deferred revenue) from acquired contracts using the revenue recognition guidance in Topic 606. At the acquisition date, the acquirer
applies the revenue model as if it had originated the acquired contracts. The ASU is effective for annual periods beginning after December
15, 2022, including interim periods within those fiscal years. We adopted this ASU prospectively on January 1, 2023. This ASU has not
and is currently not expected to have a material impact on our consolidated financial statements.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ONMD_AccountingPronouncementsNotYetAdoptedPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounting Pronouncements Not Yet Adopted [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ONMD_AccountingPronouncementsNotYetAdoptedPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ONMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ONMD_EmergingGrowthCompanyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Emerging Growth Company [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ONMD_EmergingGrowthCompanyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ONMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ONMD_OperatingSegmentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Segments [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ONMD_OperatingSegmentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ONMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ONMD_PatentsAndTrademarksPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Patents And Trademarks [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ONMD_PatentsAndTrademarksPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ONMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479515/805-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 60<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482053/820-10-60-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 35<br> -Topic 720<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481569/310-20-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-11B<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-6<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140069381765312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedule Of Aggregate Percentage Revenue and Accounts Receivable</a></td>
<td class="text"><p id="xdx_899_eus-gaap--SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_zQi7JmXQvsj9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B2_zGLv6h4dCOii">Schedule
Of Aggregate Percentage Revenue and Accounts Receivable</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20230101__20231231_zUGdB37NKUn6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December
    31, 2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20220101__20221231_zcYb7a6l5vo2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December
    31, 2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year Ended</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31, 2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31, 2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zEHO2Q3PAb9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 56%">Customer 1</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right">52</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right">31</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_405_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_zZGLElbzyVq4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Customer 2</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0725">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">22</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr id="xdx_40F_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomersMember_z5Y4MjatHXV" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Aggregate Percent of Total Revenue</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">52</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">53</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 12.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023, three customers accounted for more than <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--ThreeCustomersMember_zaeCBpShTQP9">10</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
of the Company&#8217;s accounts receivable balance, and two customers accounted for over <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--TwoCustomersMember_z1pBVCbDsh6b">10</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
of the Company&#8217;s accounts receivable balance at December 31, 2022. The following table represents these customers&#8217; aggregate
percent of total accounts receivable:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 12.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20230101__20231231_zFefwqYRVOU8" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December
    31, 2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20220101__20221231_z2cFFNbI99Sb" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December
    31, 2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year Ended</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31, 2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31, 2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zUQw8G4cVKZe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%">Customer 1</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0733">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">40</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_400_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_zbivTlCYEB3g" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">Customer 2</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">36</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0737">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerThreeMember_zUf1RqDmH0z5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Customer 3</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">33</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0740">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerFourMember_zMcJm0AG6jMd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">Customer 4</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0742">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">32</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr id="xdx_404_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerFiveMember_zXVSrVaFghWj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Customer 5</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">27</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0746">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomersMember_zdgdbAAO0zIb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Aggregate Percent of Total Accounts Receivable</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">96</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">%</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">72</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr id="xdx_40F_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomersMember_zg1FiXjCH2xe" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Aggregate Percent of Revenue and Accounts Receivable</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">96</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">%</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">72</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">%</td></tr>
</table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-16<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140069381674544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property And Equipment</a></td>
<td class="text"><p id="xdx_89A_eus-gaap--PropertyPlantAndEquipmentTextBlock_zAazqlokgi91" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B2_z8Gw2Lkw6J59">Schedule
of Property And Equipment </span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%; margin-left: 0.75in">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20231231_zxbghYXtYgG" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20221231_zt0fc4NDUIdi" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_ziE4TvzcdXC8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%">Computers</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">246,578</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">259,207</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zo9jdq1Pm0n1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Furniture and equipment</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">35,708</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3,785</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzSdJ_zRVEXvJRbLte" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Total Property and Equipment</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">282,286</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">262,992</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzSdJ_zESw8MyMt588" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Less: accumulated depreciation</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(183,415</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(179,895</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzSdJ_zkzCLNMdEYJ2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Net Property and Equipment</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">98,871</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">83,097</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140069381742608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Income Taxes</a></td>
<td class="text"><p id="xdx_897_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zOTyCca4QW1c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Components
of deferred income taxes are as follows as of December 31:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span id="xdx_8B6_zo03RUu2UEKe" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
of Deferred Income Taxes</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_490_20231231_zuzdypJa1VJe" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20221231_zvNXwFlUwyx6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsNetAbstract_iB_z1AfkgxFsRQc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Deferred Tax Assets</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzqvH_z5F5Wc4Dlonj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Net operating loss carry forward</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,823,785&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">6,973,587</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTAGzqvH_znQ6MjBxc6q2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Stock Compensation</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,035,947</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">481,144</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsOther_iI_maDTAGzqvH_zYoSYWKgPhFb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; padding-bottom: 1.5pt">Other</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0821">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">53,268</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzqvH_maDTANzhf6_zP6nBXkfV5Hc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Gross deferred tax assets</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,859,732</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">7,507,999</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzhf6_zvM5foPdYXh1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Less valuation allowance</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(7,859,732</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(7,507,999</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzhf6_zpjeP5OEWge3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Net deferred tax assets</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0830">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0831">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140069385432064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders&#8217; Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock', window );">Schedule of Common Stock Activities</a></td>
<td class="text"><p id="xdx_893_eus-gaap--ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_z57uq3swwTu3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font: normal 10pt Times New Roman, Times, Serif">The
table below summarizes the Common Stock activities during the year ended December 31, 2023.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span id="xdx_8B9_z64bu48q1ymf" style="font: normal 10pt Times New Roman, Times, Serif">Schedule
of Common Stock Activities</span><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 1in">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_z2msICVrt1Qb" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">Common
    Stock</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--SharesOutstanding_iS_zLHH8ANuCOvi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 80%">Balances, December 31, 2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">4,550,166</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--SharesOutstanding_iS_zW2yvdRyeAgd" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif">Balance</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">4,550,166</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_z2wlaGxg9Xb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Preferred Stock to Common Stock</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">7,057,797</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--StockIssuedDuringPeriodSharesConvertibleNotesToCommonStock_zJwjfDx64uRl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Convertible Notes to Common Stock</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">6,177,229</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--StockIssuedDuringPeriodSharesStockOptionsToCommonStock_z3uhYW1PO4Ql" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Stock Options to Common Stock</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">612,670</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--StockIssuedDuringPeriodSharesConvertingOfWarrantsToCommonStock_z3UmWOkuvHcd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Converting of Warrants to Common Stock</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,859,464</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--StockIssuedDuringPeriodSharesOther_zuvjfYqYrP3e" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Private OneMedNet to ONMD Public Shares</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(2,257,326</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_407_ecustom--StockIssuedDuringPeriodSharesConvertingDataKnightsCommonShares_zO0iuFy9if3i" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Converting Data Knights Common Stock (A and B) to ONMD Public Shares</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,460,275</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_z2eiIknVjv5e" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Issuance Public Shares</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">111,957</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--SharesOutstanding_iE_zyOXDTAsVnxi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif">Balances, December 31, 2023</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">23,572,232</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--SharesOutstanding_iE_zOLEX9Io8sth" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif">Balance</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">23,572,232</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
</table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140069381756400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Options (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Options Outstanding</a></td>
<td class="text"><p id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zOOwKvbrQpb1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
with respect to options outstanding is summarized as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span id="xdx_8B8_zQRZFYMZHvh1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
of Options Outstanding</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Options Outstanding</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Weighted- Average Exercise Price</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Aggregate Intrinsic Value</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 52%">Outstanding as of December 31, 2020</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210101__20211231_zadM3myKcRSg" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Options outstanding, begining balance">1,995,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231_zP106pErband" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Weighted average exercise price, begining balance">1.00</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20210101__20211231_z121yn1pvKH9" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Aggregate Intrinsic value, begining balance">1,995,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Granted - under the Plan</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210101__20211231_zXHo6mISQpKb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options, Granted - under the Plan">25,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Exercised</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20210101__20211231_zyywVTg5nGIa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options, Granted - under the Plan"><span style="-sec-ix-hidden: xdx2ixbrl0917">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Cancelled</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20210101__20211231_zSn9l0NAWEk4" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options, cancelled">(1,072,816</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Outstanding as of December 31, 2021</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220101__20221231_zaCQmCo4rgci" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options outstanding, ending balance">947,184</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210101__20211231_zXDcIpQgUsAi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, ending balance">1.00</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20210101__20211231_zhXfMFmK7TH1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic value, ending balance">947,184</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Granted - under the Plan</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231_z3d4RVyP48Li" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options, Granted - under the Plan">577,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Exercised</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20220101__20221231_z3Cg4GHDeiCb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options, Granted - under the Plan">(7,500</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Cancelled</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20220101__20221231_z6qJl1wVmuyk" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options, cancelled">(485,684</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Outstanding as of December 31, 2022</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20220101__20221231_zS1IVj8CRw3j" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options outstanding, ending balance">1,031,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231_zX1i6YPg8JM9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, ending balance">1.00</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20220101__20221231_zM05DsMkmdHa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic value, ending balance">1,031,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Options exercisable as of December 31, 2022</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20220101__20221231_ztwl4L855yl8" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options exercisable">567,581</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20220101__20221231_zYrTENj4cnQg" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, exercisable">1.00</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_c20220101__20221231_zj3Qf8Lulmh7" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic value, exercisable">567,581</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of Fair Value of Stock Options</a></td>
<td class="text"><p id="xdx_898_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zay0AEYnB9Ej" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of the Company&#8217;s previous stock options was estimated assuming no expected dividends and the following weighted average
assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span id="xdx_8B6_zJo0ngyYGTwc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
of Fair Value of Stock Options</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2021</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Expected life in years</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span id="xdx_901_ecustom--EquitySecuritiesFvNiMeasurementTerm_dtY_c20220101__20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zoolrrCQTN9h">5.89</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span id="xdx_905_ecustom--EquitySecuritiesFvNiMeasurementTerm_dtY_c20210101__20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zyneyj3ZuwJ">6.08</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Risk-free interest rate</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z9y58LCpnxXh">0.55</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90C_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zWq5I7FYdBS2">0.49</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Expected dividend yield</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_900_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z69uRpV0a13b">0.00</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90A_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z4ohD9teCjj4">0.00</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Expected volatility</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90D_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zY9O0q7FP8Pk">32</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zSQ9xugXtAYb">60</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140069389820960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measures (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of Financial Assets</a></td>
<td class="text"><p id="xdx_89F_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisTextBlock_zF46BGIp4EFd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the Company&#8217;s financial assets measured and recorded at fair value on a recurring basis using the above
input categories as of December 31, 2023 and December 31, 2022 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span id="xdx_8BF_zdP5BhYaW47c" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
of Financial Assets</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="30" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year Ended</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><b>December 31, 2023</b></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><b>December 31, 2022</b></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level 1</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level 2</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level 3</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level 1</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level 2</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level 3</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Assets:</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 28%; text-align: left">Investments held in Trust</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--AssetsHeldInTrustCurrent_iI_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByAssetClassAxis__custom--InvestmentsHeldInTrustMember_zEQFhQkyIfN" style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right" title="Investments held in Trust"><span style="-sec-ix-hidden: xdx2ixbrl0996">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--AssetsHeldInTrustCurrent_iI_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByAssetClassAxis__custom--InvestmentsHeldInTrustMember_zLZI52abmujj" style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right" title="Investments held in Trust"><span style="-sec-ix-hidden: xdx2ixbrl0998">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--AssetsHeldInTrustCurrent_iI_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByAssetClassAxis__custom--InvestmentsHeldInTrustMember_zoUYLwzbPZ09" style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right" title="Investments held in Trust"><span style="-sec-ix-hidden: xdx2ixbrl1000">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--AssetsHeldInTrustCurrent_iI_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--InvestmentsHeldInTrustMember_zXBMFEw6Jxej" style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right" title="Investments held in Trust"><span style="-sec-ix-hidden: xdx2ixbrl1002">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--AssetsHeldInTrustCurrent_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByAssetClassAxis__custom--InvestmentsHeldInTrustMember_zvIGgDiejqOl" style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right" title="Investments held in Trust">29,029,416</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--AssetsHeldInTrustCurrent_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByAssetClassAxis__custom--InvestmentsHeldInTrustMember_zcCKPwhX93uc" style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right" title="Investments held in Trust"><span style="-sec-ix-hidden: xdx2ixbrl1006">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--AssetsHeldInTrustCurrent_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByAssetClassAxis__custom--InvestmentsHeldInTrustMember_zvXhmGsmuOr7" style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right" title="Investments held in Trust"><span style="-sec-ix-hidden: xdx2ixbrl1008">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--AssetsHeldInTrustCurrent_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--InvestmentsHeldInTrustMember_zrAoAx5qHUz5" style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right" title="Investments held in Trust">29,029,416</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Total Assets</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_eus-gaap--AssetsHeldInTrustCurrent_iI_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zmIvjjLwQdvj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Assets measured and recorded fair value"><span style="-sec-ix-hidden: xdx2ixbrl1012">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98A_eus-gaap--AssetsHeldInTrustCurrent_iI_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zVtsygBqkh22" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Assets measured and recorded fair value"><span style="-sec-ix-hidden: xdx2ixbrl1014">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98F_eus-gaap--AssetsHeldInTrustCurrent_iI_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zUnskt8YvWJ7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Assets measured and recorded fair value"><span style="-sec-ix-hidden: xdx2ixbrl1016">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98B_eus-gaap--AssetsHeldInTrustCurrent_iI_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zYdjoewzQqGk" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Assets measured and recorded fair value"><span style="-sec-ix-hidden: xdx2ixbrl1018">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98A_eus-gaap--AssetsHeldInTrustCurrent_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zJDtEWqItAIb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Assets measured and recorded fair value">29,029,416</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98A_eus-gaap--AssetsHeldInTrustCurrent_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zWmgRXu5v5Aj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Assets measured and recorded fair value"><span style="-sec-ix-hidden: xdx2ixbrl1022">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98C_eus-gaap--AssetsHeldInTrustCurrent_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zMRKEoTtJrC9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Assets measured and recorded fair value"><span style="-sec-ix-hidden: xdx2ixbrl1024">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_986_eus-gaap--AssetsHeldInTrustCurrent_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_ziDpKsUYsNjf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Assets measured and recorded fair value">29,029,416</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>133
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140069379482176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Operations (Details Narrative) - Securities Purchase Agreement [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 28, 2023</div></th>
<th class="th"><div>Nov. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescription', window );">Debt Instrument, Description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The
senior secured notes are convertible to the conversion rate of $<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ONMD_SecuritiesPurchaseAgreementMember', window );">Data Knights Acquisition Corp [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuedPrincipal', window );">Debt Instrument, Issued, Principal</a></td>
<td class="nump">$ 1,595,744.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to Acquire Businesses, Gross</a></td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescription', window );">Debt Instrument, Description</a></td>
<td class="text">Pursuant
to the Securities Purchase Agreement, Data Knights will issue and sell to each of the Purchasers, a new series of senior secured convertible
notes (the &#8220;PIPE Notes&#8221;), which are convertible into shares of Common Stock at the Purchasers election at a conversion price
equal to the lower of (i) $10.00 per share, and (ii) 92.5% of the lowest volume weighted average trading price for the ten (10) Trading
Days immediately preceding the Conversion Date.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Investments', window );">Investments</a></td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480848/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIssuedPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of principal of debt issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIssuedPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Investments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(h))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Investments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ONMD_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ONMD_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ONMD_DataKnightsAcquisitionCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ONMD_DataKnightsAcquisitionCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>134
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140069375265312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule Of Aggregate Percentage Revenue and Accounts Receivable (Details) - Customer Concentration Risk [Member]<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">Revenue from Contract with Customer Benchmark [Member] | Customer One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Aggregate Percent of Revenue and Accounts Receivable</a></td>
<td class="nump">52.00%<span></span>
</td>
<td class="nump">31.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">Revenue from Contract with Customer Benchmark [Member] | Customer Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Aggregate Percent of Revenue and Accounts Receivable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">22.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">Revenue from Contract with Customer Benchmark [Member] | Customers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Aggregate Percent of Revenue and Accounts Receivable</a></td>
<td class="nump">52.00%<span></span>
</td>
<td class="nump">53.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable [Member] | Customer One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Aggregate Percent of Revenue and Accounts Receivable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable [Member] | Customer Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Aggregate Percent of Revenue and Accounts Receivable</a></td>
<td class="nump">36.00%<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable [Member] | Customers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Aggregate Percent of Revenue and Accounts Receivable</a></td>
<td class="nump">96.00%<span></span>
</td>
<td class="nump">72.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable [Member] | Customer Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Aggregate Percent of Revenue and Accounts Receivable</a></td>
<td class="nump">33.00%<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable [Member] | Customer Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Aggregate Percent of Revenue and Accounts Receivable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">32.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable [Member] | Customer Five [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Aggregate Percent of Revenue and Accounts Receivable</a></td>
<td class="nump">27.00%<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ONMD_CustomerOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ONMD_CustomerOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ONMD_CustomerTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ONMD_CustomerTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ONMD_CustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ONMD_CustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ONMD_CustomerThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ONMD_CustomerThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ONMD_CustomerFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ONMD_CustomerFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ONMD_CustomerFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ONMD_CustomerFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>135
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140069389650080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Accounts Receivable, Allowance for Credit Loss, Current</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 102,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment of Long-Lived Assets to be Disposed of</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">Revenue from Contract with Customer Benchmark [Member] | Customer Concentration Risk [Member] | One Customer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">Revenue from Contract with Customer Benchmark [Member] | Customer Concentration Risk [Member] | Two Customers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable [Member] | Customer Concentration Risk [Member] | Two Customers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable [Member] | Customer Concentration Risk [Member] | Three Customers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479344/326-20-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ONMD_OneCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ONMD_OneCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ONMD_TwoCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ONMD_TwoCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ONMD_ThreeCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ONMD_ThreeCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>136
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140069389828560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Going Concern (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained Earnings (Accumulated Deficit)</a></td>
<td class="nump">$ 55,082,677<span></span>
</td>
<td class="nump">$ 43,509,964<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>137
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140069379291440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Property And Equipment (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total Property and Equipment</a></td>
<td class="nump">$ 282,286<span></span>
</td>
<td class="nump">$ 262,992<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(183,415)<span></span>
</td>
<td class="num">(179,895)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net Property and Equipment</a></td>
<td class="nump">98,871<span></span>
</td>
<td class="nump">83,097<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total Property and Equipment</a></td>
<td class="nump">246,578<span></span>
</td>
<td class="nump">259,207<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total Property and Equipment</a></td>
<td class="nump">$ 35,708<span></span>
</td>
<td class="nump">$ 3,785<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>138
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140069385454048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation, Depletion and Amortization, Nonproduction</a></td>
<td class="nump">$ 27,983<span></span>
</td>
<td class="nump">$ 24,807<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>139
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140069388905600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Deferred Income Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred Tax Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carry forward</a></td>
<td class="nump">$ 6,823,785<span></span>
</td>
<td class="nump">$ 6,973,587<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock Compensation</a></td>
<td class="nump">1,035,947<span></span>
</td>
<td class="nump">481,144<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">53,268<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
<td class="nump">7,859,732<span></span>
</td>
<td class="nump">7,507,999<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less valuation allowance</a></td>
<td class="num">(7,859,732)<span></span>
</td>
<td class="num">(7,507,999)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>140
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140069377044384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</a></td>
<td class="nump">$ 351,734<span></span>
</td>
<td class="nump">$ 1,384,220<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Deferred Tax Assets, Valuation Allowance</a></td>
<td class="nump">7,859,732<span></span>
</td>
<td class="nump">$ 7,507,999<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ONMD_DataKnightsAcquisitionCorpMember', window );">Data Knights Acquisition Corp [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</a></td>
<td class="nump">155,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Deferred Tax Assets, Valuation Allowance</a></td>
<td class="nump">168,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration</a></td>
<td class="nump">21,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="nump">10,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration</a></td>
<td class="nump">23,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="nump">$ 8,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ONMD_DataKnightsAcquisitionCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ONMD_DataKnightsAcquisitionCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>141
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140069379785568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Convertible Promissory Notes held by Related Party (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th"><div>Nov. 11, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Nov. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,140,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent', window );">Accrued Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 690,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,056,000<span></span>
</td>
<td class="nump">174,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ONMD_ConvertiblePromissoryNotesMember', window );">Convertible Promissory Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member] | Data Knights Acquisition Corp [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="nump">$ 15,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt Instrument, Convertible, Conversion Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member] | Convertible Promissory Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance or Sale of Equity</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ONMD_EquityFinancingDescription', window );">[custom:EquityFinancingDescription]</a></td>
<td class="text">a
20% discount to the lowest price per share of shares sold in the Next Equity Financing, or (B) $2.50 per share; (ii) at the noteholder&#8217;s
option, in the event of a defined Corporate Transaction while such Note remains outstanding, into shares of the Company&#8217;s Series
A-2 Preferred Stock at a conversion price equal to $<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member] | Convertible Promissory Notes [Member] | Series A-2 Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Preferred Stock, Convertible, Conversion Price</a></td>
<td class="nump">$ 2.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember', window );">Nonrelated Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,875,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 440,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ONMD_EquityFinancingDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity financing description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ONMD_EquityFinancingDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ONMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share conversion price of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ONMD_ConvertiblePromissoryNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ONMD_ConvertiblePromissoryNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ONMD_DataKnightsAcquisitionCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ONMD_DataKnightsAcquisitionCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ONMD_SeriesATwoPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ONMD_SeriesATwoPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>142
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140069378709312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Canadian Emergency Business Loan Act (CEBA) (Details Narrative) - CEBA Loan [Member]<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt', window );">Proceeds from Issuance of Unsecured Debt</a></td>
<td class="nump">$ 44,673<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDecreaseForgiveness', window );">Debt Instrument, Decrease, Forgiveness</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,742<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Debt Conversion, Original Debt, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44,673<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt Instrument, Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDecreaseForgiveness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease for amounts of indebtedness forgiven by the holder of the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDecreaseForgiveness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of long-term debt that is not secured by collateral. Excludes proceeds from tax exempt unsecured debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfUnsecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ONMD_CEBALoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ONMD_CEBALoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>143
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140069379626640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Common Stock Activities (Details) - Common Stock [Member] - Board of Directors Chairman [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares</a></td>
<td class="nump">4,550,166<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Preferred Stock to Common Stock</a></td>
<td class="nump">7,057,797<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ONMD_StockIssuedDuringPeriodSharesConvertibleNotesToCommonStock', window );">Convertible Notes to Common Stock</a></td>
<td class="nump">6,177,229<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ONMD_StockIssuedDuringPeriodSharesStockOptionsToCommonStock', window );">Stock Options to Common Stock</a></td>
<td class="nump">612,670<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ONMD_StockIssuedDuringPeriodSharesConvertingOfWarrantsToCommonStock', window );">Converting of Warrants to Common Stock</a></td>
<td class="nump">3,859,464<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Private OneMedNet to ONMD Public Shares</a></td>
<td class="num">(2,257,326)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ONMD_StockIssuedDuringPeriodSharesConvertingDataKnightsCommonShares', window );">Converting Data Knights Common Stock (A and B) to ONMD Public Shares</a></td>
<td class="nump">3,460,275<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance Public Shares</a></td>
<td class="nump">111,957<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares</a></td>
<td class="nump">23,572,232<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ONMD_StockIssuedDuringPeriodSharesConvertibleNotesToCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares convertible notes to common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ONMD_StockIssuedDuringPeriodSharesConvertibleNotesToCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ONMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ONMD_StockIssuedDuringPeriodSharesConvertingDataKnightsCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period shares converting data knights common shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ONMD_StockIssuedDuringPeriodSharesConvertingDataKnightsCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ONMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ONMD_StockIssuedDuringPeriodSharesConvertingOfWarrantsToCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares converting of warrants to common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ONMD_StockIssuedDuringPeriodSharesConvertingOfWarrantsToCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ONMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ONMD_StockIssuedDuringPeriodSharesStockOptionsToCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares stock options to common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ONMD_StockIssuedDuringPeriodSharesStockOptionsToCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ONMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>144
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140069382084624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders&#8217; Equity (Details Narrative) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockTermsOfConversion', window );">Preferred Stock, Convertible, Terms</a></td>
<td class="text">Series
A-2 Preferred Stock and Series A-1 Preferred Stock convert 1-1 to commons stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=ONMD_BoardOfDirectorsMember', window );">Board Of Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock Issued During Period, Shares, Issued for Services</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price</a></td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ONMD_SeriesATwoPreferredStockMember', window );">Series A-2 Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="nump">$ 0.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from Issuance of Preferred Stock and Preference Stock</a></td>
<td class="nump">$ 20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ONMD_SeriesAOnePreferredStockMember', window );">Series A-1 Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="nump">$ 0.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from Issuance of Preferred Stock and Preference Stock</a></td>
<td class="nump">$ 20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockTermsOfConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of conversion terms for preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-8<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-6<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockTermsOfConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=ONMD_BoardOfDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=ONMD_BoardOfDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ONMD_SeriesATwoPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ONMD_SeriesATwoPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ONMD_SeriesAOnePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ONMD_SeriesAOnePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>145
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140069483965984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Options Outstanding (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, ending balance</a></td>
<td class="nump">947,184<span></span>
</td>
<td class="nump">1,995,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, begining balance</a></td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic value, begining balance</a></td>
<td class="nump">$ 947,184<span></span>
</td>
<td class="nump">$ 1,995,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options, Granted - under the Plan</a></td>
<td class="nump">577,000<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options, Granted - under the Plan</a></td>
<td class="nump">7,500<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Options, cancelled</a></td>
<td class="num">(485,684)<span></span>
</td>
<td class="num">(1,072,816)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, ending balance</a></td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic value, ending balance</a></td>
<td class="nump">$ 1,031,000<span></span>
</td>
<td class="nump">$ 947,184<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options, Granted - under the Plan</a></td>
<td class="num">(7,500)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, ending balance</a></td>
<td class="nump">1,031,000<span></span>
</td>
<td class="nump">947,184<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable</a></td>
<td class="nump">567,581<span></span>
</td>
<td class="nump">723,431<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, exercisable</a></td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic value, exercisable</a></td>
<td class="nump">$ 567,581<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>146
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140069388907584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Fair Value of Stock Options (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ONMD_EquitySecuritiesFvNiMeasurementTerm', window );">[custom:EquitySecuritiesFvNiMeasurementTerm]</a></td>
<td class="text">5 years 10 months 20 days<span></span>
</td>
<td class="text">6 years 29 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiMeasurementInput', window );">Equity Securities, FV-NI, Measurement Input</a></td>
<td class="nump">0.55<span></span>
</td>
<td class="nump">0.49<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Measurement Input, Expected Dividend Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiMeasurementInput', window );">Equity Securities, FV-NI, Measurement Input</a></td>
<td class="nump">0.00<span></span>
</td>
<td class="nump">0.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiMeasurementInput', window );">Equity Securities, FV-NI, Measurement Input</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">60<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ONMD_EquitySecuritiesFvNiMeasurementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity securities FvNi measurement term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ONMD_EquitySecuritiesFvNiMeasurementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ONMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>147
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140069379684544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Options (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 17, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Nov. 07, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,031,000<span></span>
</td>
<td class="nump">947,184<span></span>
</td>
<td class="nump">1,995,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 1 month 9 days<span></span>
</td>
<td class="text">6 years 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">567,581<span></span>
</td>
<td class="nump">723,431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months 21 days<span></span>
</td>
<td class="text">5 years 3 months 7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">692,153<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Description</a></td>
<td class="text">common
stock equal to 10% of the number of shares of common stock of OneMedNet following the Business Combination for issuance thereunder<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-Based Payment Arrangement, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,584<span></span>
</td>
<td class="nump">$ 47,071<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,987<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">612,720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=ONMD_EmployeesDirectorsAndConsultantsMember', window );">Employees Directors and Consultants [Member] | New Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=ONMD_EmployeesDirectorsAndConsultantsMember', window );">Employees Directors and Consultants [Member] | New Equity Incentive Plan [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=ONMD_EmployeesDirectorsAndConsultantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=ONMD_EmployeesDirectorsAndConsultantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ONMD_NewEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ONMD_NewEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>148
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140069379658256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Warrants (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</a></td>
<td class="nump">2,056,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">174,102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from Issuance of Warrants</a></td>
<td class="nump">$ 1,346,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">174,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ONMD_WarrantOneMember', window );">Warrant One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of Warrant or Right, Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,165,746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ONMD_PubliclyTradedWarrantsMember', window );">Publicly Traded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="nump">$ 0.0400<span></span>
</td>
<td class="nump">$ 0.0149<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of Warrant or Right, Outstanding</a></td>
<td class="nump">11,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ONMD_PrivateWarrantsMember', window );">Private Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of Warrant or Right, Outstanding</a></td>
<td class="nump">585,275<span></span>
</td>
<td class="nump">681,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilities', window );">Other Liabilities</a></td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ONMD_ConvertiableNotesMember', window );">Convertiable Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</a></td>
<td class="nump">2,056,000<span></span>
</td>
<td class="nump">1,670,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ONMD_TwentyTwentyOneServiceMember', window );">2021 Service [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</a></td>
<td class="nump">145,746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ONMD_TwentyTwentyTwoServiceMember', window );">2022 Service [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</a></td>
<td class="nump">294,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ONMD_WarrantOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ONMD_WarrantOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ONMD_PubliclyTradedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ONMD_PubliclyTradedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ONMD_PrivateWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ONMD_PrivateWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ONMD_ConvertiableNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ONMD_ConvertiableNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ONMD_TwentyTwentyOneServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ONMD_TwentyTwentyOneServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ONMD_TwentyTwentyTwoServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ONMD_TwentyTwentyTwoServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>149
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140069378635152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Financial Assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsHeldInTrustCurrent', window );">Assets measured and recorded fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 29,029,415<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsHeldInTrustCurrent', window );">Assets measured and recorded fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">29,029,416<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Investments Held in Trust [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsHeldInTrustCurrent', window );">Assets measured and recorded fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">29,029,416<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsHeldInTrustCurrent', window );">Assets measured and recorded fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">29,029,416<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Investments Held in Trust [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsHeldInTrustCurrent', window );">Assets measured and recorded fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">29,029,416<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsHeldInTrustCurrent', window );">Assets measured and recorded fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Investments Held in Trust [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsHeldInTrustCurrent', window );">Assets measured and recorded fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsHeldInTrustCurrent', window );">Assets measured and recorded fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Investments Held in Trust [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsHeldInTrustCurrent', window );">Assets measured and recorded fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsHeldInTrustCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash, securities, or other assets held by a third-party trustee pursuant to the terms of an agreement which assets are available to be used by beneficiaries to that agreement only within the specific terms thereof and which agreement is expected to terminate within one year of the balance sheet date (or operating cycle, if longer) at which time the assets held-in-trust will be released or forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsHeldInTrustCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=ONMD_InvestmentsHeldInTrustMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=ONMD_InvestmentsHeldInTrustMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>150
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140069379137792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 28, 2023</div></th>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,140,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,549,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent', window );">Accrued Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">690,771<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeniorNotesCurrent', window );">Senior Notes, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ONMD_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescription', window );">Debt Instrument, Description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The
senior secured notes are convertible to the conversion rate of $<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt Instrument, Convertible, Conversion Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ONMD_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Stock Issued During Period, Shares, Acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95,745<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ONMD_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member] | Senior Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
<td class="nump">4,700,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ONMD_ExtensionLoan', window );">[custom:ExtensionLoan-0]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000.0<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member] | Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent', window );">Accrued Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member] | Management and Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ONMD_ExtensionLoan', window );">[custom:ExtensionLoan-0]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ONMD_DataKnightsAcquisitionCorpMember', window );">Data Knights Acquisition Corp [Member] | Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescription', window );">Debt Instrument, Description</a></td>
<td class="text">Pursuant
to the Securities Purchase Agreement, Data Knights will issue and sell to each of the Purchasers, a new series of senior secured convertible
notes (the &#8220;PIPE Notes&#8221;), which are convertible into shares of Common Stock at the Purchasers election at a conversion price
equal to the lower of (i) $10.00 per share, and (ii) 92.5% of the lowest volume weighted average trading price for the ten (10) Trading
Days immediately preceding the Conversion Date.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ONMD_DataKnightsAcquisitionCorpMember', window );">Data Knights Acquisition Corp [Member] | Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,400,000<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt Instrument, Convertible, Conversion Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ONMD_ExtensionLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Extension loan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ONMD_ExtensionLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ONMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480848/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeniorNotesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term notes having the highest claim on the assets of the issuer in case of bankruptcy or liquidation, due within one year or the normal operating cycle, if longer. Senior note holders are paid off in full before any payments are made to debt holders having a lesser priority of repayment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeniorNotesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ONMD_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ONMD_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ONMD_SeniorConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ONMD_SeniorConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=ONMD_ManagementAndDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=ONMD_ManagementAndDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ONMD_DataKnightsAcquisitionCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ONMD_DataKnightsAcquisitionCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>151
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140069381803328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments, Contingencies, and Concentrations Operating lease (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating Lease, Cost</a></td>
<td class="nump">$ 575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Operating Leases, Rent Expense, Net</a></td>
<td class="nump">$ 7,695<span></span>
</td>
<td class="nump">$ 7,694<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481501/840-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>152
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140069385500560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 27, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from Related Party Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 465,024<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from Issuance of Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,540,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Majority Shareholder [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related Party Transaction, Amounts of Transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Business Combination, Consideration Transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Stock Repurchased During Period, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">187,745<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from Related Party Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast [Member] | Board of Directors Chairman [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Stock Repurchased During Period, Shares</a></td>
<td class="nump">147,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price</a></td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast [Member] | EF Hutton [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">256,944<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast [Member] | Kingwood Capital Partners LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,834<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_MajorityShareholderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_MajorityShareholderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ONMD_EFHuttonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ONMD_EFHuttonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ONMD_KingwoodCapitalPartnersLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ONMD_KingwoodCapitalPartnersLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
